Screen Version of the Carcinogenic Potency Database

For viewing on a computer screen, the Carcinogenic Potency Database (CPDB) is presented in a new condensed-plot format. Data are reported under the chemical name, and chemicals are sorted alphabetically.

- Each line of data is a separate tissue tumor combination.
- All codes are described in the *Appendices* listed on the main web page for the screen version, as are descriptions of *Methods of the Carcinogenic Potency Database* and the *Guide to the Screen Version*.
- Screen Usage: The screen version can be read most easily by increasing the magnification percentage so that it fills the whole screen. To find a particular chemical name or a CAS number, use the find or search command. Headings on each page describe the fields. The headings for each field are in red and blue, the average daily dose-rates in each experiment are in green, and the incidence for the tissue and tumor combination appears below each dose-rate.
- TD_{50} values are calculated from the summary data reported in the plot unless the symbol ":" appears in blue in the first line of the experiment indicating that lifetable data were used. The symbol "()" occasionally appears in blue to indicate that the test did not meet our standard criteria; usually the experiment time was slightly short for the species. Doses are average daily dose-rates for each group in mg/kg/day.

Chemical / Synonym / CAS number	Spe Strain Xpo+Xpt / Sex Route Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
A-alpha-C (2-amino-9H-pyrido(2,3-b)indole) 26148-68-5						
1	M f cdf eat 97w97 1616	0	104.mg			Ohgaki;carc,5,815-819;1984
liv mix	35.6mg P<.0005 + 21.8mg 60.7mg	0/40	33/40			
liv hpc	44.7mg P<.0005 27.6mg 77.0mg	0/40	30/40			
blv hms	381.mg P<.004 + 155.mg 2.30gm	0/40	6/40			
lun ade	795.mg P<.04 241.mg n.s.s.	0/40	3/40			
lun mix	1.15gm P<.4 234.mg n.s.s.	2/40	4/40			
2	M m cdf eat 97w97 1616	0	96.0mg			
blv mix	82.6mg P<.0005 + 48.1mg 158.mg	0/40	20/40			
blv hms	103.mg P<.0005 58.1mg 209.mg	0/40	17/40			
liv mix	122.mg P<.0005 + 66.3mg 259.mg	0/40	15/40			
liv hpc	225.mg P<.0005 105.mg 657.mg	0/40	9/40			
liv hpa	352.mg P<.004 143.mg 2.12gm	0/40	6/40			
lun ade	no dre P=1. 288.mg n.s.s.	3/40	3/40			
lun mix	no dre P=1. 390.mg n.s.s.	11/40	4/40			
ACESULFAME-K 55589-62-3						
3	M f swi eat 80w80 2649	0	3.90gm			Beems;asfk,59-70;1991
lun ala e	24.0gm P<.2 - 8.02gm n.s.s.	6/100	12/100			
liv hpc e	no dre P=1. - 47.6gm n.s.s.	1/100	0/100			
lun agc e	no dre P=1. - 20.4gm n.s.s.	3/100	3/100			
liv hpa e	no dre P=1. - 29.1gm n.s.s.	1/100	1/100			
4	M m swi eat 80w80 2649	0	3.60gm			
lun ala e	no dre P=1. - 9.27gm n.s.s.	17/100	16/100			
liv hpc e	no dre P=1. - 18.8gm n.s.s.	3/100	3/100			
liv hpa e	no dre P=1. - 36.7gm n.s.s.	8/100	1/100			
ACETALDEHYDE 75-07-0						
5	H f syg inh 52w81 1766	0	391.mg			Feron;ejca,18,13-31;1982/pers.comm.
lar mix er	728.mg P<.04 + 219.mg n.s.s.	0/14	3/15			
lar adq er	1.14gm P<.1 + 279.mg n.s.s.	0/14	2/15			
lar sqc er	2.36gm P<.3 + 383.mg n.s.s.	0/14	1/15			
6	H m syg inh 52w81 1766	0	344.mg			
lar mix er	461.mg P<.02 + 158.mg n.s.s.	0/15	4/15			
res mix er	461.mg P<.02 + 158.mg n.s.s.	0/15	4/15			
lar cic er	641.mg P<.04 + 193.mg n.s.s.	0/15	3/15			
lar sqc er	2.07gm P<.3 + 337.mg n.s.s.	0/15	1/15			
nse apc er	2.07gm P<.3 + 337.mg n.s.s.	0/15	1/15			
7	R f wis inh 26m28 1757	0	101.mg	202.mg	209.mg	Woutersen;txcy,41,213-231;1986
nse adc erv	370.mg * P<.0005 + 263.mg 540.mg	0/50	6/48	26/53	21/53	
nse sqc erv	1.03gm Z P<.0005 + 624.mg 1.92gm	0/50	0/50	5/53	17/53	
nse cic erv	3.00gm * P<.007 + 1.36gm 33.3gm	0/50	0/48	3/53	5/53	
8	R m wis inh 26m28 1757	0	70.8mg	142.mg	147.mg	
nse adc erv	185.mg * P<.0005 + 137.mg 259.mg	0/49	16/52	31/53	21/49	
nse sqc erv	627.mg Z P<.0005 + 380.mg 1.38gm	1/49	1/52	10/53	15/49	
9	R f wsr inh 12m24 1863	0	50.1mg	100.mg	149.mg	Woutersen;txcy,47,295-305;1987/1986/pers.comm.
nac mix erv	148.mg * P<.0005 + 85.3mg 288.mg	0/18	1/20	7/18	11/17	
nac adc erv	201.mg * P<.0005 + 110.mg 439.mg	0/18	0/20	7/18	8/17	
nac sqc erv	574.mg * P<.01 + 234.mg 38.9gm	0/18	1/20	0/18	5/17	
10	R m wsr inh 12m24 1863	0	35.1mg	70.1mg	104.mg	
nac mix erv	88.5mg * P<.0005 + 54.4mg 157.mg	0/19	2/20	8/20	15/22	
nac adc erv	190.mg * P<.002 + 102.mg 710.mg	0/19	2/20	6/20	6/22	
nac sqc erv	200.mg Z P<.0005 + 105.mg 463.mg	0/19	0/20	2/20	11/22	
ACETALDEHYDE METHYLFORMYLHYDRAZONE 16568-02-8						
11	M f swa gav 12m25 1267	0	6.78mg			Toth;jnci,67,881-887;1981
lun mix es	5.66mg P<.0005 + 3.21mg 14.0mg	13/50	35/50			
lun ade es	7.37mg P<.0005 4.01mg 22.5mg	12/50	31/50			

Site / Path	Notes / DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun adc es	19.6mg	P<.002		9.49mg 93.0mg	2/50	13/50			
for mix es	28.0mg	P<.002	+	12.7mg 101.mg	0/44	8/48			
for sqp es	32.4mg	P<.003		14.0mg 150.mg	0/44	7/48			
cli mix es	38.2mg	P<.005	+	15.6mg 292.mg	0/44	6/48			
cli sqc es	46.4mg	P<.01		17.6mg 3.78gm	0/44	5/48			
liv hpt es	28.0mg	P<.02	-	8.45mg n.s.s.	0/32	3/18			
12 M m swa gav 52w79 1267					0	9.40mg			
pre mix es	1.61mg	P<.0005	+	1.01mg 2.62mg	0/37	45/50			
pre sqc es	2.17mg	P<.0005		1.40mg 3.49mg	0/37	41/50			
pre fbs es	21.3mg	P<.003		9.65mg 98.0mg	0/37	8/50			
liv hpt es	11.0mg	P<.03	-	2.68mg n.s.s.	0/14	2/7			
lun ade es	13.7mg	P<.03		5.79mg n.s.s.	8/47	18/49			
lun mix es	14.4mg	P<.07	+	5.57mg n.s.s.	11/47	20/49			
ACETALDOXIME 107-29-9									
13 R m f34 wat 26m30 1853					0	19.5mg	50.3mg		Lijinsky;txih,3,337-345;1987/pers.comm.
liv hnd e	445.mg *	P<.4		100.mg n.s.s.	2/20	3/20	4/20		
adr coa e	no dre	P=1.		323.mg n.s.s.	1/20	1/20	0/20		
ACETAMIDE 60-35-5									
14 M f cb6 eat 52w69 1343 pool					0	1.15gm	2.31gm		Fleischman;jept,3,149-170;1980
lun a/a e	no dre	P=1.	-	2.22gm n.s.s.	2/89	0/34	0/28		
liv hpc e	no dre	P=1.	-	6.96gm n.s.s.	1/89	2/41	0/46		
15 M m cb6 eat 52w69 1343 pool					0	1.07gm	2.13gm		
sto sqp e	1.89gm \	P<.0005		717.mg 7.92gm	0/82	5/32	(0/22)		
mln mno e	2.66gm \	P<.002		1.01gm 13.2gm	0/74	5/44	(0/39)		
--- mix e	3.01gm *	P<.0005	+	1.62gm 6.73gm	0/95	7/50	7/46		
--- mno e	3.05gm \	P<.002		1.16gm 14.1gm	0/95	5/50	(1/46)		
--- mlh e	6.24gm *	P<.002		2.70gm 23.9gm	0/95	2/50	5/46		
mln mlh e	9.52gm *	P<.02		3.29gm n.s.s.	0/79	1/44	3/39		
liv hpc e	57.5gm *	P<.7	-	6.31gm n.s.s.	2/91	0/50	2/46		
lun a/a e	no dre	P=1.	-	1.55gm n.s.s.	1/87	0/24	0/24		
16 R f f34 eat 52w69 1343					0	888.mg			
liv hpc e	230.mg	P<.0005	+	147.mg 382.mg	0/49	33/48			
liv nnd e	4.15gm	P<.04	+	1.26gm n.s.s.	0/49	3/48			
17 R m f34 eat 52w69 1343					0	710.mg			
liv hpc es	104.mg	P<.0005	+	65.2mg 171.mg	0/50	41/47			
liv nnd es	9.96gm	P<.3	+	1.62gm n.s.s.	0/50	1/47			
18 R m wis eat 52w65 2					0	800.mg			Weisburger;txap,14,163-175;1969
liv hpt ek	372.mg	P<.02	+	158.mg n.s.s.	0/7	7/16			
ACETAMINOPHEN (tylenol, paracetamol) 103-90-2									
19 M f b6c eat 24m24 TR394 :					0	76.8mg	384.mg	770.mg	
TBA MXB	no dre	P=1.	-	955.mg n.s.s.	35/50	28/50	24/50	34/50	
liv MXB	no dre	P=1.		2.21gm n.s.s.	3/50	4/50	7/50	3/50	liv:hpa,hpc,nnd.
lun MXB	11.0gm *	P<.6		1.83gm n.s.s.	1/50	4/50	4/50	4/50	lun:a/a,a/c.
20 M f b6c eat 31m31 1955					0	390.mg	780.mg		Amo;jjhg,40,567-574;1985
liv mix e	8.32gm *	P<.05	-	3.29gm n.s.s.	2/49	2/46	8/50		
lun mix e	no dre	P=1.	-	12.0gm n.s.s.	3/49	1/46	1/50		
tba tum e	42.7gm *	P<1.	-	1.12gm n.s.s.	32/49	33/46	33/50		
21 M m b6c eat 24m24 TR394 :					0	70.6mg	354.mg	710.mg	
TBA MXB	no dre	P=1.	-	717.mg n.s.s.	35/50	29/50	31/50	28/50	
liv MXB	no dre	P=1.		2.27gm n.s.s.	16/50	9/50	10/50	7/50	liv:hpa,hpc,nnd.
lun MXB	3.56gm *	P<.3		1.05gm n.s.s.	8/50	7/50	5/50	12/50	lun:a/a,a/c.
22 M m b6c eat 70w70 1779					0	600.mg	1.20gm		Hagiwara;faat,7,376-386;1986
liv hpc e	no dre	P=1.	-	867.mg n.s.s.	0/30	0/32	0/15		
liv hpa e	no dre	P=1.	-	1.64gm n.s.s.	3/30	2/32	1/15		
lun ald e	no dre	P=1.	-	2.58gm n.s.s.	2/30	1/32	0/15		
23 M m b6c eat 31m31 1955					0	360.mg	720.mg		Amo;jjhg,40,567-574;1985
liv mix e	no dre	P=1.	-	4.85gm n.s.s.	13/43	12/39	6/45		
lun mix e	no dre	P=1.	-	7.41gm n.s.s.	5/43	3/39	2/45		
tba tum e	no dre	P=1.	-	1.99gm n.s.s.	27/43	21/39	23/45		
24 M f ifm eat 78w78 1579					0	650.mg	1.30gm		Flaks;carc,4,363-368;1983
liv mix e	4.14gm /	P<.0005	+	1.95gm 12.4gm	0/51	0/58	9/50		
lun tum e	no dre	P=1.		2.77gm n.s.s.	0/51	0/58	0/50		
25 M m ifm eat 78w78 1579					0	600.mg	1.20gm		
liv mix e	1.01gm /	P<.0005	+	591.mg 1.97gm	1/52	1/57	20/27		
liv hpc e	4.90gm /	P<.003		1.86gm 28.7gm	0/52	0/57	5/27		
lun tum e	no dre	P=1.		1.93gm n.s.s.	0/52	0/57	0/27		
26 M f swi eat 32w52 1118					0	863.mg			Cohen;canr,38,1398-1405;1978
--- leu v	no dre	P=1.		805.mg n.s.s.	1/30	1/30			
liv tum v	no dre	P=1.		1.33gm n.s.s.	0/30	0/30			
lun tum v	no dre	P=1.		1.33gm n.s.s.	0/30	0/30			
27 R f f34 eat 24m24 TR394 :					0	29.4mg	147.mg	296.mg	
--- mnl	481.mg *	P<.02	e	220.mg n.s.s.	9/50	17/50	15/50	24/50	
TBA MXB	1.01gm *	P<.7		154.mg n.s.s.	47/50	46/50	49/50	46/50	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpc,nnd.
28 R m f34 eat 24m24 TR394 :					0	23.5mg	118.mg	237.mg	
zym car #	1.49gm *	P<.02	-	580.mg n.s.s.	0/50	0/50	4/50	2/50	S
TBA MXB	591.mg *	P<.6		106.mg n.s.s.	48/50	50/50	48/50	48/50	
liv MXB	no dre	P=1.		1.04gm n.s.s.	0/50	1/50	1/50	0/50	liv:hpa,hpc,nnd.
29 R f f3d eat 24m30 1712					0	260.mg	520.mg		Hiraga;gann,76,79-85;1985
--- mnl e	6.59gm *	P<.5	-	1.56gm n.s.s.	7/50	12/50	10/50		
liv tum e	no dre	P=1.		2.79gm n.s.s.	0/50	0/50	0/50		
nas tum e	no dre	P=1.	-	2.79gm n.s.s.	0/50	0/50	0/50		
tba mix e	no dre	P=1.	-	885.mg n.s.s.	40/50	42/50	35/50		
30 R m f3d eat 24m30 1712					0	144.mg	288.mg		
liv tum e	no dre	P=1.		1.55gm n.s.s.	0/50	0/50	0/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
nas tum e		no dre	P=1.	- 1.55gm n.s.s.	0/50	0/50	0/50		
tba mix e		no dre	P=1.	- 90.8mg n.s.s.	50/50	49/50	49/50		
31 R f lee eat 78w78 1753					0	250.mg	500.mg		Flaks;apms,93,367-377;1985/pers.comm.
liv nnd e		1.34gm /	P<.0005	+ 651.mg 3.83gm	0/40	0/49	10/50		
ubl mix e		1.73gm *	P<.08	+ 782.mg n.s.s.	0/40	5/49	3/50		
ubl pam e		2.33gm *	P<.2	+ 950.mg n.s.s.	0/40	4/49	2/50		
ubl car e		7.11gm *	P<.3	+ 1.75gm n.s.s.	0/40	1/49	1/50		
liv hpc e		no dre	P=1.	953.mg n.s.s.	0/40	0/49	0/50		
tba mix e		565.mg *	P<.0005	+ 341.mg 1.08gm	0/40	6/49	16/50		
32 R m lee eat 78w78 1753					0	200.mg	400.mg		
liv nnd e		1.05gm *	P<.002	+ 512.mg 3.35gm	0/40	1/48	9/49		
ubl mix e		1.19gm *	P<.007	+ 558.mg 14.3gm	0/40	3/48	6/49		
ubl pam e		1.34gm *	P<.02	+ 608.mg n.s.s.	0/40	3/48	5/49		
ubl car e		11.2gm *	P<.3	+ 1.82gm n.s.s.	0/40	0/48	1/49		
liv hpc e		no dre	P=1.	747.mg n.s.s.	0/40	0/48	0/49		
tba mix e		440.mg *	P<.0005	+ 265.mg 820.mg	0/40	5/48	17/49		
33 R m sda eat 27m27 1459					0	214.mg			Johansson;ijcn,27,521-529;1981
liv tum		no dre	P=1.	- 1.65gm n.s.s.	0/30	0/30			
ACETOHEXAMIDE 968-81-0									
34 M f b6c eat 24m25 TR50 :					0	568.mg	1.14gm		
TBA MXB sv		no dre	P=1.	- 939.mg n.s.s.	2/15	7/35	3/35		
liv MXB sv		no dre	P=1.	1.78gm n.s.s.	1/15	1/35	1/35		liv:hpa,hpc,nnd.
lun MXB sv		no dre	P=1.	n.s.s. n.s.s.	0/15	1/35	0/35		lun:a/a,a/c.
35 M m b6c eat 24m25 TR50 :					0	525.mg	1.05gm		
TBA MXB v		2.37gm \	P<.7	- 348.mg n.s.s.	6/15	14/35	(5/35)		
liv MXB v		no dre	P=1.	3.66gm n.s.s.	3/15	2/35	1/35		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	2.34gm n.s.s.	2/15	3/35	2/35		lun:a/a,a/c.
36 R f f34 eat 24m25 TR50 :					0	348.mg	694.mg		
TBA MXB		no dre	P=1.	- 751.mg n.s.s.	9/15	23/35	18/35		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
37 R m f34 eat 24m24 TR50 :					0	278.mg	561.mg		
--- leu #		527.mg \	P<.008	- 256.mg 7.11gm	0/15	10/35	(4/35)		S
TBA MXB		2.12gm *	P<.6	386.mg n.s.s.	7/15	19/35	21/35		
liv MXB		16.6gm *	P<.4	2.70gm n.s.s.	0/15	0/35	1/35		liv:hpa,hpc,nnd.
ACETONE[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZONE 18523-69-8									
38 R f hza eat 36w54 1063m					0	33.3mg			Morris;canr,29,2145-2156;1969
for sqp es		11.0mg	P<.05	3.23mg n.s.s.	0/5	3/7			
liv tum es		no dre	P=1.	13.0mg n.s.s.	0/5	0/7			
39 R f hza eat 44w60 1063n					0	36.8mg			
for sqp es		6.05mg	P<.0005	+ 3.10mg 13.3mg	0/16	15/20			
liv tum es		no dre	P=1.	50.5mg n.s.s.	0/16	0/20			
ACETONITRILE (methyl cyanide) 75-05-8									
40 M f b6c inh 24m24 TR447 :					0	25.9mg	51.7mg	104.mg	
TBA MXB		no dre	P=1.	- 103.mg n.s.s.	35/50	36/50	37/50	32/50	
liv MXB		no dre	P=1.	168.mg n.s.s.	9/50	13/50	13/50	10/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	105.mg n.s.s.	8/50	3/50	(2/50	1/50)	lun:a/a,a/c.
41 M m b6c inh 24m24 TR447 :					0	21.6mg	43.2mg	86.5mg	
TBA MXB		no dre	P=1.	- 109.mg n.s.s.	32/50	38/50	37/50	35/50	
liv MXB		90.4mg Z	P<.2	33.1mg n.s.s.	19/50	21/50	30/50	(15/50)	liv:hpa,hpb,hpc.
lun MXB		318.mg *	P<.3	91.8mg n.s.s.	10/50	14/50	14/50	21/50	lun:a/a,a/c.
42 R f f34 inh 24m24 TR447 :					0	12.3mg	24.7mg	49.4mg	
mgl MXA #		11.5mg Z	P<.03	- 4.97mg n.s.s.	17/48	30/48	(23/48	24/48)	mgl:car,fba. S
TBA MXB		no dre	P=1.	40.7mg n.s.s.	47/48	46/48	45/48	46/48	
liv MXB		no dre	P=1.	307.mg n.s.s.	0/48	1/48	0/48	0/48	liv:hpa,hpb,hpc.
43 R m f34 inh 24m24 TR447 :					0	8.65mg	17.3mg	34.6mg	
amd MXA		14.8mg Z	P<.008	7.33mg 275.mg	4/48	15/48	14/48	(8/48)	amd:pbb,phm,pob. S
amd MXA		16.9mg Z	P<.02	7.75mg n.s.s.	4/48	14/48	12/48	(7/48)	amd:pbb,pob. S
ski MXA		81.6mg *	P<.05	36.6mg n.s.s.	0/48	2/48	1/48	5/48	ski:bca,ker,tri. S
ski ker		127.mg *	P<.05	48.1mg n.s.s.	0/48	1/48	0/48	4/48	S
liv hpa		156.mg *	P<.09	e 56.8mg n.s.s.	0/48	1/48	1/48	3/48	
liv MXA		168.mg *	P<.2	e 53.1mg n.s.s.	1/48	1/48	1/48	5/48	liv:hpa,hpc.
liv hpc		398.mg *	P<.3	e 85.4mg n.s.s.	1/48	0/48	0/48	3/48	
TBA MXB		no dre	P=1.	24.8mg n.s.s.	45/48	45/48	48/48	47/48	
liv MXB		168.mg *	P<.2	53.1mg n.s.s.	1/48	1/48	1/48	5/48	liv:hpa,hpb,hpc.
ACETOXIME 127-06-0									
44 R f mrw wat 18m30 1480					0	24.6mg			Mirvish;jnci,69,961-962;1982
liv hpa e		127.mg	P<.03	- 38.2mg n.s.s.	0/20	3/16			
liv mix e		127.mg	P<.03	- 38.2mg n.s.s.	0/20	3/16			
liv hem e		408.mg	P<.2	- 66.3mg n.s.s.	0/20	1/16			
tba mix e		91.5mg	P<.7	11.3mg n.s.s.	15/20	13/16			
45 R m mrw wat 18m26 1480					0	25.4mg			
liv hpa e		12.1mg	P<.0005	+ 5.59mg 30.1mg	0/23	12/15			
liv mix e		12.1mg	P<.0005	- 5.59mg 30.1mg	0/23	12/15			
liv hem e		136.mg	P<.05	33.4mg n.s.s.	0/23	2/15			
tba mix e		12.8mg	P<.003	4.79mg 106.mg	9/23	13/15			
1'-ACETOXYSAFROLE 34627-78-6									
46 M m cd1 eat 56w69 1042b					0	29.3mg			Borchert;canr,33,590-600;1973
liv car s		no dre	P=1.	92.9mg n.s.s.	3/35	0/35			
lun tum s		no dre	P=1.	92.9mg n.s.s.	0/35	0/35			
tba mix s		no dre	P=1.	92.9mg n.s.s.	3/35	0/35			
47 M m cd1 eat 30w69 1042c					0	26.3mg			
liv car s		no dre	P=1.	83.3mg n.s.s.	3/35	0/35			
lun tum s		no dre	P=1.	83.3mg n.s.s.	0/35	0/35			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
tba mix s		no dre	P=1.	83.3mg n.s.s.	3/35	0/35			
48 R m cdr eat 47w69 1042b					0	112.mg			
for pam sv		30.7mg	P<.0005 +	14.2mg 81.2mg	0/18	10/15			
liv car sv		no dre	P=1. -	152.mg n.s.s.	0/18	0/15			
tba mix sv		32.4mg	P<.0005	14.5mg 107.mg	1/18	10/15			
49 R m cdr eat 36w52 1042c					0	116.mg			
for pam s		21.1mg	P<.0005 +	10.2mg 52.6mg	0/18	11/18			
liv hpc s		348.mg	P<.3 -	56.7mg n.s.s.	0/18	1/18			
tba mix s		21.1mg	P<.0005	10.2mg 52.6mg	0/18	11/18			
N'-ACETYL-4-(HYDROXYMETHYL)PHENYLHYDRAZINE 65734-38-5									
50 M f swa wat 27m27 410					0	125.mg			Toth;canr,38,177-180;1978
blv mix e		287.mg	P<.0005 +	143.mg 950.mg	8/96	16/44			
lun mix e		329.mg	P<.004 +	148.mg 3.05gm	15/96	17/44			
liv tum		no dre	P=1.	1.57gm n.s.s.	0/99	0/50			
51 M m swa wat 27m27 410					0	104.mg			
lun mix e		208.mg	P<.003 +	98.6mg 1.38gm	22/92	24/48			
blv mix e		252.mg	P<.0005 +	127.mg 762.mg	5/88	15/45			
liv hpt e		no dre	P=1. -	997.mg n.s.s.	2/62	0/38			
1-ACETYL-2-ISONICOTINOYLHYDRAZINE 1078-38-2									
52 M f swa wat 94w94 1055					0	800.mg			Toth;ejca,9,285-289;1973
lun mix e		319.mg	P<.0005 +	196.mg 567.mg	14/104	37/47			
liv mix e		55.7gm	P<.9	2.66gm n.s.s.	3/73	2/41			
53 M m swa wat 92w92 1055					0	667.mg			
lun mix e		342.mg	P<.0005 +	202.mg 664.mg	11/91	29/42			
liv hem e		no dre	P=1. -	968.mg n.s.s.	2/40	0/9			
3-ACETYL-6-METHYL-2,4-PYRANDIONE (dehydroacetic acid) 520-45-6									
54 M f b6a orl 76w76 1294					0	33.9mg			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1. -	67.2mg n.s.s.	0/17	0/18			
lun ade evx		no dre	P=1. -	67.2mg n.s.s.	1/17	0/18			
tba mix evx		no dre	P=1. -	32.0mg n.s.s.	2/17	2/18			
55 M m b6a orl 76w76 1294					0	31.6mg			
lun ade evx		no dre	P=1. -	38.9mg n.s.s.	2/18	1/17			
liv hpt evx		no dre	P=1. -	59.1mg n.s.s.	1/18	0/17			
tba mix evx		no dre	P=1. -	41.6mg n.s.s.	3/18	1/17			
56 M f b6c orl 76w76 1294					0	33.9mg			
liv hpt evx		no dre	P=1. -	67.2mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1. -	67.2mg n.s.s.	0/16	0/18			
tba tum evx		no dre	P=1. -	67.2mg n.s.s.	0/16	0/18			
57 M m b6c orl 76w76 1294					0	31.6mg			
liv hpt evx		no dre	P=1. -	62.6mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1. -	62.6mg n.s.s.	0/16	0/18			
tba mix evx		202.mg	P<.3 -	32.9mg n.s.s.	0/16	1/18			
1-ACETYL-2-PHENYLHYDRAZINE 114-83-0									
58 M f swa wat 26m26 1054					0	30.0mg			Toth;bjca,39,584-587;1979
liv mix e		44.8mg	P<.0005 +	23.8mg 106.mg	4/94	16/37			
blv mix e		49.0mg	P<.0005 +	24.9mg 140.mg	8/94	16/37			
liv agm e		105.mg	P<.0005	45.1mg 463.mg	2/94	8/37			
liv ang e		105.mg	P<.0005	45.1mg 463.mg	2/94	8/37			
blv ang e		117.mg	P<.005	46.9mg 1.19gm	4/94	8/37			
blv agm e		117.mg	P<.005	46.9mg 1.19gm	4/94	8/37			
lun ade e		413.mg	P<.5 -	65.8mg n.s.s.	10/89	5/31			
lun mix e		no dre	P=1.	78.8mg n.s.s.	15/89	5/31			
59 M m swa wat 25m25 1054					0	25.0mg			
blv mix e		59.8mg	P<.0005 +	27.8mg 245.mg	5/87	12/40			
liv mix e		62.1mg	P<.0005 +	29.1mg 217.mg	3/87	11/40			
blv agm e		113.mg	P<.01	42.9mg 9.84gm	3/87	7/40			
liv agm e		128.mg	P<.01	47.1mg 9.32gm	2/87	6/40			
liv ang e		146.mg	P<.008	52.1mg 3.67gm	1/87	5/40			
blv ang e		161.mg	P<.03	53.7mg n.s.s.	2/87	5/40			
lun adc e		no dre	P=1. -	158.mg n.s.s.	6/87	1/40			
lun ade e		no dre	P=1. -	97.2mg n.s.s.	17/87	5/40			
lun mix e		no dre	P=1.	112.mg n.s.s.	22/87	5/40			
4-ACETYLAMINOBIPHENYL (4'-phenylacetanilide) 4075-79-0									
60 R f nss eat 43w65 1424					0	11.3mg			Miller;jnci,15,1571-1590;1955
mgl adc		1.18mg	P<.0005 +	.444mg 3.21mg	0/15	12/13			
liv tum		no dre	P=1.	11.9mg n.s.s.	0/15	0/13			
1-ACETYLAMINOFLUORENE (N-1-fluorenylacetamide) 28314-03-6									
61 R f buf eat 47w88 144					0	6.77mg			Morris;jnci,24,149-180;1960
pit ade e		43.5mg	P<.6	6.02mg n.s.s.	2/18	3/17			
adr car e		54.8mg	P<.3	8.92mg n.s.s.	0/18	1/17			
ova gcc e		54.8mg	P<.3	8.92mg n.s.s.	0/18	1/17			
--- ile e		54.8mg	P<.3	8.92mg n.s.s.	0/18	1/17			
ute cas e		54.8mg	P<.3	8.92mg n.s.s.	0/18	1/17			
2-ACETYLAMINOFLUORENE (N-2-fluorenylacetamide, 2-AAF) 53-96-3									
62 H m nss eat 32w56 308m					0	15.9mg			Miller;canr,24,2018-2026;1964
liv bdc		17.4mg	P<.04 +	5.24mg n.s.s.	0/17	3/18			
63 H m nss ipj 34w69 308n					0	3.21mg			
smi adc		7.26mg	P<.3	1.18mg n.s.s.	0/8	1/8			
per sar		no dre	P=1.	2.33mg n.s.s.	0/8	0/8			
for pam		no dre	P=1.	1.34mg n.s.s.	1/8	1/8			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
	Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
64	H f syg eat 26w68 347n				0	16.0mg					Della Porta;jnci,22,463-471;1959
liv	cac e	17.3mg	P<.03	4.02mg n.s.s.	1/59	2/8					
65	H m syg eat 40w84 347m				0	17.5mg					
liv	cac e	15.3mg	P<.003	3.65mg 211.mg	0/39	2/5					
66	H m syg eat 26w80 347n				0	12.0mg					
liv	cac e	31.5mg	P<.2	5.10mg n.s.s.	0/16	1/7					
67	M f asw eat 84w84 213b				0	39.0mg					Prier;txap,5,526-542;1963
tba	mix e	no dre	P=1.	8.63mg n.s.s.	14/16	15/18					
tba	mal e	51.1mg	P<.3 +	13.2mg n.s.s.	6/16	10/18					
68	M m asw eat 84w84 213b				0	36.0mg					
tba	mal e	17.4mg	P<.006 +	7.28mg 200.mg	1/10	9/14					
tba	mix e	21.7mg	P<.2	6.89mg n.s.s.	4/10	10/14					
69	M f ays eat 30m30 2034n :				0	6.50mg	13.0mg	26.0mg			Wolff;jtxe,33,327-348;1991/pers.comm.
liv	mix er	2.27mg Z	P<.0005 +	.869mg 4.73mg	4/24	11/23	17/24	23/23			
liv	hpc er	3.31mg Z	P<.0005 +	1.02mg 8.56mg	3/24	7/23	10/24	19/23			
ubl	mix er	43.0mg Z	P<.0005 +	15.5mg 118.mg	0/24	0/23	0/24	9/23			
ubl	tcc er	54.1mg Z	P<.0005 +	16.7mg 193.mg	0/24	0/23	0/24	7/23			
70	M m ays eat 30m30 2034m :				0	6.00mg	12.0mg	24.0mg			
ubl	mix er	2.45mg Z	P<.0005 +	1.43mg 4.15mg	0/24	15/24	22/24	24/24			
ubl	tcc er	4.32mg Z	P<.0005 +	2.47mg 7.13mg	0/24	9/24	18/24	21/24			
liv	mix er	4.61mg Z	P<.0005 +	2.16mg 17.1mg	6/24	14/24	10/24	5/24			
71	M f b6c eat 82w82 2020m				0	19.5mg	26.0mg	32.5mg			Fullerton;faat,16,51-60;1991/Nonoyama 1988/pers.comm.
liv	mix er	4.00mg *	P<.0005 +	2.97mg 5.45mg	43/117	67/70	89/92	91/95			
liv	mal er	5.38mg *	P<.0005	4.31mg 6.80mg	14/117	60/70	81/92	87/95			
ubl	mix er	38.3mg Z	P<.0005 +	28.0mg 54.3mg	0/108	6/67	18/85	38/93			
ubl	mal er	64.9mg Z	P<.0005	44.0mg 101.mg	0/108	3/67	10/85	26/93			
liv	hpb er	526.mg *	P<.06	215.mg n.s.s.	0/96	2/96	1/96	3/96			
72	M f b6c eat 82w82 2020n				0	19.5mg	26.0mg	32.5mg			
liv	mix er	8.80mg *	P<.0005 +	7.12mg 11.1mg	9/118	46/71	69/96	78/95			
liv	mal er	15.9mg *	P<.0005	12.6mg 20.5mg	3/118	21/71	48/96	65/95			
ubl	mix er	71.8mg Z	P<.0005 +	48.3mg 113.mg	0/117	0/69	5/95	32/93			
ubl	mal er	201.mg Z	P<.0005	108.mg 464.mg	0/117	0/69	1/95	13/93			
73	M f b6c eat 30m30 2034r :				0	6.50mg	13.0mg	26.0mg			Wolff;jtxe,33,327-348;1991/pers.comm.
liv	mix er	3.99mg *	P<.0005 +	2.89mg 5.76mg	4/48	31/47	45/47	44/48			
liv	hpc er	9.49mg Z	P<.0005 +	6.56mg 14.2mg	1/48	12/47	28/47	33/48			
ubl	mix er	47.7mg Z	P<.0005 +	26.0mg 86.6mg	0/48	0/47	0/47	20/48			
ubl	tcc er	89.2mg Z	P<.0005 +	45.5mg 198.mg	0/48	0/47	0/47	13/48			
74	M m b6c eat 82w82 2020m				0	4.80mg	7.20mg	9.60mg			Fullerton;faat,16,51-60;1991/Nonoyama 1988/pers.comm.
liv	mix er	2.35mg *	P<.0005 +	1.85mg 3.11mg	21/95	53/94	79/94	83/94			
liv	mal er	5.46mg *	P<.0005	4.11mg 7.92mg	12/95	28/94	49/94	59/94			
ubl	mix er	7.90mg Z	P<.0005 +	6.02mg 10.6mg	0/93	0/91	31/92	53/89			
ubl	mal er	21.2mg Z	P<.0005	14.2mg 33.6mg	0/93	0/91	10/92	26/89			
liv	hpb er	57.3mg *	P<.004	31.4mg 276.mg	0/96	4/96	5/96	6/96			
75	M m b6c eat 82w82 2020n				0	4.80mg	7.20mg	9.60mg			
ubl	mix er	7.29mg Z	P<.0005 +	5.23mg 10.6mg	0/94	1/96	54/96	(17/94)			
liv	mal er	40.8mg *	P<.01	21.0mg 2.69gm	4/96	7/96	8/96	15/94			
ubl	mal er	107.mg *	P<.005	48.7mg 772.mg	0/94	0/96	2/96	6/94			
liv	mix er	32.9mg *	P<.04 +	15.2mg n.s.s.	13/96	14/96	15/96	26/94			
76	M m b6c eat 30m30 2034o :				0	6.00mg	12.0mg	24.0mg			Wolff;jtxe,33,327-348;1991/pers.comm.
liv	mix er	4.34mg Z	P<.0005 +	2.78mg 7.41mg	13/47	29/48	24/48	17/48			
ubl	mix er	5.02mg Z	P<.0005 +	3.48mg 7.16mg	0/47	11/48	45/48	46/48			
ubl	tcc er	7.52mg Z	P<.0005 +	5.00mg 11.0mg	0/47	6/48	33/48	40/48			
liv	hpc er	14.4mg Z	P<.0005 +	7.90mg 31.8mg	6/47	9/48	14/48	9/48			
77	M f bal eat 52w52 1665				0	1.04mg	3.12mg	5.85mg	7.67mg	11.2mg	Haley;pseb,152,156-159;1976
liv	tum ek	no dre	P=1.	.969mg n.s.s.	0/24	0/48	0/48	0/24	0/16	0/8	
ubl	car ek	no dre	P=1. -	.969mg n.s.s.	0/24	0/48	0/48	0/24	0/16	0/8	
78	M m bal eat 52w52 1665				0	.960mg	2.88mg	5.40mg	7.08mg	10.3mg	
ubl	car ek	9.09mg Z	P<.0005 +	4.11mg 26.7mg	0/23	0/41	0/44	1/22	3/13	4/8	
79	M f bcn eat 65w78 1344a				0	6.50mg	8.13mg	10.8mg	16.3mg		Littlefield;jept,3,17-34;1980/pers.comm.
ubl	tcc ekr	66.5mg Z	P<.0005 +	40.3mg 123.mg	1/400	1/196	0/130	0/64	22/65		
liv	hpc ekr	120.mg *	P<.0005 +	61.6mg 389.mg	1/401	4/196	5/130	1/64	4/65		
80	M f bcn eat 15m24 1344b				0	4.88mg	6.09mg	8.13mg	12.2mg		
liv	hpc ekr	30.6mg *	P<.0005 +	19.7mg 55.2mg	9/383	15/114	14/86	6/35	6/28		
ubl	tcc ekr	95.5mg Z	P<.0005 +	48.6mg 234.mg	1/384	0/114	0/86	1/35	11/28		
81	M f bcn eat 52w52 1344m				0	7.80mg	9.75mg	13.0mg	19.5mg		
ubl	tcc ekr	150.mg Z	P<.0005 +	70.7mg 457.mg	0/140	0/268	0/137	0/138	9/141		
liv	hpc ekr	226.mg *	P<.2 +	92.4mg n.s.s.	0/140	2/268	0/137	3/138	1/141		
82	M f bcn eat 60w60 1344n				0	7.80mg	9.75mg	13.0mg	19.5mg		
ubl	tcc ekr	68.8mg Z	P<.0005 +	41.1mg 128.mg	0/113	0/221	0/110	0/117	21/114		
liv	hpc ekr	747.mg *	P<.2 +	184.mg n.s.s.	0/113	0/224	0/110	1/117	1/114		
83	M f bcn eat 65w65 1344o				0	7.80mg	9.75mg	13.0mg	19.5mg		
ubl	tcc ekr	45.8mg Z	P<.0005 +	29.4mg 77.0mg	0/88	0/181	1/94	0/89	28/90		
liv	hpc ekr	199.mg *	P<.07 +	86.2mg n.s.s.	0/88	1/182	1/94	4/90	1/90		
84	M f bcn eat 69w69 1344r				0	5.85mg	7.80mg	9.75mg	13.0mg	19.5mg	
ubl	tcc ekr	62.1mg Z	P<.0005 +	42.0mg 97.3mg	0/183	1/271	0/265	0/175	1/90	36/85	
liv	hpc ekr	218.mg *	P<.05 +	97.9mg n.s.s.	1/183	2/272	4/265	5/174	1/90	3/86	
85	M f bcn eat 73w73 1344s				0	4.55mg	5.85mg	7.80mg	9.75mg	13.0mg	19.5mg
ubl	tcc ekr	64.1mg Z	P<.0005 +	44.1mg 98.2mg	0/127	1/389	1/264	0/206	0/134	4/67	36/65
liv	hpc ekr	147.mg *	P<.05 +	86.0mg n.s.s.	0/128	2/389	5/264	6/206	5/134	1/67	0/65
86	M f bcn eat 78w78 1344t				0	3.90mg	4.55mg	5.85mg	7.80mg	9.75mg	13.0mg 19.5mg
ubl	tcc ekr	101.mg Z	P<.0005 +	76.4mg 139.mg	1/400	4/999	1/796	1/383	3/269	1/267	5/131 62/121
liv	hpc ekr	154.mg *	P<.0005 +	105.mg 310.mg	1/401	17/999	7/792	7/383	7/268	6/267	6/131 7/121
87	M f bcn eat 24m24 1344u				0	3.90mg	4.55mg	5.85mg	7.80mg	9.75mg	13.0mg 19.5mg
liv	hpc ekr	33.6mg Z	P<.0005 +	28.9mg 40.1mg	9/383	55/900	55/639	57/445	71/415	62/311	47/160 56/130
ubl	tcc ekr	96.0mg Z	P<.0005 +	77.4mg 121.mg	1/384	0/900	2/638	1/445	3/415	3/311	25/160 100/130

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
	Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
88	M f bcn eat 33m33 1344v				0	3.90mg	4.55mg	5.85mg	7.80mg	9.75mg	13.0mg
liv	hpc ekr	19.6mg	* P<.008 +	10.1mg 409.mg	8/23	44/92	20/45	5/12	7/11	8/12	8/10
ubl	tcc ekr	82.1mg	Z P<.0005 +	44.2mg 179.mg	0/24	1/92	0/45	0/12	1/11	4/12	8/10
89	M f bcn eat 39w78 1344w				0	3.90mg	4.88mg	6.50mg	9.75mg		
liv	hpc ekr	110.mg	* P<.002 +	49.1mg 585.mg	1/401	1/186	3/128	1/64	4/63		
ubl	tcc ekr	142.mg	* P<.004 +	57.7mg 1.16gm	1/400	0/184	2/128	1/64	4/63		
90	M f bcn eat 9m24 1344x				0	2.93mg	3.66mg	4.88mg	7.31mg		
liv	hpc ekr	19.1mg	* P<.0005 +	12.1mg 35.2mg	9/383	13/108	10/66	5/35	9/33		
ubl	tcc ekr	97.2mg	Z P<.0005 +	40.8mg 388.mg	1/384	1/108	0/66	0/35	6/33		
91	M f bcn eat 52w78 1344y				0	5.20mg	6.50mg	8.67mg	13.0mg		
ubl	tcc ekr	82.8mg	Z P<.0005 +	44.8mg 185.mg	1/400	0/190	0/132	1/65	14/63		
liv	hpc ekr	156.mg	Z P<.009 +	67.6mg 4.45gm	1/401	1/190	6/132	0/65	2/63		
92	M f bcn eat 12m24 1344z				0	3.90mg	4.88mg	6.50mg	9.75mg		
liv	hpc ekr	24.3mg	* P<.0005 +	15.6mg 43.4mg	9/383	11/118	14/74	5/33	9/29		
ubl	tcc ekr	101.mg	Z P<.0005 +	46.6mg 306.mg	1/384	0/118	1/74	1/33	7/29		
93	M f bcn eat 23m24 2066m				0	13.0mg	16.2mg	19.5mg		Fullerton;faat,18,193-199;1992/Nonoyama 1988/ pers.comm.	
liv	mix aers	11.6mg	Z P<.0005 +	7.97mg 18.3mg	5/92	51/91	(39/93	26/82)			
ubl	mix aers	12.8mg	Z P<.0005 +	10.3mg 16.1mg	1/87	29/90	58/90	63/82			
ubl	car aers	21.9mg	Z P<.0005	17.1mg 28.7mg	0/87	14/90	40/90	48/82			
liv	mal aers	30.0mg	Z P<.0005	21.2mg 46.3mg	1/92	31/91	23/93	(13/82)			
liv	hpb aers	3.20gm	* P<.5	521.mg n.s.s.	0/96	0/96	1/96	0/96			
94	M f bcn eat 23m24 2066n				0	13.0mg	16.2mg	19.5mg			
ubl	mix aer	10.4mg	Z P<.0005 +	8.47mg 12.8mg	1/92	29/91	74/95	76/91			
ubl	car aer	21.7mg	Z P<.0005	17.0mg 28.6mg	1/92	16/91	46/95	49/91			
liv	mix aer	29.8mg	* P<.0005 +	22.7mg 41.8mg	1/93	28/94	35/96	27/92			
liv	mal aer	58.3mg	* P<.0005	41.2mg 88.9mg	0/93	16/94	19/96	14/92			
95	M m bcn eat 22m24 2066m				0	2.40mg	4.80mg	7.20mg			
ubl	mix aers	3.87mg	Z P<.0005 +	3.09mg 4.93mg	0/88	4/86	50/86	82/90			
ubl	car aers	9.41mg	Z P<.0005	7.03mg 13.0mg	0/88	1/86	13/86	59/90			
liv	mix aers	3.26gm	* P<1.	27.1mg n.s.s.	19/92	18/90	15/88	19/87			
liv	mal aers	no dre	P=1.	64.3mg n.s.s.	9/92	5/90	7/88	5/87			
liv	hpb aers	no dre	P=1.	25.9mg n.s.s.	1/96	0/96	0/96	0/96			
96	M m bcn eat 22m24 2066n				0	2.40mg	4.80mg	7.20mg			
ubl	mix aer	9.05mg	Z P<.0005 +	6.85mg 12.3mg	0/90	0/91	23/91	57/95			
ubl	car aer	26.4mg	Z P<.0005	17.3mg 43.2mg	0/90	0/91	9/91	23/95			
liv	mix aer	69.0mg	Z P<.2	22.2mg n.s.s.	5/93	4/94	10/94	(1/95)			
liv	mal aer	no dre	P=1.	164.mg n.s.s.	3/93	1/94	2/94	0/95			
97	M f cd1 eat 78w78 66a				0	32.5mg				Epstein(review) {irdc};stev,6,103-154;1976	
liv	hpt e	21.3mg	P<.0005	13.5mg 37.3mg	1/57	30/66					
liv	nod e	76.2mg	P<.0005	37.1mg 218.mg	0/57	10/66					
lun	ade e	354.mg	P<.6	56.0mg n.s.s.	6/57	9/66					
98	M f cd1 eat 53w92 1635m				0	22.5mg				Weikel;jcph,19,591-604;1979/pers.comm.	
liv	hpc e	7.65mg	P<.0005 +	5.10mg 11.9mg	0/60	46/58					
99	M m cd1 eat 78w78 66a				0	30.0mg				Epstein(review) {irdc};stev,6,103-154;1976	
liv	hpt e	22.5mg	P<.0005	12.7mg 56.5mg	4/47	24/53					
lun	ade e	no dre	P=1.	155.mg n.s.s.	8/47	1/53					
100	M m cd1 eat 53w92 1635m				0	20.7mg				Weikel;jcph,19,591-604;1979/pers.comm.	
liv	hpc e	13.5mg	P<.0005 +	8.67mg 22.7mg	1/57	33/58					
ubl	pam e	34.5mg	P<.0005 +	19.2mg 71.1mg	0/57	16/58					
ubl	tcc e	34.5mg	P<.0005	19.2mg 71.1mg	0/57	16/58					
kid	mix e	86.5mg	P<.003	37.3mg 375.mg	0/57	7/58					
liv	hpa e	639.mg	P<.8 +	53.1mg n.s.s.	6/57	7/58					
101	M m cen eat 52w52 1477				0	36.0mg					Becker;canr,42,3918-3923;1982
liv	mix kr	5.61mg	P<.3	1.13mg n.s.s.	5/8	7/8					
102	M f cf1 eat 52w52 469				0	39.0mg					Newberne;txap,41,535-546;1977
mgl	car e	14.6mg	P<.0005	7.28mg 36.3mg	0/29	11/30					
liv	lcc e	16.5mg	P<.0005 +	7.98mg 43.7mg	0/29	10/30					
lun	tum e	no dre	P=1.	60.3mg n.s.s.	0/29	0/30					
103	M m cf1 eat 52w52 469				0	36.0mg					
liv	lcc e	31.4mg	P<.006 +	11.9mg 290.mg	0/31	5/28					
lun	ade e	149.mg	P<.5	22.3mg n.s.s.	1/31	2/28					
104	M f cva eat 30m30 2034u :				0	6.50mg	13.0mg	26.0mg		Wolff;jtxe,33,327-348;1991/pers.comm.	
liv	mix er	4.36mg	Z P<.0005 +	2.73mg 7.59mg	4/24	14/24	22/24	23/24			
liv	hpc er	10.3mg	* P<.0005 +	5.71mg 23.4mg	2/24	7/24	14/24	9/24			
ubl	mix er	54.8mg	Z P<.0005 +	26.5mg 125.mg	0/24	0/24	0/24	12/24			
ubl	tcc er	63.5mg	Z P<.0005 +	28.8mg 161.mg	0/24	0/24	0/24	10/24			
105	M m cva eat 30m30 2034s :				0	6.00mg	12.0mg	24.0mg			
ubl	mix er	3.59mg	Z P<.0005 +	2.13mg 5.95mg	0/24	9/24	22/24	24/24			
ubl	tcc er	5.20mg	Z P<.0005 +	2.95mg 8.96mg	0/24	5/24	17/24	21/24			
liv	mix er	7.43mg	Z P<.0005 +	3.53mg 22.2mg	8/24	6/24	10/24	9/24			
106	M f cvy eat 30m30 2034w :				0	6.50mg	13.0mg	26.0mg			
liv	mix er	2.02mg	Z P<.0005 +	1.12mg 4.04mg	16/24	23/24	23/24	24/24			
liv	hpc er	7.94mg	Z P<.0005 +	4.06mg 14.7mg	0/24	6/24	10/24	11/24			
ubl	mix er	69.0mg	Z P<.0005 +	31.1mg 188.mg	0/24	0/24	1/24	8/24			
ubl	tcc er	69.0mg	Z P<.0005 +	31.1mg 188.mg	0/24	0/24	1/24	8/24			
107	M m cvy eat 30m30 2034v :				0	6.00mg	12.0mg	24.0mg			
ubl	mix er	1.56mg	Z P<.0005 +	.643mg 3.35mg	0/24	8/24	15/21	18/23			
liv	mix er	4.23mg	* P<.0005 +	1.76mg 15.9mg	14/24	11/24	11/21	7/23			
ubl	tcc er	4.30mg	Z P<.0005 +	1.81mg 8.38mg	0/24	3/24	12/21	15/23			
108	M f ifc eat 64w64 1447				0	65.0mg					Wood;ejca,6,433-440;1970
liv	mix	4.78mg	P<.0005 +	2.16mg 9.44mg	0/17	33/34					
liv	hpt	5.95mg	P<.0005	3.13mg 11.1mg	0/17	32/34					
ubl	car	565.mg	P<.4 +	92.0mg n.s.s.	0/17	1/34					
ubl	pam	565.mg	P<.4 +	92.0mg n.s.s.	0/17	1/34					
109	M m ifc eat 64w64 1447				0	60.0mg					
liv	mix	36.1mg	P<.005 +	15.5mg 260.mg	0/13	7/20					
ubl	car	36.1mg	P<.005 +	15.5mg 260.mg	0/13	7/20					

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpt		43.7mg	P<.01	17.7mg 1.94gm	0/13	6/20			
ubl pam		69.8mg	P<.04 +	24.0mg n.s.s.	0/13	4/20			
110 M f ifm eat 60w60 1069m					0	65.0mg			Wood;ejca,5,41-47;1969
liv mix		19.6mg	P<.0005 +	10.9mg 39.8mg	0/31	17/32			
liv hpt		31.5mg	P<.0005	16.1mg 74.4mg	0/31	12/32			
ubl mix		44.9mg	P<.0005 +	21.1mg 131.mg	0/31	9/32			
111 M f ifm gav 60w60 1069n					0	22.9mg			
liv ade		91.2mg	P<.2	14.8mg n.s.s.	0/31	1/18			
112 M m ifm eat 60w60 1069m					0	60.0mg			
liv mix		42.9mg	P<.002 +	19.3mg 183.mg	1/42	9/31			
liv hpt		77.8mg	P<.004	29.5mg 475.mg	0/42	5/31			
113 M m ifm gav 60w60 1069n					0	19.0mg			
ubl mix		12.9mg	P<.0005 +	5.23mg 46.5mg	0/42	6/21			
liv mix		57.2mg	P<.3	11.2mg n.s.s.	1/42	2/21			
114 M f r3m eat 60w60 1069m					0	65.0mg			
ubl mix		104.mg	P<.07 +	35.7mg n.s.s.	0/15	4/30			
liv mix		no dre	P=1.	134.mg n.s.s.	0/15	0/30			
115 M m r3m eat 60w60 1069m					0	60.0mg			
ubl mix		51.0mg	P<.04 +	23.0mg n.s.s.	0/10	8/34			
ubl car		86.0mg	P<.1	32.6mg n.s.s.	0/10	5/34			
liv mix		no dre	P=1. +	54.4mg n.s.s.	1/10	3/34			
116 P b rhe eat 5y26 2004 :					0	6.77mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
npl adc jw		33.0mg	P<.1	5.37mg n.s.s.	0/16	1/5			
tba mal Wjw		no dre	P=1.	9.02mg n.s.s.	6/74	1/10			
117 R f cdr eat 15m24 1112					0	3.00mg	12.5mg		Weisburger;jnci,67,75-88;1981
mgl mix ae		4.75mg *	P<.0005 +	2.48mg 10.4mg	0/32	8/16	7/10		
liv hpc ae		26.9mg *	P<.02 +	9.24mg n.s.s.	0/32	2/16	2/10		
118 R m cdr eat 15m24 1112					0	2.40mg	10.0mg		
liv hpc ae		3.78mg *	P<.0005 +	1.78mg 9.52mg	1/32	3/16	10/10		
119 R m f3d eat 24m24 1756					0	.320mg	1.60mg	8.00mg	Ogiso;txpy,13,257-265;1985
liv hpc e		.640mg *	P<.0005 +	.385mg 1.11mg	0/30	3/29	26/28	23/23	
liv thc e		.697mg *	P<.0005	.421mg 1.21mg	0/30	3/29	25/28	23/23	
liv ghc e		no dre	P=1.	28.2mg n.s.s.	0/30	0/29	1/28	0/23	
liv clc e		no dre	P=1.	1.52mg n.s.s.	0/30	0/29	0/28	0/23	
120 R f hza eat 36w54 1063m					0	10.0mg			Morris;canr,29,2145-2156;1969
mam tum es		.841mg	P<.0005 +	.286mg 2.98mg	0/5	8/9			
eac car es		13.8mg	P<.4	2.24mg n.s.s.	0/5	1/8			
liv tum es		no dre	P=1.	5.00mg n.s.s.	0/5	0/9			
121 R f hza eat 44w60 1063n					0	11.0mg			
mam tum es		.981mg	P<.0005 +	.367mg 2.96mg	3/16	15/16			
eac car es		8.75mg	P<.02	3.00mg n.s.s.	0/16	4/16			
liv tum es		no dre	P=1.	12.1mg n.s.s.	0/16	0/16			
122 R f lev eat 56w56 1635m					0	15.0mg			Weikel;jcph,19,591-604;1979/pers.comm.
liv mix		1.53mg	P<.0005 +	1.05mg 2.28mg	0/60	60/70			
ski mix		12.3mg	P<.0005 +	6.60mg 33.3mg	1/60	16/70			
mgl mix		no dre	P=1. +	16.4mg n.s.s.	16/60	14/70			
123 R m lev eat 56w56 1635m					0	12.0mg			
liv mix s		1.17mg	P<.0005 +	.796mg 1.76mg	1/60	61/70			
ski mix s		20.1mg	P<.09 +	7.46mg n.s.s.	5/60	13/70			
mgl tum s		54.4mg	P<.06 +	16.5mg n.s.s.	0/60	3/70			
2,7-ACETYLAMINOFLUORENE 304-28-9									
124 P b cym eat 5y29 2003 :					0	5.72mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
lun a/c w		25.6mg	P<.4	4.17mg n.s.s.	0/2	1/4			
bre car w		307.mg	P<1.	5.76mg n.s.s.	1/15	1/6			
tba mal w		no dre	P=1.	7.84mg n.s.s.	3/15	1/6			
125 P b rhe eat 5y32 2003 :					0	10.5mg			
tba mal w		no dre	P=1.	8.81mg n.s.s.	7/74	0/6			
4-ACETYLAMINOFLUORENE (N-4-fluorenylacetamide) 28322-02-3									
126 R f buf eat 62w97 144					0	7.98mg			Morris;jnci,24,149-180;1960
--- ile e		59.4mg	P<.2	9.67mg n.s.s.	0/18	1/13			
mgl adf e		59.4mg	P<.2	9.67mg n.s.s.	0/18	1/13			
ute sar e		59.4mg	P<.2	9.67mg n.s.s.	0/18	1/13			
4-ACETYLAMINOPHENYLACETIC ACID 18699-02-0									
127 M f b6c eat 78w78 2381					0	3.00gm			Trutter;phrm,40,325-335;1990
liv hpa e		no dre	P=1. -	8.53gm n.s.s.	2/50	2/50			
liv hpc e		no dre	P=1. -	10.6gm n.s.s.	1/50	1/50			
lun mix e		no dre	P=1. -	10.6gm n.s.s.	1/50	1/50			
128 M m b6c eat 78w78 2381					0	3.00gm			
lun a/a e		27.7gm	P<.3 -	6.12gm n.s.s.	1/50	3/50			
lun a/c e		56.1gm	P<.6 -	7.66gm n.s.s.	1/50	2/50			
liv hpa e		no dre	P=1. -	6.75gm n.s.s.	9/50	6/50			
129 R f f34 eat 24m24 2385					0	3.00gm			Trutter;phrm,40,337-349;1990
liv mix e		no dre	P=1. -	18.8gm n.s.s.	1/50	1/50			
130 R m f34 eat 24m24 2385					0	3.00gm			
liv hpc e		no dre	P=1. -	18.8gm n.s.s.	1/50	1/50			
liv hpa e		no dre	P=1. -	22.2gm n.s.s.	3/50	1/50			
N-ACETYLCYSTEINE 616-91-1									
131 R m f34 eat 98w98 2405					0	522.mg			Chung;canr,56,772-778;1996
liv mix e		no dre	P=1. -	1.15gm n.s.s.	0/12	0/12			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ACIFLUORFEN 50594-66-6									
132 M f b6c eat 78w78 2129m					0	81.4mg	162.mg	325.mg	Quest;rtxp,10,149-159;1989
liv mix e	328.mg	* P<.0005	+	212.mg 599.mg	1/55	6/59	5/57	24/58	
liv hpa e	434.mg	* P<.0005	+	265.mg 926.mg	1/55	5/59	4/57	19/58	
sto pam e	1.05gm	* P<.002	+	493.mg 3.74gm	0/45	0/48	3/44	6/45	
liv hpc e	1.38gm	* P<.007	+	594.mg 17.3gm	0/45	1/47	1/44	5/46	
133 M m b6c eat 78w78 2129m					0	75.1mg	150.mg	300.mg	
liv mix es	149.mg	* P<.0005	+	97.9mg 283.mg	9/58	21/60	16/56	40/59	
liv hpa es	331.mg	* P<.003	+	174.mg 1.91gm	8/58	18/60	12/56	25/59	
liv hpc es	395.mg	* P<.0005	+	229.mg 917.mg	1/48	3/50	4/45	15/44	
sto pam es	2.05gm	* P<.008	+	709.mg 39.7gm	0/49	0/46	0/43	4/40	
134 M f cd1 eat 24m24 2129n					0	.975mg	5.85mg	29.6mg	
liv mix ev	126.mg	* P<.003	+	57.4mg 892.mg	7/80	5/69	4/80	15/66	
liv hpa ev	160.mg	* P<.005	+	69.1mg 1.93gm	5/80	2/69	4/80	11/66	
liv hpc ev	715.mg	* P<.3		157.mg n.s.s.	2/80	3/69	0/80	4/66	
135 M m cd1 eat 24m24 2129n					0	.900mg	5.40mg	27.3mg	
liv mix ev	93.8mg	* P<.06	+	35.4mg n.s.s.	19/79	18/69	28/80	27/70	
liv hpa ev	187.mg	* P<.2		61.3mg n.s.s.	9/79	3/69	14/80	12/70	
liv hpc ev	307.mg	* P<.4		66.6mg n.s.s.	10/79	15/69	14/80	15/70	
ACROLEIN 107-02-8									
136 M f cd1 gav 78w78 2181					0	.500mg	2.00mg	4.50mg	Parent;jact,10,647-659;1991/pers.comm.
lun a/c e	90.3mg	* P<.3	-	19.5mg n.s.s.	0/67	1/64	0/66	2/73	
lun a/a e	no dre	P=1.	-	19.6mg n.s.s.	11/67	5/64	4/66	6/73	
liv hpa e	no dre	P=1.	-	27.2mg n.s.s.	0/65	1/53	1/56	0/70	
137 M m cd1 gav 78w78 2181					0	.500mg	2.00mg	4.50mg	
lun a/c es	62.6mg	* P<.2	-	14.8mg n.s.s.	0/70	2/66	0/63	3/71	
lun a/a es	526.mg	* P<1.	-	12.9mg n.s.s.	6/70	3/66	6/63	5/71	
liv hpc es	no dre	P=1.	-	42.4mg n.s.s.	3/67	3/60	0/48	0/66	
liv hpa es	no dre	P=1.	-	16.2mg n.s.s.	4/67	2/60	5/48	2/66	
138 R f f34 wat 24m31 1853					0	20.1mg			Lijinsky;txih,3,337-345;1987/pers.comm.
adr coa e	93.9mg	P<.07		30.8mg n.s.s.	1/20	5/20			
liv mix e	188.mg	P<.4		39.2mg n.s.s.	2/20	4/20			
liv hnd e	388.mg	P<.7		48.5mg n.s.s.	2/20	3/20			
liv hpc e	433.mg	P<.3		70.4mg n.s.s.	0/20	1/20			
139 R m f34 wat 27m31 1853					0	2.64mg	6.81mg	14.1mg	
for tum ae	14.4mg	Z P<.002		7.36mg 55.4mg	0/20	5/20	7/20	(3/20)	
liv hpc ae	1.32gm	* P<.9		57.7mg n.s.s.	0/20	2/20	0/20	1/20	
adr coa ae	no dre	P=1.		128.mg n.s.s.	1/20	1/20	0/20	0/20	
liv hnd ae	no dre	P=1.		64.1mg n.s.s.	2/20	6/20	0/20	2/20	
liv mix ae	no dre	P=1.		52.1mg n.s.s.	2/20	8/20	0/20	3/20	
140 R f sda gav 52w52 2053m					0	50.0ug	.500mg	2.50mg	Parent;japt,12,131-139;1992/pers.comm.
liv tum k	no dre	P=1.		23.0ug n.s.s.	0/10	0/10	0/10	0/10	
141 R f sda gav 24m24 2053n					0	50.0ug	.500mg	2.50mg	
adr phe es	5.53mg	Z P<.2		1.47mg n.s.s.	0/58	3/57	4/58	(0/56)	
liv hpa es	214.mg	* P<.7		17.8mg n.s.s.	1/60	0/59	1/58	1/59	
adr coa es	no dre	P=1.		.525mg n.s.s.	2/58	0/57	0/58	0/56	
142 R m sda gav 52w52 2053m					0	50.0ug	.500mg	2.50mg	
liv tum k	no dre	P=1.		23.0ug n.s.s.	0/10	0/10	0/10	0/10	
143 R m sda gav 24m24 2053n					0	50.0ug	.500mg	2.50mg	
adr coa es	.471mg	Z P<.02		.163mg n.s.s.	0/57	4/57	(3/59	0/55)	
liv hpa es	24.7mg	* P<.07		7.78mg n.s.s.	1/57	2/57	2/59	5/55	
adr coc es	57.7mg	* P<.3		14.2mg n.s.s.	0/57	0/57	1/59	1/55	
adr phe es	no dre	P=1.		16.2mg n.s.s.	6/57	10/57	2/59	4/55	
liv hpc es	no dre	P=1.		34.2mg n.s.s.	2/57	1/57	0/59	0/55	
ACROLEIN DIETHYLACETAL 3054-95-3									
144 R f f34 wat 24m30 1853					0	15.4mg	39.5mg		Lijinsky;txih,3,337-345;1987/pers.comm.
liv mix ae	123.mg	* P<.06		47.6mg n.s.s.	2/20	5/20	7/20		
liv hnd ae	131.mg	* P<.06		50.7mg n.s.s.	2/20	4/20	7/20		
liv hpc ae	no dre	P=1.		197.mg n.s.s.	0/20	1/20	0/20		
adr coa ae	no dre	P=1.		129.mg n.s.s.	1/20	3/20	1/20		
145 R m f34 wat 24m30 1853					0	10.8mg	27.6mg		
liv hpc ae	262.mg	* P<.1		79.3mg n.s.s.	0/20	1/20	2/20		
liv mix ae	124.mg	* P<.2		42.6mg n.s.s.	2/20	3/20	6/20		
liv hnd ae	266.mg	* P<.4		60.9mg n.s.s.	2/20	2/20	4/20		
adr coa ae	no dre	P=1.		49.9mg n.s.s.	1/20	0/20	0/20		
ACROLEIN OXIME 5314-33-0									
146 R f f34 wat 7m29 1853m					0	7.96mg			Lijinsky;txih,3,337-345;1987/pers.comm.
liv hnd e	41.9mg	P<.3		11.3mg n.s.s.	2/20	5/20			
adr coa e	no dre	P=1.		45.9mg n.s.s.	1/20	0/20			
147 R f f34 wat 24m30 1853n					0	10.4mg			
liv mix e	27.1mg	P<.03		10.4mg n.s.s.	2/20	8/20			
liv hpc e	104.mg	P<.1		25.7mg n.s.s.	0/20	2/20			
liv hnd e	43.8mg	P<.2		13.8mg n.s.s.	2/20	6/20			
adr coa e	no dre	P=1.		66.2mg n.s.s.	1/20	0/20			
148 R m f34 wat 7m29 1853m					0	5.57mg			
liv mix e	16.4mg	P<.06		5.80mg n.s.s.	2/20	7/20			
liv hpc e	50.7mg	P<.1		12.5mg n.s.s.	0/20	2/20			
liv hnd e	29.3mg	P<.3		7.88mg n.s.s.	2/20	5/20			
adr coa e	no dre	P=1.		19.2mg n.s.s.	1/20	1/20			
149 R m f34 wat 24m30 1853n					0	7.37mg			
liv hpc e	72.6mg	P<.1		17.8mg n.s.s.	0/20	2/20			
liv mix e	30.4mg	P<.2		9.61mg n.s.s.	2/20	6/20			
liv hnd e	64.9mg	P<.4		13.5mg n.s.s.	2/20	4/20			
adr coa e	no dre	P=1.		46.0mg n.s.s.	1/20	0/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ACRONYCINE 7008-42-6								
150 M f b6c ipj 48w78 TR49 :				0	.850mg	2.57mg		
TBA MXB as	no dre	P=1.	i .866mg n.s.s.	20/30	9/40	(0/35)		
liv MXB as	2.46mg *	P<.3	.400mg n.s.s.	0/30	1/40	0/35		liv:hpa,hpc,nnd.
lun MXB as	2.46mg *	P<.3	.400mg n.s.s.	0/30	1/40	0/35		lun:a/a,a/c.
151 M m b6c ipj 66w78 TR49 :				0	.850mg	2.57mg		
TBA MXB as	no dre	P=1.	i 1.13mg n.s.s.	18/30	14/40	(0/35)		
liv MXB as	no dre	P=1.	2.77mg n.s.s.	2/30	0/40	0/35		liv:hpa,hpc,nnd.
lun MXB as	no dre	P=1.	n.s.s. n.s.s.	0/30	1/40	0/35		lun:a/a,a/c.
152 R f sda ipj 52w80 TR49 :				0	1.04mg	2.09mg	4.20mg	
mgl MXA e	.395mg Z	P<.003	c .200mg 2.10mg	4/20	22/35	(16/35 | 5/35)	mgl:acn,ccn,cyn,fba,pac.
mgl fba e	.455mg Z	P<.005	c .222mg 3.99mg	4/20	20/35	(13/35 | 3/35)	
MXB MXB e	.873mg Z	P<.0005	.495mg 3.02mg	4/20	23/35	17/35	12/35	mgl:acn,ccn,cyn,fba,pac; per:fbs,msm,srn. C
per MXA e	5.86mg *	P<.0005	c 2.80mg 17.7mg	0/20	1/35	2/35	7/35	per:fbs,msm,srn.
per srn e	11.4mg Z	P<.003	c 4.20mg 61.8mg	0/20	0/35	0/35	5/35	
TBA MXB e	.568mg Z	P<.0005	.353mg 1.24mg	7/20	31/35	20/35	25/35	
liv MXB e	8.75mg *	P<.06	2.98mg n.s.s.	0/20	0/35	4/35	0/35	liv:hpa,hpc,nnd.
153 R m sda ipj 51w80 TR49 :				0	1.04mg	2.09mg	6.40mg	
MXB MXB ae	.497mg Z	P<.0005	.290mg .843mg	0/20	9/35	13/35	13/35	---:ost; bon:ost; per:fbs,men,msm,srn; ver:ost. C
--- ost ae	.698mg Z	P<.0005	c .390mg 1.21mg	0/20	4/35	13/35	12/35	
MXA ost ae	1.03mg *	P<.0005	c .551mg 1.95mg	0/20	3/35	11/35	8/35	bon:ost; ver:ost.
per MXA ae	1.49mg *	P<.0005	c .573mg 6.91mg	0/20	5/35	1/35	2/35	per:fbs,men,msm,srn.
adr coa ae	1.85mg Z	P<.0005	.624mg 9.40mg	1/20	1/35	2/35	4/35	S
TBA MXB ae	.227mg Z	P<.0005	.135mg .412mg	4/20	18/35	16/35	16/35	
liv MXB ae	2.11mg *	P<.06	.519mg n.s.s.	0/20	2/35	0/35	0/35	liv:hpa,hpc,nnd.
ACRYLAMIDE (2-propenamide) 79-06-1								
154 R f f34 wat 24m24 1787m				0	10.0ug	.100mg	.500mg	2.00mg Johnson;txap,85,154-168;1986/pers.comm.
mgl ben ej	4.21mg *	P<.002	+ 2.08mg 22.0mg	10/60	11/60	9/60	19/58	23/61
cns glx ej	17.3mg *	P<.007	+ 6.59mg 361.mg	1/60	2/60	1/60	0/60	7/61
tyf mix ej	19.1mg *	P<.01	+ 7.00mg 1.33gm	1/58	0/59	1/59	1/58	5/60
cns ast ej	19.5mg *	P<.004	7.35mg 197.mg	1/60	1/60	0/60	0/60	6/61
mam fib ej	20.9mg *	P<.0005	7.94mg 87.1mg	0/60	0/60	0/60	0/58	5/61
mgl fba ej	8.73mg *	P<.07	3.15mg n.s.s.	10/60	11/60	9/60	16/58	17/61
orc sqp ej	16.2mg *	P<.02	+ 6.10mg n.s.s.	0/60	3/60	2/60	1/60	7/61
mgl adc ej	17.6mg *	P<.02	+ 6.42mg n.s.s.	2/60	1/60	1/60	2/58	6/61
cli ade j	19.0mg *	P<.04	+ 6.38mg n.s.s.	0/60	1/60	3/60	2/60	5/60
ute adc ej	26.5mg *	P<.05	+ 8.21mg n.s.s.	1/60	2/60	1/60	0/59	5/60
bra ast ej	38.8mg *	P<.04	12.9mg n.s.s.	0/60	1/60	0/60	0/60	3/60
thy fdc ej	39.5mg *	P<.05	10.9mg n.s.s.	1/58	0/59	0/59	0/58	3/60
spd ast ej	40.3mg *	P<.05	11.1mg n.s.s.	1/60	0/59	0/60	0/60	3/61
bra oli ej	259.mg *	P<.8	17.3mg n.s.s.	0/60	1/60	1/60	0/60	1/60
155 R f f34 wat 25m25 2253				0	1.00mg	3.00mg		Friedman;faat,27,95-105;1995/Damjanov 1998/pers.comm.
mgl mix e	8.18mg *	P<.002	+ 4.42mg 35.8mg	11/96	21/94	30/95		
tyf mix e	8.92mg *	P<.0005	+ 5.52mg 18.9mg	2/100	10/100	23/100		
mgl fba e	9.33mg *	P<.003	+ 4.88mg 54.9mg	9/96	20/94	26/95		
thy fca e	11.7mg *	P<.0005	+ 7.15mg 22.5mg	0/100	7/100	16/100		
thy fdc e	42.8mg *	P<.07	15.8mg n.s.s.	2/100	3/100	7/100		
cns glx	57.2mg *	P<.06	21.7mg n.s.s.	0/100	2/100	3/100		
bra ast e	71.8mg *	P<.2	24.8mg n.s.s.	0/100	2/100	2/100		
mgl adc e	100.mg *	P<.4	22.2mg n.s.s.	2/96	2/94	4/95		
spd ast e	210.mg *	P<.3	34.2mg n.s.s.	0/89	0/21	1/90		
156 R m f34 wat 24m24 1787m				0	10.0ug	.100mg	.500mg	2.00mg Johnson;txap,85,154-168;1986/pers.comm.
tnv msm ej	1.75mg Z	P<.002	+ .844mg 8.55mg	3/60	0/60	7/60	11/60	(10/60)
thy fca ej	13.5mg *	P<.003	+ 5.60mg 91.2mg	1/60	0/60	2/60	1/60	7/60
cns ast ej	23.5mg Z	P<.06	7.49mg n.s.s.	4/60	0/60	0/60	2/60	5/60
spd ast ej	39.7mg *	P<.05	11.0mg n.s.s.	1/60	0/60	0/60	0/60	3/60
adr pob ej	18.1mg *	P<.2	5.19mg n.s.s.	3/60	8/59	7/60	5/60	10/60
cns glx ejh	24.8mg *	P<.2	+ 7.30mg n.s.s.	5/60	2/60	0/60	2/60	6/60
spl leu ej	45.8mg *	P<.8	4.68mg n.s.s.	10/60	20/60	14/60	14/60	16/60
bra ast ej	82.6mg *	P<.6	11.7mg n.s.s.	3/60	0/60	0/60	2/60	2/60
bra oli ej	339.mg *	P<.8	18.9mg n.s.s.	0/60	2/60	0/60	0/60	1/60
adr phm ej	no dre	P=1.	25.0mg n.s.s.	2/60	0/59	2/60	1/60	0/60
157 R m f34 wat 25m25 2253				0	.100mg	.500mg	2.00mg	Friedman;faat,27,95-105;1995/Damjanov 1998/pers.comm.
tyf mix e	7.35mg *	P<.0005	+ 3.95mg 19.3mg	6/202	12/203	5/101	17/75	
thy fca e	7.49mg *	P<.0005	+ 4.07mg 18.8mg	3/202	9/203	5/101	15/75	
tnv msb e	9.45mg *	P<.0005	+ 4.66mg 35.2mg	8/204	9/204	8/102	13/75	
bra ast e	76.8mg *	P<.1	16.8mg n.s.s.	1/204	0/98	0/50	2/75	
cns glx	48.9mg *	P<.2	11.9mg n.s.s.	2/204	2/98	1/50	3/75	
thy fdc e	77.2mg *	P<.3	15.9mg n.s.s.	3/203	3/203	0/101	3/75	
spd ast e	82.5mg *	P<.3	12.0mg n.s.s.	0/172	1/68	0/37	1/51	
bra oli e	no dre	P=1.	27.3mg n.s.s.	1/204	1/98	1/50	0/75	
ACRYLIC ACID 79-10-7								
158 R f wis wat 52w52 2128m				0	6.86mg	45.7mg	114.mg	286.mg Hellwig;fctx,31,1-18;1993
liv tum e	no dre	P=1.	- 5.73mg n.s.s.	0/20	0/20	0/20	0/20	0/20
159 R f wis wat 28m28 2128n				0	6.86mg	22.9mg	68.6mg	
pit ade e	32.2mg *	P<.002	- 14.4mg 198.mg	40/50	41/50	43/50	49/50	
liv hpa e	10.2gm *	P<.7	- 796.mg n.s.s.	1/50	0/50	0/50	1/50	
--- mly e	no dre	P=1.	- 359.mg n.s.s.	6/50	14/50	5/50	7/50	
160 R m wis wat 52w52 2128m				0	6.00mg	40.0mg	100.mg	250.mg
liv tum e	no dre	P=1.	- 4.81mg n.s.s.	0/20	0/19	0/20	0/20	0/20
161 R m wis wat 26m26 2128n				0	6.00mg	20.0mg	60.0mg	
liv hpc e	no dre	P=1.	- 405.mg n.s.s.	4/50	3/49	1/50	3/50	
liv hpa e	no dre	P=1.	- 485.mg n.s.s.	1/50	1/49	1/50	1/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ACRYLONITRILE	107-13-1								
162	M f b6c gav 24m24	TR506 :			0	1.79mg	7.14mg	14.3mg	
MXB MXB	5.93mg	* P<.0005		3.72mg 12.2mg	14/50	15/50	38/50	35/50	for:sqc,sqp; hag:ade,anb,car. C
for MXA	6.77mg	* P<.0005	c	4.62mg 11.5mg	3/50	7/50	25/50	29/50	for:sqc,sqp.
for sqp	8.83mg	* P<.0005	c	5.65mg 17.5mg	3/50	6/50	24/50	19/50	
hag MXA	9.87mg	* P<.0005	c	5.76mg 25.4mg	11/50	10/50	26/50	25/50	hag:ade,anb,car.
hag MXA	10.7mg	* P<.0005	c	6.13mg 29.3mg	10/50	10/50	25/50	23/50	hag:ade,anb.
for sqc	40.2mg	Z P<.0005	c	21.1mg 90.4mg	0/50	1/50	1/50	11/50	
--- hem	87.2mg	* P<.01		35.3mg 6.38gm	0/50	1/50	1/50	4/50	S
lun MXA	34.6mg	* P<.04	e	14.2mg n.s.s.	6/50	6/50	14/50	9/50	lun:a/a,a/c.
ova MXA	88.1mg	* P<.03	e	33.5mg n.s.s.	0/50	0/50	4/50	1/50	ova:gcb,gcm.
TBA MXB	20.7mg	* P<.4		5.64mg n.s.s.	50/50	45/50	50/50	40/50	
liv MXB	no dre	P=1.		20.3mg n.s.s.	20/50	15/50	19/50	10/50	liv:hpa,hpb,hpc.
lun MXB	34.6mg	* P<.04		14.2mg n.s.s.	6/50	6/50	14/50	9/50	lun:a/a,a/c.
163	M m b6c gav 24m24	TR506 :			0	1.79mg	7.14mg	14.3mg	
MXB MXB	4.21mg	* P<.0005		2.89mg 6.95mg	9/50	19/50	39/50	39/50	for:sqc,sqp; hag:ade,car. C
for MXA	5.92mg	Z P<.0005	c	4.15mg 9.13mg	3/50	4/50	26/50	32/50	for:sqc,sqp.
hag MXA	6.18mg	* P<.0005	c	4.07mg 11.1mg	6/50	16/50	27/50	30/50	hag:ade,car.
hag ade	7.06mg	* P<.0005	c	4.55mg 13.4mg	5/50	16/50	24/50	27/50	
for sqp	7.74mg	Z P<.0005	c	5.15mg 13.1mg	3/50	4/50	19/50	25/50	
for sqc	27.0mg	* P<.0005	c	15.2mg 54.3mg	0/50	0/50	8/50	9/50	
hag car	69.3mg	* P<.03		26.1mg n.s.s.	1/50	1/50	4/50	3/50	S
TBA MXB	5.68mg	Z P<.0005		3.15mg 19.6mg	50/50	43/50	49/50	50/50	
liv MXB	41.6mg	* P<.6		7.87mg n.s.s.	32/50	36/50	37/50	17/50	liv:hpa,hpb,hpc.
lun MXB	119.mg	* P<.6		19.3mg n.s.s.	14/50	11/50	8/50	9/50	lun:a/a,a/c.
164	R m cdr wat 24m24	1881			0	1.00mg	5.00mg	25.0mg	Gallagher;jact,7,603-615;1988
zym sqc es	30.1mg	* P<.0005	+	14.5mg 77.9mg	0/18	0/20	1/19	9/18	
for pam s	97.4mg	* P<.003		33.6mg 591.mg	0/20	0/20	0/20	4/20	
pit ade es	no dre	P=1.		15.4mg n.s.s.	5/18	3/20	1/19	(0/18)	
tba mal es	31.3mg	* P<.02		12.6mg n.s.s.	3/18	1/20	8/20	8/18	
165	R f sda inh 12m24	BT201			0	.271mg	.542mg	1.08mg	2.17mg	Maltoni;anya,534,179-202;1988
adr phe	1.49mg	Z P<.02		.679mg n.s.s.	1/30	5/30	7/30	(2/30	0/30)
bra gli	41.2mg	* P<.2	+	10.1mg n.s.s.	0/30	0/30	0/30	1/30	1/30
liv hpt	no dre	P=1.		.893mg n.s.s.	0/30	0/30	0/30	0/30	0/30
tba mix	2.09mg	Z P<.3		.623mg n.s.s.	9/30	23/30	15/30	17/30	(10/30)
tba mal	no dre	P=1.		4.00mg n.s.s.	3/30	12/30	6/30	7/30	6/30
166	R f sda gav 12m24	BT203			0	1.07mg			
liv hpt	no dre	P=1.	-	8.83mg n.s.s.	0/75	0/40			
tba mix	2.97mg	P<.3	-	.782mg n.s.s.	39/75	25/40			
tba mal	no dre	P=1.	-	2.33mg n.s.s.	17/75	9/40			
167	R f sda inh 24m24	BT4003			0	11.1mg			
mam mix g	11.7mg	P<.003		5.82mg 75.7mg	24/60	37/54			
bra gli g	132.mg	P<.04	+	40.1mg n.s.s.	0/60	3/54			
liv hpt g	no dre	P=1.		123.mg n.s.s.	0/60	0/54			
tba mal g	25.2mg	P<.008	+	11.7mg 495.mg	9/60	20/54			
tba mix g	10.6mg	P<.02		4.69mg n.s.s.	35/60	43/54			
168	R m sda inh 12m24	BT201			0	.190mg	.379mg	.759mg	1.52mg	
bra gli	19.1mg	* P<.04	+	5.77mg n.s.s.	0/30	0/30	0/30	1/30	2/30
liv hpt	no dre	P=1.		.625mg n.s.s.	0/30	0/30	0/30	0/30	0/30
tba mix	1.30mg	* P<.002		.674mg 6.77mg	8/30	7/30	19/30	15/30	19/30
tba mal	1.43mg	Z P<.04		.565mg n.s.s.	3/30	0/30	10/30	(9/30	10/30)
169	R m sda gav 12m24	BT203			0	1.07mg			
liv hpt	no dre	P=1.	-	8.83mg n.s.s.	0/75	0/40			
tba mix	5.59mg	P<.3	-	1.55mg n.s.s.	13/75	11/40			
tba mal	33.4mg	P<.8	-	3.14mg n.s.s.	6/75	4/40			
170	R f sss inh 24m24	1251n			0	3.24mg	13.0mg		Quast;dcrp;1980
cns ast aes	49.6mg	* P<.0005	+	29.6mg 94.2mg	0/99	4/100	17/99		
ccx ast aes	62.0mg	* P<.0005		35.2mg 130.mg	0/99	3/99	14/99		
zym mix aes	81.5mg	* P<.0005	+	42.0mg 193.mg	0/93	1/98	11/89		
zym ssc aes	89.0mg	* P<.0005		44.7mg 217.mg	0/93	0/98	11/89		
brs ast aes	123.mg	* P<.002		55.6mg 444.mg	0/93	1/96	7/88		
ntu rsc aes	52.0mg	* P<.06	+	12.8mg n.s.s.	0/11	0/10	2/10		
mgl adc aes	69.1mg	* P<.02	+	31.7mg 13.1gm	9/99	8/100	20/99		
liv cho aes	362.mg	* P<.9		58.9mg n.s.s.	0/72	1/68	0/23		
liv clc aes	362.mg	* P<.9		58.9mg n.s.s.	0/72	1/68	0/23		
mgl fba aes	no dre	P=1.	+	21.6mg n.s.s.	79/99	96/100	75/99		
tba mix aes	no dre	P=1.		9.07mg n.s.s.	97/99	99/100	93/99		
171	R f sss wat 24m25	1268n			0	2.00mg	5.69mg	15.4mg	Quast;dcfr;1980
cns ast aesv	5.31mg	Z P<.0005	+	3.52mg 8.79mg	1/80	17/48	22/48	(24/47)	
smi muc aesv	8.19mg	Z P<.0005	+	3.07mg 34.3mg	0/79	1/7	4/10	(4/34)	
brs ast aesv	11.4mg	Z P<.0005		6.74mg 22.5mg	0/78	9/48	11/47	(8/46)	
stn mix aesv	13.3mg	* P<.0005	+	9.08mg 20.8mg	1/80	1/47	12/48	30/47	
ccx ast aesv	13.6mg	* P<.0005		9.11mg 24.1mg	1/80	10/48	17/47	21/47	
stn sqp aesv	13.8mg	* P<.0005		9.38mg 21.7mg	1/80	1/47	12/48	29/47	
zym mix aesv	22.6mg	* P<.0005	+	14.1mg 43.5mg	1/80	5/48	8/48	18/47	
zym ssc aesv	31.4mg	* P<.0005		18.3mg 71.7mg	1/80	4/48	6/48	14/47	
mgl mal aesv	42.6mg	* P<.004	+	20.2mg 353.mg	6/80	7/48	9/48	13/47	
stn sqc aesv	46.1mg	Z P<.0005		23.7mg 108.mg	0/79	0/46	0/45	12/34	
crl ast aesv	65.9mg	* P<.002		33.1mg 285.mg	0/79	2/47	3/48	6/46	
spd ast aesv	90.8mg	* P<.0005		41.1mg 280.mg	0/78	0/48	2/47	6/46	
zym ade aesv	93.7mg	* P<.004		42.4mg 798.mg	0/80	1/48	3/48	4/47	
liv mix aesv	169.mg	* P<.2		34.0mg n.s.s.	1/68	0/34	1/25	1/11	
mgl mix aesv	no dre	P=1.	+	11.0mg n.s.s.	57/80	42/48	42/48	35/47	
tba mix aesv	1.75mg	* P<.1		.287mg n.s.s.	78/80	47/48	48/48	48/48	
172	R f sss wat 22m25	1268o			0	15.4mg			
ton mix esv	34.5mg	P<.0005	+	17.7mg 80.9mg	0/78	12/44			
ton sqc esv	42.6mg	P<.0005		20.7mg 110.mg	0/78	10/44			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
173 R m sss inh 24m24 1251m					0	2.27mg	9.10mg		Quast;dcrp;1980
cns ast aes		32.4mg *	P<.0005 +	18.9mg 63.8mg	0/96	4/93	15/82		
itl mix aes		37.8mg *	P<.0005	20.0mg 117.mg	4/96	3/93	17/82		
ccx ast aes		38.8mg *	P<.0005	21.7mg 80.1mg	0/96	2/93	14/82		
zym ssc aes		50.1mg *	P<.0005	25.3mg 174.mg	1/96	3/93	11/82		
zym mix aes		53.0mg *	P<.003 +	25.4mg 310.mg	2/96	4/93	11/82		
stn mix aes		99.0mg *	P<.02 +	38.9mg n.s.s.	1/95	2/93	6/81		
liv hpc aes		403.mg *	P<.2	65.7mg n.s.s.	0/74	0/64	1/48		
tba mix aes		no dre	P=1.	10.9mg n.s.s.	86/100	75/100	80/100		
174 R m sss inh 24m24 1251o					0	9.10mg			
smi muc es		37.7mg	P<.0005 +	19.0mg 127.mg	2/96	14/81			
ton sqp es		73.0mg	P<.007	25.2mg 1.03gm	0/72	4/48			
ton mix es		89.1mg	P<.02 +	35.1mg n.s.s.	1/95	7/89			
175 R m sss wat 24m25 1268m					0	1.75mg	4.98mg	14.9mg	Quast;dcfr;1980
stn mix aesv		6.36mg *	P<.0005 +	4.58mg 9.11mg	0/79	3/46	23/47	39/47	
cns ast aesv		10.7mg *	P<.0005 +	7.33mg 17.9mg	1/73	8/45	19/47	23/44	
ccx ast aesv		12.0mg *	P<.0005	8.03mg 21.0mg	1/73	8/45	18/47	21/44	
stn sqp aesv		12.2mg *	P<.0005	8.40mg 18.6mg	0/79	2/46	17/47	25/47	
stn sqc aesv		14.1mg *	P<.0005	9.38mg 22.6mg	0/73	1/44	10/47	25/43	
brs ast aesv		18.6mg Z	P<.0005	9.34mg 49.5mg	0/73	3/44	8/47	(6/44)	
zym ssc aesv		34.1mg *	P<.0005 +	18.3mg 93.5mg	3/73	4/45	3/47	15/44	
smi muc aesv		128.mg Z	P<.3	29.9mg n.s.s.	3/73	6/16	1/11	6/42	
liv hpc aesv		no dre	P=1.	82.9mg n.s.s.	1/50	1/31	0/31	0/18	
tba mix aesv		5.55mg *	P<.005	2.31mg 70.8mg	67/80	37/47	47/48	46/48	
176 R m sss wat 96w96 1268r					0	14.9mg			
ton mix esv		66.6mg	P<.02 +	23.5mg n.s.s.	1/68	5/37			
ton sqc esv		66.6mg	P<.02	23.5mg n.s.s.	1/68	5/37			
ACTINOMYCIN C (sanamycin) 8052-16-2									
177 R m b46 ivj 12m24 1017					0	.500mg			Schmahl;arzn,20,1461-1467;1970
tba mix es		1.68mg	P<.08	.504mg n.s.s.	7/65	6/22			
tba ben es		2.23mg	P<.07	.635mg n.s.s.	3/65	4/22			
tba mal es		10.8mg	P<.7	1.03mg n.s.s.	4/65	2/22			
ACTINOMYCIN D 50-76-0									
178 R f cdr ipj 26w78 1336					0	3.15ug	7.93ug		Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.
per sar e		1.99ug *	P<.0005 +	1.14ug 3.87ug	0/182	18/30	1/5		
lun ade e		50.1ug *	P<.03	8.16ug n.s.s.	0/182	0/30	1/5		
liv tum e		no dre	P=1.	3.24ug n.s.s.	0/182	0/30	0/5		
tba mal e		1.21ug *	P<.0005	658.ng 2.74ug	44/182	25/30	3/5		
tba mix e		1.45ug *	P<.003	618.ng 10.0ug	103/182	26/30	4/5		
tba ben e		no dre	P=1.	11.8ug n.s.s.	59/182	1/30	1/5		
179 R m cdr ipj 26w78 1336					0	3.15ug			
per sar e		769.ng	P<.0005 +	456.ng 1.38ug	0/177	27/34			
--- plc e		20.1ug	P<.008	4.93ug .571mg	0/177	2/34			
--- lys e		20.1ug	P<.008	4.93ug .571mg	0/177	2/34			
liv hem e		40.7ug	P<.06	6.63ug n.s.s.	0/177	1/34			
tba mix e		501.ng	P<.0005	244.ng 1.10ug	59/177	32/34			
tba mal e		708.ng	P<.0005	394.ng 1.41ug	32/177	29/34			
tba ben e		no dre	P=1.	6.99ug n.s.s.	27/177	3/34			
ADIPAMIDE 628-94-4									
180 M f cb6 eat 52w69 1343 pool					0	1.57gm	2.35gm		Fleischman;jept,3,149-170;1980
lun a/a e		8.55gm \	P<.2 -	1.99gm n.s.s.	2/89	3/40	(0/39)		
liv hpc e		no dre	P=1. -	8.83gm n.s.s.	1/89	1/40	0/39		
181 M m cb6 eat 52w69 1343 pool					0	1.44gm	2.17gm		
liv hpc e		no dre	P=1. -	3.05gm n.s.s.	2/91	0/38	0/40		
lun a/a e		no dre	P=1. -	8.13gm n.s.s.	1/87	1/38	0/40		
182 R f f34 eat 52w69 1343					0	903.mg	2.18gm		
liv tum e		no dre	P=1. -	2.15gm n.s.s.	0/49	0/34	0/48		
183 R m f34 eat 52w69 1343					0	722.mg	1.75gm		
liv hpc e		6.42gm *	P<.007	2.44gm 71.7gm	0/50	0/35	5/49		
ADRIAMYCIN 23214-92-8									
184 P b cym ivj 5y15 2003n :					0	8.00ug			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
kid ade sw		4.94ug	P<.03	805.ng n.s.s.	0/22	1/2			
leg fbs sw		14.8ug	P<.04	2.41ug n.s.s.	0/39	1/5			
tba mix Wsw		3.71ug	P<.003	788.ng 65.2ug	0/39	2/5			
tba ben Wsw		4.94ug	P<.03	805.ng n.s.s.	0/22	1/2			
tba mal Wsw		14.8ug	P<.04	2.41ug n.s.s.	0/39	1/5			
185 P b cym ivj 10y15 2003o :					0	6.00ug			
tba mal Wsw		no dre	P=1.	n.s.s. n.s.s.	0/15	-/-			
186 P b rhe ivj 2y9 2003m : ()					0	25.0ug			
--- anl sw		13.7ug	P<.02	2.23ug n.s.s.	0/97	1/4			
tba mal Wsw		7.44ug	P<.04	918.ng n.s.s.	1/97	1/4			
187 P b rhe ivj 5y13 2003n :					0	8.00ug			
tba mal Wsw		no dre	P=1.	1.25ug n.s.s.	2/74	0/5			
188 P b rhe ivj 10y16 2003o :					0	6.00ug			
col adp sw		1.28ug	P<.008	208.ng .315mg	0/36	1/1			
ute ley Wsw		3.83ug	P<.02	623.ng n.s.s.	0/37	1/2			
tba ben Wsw		5.10ug	P<.06	748.ng n.s.s.	4/108	2/6			
AF-2 (furylfuramide) 3688-53-7									
189 H f syg eat 94w94 1315					0	83.6mg	167.mg		Kinebuchi;fctx,17,339-341;1979
for mix e		59.1mg *	P<.0005	34.5mg 110.mg	0/16	10/17	13/17		
eso pam e		2.34gm *	P<.3	381.mg n.s.s.	0/16	0/17	1/17		
for sqc e		2.34gm *	P<.3 +	381.mg n.s.s.	0/16	0/17	1/17		

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
liv tum e	no dre	P=1.		160.mg n.s.s.	0/16	0/17	0/17		
lun tum e	no dre	P=1.		160.mg n.s.s.	0/16	0/17	0/17		
190 H m syg eat 94w94 1315					0	73.6mg	147.mg		
for mix e	30.5mg	* P<.0005		17.6mg 55.0mg	0/19	13/20	17/17		
for sqc e	164.mg	* P<.0005	+	81.7mg 452.mg	0/19	3/20	8/17		
eso mix e	328.mg	* P<.003		133.mg 1.66gm	0/19	0/20	6/17		
eso sqc e	2.18gm	* P<.3	+	355.mg n.s.s.	0/19	0/20	1/17		
liv tum e	no dre	P=1.		156.mg n.s.s.	0/19	0/20	0/17		
lun tum e	no dre	P=1.		156.mg n.s.s.	0/19	0/20	0/17		
191 M f cdf eat 18m24 1316					0	78.0mg	390.mg		Takayama;clet,3,115-120;1977
for pam	714.mg	* P<.0005	+	415.mg 1.38gm	0/50	2/50	17/50		
for sqc	2.54gm	* P<.002	+	1.03gm 10.2gm	0/50	0/50	6/50		
lun tum	16.4gm	* P<.7		1.73gm n.s.s.	1/50	2/50	2/50		
192 M m cdf eat 18m24 1316					0	72.0mg	360.mg		
for pam	753.mg	* P<.0005	+	426.mg 1.52gm	0/50	2/50	15/50		
for sqc	928.mg	* P<.0005	+	499.mg 2.03gm	0/50	0/50	14/50		
lun tum	9.27gm	* P<.5		1.53gm n.s.s.	2/50	1/50	3/50		
193 M m ddy eat 44w80 455					0	165.mg			Sano;zkko,89,61-68;1977
for mix	60.8mg	P<.005		22.7mg 629.mg	1/10	7/10			
for sqc	72.9mg	P<.002	+	28.2mg 309.mg	0/10	6/10			
lun ade	299.mg	P<.09		73.2mg n.s.s.	0/10	2/10			
liv tum	no dre	P=1.		201.mg n.s.s.	0/10	0/10			
tba mix	60.8mg	P<.005		22.7mg 629.mg	1/10	7/10			
194 M f icr eat 62w62 359					0	104.mg	520.mg		Yokoro;gann,68,825-828;1977
for mix	95.0mg	* P<.0005	+	65.6mg 143.mg	0/65	13/50	36/50		
for sqc	225.mg	/ P<.0005	+	140.mg 393.mg	0/65	1/50	25/50		
--- leu	1.80gm	* P<.3		464.mg n.s.s.	2/65	5/50	5/50		
liv tum	no dre	P=1.		317.mg n.s.s.	0/65	0/50	0/50		
195 M f icr eat 24m24 362					0	16.3mg	65.0mg	260.mg	Miyaji;tjem,103,331-369;1971
liv hct	7.07gm	* P<.9	-	501.mg n.s.s.	6/30	2/30	6/30	5/30	
196 M m icr eat 62w62 359					0	96.0mg	480.mg		Yokoro;gann,68,825-828;1977
for mix	90.3mg	* P<.0005	+	62.6mg 151.mg	0/25	15/50	34/50		
for sqc	208.mg	/ P<.0005	+	129.mg 363.mg	0/25	1/50	25/50		
liv tum	no dre	P=1.		293.mg n.s.s.	0/25	0/50	0/50		
197 M m icr eat 24m24 362					0	15.0mg	60.0mg	240.mg	Miyaji;tjem,103,331-369;1971
liv hct	no dre	P=1.	-	489.mg n.s.s.	9/30	6/30	14/30	6/30	
198 R f sda eat 46w66 517					0	69.7mg			Cohen;gann,68,473-476;1977
mgl mix e	11.4mg	P<.0005	+	6.31mg 22.8mg	2/29	24/29			
mgl adc e	26.4mg	P<.0005	+	14.2mg 56.5mg	0/29	15/29			
199 R f wis eat 18m24 1316					0	30.0mg	150.mg		Takayama;clet,3,115-120;1977
mgl mix	74.7mg	* P<.0005	+	49.9mg 125.mg	3/50	17/50	37/50		
for pam	424.mg	* P<.0005		223.mg 962.mg	0/50	1/50	12/50		
liv hms	2.00gm	* P<.02		606.mg n.s.s.	0/50	0/50	3/50		
200 R m wis eat 18m24 1316					0	24.0mg	120.mg		
for pam	409.mg	* P<.0005		205.mg 1.04gm	0/50	1/50	10/50		
mgl mix	1.20gm	* P<.05	+	415.mg n.s.s.	0/50	1/50	3/50		
liv hms	1.60gm	* P<.02		485.mg n.s.s.	0/50	0/50	3/50		
AFLATOXICOL 29611-03-8									
201 R m f34 eat 12m24 1083					0	1.00ug	4.00ug		Nixon;jnci,66,1159-1163;1981
liv hpc	2.47ug	* P<.0005	+	1.38ug 4.97ug	0/20	4/20	14/20		
kid adc	32.9ug	* P<.06		8.08ug n.s.s.	0/20	0/20	2/20		
AFLATOXIN B1 1162-65-8									
202 M f c5v ipj 52w92 1636					0	9.69ug			Griciute;iarc,813-822;1980
lmr tum	4.02ug	P<.007	-	1.62ug 67.6ug	3/11	12/15			
lun ben	75.3ug	P<.3	-	12.3ug n.s.s.	0/11	1/15			
liv tum	no dre	P=1.	-	23.4ug n.s.s.	0/11	0/15			
tba tum	4.49ug	P<.03	-	1.68ug n.s.s.	4/11	12/15			
203 M m c5v ipj 52w92 1636					0	8.07ug			
lun ben	.245mg	P<.9	-	11.3ug n.s.s.	1/20	1/15			
liv mal	no dre	P=1.	-	19.5ug n.s.s.	2/20	0/15			
liv ben	no dre	P=1.	-	19.5ug n.s.s.	2/20	0/15			
tba tum	no dre	P=1.	-	8.52ug n.s.s.	11/20	4/14			
204 N b tst eat 40m40 1439					0	99.7ug			Reddy;canr,36,151-160;1976
liv hpc er	26.9ug	P<.0005	+	11.5ug 80.9ug	0/8	9/12			
205 P b cym mix 17y17 2004 :					0	56.0ug		Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.	
MXB MXB jmw	9.25ug	P<.0005		3.25ug 27.7ug	0/45	10/13			
bil mix jmw	20.1ug	P<.0005	+	6.34ug 72.9ug	0/45	6/13			
gab adc jmw	40.8ug	P<.0005	+	12.9ug .215mg	0/39	4/12			
bon ost jmw	62.7ug	P<.008		12.0ug 3.21mg	0/47	2/14			
liv hes jmw	73.4ug	P<.003	+	21.4ug .613mg	0/34	3/10			
k/p tcc jmw	44.6ug	P<.05		7.26ug n.s.s.	0/14	1/2			
liv clc jmw	44.6ug	P<.05	+	7.26ug n.s.s.	0/14	1/2			
liv hpc jmw	44.6ug	P<.05	+	7.26ug n.s.s.	0/14	1/2			
pel fbs jmw	.104mg	P<.05		16.9ug n.s.s.	0/26	1/4			
pnd adc jmw	.342mg	P<.09		55.7ug n.s.s.	0/39	1/12			
bil scc jmw	.371mg	P<.09	+	60.5ug n.s.s.	0/45	1/13			
tba mal Wjmw	8.36ug	P<.0005		3.26ug 24.3ug	1/47	12/14			
206 P b rhe mix 15y15 2004 :					0	45.0ug			
MXB MXB jmw	5.94ug	P<.0005		1.71ug 20.0ug	1/85	10/14			
liv clc jmw	8.20ug	P<.0005	+	1.52ug .186mg	0/44	2/4			
bil mix jmw	11.5ug	P<.0005	+	2.11ug 72.1ug	1/74	5/11			
gab adc jmw	14.7ug	P<.0005	+	2.25ug .131mg	1/74	4/11			
liv hes jmw	16.3ug	P<.0005	+	4.10ug .140mg	0/84	3/13			
pnd adc jmw	23.3ug	P<.0005		6.39ug .172mg	0/54	3/9			
liv hpc jmw	.104mg	P<.005	+	25.2ug 1.97mg	0/85	2/14			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
bon ost jmw	.159mg	P<.05		25.9ug n.s.s.	0/54	1/9				
tba mal Wjmw	6.77ug	P<.0005		2.06ug 22.3ug	2/85	10/14				
207 R m buf eat 35w65 1071					0	21.5ug				Angsubhakorn;bjca,43,881-883;1981
liv hpc ekr	noTD50	P<.004	+	n.s.s. 6.75ug	0/8	6/6				
liv mix ekr	noTD50	P<.004	+	n.s.s. 6.75ug	0/8	6/6				
liv nnd ekr	noTD50	P<.004	+	n.s.s. 6.75ug	0/8	6/6				
208 R m buf eat 26w52 1664					0	20.0ug				Angsubhakorn;ijcn,28,621-626;1981
liv hpc ekr	5.73ug	P<.002	+	2.66ug 18.7ug	0/14	9/20				
liv nnd ekr	7.95ug	P<.004	+	3.40ug 47.3ug	0/14	7/20				
209 R m cdr eat 24m24 1454					0	4.00ug				Newberne;jnci,50,439-448;1973
liv mix r	4.19ug	P<.0005	+	2.55ug 7.52ug	0/50	24/50				
210 R f f34 eat 75w75 17					0	.100mg				Ward;jnci,55,107-110;1975
col mix e	.148mg	P<.05	+	44.5ug n.s.s.	0/12	3/14				
211 R f f34 eat 24m24 1824					0	250.ng	750.ng	2.25ug		Elashoff;jnci,79,509-526;1987
liv hpc er	52.7ug *	P<.06	-	8.58ug n.s.s.	0/144	0/24	0/24	1/24		
212 R m f34 eat 75w75 17					0	80.0ug				Ward;jnci,55,107-110;1975
col mix e	55.8ug	P<.06	+	13.3ug n.s.s.	0/6	2/5				
213 R m f34 eat 12m24 1083					0	1.00ug				Nixon;jnci,66,1159-1163;1981
liv hpc	1.34ug	P<.0005	+	600.ng 4.24ug	0/20	8/20				
kid adc	13.4ug	P<.3		2.17ug n.s.s.	0/20	1/20				
214 R m f34 eat 24m24 1824					0	200.ng	600.ng	1.80ug		Elashoff;jnci,79,509-526;1987
liv hpc er	49.9ug *	P<.3	-	6.83ug n.s.s.	1/144	0/23	0/24	1/23		
215 R f fis eat 24m24 1041					0	1.00ug				Nixon;jnci,53,453-458;1974
liv hpt e	9.93ug	P<.3	+	1.62ug n.s.s.	0/15	1/15				
216 R m fis eat 22m24 18					0	40.0ng	200.ng	600.ng	2.00ug 4.00ug	Wogan;fctx,12,681-685;1974
liv hpc ae	932.ng *	P<.0005	+	614.ng 1.49ug	0/18	2/22	1/22	4/21	20/25 28/28	
217 R m fis eat 24m24 1041					0	800.ng				Nixon;jnci,53,453-458;1974
liv hpt e	1.13ug	P<.003	+	422.ng 6.52ug	0/16	5/13				
218 R f por eat 24m24 13					0	5.00ug	25.0ug			Butler;fctx,6,135-141;1968
liv hpc e	12.5ug *	P<.0005	+	7.83ug 21.2ug	0/34	5/30	26/33			
219 R m por eat 24m24 13					0	4.00ug	20.0ug			
liv hpc e	3.52ug *	P<.0005	+	2.11ug 6.01ug	0/46	17/34	25/25			
220 R b sda eat 95w95 1070					0	279.ng				Fong;fctx,19,179-183;1981
liv sar e	12.0ug	P<.3		1.96ug n.s.s.	0/90	1/76				
tba mal eh	3.96ug	P<.03	+	1.20ug n.s.s.	0/90	3/76				
221 R m wag eat 69w69 1075					0	10.0ug				Burtin;bjca,43,684-688;1981
liv hpt er	noTD50	P<.0005	+	n.s.s. 2.13ug	0/10	12/12				
222 R f wio eat 24m24 1041					0	1.00ug	5.00ug			Nixon;jnci,53,453-458;1974
liv hpt e	7.49ug *	P<.0005	+	3.36ug 22.1ug	0/18	0/19	8/18			
223 R m wio eat 24m24 1041					0	800.ng	4.00ug			
liv hpt e	6.76ug *	P<.0005	+	2.89ug 21.9ug	0/17	0/20	7/17			
224 R m wis eat 55w55 15					0	40.0ug	80.0ug	.120mg		Merkow;canr,33,1608-1614;1973
kid car er	36.6ug *	P<.006	+	18.7ug .392mg	0/9	3/12	3/12	6/12		
AFLATOXIN, CRUDE 1402-68-2										
225 M m swi gav 52w52 309					0	2.38mg				Louria;sabo,12,371-375;1974
--- lyk e	.343mg	P<.002	+	.133mg 2.34mg	11/37	11/14				
liv hpt e	no dre	P=1.		1.72mg n.s.s.	0/37	0/14				
226 R m cdr eat 52w52 16					0	40.0ug				Newberne;livt,15,962-969;1966
liv tum e	7.48ug	P<.002	+	2.90ug 31.7ug	0/10	6/10				
227 R m chm eat 68w68 333					0	8.00ug				Newberne;aenh,19,489-498;1969
liv car	1.87ug	P<.0005	+	1.12ug 3.38ug	0/20	25/35				
liv nod	6.96ug	P<.002	+	3.38ug 25.8ug	0/20	10/35				
228 R m lev eat 58w78 1514					0	.368mg	2.45mg	7.36mg	9.81mg	Lee;jnci,43,1037-1041;1969
ktu ade	3.44mg *	P<.0005		1.92mg 6.89mg	0/10	0/10	1/10	7/10	10/15	
liv nod	6.18mg *	P<.002		3.05mg 23.5mg	1/10	0/10	1/10	5/10	7/15	
liv hpc	14.5mg *	P<.05		5.91mg n.s.s.	0/10	0/10	2/10	0/10	4/15	
AGAR 9002-18-0										
229 M f b6c eat 24m24 TR230 :					0	3.19gm	6.38gm			
TBA MXB	no dre	P=1.	-	4.42gm n.s.s.	26/50	24/50	(16/50)			
liv MXB	no dre	P=1.		34.9gm n.s.s.	4/50	5/50	1/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		13.7gm n.s.s.	7/50	3/50	(1/50)			lun:a/a,a/c.
230 M m b6c eat 24m24 TR230 :					0	2.94gm	5.89gm			
liv hpa #	18.8gm *	P<.002	-	9.17gm 79.1gm	0/50	3/50	7/50			S
TBA MXB	54.9gm *	P<.8		5.67gm n.s.s.	24/50	24/50	25/50			
liv MXB	33.1gm *	P<.4		8.46gm n.s.s.	9/50	8/50	13/50			liv:hpa,hpc,nnd.
lun MXB	102.gm *	P<.8		12.1gm n.s.s.	6/50	6/50	7/50			lun:a/a,a/c.
231 R f f34 eat 24m24 TR230 :					0	1.21gm	2.45gm			
adr coa #	25.8gm *	P<.03	-	8.92gm n.s.s.	0/50	0/50	4/50			S
TBA MXB	no dre	P=1.		2.79gm n.s.s.	47/50	43/50	43/50			
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50			liv:hpa,hpc,nnd.
232 R m f34 eat 24m24 TR230 :					0	981.mg	1.96gm			
TBA MXB	39.3gm *	P<1.	-	1.67gm n.s.s.	32/50	38/50	35/50			
liv MXB	25.9gm *	P<.3		7.81gm n.s.s.	0/50	2/50	1/50			liv:hpa,hpc,nnd.
ALCLOFENAC ((4-allyloxy-3-chlorophenyl)acetic acid) 22131-79-9										
233 R f wis eat 24m24 2432					0	20.0mg	40.0mg	80.0mg		Everett;iyke,18,201-217;1987
ova mix e	390.mg Z	P<.005	-	148.mg 3.07gm	0/95	1/47	4/50	(0/50)		
liv mix e	no dre	P=1.	-	610.mg n.s.s.	8/94	1/46	1/50	3/48		
tba mix e	no dre	P=1.	-	54.2mg n.s.s.	84/95	43/48	43/50	43/50		
234 R m wis eat 24m24 2432					0	20.0mg	40.0mg	80.0mg		
liv mix e	no dre	P=1.	-	328.mg n.s.s.	9/86	4/44	5/46	4/44		
tba mix e	no dre	P=1.	-	58.2mg n.s.s.	81/94	42/46	44/48	39/48		
ALDICARB (temik) 116-06-3										
235 M f b6c eat 24m24 TR136 :					0	.260mg	.780mg			
TBA MXB	no dre	P=1.	-	1.27mg n.s.s.	15/25	21/50	22/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf								Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc				NCI/NTPPathology
liv MXB		52.7mg	/ P<.9	2.83mg n.s.s.	3/25	0/50	4/50					liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.30mg n.s.s.	1/25	4/50	1/50					lun:a/a,a/c.
236 M m b6c eat 24m24 TR136 :					0	.240mg	.720mg					
TBA MXB		1.74mg	* P<.3	- .508mg n.s.s.	8/25	27/50	30/50					
liv MXB		2.83mg	* P<.4	.776mg n.s.s.	5/25	14/50	18/50					liv:hpa,hpc,nnd.
lun MXB		14.8mg	* P<.8	1.53mg n.s.s.	1/25	6/50	5/50					lun:a/a,a/c.
237 R f f34 eat 24m24 TR136 :					0	.100mg	.300mg					
TBA MXB		no dre	P=1.	- .178mg n.s.s.	21/25	45/50	46/50					
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/25	0/50	0/50					liv:hpa,hpc,nnd.
238 R m f34 eat 24m24 TR136 :					0	80.0ug	.240mg					
TBA MXB		10.4mg	/ P<1.	- .194mg n.s.s.	16/25	23/50	28/50					
liv MXB		1.33mg	* P<.2	.411mg n.s.s.	1/25	1/50	5/50					liv:hpa,hpc,nnd.
ALDRIN 309-00-2												
239 M f b6c eat 80w90 TR21 :					0	.330mg	.640mg					
TBA MXB s		no dre	P=1.	- .844mg n.s.s.	1/10	11/50	5/50					
liv MXB s		no dre	P=1.	1.14mg n.s.s.	0/10	5/50	2/50					liv:hpa,hpc,nnd.
lun MXB s		9.02mg	* P<.6	2.22mg n.s.s.	0/10	1/50	1/50					lun:a/a,a/c.
240 M m b6c eat 80w90 TR21 :					0	.470mg	.840mg					
liv hpc		.741mg	* P<.007 c	.411mg 10.0mg	3/20	16/50	25/50					
lun MXA		3.20mg	* P<.05	1.45mg n.s.s.	0/20	3/50	5/50					lun:a/a,a/c. S
TBA MXB		1.01mg	* P<.08	.433mg n.s.s.	7/20	18/50	28/50					
liv MXB		.741mg	* P<.007	.411mg 10.0mg	3/20	16/50	25/50					liv:hpa,hpc,nnd.
lun MXB		3.20mg	* P<.05	1.45mg n.s.s.	0/20	3/50	5/50					lun:a/a,a/c.
241 M m b6c eat 80w89 TR21 : pool					0	.470mg	.840mg					
liv hpc		.861mg	* P<.0005 c	.467mg 3.01mg	17/95	16/50	25/50					
242 M b c3e eat 24m24 20a					0	1.25mg						Davis;txap,4,187-189;1962
liv hpa e		4.41mg	P<.0005 +	2.55mg 12.3mg	9/134	35/151						
lun car e		129.mg	P<.3	21.0mg n.s.s.	0/134	1/151						
lun ade e		no dre	P=1.	28.4mg n.s.s.	3/134	1/151						
243 M b c3e eat 24m24 22a					0	1.25mg						Epstein(review) {H J Davis};stev,4,1-52;1975
liv hpt		3.45mg	P<.0005	2.13mg 7.96mg	27/200	65/200						
liv hpc		no dre	P=1.	24.4mg n.s.s.	4/200	3/200						
tba ben		4.25mg	P<.0005	2.43mg 13.8mg	30/200	61/200						
tba mal		no dre	P=1.	24.7mg n.s.s.	21/200	9/200						
244 R b osm eat 24m24 23					0	22.5ug	90.0ug	.450mg	2.25mg	4.50mg	6.75mg	Fitzhugh;fctx,2,551-562;1964
lun lys es		42.3mg	* P<.5	7.89mg n.s.s.	1/17	5/19	2/19	2/22	2/18	4/11	1/9	
tba mix es		no dre	P=1.	+ 10.0mg n.s.s.	3/17	10/19	7/19	8/22	5/18	5/11	1/9	
245 R f osm eat 19m26 TR21 :					0	1.07mg	2.14mg					
TBA MXB		no dre	P=1.	- 1.55mg n.s.s.	5/10	35/50	32/50					
liv MXB		466.mg	* P<1.	9.99mg n.s.s.	1/10	1/50	3/50					liv:hpa,hpc,nnd.
246 R f osm eat 19m25 TR21 : pool					0	1.07mg	2.14mg					
adr coa #		3.12mg	\ P<.0005 -	1.41mg 10.2mg	0/60	8/50	(1/50)					S
247 R f osm eat 25m25 21					0	.250mg						Deichmann;txap,11,88-103;1967
liv tum		no dre	P=1.	- 1.67mg n.s.s.	0/30	0/30						
tba mix		no dre	P=1.	- .298mg n.s.s.	13/30	13/30						
248 R f osm eat 26m27 1004					0	.956mg	1.44mg	2.38mg				Deichmann;imed,39,426-434;1970
liv tum ev		no dre	P=1.	- 5.05mg n.s.s.	0/88	0/47	0/44	0/31				
tba mix ev		no dre	P=1.	- 5.18mg n.s.s.	60/88	20/47	24/44	(11/31)				
249 R f osm eat 24m24 1040					0	1.00mg	2.50mg					Deichmann;txoc,407-413;1979
lmr tum es		4.35mg	\ P<.03	- 1.76mg n.s.s.	2/50	9/50	(4/50)					
liv tum es		no dre	P=1.	- 7.36mg n.s.s.	0/50	0/50	0/50					
tba tum es		1.69mg	\ P<.3	.487mg n.s.s.	35/50	40/50	(18/50)					
tba mal es		no dre	P=1.	5.80mg n.s.s.	10/50	14/50	10/50					
250 R m osm eat 17m26 TR21 :					0	.800mg	1.60mg					
TBA MXB		16.4mg	* P<.9	- .875mg n.s.s.	9/10	30/50	30/50					
liv MXB		no dre	P=1.	6.34mg n.s.s.	1/10	1/50	1/50					liv:hpa,hpc,nnd.
251 R m osm eat 25m25 21					0	.200mg						Deichmann;txap,11,88-103;1967
liv tum		no dre	P=1.	- 1.33mg n.s.s.	0/30	0/30						
tba mix		4.21mg	P<.6	- .579mg n.s.s.	1/30	2/30						
252 R m osm eat 29m31 1004					0	.765mg	1.15mg	1.93mg				Deichmann;imed,39,426-434;1970
liv hem ev		no dre	P=1.	- 5.75mg n.s.s.	1/75	0/45	0/46	0/45				
tba mix ev		no dre	P=1.	- 22.9mg n.s.s.	19/75	5/45	7/46	4/45				
253 R f nss eat 24m24 1002					0	.125mg	.625mg	1.25mg				Cleveland;aenh,13,195-198;1966
tba tum		no dre	P=1.	- 8.27mg n.s.s.	6/60	1/40	3/40	1/40				
254 R m nss eat 24m24 1002					0	.100mg	.500mg	1.00mg				
tba tum		no dre	P=1.	- 8.67mg n.s.s.	3/60	1/40	0/40	1/40				
255 R f sda eat 24m24 1040					0	1.00mg	2.50mg					Deichmann;txoc,407-413;1979
liv tum es		no dre	P=1.	- 7.36mg n.s.s.	0/50	0/50	0/50					
tba tum es		no dre	P=1.	11.5mg n.s.s.	9/50	8/50	5/50					
tba mal es		no dre	P=1.	17.8mg n.s.s.	2/50	2/50	1/50					
ALKYLBENZENESULFONATE, LINEAR 42615-29-2												
256 R f sls eat 33m34 570					0	20.0mg	80.0mg	300.mg				Hiraga;gann,68,369-370;1977
pre mix er		no dre	P=1.	- 1.09gm n.s.s.	1/13	3/15	3/13	1/15				
257 R m sls eat 30m32 570					0	16.0mg	64.0mg	240.mg				
pre mix er		no dre	P=1.	- 1.04gm n.s.s.	1/12	2/12	1/12	0/12				
ALKYLDIMETHYLAMINE OXIDES, COMMERCIAL GRADE mixture												
258 R f cdr eat 24m24 1697					0	5.00mg	50.0mg	100.mg				Cardin;faat,5,869-878;1985
pit ade er		230.mg	* P<.2	- 73.8mg n.s.s.	32/49	26/50	28/50	36/50				
259 R m cdr eat 24m24 1697					0	4.00mg	40.0mg	80.0mg				
pit ade er		236.mg	Z P<.03	- 103.mg n.s.s.	16/50	4/50	11/50	20/49				
ALLANTOIN 97-59-6												
260 R f f34 eat 25m30 1654					0	82.5mg						Lijinsky;fctx,22,715-720;1984
liv nnd e		no dre	P=1.	- 217.mg n.s.s.	4/24	3/20						

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
261 R m f34 eat 25m30 1654					0	66.0mg			
liv nnd e	no dre	P=1.	-	241.mg n.s.s.	5/24	2/20			
ALLYL ALCOHOL 107-18-6									
262 R f f34 wat 25m29 1853					0	10.4mg			Lijinsky;txih,3,337-345;1987/pers.comm.
liv hpc e	64.2mg	P<.04		19.4mg n.s.s.	0/20	3/20			
liv mix e	41.5mg	P<.2		13.1mg n.s.s.	2/20	6/20			
liv hnd e	182.mg	P<.7		22.8mg n.s.s.	2/20	3/20			
adr coa e	no dre	P=1.		62.7mg n.s.s.	1/20	0/20			
263 R m f34 wat 25m29 1853					0	7.26mg			
liv mix e	128.mg	P<.7		16.0mg n.s.s.	2/20	3/20			
liv hpc e	142.mg	P<.3		23.2mg n.s.s.	0/20	1/20			
liv hnd e	no dre	P=1.		20.8mg n.s.s.	2/20	2/20			
adr coa e	no dre	P=1.		43.9mg n.s.s.	1/20	0/20			
ALLYL CHLORIDE (chloropropene) 107-05-1									
264 M f b6c gav 78w91 TR73 :					0	78.0mg	156.mg		
sto MXA dvh	706.mg *	P<.2	a	288.mg n.s.s.	0/20	3/50	3/50		sto:sqc,sqp.
TBA MXB dv	343.mg *	P<.3		106.mg n.s.s.	4/20	18/50	15/50		
liv MXB dv	2.18gm *	P<.4		536.mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB dv	1.25gm *	P<.6		258.mg n.s.s.	1/20	5/50	4/50		lun:a/a,a/c.
265 M m b6c gav 67w91 TR73 :					0	106.mg	198.mg		
sto MXA adsvh	727.mg *	P<.4	a	176.mg n.s.s.	0/20	2/50	0/50		sto:sqc,sqp.
TBA MXB adsv	184.mg *	P<.4		46.9mg n.s.s.	5/20	19/50	3/50		
liv MXB adsv	457.mg *	P<.6		83.8mg n.s.s.	2/20	8/50	1/50		liv:hpa,hpc,nnd.
lun MXB adsv	no dre	P=1.		144.mg n.s.s.	3/20	6/50	0/50		lun:a/a,a/c.
266 R f osm gav 18m26 TR73 :					0	27.9mg	37.1mg		
TBA MXB sv	35.2mg *	P<.2	i	13.4mg n.s.s.	12/20	26/50	11/50		
liv MXB sv	no dre	P=1.		175.mg n.s.s.	2/20	0/50	0/50		liv:hpa,hpc,nnd.
267 R m osm gav 18m26 TR73 :					0	28.8mg	39.8mg		
TBA MXB sv	28.1mg *	P<.2	i	8.98mg n.s.s.	9/20	15/50	4/50		
liv MXB sv	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
ALLYL GLYCIDYL ETHER 106-92-3									
268 M f b6c inh 24m24 TR376 :					0	7.13mg	14.3mg		
hag ade	121.mg *	P<.02		46.0mg n.s.s.	0/50	0/50	5/50		S
nre ade	614.mg *	P<.3	e	100.mg n.s.s.	0/50	0/50	1/50		
TBA MXB	no dre	P=1.		25.0mg n.s.s.	35/50	21/50	31/50		
liv MXB	no dre	P=1.		84.8mg n.s.s.	6/50	5/50	2/50		liv:hpa,hpc,nnd.
lun MXB	123.mg *	P<.03		46.7mg n.s.s.	0/50	1/50	4/50		lun:a/a,a/c.
269 M m b6c inh 24m24 TR376 :					0	5.94mg	11.9mg		
nre ade	182.mg *	P<.06	p	55.0mg n.s.s.	0/50	0/50	3/50		
TBA MXB	no dre	P=1.		9.02mg n.s.s.	32/50	26/50	(21/50)		
liv MXB	no dre	P=1.		20.6mg n.s.s.	23/50	11/50	(6/50)		liv:hpa,hpc,nnd.
lun MXB	727.mg *	P<1.		27.8mg n.s.s.	7/50	9/50	9/50		lun:a/a,a/c.
270 R f osm inh 24m25 TR376 :					0	1.70mg	3.40mg		
TBA MXB	25.9mg *	P<.9	-	1.78mg n.s.s.	43/50	47/50	44/50		
liv MXB	no dre	P=1.		29.7mg n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
271 R m osm inh 24m25 TR376 :					0	1.19mg	2.38mg		
MXA MXA s	14.9mg *	P<.04	e	3.48mg n.s.s.	0/50	0/50	3/50		nof:adc; nre:ppa,sqc.
TBA MXB s	1.01mg *	P<.02		.457mg n.s.s.	30/50	37/50	38/50		
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
ALLYL ISOTHIOCYANATE 57-06-7									
272 M f b6c gav 24m24 TR234 :					0	8.41mg	17.5mg		
TBA MXB	no dre	P=1.	-	15.1mg n.s.s.	18/50	20/50	20/50		
liv MXB	no dre	P=1.		56.1mg n.s.s.	2/50	3/50	1/50		liv:hpa,hpc,nnd.
lun MXB	632.mg *	P<.9		45.8mg n.s.s.	2/50	2/50	3/50		lun:a/a,a/c.
273 M m b6c gav 24m24 TR234 :					0	8.41mg	17.5mg		
lun a/c #	118.mg *	P<.04	-	40.7mg n.s.s.	0/50	1/50	3/50		S
TBA MXB	no dre	P=1.		17.0mg n.s.s.	33/50	22/50	26/50		
liv MXB	no dre	P=1.		18.6mg n.s.s.	21/50	14/50	19/50		liv:hpa,hpc,nnd.
lun MXB	106.mg *	P<.4		26.9mg n.s.s.	4/50	4/50	7/50		lun:a/a,a/c.
274 R f f34 gav 24m24 TR234 :					0	8.41mg	17.5mg		
sub fbs	207.mg *	P<.04	a	61.9mg n.s.s.	0/50	0/50	3/50		
TBA MXB	157.mg *	P<.9		10.3mg n.s.s.	42/50	43/50	42/50		
liv MXB	568.mg *	P<.3		92.6mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
275 R m f34 gav 24m24 TR234 :					0	8.41mg	17.5mg		
--- MXA e	54.3mg *	P<.03		24.1mg n.s.s.	2/50	7/50	8/50		---:lhc,ule. S
--- ule e	57.2mg *	P<.03		25.0mg n.s.s.	2/50	6/50	8/50		S
ubl tpp e	96.0mg *	P<.02	c	39.1mg n.s.s.	0/50	2/50	4/50		
TBA MXB e	38.0mg *	P<.5		8.77mg n.s.s.	38/50	45/50	39/50		
liv MXB e	174.mg *	P<.2		47.7mg n.s.s.	2/50	0/50	5/50		liv:hpa,hpc,nnd.
ALLYL ISOVALERATE 2835-39-4									
276 M f b6c gav 24m25 TR253 :					0	21.5mg	43.2mg		
--- MXA	62.8mg *	P<.03	c	26.6mg n.s.s.	11/50	11/50	18/50		---:mlh,mlm,mlp.
--- mlm	102.mg *	P<.08	c	37.7mg n.s.s.	6/50	5/50	10/50		
--- mlh	238.mg *	P<.02	c	88.9mg n.s.s.	0/50	1/50	4/50		
TBA MXB	65.5mg *	P<.3		19.8mg n.s.s.	31/50	20/50	30/50		
liv MXB	no dre	P=1.		197.mg n.s.s.	3/50	0/50	1/50		liv:hpa,hpc,nnd.
lun MXB	4.45gm *	P<1.		90.6mg n.s.s.	4/50	4/50	3/50		lun:a/a,a/c.
277 M m b6c gav 24m25 TR253 :					0	21.5mg	43.2mg		
gam sqp #	295.mg *	P<.04	-	100.mg n.s.s.	0/50	1/50	3/50		S
TBA MXB	206.mg *	P<.8		25.0mg n.s.s.	36/50	33/50	34/50		
liv MXB	no dre	P=1.		67.8mg n.s.s.	23/50	14/50	15/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		134.mg n.s.s.	13/50	6/50	5/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
278 R f f34 gav 24m25 TR253 :					0	21.5mg	43.2mg		
TBA MXB	43.5mg	* P<.08	-	17.3mg n.s.s.	38/50	43/50	43/50		
liv MXB	no dre	P=1.		276.mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
279 R m f34 gav 24m25 TR253 :					0	21.5mg	43.2mg		
--- MXA	123.mg	* P<.004	c	59.7mg 934.mg	1/50	4/50	9/50		---:mle,mlh.
pre MXA	136.mg	* P<.03		58.6mg n.s.s.	0/50	5/50	2/50		pre:adn,can,sqc. S
--- mle	149.mg	* P<.02	c	66.7mg n.s.s.	1/50	4/50	7/50		
TBA MXB	50.5mg	* P<.2		17.3mg n.s.s.	38/50	37/50	37/50		
liv MXB	264.mg	* P<.2		79.8mg n.s.s.	1/50	2/50	3/50		liv:hpa,hpc,nnd.
1-ALLYL-1-NITROSOUREA 760-56-5									
280 R f f34 gav 7m24 1915					0	.608mg			Lijinsky;txih,5,925-935;1989
for tum	.476mg	P<.0005	+	.197mg 1.66mg	0/12	7/12			
mgl adc	.601mg	P<.002	+	.238mg 2.70mg	0/12	6/12			
ute mix	1.87mg	P<.4	+	.399mg n.s.s.	2/12	4/12			
liv tum	no dre	P=1.		1.50mg n.s.s.	0/12	0/12			
lun mix	no dre	P=1.		1.50mg n.s.s.	1/12	0/12			
281 R m f34 gav 7m24 1915					0	.426mg			
for tum	.266mg	P<.0005	+	.113mg .812mg	0/12	8/12			
lun mix	.421mg	P<.002	+	.167mg 1.89mg	0/12	6/12			
col tum	.541mg	P<.005	+	.201mg 4.34mg	0/12	5/12			
zym tum	.541mg	P<.005		.201mg 4.34mg	0/12	5/12			
ALLYLHYDRAZINE.HCl 52207-83-7									
282 M f swa wat 24m24 1051					0	25.0mg			Toth;bjca,34,90-93;1976
lun mix e	38.4mg	P<.0005	+	19.3mg 156.mg	21/99	25/50			
lun ade e	46.1mg	P<.002		22.3mg 232.mg	18/99	22/50			
lun adc e	96.0mg	P<.003		41.4mg 688.mg	4/99	10/50			
blv mix e	119.mg	P<.02	+	46.5mg n.s.s.	5/99	9/50			
blv agm e	163.mg	P<.02		59.1mg n.s.s.	2/99	6/50			
liv mix e	234.mg	P<.09		69.6mg n.s.s.	3/99	5/50			
283 M m swa wat 93w93 1051					0	20.8mg			
lun ade e	28.9mg	P<.0005		14.4mg 112.mg	15/99	21/49			
lun mix e	30.9mg	P<.005	+	14.2mg 312.mg	23/99	23/49			
liv hpt e	274.mg	P<.04	-	67.4mg n.s.s.	0/99	2/49			
liv mix e	no dre	P=1.		95.1mg n.s.s.	6/99	2/49			
ALUMINUM POTASSIUM SULFATE 10043-67-1									
284 M f cd1 wat 31m31 1395					0	1.00mg			Schroeder;jnut,105,452-458;1975
--- lkm e	5.32mg	P<.02	-	2.19mg n.s.s.	3/47	10/41			
lun tum e	11.4mg	P<.4	-	2.55mg n.s.s.	9/47	11/41			
tba mal e	4.42mg	P<.02	-	1.90mg n.s.s.	4/47	12/41			
tba mix e	4.23mg	P<.2	-	1.48mg n.s.s.	14/47	19/41			
285 M m cd1 wat 35m35 1395					0	.833mg			
lun tum e	11.4mg	P<.4	-	2.95mg n.s.s.	5/38	9/41			
tba mal e	6.29mg	P<.03	-	2.52mg n.s.s.	2/38	9/41			
tba mix e	10.7mg	P<.5	-	2.21mg n.s.s.	11/38	15/41			
286 R f leb wat 38m38 1456					0	.286mg			Schroeder;jnut,105,421-427;1975
tba mix e	4.68mg	P<.9	-	.305mg n.s.s.	17/24	14/19			
tba mal e	no dre	P=1.	-	.795mg n.s.s.	8/24	6/19			
287 R m leb wat 36m36 1456					0	.250mg			
tba mix e	.663mg	P<.006	-	.295mg 7.63mg	4/26	13/25			
tba mal e	1.93mg	P<.2	-	.615mg n.s.s.	2/26	6/25			
1-AMINO-2,4-DIBROMOANTHRAQUINONE 81-49-2									
288 M f b6c eat 24m24 TR383 :					0	1.29gm	2.60gm		
liv MXA	490.mg	\ P<.0005	c	312.mg 912.mg	6/50	46/50	(50/50)		liv:hpa,hpc.
liv hpa	515.mg	\ P<.0005	c	327.mg 965.mg	6/50	45/50	(49/50)		
MXB MXB	546.mg	\ P<.0005		328.mg 1.18gm	12/50	48/50	(50/50)		for:sqc,sqp; liv:hpa,hpc; lun:a/a,a/c. C
for MXA	1.23gm	* P<.0005	c	856.mg 2.04gm	2/50	25/50	34/50		for:sqc,sqp.
liv hpc	1.53gm	* P<.0005	c	1.08gm 2.28gm	0/50	23/50	27/50		
for sqp	1.76gm	* P<.0005	c	1.15gm 3.28gm	2/50	16/50	27/50		
lun a/a	1.99gm	\ P<.003	c	966.mg 10.9gm	4/50	17/50	(13/50)		
lun MXA	1.99gm	\ P<.003	c	966.mg 10.9gm	4/50	17/50	(15/50)		lun:a/a,a/c.
pit pda	3.75gm	\ P<.006		1.64gm 38.3gm	1/50	9/50	(4/50)		S
for sqc	3.93gm	* P<.0005	c	2.39gm 8.33gm	0/50	12/50	11/50		
ute MXA	6.82gm	\ P<.008		2.57gm 107.gm	0/50	5/50	(0/50)		ute:esp,ess. S
TBA MXB	1.03gm	\ P<.02		461.mg n.s.s.	32/50	50/50	(50/50)		
liv MXB	490.mg	\ P<.0005		312.mg 912.mg	6/50	46/50	(50/50)		liv:hpa,hpb,hpc.
lun MXB	1.99gm	\ P<.003		966.mg 10.9gm	4/50	17/50	(15/50)		lun:a/a,a/c.
289 M m b6c eat 24m24 TR383 :					0	1.20gm	2.40gm		
liv hpa	464.mg	\ P<.0005	c	275.mg 955.mg	10/50	38/51	(39/50)		
MXB MXB	465.mg	\ P<.0005		261.mg 1.17gm	24/50	46/51	(45/50)		for:sqc,sqp; liv:hpa,hpb,hpc; lun:a/a,a/c. C
liv MXA	467.mg	\ P<.0005	c	269.mg 1.06gm	18/50	43/51	(42/50)		liv:hpa,hpc.
liv MXA	467.mg	\ P<.0005	c	269.mg 1.06gm	18/50	43/51	(42/50)		liv:hpa,hpb,hpc.
lun MXA	817.mg	\ P<.0005	c	445.mg 2.18gm	10/50	28/51	(25/50)		lun:a/a,a/c.
lun a/a	831.mg	\ P<.0005	c	461.mg 2.03gm	7/50	26/51	(24/50)		
for MXA	1.13gm	* P<.0005	c	773.mg 1.72gm	0/50	19/51	27/50		for:sqc,sqp.
for sqp	1.68gm	* P<.0005	c	1.07gm 2.87gm	0/50	13/51	16/50		
liv MXA	1.87gm	* P<.0005	c	1.07gm 5.46gm	9/50	20/51	24/50		liv:hpb,hpc.
liv hpc	2.24gm	* P<.0005	c	1.22gm 8.72gm	9/50	18/51	21/50		
for sqc	2.73gm	* P<.0005	c	1.67gm 4.97gm	0/50	12/51	13/50		
liv hpb	9.25gm	* P<.004	c	4.12gm 55.1gm	0/50	3/51	5/50		
TBA MXB	566.mg	\ P<.002		289.mg 2.58gm	37/50	49/51	(47/50)		
liv MXB	467.mg	\ P<.0005		269.mg 1.06gm	18/50	43/51	(42/50)		liv:hpa,hpb,hpc.
lun MXB	817.mg	\ P<.0005		445.mg 2.18gm	10/50	28/51	(25/50)		lun:a/a,a/c.
290 R f f34 eat 24m24 TR383 :					0	99.2mg	247.mg	495.mg	
MXB MXB	31.0mg	Z P<.0005		20.8mg 48.8mg	0/50	39/40	(60/60	48/50)	cec:pla; col:adc,pla; kid:rua,ruc; liv:hcc,hpa,

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
								hpc; rec:adc,pla; ubl:tcc,tpp,tsc,tsp.	C
liv MXA	40.1mg Z	P<.0005 c	26.2mg 65.7mg	0/50	33/40	(59/60	47/50)	liv:hpa,hpc.	
liv hpa	53.9mg Z	P<.0005 c	34.1mg 92.2mg	0/50	28/40	(47/60	29/50)		
MXA pla	72.9mg *	P<.0005 c	57.1mg 94.9mg	0/50	28/40	53/60	43/50	cec:pla; col:pla; rec:pla.	
rec pla	74.0mg *	P<.0005	57.9mg 96.4mg	0/50	27/40	53/60	43/50		S
liv hpc	88.4mg *	P<.0005 c	68.5mg 116.mg	0/50	12/40	57/60	45/50		
ubl MXA	304.mg Z	P<.0005 c	208.mg 466.mg	0/50	2/40	17/60	26/50	ubl:tcc,tpp,tsc,tsp.	
kid MXA	388.mg *	P<.0005 c	254.mg 628.mg	0/50	3/40	16/60	16/50	kid:rua,ruc.	
kid rua	388.mg *	P<.0005 c	254.mg 628.mg	0/50	3/40	16/60	16/50		
MXA adc	414.mg *	P<.0005 c	266.mg 699.mg	0/50	2/40	21/60	8/50	col:adc; rec:adc.	
rec adc	420.mg Z	P<.0005	246.mg 798.mg	0/50	1/40	19/60	(7/50)		S
liv hcc	566.mg Z	P<.0005 c	343.mg 1.02gm	0/50	0/40	11/60	13/50		
ubl tcc	656.mg Z	P<.0005 c	394.mg 1.18gm	0/50	0/40	8/60	16/50		
ubl tpp	782.mg *	P<.0005	446.mg 1.54gm	0/50	2/40	7/60	9/50		S
ski sqp	2.60gm *	P<.03	933.mg n.s.s.	1/50	0/40	3/60	3/50		S
TBA MXB	160.mg *	P<.0005	93.0mg 457.mg	46/50	40/40	60/60	48/50		
liv MXB	40.1mg Z	P<.0005	26.2mg 65.7mg	0/50	33/40	(59/60	47/50)	liv:hpa,hpb,hpc.	
291 R f f34 eat 66w66 TR383a :				0	1.00gm				
liv MXA	121.mg	P<.0005	65.9mg 289.mg	0/10	16/20			liv:hpa,hpc.	S
liv hpc	124.mg	P<.0005	66.9mg 309.mg	0/10	15/20				S
liv hpa	219.mg	P<.002	106.mg 787.mg	0/10	10/20				S
MXA pla	1.27gm	P<.08	381.mg n.s.s.	0/10	3/20			cec:pla; col:pla; rec:pla.	
kid MXA	1.52gm	P<.2	373.mg n.s.s.	0/10	2/20			kid:rua,ruc.	
kid rua	1.52gm	P<.2	373.mg n.s.s.	0/10	2/20				
ubl MXA	2.19gm	P<.2	535.mg n.s.s.	0/10	2/20			ubl:tcc,tpp,tsc,tsp.	
ubl tcc	4.83gm	P<.4	787.mg n.s.s.	0/10	1/20				
kid ruc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/20				
liv hcc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/20				
MXA adc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/20			col:adc; rec:adc.	
TBA MXB	147.mg	P<.002	71.1mg 803.mg	2/10	17/20				
liv MXB	121.mg	P<.0005	65.9mg 289.mg	0/10	16/20			liv:hpa,hpb,hpc.	
292 R f f34 eat 40w66 TR383b :				0	606.mg				
liv MXA	121.mg	P<.002	54.5mg 484.mg	0/10	8/10			liv:hpa,hpc.	S
liv hpc	167.mg	P<.004	68.3mg 1.16gm	0/10	6/10				S
liv hpa	191.mg	P<.004	77.5mg 1.30gm	0/10	6/10				S
MXA pla	217.mg	P<.007	82.6mg 3.52gm	0/10	5/10			cec:pla; col:pla; rec:pla.	S
rec pla	217.mg	P<.007	82.6mg 3.52gm	0/10	5/10				S
kid MXA	418.mg	P<.04	127.mg n.s.s.	0/10	3/10			kid:rua,ruc.	S
kid rua	418.mg	P<.04	127.mg n.s.s.	0/10	3/10				S
kid ruc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/10				
liv hcc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/10				
MXA adc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/10			col:adc; rec:adc.	
ubl tcc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/10				
ubl MXA	no dre	P=1.	n.s.s. n.s.s.	0/10	0/10			ubl:tcc,tpp,tsc,tsp.	
TBA MXB	135.mg	P<.02	51.5mg n.s.s.	2/10	9/10				
liv MXB	121.mg	P<.002	54.5mg 484.mg	0/10	8/10			liv:hpa,hpb,hpc.	
293 R m f34 eat 24m24 TR383 :				0	79.5mg	198.mg	396.mg		
liv MXA	53.8mg *	P<.0005 c	40.4mg 76.2mg	2/50	25/40	57/60	47/50	liv:hpa,hpc.	
MXB MXB	54.6mg *	P<.0005	40.3mg 80.3mg	4/50	30/40	59/60	48/50	col:adc,pla; kid:rua,ruc; liv:hcc,hpa,hpc; rec: adc,pla; ubl:tcc,tpp.	C
liv hpc	59.6mg Z	P<.0005 c	42.2mg 88.5mg	1/50	12/40	55/60	(46/50)		
rec pla	64.3mg *	P<.0005	48.4mg 86.9mg	0/50	13/40	51/60	40/50		S
MXA pla	64.3mg *	P<.0005 c	48.4mg 86.9mg	0/50	13/40	51/60	40/50	col:pla; rec:pla.	
liv hpa	71.4mg *	P<.0005 c	52.5mg 105.mg	1/50	20/40	40/60	34/50		
tes MXA	133.mg *	P<.002	70.4mg 630.mg	43/50	37/40	55/60	42/50	tes:iab,ica.	S
kid MXA	264.mg *	P<.0005 c	157.mg 637.mg	2/50	10/40	13/60	15/50	kid:rua,ruc.	
kid rua	292.mg *	P<.0005 c	168.mg 782.mg	2/50	10/40	11/60	14/50		
MXA adc	320.mg *	P<.0005 c	197.mg 556.mg	0/50	1/40	11/60	17/50	col:adc; rec:adc.	
rec adc	363.mg *	P<.0005	218.mg 650.mg	0/50	1/40	10/60	15/50		S
ubl MXA	564.mg Z	P<.0005 c	304.mg 1.18gm	0/50	1/40	3/60	12/50	ubl:tcc,tpp.	
lun MXA	794.mg *	P<.005	379.mg 7.40gm	0/50	3/40	4/60	4/50	lun:a/a,a/c.	S
ubl tpp	846.mg *	P<.0005	404.mg 2.30gm	0/50	1/40	2/60	8/50		S
liv hcc	1.23gm *	P<.005 c	524.mg 9.78gm	0/50	0/40	6/60	2/50		
ubl tcc	1.79gm *	P<.003 c	667.mg 11.0gm	0/50	0/40	1/60	4/50		
col adc	2.01gm *	P<.004	718.mg 13.6gm	0/50	0/40	1/60	4/50		S
lun a/a	1.29gm *	P<.02	523.mg n.s.s.	0/50	2/40	2/60	3/50		S
col pla	1.66gm *	P<.02	609.mg n.s.s.	0/50	1/40	1/60	3/50		S
TBA MXB	130.mg *	P<.002	70.0mg 532.mg	47/50	40/40	59/60	48/50		
liv MXB	53.8mg *	P<.0005	40.4mg 76.2mg	2/50	25/40	57/60	47/50	liv:hpa,hpb,hpc.	
294 R m f34 eat 66w66 TR383a :				0	800.mg				
liv MXA	102.mg	P<.0005	59.6mg 227.mg	0/10	20/20			liv:hpa,hpc.	S
liv hpc	114.mg	P<.0005	65.7mg 259.mg	0/10	19/20				S
liv hpa	386.mg	P<.008	174.mg 5.76gm	0/10	8/20				S
MXA pla	426.mg	P<.02	184.mg n.s.s.	0/10	7/20			col:pla; rec:pla.	S
rec pla	426.mg	P<.02	184.mg n.s.s.	0/10	7/20				S
kid MXA	1.77gm	P<.2	434.mg n.s.s.	0/10	2/20			kid:rua,ruc.	
kid rua	1.77gm	P<.2	434.mg n.s.s.	0/10	2/20				
MXA adc	1.87gm	P<.2	461.mg n.s.s.	0/10	2/20			col:adc; rec:adc.	
ubl tcc	3.64gm	P<.4	593.mg n.s.s.	0/10	1/20				
ubl MXA	3.64gm	P<.4	593.mg n.s.s.	0/10	1/20			ubl:tcc,tpp.	
liv hcc	no dre	P=1.	n.s.s. n.s.s.	0/10	0/20				
TBA MXB	193.mg	P<.07	76.2mg n.s.s.	5/10	20/20				
liv MXB	102.mg	P<.0005	59.6mg 227.mg	0/10	20/20			liv:hpa,hpb,hpc.	
295 R m f34 eat 39w66 TR383b :				0	473.mg				
liv MXA	70.3mg	P<.0005	32.0mg 227.mg	0/10	9/10			liv:hpa,hpc.	S
liv hpc	95.8mg	P<.002	40.5mg 395.mg	0/10	7/10				S
liv hpa	97.8mg	P<.002	41.1mg 414.mg	0/10	7/10				S
kid MXA	239.mg	P<.03	72.4mg n.s.s.	0/10	3/10			kid:rua,ruc.	S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
kid rua	239.mg	P<.03	72.4mg	n.s.s.	0/10	3/10			S
MXA pla	297.mg	P<.03	88.0mg	n.s.s.	0/10	3/10			col:pla; rec:pla. S
rec pla	297.mg	P<.03	88.0mg	n.s.s.	0/10	3/10			S
liv hcc	1.24gm	P<.3	202.mg	n.s.s.	0/10	1/10			
MXA adc	no dre	P=1.	n.s.s.	n.s.s.	0/10	0/10			col:adc; rec:adc.
ubl tcc	no dre	P=1.	n.s.s.	n.s.s.	0/10	0/10			
ubl MXA	no dre	P=1.	n.s.s.	n.s.s.	0/10	0/10			ubl:tcc,tpp.
TBA MXB	123.mg	P<.2	38.4mg	n.s.s.	5/10	9/10			
liv MXB	70.3mg	P<.0005	32.0mg	227.mg	0/10	9/10			liv:hpa,hpb,hpc.
3-AMINO-4-ETHOXYACETANILIDE 17026-81-2									
296 M f b6c eat 78w93 TR112 :					0	432.mg	845.mg		
pit MXA #	1.05gm \	P<.009 -	452.mg	39.2gm	7/100	14/50	(3/50)		pit:adn,can,cra. S
TBA MXB	569.mg \	P<.02	253.mg	n.s.s.	27/100	32/50	(21/50)		
liv MXB	no dre	P=1.	2.94gm	n.s.s.	5/100	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB	8.63gm *	P<.4	1.92gm	n.s.s.	4/100	6/50	3/50		lun:a/a,a/c.
297 M m b6c eat 78w93 TR112 :					0	398.mg	780.mg		
thy MXA	2.07gm /	P<.0005 c	1.04gm	6.70gm	2/100	2/50	12/48		thy:acn,adn,fca,fcc.
thy fcc	3.77gm /	P<.0005 c	1.63gm	12.6gm	0/100	0/50	7/48		
thy MXA	4.02gm *	P<.02 c	1.60gm	n.s.s.	2/100	1/50	7/48		thy:acn,fcc.
TBA MXB	no dre	P=1.	879.mg	n.s.s.	41/100	28/50	19/48		
liv MXB	8.99gm \	P<.9	660.mg	n.s.s.	20/100	13/50	(2/48)		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	3.47gm	n.s.s.	17/100	7/50	3/48		lun:a/a,a/c.
298 R f f34 eat 18m25 TR112 :					0	138.mg	552.mg		
adr MXA #	415.mg \	P<.005 -	175.mg	5.02gm	5/100	11/48	(0/50)		adr:coa,coc. S
TBA MXB	no dre	P=1.	763.mg	n.s.s.	80/100	37/48	30/50		
liv MXB	717.mg \	P<.002	272.mg	3.45gm	0/100	5/48	(2/50)		liv:hpa,hpc,nnd.
299 R m f34 eat 18m25 TR112 :					0	110.mg	442.mg		
thy ccr #	610.mg \	P<.05 -	213.mg	n.s.s.	3/99	7/50	(4/50)		S
TBA MXB	no dre	P=1.	142.mg	n.s.s.	62/99	34/50	(24/50)		
liv MXB	no dre	P=1.	2.66gm	n.s.s.	6/99	5/50	1/50		liv:hpa,hpc,nnd.
3-AMINO-9-ETHYLCARBAZOLE.HCl 6109-97-3									
300 M f b6c eat 78w95 TR93 :					0	127.mg			
liv hpc	33.0mg	P<.0005 c	22.2mg	54.1mg	1/50	43/50			
TBA MXB	41.8mg	P<.0005	25.4mg	86.2mg	10/50	46/50			
liv MXB	33.0mg	P<.0005	22.2mg	54.1mg	1/50	43/50			liv:hpa,hpc,nnd.
lun MXB	1.78gm	P<.6	256.mg	n.s.s.	3/50	4/50			lun:a/a,a/c.
301 M m b6c eat 78w95 TR93 :					0	118.mg			
liv hpc	46.4mg	P<.0005 c	28.6mg	95.0mg	6/50	41/50			
liv MXA	49.8mg	P<.0005 c	29.8mg	111.mg	8/50	41/50			liv:hpa,hpc.
TBA MXB	70.6mg	P<.005	34.7mg	688.mg	22/50	45/50			
liv MXB	49.8mg	P<.0005	29.8mg	111.mg	8/50	41/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	277.mg	n.s.s.	10/50	7/50			lun:a/a,a/c.
302 R f f34 eat 18m25 TR93 :					0	73.0mg			
MXB MXB	55.1mg	P<.0005	32.7mg	105.mg	1/50	25/50			liv:hpc,nnd; ute:acn; zym:can,sqc. C
ute acn	106.mg	P<.0005 c	50.9mg	339.mg	1/50	11/50			
zym MXA	151.mg	P<.0005 c	75.5mg	355.mg	0/50	12/50			zym:can,sqc.
zym sqc	212.mg	P<.0005 c	96.9mg	616.mg	0/50	9/50			
liv MXA	237.mg	P<.002 c	93.9mg	1.04gm	0/50	6/50			liv:hpc,nnd.
TBA MXB	44.7mg	P<.007	21.2mg	699.mg	38/50	45/50			
liv MXB	237.mg	P<.002	93.9mg	1.04gm	0/50	6/50			liv:hpa,hpc,nnd.
303 R m f34 eat 18m25 TR93 :					0	58.4mg			
MXB MXB	28.1mg	P<.0005	17.7mg	49.7mg	1/49	33/50			liv:hpc,nnd; ski:bcc,sqc,sqp; sub:sqc; zym:can,sqc. C
liv MXA	39.2mg	P<.0005 c	22.8mg	82.3mg	1/49	22/50			liv:hpc,nnd.
liv hpc	156.mg	P<.007 c	64.8mg	2.66gm	1/49	8/50			
MXA MXA	203.mg	P<.003 c	81.4mg	1.13gm	0/49	6/50			ski:bcc,sqc,sqp; sub:sqc.
zym MXA	240.mg	P<.003 c	102.mg	1.06gm	0/49	7/50			zym:can,sqc.
MXA MXA	257.mg	P<.007 c	95.5mg	3.17gm	0/49	5/50			ski:sqc,sqp; sub:sqc.
TBA MXB	42.7mg	P<.03	18.7mg	n.s.s.	32/49	46/50			
liv MXB	39.2mg	P<.0005	22.8mg	82.3mg	1/49	22/50			liv:hpa,hpc,nnd.
3-AMINO-9-ETHYLCARBAZOLE MIXTURE (3-amino-9-ethylcarbazole and 3-amino-9-ethylcarbazole.HCl. CAS# 132-32-1 and 6109-97-3) mixture									
304 M f b6c eat 78w95 TR93 :					0	85.8mg			
liv hpc	30.5mg	P<.0005 c	20.0mg	52.1mg	1/50	37/50			
TBA MXB	59.7mg	P<.008	28.1mg	1.26gm	20/50	38/50			
liv MXB	30.5mg	P<.0005	20.0mg	52.1mg	1/50	37/50			liv:hpa,hpc,nnd.
lun MXB	7.49gm	P<1.	204.mg	n.s.s.	4/50	4/50			lun:a/a,a/c.
305 M m b6c eat 78w94 TR93 :					0	79.2mg			
liv hpc	50.4mg	P<.0005 c	28.7mg	130.mg	7/50	32/50			
TBA MXB	64.9mg	P<.007	30.9mg	914.mg	17/50	35/50			
liv MXB	50.4mg	P<.0005	28.7mg	130.mg	7/50	32/50			liv:hpa,hpc,nnd.
lun MXB	4.13gm	P<1.	165.mg	n.s.s.	6/50	6/50			lun:a/a,a/c.
306 R f f34 eat 18m24 TR93 :					0	30.0mg			
zym MXA	58.0mg	P<.0005 c	26.2mg	163.mg	0/50	10/50			zym:can,sqc.
zym sqc	95.4mg	P<.006 c	33.1mg	1.05gm	0/50	5/50			
zym can	148.mg	P<.01 c	55.4mg	7.12gm	0/50	5/50			
TBA MXB	18.2mg	P<.04	7.42mg	n.s.s.	32/50	40/50			
liv MXB	no dre	P=1.	95.3mg	n.s.s.	2/50	1/50			liv:hpa,hpc,nnd.
307 R m f34 eat 18m24 TR93 :					0	24.0mg			
MXB MXB	11.8mg	P<.0005	6.73mg	22.6mg	0/50	22/50			liv:hpc,nnd; ski:bcc,sqc,sqp; zym:can,sqc. C
liv MXA	17.1mg	P<.0005 c	8.64mg	41.7mg	0/50	12/50			liv:hpc,nnd.
liv hpc	42.6mg	P<.002 c	16.8mg	189.mg	0/50	6/50			
ski MXA	45.0mg	P<.0005 c	19.2mg	150.mg	0/50	8/50			ski:bcc,sqc,sqp.
ski MXA	62.8mg	P<.003 c	24.0mg	324.mg	0/50	6/50			ski:sqc,sqp.
zym MXA	104.mg	P<.009 c	37.4mg	3.31gm	0/50	5/50			zym:can,sqc.
TBA MXB	10.6mg	P<.0005	5.45mg	41.8mg	20/50	37/50			
liv MXB	17.1mg	P<.0005	8.64mg	41.7mg	0/50	12/50			liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

3-AMINO-4-[2-[(2-GUANIDINOTHIAZOL-4-YL)METHYLTHIO], ETHYLAMINO]-1,2,5-THIADIAZOLE 1-OXIDE.HCl (BL-6341.HCl) ---
308 R f cdr gav 24m24 2449 0 10.0mg 55.0mg 300.mg Hirth;txpy,16,273-287;1988
gam cnd r 6.27gm * P<.02 + 1.54gm n.s.s. 0/100 0/50 0/50 2/50
309 R m cdr gav 24m24 2449 0 10.0mg 55.0mg 300.mg
gam cnd r 4.14gm * P<.004 + 1.25gm 40.8gm 0/100 0/50 0/50 3/50

1-AMINO-2-METHYLANTHRAQUINONE 82-28-0
310 M f b6c eat 70w97 TR111 : 0 61.1mg 58.5mg
liv MXA aesv 174.mg * P<.07 c 68.1mg n.s.s. 4/50 12/49 2/50 liv:hpc,nnd.
TBA MXB aesv no dre P=1. 112.mg n.s.s. 22/50 16/49 4/50
liv MXB aesv 174.mg * P<.07 68.1mg n.s.s. 4/50 12/49 2/50 liv:hpa,hpc,nnd.
lun MXB aesv no dre P=1. 325.mg n.s.s. 1/50 0/49 1/50 lun:a/a,a/c.
311 M m b6c eat 70w97 TR111 : 0 56.4mg 54.0mg
TBA MXB aesv no dre P=1. - 89.9mg n.s.s. 21/50 18/50 1/50
liv MXB aesv no dre P=1. 129.mg n.s.s. 10/50 8/50 1/50 liv:hpa,hpc,nnd.
lun MXB aesv no dre P=1. 189.mg n.s.s. 11/50 5/50 (0/50) lun:a/a,a/c.
312 R f f34 eat 18m24 TR111 : 0 37.0mg 74.0mg
liv MXA v 115.mg * P<.003 c 60.8mg 602.mg 2/50 11/45 11/48 liv:hpc,nnd.
liv hpc v 182.mg * P<.002 c 89.9mg 832.mg 1/50 3/45 10/48
TBA MXB v no dre P=1. 78.4mg n.s.s. 45/50 31/45 28/48
liv MXB v 115.mg * P<.003 60.8mg 602.mg 2/50 11/45 11/48 liv:hpa,hpc,nnd.
313 R m f34 eat 18m24 TR111 : 0 30.4mg 60.0mg
MXB MXB v 34.1mg * P<.0005 22.8mg 64.6mg 3/50 27/50 28/50 kid:acn,tla,uac; liv:hpc,nnd. C
liv MXA v 39.9mg * P<.0005 c 25.8mg 83.7mg 3/50 25/50 24/50 liv:hpc,nnd.
kid MXA v 131.mg * P<.0005 c 73.2mg 270.mg 0/50 6/50 10/50 kid:acn,tla,uac.
pit MXA v 136.mg * P<.006 70.5mg 1.61gm 1/50 10/50 8/50 pit:adn,cra. S
liv hpc v 150.mg * P<.008 c 72.9mg 3.56gm 2/50 7/50 10/50
kid tla v 196.mg * P<.003 98.4mg 929.mg 0/50 5/50 6/50 S
thy MXA v 283.mg * P<.007 127.mg 3.06gm 0/50 3/50 5/50 thy:cca,ccr. S
kid MXA v 441.mg * P<.02 167.mg n.s.s. 0/50 1/50 4/50 kid:acn,uac. S
TBA MXB v 64.4mg * P<.07 26.1mg n.s.s. 26/50 42/50 35/50
liv MXB v 39.9mg * P<.0005 25.8mg 83.7mg 3/50 25/50 24/50 liv:hpa,hpc,nnd.

2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE 3775-55-1
314 R f sda eat 46w66 1126 0 26.9mg Cohen;jnci,54,841-850;1975
mgl mix ev 3.67mg P<.0005 + 2.06mg 7.05mg 2/24 29/33
mgl adc ev 7.98mg P<.0005 4.59mg 15.4mg 0/24 20/33
for sqp ev 37.0mg P<.009 + 15.1mg 855.mg 0/24 6/33
k/p tcc evh 45.2mg P<.02 + 17.1mg n.s.s. 0/24 5/33
lun alc ev 242.mg P<.3 + 39.3mg n.s.s. 0/24 1/33
liv tum ev no dre P=1. 73.8mg n.s.s. 0/24 0/33
tba mix ev 2.74mg P<.0005 1.41mg 5.35mg 2/24 31/33

2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOLE 712-68-5
315 R f sda eat 45w66 1126 0 8.18mg Cohen;jnci,54,841-850;1975
mgl mix ev .662mg P<.0005 + .293mg 1.36mg 2/24 32/33
mgl adc ev 1.20mg P<.0005 .695mg 2.16mg 0/24 28/33
for sqp ev 23.7mg P<.07 + 7.17mg n.s.s. 0/24 3/33
k/p tcc evh 73.4mg P<.3 + 11.9mg n.s.s. 0/24 1/33
lun alc ev 73.4mg P<.3 + 11.9mg n.s.s. 0/24 1/33
liv tum ev no dre P=1. 22.4mg n.s.s. 0/24 0/33
tba mix ev .662mg P<.0005 .293mg 1.36mg 2/24 32/33

2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE 38514-71-5
316 M f swi eat 46w55 1076 0 90.2mg Cohen;canr,33,1593-1597;1973
for mix e 7.87mg P<.0005 + 4.20mg 15.3mg 0/29 24/27
for sqp e 11.5mg P<.0005 6.42mg 22.3mg 0/29 21/27
liv tum e no dre P=1. 140.mg n.s.s. 0/29 0/27
lun tum e no dre P=1. 140.mg n.s.s. 0/29 0/27
tba mix e 6.83mg P<.0005 3.40mg 14.0mg 2/29 25/27
317 R f fis eat 52w68 1423 0 63.5mg Wang;carc,3,275-277;1982
for mix 5.85mg P<.0005 + 2.49mg 12.7mg 0/10 23/24
for sqp 8.94mg P<.0005 4.66mg 18.1mg 0/10 21/24
ubl mix 30.3mg P<.003 + 15.0mg 122.mg 0/10 11/24

trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL]-1,2,4-OXADIAZOLE (SQ 18506) 28754-68-9
318 M f cd1 eat 31w75 1601 0 134.mg Dunsford;jnci,73,151-160;1984
for sqc es 105.mg P<.0005 + 59.8mg 206.mg 0/50 18/49
thm lym es 262.mg P<.005 + 115.mg 2.33gm 1/50 9/49
for sqp es 1.15gm P<.1 + 283.mg n.s.s. 0/50 2/49
lun ade es 1.01gm P<.5 188.mg n.s.s. 4/50 6/49
liv hem es no dre P=1. 705.mg n.s.s. 3/50 0/49
rel mix es no dre P=1. + 234.mg n.s.s. 9/50 7/49
tba mix es no dre P=1. 138.mg n.s.s. 32/50 24/49
319 M m cd1 eat 38w75 1601 0 152.mg
thm lym es 121.mg P<.0005 + 69.5mg 240.mg 0/50 18/50
for sqc es 130.mg P<.0005 + 73.6mg 263.mg 0/50 17/50
for sqp es 514.mg P<.008 + 195.mg 9.94gm 0/50 5/50
rel mix es 492.mg P<.08 + 171.mg n.s.s. 2/50 7/50
liv hem es no dre P=1. 586.mg n.s.s. 3/50 1/50
lun ade es no dre P=1. 652.mg n.s.s. 6/50 1/50
tba mix es 29.2mg P<.0005 16.6mg 59.4mg 18/50 45/50

2-AMINO-4-NITROPHENOL 99-57-0
320 M f b6c gav 24m24 TR339 : 0 87.6mg 175.mg
TBA MXB no dre P=1. - 181.mg n.s.s. 32/50 27/50 29/50
liv MXB 2.16gm * P<.5 449.mg n.s.s. 2/50 2/50 4/50 liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun MXB	2.18gm * P<.5			450.mg n.s.s.	2/50	2/50	4/50		lun:a/a,a/c.
321 M m b6c gav 24m24 TR339 :					0	87.6mg	175.mg		
MXA MXA #	798.mg * P<.007	-		323.mg 2.80gm	0/50	1/50	5/50	abc:hem; liv:hes; mln:hes; pan:hem; spl:hes; sub:hem.	S
TBA MXB	582.mg * P<.6			103.mg n.s.s.	34/50	39/50	35/50		
liv MXB	no dre P=1.			292.mg n.s.s.	15/50	18/50	10/50		liv:hpa,hpc,nnd.
lun MXB	no dre P=1.			363.mg n.s.s.	9/50	8/50	6/50		lun:a/a,a/c.
322 R f f34 gav 24m24 TR339 :					0	87.6mg	175.mg		
TBA MXB	no dre P=1.	-		146.mg n.s.s.	42/50	39/50	39/50		
liv MXB	no dre P=1.			n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
323 R m f34 gav 24m24 TR339 :					0	87.6mg	175.mg		
tes ict s	68.2mg * P<.003			35.2mg 387.mg	39/50	39/50	36/50		S
kcx adn s	839.mg * P<.01	p		286.mg 62.3gm	0/50	1/50	3/50		
sub MXA s	458.mg * P<.05			171.mg n.s.s.	2/50	6/50	4/50		sub:fbs,fib,nfs,srn. S
sub fib s	584.mg * P<.05			213.mg n.s.s.	1/50	5/50	3/50		S
liv MXA s	1.30gm * P<.02			368.mg n.s.s.	0/50	0/50	3/50		liv:hpc,nnd. S
TBA MXB s	84.1mg * P<.02			39.6mg 13.1gm	45/50	43/50	37/50		
liv MXB s	1.30gm * P<.02			368.mg n.s.s.	0/50	0/50	3/50		liv:hpa,hpc,nnd.
2-AMINO-5-NITROPHENOL 121-88-0									
324 M f b6c gav 24m24 TR334 :					0	283.mg	566.mg		
TBA MXB ns	5.76gm * P<.9	-		364.mg n.s.s.	29/50	30/50	8/50		
liv MXB ns	no dre P=1.			1.48gm n.s.s.	5/50	3/50	1/50		liv:hpa,hpc,nnd.
lun MXB ns	807.gm * P<1.			1.14gm n.s.s.	4/50	4/50	1/50		lun:a/a,a/c.
325 M m b6c gav 24m24 TR334 :					0	283.mg	566.mg		
TBA MXB ns	no dre P=1.	-		550.mg n.s.s.	31/50	32/50	8/50		
liv MXB ns	no dre P=1.			497.mg n.s.s.	17/50	16/50	(1/50)		liv:hpa,hpc,nnd.
lun MXB ns	no dre P=1.			1.02gm n.s.s.	7/50	8/50	2/50		lun:a/a,a/c.
326 R f f34 gav 24m24 TR334 :					0	70.7mg	142.mg		
TBA MXB	no dre P=1.	-		105.mg n.s.s.	46/50	45/50	38/50		
liv MXB	no dre P=1.			n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
327 R m f34 gav 24m24 TR334 :					0	70.7mg	142.mg		
tes ict s	28.6mg * P<.0005			16.8mg 65.2mg	42/50	40/50	39/50		S
pan MXA s	107.mg * P<.0005			52.7mg 328.mg	1/50	11/50	3/50		pan:acc,ana. S
pan ana s	111.mg * P<.0005	p		53.8mg 359.mg	1/50	10/50	3/50		
pre can s	562.mg / P<.004			163.mg 5.02gm	0/50	0/50	4/50		S
amd MXA s	101.mg * P<.02			43.3mg n.s.s.	20/50	16/50	12/50		amd:phe,phm. S
pre MXA s	392.mg * P<.04			126.mg n.s.s.	3/50	2/50	5/50		pre:adn,can. S
pni isc s	393.mg * P<.04			118.mg n.s.s.	0/50	3/50	0/50		S
TBA MXB s	33.6mg * P<.0005			19.0mg 88.7mg	42/50	44/50	34/50		
liv MXB s	1.56gm * P<.05			332.mg n.s.s.	0/50	0/50	2/50		liv:hpa,hpc,nnd.
4-AMINO-2-NITROPHENOL 119-34-6									
328 M f b6c eat 24m24 TR94 :					0	159.mg	319.mg		
TBA MXB	no dre P=1.	-		558.mg n.s.s.	8/20	17/50	16/50		
liv MXB	3.65gm * P<.3			1.26gm n.s.s.	0/20	2/50	2/50		liv:hpa,hpc,nnd.
lun MXB	no dre P=1.			1.73gm n.s.s.	2/20	3/50	2/50		lun:a/a,a/c.
329 M m b6c eat 24m24 TR94 :					0	147.mg	294.mg		
TBA MXB	no dre P=1.	-		301.mg n.s.s.	12/20	32/50	28/50		
liv MXB	2.25gm * P<.7			336.mg n.s.s.	6/20	18/50	19/50		liv:hpa,hpc,nnd.
lun MXB	no dre P=1.			863.mg n.s.s.	5/20	10/50	7/50		lun:a/a,a/c.
330 R f f34 eat 24m24 TR94 :					0	61.3mg	123.mg		
ubl tcc h	1.88gm * P<.3		a	563.mg n.s.s.	0/20	1/49	2/50		
TBA MXB	no dre P=1.			140.mg n.s.s.	13/20	34/49	28/50		
liv MXB	no dre P=1.			n.s.s. n.s.s.	0/20	0/49	0/50		liv:hpa,hpc,nnd.
331 R m f34 eat 24m24 TR94 :					0	49.0mg	98.1mg		
ubl tcc	309.mg / P<.002		c	155.mg 1.14gm	0/20	0/50	11/50		
TBA MXB	270.mg / P<.4			71.2mg n.s.s.	12/20	22/50	35/50		
liv MXB	no dre P=1.			604.mg n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
2-AMINO-4-(p-NITROPHENYL)THIAZOLE 2104-09-8									
332 M f swi eat 46w66 1076					0	9.06mg			Cohen;canr,33,1593-1597;1973
--- lle e	9.95mg P<.03	+		3.42mg n.s.s.	1/28	5/20			
liv tum e	no dre P=1.			15.0mg n.s.s.	0/28	0/20			
lun tum e	no dre P=1.			15.0mg n.s.s.	0/28	0/20			
tba mix e	9.95mg P<.03			3.42mg n.s.s.	1/28	5/20			
2-AMINO-5-NITROTHIAZOLE 121-66-4									
333 M f b6c eat 24m24 TR53 :					0	6.50mg	13.0mg		
TBA MXB	no dre P=1.	-		15.3mg n.s.s.	26/50	31/50	28/50		
liv MXB	109.mg * P<.4			29.0mg n.s.s.	2/50	6/50	5/50		liv:hpa,hpc,nnd.
lun MXB	63.5mg * P<.09			24.6mg n.s.s.	2/50	4/50	8/50		lun:a/a,a/c.
334 M m b6c eat 24m24 TR53 :					0	6.00mg	12.0mg		
TBA MXB	no dre P=1.	-		10.5mg n.s.s.	39/50	32/50	34/50		
liv MXB	no dre P=1.			19.5mg n.s.s.	20/50	16/50	15/50		liv:hpa,hpc,nnd.
lun MXB	no dre P=1.			20.8mg n.s.s.	14/50	12/50	12/50		lun:a/a,a/c.
335 R f f34 eat 26m26 TR53 :					0	14.9mg	29.7mg		
ute esp #	57.2mg \ P<.03	-		22.8mg n.s.s.	2/50	9/50	(3/50)		S
TBA MXB	326.mg * P<.9			21.1mg n.s.s.	40/50	44/50	44/50		
liv MXB	no dre P=1.			n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
336 R m f34 eat 26m26 TR53 :					0	11.9mg	23.8mg		
--- MXA u	27.6mg * P<.003		a	14.6mg 147.mg	13/50	19/50	28/50		---:leu,lym.
mul grl u	90.2mg * P<.02		a	40.1mg n.s.s.	2/50	4/50	9/50		
MXA MXA u	445.mg * P<.7		a	56.5mg n.s.s.	6/50	4/50	6/50		---:lle,mly; mul:ule.
TBA MXB	32.3mg * P<.2			11.7mg n.s.s.	36/50	37/50	39/50		
liv MXB	318.mg * P<.2			78.3mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
337 R f sda eat 46w66 1126					0	33.4mg			Cohen;jnci,54,841-850;1975
mgl mix ev	44.6mg P<.03	+		17.4mg n.s.s.	2/39	8/35			
lun alc v	157.mg P<.09	+		38.6mg n.s.s.	0/39	2/35			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
k/p tcc vh	157.mg	P<.09 +	38.6mg n.s.s.	0/39	2/35			
liv tum v	no dre	P=1.	97.1mg n.s.s.	0/39	0/35			
tba mix v	32.5mg	P<.006	14.2mg 371.mg	2/39	10/35			
2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2 (magnesium pemoline) 18968-99-5								
338 R f sda eat 46w66 200am				0	2.79mg			Cohen;jnci,51,403-417;1973
liv tum e	no dre	P=1.	8.10mg n.s.s.	0/35	0/35			
tba mix e	3.01mg	P<.04 -	1.18mg n.s.s.	4/35	11/35			
339 R f sda eat 46w66 200an				0	55.8mg			
liv tum e	no dre	P=1.	162.mg n.s.s.	0/35	0/35			
tba mix e	no dre	P=1. -	122.mg n.s.s.	4/35	1/35			
2-AMINOANTHRAQUINONE 117-79-3								
340 M f b6c eat 79w94 TR144 :				0	539.mg	1.08gm		
MXB MXB	1.49gm *	P<.0005	805.mg 4.96gm	11/100	9/50	23/50		---:lym; liv:hpc. C
liv hpc	2.82gm *	P<.004 c	1.33gm 23.7gm	5/100	5/50	12/50		
--- lym	3.16gm *	P<.02 c	1.38gm n.s.s.	7/100	6/50	12/50		
TBA MXB	1.62gm /	P<.02	742.mg n.s.s.	27/100	16/50	29/50		
liv MXB	2.82gm *	P<.004	1.33gm 23.7gm	5/100	5/50	12/50		liv:hpa,hpc,nnd.
lun MXB	33.4gm *	P<.7	3.75gm n.s.s.	4/100	2/50	3/50		lun:a/a,a/c.
341 M m b6c eat 79w93 TR144 :				0	498.mg	1.01gm		
liv hpc	755.mg *	P<.0005 c	449.mg 1.83gm	18/100	20/50	36/50		
liv MXA	798.mg *	P<.0005 c	463.mg 2.11gm	20/100	20/50	36/50		liv:hpa,hpc.
TBA MXB	952.mg /	P<.008	458.mg 20.0gm	41/100	28/50	42/50		
liv MXB	798.mg *	P<.0005	463.mg 2.11gm	20/100	20/50	36/50		liv:hpa,hpc,nnd.
lun MXB	19.4gm *	P<.8	1.94gm n.s.s.	17/100	8/50	11/50		lun:a/a,a/c.
342 R f f34 eat 18m25 TR144 :				0	71.0mg			
TBA MXB s	124.mg	P<.6 -	18.9mg n.s.s.	19/25	17/50			
liv MXB s	no dre	P=1.	89.0mg n.s.s.	2/25	1/50			liv:hpa,hpc,nnd.
343 R m f34 eat 18m25 TR144 :				0	102.mg	203.mg		
liv MXA v	101.mg \	P<.0005 c	57.8mg 204.mg	0/50	18/50	(18/50)		liv:hpc,nnd.
liv hpc v	268.mg \	P<.002 c	121.mg 1.13gm	0/50	8/50	(5/50)		
TBA MXB v	759.mg *	P<.6	145.mg n.s.s.	20/50	26/50	30/50		
liv MXB v	101.mg \	P<.0005	57.8mg 204.mg	0/50	18/50	(18/50)		liv:hpa,hpc,nnd.
o-AMINOAZOTOLUENE 97-56-3								
344 M m cf1 eat 26w65 103				0	28.8mg			Walker;fctx,11,415-432;1973
lun ade e	80.2mg	P<.6	11.5mg n.s.s.	95/288	9/23			
liv mix e	no dre	P=1.	22.7mg n.s.s.	58/288	4/23			
345 R f alb eat 63w63 30				0	28.6mg			Waters;yjbm,10,179-184;1937
liv mix ems	3.70mg	P<.002 +	1.16mg 16.9mg	0/5	6/7			
liv hpn ems	8.49mg	P<.02 +	2.77mg n.s.s.	0/5	4/7			
liv lca ems	21.4mg	P<.2 +	5.18mg n.s.s.	0/5	2/7			
346 R m alb eat 67w67 30				0	21.7mg			
liv mix ems	4.46mg	P<.005 +	1.91mg 27.7mg	0/4	9/12			
liv hpn ems	11.5mg	P<.06 +	4.27mg n.s.s.	0/4	5/12			
liv lca ems	15.2mg	P<.1 +	5.20mg n.s.s.	0/4	4/12			
6-AMINOCAPROIC ACID 60-32-2								
347 R m f3d eat 52w52 2192				0	40.0mg			Shibata;carc,14,1265-1269;1993/pers.comm.
for tum er	no dre	P=1.	20.6mg n.s.s.	0/10	0/10			
4-AMINODIPHENYL (4-aminobiphenyl) 92-67-1								
348 M f abi gav 39w94 1165				0	2.37mg			Clayson;bjca,19,297-310;1965/Williams 1962
ubl car	5.94mg	P<.05 +	.957mg n.s.s.	0/28	1/5			
liv hpt e	no dre	P=1. -	1.99mg n.s.s.	4/26	0/5			
349 M m abi gav 39w94 1165				0	1.97mg			
liv hpt e	3.84mg	P<.5 -	.761mg n.s.s.	5/13	7/13			
ubl car e	11.6mg	P<.4 +	1.88mg n.s.s.	0/5	1/11			
350 M f cif gav 50w70 31				0	6.12mg			Clayson;bjca,21,755-762;1967
liv mix r	.993mg	P<.0005 +	.544mg 1.94mg	1/31	24/28			
liv mhp r	3.05mg	P<.0005	1.58mg 6.92mg	0/31	13/28			
351 M m cif gav 50w70 31				0	5.10mg			
liv mix r	3.91mg	P<.002 +	1.67mg 16.2mg	0/19	7/21			
liv mhp r	7.50mg	P<.02	2.58mg n.s.s.	0/19	4/21			
ubl car r	32.5mg	P<.3 +	5.28mg n.s.s.	0/19	1/21			
4-AMINODIPHENYL.HCl (4-aminobiphenyl.HCl) 2113-61-3								
352 R f sda gav 31w52 1721				0	4.73mg			Tanaka;gann,76,570-576;1985/pers.comm.
mgl car ev	.980mg	P<.0005 +	.553mg 1.95mg	0/27	18/32			
mam mix ev	.984mg	P<.0005 +	.535mg 2.41mg	2/27	19/32			
liv tum ev	no dre	P=1. -	7.80mg n.s.s.	0/27	0/32			
tba mix ev	.897mg	P<.0005	.494mg 2.08mg	2/27	20/32			
2-AMINODIPHENYLENE OXIDE 3693-22-9								
353 M f cif eat 52w58 31				0	35.0mg			Clayson;bjca,21,755-762;1967
liv mhp r	noTD50	P<.0005	n.s.s. 3.31mg	0/31	30/30			
liv mix r	noTD50	P<.0005 +	n.s.s. 3.36mg	1/31	30/30			
354 M m cif eat 52w67 31				0	27.9mg			
liv mix r	5.73mg	P<.0005 +	2.94mg 12.6mg	0/19	15/20			
liv mhp r	8.67mg	P<.0005	4.32mg 20.7mg	0/19	12/20			
ubl car r	22.3mg	P<.004 +	9.02mg 126.mg	0/19	6/20			
1-(AMINOMETHYL)CYCLOHEXANEACETIC ACID (gabapentin) 60142-96-3								
355 R f wis eat 24m24 2026m				0	250.mg	1.00gm	2.00gm	Dominick;txap,111,375-387;1991/Sigler 1995
kid rcc j	no dre	P=1. -	23.7gm n.s.s.	0/50	1/50	0/50	0/50	
tba mix j	7.99gm *	P<.8 -	804.mg n.s.s.	43/50	46/50	45/50	45/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
356 R m wis eat 24m24 2026m					0	250.mg	1.00gm	2.00gm	
pan ana j	5.85gm	* P<.01	+	2.72gm 437.gm	7/50	6/50	10/50	16/50	
pan acc j	8.61gm	* P<.007	+	3.91gm 150.gm	0/50	4/50	3/50	8/50	
kid rct j	no dre	P=1.	-	1.87gm n.s.s.	0/50	0/50	0/50	0/50	
tba mix j	7.12gm	* P<.6	-	1.31gm n.s.s.	35/50	38/50	35/50	39/50	
2,2'-[(4-AMINOPHENYL)IMINO]BISETHANOL SULFATE (N,N-bis(2-hydroxyethyl)-p-phenylenediamine sulfate) 54381-16-7									
357 R f f3d eat 24m24 2269					0	15.0mg	50.0mg	150.mg	Hagiwara;fctx,34,537-546;1996
liv hpa e	7.31gm	* P<.2	-	1.19gm n.s.s.	0/50	0/50	0/50	1/50	
358 R m f3d eat 24m24 2269					0	12.0mg	40.0mg	120.mg	
liv hpa e	no dre	P=1.	-	1.08gm n.s.s.	2/50	2/50	0/50	1/50	
liv hpc e	no dre	P=1.	-	1.56gm n.s.s.	1/50	1/50	0/50	0/50	
3-AMINOTRIAZOLE (amitrol) 61-82-5									
359 H f syg eat 28m28 1557o					0	.105mg	1.05mg	10.5mg	Steinhoff;txap,69,161-169;1983
lun tum ae	no dre	P=1.		2.00mg n.s.s.	0/76	0/76	0/76	0/76	
liv ben ae	no dre	P=1.	-	242.mg n.s.s.	1/76	1/76	0/76	0/76	
tba mix ae	no dre	P=1.	-	59.5mg n.s.s.	13/76	10/76	12/76	11/76	
tba mal ae	570.mg	* P<.6	-	81.3mg n.s.s.	1/76	2/76	3/76	3/76	
360 H m syg eat 31m32 1557o					0	92.0ug	.920mg	9.20mg	
liv ben ae	no dre	P=1.	-	2.29mg n.s.s.	0/76	0/76	0/76	0/75	
lun tum ae	no dre	P=1.		2.29mg n.s.s.	0/76	0/76	0/76	0/75	
tba mix ae	no dre	P=1.	-	85.6mg n.s.s.	20/76	11/76	13/76	11/75	
tba mal ae	no dre	P=1.	-	160.mg n.s.s.	7/76	2/76	5/76	2/75	
361 M f b6a orl 59w59 35a					0	321.mg			Innes;ntis,1968/1969
liv hpt evx	24.5mg	P<.0005	+	9.88mg 58.2mg	0/17	17/18			
lun mix evx	no dre	P=1.		384.mg n.s.s.	0/17	0/18			
tba mix evx	25.6mg	P<.0005		10.0mg 66.8mg	2/17	17/18			
362 M m b6a orl 52w52 35a					0	306.mg			
liv hpt evx	26.0mg	P<.0005	+	11.5mg 72.3mg	3/18	16/18			
lun ade evx	no dre	P=1.		283.mg n.s.s.	2/18	0/18			
tba mix evx	28.0mg	P<.0005		11.8mg 98.4mg	5/18	16/18			
363 M f b6c orl 57w57 35a					0	323.mg			
liv hpt evx	noTD50	P<.0005		n.s.s. 37.3mg	0/18	18/18			
lun ade evx	no dre	P=1.		359.mg n.s.s.	1/18	0/18			
tba mix evx	noTD50	P<.0005		n.s.s. 42.2mg	3/18	18/18			
364 M m b6c orl 53w53 35a					0	305.mg			
liv hpt evx	25.4mg	P<.0005	+	11.6mg 61.4mg	1/17	16/18			
lun ade evx	no dre	P=1.		294.mg n.s.s.	2/17	0/18			
tba mix evx	30.8mg	P<.002		12.5mg 146.mg	6/17	16/18			
365 M f nmr eat 33m33 1557n					0	.130mg	1.30mg	13.0mg	Steinhoff;txap,69,161-169;1983
liv tum ae	no dre	P=1.	-	3.29mg n.s.s.	0/73	0/73	0/74	0/74	
lun tum ae	no dre	P=1.		3.29mg n.s.s.	0/73	0/73	0/74	0/74	
tba mal ae	6.92mg	Z P<.2	-	2.32mg n.s.s.	46/73	26/73	46/74	(38/74)	
tba mix ae	no dre	P=1.	-	26.3mg n.s.s.	60/73	48/73	59/74	55/74	
366 M m nmr eat 34m34 1557n					0	.120mg	1.20mg	12.0mg	
liv mal ae	2.76gm	* P<.8	-	200.mg n.s.s.	1/75	0/73	1/73	1/72	
lun tum ae	no dre	P=1.		3.20mg n.s.s.	0/75	0/73	0/73	0/72	
tba mal ae	347.mg	* P<.7	-	41.1mg n.s.s.	27/75	38/73	26/73	32/72	
tba mix ae	no dre	P=1.	-	43.7mg n.s.s.	52/75	56/73	47/73	46/72	
367 R b nss eat 24m24 1513					0	.450mg	2.25mg	4.50mg	Jukes;scie,132,296-297;1960
thy ade er	3.74mg	* P<.0005		2.17mg 8.86mg	0/5	1/10	2/15	17/26	
368 R f wis wat 16m24 35					0	96.2mg			Tsuda;jnci,57,861-864;1976
tyf mal r	102.mg	P<.002		58.9mg 299.mg	0/10	19/40			
369 R f wis eat 38m38 1557m					0	50.0ug	.500mg	5.00mg	Steinhoff;txap,69,161-169;1983
thy ben ae	11.5mg	* P<.0005	+	7.53mg 19.8mg	7/74	12/75	8/75	44/75	
thy mal ae	17.7mg	* P<.0005	+	11.4mg 30.1mg	0/74	1/75	4/75	28/75	
pit ben ae	20.8mg	* P<.0005	+	11.3mg 61.3mg	14/74	20/75	15/75	36/75	
liv tum ae	no dre	P=1.		1.71mg n.s.s.	0/74	0/75	0/75	0/75	
tba mix ae	7.55mg	* P<.01		3.11mg 626.mg	59/74	67/75	60/75	71/75	
tba mal ae	17.7mg	* P<.0005		9.13mg 73.9mg	20/74	34/75	29/75	45/75	
370 R m wis eat 38m38 1557m					0	40.0ug	.400mg	4.00mg	
thy ben ae	8.75mg	Z P<.0005	+	5.85mg 14.2mg	5/75	9/74	4/75	45/75	
thy mal ae	27.0mg	* P<.0005	+	15.2mg 60.5mg	3/75	0/74	3/75	18/75	
liv hpc ae	no dre	P=1.		115.mg n.s.s.	0/75	0/74	1/75	0/75	
tba mix ae	13.8mg	* P<.009		6.31mg 441.mg	36/75	41/74	44/75	53/75	
tba mal ae	135.mg	* P<.6		21.4mg n.s.s.	19/75	20/74	23/75	23/75	
11-AMINOUNDECANOIC ACID 2432-99-7									
371 M f b6c eat 24m25 TR216 :					0	926.mg	1.85gm		
TBA MXB es	15.6gm	* P<.8	-	1.76gm n.s.s.	28/50	27/50	19/50		
liv MXB es	37.9gm	* P<.8		3.83gm n.s.s.	7/50	8/50	5/50		liv:hpa,hpc,nnd.
lun MXB es	18.8gm	* P<.4		4.63gm n.s.s.	2/50	3/50	3/50		lun:a/a,a/c.
372 M m b6c eat 24m25 TR216 :					0	854.mg	1.71gm		
--- mly es#	4.97gm	* P<.05	-	2.09gm n.s.s.	2/50	9/50	4/50		S
TBA MXB es	6.50gm	* P<.6		1.20gm n.s.s.	30/50	29/50	18/50		
liv MXB es	6.25gm	* P<.4		1.56gm n.s.s.	17/50	18/50	12/50		liv:hpa,hpc,nnd.
lun MXB es	no dre	P=1.		4.88gm n.s.s.	10/50	3/50	4/50		lun:a/a,a/c.
373 R f f34 eat 24m25 TR216 :					0	358.mg	716.mg		
TBA MXB	1.25gm	\ P<.7	-	202.mg n.s.s.	46/50	47/50	(37/50)		
liv MXB	44.6gm	* P<.9		2.10gm n.s.s.	5/50	5/50	6/50		liv:hpa,hpc,nnd.
374 R m f34 eat 24m25 TR216 :					0	286.mg	573.mg		
MXB MXB es	833.mg	* P<.0005		494.mg 1.96gm	1/50	10/50	15/50		liv:hpc,nnd; ubl:tcc. C
liv MXA es	1.10gm	* P<.002	c	606.mg 4.27gm	1/50	10/50	10/50		liv:hpc,nnd.
liv nnd es	1.29gm	* P<.004	c	666.mg 9.39gm	1/50	9/50	8/50		
ubl tcc es	3.17gm	/ P<.002	c	1.36gm 12.8gm	0/50	0/50	7/50		
mgl fba es	2.91gm	* P<.05		1.26gm n.s.s.	0/50	5/50	2/50		S
TBA MXB es	802.mg	* P<.1		304.mg n.s.s.	31/50	37/50	37/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB es	1.10gm *	P<.002		606.mg 4.27gm	1/50	10/50	10/50		liv:hpa,hpc,nnd.
AMMONIUM CHLORIDE 12125-02-9									
375 M f ifc wat 93w93 142a					0	2.00gm			Flaks;bjca,31,585-587;1975
ubl car r	no dre	P=1.		8.57gm n.s.s.	0/26	0/26			
376 M f ifc wat 52w52 142b					0	2.00gm			Flaks;jnci,51,2007-2008;1973
ubl tum ekr	no dre	P=1.		2.68gm n.s.s.	0/26	0/26			
AMMONIUM CITRATE 3012-65-5									
377 R m wis eat 52w65 2					0	1.54gm			Weisburger;txap,14,163-175;1969
liv tum ek	no dre	P=1.	-	2.10gm n.s.s.	0/7	0/17			
AMMONIUM HYDROXIDE 1336-21-6									
378 M f c3h wat 24m24 1117					0	200.mg			Toth;ijcn,9,109-118;1972/1969a
mgl adc	no dre	P=1.	-	264.mg n.s.s.	23/30	24/40			
379 M f swi wat 28m28 1117					0	200.mg	400.mg	600.mg	
lun mix ae	no dre	P=1.	-	2.78gm n.s.s.	14/109	12/50	8/48	4/42	
liv mix ae	no dre	P=1.		7.33gm n.s.s.	3/89	1/47	2/41	0/42	
380 M m swi wat 28m29 1117					0	167.mg	333.mg	500.mg	
lun adc ae	7.33gm *	P<.03	-	2.99gm n.s.s.	0/86	2/49	2/48	2/44	
lun mix ae	15.3gm *	P<.7	-	2.36gm n.s.s.	10/86	5/49	5/48	7/44	
liv mix ae	26.7gm *	P<.7		3.47gm n.s.s.	2/67	1/46	3/28	1/43	
AMOBARBITAL 57-43-2									
381 R m f34 wat 72w72 1690					0	25.0mg			Diwan;jnci,74,509-516;1985
liv hct e	no dre	P=1.		29.6mg n.s.s.	0/13	0/12			
dl-AMPHETAMINE SULFATE 60-13-9									
382 M f b6c eat 24m24 TR387 :					0	2.56mg	12.8mg		
TBA MXB	no dre	P=1.	-	3.80mg n.s.s.	40/50	27/50	(15/50)		
liv MXB	no dre	P=1.		16.0mg n.s.s.	5/50	1/50	(1/50)		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		6.80mg n.s.s.	8/50	6/50	(1/50)		lun:a/a,a/c.
383 M m b6c eat 24m24 TR387 :					0	2.37mg	11.9mg		
thy MXA #	116.mg *	P<.05	-	40.1mg n.s.s.	0/50	1/50	3/50		thy:fca,fcc. S
TBA MXB	no dre	P=1.		3.75mg n.s.s.	30/50	25/50	(18/50)		
liv MXB	no dre	P=1.		5.75mg n.s.s.	14/50	12/50	(2/50)		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		60.4mg n.s.s.	8/50	3/50	4/50		lun:a/a,a/c.
384 R f f34 eat 24m24 TR387 :					0	.985mg	4.93mg		
TBA MXB	no dre	P=1.	-	1.14mg n.s.s.	48/50	42/50	(30/50)		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
385 R m f34 eat 24m24 TR387 :					0	.790mg	3.95mg		
TBA MXB	no dre	P=1.	-	.480mg n.s.s.	46/50	45/50	(37/50)		
liv MXB	107.mg *	P<.2		17.5mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
AMPICILLIN TRIHYDRATE 7177-48-2									
386 M f b6c gav 24m24 TR318 :					0	1.06gm	2.12gm		
TBA MXB	24.9gm *	P<.9	-	1.65gm n.s.s.	32/50	21/50	28/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB	17.7gm *	P<.3		4.60gm n.s.s.	2/50	3/50	4/50		lun:a/a,a/c.
387 M m b6c gav 24m24 TR318 :					0	1.06gm	2.12gm		
TBA MXB	10.2gm *	P<.7	-	1.48gm n.s.s.	23/50	21/50	18/50		
liv MXB	67.4gm *	P<.9		3.47gm n.s.s.	9/50	4/50	7/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		3.93gm n.s.s.	6/50	6/50	3/50		lun:a/a,a/c.
388 R f f34 gav 24m24 TR318 :					0	531.mg	1.06gm		
pta can #	5.90gm *	P<.05	-	2.39gm n.s.s.	0/50	3/50	3/50		S
TBA MXB	11.0gm *	P<.9		660.mg n.s.s.	44/50	41/50	45/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	2/50	0/50		liv:hpa,hpc,nnd.
389 R m f34 gav 24m24 TR318 :					0	531.mg	1.06gm		
amd MXA	1.31gm *	P<.04	e	560.mg n.s.s.	13/50	16/50	23/50		amd:phe,phm.
mul MXA	1.77gm *	P<.02		830.mg n.s.s.	5/50	14/50	14/50		mul:lle,mnl. S
mul mnl	1.91gm *	P<.03	e	859.mg n.s.s.	5/50	14/50	13/50		
mul MXA	1.95gm *	P<.04		851.mg n.s.s.	6/50	16/50	14/50		mul:lle,mlh,mlm,mnl. S
TBA MXB	1.95gm *	P<.5		468.mg n.s.s.	39/50	42/50	42/50		
liv MXB	34.5gm *	P<.3		5.63gm n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
1-AMYL-1-NITROSOUREA 10589-74-9									
390 R f don wat 65w65 1328					0	3.06mg	6.12mg	12.2mg	Fujii;gann,71,464-470;1980
eso tum	.967mg	Z P<.0005		.559mg 1.86mg	0/20	20/35	(15/33 | 18/33)	
dgt mix	1.15mg *	P<.0005	+	.835mg 1.77mg	0/20	24/35	27/33	27/33	
for tum	1.35mg *	P<.0005		.982mg 2.17mg	0/20	21/35	27/33	25/33	
liv hpa	13.3mg *	P<.0005		7.01mg 37.2mg	0/20	0/35	5/33	8/33	
--- mye	19.9mg *	P<.005	+	9.35mg 172.mg	0/20	1/35	2/33	6/33	
mgl mix	11.9mg *	P<.3	+	3.80mg n.s.s.	6/20	12/35	15/33	15/33	
tba mix	1.93mg *	P<.002		1.01mg 10.2mg	8/20	27/35	28/33	28/33	
391 R m don wat 65w65 1328					0	2.14mg	4.29mg	8.57mg	
dgt mix	.532mg	Z P<.0005	+	.367mg .840mg	0/14	29/35	27/35	(22/35)	
for tum	.532mg	Z P<.0005		.367mg .840mg	0/14	29/35	27/35	(20/35)	
eso tum	1.44mg	Z P<.0005		.926mg 3.19mg	0/14	13/35	18/35	(13/35)	
--- mye	9.17mg *	P<.005	+	4.93mg 69.6mg	0/14	1/35	6/35	7/35	
liv hpa	no dre	P=1.		21.7mg n.s.s.	0/14	5/35	0/35	0/35	
tba mix	.541mg	Z P<.0005		.359mg 1.03mg	1/14	29/35	28/35	(26/35)	
392 R f f34 gav 12m24 1915					0	1.25mg			Lijinsky;txih,5,925-935;1989
for tum	.478mg	P<.0005	+	.199mg 1.33mg	0/12	10/12			
lun mix	1.09mg	P<.008	+	.420mg 21.2mg	1/12	7/12			
ute mix	.934mg	P<.02	+	.353mg n.s.s.	2/12	8/12			
mgl adc	2.98mg	P<.04	+	.894mg n.s.s.	0/12	3/12			
liv tum	4.70mg	P<.09		1.15mg n.s.s.	0/12	2/12			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
393 R m f34 gav 12m24 1915					0	.875mg			
for tum	noTD50	P<.0005 +	n.s.s.	.422mg	0/12	12/12			
lun mix	.546mg	P<.0005 +	.232mg	1.67mg	0/12	8/12			
--- mso	.865mg	P<.002	.343mg	3.88mg	0/12	6/12			
liv tum	no dre	P=1.	1.27mg	n.s.s.	1/12	1/12			
AMYLOPECTIN SULFATE 9047-13-6									
394 R m f34 eat 26w52 1716m					0	1.00gm			Ishioka;clet,26,277-282;1985
clr adc r	287.mg	P<.0005 +	133.mg	830.mg	0/18	9/20			
395 R m f34 eat 39w52 1716n					0	1.50gm			
clr mix r	280.mg	P<.0005 +	140.mg	669.mg	0/18	12/20			
ANETHOLE (p-propenylanisole) 104-46-1									
396 M f cd1 eat 50w78 1582					0	162.mg			Miller;canr,43,1124-1134;1983
liv tum v	no dre	P=1.	-	563.mg	n.s.s.	0/30	0/30		
lun ade v	no dre	P=1.	-	563.mg	n.s.s.	1/30	0/30		
trans-ANETHOLE (trans-p-propenylanisole) 4180-23-8									
397 R f cdr eat 28m28 1843					0	125.mg	250.mg	500.mg	Truhaut;fctx,27,11-19;1989/pers.comm.
liv hpc e	7.71gm Z	P<.005	2.97gm	82.2gm	1/104	0/78	0/52	6/52	
liv hpa e	7.16gm *	P<.03	2.66gm	n.s.s.	2/104	2/78	0/52	6/52	
liv cho e	no dre	P=1.	9.49gm	n.s.s.	4/104	1/78	1/52	0/52	
398 R m cdr eat 28m28 1843					0	100.mg	200.mg	400.mg	
lmr rts e	3.05gm Z	P<.06	1.07gm	n.s.s.	2/104	2/78	5/52	(0/52)	
tes ict e	4.28gm *	P<.03	1.94gm	n.s.s.	0/104	3/78	3/52	2/52	
liv hpa e	12.1gm *	P<.4	2.72gm	n.s.s.	3/104	3/78	0/52	4/52	
liv cho e	21.6gm *	P<.7	4.29gm	n.s.s.	0/104	1/78	1/52	0/52	
liv hpc e	26.9gm *	P<.7	3.31gm	n.s.s.	2/104	1/78	3/52	1/52	
liv clc e	no dre	P=1.	6.06gm	n.s.s.	0/104	1/78	0/52	0/52	
ANHYDROGLUCOCHLORAL (alpha-chloralose) 15879-93-3									
399 M f b6a orl 76w76 1297					0	3.89mg			Innes;ntis,1968/1969
lun ade evx	19.5mg	P<.6	-	2.86mg	n.s.s.	1/17	2/16		
liv hpt evx	no dre	P=1.	-	6.85mg	n.s.s.	0/17	0/16		
tba mix evx	17.3mg	P<.6	-	2.41mg	n.s.s.	2/17	3/16		
400 M m b6a orl 76w76 1297					0	3.62mg			
lun ade evx	no dre	P=1.	-	4.75mg	n.s.s.	2/18	1/18		
liv hpt evx	no dre	P=1.	-	7.17mg	n.s.s.	1/18	0/18		
tba mix evx	no dre	P=1.	-	3.75mg	n.s.s.	3/18	2/18		
401 M f b6c orl 76w76 1297					0	3.89mg			
liv hpt evx	no dre	P=1.	-	7.28mg	n.s.s.	0/16	0/17		
lun mix evx	no dre	P=1.	-	7.28mg	n.s.s.	0/16	0/17		
tba tum evx	no dre	P=1.	-	7.28mg	n.s.s.	0/16	0/17		
402 M m b6c orl 76w76 1297					0	3.62mg			
liv hpt evx	7.27mg	P<.05	-	2.19mg	n.s.s.	0/16	3/18		
lun ade evx	11.2mg	P<.2	-	2.76mg	n.s.s.	0/16	2/18		
tba mix evx	4.07mg	P<.009	-	1.54mg	89.3mg	0/16	5/18		
ANILAZINE 101-05-3									
403 M f b6c eat 24m25 TR104 :					0	62.0mg	124.mg		
TBA MXB	99.2mg \	P<.02	-	47.6mg	n.s.s.	4/25	22/50	(18/50)	
liv MXB	2.55gm *	P<.5		628.mg	n.s.s.	0/25	1/50	1/50	liv:hpa,hpc,nnd.
lun MXB	1.69gm *	P<.2		511.mg	n.s.s.	0/25	1/50	2/50	lun:a/a,a/c.
404 M m b6c eat 24m25 TR104 :					0	57.7mg	114.mg		
TBA MXB	no dre	P=1.	-	224.mg	n.s.s.	15/25	20/50	25/50	
liv MXB	no dre	P=1.		365.mg	n.s.s.	9/25	6/50	12/50	liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		391.mg	n.s.s.	4/25	7/50	6/50	lun:a/a,a/c.
405 R f f34 eat 24m24 TR104 :					0	25.0mg	50.0mg		
TBA MXB	no dre	P=1.	-	32.9mg	n.s.s.	22/25	42/50	43/50	
liv MXB	1.05gm *	P<.5		257.mg	n.s.s.	0/25	1/50	1/50	liv:hpa,hpc,nnd.
406 R m f34 eat 24m24 TR104 :					0	20.0mg	40.0mg		
TBA MXB	246.mg *	P<.7	-	34.2mg	n.s.s.	12/25	26/50	28/50	
liv MXB	no dre	P=1.		n.s.s.	n.s.s.	0/25	0/50	0/50	liv:hpa,hpc,nnd.
ANILINE 62-53-3									
407 R m wis wat 80w80 1460					0	15.0mg	30.0mg	60.0mg	Hagiwara;txlt,6,71-75;1980
for pam	587.mg *	P<.2	-	144.mg	n.s.s.	0/28	0/28	1/28	1/28
ubl tum	no dre	P=1.	-	29.3mg	n.s.s.	0/28	0/28	0/28	0/28
ANILINE.HCl 142-04-1									
408 M f b6c eat 24m25 TR130 :					0	741.mg	1.50gm		
TBA MXB	9.15gm *	P<.6	-	1.61gm	n.s.s.	21/50	22/50	28/49	
liv MXB	8.85gm *	P<.2		3.27gm	n.s.s.	1/50	5/50	5/49	liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		n.s.s.	n.s.s.	0/50	0/50	0/49	lun:a/a,a/c.
409 M m b6c eat 24m25 TR130 :					0	693.mg	1.39gm		
TBA MXB	no dre	P=1.	-	2.45gm	n.s.s.	24/50	27/50	22/50	
liv MXB	no dre	P=1.		5.78gm	n.s.s.	12/50	9/50	7/50	liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		5.15gm	n.s.s.	4/50	8/50	3/50	lun:a/a,a/c.
410 R f f34 eat 24m25 TR130 :					0	144.mg	286.mg		
MXA MXA	1.74gm *	P<.02	c	786.mg	248.gm	0/25	1/50	7/50	mul:fbs,srn; spl:fbs,srn.
TBA MXB	no dre	P=1.		265.mg	n.s.s.	17/25	32/50	35/50	
liv MXB	13.0gm *	P<.4		2.12gm	n.s.s.	0/25	0/50	1/50	liv:hpa,hpc,nnd.
411 R m f34 eat 24m25 TR130 :					0	115.mg	229.mg		
MXB MXB	88.0mg *	P<.0005		64.2mg	133.mg	0/25	27/50	38/50	bod:men; mul:fbs,hes,srn; spl:fbs,hes,srn. C
MXA MXA	146.mg *	P<.0005	c	99.9mg	277.mg	0/25	19/50	23/50	bod:men; mul:hes; spl:hes.
spl hes	160.mg *	P<.0005	c	108.mg	344.mg	0/25	19/50	20/50	
MXA MXA	263.mg *	P<.0005	c	168.mg	565.mg	0/25	11/50	18/50	bod:men; mul:fbs,srn; spl:fbs,srn.
spl MXA	451.mg *	P<.006	c	251.mg	4.10gm	0/25	7/50	9/50	spl:fbs,srn.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
MXA	MXA	572.mg	* P<.002 c	312.mg 2.01gm	0/25	4/50	11/50		bod:men; mul:fbs,srn.
adr	MXA	556.mg	* P<.05	249.mg n.s.s.	2/25	6/50	12/50		adr:phe,phm. S
TBA	MXB	124.mg	* P<.005	65.9mg 1.25gm	10/25	42/50	45/50		
liv	MXB	no dre	P=1.	2.38gm n.s.s.	1/25	0/50	0/50		liv:hpa,hpc,nnd.
o-ANISIDINE.HCl 134-29-2									
412 M f b6c eat 24m24 TR89 :					0	319.mg	638.mg		
ubl	MXA	1.00gm	/ P<.0005 c	611.mg 1.81gm	0/55	1/55	22/55		ubl:tcc,tpp.
ubl	tcc	1.34gm	/ P<.0005 c	771.mg 2.64gm	0/55	0/55	18/55		
TBA	MXB	21.1gm	* P<1.	761.mg n.s.s.	34/55	20/55	33/55		
liv	MXB	no dre	P=1.	4.37gm n.s.s.	11/55	1/55	4/55		liv:hpa,hpc,nnd.
lun	MXB	no dre	P=1.	4.67gm n.s.s.	4/55	2/55	1/55		lun:a/a,a/c.
413 M m b6c eat 24m24 TR89 :					0	297.mg	589.mg		
ubl	MXA	935.mg	/ P<.0005 c	575.mg 1.67gm	0/55	2/55	22/55		ubl:tcc,tpp.
ubl	tcc	1.62gm	/ P<.0005 c	888.mg 3.46gm	0/55	0/55	15/55		
TBA	MXB	no dre	P=1.	1.14gm n.s.s.	43/55	27/55	30/55		
liv	MXB	no dre	P=1.	1.08gm n.s.s.	28/55	13/55	(7/55)		liv:hpa,hpc,nnd.
lun	MXB	no dre	P=1.	824.mg n.s.s.	12/55	9/55	(2/55)		lun:a/a,a/c.
414 R f f34 eat 22m24 TR89 :					0	248.mg	500.mg		
ubl	MXA as	27.8mg	/ P<.0005 c	11.0mg 48.6mg	0/55	46/55	50/55		ubl:tcc,tpp.
ubl	tcc as	29.1mg	/ P<.0005 c	11.2mg 52.9mg	0/55	41/55	50/55		
ubl	tpp as	693.mg	* P<.002	208.mg 3.85gm	0/55	5/55	0/55		S
TBA	MXB as	37.0mg	/ P<.0005	21.0mg 62.0mg	52/55	50/55	51/55		
liv	MXB as	no dre	P=1.	n.s.s. n.s.s.	1/55	0/55	0/55		liv:hpa,hpc,nnd.
415 R m f34 eat 22m24 TR89 :					0	198.mg	400.mg		
ubl	MXA as	31.9mg	/ P<.0005 c	20.6mg 48.8mg	0/55	52/55	52/55		ubl:tcc,tpp.
MXB	MXB as	31.9mg	/ P<.0005	20.6mg 48.8mg	0/55	52/55	52/55	k/p:tcc; thy:cyn,fca,fcc,pcn,pcy; tyf:pcn,pcy; ubl:tcc,	tpp. C
ubl	tcc as	32.7mg	/ P<.0005 c	21.0mg 50.4mg	0/55	50/55	51/55		
thy	MXA as	235.mg	/ P<.0005 c	98.9mg 595.mg	0/55	7/55	6/55		thy:cyn,fca,fcc,pcn,pcy.
MXA	MXA as	535.mg	* P<.0005 c	191.mg 1.90gm	0/55	4/55	4/55		thy:fca; tyf:pcn,pcy.
k/p	tcc as	1.04gm	* P<.002 c	304.mg 5.61gm	0/55	2/55	4/55		
TBA	MXB as	30.9mg	/ P<.0005	20.3mg 49.2mg	39/55	53/55	53/55		
liv	MXB as	483.mg	* P<.002	148.mg 3.15gm	0/55	4/55	0/55		liv:hpa,hpc,nnd.
p-ANISIDINE.HCl 20265-97-8									
416 M f b6c eat 24m24 TR116 :					0	638.mg	1.28gm		
TBA	MXB	no dre	P=1. -	2.32gm n.s.s.	34/55	33/55	24/55		
liv	MXB	no dre	P=1.	4.69gm n.s.s.	11/55	10/55	6/55		liv:hpa,hpc,nnd.
lun	MXB	no dre	P=1.	5.15gm n.s.s.	4/55	5/55	3/55		lun:a/a,a/c.
417 M m b6c eat 24m24 TR116 :					0	589.mg	1.18gm		
TBA	MXB	no dre	P=1. -	2.19gm n.s.s.	43/55	29/55	36/55		
liv	MXB	no dre	P=1.	2.78gm n.s.s.	28/55	22/55	23/55		liv:hpa,hpc,nnd.
lun	MXB	12.6gm	* P<.6	2.35gm n.s.s.	12/55	8/55	17/55		lun:a/a,a/c.
418 R f f34 eat 24m24 TR116 :					0	146.mg	291.mg		
TBA	MXB	no dre	P=1. -	568.mg n.s.s.	52/55	38/55	42/55		
liv	MXB	6.83gm	* P<.5	1.41gm n.s.s.	1/55	1/55	3/55		liv:hpa,hpc,nnd.
419 R m f34 eat 24m24 TR116 :					0	118.mg	233.mg		
pre	MXA	493.mg	\ P<.02 a	202.mg n.s.s.	1/55	8/55	(3/55)		pre:adn,can.
lun	a/a	3.59gm	* P<.06 a	1.09gm n.s.s.	0/55	0/55	3/55		
ski	sqc	3.72gm	* P<.06 a	1.12gm n.s.s.	0/55	0/55	3/55		
TBA	MXB	no dre	P=1.	424.mg n.s.s.	39/55	36/55	31/55		
liv	MXB	1.56gm	* P<.03	673.mg n.s.s.	0/55	3/55	4/55		liv:hpa,hpc,nnd.
ANTHRANILIC ACID 118-92-3									
420 M f b6c eat 18m24 TR36 :					0	1.73gm	3.45gm		
TBA	MXB	68.4gm	* P<.9 -	4.53gm n.s.s.	1/15	5/35	5/35		
liv	MXB	26.4gm	* P<.4	7.83gm n.s.s.	0/15	1/35	2/35		liv:hpa,hpc,nnd.
lun	MXB	80.7gm	* P<.4	13.1gm n.s.s.	0/15	0/35	1/35		lun:a/a,a/c.
421 M m b6c eat 18m24 TR36 :					0	1.59gm	3.18gm		
TBA	MXB	no dre	P=1. -	1.48gm n.s.s.	0/15	13/35	6/35		
liv	MXB	no dre	P=1.	1.79gm n.s.s.	0/15	6/35	5/35		liv:hpa,hpc,nnd.
lun	MXB	no dre	P=1.	n.s.s. n.s.s.	0/15	5/35	(0/35)		lun:a/a,a/c.
422 R f f34 eat 18m24 TR36 :					0	402.mg	804.mg		
TBA	MXB	no dre	P=1. -	361.mg n.s.s.	10/15	19/35	(11/35)		
liv	MXB	no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
423 R m f34 eat 18m24 TR36 :					0	318.mg	643.mg		
TBA	MXB	no dre	P=1. -	867.mg n.s.s.	6/15	14/35	11/35		
liv	MXB	no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
9,10-ANTHRAQUINONE 84-65-1									
424 M f b6a orl 76w76 1229					0	169.mg			Innes;ntis,1968/1969
lun	ade evx	847.mg	P<.6 -	124.mg n.s.s.	1/17	2/16			
liv	hpt evx	no dre	P=1. -	297.mg n.s.s.	0/17	0/16			
tba	mix evx	749.mg	P<.6 -	104.mg n.s.s.	2/17	3/16			
425 M m b6a orl 76w76 1229					0	157.mg			
liv	hpt evx	no dre	P=1. -	312.mg n.s.s.	1/18	0/18			
lun	ade evx	no dre	P=1. -	312.mg n.s.s.	2/18	0/18			
tba	mix evx	no dre	P=1. -	312.mg n.s.s.	3/18	0/18			
426 M f b6c orl 76w76 1229					0	169.mg			
lun	ade evx	494.mg	P<.1 -	121.mg n.s.s.	0/16	2/17			
liv	hpt evx	no dre	P=1. -	316.mg n.s.s.	0/16	0/17			
tba	mix evx	494.mg	P<.1 -	121.mg n.s.s.	0/16	2/17			
427 M m b6c orl 76w76 1229					0	157.mg			
liv	hpt evx	460.mg	P<.1 -	113.mg n.s.s.	0/16	2/17			
lun	mix evx	no dre	P=1. -	294.mg n.s.s.	0/16	0/17			
tba	mix evx	460.mg	P<.1 -	113.mg n.s.s.	0/16	2/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ANTIMONY POTASSIUM TARTRATE		**28300-74-5**							
428 M b cd1 wat 33m33 1036					0	.877mg			Kanisawa;canr,29,892-895;1969
lun tum e	no dre	P=1.	-	9.12mg n.s.s.	15/71	10/76			
liv tum e	no dre	P=1.	-	19.7mg n.s.s.	4/71	1/76			
tba tum e	no dre	P=1.	-	6.83mg n.s.s.	24/71	18/76			
tba mal e	no dre	P=1.	-	9.91mg n.s.s.	8/71	6/76			
ARAMITE	**140-57-8**								
429 M f b6a orl 80w80 40a					0	157.mg			Innes;ntis,1968/1969
lun ade evx	432.mg	P<.3		99.0mg n.s.s.	1/17	3/16			
liv hpt evx	no dre	P=1.		305.mg n.s.s.	0/17	0/16			
tba mix evx	391.mg	P<.4		85.9mg n.s.s.	2/17	4/16			
430 M m b6a orl 77w77 40a					0	146.mg			
liv hpt evx	15.9gm	P<1.		166.mg n.s.s.	1/18	1/17			
lun ade evx	no dre	P=1.		281.mg n.s.s.	2/18	0/17			
tba mix evx	no dre	P=1.		145.mg n.s.s.	3/18	2/17			
431 M f b6c orl 77w77 40a					0	157.mg			
liv hpt evx	973.mg	P<.3		158.mg n.s.s.	0/16	1/17			
lun ade evx	973.mg	P<.3		158.mg n.s.s.	0/16	1/17			
tba mix evx	92.7mg	P<.0005		41.1mg 295.mg	0/16	8/17			
432 M m b6c orl 80w80 40a					0	146.mg			
liv mix evx	126.mg	P<.003		50.7mg 617.mg	0/16	6/16			
liv hpt evx	158.mg	P<.006	+	59.4mg 1.56gm	0/16	5/16			
lun mix evx	no dre	P=1.		285.mg n.s.s.	0/16	0/16			
tba mix evx	103.mg	P<.002		43.6mg 375.mg	0/16	7/16			
433 R b cfn eat 24m24 42					0	4.50mg	9.00mg	18.0mg	Popper;canc,13,1035-1046;1960
liv hnd	61.8mg *	P<.0005	+	38.4mg 122.mg	5/180	3/93	10/90	22/96	
bil ade	1.01gm *	P<.05	+	248.mg n.s.s.	0/180	0/93	0/90	2/96	
434 R b fds eat 22m24 1133					0	22.5mg	71.1mg	225.mg	Oser;txap,2,441-457;1960
liv mix agrs	430.mg *	P<.002	+	202.mg 1.99gm	0/22	1/20	2/21	6/20	
435 R f osm eat 27m27 21					0	10.0mg			Deichmann;txap,11,88-103;1967
liv hem	256.mg	P<.3	-	41.7mg n.s.s.	0/30	1/30			
tba mix	no dre	P=1.	-	16.1mg n.s.s.	13/30	12/30			
436 R f osm eat 24m24 84a					0	4.00mg			Radomski;txap,7,652-656;1965
liv tum e	no dre	P=1.	-	24.7mg n.s.s.	1/30	0/30			
tba ben e	31.5mg	P<.6	-	5.40mg n.s.s.	6/30	8/30			
tba mal e	no dre	P=1.	-	13.0mg n.s.s.	6/30	3/30			
437 R m osm eat 27m27 21					0	8.00mg			Deichmann;txap,11,88-103;1967
liv tum	no dre	P=1.	-	62.6mg n.s.s.	0/30	0/30			
tba mal	101.mg	P<.1	-	24.7mg n.s.s.	0/30	2/30			
tba mix	198.mg	P<.6	-	27.2mg n.s.s.	1/30	2/30			
438 R m osm eat 24m24 84a					0	3.20mg			Radomski;txap,7,652-656;1965
liv tum e	no dre	P=1.	-	19.8mg n.s.s.	0/30	0/30			
tba ben e	64.7mg	P<.3	-	10.5mg n.s.s.	0/30	1/30			
tba mal e	no dre	P=1.	-	10.6mg n.s.s.	3/30	2/30			
439 R b sda eat 24m24 42					0	4.50mg	9.00mg	18.0mg	Popper;canc,13,1035-1046;1960
liv hnd	760.mg *	P<.3		187.mg n.s.s.	0/82	0/46	1/41	1/92	
440 R b wid eat 24m24 42					0	4.50mg	9.00mg	18.0mg	
liv hnd	79.9mg Z	P<.0005	+	48.2mg 155.mg	2/193	2/93	3/100	20/90	
bil ade	397.mg *	P<.002	+	151.mg 1.86gm	0/193	0/93	0/100	5/90	
liv hpc h	1.00gm *	P<.04	+	246.mg n.s.s.	0/193	0/93	0/100	2/90	
ARECOLINE.HCl	**61-94-9**								
441 M f swi gav 25m25 1659m					0	28.6mg			Bhide;zkko,107,169-171;1984/pers.comm.
liv tum	no dre	P=1.	-	114.mg n.s.s.	0/20	0/18			
lun tum	no dre	P=1.	-	114.mg n.s.s.	0/20	0/18			
tba tum	no dre	P=1.	-	114.mg n.s.s.	0/20	0/18			
442 M f swi gav 25m25 1659n					0	28.6mg			
lun adc b	61.9mg	P<.07	+	18.6mg n.s.s.	1/16	4/12			
liv hem b	116.mg	P<.06	+	28.4mg n.s.s.	0/16	2/12			
tba mix b	33.6mg	P<.008	+	12.5mg 690.mg	1/16	6/12			
443 M m swi gav 25m25 1659m					0	23.8mg			
liv hem	67.8mg	P<.006	+	30.6mg 524.mg	0/20	8/35			
sto sqc	196.mg	P<.1	+	59.4mg n.s.s.	0/20	3/35			
lun adc	251.mg	P<.5	+	55.5mg n.s.s.	1/20	4/35			
tba mix r	34.6mg	P<.002	+	17.8mg 143.mg	1/20	15/35			
444 M m swi gav 25m25 1659n					0	23.8mg			
liv hem b	114.mg	P<.04	+	34.5mg n.s.s.	0/21	3/21			
lun adc b	325.mg	P<.7	+	40.6mg n.s.s.	2/21	3/21			
tba mix b	57.6mg	P<.06	+	20.3mg n.s.s.	2/21	7/21			
ARISTOLOCHIC ACID, SODIUM SALT (77% AA I, 21% AA II)		**10190-99-5**							
445 R f wis gav 52w69 2424					0	75.0ug			Mengs;artx,51,107-119;1982/pers.comm.
for mix Ae	14.1ug	P<.008	+	3.89ug .254mg	0/4	4/5			
for sqp Ae	24.7ug	P<.04		6.88ug n.s.s.	0/4	3/5			
for sqc Ae	.101mg	P<.3	+	16.3ug n.s.s.	0/4	1/5			
446 R m wis gav 52w69 2424					0	75.0ug			
for sqc Ae	noTD50	P<.02	+	n.s.s. n.s.s.	0/5	4/4			
AROCLOR 1016	**(PCBs, polychlorinated biphenyls) 12674-11-2**								
447 R f sda eat 24m24 2428					0	2.50mg	5.00mg	10.0mg	Mayes;faat,41,62-76;1998/pers.comm.
liv mix e	53.9mg *	P<.003	+	25.7mg 333.mg	1/100	1/50	6/50	5/50	
liv hpa e	59.3mg *	P<.004		27.5mg 461.mg	1/100	1/50	5/50	5/50	
liv hpc e	598.mg *	P<.4		97.4mg n.s.s.	0/100	0/50	1/50	0/50	
448 R m sda eat 24m24 2428					0	2.00mg	4.00mg	8.00mg	
liv mix e	872.mg *	P<.9		42.4mg n.s.s.	7/100	2/50	2/50	4/50	
thy mix e	no dre	P=1.		39.2mg n.s.s.	2/100	4/50	3/50	1/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
AROCLOR 1242 (PCBs, polychlorinated biphenyls) 11104-29-3									
449 R f sda eat 24m24 2428					0	2.50mg	5.00mg		Mayes;faat,41,62-76;1998/pers.comm.
liv mix e	8.78mg	* P<.0005	+	5.39mg 16.4mg	1/100	11/50	15/50		
liv hpa e	10.8mg	* P<.0005		6.36mg 22.3mg	1/100	10/50	12/50		
liv hpc e	127.mg	* P<.05		31.2mg n.s.s.	0/100	0/50	2/50		
liv clc e	256.mg	* P<.5		41.7mg n.s.s.	0/100	1/50	0/50		
450 R m sda eat 24m24 2428					0	2.00mg	4.00mg		
thy mix e	18.2mg	* P<.006	+	8.47mg 204.mg	2/100	7/50	6/50		
thy fca e	22.1mg	* P<.006		9.96mg 234.mg	1/100	5/50	5/50		
thy fcc e	133.mg	* P<.5		22.9mg n.s.s.	1/100	2/50	1/50		
liv mix e	no dre	P=1.		22.4mg n.s.s.	7/100	1/50	4/50		
AROCLOR 1254 (PCBs, polychlorinated biphenyls) 11097-69-1									
451 M m baj eat 47w47 1029 ()					0	36.0mg			Kimbrough;jnci,53,547-549;1974
liv hpt e	9.58mg	P<.0005	+	4.46mg 26.3mg	0/58	9/22			
452 M m baj eat 26w47 1029m ()					0	19.6mg			
liv hpt e	64.6mg	P<.2		10.5mg n.s.s.	0/58	1/24			
453 R f f34 eat 24m24 TR38 :					0	1.30mg	2.50mg	5.00mg	
liv adn ah	34.8mg	* P<.07	a	10.5mg n.s.s.	0/24	0/24	1/24	2/24	
sto acn ah	no dre	P=1.	a	15.2mg n.s.s.	0/24	1/24	1/24	0/24	
TBA MXB a	no dre	P=1.		4.25mg n.s.s.	11/24	18/24	13/24	12/24	
liv MXB a	no dre	P=1.		n.s.s. n.s.s.	0/24	0/24	0/24	0/24	liv:hpa,hpc,nnd.
454 R m f34 eat 24m24 TR38 :					0	1.00mg	2.00mg	4.00mg	
--- MXA	5.94mg	* P<.004		2.78mg 52.3mg	3/24	2/24	5/24	9/24	---:leu,lym. S
--- leu	6.75mg	* P<.009		3.01mg 275.mg	3/24	2/24	5/24	8/24	S
liv MXA h	15.1mg	* P<.008	a	5.21mg 338.mg	0/24	0/24	1/24	3/24	liv:adn,hpc.
MXA acn h	34.6mg	* P<.3	a	8.40mg n.s.s.	0/24	0/24	2/24	0/24	cec:acn; jej:acn; sto:acn.
TBA MXB	3.23mg	* P<.004		1.60mg 23.4mg	7/24	7/24	12/24	13/24	
liv MXB	20.8mg	* P<.03		6.29mg n.s.s.	0/24	0/24	1/24	2/24	liv:hpa,hpc,nnd.
455 R f sda eat 24m24 2428					0	1.25mg	2.50mg	5.00mg	Mayes;faat,41,62-76;1998/pers.comm.
liv mix e	2.82mg	* P<.0005	+	2.09mg 3.98mg	1/100	19/50	28/50	28/50	
liv hpa e	3.07mg	* P<.0005		2.25mg 4.38mg	1/100	18/50	26/50	27/50	
liv cho e	15.3mg	Z P<.0005		6.93mg 48.7mg	0/100	2/50	6/50	(1/50)	
liv hpc e	28.6mg	* P<.0005		13.9mg 76.4mg	0/100	0/50	4/50	6/50	
456 R m sda eat 24m24 2428					0	1.00mg	2.00mg	4.00mg	
thy mix e	16.1mg	* P<.02	+	7.59mg n.s.s.	2/100	7/50	7/50	6/50	
thy fca e	20.2mg	* P<.02		9.14mg n.s.s.	1/100	6/50	4/50	5/50	
liv mix e	55.1mg	* P<.4		13.1mg n.s.s.	7/100	4/50	4/50	6/50	
thy fcc e	89.0mg	* P<.4		20.4mg n.s.s.	1/100	1/50	3/50	1/50	
AROCLOR 1260 (PCBs, clophen A 60, polychlorinated biphenyls) 11096-82-5									
457 R f sda eat 24m24 2428					0	1.25mg	2.50mg	5.00mg	Mayes;faat,41,62-76;1998/pers.comm.
liv mix e	5.51mg	* P<.0005	+	3.77mg 8.72mg	1/100	10/50	11/50	24/50	
liv hpa e	6.43mg	* P<.0005		4.30mg 10.6mg	1/100	9/50	10/50	21/50	
liv hpc e	41.4mg	* P<.002		17.9mg 181.mg	0/100	1/50	1/50	5/50	
liv cho e	98.2mg	* P<.02		29.7mg n.s.s.	0/100	0/50	0/50	3/50	
458 R m sda eat 24m24 2428					0	1.00mg	2.00mg	4.00mg	
thy fca e	11.4mg	Z P<.01		5.03mg 1.35gm	1/100	6/50	4/50	(3/50)	
thy mix e	10.3mg	Z P<.02	+	4.56mg n.s.s.	2/100	7/50	5/50	(4/50)	
liv mix e	20.0mg	* P<.02	+	8.60mg n.s.s.	7/100	3/50	6/50	10/50	
liv hpa e	24.8mg	* P<.03		10.3mg n.s.s.	4/100	2/50	5/50	7/50	
liv hpc e	121.mg	* P<.5		22.3mg n.s.s.	3/100	1/50	1/50	3/50	
thy fcc e	232.mg	* P<.7		28.1mg n.s.s.	1/100	1/50	1/50	1/50	
459 R f shc eat 89w95 1320					0	4.69mg			Kimbrough;jnci,55,1453-1456;1975
liv mix e	1.04mg	P<.0005	+	.804mg 1.35mg	0/173	170/184			
liv nnd e	1.76mg	P<.0005	+	1.39mg 2.24mg	0/173	144/184			
liv hpc e	18.3mg	P<.0005	+	11.3mg 34.3mg	1/173	26/184			
460 R m wis eat 27m27 1605					0	4.00mg			Schaeffer;txap,75,278-288;1984
liv hpc er	5.39mg	P<.0005	+	3.90mg 7.75mg	1/131	61/129			
ARSENATE, SODIUM 7631-89-2									
461 P b cym eat 14y14 2004 :					0	16.5ug			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
kcx ade jw	29.0ug	P<.1		7.14ug n.s.s.	0/11	2/11			
tba ben jw	.169mg	P<.9		9.12ug n.s.s.	2/20	2/12			
462 R b osm eat 24m24 1507					0	1.41mg	2.81mg	5.63mg	11.3mg 18.0mg Byron;txap,10,132-147;1967
tba mal s	no dre	P=1.	-	116.mg n.s.s.	8/50	14/50	8/50	10/50	6/50 5/50
tba mix s	no dre	P=1.	-	121.mg n.s.s.	17/50	21/50	15/50	16/50	13/50 6/50
ARSENIOUS OXIDE 1327-53-3									
463 M f c3s wat 24m24 2367					0	1.06mg			Schrauzer;bnch,9,245-253;1978
mgl adc Ler	no dre	P=1.		1.48mg n.s.s.	12/29	10/28			
464 M b cbl wat 23m23 1505					0	4.13mg			Hueper;aenh,5,445-462;1962
liv tum sv	no dre	P=1.		39.4mg n.s.s.	0/50	0/50			
tba mix sv	no dre	P=1.		39.4mg n.s.s.	1/50	0/50			
465 M m ssa wat 24m24 1506					0	3.33mg			Sanderson;becc,39,628-629;1961
sbg pam	54.8mg	P<.3		12.1mg n.s.s.	1/50	3/50			
466 M f swi wat 65w65 1509					0	20.0mg			Baroni;aenh,7,668-674;1963/Shubik 1962
lun ade e	215.mg	P<.9	-	8.52mg n.s.s.	34/137	4/15			
liv hpt e	no dre	P=1.	-	24.2mg n.s.s.	4/137	0/15			
467 M m swi wat 65w65 1509					0	16.7mg			
lun ade e	31.4mg	P<.06	-	11.4mg n.s.s.	18/133	15/60			
liv hpt e	no dre	P=1.	-	80.5mg n.s.s.	2/133	0/60			
ARSENITE, SODIUM 7784-46-5									
468 M f c3s wat 65w65 2369m					0	16.0mg			Schrauzer;ancl,4,441-447;1974/1976
mgl adc Ler	no dre	P=1.		8.66mg n.s.s.	22/27	6/15			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
469 M f c3s wat 24m24 2369n					0	2.00mg				
mgl adc Ler	no dre	P=1.		6.01mg n.s.s.	22/30	8/30				
470 M b cd1 wat 24m24 1512					0	.877mg				Kanisawa;canr,27,1192-1195;1967
lun mix e	no dre	P=1.	-	14.2mg n.s.s.	26/170	3/103				
liv mix e	no dre	P=1.	-	14.6mg n.s.s.	7/170	1/103				
tba mal e	no dre	P=1.	-	7.97mg n.s.s.	15/170	6/103				
tba mix e	no dre	P=1.	-	10.9mg n.s.s.	55/170	11/103				
tba ben e	no dre	P=1.	-	14.5mg n.s.s.	29/170	3/103				
471 R b leb wat 39m39 1036					0	.265mg				Kanisawa;canr,29,892-895;1969
liv tum e	10.6mg	P<.2	-	3.35mg n.s.s.	1/82	5/91				
tba mal e	no dre	P=1.	-	8.08mg n.s.s.	9/82	3/91				
tba tum e	no dre	P=1.	-	2.90mg n.s.s.	31/82	25/91				
472 R b osm eat 24m24 1507					0	.703mg	1.41mg	2.81mg	5.63mg 11.3mg	Byron;txap,10,132-147;1967
tba mal s	626.mg Z	P<1.	-	13.8mg n.s.s.	8/50	8/50	9/50	15/50	7/50 (1/50)	
tba mix s	no dre	P=1.	-	60.2mg n.s.s.	16/50	14/50	15/50	18/50	15/50 6/50	
L-ASCORBATE, SODIUM (vitamin C, sodium) 134-03-2										
473 R m f3d eat 52w52 1900					0	400.mg				Hirose;carc,8,1731-1735;1987/pers.comm.
eso tum er	no dre	P=1.	-	206.mg n.s.s.	0/10	0/10				
for tum er	no dre	P=1.	-	206.mg n.s.s.	0/10	0/10				
liv tum er	no dre	P=1.	-	206.mg n.s.s.	0/10	0/10				
L-ASCORBIC ACID (vitamin C) 50-81-7										
474 M f b6c eat 24m24 TR247 :					0	3.19gm	6.38gm			
TBA MXB	no dre	P=1.	-	8.40gm n.s.s.	30/50	28/50	27/50			
liv MXB	no dre	P=1.		30.6gm n.s.s.	3/50	1/50	3/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		24.1gm n.s.s.	1/50	4/50	1/50			lun:a/a,a/c.
475 M m b6c eat 24m24 TR247 :					0	2.94gm	5.89gm			
TBA MXB	no dre	P=1.	-	11.9gm n.s.s.	29/50	31/50	24/50			
liv MXB	no dre	P=1.		16.4gm n.s.s.	16/50	16/50	13/50			liv:hpa,hpc,nnd.
lun MXB	115.gm *	P<.7		16.5gm n.s.s.	5/50	4/50	8/50			lun:a/a,a/c.
476 R f f34 eat 24m24 TR247 :					0	1.23gm	2.45gm			
TBA MXB	no dre	P=1.	-	1.86gm n.s.s.	41/50	45/50	40/50			
liv MXB	no dre	P=1.		28.7gm n.s.s.	2/50	0/50	0/50			liv:hpa,hpc,nnd.
477 R m f34 eat 24m24 TR247 :					0	981.mg	1.96gm			
TBA MXB	no dre	P=1.	-	2.05gm n.s.s.	37/50	41/50	39/50			
liv MXB	no dre	P=1.		16.7gm n.s.s.	2/50	0/50	1/50			liv:hpa,hpc,nnd.
478 R m f3d eat 52w52 2098					0	800.mg				Shibata;carc,14,275-280;1993
for tum er	no dre	P=1.		412.mg n.s.s.	0/10	0/10				
ASPARTAME 22839-47-0										
479 R f cdr eat 24m24 2387					0	1.00gm	2.00gm	4.00gm	7.42gm	Koestner;apab,447-457;1984/Cornell 1984/ Hazleton 1973
bra mix ev	118.gm *	P<.2	-	30.4gm n.s.s.	0/60	2/40	0/40	1/40	2/40	
liv bhp ev	no dre	P=1.	-	21.4gm n.s.s.	2/60			0/40	0/40	
tba mix ev	no dre	P=1.	-	11.9gm n.s.s.	49/60			27/40	26/40	
480 R m cdr eat 24m24 2387					0	1.00gm	2.00gm	4.00gm	7.42gm	
bra mix ev	666.gm *	P<.9	-	33.9gm n.s.s.	1/59	1/40	1/40	4/40	0/40	
liv bhp ev	1.29kg	P<.9	-	54.1gm n.s.s.	1/59			0/40	1/38	
tba mix ev	no dre	P=1.	-	10.6gm n.s.s.	28/60			19/40	18/40	
481 R f sls eat 52w52 1327m					0	1.00gm	2.00gm	4.00gm		Ishii;txlt,7,433-437;1981
bra tum ekr	no dre	P=1.		471.mg n.s.s.	0/16	0/16	0/16	0/16		
482 R f sls eat 24m24 1327n					0	1.00gm	2.00gm	4.00gm		
bra mix er	no dre	P=1.	-	45.8gm n.s.s.	1/60	0/60	2/60	0/60		
483 R m sls eat 52w52 1327m					0	1.00gm	2.00gm	4.00gm		
bra tum ekr	no dre	P=1.		471.mg n.s.s.	0/16	0/16	0/16	0/16		
484 R m sls eat 24m24 1327n					0	1.00gm	2.00gm	4.00gm		
bra mix er	186.gm *	P<.5	-	35.2gm n.s.s.	0/59	1/59	0/60	1/60		
ASPIRIN 50-78-2										
485 M f cb6 eat 77w77 1028					0	382.mg				Macklin;dact,3,135-163;1980
liv tum e	no dre	P=1.	-	1.77gm n.s.s.	0/36	0/41				
486 M m cb6 eat 77w77 1028					0	382.mg				
liv tum e	no dre	P=1.	-	1.94gm n.s.s.	0/35	0/45				
487 R b alb gav 78w78 1571					0	26.9mg				Tsung-Hsien;jnci,70,1067-1069;1983
for tum r	no dre	P=1.	-	125.mg n.s.s.	0/23	0/40				
stg tum r	no dre	P=1.	-	125.mg n.s.s.	0/23	0/40				
488 R m f34 eat 68w68 1786					0	200.mg				Sakata;canr,46,3903-3906;1986
ubl pam e	1.67gm	P<.3		272.mg n.s.s.	0/36	1/29				
liv tum e	no dre	P=1.		511.mg n.s.s.	0/36	0/29				
489 R m f34 eat 56w56 2125					0	16.0mg				Reddy;carc,14,1493-1497;1993/pers.comm.
col tum r	no dre	P=1.	-	11.5mg n.s.s.	0/12	0/12				
490 R m wis eat 52w52 2184					0	400.mg				Yanagi;onco,50,275-278;1993
liv tum r	no dre	P=1.	-	433.mg n.s.s.	0/17	0/21				
ASPIRIN, PHENACETIN, AND CAFFEINE (APC) 8003-03-0										
491 M f b6c eat 78w94 TR67 :					0	755.mg	1.51gm			
TBA MXB	no dre	P=1.	-	2.92gm n.s.s.	20/50	17/50	14/50			
liv MXB	18.0gm *	P<.4		4.46gm n.s.s.	1/50	2/50	3/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		3.65gm n.s.s.	4/50	7/50	4/50			lun:a/a,a/c.
492 M m b6c eat 78w94 TR67 :					0	697.mg	1.39gm			
TBA MXB	3.01gm *	P<.3	-	975.mg n.s.s.	17/50	24/50	21/50			
liv MXB	44.5gm *	P<.9		2.35gm n.s.s.	7/50	11/50	6/50			liv:hpa,hpc,nnd.
lun MXB	3.68gm *	P<.07		1.46gm n.s.s.	6/50	9/50	12/50			lun:a/a,a/c.
493 M f cb6 eat 77w77 1028					0	696.mg				Macklin;dact,3,135-163;1980
liv hnd e	8.76gm	P<.3	-	1.43gm n.s.s.	0/36	1/34				
liv hpc e	no dre	P=1.	-	2.67gm n.s.s.	0/36	0/34				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	TD_{50}	DR / 2Tailpvl	AuOp / LoConf	UpConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
494 M m cb6 eat 77w77 1028						0	696.mg			
liv hnd e		9.54gm	P<.3	-	1.55gm n.s.s.	0/35	1/37			
liv hpc e		no dre	P=1.	-	2.91gm n.s.s.	0/35	0/37			
495 R f f34 eat 18m25 TR67 :						0	245.mg	485.mg		
TBA MXB		no dre	P=1.	-	222.mg n.s.s.	42/50	41/50	(32/49)		
liv MXB		3.05gm *	P<.07		1.32gm n.s.s.	0/50	4/50	3/49		liv:hpa,hpc,nnd.
496 R m f34 eat 18m25 TR67 :						0	196.mg	388.mg		
TBA MXB		no dre	P=1.	-	406.mg n.s.s.	30/50	37/50	33/50		
liv MXB		no dre	P=1.		2.75gm n.s.s.	5/50	4/50	1/50		liv:hpa,hpc,nnd.
ASTEMIZOLE (hismanal) 68844-77-9										
497 M f swi eat 78w78 2349						0	3.25mg	13.0mg	52.0mg	Benze;canr,55,5589-5594;1995
liv hpa		no dre	P=1.	-	37.2mg n.s.s.	10/50	4/50	5/50	(2/50)	
lun tum		no dre	P=1.	-	137.mg n.s.s.	4/50	5/50	7/50	3/50	
tba mix		164.mg *	P<.6	-	28.5mg n.s.s.	30/50	28/50	23/50	31/50	
498 M m swi eat 78w78 2349						0	3.00mg	12.0mg	48.0mg	
liv hpc		788.mg *	P<.3	-	155.mg n.s.s.	1/50	0/50	0/50	2/50	
liv hpa		8.77gm *	P<1.	-	55.4mg n.s.s.	15/50	12/50	16/50	14/50	
lun tum		no dre	P=1.	-	104.mg n.s.s.	9/50	11/50	9/50	7/50	
tba mix		no dre	P=1.	-	36.7mg n.s.s.	34/50	31/50	27/50	30/50	
499 R f crw eat 24m24 2349						0	2.50mg	10.0mg	40.0mg	
liv nnd		309.mg *	P<.2	-	89.2mg n.s.s.	6/50	4/50	5/50	9/50	
tba mix		no dre	P=1.	-	28.1mg n.s.s.	45/50	46/50	42/50	43/50	
500 R m crw eat 24m24 2349						0	2.00mg	8.00mg	32.0mg	
liv nnd		no dre	P=1.	-	228.mg n.s.s.	4/50	1/50	4/50	1/50	
tba mix		32.5mg *	P<.2	-	9.56mg n.s.s.	43/50	41/50	43/50	46/50	
dl-ATENOLOL.HCl 51706-40-2										
501 R f f34 gav 89w91 2219						0	251.mg			Zavanella;carc,15,2531-2539;1994/pers.comm.
liv mix r		no dre	P=1.	-	436.mg n.s.s.	1/24	0/11			
502 R m f34 gav 89w91 2219						0	251.mg			
liv mix r		no dre	P=1.	-	436.mg n.s.s.	1/21	0/11			
ATRAZINE 1912-24-9										
503 M f b6a orl 76w76 1244						0	11.1mg			Innes;ntis,1968/1969
lun ade evx		no dre	P=1.	-	12.4mg n.s.s.	1/17	1/17			
liv hpt evx		no dre	P=1.	-	20.7mg n.s.s.	0/17	0/17			
tba mix evx		58.8mg	P<.7	-	7.41mg n.s.s.	2/17	3/17			
504 M m b6a orl 76w76 1244						0	10.3mg			
lun ade evx		28.2mg	P<.4	-	5.90mg n.s.s.	2/18	4/18			
liv hpt evx		no dre	P=1.	-	20.4mg n.s.s.	1/18	0/18			
tba mix evx		54.6mg	P<.7	-	6.40mg n.s.s.	3/18	4/18			
505 M f b6c orl 76w76 1244						0	11.1mg			
liv hpt evx		no dre	P=1.	-	22.0mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1.	-	22.0mg n.s.s.	0/16	0/18			
tba mix evx		71.0mg	P<.3	-	11.6mg n.s.s.	0/16	1/18			
506 M m b6c orl 76w76 1244						0	10.3mg			
liv hpt evx		15.0mg	P<.02	-	5.16mg n.s.s.	0/16	4/18			
lun mix evx		no dre	P=1.	-	20.4mg n.s.s.	0/16	0/18			
tba mix evx		9.29mg	P<.004	-	3.75mg 56.8mg	0/16	6/18			
507 M f cd1 eat 78w78 2364m						0	1.30mg	39.0mg	130.mg	Stevens;jtxe,56,69-109;1999
lun mix es		943.mg *	P<.4	-	215.mg n.s.s.	2/55	3/58	8/60	5/59	
liv mix es		no dre	P=1.	-	8.39mg n.s.s.	0/55	0/58	0/60	0/59	
508 M f cd1 eat 78w78 2364n						0	1.30mg	39.0mg	195.mg	390.mg
lun mix es		7.55gm *	P<.6	-	1.15gm n.s.s.	2/60	1/59	2/60	4/60	2/60
liv hpa es		no dre	P=1.	-	8.53mg n.s.s.	1/60	0/59	0/60	0/60	0/60
509 M m cd1 eat 78w78 2364m						0	1.20mg	36.0mg	120.mg	
lun mix e		1.16gm Z	P<.9	-	59.3mg n.s.s.	6/60	12/57	9/56	(3/55)	
liv mix e		no dre	P=1.	-	609.mg n.s.s.	1/60	2/57	3/56	0/55	
510 M m cd1 eat 78w78 2364n						0	1.20mg	36.0mg	180.mg	360.mg
lun mix e		1.99gm *	P<.3	-	541.mg n.s.s.	10/59	5/60	7/60	8/60	11/58
liv mix e		no dre	P=1.	-	67.5mg n.s.s.	15/59	16/60	13/60	(4/60	2/58)
511 R f f34 eat 24m24 2362						0	.500mg	3.50mg	10.0mg	20.0mg Stevens;jtxe,56,69-109;1999/Wetzel 1994/ Thakur 1998
mgl mix e		150.mg *	P<.2	-	48.9mg n.s.s.	4/60	5/60	7/60	10/60	8/59
--- mnl e		483.mg *	P<.8	-	52.3mg n.s.s.	8/60	18/60	14/60	11/60	15/60
liv hpa e		1.14gm *	P<.5	-	179.mg n.s.s.	0/60	1/60	0/60	1/60	1/60
liv hpc e		3.71gm *	P<.9	-	219.mg n.s.s.	0/60	1/60	1/60	0/60	1/60
512 R f f34 eat 52w52 2363m						0	3.50mg	20.0mg		
mgl mix ekr		no dre	P=1.	-	1.53mg n.s.s.	0/10	0/10	0/10		
513 R f f34 eat 65w65 2363n						0	3.50mg	20.0mg		
mgl mix ekr		no dre	P=1.	-	2.40mg n.s.s.	0/10	0/10	0/10		
514 R f f34 eat 78w78 2363o						0	3.50mg	20.0mg		
mgl mix ekr		no dre	P=1.	-	3.45mg n.s.s.	0/10	0/10	0/10		
515 R f f34 eat 24m24 2363r						0	3.50mg	20.0mg		
mgl mix er		no dre	P=1.	-	40.5mg n.s.s.	3/10	2/10	0/10		
516 R m f34 eat 24m24 2362						0	.400mg	2.80mg	8.00mg	16.0mg
liv hpa e		259.mg *	P<.2	-	72.3mg n.s.s.	3/60	1/60	2/60	2/60	5/60
liv hpc e		no dre	P=1.	-	209.mg n.s.s.	0/60	0/60	1/60	0/60	0/60
517 R f f31 eat 28m29 1957						0	19.2mg	38.2mg		Pinter;nplm,35,533-544;1990/pers.comm.
ute mal ae		197.mg *	P<.09	+	77.3mg n.s.s.	7/45	10/52	14/45		
--- mix ae		158.mg *	P<.2	+	60.4mg n.s.s.	12/44	16/52	22/51		
--- leu ae		267.mg *	P<.2		87.9mg n.s.s.	8/44	10/52	15/51		
--- lym ae		698.mg *	P<.5		147.mg n.s.s.	4/44	6/52	7/51		
tba mal ae		30.0mg *	P<.0005	+	18.0mg 77.1mg	21/50	40/53	44/55		
518 R m f31 eat 29m29 1957						0	15.3mg	30.6mg		
--- mix ae		68.2mg *	P<.06		28.6mg n.s.s.	22/47	26/47	32/48		
--- leu ae		109.mg *	P<.1		42.4mg n.s.s.	13/47	21/47	21/48		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
mgl mix ae	262.mg *	P<.02	+	113.mg n.s.s.	1/45	1/52	8/45		
mgl ben ae	304.mg *	P<.03	+	124.mg n.s.s.	1/45	1/52	7/45		
--- lym ae	791.mg *	P<.7		112.mg n.s.s.	9/47	5/47	11/48		
mgl mal ae	2.17gm *	P<.3		354.mg n.s.s.	0/45	0/52	1/45		
liv hpc ae	2.19gm *	P<.3		356.mg n.s.s.	0/47	0/47	1/48		
tba mal ae	33.6mg *	P<.0005	+	19.5mg 96.2mg	24/56	30/55	43/53		
519 R f sda eat 52w52 2360m					0	3.50mg	20.0mg		Stevens;jtxe,56,69-109;1999/Wetzel 1994
mgl mix ekr	no dre	P=1.		6.04mg n.s.s.	1/10	1/9	1/10		
520 R f sda eat 65w65 2360n					0	3.50mg	20.0mg		
mgl mix ekr	no dre	P=1.		11.1mg n.s.s.	4/10	5/10	1/10		
521 R f sda eat 78w78 2360o					0	3.50mg	20.0mg		
mgl mix ekr	46.4mg *	P<.8		4.26mg n.s.s.	5/10	6/10	6/10		
522 R f sda eat 24m24 2360r					0	3.50mg	20.0mg		
mgl mix er	34.6mg *	P<.5		6.26mg n.s.s.	6/10	4/9	7/10		
523 R f sda eat 24m24 2361					0	3.50mg	20.0mg		
mgl mix ers	29.8mg *	P<.2	-	10.4mg n.s.s.	46/60	34/59	49/60		
mgl car ers	88.3mg *	P<.2	-	28.3mg n.s.s.	17/60	13/59	22/60		
524 R f sda eat 52w54 2646m					0	48.0mg			Stevens;jtxe,56,69-109;1999/1994/Ciba-Geigy 1986
mgl adc ek	24.9mg	P<.003		10.1mg 130.mg	0/20	6/20			
mgl mix ek	24.9mg	P<.003		10.1mg 130.mg	0/20	6/20			
mgl fba ek	84.2mg	P<.1		20.7mg n.s.s.	0/20	2/20			
liv tum ek	no dre	P=1.		53.3mg n.s.s.	0/20	0/20			
525 R f sda eat 25m25 2646n					0	.500mg	3.50mg	25.0mg	50.0mg
mgl mix es	37.9mg *	P<.0005	+	21.6mg 104.mg	35/68	39/69	47/69	47/70	59/69
mgl adc es	79.2mg *	P<.0005	+	44.4mg 239.mg	15/68	16/69	27/69	27/70	37/69
mgl fba es	88.3mg *	P<.009	+	41.7mg 3.54gm	29/68	29/69	36/69	39/70	43/69
mgl cas es	1.93gm *	P<.04		475.mg n.s.s.	0/68	0/69	0/69	0/70	2/69
mgl ade es	1.93gm *	P<.3		399.mg n.s.s.	1/68	0/69	1/69	1/70	2/69
liv hpc es	no dre	P=1.		1.04gm n.s.s.	0/70	1/70	1/70	0/70	0/70
liv hpa es	no dre	P=1.		822.mg n.s.s.	1/70	1/70	2/70	1/70	0/70
526 R f sda eat 24m24 2647					0	1.25mg	2.50mg	3.50mg	20.0mg Stevens;jtxe,56,69-109;1999/Environmental Protection Agency 2000
mgl car rs	50.4mg *	P<.02	+	21.5mg n.s.s.	11/60	18/60	20/60	12/60	25/60
mgl fba rs	357.mg *	P<.8		31.0mg n.s.s.	16/60	24/60	31/60	27/60	24/60
527 R m sda eat 52w54 2646m					0	38.4mg			Stevens;jtxe,56,69-109;1999/1994/Ciba-Geigy 1986
liv tum ek	no dre	P=1.		42.7mg n.s.s.	0/19	0/20			
528 R m sda eat 25m25 2646n					0	.400mg	2.80mg	20.0mg	40.0mg
tes ict e	475.mg *	P<.04		172.mg n.s.s.	1/71	3/70	2/70	2/70	7/70
liv hpa e	545.mg *	P<.02		211.mg n.s.s.	0/71	0/70	1/70	2/70	3/70
liv hpc e	no dre	P=1.		422.mg n.s.s.	3/71	2/70	0/70	1/70	2/70
ATROPINE 51-55-8									
529 R f sda ipj 24m24 1134					0	.857mg			Schmahl;zkko,86,77-84;1976
tba mal e	90.7mg	P<1.	-	2.23mg n.s.s.	3/33	3/31			
530 R m sda ipj 24m24 1134					0	.857mg			
liv hae e	no dre	P=1.		5.30mg n.s.s.	1/36	0/30			
tba mal e	no dre	P=1.	-	5.30mg n.s.s.	1/36	0/30			
AURAMINE-O 2465-27-2									
531 M f alb eat 52w79 45					0	85.0mg			Williams;bjca,16,87-91;1962
liv hpt e	94.3mg	P<.08	+	28.2mg n.s.s.	0/6	3/10			
532 M m alb eat 52w84 45					0	74.3mg			
liv hpt e	39.2mg	P<.008	+	12.8mg 860.mg	0/7	4/7			
533 M f cba eat 52w99 45					0	136.mg			
liv hpt e	67.7mg	P<.0005	+	30.5mg 197.mg	3/41	11/15			
534 M m cba eat 52w79 45					0	157.mg			
liv hpt e	77.5mg	P<.004	+	30.3mg 666.mg	1/14	7/12			
535 R m wsw eat 20m29 45					0	27.7mg			
liv hpt e	11.0mg	P<.0005	+	4.06mg 31.2mg	0/12	11/12			
AURANOFIN ((2,3,4,6-tetra-O-acetyl-1-thio-1-beta-D-glucopyranosato-S) (triethylphosphine) gold) 34031-32-8									
536 M f cd1 gav 80w81 1870					0	1.00mg	3.00mg	7.45mg	Markiewicz;faat,11,277-284;1988
liv mix erv	no dre	P=1.	-	130.mg n.s.s.	4/220	3/110	0/110	0/110	
537 M m cd1 gav 80w81 1870					0	1.00mg	3.00mg	7.45mg	
liv mix erv	42.6mg *	P<.2	-	13.8mg n.s.s.	24/220	21/110	17/110	20/110	
5-AZACYTIDINE 320-67-2									
538 M f b6c ipj 52w81 TR42 :					0	.610mg	1.60mg		
MXA MXA u	.256mg *	P<.0005	a	.138mg .716mg	0/14	17/35	0/35		---:lym; mul:grl,gsa.
mul MXA u	.520mg *	P<.008	a	.243mg 6.56mg	0/14	10/35	0/35		mul:grl,gsa.
--- lym u	.615mg *	P<.03	a	.249mg n.s.s.	0/14	7/35	0/35		
TBA MXB	.219mg *	P<.003		.112mg 1.35mg	2/14	22/35	1/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/14	0/35	0/35		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		1.65mg n.s.s.	2/14	0/35	0/35		lun:a/a,a/c.
539 M m b6c ipj 52w81 TR42 :					0	.600mg	1.20mg		
TBA MXB s	1.05mg *	P<.2	i	.360mg n.s.s.	2/16	6/35	5/35		
liv MXB s	15.7mg *	P<.9		.919mg n.s.s.	1/16	1/35	1/35		liv:hpa,hpc,nnd.
lun MXB s	61.4mg *	P<1.		1.36mg n.s.s.	1/16	0/35	1/35		lun:a/a,a/c.
540 M f bal ipj 50w72 1819					0	.198mg			Cavaliere;clet,37,51-58;1987
lmr mix e	56.9ug	P<.0005	+	35.2ug .104mg	6/50	36/50			
mgl mix e	.432mg	P<.002		.186mg 1.82mg	0/50	7/50			
mgl adb e	.618mg	P<.008	+	.235mg 12.0mg	0/50	5/50			
ski mix e	.499mg	P<.03	+	.196mg n.s.s.	1/50	7/50			
liv tum e	no dre	P=1.		.980mg n.s.s.	0/50	0/50			
lun ade e	no dre	P=1.		.329mg n.s.s.	9/50	7/50			
tba tum e	36.4ug	P<.0005		21.5ug 69.4ug	14/50	44/50			
541 M m bal ipj 50w67 1819					0	.213mg			
lun ade e	.121mg	P<.003	+	60.4ug .719mg	12/50	27/50			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes / Path	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
lmr mix e	.285mg	P<.01 +	.126mg 41.7mg	3/50	12/50			
ski mix e	.980mg	P<.04 +	.297mg n.s.s.	0/50	3/50			
liv hpa e	1.49mg	P<.1	.365mg n.s.s.	0/50	2/50			
tba tum e	53.9ug	P<.0005	31.5ug .116mg	13/50	38/50			
542 R f sda ipj 34w80 TR42 :				0	.470mg	1.68mg		
TBA MXB s	.487mg	/ P<.09 i	.164mg n.s.s.	7/15	15/35	3/35		
liv MXB s	no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
543 R m sda ipj 34w80 TR42 :				0	.470mg	1.72mg		
TBA MXB s	.328mg	* P<.004 i	.156mg 2.32mg	1/15	11/35	1/35		
liv MXB s	no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
544 R m f34 ipj 52w52 1906				0	10.7ug	.107mg	1.07mg	Carr;bjca,57,395-402;1988
tes tum e	.222mg	* P<.0005 +	.144mg .404mg	10/49	1/10	2/10	56/87	
liv tum e	no dre	P=1.	5.01ug n.s.s.	0/49	0/10	0/10	0/87	
tba tum e	.170mg	* P<.0005 +	.114mg .282mg	10/49	1/10	2/10	63/87	
6-AZACYTIDINE 3131-60-0								
545 R m f34 ipj 52w52 1906				0	1.07mg			Carr;bjca,57,395-402;1988
liv tum e	no dre	P=1.	.662mg n.s.s.	0/49	0/12			
tba tum e	no dre	P=1. -	.340mg n.s.s.	10/49	2/12			
AZASERINE 115-02-6								
546 R b wis ipj 26w78 1172				0	.475mg			Longnecker;canc,47,1562-1572;1981
pae car e	.793mg	P<.0005 +	.342mg 2.54mg	0/76	7/34			
kid tum e	.942mg	P<.0005	.384mg 3.38mg	0/76	6/34			
liv tum e	3.02mg	P<.03	.742mg n.s.s.	0/76	2/34			
547 R m wis ipj 24m24 1746				0	.714mg			McGuinness;sjge,18,189-192;1983
pan tum r	no dre	P=1. -	.736mg n.s.s.	0/9	0/5			
AZATHIOPRINE (imuran) 446-86-6								
548 M f b6c eat 86w86 1935m				0	.650mg	2.60mg		Ito;gann,80,419-423;1989/pers.comm.
liv tum k	no dre	P=1.	.366mg n.s.s.	0/5	0/5	0/5		
lun tum k	no dre	P=1.	.366mg n.s.s.	0/5	0/5	0/5		
549 M f b6c eat 94w94 1935n				0	.650mg	2.60mg		
lun tum k	4.89mg	* P<.2	1.68mg n.s.s.	0/13	2/15	2/11		
--- lsl k	7.59mg	* P<.3	2.20mg n.s.s.	0/13	2/15	2/15		
liv tum k	no dre	P=1.	1.22mg n.s.s.	0/13	0/15	0/11		
550 M f b6c eat 23m23 1935o				0	.650mg	2.60mg		
ute hae h	8.92mg	* P<.0005 +	3.85mg 30.8mg	0/32	0/30	7/34		
--- lsl	43.8mg	* P<.7 +	4.89mg n.s.s.	2/32	5/30	4/34		
liv hpa	67.5mg	* P<.2	11.0mg n.s.s.	0/32	0/30	1/34		
liv hem	no dre	P=1.	3.04mg n.s.s.	1/32	0/30	0/34		
lun tum	no dre	P=1.	3.04mg n.s.s.	0/32	0/30	0/34		
551 M m b6c eat 86w86 1935m				0	.600mg	2.40mg		
liv tum k	no dre	P=1.	.338mg n.s.s.	0/5	0/5	0/5		
lun tum k	no dre	P=1.	.338mg n.s.s.	0/5	0/5	0/5		
552 M m b6c eat 94w94 1935n				0	.600mg	2.40mg		
lun ade k	no dre	P=1.	3.18mg n.s.s.	1/15	3/16	1/15		
liv hpa k	no dre	P=1.	5.97mg n.s.s.	1/15	1/16	0/15		
--- lsl k	no dre	P=1.	5.97mg n.s.s.	1/15	1/16	0/15		
553 M m b6c eat 23m23 1935o				0	.600mg	2.40mg		
--- lsl	9.66mg	* P<.2	3.65mg n.s.s.	0/30	3/29	3/30		
liv hpc	55.9mg	* P<.2	9.10mg n.s.s.	0/30	0/29	1/30		
lun car	55.9mg	* P<.2	9.10mg n.s.s.	0/30	0/29	1/30		
liv hpa	no dre	P=1.	2.69mg n.s.s.	7/30	1/29	(1/30)		
lun ade	no dre	P=1.	2.67mg n.s.s.	1/30	0/29	0/30		
554 P b cym eat 15y16 2003 :				0	1.22mg	3.03mg		Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
tba mal Ww	no dre	P=1.	n.s.s. n.s.s.	0/15	-/-	-/-		
555 P b rhe eat 15y16 2003 :				0	1.29mg	3.00mg		
slg ade Ww	2.18mg	* P<.007	.441mg 73.8mg	0/37	1/7	1/5		
ute ley Ww	2.74mg	* P<.05	.446mg n.s.s.	0/31	1/5	-/-		
lep lcl w	6.79mg	* P<.1	1.11mg n.s.s.	0/37	1/7	0/2		
tba mix Ww	3.68mg	* P<.2	.687mg n.s.s.	6/108	3/9	1/9		
tba ben Ww	4.89mg	* P<.3	.740mg n.s.s.	4/108	2/9	1/9		
tba mal Ww	no dre	P=1.	1.45mg n.s.s.	3/74	1/8	0/9		
556 R f f34 eat 52w52 1695				0	7.50mg			Frankel;txap,17,462-480;1970
edu sqc ekr	10.1mg	P<.2	3.04mg n.s.s.	0/12	3/25			
liv tum ekr	no dre	P=1. -	9.66mg n.s.s.	0/12	0/25			
AZELNIDIPINE 123524-52-7								
557 M f b6c gav 78w78 2591				0	2.14mg	7.14mg	21.4mg	Takaoka;jjpt,25,S1113-S1126;1997/pers.comm.
lun a/a	217.mg	* P<.3 -	51.5mg n.s.s.	3/50	0/50	1/50	4/50	
liv hpc	no dre	P=1. -	66.9mg n.s.s.	2/50	3/50	2/50	2/50	
liv hpa	no dre	P=1. -	162.mg n.s.s.	4/50	2/50	0/50	0/50	
lun a/c	no dre	P=1. -	96.5mg n.s.s.	2/50	3/50	1/50	1/50	
tba mix	no dre	P=1. -	25.0mg n.s.s.	25/50	18/50	24/50	19/50	
558 M m b6c gav 78w78 2591				0	2.14mg	7.14mg	21.4mg	
lun a/a	65.0mg	* P<.05 -	24.5mg n.s.s.	3/50	4/50	4/50	9/50	
lun a/c	227.mg	* P<.4 -	46.3mg n.s.s.	1/50	2/50	2/50	3/50	
liv hpc	no dre	P=1. -	31.9mg n.s.s.	14/50	15/50	16/50	12/50	
liv hpa	no dre	P=1. -	39.9mg n.s.s.	14/50	8/50	12/50	9/50	
tba mix	83.5mg	* P<.7 -	11.9mg n.s.s.	25/50	27/50	30/50	28/50	
559 R f f3d gav 24m24 2591				0	7.14mg			
liv hpa	no dre	P=1. -	36.1mg n.s.s.	2/50	2/50			
liv hpc	no dre	P=1. -	73.6mg n.s.s.	1/50	0/50			
tba mix	no dre	P=1. -	6.85mg n.s.s.	37/50	35/50			
560 R m f3d gav 24m24 2591				0	7.14mg			
liv hpa	117.mg	P<.3 -	25.9mg n.s.s.	1/50	3/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc		237.mg	P<.6 -	32.4mg n.s.s.	1/50	2/50			
tba mix		no dre	P=1. -	2.19mg n.s.s.	50/50	48/50			
AZIDE, SODIUM 26628-22-8									
561 R f f34 gav 24m24 TR389 :					0	3.53mg	7.06mg		
TBA MXB		19.1mg	* P<.6 -	3.58mg n.s.s.	53/60	54/60	39/60		
liv MXB		no dre	P=1.	64.7mg n.s.s.	1/60	0/60	0/60		liv:hpa,hpc,nnd.
562 R m f34 gav 24m24 TR389 :					0	3.53mg	7.06mg		
tes MXA	#	3.79mg	/ P<.03 -	1.68mg n.s.s.	52/60	51/60	44/60		tes:iab,ica. S
TBA MXB		8.26mg	* P<.4	2.23mg n.s.s.	56/60	55/60	36/60		
liv MXB		no dre	P=1.	20.4mg n.s.s.	3/60	3/60	0/60		liv:hpa,hpc,nnd.
563 R f cdr eat 18m24 1112					0	3.75mg	7.50mg		Weisburger;jnci,67,75-88;1981
mgl tum e		3.01mg	\ P<.003	1.45mg 19.1mg	3/16	17/26	(10/26)		
pit cra e		16.1mg	* P<.5 -	3.92mg n.s.s.	6/16	19/26	14/26		
564 R m cdr eat 18m24 1112					0	3.00mg	6.00mg		
pit cra e		no dre	P=1. -	13.5mg n.s.s.	3/16	6/26	3/26		
AZINPHOSMETHYL (gusathion) 86-50-0									
565 M f b6c eat 80w92 TR69 :					0	7.02mg	14.3mg		
TBA MXB		2.58gm	/ P<1. -	18.2mg n.s.s.	5/10	10/50	17/50		
liv MXB		no dre	P=1.	96.3mg n.s.s.	1/10	0/50	1/50		liv:hpa,hpc,nnd.
lun MXB		118.mg	* P<.3	40.6mg n.s.s.	0/10	1/50	3/50		lun:a/a,a/c.
566 M m b6c eat 80w92 TR69 :					0	3.24mg	6.48mg		
liv hpc	#	14.3mg	* P<.007 -	7.82mg 169.mg	0/10	3/50	12/50		S
TBA MXB		46.6mg	* P<.8	4.69mg n.s.s.	4/10	23/50	23/50		
liv MXB		12.6mg	* P<.2	5.18mg n.s.s.	2/10	11/50	19/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	16.8mg n.s.s.	2/10	8/50	4/50		lun:a/a,a/c.
567 R f osm eat 19m27 TR69 :					0	2.17mg	4.34mg		
TBA MXB		no dre	P=1. -	2.58mg n.s.s.	7/10	37/49	26/50		
liv MXB		164.mg	/ P<.9	12.0mg n.s.s.	2/10	2/49	5/50		liv:hpa,hpc,nnd.
568 R f osm eat 19m25 TR69 : pool					0	2.17mg	4.34mg		
pit acn	#	6.93mg	\ P<.0005 -	3.14mg 20.4mg	0/105	8/49	(1/50)		S
thy MXA		15.9mg	* P<.004	7.20mg 123.mg	1/105	6/49	4/50		thy:adn,cyn. S
adr coa		16.4mg	* P<.02	6.72mg n.s.s.	5/105	4/49	8/50		S
569 R m osm eat 19m27 TR69 :					0	2.18mg	4.35mg		
pni MXA	v	22.9mg	* P<.04 a	9.81mg n.s.s.	0/10	1/50	6/50		pni:isa,isc.
TBA MXB	v	5.42mg	* P<.3	1.68mg n.s.s.	7/10	40/50	41/50		
liv MXB	v	52.7mg	* P<.6	10.5mg n.s.s.	1/10	3/50	5/50		liv:hpa,hpc,nnd.
570 R m osm eat 19m25 TR69 : pool					0	2.18mg	4.35mg		
pit cra	v	3.99mg	\ P<.008	1.77mg 90.0mg	15/105	21/50	(13/50)		S
pit MXA	v	3.99mg	\ P<.008	1.77mg 90.0mg	15/105	21/50	(15/50)		pit:cra,crc. S
thy MXA	v	6.06mg	* P<.0005 a	3.69mg 11.0mg	0/105	10/50	13/50		thy:acn,cyn,pcn.
thy ---	v	7.87mg	* P<.003	3.98mg 44.0mg	8/105	14/50	14/50		S
thy MXA	v	10.5mg	* P<.006 a	4.92mg 143.mg	7/105	10/50	12/50		thy:adn,cyn,fca.
adr MXA	v	15.3mg	* P<.006	6.93mg 183.mg	4/105	4/50	10/50		adr:acn,coa. S
pit MXA	v	7.43mg	* P<.02	3.32mg n.s.s.	20/105	21/50	20/50		pit:adn,cra,crc,cyn. S
liv hpa	v	23.3mg	* P<.02	9.63mg n.s.s.	1/105	3/50	5/50		S
pni MXA	v	30.6mg	* P<.03 a	11.3mg n.s.s.	2/105	1/50	6/50		pni:isa,isc.
adr acn	v	44.3mg	* P<.02	15.3mg n.s.s.	0/105	1/50	3/50		S
AZOBENZENE 103-33-3									
571 M f b6c eat 24m24 TR154 :					0	27.0mg	70.8mg		
TBA MXB	v	no dre	P=1. -	78.4mg n.s.s.	9/20	20/50	12/50		
liv MXB	v	no dre	P=1.	247.mg n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
lun MXB	v	no dre	P=1.	232.mg n.s.s.	2/20	2/50	2/50		lun:a/a,a/c.
572 M f b6c orl 76w76 1104					0	7.84mg			Innes;ntis,1968/1969
lun ade evx		47.3mg	P<.3	7.70mg n.s.s.	0/16	1/17			
liv hpt evx		no dre	P=1.	14.7mg n.s.s.	0/16	0/17			
tba mix evx		47.3mg	P<.3	7.70mg n.s.s.	0/16	1/17			
573 M m b6c eat 24m24 TR154 :					0	24.0mg	48.0mg		
TBA MXB		no dre	P=1. -	34.6mg n.s.s.	13/20	25/50	(20/50)		
liv MXB		no dre	P=1.	43.6mg n.s.s.	8/20	16/50	(2/50)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	287.mg n.s.s.	2/20	4/50	1/50		lun:a/a,a/c.
574 M m b6c orl 76w76 1104					0	7.30mg			Innes;ntis,1968/1969
liv mix evx		3.85mg	P<.0005	1.78mg 11.1mg	0/16	9/18			
liv hpt evx		4.54mg	P<.0005	2.02mg 14.9mg	0/16	8/18			
lun mix evx		no dre	P=1.	14.5mg n.s.s.	0/16	0/18			
tba mix evx		3.85mg	P<.0005	1.78mg 11.1mg	0/16	9/18			
575 M f b6a orl 76w76 1104					0	7.84mg			
lun ade evx		39.3mg	P<.6	5.76mg n.s.s.	1/17	2/16			
liv hpt evx		no dre	P=1.	13.8mg n.s.s.	0/17	0/16			
tba mix evx		343.mg	P<1.	6.39mg n.s.s.	2/17	2/16			
576 M m b6a orl 76w76 1104					0	7.30mg			
liv hpt evx		44.1mg	P<.6	6.12mg n.s.s.	1/18	2/18			
lun ade evx		no dre	P=1.	9.58mg n.s.s.	2/18	1/18			
tba mix evx		no dre	P=1.	5.74mg n.s.s.	3/18	3/18			
577 R f f34 eat 24m24 TR154 :					0	10.0mg	20.0mg		
MXA MXA		32.3mg	* P<.0005 c	19.8mg 69.9mg	0/20	5/50	19/50		jej:srn; mul:sar; spc:fbs; spl:hpm,ost,sar.
MXB MXB		32.3mg	* P<.0005	19.8mg 69.9mg	0/20	5/50	19/50		jej:srn; mul:sar; spc:fbs; spl:fbs,hpm,ost,sar. C
spl ost		90.5mg	* P<.008 c	42.7mg 1.39gm	0/20	1/50	8/50		
spl fbs		102.mg	* P<.02 c	46.2mg n.s.s.	0/20	1/50	7/50		
TBA MXB		51.5mg	* P<.5	13.0mg n.s.s.	10/20	32/50	33/50		
liv MXB		276.mg	* P<.3	83.5mg n.s.s.	0/20	1/50	2/50		liv:hpa,hpc,nnd.
578 R m f34 eat 24m24 TR154 :					0	8.00mg	16.0mg		
MXA MXA	a	19.2mg	/ P<.0005 c	11.4mg 39.1mg	0/20	6/50	16/50		abc:hes; liv:hes; mey:srn; mul:msm; spl:npm,sar.
MXB MXB	a	19.2mg	/ P<.0005	11.4mg 39.1mg	0/20	6/50	16/50		abc:hes; liv:hes; mey:srn; mul:msm; spl:fbs,npm,sar. C
mul fbs	a	43.9mg	/ P<.0005	22.9mg 110.mg	0/20	0/50	13/50		S
spl fbs	a	44.4mg	/ P<.004 c	20.8mg 121.mg	0/20	2/50	7/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TBA MXB a		11.4mg /	P<.0005	6.61mg 37.1mg	10/20	19/50	43/50		
liv MXB a		122.mg *	P<.07	41.4mg n.s.s.	0/20	1/50	3/50		liv:hpa,hpc,nnd.
AZOXYMETHANE (Z-methyl-O,N,N-azoxymethane) 25843-45-2									
579 R m f34 wat 7m23 1641					0	85.3ug	.361mg		Lijinsky;clet,24,273-280;1984/1985a
liv mix e		30.2ug \	P<.0005 +	14.6ug 73.4ug	2/20	17/20	(16/20)		
liv hpc e		67.7ug \	P<.0005 +	33.1ug .168mg	0/20	11/20	(13/20)		
kid mix e		.388mg *	P<.0005 +	.192mg .957mg	0/20	0/20	11/20		
col mix e		.585mg *	P<.0005 +	.263mg 1.73mg	0/20	0/20	8/20		
liv hes e		.982mg *	P<.2	.354mg n.s.s.	0/20	3/20	3/20		
liv nnd e		28.6mg *	P<1.	.465mg n.s.s.	2/20	5/20	3/20		
tba mix e		noTD50	P=1.	n.s.s. n.s.s.	20/20	20/20	20/20		
580 R m f34 gav 30w65 1864					0	.527mg			Lijinsky;canr,47,3968-3972;1987/pers.comm.
col tum e		.102mg	P<.0005 +	48.5ug .249mg	0/19	12/16			
col mal e		.171mg	P<.0005	77.9ug .474mg	0/19	9/16			
zym car e		.204mg	P<.0005 +	90.0ug .610mg	0/19	8/16			
kid mnp e		.300mg	P<.002 +	.121mg 1.26mg	0/19	6/16			
liv tum e		no dre	P=1. -	.679mg n.s.s.	0/19	0/16			
1-AZOXYPROPANE 17697-55-1									
581 R m sda gav 26w77 1837					0	1.40ug			Fiala;carc,8,1947-1949;1987/pers.comm.
ski mix ev		noTD50	P<.0005 +	n.s.s. 241.ng	1/29	29/29			
ski ker ev		380.ng	P<.0005 +	214.ng 751.ng	1/29	22/29			
nas mix ev		596.ng	P<.0005 +	330.ng 1.22ug	0/29	17/29			
nas ene ev		723.ng	P<.0005 +	390.ng 1.55ug	0/29	15/29			
liv hpc ev		7.36ug	P<.1	1.81ug n.s.s.	0/29	2/29			
nas pam ev		7.36ug	P<.1 +	1.81ug n.s.s.	0/29	2/29			
liv hpa ev		no dre	P=1.	2.77ug n.s.s.	1/29	1/29			
2-AZOXYPROPANE 17697-53-9									
582 R m sda gav 26w77 1837					0	1.40ug			Fiala;carc,8,1947-1949;1987/pers.comm.
ski ker ev		2.68ug	P<.04 +	971.ng n.s.s.	1/29	6/29			
liv hpc ev		7.36ug	P<.1	1.81ug n.s.s.	0/29	2/29			
liv hpa ev		no dre	P=1.	2.77ug n.s.s.	1/29	1/29			
AZT (3'-azido-3'-deoxythymidine, ZDV, zidovudine) 30516-87-1									
583 M f b6c gav 24m24 TR469 :					0	21.4mg	42.9mg	85.7mg	
vag MXA		209.mg *	P<.0005 c	116.mg 445.mg	0/50	0/50	5/50	11/50	vag:sqc,sqp.
vag sqc		246.mg *	P<.0005 c	132.mg 577.mg	0/50	0/50	5/50	9/50	
TBA MXB		221.mg *	P<.5	46.2mg n.s.s.	41/50	42/50	41/50	43/50	
liv MXB		139.mg *	P<.2	49.2mg n.s.s.	27/50	29/50	23/50	36/50	liv:hpa,hpb,hpc.
lun MXB		510.mg *	P<.3	147.mg n.s.s.	6/50	8/50	2/50	11/50	lun:a/a,a/c.
584 M m b6c gav 24m24 TR469 :					0	21.4mg	42.9mg	85.7mg	
kid MXA		929.mg *	P<.02 e	321.mg n.s.s.	0/50	0/50	0/50	4/50	kid:rua,ruc.
kid rua		1.25gm *	P<.04	378.mg n.s.s.	0/50	0/50	0/50	3/50	S
hag MXA		458.mg *	P<.2 e	159.mg n.s.s.	3/50	5/50	2/50	10/50	hag:ade,car.
TBA MXB		no dre	P=1.	64.1mg n.s.s.	43/50	49/50	45/50	50/50	
liv MXB		no dre	P=1.	87.5mg n.s.s.	36/50	39/50	36/50	39/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	209.mg n.s.s.	14/50	9/50	14/50	11/50	lun:a/a,a/c.
585 M m b6c gav 24m24 TR469 : with step					0	21.4mg	42.9mg	85.7mg	
kid MXA		929.mg *	P<.02 e	321.mg n.s.s.	0/50	0/50	0/50	4/50	kid:rua,ruc.
586 M f cd1 gav 95w95 2299					0	21.4mg	34.1mg	50.9mg	Ayers;faat,32,148-158;1996/pers.comm.
vag mix evh		508.mg *	P<.005 +	219.mg 3.30gm	0/60	0/60	1/60	6/60	
vag sqc ev		715.mg *	P<.02	272.mg n.s.s.	0/60	0/60	0/60	5/60	
tba mix ev		131.mg	P<.3	41.2mg n.s.s.	25/60			32/60	
587 M m cd1 gav 82w82 2299					0	52.7mg			
tba mix ev		no dre	P=1. -	99.3mg n.s.s.	19/60	15/60			
588 R f cdr gav 95w95 2299					0	80.0mg	220.mg	384.mg	
vag sqc evh		11.6gm *	P<.08 +	2.86gm n.s.s.	0/60	0/60	0/60	2/60	
tba mix ev		no dre	P=1.	208.mg n.s.s.	56/60			53/60	
589 R m cdr gav 24m24 2299					0	377.mg			
tba mix ev		no dre	P=1. -	442.mg n.s.s.	51/60	45/60			
BARBITAL, SODIUM 144-02-5									
590 R f f34 wat 75w75 2228					0	28.6mg			Diwan;txap,132,115-121;1995/pers.comm.
liv tum		no dre	P=1.	58.2mg n.s.s.	0/16	0/19			
591 R m f34 eat 56w56 1942					0	40.0mg			Diwan;txap,98,269-277;1989
ubl tum e		no dre	P=1. -	35.9mg n.s.s.	0/15	0/15			
592 R m f34 eat 52w52 1993m					0	160.mg			Konishi;carc,11,2149-2156;1990/pers.comm.
ktu tum kr		no dre	P=1.	41.2mg n.s.s.	0/5	0/5			
593 R m f34 eat 72w72 1993n					0	160.mg			
k/p tpp er		105.mg	P<.0005 +	52.4mg 266.mg	0/24	11/28			
ktu tla er		341.mg	P<.03 +	118.mg n.s.s.	0/24	4/28			
594 R m f34 eat 24m24 2085					0	160.mg			Kurata;fctx,30,251-259;1992/pers.comm.
kid mix		719.mg	P<.2	203.mg n.s.s.	1/23	4/23			
kid tla		1.11gm	P<.3	246.mg n.s.s.	1/23	3/23			
kid uac		2.37gm	P<.3	386.mg n.s.s.	0/23	1/23			
595 R m f34 wat 75w75 2228					0	25.0mg			Diwan;txap,132,115-121;1995/pers.comm.
kid mix		29.2mg	P<.04 +	10.6mg n.s.s.	1/20	6/20			
kid rca		54.8mg	P<.04	16.6mg n.s.s.	0/20	3/20			
k/p tpp		51.8mg	P<.2	14.7mg n.s.s.	1/20	4/20			
liv hpa		165.mg	P<.6	22.8mg n.s.s.	1/20	2/20			
BARBITURIC ACID 67-52-7									
596 R m f34 wat 72w72 1690					0	25.0mg			Diwan;jnci,74,509-516;1985
liv hct e		no dre	P=1.	32.1mg n.s.s.	0/13	0/13			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
BARIUM ACETATE 543-80-6									
597 M f cd1 wat 27m27 1395					0	1.00mg			Schroeder;jnut,105,452-458;1975
--- lkm e	4.28mg	P<.05	-	1.34mg n.s.s.	3/47	5/21			
lun tum e	no dre	P=1.	-	2.63mg n.s.s.	9/47	3/21			
tba mal e	7.21mg	P<.3	-	1.65mg n.s.s.	4/47	4/21			
tba mix e	no dre	P=1.	-	2.10mg n.s.s.	14/47	5/21			
598 M m cd1 wat 27m27 1395					0	.833mg			
lun tum e	no dre	P=1.	-	3.28mg n.s.s.	5/38	4/37			
tba mix e	14.6mg	P<.8	-	1.53mg n.s.s.	11/38	12/37			
tba mal e	5.98mg	P<.2	-	1.88mg n.s.s.	2/38	6/37			
599 R f leb wat 37m37 1456					0	.286mg			Schroeder;jnut,105,421-427;1975
tba mix e	no dre	P=1.	-	1.14mg n.s.s.	17/24	15/33			
tba mal e	no dre	P=1.	-	1.18mg n.s.s.	8/24	9/33			
600 R m leb wat 37m37 1456					0	.250mg			
tba mix e	2.87mg	P<.4	-	.738mg n.s.s.	4/26	8/30			
tba mal e	2.87mg	P<.2	-	.844mg n.s.s.	2/26	6/30			
BARIUM CHLORIDE DIHYDRATE 10326-27-9									
601 M f b6c wat 24m24 TR432 :					0	98.9mg	247.mg	495.mg	
TBA MXB s	806.mg	* P<.3	-	227.mg n.s.s.	34/50	32/53	39/50	17/54	
liv MXB s	4.41gm	* P<.8		483.mg n.s.s.	16/50	14/53	19/50	6/54	liv:hpa,hpb,hpc.
lun MXB s	13.4gm	* P<.8		1.07gm n.s.s.	3/50	3/53	5/50	1/54	lun:a/a,a/c.
602 M m b6c wat 24m24 TR432 :					0	82.4mg	207.mg	414.mg	
--- hem s#	3.47gm	* P<.02	-	1.31gm 524.gm	0/51	0/50	2/49	3/50	S
TBA MXB s	no dre	P=1.		506.mg n.s.s.	45/51	33/50	32/49	26/50	
liv MXB s	no dre	P=1.		1.06gm n.s.s.	27/51	24/50	18/49	11/50	liv:hpa,hpb,hpc.
lun MXB s	no dre	P=1.		1.03gm n.s.s.	15/51	10/50	8/49	9/50	lun:a/a,a/c.
603 R f f34 wat 24m24 TR432 :					0	28.2mg	70.7mg	142.mg	
TBA MXB	no dre	P=1.	-	110.mg n.s.s.	48/50	44/50	44/50	45/50	
liv MXB	no dre	P=1.		1.11gm n.s.s.	0/50	1/50	0/50	0/50	liv:hpa,hpb,hpc.
604 R m f34 wat 24m24 TR432 :					0	24.9mg	62.3mg	125.mg	
TBA MXB	no dre	P=1.	-	140.mg n.s.s.	47/50	46/50	43/50	43/50	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
BEMITRADINE (8-(2-ethoxyethyl)-phenyl-1,2,4-triazolo[4,3-c]pyrimidine-5 amine) 88133-11-3									
605 R f cdr eat 23m24 2103					0	46.2mg	139.mg	416.mg	Gad;japt,12,157-164;1992/pers.comm.
liv hpa e	307.mg	Z P<.0005	+	171.mg 832.mg	9/120	9/60	20/60	(18/59)	
liv hpc e	646.mg	* P<.0005	+	417.mg 1.10gm	2/120	1/60	6/60	26/59	
mgl car e	669.mg	* P<.002	+	340.mg 3.32gm	33/120	20/60	24/60	31/59	
mgl ade e	3.01gm	* P<.6		535.mg n.s.s.	48/120	36/60	29/60	29/59	
606 R m cdr eat 23m24 2103					0	46.2mg	139.mg	416.mg	
liv hpa e	2.53gm	* P<.08	+	894.mg n.s.s.	16/120	7/60	7/60	14/60	
liv hpc e	4.16gm	* P<.03	+	1.47gm n.s.s.	1/120	3/60	1/60	5/60	
BENZALAZINE (2-hydroxy-5-[(4-carboxyphenyl)azo]benzoic acid) 64896-26-0									
607 M f nmr eat 25m25 2198					0	100.mg	300.mg	1.63gm	Herzog;arzn,44,1371-1381;1994
--- lym ev	1.20gm	* P<.03	-	467.mg n.s.s.	36/50	33/50	48/50	44/50	
lun a/a ev	2.65gm	Z P<.03	-	983.mg n.s.s.	1/50	0/50	6/50	(5/50)	
liv hpa ev	no dre	P=1.	-	782.mg n.s.s.	2/50	0/50	0/50	0/50	
lun acb ev	no dre	P=1.	-	9.92gm n.s.s.	8/50	3/50	6/50	3/50	
608 M m nmr eat 28m28 2198					0	100.mg	300.mg	1.65gm	
liv hpc ev	19.5gm	* P<.07	-	6.27gm n.s.s.	1/50	0/50	3/50	4/50	
lun a/a ev	13.0gm	* P<.2	-	3.91gm n.s.s.	5/50	5/50	9/50	10/50	
lun acb ev	14.3gm	* P<.3	-	3.63gm n.s.s.	6/50	13/50	10/50	13/50	
liv hpa ev	35.2gm	* P<.3	-	7.85gm n.s.s.	1/50	1/50	2/50	3/50	
609 R f sda eat 28m28 2198					0	300.mg	900.mg	2.31gm	
liv hct ev	no dre	P=1.	-	2.77gm n.s.s.	0/50	0/50	0/50	0/50	
610 R m sda eat 27m27 2198					0	300.mg	900.mg	2.31gm	
thy fca ev	15.3gm	Z P<.007		6.65gm 270.gm	4/50	1/50	1/49	11/50	
liv hpc ev	no dre	P=1.	-	32.1gm n.s.s.	0/50	1/50	0/50	0/50	
liv hpa ev	no dre	P=1.	-	36.3gm n.s.s.	3/50	1/50	1/50	0/50	
BENZALDEHYDE 100-52-7									
611 M f b6c gav 24m24 TR378 :					0	210.mg	420.mg		
for sqp	1.31gm	* P<.008	p	653.mg 20.8gm	0/49	5/49	6/50		
TBA MXB	no dre	P=1.		528.mg n.s.s.	28/49	23/49	27/50		
liv MXB	3.42gm	* P<.4		881.mg n.s.s.	2/49	4/49	5/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		2.33gm n.s.s.	0/49	1/49	0/50		lun:a/a,a/c.
612 M m b6c gav 24m25 TR378 :					0	140.mg	280.mg		
for sqp	1.73gm	* P<.08	p	617.mg n.s.s.	1/50	2/50	5/50		
TBA MXB	985.mg	/ P<.6		198.mg n.s.s.	36/50	26/50	40/50		
liv MXB	3.77gm	* P<.8		380.mg n.s.s.	19/50	12/50	20/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		867.mg n.s.s.	8/50	4/50	6/50		lun:a/a,a/c.
613 R f f34 gav 24m24 TR378 :					0	140.mg	280.mg		
TBA MXB	101.mg	\ P<.002	-	51.9mg 491.mg	46/50	48/50	(43/50)		
liv MXB	91.7gm	* P<1.		1.81gm n.s.s.	5/50	0/50	1/50		liv:hpa,hpc,nnd.
614 R m f34 gav 24m24 TR378 :					0	140.mg	280.mg		
tes MXA #	70.1mg	\ P<.0005	-	39.6mg 181.mg	46/50	47/50	(31/50)		tes:iab,ica. S
pit ade	183.mg	\ P<.002		91.3mg 882.mg	15/50	22/50	(11/50)		S
amd MXA	193.mg	* P<.0005		117.mg 456.mg	19/50	23/50	19/50		amd:pbb,phm,pob. S
--- mnl	244.mg	* P<.0005		141.mg 668.mg	10/50	17/50	16/50		S
thy MXA	448.mg	* P<.002		240.mg 1.65gm	5/50	10/50	8/50		thy:cca,ccr. S
thy cca	478.mg	* P<.0005		260.mg 1.18gm	4/50	8/50	7/50		S
pan ade	755.mg	* P<.0005		354.mg 2.36gm	3/50	2/50	7/50		S
ski ker	1.86gm	* P<.009		632.mg 55.0gm	1/50	0/50	4/50		S
amd phm	888.mg	* P<.02		382.mg n.s.s.	2/50	5/50	5/50		S
pre MXA	907.mg	* P<.02		390.mg n.s.s.	2/50	6/50	7/50		pre:ade,car. S
--- msm	1.08gm	* P<.03		458.mg n.s.s.	0/50	5/50	2/50		S

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes Path	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
ski pam	2.18gm *	P<.03	735.mg n.s.s.	0/50	1/50	3/50		S
TBA MXB	109.mg *	P<.0005	67.0mg 241.mg	44/50	45/50	41/50		
liv MXB	9.67gm *	P<.7	969.mg n.s.s.	2/50	1/50	1/50		liv:hpa,hpc,nnd.
BENZENE 71-43-2								
615 M f b6c gav 24m24 TR289 :				0	17.7mg	35.4mg	70.7mg	
MXB MXB	23.7mg *	P<.0005	14.9mg 50.7mg	17/50	28/50	41/50	42/50	lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp, mlu,mno; ova:gct,lut,mtb,pcy,tua; spl:mlm,mlu,mno; ute:mlh; zym:sqc. M
MXB MXB	24.6mg *	P<.0005	15.3mg 54.6mg	17/50	28/50	40/50	41/50	lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp, mlu,mno; ova:gct,mtb; spl:mlm,mlu,mno; ute:mlh; zym:sqc. C
liv hpa	38.1mg Z	P<.008	15.9mg 880.mg	1/50	8/50	(5/50	4/50)	S
liv MXA	53.6mg Z	P<.009	26.3mg 2.27gm	4/50	12/50	13/50	(7/50)	liv:hpa,hpc. S
ova mtb	66.5mg Z	P<.0005 c	34.6mg 156.mg	0/50	1/50	12/50	(7/50)	
lun MXA	83.6mg *	P<.002 c	44.0mg 354.mg	4/50	5/50	10/50	13/50	lun:a/a,a/c.
lun a/c	117.mg *	P<.0005 c	63.4mg 390.mg	0/50	3/50	6/50	6/50	
ova MXB	119.mg *	P<.0005	63.8mg 374.mg	0/50	2/50	7/50	5/50	ova:lut,pcy,tua. P
mgl MXA	132.mg *	P<.0005 c	73.1mg 294.mg	0/50	2/50	5/50	10/50	mgl:can,sqc.
ova MXA	146.mg *	P<.002	74.0mg 571.mg	1/50	1/50	6/50	8/50	ova:gcc,gct. S
ova gct	157.mg *	P<.002 c	77.1mg 793.mg	1/50	1/50	6/50	7/50	
ova tua h	295.mg *	P<.006 p	120.mg 3.25gm	0/50	0/50	3/50	3/50	
mgl cas	382.mg *	P<.005 c	143.mg 3.12gm	0/50	0/50	1/50	4/50	
hag can	509.mg *	P<.006	174.mg 5.94gm	0/50	0/50	0/50	4/50	S
MXA MXA	79.1mg *	P<.04	34.3mg n.s.s.	15/50	25/50	26/50	22/50	mul:lkn,mlh,mlm,mlp,mlu,mno,ule; spl:mlm,mlu, mno; ute:mlh. S
MXA MXA	94.2mg *	P<.07 c	37.2mg n.s.s.	15/50	24/50	24/50	20/50	mul:mlh,mlm,mlp,mlu,mno; spl:mlm,mlu,mno; ute: mlh.
hag MXA	128.mg *	P<.02	57.4mg n.s.s.	5/50	6/50	10/50	10/50	hag:adn,can. S
lun a/a	169.mg *	P<.02 c	72.8mg n.s.s.	4/50	2/50	5/50	9/50	
MXA sqp	173.mg *	P<.02	77.4mg n.s.s.	1/50	3/50	6/50	5/50	cst:sqp; sto:sqp. S
ova lut h	245.mg *	P<.05 p	106.mg n.s.s.	0/50	2/50	3/50	2/50	
zym sqc	421.mg *	P<.02 c	146.mg n.s.s.	0/50	0/50	1/50	3/50	
ova pcy h	574.mg *	P<.08 p	174.mg n.s.s.	0/50	0/50	2/50	1/50	
TBA MXB	30.4mg *	P<.002	16.1mg 158.mg	36/50	40/50	48/50	48/50	
liv MXB	53.6mg Z	P<.009	26.3mg 2.27gm	4/50	12/50	13/50	(7/50)	liv:hpa,hpc,nnd.
lun MXB	83.6mg *	P<.002	44.0mg 354.mg	4/50	5/50	10/50	13/50	lun:a/a,a/c.
616 M m b6c gav 24m24 TR289 :				0	17.7mg	35.4mg	71.4mg	
MXB MXB	15.1mg *	P<.0005	10.1mg 26.0mg	13/50	28/50	35/50	42/50	hag:adn; lun:a/a,a/c; mul:mlh,mlm,mlp,mlu,mno; pre:sqc; spl:mlh,mno; zym:sqc. C
pre MXA	21.8mg Z	P<.0005	15.1mg 32.6mg	0/50	5/50	19/50	31/50	pre:can,sqc. S
pre sqc	25.5mg Z	P<.0005 c	17.3mg 38.9mg	0/50	3/50	18/50	28/50	
hag MXA	39.5mg *	P<.0005	24.5mg 79.0mg	1/50	10/50	13/50	14/50	hag:adn,can. S
hag adn	40.7mg *	P<.0005 c	25.7mg 73.0mg	0/50	9/50	13/50	11/50	
lun MXA	42.5mg *	P<.0005 c	24.1mg 121.mg	10/50	16/50	19/50	21/50	lun:a/a,a/c.
MXA MXA	50.9mg *	P<.0005	28.4mg 141.mg	4/50	10/50	10/50	15/50	mul:lkn,mlh,mlm,mlp,mlu,mno; spl:mlh,mno. S
MXA MXA	51.8mg *	P<.0005 c	28.8mg 141.mg	4/50	9/50	9/50	15/50	mul:mlh,mlm,mlp,mlu,mno; spl:mlh,mno.
zym sqc	56.3mg Z	P<.0005 c	33.8mg 101.mg	0/50	1/50	4/50	21/50	
lun a/c	59.5mg *	P<.0005 c	31.8mg 214.mg	5/50	11/50	12/50	14/50	
lun a/a	103.mg *	P<.004	48.7mg 900.mg	6/50	6/50	8/50	12/50	S
adr phe	116.mg Z	P<.01	47.9mg 14.1gm	1/50	1/50	7/50	(1/50)	S
ski MXA	262.mg *	P<.004	94.4mg 1.96gm	0/50	0/50	2/50	3/50	ski:sqc,squ. S
MXA mlh	269.mg *	P<.005 c	98.0mg 2.24gm	0/50	0/50	3/50	3/50	mul:mlh; spl:mlh.
MXA MXA	169.mg *	P<.02	66.5mg n.s.s.	2/50	2/50	3/50	5/50	cst:sqc,sqp; sto:sqc. S
cst sqp	222.mg *	P<.03	80.3mg n.s.s.	2/50	1/50	2/50	5/50	S
TBA MXB	17.1mg *	P<.0005	10.4mg 38.6mg	33/50	40/50	48/50	46/50	
liv MXB	102.mg *	P<.2	35.1mg n.s.s.	15/50	17/50	22/50	11/50	liv:hpa,hpc,nnd.
lun MXB	42.5mg *	P<.0005	24.1mg 121.mg	10/50	16/50	19/50	21/50	lun:a/a,a/c.
617 M m aks inh 72w72 1048				0	83.7mg			Snyder;txap,54,323-331;1980
--- mly e	114.mg	P<.3 -	32.4mg n.s.s.	24/50	29/49			
618 M m c56 inh 69w69 1048				0	251.mg			
thm lym h	466.mg	P<.004 +	190.mg 2.81gm	0/40	6/40			
--- mix h	441.mg	P<.04 +	167.mg n.s.s.	2/40	8/40			
--- lcl h	681.mg	P<.2 +	212.mg n.s.s.	2/40	6/40			
619 M f swi gav 18m24 BT908				0	241.mg			Maltoni;anya,534,412-426;1988
mam car	279.mg	P<.0005 +	154.mg 655.mg	2/40	19/40			
lun mix	453.mg	P<.004 +	214.mg 3.43gm	4/40	15/40			
lun ata	1.02gm	P<.004	414.mg 6.13gm	0/40	6/40			
lun ade	1.10gm	P<.2	362.mg n.s.s.	4/40	9/40			
zym car	6.52gm	P<.3 +	1.06gm n.s.s.	0/40	1/40			
liv hpt	no dre	P=1.	1.99gm n.s.s.	0/40	0/40			
tba mix	150.mg	P<.0005	77.1mg 523.mg	16/40	32/40			
tba mal	187.mg	P<.0005 +	99.1mg 589.mg	11/40	28/40			
620 M m swi gav 18m24 BT908				0	241.mg			
lun mix	382.mg	P<.0005 +	193.mg 1.39gm	3/40	16/40			
lun ade	811.mg	P<.02	330.mg n.s.s.	2/40	9/40			
lun ata	1.20gm	P<.04	436.mg n.s.s.	1/40	6/40			
zym car	1.57gm	P<.02 +	541.mg n.s.s.	0/40	4/40			
liv hpt	6.19gm	P<.7	756.mg n.s.s.	2/40	3/40			
lun adc	6.52gm	P<.3	1.06gm n.s.s.	0/40	1/40			
tba mix	370.mg	P<.05	149.mg n.s.s.	15/40	24/40			
tba mal	939.mg	P<.3 +	279.mg n.s.s.	9/40	14/40			
621 R f f34 gav 24m24 TR289 :				0	17.7mg	35.4mg	70.7mg	
MXB MXB	55.1mg *	P<.0005	37.2mg 96.2mg	1/50	10/50	16/50	21/50	cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp; zym: can. C
zym MXA	97.9mg *	P<.0005	60.8mg 179.mg	0/50	5/50	6/50	15/50	zym:adn,can. S
zym can	109.mg *	P<.0005 c	66.3mg 207.mg	0/50	5/50	5/50	14/50	
MXA MXA	113.mg *	P<.0005 c	65.7mg 333.mg	1/50	5/50	12/50	9/50	cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp.
ute esp	158.mg *	P<.008	73.3mg 4.18gm	7/50	7/50	7/50	14/50	S
MXA sqp	186.mg *	P<.01 c	90.9mg 13.1gm	1/50	4/50	8/50	5/50	cst:sqp; lpp:sqp; pal:sqp; ton:sqp.

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
MXA sqc	290.mg *	P<.002	c	141.mg 1.14gm	0/50	1/50	4/50	5/50	pal:sqc; ton:sqc.
ton MXA	295.mg *	P<.003	c	143.mg 1.56gm	0/50	1/50	5/50	4/50	ton:sqc,sqp.
ton sqc	368.mg *	P<.003	c	166.mg 1.76gm	0/50	0/50	4/50	4/50	
pal MXA	288.mg *	P<.06	c	118.mg n.s.s.	1/50	4/50	5/50	4/50	pal:sqc,sqp.
MXA MXA	364.mg *	P<.04		157.mg n.s.s.	0/50	2/50	3/50	2/50	cvu:adq; utm:acn,can. S
TBA MXB	46.7mg *	P<.006		23.3mg 567.mg	38/50	39/50	41/50	42/50	
liv MXB	no dre	P=1.		238.mg n.s.s.	0/50	3/50	1/50	0/50	liv:hpa,hpc,nnd.
622 R m f34 gav 24m24 TR289 :					0	35.4mg	70.7mg	142.mg	
MXB MXB	51.1mg *	P<.0005		35.9mg 83.8mg	3/50	21/50	27/50	37/50	lpp:sqc,sqp; pal:sqc,sqp; ski:sqc,sqp; ton:sqc, sqp; zym:can. C
MXA MXA	91.5mg *	P<.0005	c	59.4mg 174.mg	1/50	9/50	16/50	19/50	lpp:sqc,sqp; pal:sqc,sqp; ton:sqc,sqp.
MXA sqp	140.mg *	P<.0005	c	84.2mg 334.mg	1/50	6/50	11/50	13/50	lpp:sqp; pal:sqp; ton:sqp.
zym MXA	155.mg *	P<.0005		92.8mg 363.mg	2/50	7/50	10/50	18/50	zym:adn,can. S
zym can	166.mg *	P<.0005	c	98.3mg 401.mg	2/50	6/50	10/50	17/50	
ski MXA	181.mg *	P<.0005		102.mg 544.mg	1/50	7/50	5/50	12/50	ski:adq,sqc,sqp,ulc. S
ski MXA	191.mg *	P<.0005		105.mg 656.mg	1/50	7/50	5/50	11/50	ski:adq,sqc,sqp. S
lpp MXA	220.mg *	P<.0005	c	120.mg 519.mg	0/50	2/50	5/50	8/50	lpp:sqc,sqp.
pal MXA	243.mg *	P<.0005	c	135.mg 635.mg	0/50	4/50	5/50	9/50	pal:sqc,sqp.
pal sqp	250.mg *	P<.0005	c	138.mg 668.mg	0/50	4/50	4/50	9/50	
ski sqc	260.mg *	P<.0005	c	143.mg 859.mg	0/50	5/50	3/50	8/50	
lpp sqp	284.mg *	P<.002	c	145.mg 986.mg	0/50	2/50	5/50	5/50	
MXA sqc	295.mg *	P<.0005	c	156.mg 977.mg	0/50	3/50	5/50	7/50	lpp:sqc; pal:sqc; ton:sqc.
ski sqp	427.mg *	P<.003	c	192.mg 2.56gm	0/50	2/50	1/50	5/50	
ton MXA	382.mg *	P<.02	c	173.mg n.s.s.	1/50	3/50	6/50	6/50	ton:sqc,sqp.
ton sqc	430.mg *	P<.02	c	206.mg n.s.s.	0/50	3/50	4/50	4/50	
lpp sqc	1.15gm *	P<.02	c	349.mg n.s.s.	0/50	0/50	0/50	3/50	
TBA MXB	68.1mg *	P<.006		33.7mg 799.mg	39/50	44/50	45/50	47/50	
liv MXB	1.91gm *	P<.7		261.mg n.s.s.	2/50	2/50	5/50	1/50	liv:hpa,hpc,nnd.
623 R f sda inh 24m35 BT4004					0	53.4mg			Maltoni;ajim,7,415-446;1985
mgl mal egv	907.mg	P<.1		291.mg n.s.s.	2/60	6/54			
orc car egv	2.02gm	P<.09		496.mg n.s.s.	0/60	2/54			
zym car egv	1.89gm	P<.3		433.mg n.s.s.	1/60	3/54			
liv hpt egv	4.07gm	P<.3		663.mg n.s.s.	0/60	1/54			
nas car egv	4.07gm	P<.3		663.mg n.s.s.	0/60	1/54			
tba car egv	947.mg	P<.07		314.mg n.s.s.	1/60	5/54			
tba mal egv	553.mg	P<.2	+	181.mg n.s.s.	9/60	14/54			
624 R f sda gav 12m33 BT901					0	11.6mg	58.0mg		Maltoni;ajim,7,415-446;1985/1979
zym car ej	222.mg *	P<.0005	+	108.mg 716.mg	0/30	2/28	8/28		
orc car ej	945.mg *	P<.04	+	232.mg n.s.s.	0/29	0/24	2/21		
mgl mal ej	517.mg *	P<.3		141.mg n.s.s.	4/30	4/28	7/28		
liv hpt ej	no dre	P=1.		74.1mg n.s.s.	0/13	0/30	0/7		
ski car ej	no dre	P=1.		117.mg n.s.s.	0/30	0/30	0/35		
--- leu ej	no dre	P=1.		382.mg n.s.s.	1/30	2/30	1/29		
tba mal ej	75.3mg *	P<.0005		39.4mg 237.mg	7/30	10/28	21/29		
625 R f sda gav 24m33 BT902					0	237.mg			Maltoni;ajim,7,415-446;1985
orc car e	415.mg	P<.0005	+	242.mg 794.mg	0/49	20/39			
zym car e	585.mg	P<.0005	+	324.mg 1.21gm	0/49	16/40			
for cic e	787.mg	P<.002	+	318.mg 3.25gm	0/24	6/19			
liv hpt e	4.03gm	P<.3		655.mg n.s.s.	0/15	1/14			
liv ang e	7.91gm	P<.2	+	1.29gm n.s.s.	0/35	1/27			
nas car e	8.51gm	P<.2	+	1.39gm n.s.s.	0/40	1/29			
ski car e	no dre	P=1.		2.42gm n.s.s.	1/35	0/27			
tba mal e	161.mg	P<.0005		92.3mg 312.mg	10/49	35/40			
tba car	248.mg	P<.0005		152.mg 432.mg	0/50	28/40			
626 R m sda gav 12m33 BT901					0	11.6mg	58.0mg		Maltoni;ajim,7,415-446;1985/1979
--- leu ej	506.mg *	P<.008		175.mg 8.25gm	0/22	0/23	4/24		
liv hpt ej	3.09gm *	P<.2		503.mg n.s.s.	0/30	0/30	1/35		
sub ang ej	3.09gm *	P<.2		503.mg n.s.s.	0/30	0/30	1/35		
mgl mal ej	no dre	P=1.		84.1mg n.s.s.	0/22	0/22	0/22		
orc car ej	no dre	P=1.		74.2mg n.s.s.	0/19	0/20	0/17		
ski car ej	no dre	P=1.		117.mg n.s.s.	0/30	0/30	0/35		
zym car ej	no dre	P=1.		84.1mg n.s.s.	0/22	0/22	0/22		
tba mal ej	232.mg *	P<.004		101.mg 1.63gm	1/22	1/23	8/24		
627 R m sda gav 24m33 BT902					0	237.mg			Maltoni;ajim,7,415-446;1985
orc car e	386.mg	P<.0005	+	227.mg 727.mg	0/45	21/39			
zym car e	501.mg	P<.0005	+	280.mg 1.07gm	1/45	18/39			
ski car e	904.mg	P<.0005	+	424.mg 2.57gm	0/34	9/32			
nas car e	3.53gm	P<.05	+	1.07gm n.s.s.	0/35	3/37			
liv ang e	4.48gm	P<.09	+	1.10gm n.s.s.	0/32	2/31			
for ivc e	6.12gm	P<.2	+	996.mg n.s.s.	0/44	1/21			
liv hpt e	no dre	P=1.		523.mg n.s.s.	3/15	3/15			
tba mal e	131.mg	P<.0005		70.6mg 260.mg	11/45	36/39			
tba car	219.mg	P<.0005		134.mg 382.mg	1/50	30/40			
628 R m sda inh 98w98 518					0	50.4mg			Snyder;jtxe,4,605-618;1978
liv tum	no dre	P=1.	-	415.mg n.s.s.	0/27	0/45			
tba tum	no dre	P=1.	-	415.mg n.s.s.	0/27	0/45			
629 R m sda inh 29m29 2305					0	16.7mg			Snyder;ajim,5,429-434;1984
liv mix s	152.mg	P<.02		52.6mg n.s.s.	0/40	4/40			
zym car s	313.mg	P<.1		76.9mg n.s.s.	0/40	2/40			
--- grl s	634.mg	P<.3		103.mg n.s.s.	0/40	1/40			
mgl adc s	634.mg	P<.3		103.mg n.s.s.	0/40	1/40			
tba mix s	65.9mg	P<.02		27.7mg n.s.s.	3/40	11/40			
tba mal s	93.4mg	P<.04		35.5mg n.s.s.	2/40	8/40			
tba ben s	305.mg	P<.3		67.3mg n.s.s.	1/40	3/40			
630 R f wis gav 24m24 BT907					0	321.mg			Maltoni;anya,534,412-426;1988
zym sqc	1.36gm	P<.004		552.mg 8.18gm	0/40	6/40			
orc sqc	2.09gm	P<.02		722.mg n.s.s.	0/40	4/40			
nas ulc	8.70gm	P<.3		1.42gm n.s.s.	0/40	1/40			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
tba mal		482.mg	P<.02	217.mg n.s.s.	10/40	21/40			
tba mix		no dre	P=1.	408.mg n.s.s.	34/40	27/40			
631 R m wis gav 24m24 BT907					0	321.mg			
zym sqc		1.14gm	P<.002	494.mg 4.73gm	0/40	7/40			
nas ulc		4.29gm	P<.1	1.06gm n.s.s.	0/40	2/40			
orc sqc		8.48gm	P<.6	1.16gm n.s.s.	1/40	2/40			
tba mal		523.mg	P<.01	238.mg 26.9gm	8/40	19/40			
tba mix		no dre	P=1.	490.mg n.s.s.	30/40	23/40			
BENZENEDIAZONIUM SULFATE 6415-38-9									
632 M f swa gav 12m33 2616					0	5.27mg			Toth;vivo,13,125-128;1999
lun mix e		16.5mg	P<.03	+ 7.26mg n.s.s.	14/47	26/49			
lun ade e		27.1mg	P<.06	10.7mg n.s.s.	9/47	18/49			
lun adc e		39.4mg	P<.08	14.6mg n.s.s.	5/47	12/49			
liv hpt e		no dre	P=1.	99.8mg n.s.s.	0/50	0/50			
633 M m swa gav 12m30 2616					0	5.76mg			
lun mix e		12.7mg	P<.03	+ 5.60mg n.s.s.	19/49	31/50			
lun ade e		14.8mg	P<.02	6.56mg n.s.s.	15/49	27/50			
lun adc e		no dre	P=1.	28.9mg n.s.s.	8/49	7/50			
liv hpt e		no dre	P=1.	40.2mg n.s.s.	1/11	0/22			
BENZENEDIAZONIUM TETRAFLUOROBORATE 369-57-3									
634 H f syg gav 90w90 1329					0	1.25mg	2.50mg	5.00mg	Gold;clet,15,289-300;1982
liv hem es		66.1mg *	P<.2	- 10.8mg n.s.s.	0/15	0/15	0/15	1/15	
liv kcs es		66.1mg *	P<.2	- 10.8mg n.s.s.	0/15	0/15	0/15	1/15	
liv cho es		293.mg *	P<.9	- 11.9mg n.s.s.	1/15	0/15	0/15	1/15	
lun tum es		no dre	P=1.	1.65mg n.s.s.	0/15	0/15	0/15	0/15	
635 H m syg gav 90w90 1329					0	1.25mg	2.50mg	5.00mg	
liv hem es		293.mg *	P<.9	- 11.9mg n.s.s.	1/15	0/15	0/15	1/15	
lun tum es		no dre	P=1.	1.65mg n.s.s.	0/15	0/15	0/15	0/15	
BENZENESULPHONOHYDRAZIDE (BSH) 5351-65-5									
636 M f swi gav 50w60 1060					0	30.1mg			Cremlyn;fctx,9,319-321;1971
liv lct ev		46.6mg	P<.1	13.7mg n.s.s.	1/29	4/24			
lun tum ev		46.6mg	P<.1	13.7mg n.s.s.	1/29	4/24			
BENZIDINE 92-87-5									
637 M m icr eat 60w60 2594 :					0	120.mg			Osanai;jsol,52,179-201;1976
liv hpt		19.9mg	P<.02	+ 7.02mg n.s.s.	7/34	10/10			
638 R b alb inh 20m28 598					0	.440mg			Zabezhinskii;bebm,69,72-74;1970
--- myl e		2.08mg	P<.02	+ .786mg n.s.s.	0/21	5/28			
mgl car e		5.51mg	P<.2	+ 1.35mg n.s.s.	0/21	2/28			
liv hpt e		11.2mg	P<.3	+ 1.83mg n.s.s.	0/21	1/28			
tba mix e		1.73mg	P<.1	+ .610mg n.s.s.	2/21	8/28			
BENZIDINE.2HCl 531-85-1									
639 M f cbn wat 33m33 1563n					0	4.00mg	6.00mg	8.00mg	12.0mg 16.0mg 24.0mg Littlefield; jtxe,12,671-685;1983/1984/Nelson pers.comm.
liv hpc e		18.9mg *	P<.0005	+ 15.2mg 25.0mg	10/125	54/119	43/95	31/71	37/72 51/69 56/72
hag ade e		41.1mg Z	P<.0005	+ 25.9mg 104.mg	6/121	28/117	16/94	17/71	(10/70 9/67 8/68)
ute agm e		402.mg *	P<.005	+ 201.mg 3.98gm	3/124	1/114	3/94	2/71	5/70 7/68 5/71
640 M f cbn wat 60w60 1577o					0	6.00mg	12.0mg	24.0mg	40.0mg 80.0mg Schieferstein;nctr;1982/Nelson 1982
liv hpc ek		17.9mg *	P<.0005	+ 12.3mg 27.5mg	0/45	1/69	2/48	10/41	17/35 13/14
liv hpa ek		30.2mg *	P<.0005	+ 17.6mg 80.9mg	1/45	6/69	8/48	6/41	12/35 5/14
641 M f cbn wat 80w80 1577r					0	6.00mg	12.0mg	24.0mg	40.0mg 80.0mg
liv hpc e		9.60mg *	P<.0005	+ 7.42mg 12.6mg	0/50	6/45	19/47	39/48	30/34 25/30
liv hpa e		78.7mg *	P<.0005	+ 40.5mg 338.mg	0/50	7/46	4/47	11/50	10/35 7/31
642 M m cbn wat 33m33 1563n					0	5.00mg	6.67mg	10.0mg	13.3mg 20.0mg 26.7mg Littlefield; jtxe,12,671-685;1983/1984/Nelson pers.comm.
liv hpc e		60.5mg *	P<.0005	+ 43.3mg 97.6mg	17/123	20/118	20/95	23/72	24/71 37/71 32/71
hag ade e		208.mg *	P<.02	+ 99.0mg n.s.s.	10/122	19/113	17/92	13/72	13/68 16/69 13/66
643 M m cbn wat 60w60 1577o					0	5.00mg	10.0mg	20.0mg	33.3mg 66.7mg Schieferstein;nctr;1982/Nelson 1982
liv hpa ek		67.7mg *	P<.002	+ 35.9mg 414.mg	0/46	2/63	1/44	5/47	2/37 4/21
liv hpc ek		74.3mg *	P<.009	+ 38.4mg 3.64gm	0/46	1/63	3/44	3/47	4/37 2/21
644 M m cbn wat 80w80 1577r					0	5.00mg	10.0mg	20.0mg	33.3mg 66.7mg
liv hpc e		39.0mg *	P<.0005	+ 25.6mg 63.8mg	0/47	1/49	5/45	7/45	8/24 12/22
liv hpa e		186.mg *	P<.09	+ 65.4mg n.s.s.	2/49	2/50	2/47	9/46	1/25 3/23
645 M f cff wat 33m33 1563m					0	4.00mg	6.00mg	8.00mg	12.0mg 16.0mg 24.0mg Littlefield; jtxe,12,671-685;1983/1984/Nelson pers.comm.
liv hpc e		10.9mg *	P<.0005	+ 9.29mg 13.0mg	3/124	51/120	52/95	45/72	55/71 60/69 64/72
hag ade e		51.7mg Z	P<.0005	+ 33.3mg 130.mg	5/123	21/118	22/95	20/70	11/68 (12/68 8/71)
ute agm e		335.mg *	P<.006	+ 163.mg 4.82gm	4/122	5/117	5/95	5/68	4/72 5/71 10/71
646 M f cff wat 60w60 1577m					0	6.00mg	12.0mg	24.0mg	40.0mg 80.0mg Schieferstein;nctr;1982/Nelson 1982
liv hpc ek		17.1mg Z	P<.0005	+ 11.8mg 26.0mg	1/48	2/69	2/48	6/45	29/45 9/10
liv hpa ek		24.7mg *	P<.0005	+ 16.4mg 39.3mg	0/48	1/69	1/48	8/45	21/45 5/10
647 M f cff wat 79w80 1577n					0	6.00mg	12.0mg	24.0mg	40.0mg 80.0mg
liv hpc ae		8.99mg *	P<.0005	+ 6.90mg 11.9mg	0/48	6/51	16/47	39/50	26/26 35/38
liv hpa ae		41.9mg *	P<.0005	+ 29.4mg 78.7mg	0/47	3/50	9/47	12/50	8/26 16/37
648 M m cff wat 33m33 1563m					0	5.00mg	6.67mg	10.0mg	13.3mg 20.0mg 26.7mg Littlefield; jtxe,12,671-685;1983/1984/Nelson pers.comm.
liv hpc e		31.2mg *	P<.0005	+ 24.9mg 41.2mg	14/125	24/119	30/96	23/71	35/71 51/71 49/71
hag ade e		129.mg *	P<.0005	+ 73.0mg 462.mg	6/124	21/117	19/93	18/70	16/70 13/67 17/68
649 M m cff wat 60w60 1577m					0	5.00mg	10.0mg	20.0mg	33.3mg 66.7mg Schieferstein;nctr;1982/Nelson 1982
liv hpa ek		60.8mg *	P<.0005	+ 33.9mg 153.mg	0/47	0/70	3/46	5/44	3/42 5/22

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv hpc ek	97.5mg *	P<.0005 +		46.4mg 353.mg	1/47	0/70	1/46	2/44	2/42	6/22
650 M m cff wat 80w80 1577n					0	5.00mg	10.0mg	20.0mg	33.3mg	66.7mg
liv hpc e	33.2mg *	P<.0005 +		22.7mg 53.2mg	0/49	5/48	2/50	12/52	7/28	16/24
liv hpa e	94.8mg *	P<.0005 +		52.9mg 302.mg	0/47	0/47	4/50	3/49	7/26	2/21
BENZO(a)PYRENE 50-32-8										
651 M f alb eat 60w60 1274					0	.520mg				Chouroulinkov;bdca,54,67-78;1967
for pam er	1.86mg	P<.05		.707mg n.s.s.	0/40	5/81				
652 M f b6c eat 22m24 2368					0	.650mg	3.25mg	13.0mg		Culp;carc,19,117-124;1998/Gaylor 1998
for mix ae	2.06mg *	P<.0005 +		1.42mg 3.04mg	1/48	3/47	36/46	46/47		
for sqc ae	2.78mg *	P<.0005 +		1.94mg 4.04mg	0/48	1/47	30/46	45/47		
eso mix ae	13.6mg Z	P<.0005 +		8.68mg 23.1mg	0/48	0/48	2/45	27/46		
ton mix ae	17.5mg *	P<.0005 +		10.8mg 30.9mg	0/48	0/48	2/46	23/48		
eso sqc ae	40.0mg *	P<.0005 +		20.6mg 93.5mg	0/48	0/48	1/45	11/46		
lar mix ae	50.4mg *	P<.003 +		22.8mg 308.mg	0/35	0/35	3/34	5/38		
ton sqc ae	74.2mg *	P<.0005 +		32.1mg 237.mg	0/48	0/48	0/46	7/48		
mul sar ae	16.1mg Z	P<.02		6.59mg n.s.s.	1/48	2/47	7/47	(0/48)		
lar sqc ae	210.mg *	P<.04 +		51.8mg n.s.s.	0/35	0/35	0/34	2/38		
liv hpa ae	50.6mg Z	P<.6		7.88mg n.s.s.	2/48	7/48	5/47	(0/45)		
lun mix e	180.mg Z	P<.8		14.0mg n.s.s.	5/48	0/48	4/48	(0/48)		
653 M f c5v gav 52w92 1636					0	3.23ug				Griciute;iarc,813-822;1980
lun ben	12.1ug	P<.2	-	2.97ug n.s.s.	0/11	2/15				
liv tum	no dre	P=1.	-	7.81ug n.s.s.	0/11	0/15				
tba mix	2.68ug	P<.2	-	863.ng n.s.s.	4/11	10/15				
654 M m c5v gav 52w92 1636					0	2.69ug				
lun ben	15.7ug	P<.4	-	2.66ug n.s.s.	1/20	2/15				
liv mal	no dre	P=1.	-	6.51ug n.s.s.	2/20	0/15				
liv ben	no dre	P=1.	-	6.51ug n.s.s.	2/20	0/15				
tba mix	no dre	P=1.	-	3.15ug n.s.s.	11/20	4/15				
655 M m cf1 wat 95w95 1129					0	3.34mg				Horie;gann,56,429-441;1965
eso pam	11.0mg	P<.0005 +		5.37mg 29.3mg	0/67	10/63				
for pam	12.4mg	P<.03		5.10mg n.s.s.	5/67	13/63				
eso car	119.mg	P<.3 +		19.4mg n.s.s.	0/67	1/63				
656 R b sda eat 30m30 1326					0	.107mg				Brune;zkko,102,153-157;1981
mix mix r	.956mg	P<.04 +		.376mg n.s.s.	3/64	10/64				
for pam r	.972mg	P<.03 +		.393mg n.s.s.	2/64	9/64				
BENZOATE, SODIUM 532-32-1										
657 M f swa wat 31m31 1996					0	4.00gm				Toth;faat,4,494-496;1984
lun tum	no dre	P=1.	-	18.3gm n.s.s.	21/100	10/50				
liv tum	no dre	P=1.	-	68.4gm n.s.s.	0/100	0/50				
658 M m swa wat 26m26 1996					0	3.33gm				
liv hpt	133.gm	P<.2	-	21.7gm n.s.s.	0/100	1/50				
lun tum	no dre	P=1.	-	17.5gm n.s.s.	23/100	7/50				
659 R f f34 eat 24m25 1319					0	480.mg	960.mg			Sodemoto;jept,4,87-95;1980
tba mix e	24.9gm *	P<.9	-	2.03gm n.s.s.	8/43	16/52	11/52			
tba mal e	104.gm *	P<1.	-	4.00gm n.s.s.	3/43	5/52	4/52			
660 R m f34 eat 24m25 1319					0	384.mg	768.mg			
tba mix e	no dre	P=1.	-	2.78gm n.s.s.	9/25	7/50	11/50			
tba mal e	no dre	P=1.	-	7.17gm n.s.s.	0/25	1/50	0/50			
BENZOFURAN 271-89-6										
661 M f b6c gav 24m24 TR370 :					0	84.9mg	170.mg			
MXB MXB	33.4mg \	P<.0005		18.8mg 73.8mg	5/50	27/50	(29/50)			for:sqc,sqp; liv:hpa; lun:a/a,a/c. C
liv hpa	34.4mg \	P<.0005	c	19.7mg 71.5mg	1/50	22/50	(21/50)			
liv MXA	36.4mg \	P<.0005		20.4mg 80.8mg	4/50	25/50	(22/50)			liv:hpa,hpc. S
for MXA	145.mg \	P<.003	c	61.8mg 890.mg	2/50	9/50	(5/50)			for:sqc,sqp.
for sqp	172.mg \	P<.005		69.8mg 1.88gm	2/50	8/50	(5/50)			S
lun MXA	174.mg *	P<.0005	c	98.1mg 449.mg	2/50	9/50	14/50			lun:a/a,a/c.
lun a/a	224.mg *	P<.0005		122.mg 565.mg	1/50	5/50	13/50			S
MXA mlu	322.mg \	P<.04		101.mg n.s.s.	1/50	4/50	(1/50)			mul:mlu; spl:mlu. S
TBA MXB	45.9mg \	P<.002		22.3mg 255.mg	27/50	35/50	(35/50)			
liv MXB	36.4mg \	P<.0005		20.4mg 80.8mg	4/50	25/50	(22/50)			liv:hpa,hpc,nnd.
lun MXB	174.mg *	P<.0005		98.1mg 449.mg	2/50	9/50	14/50			lun:a/a,a/c.
662 M m b6c gav 24m24 TR370 :					0	42.4mg	84.9mg			
liv MXA	19.8mg \	P<.0005	c	10.7mg 52.5mg	12/50	31/50	(40/50)			liv:hpa,hpb,hpc.
liv hpa	20.5mg \	P<.0005	c	11.5mg 46.9mg	4/50	24/50	(34/50)			
liv MXA	21.3mg \	P<.0005		11.4mg 58.6mg	12/50	30/50	(37/50)			liv:hpa,hpc. S
MXB MXB	23.9mg \	P<.002		11.7mg 108.mg	20/50	32/50	(45/50)			for:sqc,sqp; liv:hpa,hpb,hpc; lun:a/a,a/c. C
liv hpb	102.mg *	P<.0005	c	60.1mg 191.mg	0/50	3/50	18/50			
for MXA	108.mg *	P<.002	c	58.7mg 438.mg	2/50	11/50	13/50			for:sqc,sqp.
liv MXA	114.mg *	P<.006		55.7mg 1.46gm	9/50	10/50	22/50			liv:hpb,hpc. S
lun a/a	136.mg *	P<.004		67.8mg 1.08gm	4/50	7/50	15/50			S
for sqp	154.mg *	P<.007		74.8mg 2.64gm	2/50	7/50	10/50			S
lun MXA	160.mg *	P<.04	c	67.6mg n.s.s.	10/50	9/50	19/50			lun:a/a,a/c.
for sqc	383.mg *	P<.03		163.mg n.s.s.	0/50	4/50	3/50			S
mul mlp	919.mg *	P<.04		272.mg n.s.s.	0/50	0/50	3/50			S
TBA MXB	54.3mg *	P<.02		25.8mg n.s.s.	29/50	32/50	45/50			
liv MXB	21.3mg \	P<.0005		11.4mg 58.6mg	12/50	30/50	(37/50)			liv:hpa,hpc,nnd.
lun MXB	160.mg *	P<.04		67.6mg n.s.s.	10/50	9/50	19/50			lun:a/a,a/c.
663 R f f34 gav 24m24 TR370 :					0	42.4mg	84.9mg			
sub nlm	98.8mg \	P<.005		42.7mg 939.mg	1/50	9/50	(3/50)			S
lun MXA	418.mg *	P<.04		159.mg n.s.s.	0/50	2/50	3/50			lun:a/a,a/c. S
kid uac	424.mg *	P<.02	p	161.mg n.s.s.	0/50	1/50	4/50			
lun a/a	530.mg *	P<.04		183.mg n.s.s.	0/50	1/50	3/50			S
ton sqp	574.mg *	P<.04		194.mg n.s.s.	0/50	1/50	3/50			S
TBA MXB	577.mg *	P<.9		40.0mg n.s.s.	46/50	48/50	42/50			
liv MXB	2.09gm *	P<.3		341.mg n.s.s.	0/50	0/50	1/50			liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
664 R m f34 gav 24m24 TR370 :				0	21.2mg	42.4mg		
tes ict #	8.03mg	\ P<.004	- 3.77mg 68.2mg	42/50	40/50	(41/50)		S
pit adn	45.8mg	* P<.03	19.5mg n.s.s.	18/50	16/50	22/50		S
MXA mnl	55.3mg	* P<.02	25.4mg n.s.s.	10/50	13/50	17/50		liv:mnl; mul:mnl. S
lun a/c	166.mg	* P<.03	60.0mg n.s.s.	0/50	3/50	2/50		S
mgl fba	271.mg	* P<.03	77.8mg n.s.s.	0/50	0/50	3/50		S
thy fcc	389.mg	* P<.03	103.mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	22.5mg	* P<.02	10.4mg n.s.s.	45/50	42/50	46/50		
liv MXB	no dre	P=1.	147.mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
BENZOGUANAMINE 91-76-9								
665 M f chi eat 77w94 381 :				0	223.mg	446.mg	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
liv mix	2.04gm	* P<.3	- 503.mg n.s.s.	0/20	1/17	1/18		
lun mix	9.34gm	* P<.9	- 433.mg n.s.s.	6/20	2/17	3/18		
tba mix	932.mg	* P<.5	- 200.mg n.s.s.	17/20	8/17	9/18		
666 M m chi eat 73w94 381 :				0	240.mg	411.mg		
lun mix a	304.mg	* P<.03	- 119.mg n.s.s.	5/18	2/13	7/14		
liv mix a	3.20gm	* P<.7	- 378.mg n.s.s.	3/18	0/13	2/14		
tba mix a	439.mg	* P<.2	- 131.mg n.s.s.	12/18	3/13	9/14		
667 R m cdr eat 77w94 381 :				0	17.1mg	34.3mg		
liv mix	no dre	P=1.	- 144.mg n.s.s.	1/22	0/20	0/21		
tba mix	16.3mg	\ P<.2	- 5.02mg n.s.s.	14/22	13/20	(9/21)		
BENZOIC ACID 65-85-0								
668 R m f3d eat 52w52 2098				0	800.mg		Shibata;carc,14,275-280;1993	
for tum er	no dre	P=1.	412.mg n.s.s.	0/10	0/10			
BENZOIN (2-hydroxy-1,2-diphenylethanone) 119-53-9								
669 M f b6c eat 24m24 TR204 :				0	322.mg	644.mg		
TBA MXB	6.83gm	* P<.9	- 572.mg n.s.s.	27/50	35/50	28/50		
liv MXB	8.42gm	* P<.4	1.93gm n.s.s.	2/50	3/50	4/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	2.85gm n.s.s.	6/50	5/50	3/50		lun:a/a,a/c.
670 M m b6c eat 24m24 TR204 :				0	297.mg	594.mg		
TBA MXB	2.46gm	* P<.6	- 451.mg n.s.s.	31/50	27/50	32/50		
liv MXB	3.56gm	* P<.5	716.mg n.s.s.	16/50	12/50	18/50		liv:hpa,hpc,nnd.
lun MXB	2.90gm	* P<.3	846.mg n.s.s.	5/50	10/50	8/50		lun:a/a,a/c.
671 R f f34 eat 24m24 TR204 :				0	12.5mg	25.0mg		
TBA MXB	no dre	P=1.	- 22.3mg n.s.s.	42/50	41/50	39/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
672 R m f34 eat 24m24 TR204 :				0	5.00mg	10.0mg		
liv MXA #	88.2mg	* P<.03	- 30.5mg n.s.s.	0/50	0/50	4/50		liv:hpc,nnd. S
TBA MXB	no dre	P=1.	10.3mg n.s.s.	36/50	32/50	35/50		
liv MXB	88.2mg	* P<.03	30.5mg n.s.s.	0/50	0/50	4/50		liv:hpa,hpc,nnd.
1,4-BENZOQUINONE 106-51-4								
673 M f swa gav 56w56 1944				0	22.9mg		El-Mofty;nutc,17,97-104;1992/pers.comm.	
liv lle es	5.03mg	P<.0005 +	2.97mg 9.35mg	0/30	22/37			
spl lle es	5.03mg	P<.0005 +	2.97mg 9.35mg	0/30	22/37			
tba mix es	5.03mg	P<.0005 +	2.97mg 9.35mg	0/30	22/37			
674 M m swa gav 56w56 1944				0	19.0mg			
liv lle es	5.12mg	P<.0005 +	3.08mg 9.33mg	0/28	23/44			
spl lle es	5.12mg	P<.0005 +	3.08mg 9.33mg	0/28	23/44			
tba mix es	5.12mg	P<.0005 +	3.08mg 9.33mg	0/28	23/44			
BENZOTHIAZYL DISULFIDE (altax) 120-78-5								
675 M f b6a orl 76w76 1301				0	215.mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- 256.mg n.s.s.	1/17	1/18			
liv hpt evx	no dre	P=1.	- 426.mg n.s.s.	0/17	0/18			
tba mix evx	1.38gm	P<.7	- 155.mg n.s.s.	2/17	3/18			
676 M m b6a orl 76w76 1301				0	200.mg			
lun ade evx	1.13gm	P<.7	- 142.mg n.s.s.	2/18	3/18			
liv hpt evx	no dre	P=1.	- 396.mg n.s.s.	1/18	0/18			
tba mix evx	511.mg	P<.5	- 102.mg n.s.s.	3/18	5/18			
677 M f b6c orl 76w76 1301				0	215.mg			
lun ade evx	669.mg	P<.2	- 164.mg n.s.s.	0/16	2/18			
liv hpt evx	no dre	P=1.	- 426.mg n.s.s.	0/16	0/18			
tba mix evx	432.mg	P<.05	- 130.mg n.s.s.	0/16	3/18			
678 M m b6c orl 76w76 1301				0	200.mg			
liv hpt evx	621.mg	P<.2	- 153.mg n.s.s.	0/16	2/18			
lun mix evx	no dre	P=1.	- 396.mg n.s.s.	0/16	0/18			
tba mix evx	401.mg	P<.05	- 121.mg n.s.s.	0/16	3/18			
1H-BENZOTRIAZOLE 95-14-7								
679 M f b6c eat 24m25 TR88 :				0	1.50gm	2.99gm		
lun MXA v	3.89gm	\ P<.0005 a	2.21gm 7.77gm	0/50	10/50	(4/50)		lun:a/a,a/c.
lun a/c v	4.39gm	\ P<.002 a	2.43gm 9.15gm	0/50	9/50	(3/50)		
TBA MXB v	18.9gm	\ P<.8	2.21gm n.s.s.	21/50	25/50	(14/50)		
liv MXB v	no dre	P=1.	25.8gm n.s.s.	1/50	2/50	1/50		liv:hpa,hpc,nnd.
lun MXB v	3.89gm	\ P<.0005	1.89gm 11.6gm	0/50	10/50	(4/50)		lun:a/a,a/c.
680 M m b6c eat 24m25 TR88 :				0	1.38gm	2.76gm		
TBA MXB v	no dre	P=1.	- 1.68gm n.s.s.	24/50	23/50	(18/50)		
liv MXB v	no dre	P=1.	9.88gm n.s.s.	12/50	12/50	7/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	7.62gm n.s.s.	4/50	7/50	5/50		lun:a/a,a/c.
681 R f f34 eat 18m24 TR88 :				0	250.mg	450.mg		
bra gln vh	20.3gm	* P<.3	a 3.31gm n.s.s.	0/50	0/50	1/50		
TBA MXB v	no dre	P=1.	535.mg n.s.s.	27/50	27/50	30/50		
liv MXB v	10.1gm	* P<.2	2.48gm n.s.s.	0/50	0/50	2/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
682 R m f34 eat 18m24 TR88 :				0	202.mg	360.mg		
liv nnd v	2.72gm *	P<.02	1.03gm n.s.s.	0/50	0/50	5/50		S
bra MXA vh	no dre	P=1. a	n.s.s. n.s.s.	0/50	3/50	0/50		bra:gln,oli.
TBA MXB v	no dre	P=1.	368.mg n.s.s.	28/50	20/50	(18/50)		
liv MXB v	2.72gm *	P<.02	1.03gm n.s.s.	0/50	0/50	5/50		liv:hpa,hpc,nnd.
BENZOTRICHLORIDE (BTC) 98-07-7								
683 M f icm gav 25w78 2187 ()				0	.115mg	.456mg	1.83mg 10.9mg	Fukuda;indh,31,127-131;1993/1978
lun mix 8	.396mg Z	P<.0005 +	.267mg .671mg	2/39	7/39	26/39	35/40 24/38	
for mix 8	.951mg *	P<.0005 +	.628mg 1.51mg	0/39	0/39	2/39	23/40 25/38	
for sqc 8	1.05mg *	P<.0005	.684mg 1.69mg	0/39	0/39	2/39	21/40 24/38	
lun adc 8	1.21mg *	P<.0005	.737mg 2.44mg	1/39	1/39	9/39	16/40 10/38	
--- mix 8	6.40mg *	P<.0005 +	2.56mg 24.5mg	1/39	2/39	1/39	3/40 8/38	
tba mix 8	.336mg Z	P<.0005	.232mg .545mg	4/39	10/39	30/39	39/40 36/38	
BENZOYL HYDRAZINE 613-94-5								
684 M f swa wat 26m26 48				0	20.0mg			Toth;ejca,8,341-345;1972/1969a
lun ade e	13.4mg	P<.0005	8.18mg 24.9mg	12/89	34/47			
lun mix e	13.8mg	P<.0005 +	8.29mg 26.1mg	14/89	34/47			
lun adc e	39.0mg	P<.0005	21.0mg 89.4mg	2/89	16/47			
--- mly e	52.1mg	P<.004 +	23.6mg 463.mg	16/106	18/49			
liv mix e	no dre	P=1.	145.mg n.s.s.	3/88	1/47			
685 M m swa wat 92w92 48				0	16.7mg			
lun mix e	7.35mg	P<.0005 +	4.40mg 13.7mg	10/86	31/42			
lun ade e	8.52mg	P<.0005	5.05mg 16.5mg	10/86	29/42			
lun adc e	24.1mg	P<.0005	12.7mg 54.5mg	0/86	13/42			
--- mly e	52.0mg	P<.07 +	16.4mg n.s.s.	2/40	5/25			
liv hem e	no dre	P=1. -	67.2mg n.s.s.	2/40	0/25			
686 M f swi gav 40w55 1095				0	10.4mg			Roe;natu,216,375-376;1967
lun tum	no dre	P=1. -	10.8mg n.s.s.	8/85	1/25			
BENZYL ACETATE 140-11-4								
687 M f b6c gav 24m24 TR250 :				0	350.mg	704.mg		
MXB MXB s	1.75gm /	P<.003	795.mg 7.34gm	0/50	0/50	9/50		for:sqp; liv:hpa. P
liv MXA s	2.03gm /	P<.02	874.mg n.s.s.	1/50	0/50	10/50		liv:hpa,hpc. S
for sqp s	2.94gm *	P<.04 p	1.02gm n.s.s.	0/50	0/50	4/50		
liv hpa s	3.21gm *	P<.02 p	1.27gm n.s.s.	0/50	0/50	6/50		
TBA MXB s	4.27gm *	P<.9	383.mg n.s.s.	14/50	26/50	25/50		
liv MXB s	2.03gm /	P<.02	874.mg n.s.s.	1/50	0/50	10/50		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.	2.30gm n.s.s.	1/50	3/50	1/50		lun:a/a,a/c.
688 M f b6c eat 24m24 TR431 :				0	42.2mg	128.mg	385.mg	
TBA MXB	107.mg Z	P<.5 -	21.9mg n.s.s.	35/50	40/50	(33/50	33/50)	
liv MXB	no dre	P=1.	1.02gm n.s.s.	14/50	15/50	13/50	14/50	liv:hpa,hpb,hpc.
lun MXB	26.4gm *	P<.9	1.29gm n.s.s.	1/50	5/50	2/50	4/50	lun:a/a,a/c.
689 M m b6c gav 24m24 TR250 :				0	350.mg	704.mg		
MXB MXB	702.mg *	P<.0005	399.mg 1.87gm	4/50	9/50	21/50		for:sqc,sqp; liv:hpa. P
liv MXA	758.mg *	P<.004	387.mg 5.38gm	10/50	18/50	23/50		liv:hpa,hpc. S
liv hpa	955.mg *	P<.0005 p	540.mg 1.96gm	0/50	5/50	13/50		
for MXA	1.91gm *	P<.03 p	808.mg n.s.s.	4/50	4/50	11/50		for:sqc,sqp.
for sqp	2.14gm *	P<.03 p	877.mg n.s.s.	3/50	3/50	9/50		
TBA MXB	829.mg *	P<.2	309.mg n.s.s.	32/50	35/50	37/50		
liv MXB	758.mg *	P<.004	387.mg 5.38gm	10/50	18/50	23/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	1.44gm n.s.s.	12/50	7/50	7/50		lun:a/a,a/c.
690 M m b6c eat 24m24 TR431 :				0	39.0mg	118.mg	355.mg	
TBA MXB	no dre	P=1. -	142.mg n.s.s.	42/50	40/50	35/50	(23/50)	
liv MXB	no dre	P=1.	223.mg n.s.s.	22/50	22/50	18/50	(9/50)	liv:hpa,hpb,hpc.
lun MXB	418.mg Z	P<.7	54.7mg n.s.s.	14/50	17/50	(8/50	7/50)	lun:a/a,a/c.
691 R f f34 gav 24m24 TR250 :				0	175.mg	352.mg		
TBA MXB	285.mg *	P<.06 -	116.mg n.s.s.	43/50	44/50	44/50		
liv MXB	6.48gm *	P<.6	950.mg n.s.s.	1/50	2/50	1/50		liv:hpa,hpc,nnd.
692 R f f34 eat 24m24 TR431 :				0	147.mg	295.mg	591.mg	
TBA MXB	7.03gm *	P<.9 -	347.mg n.s.s.	48/50	47/50	45/50	49/50	
liv MXB	6.55gm *	P<.2	2.02gm n.s.s.	1/50	1/50	1/50	4/50	liv:hpa,hpb,hpc.
693 R m f34 gav 24m24 TR250 :				0	174.mg	352.mg		
pan ana	282.mg /	P<.003 e	146.mg 1.86gm	22/50	27/50	37/50		
pre MXA	2.17gm *	P<.04	814.mg n.s.s.	1/50	1/50	6/50		pre:acn,can,ccn. S
pre MXA	2.47gm *	P<.02	916.mg n.s.s.	0/50	1/50	4/50		pre:acn,ccn. S
pre ccn	4.27gm *	P<.04	1.26gm n.s.s.	0/50	0/50	3/50		S
TBA MXB	376.mg /	P<.2	134.mg n.s.s.	44/50	46/50	45/50		
liv MXB	6.47gm *	P<.5	1.24gm n.s.s.	1/50	2/50	2/50		liv:hpa,hpc,nnd.
694 R m f34 eat 24m24 TR431 :				0	118.mg	237.mg	474.mg	
TBA MXB	no dre	P=1. -	379.mg n.s.s.	39/50	43/50	43/50	39/50	
liv MXB	no dre	P=1.	1.91gm n.s.s.	5/50	6/50	3/50	3/50	liv:hpa,hpb,hpc.
695 R m f34 eat 24m24 1988				0	320.mg			Longnecker;fctx,28,665-668;1990/pers.comm.
pan cic er	2.67gm	P<.03	807.mg n.s.s.	0/49	3/38			
pan ade er	27.0gm	P<1.	660.mg n.s.s.	10/49	8/38			
BENZYL ALCOHOL 100-51-6								
696 M f b6c gav 24m24 TR343 :				0	70.7mg	142.mg		
TBA MXB	57.5gm *	P<1. -	120.mg n.s.s.	27/50	24/50	36/50		
liv MXB	1.04gm *	P<.4	279.mg n.s.s.	1/50	6/50	4/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	588.mg n.s.s.	4/50	1/50	4/50		lun:a/a,a/c.
697 M m b6c gav 24m24 TR343 :				0	70.7mg	142.mg		
adr coa #	1.62gm *	P<.05 -	489.mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	no dre	P=1.	134.mg n.s.s.	34/50	27/50	34/50		
liv MXB	588.mg *	P<.4	148.mg n.s.s.	11/50	16/50	16/50		liv:hpa,hpc,nnd.
lun MXB	546.mg *	P<.3	174.mg n.s.s.	10/50	6/50	17/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

698 R f f34 gav 24m24 TR343 : 0 142.mg 283.mg
TBA MXB s 885.mg * P<.7 - 133.mg n.s.s. 46/50 29/50 26/50
liv MXB s no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 liv:hpa,hpc,nnd.
699 R m f34 gav 24m24 TR343 : 0 142.mg 283.mg
mgl MXA # 1.14gm * P<.03 - 465.mg n.s.s. 0/50 3/50 3/50 mgl:adn,fba. S
mgl fba 1.38gm * P<.04 523.mg n.s.s. 0/50 2/50 3/50 S
TBA MXB no dre P=1. 171.mg n.s.s. 44/50 32/50 38/50
liv MXB no dre P=1. 1.47gm n.s.s. 2/50 0/50 1/50 liv:hpa,hpc,nnd.

BENZYL CHLORIDE (alpha-chloro toluene) 100-44-7
700 M f b6c gav 24m25 1827 0 20.7mg 41.5mg Lijinsky;jnci,76,1231-1236;1986
for mix e 81.0mg * P<.0005 + 49.8mg 144.mg 0/52 5/50 19/51
lun mix e 337.mg * P<.04 132.mg n.s.s. 1/52 2/51 6/51
for car e 445.mg * P<.04 + 169.mg n.s.s. 0/52 2/50 3/51
liv mix e no dre P=1. 272.mg n.s.s. 7/52 5/51 3/51
701 M m b6c gav 24m25 1827 0 20.7mg 41.5mg
for mix e 49.6mg / P<.0005 + 33.0mg 79.2mg 0/51 4/52 32/52
for car e 221.mg * P<.002 + 108.mg 736.mg 0/51 2/52 8/52
--- vsc e 454.mg * P<.009 172.mg 10.5gm 0/52 0/52 5/52
liv mix e 225.mg * P<.5 49.7mg n.s.s. 17/52 28/52 20/51
lun mix e no dre P=1. 99.1mg n.s.s. 11/52 15/52 11/52
702 R f f34 gav 24m25 1827 0 6.22mg 12.4mg
thy mix e 40.6mg * P<.009 19.8mg 1.52gm 4/52 8/51 14/52
liv nnd e 330.mg * P<.7 49.2mg n.s.s. 2/52 5/52 3/52
703 R m f34 gav 24m25 1827 0 6.22mg 12.4mg
liv nnd e no dre P=1. 71.9mg n.s.s. 3/52 4/52 2/51

o-BENZYL-p-CHLOROPHENOL 120-32-1
704 M f b6c gav 24m24 TR424 : 0 85.2mg 170.mg 341.mg
TBA MXB 6.97gm * P<1. - 265.mg n.s.s. 39/50 35/50 29/50 28/52
liv MXB 684.mg * P<.09 256.mg n.s.s. 13/50 15/50 17/50 16/52 liv:hpa,hpb,hpc.
lun MXB 31.5gm * P<1. 1.17gm n.s.s. 5/50 3/50 1/50 4/52 lun:a/a,a/c.
705 M m b6c gav 24m24 TR424 : 0 85.2mg 170.mg 341.mg
kid MXA 1.44gm * P<.02 p 680.mg n.s.s. 0/50 2/50 4/50 3/50 kid:rua,uac.
kid rua 2.21gm * P<.09 p 903.mg n.s.s. 0/50 2/50 2/50 2/50
TBA MXB 3.16gm * P<.9 262.mg n.s.s. 38/50 33/50 37/50 28/50
liv MXB no dre P=1. 449.mg n.s.s. 25/50 25/50 26/50 16/50 liv:hpa,hpb,hpc.
lun MXB no dre P=1. 1.15gm n.s.s. 14/50 13/50 7/50 5/50 lun:a/a,a/c.
706 M m b6c gav 24m24 TR424 with step 0 85.2mg 170.mg 341.mg
kid MXA 1.35gm * P<.003 p 728.mg 6.31gm 0/50 2/50 6/50 6/50 kid:rac,rua.
kid rua 1.74gm * P<.007 p 875.mg 27.2gm 0/50 2/50 4/50 5/50
707 R f f34 gav 24m24 TR424 : 0 42.3mg 84.6mg 169.mg
amd pob 615.mg * P<.05 298.mg n.s.s. 0/50 3/50 3/51 4/50 S
kid tcc 4.07gm * P<.2 e 980.mg n.s.s. 0/50 0/50 1/51 1/50
TBA MXB 867.mg * P<.8 96.8mg n.s.s. 44/50 40/50 42/51 47/50
liv MXB no dre P=1. 1.76gm n.s.s. 1/50 0/50 0/51 0/50 liv:hpa,hpb,hpc.
708 R m f34 gav 24m24 TR424 : 0 21.2mg 42.3mg 84.6mg
TBA MXB no dre P=1. - 73.6mg n.s.s. 42/50 39/50 38/50 33/51
liv MXB 1.58gm * P<.5 305.mg n.s.s. 0/50 1/50 0/50 1/51 liv:hpa,hpb,hpc.

BENZYL ISOTHIOCYANATE 622-78-6
709 R m ain eat 53w53 2114 0 4.00mg Sugie;gann,84,865-870;1993
liv tum r no dre P=1. 3.85mg n.s.s. 0/18 0/18

BENZYL THIOCYANATE 3012-37-1
710 R m ain eat 53w53 2114 0 4.00mg Sugie;gann,84,865-870;1993
liv tum r no dre P=1. 3.85mg n.s.s. 0/18 0/18

BENZYLHYDRAZINE.2HCl 20570-96-1
711 M f swa wat 28m28 1056 0 30.0mg Toth;zkko,87,267-273;1976/1974
lun mix e 85.3mg P<.02 + 36.8mg n.s.s. 21/90 21/47
liv ang e 252.mg P<.2 - 61.4mg n.s.s. 2/56 3/22
liv mix e 304.mg P<.3 63.8mg n.s.s. 3/56 3/22
712 M m swa wat 23m23 1056 0 25.0mg
liv mix e 86.2mg P<.08 24.8mg n.s.s. 6/71 5/21
lun ade e 711.mg P<.8 - 59.5mg n.s.s. 15/99 8/47
lun mix e no dre P=1. 70.9mg n.s.s. 23/99 9/47

3-BENZYLSYDNONE-4-ACETAMIDE 14504-15-5
713 M f ddd wat 52w52 2395 0 4.00mg 20.0mg 40.0mg Ohtsubo;jtxp,4,45-54;1991/pers.comm.
liv hpa r 10.2mg Z P<.0005 5.53mg 21.8mg 0/9 0/16 2/25 13/16
liv mix r 10.2mg Z P<.0005 + 5.53mg 21.8mg 0/9 0/16 2/25 13/16
liv hpc r 22.6mg * P<.002 + 10.2mg 88.0mg 0/9 0/16 2/25 6/16
lun ade r 31.4mg * P<.02 12.8mg n.s.s. 0/6 0/16 2/25 4/16
714 R m don wat 41w91 2375m 0 13.5mg Ohtsubo;jtxp,7,35-41;1994/pers.comm.
liv hpc r 4.24mg P<.0005 + 1.99mg 10.2mg 0/13 13/16
liv mix r 4.24mg P<.0005 + 1.99mg 10.2mg 0/13 13/16
liv nnd r 15.1mg P<.005 6.07mg 105.mg 0/13 6/16
715 R m don eat 24m24 2375n 0 8.00mg
liv tum r no dre P=1. - 28.0mg n.s.s. 0/21 0/17

BERYLLIUM SULFATE 13510-49-1
716 M f cd1 wat 33m33 1395 0 1.00mg Schroeder;jnut,105,452-458;1975
lun tum e no dre P=1. - 9.07mg n.s.s. 9/47 5/52
tba mix e 9.42mg P<.4 - 2.34mg n.s.s. 14/47 20/52
tba mal e 36.9mg P<.7 - 5.36mg n.s.s. 4/47 6/52
717 M m cd1 wat 41m41 1395 0 .833mg
lun tum e 98.8mg P<.9 - 6.34mg n.s.s. 5/38 7/48

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	TD_{50}	DR 2Tailpvl	AuOp LoConf	UpConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
tba mix e		17.1mg	P<.6 -	3.29mg	n.s.s.	11/38	17/48			
tba mal e		49.6mg	P<.6 -	7.70mg	n.s.s.	2/38	4/48			
718 R f leb wat 47m47 1456						0	.286mg			Schroeder;jnut,105,421-427;1975
tba mix e		1.48mg	P<.4 -	.298mg	n.s.s.	17/24	14/17			
tba mal e		3.24mg	P<.4 -	.689mg	n.s.s.	8/24	8/17			
719 R m leb wat 38m38 1456						0	.250mg			
tba mix e		2.78mg	P<.3 -	.768mg	n.s.s.	4/26	9/33			
tba mal e		8.56mg	P<.6 -	1.33mg	n.s.s.	2/26	4/33			
BIFENTHRIN 82657-04-3										
720 M f sww eat 92w92 2534						0	6.50mg	26.0mg	65.0mg 78.0mg	Butler;txpy,25,268-274;1997
ubl mnp er		no dre	P=1.	480.mg	n.s.s.	1/48	2/50	4/49	1/46 1/49	
721 M m sww eat 86w86 2534						0	6.00mg	24.0mg	60.0mg 72.0mg	
ubl mnp er		286.mg	* P<.2	105.mg	n.s.s.	6/48	7/50	8/50	8/50 13/49	
BIPHENYL 92-52-4										
722 M f b6a orl 76w76 1307						0	73.0mg			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1. -	137.mg	n.s.s.	0/17	0/17			
lun ade evx		no dre	P=1. -	137.mg	n.s.s.	1/17	0/17			
tba mix evx		187.mg	P<.4 -	39.1mg	n.s.s.	2/17	4/17			
723 M m b6a orl 76w76 1307						0	68.0mg			
liv hpt evx		182.mg	P<.3 -	41.6mg	n.s.s.	1/18	3/17			
lun ade evx		no dre	P=1. -	83.7mg	n.s.s.	2/18	1/17			
tba mix evx		290.mg	P<.7 -	39.1mg	n.s.s.	3/18	4/17			
724 M f b6c orl 76w76 1307						0	73.0mg			
lun ade evx		467.mg	P<.3 -	76.1mg	n.s.s.	0/16	1/18			
liv hpt evx		no dre	P=1. -	145.mg	n.s.s.	0/16	0/18			
tba mix evx		227.mg	P<.2 -	55.7mg	n.s.s.	0/16	2/18			
725 M m b6c orl 76w76 1307						0	68.0mg			
lun ade evx		128.mg	P<.04 -	38.7mg	n.s.s.	0/16	3/17			
liv hpt evx		199.mg	P<.1 -	48.8mg	n.s.s.	0/16	2/17			
tba mix evx		71.5mg	P<.007 -	26.9mg	966.mg	0/16	5/17			
5,5'-(1,1'-BIPHENYL)-2,5-DIYLBIS(OXY)(2,2-DIMETHYLPENTANOIC ACID) (CI-924) 79520-77-7										
726 M f b6c eat 24m24 2283						0	5.00mg	25.0mg	75.0mg	Walker;txpy,24,265-272;1996
liv mix er		72.3mg	* P<.0005 +	46.7mg	127.mg	2/50	5/50	8/50	29/50	
liv hpa er		90.6mg	* P<.0005	59.0mg	167.mg	0/50	4/50	5/50	23/50	
liv hpc er		402.mg	* P<.02	164.mg	n.s.s.	2/50	2/50	3/50	8/50	
727 M m b6c eat 24m24 2283						0	5.00mg	25.0mg	75.0mg	
liv mix er		45.0mg	* P<.0005 +	27.0mg	97.6mg	16/50	20/50	25/50	40/50	
liv hpa er		107.mg	* P<.0005	56.8mg	370.mg	10/50	13/50	12/50	27/50	
liv hpc er		167.mg	* P<.02	73.7mg	n.s.s.	7/50	11/50	18/50	18/50	
2-BIPHENYLAMINE.HCl 2185-92-4										
728 M f b6c eat 24m24 TR233 :						0	128.mg	384.mg		
--- MXA		1.12gm	* P<.0005 c	527.mg	3.06gm	0/50	1/50	8/50		---:ang,hem.
--- ang		1.28gm	* P<.002 c	579.mg	4.87gm	0/50	1/50	7/50		
TBA MXB		1.88gm	* P<.7	269.mg	n.s.s.	31/50	30/50	31/50		
liv MXB		2.00gm	* P<.4	475.mg	n.s.s.	7/50	9/50	10/50		liv:hpa,hpc,nnd.
lun MXB		26.1gm	/ P<.9	1.15gm	n.s.s.	6/50	1/50	5/50		lun:a/a,a/c.
729 M m b6c eat 24m24 TR233 :						0	118.mg	355.mg		
--- MXA e		1.25gm	* P<.02 a	530.mg	n.s.s.	0/50	4/50	3/50		---:ang,hem,hes.
--- MXA e		1.81gm	* P<.02 a	670.mg	n.s.s.	0/50	2/50	3/50		---:ang,hes.
TBA MXB e		720.mg	* P<.4	181.mg	n.s.s.	37/50	38/50	27/50		
liv MXB e		1.70gm	* P<.5	333.mg	n.s.s.	14/50	19/50	11/50		liv:hpa,hpc,nnd.
lun MXB e		no dre	P=1.	388.mg	n.s.s.	16/50	6/50	(1/50)		lun:a/a,a/c.
730 R f f34 eat 24m24 TR233 :						0	49.3mg	148.mg		
TBA MXB		no dre	P=1. -	122.mg	n.s.s.	46/50	45/49	46/50		
liv MXB		363.mg	\ P<.2	115.mg	n.s.s.	1/50	5/49	(1/50)		liv:hpa,hpc,nnd.
731 R m f34 eat 24m24 TR233 :						0	39.4mg	118.mg		
TBA MXB		no dre	P=1. -	142.mg	n.s.s.	43/50	40/50	35/50		
liv MXB		no dre	P=1.	n.s.s.	n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, TECHNICAL GRADE (DIBROMONEOPENTYL GLYCOL) 3296-90-0										
732 M f b6c eat 24m25 TR452 :						0	39.9mg	79.9mg	160.mg	
MXB MXB		67.8mg	* P<.0005	45.6mg	118.mg	8/52	17/50	27/51	32/50	hag:ade,anb,car; lun:a/a,a/c; sub:fbs,sar. C
hag MXA		122.mg	* P<.0005 c	76.2mg	254.mg	3/52	12/50	13/51	19/50	hag:ade,anb,car.
lun MXA		127.mg	* P<.0005 c	77.3mg	263.mg	5/52	5/50	15/51	19/50	lun:a/a,a/c.
lun a/a		171.mg	Z P<.0005	101.mg	367.mg	3/52	3/50	9/51	17/50	S
hag MXA		187.mg	* P<.0005	109.mg	429.mg	2/52	6/50	8/51	15/50	hag:ade,anb. S
sub MXA		322.mg	* P<.0005 c	176.mg	656.mg	0/52	1/50	4/51	12/50	sub:fbs,sar.
hag car		323.mg	* P<.003	161.mg	2.27gm	1/52	6/50	5/51	7/50	S
sub sar		350.mg	* P<.0005 c	188.mg	737.mg	0/52	1/50	4/51	11/50	
lun a/c		398.mg	* P<.008	176.mg	9.86gm	2/52	2/50	6/51	5/50	S
for sqp		446.mg	* P<.002 e	206.mg	1.90gm	0/52	1/50	5/51	3/50	
liv hpa		301.mg	Z P<.05	116.mg	n.s.s.	16/52	12/50	5/51	16/50	S
--- MXA		846.mg	* P<.03 e	307.mg	n.s.s.	1/52	2/50	0/51	5/50	---:hem,hes.
mgl car		1.48gm	* P<.02 e	472.mg	n.s.s.	0/52	0/50	1/51	3/50	
--- hes		1.48gm	* P<.02	437.mg	n.s.s.	0/52	0/50	0/51	3/50	S
TBA MXB		57.3mg	* P<.0005	33.5mg	153.mg	35/52	42/50	43/51	42/50	
liv MXB		267.mg	Z P<.08	99.3mg	n.s.s.	20/52	19/50	9/51	18/50	liv:hpa,hpb,hpc.
lun MXB		127.mg	* P<.0005	77.3mg	263.mg	5/52	5/50	15/51	19/50	lun:a/a,a/c.
733 M m b6c eat 24m24 TR452 :						0	37.2mg	74.4mg	149.mg	
MXB MXB		106.mg	* P<.0005	60.8mg	321.mg	18/50	18/51	28/50	37/49	hag:ade,anb,car,cnb; kid:rua; lun:a/a,a/c. C
hag MXA		155.mg	* P<.0005 c	96.0mg	347.mg	4/50	7/51	16/50	22/49	hag:ade,anb,car,cnb.
hag MXA		191.mg	* P<.0005	114.mg	481.mg	3/50	6/51	12/50	18/49	hag:ade,anb. S
lun MXA		218.mg	* P<.007 c	106.mg	3.37gm	15/50	11/51	16/50	25/49	lun:a/a,a/c.
lun a/a		270.mg	Z P<.005	133.mg	2.59gm	12/50	4/51	12/50	21/49	S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun	a/c	334.mg *	P<.008	161.mg	8.52gm	3/50	7/51	8/50	11/49		S
for	MXA	581.mg *	P<.02 e	283.mg	n.s.s.	0/50	3/51	3/50	4/49	for:sqc,sqp.	
thy	fca	835.mg *	P<.04	360.mg	n.s.s.	0/50	3/51	0/50	4/49		S
kid	rua	1.19gm *	P<.03 c	451.mg	n.s.s.	0/50	0/51	3/50	2/49		
TBA	MXB	126.mg *	P<.04	54.4mg	n.s.s.	37/50	42/51	45/50	45/49		
liv	MXB	2.48gm *	P<.9	144.mg	n.s.s.	27/50	32/51	27/50	23/49	liv:hpa,hpb,hpc.	
lun	MXB	218.mg *	P<.007	106.mg	3.37gm	15/50	11/51	16/50	25/49	lun:a/a,a/c.	
734	R f f34 eat 24m24 TR452 :					0	124.mg	248.mg	496.mg		
mgl	fba	83.0mg *	P<.0005 c	56.7mg	138.mg	25/50	45/51	46/53	45/52		
mgl	MXA	83.0mg *	P<.0005	56.7mg	138.mg	25/50	45/51	46/53	45/52	mgl:ade,fba.	S
mgl	MXA	83.8mg *	P<.0005 c	57.0mg	141.mg	27/50	47/51	47/53	47/52	mgl:ade,car,fba.	
MXB	MXB	84.3mg *	P<.0005	57.2mg	142.mg	28/50	47/51	48/53	47/52	eso:sqp; mgl:ade,car,fba; pal:sqc,sqp; thy:fca, fcc; ton:sqc,sqp.	C
pit	pda	300.mg *	P<.002	155.mg	1.43gm	16/50	24/51	24/53	15/52		S
---	mnl	406.mg *	P<.0005	220.mg	1.38gm	15/50	13/51	19/53	19/52		S
MXA	MXA	1.01gm *	P<.003 c	452.mg	7.37gm	2/50	3/51	5/53	6/52	pal:sqc,sqp; ton:sqc,sqp.	
MXA	sqp	1.24gm *	P<.008	505.mg	29.9gm	2/50	2/51	4/53	5/52	pal:sqp; ton:sqp.	S
ton	MXA	1.26gm *	P<.004	539.mg	9.28gm	1/50	2/51	4/53	5/52	ton:sqc,sqp.	S
ton	sqp	1.36gm *	P<.007	559.mg	27.0gm	1/50	2/51	4/53	4/52		S
eso	sqp	1.41gm Z	P<.0005 c	669.mg	3.36gm	0/50	0/51	1/53	10/52		
thy	MXA	1.67gm *	P<.002 c	641.mg	7.11gm	0/50	0/51	2/53	4/52	thy:fca,fcc.	
thy	fca	2.16gm *	P<.004	763.mg	14.7gm	0/50	0/51	2/53	3/52		S
ute	MXA	859.mg *	P<.03	349.mg	n.s.s.	5/50	9/51	6/53	6/52	ute:esp,ess.	S
ute	esp	904.mg *	P<.03	366.mg	n.s.s.	5/50	8/51	6/53	6/52		S
sub	MXA	1.37gm *	P<.02	531.mg	n.s.s.	2/50	4/51	1/53	6/52	sub:fbs,fib,sar.	S
sub	MXA	4.20gm Z	P<.04	1.16gm	n.s.s.	1/50	0/51	0/53	4/52	sub:fbs,sar.	S
TBA	MXB	94.4mg *	P<.0005	61.0mg	179.mg	45/50	51/51	53/53	52/52		
liv	MXB	no dre	P=1.	n.s.s.	n.s.s.	0/50	0/51	0/53	0/52	liv:hpa,hpb,hpc.	
735	R m f34 eat 24m24 TR452 :					0	99.4mg	199.mg	398.mg		
tes	MXA	66.5mg Z	P<.0005	41.6mg	132.mg	49/51	48/53	51/51	51/55	tes:iab,ica.	S
MXB	MXB	68.1mg *	P<.0005	44.9mg	117.mg	33/51	37/53	49/51	52/55	---:mnl,msm; col:adp; eso:sqp; gnv:sqc; jej:car; lun:a/a,a/c; mgl:ade,fba; pal:sqp; ski:bca,bcc,ker,sqc,sqp,tri; sub:fbs,fib,sar; thy:fca,fcc; ton: sqp; ubl:tcc,tpp; zym:ade,car.	C
---	mnl	95.8mg *	P<.0005 c	58.8mg	194.mg	27/51	29/53	40/51	34/55		
ski	MXA	166.mg Z	P<.0005 c	103.mg	300.mg	4/51	6/53	14/51	24/55	ski:bca,bcc,ker,sqc,sqp,tri.	
pni	MXA	208.mg Z	P<.006	86.1mg	2.46gm	1/51	8/53	(1/51	0/55)	pni:isa,isc.	S
sub	MXA	221.mg *	P<.0005 c	131.mg	437.mg	2/51	9/53	13/51	16/55	sub:fbs,fib,sar.	
ski	ker	235.mg Z	P<.0005	135.mg	488.mg	3/51	5/53	11/51	16/55		S
mgl	MXA	262.mg *	P<.0005 c	143.mg	542.mg	0/51	4/53	7/51	7/55	mgl:ade,fba.	
sub	fib	271.mg *	P<.0005	156.mg	568.mg	2/51	8/53	11/51	15/55		S
mgl	fba	275.mg *	P<.0005	147.mg	597.mg	0/51	4/53	6/51	6/55		S
MXA	MXA	285.mg *	P<.0005 c	157.mg	555.mg	0/51	4/53	9/51	10/55	gnv:sqc; pal:sqp; ton:sqp.	
MXA	sqp	300.mg *	P<.0005	163.mg	601.mg	0/51	4/53	8/51	10/55	pal:sqp; ton:sqp.	S
---	msm	335.mg *	P<.0005 c	177.mg	690.mg	0/51	3/53	8/51	9/55		
ton	sqp	500.mg *	P<.0005	239.mg	1.19gm	0/51	2/53	5/51	8/55		S
pan	ana	516.mg *	P<.003 e	218.mg	3.81gm	1/51	2/53	4/51	3/55		
thy	MXA	629.mg *	P<.0005 c	280.mg	2.10gm	0/51	2/53	6/51	3/55	thy:fca,fcc.	
ski	MXA	720.mg Z	P<.0005	319.mg	2.10gm	0/51	1/53	2/51	6/55	ski:bca,bcc,tri.	S
lun	MXA	729.mg *	P<.003 c	287.mg	5.65gm	1/51	1/53	3/51	4/55	lun:a/a,a/c.	
pal	sqp	808.mg *	P<.005	314.mg	8.16gm	0/51	2/53	3/51	2/55		S
col	adp	997.mg *	P<.0005 c	386.mg	3.80gm	0/51	0/53	3/51	4/55		
sub	MXA	1.08gm *	P<.003	381.mg	7.58gm	0/51	1/53	2/51	3/55	sub:fbs,sar.	S
ski	MXA	1.13gm *	P<.005	376.mg	12.3gm	1/51	0/53	2/51	5/55	ski:sqc,sqp.	S
ski	sqp	1.13gm *	P<.005	376.mg	12.3gm	1/51	0/53	2/51	5/55		S
lun	a/c	1.30gm Z	P<.006	403.mg	18.8gm	0/51	1/53	0/51	3/55		S
eso	sqp	1.39gm *	P<.0005 c	472.mg	5.95gm	0/51	0/53	1/51	5/55		
ski	bca	1.53gm *	P<.007	483.mg	28.5gm	0/51	1/53	0/51	3/55		S
sub	sar	1.55gm *	P<.004	499.mg	11.5gm	0/51	0/53	2/51	3/55		S
kid	rua	1.55gm *	P<.004 e	532.mg	11.4gm	0/51	0/53	1/51	3/55		
zym	ade	1.95gm *	P<.007	532.mg	31.5gm	0/51	0/53	1/51	3/55		S
ubl	MXA	2.32gm *	P<.009 c	577.mg	79.4gm	0/51	0/53	1/51	3/55	ubl:tcc,tpp.	
pit	MXA	462.mg *	P<.03	177.mg	n.s.s.	7/51	10/53	6/51	6/55	pit:pda,pdc.	S
pit	pda	493.mg *	P<.04	187.mg	n.s.s.	7/51	9/53	6/51	6/55		S
thy	MXA	675.mg Z	P<.05	236.mg	n.s.s.	8/51	4/53	5/51	6/55	thy:cca,ccb,ccr.	S
pre	MXA	793.mg *	P<.05	276.mg	n.s.s.	5/51	4/53	5/51	5/55	pre:ade,car.	S
pre	ade	819.mg *	P<.04	286.mg	n.s.s.	3/51	3/53	4/51	4/55		S
thy	fcc	1.11gm *	P<.02	388.mg	n.s.s.	0/51	1/53	4/51	1/55		S
zym	MXA	1.60gm *	P<.03 c	547.mg	n.s.s.	2/51	1/53	4/51	5/55	zym:ade,car.	
thy	MXA	1.92gm *	P<.05	580.mg	n.s.s.	1/51	1/53	1/51	3/55	thy:ccb,ccr.	S
jej	car	5.66gm *	P<.04 c	1.35gm	n.s.s.	0/51	0/53	0/51	2/55		
for	sqp	16.0gm *	P<.2	2.60gm	n.s.s.	0/51	0/53	0/51	1/55		
sev	MXA	no dre	P=1.	n.s.s.	n.s.s.	0/51	0/53	0/51	0/55	sev:ade,car.	
TBA	MXB	63.8mg *	P<.0005	40.7mg	120.mg	44/51	50/53	51/51	53/55		
liv	MXB	1.84gm *	P<.5	453.mg	n.s.s.	0/51	2/53	0/51	0/55	liv:hpa,hpb,hpc.	
736	R m f34 eat 3m24 TR452a : ()					0	99.5mg				
tes	MXA	5.94mg	P<.0005	3.14mg	12.2mg	49/51	59/60			tes:iab,ica.	S
ski	MXA	16.9mg	P<.0005	5.27mg	53.2mg	4/51	21/60			ski:bca,ker,sqc,sqp,tri.	S
ski	MXA	21.7mg	P<.0005	5.14mg	99.9mg	1/51	12/60			ski:sqc,sqp.	S
---	mnl	22.5mg	P<.0005	9.89mg	69.4mg	27/51	25/60				S
pre	ade	22.8mg	P<.0005	5.68mg	215.mg	3/51	4/60				S
MXA	MXA	24.0mg	P<.0005	5.25mg	113.mg	0/51	13/60			pal:sqc,sqp; ton:sqp.	S
MXA	sqp	24.6mg	P<.0005	5.27mg	127.mg	0/51	12/60			pal:sqp; ton:sqp.	S
---	msm	28.4mg	P<.0005	12.4mg	58.8mg	0/51	26/60				S
ton	sqp	30.8mg	P<.0005	5.38mg	446.mg	0/51	6/60				S
pre	MXA	39.0mg	P<.004	8.59mg	724.mg	5/51	4/60			pre:ade,car.	S
ski	ker	42.5mg	P<.0005	12.5mg	184.mg	3/51	10/60				S
ski	sqp	46.2mg	P<.0005	12.5mg	164.mg	1/51	11/60				S
lun	MXA	52.4mg	P<.0005	8.26mg	348.mg	1/51	7/60			lun:a/a,a/c.	S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ski MXA	64.6mg	P<.0005	21.9mg 229.mg	0/51	7/60			ski:bca,tri. S
lun a/a	73.1mg	P<.004	8.47mg 1.42gm	1/51	4/60			S
mgl fba	78.3mg	P<.0005	26.8mg 330.mg	0/51	5/60			S
ski bca	82.3mg	P<.0005	24.3mg 348.mg	0/51	6/60			S
thy MXA	82.6mg	P<.0005	28.4mg 273.mg	0/51	9/60			thy:fca,fcc. S
sub MXA	87.3mg	P<.0005	18.4mg 430.mg	2/51	10/60			sub:fbs,fib,sar. S
sub fib	111.mg	P<.003	20.2mg 1.06gm	2/51	7/60			S
pal sqp	115.mg	P<.0005	34.3mg 434.mg	0/51	7/60			S
thy fca	132.mg	P<.0005	41.9mg 495.mg	0/51	7/60			S
zym MXA	138.mg	P<.0005	64.3mg 412.mg	2/51	15/60			zym:ade,car,cnb. S
zym MXA	138.mg	P<.0005	64.3mg 412.mg	2/51	15/60			zym:car,cnb. S
MXA MXA	146.mg	P<.0005	61.1mg 377.mg	0/51	11/60			col:adp,car; rec:adp. S
MXA adp	152.mg	P<.0005	62.1mg 415.mg	0/51	10/60			col:adp; rec:adp. S
for sqp	217.mg	P<.0005 c	72.9mg 1.00gm	0/51	5/60			
ubl MXA	223.mg	P<.007	53.3mg 6.51gm	0/51	2/60			ubl:tcc,tpp. S
lun a/c	327.mg	P<.007	85.0mg 5.55gm	0/51	3/60			S
MXA MXA	363.mg	P<.003	130.mg 2.05gm	0/51	5/60			ilm:car; jej:adp,car. S
MXA car	445.mg	P<.006	143.mg 5.40gm	0/51	4/60			ilm:car; jej:car. S
pit pda	67.3mg	P<.03	14.5mg n.s.s.	7/51	5/60			S
pan ana	193.mg	P<.05	16.8mg n.s.s.	1/51	3/60			S
sev MXA h	453.mg	P<.03 c	91.5mg n.s.s.	0/51	2/60			sev:ade,car.
lun sqc	484.mg	P<.02	111.mg n.s.s.	0/51	3/60			S
sub MXA	654.mg	P<.02	188.mg n.s.s.	0/51	3/60			sub:fbs,sar. S
kid rua	970.mg	P<.1	158.mg n.s.s.	0/51	1/60			
eso sqp	no dre	P=1.	n.s.s. n.s.s.	0/51	0/60			
TBA MXB	6.25mg	P<.0005	3.31mg 12.9mg	51/51	60/60			
liv MXB	702.mg	P<.08	114.mg n.s.s.	0/51	1/60			liv:hpa,hpb,hpc.
737 R f sss eat 24m24 1642				0	5.00mg	100.mg		Keyes;jctx,7,77-98;1980
liv hph e	2.55gm *	P<.5 -	409.mg n.s.s.	3/48	0/50	3/50		
liv hpc e	no dre	P=1. -	49.1mg n.s.s.	1/48	0/50	0/50		
tba mix e	1.73gm *	P<1. -	23.6mg n.s.s.	47/50	49/50	48/50		
738 R m sss eat 24m24 1642				0	5.00mg	100.mg		
liv hph e	no dre	P=1. -	49.1mg n.s.s.	1/50	0/50	0/50		
liv hpc e	no dre	P=1. -	1.01gm n.s.s.	1/50	1/50	0/50		
tba mix e	no dre	P=1. -	74.9mg n.s.s.	39/50	40/50	39/50		
1,1-BIS(tert-BUTYLPEROXY)-3,3,5-TRIMETHYLCYCLOHEXANE 6731-36-8								
739 M f b6c eat 78w83 2127				0	305.mg	611.mg		Mitsui;fctx,31,929-933;1993
lun a/c	19.9gm *	P<1. -	3.25gm n.s.s.	0/50	1/50	0/50		
lun a/a	no dre	P=1. -	2.92gm n.s.s.	1/50	1/50	1/50		
liv tum	no dre	P=1. -	1.34gm n.s.s.	0/50	0/50	0/50		
tba tum	4.23gm *	P<.7 -	562.mg n.s.s.	19/50	18/50	21/50		
tba mal	9.31gm *	P<.9 -	721.mg n.s.s.	14/50	15/50	15/50		
740 M m b6c eat 78w83 2127				0	282.mg	564.mg		
liv hpa	1.49gm *	P<.3 -	428.mg n.s.s.	15/50	20/50	20/50		
lun a/a	no dre	P=1. -	2.25gm n.s.s.	1/50	2/50	1/50		
liv hpc	no dre	P=1. -	1.24gm n.s.s.	8/50	7/50	7/50		
lun a/c	no dre	P=1. -	758.mg n.s.s.	5/50	4/50	(0/50)		
tba tum	4.98gm *	P<.9 -	360.mg n.s.s.	29/50	30/50	30/50		
tba mal	no dre	P=1. -	1.10gm n.s.s.	22/50	16/50	15/50		
BIS(TRI-n-BUTYLTIN)OXIDE, TECHNICAL GRADE 56-35-9								
741 R f wis eat 25m25 1975				0	25.0ug	.250mg	2.50mg	Wester;fctx,28,179-196;1990/pers.comm.
amd phe e	1.79mg *	P<.0005	1.15mg 3.04mg	3/50	3/50	3/50	34/50	
pta tum e	3.73mg *	P<.03	1.53mg n.s.s.	22/50	32/50	22/50	35/50	
742 R m wis eat 25m25 1975				0	20.0ug	.200mg	2.00mg	
amd phe e	1.93mg *	P<.0005	1.06mg 5.03mg	16/50	13/50	14/50	33/50	
pta tum e	1.90mg *	P<.02	.774mg n.s.s.	34/50	39/50	29/50	43/50	
BIS(2-CHLORO-1-METHYLETHYL)ETHER, TECHNICAL GRADE 108-60-1								
743 M f b6c gav 24m25 TR239 :				0	67.5mg	139.mg		
lun MXA	311.mg *	P<.002 c	155.mg 1.45gm	1/50	4/50	10/50		lun:a/a,a/c.
lun a/a	381.mg *	P<.006 c	177.mg 4.88gm	1/50	4/50	8/50		
sto MXA h	1.65gm *	P<.05 a	498.mg n.s.s.	0/50	0/50	3/50		sto:sqc,sqp.
TBA MXB	231.mg *	P<.2	75.0mg n.s.s.	26/50	29/50	29/50		
liv MXB	no dre	P=1.	269.mg n.s.s.	7/50	7/50	5/50		liv:hpa,hpc,nnd.
lun MXB	311.mg *	P<.002	155.mg 1.45gm	1/50	4/50	10/50		lun:a/a,a/c.
744 M m b6c gav 24m24 TR239 :				0	68.8mg	140.mg		
liv MXA	138.mg *	P<.002 c	73.4mg 693.mg	13/50	23/50	27/50		liv:hpa,hpc.
liv hpc	229.mg *	P<.004 c	117.mg 1.61gm	6/50	13/50	17/50		
lun MXA	259.mg *	P<.02 c	121.mg n.s.s.	6/50	15/50	13/50		lun:a/a,a/c.
lun a/a	306.mg *	P<.03 c	138.mg n.s.s.	5/50	13/50	11/50		
TBA MXB	116.mg *	P<.02	55.0mg n.s.s.	30/50	38/50	40/50		
liv MXB	138.mg *	P<.002	73.4mg 693.mg	13/50	23/50	27/50		liv:hpa,hpc,nnd.
lun MXB	259.mg *	P<.02	121.mg n.s.s.	6/50	15/50	13/50		lun:a/a,a/c.
745 R f f34 gav 24m24 TR191 :				0	70.1mg	140.mg		
TBA MXB s	65.6mg /	P<.006 -	30.7mg 907.mg	39/50	32/50	15/50		
liv MXB s	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
746 R m f34 gav 24m24 TR191 :				0	70.7mg	141.mg		
TBA MXB s	101.mg /	P<.02 -	45.3mg n.s.s.	30/50	30/50	18/50		
liv MXB s	no dre	P=1.	366.mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
BIS-2-CHLOROETHYLETHER 111-44-4								
747 M f b6a orl 79w79 1227				0	41.3mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	88.4mg n.s.s.	0/15	0/18			
lun mix evx	no dre	P=1.	88.4mg n.s.s.	0/15	0/18			
tba mix evx	no dre	P=1.	53.7mg n.s.s.	1/15	1/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
748 M m b6a orl 79w79 1227					0	38.4mg			
liv hpt evx	20.2mg	P<.0005	+	9.25mg 56.1mg	0/18	9/17			
lun ade evx	no dre	P=1.		40.0mg n.s.s.	3/18	2/17			
tba mix evx	21.6mg	P<.01		8.80mg 1.09gm	3/18	10/17			
749 M f b6c orl 79w79 1227					0	41.3mg			
liv hpt evx	65.0mg	P<.02		22.4mg n.s.s.	0/18	4/18			
lun ade evx	no dre	P=1.		88.4mg n.s.s.	1/18	0/18			
tba mix evx	122.mg	P<.4		25.6mg n.s.s.	2/18	4/18			
750 M m b6c orl 79w79 1227					0	38.4mg			
liv hpt evx	8.19mg	P<.0005	+	3.46mg 27.6mg	3/15	14/16			
lun ade evx	no dre	P=1.		73.1mg n.s.s.	2/15	0/16			
tba mix evx	noTD50	P<.007		n.s.s. 12.7mg	5/15	16/16			
BIS-1,4-(CHLOROMETHOXY)BUTANE 13483-19-7									
751 M f hic ipj 81w81 582					0	.571mg			Van Duuren;canr,35,2553-2557;1975
abd sar	no dre	P=1.	-	2.14mg n.s.s.	0/30	0/30			
BIS-1,2-(CHLOROMETHOXY)ETHANE 13483-18-6									
752 M f hic ipj 78w78 582					0	1.71mg			Van Duuren;canr,35,2553-2557;1975
abd mix	4.62mg	P<.02	+	1.59mg n.s.s.	0/30	4/30			
BIS-1,6-(CHLOROMETHOXY)HEXANE 56894-92-9									
753 M f hic ipj 81w81 582					0	1.71mg			Van Duuren;canr,35,2553-2557;1975
abd sar	no dre	P=1.	-	6.43mg n.s.s.	0/30	0/30			
BIS-1,4-(CHLOROMETHOXY)-p-XYLENE 56894-91-8									
754 M f hic ipj 77w77 582					0	.571mg			Van Duuren;canr,35,2553-2557;1975
abd sar	3.11mg	P<.1	+	.765mg n.s.s.	0/30	2/30			
BIS-(CHLOROMETHYL)ETHER (BCME) 542-88-1									
755 M f hic ipj 60w60 582					0	.114mg			Van Duuren;canr,35,2553-2557;1975
abd sar	.182mg	P<.02	+	62.8ug n.s.s.	0/30	4/30			
756 M m hic inh 6m25 1086					0	295.ng	2.95ug	33.6ug	Leong;txap,58,269-281;1981
lun mix es	1.16mg *	P<.4	+	.253mg n.s.s.	10/157	7/138	3/143	10/144	
lun ade es	1.26mg *	P<.3	+	.291mg n.s.s.	6/157	4/138	2/143	7/144	
liv mix es	no dre	P=1.	-	1.17mg n.s.s.	4/157	1/138	0/143	0/144	
liv hpc es	no dre	P=1.	-	1.17mg n.s.s.	3/157	1/138	0/143	0/144	
757 R m sss inh 6m28 1086					0	52.8ng	528.ng	7.78ug	
nap ene e	3.57ug Z	P<.0005	+	2.63ug 4.90ug	0/104	0/105	0/103	96/103	
lun ade e	.196mg *	P<.002	+	67.7ug 1.09mg	0/104	0/105	0/103	4/103	
nap car e	.795mg *	P<.2	+	.129mg n.s.s.	0/104	0/105	0/103	1/103	
liv bht e	no dre	P=1.	-	.234mg n.s.s.	0/104	1/105	0/103	0/103	
tba mix e	2.34ug *	P<.0005		1.43ug 3.88ug	56/104	48/105	43/103	102/103	
BIS(2,3-DIBROMOPROPYL)PHOSPHATE, MAGNESIUM SALT 36711-31-6									
758 R f wis eat 52w52 2102m					0	4.00mg	20.0mg	100.mg	Takada;japt,11,323-331;1991/pers.comm.
liv mix ek	11.8mg *	P<.0005		4.84mg 36.2mg	0/8	0/8	1/8	7/8	
liv hpa ek	33.2mg *	P<.002		11.2mg 185.mg	0/8	0/8	0/8	4/8	
liv hpc ek	35.1mg *	P<.009		12.0mg 1.19gm	0/8	0/8	1/8	3/8	
for sqp ek	47.6mg *	P<.006		14.2mg 686.mg	0/8	0/8	0/8	3/8	
759 R f wis eat 78w78 2102n					0	4.00mg	20.0mg	100.mg	
liv mix ek	11.9mg *	P<.0005		4.87mg 34.9mg	0/8	1/8	3/8	8/8	
for mix ek	19.6mg *	P<.0005		7.79mg 58.3mg	0/8	0/8	1/8	8/8	
liv hpc ek	20.1mg *	P<.0005		8.06mg 64.1mg	0/8	1/8	0/8	8/8	
for sqp ek	34.5mg *	P<.0005		14.0mg 115.mg	0/8	0/8	1/8	6/8	
eso sqp ek	107.mg *	P<.006		32.0mg 1.54gm	0/8	0/8	0/8	3/8	
smi adc ek	107.mg *	P<.006		32.0mg 1.54gm	0/8	0/8	0/8	3/8	
ton sqp ek	107.mg *	P<.006		32.0mg 1.54gm	0/8	0/8	0/8	3/8	
liv hpa ek	20.6mg Z	P<.02		6.14mg n.s.s.	0/8	0/8	3/8	(0/8)	
for sqc ek	171.mg *	P<.03		41.8mg n.s.s.	0/8	0/8	0/8	2/8	
760 R f wis eat 22m23 2102o					0	4.00mg	20.0mg	100.mg	
liv mix ae	27.8mg *	P<.0005	+	14.7mg 65.0mg	1/16	2/16	8/16	14/16	
liv hpc ae	37.1mg *	P<.0005	+	20.3mg 74.5mg	0/16	0/16	6/16	13/16	
for mix ae	40.0mg *	P<.0005	+	21.7mg 81.6mg	0/16	0/16	5/16	13/16	
for sqp ae	60.3mg *	P<.0005	+	31.4mg 134.mg	0/16	0/16	3/16	11/16	
smi adc ae	179.mg *	P<.0005	+	72.7mg 644.mg	0/16	0/16	0/16	6/16	
eso sqp ae	394.mg *	P<.008	+	119.mg 8.01gm	0/16	0/16	0/16	3/16	
for sqc ae	301.mg *	P<.08	+	104.mg n.s.s.	0/16	0/16	2/16	2/16	
ton mix ae	301.mg *	P<.08		104.mg n.s.s.	0/16	0/16	2/16	2/16	
ton sqp ae	403.mg *	P<.05		122.mg n.s.s.	0/16	0/16	1/16	2/16	
kid mix ae	608.mg *	P<.03		149.mg n.s.s.	0/16	0/16	0/16	2/16	
kid rca ae	1.25gm *	P<.2		203.mg n.s.s.	0/16	0/16	0/16	1/16	
kid rcc ae	1.25gm *	P<.2		203.mg n.s.s.	0/16	0/16	0/16	1/16	
liv hpa ae	no dre	P=1.		189.mg n.s.s.	1/16	2/16	2/16	1/16	
ton sqc ae	no dre	P=1.		227.mg n.s.s.	0/16	0/16	1/16	0/16	
761 R m wis eat 52w52 2102m					0	3.20mg	16.0mg	80.0mg	
for mix ek	38.1mg *	P<.006		11.4mg 549.mg	0/8	0/8	0/8	3/8	
smi mix ek	38.1mg *	P<.006		11.4mg 549.mg	0/8	0/8	0/8	3/8	
for sqp ek	60.9mg *	P<.03		14.9mg n.s.s.	0/8	0/8	0/8	2/8	
smi adc ek	60.9mg *	P<.03		14.9mg n.s.s.	0/8	0/8	0/8	2/8	
for sqc ek	129.mg *	P<.2		21.0mg n.s.s.	0/8	0/8	0/8	1/8	
kid rcc ek	129.mg *	P<.2		21.0mg n.s.s.	0/8	0/8	0/8	1/8	
liv hpc ek	129.mg *	P<.2		21.0mg n.s.s.	0/8	0/8	0/8	1/8	
liv mix ek	129.mg *	P<.2		21.0mg n.s.s.	0/8	0/8	0/8	1/8	
smi ade ek	129.mg *	P<.2		21.0mg n.s.s.	0/8	0/8	0/8	1/8	
eso sqp ek	no dre	P=1.		1.06mg n.s.s.	0/8	0/8	0/8	0/8	
liv hpa ek	no dre	P=1.		1.06mg n.s.s.	0/8	0/8	0/8	0/8	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
762 R m wis eat 78w78 2102n	0	3.20mg	16.0mg		
eso sqp ek 16.5mg * P<.02 4.92mg n.s.s.	0/8	0/8	3/8		
liv hpa ek 28.3mg * P<.5 5.00mg n.s.s.	2/8	1/8	3/8		
for sqp ek 56.1mg * P<.2 9.11mg n.s.s.	0/8	0/8	1/8		
kid rca ek 56.1mg * P<.2 9.11mg n.s.s.	0/8	0/8	1/8		
ton sqc ek 56.1mg * P<.2 9.11mg n.s.s.	0/8	0/8	1/8		
763 R m wis eat 21m24 2102o	0	3.20mg	16.0mg	80.0mg	
kid mix ae 35.0mg Z P<.003 13.2mg 178.mg	0/16	0/16	5/16	(0/24)	
for mix ae 37.8mg * P<.0005 + 22.5mg 72.1mg	0/16	0/16	8/16	16/24	
for sqp ae 43.5mg * P<.0005 + 25.5mg 85.9mg	0/16	0/16	7/16	15/24	
kid rca ae 45.1mg Z P<.006 15.5mg 492.mg	0/16	0/16	4/16	(0/24)	
eso mix ae 45.1mg Z P<.006 + 15.5mg 492.mg	0/16	0/16	4/16	(2/24)	
smi adc ae 79.0mg * P<.0005 + 42.0mg 175.mg	0/16	0/16	2/16	12/24	
eso sqp ae 62.1mg Z P<.02 + 18.7mg n.s.s.	0/16	0/16	3/16	(2/24)	
for sqc ae 979.mg * P<.5 178.mg n.s.s.	0/16	0/16	1/16	1/24	
eso sqc ae no dre P=1. 274.mg n.s.s.	0/16	0/16	1/16	0/24	
kid rcc ae no dre P=1. 274.mg n.s.s.	0/16	0/16	1/16	0/24	
liv hpa ae no dre P=1. 236.mg n.s.s.	5/16	2/16	4/16	2/24	
liv hpc ae no dre P=1. 245.mg n.s.s.	1/16	2/16	2/16	1/24	
liv mix ae no dre P=1. 215.mg n.s.s.	6/16	4/16	6/16	3/24	
ton sqp ae no dre P=1. 274.mg n.s.s.	0/16	0/16	1/16	0/24	
1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE 76150-91-9					
764 R m f34 eat 72w72 2322	0	40.0mg			Diwan;carc,17,37-43;1996
liv hpa 112.mg P<.09 27.4mg n.s.s.	0/18	2/18			
4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE 33372-39-3					
765 R m sda eat 50w52 1390	0	19.2mg			Cohen;jnci,57,277-282;1976
smi sar e 3.14mg P<.0005 + 1.59mg 7.25mg	0/20	13/20			
smi lei e 3.60mg P<.0005 1.79mg 8.58mg	0/20	12/20			
mgl mix e 6.45mg P<.0005 + 2.88mg 20.4mg	0/20	8/20			
mgl adc e 11.5mg P<.007 + 4.32mg 132.mg	0/20	5/20			
tba mix e 1.10mg P<.0005 .452mg 2.52mg	0/20	19/20			
4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL)QUINAZOLINE 58139-47-2					
766 R f sda eat 46w66 1390	0	17.4mg			Cohen;jnci,57,277-282;1976
tba mix e 60.1mg P<.3 12.7mg n.s.s.	6/84	4/28			
BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM 23746-34-1					
767 M f b6a orl 79w79 1217	0	157.mg			Innes;ntis,1968/1969
liv hpt evx 298.mg P<.04 90.0mg n.s.s.	0/17	3/16			
lun ade evx 850.mg P<.6 124.mg n.s.s.	1/17	2/16			
tba mix evx 138.mg P<.04 49.5mg n.s.s.	2/17	7/16			
768 M m b6a orl 79w79 1217	0	146.mg			
liv hpt evx 41.5mg P<.0005 + 19.7mg 110.mg	1/18	13/17			
lun ade evx no dre P=1. 194.mg n.s.s.	2/18	1/17			
tba mix evx 45.6mg P<.0005 20.5mg 170.mg	3/18	13/17			
769 M f b6c orl 79w79 1217	0	157.mg			
liv hpt evx 56.4mg P<.0005 27.7mg 136.mg	0/16	12/18			
lun ade evx 1.08gm P<.3 176.mg n.s.s.	0/16	1/18			
tba mix evx 48.4mg P<.0005 23.9mg 113.mg	0/16	13/18			
770 M m b6c orl 79w79 1217	0	146.mg			
liv hpt evx 34.5mg P<.0005 + 16.2mg 82.7mg	0/16	13/16			
lun mix evx no dre P=1. 278.mg n.s.s.	0/16	0/16			
tba mix evx 27.8mg P<.0005 12.5mg 66.5mg	0/16	14/16			
BIS(2-HYDROXYPROPYL)AMINE 110-97-4					
771 R m wis eat 94w94 1914	0	400.mg			Yamamoto;carc,10,1607-1611;1989
liv hpc no dre P=1. - 1.35gm n.s.s.	0/20	0/20			
lun tum no dre P=1. - 1.35gm n.s.s.	0/20	0/20			
nas tum no dre P=1. - 1.35gm n.s.s.	0/20	0/20			
BISMUTH DIMETHYLDITHIOCARBAMATE (bismate) 21260-46-8					
772 M f b6a orl 76w76 1218	0	4.64mg			Innes;ntis,1968/1969
lun ade evx 26.3mg P<.6 - 3.66mg n.s.s.	1/17	2/17			
liv hpt evx no dre P=1. - 8.68mg n.s.s.	0/17	0/17			
tba mix evx no dre P=1. - 4.08mg n.s.s.	2/17	2/17			
773 M m b6a orl 76w76 1218	0	4.31mg			
lun ade evx no dre P=1. - 4.03mg n.s.s.	2/18	2/18			
liv hpt evx no dre P=1. - 5.10mg n.s.s.	1/18	1/18			
tba mix evx no dre P=1. - 3.39mg n.s.s.	3/18	3/18			
774 M f b6c orl 76w76 1218	0	4.64mg			
liv hpt evx no dre P=1. - 9.19mg n.s.s.	0/16	0/18			
lun mix evx no dre P=1. - 9.19mg n.s.s.	0/16	0/18			
tba tum evx no dre P=1. - 9.19mg n.s.s.	0/16	0/18			
775 M m b6c orl 76w76 1218	0	4.31mg			
lun ade evx 12.6mg P<.1 - 3.10mg n.s.s.	0/16	2/17			
liv agm evx 26.0mg P<.3 - 4.24mg n.s.s.	0/16	1/17			
tba mix evx 4.53mg P<.007 - 1.71mg 61.2mg	0/16	5/17			
BISMUTH OXYCHLORIDE 7787-59-9					
776 R b bdr eat 24m28 432	0	391.mg	802.mg	1.98gm	Preussmann;fctx,13,543-544;1975
mgl fba 150.gm * P<.8 - 11.9gm n.s.s.	2/60	2/40	1/40	2/40	
mgl car no dre P=1. - 2.55gm n.s.s.	1/60	0/40	0/40	0/40	
hpl ade no dre P=1. - 22.0gm n.s.s.	2/60	0/40	0/40	1/40	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
BISPHENOL A (4,4'-isopropylidenediphenol) 80-05-7									
777 M f b6c eat 24m25 TR215 :				0	626.mg	1.25gm			
TBA MXB	no dre	P=1.	- 2.27gm n.s.s.	21/50	17/50	19/50			
liv MXB	13.1gm *	P<.05	4.53gm n.s.s.	0/50	1/50	3/50		liv:hpa,hpc,nnd.	
lun MXB	41.4gm *	P<.6	6.29gm n.s.s.	1/50	1/50	2/50		lun:a/a,a/c.	
778 M m b6c eat 24m25 TR215 :				0	116.mg	578.mg			
--- MXA #	445.mg \	P<.03	- 179.mg n.s.s.	2/50	9/50	(5/50)		---:leu,lym.	S
--- lym	508.mg \	P<.05	192.mg n.s.s.	2/50	8/50	(3/50)			S
pit crc	6.69gm *	P<.02	2.02gm n.s.s.	0/50	0/50	3/50			S
TBA MXB	1.32kg	P=1.	701.mg n.s.s.	23/50	28/50	24/50			
liv MXB	no dre	P=1.	1.61gm n.s.s.	16/50	14/50	10/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	2.31gm n.s.s.	7/50	2/50	4/50		lun:a/a,a/c.	
779 R f f34 eat 24m25 TR215 :				0	47.7mg	95.4mg			
TBA MXB	no dre	P=1.	- 115.mg n.s.s.	47/50	45/50	38/50			
liv MXB	595.mg \	P<.6	103.mg n.s.s.	4/50	6/50	(0/50)		liv:hpa,hpc,nnd.	
780 R m f34 eat 24m25 TR215 :				0	38.1mg	76.3mg			
mgl fba #	675.mg *	P<.03	- 231.mg n.s.s.	0/50	0/50	4/50			S
TBA MXB	no dre	P=1.	54.1mg n.s.s.	39/50	43/50	44/50			
liv MXB	no dre	P=1.	256.mg n.s.s.	4/50	7/50	2/50		liv:hpa,hpc,nnd.	
BLACK PN (brilliant black BN) 2519-30-4									
781 M f cws eat 80w80 378				0	130.mg	325.mg	650.mg	1.30gm	Drake;fctx,15,503-508;1977
liv tum e	no dre	P=1.	- 262.mg n.s.s.	0/58	0/28	0/28	0/28	0/29	
lun ade e	no dre	P=1.	- 2.00gm n.s.s.	14/58	6/28	3/28	5/28	6/29	
782 M m cws eat 80w80 378				0	120.mg	300.mg	600.mg	1.20gm	
lun ade e	3.66gm *	P<.3	- 1.02gm n.s.s.	9/54	1/27	8/28	5/26	7/29	
liv tum e	no dre	P=1.	- 234.mg n.s.s.	0/54	0/27	0/28	0/26	0/29	
783 R f cfe eat 24m24 1321				0	50.0mg	250.mg	500.mg		Gaunt;fctx,10,17-27;1972
liv tum es	no dre	P=1.	- 177.mg n.s.s.	0/22	0/22	0/23	0/24		
784 R m cfe eat 24m24 1321				0	40.0mg	200.mg	400.mg		
liv tum es	no dre	P=1.	- 144.mg n.s.s.	0/21	0/23	0/22	0/21		
C.I. DIRECT BLACK 38 1937-37-7									
785 M b icm wat 57w57 2147				0	526.mg				Asada;arjc,50,45-55;1981
liv hpt	71.6mg	P<.0005 +	48.0mg 111.mg	0/20	46/59				
mgl mix	262.mg	P<.0005 +	154.mg 603.mg	0/20	20/59				
tba mix	32.0mg	P<.0005	18.2mg 53.3mg	0/20	57/59				
786 R f f34 eat 13w13 TR108 : ()				0	9.50mg	18.7mg	37.5mg	75.0mg	150.mg
liv nnd	2.61mg *	P<.003 c	.992mg 14.8mg	0/10	0/10	0/10	0/10	5/10	0/10
TBA MXB	2.61mg *	P<.003	.992mg 14.8mg	0/10	0/10	0/10	0/10	5/10	0/10
liv MXB	2.61mg *	P<.003	.992mg 14.8mg	0/10	0/10	0/10	0/10	5/10	0/10 liv:hpa,hpc,nnd.
787 R m f34 eat 13w13 TR108 : ()				0	7.60mg	15.0mg	30.0mg	60.0mg	120.mg
liv MXA	.945mg Z	P<.0005 c	.438mg 2.58mg	0/10	0/10	0/10	0/10	9/10	(0/10) liv:hpc,nnd.
liv hpc	2.22mg *	P<.004	.755mg 10.1mg	0/10	0/10	0/10	0/10	4/10	0/10 S
TBA MXB	.945mg Z	P<.0005	.438mg 2.58mg	0/10	0/10	0/10	0/10	9/10	(0/10)
liv MXB	.945mg Z	P<.0005	.438mg 2.58mg	0/10	0/10	0/10	0/10	9/10	(0/10) liv:hpa,hpc,nnd.
C.I. DIRECT BLUE 6 2602-46-2									
788 R f f34 eat 13w13 TR108 : ()				0	9.50mg	18.7mg	37.5mg	75.0mg	150.mg
liv MXA	3.21mg Z	P<.0005 c	1.37mg 10.2mg	0/10	0/10	0/10	0/10	0/10	7/10 liv:hpc,nnd.
liv hpc	5.97mg *	P<.003	2.05mg 37.3mg	0/10	0/10	0/10	0/10	0/10	4/10 S
TBA MXB	3.21mg Z	P<.0005	1.37mg 10.2mg	0/10	0/10	0/10	0/10	0/10	7/10
liv MXB	3.21mg Z	P<.0005	1.37mg 10.2mg	0/10	0/10	0/10	0/10	0/10	7/10 liv:hpa,hpc,nnd.
789 R m f34 eat 13w13 TR108 : ()				0	7.60mg	15.0mg	30.0mg	60.0mg	120.mg
liv MXA	1.18mg Z	P<.0005 c	.532mg 3.59mg	0/10	0/10	0/10	0/10	8/10	(1/10) liv:hpc,nnd.
TBA MXB	1.18mg Z	P<.0005	.532mg 3.59mg	0/10	0/10	0/10	0/10	8/10	(1/10)
liv MXB	1.18mg Z	P<.0005	.532mg 3.59mg	0/10	0/10	0/10	0/10	8/10	(1/10) liv:hpa,hpc,nnd.
C.I. DIRECT BLUE 15 2429-74-5									
790 R f f34 wat 96w97 TR397 :				0	35.5mg	70.3mg	141.mg		
MXB MXB	21.3mg *	P<.0005	15.1mg 32.5mg	16/50	24/35	59/65	45/50	asc:adp; cli:ade,anb,car,cnb; col:adp; dsc:adp; duo:muc; jej:adc,muc; liv:hpc,nnd; mul:mnl; pal:sqc,sqp; ski:sqc,sqp; ton:sqc,sqp; ute:adc,ade; zym: ade,car.	C
cli MXA	46.2mg *	P<.0005 c	30.2mg 80.1mg	7/50	11/35	24/65	27/50	cli:ade,anb,car,cnb.	
mul mnl	50.0mg *	P<.0005 c	31.1mg 101.mg	7/50	13/35	27/65	15/50		
MXA MXA	81.0mg *	P<.0005 c	49.7mg 151.mg	2/50	4/35	19/65	15/50	pal:sqc,sqp; ton:sqc,sqp.	
cli MXA	90.1mg *	P<.0005	50.0mg 226.mg	5/50	5/35	12/65	12/50	cli:ade,anb.	S
zym MXA	104.mg *	P<.0005 c	63.4mg 178.mg	0/50	4/35	11/65	17/50	zym:ade,car.	
cli MXA	107.mg *	P<.0005	62.4mg 229.mg	2/50	6/35	12/65	15/50	cli:car,cnb.	S
ute MXA	122.mg *	P<.004	56.8mg 1.06gm	6/50	8/35	13/65	7/50	ute:esp,ess.	S
ute esp	132.mg *	P<.008	59.3mg 3.45gm	5/50	8/35	12/65	5/50		S
MXA sqp	132.mg *	P<.0005	71.2mg 344.mg	2/50	3/35	12/65	9/50	pal:sqp; ton:sqp.	S
zym car	150.mg *	P<.0005	85.9mg 278.mg	0/50	4/35	7/65	14/50		S
pal sqp	157.mg *	P<.0005	86.9mg 317.mg	0/50	2/35	11/65	7/50		S
ski MXA	158.mg *	P<.0005 c	79.8mg 377.mg	0/50	2/35	6/65	5/50	ski:sqc,sqp.	
ski sqp	174.mg *	P<.0005	85.6mg 442.mg	0/50	2/35	5/65	5/50		S
MXA sqc	208.mg *	P<.0005	105.mg 484.mg	0/50	1/35	8/65	6/50	pal:sqc; ton:sqc.	S
ton MXA	238.mg *	P<.002	103.mg 1.38gm	2/50	2/35	4/65	7/50	ton:sqc,sqp.	S
zym ade	321.mg *	P<.002	135.mg 1.48gm	0/50	1/35	5/65	3/50		S
ton sqc	384.mg *	P<.003	151.mg 2.35gm	0/50	1/35	3/65	3/50		S
liv MXA	394.mg *	P<.0005 c	154.mg 1.43gm	0/50	0/35	2/65	5/50	liv:hpc,nnd.	
liv nnd	429.mg *	P<.002	159.mg 1.92gm	0/50	0/35	2/65	4/50		S
pal sqc	456.mg *	P<.003	186.mg 2.33gm	0/50	0/35	5/65	3/50		S
MXA adp	491.mg *	P<.02 c	164.mg n.s.s.	0/50	0/35	3/65	1/50	asc:adp; col:adp; dsc:adp.	
ute MXA	493.mg Z	P<.02 c	162.mg n.s.s.	1/50	0/35	1/65	4/50	ute:adc,ade.	
MXA MXA	997.mg *	P<.02 c	321.mg n.s.s.	0/50	0/35	1/65	3/50	duo:muc; jej:adc,muc.	
jej MXA	1.18gm *	P<.02	340.mg n.s.s.	0/50	0/35	0/65	3/50	jej:adc,muc.	S
TBA MXB	20.4mg *	P<.0005	13.5mg 36.2mg	43/50	33/35	64/65	49/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB	394.mg *	P<.0005		154.mg 1.43gm	0/50	0/35	2/65	5/50	liv:hpa,hpc,nnd.
791 R m f34 wat 97w97 TR397 :					0	31.5mg	61.7mg	124.mg	
MXB MXB	11.8mg *	P<.0005		8.18mg 18.0mg	14/50	27/35	59/65	45/50	asc:adp; col:adc,adp; dsc:adp; jej:adc,adp,muc; liv:hpc,nnd; pal:sqp; phr:sqc; pre:ade,anb,car,cnb; ski:bca,bcc,sea,sqc,sqp; ton:sqc,sqp; zym:ade, car. C
tes MXA	12.9mg *	P<.0005		8.38mg 23.1mg	48/50	32/35	61/65	43/50	tes:iab,ica. S
ski MXA	18.1mg Z	P<.0005		12.2mg 28.2mg	2/50	10/35	29/65	28/50	ski:bca,bcc,sea. S
ski MXA	19.6mg Z	P<.0005	c	13.1mg 30.8mg	2/50	9/35	27/65	28/50	ski:bca,bcc.
ski bca	21.6mg Z	P<.0005		14.0mg 35.3mg	2/50	8/35	23/65	26/50	S
mul mnl	23.0mg *	P<.0005	e	13.7mg 46.5mg	17/50	19/35	28/65	20/50	
amd MXA	36.6mg Z	P<.0005		20.7mg 84.2mg	16/50	5/35	21/65	17/50	amd:pbb,phc,phm,pob. S
MXA MXA	39.3mg *	P<.0005	c	24.9mg 65.4mg	1/50	10/35	24/65	17/50	pal:sqp; phr:sqc; ton:sqc,sqp.
amd MXA	39.8mg Z	P<.0005		22.1mg 95.2mg	16/50	5/35	19/65	17/50	amd:pbb,pob. S
MXA sqp	43.6mg *	P<.0005		27.0mg 71.6mg	0/50	9/35	18/65	15/50	pal:sqp; ton:sqp. S
pal sqp	47.0mg *	P<.0005		29.0mg 77.1mg	0/50	9/35	17/65	15/50	S
thy fca	49.7mg Z	P<.002		15.1mg 310.mg	0/50	4/35	(1/65	0/50)	S
ski MXA	51.0mg Z	P<.0005	c	29.3mg 97.2mg	2/50	4/35	11/65	19/50	ski:sqc,sqp.
liv MXA	55.2mg *	P<.0005	c	31.4mg 102.mg	0/50	6/35	9/65	11/50	liv:hpc,nnd.
pre MXA	55.3mg *	P<.0005	c	29.8mg 148.mg	8/50	5/35	23/65	9/50	pre:ade,anb,car,cnb.
liv nnd	65.3mg *	P<.0005		34.9mg 133.mg	0/50	6/35	8/65	7/50	S
pre MXA	77.1mg *	P<.0005		36.9mg 267.mg	6/50	2/35	12/65	8/50	pre:ade,anb. S
zym MXA	89.2mg *	P<.0005	c	51.3mg 166.mg	1/50	5/35	10/65	20/50	zym:ade,car.
ski sqc	89.7mg Z	P<.0005		45.3mg 178.mg	0/50	1/35	7/65	13/50	S
ski sqp	92.8mg *	P<.0005		42.9mg 293.mg	2/50	3/35	5/65	8/50	S
ski bcc	101.mg Z	P<.0005		50.5mg 213.mg	0/50	2/35	4/65	10/50	S
thy MXA	103.mg Z	P<.002		41.8mg 464.mg	0/50	4/35	4/65	(0/50)	thy:fca,fcc. S
ski sea	108.mg *	P<.0005	c	50.7mg 279.mg	0/50	1/35	7/65	3/50	
sub MXA	131.mg *	P<.003		53.4mg 994.mg	2/50	3/35	5/65	4/50	sub:fib,sar. S
zym car	132.mg *	P<.0005		73.7mg 267.mg	1/50	3/35	8/65	17/50	S
sub fib	150.mg *	P<.007		57.0mg 2.72gm	2/50	2/35	5/65	3/50	S
ski ker	152.mg *	P<.006		60.6mg 2.32gm	2/50	1/35	7/65	2/50	S
MXA MXA	162.mg *	P<.0005	c	84.3mg 359.mg	0/50	1/35	6/65	8/50	asc:adp; col:adc,adp; dsc:adp.
zym ade	237.mg *	P<.002		88.4mg 1.09gm	0/50	2/35	2/65	4/50	S
MXA adp	310.mg *	P<.0005		131.mg 1.16gm	0/50	1/35	2/65	5/50	asc:adp; col:adp; dsc:adp. S
col adc	355.mg *	P<.002		144.mg 1.66gm	0/50	0/35	4/65	3/50	S
liv hpc	375.mg *	P<.002		129.mg 1.87gm	0/50	0/35	1/65	4/50	S
thy MXA	116.mg *	P<.03		44.4mg n.s.s.	8/50	9/35	9/65	5/50	thy:cca,ccb,ccr,cdb. S
thy MXA	143.mg *	P<.04		52.4mg n.s.s.	5/50	8/35	7/65	4/50	thy:cca,cdb. S
pre MXA	207.mg *	P<.05		79.1mg n.s.s.	2/50	3/35	11/65	1/50	pre:car,cnb. S
thy fcc	331.mg *	P<.04		85.4mg n.s.s.	0/50	0/35	3/65	0/50	S
MXA sqc	361.mg *	P<.04		117.mg n.s.s.	1/50	1/35	6/65	2/50	phr:sqc; ton:sqc. S
ton MXA	371.mg *	P<.02		108.mg n.s.s.	0/50	1/35	3/65	2/50	ton:sqc,sqp. S
phr sqc	466.mg *	P<.05		130.mg n.s.s.	1/50	0/35	4/65	2/50	S
MXA asl	600.mg *	P<.03	e	188.mg n.s.s.	0/50	1/35	1/65	2/50	bmd:asl; crb:asl.
jej MXA	1.63gm *	P<.2	c	484.mg n.s.s.	0/50	1/35	0/65	2/50	jej:adc,adp,muc.
TBA MXB	12.0mg *	P<.0005		8.00mg 20.0mg	38/50	34/35	63/65	48/50	
liv MXB	55.2mg *	P<.0005		31.4mg 102.mg	0/50	6/35	9/65	11/50	liv:hpa,hpc,nnd.
C.I. DIRECT BLUE 218 28407-37-6									
792 M f b6c eat 24m25 TR430 :					0	126.mg	379.mg	1.26gm	
liv MXA	711.mg Z	P<.0005	c	433.mg 1.51gm	10/50	15/50	21/50	45/50	liv:hpa,hpc.
liv hpa	774.mg *	P<.0005	c	480.mg 1.57gm	7/50	12/50	17/50	41/50	
liv MXA	4.00gm *	P<.03		1.65gm n.s.s.	5/50	5/50	6/50	13/50	liv:hpb,hpc. S
liv hpc	4.57gm *	P<.04	c	1.76gm n.s.s.	5/50	5/50	6/50	12/50	
TBA MXB	1.53gm *	P<.05		617.mg n.s.s.	29/50	35/50	34/50	46/50	
liv MXB	711.mg Z	P<.0005		433.mg 1.51gm	10/50	15/50	21/50	45/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		8.17gm n.s.s.	5/50	7/50	4/50	1/50	lun:a/a,a/c.
793 M m b6c eat 24m24 TR430 :					0	117.mg	352.mg	1.17gm	
liv MXA	1.08gm *	P<.0005	c	571.mg 4.17gm	21/51	20/50	23/50	45/50	liv:hpa,hpc.
liv hpa	1.21gm *	P<.0005	c	639.mg 4.52gm	16/51	19/50	17/50	40/50	
liv hpc	2.99gm *	P<.004	c	1.41gm 25.6gm	7/51	3/50	8/50	17/50	
jej car	20.3gm *	P<.2	e	5.31gm n.s.s.	1/51	0/50	0/50	3/50	
kid rua	195.gm *	P<.9	e	5.67gm n.s.s.	0/51	2/50	1/50	1/50	
kid ruc	no dre	P=1.	e	11.1gm n.s.s.	0/51	1/50	0/50	0/50	
kid MXA	no dre	P=1.	e	6.22gm n.s.s.	0/51	3/50	1/50	1/50	kid:rua,ruc.
TBA MXB	1.91gm *	P<.1		694.mg n.s.s.	31/51	37/50	28/50	46/50	
liv MXB	1.08gm *	P<.0005		571.mg 4.17gm	21/51	20/50	23/50	45/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		6.02gm n.s.s.	14/51	12/50	9/50	5/50	lun:a/a,a/c.
794 R f f34 eat 24m24 TR430 :					0	49.2mg	148.mg	495.mg	
ute esp #	83.5mg Z	P<.0005	-	40.9mg 302.mg	1/51	12/51	(10/50	10/50)	S
TBA MXB	653.mg *	P<.3		192.mg n.s.s.	45/51	46/51	46/50	45/50	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/51	0/51	0/50	0/50	liv:hpa,hpb,hpc.
795 R m f34 eat 24m24 TR430 :					0	39.4mg	119.mg	396.mg	
pal MXB	1.38gm *	P<.0005		592.mg 4.46gm	0/50	0/50	0/50	7/51	pal:bsb,sqc,sqp. P
pal MXA	1.57gm *	P<.0005	p	636.mg 5.84gm	0/50	0/50	0/50	6/51	pal:sqc,sqp.
pal sqp	1.92gm *	P<.002	p	726.mg 8.98gm	0/50	0/50	0/50	5/51	
for MXA	2.35gm *	P<.2	e	811.mg n.s.s.	0/50	0/50	3/50	1/51	for:sqc,sqp.
for sqp	3.14gm *	P<.2	e	952.mg n.s.s.	0/50	0/50	2/50	1/51	
pal sqc	9.51gm *	P<.2	p	1.55gm n.s.s.	0/50	0/50	0/50	1/51	
pal bsb	11.5gm *	P<.2	p	1.88gm n.s.s.	0/50	0/50	0/50	1/51	
for sqc	no dre	P=1.	e	1.59gm n.s.s.	0/50	0/50	1/50	0/51	
TBA MXB	921.mg *	P<.5		192.mg n.s.s.	44/50	42/50	45/50	44/51	
liv MXB	5.05gm *	P<.6		713.mg n.s.s.	5/50	6/50	2/50	6/51	liv:hpa,hpb,hpc.
C.I. DISPERSE BLUE 1 2475-45-8									
796 M f b6c eat 24m25 TR299 :					0	76.5mg	153.mg	319.mg	
liv hpa #	150.mg Z	P<.01	-	67.2mg 19.8gm	2/50	12/50	(3/50	2/50)	S
TBA MXB	no dre	P=1.		275.mg n.s.s.	29/50	33/50	33/50	30/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
liv MXB	no dre	P=1.	904.mg n.s.s.	3/50	13/50	3/50	4/50	liv:hpa,hpc,nnd.	
lun MXB	9.31gm *	P<.8	791.mg n.s.s.	1/50	5/50	2/50	3/50	lun:a/a,a/c.	
797 M m b6c eat 24m24 TR299 :				0	71.3mg	143.mg	297.mg		
lun a/a	925.mg *	P<.05	386.mg n.s.s.	1/50	3/50	5/50	5/50		S
liv MXA	534.mg *	P<.2 e	187.mg n.s.s.	9/50	21/50	20/50	16/50	liv:hpa,hpc.	
TBA MXB	1.29gm Z	P<.7	164.mg n.s.s.	35/50	44/50	34/50	34/50		
liv MXB	534.mg *	P<.2	187.mg n.s.s.	9/50	21/50	20/50	16/50	liv:hpa,hpc,nnd.	
lun MXB	701.mg *	P<.06	275.mg n.s.s.	4/50	9/50	5/50	11/50	lun:a/a,a/c.	
798 R f f34 eat 24m24 TR299 :				0	61.3mg	124.mg	248.mg		
ubl MXB	131.mg Z	P<.0005	92.4mg 192.mg	0/50	0/50	17/50	37/50	ubl:lei,ley,sqc,sqp,tcc,tpp.	C
ubl MXA	198.mg Z	P<.0005 c	131.mg 318.mg	0/50	0/50	15/50	21/50	ubl:tcc,tpp.	
ubl MXA	250.mg Z	P<.0005 c	158.mg 424.mg	0/50	0/50	3/50	26/50	ubl:lei,ley.	
ubl lei	294.mg Z	P<.0005 c	181.mg 520.mg	0/50	0/50	2/50	23/50		
ubl tcc	307.mg Z	P<.0005 c	186.mg 559.mg	0/50	0/50	10/50	13/50		
ubl tpp	317.mg Z	P<.0005 c	192.mg 571.mg	0/50	0/50	9/50	15/50		
ubl MXA	664.mg Z	P<.0005 c	338.mg 1.55gm	0/50	0/50	1/50	11/50	ubl:sqc,sqp.	
ubl sqp	1.02gm Z	P<.0005 c	454.mg 3.15gm	0/50	0/50	1/50	7/50		
ubl ley	1.54gm *	P<.004 c	579.mg 10.3gm	0/50	0/50	1/50	4/50		
ubl sqc	1.58gm *	P<.004 c	599.mg 10.9gm	0/50	0/50	1/50	4/50		
pni isc	291.mg *	P<.02	135.mg n.s.s.	10/50	21/50	20/50	15/50		S
MXA MXA	323.mg *	P<.03	139.mg n.s.s.	12/50	24/50	20/50	16/50	pit:can; pni:isc.	S
TBA MXB	130.mg *	P<.005	65.7mg 1.28gm	44/50	41/50	45/50	43/50		
liv MXB	no dre	P=1.	1.04gm n.s.s.	1/50	0/50	2/50	0/50	liv:hpa,hpc,nnd.	
799 R m f34 eat 24m24 TR299 :				0	49.3mg	99.0mg	198.mg		
ubl MXB	89.3mg Z	P<.0005	63.0mg 130.mg	0/50	0/50	17/50	45/50	ubl:lei,ley,sqc,sqp,tcc,tpp.	C
ubl MXA	129.mg Z	P<.0005 c	86.9mg 196.mg	0/50	0/50	7/50	41/50	ubl:lei,ley.	
ubl lei	131.mg Z	P<.0005 c	88.0mg 200.mg	0/50	0/50	6/50	41/50		
ubl MXA	245.mg Z	P<.0005 c	141.mg 463.mg	0/50	0/50	10/50	11/50	ubl:tcc,tpp.	
ubl tpp	370.mg *	P<.0005 c	183.mg 910.mg	0/50	0/50	8/50	4/50		
pni MXA	414.mg *	P<.005	178.mg 4.62gm	1/50	2/50	5/50	3/50	pni:isa,isc.	S
ubl tcc	506.mg Z	P<.0005 c	249.mg 1.18gm	0/50	0/50	4/50	8/50		
ubl MXA	803.mg *	P<.002 c	311.mg 3.41gm	0/50	0/50	2/50	4/50	ubl:sqc,sqp.	
ubl sqp	1.26gm *	P<.006 c	401.mg 15.0gm	0/50	0/50	1/50	3/50		
sub srn	1.83gm Z	P<.01	548.mg 99.7gm	0/50	0/50	0/50	3/50		S
tes ict	100.mg *	P<.05	41.2mg n.s.s.	44/50	44/50	38/50	16/50		S
thy MXA	474.mg *	P<.03	187.mg n.s.s.	2/50	4/50	5/50	3/50	thy:cca,ccr.	S
thy cca	529.mg *	P<.02	213.mg n.s.s.	1/50	2/50	4/50	3/50		S
pni isa	810.mg *	P<.03	278.mg n.s.s.	1/50	0/50	4/50	2/50		S
TBA MXB	39.3mg Z	P<.0005	24.9mg 79.8mg	49/50	49/50	47/50	46/50		
liv MXB	no dre	P=1.	540.mg n.s.s.	4/50	2/50	2/50	0/50	liv:hpa,hpc,nnd.	

FD & C BLUE NO. 1 (brilliant blue FCF) 3844-45-9

800 M f cd1 eat 24m24 1976				0	650.mg	1.95gm	6.50gm	Borzelleca;fctx,28,221-234;1990	
lun adc e	372.gm *	P<.2 -	60.6gm n.s.s.	0/120	0/60	0/60	1/60		
lun alc e	607.gm *	P<.6 -	64.1gm n.s.s.	1/120	0/60	0/60	1/60		
lun bcd e	856.gm *	P<.8 -	58.1gm n.s.s.	1/120	1/60	0/60	1/60		
liv hem e	no dre	P=1. -	73.5gm n.s.s.	1/120	1/60	1/60	0/60		
lun ala e	no dre	P=1. -	93.1gm n.s.s.	5/120	1/60	1/60	0/60		
lun bde e	no dre	P=1. -	5.61gm n.s.s.	2/120	0/60	0/60	0/60		
801 M m cd1 eat 24m24 1976				0	600.mg	1.80gm	6.00gm		
lun bcd e	91.1gm *	P<.08 -	29.4gm n.s.s.	0/120	1/60	1/60	2/60		
lun adc e	293.gm *	P<.4 -	43.6gm n.s.s.	0/120	1/60	0/60	1/60		
lun bde e	343.gm *	P<.2 -	55.9gm n.s.s.	0/120	0/60	0/60	1/60		
liv hpc e	no dre	P=1. -	47.9gm n.s.s.	8/120	2/60	3/60	2/60		
lun agc e	no dre	P=1. -	5.18gm n.s.s.	1/120	0/60	0/60	0/60		
lun ala e	no dre	P=1. -	53.3gm n.s.s.	4/120	0/60	2/60	1/60		
lun alc e	no dre	P=1. -	5.18gm n.s.s.	1/120	0/60	0/60	0/60		
liv hes e	no dre	P=1. -	5.18gm n.s.s.	3/120	0/60	0/60	0/60		
802 R b osm eat 24m24 415				0	225.mg	450.mg	900.mg	2.25gm	Hansen;txap,8,29-36;1966
liv hpt	62.1gm *	P<.2	10.1gm n.s.s.	0/24	0/24	0/24	0/24	1/24	
tba mix	no dre	P=1. -	3.75gm n.s.s.	7/24	10/24	7/24	9/24	6/24	

FD & C BLUE NO. 2 (indigo carmine) 860-22-0

803 M f cd1 eat 84w84 411				0	260.mg	520.mg	1.04gm	2.08gm	Hooson;fctx,13,167-176;1975
liv nod es	no dre	P=1. -	432.mg n.s.s.	0/50	0/28	0/19	0/18	0/25	
lun ade es	no dre	P=1. -	6.04gm n.s.s.	3/50	0/28	0/19	1/18	1/25	
804 M m cd1 eat 84w84 411				0	240.mg	480.mg	960.mg	1.92gm	
liv nod es	20.2gm *	P<.4 -	3.49gm n.s.s.	1/42	1/23	1/17	0/18	2/24	
lun ade es	no dre	P=1. -	4.04gm n.s.s.	3/42	7/23	0/17	1/18	2/24	
805 M f cdr eat 23m23 1698				0	650.mg	1.95gm	6.50gm		Borzelleca;fctx,23,719-722;1985
tba mal e	33.9gm *	P<.3 -	9.55gm n.s.s.	30/120	15/57	15/48	20/60		
tba mix e	no dre	P=1. -	14.1gm n.s.s.	50/120	20/57	20/48	22/60		
806 M m cdr eat 95w95 1698				0	600.mg	1.80gm	6.00gm		
tba mix e	23.4gm *	P<.2 -	7.54gm n.s.s.	26/119	13/55	19/58	19/60		
tba mal e	57.1gm *	P<.5 -	11.0gm n.s.s.	22/119	8/55	16/58	13/60		
807 R b osm eat 24m24 415				0	225.mg	450.mg	900.mg	2.25gm	Hansen;txap,8,29-36;1966
tba mix	5.43gm *	P<.06 -	1.98gm n.s.s.	6/24	5/24	5/24	4/24	11/24	

HC BLUE NO. 1 2784-94-3

808 M f b6c eat 24m24 TR271 :				0	379.mg	765.mg		
liv MXA	179.mg *	P<.0005	129.mg 274.mg	3/50	33/50	47/50		liv:hpa,hpc.	S
liv hpc	208.mg *	P<.0005 c	150.mg 304.mg	1/50	24/50	47/50			
liv hpa	697.mg \	P<.004	314.mg 4.97gm	2/50	11/50	(4/50)			S
TBA MXB	373.mg *	P<.002	199.mg 1.72gm	29/50	35/50	47/50			
liv MXB	179.mg *	P<.0005	129.mg 274.mg	3/50	33/50	47/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	2.59gm n.s.s.	4/50	2/50	2/50		lun:a/a,a/c.	
809 M f b6c eat 9m23 1860m				0	151.mg			Burnett;fctx,25,703-707;1987/pers.comm.	
liv mix er	41.3mg	P<.0005 +	19.7mg 91.7mg	3/38	20/22				

Chemical / Spe Strain Xpo+Xpt / Sex Route Paper Num	Synonym	CAS number	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
Site Notes / Path	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
liv hpc er	114.mg	P<.0005 +	56.4mg 302.mg	2/38	13/22			
liv hpa er	165.mg	P<.0005	77.2mg 499.mg	1/38	10/22			
810 M f b6c eat 15m23 1860n				0	252.mg			
liv mix er	81.5mg	P<.0005 +	41.2mg 177.mg	3/38	20/23			
liv hpc er	94.0mg	P<.0005 +	48.9mg 201.mg	2/38	19/23			
liv hpa er	969.mg	P<.05	300.mg n.s.s.	1/38	4/23			
811 M f b6c eat 91w91 1860o				0	195.mg			
liv mix ekr	85.0mg	P<.0005 +	33.8mg 291.mg	0/10	7/10			
liv hpc ekr	148.mg	P<.004 +	54.2mg 1.03gm	0/10	5/10			
liv hpa ekr	287.mg	P<.04	85.8mg n.s.s.	0/10	3/10			
812 M f b6c eat 23m23 1860r				0	195.mg			
liv mix er	51.4mg	P<.0005 +	28.5mg 95.5mg	3/38	33/36			
liv hpc er	163.mg	P<.0005 +	91.4mg 358.mg	2/38	20/36			
liv hpa er	185.mg	P<.0005	103.mg 402.mg	1/38	18/36			
813 M f b6c eat 91w91 1860s				0	390.mg			
liv hpc ekr	noTD50	P<.0005 +	n.s.s. 162.mg	0/10	10/10			
liv mix ekr	noTD50	P<.0005 +	n.s.s. 162.mg	0/10	10/10			
liv hpa ekr	574.mg	P<.04	172.mg n.s.s.	0/10	3/10			
814 M f b6c eat 23m23 1860u				0	390.mg			
liv mix er	noTD50	P<.0005 +	n.s.s. 106.mg	3/38	36/36			
liv hpc er	87.1mg	P<.0005 +	45.8mg 163.mg	2/38	34/36			
liv hpa er	1.30gm	P<.02	515.mg n.s.s.	1/38	7/36			
815 M m b6c eat 24m24 TR271 :				0	176.mg	355.mg		
liv MXA	259.mg *	P<.002	142.mg 1.13gm	15/50	31/50	37/50		liv:hpa,hpc. S
liv hpa	286.mg \	P<.008	133.mg 6.59gm	4/50	17/50	(10/50)		S
MXB MXB	369.mg *	P<.002	202.mg 1.61gm	11/50	20/50	31/50		liv:hpc; thy:fca. C
liv hpc	389.mg *	P<.002 c	210.mg 1.95gm	11/50	20/50	30/50		
thy fca	2.23gm *	P<.008 c	846.mg 39.1gm	0/50	0/50	5/50		
TBA MXB	561.mg *	P<.3	165.mg n.s.s.	36/50	44/50	43/50		
liv MXB	259.mg *	P<.002	142.mg 1.13gm	15/50	31/50	37/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	1.12gm n.s.s.	5/50	6/50	3/50		lun:a/a,a/c.
816 R f f34 eat 24m24 TR271 :				0	72.9mg	148.mg		
ute esp	429.mg *	P<.05	185.mg n.s.s.	5/50	9/50	14/50		S
lun MXA	702.mg *	P<.03 p	299.mg n.s.s.	1/50	3/50	7/50		lun:a/a,a/c.
lun a/c	1.19gm *	P<.02 p	453.mg n.s.s.	0/50	1/50	4/50		
TBA MXB	no dre	P=1.	108.mg n.s.s.	45/50	43/50	45/50		
liv MXB	3.31gm *	P<.3	809.mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
817 R m f34 eat 24m24 TR271 :				0	58.3mg	118.mg		
liv MXA	938.mg *	P<.06 e	334.mg n.s.s.	1/50	0/50	6/50		liv:hpc,nnd.
liv nnd	1.66gm *	P<.05	499.mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	no dre	P=1.	117.mg n.s.s.	41/50	41/50	37/50		
liv MXB	938.mg *	P<.06	334.mg n.s.s.	1/50	0/50	6/50		liv:hpa,hpc,nnd.
HC BLUE NO. 1 (PURIFIED) 2784-94-3								
818 M f b6c eat 91w91 1860m				0	390.mg			Burnett;fctx,25,703-707;1987/pers.comm.
liv mix ekr	noTD50	P<.0005 +	n.s.s. 162.mg	0/10	10/10			
liv hpc ekr	88.9mg	P<.0005 +	31.2mg 277.mg	0/10	9/10			
liv hpa ekr	917.mg	P<.09	224.mg n.s.s.	0/10	2/10			
819 M f b6c eat 23m23 1860n				0	390.mg			
liv mix er	70.6mg	P<.0005 +	31.7mg 141.mg	3/38	35/36			
liv hpc er	115.mg	P<.0005 +	66.1mg 210.mg	2/38	32/36			
liv hpa er	530.mg	P<.0005	275.mg 1.41gm	1/38	14/36			
HC BLUE NO. 2 33229-34-4								
820 M f b6c eat 24m24 TR293 :				0	1.29gm	2.58gm		
TBA MXB s	42.0gm *	P<.9 -	2.24gm n.s.s.	31/50	19/50	22/50		
liv MXB s	19.0gm /	P<.4	4.32gm n.s.s.	7/50	1/50	8/50		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.	8.92gm n.s.s.	1/50	3/50	0/50		lun:a/a,a/c.
821 M m b6c eat 24m24 TR293 :				0	594.mg	1.19gm		
MXA MXA #	970.mg \	P<.02 -	416.mg n.s.s.	4/50	14/50	(9/50)		ski:fbs,fib; sub:fbs,fib. S
--- MXA	4.04gm *	P<.05	1.77gm n.s.s.	1/50	5/50	8/50		---:mlh,mlm,mlp. S
--- mlp	5.45gm *	P<.03	2.35gm n.s.s.	0/50	2/50	5/50		S
TBA MXB	5.02gm *	P<.7	777.mg n.s.s.	23/50	33/50	37/50		
liv MXB	6.55gm *	P<.6	1.18gm n.s.s.	10/50	16/50	18/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	2.44gm n.s.s.	5/50	9/50	6/50		lun:a/a,a/c.
822 R f f34 eat 24m24 TR293 :				0	495.mg	990.mg		
liv MXA #	8.15gm *	P<.04 -	3.08gm n.s.s.	0/50	2/50	3/50		liv:hpc,nnd. S
TBA MXB	3.13kg	P<1.	800.mg n.s.s.	43/50	36/50	41/50		
liv MXB	8.15gm *	P<.04	3.08gm n.s.s.	0/50	2/50	3/50		liv:hpa,hpc,nnd.
823 R m f34 eat 24m24 TR293 :				0	198.mg	396.mg		
thy ccr #	1.99gm *	P<.02 -	902.mg n.s.s.	0/50	3/50	5/50		S
TBA MXB	no dre	P=1.	302.mg n.s.s.	43/50	33/50	(32/50)		
liv MXB	20.3gm *	P<.7	2.26gm n.s.s.	1/50	0/50	2/50		liv:hpa,hpc,nnd.
GARDENIA BLUE COLOR 526194-45-6								
824 R f f3d eat 24m24 2508				0	1.25gm	2.50gm		Imazawa;fctx,38,313-318;2000
liv hpa e	no dre	P=1. -	15.7gm n.s.s.	1/50	2/50	1/50		
825 R m f3d eat 24m24 2508				0	1.00gm	2.00gm		
liv hpa e	no dre	P=1. -	13.1gm n.s.s.	2/50	1/50	2/50		
BORIC ACID 10043-35-3								
826 M f b6c eat 24m24 TR324 :				0	319.mg	638.mg		
TBA MXB	no dre	P=1. -	777.mg n.s.s.	25/50	27/50	26/50		
liv MXB	31.0gm *	P<.9	1.77gm n.s.s.	5/50	4/50	6/50		liv:hpa,hpc,nnd.
lun MXB	4.19gm *	P<.3	1.38gm n.s.s.	1/50	5/50	4/50		lun:a/a,a/c.
827 M m b6c eat 24m24 TR324 :				0	296.mg	591.mg		
liv MXA s#	638.mg *	P<.009 -	296.mg 27.8gm	14/50	19/50	15/50		liv:hpa,hpc. S
sub MXA s	706.mg \	P<.004	308.mg 5.24gm	2/50	10/50	(2/50)		sub:fbs,fib,nfs,srn. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
sub MXA s	1.07gm \	P<.009	425.mg 45.2gm	1/50	7/50	(2/50)			sub:fbs,nfs,srn. S
liv hpc s	1.12gm *	P<.02	500.mg n.s.s.	5/50	12/50	8/50			S
TBA MXB s	500.mg *	P<.03	218.mg n.s.s.	31/50	37/50	23/50			
liv MXB s	638.mg *	P<.009	296.mg 27.8gm	14/50	19/50	15/50			liv:hpa,hpc,nnd.
lun MXB s	38.6gm *	P<1.	799.mg n.s.s.	11/50	11/50	4/50			lun:a/a,a/c.
BROMATE, POTASSIUM 7758-01-2									
828 H m syg wat 89w89 2318				0	15.0mg	30.0mg	60.0mg	240.mg	Takamura;srtu,32,43-46;1985
kid rct h	533.mg *	P<.2 +	202.mg n.s.s.	0/20	0/20	1/20	4/20	2/20	
liv nnd	no dre	P=1.	577.mg n.s.s.	0/20	0/20	0/20	1/20	0/20	
tba mix	no dre	P=1.	196.mg n.s.s.	10/20	14/20	7/20	8/20	9/20	
829 M f b6c wat 18m24 1789				0	75.0mg	150.mg			Kurokawa;enhp,69,221-235;1986
liv ade e	1.18gm *	P<.05	480.mg n.s.s.	0/46	3/48	3/47			
lun mix e	1.05gm *	P<.2	369.mg n.s.s.	3/46	3/48	8/47			
liv mix e	1.71gm *	P<.4	449.mg n.s.s.	3/46	3/48	6/47			
lun ade e	2.03gm *	P<.3	549.mg n.s.s.	2/46	1/48	5/47			
tba mix e	477.mg *	P<.2	163.mg n.s.s.	15/46	16/48	22/47			
830 M m b6c wat 52w53 2348m				0	13.3mg	66.7mg	133.mg		DeAngelo;txpy,26,587-594;1998/pers.comm.
kid tum ek	no dre	P=1.	3.79mg n.s.s.	0/7	0/7	0/7	0/6		
831 M m b6c wat 78w78 2348n				0	13.3mg	66.7mg	133.mg		
kid tum ek	no dre	P=1.	8.07mg n.s.s.	0/7	0/7	0/7	0/5		
832 M m b6c wat 23m23 2348o :				0	13.3mg	66.7mg	133.mg		
kid mix	53.8mg Z	P<.008 +	20.4mg 861.mg	0/40	5/38	(3/41	1/44)		
kid rcc	92.5mg Z	P<.04	28.0mg n.s.s.	0/40	3/38	(1/41	0/44)		
833 M f the eat 80w80 719				0	6.50mg	9.75mg			Ginocchio;fctx,17,41-47;1979
liv hem e	347.mg *	P<.6 -	56.4mg n.s.s.	0/53	1/54	0/52			
834 M m the eat 80w80 719				0	6.00mg	9.00mg			
liv tum e	no dre	P=1. -	21.3mg n.s.s.	0/35	0/46	0/53			
tba mal e	no dre	P=1. -	63.9mg n.s.s.	1/35	1/46	0/53			
835 R f f34 wat 26m26 1550				0	14.2mg	28.3mg			Kurokawa;jnci,71,965-972;1983
kid mix e	13.7mg *	P<.0005 +	9.90mg 19.5mg	0/47	28/50	39/49			
kid adc e	16.4mg *	P<.0005	11.7mg 23.7mg	0/47	21/50	39/49			
kid ade e	87.5mg *	P<.0005	49.6mg 234.mg	0/47	8/50	9/49			
thy mix e	97.6mg *	P<.01	48.2mg 7.87gm	3/52	10/52	12/52			
liv mix e	no dre	P=1.	220.mg n.s.s.	2/52	1/52	2/52			
tba mix e	9.05mg *	P<.003	3.96mg 62.6mg	44/52	48/52	52/52			
836 R m f34 wat 26m26 1550				0	12.4mg	22.5mg			
kid mix ev	9.62mg *	P<.0005 +	6.93mg 13.9mg	3/53	32/53	46/52			
kid adc ev	12.6mg *	P<.0005	9.00mg 18.6mg	3/53	24/53	44/52			
per mso ev	25.3mg *	P<.0005 +	16.1mg 49.8mg	6/53	17/52	28/46			
kid ade ev	46.2mg \	P<.0005	22.5mg 124.mg	0/53	10/53	(5/52)			
liv mix ev	164.mg *	P<.2	62.8mg n.s.s.	2/53	7/53	6/52			
tba mix ev	noTD50	P=1.	n.s.s. n.s.s.	53/53	53/53	52/52			
837 R m f34 wat 52w52 2348m				0	1.00mg	5.00mg	10.0mg	20.0mg	DeAngelo;txpy,26,587-594;1998/pers.comm.
kid rca ek	16.7mg *	P<.04	4.09mg n.s.s.	0/6	0/6	0/6	0/6	2/6	
tnv mso ek	36.1mg *	P<.5	5.88mg n.s.s.	0/6	0/6	0/6	1/6	0/6	
838 R m f34 wat 77w77 2348n				0	1.00mg	5.00mg	10.0mg	20.0mg	
kid rca ek	15.3mg *	P<.003	5.18mg 98.3mg	0/6	0/6	0/6	0/5	4/6	
tnv mso ek	15.3mg *	P<.003	5.18mg 98.3mg	0/6	0/6	0/6	0/5	4/6	
thy mix ek	21.8mg *	P<.01	6.53mg 1.32gm	0/6	0/6	0/6	0/5	3/6	
thy fcc ek	34.8mg *	P<.04	8.51mg n.s.s.	0/6	0/6	0/6	0/5	2/6	
839 R m f34 wat 23m23 2348o :				0	1.00mg	5.00mg	10.0mg	20.0mg	
tnv mso as	11.1mg Z	P<.0005 +	7.49mg 17.8mg	0/47	4/49	5/48	9/47	27/43	
kid mix as	20.8mg Z	P<.0005 +	11.8mg 45.6mg	1/45	1/41	6/45	3/38	12/31	
thy mix as	22.2mg Z	P<.0005 +	12.2mg 52.2mg	0/36	4/38	1/42	4/36	14/30	
kid rca as	31.1mg Z	P<.0005	15.7mg 87.6mg	1/45	1/41	4/45	2/38	9/31	
thy fca as	35.2mg Z	P<.0005	17.4mg 116.mg	0/36	2/38	1/42	2/36	8/30	
kid rcc as	62.2mg *	P<.0005	25.6mg 239.mg	0/45	0/41	2/45	1/38	4/31	
thy fcc as	62.9mg *	P<.002	25.7mg 350.mg	0/36	2/38	0/42	2/36	6/30	
840 R m f3d wat 6m24 1814m				0	6.25mg				Kurokawa;gann,78,358-364;1987/1986a
kid ade e	6.67mg	P<.0005	3.08mg 18.8mg	0/19	9/19				
kid mix e	6.67mg	P<.0005 +	3.08mg 18.8mg	0/19	9/19				
per mso e	7.84mg	P<.0005	3.50mg 24.7mg	0/19	8/19				
thy fct e	11.3mg	P<.003	4.57mg 58.1mg	0/19	6/19				
kid adc e	79.2mg	P<.3	12.9mg n.s.s.	0/19	1/19				
841 R m f3d wat 9m24 1814n				0	9.38mg				
kid mix e	4.81mg	P<.0005 +	2.42mg 10.9mg	0/19	14/19				
kid ade e	5.57mg	P<.0005	2.79mg 12.9mg	0/19	13/19				
per mso e	14.0mg	P<.002	5.97mg 52.5mg	0/19	7/19				
kid adc e	16.9mg	P<.003	6.85mg 87.2mg	0/19	6/19				
842 R m f3d wat 12m24 1814o				0	12.5mg				
kid mix e	8.32mg	P<.0005 +	3.72mg 23.3mg	0/19	9/14				
kid ade e	10.1mg	P<.0005	4.41mg 30.2mg	0/19	8/14				
per mso e	19.4mg	P<.003	7.26mg 103.mg	0/19	5/14				
thy fct e	19.4mg	P<.003	7.26mg 103.mg	0/19	5/14				
kid adc e	35.5mg	P<.02	10.7mg n.s.s.	0/19	3/14				
843 R m f3d wat 52w52 1814r				0	25.0mg				Kurokawa;gann,78,358-364;1987/19186a
kid ade e	4.98mg	P<.002	2.66mg 14.9mg	0/8	15/26				
per mso e	25.6mg	P<.2	8.84mg n.s.s.	0/8	4/26				
844 R m f3d wat 24m24 1814s				0	25.0mg				Kurokawa;gann,78,358-364;1987/1986a
per mso e	12.4mg	P<.0005	6.33mg 27.2mg	0/19	15/20				
kid mix e	28.7mg	P<.0005 +	13.3mg 81.8mg	0/19	9/20				
thy fct e	39.8mg	P<.002	17.0mg 156.mg	0/19	7/20				
kid ade e	48.0mg	P<.004	19.4mg 271.mg	0/19	6/20				
thy fca e	59.5mg	P<.008	22.5mg 895.mg	0/19	5/20				
kid adc e	105.mg	P<.04	31.8mg n.s.s.	0/19	3/20				

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
845 R m f3d wat 24m24 1851					0	.750mg	1.50mg	3.00mg	6.25mg	12.5mg	25.0mg	Kurokawa;jnci,77,977-982; 1986a/1987
per mso	19.5mg	* P<.0005		12.2mg 41.2mg	0/20	0/20	3/20	4/24	2/24	3/20	15/20	
kid rct	28.9mg	* P<.0005	+	17.0mg 55.2mg	0/20	0/20	0/20	1/24	5/24	5/20	9/20	
kid ade	35.7mg	* P<.0005	+	20.2mg 78.3mg	0/20	0/20	0/20	1/24	5/24	5/20	6/20	
thy fct e	54.7mg	* P<.0005		27.4mg 136.mg	0/16	0/19	0/20	1/24	0/24	3/20	7/19	
kid adc	224.mg	* P<.006		67.7mg 2.91gm	0/20	0/20	0/20	0/24	0/24	0/20	3/20	
liv nnd	53.2mg	Z P<.2		15.2mg n.s.s.	2/20	0/20	4/20	7/24	0/24	6/20	(5/20)	
BROMOACETALDEHYDE 17157-48-1												
846 M f b6c wat 80w80 1761					0	85.0mg						Van Durren;tcam,5,393-403;1985
liv hem e	1.02gm	P<.2	-	166.mg n.s.s.	0/50	1/30						
for sqp e	2.52gm	P<.8	-	180.mg n.s.s.	1/50	1/30						
lun tum e	no dre	P=1.	-	311.mg n.s.s.	0/50	0/30						
tba mix e	no dre	P=1.	-	150.mg n.s.s.	7/50	3/30						
847 M m b6c wat 78w78 1761					0	62.0mg						
for sqp e	1.89gm	P<.8	-	121.mg n.s.s.	1/45	1/29						
liv tum e	no dre	P=1.	-	208.mg n.s.s.	0/45	0/29						
lun ptm e	no dre	P=1.	-	155.mg n.s.s.	5/45	1/29						
tba mix e	no dre	P=1.	-	134.mg n.s.s.	8/45	2/29						
BROMOCRIPTINE MESYLATE (Parlodel) 22260-51-1												
848 M f of1 eat 74w74 2302					0	2.00mg	10.0mg	50.0mg				Richardson;stnd,19-63;1984/pers.comm.
lun ade e	no dre	P=1.	-	102.mg n.s.s.	10/50	11/50	11/50	7/50				
liv nnd e	no dre	P=1.	-	262.mg n.s.s.	1/50	3/50	1/50	0/50				
tba mix e	175.mg	* P<.6	-	26.9mg n.s.s.	29/50	22/50	26/50	28/50				
849 M m of1 eat 74w74 2302					0	2.00mg	10.0mg	50.0mg				
liv nnd e	308.mg	* P<.7	-	37.0mg n.s.s.	19/50	17/50	20/50	20/50				
lun ade e	618.mg	* P<.9	-	48.3mg n.s.s.	19/50	15/50	10/50	17/50				
tba mix e	68.0mg	* P<.3	-	18.0mg n.s.s.	32/50	26/50	32/50	34/50				
850 R f ofs eat 23m23 2302					0	1.80mg	9.90mg	44.5mg				
ute mix e	33.7mg	Z P<.0005	+	16.4mg 120.mg	0/50	2/50	8/49	(9/50)				
ute mal e	117.mg	* P<.002	+	55.2mg 649.mg	0/50	2/50	7/49	9/50				
ute ben e	no dre	P=1.		310.mg n.s.s.	0/50	0/50	1/49	0/50				
liv hct e	no dre	P=1.		14.0mg n.s.s.	0/50	0/50	0/49	0/50				
tba mix e	no dre	P=1.		3.94mg n.s.s.	44/50	29/50	(26/49 | 20/50)				
851 R m ofs eat 23m23 2302					0	1.80mg	9.90mg	44.5mg				
liv hct e	no dre	P=1.		14.0mg n.s.s.	0/50	0/50	0/50	0/50				
tba mix e	no dre	P=1.		128.mg n.s.s.	28/50	30/50	28/50	19/50				
BROMODICHLOROMETHANE (dichlorobromomethane) 75-27-4												
852 M f b6c gav 24m24 TR321 :					0	52.0mg	104.mg					
liv MXA	28.9mg	* P<.0005	c	18.6mg 52.2mg	3/50	18/50	29/50				liv:hpa,hpc.	
liv hpa	36.0mg	* P<.0005	c	22.8mg 65.0mg	1/50	13/50	23/50					
liv hpc	144.mg	* P<.002	c	69.9mg 734.mg	2/50	5/50	10/50					
MXA mlh	132.mg	\ P<.02		47.5mg n.s.s.	2/50	7/50	(1/50)				mul:mlh; spl:mlh.	S
TBA MXB	62.9mg	* P<.04		26.3mg n.s.s.	34/50	31/50	35/50					
liv MXB	28.9mg	* P<.0005		18.6mg 52.2mg	3/50	18/50	29/50				liv:hpa,hpc,nnd.	
lun MXB	644.mg	* P<.2		176.mg n.s.s.	1/50	2/50	3/50				lun:a/a,a/c.	
853 M m b6c gav 24m24 TR321 :					0	17.5mg	35.0mg					
mul mlp	74.2mg	\ P<.008		28.1mg 1.51gm	0/50	5/50	(3/50)					S
kid MXA	137.mg	* P<.02	c	61.8mg n.s.s.	1/50	2/50	9/50				kid:tla,uac.	
kid tla	215.mg	* P<.09	c	80.4mg n.s.s.	1/50	2/50	6/50					
kid uac	336.mg	* P<.03	c	116.mg n.s.s.	0/50	0/50	4/50					
TBA MXB	no dre	P=1.		42.5mg n.s.s.	38/50	36/50	35/50					
liv MXB	no dre	P=1.		51.4mg n.s.s.	17/50	16/50	20/50				liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.		158.mg n.s.s.	12/50	3/50	7/50				lun:a/a,a/c.	
854 R f f34 gav 24m24 TR321 :					0	34.7mg	70.1mg					
MXB MXB	84.8mg	/ P<.0005		52.7mg 150.mg	0/50	1/50	24/50				col:acn,apn; kid:tla,uac.	C
kid MXA	143.mg	* P<.0005	c	79.8mg 294.mg	0/50	1/50	15/50				kid:tla,uac.	
col MXA	200.mg	/ P<.0005	c	103.mg 505.mg	0/50	0/50	12/50				col:acn,apn.	
kid uac	272.mg	* P<.002	c	128.mg 934.mg	0/50	0/50	9/50					
kid tla	351.mg	* P<.008	c	152.mg 5.11gm	0/50	1/50	6/50					
col apn	364.mg	* P<.004	c	157.mg 2.04gm	0/50	0/50	7/50					
col acn	411.mg	* P<.007	c	168.mg 4.92gm	0/50	0/50	6/50					
TBA MXB	no dre	P=1.		73.5mg n.s.s.	48/50	43/50	43/50					
liv MXB	no dre	P=1.		303.mg n.s.s.	1/50	3/50	1/50				liv:hpa,hpc,nnd.	
855 R m f34 gav 24m24 TR321 :					0	35.0mg	70.1mg					
MXB MXB	30.3mg	/ P<.0005		21.7mg 43.8mg	0/50	13/50	46/50				col:acn,apn; kid:tla,uac; rec:acn,apn.	C
MXA MXA	30.7mg	/ P<.0005	c	22.0mg 44.5mg	0/50	13/50	45/50				col:acn,apn; rec:acn,apn.	
MXA acn	35.6mg	/ P<.0005	c	24.9mg 53.3mg	0/50	11/50	38/50				col:acn; rec:acn.	
MXA apn	55.6mg	/ P<.0005	c	36.8mg 89.2mg	0/50	3/50	33/50				col:apn; rec:apn.	
kid MXA	152.mg	/ P<.0005	c	81.6mg 345.mg	0/50	1/50	13/50				kid:tla,uac.	
kid uac	213.mg	/ P<.0005	c	103.mg 603.mg	0/50	0/50	10/50					
tnv men	350.mg	* P<.05		143.mg n.s.s.	0/50	3/50	3/50					S
lun MXA	366.mg	* P<.02		149.mg n.s.s.	0/50	2/50	4/50				lun:a/a,a/c.	S
lun a/a	447.mg	* P<.05		169.mg n.s.s.	0/50	2/50	3/50					S
kid tla	583.mg	* P<.05	c	201.mg n.s.s.	0/50	1/50	3/50					
TBA MXB	267.mg	* P<.7		37.0mg n.s.s.	43/50	41/50	47/50					
liv MXB	747.mg	* P<.2		207.mg n.s.s.	1/50	0/50	4/50				liv:hpa,hpc,nnd.	
856 R f wis wat 43m43 1681					0	94.9mg						Tumasonis;eaes,9,233-240;1985
liv nnd ev	544.mg	P<.002	+	307.mg 1.51gm	0/18	17/53						
857 R m wis wat 42m42 1681					0	83.7mg						
pit tum ev	911.mg	P<.06		382.mg n.s.s.	1/22	10/47						
liv nnd ev	no dre	P=1.		920.mg n.s.s.	5/22	6/47						

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
BROMOETHANE (ethyl bromide) 74-96-4										
858 M f b6c inh 24m24 TR363 :				0	137.mg	275.mg	550.mg			
ute MXA	535.mg	Z P<.0005	c 356.mg 855.mg	0/50	4/50	5/50	27/50		ute:acn,adn,sqc.	
ute MXA	596.mg	Z P<.0005	387.mg 981.mg	0/50	3/50	4/50	25/50		ute:acn,adn.	S
ute MXA	681.mg	Z P<.0005	434.mg 1.15gm	0/50	3/50	4/50	22/50		ute:acn,sqc.	S
ute acn	822.mg	Z P<.0005	503.mg 1.47gm	0/50	2/50	3/50	19/50			S
ute adn	2.61gm	* P<.002	1.17gm 11.3gm	0/50	1/50	1/50	6/50			S
ute sqc	4.44gm	* P<.03	1.67gm n.s.s.	0/50	1/50	1/50	3/50			S
TBA MXB	571.mg	* P<.009	275.mg 16.5gm	27/50	24/50	29/50	37/50			
liv MXB	no dre	P=1.	1.47gm n.s.s.	5/50	6/50	6/50	3/50		liv:hpa,hpc,nnd.	
lun MXB	5.81gm	* P<.5	1.19gm n.s.s.	6/50	3/50	5/50	6/50		lun:a/a,a/c.	
859 M m b6c inh 24m24 TR363 :				0	115.mg	229.mg	458.mg			
lun MXA	1.10gm	* P<.03	e 481.mg n.s.s.	7/50	6/50	12/50	15/50		lun:a/a,a/c.	
lun a/c	2.39gm	* P<.04	965.mg n.s.s.	2/50	0/50	5/50	6/50			S
TBA MXB	1.63gm	* P<.5	328.mg n.s.s.	30/50	30/50	34/50	33/50			
liv MXB	3.67gm	* P<.7	537.mg n.s.s.	21/50	18/50	20/50	22/50		liv:hpa,hpc,nnd.	
lun MXB	1.10gm	* P<.03	481.mg n.s.s.	7/50	6/50	12/50	15/50		lun:a/a,a/c.	
860 R f f34 inh 24m25 TR363 :				0	32.7mg	65.5mg	131.mg			
bra gln	1.02gm	* P<.05	e 373.mg n.s.s.	0/50	1/50	1/50	3/50			
lun a/a	1.28gm	* P<.03	e 388.mg n.s.s.	0/50	0/50	0/50	3/50			
TBA MXB	no dre	P=1.	99.5mg n.s.s.	49/50	46/50	40/50	44/50			
liv MXB	670.mg	Z P<.3	178.mg n.s.s.	1/50	0/50	4/50	(0/50)		liv:hpa,hpc,nnd.	
861 R m f34 inh 24m25 TR363 :				0	22.9mg	45.8mg	91.7mg			
liv nnd	1.14gm	* P<.03	339.mg n.s.s.	0/50	0/50	0/50	3/50			S
amd MXA	149.mg	* P<.2	p 49.7mg n.s.s.	8/50	23/50	18/50	21/50		amd:phe,phm.	
MXB MXB	151.mg	Z P<.2	47.4mg n.s.s.	8/50	28/50	21/50	22/50	amd:phe,phm; bra:ast,gcl,gln,oli;	lun:a/a,a/c.	P
lun MXA h	582.mg	* P<.2	p 219.mg n.s.s.	0/50	0/50	4/50	1/50		lun:a/a,a/c.	
bra gcl h	80.7gm	* P<1.	p 259.mg n.s.s.	0/50	3/50	1/50	1/50			
bra MXA h	no dre	P=1.	p 557.mg n.s.s.	0/50	3/50	0/50	0/50		bra:ast,gln,oli.	
TBA MXB	no dre	P=1.	63.2mg n.s.s.	43/50	47/50	47/50	43/50			
liv MXB	2.28gm	Z P<.6	358.mg n.s.s.	2/50	0/50	0/50	3/50		liv:hpa,hpc,nnd.	
BROMOETHANOL 540-51-2										
862 M f b6c wat 79w79 1761				0	71.0mg				Van Durren;tcam,5,393-403;1985	
for sqp e	69.7mg	P<.0005	+ 32.8mg 215.mg	1/50	10/29					
liv hem e	800.mg	P<.2	130.mg n.s.s.	0/50	1/29					
lun ptm e	1.89gm	P<.7	141.mg n.s.s.	1/50	1/29					
tba mix e	73.2mg	P<.008	30.8mg 1.68gm	7/50	12/29					
863 M m b6c wat 78w78 1761				0	76.0mg					
for sqp e	83.9mg	P<.0005	+ 37.9mg 315.mg	1/45	9/29					
liv tum e	no dre	P=1.	255.mg n.s.s.	0/45	0/29					
lun ptm e	no dre	P=1.	190.mg n.s.s.	5/45	1/29					
tba mix e	86.6mg	P<.03	33.5mg n.s.s.	8/45	12/29					
C.I. DIRECT BROWN 95 16071-86-6										
864 R f f34 eat 13w13 TR108 : ()				0	9.50mg	18.7mg	37.5mg	75.0mg	150.mg	
liv MXA	2.07mg	Z P<.002	c .765mg 9.32mg	0/10	0/10	0/10	0/10	5/10	(0/10)	liv:hpc,nnd.
TBA MXB	2.07mg	Z P<.002	.765mg 9.32mg	0/10	0/10	0/10	0/10	5/10	(0/10)	
liv MXB	2.07mg	Z P<.002	.765mg 9.32mg	0/10	0/10	0/10	0/10	5/10	(0/10)	liv:hpa,hpc,nnd.
865 R m f34 eat 13w13 TR108 : ()				0	7.60mg	15.0mg	30.0mg	60.0mg	120.mg	
TBA MXB	no dre	P=1.	- n.s.s. n.s.s.	0/10	0/10	0/10	0/10	0/10	0/10	
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/10	0/10	0/10	0/10	0/10	0/10	liv:hpa,hpc,nnd.
BUDESONIDE 51333-22-3										
866 R m cdr wat 24m24 2059				0	50.0ug				Ryrfeldt;txpy,20,115-117;1992	
liv mix ers	.291mg	P<.005	+ .131mg 2.88mg	11/200	16/100					
liv hpa ers	.491mg	P<.03	.186mg n.s.s.	7/200	10/100					
liv hpc ers	.822mg	P<.08	.256mg n.s.s.	4/200	6/100					
1,3-BUTADIENE 106-99-0										
867 M f b6c inh 61w61 TR288 :				0	435.mg	869.mg				
MXB MXB	53.0mg	\ P<.0005	30.6mg 106.mg	4/50	30/50	(44/50)	---:mno; for:sqp; hea:hes; liv:hpa,hpc; lun:a/a,a/c; mgl:acc; ova:gcc,gct.			C
MXA hes	147.mg	\ P<.0005	73.4mg 333.mg	0/50	13/50	(19/50)	hea:hes; liv:hes; sub:hes.			S
lun MXA	203.mg	* P<.0005	c 126.mg 411.mg	3/50	12/50	23/50			lun:a/a,a/c.	
lun a/c	227.mg	\ P<.0005	c 91.8mg 825.mg	0/50	6/50	(8/50)				
lun a/a	259.mg	* P<.0005	c 153.mg 585.mg	3/50	9/50	20/50				
--- mno	270.mg	\ P<.0005	c 114.mg 1.03gm	1/50	10/50	(10/50)				
hea hes	283.mg	* P<.0005	c 179.mg 483.mg	0/50	11/50	18/50				
ova MXA	370.mg	* P<.0005	c 214.mg 728.mg	0/50	6/50	13/50			ova:gcc,gct.	
for MXA	396.mg	\ P<.002	133.mg 2.44gm	0/50	4/50	(1/50)			for:sqc,sqp.	S
for sqp	461.mg	\ P<.005	c 140.mg 5.15gm	0/50	3/50	(1/50)				
for MXA	462.mg	* P<.0005	252.mg 1.03gm	0/50	5/50	10/50			for:ppn,sqc,sqp.	S
for MXA	483.mg	* P<.0005	259.mg 1.10gm	0/50	4/50	10/50			for:ppn,sqp.	S
mgl acc	1.03gm	* P<.002	c 462.mg 4.19gm	0/50	2/50	6/50				
liv MXA	1.17gm	* P<.004	c 496.mg 6.82gm	0/50	2/50	5/50			liv:hpa,hpc.	
liv hpa	1.59gm	* P<.009	c 596.mg 36.9gm	0/50	1/50	4/50				
ova gcc	7.58gm	* P<.2	c 1.23gm n.s.s.	0/50	0/50	1/50				
TBA MXB	41.5mg	\ P<.0005	25.1mg 75.8mg	6/50	40/50	(46/50)				
liv MXB	1.17gm	* P<.004	496.mg 6.82gm	0/50	2/50	5/50			liv:hpa,hpc,nnd.	
lun MXB	203.mg	* P<.0005	126.mg 411.mg	3/50	12/50	23/50			lun:a/a,a/c.	
868 M f b6c inh 19m24 TR434 :				0	4.26mg	13.7mg	42.8mg	139.mg	435.mg	
MXB MXB a	6.79mg	Z P<.0005	4.92mg 9.63mg	28/50	36/50	39/50	45/50	48/50	71/80	---:hcs,mlm,mlp,mlu,mly; for:sqc,sqp; hag:adc,ade,anb; hea:hes; liv:hpa,hpc; lun:a/a,a/c,adc; mgl:adc,ado,mtm; ova:ade,gcb,gcm,mtb. C
lun MXA a	12.4mg	Z P<.0005	c 8.55mg 19.5mg	4/50	15/50	19/50	24/50	25/50	22/80	lun:a/a,a/c,adc.
lun a/a a	20.3mg	Z P<.0005	12.9mg 35.5mg	4/50	11/50	12/50	17/50	14/50	17/80	S
liv MXA a	22.8mg	* P<.0005	c 13.7mg 44.6mg	15/50	14/50	15/50	19/50	16/50	2/80	liv:hpa,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology	
lun MXA a		23.9mg Z	P<.0005	15.3mg 39.1mg	0/50	5/50	11/50	9/50	19/50	8/80	lun:a/c,adc. S
hag MXA a		26.2mg Z	P<.0005 c	16.1mg 47.2mg	8/50	10/50	7/50	15/50	20/50	9/80	hag:adc,ade,anb.
hag MXA a		26.2mg Z	P<.0005	16.1mg 47.3mg	8/50	10/50	6/50	15/50	20/50	9/80	hag:ade,anb. S
--- MXA a		27.4mg Z	P<.0005	16.3mg 50.9mg	9/50	14/50	18/50	11/50	16/50	36/80	---:hcs,mlm,mlp,mlu,mly. S
liv hpa a		28.5mg Z	P<.0005	16.3mg 61.6mg	11/50	10/50	9/50	14/50	12/50	(1/80)	S
--- MXA a		35.0mg Z	P<.0005	21.6mg 59.1mg	5/50	3/50	3/50	9/50	24/50	27/80	---:hem,hes. S
--- MXA a		35.2mg Z	P<.0005 c	19.6mg 74.7mg	6/50	12/50	11/50	7/50	9/50	32/80	---:mlm,mlp,mlu,mly.
--- hes a		44.2mg Z	P<.0005	26.3mg 75.0mg	3/50	2/50	2/50	5/50	23/50	27/80	S
mgl MXA a		47.4mg *	P<.0005 c	28.0mg 80.9mg	0/50	2/50	4/50	12/50	15/50	16/80	mgl:adc,ado,mtm.
liv hpc a		50.5mg *	P<.0005	26.6mg 125.mg	4/50	6/50	8/50	9/50	8/50	1/80	S
ova MXA a		65.4mg *	P<.0005 c	34.9mg 133.mg	1/50	0/50	1/50	9/50	8/50	6/80	ova:gcb,gcm.
--- mlp a		74.9mg *	P<.0005 c	36.6mg 171.mg	1/50	3/50	6/50	3/50	8/50	31/80	
ova MXA a		78.9mg *	P<.0005 c	35.1mg 256.mg	2/50	4/50	1/50	4/50	6/50	2/80	ova:ade,mtb.
for MXA a		83.9mg Z	P<.0005 c	39.8mg 192.mg	0/50	0/50	3/50	2/50	4/50	22/80	for:sqc,sqp.
mgl ado a		87.7mg *	P<.0005	40.5mg 237.mg	0/50	1/50	2/50	6/50	4/50	0/80	S
mgl adc a		93.3mg *	P<.0005	49.3mg 174.mg	0/50	2/50	2/50	6/50	11/50	12/80	S
ova MXA a		98.0mg *	P<.0005	47.4mg 235.mg	1/50	0/50	1/50	6/50	6/50	6/80	ova:gcb,glb. S
hea hes a		104.mg Z	P<.0005 c	60.0mg 161.mg	0/50	0/50	0/50	1/50	21/50	23/80	
--- hcs a		125.mg *	P<.0005 c	54.2mg 431.mg	3/50	2/50	7/50	4/50	7/50	4/80	
for sqp a		126.mg Z	P<.0005	51.7mg 337.mg	0/50	0/50	2/50	1/50	3/50	16/80	S
sub MXA a		128.mg *	P<.0005 e	57.9mg 434.mg	1/50	2/50	3/50	5/50	3/50	3/80	sub:nfs,sar.
sub sar a		131.mg *	P<.0005	58.8mg 437.mg	1/50	2/50	2/50	5/50	3/50	3/80	S
ova gcm a		198.mg *	P<.0005	68.7mg 790.mg	0/50	0/50	0/50	3/50	2/50	0/80	S
ova mtb a		202.mg *	P<.0005	73.1mg 622.mg	0/50	0/50	0/50	2/50	5/50	1/80	S
for sqc a		257.mg *	P<.0005	77.9mg 1.04gm	0/50	0/50	1/50	1/50	1/50	6/80	S
kid rua a		1.06gm *	P<.01 e	199.mg 246.gm	0/50	0/50	0/50	0/50	2/50	0/80	
mgl mtm a		2.71gm *	P<.0005	869.mg 13.2gm	0/50	0/50	0/50	0/50	0/50	4/80	S
zym MXA a		3.54gm *	P<.004 e	808.mg 55.7gm	0/50	0/50	0/50	0/50	0/50	2/80	zym:ade,car.
ova ade a		217.mg *	P<.03	55.2mg n.s.s.	2/50	4/50	1/50	2/50	1/50	1/80	S
TBA MXB a		6.28mg Z	P<.0005	4.65mg 8.91mg	35/50	47/50	43/50	48/50	49/50	72/80	
liv MXB a		22.8mg *	P<.0005	13.7mg 44.6mg	15/50	14/50	15/50	19/50	16/50	2/80	liv:hpa,hpc,nnd.
lun MXB a		13.8mg Z	P<.0005	9.48mg 21.9mg	4/50	13/50	18/50	22/50	24/50	22/80	lun:a/a,a/c.
869 M m b6c inh 60w60 TR288 :					0	362.mg	724.mg				
MXB MXB		28.8mg \	P<.0005	17.5mg 50.0mg	2/50	43/50	(39/50)			---:mno; for:ppn,sqp; hea:hes; lun:a/a,a/c. C	
lun MXA		65.9mg *	P<.0005 c	38.7mg 128.mg	2/50	14/50	15/50				lun:a/a,a/c.
hea hes		96.7mg \	P<.0005 c	51.1mg 198.mg	0/50	16/50	(7/50)				
MXA hes		96.7mg \	P<.0005	51.1mg 198.mg	0/50	16/50	(8/50)				hea:hes; pec:hes. S
lun a/a		96.9mg *	P<.0005 c	54.4mg 203.mg	2/50	12/50	11/50				
--- mno		105.mg *	P<.0005 c	70.1mg 158.mg	0/50	23/50	29/50				
for MXA		120.mg \	P<.0005	49.6mg 391.mg	0/50	7/50	(1/50)				for:ppn,sqc,sqp. S
for MXA		140.mg \	P<.0005 c	53.3mg 600.mg	0/50	5/50	(0/50)				for:ppn,sqp.
lun a/c		312.mg *	P<.0005 c	126.mg 1.08gm	0/50	2/50	5/50				
pre MXA		403.mg *	P<.002	150.mg 1.92gm	0/50	3/50	2/50				pre:can,sqc. S
pre sqc		538.mg *	P<.004	181.mg 4.83gm	0/50	3/50	1/50				S
for MXA		557.mg *	P<.004	197.mg 4.31gm	0/50	4/50	1/50				for:sqc,sqp. S
TBA MXB		28.8mg \	P<.0005	17.3mg 52.5mg	10/50	44/50	(40/50)				
liv MXB		541.mg *	P<.2	149.mg n.s.s.	8/50	6/50	2/50				liv:hpa,hpc,nnd.
lun MXB		65.9mg *	P<.0005	38.7mg 128.mg	2/50	14/50	15/50				lun:a/a,a/c.
870 M m b6c inh 19m24 TR434 :					0	3.55mg	11.4mg	35.6mg	114.mg	362.mg	
MXB MXB a		10.7mg Z	P<.0005	7.80mg 15.3mg	42/50	38/50	44/50	47/50	49/50	62/73	---:hcs,mlh,mlm,mlp,mlu,mly; for:sqc,sqp; hag:adc,ade,anb; hea:hes; kid:rua; liv:hpa,hpc; lun:a/a,a/c,adc; pre:car. C
lun MXA a		19.2mg *	P<.0005 c	12.6mg 32.9mg	21/50	23/50	19/50	31/50	35/50	3/73	lun:a/a,a/c,adc.
liv MXA a		23.9mg Z	P<.0005 c	14.9mg 43.3mg	21/50	23/50	30/50	25/50	33/50	5/73	liv:hpa,hpc.
hag MXA a		26.1mg Z	P<.0005 c	17.5mg 41.5mg	6/50	7/50	9/50	20/50	31/50	6/73	hag:adc,ade,anb.
hag MXA a		27.6mg Z	P<.0005	18.4mg 45.0mg	6/50	7/50	8/50	19/50	30/50	6/73	hag:ade,anb. S
lun MXA a		32.4mg Z	P<.0005	20.5mg 58.0mg	5/50	6/50	11/50	12/50	22/50	3/73	lun:a/c,adc. S
lun a/a a		33.2mg *	P<.0005	19.7mg 69.3mg	18/50	20/50	10/50	25/50	21/50	3/73	S
liv hpa a		34.1mg Z	P<.0005	20.5mg 65.6mg	13/50	13/50	19/50	16/50	24/50	5/73	S
liv hpc a		34.4mg *	P<.0005	20.5mg 68.2mg	11/50	16/50	16/50	17/50	26/50	1/73	S
--- MXA a		38.0mg Z	P<.0005	24.5mg 63.4mg	2/50	5/50	3/50	11/50	24/50	4/73	---:hem,hes. S
--- hes a		45.5mg Z	P<.0005	28.6mg 78.7mg	1/50	4/50	3/50	7/50	24/50	4/73	S
--- MXA a		63.5mg Z	P<.0005	40.8mg 101.mg	4/50	2/50	8/50	11/50	9/50	55/73	---:hcs,mlh,mlm,mlp,mlu,mly. S
hea hes a		64.8mg Z	P<.0005 c	38.8mg 114.mg	0/50	0/50	1/50	5/50	20/50	4/73	
--- MXA a		99.8mg Z	P<.0005 c	60.0mg 174.mg	4/50	2/50	4/50	6/50	2/50	51/73	---:mlh,mlm,mlp,mlu,mly.
--- hcs a		157.mg *	P<.0005 c	82.9mg 372.mg	0/50	0/50	4/50	5/50	7/50	4/73	
--- mlp a		157.mg Z	P<.0005 c	93.7mg 248.mg	2/50	0/50	2/50	4/50	2/50	49/73	
for MXA a		197.mg Z	P<.0005 c	91.0mg 494.mg	1/50	0/50	0/50	1/50	8/50	4/73	for:sqc,sqp.
hag adc a		221.mg *	P<.005	85.7mg 3.26gm	0/50	1/50	1/50	3/50	2/50	0/73	S
for sqp a		230.mg Z	P<.0005	98.7mg 674.mg	1/50	0/50	0/50	1/50	7/50	2/73	S
pre car a		384.mg *	P<.0005 c	131.mg 1.52gm	0/50	0/50	0/50	0/50	5/50	0/73	
kid rua a		268.mg *	P<.02 c	92.1mg n.s.s.	0/50	1/50	0/50	3/50	1/50	0/73	
jej car a		310.mg *	P<.02 e	97.0mg n.s.s.	0/50	1/50	1/50	1/50	2/50	0/73	
sub hes a		666.mg *	P<.03	164.mg n.s.s.	0/50	1/50	1/50	0/50	3/50	0/73	S
bra onm a		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	0/50	0/73	
bra ogm a		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	0/50	0/73	
TBA MXB a		10.5mg Z	P<.0005	7.76mg 15.1mg	44/50	40/50	45/50	48/50	49/50	62/73	
liv MXB a		23.9mg Z	P<.0005	14.9mg 43.3mg	21/50	23/50	30/50	25/50	33/50	5/73	liv:hpa,hpc,nnd.
lun MXB a		19.6mg *	P<.0005	12.8mg 33.8mg	21/50	23/50	18/50	30/50	35/50	3/73	lun:a/a,a/c.
871 M m b6c inh 12m24 TR434a :					0	90.3mg					
MXB MXB		6.12mg	P<.0005	3.14mg 12.8mg	38/50	50/50	---:hcs,mlm,mlp,mly; for:sqc,sqp; hag:adc,ade,adi,anb; hea:hes; kid:ade,rua; liv:hpa; lun:a/a,a/c,adc; pre:car,cnb. C				
lun MXA		7.17mg	P<.0005 c	3.25mg 17.2mg	21/50	32/50					lun:a/a,a/c,adc.
lun a/a		9.13mg	P<.0005	3.90mg 24.2mg	18/50	26/50					S
--- MXA		11.1mg	P<.0005	3.83mg 29.2mg	2/50	34/50					---:hem,hes. S
--- hes		11.9mg	P<.0005	3.99mg 30.6mg	1/50	34/50					S
lun MXA		13.0mg	P<.0005	4.19mg 45.1mg	5/50	16/50					lun:a/c,adc. S
hag MXA		13.1mg	P<.0005 c	5.55mg 30.1mg	6/50	30/50					hag:adc,ade,adi,anb.
liv MXA		13.8mg	P<.0005	5.73mg 38.4mg	21/50	25/50					liv:hpa,hpb,hpc. S

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path		TD_{50}	2Tailpvl		LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
hea	hes	13.9mg	P<.0005	c	4.42mg	30.6mg	0/50	33/50				
liv	MXA	14.6mg	P<.0005		5.90mg	42.0mg	21/50	24/50			liv:hpa,hpc.	S
hag	MXA	14.9mg	P<.0005		5.97mg	35.0mg	6/50	28/50			hag:ade,anb.	S
liv	hpa	15.8mg	P<.0005	c	5.76mg	51.1mg	13/50	19/50				
pre	MXA	20.1mg	P<.0005	c	4.83mg	145.mg	0/50	4/50			pre:car,cnb.	
---	MXA	27.6mg	P<.0005		7.97mg	102.mg	4/50	15/50			---:hcs,mlm,mlp,mly.	S
liv	MXA	41.4mg	P<.0005		13.5mg	226.mg	11/50	11/50			liv:hpb,hpc.	S
for	MXA	42.8mg	P<.0005	c	7.30mg	203.mg	1/50	9/50			for:sqc,sqp.	
---	MXA	46.4mg	P<.0005	c	9.93mg	342.mg	4/50	8/50			---:mlm,mlp,mly.	
liv	hpc	47.0mg	P<.002		14.4mg	341.mg	11/50	10/50				S
---	MXA	76.2mg	P<.006		14.4mg	2.13gm	2/50	4/50			---:mlm,mly.	S
for	sqp	77.7mg	P<.004		8.51mg	1.67gm	1/50	4/50				S
hag	MXA	88.9mg	P<.007		15.0mg	1.69gm	0/50	2/50			hag:adc,adi.	S
---	hcs	110.mg	P<.0005	c	32.2mg	434.mg	0/50	7/50				
for	sqc	154.mg	P<.0005		54.0mg	670.mg	0/50	5/50				S
kid	MXA	190.mg	P<.003	c	44.1mg	2.09gm	0/50	3/50			kid:ade,rua.	
---	mlp	129.mg	P<.03	c	12.9mg	n.s.s.	2/50	4/50				
bra	onm	no dre	P=1.		n.s.s.	n.s.s.	0/50	0/50				
bra	ogm	no dre	P=1.		n.s.s.	n.s.s.	0/50	0/50				
---	hem	no dre	P=1.		18.8mg	n.s.s.	1/50	0/50				
zym	ade	no dre	P=1.		18.8mg	n.s.s.	1/50	0/50				
zym	car	no dre	P=1.		n.s.s.	n.s.s.	0/50	0/50				
TBA	MXB	5.84mg	P<.0005		3.03mg	12.3mg	44/50	50/50				
liv	MXB	14.6mg	P<.0005		5.90mg	42.0mg	21/50	24/50			liv:hpa,hpc,nnd.	
lun	MXB	7.25mg	P<.0005		3.27mg	17.6mg	21/50	31/50			lun:a/a,a/c.	
872	M m b6c inh 9m24 TR434b :						0	44.5mg				
MXB	MXB	10.9mg	P<.0005		5.96mg	27.1mg	38/50	47/50	---:hcs,mlm,mlp,mly; for:sqc,sqp; hag:adc,ade,anb; hea:hes; kid:			
										rua; liv:hpa; lun:a/a,a/c; pre:car,cnb.		C
lun	MXA	11.0mg	P<.0005	c	5.99mg	25.4mg	21/50	36/50			lun:a/a,a/c.	
lun	a/c	16.3mg	P<.0005		8.37mg	38.5mg	5/50	22/50				S
liv	MXA	16.8mg	P<.0005		8.75mg	44.4mg	21/50	33/50			liv:hpa,hpc.	S
---	MXA	17.3mg	P<.0005		9.19mg	38.5mg	2/50	20/50			---:hem,hes.	S
hag	MXA	17.5mg	P<.0005	c	9.53mg	37.5mg	6/50	27/50			hag:adc,ade,anb.	
hag	MXA	18.0mg	P<.0005		9.67mg	39.1mg	6/50	26/50			hag:ade,anb.	S
liv	hpa	18.0mg	P<.0005	c	9.14mg	46.7mg	13/50	27/50				
lun	a/a	18.1mg	P<.0005		8.53mg	63.0mg	18/50	24/50				S
---	hes	20.8mg	P<.0005		10.8mg	47.6mg	1/50	17/50				S
hea	hes	21.9mg	P<.0005	c	11.1mg	48.2mg	0/50	15/50				
---	MXA	57.1mg	P<.002		24.5mg	259.mg	4/50	13/50			---:hcs,mlm,mlp,mly.	S
---	hcs	128.mg	P<.002	c	44.7mg	670.mg	0/50	5/50				
kid	rua	161.mg	P<.005	c	49.3mg	1.60gm	0/50	4/50				
liv	hpc	62.0mg	P<.02		23.9mg	n.s.s.	11/50	14/50				S
---	hem	95.2mg	P<.02		27.8mg	n.s.s.	1/50	4/50				S
---	MXA	108.mg	P<.03	c	34.5mg	n.s.s.	4/50	8/50			---:mlm,mlp,mly.	
---	mlp	142.mg	P<.04	c	41.0mg	n.s.s.	2/50	6/50				
for	sqp	171.mg	P<.06		41.5mg	n.s.s.	1/50	3/50				
for	MXA	171.mg	P<.06	c	41.5mg	n.s.s.	1/50	3/50			for:sqc,sqp.	
pre	MXA	351.mg	P<.1		57.1mg	n.s.s.	0/50	1/50			pre:ade,car,cnb.	
pre	MXA	351.mg	P<.1	c	57.1mg	n.s.s.	0/50	1/50			pre:car,cnb.	
hag	adc	531.mg	P<.07		130.mg	n.s.s.	0/50	2/50				
---	MXA	487.mg	P<.5		63.3mg	n.s.s.	2/50	2/50			---:mlm,mly.	
zym	car	625.mg	P<.2		102.mg	n.s.s.	0/50	1/50				
zym	MXA	647.mg	P<.5		62.7mg	n.s.s.	1/50	1/50			zym:ade,car.	
bra	onm	no dre	P=1.		n.s.s.	n.s.s.	0/50	0/50				
bra	ogm	no dre	P=1.		n.s.s.	n.s.s.	0/50	0/50				
TBA	MXB	10.8mg	P<.0005		5.83mg	28.7mg	44/50	49/50				
liv	MXB	16.8mg	P<.0005		8.75mg	44.4mg	21/50	33/50			liv:hpa,hpc,nnd.	
lun	MXB	11.0mg	P<.0005		5.99mg	25.4mg	21/50	36/50			lun:a/a,a/c.	
873	M m b6c inh 6m24 TR434c :						0	90.5mg				
MXB	MXB	12.6mg	P<.0005		6.27mg	24.4mg	38/50	49/50	---:hcs,mlm,mlp,mly; bra:ogm; for:sqc,sqp; hag:adc,ade,adi,anb;			
										hea:hes; kid:rua; liv:hpa; lun:a/a,a/c; pre:car,cnb.		C
lun	MXA	13.4mg	P<.0005	c	5.01mg	36.8mg	21/50	17/50			lun:a/a,a/c.	
lun	a/a	17.3mg	P<.0005		5.62mg	57.0mg	18/50	12/50				S
---	hes	17.7mg	P<.0005		4.72mg	56.1mg	1/50	14/50				S
---	MXA	17.7mg	P<.0005		4.72mg	56.1mg	2/50	14/50			---:hem,hes.	S
lun	a/c	17.8mg	P<.0005		4.74mg	62.0mg	5/50	11/50				S
hea	hes	18.5mg	P<.0005	c	4.76mg	64.3mg	0/50	13/50				
hag	MXA	22.7mg	P<.0005		6.72mg	71.9mg	6/50	13/50			hag:ade,anb.	S
hag	MXA	22.7mg	P<.0005	c	6.72mg	71.9mg	6/50	13/50			hag:adc,ade,adi,anb.	
liv	MXA	23.8mg	P<.0005		8.28mg	77.1mg	21/50	13/50			liv:hpa,hpc.	S
liv	MXA	23.8mg	P<.0005		8.28mg	77.1mg	21/50	13/50			liv:hpa,hpb,hpc.	S
pre	MXA	27.1mg	P<.0005	c	4.99mg	390.mg	0/50	3/50			pre:car,cnb.	
pre	MXA	27.1mg	P<.0005		4.99mg	390.mg	0/50	3/50			pre:ade,car,cnb.	S
liv	hpa	27.8mg	P<.0005	c	8.53mg	103.mg	13/50	11/50				
---	MXA	28.8mg	P<.0005		13.0mg	55.5mg	4/50	35/50			---:hcs,mlm,mlp,mly.	S
---	MXA	31.3mg	P<.0005	c	13.5mg	62.6mg	4/50	33/50			---:mlm,mlp,mly.	
---	mlp	46.0mg	P<.0005	c	21.1mg	84.8mg	2/50	30/50				
liv	MXA	60.0mg	P<.004		13.0mg	1.02gm	11/50	4/50			liv:hpb,hpc.	S
liv	hpc	60.0mg	P<.004		13.0mg	1.02gm	11/50	4/50				S
for	MXA	91.4mg	P<.0005	c	36.1mg	227.mg	1/50	10/50			for:sqc,sqp.	
---	MXA	111.mg	P<.002		24.5mg	1.19gm	2/50	3/50			---:mlm,mly.	S
zym	car	135.mg	P<.005	e	25.1mg	3.58gm	0/50	2/50				
zym	MXA	135.mg	P<.005		25.1mg	3.58gm	1/50	2/50			zym:ade,car.	S
for	sqc	136.mg	P<.0005		41.3mg	533.mg	0/50	6/50				S
for	sqp	284.mg	P<.002		97.1mg	1.71gm	1/50	4/50				S
---	hcs	396.mg	P<.02	c	90.5mg	n.s.s.	0/50	2/50				
bra	ogm	403.mg	P<.05	c	65.7mg	n.s.s.	0/50	1/50				
kid	rua	961.mg	P<.1	c	157.mg	n.s.s.	0/50	1/50				

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
bra onm		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50			
--- hem		no dre	P=1.	n.s.s. n.s.s.	1/50	0/50			
TBA MXB		12.5mg	P<.0005	6.22mg 24.0mg	44/50	49/50			
liv MXB		23.8mg	P<.0005	8.28mg 77.1mg	21/50	13/50			liv:hpa,hpc,nnd.
lun MXB		13.4mg	P<.0005	5.01mg 36.8mg	21/50	17/50			lun:a/a,a/c.
874 M m b6c inh 3m24 TR434d : ()					0	45.2mg			
MXB MXB		7.00mg	P<.0005	3.95mg 14.6mg	38/50	49/50			---:hcs,mlm,mlp,mly; bra:ogm,onm; for:sqc,sqp; hag:adc,ade,adi, anb; hea:hes; kid:rua; liv:hpa; lun:a/a,a/c,adc; pre:car,cnb. C
lun MXA		8.59mg	P<.0005 c	4.42mg 20.5mg	21/50	28/50			lun:a/a,a/c,adc.
hag MXA		11.7mg	P<.0005 c	5.73mg 27.0mg	6/50	23/50			hag:adc,ade,adi,anb.
lun MXA		14.1mg	P<.0005	6.87mg 35.0mg	5/50	18/50			lun:a/c,adc. S
hag MXA		14.9mg	P<.0005	7.17mg 36.3mg	6/50	20/50			hag:ade,anb. S
liv MXA		15.1mg	P<.0005	7.17mg 45.5mg	21/50	24/50			liv:hpa,hpc. S
liv MXA		15.1mg	P<.0005	7.17mg 45.5mg	21/50	24/50			liv:hpa,hpb,hpc. S
--- MXA		16.9mg	P<.0005	7.78mg 44.7mg	2/50	14/50			---:hem,hes. S
lun a/a		17.1mg	P<.0005	7.56mg 68.5mg	18/50	17/50			S
liv hpa		17.9mg	P<.0005 c	7.86mg 58.2mg	13/50	19/50			
--- hes		21.9mg	P<.0005	9.92mg 58.7mg	1/50	12/50			S
liv MXA		23.4mg	P<.0005	9.57mg 99.0mg	11/50	14/50			liv:hpb,hpc. S
liv hpc		23.4mg	P<.0005	9.57mg 99.0mg	11/50	14/50			S
--- MXA		26.2mg	P<.0005	12.4mg 61.8mg	4/50	24/50			---:hcs,mlm,mlp,mly. S
hea hes		32.6mg	P<.0005 c	12.4mg 108.mg	0/50	7/50			
--- MXA		34.9mg	P<.0005 c	16.2mg 86.4mg	4/50	22/50			---:mlm,mlp,mly.
for sqc		43.4mg	P<.0005	13.4mg 264.mg	0/50	4/50			S
for MXA		44.8mg	P<.0005 c	14.6mg 226.mg	1/50	7/50			for:sqc,sqp.
--- hem		45.8mg	P<.003	13.7mg 449.mg	1/50	4/50			S
hag MXA		63.5mg	P<.0005	19.2mg 358.mg	0/50	4/50			hag:adc,adi. S
--- mlp		66.8mg	P<.0005 c	33.3mg 175.mg	2/50	17/50			
--- hcs		91.1mg	P<.007 c	21.1mg 2.84gm	0/50	2/50			
pre MXA		119.mg	P<.002	43.9mg 550.mg	0/50	5/50			pre:ade,car,cnb. S
pre MXA		167.mg	P<.004 c	56.7mg 1.32gm	0/50	4/50			pre:car,cnb.
--- MXA		78.1mg	P<.02	21.6mg n.s.s.	2/50	5/50			---:mlm,mly. S
for sqp		117.mg	P<.02	27.3mg n.s.s.	1/50	4/50			S
kid rua		201.mg	P<.06 c	32.8mg n.s.s.	0/50	1/50			
bra ogm		230.mg	P<.03 c	51.0mg n.s.s.	0/50	2/50			
zym car		336.mg	P<.04 e	79.6mg n.s.s.	0/50	2/50			
bra onm		394.mg	P<.05 c	93.4mg n.s.s.	0/50	2/50			
zym MXA		223.mg	P<.2	34.2mg n.s.s.	1/50	2/50			zym:ade,car.
TBA MXB		6.92mg	P<.0005	3.87mg 15.0mg	44/50	49/50			
liv MXB		15.1mg	P<.0005	7.17mg 45.5mg	21/50	24/50			liv:hpa,hpc,nnd.
lun MXB		8.59mg	P<.0005	4.42mg 20.5mg	21/50	28/50			lun:a/a,a/c.
875 R f cdr inh 24m24 1829					0	166.mg	1.32gm		Owen;amih,48,407-413;1987
mgl mix e		133.mg \	P<.0005 +	78.0mg 341.mg	50/100	79/100	(81/100)		
mgl ben e		182.mg \	P<.0005	110.mg 428.mg	32/100	64/100	(55/100)		
thy fca e		8.27gm *	P<.0005	4.26gm 24.8gm	0/100	2/100	10/100		
mgl mal e		7.72gm *	P<.07	2.91gm n.s.s.	18/100	15/100	26/100		
tba tum e		no dre	P=1.	893.mg n.s.s.	97/100	98/100	94/100		
876 R m cdr inh 26m26 1829					0	116.mg	927.mg		
tes ldc e		7.55gm *	P<.003 +	3.58gm 52.9gm	0/100	3/100	8/100		
pan exa e		9.31gm *	P<.006	3.98gm 136.gm	3/100	1/100	10/100		
tba tum e		1.47gm *	P<.08	550.mg n.s.s.	84/100	70/100	87/100		
2-BUTOXYETHANOL 111-76-2									
877 M f b6c inh 24m24 TR484 :					0	94.4mg	189.mg	378.mg	
for MXA		1.73gm *	P<.004 p	812.mg 4.70gm	0/50	1/50	2/50	6/50	for:sqc,sqp.
for sqp		1.97gm *	P<.009 p	889.mg 58.5gm	0/50	1/50	2/50	5/50	
TBA MXB		no dre	P=1.	498.mg n.s.s.	43/50	38/50	38/50	35/50	
liv MXB		no dre	P=1.	704.mg n.s.s.	22/50	16/50	18/50	18/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	2.22gm n.s.s.	7/50	4/50	5/50	1/50	lun:a/a,a/c.
878 M m b6c inh 24m24 TR484 :					0	78.9mg	158.mg	316.mg	
liv hpc		486.mg *	P<.003 e	248.mg 3.39gm	10/50	11/50	16/50	21/50	
liv hes		1.70gm *	P<.007 p	725.mg 22.6gm	0/50	1/50	2/50	4/50	
--- MXA		1.34gm *	P<.02	575.mg n.s.s.	1/50	1/50	4/50	5/50	---:hem,hes. S
--- hes		1.75gm *	P<.03	689.mg n.s.s.	1/50	1/50	2/50	5/50	S
for sqp		3.92gm *	P<.3 e	954.mg n.s.s.	1/50	1/50	2/50	2/50	
TBA MXB		375.mg *	P<.09	145.mg n.s.s.	42/50	33/50	36/50	41/50	
liv MXB		498.mg *	P<.1	187.mg n.s.s.	30/50	24/50	31/50	30/50	liv:hpa,hpb,hpc.
lun MXB		2.10gm *	P<.5	412.mg n.s.s.	14/50	8/50	12/50	11/50	lun:a/a,a/c.
879 R f f34 inh 24m24 TR484 :					0	11.2mg	22.5mg	45.1mg	
amd MXA		233.mg *	P<.09 e	80.5mg n.s.s.	3/50	4/50	1/50	8/50	amd:phm,pob.
TBA MXB		52.7mg *	P<.3	15.9mg n.s.s.	47/50	48/50	50/50	48/50	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
880 R m f34 inh 24m24 TR484 :					0	7.89mg	15.8mg	31.6mg	
TBA MXB		no dre	P=1. -	22.4mg n.s.s.	48/50	49/50	50/50	50/50	
liv MXB		no dre	P=1.	108.mg n.s.s.	1/50	3/50	0/50	2/50	liv:hpa,hpb,hpc.
tert-BUTYL ALCOHOL 75-65-0									
881 M f b6c wat 24m24 TR436 :					0	982.mg	1.96gm	3.95gm	
thy MXA		21.9gm *	P<.05 p	8.89gm n.s.s.	2/60	3/60	2/60	9/60	thy:fab,fca.
TBA MXB		no dre	P=1.	3.91gm n.s.s.	54/60	54/60	55/60	53/60	
liv MXB		no dre	P=1.	6.19gm n.s.s.	41/60	44/60	40/60	36/60	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	17.4gm n.s.s.	4/60	5/60	6/60	3/60	lun:a/a,a/c.
882 M m b6c wat 24m24 TR436 :					0	824.mg	1.65gm	3.30gm	
thy MXA		27.3gm *	P<.2 e	8.73gm n.s.s.	1/60	0/60	4/60	2/60	thy:fca,fcc.
TBA MXB		5.71gm *	P<.5	1.31gm n.s.s.	56/60	56/60	56/60	43/60	
liv MXB		6.92gm *	P<.5	1.43gm n.s.s.	48/60	52/60	54/60	36/60	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	8.92gm n.s.s.	15/60	8/60	9/60	6/60	lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
883 R f f34 wat 24m24 TR436 :					0	141.mg	282.mg	564.mg	
TBA MXB	400.mg	* P<.08	-	153.mg n.s.s.	48/50	47/50	43/50	45/50	
liv MXB	44.5gm	* P<.9		2.03gm n.s.s.	1/50	1/50	0/50	1/50	liv:hpa,hpb,hpc.
884 R m f34 wat 24m24 TR436 :					0	61.7mg	123.mg	247.mg	
tes MXA	68.8mg	* P<.006		30.4mg 926.mg	34/50	31/50	31/50	33/50	tes:iab,ica. S
kid MXA	195.mg	* P<.02	p	68.3mg n.s.s.	1/50	3/50	4/50	3/50	kid:rab,rua,ruc.
kid MXA	195.mg	* P<.02	p	68.3mg n.s.s.	1/50	3/50	4/50	3/50	kid:rab,rua.
TBA MXB	65.3mg	* P<.008		29.0mg 1.37gm	49/50	48/50	49/50	46/50	
liv MXB	no dre	P=1.		1.94gm n.s.s.	1/50	1/50	0/50	0/50	liv:hpa,hpb,hpc.
885 R m f34 wat 24m24 TR436 : with step					0	61.7mg	123.mg	247.mg	
kid rua	64.6mg	* P<.0005	p	31.8mg 226.mg	8/50	11/50	19/50	13/50	
kid MXA	65.2mg	* P<.0005	p	31.7mg 242.mg	8/50	13/50	19/50	13/50	kid:rua,ruc.
BUTYL BENZYL PHTHALATE 85-68-7									
886 M f b6c eat 24m24 TR213 :					0	762.mg	1.53gm		
TBA MXB	no dre	P=1.	-	1.64gm n.s.s.	33/50	27/50	31/50		
liv MXB	8.39gm	* P<.2		2.90gm n.s.s.	2/50	5/50	6/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		3.57gm n.s.s.	8/50	3/50	(3/50)		lun:a/a,a/c.
887 M m b6c eat 24m24 TR213 :					0	710.mg	1.41gm		
TBA MXB	no dre	P=1.	-	2.39gm n.s.s.	38/50	31/50	26/50		
liv MXB	20.7gm	* P<.8		2.49gm n.s.s.	13/50	12/50	14/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		5.49gm n.s.s.	17/50	11/50	8/50		lun:a/a,a/c.
888 R f f34 eat 24m24 TR213 :					0	296.mg	589.mg		
--- MXA u	1.41gm	* P<.03	a	639.mg n.s.s.	7/49	7/49	19/50		---:leu,lym.
--- leu u	1.54gm	* P<.04	a	673.mg n.s.s.	7/49	7/49	18/50		
TBA MXB	no dre	P=1.		402.mg n.s.s.	44/49	37/49	45/50		
liv MXB	5.62gm	* P<.2		1.65gm n.s.s.	1/49	1/49	4/50		liv:hpa,hpc,nnd.
889 R f f34 eat 24m24 TR458 :					0	300.mg	600.mg	1.20gm	
pan ana	23.5gm	* P<.07	e	5.73gm n.s.s.	0/50	0/50	0/50	2/50	
ubl tpp	47.0gm	* P<.5	e	7.42gm n.s.s.	1/50	0/50	0/50	2/50	
TBA MXB	no dre	P=1.		1.10gm n.s.s.	49/50	48/50	45/50	42/50	
liv MXB	14.0gm	* P<.07		4.23gm n.s.s.	0/50	0/50	1/50	2/50	liv:hpa,hpb,hpc.
890 R m f34 eat 29w29 TR213 : ()					0	228.mg	456.mg		
TBA MXB s	no dre	P=1.	i	n.s.s. n.s.s.	0/50	0/50	0/50		
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
891 R m f34 eat 24m24 TR458 :					0	120.mg	240.mg	480.mg	
pan MXA	1.04gm	* P<.008	p	475.mg 20.9gm	3/50	2/50	3/50	11/50	pan:acc,ana.
pre car	347.mg	Z P<.03		127.mg n.s.s.	1/50	6/50	(1/50	0/50)	S
pan ana	1.13gm	* P<.02	p	492.mg n.s.s.	3/50	2/50	3/50	10/50	
thy MXA	3.58gm	* P<.05		1.22gm n.s.s.	0/50	1/50	0/50	3/50	thy:fca,fcc. S
TBA MXB	1.08gm	* P<.6		204.mg n.s.s.	46/50	44/50	47/50	49/50	
liv MXB	5.16gm	* P<.4		1.13gm n.s.s.	2/50	2/50	1/50	4/50	liv:hpa,hpb,hpc.
n-BUTYL CHLORIDE 109-69-3									
892 M f b6c gav 24m24 TR312 :					0	350.mg			
lun a/c #	1.71gm	P<.03	-	592.mg n.s.s.	0/50	4/50			S
TBA MXB	no dre	P=1.		295.mg n.s.s.	31/50	29/50			
liv MXB	1.38gm	P<.2		442.mg n.s.s.	3/50	8/50			liv:hpa,hpc,nnd.
lun MXB	1.16gm	P<.08		411.mg n.s.s.	3/50	9/50			lun:a/a,a/c.
893 M f b6c gav 24m24 TR312a :					0	176.mg			
TBA MXB	no dre	P=1.	-	198.mg n.s.s.	35/50	35/50			
liv MXB	no dre	P=1.		521.mg n.s.s.	9/50	7/50			liv:hpa,hpc,nnd.
lun MXB	13.1gm	P<1.		366.mg n.s.s.	6/50	8/50			lun:a/a,a/c.
894 M m b6c gav 24m24 TR312 :					0	354.mg	707.mg		
liv MXA #	808.mg	* P<.02	-	359.mg n.s.s.	12/50	13/50	15/50		liv:hpa,hpc. S
MXA hes	2.83gm	* P<.04		1.03gm n.s.s.	1/50	3/50	4/50		bom:hes; k/p:hes; liv:hes; mul:hes; omt:hes; spl:hes; thx:hes. S
TBA MXB	423.mg	* P<.01		199.mg 49.9gm	32/50	38/50	29/50		
liv MXB	808.mg	* P<.02		359.mg n.s.s.	12/50	13/50	15/50		liv:hpa,hpc,nnd.
lun MXB	3.19gm	* P<.4		742.mg n.s.s.	6/50	10/50	4/50		lun:a/a,a/c.
895 M m b6c gav 24m24 TR312a :					0	177.mg			
TBA MXB	no dre	P=1.	-	135.mg n.s.s.	41/50	39/50			
liv MXB	623.mg	P<.3		177.mg n.s.s.	15/50	21/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		354.mg n.s.s.	14/50	11/50			lun:a/a,a/c.
896 R f f34 gav 24m24 TR312 :					0	42.0mg	84.1mg		
TBA MXB	100.mg	* P<.3	-	28.6mg n.s.s.	47/50	46/50	25/50		
liv MXB	1.51gm	* P<.8		187.mg n.s.s.	1/50	4/50	0/50		liv:hpa,hpc,nnd.
897 R m f34 gav 24m24 TR312 :					0	42.0mg	84.5mg		
tes ict #	45.1mg	* P<.02	-	21.3mg n.s.s.	46/50	45/50	39/50		S
TBA MXB	40.5mg	* P<.009		19.8mg 1.01gm	48/50	48/50	42/50		
liv MXB	no dre	P=1.		265.mg n.s.s.	3/50	3/50	1/50		liv:hpa,hpc,nnd.
2-sec-BUTYL-4,6-DINITROPHENOL 88-85-7									
898 M f b6a orl 76w76 1289					0	.959mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	-	1.07mg n.s.s.	1/17	1/17			
liv hpt evx	no dre	P=1.	-	1.79mg n.s.s.	0/17	0/17			
tba mix evx	no dre	P=1.	-	.843mg n.s.s.	2/17	2/17			
899 M m b6a orl 76w76 1289					0	.891mg			
lun ade evx	2.17mg	P<.4	-	.475mg n.s.s.	2/18	4/17			
liv hpt evx	94.1mg	P<1.	-	.987mg n.s.s.	1/18	1/17			
tba mix evx	1.29mg	P<.3	-	.351mg n.s.s.	3/18	6/17			
900 M f b6c orl 76w76 1289					0	.959mg			
lun ade evx	6.14mg	P<.3	-	.999mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.	-	1.90mg n.s.s.	0/16	0/18			
tba mix evx	6.14mg	P<.3	-	.999mg n.s.s.	0/16	1/18			
901 M m b6c orl 76w76 1289					0	.891mg			
liv hpt evx	1.30mg	P<.02	-	.446mg n.s.s.	0/16	4/18			
lun ade evx	2.77mg	P<.2	-	.680mg n.s.s.	0/16	2/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix evx	.662mg	P<.002 -	.282mg	2.70mg	0/16	7/18			
N-n-BUTYL-N-FORMYLHYDRAZINE 16120-70-0									
902 M f swa wat 92w92 1057					0	80.0mg			Toth;carc,1,589-593;1980
lun mix e	19.4mg	P<.0005 +	11.2mg	35.3mg	25/99	45/49			
cli mix e	252.mg	P<.004 +	95.7mg	1.78gm	0/40	5/32			
cli sqc e	321.mg	P<.01	111.mg	25.8gm	0/40	4/32			
liv mix e	no dre	P=1.	184.mg	n.s.s.	6/47	5/41			
903 M m swa wat 90w90 1057					0	66.7mg			
lun mix e	19.2mg	P<.0005 +	11.4mg	35.8mg	26/100	42/48			
pre mix e	28.2mg	P<.0005 +	18.0mg	47.0mg	0/85	33/47			
pre sqc e	35.6mg	P<.0005	22.4mg	60.9mg	0/85	29/47			
pre fbs e	304.mg	P<.002	115.mg	1.44gm	0/85	5/47			
pre ang e	519.mg	P<.02	157.mg	n.s.s.	0/85	3/47			
liv agm e	no dre	P=1. -	123.mg	n.s.s.	7/70	2/23			
BUTYL p-HYDROXYBENZOATE 94-26-8									
904 M f icr eat 24m25 1688					0	188.mg	375.mg	751.mg	Inai;fctx,23,575-578;1985
lun tum	5.10gm *	P<.06 -	2.00gm	n.s.s.	2/50	4/50	2/50	8/50	
liv tum	no dre	P=1. -	1.15gm	n.s.s.	0/50	0/50	0/50	0/50	
tba mix	2.72gm *	P<.08 -	1.04gm	n.s.s.	12/50	14/50	8/50	21/50	
905 M m icr eat 24m25 1688					0	173.mg	346.mg	693.mg	
liv tum	27.4gm *	P<.5 -	5.29gm	n.s.s.	0/50	1/50	0/50	1/50	
lun tum	119.gm *	P<1. -	3.87gm	n.s.s.	3/50	2/50	2/50	3/50	
tba mix	5.24gm *	P<.4 -	1.41gm	n.s.s.	8/50	7/50	11/50	11/50	
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE (butyl-butanol-nitrosamine) 3817-11-6									
906 R f f34 eat 24m24 1954					0	1.50mg	3.00mg	6.00mg	Fears;txih,4,221-255;1988
ubl car es	noTD50	P<.0005 +	n.s.s.	.471mg	0/118	24/24	23/23	24/24	
liv hpc es	no dre	P=1.	4.01mg	n.s.s.	0/120	0/23	0/24	0/22	
907 R m f34 wat 78w78 1718					0	.500mg			LaVoie;gann,76,266-271;1985/pers.comm.
ubl tcc er	.175mg	P<.0005 +	.100mg	.340mg	0/30	20/30			
tes ldc er	.386mg	P<.002 +	.187mg	1.55mg	2/30	13/30			
908 R m f34 eat 24m24 1954					0	1.20mg	2.40mg	4.80mg	Fears;txih,4,221-255;1988
ubl car es	.549mg *	P<.0005 +	.347mg	.873mg	1/118	21/24	23/24	23/24	
liv hpc es	185.mg *	P<.4	22.7mg	n.s.s.	1/120	0/24	0/24	1/24	
909 R m f3d wat 25m26 1606m					0	50.0ug	.250mg	.500mg	2.50mg Ito;zkko,108,169-173;1984/Shibata 1993
liv hnd aej	.169mg Z	P<.008	65.6ug	4.76mg	2/50	7/29	(5/30	1/30	0/30)
ubl tcc aej	.432mg *	P<.0005 +	.281mg	.680mg	0/50	0/29	6/30	23/30	30/30
ubl pam aej	.447mg *	P<.0005 +	.298mg	.691mg	0/50	2/29	7/30	23/30	29/30
k/p tum Caej	no dre	P=1.	.265mg	n.s.s.	0/50	0/29	0/30	0/30	0/30
liv hpc aej	no dre	P=1.	14.2mg	n.s.s.	0/50	2/29	1/30	2/30	0/30
910 R m sda wat 24m24 1192					0	10.0mg			Schmahl;arzn,28,49-51;1978
ubl car	3.30mg	P<.0005 +	1.98mg	5.64mg	0/40	35/40			
liv lcc	271.mg	P<.3	44.1mg	n.s.s.	0/40	1/40			
911 R m sda gav 39w74 1637					0	10.5mg			Tacchi;clet,22,89-94;1984
ubl mix	1.17mg	P<.0005 +	.641mg	2.03mg	0/40	44/46			
lun car	166.mg	P<.3	27.1mg	n.s.s.	0/40	1/46			
liv tum	no dre	P=1.	50.6mg	n.s.s.	0/40	0/46			
DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL 88-26-6									
912 R f nbw eat 24m24 127					0	100.mg	175.mg		Dacre;txap,17,669-678;1970
mgl fba	3.71gm *	P<.3 -	604.mg	n.s.s.	0/20	0/20	1/20		
liv tum	no dre	P=1.	262.mg	n.s.s.	0/20	0/20	0/20		
tba mix	3.71gm *	P<.3 -	604.mg	n.s.s.	0/20	0/20	1/20		
913 R m nbw eat 24m24 127					0	80.0mg	140.mg		
liv tum	no dre	P=1.	210.mg	n.s.s.	0/20	0/20	0/20		
tba tum	no dre	P=1. -	210.mg	n.s.s.	0/20	0/20	0/20		
2-tert-BUTYL-4-METHYLPHENOL 2409-55-4									
914 R m f3d eat 51w52 1950					0	392.mg			Hirose;canr,48,5310-5315;1988/pers.comm.
for tum	no dre	P=1.	303.mg	n.s.s.	0/10	0/15			
stg tum	no dre	P=1.	303.mg	n.s.s.	0/10	0/15			
N-BUTYL-N'-NITRO-N-NITROSOGUANIDINE 13010-08-7									
915 R m wis wat 52w78 1082					0	2.14mg			Matsukura;gann,70,181-185;1979
stg tum er	no dre	P=1. -	1.99mg	n.s.s.	0/9	0/8			
N-n-BUTYL-N-NITROSOUREA 869-01-2									
916 R f f34 gav 9m24 1915					0	.969mg			Lijinsky;txih,5,925-935;1989
for tum	.267mg	P<.0005 +	98.3ug	.753mg	0/12	11/12			
lun mix	.277mg	P<.0005 +	99.5ug	.880mg	1/12	11/12			
ute mix	.551mg	P<.004 +	.216mg	4.51mg	2/12	9/12			
mgl adc	.758mg	P<.0005 +	.314mg	2.64mg	0/12	7/12			
col tum	2.31mg	P<.04 +	.693mg	n.s.s.	0/12	3/12			
liv tum	no dre	P=1.	2.40mg	n.s.s.	0/12	0/12			
917 R m f34 gav 9m24 1915					0	.678mg			
lun mix	.187mg	P<.0005 +	68.8ug	.527mg	0/12	11/12			
for tum	.259mg	P<.0005 +	.108mg	.721mg	0/12	10/12			
col tum	1.61mg	P<.04 +	.485mg	n.s.s.	0/12	3/12			
liv tum	no dre	P=1.	1.68mg	n.s.s.	1/12	0/12			
918 R f f3d wat 50w50 1620m ()					0	16.8mg			Takeuchi;zkko,107,32-37;1984
dgt mix ev	1.30mg	P<.0005 +	.779mg	2.24mg	0/40	34/39			
for mix ev	2.43mg	P<.0005 +	1.48mg	4.31mg	0/40	26/39			
eso mix ev	3.21mg	P<.0005 +	1.91mg	5.96mg	0/40	22/39			
for pam ev	4.00mg	P<.0005	2.30mg	7.77mg	0/40	19/39			
vag mix ev	5.05mg	P<.0005 +	2.80mg	10.5mg	0/40	16/39			
vag pam ev	6.00mg	P<.0005	3.21mg	13.1mg	0/40	14/39			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
eso pam ev	6.58mg	P<.0005		3.45mg 14.9mg	0/40	13/39			
eso sqc ev	8.05mg	P<.0005		4.03mg 19.9mg	0/40	11/39			
phr mix ev	8.05mg	P<.0005		4.03mg 19.9mg	0/40	11/39			
for sqc ev	10.2mg	P<.0005		4.78mg 29.5mg	0/40	9/39			
phr sqc ev	10.2mg	P<.0005		4.78mg 29.5mg	0/40	9/39			
ton mix ev	10.2mg	P<.0005		4.78mg 29.5mg	0/40	9/39			
edu mix ev	11.6mg	P<.0005	+	5.25mg 38.3mg	0/40	8/39			
ton pam ev	13.5mg	P<.002		5.82mg 54.3mg	0/40	7/39			
edu ssc ev	19.4mg	P<.008		7.38mg 282.mg	0/40	5/39			
--- mix ev	24.7mg	P<.02	+	8.51mg n.s.s.	0/40	4/39			
tba mix ev	noTD50	P<.0005		n.s.s. 1.08mg	1/40	39/39			
919 R m f3d wat 50w50 1620n ()					0	14.7mg			
dgt mix ev	.910mg	P<.0005	+	.519mg 1.60mg	0/38	36/39			
for mix ev	2.62mg	P<.0005	+	1.57mg 4.80mg	0/38	23/39			
eso mix ev	3.02mg	P<.0005	+	1.77mg 5.68mg	0/38	21/39			
for pam ev	3.25mg	P<.0005		1.89mg 6.21mg	0/38	20/39			
eso pam ev	4.08mg	P<.0005		2.29mg 8.25mg	0/38	17/39			
--- mix ev	10.2mg	P<.002	+	4.60mg 34.5mg	0/38	8/39			
duo mix ev	11.8mg	P<.002		5.09mg 49.9mg	0/38	7/39			
edu mix ev	11.8mg	P<.002	+	5.09mg 49.9mg	0/38	7/39			
pls mix ev	11.8mg	P<.002		5.09mg 49.9mg	0/38	7/39			
eso sqc ev	17.0mg	P<.009		6.45mg 362.mg	0/38	5/39			
pls sqc ev	17.0mg	P<.009		6.45mg 362.mg	0/38	5/39			
tba mix ev	noTD50	P<.0005		n.s.s. .991mg	5/38	39/39			
920 R f mrw wat 39w85 2038					0	4.49mg			Mirvish;jtxe,32,59-74;1991/pers.comm.
--- mye	3.27mg	P<.004	+	1.38mg 18.1mg	0/10	7/15			
liv tum	6.63mg	P<.04		2.27mg n.s.s.	0/10	4/15			
mgl tum	6.63mg	P<.04	-	2.27mg n.s.s.	0/10	4/15			
tba tum	1.02mg	P<.0005		.453mg 2.52mg	0/10	13/15			
921 R m mrw wat 39w85 2038					0	3.93mg			
--- mye	2.86mg	P<.03	+	1.21mg n.s.s.	0/5	7/15			
liv tum	26.1mg	P<.5		4.25mg n.s.s.	0/5	1/15			
tba tum	1.64mg	P<.004		.756mg 9.09mg	0/5	10/15			
BUTYLATED HYDROXYANISOLE (BHA, 2(3)-tert-butyl-4-hydroxyanisole) 25013-16-5									
922 H m syg eat 48w72 1997m					0	1.23gm			Hirose;carc,11,239-244;1990
for sqc r	5.44gm	P<.4		884.mg n.s.s.	0/9	1/14			
for pam r	no dre	P=1.		1.70gm n.s.s.	0/9	0/14			
923 H m syg eat 72w72 1997n					0	1.84gm			
for pam r	745.mg	P<.004		270.mg 4.82gm	0/9	5/9			
for sqc r	no dre	P=1.		1.64gm n.s.s.	0/9	0/9			
924 M m b6c eat 64w64 1901m					0	600.mg	1.20gm		Masui;gann,77,1083-1090;1986/pers.comm.
for tum ekr	no dre	P=1.		312.mg n.s.s.	0/10	0/10	0/10		
925 M m b6c eat 72w72 1901n					0	600.mg	1.20gm		
for tum ekr	no dre	P=1.		395.mg n.s.s.	0/10	0/10	0/10		
926 M m b6c eat 80w80 1901o					0	600.mg	1.20gm		
for pam ekr	1.02gm *	P<.03		413.mg n.s.s.	0/10	3/10	3/10		
927 M m b6c eat 88w88 1901r					0	600.mg	1.20gm		
for pam ekr	3.75gm *	P<.3		920.mg n.s.s.	0/10	1/7	1/10		
for sqc ekrh	3.75gm *	P<.3	+	920.mg n.s.s.	0/10	1/7	1/10		
928 M m b6c eat 96w96 1901s					0	600.mg	1.20gm		
for pam ekr	1.53gm *	P<.02		620.mg n.s.s.	0/13	3/9	3/11		
for sqc ekrh	10.5gm *	P<.3	+	1.71gm n.s.s.	0/13	0/9	1/11		
929 M m b6c eat 24m24 1901u					0	600.mg	1.20gm		
for pam er	13.1gm *	P<.4		3.21gm n.s.s.	0/16	1/21	1/22		
for sqc er	no dre	P=1.		1.76gm n.s.s.	0/16	0/21	0/22		
930 M f lca eat 52w52 2402					0	325.mg			Gao;scch,37,419-428;1994
tba tum	no dre	P=1.	-	1.00gm n.s.s.	0/60	0/60			
931 M b swi eat 24m24 1525					0	625.mg			Maru;clet,17,75-80;1982
lun tum r	5.11gm	P<.2		1.30gm n.s.s.	1/47	3/30			
liv tum r	no dre	P=1.		2.39gm n.s.s.	7/47	2/30			
932 R f f34 eat 24m26 1568					0	232.mg	929.mg		Ito;jnci,70,343-352;1983
for pam e	490.mg /	P<.0005	+	334.mg 744.mg	0/51	1/51	49/51		
for sqc e	2.75gm /	P<.0005	+	1.51gm 5.82gm	0/51	0/51	15/51		
liv hnd e	162.gm *	P<.9		8.36gm n.s.s.	1/51	0/51	1/51		
933 R m f34 eat 24m26 1568					0	186.mg	743.mg		
for pam e	349.mg /	P<.0005	+	238.mg 528.mg	0/51	1/50	52/52		
for sqc e	1.80gm /	P<.0005	+	1.04gm 3.56gm	0/51	0/50	18/52		
liv hnd e	no dre	P=1.		4.38gm n.s.s.	4/51	3/50	3/52		
934 R m f34 eat 60w60 1640					0	200.mg			Rao;canr,44,1072-1076;1984
liv tum er	no dre	P=1.		343.mg n.s.s.	0/25	0/25			
935 R m f34 eat 6m24 1902m					0	200.mg			Nera;txcy,53,251-268;1988
for car e	no dre	P=1.		2.06gm n.s.s.	0/50	0/50			
for pam e	no dre	P=1.		2.06gm n.s.s.	0/50	0/50			
liv tum e	no dre	P=1.		2.06gm n.s.s.	0/50	0/50			
936 R m f34 eat 12m24 1902n					0	400.mg			
fls pam e	4.06gm	P<.04		1.23gm n.s.s.	0/50	3/46			
for sqc e	4.06gm	P<.04	+	1.23gm n.s.s.	0/50	3/46			
fgr pam e	12.5gm	P<.3		2.03gm n.s.s.	0/50	1/46			
liv tum e	no dre	P=1.		3.79gm n.s.s.	0/50	0/46			
937 R m f34 eat 24m24 1902o					0	800.mg			
fgr pam e	298.mg	P<.0005		186.mg 495.mg	0/50	37/44			
fls pam e	298.mg	P<.0005		186.mg 495.mg	0/50	37/44			
for sqc e	7.76gm	P<.04	+	2.35gm n.s.s.	0/50	3/44			
liv tum e	no dre	P=1.		7.25gm n.s.s.	0/50	0/44			
938 R m f34 eat 26m26 1973					0	480.mg			Williams;fctx,28,799-806;1990
ssq sqp eh	907.mg	P<.0005	+	424.mg 2.67gm	0/25	9/27			
liv hpa e	no dre	P=1.		1.14gm n.s.s.	9/25	6/27			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
939 R m f3d eat 24m24 1784				0	50.0mg	100.mg	200.mg	400.mg	800.mg	Ito;jnci,77,1261-1265;1986
for pam e	598.mg	Z P<.0005 +	431.mg 858.mg	0/50	0/50	0/50	0/50	10/50	50/50	
for sqc e	4.55gm	Z P<.0005 +	2.28gm 11.1gm	0/50	0/50	0/50	0/50	0/50	11/50	
liv hpc e	no dre	P=1.	6.03gm n.s.s.	0/50	0/50	0/50	3/50	0/50	0/50	
940 R m f3d eat 52w52 1883				0	400.mg	800.mg				Hasegawa;gann,79,320-328;1988/pers.comm.
for mix	1.30gm	* P<.08	393.mg n.s.s.	0/10	0/20	3/20				
for pam	1.99gm	* P<.2 -	488.mg n.s.s.	0/10	0/20	2/20				
for sqc	4.04gm	* P<.4 -	658.mg n.s.s.	0/10	0/20	1/20				
liv tum	no dre	P=1. -	275.mg n.s.s.	0/10	0/20	0/20				
941 R m f3d eat 52w52 1900				0	400.mg	800.mg				Hirose;carc,8,1731-1735;1987/pers.comm.
eso tum er	no dre	P=1. -	206.mg n.s.s.	0/10	0/15	0/15				
for tum er	no dre	P=1. -	206.mg n.s.s.	0/10	0/15	0/15				
liv tum er	no dre	P=1. -	206.mg n.s.s.	0/10	0/15	0/15				
942 R m f3d eat 51w52 1921				0	392.mg					Hirose;carc,10,2223-2226;1989
for mix er	907.mg	P<.3 -	148.mg n.s.s.	0/10	1/14					
for pam er	907.mg	P<.3 -	148.mg n.s.s.	0/10	1/14					
for sqc er	907.mg	P<.3 -	148.mg n.s.s.	0/10	1/14					
stg tum er	no dre	P=1. -	283.mg n.s.s.	0/10	0/14					
943 R m f3d eat 52w52 2098				0	800.mg					Shibata;carc,14,275-280;1993
for sqp er	442.mg	P<.04	152.mg n.s.s.	0/10	4/15					
for sqc er	no dre	P=1.	618.mg n.s.s.	0/10	0/15					
944 R m f3d eat 60w60 2134				0	800.mg					Ito;anti,183-194;1990/pers.comm.
for sqp er	1.06gm	P<.04	321.mg n.s.s.	0/19	3/19					
for sqc er	no dre	P=1.	1.04gm n.s.s.	0/19	0/19					
945 R m f3d eat 51w51 2162 ()				0	800.mg					Kawabe;gann,85,17-25;1994
for sqc er	591.mg	P<.04 +	178.mg n.s.s.	0/15	3/15					
for sqp er	591.mg	P<.04	178.mg n.s.s.	0/15	3/15					
stg tum Cer	no dre	P=1.	595.mg n.s.s.	0/15	0/15					
946 R m f3d eat 52w52 2192m				0	400.mg					Shibata;carc,14,1265-1269;1993/pers.comm.
for tum er	no dre	P=1.	412.mg n.s.s.	0/10	0/20					
947 R m f3d eat 24m24 2192n				0	800.mg					
for sqp er	289.mg	P<.0005 +	144.mg 625.mg	0/17	17/20					
for sqc er	2.46gm	P<.03 +	846.mg n.s.s.	0/17	4/20					
948 R m f3d eat 24m24 2568m				0	800.mg					Tamano;fctx,36,299-304;1998
for mix e	noTD50	P<.0005 +	n.s.s. 247.mg	1/30	30/30					
for sqp e	noTD50	P<.0005	n.s.s. 247.mg	1/30	30/30					
for sqc e	1.77gm	P<.0005 +	797.mg 5.79gm	0/30	8/30					
for lei e	16.2gm	P<.3	2.63gm n.s.s.	0/30	1/30					
949 R m lwj eat 24m24 2568r				0	800.mg					
for mix e	noTD50	P<.0005 +	n.s.s. 243.mg	0/30	30/30					
for sqp e	noTD50	P<.0005	n.s.s. 243.mg	0/30	30/30					
for sqc e	7.95gm	P<.1 +	1.95gm n.s.s.	0/30	2/30					
950 R m sdj eat 24m24 2568o				0	800.mg					
for mix e	noTD50	P<.0005 +	n.s.s. 243.mg	0/30	30/30					
for sqp e	noTD50	P<.0005	n.s.s. 243.mg	0/30	30/30					
for sqc e	1.20gm	P<.0005 +	598.mg 2.97gm	0/30	11/30					
for lei e	7.95gm	P<.1	1.95gm n.s.s.	0/30	2/30					
951 R m shj eat 24m24 2568n				0	800.mg					
for mix e	noTD50	P<.0005 +	n.s.s. 243.mg	0/30	30/30					
for sqp e	noTD50	P<.0005	n.s.s. 243.mg	0/30	30/30					
for sqc e	377.mg	P<.0005 +	217.mg 707.mg	0/30	23/30					
for lei e	16.2gm	P<.3	2.63gm n.s.s.	0/30	1/30					
BUTYLATED HYDROXYTOLUENE (BHT, 2,6-DI-tert-butyl-p-cresol) 128-37-0										
952 M f b6c eat 25m25 TR150 :				0	390.mg	780.mg				
lun MXA a#	715.mg	\ P<.02 -	357.mg n.s.s.	1/20	16/50	(7/50)				lun:a/a,a/c. s
TBA MXB a	no dre	P=1.	336.mg n.s.s.	14/20	32/50	(23/50)				
liv MXB a	10.7gm	* P<.6	2.18gm n.s.s.	1/20	4/50	5/50				liv:hpa,hpc,nnd.
lun MXB a	715.mg	\ P<.02	357.mg n.s.s.	1/20	16/50	(7/50)				lun:a/a,a/c.
953 M f b6c eat 22m24 1528				0	24.0mg	120.mg	600.mg			Shirai;fctx,20,861-865;1982
liv hnd e	5.98gm	* P<.3 -	1.40gm n.s.s.	2/47	3/47	5/46	5/44			
liv hpc e	14.4gm	* P<.5 -	2.26gm n.s.s.	2/47	2/47	1/46	3/44			
lun adc e	32.9gm	* P<.8 -	2.89gm n.s.s.	3/47	0/47	1/46	2/44			
lun ade e	no dre	P=1. -	3.81gm n.s.s.	7/47	3/47	2/46	2/44			
954 M f b6c eat 24m28 1882				0	1.13gm	2.25gm				Inai;gann,79,49-58;1988
lun a/c e	71.3gm	* P<.6	12.3gm n.s.s.	1/41	2/44	2/40				
liv hem e	126.gm	* P<.3	20.6gm n.s.s.	0/41	0/44	1/40				
liv hpa e	no dre	P=1.	13.0gm n.s.s.	5/41	7/44	2/40				
liv hpc e	no dre	P=1.	29.7gm n.s.s.	2/41	1/44	0/40				
lun a/a e	no dre	P=1.	16.4gm n.s.s.	4/41	5/44	1/40				
liv hct e	no dre	P=1. -	14.6gm n.s.s.	7/41	8/44	2/40				
tba tum e	no dre	P=1.	6.04gm n.s.s.	35/41	33/44	22/40				
955 M m b6c eat 25m25 TR150 :				0	360.mg	720.mg				
TBA MXB a	no dre	P=1. -	355.mg n.s.s.	17/20	39/50	(32/50)				
liv MXB a	no dre	P=1.	531.mg n.s.s.	11/20	23/50	(13/50)				liv:hpa,hpc,nnd.
lun MXB a	no dre	P=1.	1.23gm n.s.s.	7/20	21/50	17/50				lun:a/a,a/c.
956 M m b6c eat 22m24 1528				0	22.2mg	111.mg	554.mg			Shirai;fctx,20,861-865;1982
liv hnd e	3.00gm	* P<.3 -	784.mg n.s.s.	14/48	10/48	13/50	16/47			
lun ade e	212.gm	* P<1. -	1.48gm n.s.s.	8/48	8/48	9/50	8/47			
liv hae e	no dre	P=1. -	3.52gm n.s.s.	4/48	5/48	2/50	2/47			
liv hpc e	no dre	P=1. -	1.53gm n.s.s.	11/48	13/48	12/50	10/47			
lun adc e	no dre	P=1. -	4.36gm n.s.s.	3/48	6/48	2/50	1/47			
957 M m b6c eat 24m28 1882				0	1.04gm	2.08gm				Inai;gann,79,49-58;1988
liv hpa e	3.45gm	* P<.003	1.90gm 17.7gm	6/32	16/42	25/47				
liv hct e	2.90gm	* P<.02 +	1.42gm n.s.s.	12/32	26/42	31/47				
lun a/a e	18.5gm	* P<.3	5.38gm n.s.s.	4/32	6/42	10/47				
liv ang e	128.gm	* P<.3	20.9gm n.s.s.	0/32	0/42	1/47				
liv hem e	no dre	P=1.	21.5gm n.s.s.	4/32	3/42	1/47				

Chemical / Synonym / CAS number	Spe Strain Xpo+Xpt / Sex Route Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
Site Notes DR AuOp UpConf						Brkly Code
Path TD_{50} 2Tailpvl LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc e no dre P=1. 7.51gm n.s.s.		7/32	11/42	8/47		
lun a/c e no dre P=1. 19.0gm n.s.s.		1/32	3/42	0/47		
tba tum e no dre P=1. 1.72gm n.s.s.		27/32	36/42	38/47		
958 M f bal eat 69w69 1006		0	975.mg			Clapp;jnci,61,177-180;1978
lun tum no dre P=1. 1.15gm n.s.s.		13/50	11/50			
liv tum no dre P=1. 4.42gm n.s.s.		0/50	0/50			
959 M m bal eat 69w69 53		0	900.mg			Clapp;fctx,12,367-371;1974
lun ppa e 368.mg P<.03 + 122.mg n.s.s.		6/25	7/11			
sto sqc e 2.03gm P<.09 - 330.mg n.s.s.		0/25	1/8			
liv tum e no dre P=1. - 898.mg n.s.s.		0/25	0/11			
--- rts e no dre P=1. - 509.mg n.s.s.		14/25	1/8			
960 M m bal eat 69w69 1006		0	900.mg			Clapp;jnci,61,177-180;1978
lun tum 7.33gm P<.8 711.mg n.s.s.		45/100	47/100			
liv mix no dre P=1. 8.16gm n.s.s.		2/100	0/100			
961 M b swi eat 24m24 1525		0	625.mg			Maru;clet,17,75-80;1982
lun tum r 1.48gm P<.002 640.mg 7.00gm		1/47	8/30			
liv tum r no dre P=1. 3.02gm n.s.s.		7/47	1/30			
962 R f f34 eat 24m24 TR150 :		0	150.mg	300.mg		
TBA MXB no dre P=1. - 374.mg n.s.s.		12/20	36/50	26/50		
liv MXB no dre P=1. n.s.s. n.s.s.		0/20	0/50	0/50		liv:hpa,hpc,nnd.
963 R m f34 eat 24m24 TR150 :		0	120.mg	240.mg		
TBA MXB no dre P=1. - 210.mg n.s.s.		17/20	36/50	35/50		
liv MXB 2.30gm * P<.4 796.mg n.s.s.		0/20	2/50	2/50		liv:hpa,hpc,nnd.
964 R m f34 eat 26m26 1973		0	480.mg			Williams;fctx,28,799-806;1990
liv hpa e no dre P=1. - 1.49gm n.s.s.		9/25	3/23			
ssq tum e no dre P=1. - 2.55gm n.s.s.		0/25	0/23			
965 R m f3d eat 52w52 1900		0	280.mg			Hirose;carc,8,1731-1735;1987/pers.comm.
eso tum er no dre P=1. - 144.mg n.s.s.		0/10	0/10			
for tum er no dre P=1. - 144.mg n.s.s.		0/10	0/10			
liv tum er no dre P=1. - 144.mg n.s.s.		0/10	0/10			
966 R m f3d eat 60w60 2134		0	200.mg			Ito;anti,183-194;1990/pers.comm.
for sqc er no dre P=1. - 137.mg n.s.s.		0/19	0/10			
for sqp er no dre P=1. - 137.mg n.s.s.		0/19	0/10			
967 R f wis eat 24m24 1087		0	125.mg	500.mg		Hirose;fctx,19,147-151;1981
pit ade e 613.mg \ P<.02 - 250.mg 171.gm		0/32	6/46	(3/51)		
liv hnd e 5.99gm * P<.4 - 1.45gm n.s.s.		0/32	3/46	3/51		
tba mix e 2.31gm * P<.5 - 476.mg n.s.s.		11/32	25/46	25/51		
968 R m wis eat 24m24 1087		0	100.mg	400.mg		
liv hnd e no dre P=1. - 2.23gm n.s.s.		2/26	2/43	1/38		
tba mix e no dre P=1. - 1.12gm n.s.s.		6/26	13/43	10/51		
1,1-DI-n-BUTYLHYDRAZINE 7422-80-2						
969 M f swa wat 25m25 1438		0	62.5mg			Toth;carc,2,651-654;1981
lun ade es 51.5mg P<.0005 30.3mg 107.mg		20/99	34/50			
lun mix es 55.5mg P<.0005 + 31.5mg 128.mg		25/99	34/50			
for mix es 71.5mg P<.0005 + 41.4mg 147.mg		4/71	23/45			
for sqp es 95.9mg P<.0005 52.5mg 227.mg		4/71	19/45			
lun adc es 133.mg P<.0005 69.3mg 371.mg		6/99	17/50			
for sqc es 152.mg P<.0005 77.9mg 355.mg		0/71	12/45			
liv agm es no dre P=1. - 474.mg n.s.s.		5/71	1/45			
970 M m swa wat 25m25 1438		0	52.1mg			
lun mix es 38.1mg P<.0005 + 21.7mg 84.7mg		26/96	34/46			
lun ade es 44.9mg P<.0005 26.1mg 93.8mg		16/96	30/46			
lun adc es 82.3mg P<.0005 43.3mg 235.mg		12/96	21/46			
for mix es 84.2mg P<.0005 + 46.7mg 174.mg		0/96	16/43			
liv mix es 105.mg P<.0005 + 39.4mg 437.mg		0/40	5/16			
for sqp es 109.mg P<.0005 57.2mg 246.mg		0/96	13/43			
liv bhp es 189.mg P<.006 56.9mg 2.40gm		0/40	3/16			
for sqc es 317.mg P<.0005 120.mg 1.37gm		0/96	5/43			
n-BUTYLHYDRAZINE.HCl 56795-65-4						
971 M f swa wat 28m28 252		0	25.0mg			Nagel;ejca,11,473-478;1975/Toth 1974
lun mix e 18.4mg P<.0005 + 10.7mg 37.6mg		21/90	34/44			
lun ade e 19.3mg P<.0005 11.3mg 38.5mg		18/90	33/44			
lun adc e 50.6mg P<.0005 27.2mg 121.mg		4/90	17/44			
liv mix e no dre P=1. 101.mg n.s.s.		3/56	0/15			
972 M m swa wat 23m23 252		0	20.8mg			
lun ade e 8.40mg P<.0005 4.21mg 19.9mg		15/92	19/23			
lun mix e 9.03mg P<.0005 + 4.36mg 24.1mg		23/92	19/23			
liv mix e no dre P=1. 47.6mg n.s.s.		6/71	1/18			
1,2-DI-n-BUTYLHYDRAZINE.2HCl 78776-28-0						
973 M f swa wat 93w93 1116		0	125.mg			Toth;expa,37,773-775;1981
lun mix e 69.8mg P<.0005 + 40.5mg 149.mg		25/99	36/50			
--- mly e 198.mg P<.003 + 93.2mg 1.29gm		18/100	21/50			
liv agm e no dre P=1. - 517.mg n.s.s.		3/47	1/36			
liv ang e no dre P=1. - 379.mg n.s.s.		3/47	2/36			
974 M m swa wat 87w87 1116		0	104.mg			
lun mix e 34.5mg P<.0005 + 20.2mg 67.3mg		26/100	38/46			
kid mix e 449.mg P<.004 + 155.mg 3.51gm		0/70	4/38			
--- mly e 886.mg P<.4 + 186.mg n.s.s.		8/100	6/46			
liv agm e no dre P=1. - 416.mg n.s.s.		5/70	1/38			
liv ang e no dre P=1. - 420.mg n.s.s.		3/80	1/42			
tert-BUTYLHYDROQUINONE 1948-33-0						
975 M f b6c eat 24m24 TR459 :		0	162.mg	325.mg	650.mg	
hag MXA # 1.76gm Z P<.005 - 760.mg 14.5gm		0/51	1/52	6/51	(1/54)	hag:ade,car. S
hag ade 2.06gm Z P<.005 841.mg 16.8gm		0/51	0/52	6/51	(1/54)	S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv hpa	293.mg Z	P<.03		124.mg n.s.s.	9/51	20/52	(16/51	5/54)		s
TBA MXB	no dre	P=1.		869.mg n.s.s.	32/51	41/52	36/51	33/54		
liv MXB	283.mg Z	P<.07		110.mg n.s.s.	17/51	28/52	(23/51	10/54)	liv:hpa,hpb,hpc.	
lun MXB	no dre	P=1.		2.98gm n.s.s.	5/51	2/52	5/51	3/54	lun:a/a,a/c.	
976 M m b6c eat 24m24 TR459 :					0	150.mg	300.mg	600.mg		
TBA MXB	no dre	P=1.	-	605.mg n.s.s.	39/50	44/50	42/51	36/51		
liv MXB	no dre	P=1.		349.mg n.s.s.	31/50	28/50	29/51	(17/51)	liv:hpa,hpb,hpc.	
lun MXB	no dre	P=1.		1.33gm n.s.s.	15/50	15/50	11/51	14/51	lun:a/a,a/c.	
2,4,6-TRI-tert-BUTYLPHENOL 732-26-3										
977 R f wis eat 52w52 2340m					0	1.50mg	5.00mg	15.0mg	50.0mg	Matsumoto;jtxs,16,167-179;1991/pers.comm.
liv tum ekr	no dre	P=1.	-	.378mg n.s.s.	0/7	0/7	0/7	0/7	0/7	
978 R f wis eat 78w78 2340n					0	1.50mg	5.00mg	15.0mg	50.0mg	
liv tum ekr	no dre	P=1.	-	.851mg n.s.s.	0/7	0/7	0/7	0/7	0/7	
979 R f wis eat 24m24 2340o					0	1.50mg	5.00mg	15.0mg	50.0mg	
liv tum er	no dre	P=1.	-	4.11mg n.s.s.	0/19	0/19	0/19	0/19	0/19	
980 R m wis eat 52w52 2340m					0	1.20mg	4.00mg	12.0mg	40.0mg	
liv tum er	no dre	P=1.	-	.303mg n.s.s.	0/7	0/7	0/7	0/7	0/7	
981 R m wis eat 78w78 2340n					0	1.20mg	4.00mg	12.0mg	40.0mg	
liv tum er	no dre	P=1.	-	.681mg n.s.s.	0/7	0/7	0/7	0/7	0/7	
982 R m wis eat 24m24 2340o					0	1.20mg	4.00mg	12.0mg	40.0mg	
liv tum er	no dre	P=1.	-	3.29mg n.s.s.	0/19	0/19	0/19	0/19	0/19	
p-tert-BUTYLPHENOL 98-54-4										
983 R m f3d eat 51w52 1950					0	588.mg				Hirose;canr,48,5310-5315;1988/pers.comm.
for pam	1.46gm	P<.4		238.mg n.s.s.	0/10	1/15				
stg tum	no dre	P=1.		455.mg n.s.s.	0/10	0/15				
N-BUTYLUREA 592-31-4										
984 M f cb6 eat 52w69 1361					0	567.mg				Murthy;ijcn,23,253-259;1979
liv hpc e	no dre	P=1.	-	1.24gm n.s.s.	1/92	0/24				
lun ade e	no dre	P=1.	-	1.24gm n.s.s.	2/92	0/24				
tba mix e	no dre	P=1.	-	501.mg n.s.s.	17/92	4/24				
985 M m cb6 eat 52w69 1361					0	523.mg				
lun ade e	5.51gm	P<.4	-	682.mg n.s.s.	1/95	1/26				
liv hpc e	no dre	P=1.	-	1.23gm n.s.s.	2/95	0/26				
tba mix e	699.mg	P<.02	-	244.mg n.s.s.	8/95	7/26				
986 R f f34 eat 52w69 1361					0	218.mg				
liv tum e	no dre	P=1.	-	317.mg n.s.s.	0/44	0/16				
tba mix e	no dre	P=1.	-	127.mg n.s.s.	20/44	5/16				
987 R m f34 eat 52w69 1361					0	175.mg				
liv tum e	no dre	P=1.	-	253.mg n.s.s.	0/50	0/16				
tba mix e	no dre	P=1.	-	84.4mg n.s.s.	30/50	7/16				
beta-BUTYROLACTONE 3068-88-0										
988 R f esd gav 70w70 55					0	40.8mg				Van Duuren;jnci,37,825-838;1966
for sqc	13.8mg	P<.02	+	3.85mg n.s.s.	0/5	3/5				
gamma-BUTYROLACTONE 96-48-0										
989 M f b6c gav 24m24 TR406 :					0	185.mg	370.mg			
TBA MXB	4.30gm *	P<.9	-	307.mg n.s.s.	33/50	31/50	35/50			
liv MXB	no dre	P=1.		1.95gm n.s.s.	8/50	2/50	4/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.		1.56gm n.s.s.	7/50	4/50	4/50		lun:a/a,a/c.	
990 M m b6c gav 24m24 TR406 :					0	185.mg	371.mg			
amd MXA s	2.29gm *	P<.4	e	535.mg n.s.s.	2/50	6/50	1/50		amd:pbb,phm,pob.	
TBA MXB s	660.mg *	P<.4		170.mg n.s.s.	40/50	31/50	23/50			
liv MXB s	no dre	P=1.		690.mg n.s.s.	24/50	8/50	9/50		liv:hpa,hpc,nnd.	
lun MXB s	2.10gm *	P<.5		408.mg n.s.s.	10/50	9/50	6/50		lun:a/a,a/c.	
991 R f f34 gav 24m24 TR406 :					0	158.mg	317.mg			
TBA MXB	no dre	P=1.	-	226.mg n.s.s.	46/50	46/50	41/50			
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.	
992 R m f34 gav 24m24 TR406 :					0	79.1mg	159.mg			
amd phm #	880.mg *	P<.02	-	357.mg n.s.s.	0/50	1/50	5/50			s
--- msm	1.14gm *	P<.03		428.mg n.s.s.	0/50	1/50	4/50			s
TBA MXB	no dre	P=1.		142.mg n.s.s.	45/50	42/50	47/50			
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.	
CADMIUM ACETATE 543-90-8										
993 M f cd1 wat 30m30 56					0	1.00mg				Schroeder;jnut,83,239-250;1964
lun car e	no dre	P=1.	-	4.71mg n.s.s.	9/60	5/39				
tba tum e	no dre	P=1.	-	4.14mg n.s.s.	22/60	10/39				
994 M m cd1 wat 28m28 56					0	.833mg				
lun car e	no dre	P=1.	-	11.0mg n.s.s.	8/44	0/48				
tba tum e	no dre	P=1.	-	9.55mg n.s.s.	11/44	1/48				
995 R b leb wat 41m41 1036					0	.265mg				Kanisawa;canr,29,892-895;1969
liv tum es	37.7mg	P<.8	-	3.29mg n.s.s.	1/34	2/47				
tba tum es	1.81mg	P<.2	-	.668mg n.s.s.	10/34	22/47				
tba mal es	5.10mg	P<.2	-	1.56mg n.s.s.	2/34	7/47				
CADMIUM CHLORIDE 10108-64-2										
996 H f syg inh 60w76 1909m					0	52.5ug				Heinrich;expl,37,253-258;1989/pers.comm.
lun tum or	no dre	P=1.	-	.139mg n.s.s.	0/24	0/24				
997 H f syg inh 64w76 1909n					0	18.7ug				
lun tum or	no dre	P=1.	-	49.3ug n.s.s.	0/24	0/24				
998 H m syg inh 14m24 1909m					0	34.5ug				
lun tum or	no dre	P=1.	-	.164mg n.s.s.	0/24	0/24				
999 H m syg inh 15m26 1909n					0	11.1ug				
lun tum or	no dre	P=1.	-	64.6ug n.s.s.	0/24	0/24				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
1000 M f nmr inh 42w82 1909m				0	75.0ug				
lun mix eor	no dre	P=1.	- .126mg n.s.s.	11/43	8/41				
lun ade eor	no dre	P=1.	- .139mg n.s.s.	8/43	6/41				
lun adc eor	no dre	P=1.	- .211mg n.s.s.	3/43	2/41				
1001 M f nmr inh 69w89 1909n				0	37.8ug				
lun ade eor	no dre	P=1.	- .207mg n.s.s.	9/45	1/43				
lun mix eor	no dre	P=1.	- .221mg n.s.s.	17/45	1/43				
lun adc eor	no dre	P=1.	- .246mg n.s.s.	8/45	0/43				
1002 R m nbl wat 24m24 2599				0	2.04mg	4.07mg	8.15mg	16.3mg	Waalkes;jtxe,58,199-214;1999/pers.comm.
kid mix e	114.mg	* P<.008	+ 43.1mg 2.34gm	0/29	0/29	0/29	2/30	3/29	
kid mmt e	193.mg	* P<.08	58.4mg n.s.s.	0/29	0/29	0/29	2/30	1/29	
k/p tcc e	584.mg	* P<.2	95.1mg n.s.s.	0/29	0/29	0/29	0/30	1/29	
kid lip e	584.mg	* P<.2	95.1mg n.s.s.	0/29	0/29	0/29	0/30	1/29	
adr pbm e	686.mg	* P<.9	28.4mg n.s.s.	2/29	3/30	8/30	6/30	3/29	
liv tum e	no dre	P=1.	6.33mg n.s.s.	0/29	0/29	0/30	0/30	0/29	
pro tum e	no dre	P=1.	5.69mg n.s.s.	0/28	0/26	0/26	0/29	0/27	
1003 R f wis inh 6m29 1908m				0	11.7ug				Oldiges;txec,19,217-222;1989/Glaser 1990
lun mix eor	64.5ug	P<.03	19.5ug n.s.s.	0/20	3/18				
lun sqa eor	99.8ug	P<.08	24.5ug n.s.s.	0/20	2/18				
lun adc eor	.206mg	P<.3	33.5ug n.s.s.	0/20	1/18				
1004 R f wis inh 18m31 1908n				0	10.9ug				
lun mix eor	9.71ug	P<.0005	+ 4.81ug 22.7ug	0/20	13/18				
lun adc eor	25.3ug	P<.0005	10.8ug 88.9ug	0/20	7/18				
lun a/a eor	49.5ug	P<.02	17.0ug n.s.s.	0/20	4/18				
lun adq eor	.106mg	P<.08	25.9ug n.s.s.	0/20	2/18				
1005 R m wis inh 18m31 1907				0	3.34ug	6.68ug	13.4ug		Takenaka;jnci,70,367-373;1983
lun car eo	12.7ug	* P<.0005	+ 8.89ug 18.8ug	0/38	6/39	20/38	25/35		
lun adc eo	22.0ug	* P<.0005	14.6ug 35.9ug	0/38	4/39	16/38	15/35		
lun epc eo	58.8ug	* P<.0005	32.3ug .158mg	0/38	2/39	5/38	8/35		
lun mec eo	.315mg	* P<.03	95.5ug n.s.s.	0/38	0/39	0/38	3/35		
lun ade eo	.563mg	* P<.5	.118mg n.s.s.	0/38	1/39	0/38	1/35		
adr pbm eo	.591mg	* P<.8	49.7ug n.s.s.	2/38	8/39	4/38	4/35		
1006 R m wis inh 6m30 1908m				0	7.91ug				Oldiges;txec,19,217-222;1989/Glaser 1990
lun mix eor	10.6ug	P<.0005	+ 5.19ug 26.3ug	0/40	11/20				
lun adc eor	29.4ug	P<.002	11.1ug .128mg	0/40	5/20				
lun a/a eor	52.1ug	P<.01	15.7ug 2.57mg	0/40	3/20				
lun sqa eor	52.1ug	P<.01	15.7ug 2.57mg	0/40	3/20				
1007 R m wis inh 18m30 1908n				0	7.91ug				
lun mix eor	6.11ug	P<.0005	+ 3.13ug 13.5ug	0/40	15/20				
lun adc eor	9.24ug	P<.0005	4.61ug 22.1ug	0/40	12/20				
lun a/a eor	80.4ug	P<.04	19.8ug n.s.s.	0/40	2/20				
lun adq eor	.165mg	P<.2	26.9ug n.s.s.	0/40	1/20				
1008 R m wis eat 77w77 2027				0	1.63mg	3.26mg	6.52mg	13.0mg	Waalkes;faat,19,512-520;1992/pers.comm.
tes icb e	31.6mg	* P<.03	+ 12.1mg n.s.s.	1/28	2/27	1/25	1/24	6/27	
pro ade e	56.9mg	* P<.3	+ 15.3mg n.s.s.	0/28	1/26	2/22	1/23	2/26	
--- lle e	no dre	P=1.	+ 16.9mg n.s.s.	1/28	4/27	5/24	5/24	1/27	
1009 R m wis wat 78w78 2658				0	4.00mg				Martin;prst,46,11-20;2001
prv tum Cer	no dre	P=1.	4.64mg n.s.s.	0/10	0/10				
CADMIUM CHLORIDE MONOHYDRATE 35658-65-2									
1010 R f wsb eat 72w72 2619				0	.815mg	4.07mg	20.4mg		Bomhard;dact,22,679-703;1999/pers.comm.
kid tum er	no dre	P=1.	- .779mg n.s.s.	0/12	0/12	0/12	0/12		
1011 R m wsb eat 72w72 2619				0	.652mg	3.26mg	16.3mg		
kid tum er	no dre	P=1.	- .623mg n.s.s.	0/12	0/12	0/12	0/12		
1012 R f wws eat 24m24 1139				0	49.5ug	.149mg	.495mg	2.48mg	Loser;clet,9,191-198;1980
liv hpt e	no dre	P=1.	- .343mg n.s.s.	0/94	0/48	0/48	0/48	0/46	
tba mix e	21.6mg	* P<.7	- 2.74mg n.s.s.	54/94	23/48	17/48	31/48	25/46	
tba ben e	44.0mg	* P<.8	- 3.56mg n.s.s.	46/94	19/48	16/48	22/48	21/46	
tba mal e	124.mg	* P<.9	- 6.66mg n.s.s.	10/94	6/48	7/48	11/48	6/46	
1013 R m wws eat 24m24 1139				0	39.6ug	.119mg	.396mg	1.98mg	
adr phe e	1.33mg	Z P<.04	- .432mg n.s.s.	2/98	0/50	5/50	(2/50	2/50)	
liv hpt e	no dre	P=1.	- 24.2mg n.s.s.	0/98	1/50	0/50	0/50	0/50	
tba mal e	47.4mg	* P<.5	- 7.94mg n.s.s.	4/98	4/50	2/50	1/50	4/50	
tba ben e	no dre	P=1.	- 6.32mg n.s.s.	40/98	18/50	25/50	23/50	15/50	
tba mix e	no dre	P=1.	- 5.23mg n.s.s.	43/98	21/50	26/50	24/50	18/50	
CADMIUM DIETHYLDITHIOCARBAMATE (ethyl cadmate) 14239-68-0									
1014 M f b6a orl 76w76 1140				0	8.96mg				Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- 9.99mg n.s.s.	1/17	1/17				
liv hpt evx	no dre	P=1.	- 16.8mg n.s.s.	0/17	0/17				
tba mix evx	47.5mg	P<.7	- 5.99mg n.s.s.	2/17	3/17				
1015 M m b6a orl 76w76 1140				0	8.34mg				
liv hpt evx	no dre	P=1.	- 16.5mg n.s.s.	1/18	0/18				
lun ade evx	no dre	P=1.	- 16.5mg n.s.s.	2/18	0/18				
tba mix evx	no dre	P=1.	- 11.7mg n.s.s.	3/18	1/18				
1016 M f b6c orl 76w76 1140				0	8.96mg				
lun ade evx	57.4mg	P<.3	- 9.34mg n.s.s.	0/16	1/18				
liv hpt evx	no dre	P=1.	- 17.8mg n.s.s.	0/16	0/18				
tba mix evx	18.0mg	P<.05	- 5.43mg n.s.s.	0/16	3/18				
1017 M m b6c orl 76w76 1140				0	8.34mg				
liv hpt evx	16.7mg	P<.05	- 5.05mg n.s.s.	0/16	3/18				
lun ade evx	25.9mg	P<.2	- 6.36mg n.s.s.	0/16	2/18				
tba mix evx	6.20mg	P<.002	- 2.64mg 25.2mg	0/16	7/18				
CADMIUM SULPHATE (1:1) 10124-36-4									
1018 H f syg inh 61w76 1909m				0	60.8ug				Heinrich;expl,37,253-258;1989/pers.comm.
lun tum or	no dre	P=1.	- .160mg n.s.s.	0/24	0/24				

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD50 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
1019 H f syg inh 64w77 1909n	0	21.0ug			
lun tum or no dre P=1. - 56.9ug n.s.s.	0/24	0/24			
1020 H m syg inh 14m24 1909m	0	39.4ug			
lun tum or no dre P=1. - .191mg n.s.s.	0/24	0/24			
1021 H m syg inh 15m26 1909n	0	12.6ug			
lun tum or no dre P=1. - 73.4ug n.s.s.	0/24	0/24			
1022 M f nmr inh 42w96 1909m	0	72.9ug			
lun adc eor .829mg P<.5 - .158mg n.s.s.	3/43	5/43			
lun ade eor no dre P=1. - .232mg n.s.s.	8/43	5/43			
lun mix eor no dre P=1. - .139mg n.s.s.	11/43	10/43			
1023 M f nmr inh 69w94 1909n	0	40.7ug			
lun mix eor no dre P=1. - .102mg n.s.s.	17/45	10/43			
lun ade eor no dre P=1. - .111mg n.s.s.	9/45	6/43			
lun adc eor no dre P=1. - .145mg n.s.s.	8/45	4/43			
1024 R f wis inh 18m29 1908	0	39.9ug			Oldiges;txec,19,217-222;1989/Glaser 1990
lun mix eor 17.4ug P<.0005 + 8.29ug 38.1ug	0/20	18/20			
lun adc eor .112mg P<.003 45.6ug .587mg	0/20	6/20			
lun adq eor .112mg P<.003 45.6ug .587mg	0/20	6/20			
lun a/a eor .180mg P<.02 61.9ug n.s.s.	0/20	4/20			
lun sqa eor .381mg P<.1 93.6ug n.s.s.	0/20	2/20			
1025 R m wis inh 14m31 1908	0	20.3ug			
lun mix eor 28.9ug P<.0005 + 14.2ug 71.8ug	0/40	11/20			
lun adc eor 53.7ug P<.0005 23.0ug .172mg	0/40	7/20			
lun adq eor .219mg P<.04 53.9ug n.s.s.	0/40	2/20			
lun a/a eor .219mg P<.04 53.9ug n.s.s.	0/40	2/20			
CADMIUM SULPHATE (1:1) HYDRATE (3:8) 7790-84-3					
1026 M m swi gav 78w78 1044	0	62.9ug	.126mg	.250mg	Levy;anoh,17,213-220;1975
lun mix e 1.78mg * P<.6 - .307mg n.s.s.	33/149	14/50	9/50	14/49	
liv mix e no dre P=1. - .492mg n.s.s.	50/149	18/50	18/50	11/49	
1027 R m cbo gav 24m26 1045	0	26.2ug	52.3ug	.105mg	Levy;anoh,17,205-211;1975
liv lca 1.17mg * P<.07 - .359mg n.s.s.	1/90	2/30	0/30	3/30	
CAFFEIC ACID (3,4-dihydroxy-cinnamic acid) 331-39-5					
1028 M f b6c eat 96w96 1932	0	2.60gm			Hagiwara;canr,51,5655-5660;1991/pers.comm.
kid tla e 4.70gm P<.0005 + 2.12gm 15.4gm	0/29	8/29			
for sqc e 43.3gm P<.3 + 7.04gm n.s.s.	0/29	1/29			
liv hpc e no dre P=1. 13.2gm n.s.s.	1/29	0/29			
lun ala e no dre P=1. 6.00gm n.s.s.	4/29	3/29			
tba tum e 1.90gm P<.004 877.mg 16.6gm	9/29	20/29			
1029 M m b6c eat 96w96 1932	0	2.40gm			
for mix e 5.27gm P<.002 + 2.27gm 22.6gm	0/28	7/30			
lun mix e 5.12gm P<.02 + 2.13gm n.s.s.	1/28	8/30			
lun ala e 6.11gm P<.03 + 2.38gm n.s.s.	1/28	7/30			
for pam e 9.79gm P<.02 3.38gm n.s.s.	0/28	4/30			
for sqc e 13.3gm P<.05 4.02gm n.s.s.	0/28	3/30			
lun alc e 41.3gm P<.3 6.73gm n.s.s.	0/28	1/30			
liv hnd e no dre P=1. 4.63gm n.s.s.	6/28	5/30			
liv hpc e no dre P=1. 7.12gm n.s.s.	7/28	3/30			
tba tum e 3.21gm P<.2 977.mg n.s.s.	15/28	21/30			
1030 R f f3d eat 24m24 1932	0	1.00gm			
for mix e 298.mg P<.0005 + 162.mg 560.mg	0/30	27/30			
for pam e 426.mg P<.0005 244.mg 795.mg	0/30	24/30			
for sqc e 989.mg P<.0005 534.mg 2.11gm	0/30	15/30			
liv hnd e no dre P=1. 4.14gm n.s.s.	2/30	1/30			
tba tum e 312.mg P<.004 105.mg 3.07gm	21/30	29/30			
1031 R m f3d eat 24m24 1932	0	800.mg			
for mix e 272.mg P<.0005 + 152.mg 507.mg	0/30	26/30			
for pam e 377.mg P<.0005 217.mg 707.mg	0/30	23/30			
for sqc e 656.mg P<.0005 364.mg 1.34gm	0/30	17/30			
kid tla e 3.83gm P<.02 + 1.32gm n.s.s.	0/30	4/30			
liv hnd e no dre P=1. 3.31gm n.s.s.	2/30	1/30			
liv hpc e no dre P=1. 4.95gm n.s.s.	1/30	0/30			
tba tum e no dre P=1. 138.mg n.s.s.	30/30	29/30			
1032 R m f3d eat 51w52 2080	0	392.mg			Hirose;carc,13,1825-1828;1992/pers.comm.
for sqp e 217.mg P<.02 + 74.3mg n.s.s.	0/15	4/15			
liv tum e no dre P=1. 303.mg n.s.s.	0/15	0/15			
1033 R m f3d eat 60w60 2134	0	800.mg			Ito;anti,183-194;1990/pers.comm.
for sqp er 542.mg P<.004 + 220.mg 3.40gm	0/19	6/21			
for sqc er no dre P=1. 1.15gm n.s.s.	0/19	0/21			
CAFFEINE 58-08-2					
1034 M f cb6 eat 77w77 1028	0	55.0mg			Macklin;dact,3,135-163;1980
liv tum e no dre P=1. - 230.mg n.s.s.	0/36	0/37			
1035 M m cb6 eat 77w77 1028	0	55.0mg			
liv hnd e 775.mg P<.3 - 126.mg n.s.s.	0/35	1/38			
1036 M f chh wat 24m24 2270 :	0	100.mg			Nagasawa;ejca,24,803-805;1988/pers.comm.
mgl adc Lgr 58.1mg P<.3 14.6mg n.s.s.	17/18	15/16			
1037 R f f3d wat 54w54 2612	0	57.1mg			Hagiwara;gann,90,399-405;1999
col tum e no dre P=1. - 31.7mg n.s.s.	0/10	0/10			
mgl tum e no dre P=1. - 31.7mg n.s.s.	0/10	0/10			
1038 R f sda gav 24m24 1326	0	71.4mg			Brune;zkko,102,153-157;1981
mix mix r no dre P=1. - 471.mg n.s.s.	0/32	0/32			
1039 R f sda wat 24m24 1615	0	11.4mg	24.6mg	53.1mg 114.mg	Mohr;fctx,22,377-382;1984
liv cad e 15.6gm * P<.9 - 849.mg n.s.s.	1/100	2/50	0/50	1/50 1/50	
liv clc e no dre P=1. - 1.32gm n.s.s.	1/100	0/50	2/50	0/50 0/50	
liv hpa e no dre P=1. - 1.21gm n.s.s.	0/100	0/50	1/50	0/50 0/50	
tba mix e no dre P=1. - 281.mg n.s.s.	84/100	40/50	40/50	36/50 31/50	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
1040 R m sda gav 24m24 1326	0	71.4mg			Brune;zkko,102,153-157;1981
mix mix r 448.mg P<.3 - 113.mg n.s.s.	3/32	6/32			
eso ben r 734.mg P<.3 - 163.mg n.s.s.	1/32	3/32			
for pam r 1.44gm P<.7 - 177.mg n.s.s.	2/32	3/32			
1041 R m sda eat 25m25 1459	0	40.8mg			Johansson;ijcn,27,521-529;1981
liv tum s no dre P=1. - 267.mg n.s.s.	0/30	0/30			
1042 R m sda wat 24m24 1615	0	10.0mg	21.5mg	46.5mg 100.mg	Mohr;fctx,22,377-382;1984
liv clc e no dre P=1. - 1.18gm n.s.s.	1/100	0/50	0/50	1/50 0/50	
liv hpa e no dre P=1. - 1.65gm n.s.s.	2/100	1/50	0/50	0/50 0/50	
tba mix e no dre P=1. - 366.mg n.s.s.	69/100	35/50	29/50	27/50 22/50	
1043 R m sda eat 88w88 2211	0	40.8mg			Johansson;carc,9,783-787;1988
k/p mix e no dre P=1. 169.mg n.s.s.	0/30	0/28			
liv tum e no dre P=1. 169.mg n.s.s.	0/30	0/28			
ubl mix e no dre P=1. 169.mg n.s.s.	0/30	0/28			
1044 R f wis wat 18m24 1526	0	42.9mg	85.7mg		Takayama;gann,73,365-371;1982
tba mix e no dre P=1. - 76.3mg n.s.s.	41/50	44/48	37/50		
1045 R m wis wat 18m24 1526	0	37.5mg	75.0mg		
tba mix e no dre P=1. - 126.mg n.s.s.	24/46	31/48	18/44		
CALCIFEROL (vitamin D2) 50-14-6					
1046 M f c3h eat 24m24 1131	0	65.0ug	.130mg	.260mg .520mg 1.04mg	Gass;ircs,5,477;1977
mgl adc Lr 39.6mg Z P<1. .889mg n.s.s.	16/64	18/68	23/46	17/66 9/31 (0/7)	
CALCIUM ACETATE 62-54-4					
1047 R m sda eat 79w79 1709	0	1.20gm			Kasprzak;carc,6,279-282;1985
kid tum e no dre P=1. 4.28gm n.s.s.	0/30	0/30			
liv tum e no dre P=1. 4.28gm n.s.s.	0/30	0/30			
CALCIUM CHLORIDE 10043-52-4					
1048 R m wis wat 52w52 2083	0	100.mg	500.mg		Nishikawa;carc,13,1155-1158;1992
sto tum er no dre P=1. 64.4mg n.s.s.	0/15	0/15	0/15		
CALCIUM LACTATE 814-80-2					
1049 R f f3d wat 24m26 2014	0	1.31gm	2.63gm		Maekawa;fctx,29,589-594;1991
liv hpa e no dre P=1. 10.7gm n.s.s.	1/49	0/50	0/50		
tba tum e 103.gm * P<1. 1.84gm n.s.s.	39/49	43/50	40/50		
1050 R m f3d wat 24m26 2014	0	1.15gm	2.30gm		
liv hpa e 54.5gm * P<.4 13.0gm n.s.s.	1/49	1/50	3/50		
tba tum e noTD50 P=1. n.s.s. n.s.s.	49/49	50/50	50/50		
CALCIUM VALPROATE 33433-82-8					
1051 R f crw eat 24m24 2275	0	125.mg	250.mg	500.mg	Watkins;txcy,71,35-47;1992
ute adc 1.30gm * P<.006 + 649.mg 15.1gm	4/50	10/50	7/50	16/50	
liv tum no dre P=1. 736.mg n.s.s.	0/50	0/50	0/50	0/50	
ute esp no dre P=1. 2.30gm n.s.s.	5/50	4/50	2/50	5/50	
1052 R m crw eat 24m24 2275	0	125.mg	250.mg	500.mg	
liv tum no dre P=1. 736.mg n.s.s.	0/50	0/50	0/50	0/50	
CAMOSTAT MESYLATE (FOY 305) 59721-29-8					
1053 R m f3d eat 52w52 2192	0	40.0mg			Shibata;carc,14,1265-1269;1993/pers.comm.
for tum er no dre P=1. 20.6mg n.s.s.	0/10	0/10			
CANDESARTAN CILEXETIL (TCV-116) 145040-37-5					
1054 R f f3j eat 24m24 2418	0	100.mg	300.mg	1.00gm	Nonoyama;jjpt,24,S899-913;1996
liv hpa e no dre P=1. - 9.56gm n.s.s.	3/100	1/50	2/50	0/50	
tba mix e 11.2gm * P<.9 - 462.mg n.s.s.	89/100	45/50	43/50	45/50	
1055 R m f3j eat 24m24 2418	0	100.mg	300.mg	1.00gm	
liv hpa e no dre P=1. - 8.68gm n.s.s.	2/100	2/50	2/50	0/50	
tba mix e noTD50 P=1. - n.s.s. n.s.s.	100/100	50/50	50/50	50/50	
CAPROLACTAM 105-60-2					
1056 M f b6c eat 24m24 TR214 :	0	956.mg	1.91gm		
TBA MXB no dre P=1. - 1.62gm n.s.s.	31/50	25/50	(16/50)		
liv MXB no dre P=1. 13.4gm n.s.s.	1/50	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 26.9gm n.s.s.	3/50	0/50	0/50		lun:a/a,a/c.
1057 M m b6c eat 24m24 TR214 :	0	883.mg	1.77gm		
TBA MXB no dre P=1. - 3.51gm n.s.s.	21/50	18/50	19/50		
liv MXB 34.3gm * P<.8 3.82gm n.s.s.	8/50	10/50	10/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 6.47gm n.s.s.	4/50	5/50	4/50		lun:a/a,a/c.
1058 R f f34 eat 24m24 TR214 :	0	184.mg	368.mg		
TBA MXB no dre P=1. - 361.mg n.s.s.	45/49	46/50	38/50		
liv MXB no dre P=1. n.s.s. n.s.s.	0/49	0/50	0/50		liv:hpa,hpc,nnd.
1059 R m f34 eat 24m24 TR214 :	0	147.mg	294.mg		
pit can # 3.56gm * P<.05 - 1.08gm n.s.s.	0/50	0/50	3/50		S
TBA MXB no dre P=1. 359.mg n.s.s.	38/50	32/50	35/50		
liv MXB 5.69gm * P<.7 804.mg n.s.s.	1/50	5/50	2/50		liv:hpa,hpc,nnd.
CAPSAICIN 404-86-4					
1060 M f b6c eat 79w83 2371	0	30.9mg	103.mg	309.mg	Akagi;fctx,36,1065-1071;1998
liv mix e no dre P=1. - 486.mg n.s.s.	7/50	3/48	2/50	(1/50)	
lun ade e no dre P=1. - 1.54gm n.s.s.	2/50	1/48	1/50	1/50	
tba mix e no dre P=1. - 1.23gm n.s.s.	16/50	12/48	11/50	5/50	
1061 M m b6c eat 79w83 2371	0	28.6mg	94.8mg	286.mg	
lun ade e 16.1gm * P<.9 - 677.mg n.s.s.	4/49	3/50	5/50	4/50	
liv mix e no dre P=1. - 360.mg n.s.s.	18/49	13/50	16/50	16/50	
tba mix e 2.04gm * P<.8 - 222.mg n.s.s.	31/49	20/50	21/50	28/50	
1062 M f swa eat 35m35 2039 :	0	40.6mg			Toth;vivo,6,59-64;1992/pers.comm.
cec pla 167.mg P<.2 + 50.5mg n.s.s.	4/50	11/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun ade	225.mg	P<.7	26.3mg n.s.s.	9/50	14/50			
lun mix	1.08gm	P<1.	29.5mg n.s.s.	14/50	18/50			
duo adc	2.31gm	P<.3	377.mg n.s.s.	0/50	1/50			
liv hct	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50			
1063 M m swa eat 29m29 2039 :				0	37.5mg			
duo mix	404.mg	P<.3	93.0mg n.s.s.	0/50	2/50			
cec pla	no dre	P=1. +	72.5mg n.s.s.	4/50	7/50			
liv hct	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50			
lun ade	no dre	P=1.	59.8mg n.s.s.	15/50	18/50			
lun mix	no dre	P=1.	48.4mg n.s.s.	19/50	22/50			
CAPTAFOL 2425-06-1								
1064 M f b6c eat 22m24 1625				0	90.0mg	180.mg	390.mg	Ito;gann,75,853-865;1984
liv mix ae	89.4mg Z	P<.0005 +	52.7mg 188.mg	4/48	27/50	(22/49	0/51)	
smi mix ae	359.mg Z	P<.0005 +	216.mg 666.mg	0/48	6/50	16/49	(12/51)	
liv hpc ae	398.mg Z	P<.003 +	216.mg 2.43gm	2/48	13/50	12/49	(0/51)	
smi adc ae	512.mg Z	P<.0005 +	286.mg 1.09gm	0/48	3/50	13/49	(7/51)	
hea hae ae	1.40gm *	P<.0005 +	770.mg 3.35gm	0/48	2/50	2/49	11/51	
for mix ae	3.14gm *	P<.007 +	1.36gm 43.5gm	0/48	1/50	1/49	5/51	
spl hem ae	1.47gm Z	P<.02 +	599.mg n.s.s.	0/48	2/50	4/49	(0/51)	
for sqc ae	22.6gm *	P<.2 +	3.68gm n.s.s.	0/48	0/50	0/49	1/51	
lun adc ae	134.gm *	P<1.	n.s.s. n.s.s.	1/48	1/50	3/49	1/51	
lun mix ae	no dre	P=1.	2.61gm n.s.s.	2/48	1/50	3/49	1/51	
1065 M m b6c eat 22m24 1625				0	83.1mg	166.mg	332.mg	
smi mix e	137.mg Z	P<.0005 +	93.5mg 212.mg	0/47	10/51	32/46	(26/47)	
liv hpc e	138.mg Z	P<.003 +	68.5mg 901.mg	8/47	23/51	(15/46	1/47)	
liv mix e	144.mg Z	P<.007	72.6mg 2.88gm	19/47	41/51	30/46	(3/47)	
smi adc e	151.mg Z	P<.0005 +	101.mg 237.mg	0/47	7/51	32/46	(22/47)	
hea hae e	647.mg Z	P<.0005 +	401.mg 1.14gm	0/47	1/51	4/46	20/47	
spl hem e	1.57gm Z	P<.008 +	596.mg 30.9gm	0/47	0/51	5/46	(0/47)	
for mix e	1.81gm *	P<.02 +	882.mg n.s.s.	0/47	2/51	4/46	4/47	
for sqc e	6.19gm *	P<.06 +	1.87gm n.s.s.	0/47	0/51	1/46	2/47	
spl mix e	2.56gm Z	P<.3	674.mg n.s.s.	2/47	0/51	5/46	(1/47)	
spl hae e	79.1gm *	P<.9 +	3.37gm n.s.s.	1/47	0/51	0/46	1/47	
lun adc e	no dre	P=1.	1.68gm n.s.s.	1/47	2/51	3/46	1/47	
lun mix e	no dre	P=1.	2.22gm n.s.s.	4/47	5/51	4/46	1/47	
1066 M f cd1 eat 24m26 2133				0	36.7mg	122.mg	367.mg	Quest;rtxp,17,19-34;1993/pers.comm.
--- lys er	1.49gm *	P<.004 +	722.mg 13.2gm	6/52	8/80	10/80	21/80	
--- hes er	3.13gm *	P<.006 +	1.52gm 44.2gm	0/52	1/80	3/80	6/80	
1067 M m cd1 eat 24m26 2133				0	33.9mg	113.mg	339.mg	
hag ade er	298.mg Z	P<.0005 +	188.mg 598.mg	0/52	8/80	19/80	(2/80)	
--- lys er	1.44gm *	P<.0005 +	822.mg 4.46gm	0/52	3/80	4/80	13/80	
--- hes er	3.31gm *	P<.02 +	1.42gm n.s.s.	1/52	0/80	5/80	6/80	
1068 R f cdr eat 24m24 2133				0	2.80mg	12.1mg	54.8mg	
liv mix er	120.mg *	P<.0005 +	64.0mg 325.mg	4/50	2/49	3/50	17/50	
liv nnd er	124.mg *	P<.0005 +	65.9mg 332.mg	4/50	2/49	2/50	17/50	
kid rcc er	776.mg *	P<.009 +	235.mg 31.3gm	0/50	0/50	0/50	3/50	
mgl fba er	71.6mg *	P<.02 +	31.1mg n.s.s.	18/49	26/49	28/50	33/50	
liv hpc er	781.mg *	P<.05	236.mg n.s.s.	0/50	0/49	1/50	2/50	
kid mix er	916.mg *	P<.08	245.mg n.s.s.	1/50	0/50	0/50	3/50	
kid rca er	no dre	P=1.	22.5mg n.s.s.	1/50	0/50	0/50	0/50	
1069 R m cdr eat 24m24 2133				0	2.24mg	9.64mg	43.8mg	
kid mix er	272.mg *	P<.003 +	110.mg 2.11gm	1/50	1/50	0/50	7/50	
kid rcc er	426.mg *	P<.02	143.mg n.s.s.	0/50	1/50	0/50	4/50	
kid rca er	733.mg *	P<.08	196.mg n.s.s.	1/50	0/50	0/50	3/50	
1070 R f f34 eat 24m24 1953				0	25.0mg	100.mg	250.mg	Nyska;isjm,25,428-432;1989
kid mix aers	no dre	P=1.	191.mg n.s.s.	0/50	0/50	0/50	0/49	
1071 R m f34 eat 24m24 1953				0	20.0mg	80.0mg	200.mg	
kid mix aers	504.mg *	P<.0005 +	290.mg 1.05gm	0/50	1/49	5/49	12/49	
kid tuc aers	570.mg *	P<.0005	318.mg 1.24gm	0/50	1/49	3/49	12/49	
kid tua aers	5.01gm *	P<.6	1.23gm n.s.s.	0/50	0/49	2/49	0/49	
1072 R f f3d eat 24m26 1941				0	34.8mg	69.6mg		Tamano;gann,81,1222-1231;1990
liv hnd e	64.4mg *	P<.0005 +	43.4mg 106.mg	3/50	14/50	34/50		
kid rca e	276.mg *	P<.004 +	149.mg 1.48gm	0/50	8/50	6/50		
thy cca e	353.mg *	P<.002	177.mg 1.14gm	0/50	3/50	8/50		
liv hpc e	1.01gm *	P<.02 +	349.mg n.s.s.	0/50	0/50	4/50		
1073 R m f3d eat 24m26 1941				0	27.9mg	55.7mg		
kid rca e	30.3mg *	P<.0005 +	21.8mg 43.3mg	0/50	26/49	38/50		
liv hnd e	104.mg *	P<.0005 +	63.3mg 220.mg	2/50	8/50	21/50		
kid rcc e	345.mg *	P<.002 +	163.mg 1.16gm	0/50	1/49	8/50		
liv hpc e	no dre	P=1.	675.mg n.s.s.	2/50	0/50	1/50		
CAPTAN 133-06-2								
1074 M f b6c eat 80w91 TR15 :				0	914.mg	1.83gm		
TBA MXB	no dre	P=1. -	4.11gm n.s.s.	3/10	5/50	8/50		
liv MXB	no dre	P=1.	11.0gm n.s.s.	1/10	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	n.s.s. n.s.s.	0/10	0/50	0/50		lun:a/a,a/c.
1075 M f b6c eat 80w90 TR15 : pool				0	914.mg	1.83gm		
duo aca u	21.6gm *	P<.03 a	6.53gm n.s.s.	0/79	0/50	3/50		
1076 M f b6c orl 76w76 1092				0	78.4mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1. -	155.mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1. -	155.mg n.s.s.	0/16	0/18			
tba mix evx	244.mg	P<.2 -	59.8mg n.s.s.	0/16	2/18			
1077 M m b6c eat 80w91 TR15 :				0	844.mg	1.69gm		
TBA MXB	no dre	P=1. -	3.94gm n.s.s.	5/10	7/50	10/50		
liv MXB	no dre	P=1.	8.87gm n.s.s.	3/10	1/50	3/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	3.04gm n.s.s.	2/10	3/50	(1/50)		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

1078 M m b6c eat 80w90 TR15 : pool				0	844.mg	1.69gm		
duo adm u	7.39gm	* P<.003	a 3.35gm 38.5gm	0/80	3/50	5/50		
duo aca u	15.1gm	* P<.03	a 5.22gm n.s.s.	0/80	1/50	3/50		
1079 M m b6c orl 76w76 1092				0	73.0mg			Innes;ntis,1968/1969
liv hpt evx	86.1mg	P<.02	- 29.5mg n.s.s.	0/16	4/15			
lun ade evx	187.mg	P<.09	- 45.8mg n.s.s.	0/16	2/15			
tba mix evx	42.5mg	P<.0005	- 18.0mg 149.mg	0/16	7/15			
1080 M f b6a orl 76w76 1092				0	78.4mg			
liv hpt evx	no dre	P=1.	- 147.mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	- 147.mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	- 97.0mg n.s.s.	2/17	1/17			
1081 M m b6a orl 76w76 1092				0	73.0mg			
liv hpt evx	195.mg	P<.3	- 44.6mg n.s.s.	1/18	3/17			
lun ade evx	3.62gm	P<1.	- 63.5mg n.s.s.	2/18	2/17			
tba mix evx	161.mg	P<.4	- 34.3mg n.s.s.	3/18	5/17			
1082 M f cd1 eat 26m26 2133m				0	762.mg	1.28gm	2.05gm	Quest;rtxp,17,19-34;1993/pers.comm.
smi mix rsv	1.74gm	Z P<.0005	+ 1.03gm 3.62gm	3/80	26/80	(21/80	29/80)	
smi car rsv	2.11gm	Z P<.0005	+ 1.23gm 4.33gm	1/80	21/80	(17/80	21/80)	
smi ade rsv	13.3gm	* P<.04	+ 6.09gm n.s.s.	4/80	12/80	9/80	13/80	
1083 M m cd1 eat 26m26 2133m				0	703.mg	1.18gm	1.89gm	
smi mix rsv	2.69gm	* P<.0005	+ 1.95gm 4.12gm	3/80	19/80	22/80	39/80	
smi car rsv	3.50gm	* P<.0005	+ 2.49gm 5.51gm	2/80	11/80	20/80	32/80	
smi ade rsv	8.28gm	* P<.003	+ 4.85gm 44.6gm	1/80	12/80	9/80	12/80	
1084 R f osm eat 19m26 TR15 :				0	89.0mg	212.mg		
TBA MXB v	no dre	P=1.	- 170.mg n.s.s.	8/10	39/50	36/50		
liv MXB v	no dre	P=1.	888.mg n.s.s.	0/10	3/50	1/50		liv:hpa,hpc,nnd.
1085 R f osm eat 19m25 TR15 : pool				0	89.0mg	212.mg		
adr MXA v#	253.mg	\ P<.02	- 109.mg n.s.s.	4/75	13/50	(7/50)		adr:coa,coc. S
1086 R m osm eat 19m26 TR15 :				0	71.2mg	170.mg		
TBA MXB v	4.78gm	* P<1.	- 124.mg n.s.s.	5/10	32/50	25/50		
liv MXB v	no dre	P=1.	798.mg n.s.s.	1/10	1/50	1/50		liv:hpa,hpc,nnd.
1087 R f cdr eat 24m24 2133m				0	25.0mg	100.mg	250.mg	Quest;rtxp,17,19-34;1993/pers.comm.
kid mix r	17.9gm	* P<.2	2.92gm n.s.s.	0/70	0/70	0/70	1/70	
kid ruc r	17.9gm	* P<.2	2.92gm n.s.s.	0/70	0/70	0/70	1/70	
kid rua r	no dre	P=1.	267.mg n.s.s.	0/70	0/70	0/70	0/70	
1088 R m cdr eat 24m24 2133m				0	20.0mg	80.0mg	200.mg	
kid mix r	2.69gm	* P<.09	+ 902.mg n.s.s.	1/70	1/70	3/70	4/70	
kid rua r	3.81gm	* P<.2	1.16gm n.s.s.	1/70	0/70	2/70	3/70	
kid ruc r	11.5gm	* P<.6	1.55gm n.s.s.	0/70	1/70	1/70	1/70	
1089 R f wis eat 30m30 2133n				0	6.25mg	25.0mg	100.mg	
ute sar rh	1.70gm	* P<.004	+ 588.mg 11.8gm	0/50	0/50	0/50	4/50	

CARBAMYL HYDRAZINE.HCl 563-41-7

1090 M f swa wat 27m27 60				0	125.mg			Toth;ejca,11,17-22;1975/1974
lun mix e	223.mg	P<.002	+ 111.mg 950.mg	21/90	25/47			
lun ade e	333.mg	P<.007	149.mg 5.61gm	18/90	20/47			
blv mix e	395.mg	P<.003	+ 164.mg 2.88gm	5/81	9/31			
blv ang e	798.mg	P<.04	256.mg n.s.s.	3/81	5/31			
liv mix e	798.mg	P<.04	256.mg n.s.s.	3/81	5/31			
blv agm e	975.mg	P<.05	292.mg n.s.s.	2/81	4/31			
1091 M m swa wat 27m27 60				0	104.mg			
liv hpt e	1.42gm	P<.03	- 350.mg n.s.s.	0/87	2/32			
lun ade e	745.mg	P<.2	224.mg n.s.s.	15/99	12/48			
lun mix e	833.mg	P<.4	+ 207.mg n.s.s.	23/99	15/48			
liv mix e	933.mg	P<.2	240.mg n.s.s.	6/87	5/32			

1-CARBAMYL-2-PHENYLHYDRAZINE 103-03-7

1092 M f swa wat 79w79 60a				0	500.mg			Toth;jnci,52,241-251;1974
lun ade e	150.mg	P<.0005	92.1mg 273.mg	18/100	39/50			
lun mix e	155.mg	P<.0005	+ 93.7mg 289.mg	21/100	39/50			
lun adc e	1.25gm	P<.007	513.mg 19.6gm	4/100	9/50			
liv ang e	1.98gm	P<.03	- 682.mg n.s.s.	0/34	4/42			
liv agm e	2.67gm	P<.06	- 807.mg n.s.s.	0/34	3/42			
1093 M m swa wat 79w79 60a				0	417.mg			
lun ade e	158.mg	P<.0005	94.8mg 305.mg	15/96	33/47			
lun mix e	176.mg	P<.0005	+ 101.mg 388.mg	23/96	33/47			
liv mix e	1.79gm	P<.3	429.mg n.s.s.	3/40	5/32			
liv ang e	2.00gm	P<.3	- 477.mg n.s.s.	2/40	4/32			

CARBARSONE 121-59-5

1094 R f fdr eat 22m24 65				0	25.0mg	50.0mg	69.2mg	Oser;txap,9,528-535;1966
--- lyk aes	4.59gm	* P<.4	- 747.mg n.s.s.	0/89	0/43	1/45	0/49	
1095 R m fdr eat 22m24 65				0	25.0mg	50.0mg	69.2mg	
thm rts aes	4.50gm	* P<.4	- 732.mg n.s.s.	0/85	0/39	1/43	0/50	

CARBARYL (sevin) 63-25-2

1096 M f b6a orl 76w76 1228				0	1.93mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- 2.30mg n.s.s.	1/17	1/18			
liv hpt evx	no dre	P=1.	- 3.82mg n.s.s.	0/17	0/18			
tba mix evx	no dre	P=1.	- 1.82mg n.s.s.	2/17	2/18			
1097 M m b6a orl 76w76 1228				0	1.80mg			
liv hpt evx	no dre	P=1.	- 2.12mg n.s.s.	1/18	1/18			
lun ade evx	no dre	P=1.	- 2.36mg n.s.s.	2/18	1/18			
tba mix evx	no dre	P=1.	- 1.86mg n.s.s.	3/18	2/18			
1098 M f b6c orl 76w76 1228				0	1.93mg			
liv hpt evx	no dre	P=1.	- 3.82mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	- 3.82mg n.s.s.	0/16	0/18			
tba mix evx	12.4mg	P<.3	- 2.01mg n.s.s.	0/16	1/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1099 M m b6c orl 76w76 1228				0	1.80mg			
liv hpt evx	3.39mg	P<.04	- 1.02mg n.s.s.	0/16	3/17			
lun ade evx	3.39mg	P<.04	- 1.02mg n.s.s.	0/16	3/17			
tba mix evx	1.51mg	P<.003	- .609mg 8.19mg	0/16	6/17			
1100 R b mgr gav 22m24 1426				0	7.88mg			Andrianova;vpit,29,71-74;1970
liv tum e	no dre	P=1.	19.5mg n.s.s.	0/46	0/12			
tba mix e	14.1mg	P<.003	+ 4.62mg 139.mg	1/46	4/12			
CARBAZOLE (9H-carbazole) 86-74-8								
1101 M f b6c eat 22m24 1481				0	180.mg	360.mg	749.mg	Tsuda;jnci,69,1383-1387;1982
liv hpc e	102.mg Z	P<.0005	+ 64.8mg 174.mg	2/45	35/49	(24/43	30/46)	
for pam e	1.29gm Z	P<.002	+ 663.mg 4.65gm	0/45	5/49	7/43	(4/46)	
for mix e	1.96gm *	P<.009	+ 1.15gm 83.3gm	0/45	5/49	8/43	6/46	
lun mix e	no dre	P=1.	7.93gm n.s.s.	2/45	0/49	0/43	1/46	
1102 M m b6c eat 22m24 1481				0	166.mg	332.mg	665.mg	
liv hpc e	424.mg *	P<.0005	+ 281.mg 763.mg	9/46	12/42	20/42	37/48	
for mix e	2.79gm *	P<.0005	+ 1.44gm 6.58gm	0/46	0/42	1/42	11/48	
for sqc e	4.94gm *	P<.002	+ 2.13gm 18.0gm	0/46	0/42	0/42	7/48	
for pam e	7.03gm *	P<.01	+ 2.67gm 430.gm	0/46	0/42	1/42	4/48	
lun mix e	no dre	P=1.	4.29gm n.s.s.	4/46	0/42	1/42	3/48	
CARBOFURAN (Furadan) 1563-66-2								
1103 M f icm wat 52w78 2592				0	.400mg	1.07mg		Wang;hjkx,9,505-508;1989
lun ade	11.1mg *	P<.1	- 3.37mg n.s.s.	0/60	1/60	2/60		
1104 M m icm wat 52w78 2592				0	.333mg	.889mg		
lun ade	no dre	P=1.	- 4.25mg n.s.s.	2/60	2/60	1/60		
CARBON TETRACHLORIDE 56-23-5								
1105 M f b6c gav 78w90 1469m				0	774.mg	1.55gm		Weisburger;enhp,21,7-16;1977/National Cancer Institute 1976
liv hpc ej	184.mg *	P<.0005	+ 119.mg 287.mg	1/18	40/42	43/45		
adr mix ej	899.mg \	P<.0005	+ 490.mg 2.35gm	0/18	15/42	(10/45)		
tba mix ej	195.mg *	P<.0005	123.mg 324.mg	3/18	40/42	43/45		
1106 M m b6c gav 78w90 1469m				0	774.mg	1.55gm		
liv hpc ej	127.mg *	P<.0005	+ 70.1mg 220.mg	3/18	49/49	47/48		
adr mix ej	683.mg *	P<.0005	+ 487.mg 1.21gm	0/18	28/49	28/48		
tba mix ej	130.mg *	P<.0005	70.9mg 230.mg	4/18	49/49	47/48		
1107 M f bdj inh 24m24 2378				0	9.84mg	49.2mg	246.mg	Nagano;apor,741-746;1998/pers.comm.
liv mix e	25.2mg *	P<.0005	+ 17.1mg 38.9mg	4/50	9/49	44/50	48/49	
liv hpc e	41.9mg Z	P<.0005	+ 27.0mg 70.5mg	2/50	1/49	33/50	(48/49)	
liv hpa e	85.4mg Z	P<.0005	+ 46.4mg 265.mg	2/50	8/49	17/50	(5/49)	
adr phe e	377.mg Z	P<.0005	+ 226.mg 692.mg	0/50	0/49	0/50	22/49	
lun a/c e	46.1gm *	P<1.	1.33gm n.s.s.	2/50	2/49	1/50	2/49	
lun a/a e	no dre	P=1.	2.72gm n.s.s.	4/50	2/49	1/50	0/49	
1108 M m bdj inh 24m24 2378				0	8.20mg	41.0mg	205.mg	
liv mix e	15.1mg *	P<.0005	+ 8.96mg 29.2mg	24/50	20/50	48/50	50/50	
liv hpc e	34.0mg *	P<.0005	+ 21.1mg 59.8mg	17/50	12/50	42/50	48/50	
liv hpa e	50.2mg Z	P<.0005	+ 28.1mg 135.mg	9/50	9/50	27/50	(16/50)	
adr phe e	126.mg *	P<.0005	+ 86.8mg 190.mg	0/50	0/50	16/50	31/50	
lun a/a e	no dre	P=1.	1.68gm n.s.s.	2/50	5/50	1/50	1/50	
lun a/c e	no dre	P=1.	48.2mg n.s.s.	11/50	4/50	(3/50	0/50)	
1109 R f f3d inh 24m24 2378				0	2.34mg	11.7mg	58.6mg	
liv mix e	29.8mg Z	P<.0005	+ 20.3mg 45.6mg	0/50	0/50	3/50	44/50	
liv hpa e	38.7mg Z	P<.0005	+ 25.9mg 61.0mg	0/50	0/50	0/50	40/50	
sub mix e	65.2mg Z	P<.003	28.2mg 329.mg	0/50	1/50	6/50	(0/50)	
liv hpc e	120.mg *	P<.0005	+ 68.9mg 236.mg	0/50	0/50	3/50	15/50	
adr phe e	no dre	P=1.	148.mg n.s.s.	8/50	12/50	19/50	10/50	
adr mix e	no dre	P=1.	155.mg n.s.s.	9/50	12/50	20/50	10/50	
1110 R m f3d inh 24m24 2378				0	1.64mg	8.20mg	41.0mg	
liv mix e	26.0mg Z	P<.0005	+ 17.4mg 40.8mg	1/50	1/50	1/50	40/50	
liv hpc e	39.1mg Z	P<.0005	+ 25.2mg 65.1mg	1/50	0/50	0/50	32/50	
liv hpa e	61.8mg *	P<.0005	+ 37.5mg 112.mg	0/50	1/50	1/50	21/50	
1111 R f nss ivj 47w69 1515				0	.157mg			Tourkevitch;ijcn,20,1446-1449;1964
liv tum	.877mg	P<.1	.265mg n.s.s.	0/34	3/57			
mgl mix	.765mg	P<.3	+ .214mg n.s.s.	1/34	5/57			
tba mix	.176mg	P<.007	87.0ug 2.27mg	2/34	16/57			
1112 R f osm gav 18m26 1469n				0	40.5mg	81.0mg		Weisburger;enhp,21,7-16;1977/National Cancer Institute 1976
liv nnd ej	390.mg *	P<.3	+ 140.mg n.s.s.	1/20	11/50	9/49		
liv hpc ej	no dre	P=1.	415.mg n.s.s.	1/20	4/50	2/49		
tba mix ej	no dre	P=1.	144.mg n.s.s.	10/20	34/50	20/49		
1113 R m osm gav 18m26 1469n				0	23.8mg	47.6mg		
liv nnd ej	529.mg *	P<.2	+ 201.mg n.s.s.	0/20	2/49	3/50		
liv hpc ej	666.mg *	P<.4	230.mg n.s.s.	0/20	2/49	2/50		
tba mix ej	166.mg *	P<.4	48.7mg n.s.s.	7/20	21/49	24/50		
CARBOXYMETHYLNITROSOUREA (CMNU) 60391-92-6								
1114 R f don wat 68w68 1547				0	5.71mg	11.4mg	22.9mg	Maekawa;zkko,106,12-16;1983
mgl mix e	2.30mg Z	P<.0005	+ 1.44mg 4.77mg	9/36	28/40	30/38	(11/34)	
mgl fba e	2.92mg Z	P<.0005	1.75mg 7.34mg	9/36	27/40	27/38	(10/34)	
itn mix e	5.37mg *	P<.0005	+ 3.75mg 7.98mg	0/36	5/40	19/38	27/34	
smi ade e	8.09mg *	P<.0005	5.45mg 12.7mg	0/36	4/40	15/38	20/34	
smi adc e	11.6mg *	P<.0005	7.38mg 19.5mg	0/36	1/40	9/38	19/34	
tba mix e	1.38mg *	P<.0005	.854mg 2.48mg	14/36	34/40	35/38	34/34	
1115 R m mrw wat 17m30 1246				0	5.29mg			Bulay;jnci,62,1523-1528;1979
epi mix	34.8mg	P<.02	+ 14.2mg n.s.s.	0/26	6/40			
liv tum	no dre	P=1.	68.1mg n.s.s.	0/26	0/40			
tba mix	13.1mg	P<.09	5.06mg n.s.s.	10/26	24/40			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | NCI/NTPPathology

CARBROMAL (bromodiethylacetylurea) 77-65-6

1116 M f b6c eat 18m24 TR173 :				0	122.mg	244.mg			
lun MXA #	553.mg *	P<.05	- 314.mg	n.s.s.	0/20	8/50	9/49		lun:a/a,a/c. S
TBA MXB	5.32gm *	P<1.	210.mg	n.s.s.	7/20	30/50	25/49		
liv MXB	1.95gm *	P<.09	739.mg	n.s.s.	0/20	1/50	4/49		liv:hpa,hpc,nnd.
lun MXB	553.mg *	P<.05	314.mg	n.s.s.	0/20	8/50	9/49		lun:a/a,a/c.
1117 M m b6c eat 18m24 TR173 :				0	112.mg	225.mg			
TBA MXB	no dre	P=1.	- 344.mg	n.s.s.	12/20	16/49	21/50		
liv MXB	1.58gm *	P<.6	321.mg	n.s.s.	4/20	8/49	13/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	748.mg	n.s.s.	7/20	4/49	8/50		lun:a/a,a/c.
1118 R f f34 eat 24m24 TR173 :				0	61.9mg	124.mg			
TBA MXB	no dre	P=1.	- 138.mg	n.s.s.	10/20	24/50	26/50		
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
1119 R m f34 eat 24m24 TR173 :				0	49.5mg	99.0mg			
TBA MXB	1.03gm *	P<.8	- 125.mg	n.s.s.	8/20	14/50	24/50		
liv MXB	no dre	P=1.	886.mg	n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.

beta-CAROTENE 7235-40-7

1120 M f cd1 eat 24m24 2391				0	100.mg	250.mg	500.mg	1.00gm	Heywood;txcy,36,91-100;1985/1985b/pers.comm.
liv hpa e	15.9gm *	P<.002	- 7.19gm	55.7gm	0/100	0/100	0/100	3/100	5/100
lun ade e	93.6gm *	P<.9	- 7.33gm	n.s.s.	10/100	1/100	6/100	6/100	7/100
liv hpc e	no dre	P=1.	- 25.8gm	n.s.s.	1/100	0/100	0/100	1/100	0/100
lun adc e	no dre	P=1.	- 6.30gm	n.s.s.	14/100	18/100	12/100	10/100	14/100
1121 M m cd1 eat 24m24 2391				0	100.mg	250.mg	500.mg	1.00gm	
lun adc e	26.4gm *	P<.7	- 3.49gm	n.s.s.	15/100	18/100	17/100	23/100	17/100
liv hpc e	49.7gm *	P<.9	- 3.28gm	n.s.s.	19/100	28/100	17/100	31/100	21/100
lun ade e	71.4gm *	P<.8	- 6.93gm	n.s.s.	5/100	7/100	3/100	7/100	6/100
liv hpa e	no dre	P=1.	- 5.45gm	n.s.s.	20/100	17/100	25/100	13/100	18/100
1122 R m wis eat 52w52 2331				0	83.1mg				Jones;jnut,119,508-514;1989
liv nnd ev	no dre	P=1.	59.9mg	n.s.s.	0/15	0/14			

CARRAGEENAN, ACID-DEGRADED (poligeenan) 53973-98-1

1123 R m f34 eat 26w78 1517m				0	1.33gm				Oohashi;clet,14,267-272;1981
clr mix r	2.43gm	P<.0005	+ 1.10gm	7.80gm	0/46	8/42			
clr sqc r	3.33gm	P<.003	1.36gm	17.5gm	0/46	6/42			
1124 R m f34 eat 39w78 1517n				0	2.00gm				
clr mix r	1.49gm	P<.0005	+ 836.mg	3.00gm	0/46	17/42			
1125 R b sda wat 65w65 611				0	2.65gm				Wakabayashi;clet,4,171-176;1978
clr mix er	2.20gm	P<.0005	+ 1.10gm	5.92gm	0/30	11/40			
1126 R b sda gav 65w65 611m				0	1.00gm	5.00gm			
clr mix er	5.16gm *	P<.0005	+ 2.33gm	15.2gm	0/30	0/30	8/29		

CARRAGEENAN, NATIVE 9000-07-1

1127 H f syg eat 78w78 1330				0	523.mg	2.61gm	5.23gm		Rustia;clet,11,1-10;1980
liv hem	no dre	P=1.	- 1.40gm	n.s.s.	1/100	0/30	0/30	0/30	
tba mix	177.gm *	P<.9	- 11.0gm	n.s.s.	5/100	0/30	3/30	1/30	
1128 H m syg eat 25m26 1330				0	460.mg	2.30gm	4.60gm		
liv hem a	no dre	P=1.	- 2.49gm	n.s.s.	1/100	0/30	0/30	0/30	
tba mix a	54.1gm *	P<.3	- 12.8gm	n.s.s.	6/100	2/30	2/30	4/30	
1129 R f mrc eat 33m34 1330				0	250.mg	1.25gm	2.50gm		
pns tum a	35.4gm *	P<.03	- 11.7gm	n.s.s.	2/100	1/30	1/30	4/30	
ski tum a	no dre	P=1.	- 35.2gm	n.s.s.	1/100	3/30	0/30	0/30	
1130 R m mrc eat 32m33 1330				0	200.mg	1.00gm	2.00gm		
tba mix a	no dre	P=1.	- 6.34gm	n.s.s.	56/100	15/30	19/30	12/30	

D-CARVONE 2244-16-8

1131 M f b6c gav 24m24 TR381 :				0	263.mg	526.mg			
TBA MXB	no dre	P=1.	- 951.mg	n.s.s.	9/50	14/50	14/50		
liv MXB	no dre	P=1.	2.73gm	n.s.s.	1/50	2/50	1/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	1.34gm	n.s.s.	1/50	6/50	3/50		lun:a/a,a/c.
1132 M m b6c gav 24m24 TR381 :				0	263.mg	526.mg			
TBA MXB	no dre	P=1.	- 1.40gm	n.s.s.	27/50	15/50	16/50		
liv MXB	63.8gm *	P<1.	1.27gm	n.s.s.	7/50	7/50	7/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	1.64gm	n.s.s.	7/50	5/50	6/50		lun:a/a,a/c.

CATECHINS, COMMERCIAL MIXTURE FROM GREEN TEA (91% CATECHINS) (Camellia sinensis, Polyphenon 100) 136511-29-0

1133 R f f3d eat 52w52 2249				0	500.mg				Hirose;carc,16,217-221;1995/pers.comm.
liv tum e	no dre	P=1.	258.mg	n.s.s.	0/10	0/10			

CATECHOL (1,2-dihydroxybenzene) 120-80-9

1134 M f b6c eat 96w96 1971				0	1.04gm				Hirose;carc,14,525-529;1993/pers.comm.
stg ade e	471.mg	P<.0005	+ 268.mg	906.mg	0/29	21/29			
liv hnd e	17.3gm	P<.3	2.82gm	n.s.s.	0/29	1/29			
for pam e	17.3gm	P<.3	2.82gm	n.s.s.	0/29	1/29			
liv hpc e	no dre	P=1.	3.22gm	n.s.s.	1/27	1/29			
lun ade e	no dre	P=1.	5.30gm	n.s.s.	1/29	0/29			
1135 M m b6c eat 96w96 1971				0	960.mg				
stg ade e	165.mg	P<.0005	+ 72.8mg	335.mg	0/28	29/30			
--- lkm e	2.46gm	P<.03	955.mg	n.s.s.	1/27	7/30			
for pam e	16.5gm	P<.3	2.69gm	n.s.s.	0/27	1/30			
lun ade e	16.5gm	P<.3	2.69gm	n.s.s.	0/27	1/30			
liv hnd e	no dre	P=1.	2.25gm	n.s.s.	6/27	4/30			
liv hpc e	no dre	P=1.	2.02gm	n.s.s.	7/27	5/30			
1136 R m f34 wat 78w78 1718				0	25.0mg				LaVoie;gann,76,266-271;1985/pers.comm.
pro cic er	236.mg	P<.8	- 23.9mg	n.s.s.	5/30	6/30			
ubl tum er	no dre	P=1.	- 86.9mg	n.s.s.	0/30	0/30			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1137 R f f3d eat 24m24 1971					0	400.mg			Hirose;carc,14,525-529;1993/pers.comm.
stg ade e		noTD50	P<.0005	n.s.s. 125.mg	0/30	28/28			
stg adc e		490.mg	P<.0005 +	249.mg 1.15gm	0/30	12/28			
liv hnd e		no dre	P=1.	2.31gm n.s.s.	1/30	0/28			
1138 R m f3d eat 51w52 1845					0	335.mg			Hirose;gann,78,1144-1149;1987/pers.comm.
stg ade rv		noTD50	P<.0005	n.s.s. 35.6mg	0/10	15/15			
stg adc rv		257.mg	P<.07 +	77.6mg n.s.s.	0/10	3/15			
for pam rv		833.mg	P<.4	135.mg n.s.s.	0/10	1/15			
1139 R m f3d eat 24m24 1971					0	320.mg			Hirose;carc,14,525-529;1993/pers.comm.
stg ade e		noTD50	P<.0005	n.s.s. 100.mg	0/30	28/28			
stg adc e		286.mg	P<.0005 +	154.mg 612.mg	0/30	15/28			
for pam e		2.96gm	P<.09	727.mg n.s.s.	0/30	2/28			
liv hnd e		no dre	P=1.	1.85gm n.s.s.	1/30	0/28			
1140 R m f3d eat 48w96 2107m					0	160.mg			Hirose;canr,52,787-790;1992/pers.comm.
stg ade er		noTD50	P<.0005 +	n.s.s. 60.1mg	0/12	14/14			
stg adc er		387.mg	P<.05 +	117.mg n.s.s.	0/12	3/14			
1141 R m f3d eat 72w72 2107n					0	320.mg			
stg ade ekr		noTD50	P<.0005 +	n.s.s. 83.2mg	0/10	10/10			
stg adc ekr		206.mg	P<.02 +	69.6mg n.s.s.	0/10	4/10			
1142 R m f3d eat 72w96 2107o					0	240.mg			
stg ade er		noTD50	P<.0005 +	n.s.s. 78.7mg	0/12	18/18			
stg adc er		202.mg	P<.002 +	93.1mg 666.mg	0/12	9/18			
1143 R m f3d eat 96w96 2107r					0	320.mg			
stg ade er		noTD50	P<.0005 +	n.s.s. 116.mg	0/12	15/15			
stg adc er		141.mg	P<.0005 +	65.8mg 360.mg	0/12	11/15			
1144 R m f3d eat 51w51 2162 ()					0	320.mg			Kawabe;gann,85,17-25;1994
stg ade Cer		noTD50	P<.0005 +	n.s.s. 32.6mg	0/15	15/15			
stg adc Cer		130.mg	P<.006 +	48.8mg 1.23gm	0/15	5/15			
for tum Cer		no dre	P=1.	238.mg n.s.s.	0/15	0/15			
1145 R m f3d eat 51w52 2564					0	314.mg			Wada;clet,124,127-134;1998
stg ade er		noTD50	P<.0005 +	n.s.s. 32.1mg	0/15	16/16			
stg mix er		noTD50	P<.0005 +	n.s.s. 32.1mg	0/15	16/16			
for sqp er		833.mg	P<.3	136.mg n.s.s.	0/15	1/16			
stg adc er		833.mg	P<.3	136.mg n.s.s.	0/15	1/16			
for cic er		833.mg	P<.3	136.mg n.s.s.	0/15	1/16			
1146 R m f3d eat 24m24 2651					0	40.0mg	80.0mg	160.mg 320.mg	Hagiwara;txpy,29,180-186;2001/pers.comm.
sgp ade e		43.5mg Z	P<.0005 +	28.6mg 68.3mg	0/25	0/25	23/24	25/25 (23/25)	
pan ana e		1.18gm *	P<.0005	535.mg 4.25gm	0/25	0/25	1/24	1/25 6/25	
sgp sar e		1.94gm *	P<.004 +	738.mg 13.7gm	0/25	0/25	0/24	1/25 4/25	
for sqp e		3.30gm *	P<.02	998.mg n.s.s.	0/25	0/25	0/24	0/25 3/25	
sgp adc e		3.32gm *	P<.04 +	1.00gm n.s.s.	0/25	0/25	0/24	1/25 2/25	
for sqc e		no dre	P=1.	2.13gm n.s.s.	0/25	1/25	0/24	0/25 0/25	
stf sar e		no dre	P=1.	109.mg n.s.s.	1/25	0/25	0/24	0/25 0/25	
1147 R m lwj eat 24m24 2238o					0	320.mg			Tanaka;fctx,33,93-98;1995/pers.comm.
stg ade e		64.5mg	P<.0005 +	28.5mg 131.mg	0/20	29/30			
stg adc e		166.mg	P<.0005 +	95.3mg 314.mg	0/20	22/30			
stg sar e		2.08gm	P<.08	629.mg n.s.s.	0/20	3/30			
liv hnd e		no dre	P=1.	1.98gm n.s.s.	1/20	0/30			
for tum e		no dre	P=1.	1.98gm n.s.s.	0/20	0/30			
1148 R m sdj eat 24m24 2238r					0	320.mg			
stg ade e		noTD50	P<.0005 +	n.s.s. 97.3mg	0/21	30/30			
stg adc e		151.mg	P<.0005 +	86.6mg 283.mg	0/21	23/30			
for sqp e		983.mg	P<.01 +	400.mg 33.9gm	0/21	6/30			
for sqc e		6.47gm	P<.4	1.05gm n.s.s.	0/21	1/30			
liv tum e		no dre	P=1.	1.98gm n.s.s.	0/21	0/30			
1149 R m wky eat 60w60 2122					0	320.mg			Tatematsu;carc,14,1415-1419;1993
gam tum er		no dre	P=1.	285.mg n.s.s.	0/10	0/13			
1150 R m wky eat 24m24 2238n					0	320.mg			Tanaka;fctx,33,93-98;1995/pers.comm.
stg ade e		noTD50	P<.0005 +	n.s.s. 97.3mg	0/20	30/30			
stg adc e		2.08gm	P<.08	629.mg n.s.s.	0/20	3/30			
for sqp e		6.47gm	P<.4	1.05gm n.s.s.	0/20	1/30			
liv mix e		12.4gm	P<.9	891.mg n.s.s.	1/20	2/30			
1151 R m wsj eat 24m24 2238m					0	320.mg			
stg ade e		64.5mg	P<.0005 +	28.5mg 131.mg	0/20	29/30			
stg adc e		200.mg	P<.0005 +	114.mg 387.mg	0/20	20/30			
stg sar e		2.08gm	P<.08	629.mg n.s.s.	0/20	3/30			
for sqp e		3.18gm	P<.2	781.mg n.s.s.	0/20	2/30			
liv hnd e		3.18gm	P<.2	781.mg n.s.s.	0/20	2/30			
liv hpc e		6.47gm	P<.4	1.05gm n.s.s.	0/20	1/30			
for sqc e		6.47gm	P<.4	1.05gm n.s.s.	0/20	1/30			
CELECOXIB (Celebrex) 169590-42-5									
1152 R m f34 eat 53w53 2580					0	60.0mg			Kawamori;canr,58,409-412;1998
col tum er		no dre	P=1. -	28.9mg n.s.s.	0/9	0/9			
1153 R m f34 eat 53w53 2639					0	60.0mg			Reddy;canr,60,293-297;2000
col tum er		no dre	P=1. -	19.3mg n.s.s.	0/6	0/6			
CELIPROLOL (3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea.HCl) 56980-93-9									
1154 M f cd1 eat 24m24 1968					0	100.mg	300.mg	900.mg	Markiewicz;phrm,38,421-434;1989
lun mix e		8.02gm *	P<.3 -	2.40gm n.s.s.	13/100	8/49	9/50	20/100	
1155 M m cd1 eat 24m24 1968					0	100.mg	300.mg	900.mg	
lun mix e		4.71gm *	P<.2 -	1.61gm n.s.s.	23/100	16/51	15/50	34/100	
1156 R f sda eat 24m24 2384					0	559.mg			Markiewicz;phrm,38,407-420;1989
liv hpa ev		38.1gm	P<.3 -	6.21gm n.s.s.	0/100	1/100			
liv hpc ev		38.1gm	P<.3 -	6.21gm n.s.s.	0/100	1/100			
tba mix ev		2.48gm	P<.8 -	234.mg n.s.s.	93/100	94/100			
1157 R m sda eat 24m24 2384					0	559.mg			
liv hpa ev		12.4gm	P<.2 -	3.47gm n.s.s.	1/100	4/100			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes Path	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
liv hpc ev	no dre	P=1.	- 6.30gm n.s.s.	3/100	2/100			
tba mix ev	684.mg	P<.2	- 219.mg n.s.s.	86/100	92/100			
CEVIMELINE.HCl ((+-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine].HCl hemihydrate, SNI-2011) 153504-70-2								
1158 R f f3d gav 52w52 2661				0	36.0mg			Arisawa;phrm,60,53-72;2001
liv tum e	no dre	P=1.	- 37.1mg n.s.s.	0/20	0/20			
1159 R m f3d gav 52w52 2661				0	36.0mg			
liv tum e	no dre	P=1.	- 37.1mg n.s.s.	0/20	0/20			
CHENODEOXYCHOLIC ACID 474-25-9								
1160 M b cba eat 54w54 1445				0	31.3mg			Martin;bjca,43,884-886;1981
itn tum r	no dre	P=1.	- 17.4mg n.s.s.	0/10	0/10			
CHLORAL HYDRATE 302-17-0								
1161 M f b6c gav 24m24 TR502 :				0	17.9mg	35.7mg	71.4mg	
pit pda	477.mg	* P<.02 e	206.mg n.s.s.	0/48	2/48	0/48	5/48	
TBA MXB	251.mg	Z P<.5	59.3mg n.s.s.	48/48	19/48	21/48	48/48	
liv MXB	1.52gm	* P<.6	248.mg n.s.s.	2/48	2/48	3/48	3/48	liv:hpa,hpb,hpc.
lun MXB	675.mg	* P<.2	225.mg n.s.s.	1/48	1/48	2/48	4/48	lun:a/a,a/c.
1162 M f b6c gav 3m24 TR502a : ()				0	8.93mg			
pit pda	68.3mg	P<.04 e	20.7mg n.s.s.	0/48	3/40			
TBA MXB	no dre	P=1.	5.62mg n.s.s.	48/48	40/40			
liv MXB	no dre	P=1.	43.2mg n.s.s.	2/48	1/40			liv:hpa,hpb,hpc.
lun MXB	98.3mg	P<.3	22.5mg n.s.s.	1/48	3/40			lun:a/a,a/c.
1163 M f b6c gav 6m24 TR502b :				0	17.9mg			
pit pda	399.mg	P<.3	64.9mg n.s.s.	0/48	1/40			
TBA MXB	1.05gm	P<1.	9.57mg n.s.s.	48/48	40/40			
liv MXB	1.06gm	P<.9	56.2mg n.s.s.	2/48	2/40			liv:hpa,hpb,hpc.
lun MXB	117.mg	P<.2	34.0mg n.s.s.	1/48	4/40			lun:a/a,a/c.
1164 M f b6c gav 12m24 TR502c :				0	35.7mg			
lun a/a	119.mg	P<.02	46.8mg n.s.s.	1/48	7/40			s
pit pda	795.mg	P<.3	129.mg n.s.s.	0/48	1/40			
TBA MXB	no dre	P=1.	20.4mg n.s.s.	48/48	40/40			
liv MXB	333.mg	P<.4	74.9mg n.s.s.	2/48	4/40			liv:hpa,hpb,hpc.
lun MXB	119.mg	P<.02	46.8mg n.s.s.	1/48	7/40			lun:a/a,a/c.
1165 M m b6c gav 24m24 TR503 :				0	17.9mg	35.7mg	71.4mg	
liv MXA	481.mg	* P<.6 p	79.6mg n.s.s.	16/48	25/48	23/48	22/48	liv:hpa,hpc.
TBA MXB	1.21gm	Z P<.9	55.6mg n.s.s.	48/48	36/48	34/48	48/48	
liv MXB	481.mg	* P<.6	79.6mg n.s.s.	16/48	25/48	23/48	22/48	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	184.mg n.s.s.	15/48	11/48	5/48	14/48	lun:a/a,a/c.
1166 M m b6c gav 70w70 TR503a :				0	17.9mg	35.7mg	71.4mg	
liv MXA r	232.mg	* P<.7	29.1mg n.s.s.	2/12	3/12	3/12	3/12	liv:hpa,hpc.
liv MXB r	232.mg	* P<.7	29.1mg n.s.s.	2/12	3/12	3/12	3/12	liv:hpa,hpb,hpc.
1167 M m b6c wat 60w60 2072m				0	166.mg			Daniel;faat,19,159-168;1992/pers.comm.
liv hpc ek	74.1mg	P<.08	17.6mg n.s.s.	0/5	2/5			
1168 M m b6c wat 24m24 2072n				0	166.mg			
liv mix e	106.mg	P<.0005 +	53.2mg 334.mg	3/20	17/24			
liv hpc e	224.mg	P<.008 +	98.7mg 4.53gm	2/20	11/24			
liv hpa e	387.mg	P<.03	149.mg n.s.s.	1/20	7/24			
1169 M m b6c wat 52w52 2640m				0	20.0mg	96.7mg	213.mg	George;txpy,28,610-618;2000/pers.comm.
liv hpc Cek	160.mg	* P<.3	35.0mg n.s.s.	1/7	1/6	0/8	3/7	
liv mix Cek	191.mg	* P<.5	32.8mg n.s.s.	2/7	1/6	1/8	3/7	
liv hpa Cek	no dre	P=1.	83.4mg n.s.s.	1/7	0/6	1/8	0/7	
1170 M m b6c wat 78w78 2640n				0	20.0mg	96.7mg	213.mg	
liv hpa Cek	94.6mg	* P<.005 +	40.0mg 718.mg	0/7	0/6	4/7	3/7	
liv hpc Cek	no dre	P=1.	80.5mg n.s.s.	2/7	5/6	1/7	3/7	
liv mix Cek	no dre	P=1. +	55.7mg n.s.s.	2/7	5/6	4/7	3/7	
1171 M m b6c wat 24m24 2640o				0	20.0mg	96.7mg	213.mg	
liv mix Ce	99.6mg	* P<.003 +	46.1mg 739.mg	27/42	34/45	31/39	30/32	
liv hpc Ce	152.mg	* P<.003 +	73.8mg 1.01gm	23/42	25/45	23/39	28/32	
liv hpa Ce	275.mg	* P<.02 +	125.mg 57.9gm	9/42	19/45	20/39	17/32	
1172 R m f34 wat 52w52 2640m				0	6.00mg	29.0mg	126.mg	
liv tum Cek	no dre	P=1.	- 1.72mg n.s.s.	0/7	0/7	0/7	0/7	
1173 R m f34 wat 82w82 2640n				0	6.00mg	29.0mg	126.mg	
liv hpa Cek	no dre	P=1.	- 4.17mg n.s.s.	1/7	0/7	0/6	0/7	
1174 R m f34 wat 24m24 2640o				0	6.00mg	29.0mg	126.mg	
liv mix Ce	51.3gm	* P<1.	- 505.mg n.s.s.	1/42	6/44	1/44	3/42	
CHLORAMBEN 133-90-4								
1175 M f b6c eat 80w91 TR25 :				0	1.14gm	2.26gm		
TBA MXB	3.62gm	* P<.2	- 1.80gm n.s.s.	0/10	12/50	13/50		
liv MXB	3.97gm	* P<.2	2.28gm n.s.s.	0/10	8/50	10/50		liv:hpa,hpc,nnd.
lun MXB	58.0gm	* P<.8	9.57gm n.s.s.	0/10	1/50	1/50		lun:a/a,a/c.
1176 M f b6c eat 80w90 TR25 : pool				0	1.14gm	2.26gm		
liv hpc	5.23gm	* P<.006 c	2.58gm 57.4gm	2/69	7/50	10/50		
1177 M m b6c eat 80w91 TR25 :				0	1.05gm	2.09gm		
TBA MXB	9.80gm	* P<.7	- 1.53gm n.s.s.	2/10	20/50	20/50		
liv MXB	no dre	P=1.	2.26gm n.s.s.	2/10	18/50	14/50		liv:hpa,hpc,nnd.
lun MXB	18.0gm	* P<.1	6.22gm n.s.s.	0/10	0/50	4/50		lun:a/a,a/c.
1178 M m b6c eat 80w90 TR25 : pool				0	1.05gm	2.09gm		
liv hpc	4.96gm	* P<.07 a	2.01gm n.s.s.	9/70	16/50	14/50		
1179 R f osm eat 19m26 TR25 :				0	354.mg	708.mg		
TBA MXB	no dre	P=1.	- 616.mg n.s.s.	6/10	36/50	34/50		
liv MXB	no dre	P=1.	2.90gm n.s.s.	0/10	2/50	1/50		liv:hpa,hpc,nnd.
1180 R m osm eat 19m26 TR25 :				0	286.mg	566.mg		
TBA MXB	1.28gm	* P<.5	- 339.mg n.s.s.	2/10	25/50	24/50		
liv MXB	no dre	P=1.	1.79gm n.s.s.	0/10	4/50	1/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
1181 R m osm eat 19m25 TR25 : pool					0	286.mg	566.mg		
--- hem #		3.03gm * P<.02	-	1.31gm n.s.s.	0/75	4/50	3/50		S
CHLORAMBUCIL 305-03-3									
1182 M f swi ipj 26w78 1336					0	.213mg	.426mg	Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.	
lun mix e		97.0ug * P<.0005	+	51.4ug .225mg	20/154	16/19	4/8		
--- lys e		.709mg * P<.003		.229mg 8.39mg	3/154	1/19	3/8		
liv lys e		no dre P=1.		.215mg n.s.s.	1/154	0/19	0/8		
tba mix e		30.6ug * P<.0005		11.8ug 77.2ug	42/154	18/19	8/8		
tba mal e		60.4ug * P<.0005		30.9ug .136mg	29/154	16/19	7/8		
tba ben e		3.60mg * P<.7		.350mg n.s.s.	13/154	2/19	1/8		
1183 M m swi ipj 26w78 1336					0	.213mg	.426mg		
lun mix e		.210mg * P<.0005	+	.108mg .567mg	9/101	10/26	7/12		
--- lys e		.435mg * P<.0005	+	.194mg 1.61mg	2/101	6/26	3/12		
liv mix e		no dre P=1.		.308mg n.s.s.	2/101	0/26	0/12		
tba mix e		.102mg * P<.0005		54.3ug .256mg	28/101	18/26	10/12		
tba mal e		.126mg * P<.0005		67.7ug .305mg	19/101	14/26	10/12		
tba ben e		no dre P=1.		.535mg n.s.s.	9/101	4/26	0/12		
1184 R m cdr ipj 26w78 1336					0	.314mg	.643mg		
--- leu e		1.41mg * P<.004	+	.456mg 19.3mg	2/177	2/21	2/12		
--- lys e		1.73mg * P<.0005		.524mg 12.4mg	0/177	1/21	2/12		
liv tum e		no dre P=1.		.412mg n.s.s.	0/177	0/21	0/12		
tba mix e		.603mg * P<.07		.198mg n.s.s.	59/177	9/21	7/12		
tba mal e		.712mg * P<.03		.252mg n.s.s.	32/177	5/21	6/12		
tba ben e		no dre P=1.		.681mg n.s.s.	27/177	4/21	1/12		
1185 R f sda gav 18m24 1770					0	.323mg	.645mg		Berger;smon,13,8-13;1986
mgl mix		.657mg \ P<.0005	+	.286mg 2.96mg	8/120	10/30	(5/30)		
auc sqc		6.41mg * P<.005	+	1.94mg 65.5mg	0/120	0/30	3/30		
ner mix		3.86mg * P<.02	+	1.37mg n.s.s.	2/120	3/30	3/30		
tba mal		.588mg * P<.0005		.343mg 1.26mg	13/120	15/30	15/30		
tba ben		1.47mg * P<.09		.517mg n.s.s.	43/120	15/30	15/30		
CHLORAMINATED WATER ---									
1186 M f b6c wat 24m24 TR392 :					0	9.86mg	19.7mg	39.4mg	
TBA MXB		no dre P=1.	-	18.1mg n.s.s.	35/50	40/50	35/50	(31/50)	
liv MXB		no dre P=1.		97.9mg n.s.s.	20/50	21/50	24/50	15/50	liv:hpa,hpc,nnd.
lun MXB		no dre P=1.		207.mg n.s.s.	5/50	5/50	3/50	3/50	lun:a/a,a/c.
1187 M m b6c wat 24m24 TR392 :					0	8.21mg	16.4mg	32.8mg	
mul MXA #		37.2mg Z P<.007	-	13.8mg 466.mg	0/50	5/50	(3/50	2/51)	mul:mlm,mlp. S
TBA MXB		8.55mg Z P<.2		2.95mg n.s.s.	42/50	49/50	(41/50	37/51)	
liv MXB		13.1mg Z P<.3		3.85mg n.s.s.	35/50	39/50	(33/50	25/51)	liv:hpa,hpc,nnd.
lun MXB		no dre P=1.		27.9mg n.s.s.	21/50	19/50	17/50	(7/51)	lun:a/a,a/c.
1188 R f f34 wat 24m24 TR392 :					0	2.81mg	5.63mg	11.3mg	
pni MXA		11.7mg Z P<.008		4.42mg 226.mg	0/50	5/50	(1/50	0/50)	pni:isa,isc. S
mul mnl		23.7mg * P<.04	e	10.1mg n.s.s.	8/50	11/50	15/50	16/50	
TBA MXB		26.9mg * P<.6		5.25mg n.s.s.	48/50	45/50	44/50	47/50	
liv MXB		116.mg * P<.4		26.0mg n.s.s.	1/50	3/50	1/50	3/50	liv:hpa,hpc,nnd.
1189 R m f34 wat 24m24 TR392 :					0	2.47mg	4.94mg	9.87mg	
sub fib #		23.3mg * P<.04	-	11.3mg n.s.s.	0/51	4/50	2/51	5/50	S
TBA MXB		85.1mg * P<.9		4.22mg n.s.s.	46/51	50/50	50/51	48/50	
liv MXB		no dre P=1.		33.6mg n.s.s.	2/51	4/50	2/51	0/50	liv:hpa,hpc,nnd.
CHLORAMPHENICOL (chloromycetin) 56-75-7									
1190 R f sda eat 66w75 200a					0	22.0mg			Cohen;jnci,51,403-417;1973
liv hpt e		278.mg P<.2	-	45.3mg n.s.s.	0/71	1/36			
tba mix e		no dre P=1.	-	22.2mg n.s.s.	18/71	9/36			
CHLORANIL (tetrachloro-p-benzoquinone) 118-75-2									
1191 M f b6a orl 76w76 1241					0	89.1mg			Innes;ntis,1968/1969
lun ade evx		no dre P=1.		106.mg n.s.s.	1/17	1/18			
liv hpt evx		no dre P=1.		177.mg n.s.s.	0/17	0/18			
tba mix evx		no dre P=1.		84.1mg n.s.s.	2/17	2/18			
1192 M m b6a orl 76w76 1241					0	82.9mg			
lun ade evx		no dre P=1.		77.5mg n.s.s.	2/18	2/18			
liv hpt evx		no dre P=1.		98.0mg n.s.s.	1/18	1/18			
tba mix evx		440.mg P<.7		51.5mg n.s.s.	3/18	4/18			
1193 M f b6c orl 76w76 1241					0	89.1mg			
liv hpt evx		261.mg P<.1		64.0mg n.s.s.	0/16	2/17			
lun mix evx		no dre P=1.		167.mg n.s.s.	0/16	0/17			
tba mix evx		261.mg P<.1		64.0mg n.s.s.	0/16	2/17			
1194 M m b6c orl 76w76 1241					0	82.9mg			
liv hpt evx		57.2mg P<.002		24.3mg 220.mg	0/16	7/17			
lun ade evx		113.mg P<.02		38.9mg n.s.s.	0/16	4/17			
tba mix evx		34.2mg P<.0005		16.1mg 89.9mg	0/16	10/17			
CHLORDANE, TECHNICAL GRADE 57-74-9									
1195 M f b6c eat 80w90 TR8 :					0	3.51mg	7.41mg		
liv hpc v		4.89mg / P<.0005	c	3.28mg 7.88mg	0/20	3/50	34/50		
TBA MXB v		5.16mg / P<.0005		3.28mg 11.7mg	2/20	6/50	35/50		
liv MXB v		4.89mg / P<.0005		3.28mg 7.88mg	0/20	3/50	34/50		liv:hpa,hpc,nnd.
lun MXB v		228.mg * P<.4		37.1mg n.s.s.	0/20	0/50	1/50		lun:a/a,a/c.
1196 M f b6c eat 80w89 TR8 : pool					0	3.51mg	7.41mg		
liv hpc v		5.28mg / P<.0005	c	3.41mg 9.30mg	3/80	3/50	34/50		
1197 M m b6c eat 80w90 TR8 :					0	3.12mg	6.00mg		
liv hpc ev		2.15mg / P<.0005	c	1.45mg 4.08mg	2/18	16/50	43/50		
TBA MXB ev		2.31mg * P<.0005		1.47mg 5.55mg	4/18	19/50	43/50		
liv MXB ev		2.15mg / P<.0005		1.45mg 4.08mg	2/18	16/50	43/50		liv:hpa,hpc,nnd.
lun MXB ev		656.mg * P<1.		9.98mg n.s.s.	1/18	6/50	3/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
1198 M m b6c eat 80w89 TR8 : pool	0	3.12mg	6.00mg		
liv hpc ev 2.48mg / P<.0005 c 1.61mg 4.44mg	17/95	16/50	43/50		
1199 M m b6c eat 60w61 2246m	0	6.86mg			Malarkey;carc,16,2617-2625;1995/pers.comm.
liv mix ekrv .583mg P<.0005 + .228mg 1.94mg	7/15	29/30			
liv hpa ekrv .903mg P<.0005 + .430mg 3.39mg	6/15	27/30			
liv hpc ekrv 1.91mg P<.0005 + 1.02mg 5.61mg	1/15	18/30			
1200 M m b6c eat 60w68 2246n	0	6.11mg			
liv hpa erv noTD50 P<.002 + n.s.s. 1.42mg	0/5	10/10			
liv mix erv noTD50 P<.002 + n.s.s. 1.42mg	0/5	10/10			
liv hpc erv 1.49mg P<.005 + .591mg 9.61mg	0/5	7/10			
1201 M m b6c eat 68w68 2246o	0	6.90mg			
liv hpa ekrv noTD50 P<.0005 + n.s.s. 1.08mg	0/5	20/20			
liv mix ekrv noTD50 P<.0005 + n.s.s. 1.08mg	0/5	20/20			
liv hpc ekrv .878mg P<.0005 + .417mg 2.02mg	0/5	18/20			
1202 M m b6c eat 60w72 2246r	0	5.82mg			
liv hpa erv .727mg P<.0005 + .368mg 1.47mg	7/43	31/33			
liv hpc erv 2.67mg P<.0005 + 1.44mg 6.43mg	3/43	18/33			
1203 M m b6c eat 72w72 2246s	0	6.91mg			
liv mix erv 1.68mg P<.0005 + .966mg 3.34mg	10/70	28/36			
liv hpa erv 1.96mg P<.0005 + 1.13mg 3.92mg	8/70	26/36			
liv hpc erv 2.96mg P<.0005 + 1.67mg 6.13mg	3/70	20/36			
1204 M m c5j eat 24m24 2135	0	6.00mg			Barrass;enhp,101,219-224;1993/Tucker 1995/pers.comm.
liv mix Cr 13.1mg P<.0005 + 7.63mg 27.6mg	3/102	23/79			
1205 M f cd1 eat 78w78 66a	0	.650mg	3.25mg	6.50mg	Epstein(review) {irdc};stev,6,103-154;1976
liv nod e 1.78mg Z P<.0005 1.15mg 2.94mg	0/57	0/62	32/51	(36/51)	
liv hpt e 71.8mg * P<.2 19.0mg n.s.s.	1/57	0/62	2/51	2/51	
lun ade e no dre P=1. 13.1mg n.s.s.	6/57	2/62	2/51	(0/51)	
1206 M m cd1 eat 78w78 66a	0	.600mg	3.00mg	6.00mg	
liv nod e 1.45mg * P<.0005 1.07mg 2.05mg	1/47	6/58	34/52	38/50	
liv hpt e no dre P=1. 14.5mg n.s.s.	4/47	6/58	10/52	2/50	
lun mix e no dre P=1. 32.7mg n.s.s.	8/47	7/58	2/52	2/50	
1207 M m cen eat 52w52 1477	0	3.00mg			Becker;canr,42,3918-3923;1982
liv tum kr noTD50 P<.3 n.s.s. n.s.s.	5/8	8/8			
1208 M m d2b eat 60w61 2246u	0	6.86mg			Malarkey;carc,16,2617-2625;1995/pers.comm.
liv mix ekrv 1.93mg P<.0005 + 1.07mg 4.73mg	0/10	17/30			
liv hpa ekrv 2.33mg P<.002 + 1.26mg 6.90mg	0/10	15/30			
liv hpc ekrv 6.09mg P<.04 + 2.62mg n.s.s.	0/10	7/30			
1209 M m d2b eat 69w69 2246v	0	6.90mg			
liv mix ekrv 1.03mg P<.0005 + .579mg 2.15mg	0/5	26/30			
liv hpa ekrv 1.29mg P<.0005 + .742mg 3.02mg	0/5	24/30			
liv hpc ekrv 3.31mg P<.02 + 1.76mg n.s.s.	0/5	14/30			
1210 M m d2b eat 87w87 2246w	0	6.96mg			
liv mix erv 3.83mg P<.0005 + 2.52mg 6.58mg	1/27	40/67			
liv hpa erv 4.98mg P<.0005 + 3.18mg 9.47mg	1/27	34/67			
liv hpc erv 5.21mg P<.0005 + 3.30mg 10.1mg	1/27	33/67			
1211 M f icm eat 25m25 1948	0	.130mg	.650mg	1.62mg	Khasawinah;rtxp,10,244-254;1989/pers.comm.
liv mix e 13.4mg * P<.07 4.19mg n.s.s.	0/33	2/43	1/42	4/37	
liv hpa e 19.3mg * P<.2 4.86mg n.s.s.	0/33	2/43	1/42	3/37	
liv hpc e 60.0mg * P<.2 9.77mg n.s.s.	0/30	0/32	0/37	1/35	
--- hem e no dre P=1. 6.88mg n.s.s.	6/66	10/64	8/68	8/68	
1212 M m icm eat 25m25 1948	0	.120mg	.600mg	1.50mg	
liv mix e 1.71mg * P<.0005 1.02mg 4.10mg	15/61	15/58	21/61	37/60	
liv hpa e 2.98mg * P<.0005 1.57mg 12.0mg	12/61	12/58	13/61	28/60	
--- hem e 4.01mg * P<.0005 2.18mg 13.3mg	7/68	4/64	11/65	20/66	
liv hpc e 7.38mg * P<.03 3.11mg n.s.s.	3/57	3/54	8/59	9/55	
1213 R f osm eat 19m25 TR8 :	0	4.40mg	8.90mg		
TBA MXB ev 18.4mg * P<.5 - 4.46mg n.s.s.	7/10	34/50	29/50		
liv MXB ev 121.mg * P<.9 11.2mg n.s.s.	1/10	11/50	6/50		liv:hpa,hpc,nnd.
1214 R f osm eat 19m25 TR8 : pool	0	4.40mg	8.90mg		
ute MXA ev# 101.mg * P<.05 - 30.4mg n.s.s.	0/60	1/50	2/50		ute:adc,sar. S
1215 R m osm eat 19m25 TR8 :	0	5.96mg	11.9mg		
thy MXA v# 41.6mg * P<.04 - 17.9mg n.s.s.	0/10	1/50	6/50		thy:fca,fcc. S
--- fih v 42.5mg * P<.03 18.9mg n.s.s.	0/10	1/50	7/50		S
TBA MXB v 21.6mg * P<.4 6.13mg n.s.s.	3/10	21/50	23/50		
liv MXB v no dre P=1. 40.9mg n.s.s.	0/10	2/50	0/50		liv:hpa,hpc,nnd.
1216 R m osm eat 19m25 TR8 : pool	0	5.96mg	11.9mg		
--- fih v# 60.4mg * P<.05 - 22.3mg n.s.s.	2/60	1/50	7/50		S
1217 R f f34 eat 30m30 1949	0	50.0ug	.250mg	1.25mg	Khasawinah;rtxp,10,95-109;1989
mgl fba e .320mg Z P<.01 .142mg 21.5mg	3/64	12/62	(6/63	6/64)	
liv hpa e no dre P=1. 27.8mg n.s.s.	0/64	1/62	0/63	0/64	
1218 R m f34 eat 30m30 1949	0	40.0ug	.200mg	1.00mg	
liv hpa e 15.3mg * P<.08 4.90mg n.s.s.	2/64	4/64	2/64	7/64	
CHLORENDIC ACID 115-28-6					
1219 M f b6c eat 24m24 TR304 :	0	79.1mg	160.mg		
lun MXA # 343.mg * P<.003 - 153.mg 1.94gm	1/50	5/50	6/50		lun:a/a,a/c. S
lun a/a 412.mg * P<.002 177.mg 1.68gm	0/50	4/50	4/50		S
MXA hes 1.17gm * P<.03 367.mg n.s.s.	0/50	1/50	3/50		mey:hes; spl:hes. S
TBA MXB 87.1mg / P<.0005 46.6mg 350.mg	29/50	32/50	32/50		
liv MXB 348.mg * P<.02 150.mg 52.5gm	3/50	7/50	7/50		liv:hpa,hpc,nnd.
lun MXB 343.mg * P<.003 153.mg 1.94gm	1/50	5/50	6/50		lun:a/a,a/c.
1220 M m b6c eat 24m24 TR304 :	0	73.0mg	149.mg		
liv MXA 141.mg * P<.004 c 72.2mg 1.17gm	13/50	23/50	27/50		liv:hpa,hpc.
liv hpc 206.mg * P<.009 c 101.mg 8.47gm	9/50	17/50	20/50		
liv hpa 387.mg * P<.08 c 150.mg n.s.s.	5/50	9/50	10/50		
thy fca 1.59gm * P<.04 474.mg n.s.s.	0/50	0/50	3/50		S
TBA MXB 227.mg * P<.2 74.7mg n.s.s.	35/50	31/50	39/50		
liv MXB 141.mg * P<.004 72.2mg 1.17gm	13/50	23/50	27/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
lun MXB		no dre P=1.		379.mg n.s.s.	15/50	4/50	9/50		lun:a/a,a/c.
1221 R f f34 eat 24m24 TR304 :					0	30.7mg	61.9mg		
liv MXA		98.8mg *	P<.0005 c	56.0mg 283.mg	1/50	5/50	16/50		liv:hpc,nnd.
liv nnd		162.mg *	P<.004 c	80.3mg 1.11gm	1/50	3/50	11/50		
liv hpc		271.mg *	P<.02 c	122.mg n.s.s.	0/50	3/50	5/50		
TBA MXB		no dre	P=1.	41.7mg n.s.s.	48/50	48/50	48/50		
liv MXB		98.8mg *	P<.0005	56.0mg 283.mg	1/50	5/50	16/50		liv:hpa,hpc,nnd.
1222 R m f34 eat 24m24 TR304 :					0	24.5mg	49.5mg		
MXB MXB		25.4mg *	P<.0005	16.2mg 57.9mg	2/50	22/50	23/50		liv:nnd; pan:ana. C
liv nnd		25.7mg *	P<.0005 c	16.3mg 58.7mg	2/50	21/50	23/50		
liv MXA		32.2mg *	P<.002	18.2mg 127.mg	5/50	22/50	23/50		liv:hpc,nnd. S
pan ana		131.mg *	P<.005 c	63.4mg 1.04gm	0/50	4/50	6/50		
lun MXA		148.mg *	P<.01	69.7mg 10.1gm	0/50	4/50	5/50		lun:a/a,a/c. S
lun a/a		168.mg *	P<.01 e	75.9mg 8.53gm	0/50	3/50	5/50		
pre MXA		59.4mg \	P<.02	26.2mg n.s.s.	1/50	10/50	(4/50)		pre:adn,can,sqp. S
sub fbs		380.mg *	P<.05	130.mg n.s.s.	0/50	1/50	3/50		S
pre can		189.mg *	P<.2 e	68.2mg n.s.s.	1/50	8/50	4/50		
TBA MXB		no dre	P=1.	25.7mg n.s.s.	50/50	49/50	50/50		
liv MXB		32.2mg *	P<.002	18.2mg 127.mg	5/50	22/50	23/50		liv:hpa,hpc,nnd.
CHLORINATED PARAFFINS (C12, 60% CHLORINE) (chlorowax 500c, avg. mol. wt. = 411) 63449-39-8									
1223 M f b6c gav 24m24 TR308 :					0	87.6mg	176.mg		
MXB MXB		86.8mg *	P<.0005	53.3mg 200.mg	11/50	29/50	34/50		liv:hpa,hpc; thy:fca,fcc. C
liv MXA		93.8mg *	P<.0005 c	62.2mg 169.mg	3/50	22/50	28/50		liv:hpa,hpc.
liv hpa		105.mg *	P<.0005 c	70.9mg 164.mg	0/50	18/50	22/50		
mul mlp		599.mg *	P<.002	278.mg 2.56gm	0/50	3/50	6/50		S
thy MXA		307.mg *	P<.03 c	136.mg n.s.s.	8/50	12/50	15/50		thy:fca,fcc.
hag adn		347.mg \	P<.04	126.mg n.s.s.	1/50	6/50	(2/50)		S
thy fca		372.mg *	P<.06 c	150.mg n.s.s.	8/50	12/50	13/50		
liv hpc		596.mg *	P<.03	247.mg n.s.s.	3/50	4/50	9/50		S
TBA MXB		170.mg *	P<.2	64.1mg n.s.s.	40/50	42/50	42/50		
liv MXB		93.8mg *	P<.0005	62.2mg 169.mg	3/50	22/50	28/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	581.mg n.s.s.	3/50	4/50	1/50		lun:a/a,a/c.
1224 M m b6c gav 24m24 TR308 :					0	87.6mg	177.mg		
liv MXA		143.mg *	P<.006 c	71.9mg 1.83gm	20/50	34/50	38/50		liv:hpa,hpc.
liv hpa		157.mg *	P<.002 c	83.9mg 811.mg	11/50	20/50	29/50		
lun a/c		606.mg *	P<.004	284.mg 1.65gm	0/50	3/50	6/50		S
TBA MXB		211.mg *	P<.2	74.9mg n.s.s.	37/50	44/50	46/50		
liv MXB		143.mg *	P<.006	71.9mg 1.83gm	20/50	34/50	38/50		liv:hpa,hpc,nnd.
lun MXB		851.mg *	P<.3	263.mg n.s.s.	5/50	6/50	9/50		lun:a/a,a/c.
1225 R f f34 gav 24m24 TR308 :					0	221.mg	442.mg		
mul mnl s		345.mg \	P<.009	158.mg 11.0gm	11/50	22/50	(16/50)		S
MXB MXB s		583.mg *	P<.0005	351.mg 1.17gm	0/50	11/50	12/50		liv:hpc,nnd; thy:fca,fcc. C
thy fca s		736.mg \	P<.003	290.mg 3.62gm	0/50	6/50	(3/50)		S
liv MXA s		1.14gm *	P<.002 c	577.mg 4.00gm	0/50	5/50	7/50		liv:hpc,nnd.
thy MXA s		1.16gm *	P<.003 c	592.mg 5.24gm	0/50	6/50	6/50		thy:fca,fcc.
liv nnd s		1.20gm *	P<.002 c	597.mg 2.94gm	0/50	4/50	7/50		
ute MXA s		394.mg \	P<.02	167.mg n.s.s.	6/50	14/50	(11/50)		ute:esp,ess. S
pan ana s		839.mg \	P<.04	286.mg n.s.s.	1/50	5/50	(2/50)		S
thy fcc s		4.06gm *	P<.04	1.23gm n.s.s.	0/50	0/50	3/50		S
TBA MXB s		1.10gm *	P<.6	205.mg n.s.s.	48/50	45/50	46/50		
liv MXB s		1.14gm *	P<.002	577.mg 4.00gm	0/50	5/50	7/50		liv:hpa,hpc,nnd.
1226 R m f34 gav 24m24 TR308 :					0	221.mg	442.mg		
tes ict s		75.2mg *	P<.0005	41.7mg 187.mg	48/50	49/50	47/50		S
MXB MXB s		110.mg *	P<.0005	61.4mg 202.mg	0/50	18/50	18/50		kid:tla,uac; liv:hpc,nnd. C
liv MXA s		123.mg *	P<.0005 c	65.6mg 240.mg	0/50	13/50	16/50		liv:hpc,nnd.
pan MXA s		144.mg *	P<.0005	76.1mg 369.mg	11/50	22/50	17/50		pan:acc,ana. S
pan ana s		150.mg *	P<.0005	77.5mg 409.mg	11/50	22/50	15/50		S
liv nnd s		173.mg *	P<.0005 c	88.6mg 335.mg	0/50	10/50	16/50		
adr MXA s		192.mg *	P<.0005	88.0mg 864.mg	15/50	15/50	15/50		adr:phe,phm. S
kid MXA s		196.mg \	P<.0005 c	75.8mg 591.mg	0/50	9/50	(3/50)		kid:tla,uac.
MXA mnl s		406.mg *	P<.003	169.mg 2.48gm	7/50	12/50	14/50		mul:mnl; spl:mnl. S
kid tla s		417.mg *	P<.0005	164.mg 1.43gm	0/50	7/50	3/50		S
liv hpc s		551.mg *	P<.002	184.mg 3.24gm	0/50	3/50	2/50		S
MXA fib s		332.mg \	P<.04	90.5mg n.s.s.	3/50	5/50	(1/50)		ski:fib; sub:fib. S
pre MXA s		522.mg *	P<.03	173.mg n.s.s.	9/50	4/50	9/50		pre:adn,can. S
mgl fba s		566.mg *	P<.03	172.mg n.s.s.	2/50	4/50	2/50		S
pre adn s		568.mg *	P<.02	183.mg n.s.s.	4/50	3/50	7/50		S
TBA MXB s		75.7mg *	P<.0005	41.8mg 193.mg	50/50	49/50	48/50		
liv MXB s		123.mg *	P<.0005	65.6mg 240.mg	0/50	13/50	16/50		liv:hpa,hpc,nnd.
CHLORINATED PARAFFINS (C23, 43% CHLORINE) (chlorowax 40, avg. mol. wt. = 560) 63449-39-8									
1227 M f b6c gav 24m24 TR305 :					0	1.75gm	3.54gm		
liv MXA s		10.5gm *	P<.1 e	3.84gm n.s.s.	4/50	3/50	10/50		liv:hpa,hpc.
liv hpc s		14.0gm *	P<.05 e	5.22gm n.s.s.	1/50	1/50	6/50		
liv hpa s		16.2gm *	P<.2 e	4.96gm n.s.s.	3/50	2/50	7/50		
TBA MXB s		5.83gm *	P<.5	1.34gm n.s.s.	32/50	29/50	38/50		
liv MXB s		10.5gm *	P<.1	3.84gm n.s.s.	4/50	3/50	10/50		liv:hpa,hpc,nnd.
lun MXB s		1.22kg	P<1.	8.55gm n.s.s.	3/50	3/50	3/50		lun:a/a,a/c.
1228 M m b6c gav 24m24 TR305 :					0	1.77gm	3.54gm		
MXA MXA		6.54gm *	P<.03 c	2.96gm n.s.s.	6/50	12/50	16/50	liv:mno; mln:mlm,mlp; mul:mlh,mlm,mlp; smi:mlm; spl:mlm.	
MXA mlp		22.9gm *	P<.04 c	8.63gm n.s.s.	0/50	2/50	3/50		mln:mlp; mul:mlp.
mul mlh		43.2gm *	P<.05 c	13.0gm n.s.s.	0/50	0/50	3/50		
thy fcc		44.0gm *	P<.05	13.2gm n.s.s.	0/50	0/50	3/50		S
MXA mlm		12.1gm *	P<.2 c	4.09gm n.s.s.	5/50	10/50	10/50	mln:mlm; mul:mlm; smi:mlm; spl:mlm.	
TBA MXB		36.4gm *	P<.9	2.12gm n.s.s.	43/50	41/50	43/50		
liv MXB		12.3gm *	P<.4	3.06gm n.s.s.	18/50	21/50	23/50		liv:hpa,hpc,nnd.
lun MXB		31.1gm *	P<.7	4.75gm n.s.s.	11/50	10/50	13/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
1229 R f f34 gav 24m24 TR305 :				0	70.1mg	210.mg	631.mg		
amd MXA	2.35gm	* P<.06	e 868.mg n.s.s.	1/50	4/50	6/50	7/50	amd:phe,phm.	
TBA MXB	no dre	P=1.	511.mg n.s.s.	46/50	45/50	40/50	41/50		
liv MXB	24.8gm	* P<.7	2.49gm n.s.s.	1/50	2/50	1/50	2/50	liv:hpa,hpc,nnd.	
1230 R m f34 gav 24m24 TR305 :				0	1.31gm	2.63gm			
liv nnd #	14.5gm	* P<.04	- 5.89gm n.s.s.	0/50	3/50	3/50			S
pni isa	17.6gm	* P<.02	6.56gm n.s.s.	0/50	1/50	4/50			S
TBA MXB	no dre	P=1.	1.78gm n.s.s.	46/50	42/50	41/50			
liv MXB	14.5gm	* P<.04	5.89gm n.s.s.	0/50	3/50	3/50		liv:hpa,hpc,nnd.	
CHLORINATED TRISODIUM PHOSPHATE 32680-25-4									
1231 M f b6c gav 24m24 TR294 :				0	350.mg	701.mg			
sub srn s#	1.49gm	\ P<.009	- 488.mg 48.3gm	0/50	4/50	(0/50)			S
TBA MXB s	958.mg	* P<.2	305.mg n.s.s.	29/50	32/50	29/50			
liv MXB s	3.71gm	* P<.5	774.mg n.s.s.	6/50	8/50	6/50		liv:hpa,hpc,nnd.	
lun MXB s	no dre	P=1.	2.31gm n.s.s.	6/50	2/50	3/50		lun:a/a,a/c.	
1232 M m b6c gav 24m24 TR294 :				0	352.mg	707.mg			
adr coa #	5.84gm	* P<.04	- 2.02gm n.s.s.	0/50	1/50	3/50			S
mul mlp	8.42gm	* P<.04	2.54gm n.s.s.	0/50	0/50	3/50			S
TBA MXB	11.6gm	* P<.9	577.mg n.s.s.	35/50	37/50	30/50			
liv MXB	2.95gm	* P<.4	812.mg n.s.s.	14/50	14/50	17/50		liv:hpa,hpc,nnd.	
lun MXB	19.9gm	* P<.9	1.22gm n.s.s.	8/50	12/50	7/50		lun:a/a,a/c.	
CHLORINATED WATER ---									
1233 M f b6c wat 24m24 TR392 :				0	13.8mg	27.5mg	54.1mg		
ute esp #	657.mg	* P<.03	- 225.mg n.s.s.	0/50	0/51	1/50	3/50		S
TBA MXB	no dre	P=1.	40.7mg n.s.s.	35/50	43/51	37/50	39/50		
liv MXB	386.mg	* P<.7	48.8mg n.s.s.	20/50	22/51	23/50	24/50	liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	163.mg n.s.s.	5/50	10/51	7/50	4/50	lun:a/a,a/c.	
1234 M m b6c wat 24m24 TR392 :				0	11.5mg	22.9mg	45.1mg		
mul MXA #	187.mg	* P<.05	- 90.5mg n.s.s.	0/50	3/50	3/50	4/51	mul:mlm,mlu.	S
TBA MXB	161.mg	* P<.7	25.1mg n.s.s.	42/50	45/50	44/50	47/51		
liv MXB	no dre	P=1.	42.5mg n.s.s.	35/50	38/50	33/50	34/51	liv:hpa,hpc,nnd.	
lun MXB	893.mg	* P<.9	57.5mg n.s.s.	21/50	12/50	21/50	19/51	lun:a/a,a/c.	
1235 R f f34 wat 24m24 TR392 :				0	3.95mg	7.89mg	15.5mg		
pni MXA	19.3mg	* P<.03	5.27mg n.s.s.	0/50	0/50	3/51	3/50	pni:isa,isc.	S
mul mnl	29.7mg	* P<.06	e 9.89mg n.s.s.	8/50	7/50	19/51	16/50		
pni isa	36.0mg	* P<.03	7.45mg n.s.s.	0/50	0/50	2/51	3/50		S
TBA MXB	no dre	P=1.	8.52mg n.s.s.	48/50	46/50	46/51	43/50		
liv MXB	no dre	P=1.	99.6mg n.s.s.	1/50	1/50	2/51	0/50	liv:hpa,hpc,nnd.	
1236 R m f34 wat 24m24 TR392 :				0	3.46mg	6.91mg	13.3mg		
tes MXA #	1.29mg	Z P<.02	- .545mg n.s.s.	33/51	41/51	(42/50	38/51)	tes:iab,ica.	S
MXA MXA	136.mg	* P<.04	36.4mg n.s.s.	0/51	0/51	0/50	3/51	gnv:sqc; pal:sqp; ton:sqp.	S
TBA MXB	1.95mg	Z P<.09	.684mg n.s.s.	46/51	48/51	(48/50	46/51)		
liv MXB	251.mg	* P<.8	22.0mg n.s.s.	2/51	2/51	4/50	3/51	liv:hpa,hpc,nnd.	
1237 R f sda wat 24m32 BT7003				0	4.28mg	21.4mg	32.1mg	Soffritti;anya,837,189-208;1997	
--- lkm	183.mg	Z P<.006	85.0mg 2.21gm	0/50	8/50	7/50	11/50		
for ama	no dre	P=1.	510.mg n.s.s.	1/50	1/50	2/50	0/50		
liv hpc	no dre	P=1.	59.0mg n.s.s.	1/50	0/50	0/50	0/50		
lun ade	no dre	P=1.	748.mg n.s.s.	0/50	3/50	0/50	0/50		
tba mal	432.mg	* P<.6	79.6mg n.s.s.	21/50	20/50	20/50	24/50		
tba ben	no dre	P=1.	77.9mg n.s.s.	37/50	35/50	32/50	34/50		
1238 R m sda wat 24m32 BT7003				0	3.74mg	18.7mg	28.1mg		
--- lkm	644.mg	* P<.4	154.mg n.s.s.	4/50	4/50	6/50	6/50		
for ama	865.mg	* P<.4	204.mg n.s.s.	1/50	3/50	2/50	4/50		
stg sar	5.07gm	* P<.7	411.mg n.s.s.	0/50	1/50	0/50	1/50		
for sqc	no dre	P=1.	665.mg n.s.s.	0/50	1/50	0/50	0/50		
liv hpc	no dre	P=1.	605.mg n.s.s.	1/50	0/50	1/50	0/50		
lun tum	no dre	P=1.	51.6mg n.s.s.	0/50	0/50	0/50	0/50		
tba mal	726.mg	* P<.7	92.7mg n.s.s.	13/50	17/50	16/50	16/50		
tba ben	no dre	P=1.	68.9mg n.s.s.	25/50	37/50	24/50	31/50		
CHLORINE 7782-50-5									
1239 M f b6c inh 24m24 2356n				0	2.28mg			Wolf;faat,24,111-131;1995/Popp 1993/pers.comm.	
liv mix e	38.5mg	P<.5	- 7.45mg n.s.s.	4/62	6/59				
lun mix e	no dre	P=1.	- 16.1mg n.s.s.	4/62	2/59				
nas tum e	no dre	P=1.	- 3.03mg n.s.s.	0/64	0/66	0/57	0/61		
1240 M m b6c inh 24m24 2356n				0	1.90mg				
liv mix e	12.1mg	P<.5	- 2.70mg n.s.s.	21/62	26/64				
lun mix e	28.8mg	P<.6	- 5.32mg n.s.s.	7/61	10/65				
nas tum e	no dre	P=1.	- 2.63mg n.s.s.	0/61	0/65	0/67	0/66		
1241 R b bd2 wat 35m35 1421				0	5.29mg			Druckrey;fctx,6,147-154;1968	
tba mix g	no dre	P=1.	- 52.6mg n.s.s.	3/20	5/60				
tba mal g	no dre	P=1.	- 64.6mg n.s.s.	2/20	3/60				
tba ben g	no dre	P=1.	- 69.1mg n.s.s.	1/20	2/60				
1242 R f f34 inh 52w52 2356m				0	52.1ug	.130mg	.326mg	Wolf;faat,24,111-131;1995/Popp 1993/pers.comm.	
nas tum ek	no dre	P=1.	- 17.2ug n.s.s.	0/10	0/10	0/10	0/10		
liv hpa ek	no dre	P=1.	- .168mg n.s.s.	0/10			0/10		
1243 R f f34 inh 24m24 2356n				0	.326mg				
liv hpa e	3.15mg	P<.2	- .965mg n.s.s.	2/59	6/60				
nas tum e	no dre	P=1.	- .407mg n.s.s.	0/59	0/59	0/59	0/60		
1244 R m f34 inh 52w52 2356m				0	60.8ug	.152mg	.380mg		
nas tum ek	no dre	P=1.	- 18.7ug n.s.s.	0/10	0/9	0/10	0/10		
liv hpa ek	no dre	P=1.	- .196mg n.s.s.	0/10			0/10		
1245 R m f34 inh 24m24 2356n				0	60.8ug	.152mg	.380mg		
nas tum e	no dre	P=1.	- .479mg n.s.s.	0/59	0/60	0/59	0/59		
liv hpa e	no dre	P=1.	- 1.72mg n.s.s.	4/58			4/58		

Chemical / Spe / Strain / Xpo+Xpt / Sex / Route / Paper Num	Synonym / CAS number	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
Site / Notes / DR / AuOp / UpConf / Path / TD_{50} / 2Tailpvl / LoConf		**Cntrl**	**1 Inc**	**2 Inc**	**3 Inc**	**Brkly Code / NCI/NTPPathology**
CHLORMADINONE ACETATE	302-22-7					
1246 M f c3h eat 24m24 1175		0	.104mg	1.04mg		Rudali;jnci,49,813-819;1972
mam tum Ler 3.77mg * P<.5	.713mg n.s.s.	54/92	28/43	24/36		
1247 M f crf eat 24m24 1175 pool		0	.104mg	1.04mg		
mam tum Ler no dre P=1.	.966mg n.s.s.	161/167	45/46	34/40		
1248 M f r3m eat 24m24 1175		0	.104mg	1.04mg		
mam tum Ler no dre P=1.	1.11mg n.s.s.	50/73	10/19	18/30		
4-CHLORO-4'-AMINODIPHENYLETHER	101-79-1					
1249 M f chi eat 68w86 381 :		0	287.mg	624.mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv mix av 905.mg * P<.05	225.mg n.s.s.	1/15	1/17	2/18		
lun mix av no dre P=1.	286.mg n.s.s.	5/15	2/17	0/18		
tba mix av 598.mg * P<.4	126.mg n.s.s.	10/15	7/17	5/18		
1250 M f chi eat 68w86 381 : pool		0	287.mg	624.mg		
--- vsc av 346.mg * P<.0005 +	130.mg 1.49gm	8/102	5/17	3/18		
ubl mix av 1.13gm * P<.0005 +	389.mg 5.82gm	0/102	0/17	4/18		
1251 M m chi eat 51w55 381 :		0	300.mg	600.mg		
liv mix v no dre P=1. -	n.s.s. n.s.s.	1/14	0/16	0/9		
lun mix v no dre P=1. -	n.s.s. n.s.s.	3/14	0/16	0/9		
tba mix v no dre P=1. -	110.mg n.s.s.	7/14	3/16	0/9		
1252 R m cdr eat 77w98 381 :		0	38.2mg	84.0mg		
liv hpt v 37.9mg \ P<.005 +	11.8mg 381.mg	0/16	4/13	(1/23)		
liv mix v 37.9mg \ P<.005 +	11.8mg 381.mg	0/16	4/13	(1/23)		
tba mix v 25.1mg * P<.004	8.14mg 248.mg	10/16	9/13	9/23		
1253 R m cdr eat 77w98 381 : pool		0	38.2mg	84.0mg		
liv hpt v 37.6mg \ P<.0005 +	12.1mg 258.mg	2/111	4/13	(1/23)		
3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE (MX)	77439-76-0					
1254 R f wis wat 24m24 2447		0	.337mg	1.07mg	4.00mg	Komulainen;jnci,89,848-856;1997/McDonald 2000/ pers.comm.
thy fca e .645mg Z P<.0005 +	.432mg 1.07mg	4/50	16/49	36/50	(36/50)	
thy mix e .741mg * P<.0005 +	.513mg 1.14mg	5/50	18/49	38/50	47/50	
liv caa e 2.73mg * P<.0005 +	1.87mg 4.30mg	1/50	4/50	10/50	34/50	
liv cho e 2.73mg * P<.0005 +	1.89mg 4.12mg	0/50	4/50	10/50	33/50	
thy fcc e 5.20mg * P<.0005 +	3.24mg 9.87mg	1/50	3/49	6/50	22/50	
mgl mix e 13.0mg * P<.004 +	6.00mg 122.mg	3/50	2/50	7/50	11/50	
mgl adc e 14.0mg * P<.004 +	6.43mg 111.mg	3/50	2/50	5/50	11/50	
liv hct e 14.9mg * P<.003 +	6.84mg 106.mg	2/50	2/50	4/50	10/50	
liv hpa e 16.0mg * P<.0005 +	7.69mg 55.4mg	1/50	1/50	1/50	10/50	
mgl fba e 5.13mg * P<.03 +	2.17mg n.s.s.	23/50	25/50	32/50	34/50	
adr coa e 10.6mg * P<.02 +	4.50mg n.s.s.	5/50	10/50	12/50	16/50	
--- lkm e 41.5mg * P<.1 +	12.8mg n.s.s.	1/50	1/50	2/50	4/50	
liv clc e 122.mg * P<.3	23.7mg n.s.s.	1/50	0/50	0/50	2/50	
liv hpc e no dre P=1.	30.5mg n.s.s.	1/50	1/50	3/50	0/50	
1255 R m wis wat 24m24 2447		0	.295mg	.935mg	3.50mg	
thy fca e .532mg Z P<.0005 +	.364mg .856mg	2/49	20/50	34/50	(21/49)	
thy mix e .678mg * P<.0005 +	.481mg 1.04mg	2/49	20/50	38/50	44/49	
thy fcc e 3.25mg * P<.0005 +	2.17mg 5.16mg	0/49	1/50	9/50	27/49	
adr coa e 9.68mg * P<.002 +	4.69mg 53.8mg	5/50	2/50	7/50	14/50	
liv hct e 17.7mg * P<.009 +	8.11mg 706.mg	0/50	1/50	3/50	5/50	
liv cho e 31.4mg * P<.005 +	11.9mg 272.mg	0/50	0/50	1/50	4/50	
pni isa e 16.0mg * P<.09 +	5.57mg n.s.s.	5/50	8/50	8/50	12/50	
lun a/a e 23.4mg * P<.02 +	9.07mg n.s.s.	2/50	1/50	1/50	7/50	
liv hpa e 24.4mg * P<.03 +	9.69mg n.s.s.	0/50	1/50	2/50	4/50	
pni mix e 16.6mg * P<.2	5.06mg n.s.s.	9/50	11/50	12/50	15/50	
--- lkm e 53.1mg * P<.4 +	10.0mg n.s.s.	0/50	3/50	4/50	3/50	
liv hpc e 53.4mg * P<.3	16.2mg n.s.s.	0/50	0/50	2/50	1/50	
liv clc e no dre P=1.	36.6mg n.s.s.	0/50	1/50	0/50	0/50	
2-CHLORO-5-(3,5-DIMETHYLPIPERIDINOSULPHONYL)BENZOIC ACID	(tibric acid) 37087-94-8					
1256 R m f34 eat 70w71 1331		0	52.1mg			Reddy;natu,283,397-398;1980
liv hpc erv 4.85mg P<.0005 +	2.15mg 9.78mg	0/30	30/31			
1-CHLORO-2,4-DINITROBENZENE	97-00-7					
1257 M f chi eat 77w94 381 :		0	169.mg	306.mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
lun mix v 150.mg \ P<.007 -	51.7mg 2.37gm	3/13	5/19	(5/16)		
liv mix v 1.52gm * P<.3 -	247.mg n.s.s.	0/13	0/19	1/16		
tba mix v 124.mg * P<.004 -	57.4mg 1.03gm	9/13	9/19	11/16		
1258 M m chi eat 77w94 381 :		0	207.mg	354.mg		
liv mix v 365.mg * P<.03 -	138.mg n.s.s.	2/16	2/15	4/21		
lun mix v 541.mg * P<.06 -	203.mg n.s.s.	2/16	3/15	3/21		
tba mix v 255.mg \ P<.09 -	79.2mg n.s.s.	9/16	6/15	(10/21)		
1259 R m cdr eat 18m24 381 :		0	17.6mg	32.2mg		
liv mix v no dre P=1. -	66.5mg n.s.s.	1/17	2/18	0/18		
tba mix v 12.3mg \ P<.01 -	5.05mg 1.78gm	13/17	12/18	(14/18)		
3-CHLORO-2-METHYLPROPENE	563-47-3					
1260 M f bd1 inh 24m24 2624		0	57.9mg	116.mg	232.mg	Katagiri;indh,38,309-318;2000/pers.comm.
hag ade e 665.mg * P<.002 +	388.mg 2.38gm	0/50	4/48	7/50	8/49	
for sqp e 1.85gm * P<.05 +	740.mg n.s.s.	1/50	0/48	5/50	4/49	
lun a/c e 6.75gm * P<.07	1.66gm n.s.s.	0/50	0/48	0/50	2/49	
liv hpc e 60.0gm * P<.9	2.45gm n.s.s.	1/50	0/48	0/50	1/49	
liv hpa e no dre P=1.	1.30gm n.s.s.	3/50	4/48	1/50	3/49	
lun a/a e no dre P=1.	2.11gm n.s.s.	1/50	3/48	1/50	0/49	
1261 M m bd1 inh 24m24 2624		0	48.3mg	96.6mg	193.mg	
for sqp e 2.04gm * P<.07 +	741.mg n.s.s.	1/50	0/49	3/50	4/50	
lun a/a e 1.02gm * P<.2	378.mg n.s.s.	1/50	8/49	5/50	7/50	
lun a/c e 1.57gm * P<.2	637.mg n.s.s.	0/50	3/49	2/50	3/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
for sqc	e	11.5gm	* P<.7	+ 1.87gm	n.s.s.	0/50	0/49	1/50	0/50	
liv hpa	e	no dre	P=1.		1.23gm	n.s.s.	5/50	5/49	2/50	3/50	
liv hpc	e	no dre	P=1.		1.43gm	n.s.s.	5/50	2/49	5/50	1/50	
3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE (CONTAINING 5% DIMETHYLVINYL CHLORIDE) 563-47-3									
1262 M f b6c gav 24m24 TR300 :						0	70.1mg	140.mg	
for MXA		82.3mg	/ P<.0005	c	57.4mg	124.mg	0/50	16/50	31/50	for:sqc,sqp.
for sqp		87.7mg	/ P<.0005	c	60.5mg	134.mg	0/50	15/50	29/50	
TBA MXB		149.mg	/ P<.03		66.0mg	n.s.s.	28/50	32/50	37/50	
liv MXB		no dre	P=1.		707.mg	n.s.s.	4/50	3/50	1/50	liv:hpa,hpc,nnd.
lun MXB		5.18gm	* P<.8		469.mg	n.s.s.	3/50	2/50	3/50	lun:a/a,a/c.
1263 M m b6c gav 24m24 TR300 :						0	70.1mg	140.mg	
for MXA		73.5mg	* P<.0005	c	49.2mg	141.mg	3/50	24/50	36/50	for:sqc,sqp.
for sqp		96.2mg	* P<.0005	c	61.5mg	212.mg	3/50	19/50	30/50	
for sqc		432.mg	* P<.005	c	221.mg	2.76gm	0/50	5/50	7/50	
TBA MXB		402.mg	* P<.6		74.5mg	n.s.s.	33/50	42/50	45/50	
liv MXB		no dre	P=1.		177.mg	n.s.s.	22/50	16/50	(13/50)	liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.		472.mg	n.s.s.	7/50	10/50	3/50	lun:a/a,a/c.
1264 R f f34 gav 24m24 TR300 :						0	52.6mg	105.mg	
for ppn		320.mg	/ P<.003	c	149.mg	1.82gm	1/50	1/50	10/50	
sub fib		524.mg	* P<.02		213.mg	n.s.s.	0/50	2/50	4/50	s
TBA MXB		323.mg	* P<.7		49.7mg	n.s.s.	43/50	42/50	41/50	
liv MXB		no dre	P=1.		714.mg	n.s.s.	2/50	1/50	0/50	liv:hpa,hpc,nnd.
1265 R m f34 gav 24m24 TR300 :						0	52.6mg	105.mg	
for ppn		68.7mg	/ P<.0005	c	43.8mg	119.mg	1/50	5/50	30/50	
tes ict		54.0mg	* P<.02		25.0mg	n.s.s.	36/50	43/50	43/50	s
TBA MXB		109.mg	* P<.2		37.1mg	n.s.s.	40/50	32/50	40/50	
liv MXB		714.mg	/ P<.2		204.mg	n.s.s.	2/50	0/50	5/50	liv:hpa,hpc,nnd.
1-CHLORO-2-NITROBENZENE 88-73-3									
1266 M f chi eat 77w98 381 :						0	241.mg	461.mg	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv hpt v		289.mg	\ P<.007	+	109.mg	3.78gm	0/20	5/22	(5/19)	
liv mix v		289.mg	\ P<.007		109.mg	3.78gm	0/20	5/22	(7/19)	
lun mix v		10.9gm	* P<1.	-	395.mg	n.s.s.	6/20	4/22	4/19	
tba mix v		287.mg	\ P<.2		86.3mg	n.s.s.	17/20	12/22	(11/19)	
1267 M f chi eat 77w98 381 : pool						0	241.mg	461.mg	
liv hpt v		289.mg	\ P<.0005	+	109.mg	1.19gm	1/102	5/22	(5/19)	
1268 M m chi eat 73w81 381 :						0	260.mg	540.mg	
liv mix av		113.mg	* P<.003		46.0mg	885.mg	3/18	8/17	3/16	
lun mix av		no dre	P=1.		246.mg	n.s.s.	5/18	1/17	0/16	
tba mix av		186.mg	* P<.07		56.4mg	n.s.s.	12/18	9/17	4/16	
1269 M m chi eat 73w81 381 : pool						0	260.mg	540.mg	
liv hpt av		108.mg	* P<.0005	+	45.2mg	352.mg	7/99	7/17	3/16	
1270 R m cdr eat 77w98 381 :						0	20.9mg	43.6mg	
liv mix v		no dre	P=1.	-	46.2mg	n.s.s.	1/22	2/22	0/19	
tba mix v		no dre	P=1.		15.3mg	n.s.s.	14/22	14/22	8/19	
1-CHLORO-4-NITROBENZENE 100-00-5									
1271 M f chi eat 73w90 381 :						0	351.mg	780.mg	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
--- vsc a		526.mg	* P<.0005	+	208.mg	1.88gm	0/15	2/20	7/18	
lun mix a		539.mg	* P<.08	-	46.8mg	n.s.s.	8/15	3/20	4/18	
liv mix a		1.44gm	* P<.04	-	338.mg	n.s.s.	0/15	1/20	2/18	
tba mix a		125.mg	* P<.0005		31.3mg	512.mg	11/15	10/20	12/18	
1272 M f chi eat 73w90 381 : pool						0	351.mg	780.mg	
--- vsc a		634.mg	* P<.0005	+	240.mg	2.39gm	8/102	2/20	7/18	
1273 M m chi eat 73w86 381 :						0	341.mg	720.mg	
--- vsc a		430.mg	* P<.006	+	146.mg	4.99gm	0/14	2/14	4/14	
liv mix a		262.mg	* P<.03		96.2mg	n.s.s.	1/14	5/14	1/14	
lun mix a		1.69gm	/ P<.4	-	293.mg	n.s.s.	4/14	0/14	3/14	
tba mix a		215.mg	* P<.02		83.9mg	n.s.s.	8/14	7/14	7/14	
1274 M m chi eat 73w86 381 : pool						0	341.mg	720.mg	
--- vsc a		483.mg	* P<.0005	+	158.mg	2.62gm	5/99	2/14	4/14	
liv hpt a		558.mg	* P<.02	+	153.mg	n.s.s.	7/99	4/14	0/14	
1275 R m cdr eat 77w98 381 :						0	22.6mg	45.2mg	
liv mix v		no dre	P=1.	-	n.s.s.	n.s.s.	0/16	0/14	0/15	
tba mix v		60.4mg	* P<.5	-	12.0mg	n.s.s.	9/16	10/14	10/15	
4-CHLORO-m-PHENYLENEDIAMINE 5131-60-2									
1276 M f b6c eat 78w95 TR85 :						0	732.mg	1.46gm	
liv MXA v		1.23gm	\ P<.0005	c	620.mg	3.25gm	0/50	11/50	(8/49)	liv:hpa,hpc.
liv hpc v		1.78gm	\ P<.002	c	804.mg	6.61gm	0/50	8/50	(5/49)	
TBA MXB v		15.4gm	* P<.8		1.49gm	n.s.s.	14/50	21/50	16/49	
liv MXB v		1.23gm	\ P<.0005		620.mg	3.25gm	0/50	11/50	(8/49)	liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.		9.28gm	n.s.s.	4/50	1/50	1/49	lun:a/a,a/c.
1277 M m b6c eat 78w94 TR85 :						0	676.mg	1.35gm	
TBA MXB v		7.32gm	* P<.7	-	1.20gm	n.s.s.	22/50	19/50	25/50	
liv MXB v		7.05gm	* P<.5		1.53gm	n.s.s.	15/50	10/50	19/50	liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.		5.75gm	n.s.s.	7/50	4/50	3/50	lun:a/a,a/c.
1278 R f f34 eat 18m24 TR85 :						0	75.0mg	149.mg	
ute esp #		175.mg	\ P<.007	-	79.8mg	3.15gm	2/50	12/50	(5/50)	s
TBA MXB		479.mg	* P<.5		105.mg	n.s.s.	27/50	33/50	30/50	
liv MXB		2.68gm	* P<.1		660.mg	n.s.s.	0/50	0/50	2/50	liv:hpa,hpc,nnd.
1279 R m f34 eat 18m24 TR85 :						0	60.0mg	119.mg	
adr phe		315.mg	* P<.03	c	144.mg	n.s.s.	4/50	7/50	14/49	
TBA MXB		422.mg	/ P<.5		97.9mg	n.s.s.	28/50	21/50	36/49	
liv MXB		1.57gm	* P<.2		474.mg	n.s.s.	0/50	1/50	2/49	liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4-CHLORO-o-PHENYLENEDIAMINE 95-83-0								
1280 M f b6c eat 78w95 TR63 :				0	752.mg	1.50gm		
liv MXA v	2.24gm	* P<.0005	c 1.34gm 6.00gm	0/50	11/50	10/50		liv:hpa,hpc.
liv hpc v	5.06gm	* P<.006	c 2.47gm 42.9gm	0/50	4/50	6/50		
TBA MXB v	4.09gm	* P<.4	1.15gm n.s.s.	14/50	24/50	21/50		
liv MXB v	2.24gm	* P<.0005	1.34gm 6.00gm	0/50	11/50	10/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	6.11gm n.s.s.	4/50	2/50	3/50		lun:a/a,a/c.
1281 M m b6c eat 78w95 TR63 :				0	701.mg	1.39gm		
liv MXA v	957.mg	* P<.002	c 521.mg 4.25gm	15/50	28/50	34/50		liv:hpa,hpc.
liv hpc v	1.37gm	* P<.002	c 729.mg 7.14gm	10/50	18/50	26/50		
TBA MXB v	905.mg	* P<.005	460.mg 8.99gm	22/50	37/50	39/50		
liv MXB v	957.mg	* P<.002	521.mg 4.25gm	15/50	28/50	34/50		liv:hpa,hpc,nnd.
lun MXB v	21.3gm	* P<.8	2.41gm n.s.s.	7/50	9/50	7/50		lun:a/a,a/c.
1282 R f f34 eat 18m24 TR63 :				0	184.mg	368.mg		
ubl MXA	212.mg	/ P<.0005	c 148.mg 318.mg	0/50	15/50	32/50		ubl:pas,ppc,ppn,tcc,tpp.
MXB MXB	212.mg	/ P<.0005	148.mg 318.mg	0/50	15/50	32/50		sto:sqp; ubl:pas,ppc,ppn,tcc,tpp. C
ubl MXA	429.mg	/ P<.0005	c 270.mg 740.mg	0/50	5/50	22/50		ubl:ppc,tcc.
thy MXA	2.16gm	* P<.02	878.mg n.s.s.	0/50	2/50	4/50		thy:fca,fcc. S
sto sqp	5.27gm	* P<.04	c 1.58gm n.s.s.	0/50	0/50	3/50		
TBA MXB	351.mg	* P<.03	157.mg n.s.s.	27/50	35/50	37/50		
liv MXB	6.50gm	* P<.08	1.60gm n.s.s.	0/50	0/50	2/50		liv:hpa,hpc,nnd.
1283 R m f34 eat 18m24 TR63 :				0	149.mg	294.mg		
MXB MXB	197.mg	* P<.0005	136.mg 301.mg	0/50	15/49	29/50		sto:sqc,sqp; ubl:ppn,sqc,tcc,tpp. C
ubl MXA	216.mg	* P<.0005	c 146.mg 337.mg	0/50	15/49	25/50		ubl:ppn,tcc,tpp.
ubl tcc	363.mg	* P<.0005	c 224.mg 650.mg	0/50	7/49	18/50		
sto MXA h	2.50gm	* P<.02	c 862.mg n.s.s.	0/50	0/49	4/50		sto:sqc,sqp.
thy MXA	3.38gm	* P<.04	1.02gm n.s.s.	0/50	0/49	3/50		thy:fca,fcc. S
ubl sqc	3.78gm	* P<.04	c 1.13gm n.s.s.	0/50	0/49	3/50		
TBA MXB	362.mg	* P<.07	147.mg n.s.s.	28/50	31/49	39/50		
liv MXB	1.24gm	* P<.02	558.mg n.s.s.	0/50	4/49	4/50		liv:hpa,hpc,nnd.
2-CHLORO-p-PHENYLENEDIAMINE SULFATE 61702-44-1								
1284 M f b6c eat 22m24 TR113 :				0	390.mg	646.mg		
TBA MXB a	1.43gm	* P<.5	- 359.mg n.s.s.	12/20	27/50	22/50		
liv MXB a	1.59gm	* P<.07	656.mg n.s.s.	2/20	5/50	9/50		liv:hpa,hpc,nnd.
lun MXB a	3.33gm	* P<.2	1.26gm n.s.s.	0/20	3/50	2/50		lun:a/a,a/c.
1285 M m b6c eat 22m24 TR113 :				0	360.mg	596.mg		
TBA MXB a	4.38gm	/ P<.8	- 527.mg n.s.s.	12/20	21/50	30/50		
liv MXB a	1.31gm	* P<.2	543.mg n.s.s.	4/20	12/50	20/50		liv:hpa,hpc,nnd.
lun MXB a	no dre	P=1.	1.55gm n.s.s.	3/20	7/50	6/50		lun:a/a,a/c.
1286 R f f34 eat 24m24 TR113 :				0	75.0mg	150.mg		
TBA MXB a	no dre	P=1.	- 112.mg n.s.s.	17/20	26/50	(19/50)		
liv MXB a	3.60gm	* P<.6	886.mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
1287 R m f34 eat 24m24 TR113 :				0	60.0mg	120.mg		
TBA MXB a	244.mg	* P<.2	- 95.0mg n.s.s.	7/20	21/50	27/50		
liv MXB a	665.mg	* P<.4	301.mg n.s.s.	0/20	5/50	3/50		liv:hpa,hpc,nnd.
1-CHLORO-2-PROPANOL, TECHNICAL GRADE (~75% 1-CHLORO-2-PROPANOL; ~25% 2-CHLORO-1-PROPANOL) 127-00-4								
1288 M f b6c wat 24m24 TR477 :				0	50.0mg	100.mg	200.mg	
TBA MXB	no dre	P=1.	- 124.mg n.s.s.	46/50	49/50	47/50	44/50	
liv MXB	1.04gm	* P<.8	111.mg n.s.s.	41/50	41/50	43/50	42/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	676.mg n.s.s.	9/50	2/50	5/50	6/50	lun:a/a,a/c.
1289 M m b6c wat 24m24 TR477 :				0	41.7mg	83.3mg	167.mg	
TBA MXB	no dre	P=1.	- 123.mg n.s.s.	48/50	44/50	40/50	42/50	
liv MXB	no dre	P=1.	132.mg n.s.s.	40/50	39/50	37/50	36/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	513.mg n.s.s.	16/50	11/50	9/50	9/50	lun:a/a,a/c.
1290 R f f34 wat 24m24 TR477 :				0	8.57mg	18.6mg	37.1mg	
TBA MXB	no dre	P=1.	- 24.5mg n.s.s.	48/50	46/50	49/50	48/50	
liv MXB	707.mg	* P<.2	174.mg n.s.s.	0/50	0/50	1/50	1/50	liv:hpa,hpb,hpc.
1291 R m f34 wat 24m24 TR477 :				0	7.50mg	16.3mg	32.5mg	
TBA MXB	no dre	P=1.	- 17.4mg n.s.s.	48/50	50/50	50/50	50/50	
liv MXB	427.mg	* P<.6	73.9mg n.s.s.	1/50	3/50	2/50	3/50	liv:hpa,hpb,hpc.
3-CHLORO-p-TOLUIDINE 95-74-9								
1292 M f b6c eat 78w90 TR145 :				0	67.6mg	135.mg		
TBA MXB	1.98gm	* P<.8	- 220.mg n.s.s.	5/20	6/50	11/50		
liv MXB	919.mg	* P<.6	310.mg n.s.s.	0/20	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB	5.11gm	/ P<.8	483.mg n.s.s.	2/20	0/50	4/50		lun:a/a,a/c.
1293 M m b6c eat 78w90 TR145 :				0	62.4mg	125.mg		
TBA MXB	3.11gm	* P<1.	- 148.mg n.s.s.	5/20	15/50	14/50		
liv MXB	no dre	P=1.	261.mg n.s.s.	4/20	10/50	7/50		liv:hpa,hpc,nnd.
lun MXB	733.mg	* P<.3	299.mg n.s.s.	0/20	3/50	3/50		lun:a/a,a/c.
1294 R f f34 eat 18m24 TR145 :				0	62.0mg	124.mg		
ute esp v#	406.mg	* P<.02	- 214.mg n.s.s.	0/20	4/50	9/50		S
TBA MXB v	365.mg	* P<.4	102.mg n.s.s.	7/20	22/50	28/50		
liv MXB v	5.68gm	* P<.4	925.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
1295 R m f34 eat 18m24 TR145 :				0	49.6mg	100.mg		
TBA MXB v	no dre	P=1.	- 196.mg n.s.s.	9/20	21/50	17/50		
liv MXB v	no dre	P=1.	761.mg n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
5-CHLORO-o-TOLUIDINE 95-79-4								
1296 M f b6c eat 78w91 TR187 :				0	222.mg	446.mg		
MXB MXB	143.mg	* P<.0005	104.mg 221.mg	0/20	26/50	35/50		---:hes; liv:hpa,hpc. C
liv MXA	180.mg	* P<.0005	c 128.mg 290.mg	0/20	21/50	31/50		liv:hpa,hpc.
liv hpc	217.mg	* P<.0005	c 151.mg 379.mg	0/20	19/50	26/50		
--- hes	373.mg	/ P<.0005	c 237.mg 676.mg	0/20	6/50	22/50		
TBA MXB	164.mg	* P<.0005	103.mg 446.mg	4/20	32/50	38/50		
liv MXB	180.mg	* P<.0005	128.mg 290.mg	0/20	21/50	31/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
lun MXB		7.48gm *	P<.5	1.39gm n.s.s.	1/20	0/50	3/50		lun:a/a,a/c.
1297 M m b6c eat 78w91 TR187 :					0	205.mg	412.mg		
MXB MXB		134.mg /	P<.0005	88.6mg 269.mg	5/20	29/50	45/50		---:hes; liv:hpa,hpc. C
--- hes		213.mg /	P<.0005 c	145.mg 356.mg	1/20	11/50	37/50		
liv MXA		249.mg *	P<.0005 c	146.mg 876.mg	4/20	20/50	27/50		liv:hpa,hpc.
liv hpc		271.mg *	P<.002 c	155.mg 1.16gm	4/20	19/50	25/50		
TBA MXB		132.mg /	P<.0005	85.9mg 279.mg	6/20	31/50	46/50		
liv MXB		249.mg *	P<.0005	146.mg 876.mg	4/20	20/50	27/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	1.18gm n.s.s.	2/20	2/50	2/50		lun:a/a,a/c.
1298 R f f34 eat 18m24 TR187 :					0	94.0mg	189.mg		
TBA MXB		no dre	P=1. -	218.mg n.s.s.	8/20	22/50	23/50		
liv MXB		no dre	P=1.	1.44gm n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
1299 R m f34 eat 18m24 TR187 :					0	75.2mg	151.mg		
adr phe #		714.mg *	P<.03 -	336.mg n.s.s.	0/20	2/50	7/50		S
TBA MXB		1.02gm *	P<.7	166.mg n.s.s.	8/20	17/50	24/50		
liv MXB		3.34gm *	P<.6	821.mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
4-CHLORO-o-TOLUIDINE.HCl 3165-93-3									
1300 M f b6c eat 95w99 TR165 :					0	162.mg	650.mg		
--- MXA as		40.0mg /	P<.0005 c	26.9mg 62.0mg	1/20	43/50	39/50		---:hem,hes.
--- hes as		42.3mg /	P<.0005 c	28.6mg 64.0mg	0/20	40/50	39/50		
TBA MXB as		38.8mg /	P<.0005	25.6mg 63.4mg	5/20	45/50	42/50		
liv MXB as		754.mg *	P<.3	191.mg n.s.s.	1/20	4/50	0/50		liv:hpa,hpc,nnd.
lun MXB as		798.mg *	P<.01	217.mg 76.0gm	0/20	2/50	3/50		lun:a/a,a/c.
1301 M m b6c eat 99w99 TR165 :					0	450.mg	1.80gm		
--- MXA s		743.mg /	P<.0005 c	507.mg 1.13gm	0/20	6/50	41/50		---:hem,hes.
--- hes s		911.mg /	P<.0005 c	605.mg 1.44gm	0/20	3/50	37/50		
TBA MXB s		537.mg /	P<.0005	336.mg 1.09gm	11/20	28/50	45/50		
liv MXB s		3.26gm *	P<.03	1.29gm n.s.s.	4/20	7/50	10/50		liv:hpa,hpc,nnd.
lun MXB s		no dre	P=1.	2.15gm n.s.s.	4/20	14/50	3/50		lun:a/a,a/c.
1302 M f chi eat 51w60 381 :					0	260.mg	520.mg	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
--- vsc a		15.7mg *	P<.0005 +	6.23mg 37.4mg	0/15	18/19	12/16		
liv mix a		139.mg *	P<.02 -	24.8mg n.s.s.	0/15	1/19	1/16		
lun mix a		153.mg *	P<.06 -	25.0mg n.s.s.	8/15	1/19	0/16		
tba mix a		15.6mg *	P<.0005	6.21mg 36.4mg	11/15	18/19	13/16		
1303 M f chi eat 51w60 381 : pool					0	260.mg	520.mg		
--- vsc a		18.4mg *	P<.0005 +	7.46mg 41.3mg	8/102	18/19	12/16		
1304 M m chi eat 55w60 381 :					0	90.0mg	180.mg		
lun mix		8.85mg \	P<.0005 -	2.51mg 55.6mg	4/14	7/20	(2/20)		
--- vsc		15.4mg *	P<.0005 +	8.35mg 30.2mg	0/14	12/20	13/20		
liv mix		95.7mg *	P<.04 -	17.2mg n.s.s.	1/14	0/20	2/20		
tba mix		7.72mg *	P<.0005	4.02mg 15.1mg	8/14	18/20	16/20		
1305 M m chi eat 55w60 381 : pool					0	90.0mg	180.mg		
--- vsc		15.4mg *	P<.0005 +	8.35mg 27.4mg	5/99	12/20	13/20		
1306 R f f34 eat 25m25 TR165 :					0	62.5mg	250.mg		
TBA MXB		no dre	P=1. -	299.mg n.s.s.	12/20	34/50	32/50		
liv MXB		no dre	P=1.	1.90gm n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.
1307 R m f34 eat 25m25 TR165 :					0	50.0mg	200.mg		
pit cra #		576.mg *	P<.05 -	239.mg n.s.s.	2/20	6/50	15/50		S
TBA MXB		no dre	P=1.	209.mg n.s.s.	13/20	30/50	33/50		
liv MXB		6.18gm *	P<.8	452.mg n.s.s.	0/20	5/50	4/50		liv:hpa,hpc,nnd.
1308 R m cdr eat 77w98 381 :					0	24.6mg	49.1mg	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
liv mix v		123.mg *	P<.2 -	36.2mg n.s.s.	0/16	2/19	1/13		
tba mix v		24.9mg *	P<.03 -	10.7mg n.s.s.	9/16	12/19	10/13		
2-CHLORO-1,1,1-TRIFLUOROETHANE (fluorocarbon 133a, HCFC 133a) 75-88-7									
1309 R f aap gav 12m29 1623 pool					0	89.1mg		Longstaff;txap,72,15-31;1984/pers.comm.	
ute adc e		160.mg	P<.0005 +	86.4mg 351.mg	1/104	15/35			
1310 R m aap gav 12m29 1623 pool					0	89.1mg			
tes ict e		60.0mg	P<.0005 +	34.4mg 117.mg	16/104	29/36			
[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID (WY14643) 50892-23-4									
1311 H m smb eat 60w60 2190					0	23.0mg		Lake;enhp,101(Supp5),241-247;1993/pers.comm.	
liv mix Cr		no dre	P=1. -	12.6mg n.s.s.	0/9	0/8			
1312 M m csb eat 53w63 1656					0	76.3mg		Reddy;canr,29,152-161;1979	
liv hpc erv		noTD50	P<.0005 +	n.s.s. 10.8mg	0/10	18/18			
1313 R m f34 eat 65w65 1332					0	80.0mg		Lalwani;carc,2,645-650;1981	
liv hpc e		noTD50	P<.0005 +	n.s.s. 13.8mg	0/12	14/14			
tba mix e		noTD50	P<.005	n.s.s. 17.8mg	3/12	14/14			
1314 R m f34 eat 69w69 1656					0	40.0mg		Reddy;canr,29,152-161;1979	
liv thc er		noTD50	P<.0005 +	n.s.s. 7.47mg	0/10	15/15			
1315 R m f34 eat 37w52 2156m					0	28.5mg		Marsman;carc,15,111-117;1994/pers.comm.	
liv hpa Cr		95.1mg	P<.3	15.5mg n.s.s.	0/20	1/20			
1316 R m f34 eat 9m24 2156n					0	14.2mg			
liv mix Cr		60.0mg	P<.06	18.1mg n.s.s.	0/16	3/20			
liv hpc Cr		92.6mg	P<.2	22.7mg n.s.s.	0/16	2/20			
liv hpa Cr		190.mg	P<.3	30.9mg n.s.s.	0/16	1/20			
1317 R m f34 eat 52w52 2156o					0	40.0mg			
liv mix Cr		noTD50	P<.0005 +	n.s.s. 3.65mg	0/20	20/20			
liv hpa Cr		2.29mg	P<.0005 +	.941mg 5.24mg	0/20	19/20			
liv hpc Cr		19.2mg	P<.003 +	7.78mg 100.mg	0/20	6/20			
1318 R m f34 eat 12m24 2156r					0	20.0mg			
liv mix Cr		22.9mg	P<.0005 +	10.6mg 69.5mg	0/16	9/20			
liv hpc Cr		26.8mg	P<.002 +	12.0mg 96.0mg	0/16	8/20			
liv hpa Cr		84.3mg	P<.06	25.5mg n.s.s.	0/16	3/20			
1319 R m f3d eat 52w52 2161m					0	40.0mg		Hayashi;carc,15,2215-2219;1994	
liv mix ekr		4.26mg	P<.0005 +	1.67mg 13.4mg	0/10	8/10			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
1320 R m f3d eat 78w78 2161n				0	40.0mg				
liv mix er	noTD50	P<.003	+ n.s.s. 15.9mg	0/8	7/7				
1321 R m sda eat 60w60 2190				0	10.0mg			Lake;enhp,101(Supp5),241-247;1993/pers.comm.	
liv mix Cr	noTD50	P<.0005	+ n.s.s. 1.61mg	0/8	12/12				
4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO(N-beta-HYDROXYETHYL)ACETAMIDE 65089-17-0									
1322 M f csb eat 82w82 1331				0	260.mg			Reddy;natu,283,397-398;1980	
liv hpc er	44.6mg	P<.0005	+ 16.4mg 126.mg	0/15	11/12				
1323 R m f34 eat 75w82 1331				0	20.0mg	80.0mg			
liv hpc aer	6.49mg *	P<.0005	+ 2.77mg 14.7mg	0/30	7/10	20/20			
CHLOROACETALDEHYDE 107-20-0									
1324 M m b6c wat 60w60 2072m				0	17.0mg			Daniel;faat,19,159-168;1992/pers.comm.	
liv hpc ek	17.4mg	P<.3	2.80mg n.s.s.	0/5	1/5				
1325 M m b6c wat 24m24 2072n				0	17.0mg				
liv mix e	36.1mg	P<.08	+ 13.3mg n.s.s.	3/20	10/26				
liv hpc e	44.4mg	P<.09	+ 15.8mg n.s.s.	2/20	8/26				
liv hpa e	405.mg	P<.8	40.2mg n.s.s.	1/20	2/26				
1326 M f hic gav 90w90 1011				0	1.43mg			Van Duuren;jnci,63,1433-1439;1979	
for tum	13.6mg	P<.4	- 2.43mg n.s.s.	5/100	3/30				
1327 M m hic gav 90w90 1011				0	1.19mg				
for tum	no dre	P=1.	- 4.29mg n.s.s.	8/60	1/30				
2-CHLOROACETOPHENONE 532-27-4									
1328 M f b6c inh 24m24 TR379 :				0	.618mg	1.22mg			
TBA MXB	4.31mg *	P<.7	- .692mg n.s.s.	42/50	40/50	38/50			
liv MXB	no dre	P=1.	2.74mg n.s.s.	12/50	13/50	7/50		liv:hpa,hpc,nnd.	
lun MXB	33.4mg *	P<.8	3.13mg n.s.s.	6/50	2/50	6/50		lun:a/a,a/c.	
1329 M m b6c inh 24m25 TR379 :				0	.515mg	1.01mg			
TBA MXB	2.69mg *	P<.4	- .668mg n.s.s.	33/50	35/50	39/50			
liv MXB	5.24mg *	P<.5	1.23mg n.s.s.	16/50	19/50	20/50		liv:hpa,hpc,nnd.	
lun MXB	10.4mg *	P<.7	1.58mg n.s.s.	11/50	9/50	13/50		lun:a/a,a/c.	
1330 R f f34 inh 24m24 TR379 :				0	73.6ug	.147mg			
mgl MXA	.208mg *	P<.07	84.8ug n.s.s.	12/50	20/50	23/50		mgl:ade,fba.	
mgl fba	.211mg *	P<.07	e 85.6ug n.s.s.	12/50	19/50	23/50			
mgl MXA	.224mg *	P<.2	85.4ug n.s.s.	13/50	22/50	23/50		mgl:adc,ade,fba.	
TBA MXB	.859mg *	P<.9	68.0ug n.s.s.	45/50	50/50	48/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.	
1331 R m f34 inh 24m24 TR379 :				0	51.5ug	.103mg			
TBA MXB	no dre	P=1.	- 53.4ug n.s.s.	46/50	48/50	47/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.	
4'-(CHLOROACETYL)-ACETANILIDE 140-49-8									
1332 M f b6c eat 21m24 TR177 :				0	557.mg	1.11gm			
liv hpa v	4.70gm *	P<.02	a 2.29gm n.s.s.	0/20	2/50	8/50			
TBA MXB v	3.50gm \	P<.7	590.mg n.s.s.	6/20	21/50	(12/50)			
liv MXB v	4.70gm *	P<.02	2.29gm n.s.s.	0/20	2/50	8/50		liv:hpa,hpc,nnd.	
lun MXB v	3.02gm \	P<.09	1.14gm n.s.s.	0/20	5/50	(1/50)		lun:a/a,a/c.	
1333 M m b6c eat 21m24 TR177 :				0	514.mg	1.03gm			
TBA MXB v	no dre	P=1.	- 877.mg n.s.s.	9/20	19/50	(5/50)			
liv MXB v	no dre	P=1.	1.51gm n.s.s.	3/20	6/50	(0/50)		liv:hpa,hpc,nnd.	
lun MXB v	no dre	P=1.	3.71gm n.s.s.	3/20	6/50	4/50		lun:a/a,a/c.	
1334 R f f34 eat 20m24 TR177 :				0	42.2mg	84.5mg			
TBA MXB v	no dre	P=1.	- 90.1mg n.s.s.	11/20	31/50	29/50			
liv MXB v	no dre	P=1.	616.mg n.s.s.	1/20	1/50	1/50		liv:hpa,hpc,nnd.	
1335 R m f34 eat 20m24 TR177 :				0	33.8mg	67.6mg			
TBA MXB v	325.mg *	P<.7	- 54.6mg n.s.s.	9/20	27/50	28/50			
liv MXB v	2.47gm *	P<.8	242.mg n.s.s.	1/20	2/50	3/50		liv:hpa,hpc,nnd.	
p-CHLOROANILINE 106-47-8									
1336 M f b6c eat 78w91 TR189 :				0	278.mg	558.mg			
--- MXA	1.48gm *	P<.01	a 744.mg 86.1gm	0/20	3/50	8/50		---:hem,hes.	
--- hes	1.65gm *	P<.02	a 802.mg n.s.s.	0/20	3/50	7/50			
liv MXA	2.35gm *	P<.02	1.02gm n.s.s.	0/20	1/50	6/50		liv:hpa,hpc.	S
TBA MXB	889.mg *	P<.05	405.mg n.s.s.	3/20	11/50	18/50			
liv MXB	2.35gm *	P<.02	1.02gm n.s.s.	0/20	1/50	6/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	1.89gm n.s.s.	1/20	2/50	2/50		lun:a/a,a/c.	
1337 M m b6c eat 78w91 TR189 :				0	257.mg	275.mg			
--- MXA h	769.mg *	P<.2	a 332.mg n.s.s.	2/20	10/50	14/50		---:hem,hes.	
TBA MXB	no dre	P=1.	374.mg n.s.s.	9/20	18/50	19/50			
liv MXB	no dre	P=1.	1.01gm n.s.s.	3/20	7/50	2/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	2.25gm n.s.s.	2/20	1/50	1/50		lun:a/a,a/c.	
1338 R f f34 eat 18m24 TR189 :				0	9.60mg	19.0mg			
TBA MXB	60.7mg *	P<.4	- 16.0mg n.s.s.	7/20	24/50	25/50			
liv MXB	867.mg *	P<.4	141.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.	
1339 R m f34 eat 18m24 TR189 :				0	7.70mg	15.2mg			
spl MXA h	85.9mg /	P<.009	a 37.0mg 2.23gm	0/20	0/50	7/50		spl:fbs,fib.	
MXA MXA	72.0mg /	P<.03	31.4mg n.s.s.	1/20	0/50	10/50		spc:srn; spl:fbs,fib,hes,ost.	S
spl fib	101.mg *	P<.02	41.3mg n.s.s.	0/20	0/50	6/50			S
TBA MXB	31.4mg *	P<.09	13.1mg n.s.s.	7/20	14/50	26/50			
liv MXB	609.mg *	P<.4	99.2mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.	
p-CHLOROANILINE.HCl 20265-96-7									
1340 M f b6c gav 24m24 TR351 :				0	2.11mg	7.04mg	21.1mg		
TBA MXB	no dre	P=1.	- 28.9mg n.s.s.	36/50	26/50	21/50	31/50		
liv MXB	176.mg *	P<.5	33.4mg n.s.s.	6/50	9/50	8/50	11/50	liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	88.7mg n.s.s.	6/50	2/50	1/50	4/50	lun:a/a,a/c.	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1341 M m b6c gav 24m24 TR351 :					0	2.11mg	7.04mg	21.1mg	
liv hpc	33.8mg	* P<.002		17.3mg 146.mg	3/50	7/50	11/50	17/50	S
--- hes	89.5mg	* P<.04	p	33.5mg n.s.s.	4/50	4/50	1/50	10/50	
liv MXA	49.3mg	* P<.2	p	16.4mg n.s.s.	11/50	21/50	20/50	21/50	liv:hpa,hpc.
MXB MXB	56.0mg	* P<.2		16.8mg n.s.s.	14/50	24/50	21/50	23/50	---:hes; liv:hpa,hpc. P
TBA MXB	83.7mg	* P<.6		14.6mg n.s.s.	40/50	30/50	35/50	36/50	
liv MXB	49.3mg	* P<.2		16.4mg n.s.s.	11/50	21/50	20/50	21/50	liv:hpa,hpc,nnd.
lun MXB	2.78gm	* P<1.		43.1mg n.s.s.	8/50	5/50	7/50	6/50	lun:a/a,a/c.
1342 R f f34 gav 24m24 TR351 :					0	1.40mg	4.20mg	12.6mg	
amd pob	105.mg	* P<.2	e	29.5mg n.s.s.	2/50	3/50	1/50	6/50	
spl MXA	232.mg	* P<.3	e	57.0mg n.s.s.	0/50	0/50	1/50	1/50	spl:fbs,ost.
TBA MXB	145.mg	Z P<.9		10.8mg n.s.s.	37/50	30/50	34/50	40/50	
liv MXB	no dre	P=1.		130.mg n.s.s.	1/50	1/50	0/50	0/50	liv:hpa,hpc,nnd.
1343 R m f34 gav 24m24 TR351 :					0	1.40mg	4.20mg	12.6mg	
spl MXA	7.62mg	Z P<.0005	c	5.14mg 11.8mg	0/49	1/50	3/50	38/50	spl:fbs,hes,ost.
spl MXA	7.90mg	Z P<.0005		5.28mg 12.4mg	0/49	1/50	3/50	36/50	spl:fbs,ost. S
amd MXA	13.3mg	Z P<.009	e	6.01mg 494.mg	13/49	14/50	15/50	26/50	amd:pbb,phm,pob.
spl ost	15.5mg	Z P<.0005		9.01mg 29.7mg	0/49	0/50	1/50	19/50	S
spl MXA	16.9mg	* P<.0005		10.1mg 31.2mg	0/49	1/50	2/50	19/50	spl:fbs,fib. S
spl fbs	19.0mg	* P<.0005		11.0mg 36.3mg	0/49	1/50	2/50	17/50	S
spl hes	107.mg	* P<.005		36.3mg 1.04gm	0/49	0/50	0/50	4/50	S
amd MXA	14.8mg	Z P<.02		6.47mg n.s.s.	13/49	14/50	14/50	25/50	amd:pbb,pob. S
TBA MXB	20.8mg	Z P<.4		5.46mg n.s.s.	42/49	42/50	39/50	48/50	
liv MXB	no dre	P=1.		42.8mg n.s.s.	1/49	6/50	5/50	0/50	liv:hpa,hpc,nnd.
o-CHLOROBENZALMALONITRILE (CS2 [94% o-chlorobenzalmalononitrile, 5% Cab-O-Sil colloidal silica, 1% hexamethyldisilizane]) 2698-41-1									
1344 M f b6c inh 24m25 TR377 :					0	.230mg	.464mg		
TBA MXB	no dre	P=1.	-	1.28mg n.s.s.	46/50	27/50	27/50		
liv MXB	no dre	P=1.		1.73mg n.s.s.	11/50	4/50	9/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		2.71mg n.s.s.	5/50	2/50	3/50		lun:a/a,a/c.
1345 M m b6c inh 24m25 TR377 :					0	.191mg	.386mg		
TBA MXB	no dre	P=1.	-	.515mg n.s.s.	31/50	24/50	30/50		
liv MXB	no dre	P=1.		1.06mg n.s.s.	18/50	14/50	13/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		1.22mg n.s.s.	14/50	8/50	10/50		lun:a/a,a/c.
1346 R f f34 inh 24m25 TR377 :					0	5.48ug	18.1ug	54.9ug	
TBA MXB	no dre	P=1.	-	37.8ug n.s.s.	47/50	47/50	47/50	50/50	
liv MXB	no dre	P=1.		.516mg n.s.s.	3/50	1/50	0/50	0/50	liv:hpa,hpc,nnd.
1347 R m f34 inh 24m25 TR377 :					0	3.83ug	12.7ug	38.4ug	
thy MXA #	6.49ug	Z P<.004	-	2.85ug 54.5ug	2/50	10/50	(9/50	6/50)	thy:cca,ccr. S
thy cca	7.34ug	Z P<.008		3.08ug .178mg	2/50	9/50	(7/50	6/50)	S
TBA MXB	no dre	P=1.		28.8ug n.s.s.	48/50	49/50	47/50	48/50	
liv MXB	no dre	P=1.		.176mg n.s.s.	4/50	3/50	0/50	2/50	liv:hpa,hpc,nnd.
CHLOROBENZENE (monochlorobenzene) 108-90-7									
1348 M f b6c gav 24m24 TR261 :					0	42.0mg	84.1mg		
TBA MXB	373.mg	* P<.5	-	82.2mg n.s.s.	25/50	26/50	29/50		
liv MXB	235.mg	\ P<.09		79.9mg n.s.s.	2/50	7/50	(2/50)		liv:hpa,hpc,nnd.
lun MXB	623.mg	* P<.08		223.mg n.s.s.	1/50	2/50	5/50		lun:a/a,a/c.
1349 M m b6c gav 24m24 TR261 :					0	21.0mg	42.0mg		
TBA MXB	60.1mg	* P<.2	-	22.3mg n.s.s.	30/50	31/50	35/50		
liv MXB	382.mg	* P<.7		48.4mg n.s.s.	16/50	15/50	14/50		liv:hpa,hpc,nnd.
lun MXB	190.mg	* P<.2		62.2mg n.s.s.	6/50	4/50	10/50		lun:a/a,a/c.
1350 R f f34 gav 24m24 TR261 :					0	42.4mg	84.9mg		
MXA MXA #	520.mg	* P<.05	-	198.mg n.s.s.	0/50	2/50	3/50		pty:adn; thy:fcc; tyf:cyn. S
TBA MXB	no dre	P=1.		64.1mg n.s.s.	36/50	30/50	36/50		
liv MXB	867.mg	* P<.2		263.mg n.s.s.	0/50	1/50	2/50		liv:hpa,hpc,nnd.
1351 R m f34 gav 24m24 TR261 :					0	42.4mg	84.9mg		
liv nnd	247.mg	* P<.02	p	109.mg n.s.s.	2/50	4/50	8/50		
TBA MXB	190.mg	* P<.4		48.4mg n.s.s.	33/50	36/50	28/50		
liv MXB	328.mg	* P<.08		119.mg n.s.s.	4/50	4/50	8/50		liv:hpa,hpc,nnd.
CHLOROBENZILATE 510-15-6									
1352 M f b6c eat 78w90 TR75 :					0	356.mg	658.mg		
liv hpc dv	848.mg	* P<.004	c	523.mg 4.51gm	0/20	11/50	13/50		
TBA MXB dv	3.93gm	* P<.7		623.mg n.s.s.	5/20	18/50	15/50		
liv MXB dv	848.mg	* P<.004		523.mg 4.51gm	0/20	11/50	13/50		liv:hpa,hpc,nnd.
lun MXB dv	no dre	P=1.		2.93gm n.s.s.	2/20	2/50	2/50		lun:a/a,a/c.
1353 M f b6c orl 82w82 67a					0	83.4mg			Innes;ntis,1968/1969
lun ade evx	621.mg	P<.3		101.mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.		192.mg n.s.s.	0/16	0/18			
tba mix evx	302.mg	P<.2		74.1mg n.s.s.	0/16	2/18			
1354 M m b6c eat 78w90 TR75 :					0	440.mg	773.mg		
liv hpc dv	235.mg	\ P<.03	c	114.mg n.s.s.	4/20	32/50	(22/50)		
TBA MXB dv	256.mg	\ P<.05		117.mg n.s.s.	5/20	34/50	(25/50)		
liv MXB dv	235.mg	\ P<.03		114.mg n.s.s.	4/20	32/50	(22/50)		liv:hpa,hpc,nnd.
lun MXB dv	no dre	P=1.		4.20gm n.s.s.	1/20	1/50	1/50		lun:a/a,a/c.
1355 M m b6c orl 82w82 67a					0	77.6mg			Innes;ntis,1968/1969
liv hpt evx	43.8mg	P<.0005	+	20.1mg 124.mg	0/16	9/17			
lun mix evx	no dre	P=1.		169.mg n.s.s.	0/16	0/17			
tba mix evx	31.7mg	P<.0005		15.2mg 79.6mg	0/16	11/17			
1356 M f b6a orl 82w82 67a					0	83.4mg			
lun ade evx	621.mg	P<.6		81.7mg n.s.s.	1/17	2/18			
liv hpt evx	no dre	P=1.		192.mg n.s.s.	0/17	0/18			
tba mix evx	621.mg	P<.7		69.7mg n.s.s.	2/17	3/18			
1357 M m b6a orl 82w82 67a					0	77.6mg			
liv hpt evx	69.8mg	P<.01	+	27.6mg 4.09gm	1/18	7/17			
lun ade evx	no dre	P=1.		169.mg n.s.s.	2/18	0/17			
tba mix evx	72.8mg	P<.06		25.8mg n.s.s.	3/18	8/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD50	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
1358 R f osm eat 18m26 TR75 :					0	41.0mg	78.0mg		
adr coa dv#		490.mg *	P<.01 -	211.mg 28.5gm	0/50	2/50	5/50		S
TBA MXB dv		no dre	P=1.	81.4mg n.s.s.	36/50	38/50	34/50		
liv MXB dv		no dre	P=1.	635.mg n.s.s.	1/50	0/50	1/50		liv:hpa,hpc,nnd.
1359 R m osm eat 18m26 TR75 :					0	45.6mg	84.8mg		
adr coa dv#		186.mg \	P<.007 -	75.1mg 2.25gm	0/50	6/50	(3/50)		S
TBA MXB dv		no dre	P=1.	145.mg n.s.s.	28/50	31/50	23/50		
liv MXB dv		1.60gm *	P<.4	395.mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
1360 R f cwf eat 24m24 67					0	25.0mg			Horn;agfc,3,752-756;1955
mgl adf		no dre	P=1. -	73.2mg n.s.s.	3/20	1/20			
CHLORODIBROMOMETHANE (dibromochloromethane) 124-48-1									
1361 M f b6c gav 24m25 TR282 :					0	35.0mg	70.4mg		
liv MXA		139.mg *	P<.03 p	64.4mg n.s.s.	6/50	10/50	19/50		liv:hpa,hpc.
liv hpa		211.mg *	P<.02 p	96.2mg n.s.s.	2/50	4/50	11/50		
TBA MXB		no dre	P=1.	61.6mg n.s.s.	33/50	32/50	37/50		
liv MXB		139.mg *	P<.03	64.4mg n.s.s.	6/50	10/50	19/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	276.mg n.s.s.	5/50	0/50	5/50		lun:a/a,a/c.
1362 M m b6c gav 24m25 TR282 :					0	35.0mg	70.8mg		
liv MXA ns		20.7mg \	P<.006	8.25mg 294.mg	23/50	14/50	(27/50)		liv:hpa,hpc. S
liv hpc ns		33.5mg \	P<.006 e	12.5mg 491.mg	10/50	9/50	(19/50)		
TBA MXB ns		11.3mg \	P<.002	5.19mg 58.7mg	41/50	23/50	(31/50)		
liv MXB ns		20.7mg \	P<.006	8.25mg 294.mg	23/50	14/50	(27/50)		liv:hpa,hpc,nnd.
lun MXB ns		115.mg \	P<.4	22.3mg n.s.s.	11/50	5/50	(4/50)		lun:a/a,a/c.
1363 R f f34 gav 24m24 TR282 :					0	28.3mg	56.6mg		
TBA MXB		no dre	P=1. -	23.7mg n.s.s.	43/50	38/50	(32/50)		
liv MXB		591.mg *	P<.1	204.mg n.s.s.	0/50	2/50	2/50		liv:hpa,hpc,nnd.
1364 R m f34 gav 24m24 TR282 :					0	28.3mg	56.6mg		
TBA MXB		no dre	P=1. -	31.5mg n.s.s.	43/50	37/50	(29/50)		
liv MXB		150.mg \	P<.2	46.3mg n.s.s.	3/50	8/50	(3/50)		liv:hpa,hpc,nnd.
CHLORODIFLUOROMETHANE (CFC 22, fluorocarbon 22) 75-45-6									
1365 M f swi inh 18m24 BT606					0	556.mg	2.78gm		Maltoni;anya,534,261-282;1988
lun ade		no dre	P=1. -	30.0gm n.s.s.	2/60	3/60	0/60		
tba mal		no dre	P=1. -	8.72gm n.s.s.	12/60	13/60	11/60		
tba mix		no dre	P=1. -	10.4gm n.s.s.	14/60	19/60	11/60		
1366 M m swi inh 18m24 BT606					0	463.mg	2.32gm		
lun ade		no dre	P=1. -	13.0gm n.s.s.	6/60	2/60	4/60		
tba mix		no dre	P=1. -	8.02gm n.s.s.	10/60	10/60	9/60		
tba mal		98.3gm *	P<.8 -	9.13gm n.s.s.	1/60	5/60	3/60		
1367 R f sda inh 24m24 BT605					0	176.mg	882.mg		
liv ang		no dre	P=1. -	10.6gm n.s.s.	1/60	1/60	0/60		
tba mix		26.0gm *	P<1. -	718.mg n.s.s.	45/60	44/60	45/60		
tba mal		20.1gm *	P<.8 -	2.06gm n.s.s.	13/60	12/60	14/60		
1368 R m sda inh 24m24 BT605					0	124.mg	618.mg		
liv ang		no dre	P=1. -	1.27gm n.s.s.	0/60	0/60	0/60		
tba mix		6.54gm *	P<.6 -	1.11gm n.s.s.	19/60	14/60	20/60		
tba mal		no dre	P=1. -	2.23gm n.s.s.	9/60	6/60	8/60		
CHLOROETHANE (ethyl chloride) 75-00-3									
1369 M f b6c inh 23m23 TR346 :					0	12.4gm			
ute car		1.81gm	P<.0005 c	823.mg 3.55gm	1/50	43/50			
liv MXA		7.22gm	P<.0005 e	2.24gm 38.5gm	3/50	8/50			liv:hpa,hpc.
liv hpc		7.58gm	P<.0005	2.29gm 46.7gm	3/50	7/50			S
--- MXA		9.96gm	P<.002	2.82gm 59.7gm	4/50	10/50			---:mlh,mlm,mlp,mlu,mly. S
lun MXA		8.64gm	P<.02	1.97gm n.s.s.	5/50	4/50			lun:a/a,a/c. S
TBA MXB		1.38gm	P<.0005	721.mg 2.85gm	28/50	47/50			
liv MXB		7.22gm	P<.0005	2.24gm 38.5gm	3/50	8/50			liv:hpa,hpc,nnd.
lun MXB		8.64gm	P<.02	1.97gm n.s.s.	5/50	4/50			lun:a/a,a/c.
1370 M m b6c inh 23m23 TR346 :					0	10.4gm			
lun MXA s#		9.91gm	P<.005 i	4.00gm 107.gm	5/50	10/50			lun:a/a,a/c. S
lun a/a s		12.7gm	P<.005	4.89gm 159.gm	3/50	8/50			S
TBA MXB s		10.1gm	P<.2	3.22gm n.s.s.	27/50	20/50			
liv MXB s		34.1gm	P<.5	6.36gm n.s.s.	15/50	10/50			liv:hpa,hpc,nnd.
lun MXB s		9.91gm	P<.005	4.00gm 107.gm	5/50	10/50			lun:a/a,a/c.
1371 R f f34 inh 24m24 TR346 :					0	2.88gm			
ute esp		10.2gm	P<.05	3.58gm n.s.s.	2/50	7/50			S
bra asl		21.0gm	P<.04 e	6.08gm n.s.s.	0/50	3/50			
TBA MXB		2.66gm	P<.2	936.mg n.s.s.	45/50	48/50			
liv MXB		no dre	P=1.	13.6gm n.s.s.	1/50	0/50			liv:hpa,hpc,nnd.
1372 R m f34 inh 24m24 TR346 :					0	2.01gm			
ski MXA		3.21gm	P<.004 e	1.15gm 20.6gm	0/50	5/50			ski:bcc,sea,tri.
ski bcc		4.97gm	P<.02	1.39gm n.s.s.	0/50	3/50			S
TBA MXB		1.60gm	P<.3	468.mg n.s.s.	48/50	47/50			
liv MXB		47.7gm	P<.8	2.58gm n.s.s.	1/50	1/50			liv:hpa,hpc,nnd.
(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE (CCC) 999-81-5									
1373 M f b6c eat 24m24 TR158 :					0	65.0mg	260.mg		
TBA MXB		no dre	P=1. -	404.mg n.s.s.	14/20	25/50	26/50		
liv MXB		no dre	P=1.	1.11gm n.s.s.	4/20	7/50	4/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	1.15gm n.s.s.	1/20	3/50	2/50		lun:a/a,a/c.
1374 M f b6c orl 76w76 1103					0	8.96mg			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1.	17.8mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1.	17.8mg n.s.s.	0/16	0/18			
tba mix evx		57.4mg	P<.3	9.34mg n.s.s.	0/16	1/18			
1375 M m b6c eat 24m24 TR158 :					0	60.0mg	240.mg		
TBA MXB		3.24gm *	P<.9 -	218.mg n.s.s.	12/20	29/50	29/50		
liv MXB		599.mg *	P<.2	214.mg n.s.s.	7/20	13/50	23/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun MXB	no dre	P=1.		806.mg n.s.s.	4/20	9/50	5/50		lun:a/a,a/c.
1376 M m b6c orl 76w76 1103					0	8.34mg			Innes;ntis,1968/1969
liv hpt evx	9.38mg	P<.009		3.53mg 206.mg	0/16	5/18			
lun mix evx	no dre	P=1.		16.5mg n.s.s.	0/16	0/18			
tba mix evx	5.19mg	P<.0005		2.31mg 17.1mg	0/16	8/18			
1377 M f b6a orl 76w76 1103					0	8.96mg			
liv hpt evx	no dre	P=1.		14.8mg n.s.s.	0/17	0/15			
lun ade evx	no dre	P=1.		14.8mg n.s.s.	1/17	0/15			
tba mix evx	33.5mg	P<.6		5.11mg n.s.s.	2/17	3/15			
1378 M m b6a orl 76w76 1103					0	8.34mg			
liv hpt evx	11.4mg	P<.07		3.73mg n.s.s.	1/18	5/18			
lun ade evx	no dre	P=1.		10.9mg n.s.s.	2/18	1/18			
tba mix evx	21.3mg	P<.5		4.25mg n.s.s.	3/18	5/18			
1379 R f f34 eat 25m25 TR158 :					0	75.0mg	150.mg		
TBA MXB	no dre	P=1.	-	135.mg n.s.s.	13/20	41/50	37/50		
liv MXB	8.09gm *	P<.4		1.32gm n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
1380 R m f34 eat 25m25 TR158 :					0	60.0mg	120.mg		
pni isa #	458.mg *	P<.02	-	216.mg n.s.s.	0/20	2/50	7/50		s
TBA MXB	3.36gm *	P<1.		83.9mg n.s.s.	16/20	37/50	36/50		
liv MXB	no dre	P=1.		487.mg n.s.s.	1/20	2/50	2/50		liv:hpa,hpc,nnd.
1-CHLOROETHYLNITROSO-3-(2-HYDROXYPROPYL)UREA ---									
1381 R f f34 wat 7m24 2010					0	.140mg			Lijinsky;vivo,4,1-6;1990
liv tum e	no dre	P=1.		.346mg n.s.s.	0/12	0/12			
1382 R m f34 wat 7m24 2010					0	97.8ug			
lun abt e	.124mg	P<.005	+	46.3ug .997mg	0/12	5/12			
liv hct e	.368mg	P<.09		90.0ug n.s.s.	0/12	2/12			
CHLOROFLUOROMETHANE (fluorocarbon 31, HCFC 31) 593-70-4									
1383 R f aap gav 12m25 1623 pool					0	103.mg			Longstaff;txap,72,15-31;1984/pers.comm.
sto mix e	26.5mg	P<.0005	+	14.0mg 48.8mg	1/104	34/36			
sto sqc e	69.4mg	P<.0005	+	41.4mg 126.mg	0/104	24/36			
sto fbs e	119.mg	P<.0005	+	66.8mg 242.mg	0/104	17/36			
sto car e	2.71gm	P<.1	+	441.mg n.s.s.	0/104	1/36			
sto sar e	2.71gm	P<.1	+	441.mg n.s.s.	0/104	1/36			
1384 R m aap gav 12m23 1623 pool					0	111.mg			
sto mix e	28.5mg	P<.0005	+	16.0mg 51.3mg	1/104	33/36			
sto sqc e	46.9mg	P<.0005	+	28.2mg 82.9mg	0/104	28/36			
sto fbs e	88.1mg	P<.0005	+	50.8mg 171.mg	1/104	20/36			
CHLOROFORM 67-66-3									
1385 D f beg eat 87m92 1003					0	12.2mg	24.4mg		Heywood;jept,2,835-851;1979
liv tum e	no dre	P=1.	-	6.52mg n.s.s.	0/16	0/8	0/8		
tba mix e	10.0mg \	P<.3	-	2.22mg n.s.s.	4/16	4/8	(0/8)		
1386 D m beg eat 87m92 1003					0	12.2mg	24.4mg		
liv tum e	no dre	P=1.	-	6.52mg n.s.s.	0/16	0/8	0/8		
tba mix e	13.3mg *	P<.008	-	5.39mg 230.mg	0/16	4/8	2/8		
1387 M f b6c gav 78w92 TR-A :					0	144.mg	289.mg		
liv hpc v	48.0mg *	P<.0005 c		35.2mg 68.0mg	0/20	36/50	39/50		
TBA MXB v	54.1mg *	P<.0005		37.8mg 91.8mg	2/20	37/50	39/50		
liv MXB v	48.0mg *	P<.0005		35.2mg 68.0mg	0/20	36/50	39/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		n.s.s. n.s.s.	0/20	1/50	0/50		lun:a/a,a/c.
1388 M f b6c wat 24m24 1671					0	40.0mg	80.0mg	180.mg 360.mg	Jorgenson;faat,5,760-769;1985
liv hpc e	20.2gm *	P<.5	-	2.69gm n.s.s.	2/415	7/410	1/142	0/47 1/44	
liv hpa e	no dre	P=1.	-	5.18gm n.s.s.	19/415	8/410	8/142	0/47 0/44	
liv mix e	no dre	P=1.	-	3.73gm n.s.s.	21/415	15/410	9/142	0/47 1/44	
tba mix e	no dre	P=1.	-	664.mg n.s.s.	225/423	217/415	90/142	16/47 24/44	
1389 M m b6c gav 78w92 TR-A :					0	83.6mg	168.mg		
liv hpc v	56.2mg /	P<.0005 c		38.7mg 118.mg	1/20	19/50	44/50		
TBA MXB v	71.1mg *	P<.004		40.4mg 491.mg	4/20	26/50	44/50		
liv MXB v	56.2mg /	P<.0005		38.7mg 118.mg	1/20	19/50	44/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		490.mg n.s.s.	1/20	3/50	2/50		lun:a/a,a/c.
1390 M f bdj inh 24m24 2378					0	7.64mg	44.5mg	131.mg	Nagano;apor,741-746;1998/pers.comm.
liv mix ev	909.mg *	P<.07	+	316.mg n.s.s.	2/50	2/49	4/50	6/48	
pit ade ev	2.07gm *	P<.7		273.mg n.s.s.	5/50	9/49	13/50	8/48	
liv hpc ev	2.67gm *	P<.3	+	611.mg n.s.s.	1/50	1/49	0/50	3/48	
lun tum ev	no dre	P=1.		62.8mg n.s.s.	0/50	0/49	0/50	0/48	
1391 M m bdj inh 24m24 2378					0	6.37mg	37.1mg	109.mg	
kid mix ev	226.mg *	P<.0005	+	133.mg 477.mg	0/50	1/50	7/50	12/48	
kid rcc ev	287.mg *	P<.0005	+	160.mg 674.mg	0/50	1/50	4/50	11/48	
liv mix ev	402.mg *	P<.09		145.mg n.s.s.	14/50	7/50	12/50	17/48	
kid rca ev	1.25gm *	P<.2	+	432.mg n.s.s.	0/50	0/50	3/50	1/48	
lun a/c ev	3.53gm *	P<.7		461.mg n.s.s.	3/50	3/50	1/50	4/48	
lun a/a ev	no dre	P=1.		658.mg n.s.s.	3/50	3/50	2/50	2/48	
1392 M m c5l gav 19m24 710m					0	39.6mg			Roe;jept,2,799-819;1979
lun mix e	728.mg	P<.5	-	134.mg n.s.s.	2/46	4/51			
liv tum e	no dre	P=1.	-	416.mg n.s.s.	2/46	0/51			
tba mix e	no dre	P=1.	-	112.mg n.s.s.	16/46	13/51			
1393 M m cba gav 19m24 710m					0	39.6mg			
liv mix e	no dre	P=1.	-	70.7mg n.s.s.	37/51	29/51			
lun mix e	no dre	P=1.	-	155.mg n.s.s.	13/51	8/51			
tba mix e	no dre	P=1.	-	64.7mg n.s.s.	42/51	33/51			
1394 M m cf1 gav 80w93 710m					0	44.2mg			
lun mix e	376.mg	P<.6	-	64.2mg n.s.s.	9/45	12/48			
liv tum e	1.43gm	P<.9	-	111.mg n.s.s.	4/45	5/48			
tba mix e	140.mg	P<.4	-	37.2mg n.s.s.	16/45	22/48			
1395 M m cf1 gav 19m24 710m					0	39.6mg			
kid mix e	153.mg	P<.0005	+	66.6mg 613.mg	6/240	9/49			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
lun tum e	4.35gm	P<1.	- 65.8mg	n.s.s.	102/240	21/49			
liv tum e	no dre	P=1.	- 189.mg	n.s.s.	69/240	8/49			
tba mix e	no dre	P=1.	68.4mg	n.s.s.	170/240	30/49			
1396 M f ici gav 80w96 710m					0	12.1mg	42.9mg		
lun tum e	316.mg	* P<.3	- 81.3mg	n.s.s.	5/59	2/35	6/38		
liv tum e	no dre	P=1.	- 59.2mg	n.s.s.	1/59	0/35	0/38		
tba mix e	no dre	P=1.	- 71.5mg	n.s.s.	29/59	10/35	15/38		
1397 M m ici gav 80w96 710m					0	12.1mg	42.9mg		
kid mix e	139.mg	* P<.0005 +	62.8mg	407.mg	0/72	0/37	8/38		
liv tum e	324.mg	* P<.4	- 73.5mg	n.s.s.	5/72	6/37	5/38		
lun tum e	9.83gm	* P<1.	- 95.4mg	n.s.s.	7/72	7/37	4/38		
tba mix e	45.4mg	* P<.006	21.0mg	643.mg	20/72	20/37	21/38		
1398 M m ici gav 80w98 710n					0	42.0mg			
kid mix e	278.mg	P<.08 +	91.2mg	n.s.s.	1/49	5/47			
lun mix e	336.mg	P<.3	- 83.7mg	n.s.s.	4/49	7/47			
liv mix e	437.mg	P<.6	- 78.3mg	n.s.s.	7/49	9/47			
tba mix e	88.5mg	P<.2	31.8mg	n.s.s.	17/49	24/47			
1399 M m ici gav 80w98 710o					0	42.0mg			
kid mix e	95.5mg	P<.0005 +	47.1mg	325.mg	1/50	12/48			
liv mix e	no dre	P=1.	- 105.mg	n.s.s.	9/50	8/48			
lun mix e	no dre	P=1.	- 182.mg	n.s.s.	5/50	3/48			
tba mix e	no dre	P=1.	66.8mg	n.s.s.	24/50	20/48			
1400 R f osm gav 18m26 TR-A :					0	50.2mg	100.mg		
thy MXA v#	126.mg	* P<.004 -	65.8mg	936.mg	1/20	8/50	11/50		thy:cca,ccr,fca,fcc. S
TBA MXB v	68.2mg	* P<.05	28.8mg	n.s.s.	12/20	24/50	25/50		
liv MXB v	1.13gm	* P<.7	156.mg	n.s.s.	2/20	4/50	3/50		liv:hpa,hpc,nnd.
1401 R m osm gav 18m26 TR-A :					0	45.2mg	90.3mg		
kid MXA	119.mg	/ P<.0005 c	65.5mg	334.mg	0/20	4/50	12/50		kid:tla,uac.
TBA MXB	194.mg	* P<.5	43.5mg	n.s.s.	9/20	24/50	20/50		
liv MXB	455.mg	* P<.08	157.mg	n.s.s.	0/20	1/50	3/50		liv:hpa,hpc,nnd.
1402 R m osm wat 24m24 1671					0	10.0mg	20.0mg	45.0mg 90.0mg	Jorgenson;faat,5,760-769;1985
kid mix e	519.mg	* P<.0005 +	265.mg	1.79gm	5/301	6/313	7/148	3/48 7/50	
kid mix e	606.mg	* P<.0005	305.mg	1.97gm	4/301	4/313	4/148	3/48 7/50	
kid tla e	972.mg	* P<.002	420.mg	6.25gm	4/301	2/313	3/148	2/48 5/50	
--- nfm e	2.20gm	* P<.04	676.mg	n.s.s.	2/303	2/316	1/148	0/48 3/50	
--- mix e	1.36gm	* P<.3	343.mg	n.s.s.	5/303	19/316	5/148	2/48 3/50	
tba mix e	1.97gm	* P<.9	90.2mg	n.s.s.	212/303	227/316	105/148	38/48 34/50	
1403 R f f3d inh 24m24 2378					0	3.64mg	10.9mg	32.7mg	Nagano;apor,741-746;1998/pers.comm.
kid rca e	1.59gm	* P<.2	- 258.mg	n.s.s.	0/50	0/50	0/50	1/49	
kid tcc e	1.59gm	* P<.2	- 258.mg	n.s.s.	0/50	0/50	0/50	1/49	
liv hpa e	2.18gm	* P<.8	- 191.mg	n.s.s.	1/50	0/50	2/50	1/49	
1404 R m f3d inh 24m24 2378					0	2.55mg	7.64mg	22.9mg	
kid tum e	no dre	P=1.	- 18.2mg	n.s.s.	0/50	0/50	0/50	0/50	
liv mix e	no dre	P=1.	- 18.2mg	n.s.s.	0/50	0/50	0/50	0/50	
1405 R f sda gav 80w95 711					0	43.3mg			Palmer;jept,2,821-833;1979
liv cye e	1.20gm	P<.3	- 196.mg	n.s.s.	0/50	1/49			
tba mix e	78.3mg	P<.2	- 27.1mg	n.s.s.	22/50	29/49			
tba mal e	276.mg	P<.2	- 86.0mg	n.s.s.	2/50	6/49			
1406 R m sda gav 80w95 711					0	43.3mg			
liv tum e	no dre	P=1.	- 365.mg	n.s.s.	0/48	0/49			
tba mix e	no dre	P=1.	- 115.mg	n.s.s.	12/48	9/49			
tba mal e	no dre	P=1.	- 195.mg	n.s.s.	6/48	3/49			
1407 R f wis wat 43m43 1681					0	115.mg			Tumasonis;eaes,9,233-240;1985
liv nnd ev	883.mg	P<.005 +	429.mg	5.42gm	0/18	10/40			
liv hpc ev	10.0gm	P<.4	1.63gm	n.s.s.	0/18	1/40			
kid tum ev	no dre	P=1.	3.06gm	n.s.s.	0/18	0/40			
1408 R m wis wat 40m40 1681					0	103.mg			
kid adc ev	5.30gm	P<.3 +	862.mg	n.s.s.	0/22	1/28			
kid ade ev	5.30gm	P<.3 +	862.mg	n.s.s.	0/22	1/28			
liv hpc ev	5.30gm	P<.3	862.mg	n.s.s.	0/22	1/28			
liv nnd ev	no dre	P=1.	574.mg	n.s.s.	5/22	5/28			

CHLOROMETHYL METHYL ETHER (CMME) 107-30-2

1409 H m syg inh 26m29 348					0	.377mg			Laskin;aenh,30,70-72;1975
mix mix	16.4mg	P<.1 +	4.02mg	n.s.s.	0/88	2/90			
lun adc	32.9mg	P<.3	5.36mg	n.s.s.	0/88	1/90			
1410 R m sda inh 26m28 348					0	.160mg			
mix mix	5.50mg	P<.1 +	1.35mg	n.s.s.	0/74	2/74			

2-(CHLOROMETHYL)PYRIDINE.HCl 6959-47-3

1411 M f b6c gav 23m24 TR178 :					0	51.0mg	102.mg		
TBA MXB	9.79gm	* P<1.	- 174.mg	n.s.s.	5/20	11/50	10/50		
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB	2.17gm	* P<.6	368.mg	n.s.s.	1/20	1/50	3/50		lun:a/a,a/c.
1412 M m b6c gav 23m24 TR178 :					0	51.0mg	102.mg		
TBA MXB	no dre	P=1.	- 162.mg	n.s.s.	9/20	18/50	13/50		
liv MXB	no dre	P=1.	266.mg	n.s.s.	3/20	6/50	4/50		liv:hpa,hpc,nnd.
lun MXB	2.94gm	* P<.9	210.mg	n.s.s.	2/20	5/50	5/50		lun:a/a,a/c.
1413 R f f34 gav 23m24 TR178 :					0	30.3mg	60.6mg		
TBA MXB	114.mg	* P<.4	- 32.8mg	n.s.s.	12/20	35/50	39/50		
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
1414 R m f34 gav 23m24 TR178 :					0	30.3mg	60.6mg		
sub fib #	515.mg	* P<.03 -	194.mg	n.s.s.	0/20	0/50	5/49		S
TBA MXB	671.mg	* P<.9	54.0mg	n.s.s.	13/20	28/50	29/49		
liv MXB	no dre	P=1.	743.mg	n.s.s.	3/20	0/50	0/49		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
3-(CHLOROMETHYL)PYRIDINE.HCl 6959-48-4					
1415 M f b6c gav 21m24 TR95 :	0	42.0mg	66.8mg		
sto MXA ash 394.mg * P<.04 c 161.mg n.s.s.	0/20	1/50	5/50		sto:sqc,sqp.
TBA MXB as 141.mg * P<.2 56.8mg n.s.s.	5/20	15/50	20/50		
liv MXB as 16.3gm * P<1. 376.mg n.s.s.	1/20	0/50	2/50		liv:hpa,hpc,nnd.
lun MXB as 1.97gm * P<.7 269.mg n.s.s.	1/20	1/50	3/50		lun:a/a,a/c.
1416 M m b6c gav 21m24 TR95 :	0	42.0mg	66.8mg		
sto MXA as 161.mg / P<.003 c 81.9mg 683.mg	0/20	2/50	10/50		sto:sqc,sqp.
TBA MXB as 64.9mg * P<.02 32.3mg n.s.s.	7/20	20/50	28/50		
liv MXB as 324.mg * P<.4 93.6mg n.s.s.	3/20	5/50	9/50		liv:hpa,hpc,nnd.
lun MXB as 624.mg * P<.6 122.mg n.s.s.	2/20	4/50	5/50		lun:a/a,a/c.
1417 R f f34 gav 22m24 TR95 :	0	31.8mg	51.3mg		
TBA MXB as 160.mg * P<.6 - 32.3mg n.s.s.	14/20	31/49	23/50		
liv MXB as no dre P=1. n.s.s. n.s.s.	0/20	0/49	0/50		liv:hpa,hpc,nnd.
1418 R m f34 gav 22m24 TR95 :	0	31.8mg	51.3mg		
sto MXA ash 433.mg * P<.07 c 148.mg n.s.s.	0/20	1/50	3/50		sto:sqc,sqp.
TBA MXB as no dre P=1. 70.7mg n.s.s.	14/20	21/50	11/50		
liv MXB as no dre P=1. 377.mg n.s.s.	1/20	1/50	0/50		liv:hpa,hpc,nnd.
p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE (ovex) 80-33-1					
1419 M f b6a orl 76w76 1287	0	145.mg			Innes;ntis,1968/1969
lun ade evx no dre P=1. - 162.mg n.s.s.	1/17	1/17			
liv hpt evx no dre P=1. - 272.mg n.s.s.	0/17	0/17			
tba mix evx no dre P=1. - 128.mg n.s.s.	2/17	2/17			
1420 M m b6a orl 76w76 1287	0	136.mg			
lun ade evx no dre P=1. - 127.mg n.s.s.	2/18	2/18			
liv hpt evx no dre P=1. - 160.mg n.s.s.	1/18	1/18			
tba mix evx no dre P=1. - 107.mg n.s.s.	3/18	3/18			
1421 M f b6c orl 76w76 1287	0	145.mg			
liv hpt evx 931.mg P<.3 - 152.mg n.s.s.	0/16	1/18			
lun mix evx no dre P=1. - 288.mg n.s.s.	0/16	0/18			
tba mix evx 931.mg P<.3 - 152.mg n.s.s.	0/16	1/18			
1422 M m b6c orl 76w76 1287	0	136.mg			
liv hpt evx 422.mg P<.2 - 104.mg n.s.s.	0/16	2/18			
lun ade evx 869.mg P<.3 - 141.mg n.s.s.	0/16	1/18			
tba mix evx 84.5mg P<.0005 - 37.6mg 278.mg	0/16	8/18			
3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA (telvar, monuron) 150-68-5					
1423 M f b6c eat 24m24 TR266 :	0	638.mg	1.29gm		
TBA MXB no dre P=1. - 656.mg n.s.s.	30/50	21/50	(14/50)		
liv MXB no dre P=1. 7.79gm n.s.s.	6/50	0/50	3/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 5.33gm n.s.s.	6/50	7/50	3/50		lun:a/a,a/c.
1424 M f b6c orl 76w76 1278	0	73.0mg			Innes;ntis,1968/1969
liv hpt evx no dre P=1. 145.mg n.s.s.	0/16	0/18			
lun mix evx no dre P=1. 145.mg n.s.s.	0/16	0/18			
tba tum evx no dre P=1. 145.mg n.s.s.	0/16	0/18			
1425 M m b6c eat 24m24 TR266 :	0	589.mg	1.19gm		
sub MXA # 2.10gm \ P<.02 - 864.mg n.s.s.	1/50	8/50	(1/50)		sub:fbs,fib. S
sub MXA 2.21gm \ P<.04 870.mg n.s.s.	2/50	9/50	(2/50)		sub:fbs,fib,srn. S
TBA MXB no dre P=1. 1.01gm n.s.s.	30/50	22/50	(19/50)		
liv MXB no dre P=1. 1.57gm n.s.s.	12/50	8/50	(6/50)		liv:hpa,hpc,nnd.
lun MXB 17.6gm * P<.7 2.72gm n.s.s.	6/50	5/50	10/50		lun:a/a,a/c.
1426 M m b6c orl 76w76 1278	0	68.0mg			Innes;ntis,1968/1969
liv hpt evx 112.mg P<.04 33.6mg n.s.s.	0/16	3/15			
lun ade evx 174.mg P<.09 42.7mg n.s.s.	0/16	2/15			
tba mix evx 39.6mg P<.0005 16.7mg 139.mg	0/16	7/15			
1427 M f b6a orl 76w76 1278	0	73.0mg			
lun ade evx 414.mg P<.6 57.6mg n.s.s.	1/17	2/17			
liv hpt evx no dre P=1. 137.mg n.s.s.	0/17	0/17			
tba mix evx 387.mg P<.7 48.8mg n.s.s.	2/17	3/17			
1428 M m b6a orl 76w76 1278	0	68.0mg			
lun ade evx 70.7mg P<.07 23.3mg n.s.s.	2/18	6/16			
liv hpt evx no dre P=1. 120.mg n.s.s.	1/18	0/16			
tba mix evx 86.6mg P<.2 24.5mg n.s.s.	3/18	6/16			
1429 R f f34 eat 24m24 TR266 :	0	36.8mg	73.6mg		
TBA MXB no dre P=1. - 79.7mg n.s.s.	41/50	45/50	37/50		
liv MXB no dre P=1. 527.mg n.s.s.	4/50	1/50	2/50		liv:hpa,hpc,nnd.
1430 R m f34 eat 24m24 TR266 :	0	29.4mg	58.9mg		
MXB MXB 86.3mg * P<.0005 52.1mg 225.mg	1/50	8/50	20/50		kid:tla,uac; liv:hpc,nnd. C
kid MXA 131.mg * P<.0005 c 75.2mg 286.mg	0/50	3/50	15/50		kid:tla,uac.
kid tla 272.mg * P<.006 c 128.mg 2.64gm	0/50	2/50	7/50		
kid uac 281.mg * P<.003 c 132.mg 764.mg	0/50	1/50	8/50		
liv MXA 201.mg * P<.04 c 93.9mg n.s.s.	1/50	6/50	9/50		liv:hpc,nnd.
TBA MXB no dre P=1. 78.4mg n.s.s.	36/50	41/50	36/50		
liv MXB 201.mg * P<.04 93.9mg n.s.s.	1/50	6/50	9/50		liv:hpa,hpc,nnd.
(+-)-(4)-(2-CHLOROPHENYL)-2-[2-(4-ISOBUTYLPHENYL)ETHYL]-6,9-DIMETHYL-6H-THIENO[3,2-f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINE 117279-73-9					
1431 R f sdj gav 52w52 2583	0	30.0mg	100.mg	300.mg 600.mg	Nishimura;phrm,53,259-280;1997/pers.comm.
liv tum no dre P=1. - 14.9mg n.s.s.	0/14	0/14	0/14	0/14 0/14	
1432 R m sdj gav 52w52 2583	0	30.0mg	100.mg	300.mg 600.mg	
liv tum no dre P=1. - 14.9mg n.s.s.	0/14	0/14	0/14	0/14 0/14	
1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE 10473-70-8					
1433 R m hrl eat 72w94 1348	0	10.0mg	20.0mg	40.0mg	Harris;txap,21,414-418;1972
jej adc ae 8.78mg * P<.0005 + 4.78mg 18.3mg	0/10	6/10	5/10	10/10	
duo adc ae 24.9mg * P<.0005 + 12.2mg 65.5mg	0/10	1/10	2/10	8/10	
liv mix ae 58.5mg * P<.2 23.8mg n.s.s.	0/10	2/10	2/10	2/10	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
bra mix aeh	462.mg *	P<.8	+	39.7mg n.s.s.	0/10	2/10	0/10	1/10	
tba mix ae	3.88mg *	P<.0005		1.73mg 10.9mg	2/10	9/10	9/10	10/10	
p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE (tetrasul) 2227-13-6									
1434 R f wis eat 27m27 281m					0	2.50mg	10.0mg	50.0mg 150.mg	Verschuuren;txcy,1,63-78;1973
liv tum	no dre	P=1.	-	15.6mg n.s.s.	0/32	0/32	0/32	0/32 0/32	
1435 R f wis eat 24m24 281n					0	.500mg	1.25mg		
liv tum	no dre	P=1.	-	2.36mg n.s.s.	0/32	0/32	0/32		
1436 R m wis eat 27m27 281m					0	2.00mg	8.00mg	40.0mg 120.mg	
liv hpt	4.59gm *	P<.2	-	747.mg n.s.s.	0/32	0/32	0/32	0/32 1/32	
1437 R m wis eat 24m24 281n					0	.400mg	1.00mg		
liv tum	no dre	P=1.	-	1.88mg n.s.s.	0/32	0/32	0/32		
CHLOROPICRIN 76-06-2									
1438 M f b6c gav 78w91 TR65 :					0	20.0mg	40.0mg		
TBA MXB v	82.0mg *	P<.2	-	29.9mg n.s.s.	4/20	9/50	10/50		
liv MXB v	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB v	111.mg *	P<.06		44.2mg n.s.s.	1/20	3/50	6/50		lun:a/a,a/c.
1439 M m b6c gav 78w91 TR65 :					0	20.0mg	34.0mg		
TBA MXB v	no dre	P=1.	-	36.5mg n.s.s.	5/20	7/50	9/50		
liv MXB v	no dre	P=1.		63.8mg n.s.s.	2/20	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		67.7mg n.s.s.	3/20	1/50	5/50		lun:a/a,a/c.
1440 R f osm gav 18m26 TR65 :					0	10.0mg	11.0mg		
TBA MXB dsv	no dre	P=1.	i	7.12mg n.s.s.	11/20	14/50	9/50		
liv MXB dsv	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
1441 R m osm gav 18m26 TR65 :					0	12.4mg	13.0mg		
TBA MXB dsv	no dre	P=1.	i	9.97mg n.s.s.	5/20	3/50	(0/50)		
liv MXB dsv	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
CHLOROPRENE (>96% CHLOROPRENE) 126-99-8									
1442 M f b6c inh 24m24 TR467 :					0	14.6mg	36.4mg	91.1mg	
MXB MXB	4.00mg Z	P<.0005		2.58mg 6.74mg	28/50	43/50	47/50	(48/50)	---:hem,hes; for:sqc,sqp; hag:ade,car; liv:hpa, hpc; lun:a/a,a/c; mey:sar; mgl:ade,car; sub:sar; zym:car. C
lun MXA	5.36mg Z	P<.0005	c	3.45mg 8.68mg	4/50	28/50	34/50	(42/50)	lun:a/a,a/c.
liv MXA	7.07mg Z	P<.0005	c	4.03mg 15.4mg	20/50	26/50	20/50	(30/50)	liv:hpa,hpc.
lun a/a	8.65mg Z	P<.0005	c	5.29mg 14.7mg	2/50	16/50	29/50	(26/50)	
lun a/c	14.6mg *	P<.0005	c	9.17mg 24.6mg	2/50	14/50	16/50	28/50	
liv hpc	15.2mg Z	P<.0005	c	7.94mg 35.2mg	4/50	11/50	14/50	(19/50)	
liv hpa	19.8mg *	P<.0005		10.5mg 51.3mg	17/50	19/50	11/50	16/50	S
--- MXA	21.5mg Z	P<.0005	c	10.6mg 52.2mg	4/50	6/50	18/50	(8/50)	---:hem,hes.
--- hes	22.2mg Z	P<.0005	c	10.8mg 55.9mg	4/50	6/50	17/50	(5/50)	
mey MXA	25.9mg Z	P<.0005		12.7mg 53.4mg	0/50	4/50	15/50	(5/50)	mey:hem,hes. S
sub sar	28.9mg *	P<.0005	c	17.1mg 49.5mg	0/50	11/50	11/50	18/50	
mey hes	32.2mg Z	P<.0005		15.5mg 67.1mg	0/50	4/50	13/50	(4/50)	S
mey sar	40.0mg Z	P<.0005	c	17.5mg 98.8mg	0/50	4/50	8/50	(3/50)	
hag MXA	55.2mg *	P<.0005	c	22.6mg 208.mg	2/50	5/50	3/50	9/50	hag:ade,car.
hag ade	61.3mg *	P<.0005	c	24.1mg 231.mg	1/50	3/50	3/50	8/50	
mgl MXA	65.6mg *	P<.0005	c	29.4mg 199.mg	3/50	5/50	8/50	12/50	mgl:ade,car.
pit pda	68.1mg *	P<.006		26.0mg 1.13gm	4/50	6/50	4/50	4/50	S
mgl car	75.3mg *	P<.0005	c	32.9mg 233.mg	3/50	4/50	7/50	12/50	
--- hem	134.mg *	P<.0005	c	38.8mg 793.mg	0/50	0/50	2/50	3/50	
for MXA	332.mg *	P<.01	c	74.2mg 65.9gm	1/50	0/50	0/50	4/50	for:sqc,sqp.
zym car	864.mg *	P<.01	c	259.mg 68.6gm	0/50	0/50	0/50	3/50	
ute esp	133.mg *	P<.04		38.3mg n.s.s.	2/50	4/50	2/50	3/50	S
TBA MXB	3.92mg Z	P<.0005		2.54mg 6.62mg	34/50	47/50	50/50	(48/50)	
liv MXB	7.07mg Z	P<.0005		4.03mg 15.4mg	20/50	26/50	20/50	(30/50)	liv:hpa,hpb,hpc.
lun MXB	5.36mg Z	P<.0005		3.45mg 8.68mg	4/50	28/50	34/50	(42/50)	lun:a/a,a/c.
1443 M m b6c inh 24m24 TR467 :					0	12.1mg	30.4mg	75.9mg	
MXB MXB	8.68mg Z	P<.0005		5.45mg 17.3mg	16/50	33/50	44/50	(48/50)	---:hem,hes; for:sqc,sqp; hag:ade,anb,car; lun: a/a,a/c. C
lun MXA	17.2mg *	P<.0005	c	11.0mg 31.9mg	13/50	28/50	36/50	43/50	lun:a/a,a/c.
--- MXA	17.9mg Z	P<.0005	c	11.1mg 35.5mg	3/50	14/50	23/50	(21/50)	---:hem,hes.
--- hes	19.1mg Z	P<.0005	c	11.7mg 39.0mg	3/50	13/50	22/50	(19/50)	
liv MXA	19.5mg Z	P<.0005		10.4mg 79.1mg	24/50	29/50	39/50	(34/50)	liv:hpb,hpc. S
--- MXA	21.3mg Z	P<.0005	c	13.2mg 41.6mg	1/50	12/50	18/50	(17/50)	---:hem,hes.
liv hpc	21.6mg Z	P<.002		11.1mg 112.mg	24/50	28/50	37/50	(33/50)	S
--- hes	23.8mg Z	P<.0005	c	14.3mg 49.6mg	1/50	11/50	16/50	(15/50)	
lun a/c	26.4mg *	P<.0005	c	16.8mg 50.0mg	6/50	12/50	23/50	28/50	
lun a/a	30.7mg *	P<.0005	c	18.4mg 67.9mg	8/50	18/50	22/50	28/50	
mey MXA	37.6mg Z	P<.0005		20.7mg 76.6mg	0/50	3/50	14/50	(9/50)	mey:hem,hes. S
mey hes	39.0mg Z	P<.0005		21.2mg 81.4mg	0/50	3/50	13/50	(7/50)	S
liv MXA	39.9mg *	P<.009		18.6mg 1.05gm	43/50	38/50	43/50	42/50	liv:hpa,hpb,hpc. S
hag MXA	60.9mg *	P<.0005	c	33.3mg 172.mg	2/50	5/50	10/50	12/50	hag:ade,anb,car.
hag MXA	79.5mg *	P<.0005	c	40.4mg 309.mg	2/50	5/50	8/50	10/50	hag:ade,anb.
liv hes	123.mg *	P<.005		55.7mg 1.30gm	2/50	5/50	6/50	8/50	S
sub hes	177.mg *	P<.006		73.5mg 2.71gm	1/50	4/50	1/50	7/50	S
for MXA	291.mg *	P<.008	c	108.mg 7.29gm	1/50	0/50	2/50	5/50	for:sqc,sqp.
liv MXA	42.5mg *	P<.02		19.4mg n.s.s.	43/50	37/50	42/50	41/50	liv:hpa,hpc. S
liv hpa	71.9mg *	P<.03		30.1mg n.s.s.	22/50	16/50	19/50	21/50	S
kid rua	301.mg *	P<.02		108.mg n.s.s.	0/50	1/50	1/50	3/50	S
for sqp	335.mg *	P<.02	c	114.mg n.s.s.	1/50	0/50	2/50	4/50	
TBA MXB	28.4mg *	P<.003		14.2mg 182.mg	48/50	48/50	50/50	50/50	
liv MXB	39.9mg *	P<.009		18.6mg 1.05gm	43/50	38/50	43/50	42/50	liv:hpa,hpb,hpc.
lun MXB	17.2mg *	P<.0005		11.0mg 31.9mg	13/50	28/50	36/50	43/50	lun:a/a,a/c.
1444 M m b6c inh 24m24 TR467 with step					0	12.1mg	30.4mg	75.9mg	
kid rua	129.mg *	P<.0005	c	65.9mg 327.mg	0/50	2/50	3/50	9/50	
1445 R f f34 inh 24m24 TR467 :					0	3.47mg	8.67mg	21.7mg	
cli MXA	7.14mg Z	P<.007		3.30mg 99.4mg	2/50	12/50	(5/50	3/50)	cli:ade,anb,car,cnb. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
cli MXA	12.4mg	z P<.005		5.01mg 102.mg	0/50	6/50	(4/50	2/50)	cli:car,cnb. S
ton MXA	32.9mg	* P<.0005		18.5mg 83.7mg	0/50	3/50	3/50	11/50	ton:sqc,sqp. S
MXA MXA	33.9mg	* P<.0005	c	17.9mg 118.mg	1/50	3/50	5/50	11/50	gnv:sqp; orm:sqp; phr:sqc,sqp; ton:sqc,sqp.
ton sqp	53.5mg	* P<.002		25.9mg 230.mg	0/50	2/50	1/50	7/50	S
MXA sqp	61.2mg	* P<.007	c	26.5mg 991.mg	1/50	2/50	2/50	7/50	gnv:sqp; orm:sqp; phr:sqp; ton:sqp.
MXA sqc	77.8mg	* P<.009	c	34.8mg 2.24gm	0/50	1/50	3/50	4/50	phr:sqc; ton:sqc.
ton sqc	91.1mg	* P<.01		38.8mg 6.01gm	0/50	1/50	2/50	4/50	S
mgl fba	16.3mg	* P<.03	c	7.18mg n.s.s.	24/50	32/50	36/50	36/50	
mgl MXA	20.4mg	* P<.07	c	7.90mg n.s.s.	28/50	34/50	36/50	36/50	mgl:car,fba.
--- mnl	30.4mg	* P<.04		12.3mg n.s.s.	18/50	18/50	20/50	26/50	S
thy MXA	113.mg	* P<.03	c	41.2mg n.s.s.	1/50	1/50	1/50	5/50	thy:fca,fcc.
kid rua	461.mg	* P<.06		113.mg n.s.s.	0/50	0/50	0/50	2/50	
ubl tcc	467.mg	* P<.06	e	115.mg n.s.s.	0/50	0/50	0/50	2/50	
MXB MXB	23.3mg	* P<.2		8.31mg n.s.s.	30/50	35/50	36/50	36/50	gnv:sqp; mgl:car,fba; orm:sqp; phr:sqc,sqp; thy: fca,fcc; ton:sqc,sqp. C
lun a/a	279.mg	* P<.2	e	70.2mg n.s.s.	1/50	0/50	0/50	3/50	
TBA MXB	25.4mg	* P<.3		7.49mg n.s.s.	47/50	50/50	50/50	49/50	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
1446 R f f34 inh 24m24 TR467 with step					0	3.47mg	8.67mg	21.7mg	
kid rua	183.mg	* P<.006		61.4mg 1.92gm	0/50	0/50	0/50	4/50	S
kid MXA	183.mg	* P<.006	c	61.4mg 1.92gm	0/50	0/50	0/50	4/50	kid:rua,ruc.
1447 R m f34 inh 24m24 TR467 :					0	2.43mg	6.07mg	15.2mg	
MXB MXB	5.79mg	* P<.0005		3.09mg 13.6mg	2/50	5/50	11/50	18/50	gnv:sqp; lun:a/a,a/c; orm:sqp; phr:sqp; thy:fca, fcc; ton:sqc,sqp. C
MXA MXA	10.1mg	* P<.0005	c	5.13mg 21.9mg	0/50	2/50	5/50	12/50	gnv:sqp; orm:sqp; phr:sqp; ton:sqc,sqp.
MXA sqp	11.1mg	* P<.0005	c	5.41mg 27.3mg	0/50	2/50	4/50	10/50	gnv:sqp; orm:sqp; phr:sqp; ton:sqp.
ton MXA	13.6mg	* P<.0005		6.02mg 35.9mg	0/50	0/50	4/50	8/50	ton:sqc,sqp. S
ton sqp	15.6mg	* P<.0005		6.39mg 50.6mg	0/50	0/50	3/50	6/50	S
thy MXA	18.7mg	* P<.003	c	7.52mg 134.mg	0/50	2/50	4/50	5/50	thy:fca,fcc.
thy fca	22.0mg	* P<.009		7.98mg 1.25gm	0/50	2/50	2/50	4/50	S
lun a/c	24.5mg	* P<.009	c	9.02mg 961.mg	0/50	2/50	1/50	4/50	
--- msm	27.1mg	* P<.008		11.6mg 575.mg	0/50	1/50	5/50	3/50	S
thy cca	20.0mg	* P<.05		6.72mg n.s.s.	3/50	6/50	4/50	7/50	S
lun MXA	23.8mg	* P<.02	c	8.34mg n.s.s.	2/50	2/50	4/50	6/50	lun:a/a,a/c.
kid rua	38.9mg	* P<.05		12.4mg n.s.s.	0/50	1/50	1/50	2/50	S
MXA sqp	39.2mg	* P<.02		15.3mg n.s.s.	0/50	2/50	1/50	4/50	gnv:sqp; orm:sqp; phr:sqp. S
ubl tcc	99.9mg	* P<.4	e	16.3mg n.s.s.	0/50	0/50	1/50	0/50	
ubl tpp	468.mg	* P<.2	e	76.2mg n.s.s.	0/50	0/50	0/50	1/50	
TBA MXB	6.12mg	* P<.04		2.52mg n.s.s.	50/50	50/50	50/50	50/50	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
1448 R m f34 inh 24m24 TR467 with step					0	2.43mg	6.07mg	15.2mg	
kid rua	15.4mg	* P<.008	c	6.18mg 462.mg	1/50	7/50	6/50	8/50	
kid MXA	16.1mg	* P<.02		6.26mg n.s.s.	1/50	8/50	6/50	8/50	kid:rua,ruc. S
CHLOROPRENE (99.6% CHLOROPRENE) 126-99-8									
1449 H f syg inh 78w78 2578					0	25.9mg			Trochimowicz;intx,10,443-472;1998/pers.comm.
liv tum e	no dre	P=1.	-	291.mg n.s.s.	0/94	0/97			
lun tum e	no dre	P=1.	-	291.mg n.s.s.	0/94	0/97			
tba mix e	180.mg	P<.4	-	46.8mg n.s.s.	10/94	15/97			
1450 H m syg inh 78w78 2578					0	22.8mg			
liv tum e	no dre	P=1.	-	256.mg n.s.s.	0/100	0/97			
lun tum e	no dre	P=1.	-	256.mg n.s.s.	0/100	0/97			
tba mix e	110.mg	P<.3	-	33.4mg n.s.s.	14/100	20/97			
1451 R f wsr inh 24m24 2578					0	13.6mg			
mgl fba e	55.1mg	P<.08	-	21.8mg n.s.s.	24/99	36/100			
liv tum e	no dre	P=1.	-	279.mg n.s.s.	1/99	0/100			
tba mix e	37.4mg	P<.3	-	11.1mg n.s.s.	66/99	74/100			
1452 R m wsr inh 24m24 2578					0	9.49mg			
liv tum e	no dre	P=1.	-	195.mg n.s.s.	0/97	0/100			
tba mix e	66.4mg	P<.6	-	12.7mg n.s.s.	51/97	57/100			
2-CHLOROPROPANAL 683-50-1									
1453 M f hic gav 89w89 1011					0	5.71mg			Van Duuren;jnci,63,1433-1439;1979
for tum	12.9mg	P<.004	+	5.23mg 73.7mg	0/30	6/30			
1454 M m hic gav 89w89 1011					0	4.76mg			
for tum	22.7mg	P<.04		6.86mg n.s.s.	0/30	3/30			
1-CHLOROPROPENE 590-21-6									
1455 M f hic gav 89w89 1011					0	5.71mg			Van Duuren;jnci,63,1433-1439;1979
for tum	5.05mg	P<.0005	+	2.63mg 11.5mg	0/30	13/30			
1456 M m hic gav 89w89 1011					0	4.76mg			
for tum	16.7mg	P<.02		5.76mg n.s.s.	0/30	4/30			
CHLOROTETRAFLUOROETHANE (HCFC-124) 2837-89-0									
1457 R f cdr inh 24m24 2586					0	836.mg	4.18gm	20.9gm	Malley;dact,21,417-447;1998
mgl fba e	56.3gm	* P<.008	-	26.0gm 1.21kg	21/77	14/77	20/77	31/77	
mgl mix e	54.0gm	* P<.02	-	24.0gm n.s.s.	27/77	20/77	22/77	36/77	
CHLOROTHALONIL 1897-45-6									
1458 M f b6c eat 80w91 TR41 :					0	343.mg	679.mg		
TBA MXB v	no dre	P=1.	-	1.38gm n.s.s.	3/10	6/50	8/50		
liv MXB v	no dre	P=1.		n.s.s. n.s.s.	0/10	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		2.16gm n.s.s.	1/10	2/50	3/50		lun:a/a,a/c.
1459 M m b6c eat 80w91 TR41 :					0	283.mg	560.mg		
TBA MXB v	no dre	P=1.	-	460.mg n.s.s.	3/10	9/50	(1/50)		
liv MXB v	no dre	P=1.		1.42gm n.s.s.	2/10	1/50	(1/50)		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		634.mg n.s.s.	1/10	4/50	(0/50)		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
1460 R f osm eat 19m26 TR41 :				0	184.mg	368.mg			
TBA MXB v	1.58gm	* P<.7	- 240.mg n.s.s.	5/10	25/49	34/50			
liv MXB v	no dre	P=1.	1.19gm n.s.s.	0/10	3/49	2/50		liv:hpa,hpc,nnd.	
1461 R f osm eat 19m25 TR41 : pool				0	184.mg	368.mg			
kid MXA v	2.51gm	* P<.009	c 1.02gm 58.1gm	0/65	1/49	5/50		kid:adn,can,tla,uac.	
kid MXA v	4.97gm	* P<.04	c 1.50gm n.s.s.	0/65	0/49	3/50		kid:adn,tla.	
1462 R m osm eat 19m26 TR41 :				0	147.mg	292.mg			
TBA MXB v	20.1gm	* P<1.	- 212.mg n.s.s.	4/10	22/50	16/49			
liv MXB v	no dre	P=1.	n.s.s. n.s.s.	0/10	0/50	0/49		liv:hpa,hpc,nnd.	
1463 R m osm eat 19m25 TR41 : pool				0	147.mg	292.mg			
kid MXA v	1.18gm	* P<.003	500.mg 6.60gm	0/65	3/50	4/49		kid:adc,can,ppa,tla,uac.	S
kid MXA v	2.08gm	* P<.02	c 701.mg n.s.s.	0/65	1/50	3/49		kid:adc,can,uac.	
sub fih v	2.81gm	* P<.02	835.mg n.s.s.	0/65	0/50	3/49			S
CHLOROZOTOCIN 54749-90-5									
1464 R f sda ipj 20m26 1195				0	57.1ug	.286mg		Habs;clet,8,133-137;1979	
pec mix aes	84.4ug	* P<.0005	+ 44.6ug .199mg	1/17	10/16	16/18			
tba mal aes	.108mg	* P<.0005	+ 50.6ug .370mg	4/17	10/16	16/18			
1465 R m sda ipj 18m23 1195				0	57.1ug	.286mg			
pec mix aes	24.1ug	\ P<.0005	+ 11.9ug 55.1ug	0/20	14/18	(13/16)			
tba mal aes	52.1ug	* P<.0005	+ 26.9ug .140mg	2/20	15/18	14/16			
CHLORPHENIRAMINE MALEATE 113-92-8									
1466 M f b6c gav 24m24 TR317 :				0	70.7mg	142.mg			
TBA MXB	no dre	P=1.	- 66.8mg n.s.s.	37/50	35/50	(20/50)			
liv MXB	no dre	P=1.	498.mg n.s.s.	6/50	3/50	5/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	480.mg n.s.s.	6/50	6/50	4/50		lun:a/a,a/c.	
1467 M m b6c gav 24m24 TR317 :				0	17.7mg	35.4mg			
arp adn s#	84.0mg	* P<.03	- 34.7mg n.s.s.	2/50	7/50	4/50			S
sub MXA s	94.7mg	* P<.02	39.7mg n.s.s.	4/50	5/50	8/50		sub:fbs,fib,nfs,srn.	S
sub MXA s	95.2mg	* P<.02	41.2mg 13.1gm	3/50	4/50	8/50		sub:fbs,nfs,srn.	S
sub fbs s	140.mg	* P<.05	51.1mg n.s.s.	3/50	3/50	6/50			S
TBA MXB s	54.1mg	* P<.4	14.3mg n.s.s.	39/50	36/50	21/50			
liv MXB s	101.mg	* P<.4	25.8mg n.s.s.	16/50	19/50	9/50		liv:hpa,hpc,nnd.	
lun MXB s	no dre	P=1.	105.mg n.s.s.	16/50	5/50	3/50		lun:a/a,a/c.	
1468 R f f34 gav 24m24 TR317 :				0	21.2mg	42.5mg			
TBA MXB s	no dre	P=1.	- 21.5mg n.s.s.	42/50	30/50	8/50			
liv MXB s	3.18gm	* P<.9	96.6mg n.s.s.	2/50	0/50	1/50		liv:hpa,hpc,nnd.	
1469 R f f34 eat 25m30 1654				0	42.0mg			Lijinsky;fctx,22,715-720;1984	
liv nnd ev	no dre	P=1.	- 141.mg n.s.s.	4/24	3/24				
1470 R m f34 gav 24m24 TR317 :				0	10.6mg	21.2mg			
TBA MXB	no dre	P=1.	- 14.2mg n.s.s.	44/50	41/50	31/50			
liv MXB	208.mg	* P<.6	38.5mg n.s.s.	5/50	3/50	6/50		liv:hpa,hpc,nnd.	
1471 R m f34 eat 25m30 1654				0	33.6mg			Lijinsky;fctx,22,715-720;1984	
liv nnd ev	no dre	P=1.	- 122.mg n.s.s.	5/24	3/24				
CHLORPROPAMIDE 94-20-2									
1472 M f b6c eat 24m24 TR45 :				0	301.mg	616.mg			
TBA MXB sv	no dre	P=1.	- 425.mg n.s.s.	1/15	9/35	2/35			
liv MXB sv	no dre	P=1.	693.mg n.s.s.	0/15	4/35	0/35		liv:hpa,hpc,nnd.	
lun MXB sv	1.44gm	* P<.2	546.mg n.s.s.	0/15	3/35	2/35		lun:a/a,a/c.	
1473 M m b6c eat 24m24 TR45 :				0	284.mg	569.mg			
TBA MXB sv	no dre	P=1.	- 642.mg n.s.s.	4/15	7/35	5/35			
liv MXB sv	no dre	P=1.	952.mg n.s.s.	2/15	3/35	2/35		liv:hpa,hpc,nnd.	
lun MXB sv	no dre	P=1.	n.s.s. n.s.s.	0/15	1/35	0/35		lun:a/a,a/c.	
1474 R f f34 eat 24m24 TR45 :				0	107.mg	214.mg			
TBA MXB a	no dre	P=1.	- 115.mg n.s.s.	13/15	21/35	(8/35)			
liv MXB a	no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.	
1475 R m f34 eat 24m24 TR45 :				0	85.6mg	171.mg			
TBA MXB a	no dre	P=1.	- 313.mg n.s.s.	7/15	4/35	(3/35)			
liv MXB a	no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.	
CHOCOLATE BROWN FB 12236-46-3									
1476 M f cws eat 80w80 1335				0	39.0mg	130.mg	390.mg	1.30gm	Gaunt;fctx,11,375-382;1973
liv tum e	no dre	P=1.	- 98.7mg n.s.s.	0/60	0/30	0/30	0/26	0/30	
lun ade e	no dre	P=1.	- 3.07gm n.s.s.	19/60	13/30	9/30	6/26	4/30	
1477 M m cws eat 80w80 1335				0	36.0mg	120.mg	360.mg	1.20gm	
lun ade e	3.67gm	* P<.3	- 907.mg n.s.s.	13/53	2/29	5/29	8/29	8/29	
liv tum e	no dre	P=1.	- 89.0mg n.s.s.	0/53	0/29	0/29	0/29	0/29	
1478 R f cfe eat 24m24 1334				0	50.0mg	150.mg	500.mg	1.50gm	Gaunt;fctx,10,3-15;1972
liv tum e	no dre	P=1.	- 205.mg n.s.s.	0/29	0/29	0/30	0/29	0/29	
1479 R m cfe eat 24m24 1334				0	40.0mg	120.mg	400.mg	1.20gm	
liv tum e	no dre	P=1.	- 158.mg n.s.s.	0/29	0/28	0/28	0/29	0/30	
CHOCOLATE BROWN HT 4553-89-3									
1480 M f tf1 eat 80w80 1337				0	13.0mg	130.mg	650.mg		Drake;txcy,10,17-27;1978
--- lys e	36.3mg	Z P<.007	- 13.8mg 447.mg	0/39	5/37	(3/41	1/42)		
liv hnd e	8.44gm	* P<.6	- 1.21gm n.s.s.	2/39	1/37	3/41	3/42		
lun ade e	no dre	P=1.	- 1.76gm n.s.s.	6/39	3/37	4/41	3/42		
1481 M m tf1 eat 80w80 1337				0	12.0mg	120.mg	600.mg		
liv hnd e	106.gm	* P<1.	- 956.mg n.s.s.	8/42	4/39	6/43	6/40		
liv lca e	no dre	P=1.	- 2.55gm n.s.s.	1/42	1/39	2/43	0/40		
lun ade e	no dre	P=1.	- 1.35gm n.s.s.	5/42	2/39	4/43	3/40		
CHOLINE CHLORIDE 67-48-1									
1482 M m cen eat 52w52 1992				0	1.20gm			Fullerton;carc,11,1301-1305;1990	
liv mix r	2.77gm	P<.4	569.mg n.s.s.	2/30	4/30				
liv hpa r	5.65gm	P<.7	695.mg n.s.s.	2/30	3/30				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc r		6.06gm	P<.3	987.mg n.s.s.	0/30	1/30			
lun mix r		no dre	P=1.	897.mg n.s.s.	2/30	2/30			
1483 R m f34 eat 17m24 1803					0	280.mg			Shivapurkar;carc,7,547-550;1986
liv nnd e		no dre	P=1.	- 764.mg n.s.s.	2/28	2/28			
CHROMIC OXIDE PIGMENT 1308-38-9									
1484 R b bdr eat 20m43 413					0	215.mg	459.mg	1.09gm	Ivankovic;fctx,13,347-351;1975
mgl fba		237.gm *	P<.8	- 20.7gm n.s.s.	2/60	3/60	1/60	3/60	
mgl car		no dre	P=1.	- 5.16gm n.s.s.	1/60	0/60	0/60	0/60	
hpl ade		no dre	P=1.	- 45.7gm n.s.s.	2/60	0/60	0/60	1/60	
CHROMIUM (III) ACETATE 1066-30-4									
1485 M f cd1 wat 34m34 56					0	1.00mg			Schroeder;jnut,83,239-250;1964
lun tum e		no dre	P=1.	- 4.60mg n.s.s.	9/60	4/29			
tba tum e		no dre	P=1.	- 3.34mg n.s.s.	22/60	9/29			
1486 M m cd1 wat 32m32 56					0	.833mg			
lun tum e		no dre	P=1.	- 4.06mg n.s.s.	8/44	6/39			
tba tum e		no dre	P=1.	- 4.87mg n.s.s.	11/44	6/39			
1487 R b leb wat 42m42 1036					0	.265mg			Kanisawa;canr,29,892-895;1969
liv tum e		no dre	P=1.	- 5.96mg n.s.s.	1/34	1/56			
tba tum e		1.61mg	P<.06	- .681mg n.s.s.	10/34	28/56			
tba mal e		7.62mg	P<.3	- 2.09mg n.s.s.	2/34	7/56			
CHRYSAZIN (danthron) 117-10-2									
1488 M m cen eat 77w77 1796					0	240.mg			Mori;gann,77,871-876;1986
liv hpc e		336.mg	P<.02	+ 115.mg n.s.s.	0/19	4/17			
liv hpa e		201.mg	P<.2	+ 65.2mg n.s.s.	5/19	9/17			
liv mix e		201.mg	P<.2	+ 65.2mg n.s.s.	5/19	9/17			
1489 R m aci eat 69w69 1725					0	400.mg			Mori;bjca,52,781-783;1985
lgi mix r		245.mg	P<.003	+ 104.mg 1.06gm	0/15	7/18			
liv tum r		no dre	P=1.	653.mg n.s.s.	0/15	0/18			
CIMETIDINE 51481-61-9									
1490 M f cb6 wat 29m29 1925					0	22.6mg	226.mg		Anderson;canr,45,3561-3566;1985
liv mix g		52.2gm *	P<1.	- 541.mg n.s.s.	3/20	1/15	2/16		
lun tum g		no dre	P=1.	- 627.mg n.s.s.	1/20	2/15	1/16		
1491 R f cdr gav 24m24 2449					0	950.mg			Hirth;txpy,16,273-287;1988
gam cnd r		no dre	P=1.	- 12.0gm n.s.s.	0/100	0/60			
1492 R m cdr gav 24m24 2449					0	950.mg			
gam cnd r		no dre	P=1.	- 12.0gm n.s.s.	0/100	0/60			
trans-CINNAMALDEHYDE 14371-10-9									
1493 M f b6c eat 24m24 TR514 :					0	130.mg	273.mg	533.mg	
TBA MXB		140.mg Z	P<.1	- 52.3mg n.s.s.	38/50	50/50	(37/50	21/50)	
liv MXB		no dre	P=1.	4.35gm n.s.s.	5/50	4/50	2/50	1/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	3.98gm n.s.s.	2/50	3/50	1/50	1/50	lun:a/a,a/c.
1494 M m b6c eat 24m24 TR514 :					0	120.mg	252.mg	492.mg	
TBA MXB		no dre	P=1.	- 1.03gm n.s.s.	50/50	41/50	17/50	36/50	
liv MXB		no dre	P=1.	2.51gm n.s.s.	16/50	12/50	7/50	7/50	liv:hpa,hpb,hpc.
lun MXB		6.43gm *	P<.6	1.21gm n.s.s.	10/50	7/50	3/50	13/50	lun:a/a,a/c.
1495 R f f34 eat 24m24 TR514 :					0	50.0mg	105.mg	205.mg	
TBA MXB		634.mg *	P<.6	- 105.mg n.s.s.	47/50	50/50	44/50	50/50	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
1496 R m f34 eat 24m24 TR514 :					0	40.0mg	84.0mg	164.mg	
TBA MXB		no dre	P=1.	- 126.mg n.s.s.	42/50	44/50	39/50	50/50	
liv MXB		no dre	P=1.	1.51gm n.s.s.	1/50	0/50	1/50	0/50	liv:hpa,hpb,hpc.
CINNAMYL ANTHRANILATE 87-29-6									
1497 M f b6c eat 24m24 TR196 :					0	1.91gm	3.79gm		
liv MXA		2.47gm *	P<.0005 c	1.66gm 4.50gm	3/50	20/50	33/50		liv:hpa,hpc.
liv hpc		7.50gm *	P<.0005 c	4.28gm 21.9gm	1/50	8/50	14/50		
TBA MXB		14.4gm *	P<.5	2.96gm n.s.s.	32/50	30/50	36/50		
liv MXB		2.47gm *	P<.0005	1.66gm 4.50gm	3/50	20/50	33/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	20.2gm n.s.s.	6/50	4/50	2/50		lun:a/a,a/c.
1498 M m b6c eat 24m24 TR196 :					0	1.75gm	3.53gm		
liv MXA		2.70gm *	P<.0005 c	1.53gm 9.53gm	14/50	30/50	37/50		liv:hpa,hpc.
TBA MXB		3.08gm *	P<.008	1.53gm 73.0gm	22/50	39/50	40/50		
liv MXB		2.70gm *	P<.0005	1.53gm 9.53gm	14/50	30/50	37/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	12.5gm n.s.s.	7/50	8/50	4/50		lun:a/a,a/c.
1499 R f f34 eat 24m24 TR196 :					0	736.mg	1.46gm		
ute esp #		1.46gm \	P<.002	- 740.mg 6.34gm	2/49	16/50	(9/50)		S
TBA MXB		no dre	P=1.	2.38gm n.s.s.	34/49	37/50	28/50		
liv MXB		no dre	P=1.	13.6gm n.s.s.	2/49	2/50	0/50		liv:hpa,hpc,nnd.
1500 R m f34 eat 24m24 TR196 :					0	583.mg	1.18gm		
MXB MXB		7.00gm *	P<.003	3.02gm 35.3gm	0/50	0/50	7/50		kcx:acn,adn; pan:acc,ana. C
MXA msm		10.9gm *	P<.03	4.13gm n.s.s.	0/50	1/50	4/50		abc:msm; per:msm. S
kcx MXA		12.1gm *	P<.03	c 4.18gm n.s.s.	0/50	0/50	4/50		kcx:acn,adn.
pan MXA		17.5gm *	P<.05	c 5.26gm n.s.s.	0/50	0/50	3/50		pan:acc,ana.
TBA MXB		7.69gm *	P<.7	1.12gm n.s.s.	26/50	30/50	32/50		
liv MXB		9.40gm *	P<.3	3.01gm n.s.s.	1/50	4/50	4/50		liv:hpa,hpc,nnd.
CIPROFIBRATE 52214-84-3									
1501 M m c5n eat 78w78 1895m					0	15.0mg			Rao;bjca,58,46-51;1988/pers.comm.
liv mix e		4.17mg	P<.0005	+ 1.50mg 15.8mg	0/12	6/8			
liv hpa e		5.89mg	P<.002	+ 2.09mg 26.4mg	0/12	5/8			
liv hpc e		12.3mg	P<.02	+ 3.65mg n.s.s.	0/12	3/8			
lun tum e		no dre	P=1.	13.9mg n.s.s.	0/12	0/8			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1502 M m c5n eat 89w91 1895n					0	25.4mg			
liv mix ev	12.1mg	P<.0005	+	5.16mg 37.1mg	0/12	8/12			
liv hpa ev	19.2mg	P<.002	+	7.63mg 86.4mg	0/12	6/12			
liv hpc ev	46.4mg	P<.04	+	13.9mg n.s.s.	0/12	3/12			
1503 R f f34 eat 24m24 1952					0	.500mg	2.50mg	10.0mg	Spencer;txpy,17,7-15;1989/pers.comm.
stg cnd er	531.mg *	P<.2	+	86.5mg n.s.s.	0/60	0/60	0/60	1/60	
1504 R m f34 eat 60w60 1640					0	10.0mg			Rao;canr,44,1072-1076;1984
liv hpc er	noTD50	P<.0005	+	n.s.s. 1.09mg	0/25	25/25			
liv mix er	noTD50	P<.0005	+	n.s.s. 1.09mg	0/25	25/25			
liv nnd er	noTD50	P<.0005	+	n.s.s. 1.09mg	0/25	25/25			
1505 R m f34 eat 24m24 1952					0	.500mg	2.50mg	10.0mg	Spencer;txpy,17,7-15;1989/pers.comm.
stg cnd er	103.mg *	P<.002	+	39.3mg 461.mg	0/60	0/60	0/60	5/60	
1506 R m f34 eat 95w95 2234					0	10.0mg			Rao;clet,97,185-188;1995/pers.comm.
liv mix er	noTD50	P<.0005	+	n.s.s. 3.54mg	0/15	15/15			
tes ldc er	noTD50	P<.6	-	n.s.s. n.s.s.	14/15	15/15			
1507 R m f34 eat 60w60 2524					0	10.0mg			Rao;vivo,11,495-498;1997/pers.comm.
liv hpc er	noTD50	P<.0005	+	n.s.s. 1.61mg	0/10	12/12			
liv mix er	noTD50	P<.0005	+	n.s.s. 1.61mg	0/10	12/12			
liv nnd er	noTD50	P<.0005	+	n.s.s. 1.61mg	0/10	12/12			
1508 R m f34 eat 60w60 2611					0	10.0mg			Rao;oncr,6,1285-1288;1999
liv hpc er	noTD50	P<.0005	+	n.s.s. 1.41mg	0/10	15/15			
liv nnd er	noTD50	P<.0005	+	n.s.s. 1.41mg	0/10	15/15			
CITRAL 5392-40-5									
1509 M f b6c eat 24m24 TR505 :					0	65.0mg	130.mg	260.mg	
--- mly	707.mg *	P<.008	e	347.mg 17.1gm	3/50	5/50	9/50	12/50	
liv hpa	1.09gm *	P<.04		463.mg n.s.s.	3/50	2/50	8/50	8/50	S
TBA MXB	384.mg Z	P<.2		126.mg n.s.s.	36/50	50/50	37/50	50/50	
liv MXB	1.53gm *	P<.2		492.mg n.s.s.	6/50	3/50	9/50	9/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		487.mg n.s.s.	5/50	8/50	3/50	(1/50)	lun:a/a,a/c.
1510 M m b6c eat 24m24 TR505 :					0	60.0mg	120.mg	240.mg	
spl hes #	2.28gm *	P<.04	-	865.mg n.s.s.	0/50	0/50	3/50	2/50	S
TBA MXB	1.70gm *	P<.9		135.mg n.s.s.	50/50	50/50	50/50	50/50	
liv MXB	1.32gm *	P<.5		290.mg n.s.s.	15/50	22/50	15/50	21/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		1.20gm n.s.s.	12/50	6/50	7/50	4/50	lun:a/a,a/c.
1511 R f f34 eat 24m24 TR505 :					0	50.0mg	100.mg	200.mg	
--- mnl #	89.7mg Z	P<.02	-	39.9mg n.s.s.	10/50	22/50	(14/50	15/50)	S
TBA MXB	1.90gm *	P<.9		121.mg n.s.s.	45/50	47/50	49/50	43/50	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
1512 R m f34 eat 24m24 TR505 :					0	40.0mg	80.0mg	160.mg	
TBA MXB	no dre	P=1.	-	40.0mg n.s.s.	50/50	48/50	(47/50	44/50)	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
CITRIC ACID 77-92-9									
1513 R m f3d eat 52w52 2098					0	800.mg			Shibata;carc,14,275-280;1993
for tum er	no dre	P=1.		412.mg n.s.s.	0/10	0/10			
CITRININ (antimycin) 518-75-2									
1514 R m f34 eat 60w60 1533m					0	40.0mg			Arai;clet,17,281-287;1983
kid cla kr	noTD50	P<.0005	+	n.s.s. 5.28mg	0/5	17/17			
1515 R m f34 eat 80w80 1533n					0	40.0mg			
kid cla r	noTD50	P<.0005	+	n.s.s. 12.8mg	0/10	10/10			
CLIVORINE 33979-15-6									
1516 R b aci wat 48w68 1338					0	1.88mg			Kuhara;clet,10,117-122;1980
liv mix eh	.500mg	P<.0005	+	.213mg 1.51mg	0/17	8/12			
liv nnd eh	.697mg	P<.0005	+	.274mg 2.56mg	0/17	6/11			
liv hms eh	3.01mg	P<.06	+	.738mg n.s.s.	0/17	2/12			
CLOBUZARIT 22494-47-9									
1517 H f syg eat 24m24 2241					0	5.00mg	12.5mg	25.0mg	Tucker;cthf,74-81;1995
liv tum	no dre	P=1.	-	33.5mg n.s.s.	1/156	0/52	0/52	0/52	
lun tum	no dre	P=1.	-	33.5mg n.s.s.	1/156	0/52	0/52	0/52	
1518 H m syg eat 24m24 2241					0	5.00mg	12.5mg	25.0mg	
lun tum	1.51gm *	P<.3	-	246.mg n.s.s.	0/156	0/52	1/52	0/52	
liv tum	no dre	P=1.	-	33.5mg n.s.s.	1/156	0/52	0/52	0/52	
1519 M f c5j eat 78w78 2241					0	12.5mg	25.0mg	50.0mg	
liv hpc	870.mg *	P<.1		214.mg n.s.s.	0/102	0/52	1/52	1/52	
lun tum	1.01gm *	P<.4		194.mg n.s.s.	1/102	0/52	2/52	1/52	
1520 M m c5j eat 78w78 2241					0	12.5mg	25.0mg	50.0mg	
liv hpa	154.mg *	P<.002	+	74.4mg 630.mg	1/102	2/52	2/52	8/52	
liv hpc	214.mg *	P<.02	+	89.5mg n.s.s.	2/102	1/52	3/52	6/52	
lun tum	no dre	P=1.		236.mg n.s.s.	2/102	1/52	1/52	1/52	
1521 R f aap eat 24m24 2241					0	1.00mg	1.50mg	5.00mg	
liv tum	no dre	P=1.		2.76mg n.s.s.	0/25	0/25	0/25	0/25	
1522 R m aap eat 24m24 2241					0	1.00mg	1.50mg	5.00mg	
liv hpa	62.5mg *	P<.05		15.4mg n.s.s.	0/25	0/25	0/25	2/25	
CLOFIBRATE 637-07-0									
1523 M f aps eat 78w78 2239m					0	130.mg	325.mg	650.mg	Tucker;cthf,13-16;1995/pers.comm.
liv hpa	1.48gm Z	P<.06	-	540.mg n.s.s.	4/25	0/25	2/25	8/25	
1524 M m aps eat 78w78 2239m					0	120.mg	300.mg	600.mg	
liv hpa	313.mg Z	P<.04	-	127.mg n.s.s.	8/25	2/25	15/25	(5/25)	
liv hpc	9.71gm *	P<.2	-	1.58gm n.s.s.	0/25	0/25	0/25	1/25	
1525 M f c5j eat 78w78 2239n					0	150.mg	250.mg	350.mg	
liv hpa	14.7gm *	P<.6	-	2.40gm n.s.s.	0/151	1/51	0/51	0/51	
lun tum	no dre	P=1.	-	3.15gm n.s.s.	4/151	0/51	0/51	1/51	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
1526 M m c5j eat 78w78 2239n	0	150.mg	250.mg	350.mg	
liv hpa 3.64gm * P<.05 - 1.26gm n.s.s.	0/151	2/51	1/51	1/51	
lun tum no dre P=1. - 3.57gm n.s.s.	6/151	0/51	1/51	0/51	
1527 R m f34 eat 28m28 1339	0	200.mg			Reddy;bjca,40,476-482;1979
liv hpc e 169.mg P<.0005 + 77.9mg 447.mg	0/15	10/15			
pan acc eh 1.30gm P<.09 + 318.mg n.s.s.	0/15	2/15			
CLOMIPHENE CITRATE 43054-45-1					
1528 M f csc gav 69w69 585m	0	1.14mg			Poel;canr,28,845-859;1968
lun tum ek 5.00mg P<.3 - .813mg n.s.s.	0/15	1/15			
tba mix ek 3.62mg P<.7 - .413mg n.s.s.	4/15	5/15			
1529 M f csc gav 69w82 585n	0	.962mg			
tba mix ek no dre P=1. - .367mg n.s.s.	8/15	8/15			
CLONITRALID (niclosamide) 1420-04-8					
1530 M f b6c eat 78w91 TR91 :	0	29.9mg	61.1mg		
TBA MXB sv no dre P=1. - 275.mg n.s.s.	9/20	5/50	5/50		
liv MXB sv no dre P=1. n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB sv no dre P=1. 493.mg n.s.s.	3/20	0/50	1/50		lun:a/a,a/c.
1531 M m b6c eat 78w91 TR91 :	0	27.6mg	56.4mg		
TBA MXB sv 175.mg * P<.7 i 24.8mg n.s.s.	1/20	5/50	5/50		
liv MXB sv no dre P=1. 44.1mg n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB sv no dre P=1. 28.5mg n.s.s.	0/20	1/50	0/50		lun:a/a,a/c.
1532 R f osm eat 18m26 TR91 :	0	504.mg	999.mg		
ute esp v# 5.06gm * P<.03 - 2.29gm n.s.s.	0/20	2/50	6/50		S
thy MXA v 6.67gm * P<.04 2.72gm n.s.s.	0/20	1/50	5/50		thy:cca,ccr. S
TBA MXB v 2.07gm * P<.4 607.mg n.s.s.	11/20	33/50	37/50		
liv MXB v 13.3gm * P<.3 4.01gm n.s.s.	0/20	1/50	2/50		liv:hpa,hpc,nnd.
1533 R m osm eat 18m26 TR91 :	0	403.mg	799.mg		
TBA MXB v no dre P=1. - 1.44gm n.s.s.	10/20	20/50	20/50		
liv MXB v no dre P=1. n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
CLOPHEN A 30 55600-34-5					
1534 R m wis eat 27m27 1605	0	4.00mg			Schaeffer;txap,75,278-288;1984
liv hpc e 157.mg P<.2 + 43.0mg n.s.s.	1/131	4/138			
COBALT SULFATE HEPTAHYDRATE 10026-24-1					
1535 M f b6c inh 24m24 TR471 :	0	94.3ug	.315mg	.942mg	
lun MXA 1.19mg * P<.0005 c .629mg 4.44mg	4/50	7/50	13/50	18/50	lun:a/a,a/c.
lun a/c 2.65mg * P<.002 1.30mg 11.1mg	1/50	1/50	4/50	9/50	S
lun a/a 2.37mg * P<.03 .945mg n.s.s.	3/50	6/50	9/50	10/50	S
TBA MXB 3.67mg * P<.7 .546mg n.s.s.	42/50	41/50	43/50	39/50	
liv MXB 21.9mg * P<.9 1.06mg n.s.s.	18/50	18/50	24/50	16/50	liv:hpa,hpb,hpc.
lun MXB 1.19mg * P<.0005 .629mg 4.44mg	4/50	7/50	13/50	18/50	lun:a/a,a/c.
1536 M m b6c inh 24m24 TR471 :	0	78.6ug	.262mg	.786mg	
lun MXA .554mg * P<.0005 c .297mg 1.83mg	11/50	14/50	19/50	28/50	lun:a/a,a/c.
lun a/a 1.13mg * P<.02 .488mg n.s.s.	9/50	12/50	13/50	18/50	S
lun a/c 1.38mg * P<.02 .588mg 173.mg	4/50	5/50	7/50	11/50	S
--- hes 1.85mg * P<.04 .710mg n.s.s.	3/50	6/50	8/50	9/50	S
liv hes 1.98mg * P<.04 .762mg n.s.s.	2/50	4/50	8/50	7/50	S
TBA MXB 1.08mg * P<.4 .289mg n.s.s.	49/50	48/50	47/50	46/50	
liv MXB 1.28mg * P<.4 .338mg n.s.s.	40/50	41/50	44/50	39/50	liv:hpa,hpb,hpc.
lun MXB .554mg * P<.0005 .297mg 1.83mg	11/50	14/50	19/50	28/50	lun:a/a,a/c.
1537 R f f34 inh 24m24 TR471 :	0	22.4ug	74.9ug	.224mg	
lun MXA 82.6ug Z P<.0005 c 47.9ug .165mg	0/50	3/50	16/50	(16/50)	lun:a/a,a/c,sqc.
MXB MXB 82.8ug Z P<.0005 46.5ug .210mg	2/50	4/50	19/50	(23/50)	amd:pbb,phc,phm,pob; lun:a/a,a/c,sqc. C
lun MXA 89.0ug Z P<.0005 c 50.8ug .182mg	0/50	3/50	15/50	(15/50)	lun:a/a,a/c.
lun a/a .151mg Z P<.0005 75.5ug .398mg	0/50	1/50	10/50	(9/50)	S
amd MXA .580mg * P<.003 c .271mg 4.01mg	2/50	1/50	4/50	10/50	amd:pbb,phc,phm,pob.
lun a/c .567mg * P<.02 .255mg n.s.s.	0/50	2/50	6/50	6/50	S
amd MXA .770mg * P<.02 .321mg n.s.s.	2/50	1/50	3/50	8/50	amd:pbb,pob. S
TBA MXB no dre P=1. .155mg n.s.s.	48/50	47/50	50/50	46/50	
liv MXB no dre P=1. n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
1538 R m f34 inh 24m24 TR471 :	0	15.7ug	52.5ug	.157mg	
lun MXA .397mg * P<.04 p .144mg n.s.s.	1/50	4/50	4/50	7/50	lun:a/a,a/c.
sub MXA .435mg * P<.05 .148mg n.s.s.	0/50	3/50	2/50	5/50	sub:fbs,fib,sar. S
lun a/a .639mg * P<.09 .199mg n.s.s.	1/50	4/50	1/50	6/50	
amd MXA .352mg * P<.4 e 82.0ug n.s.s.	15/50	19/50	25/50	20/50	amd:pbb,phc,phm,pob.
TBA MXB .452mg * P<.7 60.5ug n.s.s.	50/50	50/50	49/50	50/50	
liv MXB 38.2mg * P<1. .534mg n.s.s.	1/50	1/50	1/50	1/50	liv:hpa,hpb,hpc.
CODEINE 76-57-3					
1539 M f b6c eat 24m24 TR455 :	0	97.5mg	195.mg	390.mg	
TBA MXB no dre P=1. - 418.mg n.s.s.	34/50	36/51	38/51	31/51	
liv MXB no dre P=1. 1.17gm n.s.s.	16/50	15/51	15/51	8/51	liv:hpa,hpb,hpc.
lun MXB 3.20gm * P<.4 843.mg n.s.s.	2/50	3/51	7/51	4/51	lun:a/a,a/c.
1540 M m b6c eat 24m24 TR455 :	0	90.0mg	180.mg	360.mg	
TBA MXB no dre P=1. - 227.mg n.s.s.	41/50	39/50	36/50	(28/50)	
liv MXB no dre P=1. 330.mg n.s.s.	29/50	30/50	23/50	(16/50)	liv:hpa,hpb,hpc.
lun MXB no dre P=1. 984.mg n.s.s.	15/50	9/50	16/50	10/50	lun:a/a,a/c.
1541 R f f34 eat 24m24 TR455 :	0	20.0mg	40.0mg	80.0mg	
TBA MXB no dre P=1. - 26.4mg n.s.s.	46/50	44/50	47/51	(37/51)	
liv MXB no dre P=1. n.s.s. n.s.s.	0/50	0/50	0/51	0/51	liv:hpa,hpb,hpc.
1542 R m f34 eat 24m24 TR455 :	0	16.0mg	32.0mg	64.0mg	
TBA MXB 689.mg * P<.9 - 35.8mg n.s.s.	47/50	47/50	45/50	44/50	
liv MXB no dre P=1. 364.mg n.s.s.	3/50	0/50	0/50	1/50	liv:hpa,hpb,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

COLCEMID 477-30-5
1543 R m b46 ivj 12m24 1017 | 0 | 7.86ug | | | Schmahl;arzn,20,1461-1467;1970
tba mix es | 78.7ug | P<.5 | - | 14.2ug n.s.s. | 7/65 | 5/30
tba mal es | .129mg | P<.6 | - | 18.4ug n.s.s. | 4/65 | 3/30
tba ben es | .248mg | P<.7 | - | 22.4ug n.s.s. | 3/65 | 2/30

COMPOUND 50-892 (1-isopropyl-4-(m-methoxyphenyl)-7-methyl-2(1H)-quinazolinone) 65765-07-3
1544 M f cd1 eat 86w86 1667 | 0 | 25.0mg | 150.mg | | Van Ryzin;dact,3,361-379;1980
lun a/c | 4.60gm * | P<.7 | - | 455.mg n.s.s. | 1/50 | 2/50 | 2/50
lun a/a | no dre | P=1. | - | 96.6mg n.s.s. | 10/50 | 4/50 | (3/50)
liv hes | no dre | P=1. | - | 1.08gm n.s.s. | 2/50 | 1/50 | 0/50
lun mhb | no dre | P=1. | - | 802.mg n.s.s. | 0/50 | 1/50 | 0/50
1545 M m cd1 eat 86w86 1667 | 0 | 25.0mg | 150.mg | |
lun a/c | 8.40gm * | P<.8 | - | 463.mg n.s.s. | 0/50 | 2/50 | 1/50
lun a/a | no dre | P=1. | - | 261.mg n.s.s. | 13/50 | 8/50 | 11/50
liv hes | no dre | P=1. | - | 1.08gm n.s.s. | 2/50 | 1/50 | 0/50
1546 R f sdz eat 24m24 1667 | 0 | 4.30mg | 20.0mg | 102.mg
liv nnd | 2.22gm * | P<.7 | - | 286.mg n.s.s. | 7/50 | 4/50 | 6/50 | 7/50
liv hpc | no dre | P=1. | - | 35.2mg n.s.s. | 1/50 | 0/50 | 0/50 | 0/50
mam fba | no dre | P=1. | - | 156.mg n.s.s. | 22/50 | 32/50 | 27/50 | 25/50
1547 R m sdz eat 24m24 1667 | 0 | 4.30mg | 20.0mg | 102.mg
adr mal | 113.mg | Z P<.003 | - | 48.7mg 566.mg | 0/50 | 1/50 | 6/50 | (1/50)
liv tum | no dre | P=1. | - | 35.2mg n.s.s. | 0/50 | 0/50 | 0/50 | 0/50

COMPOUND LY171883 (1-(2-hydroxy-3-propyl-4-(4-(1H-tetrazol-5-yl)-butoxy)phenyl)ethanone) 88107-10-2
1548 M f b6c eat 24m24 1969 | 0 | 8.81mg | 26.4mg | 88.1mg | Bendele;faat,15,676-682;1990
liv hpc v | 112.mg | Z P<.0005 | + | 57.7mg 267.mg | 0/60 | 1/60 | 11/60 | (11/60)
liv hpa v | 369.mg | * P<.002 | | 194.mg 1.77gm | 0/60 | 2/60 | 3/60 | 8/60
1549 M m b6c eat 24m24 1969 | 0 | 8.13mg | 24.4mg | 81.3mg
liv hpc v | 426.mg | * P<.06 | | 159.mg n.s.s. | 10/60 | 8/60 | 4/60 | 16/60
liv hpa v | 2.74gm | * P<.6 | | 372.mg n.s.s. | 1/60 | 1/60 | 4/60 | 2/60

COPPER DIMETHYLDITHIOCARBAMATE (cumate) 137-29-1
1550 M f b6a orl 76w76 1203 | 0 | 22.8mg | | | Innes;ntis,1968/1969
lun bro evx | 146.mg | P<.3 | - | 23.8mg n.s.s. | 0/17 | 1/18
liv hpt evx | no dre | P=1. | - | 45.2mg n.s.s. | 0/17 | 0/18
tba mix evx | no dre | P=1. | - | 30.1mg n.s.s. | 2/17 | 1/18
1551 M m b6a orl 76w76 1203 | 0 | 21.2mg
liv hpt evx | 655.mg | P<.9 | - | 20.4mg n.s.s. | 1/18 | 1/15
lun ade evx | no dre | P=1. | - | 22.6mg n.s.s. | 2/18 | 1/15
tba mix evx | no dre | P=1. | - | 17.4mg n.s.s. | 3/18 | 2/15
1552 M f b6c orl 76w76 1203 | 0 | 22.8mg
liv hpt evx | no dre | P=1. | - | 45.2mg n.s.s. | 0/16 | 0/18
lun mix evx | no dre | P=1. | - | 45.2mg n.s.s. | 0/16 | 0/18
tba mix evx | 70.8mg | P<.2 | - | 17.4mg n.s.s. | 0/16 | 2/18
1553 M m b6c orl 76w76 1203 | 0 | 21.2mg
liv hpt evx | 34.7mg | P<.04 | - | 10.5mg n.s.s. | 0/16 | 3/15
lun ade evx | 112.mg | P<.3 | - | 18.3mg n.s.s. | 0/16 | 1/15
tba mix evx | 19.1mg | P<.005 | - | 7.18mg 151.mg | 0/16 | 5/15

COPPER-8-HYDROXYQUINOLINE 10380-28-6
1554 M f b6a orl 76w76 1295 | 0 | 389.mg | | | Innes;ntis,1968/1969
liv hpt evx | no dre | P=1. | - | 771.mg n.s.s. | 0/17 | 0/18
lun ade evx | no dre | P=1. | - | 771.mg n.s.s. | 1/17 | 0/18
tba mix evx | 2.49gm | P<.7 | - | 279.mg n.s.s. | 2/17 | 3/18
1555 M m b6a orl 76w76 1295 | 0 | 362.mg
liv hpt evx | 967.mg | P<.3 | - | 221.mg n.s.s. | 1/18 | 3/17
lun ade evx | no dre | P=1. | - | 677.mg n.s.s. | 2/18 | 0/17
tba mix evx | 11.2gm | P<1. | - | 263.mg n.s.s. | 3/18 | 3/17
1556 M f b6c orl 76w76 1295 | 0 | 389.mg
liv hpt evx | no dre | P=1. | - | 771.mg n.s.s. | 0/16 | 0/18
lun mix evx | no dre | P=1. | - | 771.mg n.s.s. | 0/16 | 0/18
tba mix evx | 2.49gm | P<.3 | - | 405.mg n.s.s. | 0/16 | 1/18
1557 M m b6c orl 76w76 1295 | 0 | 362.mg
liv hpt evx | no dre | P=1. | - | 638.mg n.s.s. | 0/16 | 0/16
lun mix evx | no dre | P=1. | - | 638.mg n.s.s. | 0/16 | 0/16
tba mix evx | 2.05gm | P<.3 | - | 334.mg n.s.s. | 0/16 | 1/16

COUMAPHOS 56-72-4
1558 M f b6c eat 24m24 TR96 : | 0 | 1.30mg | 2.60mg
TBA MXB | 10.1mg * | P<.5 | - | 2.50mg n.s.s. | 8/25 | 20/50 | 24/50
liv MXB | 11.6mg * | P<.08 | | 5.46mg n.s.s. | 0/25 | 4/50 | 5/50 | liv:hpa,hpc,nnd.
lun MXB | 42.6mg * | P<.7 | | 7.02mg n.s.s. | 1/25 | 4/50 | 4/50 | lun:a/a,a/c.
1559 M m b6c eat 24m24 TR96 : | 0 | 1.20mg | 2.40mg
TBA MXB | no dre | P=1. | - | 3.31mg n.s.s. | 15/25 | 26/50 | 22/50
liv MXB | no dre | P=1. | | 5.22mg n.s.s. | 7/25 | 14/50 | 9/50 | liv:hpa,hpc,nnd.
lun MXB | no dre | P=1. | | 6.82mg n.s.s. | 4/25 | 4/50 | 6/50 | lun:a/a,a/c.
1560 R f f34 eat 24m24 TR96 : | 0 | .500mg | 1.00mg
TBA MXB | 98.1mg * | P<1. | - | .635mg n.s.s. | 17/23 | 41/50 | 38/50
liv MXB | 6.99mg * | P<.2 | | 2.65mg n.s.s. | 0/23 | 2/50 | 3/50 | liv:hpa,hpc,nnd.
1561 R m f34 eat 24m24 TR96 : | 0 | .400mg | .800mg
TBA MXB | 1.58mg * | P<.3 | - | .471mg n.s.s. | 12/25 | 32/50 | 32/50
liv MXB | 12.3mg * | P<.4 | | 3.02mg n.s.s. | 0/25 | 1/50 | 1/50 | liv:hpa,hpc,nnd.

COUMARIN (1,2-benzopyrone) 91-64-5
1562 H f syg eat 22m24 1340 | 0 | 105.mg | 523.mg | | Ueno;fctx,19,353-355;1981
liv tum ae | no dre | P=1. | - | 222.mg n.s.s. | 0/12 | 0/13 | 0/10
tba mix ae | 5.52gm * | P<.9 | - | 350.mg n.s.s. | 5/12 | 3/13 | 4/10

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1563 H m syg eat 24m24 1340					0	92.0mg	460.mg		
liv tum e		no dre	P=1.	- 174.mg n.s.s.	0/12	0/11	0/11		
tba mix e		603.mg *	P<.04	- 212.mg n.s.s.	1/12	2/11	5/11		
1564 M f b6c gav 24m24 TR422 :					0	35.1mg	70.4mg	141.mg	
liv MXA		65.7mg Z	P<.003	c 35.7mg 438.mg	8/52	27/50	31/51	(13/51)	liv:hpa,hpc.
liv hpa		72.8mg Z	P<.006	c 38.0mg 966.mg	8/52	26/50	29/51	(12/51)	
MXB MXB		85.5mg *	P<.0005	48.1mg 302.mg	10/52	28/50	33/51	31/51	liv:hpa,hpc; lun:a/a,a/c. C
lun MXA		135.mg Z	P<.0005	c 87.4mg 252.mg	2/52	5/50	7/51	27/51	lun:a/a,a/c.
lun a/a		179.mg Z	P<.0005	c 108.mg 403.mg	2/52	5/50	7/51	20/51	
lun a/c		825.mg Z	P<.0005	c 355.mg 2.92gm	0/52	0/50	0/51	7/51	
for sqp		12.2gm *	P<1.	e 417.mg n.s.s.	1/52	5/50	2/51	2/51	
for MXA		42.0gm *	P<1.	e 376.mg n.s.s.	1/52	6/50	3/51	2/51	for:sqc,sqp.
TBA MXB		198.mg *	P<.2	67.2mg n.s.s.	25/52	41/50	36/51	34/51	
liv MXB		65.7mg Z	P<.003	35.7mg 438.mg	8/52	27/50	31/51	(13/51)	liv:hpa,hpb,hpc.
lun MXB		135.mg Z	P<.0005	87.4mg 252.mg	2/52	5/50	7/51	27/51	lun:a/a,a/c.
1565 M m b6c gav 24m24 TR422 :					0	35.2mg	70.5mg	141.mg	
lun MXA		241.mg Z	P<.006	p 118.mg 3.20gm	14/50	9/50	15/50	25/51	lun:a/a,a/c.
lun a/a		265.mg Z	P<.009	p 127.mg 7.96gm	14/50	8/50	14/50	24/51	
liv hpb		632.mg Z	P<.009	240.mg 16.1gm	0/50	0/50	5/50	(1/51)	S
for MXA		152.mg Z	P<.04	e 59.2mg n.s.s.	2/50	9/50	(4/50	0/51)	for:sqc,sqp.
for sqp		179.mg Z	P<.07	e 65.3mg n.s.s.	2/50	8/50	(2/50	0/51)	
--- MXA		600.mg *	P<.02	301.mg n.s.s.	0/50	3/50	4/50	4/51	---:hcs,mlh,mlm,mlp,mly. S
pni isa		1.31gm *	P<.03	499.mg n.s.s.	0/50	0/50	3/50	2/51	S
TBA MXB		461.mg *	P<.6	86.4mg n.s.s.	42/50	40/50	42/50	39/51	
liv MXB		no dre	P=1.	137.mg n.s.s.	35/50	34/50	32/50	29/51	liv:hpa,hpb,hpc.
lun MXB		241.mg Z	P<.006	118.mg 3.20gm	14/50	9/50	15/50	25/51	lun:a/a,a/c.
1566 M f cd1 eat 25m25 2260					0	39.0mg	130.mg	390.mg	Carlton;faat,30,145-151;1996/pers.comm.
liv mix e		176.mg Z	P<.002	- 79.5mg 598.mg	0/52	8/52	(4/52	3/52)	
lun ade e		4.50gm *	P<.1	- 1.42gm n.s.s.	2/52	1/52	2/52	5/52	
lun adc e		3.14gm *	P<.4	- 760.mg n.s.s.	10/52	11/52	11/52	14/52	
1567 M m cd1 eat 23m23 2260					0	36.0mg	120.mg	360.mg	
lun adc e		1.02gm *	P<.04	- 417.mg n.s.s.	11/52	12/52	10/52	20/52	
liv mix e		no dre	P=1.	- 1.36gm n.s.s.	20/52	22/52	19/52	12/52	
lun ade e		no dre	P=1.	- 2.23gm n.s.s.	0/52	1/52	2/52	0/52	
1568 R f f34 gav 24m24 TR422 :					0	17.6mg	35.2mg	70.3mg	
kid rua		1.41gm *	P<.07	e 347.mg n.s.s.	0/50	0/50	0/50	2/50	
TBA MXB		456.mg *	P<.8	41.8mg n.s.s.	41/50	44/50	40/50	43/50	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
1569 R f f34 gav 24m24 TR422 : with step					0	17.6mg	35.2mg	70.3mg	
kid rua		930.mg *	P<.06	e 281.mg n.s.s.	0/50	0/50	1/50	2/50	
1570 R m f34 gav 23m24 TR422 :					0	17.7mg	35.3mg	71.4mg	
tes ica as		3.62mg *	P<.0005	2.33mg 6.05mg	38/50	43/50	42/51	46/50	S
pit pda as		19.7mg Z	P<.004	8.31mg 174.mg	19/50	12/50	16/51	(6/50)	S
for sqp as		142.mg *	P<.04	24.5mg n.s.s.	0/50	1/50	0/51	1/50	S
kid MXA as		226.mg *	P<.2	p 35.2mg n.s.s.	1/50	2/50	2/51	1/50	kid:ade,rua.
TBA MXB as		12.0mg *	P<.0005	5.71mg 47.9mg	40/50	36/50	30/51	15/50	
liv MXB as		no dre	P=1.	50.3mg n.s.s.	2/50	0/50	0/51	0/50	liv:hpa,hpb,hpc.
1571 R m f34 gav 23m24 TR422 : with step					0	17.7mg	35.3mg	71.4mg	
kid MXA as		13.9mg *	P<.0005	p 6.49mg 37.1mg	1/50	6/50	7/51	5/50	kid:ade,rua.
kid MXA as		13.9mg *	P<.0005	p 6.49mg 37.1mg	1/50	6/50	7/51	5/50	kid:ade,rua,ruc.
kid ruc as		151.mg *	P<.2	24.7mg n.s.s.	0/50	1/50	0/51	0/50	
1572 R m f34 gav 15m24 TR422a :					0	44.6mg			
tes ica		8.22mg	P<.003	3.36mg 70.0mg	38/50	15/20			S
kid rua		67.6mg	P<.04	12.2mg n.s.s.	1/50	2/20			S
TBA MXB		12.2mg	P<.01	4.59mg 1.23gm	40/50	15/20			
liv MXB		171.mg	P<.4	19.3mg n.s.s.	2/50	1/20			liv:hpa,hpb,hpc.
1573 R m f34 gav 15m24 TR422a : with step					0	44.6mg			
kid rua		67.6mg	P<.04	12.2mg n.s.s.	1/50	2/20			S
1574 R m f34 gav 9m24 TR422b :					0	27.1mg			
tes ica		19.8mg	P<.3	5.48mg n.s.s.	38/50	18/20			
kid rua		234.mg	P<.5	27.3mg n.s.s.	1/50	1/20			
TBA MXB		210.mg	P<.9	9.96mg n.s.s.	40/50	14/20			
liv MXB		no dre	P=1.	51.0mg n.s.s.	2/50	0/20			liv:hpa,hpb,hpc.
1575 R m f34 gav 9m24 TR422b : with step					0	27.1mg			
kid rua		43.6mg	P<.01	13.6mg 11.6gm	1/50	4/20			S
1576 R f sda eat 26m26 2260					0	150.mg	250.mg		Carlton;faat,30,145-151;1996/pers.comm.
liv clc e		767.mg /	P<.0005	+ 467.mg 1.39gm	0/65	0/65	23/65		
liv mix e		1.44gm /	P<.0005	+ 758.mg 3.41gm	0/65	1/65	12/65		
1577 R m sda eat 24m24 2260					0	120.mg	200.mg		
liv clc e		302.mg /	P<.0005	+ 204.mg 475.mg	0/65	1/65	37/65		
liv mix e		365.mg /	P<.0005	+ 234.mg 659.mg	2/65	6/65	29/65		
m-CRESIDINE 102-50-1									
1578 M f b6c gav 53w93 TR105 :					0	22.6mg	45.3mg		
liv MXA sv#		206.mg *	P<.02	- 83.9mg n.s.s.	0/25	1/50	5/50		liv:hpa,hpc. S
TBA MXB sv		69.2mg *	P<.03	32.9mg n.s.s.	3/25	10/50	15/50		
liv MXB sv		206.mg *	P<.02	83.9mg n.s.s.	0/25	1/50	5/50		liv:hpa,hpc,nnd.
lun MXB sv		250.mg *	P<.08	95.1mg n.s.s.	0/25	2/50	3/50		lun:a/a,a/c.
1579 M m b6c gav 53w93 TR105 :					0	22.9mg	54.6mg		
TBA MXB sv		72.2mg *	P<.6	i 12.5mg n.s.s.	9/25	10/50	0/50		
liv MXB sv		no dre	P=1.	23.8mg n.s.s.	5/25	3/50	0/50		liv:hpa,hpc,nnd.
lun MXB sv		no dre	P=1.	26.9mg n.s.s.	4/25	4/50	0/50		lun:a/a,a/c.
1580 R f f34 gav 18m25 TR105 :					0	40.4mg	80.0mg		
mgl fba		52.7mg \	P<.03	24.9mg n.s.s.	3/25	21/49	(8/50)		S
ubl tcc h		769.mg *	P<.2	c 232.mg n.s.s.	0/25	1/49	2/50		
TBA MXB		51.5mg \	P<.3	17.1mg n.s.s.	12/25	38/49	(20/50)		
liv MXB		1.10gm *	P<.4	270.mg n.s.s.	0/25	1/49	1/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1581 R m f34 gav 18m25 TR105 :					0	40.4mg	80.0mg		
ubl tcc	470.mg	* P<.02	c	178.mg n.s.s.	0/25	0/50	5/50		
TBA MXB	368.mg	* P<.7		56.4mg n.s.s.	14/25	30/50	21/50		
liv MXB	506.mg	* P<.4		191.mg n.s.s.	0/25	4/50	1/50		liv:hpa,hpc,nnd.
p-CRESIDINE 120-71-8									
1582 M f b6c eat 97w97 TR142 :					0	281.mg	563.mg		
ubl MXA sv	69.0mg	/ P<.0005	c	49.9mg 97.7mg	0/50	42/50	45/50		ubl:can,nen,npm,sqc,tcc.
MXB MXB sv	69.0mg	/ P<.0005		49.9mg 97.7mg	0/50	42/50	45/50		liv:hpa,hpc; ubl:can,nen,npm,sqc,tcc. C
ubl MXA sv	70.1mg	/ P<.0005	c	50.5mg 99.5mg	0/50	41/50	44/50		ubl:can,sqc,tcc.
liv MXA sv	301.mg	* P<.0005	c	172.mg 587.mg	0/50	14/50	6/50		liv:hpa,hpc.
liv hpc sv	315.mg	* P<.0005	c	177.mg 627.mg	0/50	13/50	6/50		
TBA MXB sv	75.0mg	/ P<.0005		51.5mg 117.mg	14/50	45/50	45/50		
liv MXB sv	301.mg	* P<.0005		172.mg 587.mg	0/50	14/50	6/50		liv:hpa,hpc,nnd.
lun MXB sv	3.81gm	* P<.6		573.mg n.s.s.	4/50	4/50	1/50		lun:a/a,a/c.
1583 M m b6c eat 97w97 TR142 :					0	260.mg	552.mg		
ubl MXA sv	44.7mg	/ P<.0005	c	28.7mg 70.9mg	0/50	40/50	31/50		ubl:sqc,tcc.
TBA MXB sv	46.4mg	/ P<.0005		29.3mg 78.2mg	22/50	42/50	32/50		
liv MXB sv	255.mg	* P<.01		95.5mg 32.7gm	15/50	11/50	3/50		liv:hpa,hpc,nnd.
lun MXB sv	1.17gm	/ P<.4		207.mg n.s.s.	7/50	2/50	1/50		lun:a/a,a/c.
1584 R f f34 eat 24m24 TR142 :					0	245.mg	491.mg		
ubl MXA s	110.mg	/ P<.0005	c	79.6mg 157.mg	0/50	31/50	43/50		ubl:nen,ppc,sqc,tcc.
MXB MXB s	110.mg	/ P<.0005		79.6mg 157.mg	0/50	31/50	43/50		nas:oln; ubl:nen,ppc,sqc,tcc. C
ute esp s	913.mg	* P<.007		401.mg 14.2gm	2/50	8/50	4/50		S
nas oln s	1.19gm	/ P<.0005	c	568.mg 2.89gm	0/50	0/50	11/50		
adr coa s	1.49gm	* P<.02		578.mg n.s.s.	0/50	5/50	1/50		S
TBA MXB s	93.8mg	/ P<.0005		62.4mg 162.mg	27/50	48/50	44/50		
liv MXB s	2.18gm	* P<.06		712.mg n.s.s.	0/50	4/50	0/50		liv:hpa,hpc,nnd.
1585 R m f34 eat 24m24 TR142 :					0	198.mg	396.mg		
MXB MXB s	76.3mg	/ P<.0005		55.7mg 107.mg	0/50	35/50	46/50	liv:hpc,mhc,nnd; nas:adn,can,neu,npm,oln; nsp:acn; ubl: ppc,sqc,tcc,tpp,ulc.	C
ubl MXA s	88.4mg	/ P<.0005	c	63.9mg 126.mg	0/50	30/50	44/50		ubl:ppc,sqc,tcc,tpp,ulc.
tes ict s	165.mg	/ P<.006		81.1mg 2.05gm	37/50	45/50	23/50		S
nas MXA s	397.mg	/ P<.0005	c	236.mg 711.mg	0/50	2/50	23/50		nas:adn,can,neu,npm,oln.
liv MXA s	406.mg	* P<.0005	c	220.mg 968.mg	0/50	13/50	2/50		liv:hpc,mhc,nnd.
nas MXA s	450.mg	/ P<.0005	c	260.mg 836.mg	0/50	1/50	21/50		nas:neu,oln.
MXA gln s	3.51gm	/ P<.02		942.mg n.s.s.	0/50	0/50	3/50		bra:gln; brs:gln. S
MXA MXA s	4.62gm	* P<.03	c	1.35gm n.s.s.	0/50	0/50	3/50		nas:can,npm; nsp:acn.
TBA MXB s	98.0mg	/ P<.0005		63.6mg 181.mg	28/50	44/50	46/50		
liv MXB s	443.mg	* P<.0005		235.mg 1.11gm	0/50	12/50	2/50		liv:hpa,hpc,nnd.
CROTONALDEHYDE (trans-2-butenal) 123-73-9									
1586 R m chm wat 26m26 1774					0	2.10mg	21.0mg		Chung;canr,46,1285-1289;1986
liv mix	4.20mg	\ P<.0005	+	1.96mg 12.8mg	0/23	9/27	(1/23)		
liv nnd	4.20mg	\ P<.0005		1.96mg 12.8mg	0/23	9/27	(1/23)		
liv hpc	no dre	P=1.		94.1mg n.s.s.	0/23	2/27	0/23		
CUPFERRON 135-20-6									
1587 M f b6c eat 78w95 TR100 :					0	200.mg	405.mg		
MXB MXB v	253.mg	* P<.0005		163.mg 495.mg	3/50	18/50	25/50		---:hem,hes; hag:adn; liv:hpa,hpc; zym:sec,sqc. C
liv MXA v	413.mg	* P<.0005	c	243.mg 1.05gm	2/50	12/50	16/50		liv:hpa,hpc.
--- MXA v	419.mg	\ P<.003	c	192.mg 2.20gm	1/50	10/50	(6/50)		---:hem,hes.
liv hpc v	564.mg	* P<.0005	c	309.mg 1.96gm	2/50	9/50	13/50		
hag adn v	1.27gm	* P<.002	c	576.mg 5.56gm	0/50	2/50	6/50		
lun MXA v	798.mg	* P<.04		344.mg n.s.s.	4/50	11/50	9/50		lun:a/a,a/c. S
--- hes v	1.33gm	* P<.03		582.mg n.s.s.	1/50	5/50	6/50		S
zym MXA v	3.93gm	* P<.04	c	1.19gm n.s.s.	0/50	0/50	3/50		zym:sec,sqc.
TBA MXB v	211.mg	* P<.0005		125.mg 591.mg	12/50	33/50	31/50		
liv MXB v	413.mg	* P<.0005		243.mg 1.05gm	2/50	12/50	16/50		liv:hpa,hpc,nnd.
lun MXB v	798.mg	* P<.04		344.mg n.s.s.	4/50	11/50	9/50		lun:a/a,a/c.
1588 M m b6c eat 78w95 TR100 :					0	185.mg	374.mg		
--- hes v	1.00gm	* P<.005	c	451.mg 8.40gm	1/50	3/50	7/50		
hag adn v	1.04gm	* P<.004		450.mg 6.19gm	0/50	3/50	4/50		S
TBA MXB v	252.mg	* P<.004		128.mg 1.78gm	20/50	25/50	26/50		
liv MXB v	5.45gm	* P<.9		416.mg n.s.s.	15/50	9/50	9/50		liv:hpa,hpc,nnd.
lun MXB v	2.39gm	* P<.6		449.mg n.s.s.	7/50	8/50	5/50		lun:a/a,a/c.
1589 R f f34 eat 18m25 TR100 :					0	55.2mg	110.mg		
MXB MXB	14.1mg	* P<.0005		9.23mg 21.8mg	2/50	40/50	40/50		---:hes; liv:hpc,nnd; sto:sqc,sqp; zym:cuc,sqc. C
--- hes	17.4mg	/ P<.0005	c	10.9mg 27.9mg	0/50	28/50	37/50		
liv MXA	17.7mg	* P<.0005	c	10.6mg 31.2mg	1/50	26/50	12/50		liv:hpc,nnd.
liv hpc	20.1mg	* P<.0005	c	11.9mg 36.0mg	1/50	24/50	10/50		
sto MXA	27.8mg	/ P<.0005	c	17.0mg 45.7mg	0/50	19/50	24/50		sto:sqc,sqp.
sto sqc	31.3mg	/ P<.0005	c	18.3mg 53.9mg	0/50	14/50	22/50		
zym MXA h	171.mg	* P<.002	c	53.9mg 1.18gm	1/50	5/50	4/50		zym:cuc,sqc.
TBA MXB	11.2mg	/ P<.0005		7.18mg 18.9mg	31/50	42/50	42/50		
liv MXB	17.7mg	* P<.0005		10.6mg 31.2mg	1/50	26/50	12/50		liv:hpa,hpc,nnd.
1590 R m f34 eat 18m24 TR100 :					0	45.0mg	96.5mg		
MXB MXB	5.33mg	/ P<.0005		2.06mg 9.79mg	0/50	42/50	38/49		---:hes; liv:hpc,nnd; sto:sqc,sqp. C
--- hes	5.49mg	/ P<.0005	c	2.09mg 10.4mg	0/50	38/50	35/49		
sto MXA	6.28mg	/ P<.0005	c	2.17mg 13.1mg	0/50	32/50	24/49		sto:sqc,sqp.
sto sqc	6.94mg	/ P<.0005	c	2.24mg 16.5mg	0/50	19/50	17/49		
liv MXA	9.28mg	* P<.0005	c	2.40mg 28.6mg	0/50	12/50	5/49		liv:hpc,nnd.
sub fib	10.5mg	* P<.0005		2.43mg 35.7mg	1/50	15/50	5/49		S
liv hpc	30.7mg	* P<.0005	c	10.8mg 80.8mg	0/50	8/50	4/49		
bod MXA	139.mg	* P<.002		54.4mg 571.mg	0/50	5/50	1/49		bod:men,mso. S
TBA MXB	8.85mg	/ P<.0005		5.01mg 14.6mg	31/50	45/50	41/49		
liv MXB	9.28mg	* P<.0005		2.40mg 28.6mg	0/50	12/50	5/49		liv:hpa,hpc,nnd.

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
CYANAMIDE, CALCIUM 156-62-7					
1591 M f b6c eat 23m23 TR163 :	0	65.0mg	260.mg		
--- MXA # 478.mg * P<.03 - 213.mg n.s.s.	1/20	11/50	18/50		---:leu,lym. S
TBA MXB no dre P=1. 264.mg n.s.s.	11/20	25/50	27/50		
liv MXB no dre P=1. 685.mg n.s.s.	0/20	6/50	3/50		liv:hpa,hpc,nnd.
lun MXB 4.04gm / P<.6 716.mg n.s.s.	3/20	1/50	6/50		lun:a/a,a/c.
1592 M f b6c orl 76w76 1066	0	33.9mg			Innes;ntis,1968/1969
liv hpt evx no dre P=1. 67.2mg n.s.s.	0/16	0/18			
lun mix evx no dre P=1. 67.2mg n.s.s.	0/16	0/18			
tba mix evx 68.0mg P<.05 20.5mg n.s.s.	0/16	3/18			
1593 M m b6c eat 23m23 TR163 :	0	60.0mg	240.mg		
--- hes # 766.mg * P<.009 - 349.mg 26.9gm	1/20	2/50	10/50		S
TBA MXB 909.mg * P<.6 174.mg n.s.s.	13/20	29/50	30/50		
liv MXB no dre P=1. 675.mg n.s.s.	8/20	11/50	7/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 411.mg n.s.s.	7/20	11/50	11/50		lun:a/a,a/c.
1594 M m b6c orl 76w76 1066	0	31.6mg			Innes;ntis,1968/1969
--- rts evx 30.9mg P<.006 11.6mg 305.mg	0/16	5/16			
liv hpt evx 55.7mg P<.04 16.8mg n.s.s.	0/16	3/16			
lun mix evx no dre P=1. 55.6mg n.s.s.	0/16	0/16			
tba mix evx 16.7mg P<.0005 7.37mg 51.7mg	0/16	8/16			
1595 M f b6a orl 76w76 1066	0	33.9mg			
liv hpt evx no dre P=1. 63.4mg n.s.s.	0/17	0/17			
lun ade evx no dre P=1. 63.4mg n.s.s.	1/17	0/17			
tba mix evx no dre P=1. 29.8mg n.s.s.	2/17	2/17			
1596 M m b6a orl 76w76 1066	0	31.6mg			
liv hpt evx 191.mg P<.6 26.5mg n.s.s.	1/18	2/18			
lun ade evx no dre P=1. 41.5mg n.s.s.	2/18	1/18			
tba mix evx no dre P=1. 24.8mg n.s.s.	3/18	3/18			
1597 R f f34 eat 25m25 TR163 :	0	5.00mg	20.0mg		
TBA MXB 267.mg * P<.9 - 13.8mg n.s.s.	18/20	40/50	42/50		
liv MXB no dre P=1. 138.mg n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.
1598 R m f34 eat 25m25 TR163 :	0	4.00mg	8.00mg		
--- MXA # 7.45mg \ P<.05 - 3.39mg n.s.s.	2/20	18/50	(7/50)		---:leu,lym,nen. S
TBA MXB no dre P=1. 5.39mg n.s.s.	18/20	43/50	45/50		
liv MXB no dre P=1. 40.5mg n.s.s.	1/20	3/50	1/50		liv:hpa,hpc,nnd.
CYANAZINE (2-((4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl)amino)-2-methylpropanenitrile) 21725-46-2					
1599 R f cdr eat 52w52 2627m	0	50.0ug	.250mg	1.25mg 2.50mg	Bogdanffy;jtxe,60,567-586;2000/pers.comm.
mgl fba ek 3.03mg * P<.4 .591mg n.s.s.	0/10	0/10	1/4	1/7 1/10	
mgl ben ek 8.77mg * P<.8 .837mg n.s.s.	0/10	1/10	1/4	1/7 1/10	
mgl adc ek no dre P=1. .883mg n.s.s.	0/10	1/10	0/4	2/7 0/10	
liv tum ek no dre P=1. 20.4ug n.s.s.	0/10	0/10	0/10	0/10 0/10	
1600 R f cdr eat 24m24 2627n	0	50.0ug	.250mg	1.25mg 2.50mg	
mgl mal e 6.33mg * P<.02 + 2.88mg n.s.s.	5/50	6/44	12/41	18/47 15/52	
mgl adc e 6.65mg * P<.02 + 2.98mg n.s.s.	5/50	6/44	12/41	17/47 15/52	
mgl mix e 22.9mg * P<.8 2.55mg n.s.s.	26/50	29/44	30/41	28/47 34/52	
mgl cas e 140.mg * P<.4 22.8mg n.s.s.	0/50	0/44	0/41	1/47 0/52	
liv hpa e 280.mg * P<.7 25.5mg n.s.s.	1/52	0/52	0/52	0/52 1/52	
mgl fba e no dre P=1. 4.53mg n.s.s.	22/50	20/44	20/41	18/47 24/52	
1601 R m cdr eat 52w52 2627m	0	40.0ug	.200mg	1.00mg 2.00mg	
liv tum ek no dre P=1. - 16.4ug n.s.s.	0/10	0/10	0/10	0/10 0/10	
1602 R m cdr eat 24m24 2627n	0	40.0ug	.200mg	1.00mg 2.00mg	
liv hpa e no dre P=1. - 23.9mg n.s.s.	2/52	4/52	2/52	0/52 1/52	
CYANOGUANIDINE 157480-33-6					
1603 R f f3d eat 24m26 2522	0	1.15gm	2.30gm		Yasuhara;fctx,35,475-480;1997
liv tum no dre P=1. - 9.33gm n.s.s.	0/50	0/50	0/50		
tba mix no dre P=1. - 3.76gm n.s.s.	38/50	36/50	32/50		
1604 R m f3d eat 24m26 2522	0	920.mg	1.84gm		
sub lip 15.6gm * P<.03 - 6.33gm n.s.s.	1/50	1/50	7/50		
liv hpa 109.gm * P<.6 - 14.9gm n.s.s.	1/50	0/50	2/50		
tba mix no dre P=1. - 577.mg n.s.s.	49/50	49/50	48/50		
CYCASIN AND METHYLAZOXYMETHANOL ACETATE (CAS# 592-62-1 and 14901-08-7) mixture					
1605 P b cym eat 18y24 2004 :	0	3.61mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
liv hpc jmw 19.4mg P<.04 + 3.16mg n.s.s.	0/51	1/6			
tba mal jmw 8.25mg P<.5 .814mg n.s.s.	3/51	1/6			
1606 P b rhe ipj 8y8 2004 : ()	0	.795mg			
liv hpc jw 32.9ug P<.0005 + 7.58ug .218mg	0/84	4/5			
MXB MXB jw 32.9ug P<.0005 7.58ug .218mg	0/84	4/5			
kid rcc jw 47.8ug P<.005 + 7.79ug 7.10mg	0/59	1/1			
eso sqc jw 47.8ug P<.005 7.79ug 7.10mg	0/59	1/1			
smi adc jw 47.8ug P<.005 7.79ug 7.10mg	0/59	1/1			
tba mal Wjw 52.0ug P<.0005 10.7ug .360mg	1/84	4/5			
1607 P b rhe eat 18y24 2004m :	0	7.27mg			
asc adc jmw 11.3mg P<.05 1.83mg n.s.s.	0/12	1/2			
bil ppa jmw 18.8mg P<.07 3.06mg n.s.s.	0/13	1/3			
pan adc jmw 33.8mg P<.04 5.50mg n.s.s.	0/37	1/5			
kid rcc jmw 41.3mg P<.05 + 6.73mg n.s.s.	0/43	1/6			
liv hpc jmw 41.3mg P<.05 + 6.73mg n.s.s.	0/43	1/6			
MXB MXB jmw 41.3mg P<.05 6.73mg n.s.s.	0/43	1/6			
bil adc jmw 52.9mg P<.2 7.69mg n.s.s.	1/74	1/7			
tba mal Wjmw 11.9mg P<.1 2.66mg n.s.s.	6/74	3/7			
tba mix Wjmw 12.1mg P<.4 2.07mg n.s.s.	17/108	4/10			
tba ben Wjmw no dre P=1. 3.89mg n.s.s.	12/108	1/10			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
CYCLAMATE, SODIUM 139-05-9									
1608 M f asp eat 80w82 1341					0	888.mg	2.22gm	4.44gm	8.88gm	Brantom;fctx,11,735-746;1973
rel lys e	16.7gm	* P<.04	-	6.45gm n.s.s.	3/45	2/19	3/18	4/21	6/25	
lun ade e	228.gm	* P<1.	-	9.13gm n.s.s.	6/45	2/19	6/18	6/21	3/25	
liv tum e	no dre	P=1.	-	1.29gm n.s.s.	0/45	0/19	0/18	0/21	0/25	
1609 M m asp eat 80w82 1341					0	820.mg	2.05gm	4.10gm	8.20gm	
liv tum e	no dre	P=1.	-	1.39gm n.s.s.	0/46	0/21	0/27	0/23	0/24	
lun ade e	no dre	P=1.	-	12.4gm n.s.s.	15/46	5/21	6/27	1/23	7/24	
1610 M f c3h wat 24m24 1275					0	1.20gm				Rudali;adsc,269,1910-1913;1969
liv tum e	no dre	P=1.		2.47gm n.s.s.	0/19	0/10				
lun tum e	no dre	P=1.		2.47gm n.s.s.	0/19	0/10				
tba mix e	no dre	P=1.		201.mg n.s.s.	18/19	9/10				
1611 M m c3h wat 24m24 1275					0	1.00gm				
liv mix e	no dre	P=1.		652.mg n.s.s.	3/9	3/9				
lun mix e	no dre	P=1.		1.85gm n.s.s.	2/9	0/9				
tba mix e	no dre	P=1.		795.mg n.s.s.	5/9	3/9				
1612 M f cd1 eat 24m24 1450					0	1.30gm	6.50gm			Homburger;ctxf,359-373;1978
liv tum e	no dre	P=1.		8.27gm n.s.s.	0/17	0/38	0/33			
lun tum e	no dre	P=1.		16.2gm n.s.s.	4/17	6/38	5/33			
tba mix e	no dre	P=1.		10.5gm n.s.s.	11/17	19/38	14/33			
1613 M m crf wat 24m24 1275					0	1.00gm				Rudali;adsc,269,1910-1913;1969
liv mix e	1.42gm	P<.09	+	528.mg n.s.s.	12/28	22/34				
lun mix e	4.38gm	P<.2		1.44gm n.s.s.	2/28	7/34				
tba mix e	772.mg	P<.03	+	314.mg n.s.s.	16/28	28/34				
1614 M m r3m wat 24m24 1275					0	1.00gm				
lun mix e	4.67gm	P<.05		1.41gm n.s.s.	0/19	3/22				
liv tum e	no dre	P=1.		4.53gm n.s.s.	0/19	0/22				
tba mix e	4.67gm	P<.05		1.41gm n.s.s.	0/19	3/22				
1615 M f swa eat 76w76 1090					0	6.50gm				Roe;fctx,8,135-145;1970
liv hpt e	no dre	P=1.	-	24.3gm n.s.s.	3/45	1/47				
1616 M f swi eat 91w91 1349					0	2.60gm	6.50gm			Kroes;txcy,8,285-300;1977
ubl apc eg	no dre	P=1.	-	9.41gm n.s.s.	1/41	0/30	0/39			
1617 M m swi eat 91w91 1349					0	2.40gm	6.00gm			
ubl tum e	no dre	P=1.	-	11.1gm n.s.s.	0/40	0/41	0/41			
1618 M f xvi wat 24m24 1275					0	1.20gm				Rudali;adsc,269,1910-1913;1969
lun mix e	587.mg	P<.0005		277.mg 1.95gm	3/16	16/20				
liv mix e	16.0gm	P<.3		2.61gm n.s.s.	0/16	1/20				
tba mix e	587.mg	P<.0005	+	277.mg 1.95gm	3/16	16/20				
1619 P b cym eat 24y24 2003 :					0	71.4mg	357.mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
pro adc w	35.6mg	\ P<.1		5.81mg n.s.s.	0/3	1/1	(0/4)			
liv hpc w	1.25gm	* P<.3		203.mg n.s.s.	0/3	-/-	1/4			
tba mal w	no dre	P=1.		285.mg n.s.s.	3/15	1/3	1/4			
1620 P b rhe eat 24y24 2003 :					0	71.4mg	357.mg			
thy ppa w	182.mg	* P<.08		29.6mg n.s.s.	0/12	1/3	-/-			
col adc w	764.mg	* P<.05		124.mg n.s.s.	0/13	0/3	1/2			
ute ley w	no dre	P=1.		42.2mg n.s.s.	6/29	1/4	0/2			
tba mal Ww	3.16gm	* P<.8		193.mg n.s.s.	6/74	0/4	1/5			
tba ben Ww	no dre	P=1.		77.5mg n.s.s.	12/108	2/4	0/5			
tba mix Ww	no dre	P=1.		80.2mg n.s.s.	17/108	2/4	1/5			
1621 R b sda eat 30m30 1416					0	900.mg	2.25gm			Schmahl;arzn,23,1466-1470;1973
ubl pam e	no dre	P=1.	-	56.6gm n.s.s.	0/98	1/97	0/101			
ubl tcc e	no dre	P=1.	-	56.6gm n.s.s.	0/98	1/97	0/101			
tba mal e	30.7gm	* P<.3	-	9.59gm n.s.s.	13/98	16/97	20/101			
1622 R b wis eat 24m24 1465					0	1.00gm	2.00gm			Hicks;carm,2,475-489;1978
ubl tum er	83.9gm	* P<.2		25.4gm n.s.s.	0/98	1/84	2/143			
CYCLOCHLOROTINE 12663-46-6									
1623 M m ddn eat 37m37 1346					0	1.33mg	2.00mg			Uraguchi;fctx,10,193-207;1972
liv mix e	23.6mg	* P<.1	+	8.15mg n.s.s.	0/11	1/18	3/19			
liv lca e	48.6mg	* P<.2	+	12.0mg n.s.s.	0/11	0/18	2/19			
liv lcc e	98.9mg	* P<.4	+	16.1mg n.s.s.	0/11	0/18	1/19			
liv hpt e	99.5mg	* P<.9	+	16.2mg n.s.s.	0/11	1/18	0/19			
CYCLOCYTIDINE 31698-14-3									
1624 R f wis ipj 52w52 2383m					0	10.7mg	21.4mg	42.9mg	85.7mg	Hirayama;phrm,8,1693-1712;1974
tba tum k	no dre	P=1.	-	1.47mg n.s.s.	0/5	0/5	0/5	0/5	0/5	
1625 R f wis ipj 24m24 2383n					0	10.7mg	21.4mg	42.9mg	85.7mg	
tba mix	no dre	P=1.	-	310.mg n.s.s.	2/15	2/15	1/15	1/15	0/15	
1626 R m wis ipj 52w52 2383m					0	10.7mg	21.4mg	42.9mg	85.7mg	
tba tum k	no dre	P=1.	-	1.47mg n.s.s.	0/5	0/5	0/5	0/5	0/5	
1627 R m wis ipj 24m24 2383n					0	10.7mg	21.4mg	42.9mg	85.7mg	
tba mix	no dre	P=1.	-	17.7mg n.s.s.	0/15	0/15	0/15	0/15	0/15	
beta-CYCLODEXTRIN 7585-39-9									
1628 M f cd1 eat 24m24 2407					0	25.0mg	75.0mg	225.mg	675.mg	Waner;artx,69,631-639;1995
lun mix e	no dre	P=1.	-	2.47gm n.s.s.	7/51	7/48	6/52	9/52	6/52	
1629 M m cd1 eat 93w93 2407					0	25.0mg	75.0mg	225.mg	675.mg	
lun mix e	728.mg	Z P<.05	-	284.mg n.s.s.	9/52	2/52	12/52	13/52	(6/52)	
1630 R f cdr eat 52w52 2237					0	625.mg	1.25gm	2.50gm		Bellringer;fctx,33,367-376;1995
liv tum e	no dre	P=1.	-	357.mg n.s.s.	0/20	0/19	0/20	0/20		
1631 R m cdr eat 52w52 2237					0	500.mg	1.00gm	2.00gm		
liv tum e	no dre	P=1.	-	294.mg n.s.s.	0/17	0/20	0/20	0/20		
1632 R f f34 eat 30m30 2407					0	25.0mg	75.0mg	225.mg	675.mg	Waner;artx,69,631-639;1995
ute adc e	22.7gm	* P<.8	-	2.18gm n.s.s.	12/50	15/50	14/50	9/50	15/50	
1633 R m f34 eat 28m28 2407					0	25.0mg	75.0mg	225.mg	675.mg	
tes ict e	157.mg	* P<.0005	-	60.8mg 867.mg	42/50	46/50	44/50	48/50	50/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1634 R f f3d eat 24m25 2533					0	1.19gm	2.39gm		Toyoda;fctx,35,331-336;1997
liv hpa e	no dre	P=1.	-	19.7gm n.s.s.	1/49	1/50	1/50		
tba mix e	85.9gm *	P<1.	-	1.51gm n.s.s.	39/49	44/50	40/50		
1635 R m f3d eat 24m25 2533					0	954.mg	1.91gm		
liv hpa	no dre	P=1.	-	11.3gm n.s.s.	1/50	3/50	1/50		
tba mix	no dre	P=1.	-	525.mg n.s.s.	47/50	50/50	47/50		
CYCLOHEXANONE 108-94-1									
1636 M f b6c wat 24m25 1850					0	1.26gm	2.53gm	4.86gm	Lijinsky;jnci,77,941-949;1986
--- mly ers	3.69gm Z	P<.03		1.54gm n.s.s.	8/52	17/50	(4/50	0/41)	
liv mix ers	no dre	P=1.		24.1gm n.s.s.	3/52	6/50	3/50	2/41	
lun mix ers	no dre	P=1.		36.8gm n.s.s.	3/52	2/50	2/50	1/41	
1637 M m b6c wat 24m25 1850					0	1.05gm	2.11gm		
liv mix er	no dre	P=1.		3.72gm n.s.s.	16/52	25/51	13/46		
lun mix er	no dre	P=1.		4.90gm n.s.s.	13/52	7/51	(3/47)		
1638 R f f34 wat 24m25 1850					0	183.mg	361.mg		
liv nnd e	6.30gm *	P<.5		1.32gm n.s.s.	3/52	4/52	5/52		
1639 R m f34 wat 24m25 1850					0	160.mg	316.mg		
adr coa e	929.mg \	P<.03		364.mg n.s.s.	1/52	7/52	(1/51)		
liv car e	no dre	P=1.		1.20gm n.s.s.	2/52	0/52	0/51		
liv mix e	no dre	P=1.		1.66gm n.s.s.	6/52	5/52	4/51		
N-CYCLOHEXYL-2-BENZOTHIAZOLE SULFENAMIDE (durax) 95-33-0									
1640 M f b6a orl 76w76 1299					0	94.9mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	177.mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	-	177.mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	-	83.4mg n.s.s.	2/17	2/17			
1641 M m b6a orl 76w76 1299					0	88.2mg			
liv hpt evx	no dre	P=1.	-	104.mg n.s.s.	1/18	1/18			
lun ade evx	no dre	P=1.	-	116.mg n.s.s.	2/18	1/18			
tba mix evx	no dre	P=1.	-	69.4mg n.s.s.	3/18	3/18			
1642 M f b6c orl 76w76 1299					0	94.9mg			
liv hpt evx	no dre	P=1.	-	157.mg n.s.s.	0/16	0/15			
lun mix evx	no dre	P=1.	-	157.mg n.s.s.	0/16	0/15			
tba mix evx	243.mg	P<.09	-	59.5mg n.s.s.	0/16	2/15			
1643 M m b6c orl 76w76 1299					0	88.2mg			
liv hpt evx	92.7mg	P<.007	-	34.9mg 1.25gm	0/16	5/17			
lun ade evx	532.mg	P<.3	-	86.7mg n.s.s.	0/16	1/17			
tba mix evx	50.8mg	P<.0005	-	22.5mg 161.mg	0/16	8/17			
CYCLOHEXYLAMINE.HCl 4998-76-9									
1644 M f asp eat 80w84 398					0	37.1mg	124.mg	371.mg	Hardy;fctx,14,269-276;1976
lun ade e	no dre	P=1.	-	875.mg n.s.s.	6/44	9/46	7/42	5/44	
liv nod e	no dre	P=1.	-	1.72gm n.s.s.	1/44	3/46	0/42	1/44	
tba mix e	no dre	P=1.	-	595.mg n.s.s.	11/44	15/46	15/42	10/44	
1645 M m asp eat 80w84 398					0	34.3mg	114.mg	343.mg	
liv nod e	231.mg Z	P<.02	-	95.1mg n.s.s.	5/46	3/45	10/31	(3/46)	
lun adc e	no dre	P=1.	-	1.54gm n.s.s.	0/46	0/45	1/31	0/46	
lun ade e	no dre	P=1.	-	1.00gm n.s.s.	14/46	10/45	4/31	7/46	
tba mix e	no dre	P=1.	-	665.mg n.s.s.	16/46	14/45	10/31	11/46	
1646 R b fdr eat 24m24 1458					0	15.0mg	50.0mg	100.mg 150.mg	Oser;txcy,6,47-65;1976
liv mix g	no dre	P=1.		1.91gm n.s.s.	0/60	2/60	0/60	0/60 1/60	
tba mix g	no dre	P=1.	-	324.mg n.s.s.	16/60	18/60	15/60	14/60 (3/60)	
1647 R b sda eat 30m30 1416					0	200.mg			Schmahl;arzn,23,1466-1470;1973
liv lca e	14.5gm	P<.2	-	2.35gm n.s.s.	0/98	1/68			
ubl tum e	no dre	P=1.	-	4.38gm n.s.s.	0/98	0/68			
tba mal e	no dre	P=1.	-	1.81gm n.s.s.	13/98	6/68			
1648 R f wis eat 24m24 396					0	30.0mg	100.mg	300.mg	Gaunt;fctx,14,255-267;1976
liv hem e	1.33gm Z	P<.04	-	404.mg n.s.s.	0/38	0/43	3/47	(0/41)	
1649 R m wis eat 24m24 396					0	24.0mg	80.0mg	240.mg	
liv nod e	47.0gm *	P<1.	-	1.43gm n.s.s.	2/34	1/40	0/39	2/46	
liv hem e	no dre	P=1.	-	2.54gm n.s.s.	3/34	1/40	1/39	0/46	
CYCLOHEXYLAMINE SULFATE 19834-02-7									
1650 M f swi eat 91w91 1349					0	650.mg			Kroes;txcy,8,285-300;1977
ubl apc eg	no dre	P=1.	-	3.49gm n.s.s.	1/41	0/34			
1651 M m swi eat 91w91 1349					0	600.mg			
ubl tum e	no dre	P=1.	-	3.98gm n.s.s.	0/40	0/42			
1652 R f csa eat 24m24 1350					0	.150mg	1.50mg	15.0mg	Price;scie,167,1131-1132;1970
ubl tum r	no dre	P=1.		.696mg n.s.s.	0/25	0/25	0/25	0/25	
1653 R m csa eat 24m24 1350					0	.150mg	1.50mg	15.0mg	
ubl tcc r	280.mg *	P<.2		45.6mg n.s.s.	0/25	0/25	0/25	1/25	
CYCLOPENTANONE OXIME 1192-28-5									
1654 R m f34 gav 50w83 2265					0	17.1mg			Fiala;txcy,99,89-97;1995/pers.comm.
liv mix er	40.9mg	P<.008	+	15.5mg 607.mg	0/30	5/30			
liv hpc er	70.7mg	P<.04	+	21.4mg n.s.s.	0/30	3/30			
3-(CYCLOPENTYLOXY)-N-(3,5-DICHLORO-4-PYRIDYL)-4-METHOXYBENZAMIDE (RP 73401) 144035-83-6									
1655 R f sdi inh 24m24 2609					0	89.3ug	.357mg	.714mg	Pino;txpy,27,383-394;1999/pers.comm.
nof mix eor	1.18mg Z	P<.0005	+	.784mg 1.89mg	0/65	0/65	3/65	32/65	
nof mal eor	1.22mg Z	P<.0005	+	.805mg 1.97mg	0/65	0/65	2/65	32/65	
nof neu eor	1.68mg Z	P<.0005	+	1.05mg 2.92mg	0/65	0/65	2/65	24/65	
nof nis eor	12.2mg *	P<.008		4.21mg 224.mg	0/65	0/65	0/65	4/65	
nof car eor	24.6mg *	P<.06		6.06mg n.s.s.	0/65	0/65	0/65	2/65	
nbo adc eor	24.6mg *	P<.06		6.06mg n.s.s.	0/65	0/65	0/65	2/65	
nbo ade eor	24.7mg *	P<.2		6.07mg n.s.s.	0/65	0/65	1/65	1/65	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
1656 R m sdi inh 24m24 2609	0	89.3ug	.357mg	.714mg	
nof mix eor 2.22mg Z P<.0005 + 1.33mg 4.13mg	0/65	0/65	2/65	19/65	
nof mal eor 2.48mg Z P<.0005 + 1.45mg 4.79mg	0/65	0/65	2/65	17/65	
nof neu eor 3.75mg * P<.0005 + 1.98mg 8.44mg	0/65	0/65	2/65	11/65	
nbo ade eor 12.7mg * P<.008 4.38mg 233.mg	0/65	0/65	0/65	4/65	
nof nis eor 17.0mg * P<.03 5.14mg n.s.s.	0/65	0/65	0/65	3/65	
nbo adc eor 25.6mg * P<.06 6.30mg n.s.s.	0/65	0/65	0/65	2/65	
nof car eor 51.5mg * P<.2 8.38mg n.s.s.	0/65	0/65	0/65	1/65	
CYCLOPHOSPHAMIDE (endoxan) 50-18-0					
1657 M f swi ipj 26w79 1336	0	1.69mg	3.52mg	Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.	
--- lys e 7.09mg * P<.003 + 2.50mg 61.3mg	3/154	1/19	4/16		
ski sqc e 11.1mg * P<.002 3.35mg 81.6mg	0/154	1/19	2/16		
lun mix e 6.15mg * P<.06 + 1.97mg n.s.s.	20/154	4/19	5/16		
liv lys e no dre P=1. 2.43mg n.s.s.	1/154	0/19	0/16		
tba mal e 1.78mg * P<.0005 .858mg 5.93mg	29/154	7/19	11/16		
tba mix e 1.78mg * P<.0005 .815mg 8.25mg	42/154	9/19	11/16		
tba ben e no dre P=1. 6.99mg n.s.s.	13/154	2/19	0/16		
1658 M m swi ipj 26w79 1336	0	1.72mg	3.52mg		
--- leu e 8.69mg * P<.004 2.63mg 84.8mg	0/101	2/22	1/9		
lun mix e 5.78mg * P<.07 + 1.78mg n.s.s.	9/101	5/22	2/9		
liv mix e 40.9mg * P<.5 4.60mg n.s.s.	2/101	0/22	1/9		
tba mix e 3.66mg * P<.09 1.15mg n.s.s.	28/101	8/22	5/9		
tba mal e 3.77mg * P<.05 1.27mg n.s.s.	19/101	7/22	4/9		
tba ben e no dre P=1. 4.42mg n.s.s.	9/101	1/22	1/9		
1659 P b cym eat 11y13 2003 :	0	3.46mg		Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.	
bre pam w 1.04mg P<.002 .245mg 16.0mg	0/32	2/3			
hea car w 8.30mg P<.08 1.35mg n.s.s.	0/33	1/8			
lun car w 8.30mg P<.08 1.35mg n.s.s.	0/33	1/8			
ute ley Ww 8.30mg P<.08 1.35mg n.s.s.	0/33	1/8			
tba mix Ww .818mg P<.0005 .234mg 4.62mg	0/33	4/8			
tba ben Ww .922mg P<.0005 .240mg 7.54mg	0/33	3/8			
tba mal Ww 8.30mg P<.08 1.35mg n.s.s.	0/33	1/8			
1660 P b rhe eat 11y13 2003 :	0	2.94mg			
liv fbl w .436mg P<.007 71.0ug 82.2mg	0/42	1/1			
liv hem w .436mg P<.007 71.0ug 82.2mg	0/42	1/1			
bre pam Ww 5.67mg P<.05 .923mg n.s.s.	0/51	1/7			
ubl tcc w 8.28mg P<.04 1.35mg n.s.s.	0/93	1/10			
tba mix Ww 1.75mg P<.03 .341mg n.s.s.	5/108	3/12			
tba ben Ww 2.29mg P<.08 .337mg n.s.s.	4/108	2/12			
tba mal Ww 6.54mg P<.3 .769mg n.s.s.	2/93	1/10			
1661 R m b46 ivj 12m24 1017	0	.929mg			Schmahl;arzn,20,1461-1467;1970
tba mix es 3.01mg P<.04 + 1.12mg n.s.s.	7/65	10/36			
tba mal es 5.36mg P<.1 + 1.62mg n.s.s.	4/65	6/36			
tba ben es 9.02mg P<.3 2.12mg n.s.s.	3/65	4/36			
1662 R b sda wat 32m36 1705	0	.221mg	.450mg	.893mg 1.79mg	Schmahl;ijcn,23,706-712;1979
ubl tcc ae 21.4mg * P<.0005 + 12.1mg 70.4mg	0/74	2/77	2/78	5/73 8/72	
--- mix ae 34.9mg * P<.2 + 12.1mg n.s.s.	0/74	3/77	6/78	6/73 4/72	
vse hms ae 65.6mg * P<.3 17.1mg n.s.s.	1/74	4/77	2/78	7/73 3/72	
liv tum ae 189.mg * P<.3 46.4mg n.s.s.	0/74	0/77	1/78	0/73 1/72	
ner ngs ae no dre P=1. + 29.6mg n.s.s.	1/74	7/77	5/78	6/73 1/72	
tba mal ae 12.8mg * P<.05 + 5.20mg n.s.s.	9/74	22/77	27/78	26/73 22/72	
1663 R f sda ipj 24m24 1134	0	.571mg			Schmahl;zkko,86,77-84;1976
mam mal es 1.70mg P<.05 .660mg n.s.s.	3/33	10/36			
tba mal es 1.26mg P<.02 + .549mg n.s.s.	3/33	12/36			
1664 R m sda ipj 25m25 1134	0	.571mg			
liv hae es no dre P=1. 3.91mg n.s.s.	1/36	0/32			
tba mal es 2.87mg P<.06 + .956mg n.s.s.	1/36	5/32			
1665 R m sda ivj 12m24 1703	0	.929mg			Schmahl;zkko,81,211-215;1974
mix hae e 3.38mg P<.007 1.29mg 65.1mg	1/52	6/32			
tba mal e 1.41mg P<.002 + .656mg 6.75mg	6/52	14/32			
CYCLOSPORIN A 59865-13-3					
1666 M f of1 eat 78w78 1927	0	1.00mg	4.00mg	16.0mg	Ryffel;artx,5,107-141;1983/pers.comm.
--- lcl es 16.8mg * P<.01 - 7.50mg 2.10gm	15/50	13/50	17/50	25/50	
liv hpc es 402.mg * P<.2 - 65.4mg n.s.s.	0/50	0/50	0/50	1/50	
lun adc es no dre P=1. - 67.6mg n.s.s.	7/50	3/50	2/50	2/50	
lun ade es no dre P=1. - 28.5mg n.s.s.	8/50	10/50	7/50	8/50	
tba tum es 38.2mg * P<.7 - 4.51mg n.s.s.	42/50	42/50	40/50	43/50	
1667 M m of1 eat 78w78 1927	0	1.00mg	4.00mg	16.0mg	
liv hpc e 111.mg * P<.6 - 18.6mg n.s.s.	6/50	7/50	12/50	9/50	
lun adc e 334.mg Z P<.8 - 33.6mg n.s.s.	9/50	1/50	2/50	6/50	
liv hpa e no dre P=1. - 33.1mg n.s.s.	11/50	10/50	7/50	8/50	
lun ade e no dre P=1. - 24.5mg n.s.s.	7/50	13/50	13/50	9/50	
tba tum e 11.6mg * P<.2 - 3.47mg n.s.s.	42/50	37/50	39/50	44/50	
1668 R f ofs eat 24m24 1927	0	.500mg	2.00mg	8.00mg	
liv cho e no dre P=1. - 4.00mg n.s.s.	1/50	0/50	0/50	0/50	
liv hpc e no dre P=1. - 63.0mg n.s.s.	0/50	0/50	1/50	0/50	
liv hpa e no dre P=1. - 89.6mg n.s.s.	2/50	0/50	1/50	0/50	
tba tum e no dre P=1. - 13.4mg n.s.s.	47/50	46/50	41/50	37/50	
1669 R m ofs eat 96w96 1927	0	.500mg	2.00mg	8.00mg	
liv hpc es no dre P=1. - 74.6mg n.s.s.	0/50	1/50	0/50	0/50	
tba tum es no dre P=1. - 5.54mg n.s.s.	25/50	18/50	15/50	(11/50)	
CYPROTERONE ACETATE (androcur) 427-51-0					
1670 M f c5j eat 97w97 2290	0	104.mg			Tucker;carc,17,1473-1476;1996/pers.comm.
pyl adp es 16.8mg P<.0005 + 7.76mg 32.0mg	0/8	39/40			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc Ces	254.mg	P<.07	+	115.mg n.s.s.	0/8	8/37			
liv mix Ces	254.mg	P<.07	+	115.mg n.s.s.	0/8	8/37			
liv hpa Ces	1.12gm	P<.4		274.mg n.s.s.	0/8	2/37			
1671 M m c5j eat 24m24 2290					0	96.0mg			
pyl adp e	31.6mg	P<.0005	+	19.0mg 54.6mg	0/8	35/40			
liv mix Ce	115.mg	P<.005	+	64.5mg 731.mg	0/8	17/39			
liv hpc Ce	179.mg	P<.03	+	91.7mg n.s.s.	0/8	12/39			
liv hpa Ce	333.mg	P<.1		143.mg n.s.s.	0/8	7/39			
L-CYSTEINE.HCl 52-89-1									
1672 R f f3d wat 25m25 2538					0	143.mg	286.mg		Kitahori;jtxp,10,83-89;1997
liv tum e	no dre	P=1.	-	872.mg n.s.s.	0/44	0/43	0/38		
tba mix e	no dre	P=1.	-	459.mg n.s.s.	21/44	14/43	18/38		
1673 R m f3d wat 25m25 2538					0	125.mg	250.mg		
liv tum e	no dre	P=1.	-	654.mg n.s.s.	0/37	0/33	0/41		
tba mix e	no dre	P=1.	-	54.2mg n.s.s.	37/37	32/33	40/41		
CYTEMBENA 16170-75-5									
1674 M f b6c ipj 24m24 TR207 :					0	5.12mg	10.2mg		
--- lhc #	50.6mg *	P<.02	-	21.8mg n.s.s.	0/50	3/50	4/50		S
liv hpa	85.1mg *	P<.02		29.4mg n.s.s.	0/50	0/50	4/50		S
TBA MXB	28.4mg *	P<.4		7.91mg n.s.s.	26/50	23/50	29/50		
liv MXB	72.6mg *	P<.3		21.6mg n.s.s.	3/50	3/50	6/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		50.0mg n.s.s.	7/50	4/50	2/50		lun:a/a,a/c.
1675 M m b6c ipj 24m24 TR207 :					0	5.12mg	10.2mg		
TBA MXB	18.9mg *	P<.5	-	4.29mg n.s.s.	28/50	30/50	24/50		
liv MXB	47.8mg *	P<.7		7.03mg n.s.s.	16/50	18/50	13/50		liv:hpa,hpc,nnd.
lun MXB	161.mg *	P<.9		12.7mg n.s.s.	6/50	7/50	5/50		lun:a/a,a/c.
1676 R f f34 ipj 24m24 TR207 :					0	2.99mg	5.97mg		
mgl fba	4.45mg *	P<.002	c	2.45mg 18.3mg	13/50	22/50	36/50		
liv nnd	44.7mg *	P<.03		16.8mg n.s.s.	0/50	1/50	4/50		S
TBA MXB	9.46mg *	P<.4		2.63mg n.s.s.	38/50	44/50	47/50		
liv MXB	44.7mg *	P<.03		16.8mg n.s.s.	0/50	1/50	4/50		liv:hpa,hpc,nnd.
1677 R m f34 ipj 24m24 TR207 :					0	2.99mg	5.97mg		
MXB MXB	1.05mg \	P<.0005		.624mg 1.90mg	3/50	37/50	(36/50)		mul:msm; tnv:men. C
mul msm	2.01mg \	P<.0005	c	1.15mg 4.05mg	3/50	26/50	(26/50)		
tnv men	2.48mg \	P<.0005	c	1.14mg 6.60mg	0/50	11/50	(10/50)		
TBA MXB	1.16mg \	P<.002		.572mg 6.25mg	42/50	45/50	(48/50)		
liv MXB	56.5mg *	P<.4		11.3mg n.s.s.	1/50	1/50	2/50		liv:hpa,hpc,nnd.
DACARBAZINE (DIC) 4342-03-4									
1678 M f swi ipj 26w61 1336					0	4.56mg			Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.
lun mix e	.595mg	P<.0005	+	.249mg 1.74mg	20/154	12/14			
ute adc e	3.20mg	P<.0005	+	1.09mg 16.5mg	0/154	4/14			
--- lys e	8.00mg	P<.05	+	1.76mg n.s.s.	3/154	2/14			
spl hae e	14.5mg	P<.03	+	2.36mg n.s.s.	0/154	1/14			
liv lys e	no dre	P=1.		4.53mg n.s.s.	1/154	0/14			
tba mal e	.807mg	P<.0005		.336mg 2.84mg	29/154	11/14			
tba ben e	7.03mg	P<.2		1.50mg n.s.s.	13/154	3/14			
tba mix e	noTD50	P<.2		n.s.s. n.s.s.	42/154	14/14			
1679 M m swi ipj 26w78 1336					0	3.56mg			
lun mix e	2.57mg	P<.0005	+	1.26mg 7.71mg	9/101	14/30			
spl mix e	5.17mg	P<.0005	+	2.23mg 16.6mg	0/101	7/30			
--- lyk e	13.0mg	P<.004	+	3.94mg 114.mg	0/101	3/30			
--- lys e	16.1mg	P<.07	+	4.16mg n.s.s.	2/101	3/30			
liv mix e	98.8mg	P<.7		7.22mg n.s.s.	2/101	1/30			
tba mix e	.813mg	P<.0005		.419mg 1.86mg	28/101	26/30			
tba mal e	1.54mg	P<.0005		.796mg 4.06mg	19/101	20/30			
tba ben e	10.6mg	P<.2		2.97mg n.s.s.	9/101	6/30			
1680 R f sda eat 46w60 1412					0	3.83mg			Beal;jnci,54,951-957;1975
mgl adf	.710mg	P<.0005	+	.316mg 2.38mg	4/28	12/16			
thm lys	4.21mg	P<.02	+	1.27mg n.s.s.	0/28	3/16			
ute lei	6.55mg	P<.05	+	1.61mg n.s.s.	0/28	2/16			
DAMINOZIDE (succinic acid 2,2-dimethyl hydrazide, DMASA) 1596-84-5									
1681 M f b6c eat 24m24 TR83 :					0	644.mg	1.29gm		
TBA MXB	56.4gm *	P<1.	-	1.04gm n.s.s.	13/20	27/50	25/50		
liv MXB	6.82gm \	P<.5		1.36gm n.s.s.	1/20	4/50	(0/50)		liv:hpa,hpc,nnd.
lun MXB	2.92gm *	P<.06		1.35gm n.s.s.	1/20	8/50	10/50		lun:a/a,a/c.
1682 M m b6c eat 24m24 TR83 :					0	594.mg	1.19gm		
liv hpc	2.15gm *	P<.005	a	1.26gm 14.9gm	0/20	7/50	13/50		
liv MXA	2.45gm *	P<.05	a	1.20gm n.s.s.	1/20	9/50	14/50		liv:hpa,hpc.
TBA MXB	1.50gm *	P<.2		588.mg n.s.s.	8/20	28/50	37/50		
liv MXB	2.45gm *	P<.05		1.20gm n.s.s.	1/20	9/50	14/50		liv:hpa,hpc,nnd.
lun MXB	3.40gm *	P<.4		1.01gm n.s.s.	4/20	15/50	18/50		lun:a/a,a/c.
1683 M f swa wat 92w92 401					0	4.00gm			Toth;canr,37,3497-3500;1977
blv mix e	1.24gm	P<.0005	+	757.mg 2.16gm	8/96	36/43			
lun mix e	1.37gm	P<.0005	+	831.mg 2.47gm	15/99	37/45			
liv tum e	no dre	P=1.		29.0gm n.s.s.	0/71	0/45			
1684 M m swa wat 81w81 401					0	3.33gm			
blv mix e	880.mg	P<.0005	+	552.mg 1.49gm	5/89	37/46			
lun mix e	1.11gm	P<.0005	+	649.mg 2.21gm	22/92	36/46			
kid ade e	10.9gm	P<.002	+	4.15gm 51.1gm	0/77	5/42			
liv hpt e	38.8gm	P<.3	-	7.39gm n.s.s.	1/77	2/42			
1685 R f f34 eat 24m24 TR83 :					0	248.mg	495.mg		
lun a/a	4.89gm *	P<.05		1.69gm n.s.s.	0/20	0/50	4/50		S
MXB MXB	1.84gm *	P<.2		922.mg n.s.s.	0/20	6/50	5/50		ute:lei; utm:acn. C
utm acn h	2.50gm *	P<.3	c	1.13gm n.s.s.	0/20	5/50	3/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ute lei h	5.27gm *	P<.2	c	1.81gm n.s.s.	0/20	1/50	3/50		
TBA MXB	3.45gm *	P<.8		404.mg n.s.s.	11/20	32/50	28/50		
liv MXB	9.64gm *	P<.5		2.37gm n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
1686 R m f34 eat 24m24 TR83 :					0	198.mg	396.mg		
TBA MXB	no dre	P=1.	-	771.mg n.s.s.	10/20	21/50	19/50		
liv MXB	no dre	P=1.		3.37gm n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
DAPSONE 80-08-0									
1687 M f b6c eat 18m25 TR20 :					0	33.8mg	67.6mg		
TBA MXB	no dre	P=1.	-	45.8mg n.s.s.	6/14	4/35	(2/36)		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/14	0/35	0/36		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		262.mg n.s.s.	1/14	0/35	0/36		lun:a/a,a/c.
1688 M m b6c eat 18m25 TR20 :					0	31.2mg	62.4mg		
TBA MXB	no dre	P=1.	-	67.2mg n.s.s.	0/14	11/35	5/34		
liv MXB	no dre	P=1.		106.mg n.s.s.	0/14	6/35	2/34		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		133.mg n.s.s.	0/14	5/35	1/34		lun:a/a,a/c.
1689 R f f34 eat 18m24 TR20 :					0	16.0mg	32.0mg		
TBA MXB	no dre	P=1.	-	35.7mg n.s.s.	8/15	15/35	14/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
1690 R m f34 eat 18m24 TR20 :					0	12.8mg	25.6mg		
spl MXA	22.4mg *	P<.0005	c	13.1mg 61.0mg	0/15	6/35	14/35		spl:fbs,fib,srn.
spl fib	28.5mg *	P<.004	c	15.7mg 157.mg	0/15	6/35	10/35		
TBA MXB	22.4mg *	P<.1		8.91mg n.s.s.	6/15	23/35	24/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
1691 R m f34 eat 18m24 TR20 : pool					0	12.8mg	25.6mg		
spl MXA	22.4mg *	P<.0005	c	13.1mg 42.8mg	0/45	6/35	14/35		spl:fbs,fib,srn.
spl fib	28.5mg *	P<.0005	c	15.7mg 62.2mg	0/45	6/35	10/35		
--- lym	50.1mg \	P<.008		16.9mg 1.09gm	0/45	4/35	(0/35)		S
per MXA	56.3mg *	P<.002	c	27.8mg 202.mg	0/45	5/35	6/35		per:fbs,srn.
per srn	91.3mg *	P<.02		38.7mg n.s.s.	0/45	4/35	3/35		S
per fbs	148.mg *	P<.03	c	50.0mg n.s.s.	0/45	1/35	3/35		
spl fbs	167.mg *	P<.03	c	50.0mg n.s.s.	0/45	0/35	3/35		
spl srn	170.mg *	P<.03	c	50.7mg n.s.s.	0/45	0/35	3/35		
o,p'-DDD 53-19-0									
1692 M f b6a orl 76w76 1202					0	78.4mg			Innes;ntis,1968/1969
lun ade evx	236.mg	P<.4		51.4mg n.s.s.	1/17	3/18			
liv hpt evx	no dre	P=1.		155.mg n.s.s.	0/17	0/18			
tba mix evx	102.mg	P<.2		31.8mg n.s.s.	2/17	6/18			
1693 M m b6a orl 76w76 1202					0	73.0mg			
lun ade evx	414.mg	P<.7		52.0mg n.s.s.	2/18	3/18			
lun car evx	467.mg	P<.3		76.1mg n.s.s.	0/18	1/18			
liv hpt evx	no dre	P=1.		86.3mg n.s.s.	1/18	1/18			
tba mix evx	187.mg	P<.5		37.2mg n.s.s.	3/18	5/18			
1694 M f b6c orl 76w76 1202					0	78.4mg			
liv hpt evx	no dre	P=1.		155.mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.		155.mg n.s.s.	0/16	0/18			
tba tum evx	no dre	P=1.		155.mg n.s.s.	0/16	0/18			
1695 M m b6c orl 76w76 1202					0	73.0mg			
--- rts evx	82.1mg	P<.009		30.9mg 1.80gm	0/16	5/18			
liv hpt evx	147.mg	P<.05		44.2mg n.s.s.	0/16	3/18			
lun ade evx	467.mg	P<.3		76.1mg n.s.s.	0/16	1/18			
tba mix evx	38.5mg	P<.0005		17.8mg 111.mg	0/16	9/18			
p,p'-DDD (TDE) 72-54-8									
1696 M f b6c eat 78w90 TR131 :					0	45.5mg	89.7mg		
TBA MXB v	108.mg \	P<.2	-	40.9mg n.s.s.	2/20	13/50	(6/50)		
liv MXB v	493.mg *	P<.1		201.mg n.s.s.	0/20	2/50	4/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		240.mg n.s.s.	0/20	4/50	1/50		lun:a/a,a/c.
1697 M f b6c orl 76w76 79					0	41.4mg			Innes;ntis,1968/1969
lun ade evx	250.mg	P<.3		40.7mg n.s.s.	0/16	1/17			
liv hpt evx	no dre	P=1.		77.4mg n.s.s.	0/16	0/17			
tba mix evx	250.mg	P<.3		40.7mg n.s.s.	0/16	1/17			
1698 M m b6c eat 78w90 TR131 :					0	42.0mg	84.0mg		
TBA MXB v	997.mg *	P<.9	-	53.0mg n.s.s.	8/20	19/50	19/50		
liv MXB v	116.mg *	P<.2		48.5mg n.s.s.	2/20	12/50	14/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		173.mg n.s.s.	1/20	4/50	2/50		lun:a/a,a/c.
1699 M m b6c orl 76w76 79					0	38.5mg			Innes;ntis,1968/1969
liv hpt evx	43.3mg	P<.009		16.3mg 950.mg	0/16	5/18			
lun ade evx	120.mg	P<.2		29.4mg n.s.s.	0/16	2/18			
tba mix evx	34.8mg	P<.004		14.0mg 212.mg	0/16	6/18			
1700 M f b6a orl 76w76 79					0	41.4mg			
lun ade evx	73.0mg	P<.2		20.7mg n.s.s.	1/17	4/17			
liv hpt evx	no dre	P=1.		77.4mg n.s.s.	0/17	0/17			
tba mix evx	37.4mg	P<.05		13.2mg n.s.s.	2/17	7/17			
1701 M m b6a orl 76w76 79					0	38.5mg			
lun ade evx	82.9mg	P<.3		19.0mg n.s.s.	2/18	4/16			
liv hpt evx	no dre	P=1.		67.8mg n.s.s.	1/18	0/16			
tba mix evx	49.0mg	P<.2		13.9mg n.s.s.	3/18	6/16			
1702 M f cf1 eat 29m29 80					0	32.5mg			Tomatis;jnci,52,883-891;1974
lun mix	39.9mg	P<.0005	+	21.8mg 115.mg	37/97	43/60			
liv hpt	4.83gm	P<.8	-	328.mg n.s.s.	1/97	1/60			
tba mix	67.1mg	P<.3		18.5mg n.s.s.	79/97	53/60			
1703 M m cf1 eat 29m29 80					0	30.0mg			
lun mix	24.9mg	P<.0005	+	13.5mg 68.6mg	53/101	51/60			
liv hpt	86.8mg	P<.02	+	37.6mg n.s.s.	33/101	31/60			
tba mix	33.2mg	P<.2		9.92mg n.s.s.	89/101	57/60			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1704 R f osm eat 18m26 TR131 :					0	29.0mg	59.0mg		
TBA MXB	no dre	P=1.	-	59.0mg n.s.s.	17/20	35/50	36/50		
liv MXB	2.08gm *	P<.7		295.mg n.s.s.	1/20	0/50	3/50		liv:hpa,hpc,nnd.
1705 R m osm eat 18m26 TR131 :					0	45.6mg	91.2mg		
thy MXA v	75.8mg	\ P<.05	a	35.9mg n.s.s.	1/20	16/50	(11/50)		thy:fca,fcc.
TBA MXB v	82.6mg	\ P<.4		25.3mg n.s.s.	7/20	33/50	(25/50)		
liv MXB v	no dre	P=1.		450.mg n.s.s.	1/20	1/50	2/50		liv:hpa,hpc,nnd.
p,p'-DDE 72-55-9									
1706 H f syg eat 28m28 1556					0	52.3mg	105.mg		Rossi;canr,43,776-781;1983
liv nnd e	354.mg *	P<.003	+	166.mg 1.76gm	0/31	4/26	5/24		
adr mix e	458.mg *	P<.03		205.mg n.s.s.	2/42	7/39	8/39		
lun tum e	no dre	P=1.		1.13gm n.s.s.	2/42	0/39	1/39		
tba mix e	634.mg *	P<.4		163.mg n.s.s.	13/42	13/39	16/39		
1707 H m syg eat 28m28 1556					0	46.0mg	92.0mg		
liv nnd e	141.mg *	P<.04	+	77.0mg n.s.s.	0/10	7/15	8/24		
lun tum e	no dre	P=1.		273.mg n.s.s.	1/31	0/30	0/39		
tba mix e	1.30gm *	P<.8		136.mg n.s.s.	15/31	11/30	20/39		
1708 M f b6c eat 78w92 TR131 :					0	15.6mg	28.6mg		
liv hpc dv	9.45mg /	P<.0005	c	6.69mg 14.3mg	0/20	19/50	34/50		
TBA MXB dv	11.9mg /	P<.0005		7.31mg 32.8mg	5/20	25/50	35/50		
liv MXB dv	9.45mg /	P<.0005		6.69mg 14.3mg	0/20	19/50	34/50		liv:hpa,hpc,nnd.
lun MXB dv	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		lun:a/a,a/c.
1709 M m b6c eat 78w92 TR131 :					0	15.6mg	26.4mg		
liv hpc dsv	11.1mg *	P<.03	c	6.68mg n.s.s.	0/20	7/50	17/50		
TBA MXB dsv	7.48mg *	P<.05		4.86mg n.s.s.	0/20	15/50	22/50		
liv MXB dsv	11.1mg *	P<.03		6.68mg n.s.s.	0/20	7/50	17/50		liv:hpa,hpc,nnd.
lun MXB dsv	119.mg *	P<.5		35.8mg n.s.s.	0/20	1/50	2/50		lun:a/a,a/c.
1710 M f cf1 eat 25m25 80					0	32.5mg			Tomatis;jnci,52,883-891;1974
liv hpt	10.5mg	P<.0005	+	6.80mg 16.3mg	1/97	54/60			
lun mix	no dre	P=1.	-	231.mg n.s.s.	37/97	9/60			
tba mix	14.8mg	P<.0005		8.34mg 32.3mg	48/97	54/60			
1711 M m cf1 eat 25m25 80					0	30.0mg			
liv hpt	33.9mg	P<.0005	+	18.4mg 103.mg	33/101	39/60			
lun mix	no dre	P=1.	-	136.mg n.s.s.	53/101	19/60			
tba mix	no dre	P=1.		35.9mg n.s.s.	89/101	48/60			
1712 R f osm eat 18m26 TR131 :					0	8.40mg	14.4mg		
thy MXA dev#	33.2mg *	P<.04	-	15.5mg n.s.s.	2/20	9/50	12/50		thy:fca,fcc. S
TBA MXB dev	58.0mg *	P<.7		9.00mg n.s.s.	16/20	36/50	29/50		
liv MXB dev	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
1713 R m osm eat 18m26 TR131 :					0	12.0mg	23.2mg		
TBA MXB dv	48.1mg *	P<.4	-	13.6mg n.s.s.	9/20	21/50	20/50		
liv MXB dv	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
DDT 50-29-3									
1714 H f nss eat 78w78 2596					0	26.1mg	52.3mg	105.mg	Graillot;ejtx,8,353-359;1975
liv tum	no dre	P=1.	-	51.9mg n.s.s.	0/30	0/30	0/30	0/30	
1715 H m nss eat 78w78 2596					0	23.0mg	46.0mg	92.0mg	
liv tum	no dre	P=1.	-	45.7mg n.s.s.	0/30	0/30	0/30	0/30	
1716 H f syg eat 28m28 1179					0	13.1mg	26.1mg	52.3mg	Cabral;tumo,68,5-10;1982
liv tum e	no dre	P=1.		59.9mg n.s.s.	0/39	0/28	0/28	0/40	
tba mix e	639.mg *	P<.4	-	154.mg n.s.s.	5/39	3/28	2/28	8/40	
1717 H f syg eat 48w88 1400					0	28.5mg			Agthe;pseb,134,113-116;1970
tba mix e	no dre	P=1.	-	34.8mg n.s.s.	3/6	3/17			
1718 H f syg eat 28m28 1556					0	105.mg			Rossi;canr,43,776-781;1983
adr ade e	345.mg	P<.005	-	152.mg 3.14gm	2/42	10/36			
liv hem e	3.39gm	P<.3	-	551.mg n.s.s.	0/42	1/36			
lun tum e	no dre	P=1.	-	1.03gm n.s.s.	2/42	0/36			
tba mix e	781.mg	P<.5	-	158.mg n.s.s.	13/42	14/36			
1719 H m syg eat 28m28 1179					0	11.5mg	23.0mg	46.0mg	Cabral;tumo,68,5-10;1982
liv mix e	311.mg Z	P<.03		94.1mg n.s.s.	0/40	0/30	3/31	(0/39)	
tba mix e	145.mg *	P<.02	-	68.7mg n.s.s.	3/40	5/30	8/31	11/39	
1720 H m syg eat 48w85 1400					0	26.0mg			Agthe;pseb,134,113-116;1970
tba mix e	113.mg	P<.2	-	34.1mg n.s.s.	0/11	3/30			
1721 H m syg eat 28m28 1556					0	92.0mg			Rossi;canr,43,776-781;1983
liv tum e	no dre	P=1.	-	883.mg n.s.s.	0/31	0/35			
lun tum e	no dre	P=1.	-	883.mg n.s.s.	1/31	0/35			
tba mix e	no dre	P=1.	-	167.mg n.s.s.	15/31	15/35			
1722 M f b6c eat 78w92 TR131 :					0	9.50mg	19.5mg		
--- lym v#	61.2mg *	P<.02	-	29.8mg n.s.s.	0/20	3/50	7/50		S
TBA MXB v	59.2mg *	P<.2		22.4mg n.s.s.	2/20	8/50	10/50		
liv MXB v	151.mg *	P<.09		52.1mg n.s.s.	0/20	1/50	3/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		n.s.s. n.s.s.	0/20	1/50	0/50		lun:a/a,a/c.
1723 M f b6c orl 80w80 133					0	19.3mg			Innes;ntis,1968/1969
liv hpt evx	31.1mg	P<.02		10.7mg n.s.s.	0/16	4/18			
lun mix evx	no dre	P=1.		42.3mg n.s.s.	0/16	0/18			
tba mix evx	24.0mg	P<.009		9.05mg 526.mg	0/16	5/18			
1724 M m b6c eat 78w91 TR131 :					0	2.30mg	4.40mg		
TBA MXB sv	2.04mg	\ P<.4	-	.345mg n.s.s.	4/20	6/50	(4/50)		
liv MXB sv	no dre	P=1.		4.67mg n.s.s.	2/20	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB sv	no dre	P=1.		4.67mg n.s.s.	1/20	1/50	0/50		lun:a/a,a/c.
1725 M m b6c orl 80w80 133					0	17.9mg			Innes;ntis,1968/1969
liv hpt evx	8.95mg	P<.0005	+	4.24mg 23.7mg	0/16	10/18			
lun ade evx	127.mg	P<.3		20.7mg n.s.s.	0/16	1/18			
lun car evx	127.mg	P<.3		20.7mg n.s.s.	0/16	1/18			
tba mix evx	7.69mg	P<.0005		3.72mg 19.2mg	0/16	11/18			
1726 M f b6a orl 80w80 133					0	19.3mg			
--- rts evx	19.3mg	P<.003	+	7.78mg 106.mg	0/17	6/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
	Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv	hpt evx	137.mg	P<.3	22.2mg n.s.s.	0/17	1/18			
lun	ade evx	no dre	P=1.	42.3mg n.s.s.	1/17	0/18			
tba	mix evx	21.3mg	P<.07	7.42mg n.s.s.	2/17	7/18			
1727	M m b6a orl 80w80 133				0	17.9mg			
liv	hpt evx	16.7mg	P<.02 +	6.56mg n.s.s.	1/18	7/18			
lun	ade evx	no dre	P=1.	18.5mg n.s.s.	2/18	2/18			
tba	mix evx	17.9mg	P<.07	6.21mg n.s.s.	3/18	8/18			
1728	M f bal eat 31m31 88				0	.260mg	2.60mg	32.5mg	Terracini;ijcn,11,747-764;1973
liv	lct eg	59.5mg *	P<.0005 +	37.8mg 101.mg	0/50	0/58	1/50	28/57	
lun	ade g	no dre	P=1. -	238.mg n.s.s.	20/62	20/63	20/61	14/63	
tba	mix g	no dre	P=1.	73.1mg n.s.s.	56/62	51/63	48/61	48/63	
1729	M f cf1 eat 26m26 89				0	12.6mg			Thorpe;fctx,11,433-442;1973
liv	mix e	5.82mg	P<.0005 +	3.06mg 13.0mg	10/44	26/30			
liv	lct e	20.0mg	P<.0005 +	10.2mg 47.1mg	0/44	12/30			
lun	tum e	no dre	P=1. -	40.4mg n.s.s.	27/44	9/30			
1730	M f cf1 eat 31m31 90				0	.260mg	1.30mg	6.50mg	32.5mg Tomatis;ijcn,10,489-506;1972
liv	hpt eg	43.0mg *	P<.0005 +	28.1mg 71.8mg	2/56	3/56	2/59	7/55	31/49
lun	tum eg	121.mg *	P<.04 -	47.7mg n.s.s.	13/56	17/56	22/59	23/55	23/49
ute	tum eg	no dre	P=1. -	334.mg n.s.s.	2/56	8/56	3/59	4/55	2/49
tba	mix eg	106.mg *	P<.5	20.1mg n.s.s.	45/56	50/56	52/59	48/55	44/49
1731	M f cf1 eat 26m26 103				0	6.50mg	13.0mg		Walker;fctx,11,415-432;1973
liv	mix e	9.11mg *	P<.0005 +	5.53mg 18.6mg	8/47	15/30	24/32		
liv	lpb e	76.5mg *	P<.007	31.2mg 895.mg	0/47	2/30	4/32		
lun	ade e	no dre	P=1. -	52.1mg n.s.s.	19/47	6/30	7/32		
lun	car e	no dre	P=1. -	48.8mg n.s.s.	3/47	5/30	1/32		
1732	M f cf1 eat 7m28 1012				0	8.13mg			Tomatis;zkko,82,25-35;1974
liv	hpt	34.2mg	P<.0005 +	16.7mg 99.9mg	1/90	11/54			
tba	tum	no dre	P=1.	13.0mg n.s.s.	77/90	41/54			
1733	M f cf1 eat 30w95 1012m				0	10.3mg			
liv	hpt	26.3mg	P<.0005 +	13.2mg 64.3mg	0/72	11/55			
tba	tum	17.9mg	P<.4	4.65mg n.s.s.	52/72	44/55			
1734	M f cf1 eat 30w65 1012n				0	15.0mg			
liv	hpt	52.2mg	P<.01 +	18.0mg 5.13gm	0/69	4/54			
tba	tum	150.mg	P<.9	9.20mg n.s.s.	27/69	22/54			
1735	M m cf1 eat 26m26 89				0	11.7mg			Thorpe;fctx,11,433-442;1973
liv	mix e	8.04mg	P<.0005 +	4.17mg 21.3mg	11/45	23/30			
liv	lct e	30.3mg	P<.003 +	13.1mg 195.mg	2/45	9/30			
lun	tum e	no dre	P=1. -	29.5mg n.s.s.	27/45	11/30			
1736	M m cf1 eat 29m31 90				0	.240mg	1.20mg	6.00mg	30.0mg Tomatis;ijcn,10,489-506;1972
liv	hpt e	34.7mg *	P<.0005 +	19.4mg 86.6mg	12/55	25/58	28/53	24/53	38/50
lun	tum e	no dre	P=1. -	151.mg n.s.s.	23/55	38/58	29/53	27/53	19/50
tba	mix e	no dre	P=1.	24.9mg n.s.s.	46/55	53/58	48/53	49/53	44/50
1737	M m cf1 eat 26m26 103				0	6.00mg	12.0mg		Walker;fctx,11,415-432;1973
liv	mix e	15.0mg *	P<.0005 +	8.40mg 43.3mg	6/47	12/32	17/32		
liv	lpb e	72.6mg *	P<.02	29.6mg n.s.s.	0/47	3/32	3/32		
lun	ade e	49.3mg *	P<.4 -	12.9mg n.s.s.	18/47	13/32	16/32		
lun	car e	no dre	P=1. -	30.6mg n.s.s.	0/47	0/32	0/32		
1738	M m cf1 eat 7m28 1012				0	7.50mg			Tomatis;zkko,82,25-35;1974
liv	hpt	12.5mg	P<.002 +	6.40mg 53.1mg	33/98	37/60			
tba	tum	no dre	P=1.	8.22mg n.s.s.	83/98	49/60			
1739	M m cf1 eat 30w95 1012m				0	9.47mg			
liv	hpt	6.70mg	P<.0005 +	3.86mg 15.9mg	24/83	41/60			
tba	tum	4.59mg	P<.02	1.90mg n.s.s.	65/83	56/60			
1740	M m cf1 eat 30w65 1012n				0	13.8mg			
liv	hpt	4.55mg	P<.0005 +	2.76mg 9.13mg	12/70	38/60			
tba	tum	5.35mg	P<.02	2.39mg n.s.s.	42/70	48/60			
1741	M f swi eat 80w80 2176m				0	13.0mg			Kashyap;ijcn,19,725-729;1977/pers.comm.
---	lkm	21.9mg	P<.04 +	8.35mg n.s.s.	2/30	8/30			
liv	hpc	50.0mg	P<.04 +	15.1mg n.s.s.	0/30	3/30			
lun	ade	73.8mg	P<.3 +	16.3mg n.s.s.	1/30	3/30			
tba	mix	10.3mg	P<.006	4.68mg 138.mg	5/30	15/30			
1742	M f swi gav 80w80 2176n				0	7.14mg			
---	lkm	12.0mg	P<.04 +	4.59mg n.s.s.	2/30	8/30			
lun	ade	19.5mg	P<.08 +	6.37mg n.s.s.	1/30	5/30			
liv	hpc	20.2mg	P<.02 +	6.98mg n.s.s.	0/30	4/30			
tba	mix	3.16mg	P<.0005	1.64mg 9.24mg	5/30	20/30			
1743	M m swi eat 80w80 2176m				0	12.0mg			
---	lkm	20.2mg	P<.04 +	7.70mg n.s.s.	2/30	8/30			
lun	ade	29.1mg	P<.2 +	8.51mg n.s.s.	4/30	8/30			
liv	hpc	44.6mg	P<.2 +	12.5mg n.s.s.	1/30	4/30			
tba	mix	5.31mg	P<.003	2.52mg 30.6mg	10/30	22/30			
1744	M m swi gav 80w80 2176n				0	7.14mg			
---	lkm	18.8mg	P<.2	5.87mg n.s.s.	2/30	6/30			
lun	ade	23.6mg	P<.4	5.77mg n.s.s.	4/30	7/30			
liv	hpc	82.5mg	P<.6	11.3mg n.s.s.	1/30	2/30			
tba	mix	10.1mg	P<.2	3.09mg n.s.s.	10/30	15/30			
1745	P b cym eat 11y25 2003 :				0	9.95mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
eso	ley w	16.6mg	P<.2	2.70mg n.s.s.	0/3	1/2			
liv	hpc w	49.8mg	P<.2	8.11mg n.s.s.	0/10	1/5			
pro	car w	105.mg	P<.2	17.1mg n.s.s.	0/13	1/10			
ute	ley w	271.mg	P<.7	21.0mg n.s.s.	1/25	1/12			
tba	mix w	21.4mg	P<.4	3.57mg n.s.s.	4/25	4/12			
tba	ben w	60.1mg	P<.6	4.77mg n.s.s.	2/25	2/12			
tba	mal w	78.8mg	P<.8	5.33mg n.s.s.	3/15	2/10			
1746	P b rhe eat 11y25 2003 :				0	10.8mg			
ute	ley w	no dre	P=1.	7.35mg n.s.s.	6/29	1/5			
tba	ben Ww	no dre	P=1.	8.99mg n.s.s.	12/108	1/11			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1747 R f osm eat 18m26 TR131 :					0	7.40mg	15.0mg		
TBA MXB v	no dre	P=1.	-	16.8mg n.s.s.	16/20	38/50	27/50		
liv MXB v	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
1748 R f osm eat 27m27 21					0	10.0mg			Deichmann;txap,11,88-103;1967
liv hpt	256.mg	P<.3	-	41.7mg n.s.s.	0/30	1/30			
tba mix	no dre	P=1.	-	24.3mg n.s.s.	13/30	9/30			
1749 R f osm eat 24m24 84a					0	4.00mg			Radomski;txap,7,652-656;1965
liv mal	no dre	P=1.	-	24.7mg n.s.s.	1/30	0/30			
1750 R m osm eat 18m26 TR131 :					0	8.80mg	18.4mg		
TBA MXB v	no dre	P=1.	-	14.2mg n.s.s.	10/20	29/50	32/50		
liv MXB v	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
1751 R m osm eat 27m27 21					0	8.00mg			Deichmann;txap,11,88-103;1967
liv tum	no dre	P=1.	-	62.6mg n.s.s.	0/30	0/30			
tba mix	no dre	P=1.	-	37.8mg n.s.s.	1/30	1/30			
1752 R m osm eat 24m24 84a					0	3.20mg			Radomski;txap,7,652-656;1965
liv mal	no dre	P=1.	-	19.8mg n.s.s.	0/30	0/30			
1753 R b alb eat 60w60 1457					0	.360mg			Cameron;bmjl,2,819-821;1951
liv tum k	no dre	P=1.	-	.148mg n.s.s.	0/6	0/6			
1754 R m f34 eat 17m24 1803					0	14.0mg			Shivapurkar;carc,7,547-550;1986
liv nnd er	56.2mg	P<.2	-	17.6mg n.s.s.	2/28	6/28			
1755 R f por eat 33m33 1178					0	6.25mg	12.5mg	25.0mg	Cabral;tumo,68,11-17;1982
liv lct	140.mg	* P<.002	+	74.0mg 552.mg	0/38	2/30	4/30	7/38	
tba mix	no dre	P=1.		47.0mg n.s.s.	32/38	26/30	27/30	27/38	
1756 R m por eat 33m33 1178					0	5.00mg	10.0mg	20.0mg	
liv lct	902.mg	* P<.4	-	174.mg n.s.s.	1/38	0/30	1/30	2/38	
tba mix	90.1mg	* P<.3		24.5mg n.s.s.	20/38	19/30	18/30	25/38	
1757 R f wis eat 34m34 85					0	25.0mg			Rossi;ijcn,19,179-185;1977
liv hpt ev	57.2mg	P<.0005	+	31.1mg 122.mg	0/32	15/34			
tba mix v	116.mg	P<.4		29.5mg n.s.s.	19/35	23/35			
1758 R m wis eat 34m34 85					0	20.0mg			
liv hpt e	92.6mg	P<.0005	+	43.5mg 272.mg	0/35	9/36			
tba mix	no dre	P=1.		42.6mg n.s.s.	19/36	19/37			
DECABROMODIPHENYL OXIDE 1163-19-5									
1759 M f b6c eat 24m24 TR309 :					0	3.22gm	6.44gm		
TBA MXB	no dre	P=1.	-	5.88gm n.s.s.	35/50	37/50	35/50		
liv MXB	33.4gm	* P<.5		6.93gm n.s.s.	8/50	13/50	13/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		22.4gm n.s.s.	6/50	4/50	4/50		lun:a/a,a/c.
1760 M m b6c eat 24m24 TR309 :					0	2.97gm	6.00gm		
thy MXA	20.5gm	* P<.09	e	8.82gm n.s.s.	0/50	4/50	3/50		thy:fca,fcc.
liv MXA	11.2gm	* P<.3	e	3.50gm n.s.s.	8/50	22/50	18/50		liv:hpa,hpc.
TBA MXB	9.06gm	* P<.4		2.36gm n.s.s.	21/50	37/50	36/50		
liv MXB	11.2gm	* P<.3		3.50gm n.s.s.	8/50	22/50	18/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		12.7gm n.s.s.	5/50	4/50	5/50		lun:a/a,a/c.
1761 R f f34 eat 24m24 TR309 :					0	1.24gm	2.48gm		
liv MXA	6.58gm	* P<.004		3.25gm 48.3gm	1/50	5/50	9/50		liv:hpc,nnd. S
liv nnd	7.74gm	* P<.005	p	3.68gm 61.9gm	1/50	3/50	9/50		
TBA MXB	4.38gm	* P<.5		1.06gm n.s.s.	49/50	49/50	50/50		
liv MXB	6.58gm	* P<.004		3.25gm 48.3gm	1/50	5/50	9/50		liv:hpa,hpc,nnd.
1762 R m f34 eat 24m24 TR309 :					0	990.mg	1.98gm		
liv nnd	2.13gm	* P<.0005	p	1.22gm 5.14gm	1/50	7/50	15/50		
liv MXA	2.22gm	* P<.0005		1.23gm 6.55gm	2/50	8/50	15/50		liv:hpc,nnd. S
pan ana	13.9gm	* P<.02		4.77gm n.s.s.	0/50	0/50	4/50		S
TBA MXB	2.23gm	* P<.3		681.mg n.s.s.	49/50	50/50	49/50		
liv MXB	2.22gm	* P<.0005		1.23gm 6.55gm	2/50	8/50	15/50		liv:hpa,hpc,nnd.
DECABROMODIPHENYL OXIDE, TECHNICAL GRADE (77.4% DBDPO, 21.8% NONABROMODIPHENYL OXIDE, 0.8% OCTABROMODIPHENYL OXIDE) 1163-19-5									
1763 R f sss eat 24m24 2593					0	10.0ug	.100mg	1.00mg	Kociba;jctx,2,267-285;1975
liv hct e	no dre	P=1.	-	47.3ug n.s.s.	0/25	0/25	0/25	0/25	
tba mix e	.987mg	* P<.5	-	.138mg n.s.s.	23/25	23/25	23/25	24/25	
1764 R m sss eat 23m23 2593					0	10.0ug	.100mg	1.00mg	
liv hct e	no dre	P=1.	-	42.9ug n.s.s.	0/25	0/25	0/25	0/25	
tba mix e	no dre	P=1.	-	1.21mg n.s.s.	12/25	7/25	10/25	9/25	
DEFLAZACORT 14484-47-0									
1765 R f cdr eat 52w52 2420m					0	30.0ug	60.0ug	.120mg	.250mg	.500mg	1.00mg	Zwicker;txpy,24,246-250;1996
bon tum r	no dre	P=1.		39.4ug n.s.s.	0/50	0/50	0/50	0/50	0/50	0/50	0/50	
1766 R f cdr eat 24m24 2420n					0	30.0ug	60.0ug	.120mg	.250mg	.500mg	1.00mg	
hed ost rs	66.8mg	* P<.2		10.9mg n.s.s.	0/50	0/50	0/50	0/50	0/50	0/50	1/50	
1767 R m cdr eat 52w52 2420m					0	30.0ug	60.0ug	.120mg	.250mg	.500mg	1.00mg	
bon tum r	no dre	P=1.		39.4ug n.s.s.	0/50	0/50	0/50	0/50	0/50	0/50	0/50	
1768 R m cdr eat 24m24 2420n					0	30.0ug	60.0ug	.120mg	.250mg	.500mg	1.00mg	
bon mix rs	no dre	P=1.	+	5.27mg n.s.s.	0/50	0/50	1/50	0/50	7/50	0/50	0/50	
hed ost rs	no dre	P=1.	+	5.46mg n.s.s.	0/50	0/50	0/50	0/50	5/50	0/50	0/50	
DEHYDROEPIANDROSTERONE 53-43-0									
1769 R m f3d eat 52w52 2161m					0	200.mg	400.mg		Hayashi;carc,15,2215-2219;1994
liv mix ekr	230.mg	* P<.09		79.2mg n.s.s.	0/10	2/10	2/10		
1770 R m f3d eat 78w78 2161n					0	200.mg	400.mg		
liv mix er	68.1mg	* P<.0005	+	30.5mg 174.mg	0/8	5/9	7/7		
1771 R f sda eat 72w72 2562m					0	300.mg			Metzger;clet,121,125-131;1997/pers.comm.
liv mix ekr	108.mg	P<.02	+	30.0mg n.s.s.	0/5	3/5			
liv hpc ekr	193.mg	P<.08	+	45.9mg n.s.s.	0/5	2/5			
liv hpa ekr	442.mg	P<.3		71.2mg n.s.s.	0/5	1/5			
1772 R f sda eat 84w84 2562n					0	300.mg			
liv mix er	83.3mg	P<.005	+	23.1mg 742.mg	0/5	4/5			
liv hpc er	263.mg	P<.08	+	62.5mg n.s.s.	0/5	2/5			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpa er	263.mg	P<.08	62.5mg n.s.s.	0/5	2/5			
1773 R m sda eat 72w72 2562m				0	240.mg			
liv mix ekr	274.mg	P<.5 +	39.9mg n.s.s.	1/5	2/5			
liv hpc ekr	353.mg	P<.3 +	56.9mg n.s.s.	0/5	1/5			
liv hpa ekr	no dre	P=1.	64.5mg n.s.s.	1/5	1/5			
1774 R m sda eat 84w84 2562n				0	240.mg			
liv hpa er	no dre	P=1.	161.mg n.s.s.	0/5	0/5			
liv hpc er	no dre	P=1.	161.mg n.s.s.	0/5	0/5			
DEHYDROEPIANDROSTERONE ACETATE 853-23-6								
1775 R f f34 eat 23m23 2567				0	225.mg			Rao;clet,125,111-116;1998/pers.comm.
liv mix er	230.mg	P<.005 +	91.8mg 1.58gm	0/10	6/13			
liv nnd er	230.mg	P<.005 +	91.8mg 1.58gm	0/10	6/13			
liv hpc er	853.mg	P<.2 +	209.mg n.s.s.	0/10	2/13			
1776 R m f34 eat 84w84 2057				0	180.mg			Rao;canr,52,2977-2979;1992a/Rao 1992b/pers.comm.
liv mix ber	31.4mg	P<.0005 +	11.8mg 85.1mg	0/8	12/13			
liv hpc ber	43.0mg	P<.0005 +	18.4mg 114.mg	0/8	11/13			
tes ldc ber	no dre	P=1. -	315.mg n.s.s.	8/8	0/13			
1777 R m f34 eat 23m23 2567				0	180.mg			Rao;clet,125,111-116;1998/pers.comm.
liv mix er	41.1mg	P<.0005 +	16.2mg 102.mg	0/10	15/16			
liv nnd er	41.1mg	P<.0005 +	16.2mg 102.mg	0/10	15/16			
liv hpc er	68.1mg	P<.0005 +	32.1mg 163.mg	0/10	13/16			
DEHYDROEPIANDROSTERONE SULFATE 651-48-9								
1778 M f umh wat 34m34 2641				0	20.0mg			Miller;jags,47,960-966;1999/pers.comm.
lun mix e	220.mg	P<.3 -	63.0mg n.s.s.	2/20	8/39			
liv mix e	no dre	P=1. -	103.mg n.s.s.	4/20	6/39			
tba mix e	no dre	P=1. -	8.83mg n.s.s.	19/20	37/39			
1779 M m umh wat 33m33 2641				0	16.7mg			
lun mix e	61.5mg	P<.2 -	20.1mg n.s.s.	9/30	13/26			
liv mix e	no dre	P=1. -	53.6mg n.s.s.	11/30	7/26			
tba mix e	no dre	P=1. -	14.7mg n.s.s.	28/30	22/26			
DELTAMETHRIN 52918-63-5								
1780 M f cb6 gav 24m26 1965				0	.652mg	2.61mg	5.21mg	Cabral;clet,49,147-152;1990/pers.comm.
--- lym	no dre	P=1. -	13.7mg n.s.s.	19/50	12/30	17/30	15/50	
liv hpt	no dre	P=1. -	53.4mg n.s.s.	2/50	1/30	2/30	0/50	
lun ade	no dre	P=1. -	53.4mg n.s.s.	2/50	1/30	2/30	0/50	
tba tum	no dre	P=1. -	13.0mg n.s.s.	22/50	14/30	20/30	17/50	
1781 M m cb6 gav 24m26 1965				0	.652mg	2.61mg	5.21mg	
lun ade	no dre	P=1. -	29.6mg n.s.s.	2/50	3/30	3/30	2/50	
liv hpt	no dre	P=1. -	32.0mg n.s.s.	4/50	2/30	0/30	4/50	
tba tum	no dre	P=1. -	28.3mg n.s.s.	25/50	10/30	11/30	11/50	
1782 R f bdf gav 24m26 1965				0	1.95mg	3.91mg		
thy ade	16.9mg *	P<.01 -	7.94mg 1.16gm	4/50	4/50	14/50		
liv hpt	no dre	P=1. -	16.1mg n.s.s.	0/50	0/50	0/50		
tba tum	36.1mg *	P<.7 -	4.68mg n.s.s.	30/50	25/50	32/50		
1783 R m bdf gav 24m26 1965				0	1.95mg	3.91mg		
thy ade	4.60mg \	P<.003 -	2.25mg 28.9mg	6/50	19/50	(10/50)		
liv hpt	no dre	P=1. -	16.1mg n.s.s.	0/50	0/50	0/50		
tba tum	no dre	P=1. -	14.7mg n.s.s.	23/50	22/50	14/50		
DEOXYNIVALENOL (3-alpha,7-alpha,15-trihydroxy-12-13-epoxytrichothecene-9-en-8-one) 51481-10-8								
1784 M m b6c eat 24m24 2359				0	.120mg	.600mg	1.20mg	Iverson;tcam,15,283-306;1995
liv hpa e	no dre	P=1. -	8.78mg n.s.s.	8/50	8/48	6/50	2/48	
liv hpc e	no dre	P=1. -	11.2mg n.s.s.	7/50	4/48	3/50	1/48	
DESERPIDINE 131-01-1								
1785 R b wis eat 78w78 1188				0	.100mg			Tuchmann-Duplessis;adsc,254,1535-1537;1962
mix mix r	1.28mg	P<.6 -	.272mg n.s.s.	17/130	36/230			
DEXAMETHAZONE 50-02-2								
1786 R m f3d eat 52w52 2192				0	73.5ug			Shibata;carc,14,1265-1269;1993/pers.comm.
for tum ersv	no dre	P=1.	37.8ug n.s.s.	0/10	0/10			
DEXTRAN 9004-54-0								
1787 R f aci eat 68w68 1540				0	1.25gm			Hirono;clet,18,29-34;1983
ubl tum	1.64gm	P<.02 -	494.mg n.s.s.	0/20	3/15			
1788 R m aci eat 68w68 1540				0	1.00gm			
ubl tum	3.19gm	P<.4 -	540.mg n.s.s.	1/20	2/15			
DEXTRAN SULFATE SODIUM (DS-M-1) (mol. wt. = 54,000) 9011-18-1								
1789 R b aci eat 94w94 1482				0	450.mg			Hirono;carc,3,353-355;1982
itn mix e	191.mg	P<.0005 +	110.mg 361.mg	0/20	22/30			
clr pam e	331.mg	P<.0005	181.mg 691.mg	0/20	16/30			
clr sqc e	1.76gm	P<.04 +	607.mg n.s.s.	0/20	4/30			
1790 R f aci eat 68w68 1540				0	1.25gm			Hirono;clet,18,29-34;1983
clr pam	219.mg	P<.0005 +	103.mg 525.mg	0/20	13/16			
clr adc	373.mg	P<.0005 +	174.mg 982.mg	0/20	10/16			
clr ade	977.mg	P<.004 +	368.mg 5.89gm	0/20	5/16			
cec ade	1.27gm	P<.009	437.mg 31.1gm	0/20	4/16			
clr sqc	1.76gm	P<.03 +	532.mg n.s.s.	0/20	3/16			
1791 R m aci eat 68w68 1540				0	1.00gm			
clr adc	182.mg	P<.0005 +	84.0mg 452.mg	0/20	12/15			
clr pam	466.mg	P<.0005 +	197.mg 1.53gm	0/20	7/15			
clr sqc	2.05gm	P<.06 +	502.mg n.s.s.	0/20	2/15			
clr ade	1.70gm	P<.2 +	419.mg n.s.s.	1/20	3/15			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
DEXTRAN SULFATE SODIUM (DST-H) (mol. wt. = 9500) 9011-18-1								
1792 R f aci eat 68w68 1540				0	1.25gm			Hirono;clet,18,29-34;1983
ubl tum	2.56gm	P<.06	- 628.mg n.s.s.	0/20	2/15			
1793 R m aci eat 68w68 1540				0	1.00gm			
cec ade	4.25gm	P<.2	- 691.mg n.s.s.	0/20	1/15			
DEXTRAN SULFATE SODIUM (KMDS-H) (mol. wt. = 520,000) 9011-18-1								
1794 R f aci eat 68w68 1540				0	1.25gm			Hirono;clet,18,29-34;1983
ubl tum	1.64gm	P<.02	- 494.mg n.s.s.	0/20	3/15			
1795 R m aci eat 68w68 1540				0	1.00gm			
clr pam	4.25gm	P<.2	- 691.mg n.s.s.	0/20	1/15			
N-1-DIACETAMIDOFLUORENE 63019-65-8								
1796 R f buf eat 53w93 144				0	7.21mg			Morris;jnci,24,149-180;1960
pit ade e	8.63mg	P<.03	3.14mg n.s.s.	2/18	7/16			
mgl adc e	19.0mg	P<.03	+ 5.74mg n.s.s.	0/18	3/16			
liv hem e	61.2mg	P<.3	9.96mg n.s.s.	0/18	1/16			
edu sqc e	61.2mg	P<.3	+ 9.96mg n.s.s.	0/18	1/16			
DIACETYL HYDRAZINE 3148-73-0								
1797 M f swi gav 95w95 1661m				0	22.9mg			Bhide;clet,23,235-240;1984/pers.comm.
lun mix rs	no dre	P=1.	- 59.0mg n.s.s.	3/20	0/15			
1798 M f swi gav 34w95 1661n				0	11.4mg			
lun mix rs	no dre	P=1.	- 29.5mg n.s.s.	3/20	0/15			
1799 M m swi gav 95w95 1661m				0	19.0mg	26.2mg		
lun mix rs	411.mg *	P<.7	- 43.8mg n.s.s.	2/20	0/15	3/15		
1800 M m swi gav 34w95 1661n				0	9.52mg			
lun mix rs	144.mg	P<.8	- 10.9mg n.s.s.	2/20	2/15			
DIALLATE (avadex) 2303-16-4								
1801 M f b6a orl 85w85 1219				0	77.8mg			Innes;ntis,1968/1969
liv hpt evx	516.mg	P<.3	84.0mg n.s.s.	0/17	1/15			
lun ade evx	4.26gm	P<1.	94.1mg n.s.s.	1/17	1/15			
tba mix evx	1.99gm	P<.9	73.2mg n.s.s.	2/17	2/15			
1802 M m b6a orl 84w84 1219				0	72.5mg			
liv hpt evx	43.0mg	P<.002	+ 19.5mg 172.mg	1/18	10/18			
lun ade evx	243.mg	P<.4	50.7mg n.s.s.	2/18	4/18			
tba mix evx	35.4mg	P<.003	15.6mg 210.mg	3/18	12/18			
1803 M f b6c orl 83w83 1219				0	77.9mg			
liv mix evx	164.mg	P<.04	49.4mg n.s.s.	0/16	3/16			
lun ade evx	255.mg	P<.09	62.5mg n.s.s.	0/16	2/16			
tba mix evx	90.8mg	P<.006	34.1mg 898.mg	0/16	5/16			
1804 M m b6c orl 84w84 1219				0	72.5mg			
liv hpt evx	19.4mg	P<.0005	+ 9.11mg 46.4mg	0/16	13/16			
lun ade evx	113.mg	P<.02	38.7mg n.s.s.	0/16	4/16			
tba mix evx	15.6mg	P<.0005	7.03mg 37.3mg	0/16	14/16			
DIALLYL PHTHALATE 131-17-9								
1805 M f b6c gav 24m25 TR242 :				0	104.mg	208.mg		
for ppn h	2.73gm *	P<.1	a 826.mg n.s.s.	0/50	1/50	2/50		
TBA MXB	10.1gm *	P<1.	215.mg n.s.s.	31/50	28/50	32/50		
liv MXB	2.93gm *	P<.4	736.mg n.s.s.	1/50	2/50	3/50		liv:hpa,hpc,nnd.
lun MXB	4.18gm *	P<.4	911.mg n.s.s.	1/50	0/50	3/50		lun:a/a,a/c.
1806 M m b6c gav 24m25 TR242 :				0	104.mg	208.mg		
--- mno	816.mg *	P<.09	e 304.mg n.s.s.	6/50	5/50	12/50		
liv hpa	2.45gm *	P<.04	740.mg n.s.s.	0/50	0/50	3/50		s
for ppn h	2.46gm *	P<.08	a 744.mg n.s.s.	0/50	1/50	2/50		
TBA MXB	717.mg *	P<.4	180.mg n.s.s.	23/50	23/50	26/50		
liv MXB	6.68gm *	P<.9	517.mg n.s.s.	7/50	5/50	7/50		liv:hpa,hpc,nnd.
lun MXB	8.52gm *	P<.9	587.mg n.s.s.	5/50	4/50	5/50		lun:a/a,a/c.
1807 R f f34 gav 24m24 TR284 :				0	35.5mg	71.1mg		
--- mnl	138.mg *	P<.05	e 58.3mg n.s.s.	15/50	15/50	25/50		
TBA MXB	163.mg *	P<.5	37.9mg n.s.s.	41/50	37/50	42/50		
liv MXB	no dre	P=1.	371.mg n.s.s.	5/50	0/50	3/50		liv:hpa,hpc,nnd.
1808 R m f34 gav 24m24 TR284 :				0	35.5mg	71.1mg		
TBA MXB	2.99gm *	P<1.	- 61.9mg n.s.s.	36/50	37/50	29/50		
liv MXB	no dre	P=1.	542.mg n.s.s.	2/50	0/50	1/50		liv:hpa,hpc,nnd.
1,1-DIALLYLHYDRAZINE 5164-11-4								
1809 M f swa wat 23m23 1676				0	62.5mg			Toth;acnr,1,259-262;1981
lun mix es	34.9mg	P<.0005	+ 20.6mg 70.2mg	25/99	38/50			
lun ade es	37.8mg	P<.0005	22.6mg 74.3mg	20/99	36/50			
lun adc es	112.mg	P<.0005	58.3mg 312.mg	6/99	17/50			
for sqp es	332.mg	P<.1	+ 105.mg n.s.s.	4/61	7/41			
liv agm es	no dre	P=1.	- 421.mg n.s.s.	5/67	1/47			
liv ang es	no dre	P=1.	- 336.mg n.s.s.	3/61	1/41			
1810 M m swa wat 93w93 1676				0	52.1mg			
lun mix es	25.7mg	P<.0005	+ 15.0mg 53.2mg	26/96	38/50			
lun ade es	29.8mg	P<.0005	17.9mg 58.3mg	16/96	34/50			
lun adc es	38.9mg	P<.0005	22.8mg 80.1mg	12/96	29/50			
for sqp es	48.1mg	P<.0005	+ 27.0mg 97.4mg	0/63	17/38			
liv ang es	723.mg	P<.5	- 120.mg n.s.s.	4/68	4/42			
liv agm es	no dre	P=1.	- 254.mg n.s.s.	7/63	1/38			
1,2-DIALLYLHYDRAZINE.2HCl 26072-78-6								
1811 M f swa wat 83w83 1531				0	125.mg			Toth;onco,39,104-108;1982
lun mix es	33.8mg	P<.0005	+ 20.0mg 63.9mg	25/99	40/47			
lun ade es	47.9mg	P<.0005	28.4mg 93.7mg	20/99	35/47			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun adc es	78.3mg	P<.0005		46.2mg 154.mg	6/99	25/47			
liv hpt es	409.mg	P<.4	-	66.3mg n.s.s.	0/5	1/8			
liv ang es	no dre	P=1.	-	389.mg n.s.s.	3/32	1/33			
liv agm es	no dre	P=1.	-	328.mg n.s.s.	1/32	1/33			
1812 M m swa wat 82w82 1531					0	104.mg			
lun mix es	33.9mg	P<.0005	+	20.2mg 65.8mg	26/100	40/50			
lun ade es	35.4mg	P<.0005		21.8mg 64.0mg	16/100	38/50			
lun adc es	60.0mg	P<.0005		35.3mg 122.mg	12/100	29/50			
liv mix es	no dre	P=1.		290.mg n.s.s.	6/52	2/36			
liv agm es	no dre	P=1.	-	202.mg n.s.s.	4/47	2/29			
DIALLYLNITROSAMINE 16338-97-9									
1813 H b syg gav 53w59 1826					0	3.11mg	6.21mg	12.4mg	Grandjean;jnci,74,1043-1046;1985/pers.comm.
trh ppp ae	2.84mg *	P<.0005		1.86mg 5.49mg	0/30	11/28	8/27	15/27	
ncp adc ae	2.86mg *	P<.0005	+	1.85mg 4.74mg	0/30	1/28	13/27	18/27	
lar ppp ae	3.69mg Z	P<.0005		2.33mg 11.8mg	0/30	13/28	1/27	14/27	
phr pam ae	25.3mg *	P<.2		9.60mg n.s.s.	0/30	1/28	3/27	1/27	
liv cho ae	743.mg *	P<1.		n.s.s. n.s.s.	1/30	1/28	1/27	1/27	
lun ade ae	no dre	P=1.		23.6mg n.s.s.	0/30	1/28	0/27	0/27	
tba mix ae	1.54mg *	P<.0005	+	.933mg 3.37mg	7/30	18/28	16/27	24/27	
1814 R f bd9 wat 24m24 1714					0	20.0mg	40.0mg	80.0mg	Pour;zkko,109,5-8;1985
npc mix r	32.1mg *	P<.0005	+	20.9mg 53.2mg	0/20	6/20	17/20	13/20	
npc adc r	33.6mg *	P<.0005	+	21.8mg 56.3mg	0/20	6/20	16/20	13/20	
1815 R m bd9 wat 24m24 1714					0	20.0mg	40.0mg	80.0mg	
npc mix r	36.0mg Z	P<.0005	+	19.7mg 75.0mg	0/20	0/20	16/20	(15/20)	
npc adc r	46.9mg Z	P<.0005	+	29.0mg 81.8mg	0/20	0/20	13/20	14/20	
4,6-DIAMINO-2-(5-NITRO-2-FURYL)-s-TRIAZINE 720-69-4									
1816 R f sda eat 46w66 200a					0	17.4mg			Cohen;jnci,51,403-417;1973
mgl mix e	1.71mg	P<.0005	+	.895mg 3.23mg	2/39	33/35			
mgl adc e	4.49mg	P<.0005		2.66mg 8.28mg	0/39	23/35			
liv tum e	no dre	P=1.		50.6mg n.s.s.	0/39	0/35			
tba mix e	1.71mg	P<.0005		.895mg 3.23mg	2/39	33/35			
4,4'-DIAMINO-2,2'-STILBENEDISULFONIC ACID, DISODIUM SALT 7336-20-1									
1817 M f b6c eat 24m24 TR412 :					0	803.mg	1.61gm		
TBA MXB	no dre	P=1.	-	3.18gm n.s.s.	34/50	17/50	24/50		
liv MXB	no dre	P=1.		12.0gm n.s.s.	5/50	0/50	2/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		8.73gm n.s.s.	13/50	3/50	5/50		lun:a/a,a/c.
1818 M m b6c eat 24m24 TR412 :					0	741.mg	1.48gm		
liv hpa #	2.57gm \	P<.03	-	1.03gm n.s.s.	2/50	9/50	(6/50)		S
TBA MXB	12.9gm *	P<.8		1.57gm n.s.s.	23/50	24/50	25/50		
liv MXB	9.72gm *	P<.4		2.47gm n.s.s.	5/50	11/50	8/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		5.18gm n.s.s.	15/50	4/50	10/50		lun:a/a,a/c.
1819 R f f34 eat 24m24 TR412 :					0	615.mg	1.23gm		
TBA MXB	17.6gm *	P<1.	-	706.mg n.s.s.	45/50	44/50	50/50		
liv MXB	no dre	P=1.		9.09gm n.s.s.	3/50	0/50	1/50		liv:hpa,hpc,nnd.
1820 R m f34 eat 24m24 TR412 :					0	492.mg	984.mg		
TBA MXB	5.81gm *	P<.9	-	499.mg n.s.s.	44/50	46/50	49/50		
liv MXB	5.02gm *	P<.2		1.68gm n.s.s.	1/50	1/50	5/50		liv:hpa,hpc,nnd.
2,4-DIAMINOANISOLE SULFATE 39156-41-7									
1821 M f b6c eat 78w96 TR84 :					0	126.mg	253.mg		
--- lym	262.mg \	P<.005		116.mg 2.51gm	7/100	14/50	(9/50)		S
thy MXA	1.06gm /	P<.0005	c	480.mg 3.18gm	0/100	0/50	8/50		thy:fca,fcc.
thy fca	1.45gm *	P<.002	c	591.mg 5.87gm	0/100	0/50	6/50		
TBA MXB	311.mg *	P<.02		145.mg n.s.s.	30/100	25/50	30/50		
liv MXB	7.35gm *	P<.6		1.03gm n.s.s.	2/100	1/50	2/50		liv:hpa,hpc,nnd.
lun MXB	10.9gm *	P<.9		716.mg n.s.s.	7/100	5/50	4/50		lun:a/a,a/c.
1822 M m b6c eat 78w96 TR84 :					0	116.mg	234.mg		
thy fca	791.mg /	P<.0005	c	383.mg 2.47gm	1/100	0/50	11/50		
TBA MXB	354.mg *	P<.04		148.mg n.s.s.	39/100	24/50	33/50		
liv MXB	926.mg *	P<.2		296.mg n.s.s.	15/100	14/50	12/50		liv:hpa,hpc,nnd.
lun MXB	2.56gm /	P<.5		480.mg n.s.s.	16/100	3/50	12/50		lun:a/a,a/c.
1823 R f f34 eat 18m25 TR84 :					0	44.0mg	182.mg		
MXB MXB v	301.mg *	P<.0005		155.mg 785.mg	3/100	1/50	14/50		thy:acn,fcc,pcn; zym:sec. C
MXA MXA v	408.mg *	P<.0005		191.mg 1.11gm	0/100	4/50	5/50		cli:can; utm:acn,can,ppc. S
cli MXA v	416.mg *	P<.003		184.mg 2.88gm	3/100	5/50	8/50		cli:adn,can,cyn,sqc,sqp. S
thy MXA v	425.mg *	P<.0005	c	195.mg 1.62gm	3/100	1/50	10/50		thy:acn,fcc,pcn.
zym sec v	665.mg *	P<.0005	c	284.mg 2.08gm	0/100	0/50	7/50		
TBA MXB v	181.mg *	P<.09		65.1mg n.s.s.	70/100	44/50	37/50		
liv MXB v	14.5gm *	P<.8		773.mg n.s.s.	2/100	0/50	1/50		liv:hpa,hpc,nnd.
1824 R f f34 eat 83w86 1027					0	60.0mg	120.mg	250.mg	Evarts;jnci,65,197-204;1980
cli mix ae	113.mg Z	P<.0005	+	68.8mg 206.mg	0/37	8/47	15/33	(9/40)	
cli ssc ae	162.mg Z	P<.0005	+	91.4mg 336.mg	0/37	5/47	12/33	(9/40)	
thy mix ae	162.mg Z	P<.0005	+	107.mg 267.mg	1/37	2/47	3/33	31/40	
thy fca ae	296.mg Z	P<.0005		178.mg 545.mg	0/37	0/47	1/33	21/40	
mgl mix ae	1.29gm *	P<.5	+	297.mg n.s.s.	2/37	7/47	8/33	5/40	
tba mix ae	67.3mg *	P<.0005		47.3mg 103.mg	3/37	14/47	19/33	36/40	
1825 R m f34 eat 18m25 TR84 :					0	35.2mg	146.mg		
MXB MXB v	72.6mg *	P<.0005		48.0mg 123.mg	4/99	11/50	36/50	eac:sec,sqc; ear:sqc; pre:adn,can,cyn,ppa; ski:bcc,sec; thy:acn,ccr,fcc,pac,pcn; zym:sec. C	
thy MXA v	192.mg *	P<.0005	c	107.mg 430.mg	2/99	2/50	17/50		thy:acn,fcc,pac,pcn.
thy acn v	252.mg *	P<.0005	c	131.mg 648.mg	2/99	1/50	14/50		
thy MXA v	319.mg *	P<.0005	c	154.mg 1.27gm	2/99	4/50	10/50		thy:cca,ccr.
pre MXA v	351.mg *	P<.0005	c	171.mg 954.mg	0/99	2/50	8/50		pre:adn,can,cyn,ppa.
ski MXA v	358.mg *	P<.0005	c	177.mg 875.mg	0/99	2/50	9/50		ski:bcc,sec,sqc.
pre MXA v	530.mg *	P<.002	c	228.mg 2.44gm	0/99	2/50	5/50		pre:adn,cyn,ppa.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
MXA MXA v	709.mg *	P<.0005	c	305.mg 2.51gm	0/99	1/50	6/50		eac:sec,sqc; ear:sqc; zym:sec.
TBA MXB v	135.mg *	P<.03		57.5mg n.s.s.	52/99	35/50	41/50		
liv MXB v	1.61gm *	P<.3		356.mg n.s.s.	1/99	2/50	2/50		liv:hpa,hpc,nnd.
1826 R m f3d eat 52w52 2024					0	24.4mg			Hasegawa;carc,12,1515-1518;1991/pers.comm.
liv tum r	no dre	P=1.		26.4mg n.s.s.	0/20	0/21			
thy tum r	no dre	P=1.		26.4mg n.s.s.	0/20	0/21			
4,4'-DIAMINOAZOBENZENE (DAAB) 538-41-0									
1827 M f bld eat 14m31 1368					0	5.91mg	17.7mg	35.5mg	Della Porta;clet,14,329-336;1981
lun mix e	240.mg *	P<.2	-	75.0mg n.s.s.	11/40	7/40	11/40	14/39	
liv mix e	no dre	P=1.	-	52.2mg n.s.s.	1/40	0/40	0/40	0/39	
1828 M m bld eat 14m31 1368					0	5.45mg	16.4mg	32.7mg	
lun mix e	213.mg *	P<.2	-	70.9mg n.s.s.	10/39	6/39	10/40	14/40	
liv mix e	no dre	P=1.	-	492.mg n.s.s.	1/39	0/39	1/40	0/40	
4,4'-DIAMINOBENZANILIDE (DABA) 785-30-8									
1829 M f bld eat 14m31 1368					0	5.91mg	17.7mg	35.5mg	Della Porta;clet,14,329-336;1981
lun mix e	360.mg *	P<.5	-	77.8mg n.s.s.	11/40	13/40	10/38	15/40	
liv mix e	no dre	P=1.	-	51.7mg n.s.s.	1/40	0/40	0/38	0/40	
1830 M m bld eat 14m31 1368					0	5.45mg	16.4mg	32.7mg	
lun mix e	no dre	P=1.	-	90.6mg n.s.s.	10/39	17/39	10/40	13/39	
liv mix e	no dre	P=1.	-	596.mg n.s.s.	1/39	1/39	0/40	0/39	
2,4-DIAMINOPHENOL.2HCl 137-09-7									
1831 M f b6c gav 24m24 TR401 :					0	13.4mg	26.8mg		
TBA MXB	no dre	P=1.	-	29.6mg n.s.s.	24/50	29/50	17/50		
liv MXB	2.89gm *	P<1.		60.1mg n.s.s.	4/50	7/50	3/50		liv:hpa,hpc,nnd.
lun MXB	239.mg *	P<.5		53.3mg n.s.s.	2/50	5/50	3/50		lun:a/a,a/c.
1832 M m b6c gav 24m24 TR401 :					0	13.3mg	26.7mg		
kid rua	320.mg *	P<.06	p	97.0mg n.s.s.	0/50	0/50	3/50		
TBA MXB	no dre	P=1.		30.8mg n.s.s.	30/50	27/50	31/50		
liv MXB	164.mg \	P<.8		15.5mg n.s.s.	15/50	18/50	(8/50)		liv:hpa,hpc,nnd.
lun MXB	194.mg *	P<.4		53.0mg n.s.s.	3/50	4/50	7/50		lun:a/a,a/c.
1833 M m b6c gav 24m24 TR401 with step					0	26.7mg			
kid rua	143.mg	P<.004	p	58.3mg 892.mg	0/50	6/50			
1834 R f f34 gav 24m24 TR401 :					0	8.78mg	17.6mg		
TBA MXB	46.3mg *	P<.6	-	9.06mg n.s.s.	40/50	41/50	47/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
1835 R m f34 gav 24m24 TR401 :					0	8.80mg	17.6mg		
TBA MXB	543.mg *	P<1.	-	9.45mg n.s.s.	44/51	34/50	36/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/51	0/50	0/50		liv:hpa,hpc,nnd.
2,4-DIAMINOTOLUENE 95-80-7									
1836 M f b6c eat 23m23 TR162 :					0	13.0mg	26.0mg		
--- MXA	10.6mg \	P<.004	a	5.93mg 75.5mg	2/20	29/50	(11/50)		---:leu,lym.
liv hpc	26.7mg *	P<.002	c	17.3mg 99.8mg	0/20	13/50	18/50		
TBA MXB	8.64mg \	P<.01		4.52mg 629.mg	5/20	40/50	(26/50)		
liv MXB	26.7mg *	P<.002		17.3mg 99.8mg	0/20	13/50	18/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		134.mg n.s.s.	0/20	2/50	0/50		lun:a/a,a/c.
1837 M m b6c eat 23m23 TR162 :					0	12.0mg	24.0mg		
lun a/c #	35.8mg \	P<.02	-	16.9mg n.s.s.	0/20	9/50	(6/50)		S
TBA MXB	105.mg *	P<.7		17.4mg n.s.s.	10/20	31/50	30/50		
liv MXB	no dre	P=1.		34.9mg n.s.s.	5/20	17/50	13/50		liv:hpa,hpc,nnd.
lun MXB	35.8mg \	P<.02		16.9mg n.s.s.	0/20	9/50	(6/50)		lun:a/a,a/c.
1838 R f f34 eat 22m24 TR162 :					0	3.95mg	8.55mg		
MXB MXB asv	1.43mg /	P<.0005		.984mg 2.24mg	1/20	34/50	41/50		liv:hpc,nnd; mgl:ade,ade,car. C
mgl ade asv	1.46mg *	P<.0005	c	1.00mg 2.33mg	1/20	34/50	38/50		
mgl MXA asv	5.54mg *	P<.0005	c	3.14mg 11.5mg	0/20	11/50	14/50		mgl:ade,car.
mgl car asv	8.98mg *	P<.002		4.53mg 32.3mg	0/20	9/50	8/50		S
sub fib asv	16.4mg *	P<.002		7.85mg 55.9mg	0/20	4/50	10/50		S
liv MXA asv	58.0mg *	P<.02	c	23.6mg n.s.s.	0/20	0/50	6/50		liv:hpc,nnd.
TBA MXB asv	1.46mg /	P<.0005		.918mg 2.96mg	13/20	49/50	49/50		
liv MXB asv	58.0mg *	P<.02		23.6mg n.s.s.	0/20	0/50	6/50		liv:hpa,hpc,nnd.
1839 R m f34 eat 21m24 TR162 :					0	3.20mg	7.00mg		
sub fib asv	2.52mg /	P<.0005		1.50mg 4.48mg	0/20	15/50	19/50		S
--- mso asv	6.81mg /	P<.0005		3.13mg 18.9mg	0/20	5/50	8/50		S
liv MXA asv	8.11mg /	P<.0005	c	3.81mg 21.2mg	0/20	5/50	10/50		liv:hpc,nnd.
sub lip asv	13.2mg *	P<.002		5.48mg 49.3mg	0/20	3/50	8/50		S
TBA MXB asv	.991mg /	P<.0005		.627mg 1.85mg	13/20	42/50	44/50		
liv MXB asv	8.11mg /	P<.0005		3.81mg 21.2mg	0/20	5/50	10/50		liv:hpa,hpc,nnd.
2,4-DIAMINOTOLUENE.2HCl (2,4-toluenediamine.2HCl) 636-23-7									
1840 M f chi eat 77w90 381 :					0	58.5mg	111.mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
lun mix	72.0mg \	P<.007	-	29.3mg 894.mg	5/22	6/19	(2/17)		
liv mix	180.mg *	P<.09		58.7mg n.s.s.	1/22	1/19	5/17		
tba mix	100.mg \	P<.4		24.6mg n.s.s.	18/22	12/19	(10/17)		
1841 M f chi eat 77w90 381 : pool					0	58.5mg	111.mg		
liv hpt	206.mg *	P<.006	+	65.9mg 3.37gm	1/102	1/19	3/17		
1842 M m chi eat 77w90 381 :					0	54.0mg	103.mg		
liv mix	191.mg *	P<.2		54.2mg n.s.s.	1/18	2/22	4/17		
lun mix	no dre	P=1.	-	118.mg n.s.s.	8/18	1/22	(2/17)		
tba mix	no dre	P=1.		45.1mg n.s.s.	13/18	7/22	11/17		
1843 M m chi eat 77w90 381 : pool					0	54.0mg	103.mg		
liv hpt	201.mg *	P<.1	+	54.8mg n.s.s.	7/99	2/22	4/17		
--- vsc	317.mg *	P<.2	+	76.7mg n.s.s.	5/99	0/22	4/17		
1844 R m cdr eat 64w73 381 :					0	12.4mg	25.7mg		
sub fib av	5.42mg /	P<.0005	+	2.81mg 10.7mg	0/24	6/19	15/24		
liv mix av	26.2mg *	P<.02		6.43mg n.s.s.	0/24	1/19	3/24		

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
tba mix av		2.98mg /	P<.0005	1.58mg 7.35mg	7/24	12/19	20/24		
1845 R m cdr eat 64w73 381 : pool					0	12.4mg	25.7mg		
sub fib av		4.42mg /	P<.0005 +	2.27mg 10.2mg	14/111	6/19	15/24		
liv hpt av		22.2mg *	P<.003 +	5.70mg 263.mg	2/111	1/19	3/24		
2,6-DIAMINOTOLUENE.2HCl (2,6-toluenediamine.2HCl) 15481-70-6									
1846 M f b6c eat 24m24 TR200 :					0	6.40mg	12.9mg		
liv hpc #		181.mg *	P<.05 -	54.8mg n.s.s.	0/50	0/50	3/50		s
TBA MXB		75.9mg *	P<.7	12.6mg n.s.s.	21/50	30/50	24/50		
liv MXB		129.mg *	P<.4	32.0mg n.s.s.	4/50	3/50	7/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	38.9mg n.s.s.	4/50	8/50	3/50		lun:a/a,a/c.
1847 M m b6c eat 24m24 TR200 :					0	5.90mg	11.9mg		
--- lym #		20.5mg \	P<.05 -	7.63mg n.s.s.	2/50	8/50	(2/50)		s
TBA MXB		no dre	P=1.	12.2mg n.s.s.	31/50	36/50	26/50		
liv MXB		no dre	P=1.	17.1mg n.s.s.	21/50	17/50	18/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	25.7mg n.s.s.	11/50	13/50	7/50		lun:a/a,a/c.
1848 R f f34 eat 24m24 TR200 :					0	12.4mg	24.8mg		
TBA MXB		no dre	P=1. -	22.7mg n.s.s.	42/50	38/50	39/50		
liv MXB		455.mg *	P<.1	112.mg n.s.s.	0/50	0/50	2/50		liv:hpa,hpc,nnd.
1849 R m f34 eat 24m24 TR200 :					0	9.90mg	19.8mg		
liv MXA #		117.mg *	P<.03 -	47.6mg n.s.s.	0/50	2/50	4/50		liv:hpc,nnd. S
pni isa		140.mg *	P<.03	53.0mg n.s.s.	0/50	1/50	4/50		s
TBA MXB		no dre	P=1.	16.3mg n.s.s.	32/50	38/50	36/50		
liv MXB		117.mg *	P<.03	47.6mg n.s.s.	0/50	2/50	4/50		liv:hpa,hpc,nnd.
2,5-DIAMINOTOLUENE SULFATE (2,5-toluenediamine sulfate) 6369-59-1									
1850 M f b6c eat 78w94 TR126 :					0	64.7mg	104.mg		
lun MXA #		364.mg *	P<.03 -	152.mg n.s.s.	5/100	6/50	8/50		lun:a/a,a/c. S
TBA MXB		33.2gm *	P<1.	128.mg n.s.s.	42/100	15/50	22/50		
liv MXB		1.96gm *	P<.6	307.mg n.s.s.	5/100	2/50	4/50		liv:hpa,hpc,nnd.
lun MXB		364.mg *	P<.03	152.mg n.s.s.	5/100	6/50	8/50		lun:a/a,a/c.
1851 M m b6c eat 78w94 TR126 :					0	59.8mg	96.5mg		
TBA MXB		272.mg *	P<.3 -	83.9mg n.s.s.	38/100	19/50	27/50		
liv MXB		288.mg /	P<.06	113.mg n.s.s.	17/100	8/50	18/50		liv:hpa,hpc,nnd.
lun MXB		3.56gm *	P<.9	211.mg n.s.s.	17/100	6/50	10/50		lun:a/a,a/c.
1852 R f f34 eat 18m25 TR126 :					0	21.9mg	71.6mg		
TBA MXB v		no dre	P=1. -	27.0mg n.s.s.	51/75	34/50	(33/50)		
liv MXB v		no dre	P=1.	520.mg n.s.s.	4/75	1/50	1/50		liv:hpa,hpc,nnd.
1853 R m f34 eat 18m25 TR126 :					0	17.1mg	57.8mg		
TBA MXB v		no dre	P=1. -	102.mg n.s.s.	36/75	20/50	25/50		
liv MXB v		233.mg \	P<.09	57.1mg n.s.s.	0/75	2/50	(0/50)		liv:hpa,hpc,nnd.
DIAZEPAM 439-14-5									
1854 M f cf1 eat 80w80 2139					0	75.0mg			de la Iglesia;txap,57,39-54;1981/pers.comm.
bon ost e		247.mg	P<.03 -	89.5mg n.s.s.	5/100	8/50			
liv hpc e		988.mg	P<.3 -	193.mg n.s.s.	1/100	2/50			
liv hpa e		no dre	P=1. -	457.mg n.s.s.	1/100	0/50			
lun agt e		no dre	P=1. -	247.mg n.s.s.	16/100	4/50			
tba ben e		371.mg	P<.3 -	95.7mg n.s.s.	11/100	9/50			
tba mal e		no dre	P=1. -	121.mg n.s.s.	41/100	16/50			
tba mix e		no dre	P=1. -	113.mg n.s.s.	49/100	19/50			
1855 M m cf1 eat 80w80 2139					0	75.0mg			
liv hpc e		242.mg	P<.05 -	85.2mg n.s.s.	7/100	9/50			
liv hpa e		988.mg	P<.3 -	193.mg n.s.s.	1/100	2/50			
lun agt e		no dre	P=1. -	173.mg n.s.s.	19/100	7/50			
tba mal e		204.mg	P<.3 -	53.2mg n.s.s.	35/100	22/50			
tba mix e		220.mg	P<.4 -	52.5mg n.s.s.	38/100	23/50			
tba ben e		no dre	P=1. -	201.mg n.s.s.	6/100	3/50			
1856 R f wal eat 24m24 2139					0	75.0mg			
liv hpa e		no dre	P=1. -	1.00gm n.s.s.	1/115	0/65			
tba mix e		no dre	P=1. -	110.mg n.s.s.	80/115	42/65			
tba mal e		457.mg	P<.2 -	145.mg n.s.s.	18/115	16/65			
tba ben e		no dre	P=1. -	185.mg n.s.s.	72/115	33/65			
1857 R m wal eat 24m24 2139					0	75.0mg			
liv hpc e		1.09gm	P<.02 -	329.mg n.s.s.	0/115	3/65			
liv hpa e		no dre	P=1. -	1.00gm n.s.s.	1/115	0/65			
tba mal e		865.mg	P<.5 -	168.mg n.s.s.	23/115	16/65			
tba ben e		no dre	P=1. -	277.mg n.s.s.	37/115	16/65			
tba mix e		no dre	P=1. -	193.mg n.s.s.	57/115	27/65			
DIAZINON 333-41-5									
1858 M f b6c eat 24m24 TR137 :					0	12.7mg	25.5mg		
TBA MXB		230.mg *	P<.7 -	33.4mg n.s.s.	9/25	14/50	21/50		
liv MXB		no dre	P=1.	143.mg n.s.s.	2/25	0/50	3/50		liv:hpa,hpc,nnd.
lun MXB		6.23gm *	P<1.	139.mg n.s.s.	1/25	1/50	2/50		lun:a/a,a/c.
1859 M m b6c eat 24m24 TR137 :					0	11.8mg	23.5mg		
TBA MXB		no dre	P=1. -	29.6mg n.s.s.	12/25	30/50	24/50		
liv MXB		26.8mg \	P<.2	9.56mg n.s.s.	5/25	20/50	(13/50)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	126.mg n.s.s.	2/25	3/50	1/50		lun:a/a,a/c.
1860 R f f34 eat 24m24 TR137 :					0	19.8mg	39.6mg		
TBA MXB		51.3mg *	P<.4 -	14.7mg n.s.s.	20/25	44/50	41/50		
liv MXB		no dre	P=1.	231.mg n.s.s.	1/25	1/50	0/50		liv:hpa,hpc,nnd.
1861 R m f34 eat 24m24 TR137 :					0	15.7mg	31.4mg		
--- MXA #		20.4mg \	P<.03 -	9.49mg n.s.s.	5/25	25/50	(12/50)		---:leu,lym. S
TBA MXB		53.4mg \	P<.7	7.64mg n.s.s.	20/25	41/50	(33/50)		
liv MXB		no dre	P=1.	203.mg n.s.s.	1/25	2/50	0/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

3-DIAZOTYRAMINE.HCl (4-(2-aminoethyl)-6-diazo-2,4-cyclohexadienone.HCl) ---
1862 R m f3d wat 27m27 1825 0 50.0mg Fujita;carc,8,527-529;1987
orc sqc e 37.6mg P<.0005 + 21.1mg 74.3mg 0/16 19/28

DIBENZ(a,h)ANTHRACENE 53-70-3
1863 M m dba wat 60w60 1128 0 28.3mg Snell;jnci,28,1043-1051;1962
lun alc 5.88mg P<.0005 + 3.03mg 13.2mg 0/25 14/21

DIBENZO-p-DIOXIN 262-12-4
1864 M f b6c eat 90w91 TR122 : 0 636.mg 1.29gm
TBA MXB s no dre P=1. - 1.74gm n.s.s. 15/50 12/50 9/50
liv MXB s no dre P=1. n.s.s. n.s.s. 0/50 1/50 0/50 liv:hpa,hpc,nnd.
lun MXB s 8.09gm * P<.2 2.28gm n.s.s. 3/50 2/50 5/50 lun:a/a,a/c.
1865 M m b6c eat 88w92 TR122 : 0 557.mg 1.12gm
lun a/c as# 2.84gm \ P<.01 - 1.08gm 289.gm 0/50 5/50 (1/50) S
TBA MXB as no dre P=1. 1.67gm n.s.s. 19/50 19/50 16/50
liv MXB as no dre P=1. 3.33gm n.s.s. 8/50 8/50 5/50 liv:hpa,hpc,nnd.
lun MXB as no dre P=1. 2.58gm n.s.s. 8/50 11/50 6/50 lun:a/a,a/c.
1866 R f osm eat 26m26 TR122 : 0 250.mg 500.mg
TBA MXB s no dre P=1. - 500.mg n.s.s. 26/35 19/35 13/35
liv MXB s 5.37gm * P<.08 1.32gm n.s.s. 0/35 0/35 2/35 liv:hpa,hpc,nnd.
1867 R m osm eat 26m26 TR122 : 0 200.mg 400.mg
TBA MXB no dre P=1. - 1.13gm n.s.s. 21/35 11/35 11/35
liv MXB no dre P=1. 3.52gm n.s.s. 1/35 0/35 0/35 liv:hpa,hpc,nnd.

3-DIBENZOFURANAMINE 4106-66-5
1868 R m wis eat 89w89 1420 0 3.43mg Hackmann;zkko,61,45-54;1956
liv hpt e 9.44mg P<.3 1.53mg n.s.s. 0/6 1/6
tba ben e 1.57mg P<.06 .329mg n.s.s. 0/3 2/3
tba mal e 2.48mg P<.02 + .825mg n.s.s. 0/6 4/8

O,S-DIBENZOYL THIAMINE.HCl 35660-60-7
1869 R f sda eat 24m24 1728 0 50.0mg 500.mg Heywood;txlt,26,53-58;1985
liv hga e no dre P=1. - 4.65gm n.s.s. 0/55 1/55 0/55
tba mix e no dre P=1. - 212.mg n.s.s. 53/55 50/55 51/55
tba mal e 14.3gm * P<.9 - 998.mg n.s.s. 13/55 18/55 16/55
1870 R m sda eat 24m24 1728 0 40.0mg 400.mg
liv lcm e 6.77gm * P<.2 - 1.75gm n.s.s. 1/55 0/55 3/55
liv lcb e 6.98gm * P<.2 - 1.14gm n.s.s. 0/21 0/25 1/23
tba mal e 2.34gm / P<.4 - 544.mg n.s.s. 25/55 13/55 24/55
tba mix e no dre P=1. - 429.mg n.s.s. 48/55 42/55 42/55

1,2-DIBROMO-3-CHLOROPROPANE (DBCP) 96-12-8
1871 M f b6c inh 21m24 TR206 : 0 1.80mg 9.00mg
MXB MXB a 1.28mg / P<.0005 .851mg 2.03mg 4/50 20/50 43/50 b/l:ppa,ppc; l/b:ppc,sqc; lun:a/a,a/c,sqc; nas:---,acn, can,cas,fbs,sqc,sqp; ntu:apn. C
MXA MXA a 2.13mg / P<.0005 c 1.35mg 3.43mg 0/50 11/50 38/50 nas:---; ntu:apn.
MXA MXA a 2.27mg / P<.0005 c 1.33mg 4.37mg 4/50 13/50 20/50 b/l:ppa,ppc; l/b:ppc,sqc; lun:a/a,a/c,sqc.
lun MXA a 5.21mg / P<.0005 c 2.54mg 13.8mg 4/50 5/50 13/50 lun:a/a,a/c.
nas can a 6.49mg / P<.0005 c 3.28mg 12.7mg 0/50 3/50 17/50
lun a/a a 7.89mg / P<.0005 c 3.39mg 25.9mg 3/50 3/50 10/50
hag adn a 8.21mg * P<.003 3.19mg 50.0mg 0/50 5/50 1/50 S
nas MXA a 10.2mg * P<.0005 c 3.99mg 33.2mg 0/50 3/50 6/50 nas:sqc,sqp.
nas acn a 14.5mg * P<.0005 c 5.14mg 51.6mg 0/50 2/50 6/50
nas sqc a 19.0mg * P<.0005 c 6.40mg 69.0mg 0/50 1/50 6/50
nas cas a 40.0mg * P<.003 c 11.3mg 346.mg 0/50 0/50 3/50
nas fbs a 46.8mg * P<.003 c 14.1mg 395.mg 0/50 0/50 3/50
l/b ppc a 72.2mg * P<.02 a 17.6mg n.s.s. 0/50 0/50 2/50
TBA MXB a .945mg / P<.0005 .629mg 1.53mg 23/50 32/50 45/50
liv MXB a 9.84mg * P<.02 3.41mg n.s.s. 2/50 5/50 2/50 liv:hpa,hpc,nnd.
lun MXB a 5.21mg / P<.0005 2.54mg 13.8mg 4/50 5/50 13/50 lun:a/a,a/c.
1872 M f b6c gav 53w59 TR28 : 0 79.0mg 149.mg
sto sqc av 4.29mg / P<.0005 c 2.79mg 6.57mg 0/20 50/50 47/50
TBA MXB av 4.29mg / P<.0005 2.79mg 6.57mg 0/20 50/50 47/50
liv MXB av 1.42gm * P<.3 231.mg n.s.s. 0/20 0/50 1/50 liv:hpa,hpc,nnd.
lun MXB av 150.mg * P<.04 29.4mg n.s.s. 0/20 1/50 2/50 lun:a/a,a/c.
1873 M m b6c inh 76w76 TR206 : 0 1.50mg 7.50mg
MXB MXB 1.44mg * P<.0005 .847mg 2.61mg 0/50 4/50 22/50 l/b:sqc; lun:a/a,a/c; nas:---,apn,can,sqc; trh:---. C
MXA MXA 1.82mg * P<.0005 c 1.03mg 3.42mg 0/50 1/50 21/50 l/b:sqc; nas:---; trh:---.
lun --- 2.48mg * P<.0005 a 1.26mg 6.41mg 0/50 3/50 11/50
lun MXA 3.95mg * P<.002 c 1.81mg 20.5mg 0/50 3/50 7/50 lun:a/a,a/c.
nas apn 4.75mg * P<.002 c 1.85mg 26.7mg 0/50 1/50 5/50
nas can 6.09mg * P<.0005 c 2.48mg 20.9mg 0/50 0/50 7/50
nas sqc 7.05mg * P<.002 c 2.70mg 28.8mg 0/50 0/50 6/50
lun a/a 7.38mg * P<.003 c 3.06mg 42.1mg 0/50 1/50 6/50
nas hes 16.3mg * P<.02 a 4.77mg n.s.s. 0/50 0/50 3/50
sto MXA 16.8mg * P<.02 a 4.85mg n.s.s. 0/50 0/50 3/50 sto:sqc,sqp.
sto sqp 21.5mg * P<.05 a 5.20mg n.s.s. 0/50 0/50 2/50
TBA MXB 1.32mg * P<.0005 .735mg 3.11mg 3/50 7/50 23/50
liv MXB 32.4mg * P<.7 3.68mg n.s.s. 3/50 2/50 3/50 liv:hpa,hpc,nnd.
lun MXB 3.95mg * P<.002 1.81mg 20.5mg 0/50 3/50 7/50 lun:a/a,a/c.
1874 M m b6c gav 53w59 TR28 : 0 81.0mg 156.mg
sto sqc av 4.62mg / P<.0005 c 2.96mg 7.21mg 0/20 43/50 47/50
TBA MXB av 4.64mg / P<.0005 2.98mg 7.51mg 0/20 43/50 47/50
liv MXB av no dre P=1. 50.6mg n.s.s. 2/20 1/50 0/50 liv:hpa,hpc,nnd.
lun MXB av 1.11gm * P<.3 181.mg n.s.s. 0/20 0/50 1/50 lun:a/a,a/c.
1875 R f f34 inh 22m24 TR206 : 0 .429mg 2.14mg
MXB MXB a .199mg / P<.0005 .139mg .295mg 1/50 32/50 45/51 adr:coa; nas:acn,adn,apn,can,sqc,sqp; ntu:---; phr:sqc,

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
									sqp; ton:sqc,sqp. C
MXA MXA a		.252mg /	P<.0005 c	.172mg .382mg	1/50	26/50	42/51		nas:acn,adn,apn,can,sqc,sqp; ntu:---.
mgl --- a		.727mg /	P<.0005	.392mg 1.79mg	5/50	14/50	9/51		S
mgl fba a		.896mg *	P<.0005	.444mg 3.03mg	4/50	13/50	4/51		S
nas sqp a		.948mg *	P<.0005 c	.486mg 2.19mg	0/50	10/50	3/51		
adr coa a		1.20mg *	P<.0005 c	.586mg 2.93mg	0/50	7/50	5/51		
nas adn a		1.51mg *	P<.0005 c	.683mg 4.25mg	0/50	6/50	5/51		
nas apn a		1.70mg *	P<.0005 c	.750mg 4.88mg	0/50	5/50	5/51		
ton MXA a		1.80mg *	P<.0005 c	.828mg 4.33mg	0/50	4/50	9/51		ton:sqc,sqp.
nas can a		1.83mg /	P<.0005 c	1.05mg 3.36mg	0/50	0/50	23/51		
ntu apn a		2.08mg *	P<.002	.830mg 10.1mg	0/50	5/50	1/51		S
ton sqp a		2.46mg *	P<.0005 c	.985mg 7.58mg	0/50	3/50	6/51		
nas sqc a		2.90mg /	P<.0005 c	1.13mg 11.4mg	1/50	2/50	7/51		
nas acn a		3.55mg *	P<.0005 c	1.27mg 12.9mg	0/50	2/50	6/51		
phr MXA a		4.70mg /	P<.0005 c	1.71mg 22.1mg	1/50	0/50	6/51		phr:sqc,sqp.
phr sqp a		5.86mg /	P<.0005 c	2.14mg 24.2mg	0/50	0/50	5/51		
ton sqc a		6.75mg *	P<.003 c	1.96mg 54.8mg	0/50	1/50	3/51		
TBA MXB a		.164mg /	P<.0005	.110mg .264mg	33/50	44/50	47/51		
liv MXB a		5.52mg *	P<.4	1.17mg n.s.s.	2/50	4/50	0/51		liv:hpa,hpc,nnd.
1876 R f osm gav 68w72 TR28 :					0	10.0mg	20.0mg		
MXB MXB av		.855mg /	P<.0005	.544mg 1.38mg	1/20	43/50	42/50		mgl:acn,fba; sto:sqc,sqp. C
sto sqc av		.909mg /	P<.0005 c	.568mg 1.47mg	0/20	38/50	29/50		
mgl MXA av		2.33mg /	P<.0005 c	1.35mg 4.15mg	1/20	24/50	30/50		mgl:acn,fba.
mgl acn av		2.37mg *	P<.0005 c	1.39mg 3.84mg	0/20	24/50	30/50		
sto sqp av		30.1mg /	P<.002 c	13.5mg 117.mg	0/20	1/50	9/50		
TBA MXB av		.892mg /	P<.0005	.560mg 1.49mg	4/20	44/50	43/50		
liv MXB av		90.3mg *	P<.4	14.7mg n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
1877 R m f34 inh 22m24 TR206 :					0	.300mg	1.50mg		
MXB MXB a		.106mg /	P<.0005	75.6ug .154mg	0/50	41/50	40/49		nas:acn,adn,apn,can,cas,sqc,sqp; nsm:sqc; ntu:---; ton: sqc,sqp. C
MXA MXA a		.107mg /	P<.0005 c	76.4ug .156mg	0/50	40/50	39/49		nas:acn,adn,apn,can,cas,sqc,sqp; nsm:sqc; ntu:---.
nas apn a		.567mg *	P<.0005 c	.301mg 1.29mg	0/50	13/50	1/49		
nas adn a		.837mg *	P<.0005 c	.399mg 2.46mg	0/50	9/50	1/49		
nas acn a		.864mg *	P<.0005 c	.424mg 2.09mg	0/50	8/50	6/49		
ntu apn a		.976mg *	P<.002	.442mg 3.71mg	0/50	8/50	0/49		S
nas sqp a		.978mg *	P<.0005 c	.456mg 2.72mg	0/50	7/50	3/49		
nas can a		1.15mg /	P<.0005 c	.625mg 2.01mg	0/50	2/50	22/49		
nas sqc a		1.44mg /	P<.0005 c	.684mg 3.18mg	0/50	2/50	11/49		
ton MXA a		2.08mg /	P<.0005 c	1.01mg 4.85mg	0/50	1/50	11/49		ton:sqc,sqp.
tnv mso a		2.73mg *	P<.002	.947mg 18.0mg	1/50	2/50	5/49		S
ton sqp a		2.75mg *	P<.0005 c	1.23mg 7.53mg	0/50	1/50	8/49		
ski tri a		3.25mg /	P<.0005	1.07mg 18.8mg	0/50	1/50	3/49		S
tnv men a		3.70mg *	P<.0005	1.19mg 16.3mg	0/50	1/50	5/49		S
tnv men a		3.70mg *	P<.0005	1.19mg 16.3mg	0/50	1/50	5/49		S
ton sqc a		9.14mg *	P<.005 c	2.47mg 104.mg	0/50	0/50	3/49		
TBA MXB a		.112mg /	P<.0005	75.9ug .179mg	30/50	48/50	47/49		
liv MXB a		5.65mg *	P<.03	1.30mg n.s.s.	0/50	1/50	1/49		liv:hpa,hpc,nnd.
1878 R m osm gav 71w83 TR28 :					0	10.0mg	21.0mg		
sto sqc av		.967mg /	P<.0005 c	.584mg 1.55mg	0/20	47/50	47/50		
--- MXA av		4.23mg *	P<.02	1.71mg n.s.s.	0/20	13/50	2/50		---:hem,hes. S
TBA MXB av		.988mg /	P<.0005	.600mg 1.61mg	1/20	49/50	48/50		
liv MXB av		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
DIBROMODULCITOL 10318-26-0									
1879 M f swi ipj 26w78 1336					0	6.40mg	12.8mg	Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.	
lun mix e		9.23mg *	P<.003 +	3.83mg 79.3mg	20/154	9/21	3/9		
--- lys e		12.2mg *	P<.0005 +	5.05mg 46.7mg	3/154	2/21	5/9		
--- leu e		46.3mg *	P<.006	11.4mg 1.06gm	0/154	1/21	1/9		
liv lys e		no dre	P=1.	7.19mg n.s.s.	1/154	0/21	0/9		
tba mix e		2.45mg *	P<.0005	1.23mg 6.20mg	42/154	14/21	9/9		
tba mal e		4.75mg *	P<.0005	2.28mg 15.2mg	29/154	10/21	7/9		
tba ben e		24.5mg *	P<.09	6.95mg n.s.s.	13/154	4/21	2/9		
1880 M m swi ipj 26w78 1336					0	6.40mg	15.8mg		
--- lys e		17.6mg *	P<.002 +	7.37mg 97.0mg	2/101	6/29	2/11		
--- lyk e		32.4mg *	P<.002 +	11.2mg 179.mg	0/101	2/29	2/11		
lun mix e		13.5mg \	P<.05 +	4.45mg n.s.s.	9/101	7/29	(0/11)		
liv mix e		no dre	P=1.	10.4mg n.s.s.	2/101	0/29	0/11		
tba mix e		12.7mg *	P<.06	4.53mg n.s.s.	28/101	14/29	5/11		
tba mal e		15.2mg *	P<.04	5.56mg n.s.s.	19/101	9/29	5/11		
tba ben e		no dre	P=1.	16.1mg n.s.s.	9/101	5/29	0/11		
1881 R m cdr ipj 26w78 1336					0	10.7mg	21.5mg		
ski mix e		8.37mg *	P<.0005 +	4.50mg 18.2mg	4/177	8/23	8/11		
per sar e		59.2mg *	P<.002	17.9mg 435.mg	0/177	2/23	1/11		
mgl sqc e		182.mg *	P<.04	29.6mg n.s.s.	0/177	0/23	1/11		
--- lys e		182.mg *	P<.04	29.6mg n.s.s.	0/177	0/23	1/11		
liv tum e		no dre	P=1.	14.0mg n.s.s.	0/177	0/23	0/11		
tba mix e		3.13mg *	P<.0005	1.58mg 7.35mg	59/177	18/23	11/11		
tba mal e		5.05mg *	P<.0005	2.69mg 11.4mg	32/177	12/23	11/11		
tba ben e		no dre	P=1.	21.6mg n.s.s.	27/177	6/23	0/11		
1,2-DIBROMOETHANE (ethylene dibromide, EDB) 106-93-4									
1882 M f b6c inh 22m24 TR210 :					0	23.9mg	95.6mg		
MXB MXB s		9.60mg /	P<.0005	6.41mg 14.8mg	6/50	31/50	47/50		---:hem,hes; lun:a/a,a/c,adn,apn,can; mgl:acn; nas:---, adn,apn,can; sub:fbs. C
lun MXA s		18.4mg /	P<.0005 c	11.3mg 30.9mg	4/50	11/50	42/50		lun:a/a,a/c,adn,apn,can.
lun MXA s		18.7mg /	P<.0005 c	11.4mg 31.6mg	4/50	11/50	41/50		lun:a/a,a/c.
--- MXA s		24.1mg /	P<.0005 c	14.1mg 41.6mg	0/50	12/50	25/50		---:hem,hes.
--- hes s		25.7mg /	P<.0005 c	14.7mg 45.6mg	0/50	11/50	23/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
mgl acn s	26.2mg *	P<.0005	c	13.7mg 61.7mg	2/50	14/50	8/50		
lun a/c s	30.3mg /	P<.0005	c	18.0mg 50.3mg	1/50	5/50	37/50		
lun a/a s	38.6mg /	P<.0005	c	18.6mg 98.3mg	3/50	7/50	13/50		
sub fbs s	90.7mg *	P<.0005	c	41.5mg 201.mg	0/50	4/50	11/50		
l/b MXA s	169.mg *	P<.0005		64.5mg 470.mg	0/50	1/50	8/50		l/b:adn,can. S
nas --- s	187.mg /	P<.0005	c	89.0mg 425.mg	0/50	0/50	12/50		
--- hem s	245.mg *	P<.0005		81.6mg 1.18gm	0/50	1/50	4/50		S
l/b can s	259.mg *	P<.002		74.7mg 1.51gm	0/50	1/50	4/50		S
l/b MXA s	272.mg /	P<.0005		105.mg 968.mg	0/50	0/50	6/50		l/b:adn,apn. S
nas MXA s	337.mg *	P<.0005	c	148.mg 978.mg	0/50	0/50	8/50		nas:adn,can.
nas MXA s	353.mg *	P<.0005	c	122.mg 1.57gm	0/50	0/50	5/50		nas:adn,apn.
l/b adn s	361.mg *	P<.0005		129.mg 1.55gm	0/50	0/50	5/50		S
nas can s	443.mg *	P<.0005	c	173.mg 1.67gm	0/50	0/50	6/50		
nas apn s	470.mg *	P<.004	c	133.mg 4.80gm	0/50	0/50	3/50		
TBA MXB s	6.83mg /	P<.0005		4.55mg 10.9mg	23/50	45/50	49/50		
liv MXB s	107.mg *	P<.07		31.4mg n.s.s.	2/50	6/50	1/50		liv:hpa,hpc,nnd.
lun MXB s	18.7mg /	P<.0005		11.4mg 31.6mg	4/50	11/50	41/50		lun:a/a,a/c.
1883 M f b6c gav 53w78 TR86 :					0	26.0mg	52.0mg		
MXB MXB sv	3.74mg *	P<.0005		2.58mg 6.93mg	0/20	46/50	30/50		lun:a/a,a/c; sto:sqc. C
sto sqc sv	4.07mg *	P<.0005	c	2.81mg 8.09mg	0/20	46/50	28/50		
lun MXA sv	15.4mg *	P<.04	c	8.06mg n.s.s.	0/20	11/50	6/50		lun:a/a,a/c.
lun a/a sv	17.3mg *	P<.03	c	8.85mg n.s.s.	0/20	10/50	6/50		
TBA MXB sv	3.52mg *	P<.0005		2.42mg 6.31mg	0/20	47/50	31/50		
liv MXB sv	no dre	P=1.		n.s.s. n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB sv	15.4mg *	P<.04		8.06mg n.s.s.	0/20	11/50	6/50		lun:a/a,a/c.
1884 M f b6c wat 73w73 1761					0	103.mg			Van Durren;tcam,5,393-403;1985
for mix e	13.1mg	P<.0005	+	6.68mg 25.7mg	1/50	27/29			
for sqc e	24.5mg	P<.0005	+	13.9mg 46.5mg	0/50	22/29			
eso sqp e	318.mg	P<.02	+	96.3mg n.s.s.	0/50	3/29			
lun ptm e	2.34gm	P<.7	-	175.mg n.s.s.	1/50	1/29			
liv tum e	no dre	P=1.	-	303.mg n.s.s.	0/50	0/29			
tba mix e	13.8mg	P<.0005		6.84mg 28.6mg	7/50	27/29			
1885 M f b6c wat 78w78 1806					0	48.0mg			Van Duuren;enhp,69,109-117;1986
for pam e	23.2mg	P<.0005		13.9mg 44.8mg	9/96	29/49			
for sqc e	35.3mg	P<.0005	+	20.7mg 67.1mg	0/96	20/49			
eso pam e	217.mg	P<.004		75.0mg 1.58gm	0/96	4/49			
liv hpt e	no dre	P=1.		273.mg n.s.s.	2/96	0/49			
lun ptm e	no dre	P=1.		192.mg n.s.s.	13/96	2/49			
tba mix e	noTD50	P<.2		n.s.s. n.s.s.	84/96	49/49			
1886 M m b6c inh 78w78 TR210 :					0	19.9mg	79.5mg		
MXB MXB	18.0mg *	P<.0005		11.3mg 32.5mg	0/50	3/50	26/50		---:hem,hes; lun:---,a/a,a/c. C
lun ---	18.2mg *	P<.0005	c	11.4mg 33.6mg	0/50	3/50	25/50		
lun MXA	21.0mg *	P<.0005	c	13.0mg 40.2mg	0/50	3/50	23/50		lun:a/a,a/c.
lun a/c	24.7mg *	P<.0005	c	14.7mg 53.7mg	0/50	3/50	19/50		
lun a/a	60.1mg *	P<.0005	c	29.9mg 146.mg	0/50	0/50	11/50		
MXA apn	124.mg *	P<.02		47.1mg n.s.s.	0/50	0/50	5/50		b/l:apn; l/b:apn. S
l/b MXA	124.mg *	P<.02		47.1mg n.s.s.	0/50	0/50	5/50		l/b:adn,apn. S
--- MXA	200.mg *	P<.03	c	67.2mg n.s.s.	0/50	0/50	4/50		---:hem,hes.
l/b apn	217.mg *	P<.05		65.7mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	21.2mg *	P<.0005		11.7mg 65.5mg	3/50	5/50	27/50		
liv MXB	no dre	P=1.		87.5mg n.s.s.	3/50	1/50	3/50		liv:hpa,hpc,nnd.
lun MXB	21.0mg *	P<.0005		13.0mg 40.2mg	0/50	3/50	23/50		lun:a/a,a/c.
1887 M m b6c gav 53w78 TR86 :					0	30.0mg	53.0mg		
MXB MXB esv	2.34mg *	P<.0005		1.07mg 4.23mg	0/20	45/50	33/50		lun:a/a; sto:sqc,sqp. C
sto MXA esv	2.36mg *	P<.0005	c	1.07mg 4.32mg	0/20	45/50	31/50		sto:sqc,sqp.
sto sqc esv	2.38mg *	P<.0005	c	1.08mg 4.43mg	0/20	45/50	29/50		
lun a/a esv	13.4mg *	P<.003	c	4.58mg 55.8mg	0/20	4/50	10/50		
TBA MXB esv	2.66mg *	P<.0005		1.19mg 5.83mg	2/20	45/50	33/50		
liv MXB esv	no dre	P=1.		51.5mg n.s.s.	2/20	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB esv	13.4mg *	P<.003		4.58mg 55.8mg	0/20	4/50	10/50		lun:a/a,a/c.
1888 M m b6c wat 65w65 1761					0	116.mg			Van Durren;tcam,5,393-403;1985
for sqc e	11.8mg	P<.0005	+	5.98mg 23.1mg	0/45	26/28			
for mix e	11.9mg	P<.0005	+	6.01mg 23.5mg	1/45	26/28			
liv tum e	no dre	P=1.		261.mg n.s.s.	0/45	0/28			
lun ptm e	no dre	P=1.	-	146.mg n.s.s.	5/45	2/28			
tba mix e	12.7mg	P<.0005		6.21mg 27.4mg	8/45	26/28			
1889 M m b6c wat 78w78 1806					0	46.7mg			Van Duuren;enhp,69,109-117;1986
for sqc e	9.44mg	P<.0005	+	5.97mg 15.5mg	2/99	41/48			
eso sqc e	207.mg	P<.003		71.4mg 1.40gm	0/99	4/48			
eso pam e	207.mg	P<.003		71.4mg 1.40gm	0/99	4/48			
liv hpt e	no dre	P=1.		215.mg n.s.s.	12/99	1/48			
tba mix e	noTD50	P<.05		n.s.s. n.s.s.	76/99	48/48			
1890 R f f34 inh 23m24 TR210 :					0	5.71mg	22.8mg		
MXB MXB as	1.81mg /	P<.0005		1.27mg 2.71mg	6/50	44/50	45/50	---:hes; lun:a/a,a/c; mgl:fba; nas:---,acn,adn,apn,can, sqc; pit:adn; spl:hes. C	
nas --- as	2.33mg /	P<.0005	c	1.64mg 3.43mg	1/50	34/50	43/50		
mgl fba as	3.60mg /	P<.0005	c	2.37mg 5.91mg	4/50	29/50	24/50		
nas acn as	4.28mg /	P<.0005	c	2.81mg 6.78mg	0/50	20/50	29/50		
pit adn as	7.46mg *	P<.0005	c	4.25mg 16.0mg	1/50	18/50	4/50		
nas adn as	10.8mg *	P<.0005	c	5.67mg 24.0mg	0/50	11/50	3/50		
nas can as	21.6mg /	P<.0005	c	13.0mg 38.3mg	0/50	0/50	25/50		
nas apn as	22.9mg *	P<.0005	c	10.0mg 62.4mg	0/50	5/50	5/50		
nas sqc as	54.2mg /	P<.002	c	18.6mg 358.mg	1/50	1/50	5/50		
liv hpc as	66.4mg *	P<.002		20.4mg 461.mg	0/50	1/50	3/50		S
lun MXA as	83.5mg *	P<.0005	c	30.9mg 350.mg	0/50	0/50	5/50		lun:a/a,a/c.
spl hes as	87.3mg *	P<.0005	c	31.8mg 319.mg	0/50	0/50	5/50		
--- hes as	87.3mg *	P<.0005	c	31.8mg 319.mg	0/50	0/50	5/50		
lun a/c as	99.9mg *	P<.002	c	33.6mg 555.mg	0/50	0/50	4/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
sub fib as		170.mg	* P<.008	47.7mg 4.00gm	0/50	0/50	3/50		S
sub MXA as		170.mg	* P<.008	47.7mg 4.00gm	0/50	0/50	3/50		sub:fbs,fib. S
mgl acn as		98.8mg	/ P<.02	26.5mg 27.1gm	1/50	0/50	4/50		S
TBA MXB as		2.02mg	/ P<.0005	1.36mg 3.30mg	33/50	49/50	48/50		
liv MXB as		45.6mg	/ P<.003	16.0mg 364.mg	2/50	1/50	5/50		liv:hpa,hpc,nnd.
1891 R f osm gav 50w61 TR86 :					0	26.7mg	28.1mg		
sto sqc ades		1.26mg	* P<.0005 c	.665mg 2.14mg	0/20	40/50	29/50		
MXB MXB ades		1.26mg	* P<.0005	.665mg 2.14mg	0/20	40/50	29/50		liv:hpc,nnd; sto:sqc. C
liv MXA ades		5.38mg	/ P<.0005 c	1.51mg 32.8mg	0/20	1/50	6/50		liv:hpc,nnd.
liv hpc ades		5.52mg	/ P<.0005 c	1.52mg 38.6mg	0/20	1/50	5/50		
adr MXA ades		20.9mg	/ P<.02	5.40mg n.s.s.	0/20	0/50	4/50		adr:coa,coc. S
TBA MXB ades		1.19mg	* P<.0005	.628mg 2.23mg	2/20	40/50	29/50		
liv MXB ades		5.38mg	/ P<.0005	1.51mg 32.8mg	0/20	1/50	6/50		liv:hpa,hpc,nnd.
1892 R m f34 inh 22m24 TR210 :					0	4.00mg	15.9mg		
MXB MXB as		1.10mg	/ P<.0005	.787mg 1.60mg	1/50	43/50	48/50	nas:---,acn,adn,apn,can; nse:sqp; pit:adn; spl:hes; tnv:men,mso. C	
MXA MXA as		1.23mg	/ P<.0005 c	.872mg 1.79mg	0/50	39/50	41/50		nas:---; nse:sqp.
nas acn as		2.73mg	/ P<.0005 c	1.78mg 4.36mg	0/50	20/50	28/50		
nas apn as		3.97mg	* P<.0005 c	2.34mg 7.45mg	0/50	18/50	5/50		
tnv mso as		5.63mg	/ P<.0005 c	3.36mg 10.1mg	1/50	8/50	25/50		
tnv men as		6.06mg	/ P<.0005 c	3.61mg 10.6mg	0/50	7/50	25/50		
nas adn as		7.66mg	* P<.0005 c	3.84mg 19.7mg	0/50	11/50	0/50		
pit adn as		13.8mg	* P<.0005 c	6.07mg 46.3mg	0/50	7/50	2/50		
spl hes as		16.5mg	/ P<.0005 c	8.48mg 33.7mg	0/50	1/50	15/50		
nas can as		18.0mg	/ P<.0005 c	10.4mg 33.2mg	0/50	0/50	21/50		
mul msm as		18.5mg	* P<.003	7.21mg 109.mg	0/50	5/50	1/50		S
slg sar as		58.8mg	* P<.004	17.3mg 528.mg	0/50	1/50	3/50		S
thy MXA as		86.1mg	* P<.004	24.6mg 856.mg	0/50	0/50	3/50		thy:fca,fcc. S
TBA MXB as		1.34mg	/ P<.0005	.904mg 2.14mg	30/50	48/50	49/50		
liv MXB as		78.5mg	* P<.06	15.3mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
1893 R m osm gav 40w49 TR86 : ()					0	27.4mg	29.2mg		
MXB MXB adsv		1.64mg	/ P<.0005	1.18mg 2.33mg	0/20	45/50	34/50		---:hes; sto:sqc. C
sto sqc adsv		1.65mg	/ P<.0005 c	1.18mg 2.35mg	0/20	45/50	33/50		
--- hes adsv		9.62mg	* P<.002 c	4.98mg 21.1mg	0/20	11/50	4/50		
thy MXA adsv		10.4mg	/ P<.002	5.20mg 34.2mg	0/20	5/50	8/50		thy:fca,fcc. S
TBA MXB adsv		1.56mg	/ P<.0005	1.12mg 2.22mg	0/20	46/50	35/50		
liv MXB adsv		23.8mg	* P<.03	8.97mg n.s.s.	0/20	3/50	2/50		liv:hpa,hpc,nnd.
1894 R f cdr inh 78w78 1032					0	13.4mg		Wong;txap,63,155-165;1982/Plotnick pers.comm.	
nas tum e		2.20mg	P<.0005 +	1.31mg 3.75mg	0/47	38/42			
nas ben e		5.02mg	P<.0005 +	3.09mg 8.79mg	0/47	27/42			
nas mal e		8.59mg	P<.0005 +	4.96mg 16.7mg	0/47	19/42			
mgl car		19.9mg	P<.0005 +	9.95mg 49.5mg	0/48	11/48			
liv hpc		59.4mg	P<.02	20.5mg n.s.s.	0/48	4/48			
spl hes		122.mg	P<.1	29.9mg n.s.s.	0/48	2/48			
1895 R m cdr inh 78w78 1032					0	9.39mg			
nas tum e		1.19mg	P<.0005 +	.645mg 2.11mg	0/47	40/42			
nas ben e		2.52mg	P<.0005 +	1.57mg 4.27mg	0/47	32/42			
nas mal e		3.52mg	P<.0005 +	2.17mg 6.15mg	0/47	27/42			
spl hes		12.6mg	P<.0005 +	6.47mg 29.7mg	0/48	12/48			
bra mng		56.1mg	P<.04	17.0mg n.s.s.	0/48	3/48			
liv hpc		85.1mg	P<.1	20.9mg n.s.s.	0/48	2/48			

DIBROMOMANNITOL (DBM) 488-41-5

1896 M f swi ipj 26w78 1336m					0	12.8mg	25.7mg	Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.	
lun mix e		21.4mg	* P<.002 +	9.53mg 136.mg	20/154	11/23	5/17		
--- lys e		38.4mg	* P<.0005 +	15.8mg 162.mg	3/154	1/23	6/17		
sub car e		66.0mg	* P<.0005	22.8mg 340.mg	0/154	1/23	3/17		
--- lyk e		89.8mg	* P<.002	27.2mg 684.mg	0/154	1/23	2/17		
adr coa e		136.mg	* P<.006	33.4mg 2.86gm	0/154	0/23	2/17		
liv lys e		no dre	P=1.	20.4mg n.s.s.	1/154	0/23	0/17		
tba mix e		7.67mg	* P<.0005	4.05mg 19.2mg	42/154	12/23	15/17		
tba mal e		11.2mg	* P<.0005	5.76mg 30.7mg	29/154	10/23	12/17		
tba ben e		130.mg	* P<.4	25.3mg n.s.s.	13/154	2/23	3/17		
1897 M m swi ipj 26w78 1336m					0	12.8mg			
lun mix e		11.4mg	P<.002 +	4.75mg 60.4mg	9/101	9/22			
liv mix e		65.7mg	P<.2	13.4mg n.s.s.	2/101	2/22			
tba mix e		6.03mg	P<.0005	2.64mg 28.7mg	28/101	15/22			
tba mal e		8.53mg	P<.002	3.62mg 50.3mg	19/101	12/22			
tba ben e		92.8mg	P<.6	12.4mg n.s.s.	9/101	3/22			
1898 R f cdr ipj 26w78 1336n					0	17.9mg			
mgl adc e		24.9mg	P<.003 +	9.35mg 232.mg	12/182	7/24			
per sar e		79.2mg	P<.004 +	19.5mg 1.19gm	0/182	2/24			
lun car e		84.6mg	P<.03	19.8mg n.s.s.	1/182	2/24			
liv tum e		no dre	P=1.	49.8mg n.s.s.	0/182	0/24			
tba mal e		11.5mg	P<.002	4.92mg 68.1mg	44/182	14/24			
tba mix e		12.5mg	P<.08	3.95mg n.s.s.	103/182	18/24			
tba ben e		no dre	P=1.	27.8mg n.s.s.	59/182	4/24			
1899 R m cdr ipj 26w78 1336n					0	17.9mg	53.0mg		
per sar e		30.9mg	\ P<.0005 +	11.7mg 129.mg	0/177	5/25	(0/12)		
ski mix e		103.mg	* P<.03 +	32.5mg n.s.s.	4/177	4/25	1/12		
mgl fba e		255.mg	* P<.2	52.7mg n.s.s.	1/177	2/25	0/12		
liv tum e		no dre	P=1.	30.4mg n.s.s.	0/177	0/25	0/12		
tba mix e		7.95mg	\ P<.0005	3.57mg 34.3mg	59/177	18/25	(2/12)		
tba ben e		16.6mg	\ P<.003	6.83mg 125.mg	27/177	11/25	(1/12)		
tba mal e		no dre	P=1.	44.3mg n.s.s.	32/177	7/25	1/12		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
5,7-DIBROMOQUINOLINE 34522-69-5									
1900 R f f34 eat 24m24 1529					0	50.0mg			Fukushima;clet,14,115-123;1981
liv hnd e	no dre	P=1.	-	199.mg n.s.s.	3/44	2/37			
1901 R m f34 eat 24m24 1529					0	40.0mg			
tes ict e	69.4mg	P<.06	-	26.1mg n.s.s.	8/31	14/28			
liv hnd e	754.mg	P<.3	-	123.mg n.s.s.	0/31	1/28			
1,3-DIBUTYL-1-NITROSOUREA 56654-52-5									
1902 R f don wat 75w75 1216					0	5.71mg	11.4mg	22.9mg	Ogiu;zkko,96,35-41;1980
mam fba e	2.23mg	Z P<.0005		1.31mg 4.93mg	5/25	21/26	19/24	(11/19)	
mam mix e	4.28mg	* P<.002	+	2.26mg 18.1mg	8/25	21/26	20/24	15/19	
mgl adc e	22.7mg	* P<.002		11.7mg 86.6mg	0/25	1/26	7/24	4/19	
ute mix e	15.3mg	Z P<.03		7.22mg n.s.s.	0/25	6/26	3/24	(2/19)	
--- leu e	32.0mg	* P<.06	+	13.0mg n.s.s.	1/25	3/26	5/24	4/19	
liv ade e	303.mg	* P<.6		49.4mg n.s.s.	0/25	0/26	1/24	0/19	
tba mix e	2.67mg	* P<.0005		1.45mg 7.88mg	10/25	23/26	22/24	17/19	
DIBUTYLTIN DIACETATE 1067-33-0									
1903 M f b6c eat 78w92 TR183 :					0	8.30mg	16.8mg		
liv hpa ev#	31.6mg	* P<.006	-	16.1mg 313.mg	1/20	4/50	12/50		S
TBA MXB ev	29.6mg	* P<.07		12.8mg n.s.s.	3/20	12/50	13/50		
liv MXB ev	31.6mg	* P<.006		16.1mg 313.mg	1/20	4/50	12/50		liv:hpa,hpc,nnd.
lun MXB ev	no dre	P=1.		69.4mg n.s.s.	2/20	4/50	0/50		lun:a/a,a/c.
1904 M m b6c eat 78w92 TR183 :					0	7.70mg	15.5mg		
TBA MXB v	178.mg	* P<.9	-	15.4mg n.s.s.	6/20	19/50	16/50		
liv MXB v	29.2mg	* P<.06		13.3mg n.s.s.	2/20	11/50	15/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		47.6mg n.s.s.	2/20	8/50	2/50		lun:a/a,a/c.
1905 R f f34 eat 18m24 TR183 :					0	2.50mg	5.00mg		
TBA MXB v	no dre	P=1.	i	3.35mg n.s.s.	12/19	26/50	(13/50)		
liv MXB v	94.4mg	* P<.5		23.2mg n.s.s.	0/19	1/50	1/50		liv:hpa,hpc,nnd.
1906 R m f34 eat 18m24 TR183 :					0	2.00mg	4.00mg		
TBA MXB v	no dre	P=1.	-	5.12mg n.s.s.	8/20	20/50	11/50		
liv MXB v	no dre	P=1.		n.s.s. n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
3,5-DICHLORO(N-1,1-DIMETHYL-2-PROPYNYL)BENZAMIDE 23950-58-5									
1907 M m b6c eat 52w52 1473m					0	2.40mg	12.0mg	60.0mg	300.mg Essigmann;canr,41,2823-2831;1981/ pers.comm.
liv mix r	1.36gm	* P<.6		206.mg n.s.s.	6/84	1/42	4/42	5/42	4/42
liv hpc r	no dre	P=1.		394.mg n.s.s.	3/84	0/42	2/42	2/42	1/42
1908 M m b6c eat 78w78 1473n					0	2.40mg	12.0mg	60.0mg	300.mg
liv mix r	700.mg	* P<.07		239.mg n.s.s.	13/84	7/42	7/42	6/42	12/41
liv hpc r	1.48gm	* P<.2		376.mg n.s.s.	7/84	3/42	3/42	4/42	6/41
1909 M m b6c eat 24m24 1473o					0	2.40mg	12.0mg	60.0mg	300.mg
liv hpc r	140.mg	Z P<.0005	+	71.5mg 508.mg	11/126	9/63	12/63	20/63	(14/63)
liv mix r	209.mg	* P<.0005	+	133.mg 382.mg	21/126	15/63	19/63	28/63	(42/63)
2,3-DICHLORO-p-DIOXANE 3883-43-0									
1910 M f hic ipj 64w64 1143					0	2.86mg			Van Duuren;jnci,53,695-700;1974
lun ptm	7.04mg	P<.6		1.11mg n.s.s.	10/30	12/30			
1,1-DICHLORO-1-FLUOROETHANE (HCFC 141b) 1717-00-6									
1911 R f sda inh 24m24 2231					0	537.mg	1.79gm	6.87gm	Millischer;fctx,33,491-500;1995
tba mix ev	no dre	P=1.		6.52gm n.s.s.	65/70	59/70	60/70	59/70	
1912 R m sda inh 24m24 2231					0	376.mg	1.25gm	4.81gm	
tes ica ev	5.26gm	Z P<.002	+	2.61gm 27.9gm	3/70	4/70	14/70	(12/70)	
tba mix ev	5.79gm	* P<.2		1.93gm n.s.s.	62/70	55/70	54/70	64/70	
alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID (mucochloric acid) 87-56-9									
1913 M f b6a orl 76w76 1296					0	7.84mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	15.5mg n.s.s.	0/17	0/18			
lun ade evx	no dre	P=1.	-	15.5mg n.s.s.	1/17	0/18			
tba mix evx	no dre	P=1.	-	10.3mg n.s.s.	2/17	1/18			
1914 M m b6a orl 76w76 1296					0	7.30mg			
lun mix evx	17.8mg	P<.4	-	3.89mg n.s.s.	2/18	4/17			
liv hpt evx	771.mg	P<1.	-	8.09mg n.s.s.	1/18	1/17			
tba mix evx	16.1mg	P<.4	-	3.43mg n.s.s.	3/18	5/17			
1915 M f b6c orl 76w76 1296					0	7.84mg			
liv hpt evx	no dre	P=1.	-	15.5mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	-	15.5mg n.s.s.	0/16	0/18			
tba mix evx	24.4mg	P<.2	-	5.98mg n.s.s.	0/16	2/18			
1916 M m b6c orl 76w76 1296					0	7.30mg			
liv hpt evx	44.1mg	P<.3	-	7.17mg n.s.s.	0/16	1/17			
lun ade evx	44.1mg	P<.3	-	7.17mg n.s.s.	0/16	1/17			
tba mix evx	5.03mg	P<.002	-	2.14mg 19.3mg	0/16	7/17			
3,4'-DICHLORO-2-METHYLACRYLANILIDE (dicryl) 2164-09-2									
1917 M f b6a orl 76w76 1279					0	9.96mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	18.6mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	-	18.6mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	-	18.6mg n.s.s.	2/17	0/17			
1918 M m b6a orl 76w76 1279					0	9.26mg			
liv hpt evx	27.1mg	P<.3	-	6.05mg n.s.s.	1/18	3/18			
lun ade evx	no dre	P=1.	-	18.3mg n.s.s.	2/18	0/18			
tba mix evx	49.1mg	P<.7	-	5.75mg n.s.s.	3/18	4/18			
1919 M f b6c orl 76w76 1279					0	9.96mg			
liv hpt evx	no dre	P=1.	-	19.7mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	-	19.7mg n.s.s.	0/16	0/18			
tba tum evx	no dre	P=1.	-	19.7mg n.s.s.	0/16	0/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1920 M m b6c orl 76w76 1279					0	9.26mg			
liv hpt evx	15.2mg	P<.04	-	4.58mg n.s.s.	0/16	3/15			
lun ade evx	23.7mg	P<.09	-	5.81mg n.s.s.	0/16	2/15			
tba mix evx	5.39mg	P<.0005	-	2.28mg 18.9mg	0/16	7/15			
2,3-DICHLORO-1,4-NAPHTHOQUINONE (dichlone) 117-80-6									
1921 M f b6a orl 76w76 1240					0	4.14mg			Innes;ntis,1968/1969
liv hpt evx	26.5mg	P<.3	-	4.31mg n.s.s.	0/17	1/18			
lun ade evx	no dre	P=1.	-	4.92mg n.s.s.	1/17	1/18			
tba mix evx	no dre	P=1.	-	3.91mg n.s.s.	2/17	2/18			
1922 M m b6a orl 76w76 1240					0	3.85mg			
liv hpt evx	no dre	P=1.	-	7.63mg n.s.s.	1/18	0/18			
lun ade evx	no dre	P=1.	-	7.63mg n.s.s.	2/18	0/18			
tba mix evx	no dre	P=1.	-	7.63mg n.s.s.	3/18	0/18			
1923 M f b6c orl 76w76 1240					0	4.14mg			
lun ade evx	26.5mg	P<.3	-	4.31mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.	-	8.20mg n.s.s.	0/16	0/18			
tba mix evx	8.31mg	P<.05	-	2.51mg n.s.s.	0/16	3/18			
1924 M m b6c orl 76w76 1240					0	3.85mg			
lun ade evx	7.26mg	P<.04	-	2.19mg n.s.s.	0/16	3/17			
liv hpt evx	23.2mg	P<.3	-	3.78mg n.s.s.	0/16	1/17			
tba mix evx	3.24mg	P<.003	-	1.31mg 17.6mg	0/16	6/17			
2,6-DICHLORO-4-NITROANILINE (botran) 99-30-9									
1925 M f b6a orl 76w76 1291					0	99.7mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	-	119.mg n.s.s.	1/17	1/18			
liv hpt evx	no dre	P=1.	-	198.mg n.s.s.	0/17	0/18			
tba mix evx	182.mg	P<.3	-	47.7mg n.s.s.	2/17	5/18			
1926 M f b6a orl 76w76 1292					0	83.8mg			
liv hpt evx	no dre	P=1.	-	157.mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	-	157.mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	-	157.mg n.s.s.	2/17	0/17			
1927 M m b6a orl 76w76 1291					0	92.7mg			
liv hpt evx	no dre	P=1.	-	184.mg n.s.s.	1/18	0/18			
lun ade evx	no dre	P=1.	-	184.mg n.s.s.	2/18	0/18			
tba mix evx	no dre	P=1.	-	130.mg n.s.s.	3/18	1/18			
1928 M m b6a orl 76w76 1292					0	78.0mg			
liv hpt evx	471.mg	P<.6	-	65.3mg n.s.s.	1/18	2/18			
lun ade evx	no dre	P=1.	-	102.mg n.s.s.	2/18	1/18			
tba mix evx	no dre	P=1.	-	61.3mg n.s.s.	3/18	3/18			
1929 M f b6c orl 76w76 1291					0	99.7mg			
lun ade evx	602.mg	P<.3	-	98.0mg n.s.s.	0/16	1/17			
liv hpt evx	no dre	P=1.	-	187.mg n.s.s.	0/16	0/17			
tba mix evx	188.mg	P<.04	-	56.7mg n.s.s.	0/16	3/17			
1930 M f b6c orl 76w76 1292					0	83.8mg			
lun ade evx	506.mg	P<.3	-	82.3mg n.s.s.	0/16	1/17			
liv hpt evx	no dre	P=1.	-	157.mg n.s.s.	0/16	0/17			
tba mix evx	114.mg	P<.02	-	39.3mg n.s.s.	0/16	4/17			
1931 M m b6c orl 76w76 1291					0	92.7mg			
liv mix evx	104.mg	P<.009	-	39.3mg 2.29gm	0/16	5/18			
lun ade evx	594.mg	P<.3	-	96.6mg n.s.s.	0/16	1/18			
tba mix evx	57.7mg	P<.0005	-	25.7mg 190.mg	0/16	8/18			
1932 M m b6c orl 76w76 1292					0	78.0mg			
liv agm evx	499.mg	P<.3	-	81.2mg n.s.s.	0/16	1/18			
liv hpt evx	499.mg	P<.3	-	81.2mg n.s.s.	0/16	1/18			
lun ade evx	499.mg	P<.3	-	81.2mg n.s.s.	0/16	1/18			
tba mix evx	156.mg	P<.05	-	47.2mg n.s.s.	0/16	3/18			
2,6-DICHLORO-p-PHENYLENEDIAMINE 609-20-1									
1933 M f b6c eat 24m26 TR219 :					0	121.mg	362.mg		
liv MXA	883.mg	* P<.008	c	409.mg 18.5gm	6/50	6/50	16/50		liv:hpa,hpc.
liv hpc	2.03gm	* P<.04	c	770.mg n.s.s.	2/50	2/50	7/50		
TBA MXB	801.mg	* P<.2		273.mg n.s.s.	31/50	26/50	37/50		
liv MXB	883.mg	* P<.008		409.mg 18.5gm	6/50	6/50	16/50		liv:hpa,hpc,nnd.
lun MXB	42.1gm	* P<.9		1.67gm n.s.s.	2/50	2/50	2/50		lun:a/a,a/c.
1934 M m b6c eat 24m26 TR219 :					0	111.mg	334.mg		
liv MXA	737.mg	* P<.07	c	284.mg n.s.s.	16/50	19/50	29/50		liv:hpa,hpc.
liv hpa	933.mg	* P<.02	c	431.mg n.s.s.	4/50	7/50	15/50		
TBA MXB	1.73gm	* P<.6		299.mg n.s.s.	32/50	30/50	38/50		
liv MXB	737.mg	* P<.07		284.mg n.s.s.	16/50	19/50	29/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		559.mg n.s.s.	13/50	5/50	(4/50)		lun:a/a,a/c.
1935 R f f34 eat 24m26 TR219 :					0	92.8mg	278.mg		
TBA MXB	no dre	P=1.	-	66.1mg n.s.s.	49/50	45/50	(38/50)		
liv MXB	2.96gm	* P<.3		757.mg n.s.s.	3/50	2/50	6/50		liv:hpa,hpc,nnd.
1936 R m f34 eat 24m26 TR219 :					0	37.1mg	74.2mg		
TBA MXB	914.mg	* P<.9	-	58.3mg n.s.s.	42/50	37/50	34/50		
liv MXB	340.mg	* P<.05		132.mg n.s.s.	1/50	3/50	5/50		liv:hpa,hpc,nnd.
DICHLOROACETIC ACID 79-43-6									
1937 M f b6c wat 51w51 2191m ()					0	51.6mg	172.mg	516.mg	Pereira;faat,31,192-199;1996/pers.comm.
liv hpa Cekr	238.mg	* P<.0005	+	112.mg 765.mg	1/40	0/40	3/20	7/20	
liv hpc Cekr	2.56gm	* P<.1		417.mg n.s.s.	0/40	0/40	0/20	1/20	
1938 M f b6c wat 82w82 2191n					0	51.6mg	172.mg	516.mg	
liv hpa Cer	197.mg	* P<.0005	+	119.mg 362.mg	2/90	3/50	7/28	16/19	
liv hpc Cer	1.23gm	* P<.002	+	473.mg 7.47gm	2/90	0/50	1/28	5/19	
1939 M m b6c wat 61w61 2071					0	833.mg			Herren-Freund;txap,90,183-189;1987
liv hpa er	62.1mg	P<.0005		26.3mg 137.mg	2/22	25/26			
liv hpc er	119.mg	P<.0005	+	65.6mg 234.mg	0/22	21/26			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
1940 M m b6c wat 24m24 2072					0	88.0mg				Daniel;faat,19,159-168;1992/pers.comm.
liv mix e	49.3mg	P<.0005 +	24.9mg	139.mg	3/20	18/24				
liv hpc e	68.9mg	P<.0005 +	34.3mg	223.mg	2/20	15/24				
liv hpa e	124.mg	P<.004	56.0mg	817.mg	1/20	10/24				
1941 M m b6c wat 60w60 2073m					0	8.33mg	83.3mg	833.mg		DeAngelo;faat,16,337-347;1991/pers.comm.
liv mix ekr	89.2mg *	P<.0005 +	50.8mg	177.mg	0/9	2/9	1/9	27/30		
liv hpc ekr	114.mg *	P<.0005 +	68.5mg	232.mg	0/9	2/9	1/9	25/30		
liv hpa ekr	128.mg *	P<.0005 +	74.0mg	237.mg	0/9	0/9	0/9	24/30		
1942 M m b6c wat 75w75 2073n					0	8.33mg	83.3mg			
liv hpa er	1.77gm *	P<.9	75.1mg	n.s.s.	0/19	2/20	1/18			
liv hpc er	no dre	P=1.	105.mg	n.s.s.	2/19	3/20	1/18			
liv mix er	no dre	P=1.	79.3mg	n.s.s.	2/19	5/20	2/18			
1943 M m b6c wat 52w52 2453m :					0	83.3mg	167.mg	333.mg	583.mg	DeAngelo;jtxe,58,485;1999/pers.comm.
liv mix Ck	143.mg *	P<.002 +	71.7mg	604.mg	0/10	1/10	1/10	2/10	7/10	
liv hpc Ck	242.mg *	P<.002 +	104.mg	1.07gm	0/10	0/10	0/10	2/10	5/10	
liv hpa Ck	247.mg *	P<.02	107.mg	n.s.s.	0/10	1/10	1/10	0/10	5/10	
1944 M m b6c wat 78w78 2453n :					0	83.3mg	167.mg	333.mg	583.mg	
liv mix Ck	179.mg *	P<.003 +	89.0mg	1.27gm	2/10	1/10	4/10	8/10	9/10	
liv hpc Ck	278.mg *	P<.003 +	136.mg	1.66gm	1/10	0/10	2/10	5/10	7/10	
liv hpa Ck	368.mg *	P<.03	159.mg	n.s.s.	1/10	1/10	2/10	5/10	5/10	
1945 M m b6c wat 23m23 2453o :					0	8.33mg	83.3mg	167.mg	333.mg	583.mg
liv mix C	176.mg *	P<.0005 +	103.mg	413.mg	18/50	11/33	14/25	30/35	21/21	11/11
liv hpc C	188.mg *	P<.0005 +	112.mg	418.mg	13/50	11/33	12/25	25/35	20/21	11/11
liv hpa C	313.mg *	P<.0005	184.mg	744.mg	5/50	1/33	5/25	18/35	9/21	5/11
1946 R m f34 wat 53w53 2261m :					0	139.mg				DeAngelo;txcy,114,207-221;1996/pers.comm.
liv mix Ckv	no dre	P=1.	n.s.s.	n.s.s.	0/7	0/7				
1947 R m f34 wat 78w78 2261n :					0	139.mg				
liv mix Ckv	no dre	P=1.	75.1mg	n.s.s.	1/8	1/8				
1948 R m f34 wat 24m24 2261o :					0	139.mg				
liv mix Cv	278.mg	P<.004 +	122.mg	1.99gm	1/43	9/41				
liv hpc Cv	386.mg	P<.02	151.mg	n.s.s.	1/43	7/41				
liv hpa Cv	795.mg	P<.03	241.mg	n.s.s.	0/43	3/41				
1949 R m f34 wat 60w60 2261r :					0	3.60mg	40.2mg	296.mg		
liv hpa Ckv	251.mg *	P<.02	108.mg	n.s.s.	0/10	0/13	0/13	7/34		
liv mix Ckv	251.mg *	P<.02 +	108.mg	n.s.s.	0/10	0/13	0/13	7/34		
liv hpc Ckv	1.85gm *	P<.4	301.mg	n.s.s.	0/10	0/13	0/13	1/34		
1950 R m f34 wat 23m23 2261s :					0	3.60mg	40.2mg			
liv mix C	90.6mg *	P<.004 +	36.6mg	768.mg	1/23	0/26	7/28			
liv hpa C	138.mg *	P<.03	47.8mg	n.s.s.	1/23	0/26	5/28			
liv hpc C	212.mg *	P<.02	64.1mg	n.s.s.	0/23	0/26	3/28			
DICHLOROACETYLENE 7572-29-4										
1951 M f nmr inh 18m28 1651m					0	.321mg				Reichert;carc,5,1411-1420;1984
hag cye es	.550mg	P<.002 +	.264mg	2.65mg	3/30	14/30				
kid cye es	1.08mg	P<.002 +	.467mg	4.34mg	0/30	7/30				
lun ade es	2.73mg	P<.04	.827mg	n.s.s.	0/30	3/30				
lun car es	no dre	P=1.	2.60mg	n.s.s.	4/30	0/30				
lun mix es	no dre	P=1.	1.18mg	n.s.s.	4/30	3/30				
1952 M f nmr inh 52w98 1651n					0	1.17mg				
kid cye es	1.03mg	P<.0005 +	.554mg	2.19mg	0/30	15/30				
hag cye es	3.02mg	P<.07 +	1.10mg	n.s.s.	2/24	8/29				
lun ade es	no dre	P=1.	4.98mg	n.s.s.	5/30	1/30				
lun car es	no dre	P=1.	6.42mg	n.s.s.	1/30	0/30				
1953 M f nmr inh 18m30 1651o					0	.592mg				
hag cye es	.499mg	P<.0005 +	.280mg	1.01mg	1/28	21/29				
kid cye es	7.80mg	P<.5 +	1.44mg	n.s.s.	4/30	6/30				
lun ade es	no dre	P=1.	3.40mg	n.s.s.	1/30	1/30				
lun car es	no dre	P=1.	3.40mg	n.s.s.	1/30	1/30				
1954 M m nmr inh 18m30 1651m					0	.251mg				
kid cye es	.466mg	P<.003 +	.221mg	2.66mg	4/30	15/30				
kid cyc es	.501mg	P<.0005 +	.256mg	1.18mg	0/30	12/30				
hag cye es	1.01mg	P<.2 +	.332mg	n.s.s.	6/30	11/29				
lun ade es	no dre	P=1.	.842mg	n.s.s.	4/30	4/30				
lun car es	no dre	P=1.	1.79mg	n.s.s.	5/30	1/30				
1955 M m nmr inh 52w92 1651n					0	1.04mg				
kid cye es	.486mg	P<.0005 +	.248mg	1.50mg	8/30	23/30				
kid cyc es	3.89mg	P<.02 +	1.34mg	n.s.s.	0/30	4/30				
hag cye es	no dre	P=1. +	1.18mg	n.s.s.	6/26	5/22				
lun ade es	no dre	P=1.	3.08mg	n.s.s.	5/30	2/30				
1956 M m nmr inh 18m27 1651o					0	.540mg				
hag cye es	.687mg	P<.0005 +	.345mg	2.45mg	4/30	17/30				
kid cye es	.769mg	P<.002 +	.376mg	3.31mg	4/30	16/30				
kid cyc es	4.52mg	P<.04 +	1.37mg	n.s.s.	0/30	3/30				
lun ade es	no dre	P=1.	2.49mg	n.s.s.	8/30	3/30				
lun car es	no dre	P=1.	4.30mg	n.s.s.	3/30	0/30				
1957 R f wis inh 18m35 1651n					0	.849mg				
--- mly es	3.86mg	P<.04 +	1.52mg	n.s.s.	4/30	11/30				
liv cho es	3.86mg	P<.04 +	1.52mg	n.s.s.	4/30	11/30				
kid cye es	11.5mg	P<.04 +	3.47mg	n.s.s.	0/30	3/30				
liv hpa es	17.5mg	P<.1 +	4.31mg	n.s.s.	0/30	2/30				
1958 R m wis inh 18m36 1651n					0	.568mg				
kid cye es	3.34mg	P<.002 +	1.44mg	13.4mg	0/30	7/30				
liv cho es	3.97mg	P<.004 +	1.62mg	22.8mg	0/30	6/30				
liv hpa es	12.9mg	P<.1 +	3.16mg	n.s.s.	0/30	2/30				
kid cyc es	26.2mg	P<.3 +	4.26mg	n.s.s.	0/30	1/30				
liv cvh es	no dre	P=1.	8.00mg	n.s.s.	1/30	0/30				
liv hpc es	no dre	P=1.	8.00mg	n.s.s.	1/30	0/30				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1,2-DICHLOROBENZENE (o-dichlorobenzene) 95-50-1									
1959 M f b6c gav 24m24 TR255 :					0	42.0mg	84.1mg		
--- mlh #	1.11gm	* P<.05	-	335.mg n.s.s.	0/50	0/50	3/50		s
TBA MXB	no dre	P=1.		120.mg n.s.s.	32/50	28/50	29/50		
liv MXB	no dre	P=1.		319.mg n.s.s.	4/50	5/50	3/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		306.mg n.s.s.	3/50	4/50	3/50		lun:a/a,a/c.
1960 M m b6c gav 24m24 TR255 :					0	42.0mg	84.1mg		
--- mlh #	648.mg	* P<.04	-	245.mg n.s.s.	0/50	1/50	4/50		s
TBA MXB	no dre	P=1.		109.mg n.s.s.	38/50	32/50	36/50		
liv MXB	no dre	P=1.		93.2mg n.s.s.	19/50	14/50	(11/50)		liv:hpa,hpc,nnd.
lun MXB	767.mg	* P<.6		130.mg n.s.s.	8/50	8/50	13/50		lun:a/a,a/c.
1961 R f f34 gav 24m24 TR255 :					0	42.0mg	84.9mg		
TBA MXB	1.16gm	* P<.9	-	57.8mg n.s.s.	39/50	40/50	40/50		
liv MXB	1.13gm	* P<.4		269.mg n.s.s.	1/50	1/50	3/50		liv:hpa,hpc,nnd.
1962 R m f34 gav 24m24 TR255 :					0	42.2mg	84.9mg		
tes ict s#	48.5mg	* P<.03	-	22.1mg n.s.s.	47/50	49/50	41/50		s
TBA MXB s	81.4mg	* P<.05		34.0mg n.s.s.	33/50	38/50	29/50		
liv MXB s	696.mg	* P<.09		211.mg n.s.s.	0/50	2/50	1/50		liv:hpa,hpc,nnd.
1,4-DICHLOROBENZENE 106-46-7									
1963 M f b6c gav 24m24 TR319 :					0	212.mg	424.mg		
liv MXA	483.mg	/ P<.005	c	244.mg 4.20gm	15/50	10/50	36/50		liv:hpa,hpc.
liv hpc	852.mg	/ P<.005	c	427.mg 7.32gm	5/50	5/50	19/50		
liv hpa	1.03gm	/ P<.06	c	422.mg n.s.s.	10/50	6/50	21/50		
thy fca	5.09gm	* P<.05		1.54gm n.s.s.	0/50	0/50	3/50		s
TBA MXB	870.mg	* P<.4		220.mg n.s.s.	37/50	36/50	46/50		
liv MXB	483.mg	/ P<.005		244.mg 4.20gm	15/50	10/50	36/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		2.27gm n.s.s.	5/50	5/50	1/50		lun:a/a,a/c.
1964 M m b6c gav 24m24 TR319 :					0	212.mg	424.mg		
liv MXA	339.mg	/ P<.005	c	172.mg 3.15gm	17/50	22/50	40/50		liv:hpa,hpc.
liv hpc	559.mg	/ P<.02	c	267.mg n.s.s.	14/50	11/50	32/50		
liv hpa	700.mg	* P<.03	c	324.mg n.s.s.	5/50	13/50	16/50		
amd MXA	2.24gm	* P<.03		916.mg n.s.s.	0/50	2/50	4/50		amd:phe,phm. s
liv hpb	3.51gm	* P<.03		1.21gm n.s.s.	0/50	0/50	4/50		s
TBA MXB	1.31gm	* P<.6		230.mg n.s.s.	35/50	33/50	42/50		
liv MXB	339.mg	/ P<.005		172.mg 3.15gm	17/50	22/50	40/50		liv:hpa,hpc,nnd.
lun MXB	666.mg	\ P<.2		213.mg n.s.s.	6/50	13/50	(2/50)		lun:a/a,a/c.
1965 M f bdj inh 24m24 2378					0	37.6mg	141.mg	564.mg	Nagano;apor,741-746;1998/pers.comm.
liv mix e	250.mg	Z P<.0005	+	167.mg 402.mg	4/50	13/50	7/49	45/50	
liv hpc e	351.mg	Z P<.0005	+	238.mg 552.mg	2/50	4/50	2/49	41/50	
liv hpa e	947.mg	* P<.0005	+	505.mg 2.80gm	2/50	10/50	6/49	20/50	
liv hpb e	4.03gm	* P<.0005	+	1.64gm 14.6gm	0/50	0/50	0/49	6/50	
lun mix e	3.62gm	* P<.05		1.28gm n.s.s.	1/50	4/50	2/49	7/50	
1966 M m bdj inh 24m24 2378					0	31.3mg	118.mg	470.mg	
liv mix e	296.mg	* P<.0005	+	171.mg 689.mg	20/49	21/49	18/50	41/49	
liv hpc e	301.mg	* P<.0005	+	183.mg 618.mg	12/49	17/49	16/50	38/49	
liv hpb e	1.95gm	* P<.002	+	896.mg 9.15gm	0/49	2/49	1/50	8/49	
liv hcs e	2.98gm	* P<.02	+	1.07gm n.s.s.	0/49	3/49	1/50	6/49	
liv hpa e	5.60gm	* P<.6		963.mg n.s.s.	13/49	9/49	7/50	13/49	
1967 M f swi inh 57w76 2304					0	88.6mg	591.mg		Loeser;fctx,21,825-832;1983
liv nnd e	12.5gm	* P<.6	-	1.56gm n.s.s.	0/48	1/47	1/50		
lun ade e	no dre	P=1.	-	1.77gm n.s.s.	3/48	3/47	2/50		
tba mal e	no dre	P=1.	-	124.mg n.s.s.	16/48	12/47	(5/50)		
tba tum e	no dre	P=1.	-	949.mg n.s.s.	23/48	22/47	16/50		
1968 R f f34 gav 24m24 TR319 :					0	212.mg	424.mg		
TBA MXB	no dre	P=1.	-	289.mg n.s.s.	43/50	45/50	36/50		
liv MXB	9.29gm	* P<.5		1.62gm n.s.s.	1/50	1/50	2/50		liv:hpa,hpc,nnd.
1969 R m f34 gav 24m24 TR319 :					0	106.mg	212.mg		
kid MXA	586.mg	* P<.005		270.mg 5.06gm	1/50	3/50	8/50		kid:tla,uac. s
kid uac	644.mg	* P<.009	c	285.mg 20.0gm	1/50	3/50	7/50		
mul mnl	615.mg	* P<.05		250.mg n.s.s.	5/50	7/50	11/50		s
TBA MXB	224.mg	* P<.2		78.2mg n.s.s.	38/50	38/50	38/50		
liv MXB	no dre	P=1.		933.mg n.s.s.	2/50	2/50	0/50		liv:hpa,hpc,nnd.
1970 R f aap inh 18m26 2304					0	19.1mg	127.mg		Loeser;fctx,21,825-832;1983
liv hpa e	no dre	P=1.	-	240.mg n.s.s.	1/61	0/61	0/58		
tba tum e	507.mg	* P<.8	-	57.1mg n.s.s.	55/61	54/61	53/58		
tba mal e	893.mg	* P<.4	-	203.mg n.s.s.	19/61	22/61	23/58		
1971 R m aap inh 18m26 2304					0	13.4mg	89.1mg		
liv tum e	no dre	P=1.	-	167.mg n.s.s.	0/60	0/60	0/60		
tba tum e	no dre	P=1.	-	141.mg n.s.s.	39/60	31/60	35/60		
tba mal e	2.37gm	* P<.8	-	216.mg n.s.s.	19/60	13/60	18/60		
1972 R f f3d inh 24m24 2378					0	8.96mg	33.6mg	134.mg	Nagano;apor,741-746;1998/pers.comm.
thy cca e	2.65gm	* P<.7	-	325.mg n.s.s.	2/47	7/50	9/49	6/49	
liv hpa e	6.97gm	* P<.7	-	698.mg n.s.s.	0/50	1/50	1/50	1/50	
liv hpc e	no dre	P=1.	-	1.04gm n.s.s.	0/50	0/50	1/50	0/50	
1973 R m f3d inh 24m24 2378					0	6.27mg	23.5mg	94.0mg	
liv hpa e	no dre	P=1.	-	725.mg n.s.s.	1/50	2/50	0/50	1/50	
3,3'-DICHLOROBENZIDINE (DCB) 91-94-1									
1974 D f beg cap 86m86 1379					0	4.42mg			Stula;jept,1,475-490;1978
liv mix ev	noTD50	P<.008	+	n.s.s. 1.78mg	0/6	5/5			
ubl mix ev	noTD50	P<.008	+	n.s.s. 1.78mg	0/6	5/5			
tba mix ev	noTD50	P<.6		n.s.s. n.s.s.	5/6	5/5			
1975 R f cdr eat 69w69 192					0	50.0mg			Stula;txap,31,159-176;1975/pers.comm.
mgl adc	18.3mg	P<.0005	+	10.8mg 36.6mg	3/44	26/44			
liv tum	no dre	P=1.	-	200.mg n.s.s.	0/44	0/44			
1976 R m cdr eat 69w69 192					0	40.0mg			
zym sqc	60.1mg	P<.002	+	27.2mg 203.mg	0/44	8/44			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
mgl adc		69.6mg	P<.002 +	30.0mg 290.mg	0/44	7/44			
--- grl		66.2mg	P<.03 +	26.9mg n.s.s.	2/44	9/44			
liv tum		no dre	P=1. -	160.mg n.s.s.	0/44	0/44			
3,3'-DICHLOROBENZIDINE.2HCl 612-83-9									
1977 M m icr eat 52w52 2594					0	120.mg			Osanai;jsol,52,179-201;1976
liv hpt e		noTD50	P<.0005 +	n.s.s. 12.3mg	2/21	18/18			
1,4-DICHLOROBUTENE-2 (65% trans-, 35% cis-) 764-41-0									
1978 R f cdr inh 12m24 2645m					0	.757mg			Mullin;dact,25,227-230;2002/2000
nas mal erv		.242mg	P<.0005 +	.181mg .326mg	0/128	113/128			
nas ade erv		13.0mg	P<.009	4.95mg 349.mg	0/128	5/128			
1979 R f cdr inh 24m24 2645n					0	.191mg			
nas ade er		.695mg	P<.0005 +	.420mg 1.27mg	0/128	22/128			
nas mal er		8.32mg	P<.1	2.05mg n.s.s.	0/128	2/128			
1980 R m cdr inh 19m24 2644					0	21.2ug	63.6ug	.212mg	Mullin;dact,23,403-417;2000/2002
nas mix rs		.467mg	* P<.0005 +	.328mg .715mg	1/159	4/144	14/148	35/126	
nre ade rs		.653mg	* P<.0005 +	.442mg 1.05mg	0/159	3/144	12/148	23/126	
nof mal rs		1.27mg	* P<.0005 +	.742mg 2.56mg	1/159	1/144	2/148	18/126	
nof adc rs		2.00mg	* P<.0005	1.06mg 4.50mg	0/159	0/144	2/148	11/126	
nof car rs		8.88mg	* P<.01	2.69mg 531.mg	0/159	0/144	0/148	3/126	
nof cas rs		8.88mg	* P<.01	2.69mg 531.mg	0/159	0/144	0/148	3/126	
1981 R m cdr inh 12m24 2645m					0	.530mg			Mullin;dact,25,227-230;2002/2000
nas mal erv		.169mg	P<.0005 +	.127mg .227mg	0/127	114/129			
nas ade erv		23.2mg	P<.1	5.72mg n.s.s.	0/127	2/129			
1982 R m cdr inh 24m24 2645n					0	.134mg			
nas ade er		.313mg	P<.0005 +	.206mg .510mg	0/127	33/130			
nas mal er		1.04mg	P<.0005 +	.521mg 2.64mg	0/127	11/130			
trans-1,4-DICHLOROBUTENE-2 110-57-6									
1983 M f hic ipj 76w76 582					0	.286mg			Van Duuren;canr,35,2553-2557;1975
abd sar		1.52mg	P<.1 +	.373mg n.s.s.	0/30	2/30			
2,7-DICHLORODIBENZO-p-DIOXIN (DCDD) 33857-26-0									
1984 M f b6c eat 90w91 TR123 :					0	636.mg	1.19gm		
TBA MXB		no dre	P=1. -	2.30gm n.s.s.	15/50	18/50	9/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	8.39gm n.s.s.	3/50	2/50	0/50		lun:a/a,a/c.
1985 M m b6c eat 90w92 TR123 :					0	540.mg	1.09gm		
--- MXA		1.92gm \	P<.003 a	831.mg 9.58gm	0/50	7/50	(3/50)		---:leu,lym.
--- MXA		2.75gm \	P<.01 a	1.04gm 281.gm	0/50	5/50	(1/50)		---:hem,hes.
liv MXA		2.12gm *	P<.07 a	885.mg n.s.s.	8/50	20/50	17/50		liv:hpa,hpc.
TBA MXB		2.91gm *	P<.4	787.mg n.s.s.	19/50	30/50	25/50		
liv MXB		2.12gm *	P<.07	885.mg n.s.s.	8/50	20/50	17/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.95gm n.s.s.	8/50	5/50	5/50		lun:a/a,a/c.
1986 R f osm eat 26m26 TR123 :					0	250.mg	500.mg		
TBA MXB		no dre	P=1. -	456.mg n.s.s.	26/35	22/35	16/35		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/35	0/35	0/35		liv:hpa,hpc,nnd.
1987 R m osm eat 26m26 TR123 :					0	198.mg	396.mg		
TBA MXB		no dre	P=1. -	131.mg n.s.s.	21/35	14/35	(6/35)		
liv MXB		12.9gm *	P<.8	716.mg n.s.s.	1/35	0/35	1/35		liv:hpa,hpc,nnd.
DICHLORODIFLUOROMETHANE (CFC 12, fluorocarbon 12) 75-71-8									
1988 M f swi inh 18m24 BT602					0	777.mg	3.89gm		Maltoni;anya,534,261-282;1988
--- leu		4.10gm \	P<.06 -	1.51gm n.s.s.	8/90	12/60	(6/60)		
lun ade		91.9gm *	P<.4 -	19.1gm n.s.s.	2/90	1/60	3/60		
tba mal		3.32gm \	P<.03 -	1.33gm n.s.s.	9/90	14/60	(6/60)		
tba mix		59.0gm *	P<.7 -	8.68gm n.s.s.	15/90	15/60	13/60		
1989 M m swi inh 18m24 BT602					0	648.mg	3.24gm		
lun ade		41.9gm *	P<.2 -	11.1gm n.s.s.	3/90	3/60	5/60		
tba mix		12.1gm *	P<.02 -	5.11gm n.s.s.	9/90	9/60	15/60		
tba mal		33.1gm *	P<.2 -	9.46gm n.s.s.	5/90	4/60	7/60		
1990 R f sda inh 24m24 BT601					0	247.mg	1.23gm		
liv ang		31.3gm *	P<.2 -	8.46gm n.s.s.	1/150	1/90	3/90		
tba mal		no dre	P=1. -	6.91gm n.s.s.	43/150	24/90	18/90		
tba mix		no dre	P=1. -	1.34gm n.s.s.	124/150	71/90	72/90		
1991 R m sda inh 24m24 BT601					0	173.mg	864.mg		
adr phe		1.32gm \	P<.02 -	529.mg n.s.s.	6/150	11/90	(5/90)		
liv ang		no dre	P=1. -	2.67gm n.s.s.	1/150	0/90	0/90		
tba mix		555.mg \	P<.06 -	221.mg n.s.s.	51/150	42/90	(27/90)		
tba mal		no dre	P=1. -	6.54gm n.s.s.	25/150	16/90	9/90		
p,p'-DICHLORODIPHENYL SULFONE 80-07-9									
1992 M f b6c eat 24m24 TR501 :					0	3.90mg	13.0mg	39.0mg	
lun MXA #		18.1mg Z	P<.004 -	7.38mg 121.mg	0/50	6/50	(3/50)	3/50)	lun:a/a,a/c. S
sub sar		582.mg *	P<.02	176.mg n.s.s.	0/50	0/50	0/50	3/50	S
TBA MXB		no dre	P=1.	58.9mg n.s.s.	23/50	28/50	20/50	26/50	
liv MXB		601.mg *	P<.6	95.7mg n.s.s.	6/50	5/50	6/50	8/50	liv:hpa,hpb,hpc.
lun MXB		18.1mg Z	P<.004	7.38mg 121.mg	0/50	6/50	(3/50)	3/50)	lun:a/a,a/c.
1993 M m b6c eat 24m24 TR501 :					0	3.60mg	12.0mg	36.0mg	
TBA MXB		no dre	P=1. -	80.7mg n.s.s.	32/50	28/50	22/50	21/50	
liv MXB		10.5gm *	P<1.	78.5mg n.s.s.	15/50	11/50	9/50	13/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	40.5mg n.s.s.	13/50	11/50	8/50	(4/50)	lun:a/a,a/c.
1994 R f f34 eat 24m24 TR501 :					0	1.50mg	5.00mg	15.0mg	
TBA MXB		no dre	P=1. -	14.1mg n.s.s.	43/50	40/50	42/50	36/50	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
1995 R m f34 eat 24m24 TR501 :					0	.400mg	1.20mg	4.00mg	
TBA MXB		no dre	P=1. -	2.97mg n.s.s.	46/50	48/50	45/50	45/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB	62.8mg	* P<.3		13.2mg n.s.s.	2/50	0/50	0/50	3/50	liv:hpa,hpb,hpc.
1,1-DICHLOROETHANE 75-34-3									
1996 M f b6c gav 78w90 TR66 :					0	1.02gm	2.04gm		
TBA MXB sv	8.40gm	/ P<.5	-	2.03gm n.s.s.	6/20	6/50	12/50		
liv MXB sv	no dre	P=1.		10.3gm n.s.s.	1/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB sv	no dre	P=1.		8.16gm n.s.s.	1/20	2/50	0/50		lun:a/a,a/c.
1997 M f b6c gav 78w90 TR66 : pool					0	1.02gm	2.04gm		
ute esp sv	11.2gm	* P<.004	a	3.89gm 86.3gm	0/80	0/50	4/50		
1998 M m b6c gav 78w90 TR66 :					0	883.mg	1.77gm		
TBA MXB esv	1.37gm	* P<.07	-	588.mg n.s.s.	4/20	19/50	15/50		
liv MXB esv	2.04gm	* P<.05		936.mg n.s.s.	1/20	8/50	8/50		liv:hpa,hpc,nnd.
lun MXB esv	7.32gm	* P<.04		2.67gm n.s.s.	0/20	1/50	4/50		lun:a/a,a/c.
1999 R f osm gav 18m26 TR66 :					0	238.mg	477.mg		
mgl adc dsv	986.mg	* P<.04	a	377.mg n.s.s.	0/20	1/50	5/50		
--- hes dsv	1.35gm	* P<.05	a	450.mg n.s.s.	0/20	0/50	4/50		
TBA MXB dsv	336.mg	* P<.2		119.mg n.s.s.	4/20	12/50	18/50		
liv MXB dsv	4.65gm	* P<.4		758.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
2000 R f osm gav 18m26 TR66 : pool					0	238.mg	477.mg		
--- hes dsv	1.36gm	* P<.02	a	456.mg n.s.s.	0/40	0/50	4/50		
2001 R m osm gav 18m26 TR66 :					0	192.mg	383.mg		
TBA MXB dsv	no dre	P=1.	-	258.mg n.s.s.	6/20	6/50	5/50		
liv MXB dsv	no dre	P=1.		926.mg n.s.s.	1/20	0/50	0/50		liv:hpa,hpc,nnd.
1,2-DICHLOROETHANE (ethylene dichloride, EDC) 107-06-2									
2002 M f b6c gav 78w90 TR55 :					0	92.5mg	183.mg		
MXB MXB v	61.2mg	/ P<.0005		38.2mg 113.mg	1/20	16/50	19/50		lun:a/a; mgl:acn. C
lun a/a v	118.mg	/ P<.0005	c	65.2mg 280.mg	1/20	7/50	15/50		
mgl acn v	133.mg	/ P<.0005	c	71.4mg 312.mg	0/20	9/50	7/50		
TBA MXB v	36.0mg	/ P<.0005		23.5mg 65.4mg	6/20	33/50	29/50		
liv MXB v	4.74gm	/ P<.8		349.mg n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.
lun MXB v	112.mg	/ P<.0005		63.2mg 253.mg	1/20	7/50	16/50		lun:a/a,a/c.
2003 M f b6c gav 78w90 TR55 : pool					0	92.5mg	183.mg		
lun a/a v	116.mg	/ P<.0005	c	64.5mg 244.mg	2/60	7/50	15/50		
mgl acn v	133.mg	/ P<.0005	c	71.4mg 280.mg	0/60	9/50	7/50		
ute MXA v	230.mg	/ P<.0005	c	108.mg 598.mg	0/60	5/50	5/50		ute:esp,ess.
sto sqc v	438.mg	/ P<.003		170.mg 3.27gm	1/60	2/50	5/50		S
2004 M m b6c gav 78w90 TR55 :					0	60.0mg	120.mg		
lun a/a v	89.7mg	* P<.0005	c	49.7mg 230.mg	0/20	1/50	15/50		
liv hpc v	133.mg	* P<.04		62.1mg n.s.s.	1/20	6/50	12/50		S
TBA MXB v	57.7mg	* P<.02		29.3mg n.s.s.	4/20	15/50	28/50		
liv MXB v	133.mg	* P<.04		62.1mg n.s.s.	1/20	6/50	12/50		liv:hpa,hpc,nnd.
lun MXB v	89.7mg	* P<.0005		49.7mg 230.mg	0/20	1/50	15/50		lun:a/a,a/c.
2005 M m b6c gav 78w90 TR55 : pool					0	60.0mg	120.mg		
lun a/a v	89.7mg	* P<.0005	c	49.7mg 186.mg	0/60	1/50	15/50		
liv hpc v	148.mg	* P<.02		67.0mg n.s.s.	4/60	6/50	12/50		S
2006 M f bdj inh 24m24 2378					0	12.7mg	38.0mg	114.mg	Nagano;apor,741-746;1998/pers.comm.
lun mix e	510.mg	* P<.02	+	219.mg n.s.s.	5/49	1/50	4/50	11/50	
lun a/a e	766.mg	* P<.05	+	281.mg n.s.s.	4/49	1/50	3/50	8/50	
liv hpa e	849.mg	* P<.02	+	330.mg n.s.s.	1/49	1/50	1/50	6/50	
mgl adc e	864.mg	* P<.03	+	319.mg n.s.s.	1/49	2/50	1/50	6/50	
liv mix e	912.mg	* P<.05	+	326.mg n.s.s.	2/49	1/50	2/50	6/50	
ute esp e	983.mg	* P<.03	+	361.mg n.s.s.	2/49	0/50	1/50	6/50	
lun a/c e	1.83gm	* P<.2	+	511.mg n.s.s.	1/49	0/50	1/50	3/50	
liv hpc e	no dre	P=1.		1.22gm n.s.s.	1/49	0/50	1/50	0/50	
2007 M m bdj inh 24m24 2378					0	10.6mg	31.7mg	95.0mg	
liv hes e	576.mg	* P<.2	+	183.mg n.s.s.	0/50	4/49	6/50	5/50	
lun a/c e	631.mg	* P<.3		160.mg n.s.s.	4/50	10/49	12/50	10/50	
liv hpa e	no dre	P=1.		528.mg n.s.s.	14/50	9/49	6/50	6/50	
liv hpc e	no dre	P=1.		348.mg n.s.s.	17/50	8/49	15/50	9/50	
2008 M f swi inh 18m25 1001m					0	5.31mg	11.9mg	53.1mg 195.mg	Maltoni;banb,5,3-33;1980
liv mix ev	16.9gm	* P<.7	-	2.76gm n.s.s.	0/133	0/89	0/88	1/87 0/84	
lun ade ev	55.4gm	* P<1.	-	1.80gm n.s.s.	4/133	4/89	2/88	2/87 3/84	
liv hpt ev	no dre	P=1.	-	67.7mg n.s.s.	0/133	0/89	0/88	0/87 0/84	
liv ang ev	no dre	P=1.	-	67.7mg n.s.s.	0/133	0/89	0/88	0/87 0/84	
tba mix ev	no dre	P=1.	-	1.52gm n.s.s.	27/133	19/89	17/88	15/87 11/84	
2009 M m swi inh 18m25 1001m					0	4.43mg	9.19mg	49.7mg 156.mg	
liv ang ev	no dre	P=1.	-	47.1mg n.s.s.	0/111	0/69	0/89	0/87 0/81	
liv hpt ev	no dre	P=1.	-	47.1mg n.s.s.	4/111	0/69	0/89	0/87 0/81	
liv mix ev	no dre	P=1.	-	47.1mg n.s.s.	1/111	0/69	0/89	0/87 0/81	
lun ade ev	no dre	P=1.	-	2.69gm n.s.s.	4/111	1/69	4/89	3/87 0/81	
tba mix ev	no dre	P=1.	-	285.mg n.s.s.	14/111	4/69	12/89	9/87 (2/81)	
2010 R f osm gav 18m26 TR55 :					0	24.0mg	48.0mg		
mgl MXA dsv	5.49mg	/ P<.0005	c	1.98mg 13.7mg	0/20	15/50	24/50		mgl:acn,fba.
mgl fba dsv	5.84mg	/ P<.0005		2.02mg 17.2mg	0/20	14/50	8/50		S
mgl acn dsv	74.8mg	/ P<.0005	c	40.8mg 147.mg	0/20	1/50	18/50		
TBA MXB dsv	3.19mg	/ P<.0005		1.47mg 7.60mg	7/20	24/50	33/50		
liv MXB dsv	60.6mg	* P<.2		10.4mg n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
2011 R f osm gav 18m26 TR55 : pool					0	24.0mg	48.0mg		
mgl MXA dsv	5.63mg	/ P<.0005	c	2.27mg 13.8mg	6/60	15/50	24/50		mgl:acn,fba.
mgl fba dsv	6.38mg	/ P<.0005		2.42mg 18.9mg	5/60	14/50	8/50		S
--- hes dsv	19.5mg	* P<.0005		4.35mg 99.1mg	0/60	4/50	4/50		S
mgl acn dsv	54.0mg	/ P<.0005	c	20.3mg 125.mg	1/60	1/50	18/50		
2012 R m osm gav 18m26 TR55 :					0	24.0mg	48.0mg		
MXB MXB dsv	11.5mg	/ P<.0005		3.91mg 27.3mg	0/20	12/50	14/50		---:hes; sto:sqc. C
--- hes dsv	15.0mg	* P<.0005	c	4.16mg 56.2mg	0/20	9/50	7/50		
sto sqc dsv	46.3mg	/ P<.0005	c	17.4mg 153.mg	0/20	3/50	9/50		
TBA MXB dsv	3.18mg	/ P<.0005		1.12mg 10.7mg	4/20	20/50	20/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB dsv	132.mg / P<.07		23.8mg n.s.s.		0/20	0/50	2/50		liv:hpa,hpc,nnd.
2013 R m osm gav 18m26 TR55 : pool					0	24.0mg	48.0mg		
--- hes dsv	18.4mg * P<.0005 c		4.98mg 61.0mg		1/60	9/50	7/50		
sub fib dsv	43.2mg / P<.0005 c		17.6mg 108.mg		0/60	5/50	6/50		
sto sqc dsv	46.3mg / P<.0005 c		17.4mg 121.mg		0/60	3/50	9/50		
2014 R f cdr inh 24m24 1962					0	17.5mg			Cheever;faat,14,243-261;1990
liv hpc e	594.mg	P<.3	- 96.7mg n.s.s.		0/50	1/50			
liv nnd e	no dre	P=1.	- 110.mg n.s.s.		1/50	1/50			
tba tum e	no dre	P=1.	- 5.32mg n.s.s.		47/50	47/50			
2015 R m cdr inh 24m24 1962					0	12.3mg			
liv nnd e	206.mg	P<.1	- 50.6mg n.s.s.		0/50	2/50			
liv hpc e	no dre	P=1.	- 76.8mg n.s.s.		1/50	1/50			
tba tum e	17.9mg	P<.4	- 4.15mg n.s.s.		42/50	45/50			
2016 R f f3d inh 24m24 2378					0	3.01mg	12.1mg	48.2mg	Nagano;apor,741-746;1998/pers.comm.
mgl mix e	64.5mg * P<.0005		+ 35.8mg 176.mg		8/50	8/50	11/50	25/50	
mgl fba e	136.mg * P<.002		+ 66.8mg 593.mg		4/50	1/50	6/50	13/50	
sub fib e	347.mg * P<.002		+ 141.mg 1.59gm		0/50	0/50	1/50	5/50	
mgl ade e	191.mg * P<.02		+ 78.5mg n.s.s.		3/50	5/50	5/50	11/50	
mgl adc e	489.mg * P<.06		+ 155.mg n.s.s.		1/50	2/50	0/50	5/50	
liv tum e	no dre	P=1.	23.7mg n.s.s.		0/50	0/50	0/50	0/50	
2017 R m f3d inh 24m24 2378					0	2.11mg	8.44mg	33.8mg	
mgl mix e	203.mg * P<.01		+ 80.2mg 15.1gm		1/50	2/50	1/50	7/50	
mgl fba e	243.mg * P<.002		+ 99.0mg 1.12gm		0/50	0/50	1/50	5/50	
sub fib e	108.mg * P<.04		+ 42.3mg n.s.s.		6/50	9/50	12/50	15/50	
thy cca e	199.mg * P<.09		65.7mg n.s.s.		2/50	5/50	6/50	8/50	
per mso e	291.mg * P<.03		+ 101.mg n.s.s.		1/50	1/50	1/50	5/50	
liv hpa e	3.35gm * P<.9		158.mg n.s.s.		2/50	1/50	3/50	2/50	
2018 R f sda inh 18m31 1001m					0	1.08mg	2.15mg	10.4mg	39.8mg Maltoni;banb,5,3-33;1980
liv mix ev	no dre	P=1.	- 19.7mg n.s.s.		0/90	0/90	0/90	0/90	0/90
mam mix ev	no dre	P=1.	- 117.mg n.s.s.		52/90	65/90	43/90	58/90	52/90
tba mix ev	no dre	P=1.	- 111.mg n.s.s.		56/90	65/90	43/90	56/90	54/90
2019 R f sda inh 18m31 1001n					0	1.08mg	2.15mg	10.4mg	39.8mg
mam mix ev	38.1mg Z P<.07		- 14.6mg n.s.s.		38/90	65/90	43/90	58/90	(52/90)
liv mix ev	no dre	P=1.	- 19.7mg n.s.s.		0/90	0/90	0/90	0/90	0/90
tba mix ev	48.8mg Z P<.2		- 16.4mg n.s.s.		38/90	65/90	43/90	56/90	(54/90)
2020 R m sda inh 18m33 1001m					0	.670mg	1.79mg	7.09mg	26.8mg
liv mix ev	no dre	P=1.	- 15.9mg n.s.s.		0/90	0/90	0/89	0/90	0/89
tba mix ev	2.40gm Z P<1.		- 45.6mg n.s.s.		14/90	30/90	13/89	20/90	(15/89)
2021 R m sda inh 18m33 1001n					0	.670mg	1.79mg	7.09mg	26.8mg
liv mix ev	no dre	P=1.	- 15.9mg n.s.s.		0/90	0/90	0/89	0/90	0/89
tba mix ev	no dre	P=1.	- 51.5mg n.s.s.		17/90	30/90	13/89	20/90	(15/89)

2,4-DICHLOROPHENOL 120-83-2

2022 M f b6c eat 24m24 TR353 :					0	638.mg	1.29gm		
TBA MXB	no dre	P=1.	- 2.31gm n.s.s.		26/50	18/50	21/50		
liv MXB	no dre	P=1.	8.98gm n.s.s.		2/50	3/50	0/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	7.95gm n.s.s.		3/50	1/50	2/50		lun:a/a,a/c.
2023 M m b6c eat 24m24 TR353 :					0	589.mg	1.19gm		
for MXA #	12.4gm * P<.04		- 3.77gm n.s.s.		0/50	0/50	3/50		for:sqc,sqp. S
TBA MXB	no dre	P=1.	1.20gm n.s.s.		29/50	29/50	24/50		
liv MXB	458.gm * P<1.		1.93gm n.s.s.		10/50	12/50	9/50		liv:hpa,hpc,nnd.
lun MXB	13.3gm * P<.5		2.85gm n.s.s.		3/50	2/50	5/50		lun:a/a,a/c.
2024 R f f34 eat 24m24 TR353 :					0	123.mg	248.mg		
TBA MXB	no dre	P=1.	- 254.mg n.s.s.		47/50	36/50	44/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.		0/50	1/50	0/50		liv:hpa,hpc,nnd.
2025 R m f34 eat 24m24 TR353 :					0	196.mg	396.mg		
TBA MXB	no dre	P=1.	- 343.mg n.s.s.		48/50	38/50	41/50		
liv MXB	no dre	P=1.	748.mg n.s.s.		5/50	1/50	(1/50)		liv:hpa,hpc,nnd.

alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID (2-(2,4-dichlorophenoxy)propionic acid) 120-36-5

2026 M f b6a orl 76w76 1230					0	36.4mg			Innes;ntis,1968/1969
liv agm evx	233.mg	P<.3	- 37.9mg n.s.s.		0/17	1/18			
lun ade evx	no dre	P=1.	- 43.3mg n.s.s.		1/17	1/18			
tba mix evx	66.5mg	P<.3	- 17.4mg n.s.s.		2/17	5/18			
2027 M f b6a orl 76w76 1238					0	3.89mg			
lun ade evx	364.mg	P<1.	- 4.05mg n.s.s.		1/17	1/16			
liv hpt evx	no dre	P=1.	- 6.85mg n.s.s.		0/17	0/16			
tba mix evx	no dre	P=1.	- 4.49mg n.s.s.		2/17	1/16			
2028 M m b6a orl 76w76 1230					0	33.9mg			
liv hpt evx	3.58gm	P<1.	- 37.6mg n.s.s.		1/18	1/17			
lun ade evx	no dre	P=1.	- 41.7mg n.s.s.		2/18	1/17			
tba mix evx	no dre	P=1.	- 32.7mg n.s.s.		3/18	2/17			
2029 M m b6a orl 76w76 1238					0	3.62mg			
lun mix evx	no dre	P=1.	- 3.38mg n.s.s.		2/18	2/18			
liv hpt evx	no dre	P=1.	- 4.28mg n.s.s.		1/18	1/18			
tba mix evx	9.26mg	P<.5	- 1.84mg n.s.s.		3/18	5/18			
2030 M f b6c orl 76w76 1230					0	36.4mg			
lun ade evx	220.mg	P<.3	- 35.8mg n.s.s.		0/16	1/17			
liv hpt evx	no dre	P=1.	- 68.1mg n.s.s.		0/16	0/17			
tba mix evx	106.mg	P<.1	- 26.1mg n.s.s.		0/16	2/17			
2031 M f b6c orl 76w76 1238					0	3.89mg			
liv hpt evx	no dre	P=1.	- 7.71mg n.s.s.		0/16	0/18			
lun mix evx	no dre	P=1.	- 7.71mg n.s.s.		0/16	0/18			
tba tum evx	no dre	P=1.	- 7.71mg n.s.s.		0/16	0/18			
2032 M m b6c orl 76w76 1230					0	33.9mg			
liv hpt evx	99.1mg	P<.1	- 24.3mg n.s.s.		0/16	2/17			
lun mix evx	no dre	P=1.	- 63.4mg n.s.s.		0/16	0/17			
tba mix evx	99.1mg	P<.1	- 24.3mg n.s.s.		0/16	2/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2033 M m b6c orl 76w76 1238					0	3.62mg			
liv hpt evx	4.27mg	P<.02	-	1.46mg n.s.s.	0/16	4/15			
lun mix evx	no dre	P=1.	-	5.98mg n.s.s.	0/16	0/15			
tba mix evx	2.59mg	P<.002	-	1.04mg 11.7mg	0/16	6/15			
alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID 6965-71-5									
2034 M f b6a orl 76w76 1231					0	13.4mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	-	16.0mg n.s.s.	1/17	1/18			
liv hpt evx	no dre	P=1.	-	26.6mg n.s.s.	0/17	0/18			
tba mix evx	no dre	P=1.	-	17.7mg n.s.s.	2/17	1/18			
2035 M m b6a orl 76w76 1231					0	12.5mg			
lun ade evx	no dre	P=1.	-	15.4mg n.s.s.	2/18	1/17			
liv hpt evx	no dre	P=1.	-	23.5mg n.s.s.	1/18	0/17			
tba mix evx	no dre	P=1.	-	16.5mg n.s.s.	3/18	1/17			
2036 M f b6c orl 76w76 1231					0	13.4mg			
liv hpt evx	no dre	P=1.	-	25.1mg n.s.s.	0/16	0/17			
lun mix evx	no dre	P=1.	-	25.1mg n.s.s.	0/16	0/17			
tba tum evx	no dre	P=1.	-	25.1mg n.s.s.	0/16	0/17			
2037 M m b6c orl 76w76 1231					0	12.5mg			
liv hpt evx	36.7mg	P<.1	-	9.00mg n.s.s.	0/16	2/17			
lun ade evx	36.7mg	P<.1	-	9.00mg n.s.s.	0/16	2/17			
tba mix evx	10.5mg	P<.003	-	4.25mg 57.2mg	0/16	6/17			
2,4-DICHLOROPHENOXYACETIC ACID (2,4-D) 94-75-7									
2038 M f b6a orl 76w76 1232					0	20.4mg	44.3mg		Innes;ntis,1968/1969
lun ade evx	2.75gm *	P<1.	-	64.6mg n.s.s.	1/17	0/16	1/15		
liv hpt evx	no dre	P=1.	-	24.1mg n.s.s.	0/17	0/16	0/15		
tba mix evx	1.07gm *	P<.9	-	43.4mg n.s.s.	2/17	1/16	2/15		
2039 M m b6a orl 76w76 1232					0	19.0mg	41.2mg		
liv hpt evx	no dre	P=1.	-	22.2mg n.s.s.	1/18	0/18	0/12		
lun ade evx	no dre	P=1.	-	40.0mg n.s.s.	2/18	2/18	1/12		
tba mix evx	no dre	P=1.	-	45.0mg n.s.s.	3/18	2/18	1/12		
2040 M f b6c orl 76w76 1232					0	20.4mg			
liv hpt evx	123.mg	P<.3	-	20.1mg n.s.s.	0/16	1/17			
lun mix evx	no dre	P=1.	-	38.2mg n.s.s.	0/16	0/17			
tba mix evx	123.mg	P<.3	-	20.1mg n.s.s.	0/16	1/17			
2041 M f b6c eat 24m24 2286					0	5.00mg	150.mg	300.mg	Charles;faat,33,166-172;1996
liv hpa	4.53gm *	P<.6	-	756.mg n.s.s.	5/50	11/50	8/50	10/50	
liv hpc	no dre	P=1.	-	3.10gm n.s.s.	1/50	2/50	0/50	1/50	
2042 M m b6c orl 76w76 1232					0	19.0mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	35.5mg n.s.s.	0/16	0/17			
lun mix evx	no dre	P=1.	-	35.5mg n.s.s.	0/16	0/17			
tba mix evx	55.5mg	P<.1	-	13.6mg n.s.s.	0/16	2/17			
2043 M m b6c eat 24m24 2286					0	5.00mg	62.5mg	125.mg	Charles;faat,33,166-172;1996
liv hpa	585.mg *	P<.2	-	193.mg n.s.s.	12/50	9/50	13/50	16/50	
liv hpc	no dre	P=1.	-	486.mg n.s.s.	6/50	3/50	7/50	4/50	
2044 R f f34 eat 24m24 2286					0	150.mg			
bra ast	no dre	P=1.	-	940.mg n.s.s.	1/50	1/50			
2045 R m f34 eat 24m24 2286					0	150.mg			
bra ast	5.09gm	P<.3	-	829.mg n.s.s.	0/50	1/50			
2,4-DICHLOROPHENOXYACETIC ACID, n-BUTYL ESTER 94-80-4									
2046 M f b6a orl 76w76 1237					0	20.4mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	36.0mg n.s.s.	0/17	0/16			
lun ade evx	no dre	P=1.	-	36.0mg n.s.s.	1/17	0/16			
tba mix evx	no dre	P=1.	-	36.0mg n.s.s.	2/17	0/16			
2047 M m b6a orl 76w76 1237					0	19.0mg			
lun ade evx	no dre	P=1.	-	24.9mg n.s.s.	2/18	1/18			
liv hpt evx	no dre	P=1.	-	37.6mg n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	-	14.9mg n.s.s.	3/18	3/18			
2048 M f b6c orl 76w76 1237					0	20.4mg			
liv hpt evx	no dre	P=1.	-	40.5mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	-	40.5mg n.s.s.	0/16	0/18			
tba mix evx	29.7mg	P<.02	-	10.2mg n.s.s.	0/16	4/18			
2049 M m b6c orl 76w76 1237					0	19.0mg			
lun ade evx	59.0mg	P<.2	-	14.5mg n.s.s.	0/16	2/18			
liv hpt evx	122.mg	P<.3	-	19.8mg n.s.s.	0/16	1/18			
tba mix evx	38.1mg	P<.05	-	11.5mg n.s.s.	0/16	3/18			
2,4-DICHLOROPHENOXYACETIC ACID, ISOOCTYL ESTER 25168-26-7									
2050 M f b6a orl 76w76 1236					0	18.1mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	33.8mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	-	33.8mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	-	22.3mg n.s.s.	2/17	1/17			
2051 M m b6a orl 76w76 1236					0	16.8mg			
lun mix evx	no dre	P=1.	-	15.7mg n.s.s.	2/18	2/18			
liv hpt evx	no dre	P=1.	-	19.9mg n.s.s.	1/18	1/18			
tba mix evx	no dre	P=1.	-	13.2mg n.s.s.	3/18	3/18			
2052 M f b6c orl 76w76 1236					0	18.1mg			
lun ade evx	34.0mg	P<.04	-	10.3mg n.s.s.	0/16	3/17			
liv hpt evx	no dre	P=1.	-	33.8mg n.s.s.	0/16	0/17			
tba mix evx	24.6mg	P<.02	-	8.46mg n.s.s.	0/16	4/17			
2053 M m b6c orl 76w76 1236					0	16.8mg			
liv hpt evx	31.7mg	P<.04	-	9.56mg n.s.s.	0/16	3/17			
lun mix evx	no dre	P=1.	-	31.4mg n.s.s.	0/16	0/17			
tba mix evx	17.7mg	P<.007	-	6.65mg 239.mg	0/16	5/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER 94-11-1								
2054 M f b6a orl 76w76 1235				0	15.7mg			Innes;ntis,1968/1969
liv hpc evx	94.7mg	P<.3	- 15.4mg n.s.s.	0/17	1/17			
lun ade evx	no dre	P=1.	- 29.3mg n.s.s.	1/17	0/17			
tba mix evx	83.2mg	P<.7	- 10.5mg n.s.s.	2/17	3/17			
2055 M m b6a orl 76w76 1235				0	14.6mg			
lun ade evx	no dre	P=1.	- 13.7mg n.s.s.	2/18	2/18			
liv hpt evx	no dre	P=1.	- 29.0mg n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	- 11.5mg n.s.s.	3/18	3/18			
2056 M f b6c orl 76w76 1235				0	15.7mg			
liv hpt evx	100.mg	P<.3	- 16.3mg n.s.s.	0/16	1/18			
lun ade evx	100.mg	P<.3	- 16.3mg n.s.s.	0/16	1/18			
tba mix evx	48.7mg	P<.2	- 12.0mg n.s.s.	0/16	2/18			
2057 M m b6c orl 76w76 1235				0	14.6mg			
lun ade evx	21.3mg	P<.02	- 7.32mg n.s.s.	0/16	4/18			
liv hpt evx	93.6mg	P<.3	- 15.2mg n.s.s.	0/16	1/18			
tba mix evx	16.4mg	P<.009	- 6.20mg 361.mg	0/16	5/18			
3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA (karmex, diuron) 330-54-1								
2058 M f b6a orl 76w76 1276				0	193.mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- 215.mg n.s.s.	1/17	1/17			
liv hpt evx	no dre	P=1.	- 361.mg n.s.s.	0/17	0/17			
tba mix evx	no dre	P=1.	- 170.mg n.s.s.	2/17	2/17			
2059 M m b6a orl 76w76 1276				0	180.mg			
lun ade evx	437.mg	P<.4	- 95.6mg n.s.s.	2/18	4/17			
liv hpt evx	no dre	P=1.	- 336.mg n.s.s.	1/18	0/17			
tba mix evx	260.mg	P<.3	- 70.7mg n.s.s.	3/18	6/17			
2060 M f b6c orl 76w76 1276				0	193.mg			
lun ade evx	600.mg	P<.2	- 147.mg n.s.s.	0/16	2/18			
liv hpt evx	no dre	P=1.	- 382.mg n.s.s.	0/16	0/18			
tba mix evx	388.mg	P<.05	- 117.mg n.s.s.	0/16	3/18			
2061 M m b6c orl 76w76 1276				0	180.mg			
liv hpt evx	1.15gm	P<.3	- 187.mg n.s.s.	0/16	1/18			
lun ade evx	1.15gm	P<.3	- 187.mg n.s.s.	0/16	1/18			
tba mix evx	361.mg	P<.05	- 109.mg n.s.s.	0/16	3/18			
2,4-DICHLOROPHENYLBENZENE SULFONATE (genite-R99) 97-16-5								
2062 M f b6a orl 76w76 1288				0	339.mg			Innes;ntis,1968/1969
lun mix evx	1.92gm	P<.6	- 267.mg n.s.s.	1/17	2/17			
liv hpt evx	no dre	P=1.	- 634.mg n.s.s.	0/17	0/17			
tba mix evx	867.mg	P<.4	- 182.mg n.s.s.	2/17	4/17			
2063 M m b6a orl 76w76 1288				0	316.mg			
lun ade evx	866.mg	P<.4	- 181.mg n.s.s.	2/18	4/18			
liv hpt evx	no dre	P=1.	- 626.mg n.s.s.	1/18	0/18			
tba mix evx	1.68gm	P<.7	- 196.mg n.s.s.	3/18	4/18			
2064 M f b6c orl 76w76 1288				0	339.mg			
lun ade evx	1.92gm	P<.3	- 313.mg n.s.s.	0/16	1/16			
liv hpt evx	no dre	P=1.	- 597.mg n.s.s.	0/16	0/16			
tba mix evx	929.mg	P<.09	- 228.mg n.s.s.	0/16	2/16			
2065 M m b6c orl 76w76 1288				0	316.mg			
liv hpt evx	266.mg	P<.003	- 107.mg 1.44gm	0/16	6/17			
lun ade evx	924.mg	P<.1	- 227.mg n.s.s.	0/16	2/17			
tba mix evx	218.mg	P<.002	- 92.7mg 837.mg	0/16	7/17			
1,2-DICHLOROPROPANE (propylene dichloride) 78-87-5								
2066 M f b6c gav 24m24 TR263 :				0	86.8mg	175.mg		
liv MXA s	346.mg *	P<.008	p 168.mg 6.75gm	2/50	8/50	9/50		liv:hpa,hpc.
liv hpa s	562.mg *	P<.04	p 235.mg n.s.s.	1/50	5/50	5/50		
for MXA s	1.02gm *	P<.03	387.mg n.s.s.	0/50	2/50	3/50		for:sqc,sqp. S
TBA MXB s	341.mg *	P<.4	92.1mg n.s.s.	35/50	29/50	34/50		
liv MXB s	346.mg *	P<.008	168.mg 6.75gm	2/50	8/50	9/50		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.	1.07gm n.s.s.	6/50	1/50	1/50		lun:a/a,a/c.
2067 M m b6c gav 24m24 TR263 :				0	86.8mg	175.mg		
liv MXA	229.mg *	P<.05	p 98.6mg n.s.s.	18/50	26/50	33/50		liv:hpa,hpc.
liv hpa	384.mg *	P<.05	p 165.mg n.s.s.	7/50	10/50	17/50		
for sqp	1.52gm *	P<.05	524.mg n.s.s.	0/50	1/50	3/50		S
TBA MXB	397.mg *	P<.4	102.mg n.s.s.	33/50	36/50	42/50		
liv MXB	229.mg *	P<.05	98.6mg n.s.s.	18/50	26/50	33/50		liv:hpa,hpc,nnd.
lun MXB	5.07gm *	P<.9	312.mg n.s.s.	11/50	8/50	12/50		lun:a/a,a/c.
2068 R f f34 gav 24m24 TR263 :				0	86.8mg	175.mg		
mgl acn	767.mg *	P<.03	e 294.mg n.s.s.	1/50	2/50	5/50		
TBA MXB	240.mg *	P<.3	72.5mg n.s.s.	42/50	46/50	30/50		
liv MXB	no dre	P=1.	2.18gm n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
2069 R m f34 gav 24m25 TR263 :				0	42.8mg	86.4mg		
TBA MXB	69.7mg /	P<.04	- 29.8mg n.s.s.	45/50	37/50	43/50		
liv MXB	2.57gm *	P<.8	208.mg n.s.s.	3/50	3/50	2/50		liv:hpa,hpc,nnd.
DICHLORVOS (DDVP, Vapona) 62-73-7								
2070 M f b6c eat 80w92 TR10 :				0	35.1mg	70.2mg		
TBA MXB v	7.85gm *	P<1.	- 86.5mg n.s.s.	1/10	11/50	9/50		
liv MXB v	no dre	P=1.	n.s.s. n.s.s.	0/10	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB v	1.53gm *	P<.8	277.mg n.s.s.	0/10	1/50	1/50		lun:a/a,a/c.
2071 M f b6c gav 24m24 TR342 :				0	14.0mg	28.0mg		
for MXA	56.3mg *	P<.02	26.8mg n.s.s.	5/50	6/50	19/50		for:sqc,sqp. S
for sqp	61.3mg *	P<.03	c 28.2mg n.s.s.	5/50	6/50	18/50		
TBA MXB	no dre	P=1.	31.8mg n.s.s.	37/50	26/50	37/50		
liv MXB	no dre	P=1.	75.7mg n.s.s.	6/50	4/50	7/50		liv:hpa,hpc,nnd.
lun MXB	321.mg *	P<.5	63.6mg n.s.s.	3/50	3/50	6/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2072 M m b6c eat 80w92 TR10 :					0	32.4mg	64.8mg		
TBA MXB v	40.3mg	\ P<.08	-	20.1mg n.s.s.	1/10	22/50	(14/50)		
liv MXB v	no dre	P=1.		76.1mg n.s.s.	0/10	12/50	7/50		liv:hpa,hpc,nnd.
lun MXB v	725.mg	* P<.8		103.mg n.s.s.	0/10	7/50	5/50		lun:a/a,a/c.
2073 M m b6c gav 24m24 TR342 :					0	7.01mg	14.0mg		
for sqp	82.8mg	* P<.07	p	28.9mg n.s.s.	1/50	1/50	5/50		
TBA MXB	38.2mg	* P<.6		7.52mg n.s.s.	37/50	41/50	37/50		
liv MXB	43.4mg	* P<.3		12.5mg n.s.s.	16/50	18/50	20/50		liv:hpa,hpc,nnd.
lun MXB	121.mg	* P<.7		17.2mg n.s.s.	10/50	15/50	10/50		lun:a/a,a/c.
2074 R f osm eat 19m26 TR10 :					0	5.50mg	11.9mg		
TBA MXB v	no dre	P=1.	-	5.73mg n.s.s.	8/10	34/50	(30/50)		
liv MXB v	no dre	P=1.		75.7mg n.s.s.	1/10	3/50	1/50		liv:hpa,hpc,nnd.
2075 R f f34 gav 24m24 TR342 :					0	2.80mg	5.61mg		
mgl fba	3.97mg	\ P<.03	e	1.65mg n.s.s.	9/50	19/50	(16/50)		
mgl MXA	8.51mg	* P<.05		3.66mg n.s.s.	9/50	19/50	17/50		mgl:ade,fba. S
sub MXA	27.3mg	* P<.03		11.1mg n.s.s.	0/50	3/50	3/50		sub:fbs,fib. S
mgl MXA	10.4mg	* P<.2		3.91mg n.s.s.	11/50	20/50	17/50		mgl:ade,car,fba.
pan ade	44.6mg	* P<.2	e	13.6mg n.s.s.	1/50	1/50	4/50		
TBA MXB	13.9mg	* P<.6		2.62mg n.s.s.	47/50	46/50	46/50		
liv MXB	83.9mg	* P<.3		20.5mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
2076 R m osm eat 19m26 TR10 :					0	4.40mg	9.50mg		
TBA MXB v	no dre	P=1.	-	8.10mg n.s.s.	6/10	21/50	33/50		
liv MXB v	no dre	P=1.		n.s.s. n.s.s.	0/10	0/50	0/50		liv:hpa,hpc,nnd.
2077 R m f34 gav 24m24 TR342 :					0	2.80mg	5.61mg		
MXB MXB	3.21mg	* P<.005		1.62mg 31.1mg	25/50	37/50	41/50		---:mnl; pan:ade. P
pan ade	4.16mg	* P<.005	p	2.09mg 44.6mg	16/50	25/50	30/50		
--- mnl	6.89mg	* P<.02	p	3.24mg n.s.s.	11/50	20/50	21/50		
lun a/a	52.2mg	* P<.04		15.5mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	12.3mg	* P<.6		2.34mg n.s.s.	48/50	45/50	45/50		
liv MXB	56.2mg	* P<.4		12.7mg n.s.s.	1/50	3/50	2/50		liv:hpa,hpc,nnd.
2078 R f cfe inh 24m24 96					0	18.9ug	.189mg	1.89mg	Blair;artx,35,281-294;1976
pit tum e	4.65mg	* P<.009	-	1.97mg 172.mg	7/47	5/47	12/47	16/46	
liv tum e	no dre	P=1.	-	.165mg n.s.s.	0/47	0/47	0/47	0/46	
tba mix e	24.5mg	* P<.9	-	1.48mg n.s.s.	36/47	28/47	36/47	33/46	
2079 R m cfe inh 24m24 96					0	13.3ug	.133mg	1.33mg	
pit tum e	11.3mg	* P<.3	-	2.76mg n.s.s.	4/50	10/50	6/50	10/50	
liv tum e	50.0mg	* P<.2	-	8.14mg n.s.s.	0/50	0/50	0/50	1/50	
thy tum e	no dre	P=1.	-	5.04mg n.s.s.	2/50	9/50	5/50	5/50	
tba mix e	no dre	P=1.	-	1.97mg n.s.s.	18/50	30/50	26/50	24/50	
DICHROMATE, SODIUM 10588-01-9									
2080 R m wis inh 18m30 2346					0	.105mg	.210mg	.419mg	Glaser;txcy,42,219-232;1986
lun mix e	4.64mg	* P<.02	+	1.40mg n.s.s.	0/37	0/18	0/18	3/19	
lun adc e	7.07mg	* P<.05		1.74mg n.s.s.	0/37	0/18	0/18	2/19	
lun ade e	14.4mg	* P<.2		2.34mg n.s.s.	0/37	0/18	0/18	1/19	
liv mal e	14.4mg	* P<.2		2.34mg n.s.s.	0/37	0/18	0/18	1/19	
phr sqc e	14.4mg	* P<.2		2.34mg n.s.s.	0/37	0/18	0/18	1/19	
tba mix e	.875mg	* P<.2		.268mg n.s.s.	24/37	7/18	13/18	15/19	
DICOFOL (kelthane) 115-32-2									
2081 M f b6c eat 78w91 TR90 :					0	13.0mg	26.0mg		
TBA MXB v	no dre	P=1.	-	65.1mg n.s.s.	5/20	6/50	8/50		
liv MXB v	no dre	P=1.		309.mg n.s.s.	1/20	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		296.mg n.s.s.	1/20	0/50	0/50		lun:a/a,a/c.
2082 M m b6c eat 78w91 TR90 :					0	26.4mg	54.0mg		
liv MXA v	32.9mg	* P<.04	c	15.9mg n.s.s.	3/20	23/50	36/50		liv:hpa,hpc.
liv hpc v	34.8mg	* P<.04	c	16.8mg n.s.s.	3/20	22/50	35/50		
TBA MXB v	59.2mg	* P<.4		16.1mg n.s.s.	5/20	34/50	38/50		
liv MXB v	32.9mg	* P<.04		15.9mg n.s.s.	3/20	23/50	36/50		liv:hpa,hpc,nnd.
lun MXB v	616.mg	* P<.6		114.mg n.s.s.	1/20	2/50	5/50		lun:a/a,a/c.
2083 R f osm eat 18m26 TR90 :					0	13.0mg	26.0mg		
TBA MXB	no dre	P=1.	-	46.3mg n.s.s.	16/20	27/50	28/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
2084 R m osm eat 18m26 TR90 :					0	12.8mg	26.4mg		
TBA MXB v	no dre	P=1.	-	13.4mg n.s.s.	10/20	23/50	(16/50)		
liv MXB v	517.mg	* P<.7		103.mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
N,N'-DICYCLOHEXYLTHIOUREA 1212-29-9									
2085 M f b6c eat 25m24 TR56 :					0	3.25gm	6.50gm		
TBA MXB	122.gm	* P<1.	-	4.84gm n.s.s.	36/49	37/50	37/50		
liv MXB	no dre	P=1.		30.1gm n.s.s.	5/49	2/50	3/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		23.9gm n.s.s.	4/49	2/50	4/50		lun:a/a,a/c.
2086 M m b6c eat 25m24 TR56 :					0	3.00gm	6.00gm		
TBA MXB	no dre	P=1.	-	4.43gm n.s.s.	39/50	37/50	39/50		
liv MXB	no dre	P=1.		6.61gm n.s.s.	26/50	18/50	25/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		13.6gm n.s.s.	9/50	5/50	9/50		lun:a/a,a/c.
2087 R f f34 eat 25m25 TR56 :					0	1.25gm	2.50gm		
TBA MXB	no dre	P=1.	-	3.02gm n.s.s.	48/50	31/50	43/50		
liv MXB	no dre	P=1.		15.2gm n.s.s.	1/50	1/50	1/50		liv:hpa,hpc,nnd.
2088 R m f34 eat 25m25 TR56 :					0	1.00gm	2.00gm		
thy cca #	5.48gm	* P<.03	-	2.45gm n.s.s.	4/50	9/50	12/50		S
thy MXA	7.41gm	* P<.04		3.32gm n.s.s.	1/50	7/50	6/50		thy:fca,fcc. S
ski bcc	26.1gm	* P<.04		7.90gm n.s.s.	0/50	0/50	3/50		S
TBA MXB	3.91gm	* P<.3		1.18gm n.s.s.	36/50	36/50	43/50		
liv MXB	15.6gm	* P<.09		5.92gm n.s.s.	0/50	3/50	2/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
DICYCLOPENTADIENE DIOXIDE 81-21-0									
2089 M f chi eat 64w86 381 :					0	493.mg	1.04gm	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
lun mix a	1.66gm	* P<.2	-	407.mg n.s.s.	3/13	2/19	0/15		
liv mix a	no dre	P=1.	-	n.s.s. n.s.s.	0/13	0/19	0/15		
tba mix a	789.mg	* P<.2	-	232.mg n.s.s.	9/13	7/19	1/15		
2090 M m chi eat 77w86 381 :					0	455.mg	909.mg		
lun mix	373.mg	\ P<.009	-	140.mg 12.1gm	2/16	5/15	(2/16)		
liv mix	930.mg	* P<.05	-	380.mg n.s.s.	2/16	3/15	3/16		
tba mix	149.mg	\ P<.003	-	66.5mg 962.mg	9/16	13/15	(8/16)		
2091 R m cdr eat 18m25 381 :					0	120.mg	240.mg		
liv mix	3.91gm	* P<.8	-	309.mg n.s.s.	1/17	1/19	1/13		
tba mix	176.mg	* P<.03	-	74.5mg n.s.s.	13/17	10/19	9/13		
DIELDRIN 60-57-1									
2092 H f syg eat 23m26 1000					0	2.09mg	6.27mg	18.8mg	Cabral;clet,6,241-246;1979
liv hpt e	176.mg	* P<.3	-	28.7mg n.s.s.	0/6	0/2	0/8	1/9	
lun tum e	no dre	P=1.	-	11.8mg n.s.s.	0/39	0/32	0/34	0/38	
tba mix e	355.mg	* P<.6	-	54.3mg n.s.s.	5/39	1/32	5/34	5/38	
2093 H m syg eat 26m26 1000					0	1.84mg	5.52mg	16.6mg	
liv hpt e	198.mg	* P<.4	-	32.2mg n.s.s.	0/2	0/3	0/5	1/13	
lun ade e	732.mg	* P<.2	-	119.mg n.s.s.	0/40	0/32	0/32	1/40	
tba mix e	69.9mg	* P<.05	-	26.5mg n.s.s.	3/40	5/32	5/32	10/40	
2094 M f b6c eat 80w91 TR21 :					0	.290mg	.560mg		
TBA MXB s	no dre	P=1.	-	.878mg n.s.s.	3/20	13/50	9/50		
liv MXB s	1.09mg	\ P<.06		.446mg n.s.s.	0/20	6/50	(2/50)		liv:hpa,hpc,nnd.
lun MXB s	5.05mg	* P<.4		1.75mg n.s.s.	0/20	2/50	2/50		lun:a/a,a/c.
2095 M m b6c eat 80w91 TR21 :					0	.260mg	.520mg		
TBA MXB s	1.06mg	* P<.2	-	.399mg n.s.s.	4/20	14/50	18/50		
liv MXB s	1.04mg	* P<.2		.422mg n.s.s.	3/20	12/50	16/50		liv:hpa,hpc,nnd.
lun MXB s	24.7mg	* P<.9		1.30mg n.s.s.	1/20	4/50	3/50		lun:a/a,a/c.
2096 M m b6c eat 80w89 TR21 : pool					0	.260mg	.520mg		
liv hpc s	1.35mg	* P<.08	a	.508mg n.s.s.	17/95	12/50	16/50		
2097 M b c3e eat 24m24 20a					0	1.25mg			Davis;txap,4,187-189;1962
liv hpa e	4.09mg	P<.0005	+	2.40mg 10.6mg	9/134	36/148			
lun ade e	no dre	P=1.		27.8mg n.s.s.	3/134	1/148			
lun car e	no dre	P=1.		38.1mg n.s.s.	0/134	0/148			
2098 M b c3e eat 24m24 22a					0	1.25mg		Epstein(review)	{H J Davis};stev,4,1-52;1975
liv hpt	3.08mg	P<.0005		1.95mg 6.43mg	27/200	69/200			
liv hpc	167.mg	P<.8		16.8mg n.s.s.	4/200	5/200			
tba ben	3.10mg	P<.0005		1.94mg 6.79mg	30/200	71/200			
tba mal	no dre	P=1.		24.7mg n.s.s.	21/200	9/200			
2099 M f cf1 eat 26m26 89					0	1.30mg			Thorpe;fctx,11,433-442;1973
liv mix e	.567mg	P<.0005	+	.298mg 1.27mg	10/44	26/30			
liv lct e	1.59mg	P<.0005	+	.842mg 3.48mg	0/44	14/30			
lun tum e	no dre	P=1.	-	4.36mg n.s.s.	27/44	8/30			
2100 M f cf1 eat 28m32 103a					0	12.8ug	.124mg	1.30mg	Walker;fctx,11,415-432;1973
lun ade ae	.606mg	Z P<.002	-	.300mg 2.84mg	48/297	23/90	30/87	(15/148)	
liv mix ae	.642mg	* P<.0005	+	.481mg .870mg	39/297	24/90	32/87	136/148	
liv lpb ae	1.96mg	Z P<.0005		1.49mg 2.66mg	0/297	4/90	5/87	81/148	
lun car ae	1.78mg	Z P<.06	-	.624mg n.s.s.	18/297	12/90	12/87	(0/148)	
2101 M f cf1 eat 25m30 103b					0	.162mg	.325mg	.650mg 1.30mg 2.60mg	
liv mix aes	1.49mg	* P<.0005	+	.959mg 2.69mg	8/78	5/30	12/28	18/30 9/17 16/21	
liv lpb aes	9.72mg	* P<.0005		4.87mg 29.5mg	0/78	0/30	1/28	5/30 2/17 3/21	
lun ade aes	no dre	P=1.	-	2.03mg n.s.s.	24/78	7/30	3/28	(3/30 1/17 0/21)	
lun car aes	no dre	P=1.	-	30.6mg n.s.s.	8/78	0/30	0/28	1/30 0/17 0/21	
2102 M f cf1 eat 90w90 103c					0	1.30mg			
liv lpb e	2.59mg	P<.007		.978mg 31.8mg	0/22	5/22			
liv mix e	1.05mg	P<.02	+	.438mg n.s.s.	5/22	13/22			
lun ade e	no dre	P=1.	-	2.93mg n.s.s.	7/22	2/22			
lun car e	no dre	P=1.	-	4.41mg n.s.s.	0/22	0/22			
2103 M f cf1 eat 30m30 103d					0	1.30mg			
liv mix e	3.11mg	P<.02	+	1.20mg n.s.s.	3/28	8/19			
liv lpb e	12.1mg	P<.06		2.98mg n.s.s.	0/28	2/19			
lun ade e	no dre	P=1.	-	7.71mg n.s.s.	5/28	0/19			
lun car e	no dre	P=1.	-	7.71mg n.s.s.	0/28	0/19			
2104 M f cf1 eat 25m25 103e					0	1.30mg			
liv mix e	1.16mg	P<.002	+	.548mg 5.32mg	4/24	15/24			
liv lpb e	3.96mg	P<.007		1.50mg 51.4mg	0/24	5/24			
lun ade e	5.69mg	P<.4	-	1.41mg n.s.s.	4/24	7/24			
lun car e	no dre	P=1.	-	6.68mg n.s.s.	3/24	0/24			
2105 M m cf1 eat 26m26 89					0	1.20mg			Thorpe;fctx,11,433-442;1973
liv mix e	noTD50	P<.0005	+	n.s.s. .469mg	11/45	30/30			
liv lct e	1.28mg	P<.0005	+	.682mg 3.03mg	2/45	16/30			
lun tum e	no dre	P=1.	-	2.87mg n.s.s.	27/45	11/30			
2106 M m cf1 eat 28m31 103a					0	11.8ug	.118mg	1.15mg	Walker;fctx,11,415-432;1973
liv mix ae	.547mg	* P<.0005	+	.416mg .729mg	58/288	32/124	34/111	165/176	
liv lpb ae	1.68mg	* P<.0005		1.29mg 2.25mg	12/288	5/124	9/111	100/176	
lun ade ae	2.13mg	Z P<.5	-	.439mg n.s.s.	95/288	47/124	42/111	(32/176)	
lun car ae	3.71mg	Z P<.4	-	.844mg n.s.s.	23/288	14/124	13/111	(2/176)	
2107 M m cf1 eat 26m30 103b					0	.150mg	.300mg	.600mg 1.20mg 2.40mg	
liv mix aes	1.12mg	Z P<.0005	+	.714mg 2.09mg	9/78	6/30	13/30	26/30 5/11 12/17	
liv lpb aes	4.66mg	* P<.0005		2.59mg 9.94mg	0/78	2/30	1/30	3/30 1/11 9/17	
lun ade aes	no dre	P=1.	-	3.96mg n.s.s.	45/78	17/30	11/30	14/30 2/11 (1/17)	
lun car aes	no dre	P=1.	-	14.7mg n.s.s.	1/78	1/30	1/30	1/30 0/11 0/17	
2108 M m cf1 eat 30m30 103c					0	1.20mg			
liv mix e	.913mg	P<.002	+	.420mg 3.87mg	8/23	20/24			
liv lpb e	5.12mg	P<.04		1.85mg n.s.s.	1/23	6/24			
lun ade e	no dre	P=1.	-	4.13mg n.s.s.	7/23	4/24			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf								Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc				NCI/NTPPathology
lun car e		no dre	P=1.	- 8.99mg n.s.s.	0/23	0/24						
2109 M m cf1 eat 30m30 103d					0	1.20mg						
liv mix e		1.91mg	P<.04	+ .589mg n.s.s.	7/30	6/10						
liv lpb e		6.58mg	P<.2	1.41mg n.s.s.	1/30	2/10						
lun ade e		no dre	P=1.	- 2.93mg n.s.s.	13/30	1/10						
lun car e		no dre	P=1.	- 3.75mg n.s.s.	1/30	0/10						
2110 M m cf1 eat 26m29 103e					0	1.06mg						
liv mix e		.713mg	P<.002	+ .305mg 3.96mg	10/24	19/22						
liv lpb e		4.02mg	P<.006	1.52mg 35.7mg	0/24	5/22						
lun ade e		no dre	P=1.	- 1.93mg n.s.s.	11/24	8/22						
lun car e		no dre	P=1.	- 6.86mg n.s.s.	1/24	0/22						
2111 R b osm eat 24m24 23					0	22.5ug	90.0ug	.450mg	2.25mg	4.50mg	6.75mg	Fitzhugh;fctx,2,551-562;1964
lun lys es		no dre	P=1.	35.4mg n.s.s.	1/17	4/22	2/23	2/18	1/20	0/18	0/11	
tba mix es		no dre	P=1.	+ 23.3mg n.s.s.	3/17	8/22	8/23	4/18	4/20	3/18	0/11	
2112 R f osm eat 21m26 TR21 :					0	1.10mg	1.70mg					
TBA MXB sv		no dre	P=1.	- .635mg n.s.s.	7/10	39/50	(27/50)					
liv MXB sv		38.4mg	* P<.8	9.44mg n.s.s.	0/10	1/50	1/50					liv:hpa,hpc,nnd.
2113 R f osm eat 21m25 TR21 : pool					0	1.10mg	1.70mg					
adr MXA sv#		4.42mg	\ P<.003	- 1.80mg 22.2mg	0/60	6/50	(2/50)					adr:coa,coc. S
2114 R f f34 eat 24m24 TR22 :					0	.100mg	.500mg	2.50mg				
TBA MXB a		489.mg	* P<1.	- 1.62mg n.s.s.	17/24	17/24	16/24	14/24				
liv MXB a		no dre	P=1.	n.s.s. n.s.s.	0/24	0/24	0/24	0/24				liv:hpa,hpc,nnd.
2115 R f osm eat 28m29 1004					0	.960mg	1.44mg	2.40mg				Deichmann;imed,39,426-434;1970
liv tum ev		no dre	P=1.	- 6.19mg n.s.s.	0/88	0/48	0/41	0/41				
tba mix ev		no dre	P=1.	- 15.1mg n.s.s.	60/88	23/48	16/41	16/41				
2116 R m osm eat 21m26 TR21 :					0	.880mg	1.36mg					
TBA MXB sv		3.34mg	* P<.6	- .774mg n.s.s.	5/10	24/50	22/50					
liv MXB sv		no dre	P=1.	7.38mg n.s.s.	1/10	0/50	1/50					liv:hpa,hpc,nnd.
2117 R m f34 eat 24m24 TR22 :					0	80.0ug	.400mg	2.00mg				
TBA MXB a		7.28mg	* P<.4	- 1.64mg n.s.s.	5/24	9/24	7/24	9/24				
liv MXB a		no dre	P=1.	n.s.s. n.s.s.	0/24	0/24	0/24	0/24				liv:hpa,hpc,nnd.
2118 R m osm eat 29m29 1004					0	.768mg	1.15mg	1.92mg				Deichmann;imed,39,426-434;1970
liv hem ev		no dre	P=1.	- 4.90mg n.s.s.	1/75	0/48	0/38	0/44				
tba mix ev		no dre	P=1.	- 8.93mg n.s.s.	19/75	4/48	7/38	(1/44)				
2119 R f cfe eat 24m24 100					0	5.00ug	50.0ug	.500mg				Stevenson;txap,36,247-254;1976
tba mix e		no dre	P=1.	- .388mg n.s.s.	18/43	18/23	16/23	13/23				
2120 R m cfe eat 24m24 100					0	4.00ug	40.0ug	.400mg				
tba mix e		2.01mg	* P<.5	- .384mg n.s.s.	12/43	9/23	5/23	9/23				
2121 R f nss eat 24m24 1002					0	.125mg	.625mg	1.25mg				Cleveland;aenh,13,195-198;1966
tba tum		57.2mg	* P<.9	- 3.29mg n.s.s.	6/60	7/40	7/40	5/40				
2122 R m nss eat 24m24 1002					0	.100mg	.500mg	1.00mg				
tba tum		40.5mg	* P<.8	- 4.09mg n.s.s.	3/60	1/40	3/40	2/40				
DIELDRIN, PHOTO- 13366-73-9												
2123 M f b6c eat 80w92 TR17 :					0	38.0ug	71.5ug					
TBA MXB		.743mg	* P<.6	- .147mg n.s.s.	3/20	3/50	8/50					
liv MXB		2.53mg	* P<.4	.412mg n.s.s.	0/20	0/50	1/50					liv:hpa,hpc,nnd.
lun MXB		6.78mg	* P<.9	.368mg n.s.s.	1/20	0/50	2/50					lun:a/a,a/c.
2124 M m b6c eat 80w93 TR17 :					0	34.0ug	66.0ug					
TBA MXB		.494mg	* P<.7	- 73.1ug n.s.s.	3/20	14/50	13/50					
liv MXB		1.96mg	* P<1.	97.7ug n.s.s.	3/20	10/50	10/50					liv:hpa,hpc,nnd.
lun MXB		.465mg	* P<.09	.176mg n.s.s.	0/20	1/50	4/50					lun:a/a,a/c.
2125 R f osm eat 16m26 TR17 :					0	.120mg	.200mg					
mgl MXA av#		.612mg	* P<.04	- .327mg n.s.s.	0/10	5/50	9/50					mgl:ade,fba. S
TBA MXB av		.327mg	* P<.4	.106mg n.s.s.	4/10	29/50	29/50					
liv MXB av		no dre	P=1.	1.30mg n.s.s.	0/10	1/50	0/50					liv:hpa,hpc,nnd.
2126 R m osm eat 19m26 TR17 :					0	.140mg	.290mg					
TBA MXB		no dre	P=1.	- .263mg n.s.s.	5/10	23/50	21/50					
liv MXB		7.72mg	* P<.4	1.26mg n.s.s.	0/10	0/50	1/50					liv:hpa,hpc,nnd.
2127 R m osm eat 19m25 TR17 : pool					0	.140mg	.290mg					
--- hem #		2.89mg	* P<.02	- .868mg n.s.s.	0/75	0/50	3/50					S
D,L-DIEPOXYBUTANE 298-18-0												
2128 R f esd gav 52w52 55					0	2.04mg						Van Duuren;jnci,37,825-838;1966
sto tum		no dre	P=1.	- .506mg n.s.s.	0/5	0/5						
DIETHYL-beta,gamma-EPOXYPROPYLPHOSPHONATE 7316-37-2												
2129 M f hic ipj 64w64 1143					0	28.6mg						Van Duuren;jnci,53,695-700;1974
lun ptm		12.4mg	P<.02	5.23mg n.s.s.	10/30	19/30						
N,N-DIETHYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE 7347-49-1												
2130 R m sda eat 52w52 1176					0	12.0mg						Brown;jnci,37,365-367;1966
liv tum bfr		noTD50	P<.0005	+ n.s.s. 1.63mg	0/10	10/10						
N,N-DIETHYL-m-TOLUAMIDE (DEET) 134-62-3												
2131 M f cd1 eat 78w78 2608					0	250.mg	500.mg	1.00gm				Schoenig;faat,47,99-109;1999/pers.comm.
lun a/a e		14.5gm	* P<.8	- 1.40gm n.s.s.	29/120	15/60	14/60	16/60				
liv hpc e		87.0gm	* P<.7	- 7.07gm n.s.s.	1/120	0/60	0/60	1/60				
liv hpa e		150.gm	* P<.9	- 5.19gm n.s.s.	1/120	2/60	0/60	1/60				
2132 M m cd1 eat 78w78 2608					0	250.mg	500.mg	1.00gm				
liv hpa e		2.58gm	Z P<.05	- 976.mg n.s.s.	2/120	5/60	4/60	(0/60)				
liv hpc e		11.5gm	* P<.2	- 3.13gm n.s.s.	2/120	1/60	2/60	3/60				
lun a/a e		no dre	P=1.	- 2.03gm n.s.s.	27/120	12/60	7/60	14/60				
2133 R f cdr eat 24m24 2608					0	30.0mg	100.mg	400.mg				
liv hpa e		16.7gm	* P<.4	- 2.87gm n.s.s.	2/120	0/60	0/60	2/60				
liv hpc e		no dre	P=1.	- 4.69gm n.s.s.	1/120	0/60	1/60	0/60				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc				NCI/NTPPathology
2134 R m cdr eat 24m24 2608				0	10.0mg	30.0mg	100.mg				
liv hpa e	3.39gm *	P<.6	- 492.mg n.s.s.	1/119	3/60	2/60	2/60				
liv hpc e	no dre	P=1.	- 1.05gm n.s.s.	7/119	2/60	5/60	0/60				
O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL) PHOSPHOROTHIOATE (chlorpyrifos) 2921-88-2											
2135 R f f34 eat 52w52 2634m				0	50.0ug	.100mg	1.00mg	10.0mg			Yano;faat,53,135-144;2000/pers.comm.
liv tum ek	no dre	P=1.	- 16.6ug n.s.s.	0/10	0/10	0/10	0/10	0/10			
2136 R f f34 eat 24m24 2634n				0	50.0ug	.100mg	1.00mg	10.0mg			
liv hpc e	no dre	P=1.	- .331mg n.s.s.	0/50	0/50	0/50	0/50	0/50			
tba mix e	31.1mg *	P<.6	- 5.33mg n.s.s.	44/50	39/50	38/50	38/50	42/50			
2137 R m f34 eat 52w52 2634m				0	50.0ug	.100mg	1.00mg	10.0mg			
liv hpa ek	no dre	P=1.	- 16.6ug n.s.s.	1/10	0/10	0/10	0/10	0/10			
2138 R m f34 eat 24m24 2634n				0	50.0ug	.100mg	1.00mg	10.0mg			
liv hpc e	246.mg *	P<.3	- 46.9mg n.s.s.	0/50	0/50	0/50	1/50	1/50			
spl grl e	no dre	P=1.	- 45.4mg n.s.s.	6/50	12/50	9/50	15/50	6/50			
tba mix e	noTD50	P=1.	- n.s.s. n.s.s.	50/50	40/50	50/50	50/50	50/50			
2139 R f she eat 24m24 1333				0	10.0ug	30.0ug	.100mg	1.00mg	3.00mg		McCollister;fctx,12,45-61;1974
liv tum e	no dre	P=1.	- 35.6ug n.s.s.	0/25	0/25	0/25	0/25	0/25	0/25		
tba mix e	no dre	P=1.	- 4.60mg n.s.s.	12/25	6/25	11/25	4/25	8/25	8/25		
2140 R m she eat 24m24 1333				0	10.0ug	30.0ug	.100mg	1.00mg	3.00mg		
liv bda e	70.6mg *	P<.4	- 11.5mg n.s.s.	0/25	0/25	0/25	0/25	1/25	0/25		
tba mix e	203.mg *	P<1.	- 6.32mg n.s.s.	4/25	2/25	3/25	6/25	3/25	4/25		
DIETHYLACETAMIDE 685-91-6											
2141 R m wis gav 73w73 104				0	.889mg						Argus;jnci,35,949-958;1965
kid ptc e	8.85mg	P<.5	+ 1.44mg n.s.s.	0/9	1/30						
liv tum e	no dre	P=1.	2.71mg n.s.s.	0/9	0/30						
tba mix e	11.8mg	P<.9	.854mg n.s.s.	1/9	4/30						
DIETHYLACETYLUREA ---											
2142 R m f34 eat 71w71 1951				0	13.6mg						Diwan;carc,10,189-194;1989
kid tla e	30.4mg	P<.09	7.47mg n.s.s.	0/15	2/15						
liv hpt e	no dre	P=1.	19.7mg n.s.s.	0/15	0/15						
(+-)-4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-PHENYLACETATE.HCl MONOHYDRATE (NS-21) ---											
2143 M f b6c eat 78w78 2540				0	30.0mg	100.mg	300.mg				Hatch;jtxs,22,275-287;1997
liv hpa e	8.70gm *	P<.8	- 691.mg n.s.s.	2/50	3/50	3/50	3/50				
liv hpc e	no dre	P=1.	- 1.79gm n.s.s.	1/50	0/50	1/50	0/50				
tba mix e	no dre	P=1.	- 374.mg n.s.s.	19/50			16/50				
2144 M m b6c eat 78w78 2540				0	30.0mg	100.mg	300.mg				
liv hpa e	no dre	P=1.	- 733.mg n.s.s.	6/50	11/50	3/50	6/50				
liv hpc e	no dre	P=1.	- 904.mg n.s.s.	3/50	1/50	3/50	2/50				
tba mix e	no dre	P=1.	- 400.mg n.s.s.	22/50			17/50				
2145 R f f34 eat 24m24 2536				0	10.0mg	30.0mg	100.mg				Hatch;jtxs,22,289-309;1997
thy cca e	773.mg *	P<.2	- 216.mg n.s.s.	2/50	8/50	4/50	8/50				
liv hpc e	no dre	P=1.	- 1.04gm n.s.s.	0/50	1/50	0/50	0/50				
liv hpa e	no dre	P=1.	- 1.04gm n.s.s.	0/50	1/50	0/50	0/50				
tba mix e	152.mg	P<.3	- 40.1mg n.s.s.	39/50			43/50				
2146 R m f34 eat 24m24 2536				0	10.0mg	30.0mg	100.mg				
liv hpa e	no dre	P=1.	- 621.mg n.s.s.	0/50	4/50	1/50	1/50				
tba mix e	noTD50	P=1.	- n.s.s. n.s.s.	50/50			50/50				
DIETHYLENE GLYCOL 111-46-6											
2147 R f f3d wat 25m25 2379				0	714.mg	1.43gm					Hiasa;jtxp,3,97-104;1990
liv nnd	no dre	P=1.	- 5.29gm n.s.s.	0/50	0/50	0/50					
tba mix	no dre	P=1.	- 2.60gm n.s.s.	31/50	28/50	26/50					
2148 R m f3d wat 25m25 2379				0	625.mg	1.25gm					
liv nnd	34.2gm *	P<.1	- 8.41gm n.s.s.	0/50	0/50	2/50					
tba mix	no dre	P=1.	- 1.42gm n.s.s.	46/50	46/50	39/50					
2149 R m osm eat 24m24 105				0	400.mg	800.mg	1.60gm				Fitzhugh;jiht,28,40-43;1946
ubl mix r	1.66gm *	P<.002	+ 824.mg 5.28gm	0/12	0/12	6/12	5/12				
DIETHYLFORMAMIDE 617-84-5											
2150 R m wis gav 73w73 104				0	.780mg						Argus;jnci,35,949-958;1965
liv tum e	no dre	P=1.	2.14mg n.s.s.	0/9	0/27						
tba mix e	no dre	P=1.	1.40mg n.s.s.	1/9	1/27						
DIETHYLMALEATE 141-05-9											
2151 R m f3d eat 51w52 1921				0	78.5mg						Hirose;carc,10,2223-2226;1989
for tum er	no dre	P=1.	- 60.6mg n.s.s.	0/10	0/15						
stg tum er	no dre	P=1.	- 60.6mg n.s.s.	0/10	0/15						
2152 R m f3d eat 52w52 2192m				0	80.0mg						Shibata;carc,14,1265-1269;1993/pers.comm.
for tum er	no dre	P=1.	41.2mg n.s.s.	0/10	0/10						
2153 R m f3d eat 24m24 2192n				0	80.0mg						
for sqp er	1.07gm	P<.3	174.mg n.s.s.	0/17	1/20						
for sqc er	no dre	P=1.	330.mg n.s.s.	0/17	0/20						
DIETHYLSTILBESTROL (DES) 56-53-1											
2154 M f b62 eat 33m36 1936r				0	650.ng	1.30ug	2.60ug	5.20ug	20.8ug	41.6ug	83.2ug Greenman; jtxe,29,269-278;1990/1988
pit ade aes	45.6ug *	P<.0005	+ 34.6ug 62.2ug	7/57	8/56	9/61	10/53	16/53	41/61	47/62	54/60
thy fca aes	.186mg Z	P<.003	+ 82.4ug 1.49mg	4/58	1/45	3/50	2/50	5/55	10/51	(2/49	1/53)
cvx sqc aes	1.03mg *	P<.0005	+ .567mg 2.19mg	0/72	0/71	0/72	0/72	0/71	1/72	2/68	12/72
ute mso aes	1.72mg *	P<.0005	+ .810mg 4.69mg	0/67	0/71	0/72	0/70	0/70	0/69	2/66	7/71
ova gct aes	1.74mg *	P<.03	.839mg n.s.s.	0/57	1/64	0/63	2/66	0/57	5/62	2/48	3/61
pit adc aes	17.0mg *	P<.8	1.24mg n.s.s.	1/57	0/56	0/61	0/53	3/53	3/61	1/62	1/60
2155 M m b62 eat 34m37 1936r				0	600.ng	1.20ug	2.40ug	4.80ug	19.2ug	38.4ug	76.8ug
tes ict aes	66.1ug Z	P<.0005	+ 52.3ug 84.8ug	1/71	1/70	2/70	1/72	1/70	15/68	56/68	60/71

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf								Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc				NCI/NTPPathology
pit ade aes	79.4ug *	P<.0005 +	61.2ug	.107mg	0/51	1/55	2/52	2/53	6/51	25/56	34/59	38/57
pit adc aes	4.36mg *	P<.4	1.01mg	n.s.s.	0/51	0/55	0/52	0/53	1/51	2/56	2/59	0/57
2156 M f bcn eat 31m31 1936n					0	650.ng	1.30ug	2.60ug	5.20ug	20.8ug	41.6ug	83.2ug
ova gct ae	.166mg Z	P<.0005 +	.104mg	.291mg	1/36	0/65	0/55	0/56	0/63	10/69	17/57	(14/57)
pit ade ae	.200mg Z	P<.0005 +	.137mg	.307mg	0/48	0/53	1/51	0/48	0/50	3/53	3/52	35/65
cvx sqc ae	.311mg *	P<.0005 +	.205mg	.512mg	1/68	0/72	1/67	0/68	1/68	2/72	9/64	23/72
mgl adb ae	.476mg *	P<.0005 +	.259mg	1.29mg	1/58	1/62	4/62	4/57	3/57	6/62	4/59	16/67
cvx ado ae	1.28mg *	P<.0005 +	.605mg	3.50mg	0/63	0/71	0/66	0/66	0/68	1/71	2/64	6/70
vag sqc ae	1.31mg *	P<.003	.550mg	10.6mg	0/65	0/71	0/64	2/65	1/68	1/71	4/64	4/70
mgl ado ae	1.88mg *	P<.004 +	.718mg	19.3mg	0/58	0/62	1/62	0/57	0/57	1/62	1/59	4/67
pit adc ae	5.10mg *	P<.2	1.26mg	n.s.s.	0/48	0/53	0/51	0/48	0/50	1/53	0/52	1/65
ute adc ae	5.32mg *	P<.3	1.19mg	n.s.s.	0/63	0/71	0/66	2/66	0/68	0/71	2/64	1/70
2157 M m bcn eat 28m29 1936n					0	600.ng	1.20ug	2.40ug	4.80ug	19.2ug	38.4ug	76.8ug
tes ict aes	21.5ug Z	P<.0005 +	17.0ug	27.2ug	0/72	2/70	2/64	3/68	2/71	40/69	65/70	69/69
pit ade aes	.171mg Z	P<.0005 +	95.3ug	.373mg	0/50	0/52	1/47	0/46	0/46	10/50	5/40	(5/56)
2158 M m c3c eat 24m24 109m					0	30.0ug	60.0ug					Okey;jnci,40,225-230;1968
mgl car er	35.9ug *	P<.0005 +	27.9ug	46.9ug	0/78	48/92	58/94					
2159 M m c3c eat 24m24 109n					0	30.0ug	60.0ug					
mgl car er	42.1ug \	P<.0005 +	27.7ug	68.1ug	0/78	34/88	(35/92)					
2160 M m c3c eat 24m24 109o					0	30.0ug	60.0ug					
mgl car er	78.9ug *	P<.0005 +	57.1ug	.113mg	0/78	26/93	32/89					
2161 M f c3h eat 85w85 106a					0	813.ng	1.63ug	3.25ug	6.50ug	13.0ug	65.0ug	.130mg Gass; jnci,33,971-977;1964
mgl car Lr	29.2ug *	P<.0005	19.4ug	48.1ug	40/121	27/56	26/60	26/60	36/68	42/64	50/59	50/58
2162 M f c3h eat 24m24 1131					0	32.5ug						Gass;ircs,5,477;1977
mgl adc Lr	26.0ug	P<.0005	15.7ug	55.6ug	16/64	45/66						
2163 M f c3j eat 52w52 1468m					0	1.30ug	13.0ug	65.0ug				Highman;jept,4,81-95;1980/pers.comm.
mgl adc ek	82.5ug *	P<.03	30.2ug	n.s.s.	2/43	0/29	3/35	6/41				
2164 M f c3j eat 78w78 1468n					0	1.30ug	13.0ug					
ova tua ek	22.2ug *	P<.3	5.68ug	n.s.s.	2/14	5/24	6/18					
mgl adc ek	no dre	P=1.	11.8ug	n.s.s.	1/13	7/22	2/16					
2165 M f c3j eat 24m24 1468o					0	1.30ug	13.0ug	65.0ug				
mgl adc ek	14.2mg *	P<1.	35.5ug	n.s.s.	4/24	10/38	3/9	1/5				
ova tua ek	no dre	P=1.	35.7ug	n.s.s.	12/24	19/40	7/11	2/6				
2166 M f c3v eat 25m25 1852m					0	83.2ug						Greenman;jnci,77,891-898;1986/pers.comm.
mgl mix e	24.7ug	P<.0005 +	19.0ug	32.3ug	4/73	167/182						
mgl adb e	30.2ug	P<.0005	23.7ug	38.9ug	2/73	158/182						
mgl ada e	2.63mg	P<.5	.673mg	n.s.s.	2/73	9/182						
liv ade e	no dre	P=1.	3.29mg	n.s.s.	3/77	0/181						
lun act e	no dre	P=1.	1.97mg	n.s.s.	5/75	3/182						
liv adc e	no dre	P=1.	2.93mg	n.s.s.	10/77	1/181						
2167 M f c3v eat 26m26 1852n					0	83.2ug						
mgl mix e	42.7ug	P<.0005 +	33.7ug	55.3ug	4/73	151/189						
mgl adb e	43.4ug	P<.0005	34.3ug	55.6ug	2/73	149/189						
--- mso e	.928mg	P<.003	.490mg	4.06mg	0/77	13/189						
ute ena e	2.05mg	P<.05	.836mg	n.s.s.	0/77	6/189						
cvu adc e	2.47mg	P<.07	.936mg	n.s.s.	0/77	5/189						
liv adc e	no dre	P=1.	2.24mg	n.s.s.	10/77	5/188						
liv ade e	no dre	P=1.	3.74mg	n.s.s.	3/77	0/188						
lun act e	no dre	P=1.	1.71mg	n.s.s.	5/75	5/189						
mgl ada e	no dre	P=1.	2.13mg	n.s.s.	2/73	2/189						
2168 M f c3v eat 29m29 1852o					0	83.2ug						
mgl mix e	87.2ug	P<.0005 +	67.3ug	.118mg	4/73	117/185						
mgl adb e	95.6ug	P<.0005	73.9ug	.128mg	2/73	109/185						
--- mso e	.520mg	P<.0005	.331mg	.932mg	0/77	28/191						
cvu adc e	1.17mg	P<.004	.616mg	5.24mg	0/77	13/191						
ute ena e	1.71mg	P<.02	.804mg	n.s.s.	0/77	9/191						
mgl ada e	2.10mg	P<.3	.737mg	n.s.s.	2/73	12/185						
liv adc e	no dre	P=1.	1.85mg	n.s.s.	10/77	10/191						
liv ade e	no dre	P=1.	2.05mg	n.s.s.	3/77	4/191						
lun act e	no dre	P=1.	1.70mg	n.s.s.	5/75	7/191						
2169 M f c3v eat 29m29 1852r					0	83.2ug						
mgl mix e	.115mg	P<.0005 +	86.3ug	.164mg	4/73	96/182						
mgl adb e	.118mg	P<.0005	89.3ug	.163mg	2/73	92/182						
--- mso e	.487mg	P<.0005	.312mg	.860mg	0/77	29/192						
cvu adc e	1.66mg	P<.02	.783mg	n.s.s.	0/77	9/192						
ute ena e	1.87mg	P<.02	.849mg	n.s.s.	0/77	8/192						
mgl ada e	4.39mg	P<.5	1.04mg	n.s.s.	2/96	7/182						
liv adc e	no dre	P=1.	1.81mg	n.s.s.	10/77	10/192						
liv ade e	no dre	P=1.	2.00mg	n.s.s.	3/77	4/192						
lun act e	no dre	P=1.	1.00mg	n.s.s.	5/75	12/192						
2170 M f c7b eat 34m37 1936o					0	650.ng	1.30ug	2.60ug	5.20ug	20.8ug	41.6ug	83.2ug Greenman; jtxe,29,269-278;1990/1988
pit ade aes	38.7ug *	P<.0005 +	29.6ug	51.9ug	4/55	6/55	10/54	14/55	19/63	50/67	54/64	59/64
cvx sqc aes	1.98mg *	P<.0005 +	.933mg	5.40mg	0/71	0/68	0/71	0/67	0/68	0/72	4/72	5/72
pit adc aes	2.01mg *	P<.03	.765mg	n.s.s.	0/55	0/55	0/54	1/55	2/63	2/67	5/64	2/64
mgl adb aes	no dre	P=1. +	.647mg	n.s.s.	0/56	0/54	4/58	4/61	5/64	5/61	1/65	(0/61)
thy fca aes	no dre	P=1.	1.26mg	n.s.s.	1/43	1/45	1/50	0/49	1/50	4/54	2/61	0/42
2171 M m c7b eat 35m39 1936o					0	600.ng	1.20ug	2.40ug	4.80ug	19.2ug	38.4ug	76.8ug
tes ict aes	40.8ug Z	P<.0005 +	32.4ug	51.9ug	0/72	1/66	0/71	1/70	1/65	37/67	70/71	65/67
pit ade aes	72.2ug Z	P<.0005 +	53.5ug	.101mg	1/52	1/49	1/58	2/53	3/47	32/60	36/64	(24/57)
pit adc aes	no dre	P=1.	1.04mg	n.s.s.	0/52	0/49	0/58	1/53	0/47	8/60	0/64	0/57
2172 M f cb6 eat 27m33 1936m					0	650.ng	1.30ug	2.60ug	5.20ug	20.8ug	41.6ug	83.2ug
pit ade aes	25.9ug *	P<.0005 +	17.9ug	39.3ug	21/57	22/60	21/65	32/63	49/65	46/53	59/62	58/62
pit adc aes	no dre	P=1.	1.65mg	n.s.s.	1/57	1/60	4/65	0/63	3/65	1/53	0/62	2/62
thy fct aes	no dre	P=1. +	.504mg	n.s.s.	13/64	11/56	10/51	10/55	16/61	14/48	4/60	(0/50)
2173 M m cb6 eat 29m36 1936m					0	600.ng	1.20ug	2.40ug	4.80ug	19.2ug	38.4ug	76.8ug
pit ade aes	17.6ug Z	P<.0005 +	13.3ug	23.7ug	0/52	2/57	3/57	13/59	21/59	51/64	(39/62	22/43)

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf									Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc					NCI/NTPPathology
thy fct aes	50.0ug Z	P<.0005	+	32.7ug 84.1ug	2/48	0/51	1/47	3/48	6/51	27/54	(3/58	0/43)	
tes ict aes	.257mg Z	P<.0005	+	.155mg .489mg	0/70	1/71	0/66	0/69	1/69	3/64	17/61	(3/52)	
pit adc aes	1.42mg *	P<.0005		.592mg 6.74mg	0/52	0/57	1/57	0/59	1/59	0/64	2/62	5/43	
2174 M f cbj eat 52w52 1468r					0	1.30ug	13.0ug	65.0ug					Highman;jept,4,81-95;1980/pers.comm.
mgl tum ek	no dre	P=1.		2.06ug n.s.s.	0/17	0/38	0/18	0/30					
2175 M f cbj eat 78w78 1468s					0	1.30ug	13.0ug	65.0ug					
mgl adc ek	.295mg *	P<.04		89.2ug n.s.s.	0/31	0/40	1/33	2/29					
ova tua ek	.329mg *	P<.3		70.9ug n.s.s.	0/34	5/42	3/34	4/31					
2176 M f cbj eat 24m24 1468t					0	1.30ug	13.0ug	65.0ug					
ova tua ek	.597mg *	P<.8		48.1ug n.s.s.	9/29	10/31	12/36	4/11					
2177 M f cbj eat 30m30 1468u					0	1.30ug							
ova tua ek	no dre	P=1.		2.14ug n.s.s.	4/11	3/12							
mgl adc ek	no dre	P=1.		3.54ug n.s.s.	3/11	1/12							
2178 R f cdr eat 21m24 108					0	20.0ug	.200mg						Gibson;txap,11,489-510;1967
liv hpt aes	.130mg \	P<.1	-	32.0ug n.s.s.	0/20	2/20	(0/20)						
2179 R m cdr eat 21m24 108					0	20.0ug	.200mg						
liv tum aes	no dre	P=1.	-	74.9ug n.s.s.	0/20	0/20	0/20						
2180 R m cdr eat 66w66 333					0	.160mg							Newberne;aenh,19,489-498;1969
pit cra	.114mg	P<.002	+	53.3ug .391mg	0/20	9/28							
liv nod	.390mg	P<.07		.118mg n.s.s.	0/20	3/28							
adr coa	.390mg	P<.07	+	.118mg n.s.s.	0/20	3/28							
liv car	1.21mg	P<.3		.198mg n.s.s.	0/20	1/28							
2181 R f sda gav 52w52 2136					0	10.0mg							Williams;clet,68,193-198;1993/pers.comm.
liv hpc	4.80mg	P<.04	+	1.44mg n.s.s.	0/10	3/10							
pit ade	7.68mg	P<.09	+	1.88mg n.s.s.	0/10	2/10							
liv hpa	16.3mg	P<.3		2.64mg n.s.s.	0/10	1/10							
N,N'-DIETHYLTHIOUREA 105-55-5													
2182 M f b6c eat 24m24 TR149 :					0	32.2mg	64.3mg						
TBA MXB	no dre	P=1.	-	102.mg n.s.s.	11/20	23/50	15/50						
liv MXB	687.mg *	P<.3		208.mg n.s.s.	0/20	1/50	2/50						liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		472.mg n.s.s.	1/20	1/50	0/50						lun:a/a,a/c.
2183 M m b6c eat 24m24 TR149 :					0	29.8mg	59.4mg						
TBA MXB	no dre	P=1.	-	77.7mg n.s.s.	8/19	21/50	23/50						
liv MXB	no dre	P=1.		94.1mg n.s.s.	5/19	7/50	(3/50)						liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		163.mg n.s.s.	2/19	4/50	6/50						lun:a/a,a/c.
2184 R f f34 eat 24m24 TR149 :					0	6.20mg	12.4mg						
thy MXA	23.8mg *	P<.0005	c	14.2mg 55.0mg	0/20	4/50	17/50						thy:fca,fcc.
thy fcc	57.9mg *	P<.008	c	27.3mg 774.mg	0/20	1/50	8/50						
TBA MXB	21.5mg *	P<.3		6.90mg n.s.s.	13/20	33/50	41/50						
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50						liv:hpa,hpc,nnd.
2185 R m f34 eat 24m24 TR149 :					0	5.00mg	9.90mg						
thy MXA	24.3mg /	P<.0005	c	13.5mg 50.0mg	0/20	1/50	15/50						thy:fca,fcc.
thy fcc	33.6mg *	P<.003	c	17.3mg 136.mg	0/20	1/50	11/50						
TBA MXB	12.9mg *	P<.04		6.15mg n.s.s.	5/20	23/50	31/50						
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50						liv:hpa,hpc,nnd.
2186 R m f3d eat 52w52 2024					0	8.00mg							Hasegawa;carc,12,1515-1518;1991/pers.comm.
thy fcc r	28.1mg	P<.3		4.57mg n.s.s.	0/20	1/21							
liv tum r	no dre	P=1.		8.66mg n.s.s.	0/20	0/21							
2-(DIFLUOROMETHYL)-DL-ORNITHINE 70052-12-9													
2187 R f cdr gav 52w52 2194					0	400.mg	800.mg	1.60gm					Crowell;faat,22,341-354;1994/pers.comm.
liv tum	no dre	P=1.		294.mg n.s.s.	0/25	0/25	0/25	0/25					
2188 R m cdr gav 52w52 2194					0	400.mg	800.mg	1.60gm					
liv tum	no dre	P=1.		294.mg n.s.s.	0/25	0/25	0/25	0/25					
2189 R m wis eat 70w70 2548					0	20.0mg	80.0mg						Tanakamaru;clet,120,95-100;1997
stg tum e	no dre	P=1.	-	14.9mg n.s.s.	0/10	0/10	0/10						
1,2-DIFORMYLHYDRAZINE 628-36-4													
2190 M f swa wat 83w83 491					0	4.00gm							Toth;zkko,92,11-16;1978
lun ade e	561.mg	P<.0005		307.mg 987.mg	10/100	48/50							
lun mix e	571.mg	P<.0005	+	310.mg 1.02gm	15/100	48/50							
lun adc e	2.17gm	P<.0005		1.33gm 3.98gm	6/100	29/50							
liv hpt e	7.82gm	P<.07	-	1.26gm n.s.s.	0/19	1/5							
liv mix e	89.2gm	P<.8		7.47gm n.s.s.	3/46	3/36							
2191 M m swa wat 83w83 491					0	3.33gm							
lun ade e	779.mg	P<.0005		469.mg 1.38gm	17/98	41/47							
lun mix e	806.mg	P<.0005	+	479.mg 1.48gm	22/98	41/47							
lun adc e	4.53gm	P<.0005		2.25gm 14.5gm	6/98	15/47							
liv mix e	8.14gm	P<.02		2.86gm n.s.s.	3/69	6/30							
liv hpt e	11.3gm	P<.02	-	3.62gm n.s.s.	1/69	4/30							
DIFTALONE 21626-89-1													
2192 M f bld eat 19m28 1638					0	26.2mg	52.4mg	105.mg					Della Porta;zkko,108,308-311;1984
liv ang e	852.mg *	P<.002	+	386.mg 2.95gm	0/38	0/43	1/45	7/43					
liv hpa e	1.15gm *	P<.009	+	471.mg 39.9gm	0/38	1/43	0/45	5/43					
lun mix e	269.mg *	P<.04	-	118.mg n.s.s.	8/38	13/43	19/45	18/43					
liv hpc e	3.54gm *	P<.08	+	871.mg n.s.s.	0/38	0/43	0/45	2/43					
liv agm e	7.13gm *	P<.3		1.16gm n.s.s.	0/38	0/43	0/45	1/43					
2193 M m bld eat 19m28 1638					0	24.2mg	48.4mg	96.8mg					
liv ang e	879.mg Z	P<.0005	+	398.mg 2.78gm	0/40	0/48	0/50	8/48					
liv agm e	1.37gm Z	P<.03	+	507.mg n.s.s.	1/40	0/48	0/50	6/48					
lun mix e	412.mg *	P<.3	-	122.mg n.s.s.	13/40	19/48	26/50	21/48					
liv hpa e	no dre	P=1.		563.mg n.s.s.	3/40	5/48	2/50	4/48					
liv hpc e	no dre	P=1.		847.mg n.s.s.	2/40	1/48	3/50	1/48					

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
DIGLYCIDYL RESORCINOL ETHER, TECHNICAL GRADE 101-90-6								
2194 M f b6c gav 24m24 TR257 :				0	35.0mg	70.1mg		
sto MXA s	17.9mg	* P<.0005	c 11.9mg 27.9mg	0/50	17/50	33/50		sto:pas,sqc,sqp.
sto sqc s	36.3mg	* P<.0005	c 23.1mg 59.8mg	0/50	12/50	23/50		
sto MXA s	48.2mg	* P<.0005	c 25.4mg 113.mg	0/50	5/50	10/50		sto:pas,sqp.
liv hpc s	221.mg	* P<.02	74.9mg n.s.s.	0/50	1/50	3/50		S
TBA MXB s	32.3mg	* P<.007	15.5mg 484.mg	28/50	27/50	38/50		
liv MXB s	169.mg	* P<.06	58.0mg n.s.s.	3/50	1/50	7/50		liv:hpa,hpc,nnd.
lun MXB s	4.79gm	* P<1.	112.mg n.s.s.	3/50	3/50	2/50		lun:a/a,a/c.
2195 M m b6c gav 24m24 TR257 :				0	35.0mg	70.4mg		
sto MXA s	37.8mg	* P<.0005	c 26.5mg 56.5mg	0/50	17/50	33/50		sto:pas,sqc,sqp.
sto sqc s	55.5mg	* P<.0005	c 37.4mg 88.8mg	0/50	14/50	25/50		
sto MXA s	145.mg	* P<.0005	c 78.0mg 423.mg	0/50	4/50	10/50		sto:pas,sqp.
TBA MXB s	36.6mg	\ P<.2	12.6mg n.s.s.	31/50	40/50	(41/50)		
liv MXB s	84.7mg	\ P<.3	24.7mg n.s.s.	13/50	18/50	(11/50)		liv:hpa,hpc,nnd.
lun MXB s	1.35gm	* P<.8	156.mg n.s.s.	6/50	2/50	8/50		lun:a/a,a/c.
2196 R f f34 gav 24m24 TR257 :				0	17.7mg	35.4mg		
sto MXB s	4.47mg	* P<.0005	2.88mg 7.26mg	0/50	38/50	4/50		sto:sqc,sqp. C
sto sqc s	5.10mg	* P<.0005	c 3.23mg 8.51mg	0/50	34/50	3/50		
sto sqp s	45.5mg	* P<.0005	c 19.4mg 141.mg	0/50	7/50	1/50		
TBA MXB s	8.53mg	* P<.004	4.09mg 64.0mg	46/50	41/50	6/50		
liv MXB s	no dre	P=1.	66.5mg n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
2197 R f f34 gav 24m24 TR257a :				0	8.45mg			
for MXB	3.53mg	P<.0005	2.36mg 5.59mg	0/50	38/50			for:sqc,sqp. C
for sqc	5.93mg	P<.0005	c 3.72mg 10.3mg	0/50	27/50			
for sqp	8.95mg	P<.0005	c 5.20mg 17.3mg	0/50	19/50			
TBA MXB	16.0mg	P<.4	3.84mg n.s.s.	45/50	49/50			
liv MXB	174.mg	P<.6	24.5mg n.s.s.	2/50	3/50			liv:hpa,hpc,nnd.
2198 R m f34 gav 23m24 TR257 :				0	17.7mg	35.7mg		
tes ict a	2.35mg	/ P<.0005	1.33mg 4.84mg	47/50	39/50	11/50		S
sto MXB a	2.89mg	* P<.0005	1.61mg 5.01mg	0/50	45/50	10/50		sto:sqc,sqp. C
sto sqc a	3.06mg	* P<.0005	c 1.67mg 5.54mg	0/50	38/50	4/50		
pit adn a	12.2mg	* P<.008	4.25mg 446.mg	17/50	8/50	2/50		S
sto sqp a	24.7mg	* P<.0005	c 14.5mg 45.0mg	0/50	17/50	6/50		
TBA MXB a	2.43mg	* P<.0005	1.41mg 4.70mg	39/50	47/50	11/50		
liv MXB a	114.mg	* P<.3	14.0mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
2199 R m f34 gav 24m24 TR257a :				0	8.49mg			
for MXB	2.33mg	P<.0005	1.55mg 3.66mg	0/50	44/50			for:sqc,sqp. C
for sqc	2.73mg	P<.0005	c 1.79mg 4.38mg	0/50	39/50			
for sqp	8.16mg	P<.0005	c 4.42mg 17.1mg	0/50	16/50			
TBA MXB	4.61mg	P<.006	2.19mg 61.9mg	40/50	49/50			
liv MXB	640.mg	P<.9	29.7mg n.s.s.	1/50	1/50			liv:hpa,hpc,nnd.
5,6-DIHYDRO-5-AZACYTIDINE (DHAC) 62488-57-7								
2200 R m f34 ipj 52w52 1906				0	21.4mg			Carr;bjca,57,395-402;1988
liv tum e	no dre	P=1.	9.94mg n.s.s.	0/49	0/9			
tba tum e	20.7mg	P<.5	3.21mg n.s.s.	10/49	3/9			
1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE 33389-33-2								
2201 R f sda eat 46w66 1390				0	17.4mg			Cohen;jnci,57,277-282;1976
mgl adc e	13.3mg	P<.0005	5.76mg 48.5mg	2/84	8/25			
tba mix e	1.53mg	P<.0005	+ .647mg 3.36mg	6/84	24/25			
3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE (N-nitroso-3,6-dihydrooxazine-1,2) 3276-41-3								
2202 R b sda wat 20m23 1417				0	33.1mg			Wiessler;zkko,79,114-117;1973
liv hpt	417.mg	P<.3	- 67.9mg n.s.s.	0/20	1/20			
tba mal	90.6mg	P<.07	+ 29.7mg n.s.s.	1/20	5/20			
tba mix	110.mg	P<.3	28.5mg n.s.s.	3/20	6/20			
3,4-DIHYDROCOUMARIN 119-84-6								
2203 M f b6c gav 24m24 TR423 :				0	141.mg	282.mg	564.mg	
--- MXA	4.81gm	* P<.007	1.82gm 67.5gm	0/51	0/50	1/51	4/52	---:hem,hes. S
--- hes	6.14gm	* P<.009	2.11gm 169.gm	0/51	0/50	0/51	4/52	S
liv MXA	723.mg	* P<.02	p 334.mg n.s.s.	13/51	21/50	25/51	24/52	liv:hpa,hpc.
liv hpa	790.mg	* P<.03	p 352.mg n.s.s.	10/51	20/50	22/51	20/52	
TBA MXB	541.mg	* P<.02	249.mg n.s.s.	24/51	36/50	36/51	38/52	
liv MXB	723.mg	* P<.02	334.mg n.s.s.	13/51	21/50	25/51	24/52	liv:hpa,hpb,hpc.
lun MXB	96.1gm	* P<1.	1.83gm n.s.s.	2/51	6/50	1/51	3/52	lun:a/a,a/c.
2204 M m b6c gav 24m24 TR423 :				0	141.mg	282.mg	565.mg	
--- MXA #	3.78gm	* P<.006	- 1.63gm 39.0gm	0/50	0/51	3/51	4/50	---:mlh,mlm,mlp,mly. S
lun a/a	596.mg	Z P<.05	252.mg n.s.s.	8/50	15/51	15/51	(10/50)	S
--- MXA	3.32gm	* P<.02	1.50gm 451.gm	0/50	1/51	3/51	4/50	---:hcs,mlh,mlp,mly. S
TBA MXB	1.40gm	* P<.5	314.mg n.s.s.	42/50	40/51	44/51	44/50	
liv MXB	2.89gm	* P<.7	423.mg n.s.s.	36/50	30/51	40/51	34/50	liv:hpa,hpb,hpc.
lun MXB	3.26gm	* P<.5	653.mg n.s.s.	9/50	18/51	16/51	13/50	lun:a/a,a/c.
2205 R f f34 gav 24m24 TR423 :				0	106.mg	210.mg	422.mg	
amd MXA #	538.mg	Z P<.03	- 242.mg n.s.s.	1/50	7/51	6/50	(4/51)	amd:pbb,pob. S
TBA MXB	3.18gm	* P<.9	214.mg n.s.s.	46/50	43/51	48/50	39/51	
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/51	0/50	0/51	liv:hpa,hpb,hpc.
2206 R m f34 gav 24m24 TR423 :				0	106.mg	212.mg	423.mg	
tes ica s	70.6mg	* P<.0005	41.0mg 164.mg	43/51	39/50	39/50	42/50	S
kid rua s	3.87gm	* P<.08	p 1.08gm n.s.s.	0/51	1/50	0/50	2/50	
kid tcc s	11.8gm	* P<.07	e 2.90gm n.s.s.	0/51	0/50	0/50	2/50	
TBA MXB s	143.mg	* P<.005	66.8mg 1.53gm	43/51	39/50	32/50	29/50	
liv MXB s	1.38gm	* P<.02	405.mg n.s.s.	0/51	1/50	2/50	2/50	liv:hpa,hpb,hpc.
2207 R m f34 gav 24m24 TR423 with step				0	106.mg	212.mg	423.mg	
kid rua s	2.97gm	* P<.02	p 1.26gm n.s.s.	1/51	1/50	3/50	6/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2208 R m f34 gav 15m24 TR423a :					0	266.mg			
tes ica	51.7mg	P<.006	19.8mg	730.mg	43/51	16/20			S
ski bca	378.mg	P<.002	109.mg	3.03gm	0/51	3/20			S
ski MXA	258.mg	P<.02	60.8mg	n.s.s.	2/51	3/20			ski:bca,ker,sqp. S
ski fib	403.mg	P<.04	73.8mg	n.s.s.	1/51	2/20			S
kid rua	no dre	P=1.	n.s.s.	n.s.s.	0/51	0/20			
TBA MXB	186.mg	P<.3	40.2mg	n.s.s.	43/51	10/20			
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/51	0/20			liv:hpa,hpb,hpc.
2209 R m f34 gav 15m24 TR423a : with step					0	266.mg			
kid rua	408.mg	P<.04	63.9mg	n.s.s.	1/51	2/20			S
2210 R m f34 gav 9m24 TR423b :					0	159.mg			
kid rua	no dre	P=1.	n.s.s.	n.s.s.	0/51	0/20			
ski bca	no dre	P=1.	n.s.s.	n.s.s.	0/51	0/20			
TBA MXB	1.37gm	P<1.	49.7mg	n.s.s.	43/51	14/20			
liv MXB	819.mg	P<.09	133.mg	n.s.s.	0/51	1/20			liv:hpa,hpb,hpc.
2211 R m f34 gav 9m24 TR423b : with step					0	159.mg			
kid rua	310.mg	P<.03	86.2mg	n.s.s.	1/51	3/20			S
DIHYDROSAFROLE 94-58-6									
2212 M f b6a orl 81w81 111					0	192.mg			Innes;ntis,1968/1969
sto pam evx	84.7mg	P<.0005	41.0mg	212.mg	0/15	11/18			
lun ade evx	739.mg	P<.6	128.mg	n.s.s.	2/15	4/18			
liv agm evx	1.40gm	P<.3	228.mg	n.s.s.	0/15	1/18			
liv hpt evx	no dre	P=1.	263.mg	n.s.s.	1/15	1/18			
tba mix evx	305.mg	P<.2	89.7mg	n.s.s.	2/15	6/18			
2213 M m b6a orl 81w81 111					0	179.mg			
liv hpt evx	117.mg	P<.0005 +	51.9mg	358.mg	0/18	8/17			
lun ade evx	323.mg	P<.2	89.7mg	n.s.s.	2/18	5/17			
lun mix evx	448.mg	P<.4	95.6mg	n.s.s.	3/18	5/17			
tba mix evx	86.6mg	P<.004	37.0mg	685.mg	3/18	11/17			
2214 M f b6c orl 81w81 111					0	192.mg			
lun ade evx	230.mg	P<.006 +	86.5mg	2.37gm	0/17	5/17			
liv hpt evx	no dre	P=1.	409.mg	n.s.s.	0/17	0/17			
tba mix evx	170.mg	P<.02	66.8mg	n.s.s.	1/17	7/17			
2215 M m b6c orl 81w81 111					0	179.mg			
liv hpt evx	90.0mg	P<.0005 +	40.6mg	352.mg	1/17	10/17			
lun ade evx	358.mg	P<.2	101.mg	n.s.s.	1/17	4/17			
tba mix evx	107.mg	P<.09	36.1mg	n.s.s.	7/17	12/17			
2216 R b osm eat 24m24 110					0	225.mg	450.mg		Hagan;txap,7,18-24;1965
eso mix	143.mg *	P<.0005 +	98.5mg	215.mg	0/20	37/50	15/20		
3,3'-DIHYDROXYBENZIDINE.2HCl 1592-36-5									
2217 M m icr eat 65w65 2594 :					0	120.mg			Osanai;jsol,52,179-201;1976
liv hpt	353.mg	P<.8 +	30.8mg	n.s.s.	7/34	9/20			
24R,25-DIHYDROXYVITAMIN D3 (SECALCIFEROL) 55721-11-4									
2218 R m sls eat 57w57 2406					0	.200mg			Ikezaki;canr,56,2767-2770;1996
stg adc e	no dre	P=1. -	.248mg	n.s.s.	0/20	0/20			
2219 R m sls eat 57w57 2607					0	.200mg			Ikezaki;jtxs,24,133-139;1999
amd phe Ce	.803mg	P<.3	.131mg	n.s.s.	0/20	1/20			
DIISONONYL PHTHALATE (DINP) 68515-48-0									
2220 M f b6c eat 18m24 2642m					0	780.mg			Butala;txst,36,173;1997/Babich 2002/pers.comm.
liv hpc e	3.34gm	P<.003 +	1.43gm	20.5gm	1/70	8/50			
2221 M f b6c eat 79w79 2642n					0	65.0mg	195.mg	520.mg	1.04gm
liv mix Cek	2.86gm *	P<.1	784.mg	n.s.s.	0/15	1/15	1/14	0/14	3/15
liv hpc Cek	5.24gm *	P<.2	1.08gm	n.s.s.	0/15	1/15	0/14	0/14	2/15
2222 M f b6c eat 24m24 2642o					0	65.0mg	195.mg	520.mg	1.04gm
liv mix Ce	1.44gm *	P<.0005 +	968.mg	2.49gm	3/70	5/68	10/68	11/67	33/70
liv hpc Ce	2.62gm *	P<.0005 +	1.62gm	5.29gm	1/70	2/68	5/68	7/67	19/70
2223 M m b6c eat 18m24 2642m					0	720.mg			
liv hpc e	4.10gm	P<.2	1.23gm	n.s.s.	10/70	12/50			
2224 M m b6c eat 79w79 2642n					0	60.0mg	180.mg	480.mg	960.mg
liv hpc Cek	1.46gm *	P<.01	596.mg	131.gm	0/15	0/14	1/13	2/14	3/15
liv mix Cek	1.46gm *	P<.2	447.mg	n.s.s.	1/15	1/14	4/13	3/14	4/15
2225 M m b6c eat 24m24 2642o					0	60.0mg	180.mg	480.mg	960.mg
liv mix Ce	1.59gm *	P<.0005 +	887.mg	5.21gm	16/70	13/67	18/66	28/65	31/70
liv hpc Ce	2.92gm *	P<.004 +	1.44gm	24.4gm	10/70	8/67	10/66	17/65	20/70
2226 R f f34 eat 24m24 2429					0	15.0mg	150.mg	300.mg	Lington;faat,36,79-89;1997
--- mnl e	458.mg *	P<.0005	268.mg	1.25gm	22/81	20/81	30/80	43/80	
liv mix e	81.3gm *	P<.9	3.47gm	n.s.s.	1/81	2/81	0/80	2/80	
2227 R f f34 eat 18m24 2643m					0	450.mg			Butala;txst,30,202;1996/Babich 2002/pers.comm.
--- mnl e	1.14gm	P<.05 +	460.mg	n.s.s.	17/65	24/55			
liv hpc e	14.3gm	P<.5	2.23gm	n.s.s.	1/65	2/55			
2228 R f f34 eat 79w79 2643n					0	300.mg	600.mg		
--- mnl ek	1.69gm *	P<.3	415.mg	n.s.s.	0/10	1/10	1/10		
liv hpa ek	3.44gm *	P<.3	559.mg	n.s.s.	0/10	0/10	1/10		
2229 R f f34 eat 24m24 2643o					0	25.0mg	75.0mg	300.mg	600.mg
--- mnl e	1.15gm *	P<.003 +	585.mg	7.87gm	17/65	16/49	9/50	30/65	29/65
liv mix Ce	4.57gm *	P<.003 +	2.06gm	25.8gm	1/65	1/49	0/50	2/65	8/65
liv hpc Ce	7.98gm *	P<.02 +	3.00gm	n.s.s.	1/65	0/49	0/50	1/65	5/65
2230 R m f34 eat 24m24 2429					0	12.0mg	120.mg	240.mg	Lington;faat,36,79-89;1997
--- mnl e	266.mg *	P<.0005	156.mg	735.mg	33/81	28/80	48/80	51/80	
liv mix e	9.76gm *	P<.5	1.83gm	n.s.s.	3/81	1/80	1/80	4/80	
2231 R m f34 eat 18m24 2643m					0	360.mg			Butala;txst,30,202;1996/Babich 2002/pers.comm.
--- mnl e	445.mg	P<.004 +	216.mg	3.21gm	22/65	31/50			
kid tuc e	2.96gm	P<.01 +	1.02gm	159.gm	0/65	4/50			
liv hpc e	9.74gm	P<.5	1.60gm	n.s.s.	1/65	2/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
2232 R m f34 eat 79w79 2643n				0	240.mg	480.mg			
liv hpc ek	2.75gm	* P<.3	448.mg n.s.s.	0/10	0/10	1/10			
liv mix ek	no dre	P=1.	508.mg n.s.s.	1/10	0/10	1/10			
2233 R m f34 eat 24m24 2643o				0	20.0mg	60.0mg	240.mg	480.mg	
liv mix Ce	1.54gm	* P<.0005 +	836.mg 4.74gm	5/65	3/50	2/50	7/65	18/65	
liv hpc Ce	2.64gm	* P<.0005 +	1.36gm 6.80gm	1/65	0/50	0/50	1/65	12/65	
kid tuc e	17.2gm	* P<.05 +	4.24gm n.s.s.	0/65	0/50	0/50	0/65	2/65	
--- mnl e	2.10gm	* P<.3 +	602.mg n.s.s.	22/65	23/50	21/50	32/65	30/65	
(R,R)-DILEVALOL.HCl 75659-08-4									
2234 R f sda eat 24m24 2174				0	50.0mg	100.mg	200.mg		Selan;faat,18,471-476;1992
hea ens e	no dre	P=1.	- 294.mg n.s.s.	1/97	0/50	0/50	0/50		
2235 R m sda eat 24m24 2174				0	50.0mg	100.mg	200.mg		
hea ens e	no dre	P=1.	- 1.25gm n.s.s.	0/100	4/49	0/50	0/49		
DIMETHADIONE (5,5-dimethyl-2,4-oxazolidinedione) 695-53-4									
2236 R m f34 eat 71w71 2109				0	11.2mg				Diwan;artx,66,413-422;1992
liv hct e	no dre	P=1.	16.1mg n.s.s.	0/27	0/15				
DIMETHOATE 60-51-5									
2237 M f b6c eat 80w93 TR4 :				0	28.0mg	55.4mg			
TBA MXB	no dre	P=1.	- 85.1mg n.s.s.	3/10	15/50	12/50			
liv MXB	no dre	P=1.	632.mg n.s.s.	1/10	0/50	0/50			liv:hpa,hpc,nnd.
lun MXB	222.mg	* P<.4	102.mg n.s.s.	0/10	4/50	5/50			lun:a/a,a/c.
2238 M m b6c eat 69w93 TR4 :				0	22.3mg	38.3mg			
TBA MXB	no dre	P=1.	- 48.0mg n.s.s.	6/7	11/50	(11/50)			
liv MXB	no dre	P=1.	51.0mg n.s.s.	4/7	8/50	(6/50)			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	101.mg n.s.s.	3/7	2/50	(1/50)			lun:a/a,a/c.
2239 R f osm eat 19m26 TR4 :				0	6.70mg	13.4mg			
TBA MXB sv	92.4mg	* P<.8	- 9.18mg n.s.s.	7/10	30/50	21/50			
liv MXB sv	126.mg	* P<.3	35.8mg n.s.s.	1/10	1/50	5/50			liv:hpa,hpc,nnd.
2240 R m osm eat 19m26 TR4 :				0	4.30mg	8.60mg			
TBA MXB sv	no dre	P=1.	- 9.62mg n.s.s.	7/10	23/50	24/50			
liv MXB sv	215.mg	* P<.8	39.5mg n.s.s.	0/10	1/50	1/50			liv:hpa,hpc,nnd.
2241 R b wis gav 24m24 2386				0	1.43mg	4.29mg	8.57mg		Stieglitz;ahae,52,70-76;1974/Gibel 1973/Gibel 1975
liv hpc e	215.mg	* P<.4	35.0mg n.s.s.	0/36	0/26	1/25	0/20		
tba mal e	22.1mg	* P<.004	10.4mg 183.mg	0/36	2/26	3/25	4/20		
tba ben e	no dre	P=1.	14.9mg n.s.s.	3/36	7/26	5/25	2/20		
DIMETHOXANE 828-00-2									
2242 R m wis wat 20m23 112				0	436.mg				Hoch-Ligeti;jnci,53,791-793;1974
liv hpt e	716.mg	P<.005 +	322.mg 4.88gm	0/14	8/25				
--- mlk e	6.77gm	P<.4 +	1.10gm n.s.s.	0/14	1/25				
kid ptc e	6.77gm	P<.4 +	1.10gm n.s.s.	0/14	1/25				
ski epc e	6.77gm	P<.4 +	1.10gm n.s.s.	0/14	1/25				
sub fbs e	6.77gm	P<.4 +	1.10gm n.s.s.	0/14	1/25				
--- lys e	29.8gm	P<1. +	946.mg n.s.s.	1/14	2/25				
lun tum e	no dre	P=1.	2.08gm n.s.s.	0/14	0/25				
tba mix e	419.mg	P<.004	203.mg 2.46gm	1/14	13/25				
DIMETHOXANE, COMMERCIAL GRADE 828-00-2									
2243 M f b6c gav 24m24 TR354 :				0	176.mg	352.mg			
TBA MXB	3.38gm	* P<.8	- 322.mg n.s.s.	32/50	26/50	33/50			
liv MXB	no dre	P=1.	1.39gm n.s.s.	8/50	5/50	4/50			liv:hpa,hpc,nnd.
lun MXB	10.4gm	* P<.8	1.15gm n.s.s.	4/50	1/50	5/50			lun:a/a,a/c.
2244 M m b6c gav 24m24 TR354 :				0	176.mg	352.mg			
for MXA	1.44gm	* P<.04 e	584.mg n.s.s.	2/50	3/50	8/50			for:sqc,sqp.
TBA MXB	1.82gm	* P<.7	237.mg n.s.s.	38/50	31/50	37/50			
liv MXB	1.18gm	* P<.3	355.mg n.s.s.	14/50	12/50	19/50			liv:hpa,hpc,nnd.
lun MXB	1.45gm	* P<.2	462.mg n.s.s.	8/50	4/50	13/50			lun:a/a,a/c.
2245 R f f34 gav 24m24 TR354 :				0	88.1mg	176.mg			
TBA MXB	no dre	P=1.	- 135.mg n.s.s.	41/50	37/50	32/50			
liv MXB	2.43gm	* P<.2	598.mg n.s.s.	0/50	1/50	1/50			liv:hpa,hpc,nnd.
2246 R m f34 gav 24m24 TR354 :				0	44.0mg	88.1mg			
TBA MXB	no dre	P=1.	- 58.7mg n.s.s.	39/50	36/50	32/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50			liv:hpa,hpc,nnd.
2,5-DIMETHOXY-4'-AMINOSTILBENE 5803-51-0									
2247 M f chi eat 77w90 381 :				0	234.mg	468.mg			Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
lun mix	152.mg	\ P<.09	- 39.1mg n.s.s.	5/15	6/16	(3/17)			
liv mix	no dre	P=1.	- n.s.s. n.s.s.	1/15	0/16	0/17			
tba mix	118.mg	\ P<.06	- 39.2mg n.s.s.	10/15	12/16	(10/17)			
2248 M m chi eat 77w90 381 :				0	227.mg	432.mg			
lun mix	95.9mg	\ P<.02	+ 41.6mg n.s.s.	3/14	11/17	(7/20)			
liv mix	329.mg	\ P<.04	111.mg n.s.s.	1/14	4/17	(3/20)			
tba mix	126.mg	\ P<.09	44.5mg n.s.s.	7/14	14/17	(10/20)			
2249 M m chi eat 77w90 381 : pool				0	227.mg	432.mg			
lun mix	115.mg	\ P<.0005 +	50.2mg 389.mg	23/99	11/17	(7/20)			
liv hpt	376.mg	\ P<.005 +	119.mg 5.61gm	7/99	4/17	(2/20)			
2250 R m cdr eat 47w51 381 : ()				0	3.20mg	6.40mg			
sto mix v	.721mg	* P<.0005 +	.361mg 1.69mg	0/16	6/23	8/24			
smi mix v	.866mg	* P<.0005 +	.369mg 2.82mg	0/16	3/23	6/24			
ear mix v	1.45mg	* P<.0005 +	.712mg 4.51mg	0/16	8/23	8/24			
liv mix v	2.61mg	* P<.02	.777mg n.s.s.	0/16	2/23	2/24			
tba mix v	.269mg	* P<.0005	.162mg .458mg	10/16	18/23	22/24			
2251 R m cdr eat 47w51 381 : () pool				0	3.20mg	6.40mg			
sto mix v	.721mg	* P<.0005 +	.361mg 1.61mg	2/111	6/23	8/24			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
smi mix v	.866mg	* P<.0005	+	.369mg 2.54mg	0/111	3/23	6/24		
ski mix v	1.48mg	* P<.0005	+	.601mg 4.01mg	0/111	4/23	5/24		
ear mix v	1.54mg	* P<.0005	+	.759mg 3.35mg	1/111	8/23	8/24		
2,4-DIMETHOXYANILINE.HCl 54150-69-5									
2252 M f b6c eat 24m24 TR171 :					0	325.mg	650.mg		
TBA MXB	986.mg	* P<.08	-	427.mg n.s.s.	5/20	25/50	24/50		
liv MXB	2.79gm	* P<.4		805.mg n.s.s.	3/20	12/50	11/50		liv:hpa,hpc,nnd.
lun MXB	50.6gm	* P<.9		3.01gm n.s.s.	1/20	1/50	2/50		lun:a/a,a/c.
2253 M m b6c eat 24m24 TR171 :					0	300.mg	600.mg		
TBA MXB	1.65gm	/ P<.3	-	521.mg n.s.s.	11/20	15/50	33/50		
liv MXB	1.39gm	/ P<.09		573.mg n.s.s.	7/20	9/50	27/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		1.03gm n.s.s.	4/20	6/50	(2/50)		lun:a/a,a/c.
2254 R f f34 eat 24m24 TR171 :					0	75.0mg	150.mg		
TBA MXB	no dre	P=1.	-	124.mg n.s.s.	16/20	31/50	(21/50)		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
2255 R m f34 eat 24m24 TR171 :					0	60.0mg	120.mg		
TBA MXB	no dre	P=1.	-	143.mg n.s.s.	11/20	28/50	25/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
3,3'-DIMETHOXYBENZIDINE-4,4'-DIISOCYANATE 91-93-0									
2256 M f b6c eat 18m24 TR128 :					0	1.67gm	3.33gm		
TBA MXB	32.8gm	* P<.8	-	4.03gm n.s.s.	6/20	14/50	13/50		
liv MXB	no dre	P=1.		24.2gm n.s.s.	1/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		18.6gm n.s.s.	3/20	2/50	1/50		lun:a/a,a/c.
2257 M m b6c eat 18m24 TR128 :					0	1.67gm	3.33gm		
TBA MXB	24.0gm	* P<.7	-	3.71gm n.s.s.	7/20	17/50	21/50		
liv MXB	12.1gm	* P<.2		4.87gm n.s.s.	1/20	8/50	10/50		liv:hpa,hpc,nnd.
lun MXB	87.9gm	* P<.9		6.79gm n.s.s.	2/20	8/50	7/50		lun:a/a,a/c.
2258 R f f34 orl 18m24 TR128 :					0	819.mg	1.64gm		
MXB MXB v	1.45gm	* P<.0005		869.mg 4.77gm	1/20	13/50	20/49		---:leu,lym; ute:esp. C
--- MXA v	2.28gm	* P<.004	c	1.25gm 16.1gm	1/20	8/50	15/49		---:leu,lym.
ute esp v	2.74gm	* P<.003	c	1.47gm 11.9gm	0/20	5/50	10/49		
MXA MXA v	2.59gm	\ P<.02	a	1.14gm n.s.s.	0/20	8/50	(6/49)		ear:sec,sqc,tri; zym:sec,sqc,tri.
TBA MXB v	773.mg	* P<.006		405.mg 8.45gm	10/20	40/50	44/49		
liv MXB v	17.1gm	* P<.2		4.21gm n.s.s.	0/20	0/50	2/49		liv:hpa,hpc,nnd.
2259 R m f34 orl 18m24 TR128 :					0	819.mg	1.64gm		
MXB MXB ev	742.mg	* P<.0005		498.mg 1.56gm	1/20	29/50	27/50	---:leu,lym; sft:ker; skb:bct,ker; skf:bct; ski:bct,ker, ppn,sea,seb,sqc,tri. C
--- MXA ev	1.27gm	* P<.0005	c	826.mg 2.97gm	0/20	18/50	16/50		---:leu,lym.
MXA MXA ev	1.33gm	* P<.002	c	775.mg 6.21gm	1/20	17/50	15/50	sft:ker; skb:bct,ker; skf:bct; ski:bct,ker,ppn,seb,sqc, tri.
MXA MXA ev	1.77gm	* P<.006	c	954.mg 17.9gm	1/20	12/50	12/50	sft:ker; skb:bct,ker; skf:bct; ski:bct,ker,ppn,sea,tri.
MXA sqc ev	7.01gm	* P<.02	a	3.07gm n.s.s.	0/20	2/50	6/50		ear:sqc; zym:sqc.
TBA MXB ev	809.mg	* P<.005		430.mg 7.28gm	10/20	42/50	38/50		
liv MXB ev	6.60gm	* P<.5		1.76gm n.s.s.	1/20	8/50	3/50		liv:hpa,hpc,nnd.
3,3'-DIMETHOXYBENZIDINE.2HCl 20325-40-0									
2260 M f bcn wat 78w78 1919m					0	4.00mg	8.00mg	16.0mg 32.0mg 63.0mg 126.mg	Schieferstein;jact,9,71-77; 1990/pers.comm.
hag ade kr	no dre	P=1.	-	243.mg n.s.s.	4/24	3/21	1/19	6/24 0/20 2/21 2/22	
hag car kr	no dre	P=1.	-	551.mg n.s.s.	0/24	1/21	0/19	0/24 0/20 0/21 0/22	
2261 M f bcn wat 26m26 1919n					0	4.00mg	8.00mg	16.0mg 32.0mg 63.0mg 126.mg	
hag ade r	no dre	P=1.	-	352.mg n.s.s.	1/25	3/27	3/26	3/22 6/28 3/24 2/26	
2262 M m bcn wat 78w78 1919m					0	3.33mg	6.67mg	13.3mg 26.7mg 52.5mg 105.mg	
hag ade kr	3.56gm	* P<.9	-	151.mg n.s.s.	2/20	3/22	2/21	3/19 0/23 1/20 3/20	
2263 M m bcn wat 26m26 1919n					0	3.33mg	6.67mg	13.3mg 26.7mg 52.5mg 105.mg	
hag ade r	no dre	P=1.	-	615.mg n.s.s.	2/26	4/25	4/25	3/27 4/26 4/30 0/28	
2264 M m icr eat 65w65 2594 :					0	120.mg			Osanai;jsol,52,179-201;1976
liv hpt	73.8mg	P<.3	+	21.4mg n.s.s.	7/34	11/17			
2265 R f f34 wat 91w93 TR372 :					0	4.57mg	9.71mg	18.9mg	
MXB MXB	1.19mg	* P<.0005		.844mg 1.72mg	9/60	37/45	67/75	53/60	cli:ade,anb,car,cnb; cvu:car,ppa; dsc:adc,adp; liv:hpc,nnd; mgl:adc; pal:sqc,sqp; phr:sqp; rec:adc,adp; ski:bca,bcc; ton:sqc,sqp; ute:ade,car; zym: ade,car,cnb. C
cli MXA	1.60mg	* P<.0005	c	1.12mg 2.39mg	7/60	27/45	48/75	41/60	cli:ade,anb,car,cnb.
cli MXA	2.62mg	* P<.0005		1.73mg 4.02mg	2/60	17/45	41/75	30/60	cli:car,cnb. S
mgl MXA	3.24mg	Z P<.0005		1.93mg 6.12mg	15/60	13/45	21/75	22/60	mgl:adc,ade,fba. S
cli MXA	3.84mg	* P<.0005		2.26mg 7.35mg	5/60	15/45	13/75	16/60	cli:ade,anb. S
mgl MXA	6.22mg	* P<.0005		2.91mg 24.8mg	14/60	11/45	9/75	6/60	mgl:ade,fba. S
--- mnl	6.71mg	* P<.003		2.98mg 51.2mg	21/60	15/45	12/75	4/60	S
zym MXA	6.74mg	* P<.0005	c	4.19mg 11.2mg	1/60	12/45	21/75	16/60	zym:ade,car,cnb.
mgl fba	7.05mg	* P<.002		3.09mg 44.0mg	14/60	11/45	9/75	4/60	S
mgl adc	7.70mg	Z P<.0005	c	4.23mg 14.0mg	1/60	2/45	14/75	20/60	
zym MXA	8.41mg	* P<.0005		4.92mg 15.3mg	1/60	10/45	17/75	13/60	zym:car,cnb. S
pit MXA	8.84mg	Z P<.002		3.83mg 47.8mg	15/60	9/45	5/75	8/60	pit:ade,pda. S
pit MXA	9.40mg	Z P<.003		3.97mg 66.1mg	17/60	9/45	5/75	8/60	pit:ade,pda,pdc. S
ski MXA	10.2mg	* P<.0005	c	4.47mg 29.6mg	0/60	4/45	3/75	2/60	ski:bca,bcc.
ute esp	11.6mg	* P<.002		4.90mg 62.8mg	6/60	8/45	7/75	5/60	S
ski bca	12.3mg	* P<.0005		5.10mg 38.6mg	0/60	3/45	3/75	2/60	S
MXA MXA	13.8mg	* P<.0005	c	5.69mg 50.3mg	2/60	2/45	6/75	5/60	pal:sqc,sqp; phr:sqp; ton:sqc,sqp.
MXA MXA	14.0mg	* P<.0005	c	5.69mg 47.3mg	0/60	4/45	2/75	2/60	cvu:car,ppa; ute:ade,car.
MXA MXA	15.8mg	* P<.0005		6.01mg 63.7mg	0/60	3/45	1/75	2/60	cvu:ppa; ute:ade. S
MXA sqp	16.6mg	* P<.002		6.07mg 107.mg	2/60	2/45	3/75	3/60	pal:sqp; ton:sqp. S
ton MXA	19.9mg	* P<.0005		7.17mg 106.mg	1/60	2/45	2/75	4/60	ton:sqc,sqp. S
zym ade	27.5mg	* P<.0005		11.6mg 94.6mg	0/60	3/45	4/75	3/60	S
liv MXA	33.3mg	Z P<.002	c	9.60mg 237.mg	0/60	1/45	0/75	3/60	liv:hpc,nnd.
MXA MXA	44.3mg	* P<.003	c	10.7mg 416.mg	0/60	1/45	1/75	3/60	dsc:adc,adp; rec:adc,adp.
MXA sqc	113.mg	* P<.01		40.3mg 8.26gm	0/60	0/45	3/75	2/60	pal:sqc; ton:sqc. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
pal MXA		45.3mg	* P<.04	10.6mg n.s.s.	1/60	0/45	4/75	1/60	pal:sqc,sqp. S
pal sqp		47.8mg	* P<.04	10.8mg n.s.s.	1/60	0/45	3/75	1/60	S
TBA MXB		1.09mg	Z P<.0005	.764mg 1.64mg	48/60	42/45	73/75	57/60	
liv MXB		33.3mg	Z P<.002	9.60mg 237.mg	0/60	1/45	0/75	3/60	liv:hpa,hpc,nnd.
2266 R m f34 wat 88w92 TR372 :					0	4.00mg	8.50mg	16.5mg	
tes MXA a		.612mg	Z P<.0005	.412mg .961mg	57/60	39/45	68/75	42/60	tes:iab,ica. S
MXB MXB a		.677mg	* P<.0005	.461mg 1.03mg	22/60	41/45	71/75	60/60	---:msb,msm; asc:adp; cec:muc; col:adc; dsc:adc, adp; duo:adc,muc; ilm:adc; jej:adc,muc; liv:hpc,nnd; pal:sqc; phr:sqp; pre:ade,anb,car,cnb; rec:adc, adp; ski:bca,bcc,sbr,sea,sqc,sqp; ton:sqc,sqp; zym:ade,anb,car,cnb. C
ski MXA a		.767mg	* P<.0005 c	.507mg 1.16mg	2/60	33/45	56/75	41/60	ski:bca,bcc,sbr,sea.
ski MXA a		.770mg	* P<.0005	.508mg 1.17mg	2/60	32/45	54/75	40/60	ski:bca,bcc. S
ski MXA a		.785mg	* P<.0005	.515mg 1.21mg	1/60	32/45	49/75	35/60	ski:bca,sea. S
ski bca a		.789mg	* P<.0005	.516mg 1.22mg	1/60	31/45	47/75	35/60	S
pre MXA a		1.78mg	Z P<.0005 c	1.06mg 3.19mg	16/60	12/45	33/75	29/60	pre:ade,anb,car,cnb.
ski MXA a		2.01mg	* P<.0005 c	1.20mg 3.29mg	0/60	13/45	28/75	22/60	ski:sqc,sqp.
amd MXA a		2.06mg	* P<.0005	1.18mg 4.09mg	14/60	17/45	23/75	9/60	amd:pbb,pob. S
amd MXA a		2.11mg	* P<.0005	1.22mg 4.24mg	15/60	18/45	23/75	9/60	amd:pbb,phm,pob. S
ski sqc a		2.35mg	Z P<.0005	1.38mg 3.92mg	0/60	9/45	24/75	21/60	S
--- mnl a		2.50mg	* P<.0005	1.23mg 7.45mg	19/60	17/45	17/75	4/60	S
zym MXA a		3.02mg	* P<.0005 c	1.65mg 5.21mg	0/60	10/45	25/75	30/60	zym:ade,anb,car,cnb.
pre MXA a		3.28mg	Z P<.0005	1.67mg 7.70mg	14/60	6/45	19/75	12/60	pre:ade,anb. S
MXA MXA a		4.22mg	* P<.0005 c	2.04mg 9.43mg	1/60	8/45	10/75	11/60	pal:sqc; phr:sqp; ton:sqc,sqp.
MXA sqp a		4.49mg	* P<.0005	2.11mg 10.6mg	1/60	7/45	10/75	9/60	phr:sqp; ton:sqp. S
pre MXA a		4.65mg	* P<.0005	2.28mg 9.77mg	2/60	6/45	15/75	19/60	pre:car,cnb. S
thy MXA a		4.70mg	* P<.0005	2.01mg 17.8mg	6/60	7/45	7/75	2/60	thy:cca,ccr. S
sub MXA a		5.19mg	* P<.0005	2.13mg 14.9mg	0/60	6/45	6/75	4/60	sub:fib,nfm. S
zym MXA a		5.84mg	* P<.0005	2.51mg 13.8mg	0/60	4/45	11/75	9/60	zym:ade,anb. S
sub MXA a		6.49mg	* P<.0005	2.51mg 25.8mg	2/60	6/45	6/75	5/60	sub:fbs,fib,nfm,sar. S
ski MXA a		6.50mg	* P<.0005	3.44mg 11.5mg	1/60	4/45	18/75	18/60	ski:bcc,sbr. S
ski bcc a		6.55mg	* P<.0005	3.46mg 11.7mg	1/60	4/45	18/75	17/60	S
ski sqp a		6.60mg	* P<.0005	2.81mg 16.4mg	0/60	5/45	7/75	5/60	S
zym MXA a		6.71mg	* P<.0005	3.25mg 11.7mg	0/60	7/45	14/75	21/60	zym:car,cnb. S
thy cca a		6.92mg	* P<.003	2.61mg 57.2mg	6/60	6/45	5/75	1/60	S
liv MXA a		7.80mg	* P<.0005 c	3.05mg 21.9mg	1/60	4/45	7/75	8/60	liv:hpc,nnd.
pal MXA a		8.21mg	* P<.0005	3.05mg 25.6mg	0/60	4/45	5/75	4/60	pal:sqc,sqp. S
ton MXA a		8.25mg	* P<.0005	3.39mg 23.6mg	1/60	4/45	5/75	8/60	ton:sqc,sqp. S
pal sqp a		8.35mg	* P<.0005	3.06mg 27.2mg	0/60	4/45	5/75	3/60	S
MXA MXA a		8.44mg	* P<.0005 c	3.04mg 27.0mg	0/60	4/45	7/75	5/60	duo:adc,muc; ilm:adc; jej:adc,muc.
ski ker a		9.13mg	* P<.0005	3.33mg 42.4mg	1/60	5/45	7/75	1/60	S
ton sqp a		9.16mg	* P<.0005	3.57mg 28.6mg	1/60	3/45	5/75	7/60	S
MXA MXA a		9.91mg	* P<.0005 c	3.90mg 23.1mg	0/60	1/45	8/75	8/60	asc:adp; cec:muc; col:adc; dsc:adc,adp; rec:adc, adp.
MXA asl a		10.9mg	* P<.0005 e	3.35mg 57.4mg	0/60	2/45	3/75	1/60	bra:asl; clb:asl; crb:asl; crl:asl.
liv nnd a		12.4mg	* P<.0005	4.43mg 30.2mg	0/60	3/45	7/75	6/60	S
MXA adp a		13.6mg	* P<.0005	4.44mg 42.8mg	0/60	1/45	4/75	5/60	asc:adp; dsc:adp; rec:adp. S
sub MXA a		13.6mg	* P<.0005	4.44mg 50.4mg	0/60	4/45	4/75	3/60	sub:fbs,fib. S
sub fib a		13.9mg	* P<.0005	4.46mg 57.2mg	0/60	4/45	4/75	2/60	S
ski MXA a		24.6mg	* P<.009	5.01mg 1.67gm	0/60	2/45	3/75	2/60	ski:sbr,sea. S
--- MXA a		27.4mg	* P<.002 c	7.62mg 165.mg	2/60	1/45	7/75	6/60	---:msb,msm.
MXA MXA a		38.0mg	* P<.002	10.5mg 194.mg	0/60	0/45	4/75	3/60	cec:muc; col:adc; dsc:adc; rec:adc. S
TBA MXB a		.565mg	Z P<.0005	.386mg .868mg	59/60	45/45	75/75	60/60	
liv MXB a		7.80mg	* P<.0005	3.05mg 21.9mg	1/60	4/45	7/75	8/60	liv:hpa,hpc,nnd.
5,7-DIMETHOXYCYCLOPENTENE[c]COUMARIN 1146-71-0									
2267 R m fis gav 52w87 1455					0	.512mg			Wogan;canr,31,1936-1942;1971
liv tum r	no dre	P=1.	-	.591mg n.s.s.	0/9	0/8			
5,7-DIMETHOXYCYCLOPENTENONE[2,3-c]COUMARIN 1150-37-4									
2268 R m fis gav 52w74 1455					0	.602mg			Wogan;canr,31,1936-1942;1971
liv tum r	no dre	P=1.	-	.566mg n.s.s.	0/9	0/9			
5,7-DIMETHOXYCYCLOPENTENONE[3,2-c]COUMARIN 1150-42-1									
2269 R m fis gav 52w87 1455					0	.512mg			Wogan;canr,31,1936-1942;1971
liv tum r	no dre	P=1.	-	.665mg n.s.s.	0/9	0/9			
5,6-DIMETHOXYSTERIGMATOCYSTIN 65176-75-2									
2270 R m ain eat 38w80 1889					0	.967mg			Mori;carc,9,1039-1042;1988
liv mix e	noTD50	P<.002	+	n.s.s. .364mg	0/10	8/8			
liv nnd e	noTD50	P<.002		n.s.s. .364mg	0/10	8/8			
liv hpc e	.400mg	P<.002		.142mg 1.94mg	0/10	5/8			
liv hms e	.566mg	P<.006		.188mg 5.90mg	0/10	4/8			
bon ost e	1.36mg	P<.06		.332mg n.s.s.	0/10	2/8			
O,O-DIMETHYL S-2(ACETYLAMINO)ETHYL DITHIOPHOSPHATE, TECHNICAL GRADE (Amiphos, DAEP) 13265-60-6									
2271 R f sda eat 24m24 2377					0	.160mg	.800mg	4.00mg	20.0mg 100.mg Hashimoto;phrm,6,1189-1205;1972
liv tum	no dre	P=1.	-	.528mg n.s.s.	0/20	0/20	0/20	0/20	0/20 0/20
2272 R m sda eat 24m24 2377					0	.128mg	.640mg	3.20mg	16.0mg 80.0mg
liv tum	no dre	P=1.	-	.422mg n.s.s.	0/20	0/20	0/20	0/20	0/20 0/20
N,N-DIMETHYL-4-AMINOAZOBENZENE (butter yellow) 60-11-7									
2273 P b rhe eat 5y20 2004 :					0	14.3mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
lun a/c Wjw	4.84mg	P<.02		.788mg n.s.s.	0/23	1/1			
tba mal Wjw	17.2mg	P<.3		1.98mg n.s.s.	4/74	1/3			
2274 R f wal eat 33w56 27					0	20.9mg			Kirby;jpat,59,1-18;1947
liv hpt fv	3.31mg	P<.002	+	1.12mg 16.3mg	0/8	5/7			
liv bdt fv	4.90mg	P<.006	+	1.60mg 56.0mg	0/8	4/7			
liv lcc fv	7.42mg	P<.03	+	2.18mg n.s.s.	0/8	3/7			

Chemical / Synonym / CAS number / Spe Strain Xpo+Xpt / Sex Route Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
N,N'-DIMETHYL-N,N'-DINITROSOPHTHALAMIDE 3851-16-9					
2275 R m wis gav 67w67 104	0	3.46mg			Argus;jnci,35,949-958;1965
liv tum ev no dre P=1. 8.28mg n.s.s.	0/9	0/28			
tba mix ev no dre P=1. - 5.45mg n.s.s.	1/9	1/28			
DIMETHYL HYDROGEN PHOSPHITE (DMHP) 868-85-9					
2276 M f b6c gav 24m24 TR287 :	0	70.1mg	140.mg		
liv hpa # 286.mg \ P<.005 - 117.mg 2.00gm	0/50	6/50	(3/50)		S
TBA MXB no dre P=1. 145.mg n.s.s.	37/50	30/50	32/50		
liv MXB 1.71gm * P<.6 331.mg n.s.s.	2/50	6/50	3/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 839.mg n.s.s.	4/50	3/50	1/50		lun:a/a,a/c.
2277 M m b6c gav 24m24 TR287 :	0	70.1mg	140.mg		
TBA MXB 864.mg * P<.7 - 124.mg n.s.s.	34/50	21/50	31/50		
liv MXB no dre P=1. 277.mg n.s.s.	19/50	10/50	13/50		liv:hpa,hpc,nnd.
lun MXB 2.43gm * P<.8 251.mg n.s.s.	12/50	7/50	11/50		lun:a/a,a/c.
2278 R f f34 gav 24m24 TR287 :	0	35.2mg	70.4mg		
lun a/c 600.mg * P<.04 e 207.mg n.s.s.	0/50	1/50	3/50		
for MXA h 1.27gm * P<.09 e 312.mg n.s.s.	0/50	0/50	2/50		for:sqc,sqp.
TBA MXB 183.mg * P<.5 42.8mg n.s.s.	36/50	38/50	38/50		
liv MXB 2.46gm * P<.3 401.mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
2279 R m f34 gav 24m24 TR287 :	0	70.4mg	141.mg		
MXB MXB s 105.mg / P<.0005 68.4mg 172.mg	0/50	2/50	31/50		for:sqc,sqp; lun:a/a,a/c,sqc. C
lun MXA s 139.mg / P<.0005 c 85.7mg 246.mg	0/50	1/50	24/50		lun:a/a,a/c.
lun a/c s 167.mg / P<.0005 c 98.8mg 311.mg	0/50	1/50	20/50		
for MXA s 577.mg * P<.002 c 248.mg 2.58gm	0/50	1/50	6/50		for:sqc,sqp.
lun a/a s 903.mg * P<.006 c 339.mg 8.99gm	0/50	0/50	5/50		
lun sqc s 951.mg * P<.006 c 358.mg 3.71gm	0/50	0/50	5/50		
for sqp s 990.mg * P<.03 c 342.mg n.s.s.	0/50	1/50	3/50		
for sqc s 1.42gm * P<.03 c 426.mg n.s.s.	0/50	0/50	3/50		
TBA MXB s 119.mg * P<.04 52.0mg n.s.s.	38/50	36/50	45/50		
liv MXB s no dre P=1. 1.34gm n.s.s.	3/50	0/50	0/50		liv:hpa,hpc,nnd.
DIMETHYL METHYLPHOSPHONATE (DMMP) 756-79-6					
2280 M f b6c gav 24m24 TR323 :	0	701.mg	1.40gm		
lun a/a as# 4.09gm * P<.04 - 1.41gm n.s.s.	1/50	5/50	1/50		S
TBA MXB as 851.mg * P<.02 382.mg n.s.s.	27/50	31/50	8/50		
liv MXB as 6.56gm * P<.4 1.40gm n.s.s.	3/50	5/50	0/50		liv:hpa,hpc,nnd.
lun MXB as 7.25gm * P<.3 1.69gm n.s.s.	3/50	5/50	1/50		lun:a/a,a/c.
2281 M m b6c gav 23m24 TR323 :	0	701.mg	1.43gm		
liv MXA as# 458.mg * P<.002 i 211.mg 2.42gm	17/50	21/50	4/50		liv:hpa,hpc. S
liv hpa as 563.mg * P<.003 242.mg 4.34gm	12/50	15/50	3/50		S
TBA MXB as 370.mg / P<.002 178.mg 1.95gm	34/50	27/50	10/50		
liv MXB as 458.mg * P<.002 211.mg 2.42gm	17/50	21/50	4/50		liv:hpa,hpc,nnd.
lun MXB as 7.27gm / P<.5 1.05gm n.s.s.	6/50	0/50	3/50		lun:a/a,a/c.
2282 R f f34 gav 24m24 TR323 :	0	350.mg	701.mg		
TBA MXB 868.mg * P<.3 - 280.mg n.s.s.	40/50	42/50	40/50		
liv MXB no dre P=1. n.s.s. n.s.s.	0/50	2/50	0/50		liv:hpa,hpc,nnd.
2283 R m f34 gav 24m24 TR323 :	0	350.mg	701.mg		
tes ict 169.mg * P<.0005 93.5mg 500.mg	41/50	39/50	39/50		S
amd MXA 306.mg * P<.0005 163.mg 899.mg	12/50	18/50	18/50		amd:phe,phm. S
MXA mnl 453.mg / P<.0005 227.mg 1.58gm	10/50	11/50	17/50		mul:mnl; spl:mnl. S
MXB MXB 520.mg * P<.0005 267.mg 1.18gm	0/50	9/50	6/50		k/p:tpp; kid:uac. P
k/p MXA 608.mg * P<.0005 292.mg 1.66gm	0/50	8/50	3/50		k/p:tcc,tpp. S
k/p tpp 700.mg * P<.0005 p 324.mg 2.07gm	0/50	7/50	3/50		
thy ccr 983.mg * P<.005 384.mg 9.77gm	1/50	4/50	4/50		S
tnv men 1.01gm * P<.0005 438.mg 3.03gm	0/50	4/50	6/50		S
MXA MXA 1.02gm * P<.005 415.mg 10.2gm	2/50	5/50	6/50		mul:men,msm; tnv:men. S
thy MXA 1.66gm * P<.004 591.mg 11.5gm	0/50	2/50	3/50		thy:fca,fcc. S
kid uac 2.24gm * P<.008 p 737.mg 44.7gm	0/50	2/50	3/50		
thy MXA 1.14gm * P<.04 398.mg n.s.s.	4/50	4/50	5/50		thy:cca,ccr. S
amd phm 2.02gm * P<.05 647.mg n.s.s.	0/50	4/50	0/50		S
TBA MXB 178.mg * P<.0005 97.5mg 549.mg	40/50	36/50	37/50		
liv MXB 1.63gm * P<.09 498.mg n.s.s.	1/50	4/50	1/50		liv:hpa,hpc,nnd.
DIMETHYL MORPHOLINOPHOSPHORAMIDATE 597-25-1					
2284 M f b6c gav 24m24 TR298 :	0	210.mg	420.mg		
TBA MXB s no dre P=1. - 493.mg n.s.s.	31/50	28/50	24/50		
liv MXB s no dre P=1. 2.18gm n.s.s.	7/50	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB s 17.6gm * P<.9 1.34gm n.s.s.	4/50	3/50	4/50		lun:a/a,a/c.
2285 M m b6c gav 24m24 TR298 :	0	105.mg	210.mg		
TBA MXB no dre P=1. - 247.mg n.s.s.	26/50	29/50	25/50		
liv MXB 1.27gm * P<.4 310.mg n.s.s.	11/50	13/50	15/50		liv:hpa,hpc,nnd.
lun MXB 3.90gm * P<.8 458.mg n.s.s.	6/50	8/50	7/50		lun:a/a,a/c.
2286 R f f34 gav 24m24 TR298 :	0	105.mg	210.mg	420.mg	
--- mnl s 788.mg * P<.02 p 362.mg n.s.s.	9/50	13/50	12/50	18/50	
TBA MXB s 774.mg * P<.3 229.mg n.s.s.	35/50	37/50	35/50	34/50	
liv MXB s 8.24gm * P<.2 2.01gm n.s.s.	0/50	0/50	1/50	1/50	liv:hpa,hpc,nnd.
2287 R m f34 gav 24m24 TR298 :	0	105.mg	210.mg	420.mg	
--- mnl 503.mg * P<.006 p 247.mg 6.51gm	14/50	21/50	19/50	25/50	
tes ict 283.mg * P<.04 124.mg n.s.s.	45/50	45/50	44/50	46/50	S
TBA MXB 283.mg * P<.04 122.mg n.s.s.	49/50	47/50	48/50	49/50	
liv MXB 2.82gm * P<.2 880.mg n.s.s.	1/50	3/50	3/50	3/50	liv:hpa,hpc,nnd.
4,6-DIMETHYL-2-(5-NITRO-2-FURYL)PYRIMIDINE 59-35-8					
2288 R f sda eat 42w59 1390	0	14.2mg			Cohen;jnci,57,277-282;1976
for sqc e noTD50 P<.0005 + n.s.s. 1.39mg	0/84	30/30			
itn sar e 2.61mg P<.0005 + 1.49mg 4.99mg	0/84	21/30			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
itn hms e	3.43mg	P<.0005 +	1.92mg 6.85mg	0/84	18/30			
mgl adc e	6.45mg	P<.0005 +	3.21mg 16.8mg	2/84	12/30			
kid tcc e	45.5mg	P<.03 +	11.2mg n.s.s.	0/84	2/30			
tba mix e	noTD50	P<.0005	n.s.s. 1.44mg	6/84	30/30			
1,2-DIMETHYL-5-NITROIMIDAZOLE 551-92-8								
2289 R f sda eat 46w66 200a				0	69.7mg			Cohen;jnci,51,403-417;1973
mgl fba e	17.0mg	P<.0005 +	9.67mg 35.9mg	4/35	25/35			
liv tum e	no dre	P=1.	202.mg n.s.s.	0/35	0/35			
tba mix e	17.0mg	P<.0005	9.67mg 35.9mg	4/35	25/35			
DIMETHYL TEREPHTHALATE (DMT) 120-61-6								
2290 M f b6c eat 24m24 TR121 :				0	319.mg	638.mg		
TBA MXB	4.34gm / P<.7	-	660.mg n.s.s.	29/50	20/50	32/50		
liv MXB	no dre	P=1.	2.21gm n.s.s.	5/50	1/50	(0/50)		liv:hpa,hpc,nnd.
lun MXB	44.0gm \ P<1.		926.mg n.s.s.	4/50	5/50	(0/50)		lun:a/a,a/c.
2291 M m b6c eat 24m24 TR121 :				0	294.mg	589.mg		
lun MXA #	1.16gm * P<.002	-	640.mg 5.49gm	1/50	8/50	13/50		lun:a/a,a/c. S
TBA MXB	no dre	P=1.	731.mg n.s.s.	36/50	33/50	34/50		
liv MXB	no dre	P=1.	1.33gm n.s.s.	19/50	13/50	16/50		liv:hpa,hpc,nnd.
lun MXB	1.16gm * P<.002		640.mg 5.49gm	1/50	8/50	13/50		lun:a/a,a/c.
2292 R f f34 eat 24m24 TR121 :				0	123.mg	245.mg		
TBA MXB	342.mg \ P<.5	-	75.7mg n.s.s.	38/50	38/50	(29/50)		
liv MXB	no dre	P=1.	2.03gm n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
2293 R m f34 eat 24m24 TR121 :				0	98.2mg	196.mg		
TBA MXB	no dre	P=1.	- 168.mg n.s.s.	40/50	28/50	(26/50)		
liv MXB	no dre	P=1.	1.91gm n.s.s.	4/50	0/50	1/50		liv:hpa,hpc,nnd.
DIMETHYLACETAMIDE 127-19-5								
2294 M f cd1 inh 78w78 2252				0	28.0mg	112.mg	392.mg	Malley;faat,28,80-93;1995
liv hpa Ce	13.2gm * P<.2	-	2.14gm n.s.s.	0/63	0/64	0/63	1/65	
2295 M m cd1 inh 78w78 2252				0	23.3mg	93.4mg	327.mg	
liv hpa Ce	no dre	P=1.	- 1.04gm n.s.s.	14/64	12/64	10/64	8/65	
liv hpc Ce	no dre	P=1.	- 1.64gm n.s.s.	2/64	5/64	4/64	1/65	
2296 R f cdr inh 24m24 2252				0	6.67mg	26.7mg	93.4mg	
liv hpa Ce	no dre	P=1.	- 895.mg n.s.s.	0/62	0/62	1/62	0/64	
2297 R m cdr inh 24m24 2252				0	4.67mg	18.7mg	65.4mg	
liv hpc Ce	6.00gm * P<.7	-	536.mg n.s.s.	1/65	0/63	1/63	1/62	
liv hpa Ce	no dre	P=1.	- 636.mg n.s.s.	3/65	3/63	2/63	1/62	
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl (L-alpha-acetylmethadol.HCl, LAAM) 43033-72-3								
2298 M f b6c eat 25m25 1894				0	7.60mg	30.0mg		Rosenkrantz;faat,11,626-639;1988/pers.comm.
liv hct e	1.85gm * P<.9		85.3mg n.s.s.	6/50	8/50	7/50		
lun mix e	no dre	P=1.	186.mg n.s.s.	5/50	0/50	3/50		
2299 M m b6c eat 25m25 1894				0	7.60mg	30.0mg		
liv hct e	no dre	P=1.	13.4mg n.s.s.	18/50	18/50	(5/50)		
lun mix e	no dre	P=1.	182.mg n.s.s.	11/50	8/50	4/50		
2300 R f f34 eat 25m25 1894				0	5.70mg	16.6mg		
ute esp e	43.3mg * P<.006		21.6mg 520.mg	2/50	10/50	12/50		
liv nnd e	60.7mg * P<.007	+	28.2mg 999.mg	3/50	4/50	12/50		
liv hpc eh	260.mg * P<.1	+	78.7mg n.s.s.	0/50	1/50	2/50		
2301 R m f34 eat 25m25 1894				0	3.10mg	9.70mg		
liv nnd e	77.3mg * P<.09	+	27.2mg n.s.s.	1/50	3/50	5/50		
liv hpc eh	110.mg * P<.02	+	38.1mg 19.3gm	0/50	0/50	4/50		
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl (DL-methadone.HCl) 1095-90-5								
2302 M f b6c eat 25m25 1893				0	15.0mg	60.0mg		Rosenkrantz;faat,11,640-651;1988/pers.comm.
pta ade e	42.5mg \ P<.02	-	19.0mg n.s.s.	5/50	15/50	(4/50)		
lun a/a e	371.mg * P<.09	-	132.mg n.s.s.	1/50	5/50	6/50		
liv hpa e	385.mg * P<.2	-	124.mg n.s.s.	3/50	6/50	8/50		
liv hpc e	no dre	P=1.	- 217.mg n.s.s.	5/50	6/50	5/50		
lun a/c e	no dre	P=1.	- 128.mg n.s.s.	1/50	0/50	0/50		
2303 M m b6c eat 25m25 1893				0	15.0mg	60.0mg		
liv hpc e	281.mg * P<.2	-	86.0mg n.s.s.	12/50	11/50	17/50		
liv hpa e	2.13gm / P<.8	-	196.mg n.s.s.	9/50	2/50	8/50		
lun a/a e	no dre	P=1.	- 384.mg n.s.s.	8/50	5/50	3/50		
lun a/c e	no dre	P=1.	- 607.mg n.s.s.	5/50	0/50	1/50		
2304 R f f34 eat 25m25 1893				0	28.0mg	88.0mg		
liv nnd e	1.42gm * P<.4	-	328.mg n.s.s.	3/50	1/50	5/50		
2305 R m f34 eat 25m25 1893				0	16.0mg	46.0mg		
liv hpc e	1.09gm * P<.3	-	269.mg n.s.s.	0/50	1/50	1/50		
liv nnd e	no dre	P=1.	- 155.mg n.s.s.	10/50	9/50	8/50		
trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE 55738-54-0								
2306 R f sda eat 46w66 1126				0	69.7mg			Cohen;jnci,54,841-850;1975
mgl adc e	20.4mg	P<.0005	12.0mg 37.9mg	0/24	22/36			
mgl mix e	22.4mg	P<.0005 +	12.6mg 53.5mg	2/24	22/36			
for sqp e	221.mg	P<.08 +	66.9mg n.s.s.	0/24	3/36			
duo adp e	336.mg	P<.2 +	82.7mg n.s.s.	0/24	2/36			
duo adc e	336.mg	P<.2 +	82.7mg n.s.s.	0/24	2/36			
lun alc eh	683.mg	P<.4 +	111.mg n.s.s.	0/24	1/36			
liv tum e	no dre	P=1.	208.mg n.s.s.	0/24	0/36			
tba mix e	20.6mg	P<.0005	11.7mg 46.8mg	2/24	23/36			
4-DIMETHYLAMINO-3,5-XYLENOL 6120-10-1								
2307 M f b6a orl 76w76 1248				0	41.4mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- 46.1mg n.s.s.	1/17	1/17			
liv hpt evx	no dre	P=1.	- 77.4mg n.s.s.	0/17	0/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix evx	220.mg	P<.7	-	27.7mg n.s.s.	2/17	3/17			
2308 M m b6a orl 76w76 1248					0	38.5mg			
liv hpt evx	207.mg	P<.6	-	30.2mg n.s.s.	1/18	2/17			
lun ade evx	no dre	P=1.	-	47.4mg n.s.s.	2/18	1/17			
tba mix evx	1.19gm	P<1.	-	28.0mg n.s.s.	3/18	3/17			
2309 M f b6c orl 76w76 1248					0	41.4mg			
lun ade evx	265.mg	P<.3	-	43.1mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.	-	82.0mg n.s.s.	0/16	0/18			
tba mix evx	265.mg	P<.3	-	43.1mg n.s.s.	0/16	1/18			
2310 M m b6c orl 76w76 1248					0	38.5mg			
lun ade evx	56.1mg	P<.02	-	19.3mg n.s.s.	0/16	4/18			
liv hpt evx	247.mg	P<.3	-	40.1mg n.s.s.	0/16	1/18			
tba mix evx	34.8mg	P<.004	-	14.0mg 212.mg	0/16	6/18			
4-DIMETHYLAMINOANTIPYRINE (aminopyrine) 58-15-1									
2311 M f b6c wat 23m24 1991					0	76.9mg	154.mg		Inai;gann,81,122-128;1990
liv hpa e	6.15gm *	P<.6	-	874.mg n.s.s.	1/45	0/41	2/42		
lun a/c e	6.54gm *	P<.3	-	1.06gm n.s.s.	0/45	0/41	1/42		
liv hpc e	no dre	P=1.	-	437.mg n.s.s.	1/45	0/41	0/42		
lun a/a e	no dre	P=1.	-	932.mg n.s.s.	2/45	2/41	1/42		
tba tum e	no dre	P=1.	-	196.mg n.s.s.	22/45	21/41	20/42		
2312 M m b6c wat 23m24 1991					0	64.1mg	128.mg		
lun a/a e	1.48gm *	P<.09	-	478.mg n.s.s.	1/46	0/44	5/48		
liv hpa e	683.mg *	P<.3	-	213.mg n.s.s.	10/46	6/44	16/48		
liv hpc e	5.39gm *	P<.9	-	406.mg n.s.s.	6/46	4/44	7/48		
lun a/c e	no dre	P=1.	-	902.mg n.s.s.	1/46	1/44	1/48		
tba tum e	156.mg *	P<.02	-	74.5mg n.s.s.	22/46	19/44	36/48		
2-DIMETHYLAMINOETHANOL 108-01-0									
2313 M f c3j wat 29m29 1877					0	268.mg			Stenback;made,42,129-138;1988
liv tum e	6.72gm	P<.7	-	931.mg n.s.s.	4/44	5/40			
tba tum e	no dre	P=1.	-	166.mg n.s.s.	39/44	35/40			
2314 M f cen wat 24m24 1877					0	178.mg			
liv tum e	2.99gm	P<.6	-	478.mg n.s.s.	6/58	7/50			
tba tum e	1.66gm	P<.8	-	177.mg n.s.s.	33/58	30/50			
DIMETHYLAMINOETHYLNITROSOETHYLUREA, NITRITE SALT 142713-78-8									
2315 R f f34 gav 9m24 2111					0	1.48mg			Lijinsky;clet,63,101-107;1992
mgl fba e	.704mg	P<.0005	+	.301mg 2.02mg	0/12	9/12			
ute emp e	1.41mg	P<.002	+	.558mg 6.32mg	0/12	6/12			
mgl adc e	3.39mg	P<.04	+	1.02mg n.s.s.	0/12	3/12			
lun tum e	5.35mg	P<.09		1.31mg n.s.s.	0/12	2/12			
cvx adc e	5.35mg	P<.09		1.31mg n.s.s.	0/12	2/12			
mgl ade e	11.2mg	P<.3		1.82mg n.s.s.	0/12	1/12			
ute ade e	11.2mg	P<.3		1.82mg n.s.s.	0/12	1/12			
liv tum e	no dre	P=1.		3.52mg n.s.s.	0/12	0/12			
2316 R m f34 gav 9m24 2111					0	1.04mg			
lun tum e	2.37mg	P<.04		.713mg n.s.s.	0/12	3/12			
ski ker e	1.92mg	P<.2		.526mg n.s.s.	2/12	5/12			
liv tum e	no dre	P=1.		2.47mg n.s.s.	0/12	0/12			
2,6-DIMETHYLANILINE 87-62-7									
2317 R m f3d eat 53w53 2606					0	120.mg			Koujitani;clet,142,161-171;1999
nas tum er	no dre	P=1.		96.3mg n.s.s.	0/10	0/15			
N,N-DIMETHYLANILINE 121-69-7									
2318 M f b6c gav 24m24 TR360 :					0	10.6mg	21.2mg		
for sqp	99.3mg *	P<.05	e	39.3mg n.s.s.	2/50	2/50	8/50		
TBA MXB	108.mg /	P<.7		15.7mg n.s.s.	39/50	27/50	41/50		
liv MXB	163.mg *	P<.4		40.2mg n.s.s.	5/50	5/50	8/50		liv:hpa,hpc,nnd.
lun MXB	276.mg *	P<.5		54.8mg n.s.s.	4/50	3/50	6/50		lun:a/a,a/c.
2319 M m b6c gav 24m24 TR360 :					0	10.6mg	21.2mg		
TBA MXB	489.mg *	P<1.	-	17.4mg n.s.s.	32/50	37/50	33/50		
liv MXB	216.mg *	P<.7		28.3mg n.s.s.	11/50	16/50	13/50		liv:hpa,hpc,nnd.
lun MXB	102.mg *	P<.4		26.7mg n.s.s.	7/50	12/50	11/50		lun:a/a,a/c.
2320 R f f34 gav 24m24 TR360 :					0	2.12mg	21.2mg		
TBA MXB	no dre	P=1.	-	2.41mg n.s.s.	48/50	42/50	(42/50)		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
2321 R m f34 gav 24m24 TR360 :					0	2.12mg	21.2mg		
srp MXA	125.mg *	P<.005	p	42.5mg 1.09gm	0/50	0/50	4/50		srp:ost,srn.
srp srn	175.mg *	P<.02		52.3mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	93.2mg *	P<.7		12.8mg n.s.s.	42/50	35/50	39/50		
liv MXB	no dre	P=1.		126.mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
DIMETHYLARSINIC ACID (cacodylic acid) 75-60-5									
2322 M f b6a orl 76w76 1198					0	16.9mg			Innes;ntis,1968/1969
lun ade evx	108.mg	P<.3	-	17.6mg n.s.s.	0/18	1/18			
liv hpt evx	no dre	P=1.	-	33.5mg n.s.s.	0/18	0/18			
tba mix evx	34.0mg	P<.04	-	10.3mg n.s.s.	0/18	3/18			
2323 M m b6a orl 76w76 1198					0	15.8mg			
lun ade evx	95.2mg	P<.3	-	15.5mg n.s.s.	0/18	1/17			
liv hpt evx	no dre	P=1.	-	29.5mg n.s.s.	1/18	0/17			
tba mix evx	no dre	P=1.	-	19.4mg n.s.s.	2/18	1/17			
2324 M f b6c orl 76w76 1198					0	16.9mg			
liv hpt evx	no dre	P=1.	-	33.5mg n.s.s.	0/18	0/18			
lun ade evx	no dre	P=1.	-	33.5mg n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	-	33.5mg n.s.s.	2/18	0/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf								Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc				NCI/NTPPathology
2325 M m b6c orl 76w76 1198					0	15.8mg						
liv hpt evx	no dre	P=1.	-	17.1mg n.s.s.	3/14	1/14						
lun mix evx	no dre	P=1.	-	24.3mg n.s.s.	0/14	0/14						
tba mix evx	no dre	P=1.	-	10.3mg n.s.s.	4/14	3/14						
2326 R m f3d wat 24m24 2441					0	.625mg	2.50mg	10.0mg				Wei;carc,20,1873-1876;1999/2002/pers.comm.
ubl mix Ce	11.4mg *	P<.0005	+	6.67mg 22.6mg	0/28	0/33	8/31	12/31				
ubl tcc Ce	12.8mg *	P<.0005	+	7.30mg 25.7mg	0/28	0/33	6/31	12/31				
ubl tpp Ce	67.7mg *	P<.07	+	23.4mg n.s.s.	0/28	0/33	2/31	2/31				
liv hpc e	545.mg *	P<.7		48.2mg n.s.s.	1/28	0/33	0/31	1/31				
liv nnd e	no dre	P=1.		63.3mg n.s.s.	1/28	2/33	1/31	0/31				
5,5-DIMETHYLBARBITURIC ACID 24448-94-0												
2327 R m f34 eat 71w71 2109					0	13.6mg						Diwan;artx,66,413-422;1992
liv hct e	no dre	P=1.		19.6mg n.s.s.	0/27	0/15						
7,12-DIMETHYLBENZ(a)ANTHRACENE 57-97-6												
2328 M f alb eat 60w60 1274					0	.390mg						Chouroulinkov;bdca,54,67-78;1967
mei ane er	84.0ug	P<.0005	+	58.2ug .126mg	0/40	49/75						
for pam er	.287mg	P<.0005		.169mg .563mg	0/40	20/75						
3,3'-DIMETHYLBENZIDINE.2HCl 612-82-8												
2329 M f bcn wat 52w52 1913m					0	1.00mg	1.80mg	3.60mg	7.00mg	14.0mg	28.0mg	Schieferstein; fctx,27,801-806;1989
lun mix ekr	28.1mg *	P<.2		8.34mg n.s.s.	0/16	1/15	2/16	1/13	3/16	0/16	4/16	
lun adc ekr	147.mg *	P<.2		24.0mg n.s.s.	0/16	0/15	0/16	0/13	0/16	0/16	1/16	
2330 M f bcn wat 78w78 1913n					0	1.00mg	1.80mg	3.60mg	7.00mg	14.0mg	28.0mg	
lun adc ekr	168.mg *	P<.2		36.9mg n.s.s.	0/21	0/23	1/20	1/21	0/20	0/21	2/18	
lun mix ekr	295.mg *	P<.8		23.8mg n.s.s.	4/21	1/23	8/20	5/21	4/20	2/21	5/18	
2331 M f bcn wat 26m26 1913o					0	1.00mg	1.80mg	3.60mg	7.00mg	14.0mg	28.0mg	
lun mix er	no dre	P=1.		55.2mg n.s.s.	8/26	6/25	7/28	8/25	10/28	9/25	7/29	
lun adc er	no dre	P=1.		115.mg n.s.s.	5/26	3/25	3/28	4/25	5/28	2/25	3/29	
2332 M m bcn wat 52w52 1913m					0	.833mg	1.50mg	3.00mg	5.83mg	11.7mg	23.3mg	
lun adc ekr	123.mg *	P<.3		20.0mg n.s.s.	0/15	0/16	0/14	0/14	0/15	1/16	0/16	
lun mix ekr	684.mg *	P<1.		8.25mg n.s.s.	1/15	3/16	1/14	5/14	2/15	4/16	2/16	
2333 M m bcn wat 78w78 1913n					0	.833mg	1.50mg	3.00mg	5.83mg	11.7mg	23.3mg	
lun mix ekr	423.mg *	P<1.		15.7mg n.s.s.	11/23	4/20	8/18	8/23	5/18	7/21	8/20	
lun adc ekr	no dre	P=1.		60.0mg n.s.s.	0/23	0/20	0/18	2/23	0/18	0/21	0/20	
2334 M m bcn wat 26m26 1913o					0	.833mg	1.50mg	3.00mg	5.83mg	11.7mg	23.3mg	
lun mix er	28.6mg *	P<.002	+	14.0mg 168.mg	8/26	12/26	5/29	11/28	10/32	15/27	17/27	
lun adc er	50.1mg *	P<.002	+	24.3mg 278.mg	3/26	5/26	2/29	2/28	7/32	6/27	11/27	
2335 R f f34 wat 60w60 TR390 :					0	1.71mg	4.00mg	8.57mg				
MXB MXB	.418mg *	P<.0005		.330mg .542mg	1/60	25/45	70/75	58/60	cli:ade,anb,car,cnb; col:adc,adp; duo:adc; ilm: adp,mua; jej:adc,adp,muc; liv:hpc,nnd; lun:a/a,a/c; mgl:adc; phr:sqc,sqp; rec:adc,adp; ski:bca,bcc, sqc,sqp; ton:sqc,sqp; zym:ade,anb,car,cnb.				C
cli MXA	.847mg *	P<.0005	c	.634mg 1.16mg	0/60	14/45	42/75	32/60				cli:ade,anb,car,cnb.			
zym MXA	1.27mg *	P<.0005	c	.936mg 1.76mg	0/60	6/45	32/75	42/60				zym:ade,anb,car,cnb.			
cli MXA	1.31mg *	P<.0005		.926mg 1.93mg	0/60	9/45	32/75	17/60				cli:ade,anb.			S
zym MXA	2.00mg Z	P<.0005		1.42mg 2.90mg	0/60	2/45	22/75	35/60				zym:car,cnb.			S
cli MXA	2.58mg *	P<.0005		1.66mg 4.23mg	0/60	5/45	11/75	18/60				cli:car,cnb.			S
zym MXA	3.08mg *	P<.0005		1.88mg 5.43mg	0/60	4/45	11/75	12/60				zym:ade,anb.			S
ski MXA	3.17mg *	P<.0005	c	1.91mg 5.75mg	0/60	3/45	9/75	12/60				ski:sqc,sqp.			
MXA MXA	3.20mg *	P<.0005	c	1.92mg 5.76mg	0/60	3/45	9/75	13/60				phr:sqc,sqp; ton:sqc,sqp.			
ski MXA	3.80mg *	P<.0005	c	2.22mg 7.20mg	0/60	3/45	10/75	9/60				ski:bca,bcc.			
MXA sqp	4.26mg *	P<.0005		2.40mg 8.54mg	0/60	3/45	7/75	9/60				phr:sqp; ton:sqp.			S
ski sqc	5.56mg *	P<.0005		2.87mg 13.1mg	0/60	2/45	4/75	7/60							S
mgl MXA	5.77mg *	P<.0005		2.81mg 22.3mg	2/60	2/45	7/75	6/60				mgl:adc,fba.			S
ski bca	5.77mg *	P<.0005		2.95mg 15.5mg	0/60	3/45	5/75	5/60							S
--- mnl	6.46mg *	P<.002	e	3.09mg 33.1mg	1/60	3/45	6/75	4/60							
MXA MXA	6.65mg *	P<.0005	c	3.31mg 17.3mg	0/60	1/45	7/75	4/60				col:adc,adp; rec:adc,adp.			
liv MXA	6.97mg *	P<.0005	c	3.41mg 17.7mg	0/60	0/45	7/75	4/60				liv:hpc,nnd.			
ski sqp	7.06mg *	P<.0005		3.51mg 17.9mg	0/60	1/45	6/75	5/60							S
MXA adp	7.11mg *	P<.0005		3.45mg 19.6mg	0/60	1/45	6/75	4/60				col:adp; rec:adp.			S
liv nnd	7.62mg *	P<.0005		3.60mg 21.2mg	0/60	0/45	7/75	3/60							S
mgl adc	8.33mg *	P<.0005	c	3.87mg 23.4mg	0/60	1/45	3/75	6/60							
MXA MXA	11.0mg *	P<.0005	c	5.01mg 37.5mg	0/60	1/45	3/75	5/60				duo:adc; ilm:adp,mua; jej:adc,adp,muc.			
ski bcc	11.6mg *	P<.0005		5.21mg 37.6mg	0/60	0/45	5/75	4/60							S
MXA sqc	11.8mg *	P<.002		4.82mg 52.6mg	0/60	1/45	2/75	4/60				phr:sqc; ton:sqc.			S
lun MXA	11.9mg *	P<.006	c	4.75mg 174.mg	1/60	1/45	3/75	4/60				lun:a/a,a/c.			
MXA MXA	15.4mg *	P<.0005		6.37mg 56.1mg	0/60	0/45	2/75	5/60				duo:adc; ilm:mua; jej:adc,muc.			S
lun a/a	13.6mg *	P<.02		5.07mg n.s.s.	1/60	1/45	3/75	3/60							S
bra MXA	15.4mg *	P<.06	e	5.67mg n.s.s.	0/60	2/45	2/75	1/60				bra:asl,mag,mnm.			
TBA MXB	.462mg *	P<.0005		.344mg .660mg	18/60	33/45	71/75	58/60							
liv MXB	6.97mg *	P<.0005		3.41mg 17.7mg	0/60	0/45	7/75	4/60				liv:hpa,hpc,nnd.			
2336 R m f34 wat 58w60 TR390 :					0	1.48mg	3.45mg	7.50mg							
MXB MXB a	.346mg Z	P<.0005		.270mg .454mg	5/60	19/45	73/75	58/60	cec:adp; col:adc,adp,muc; duo:muc; ilm:adc,adp; jej:muc; lgi:adc; liv:hpc,nnd; lun:a/a,a/c; mul:msm; phr:sqc,sqp; pre:ade,car; rec:adc,adp; ski:bca, bcc,ker,sea,sqc,sqp; ton:sqc,sqp; zym:ade,anb,car,cnb.				C
ski MXA a	.500mg Z	P<.0005	c	.380mg .672mg	0/60	11/45	54/75	30/60				ski:bca,bcc.			
ski bca a	.534mg Z	P<.0005		.405mg .723mg	0/60	10/45	52/75	29/60							S
liv MXA a	.898mg Z	P<.0005	c	.650mg 1.28mg	0/60	0/45	35/75	33/60				liv:hpc,nnd.			
zym MXA a	1.12mg Z	P<.0005	c	.806mg 1.59mg	1/60	3/45	32/75	36/60				zym:ade,anb,car,cnb.			
liv nnd a	1.12mg Z	P<.0005		.789mg 1.66mg	0/60	0/45	29/75	26/60							S
ski MXA a	1.55mg Z	P<.0005	c	1.05mg 2.38mg	0/60	2/45	17/75	27/60				ski:sqc,sqp.			
zym MXA a	1.93mg Z	P<.0005		1.30mg 2.98mg	0/60	2/45	21/75	23/60				zym:car,cnb.			S
zym MXA a	2.38mg Z	P<.0005		1.48mg 4.22mg	1/60	1/45	13/75	16/60				zym:ade,anb.			S
liv hpc a	2.76mg Z	P<.0005		1.65mg 5.02mg	0/60	0/45	12/75	12/60							S
ski sqc a	2.80mg Z	P<.0005		1.68mg 5.05mg	0/60	2/45	10/75	13/60							S
ski sqp a	3.28mg Z	P<.0005		1.93mg 6.04mg	0/60	0/45	8/75	15/60							S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
MXA MXA a	3.76mg Z	P<.0005 c	2.18mg	7.05mg	0/60	0/45	6/75	15/60	cec:adp; col:adc,adp,muc; lgi:adc; rec:adc,adp.
pre MXA a	3.96mg Z	P<.0005 c	2.09mg	10.8mg	2/60	4/45	6/75	9/60	pre:ade,car.
ski ker a	4.58mg Z	P<.0005 c	2.34mg	12.4mg	1/60	1/45	8/75	5/60	
MXA adp a	4.87mg Z	P<.0005	2.58mg	10.4mg	0/60	0/45	6/75	9/60	cec:adp; col:adp; rec:adp. S
lun MXA a	4.93mg Z	P<.0005 c	2.47mg	13.2mg	1/60	0/45	8/75	6/60	lun:a/a,a/c.
pre ade a	4.94mg Z	P<.0005	2.43mg	16.8mg	2/60	4/45	4/75	8/60	S
lun a/a a	5.47mg Z	P<.0005	2.67mg	15.5mg	1/60	0/45	7/75	6/60	S
ski sea a	5.62mg Z	P<.0005 c	2.79mg	13.4mg	0/60	0/45	7/75	5/60	
MXA MXA a	6.99mg Z	P<.0005 c	3.39mg	16.6mg	0/60	0/45	4/75	8/60	duo:muc; ilm:adc,adp; jej:muc.
MXA MXA a	7.79mg Z	P<.0005	3.64mg	19.3mg	0/60	0/45	3/75	8/60	duo:muc; ilm:adc; jej:muc. S
MXA MXA a	8.47mg Z	P<.0005 c	3.80mg	23.9mg	0/60	0/45	4/75	5/60	phr:sqc,sqp; ton:sqc,sqp.
ski bcc a	8.85mg *	P<.002	3.67mg	43.0mg	0/60	1/45	4/75	2/60	S
mul msm a	9.45mg Z	P<.0005 c	3.95mg	31.6mg	0/60	0/45	3/75	4/60	
amd pob a	10.6mg Z	P<.003	4.22mg	78.6mg	0/60	2/45	1/75	3/60	S
MXA MXA a	14.4mg Z	P<.0005	6.16mg	45.9mg	0/60	0/45	0/75	7/60	col:adc,muc; lgi:adc; rec:adc. S
MXA sqc a	26.7mg *	P<.007	9.18mg	129.mg	0/60	0/45	1/75	3/60	phr:sqc; ton:sqc. S
bra MXA a	26.1mg *	P<.02 e	7.38mg	n.s.s.	0/60	0/45	1/75	2/60	bra:gmf,mag,mnm.
TBA MXB a	.334mg Z	P<.0005	.260mg	.445mg	9/60	25/45	73/75	58/60	
liv MXB a	.898mg Z	P<.0005	.650mg	1.28mg	0/60	0/45	35/75	33/60	liv:hpa,hpc,nnd.
DIMETHYLCARBAMYL CHLORIDE 79-44-7									
2337 H m syg inh 26m26 1142					0	.553mg			Sellakumar;jept,4,107-115;1980
nas sqc erh	.625mg	P<.0005 +	.439mg	.928mg	0/50	50/99			
2338 M f hic ipj 64w64 1143					0	5.71mg			Van Duuren;jnci,53,695-700;1974
abd mix	4.59mg	P<.004	2.02mg	34.7mg	1/30	9/30			
abd sar	5.37mg	P<.008 +	2.25mg	134.mg	1/30	8/30			
lun ptm	6.65mg	P<.3	1.76mg	n.s.s.	10/30	14/30			
DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE 598-64-1									
2339 M f b6a orl 76w76 1222					0	36.4mg			Innes;ntis,1968/1969
liv agm evx	233.mg	P<.3 -	37.9mg	n.s.s.	0/17	1/18			
lun ade evx	no dre	P=1. -	43.3mg	n.s.s.	1/17	1/18			
tba mix evx	no dre	P=1. -	34.4mg	n.s.s.	2/17	2/18			
2340 M m b6a orl 76w76 1222					0	33.9mg			
liv hpt evx	99.1mg	P<.3 -	22.1mg	n.s.s.	1/18	3/18			
lun ade evx	no dre	P=1. -	44.5mg	n.s.s.	2/18	1/18			
tba mix evx	180.mg	P<.7 -	21.1mg	n.s.s.	3/18	4/18			
2341 M f b6c orl 76w76 1222					0	36.4mg			
liv hpt evx	233.mg	P<.3 -	37.9mg	n.s.s.	0/16	1/18			
lun mix evx	no dre	P=1. -	72.1mg	n.s.s.	0/16	0/18			
tba mix evx	113.mg	P<.2 -	27.8mg	n.s.s.	0/16	2/18			
2342 M m b6c orl 76w76 1222					0	33.9mg			
lun ade evx	63.9mg	P<.04 -	19.3mg	n.s.s.	0/16	3/17			
liv hpt evx	99.1mg	P<.1 -	24.3mg	n.s.s.	0/16	2/17			
tba mix evx	19.5mg	P<.0005 -	8.66mg	62.1mg	0/16	8/17			
N,N-DIMETHYLDODECYLAMINE-N-OXIDE 1643-20-5									
2343 R f f34 wat 22m30 1654					0	31.8mg			Lijinsky;fctx,22,715-720;1984
liv nnd e	no dre	P=1. -	107.mg	n.s.s.	4/24	3/24			
2344 R m f34 wat 22m30 1654					0	22.2mg			
liv mix e	231.mg	P<.5 -	45.1mg	n.s.s.	3/24	5/24			
liv nnd e	496.mg	P<.7 -	61.5mg	n.s.s.	2/24	3/24			
liv hpc e	519.mg	P<.6 -	71.6mg	n.s.s.	1/24	2/24			
DIMETHYLFORMAMIDE 68-12-2									
2345 M f cd1 inh 78w78 2145					0	23.5mg	94.0mg	376.mg	Malley;faat,23,268-279;1994
liv hpa Ce	15.8gm *	P<.8 -	1.22gm	n.s.s.	0/61	1/63	2/61	1/63	
2346 M m cd1 inh 78w78 2145					0	19.6mg	78.3mg	313.mg	
liv hpc Ce	3.07gm *	P<.4 -	629.mg	n.s.s.	0/60	1/62	4/60	2/59	
liv hpa Ce	no dre	P=1. -	559.mg	n.s.s.	13/60	11/62	11/60	11/59	
2347 R f cdr inh 24m24 2145					0	5.60mg	22.4mg	89.5mg	
liv hpa Ce	no dre	P=1. -	1.17gm	n.s.s.	0/60	1/59	0/59	0/60	
2348 R m cdr inh 24m24 2145					0	3.92mg	15.7mg	62.7mg	
liv hpa Ce	2.64gm *	P<.7 -	310.mg	n.s.s.	1/57	1/59	3/58	2/60	
liv hpc Ce	3.34gm *	P<.2 -	543.mg	n.s.s.	0/57	0/59	0/58	1/60	
1,1-DIMETHYLHYDRAZINE (UDMH) 57-14-7									
2349 H f syg wat 79w79 367					0	136.mg			Toth;canc,40,2427-2431;1977
cec mix e	104.mg	P<.0005 +	49.0mg	301.mg	1/50	10/24			
blv mix e	620.mg	P<.04	152.mg	n.s.s.	0/50	2/24			
liv mix e	620.mg	P<.04	152.mg	n.s.s.	0/50	2/24			
lun tum e	no dre	P=1.	519.mg	n.s.s.	0/100	0/32			
2350 H m syg wat 91w91 367					0	120.mg			
cec mix e	155.mg	P<.0005 +	84.8mg	329.mg	0/64	15/45			
blv mix e	183.mg	P<.0005	98.0mg	399.mg	0/85	14/48			
liv mix e	183.mg	P<.0005	98.0mg	399.mg	0/85	14/48			
liv ang e	242.mg	P<.0005	121.mg	592.mg	0/85	11/48			
cec adc e	322.mg	P<.0005	145.mg	957.mg	0/64	8/45			
cec pla e	372.mg	P<.0005	161.mg	1.25gm	0/64	7/45			
liv agm e	975.mg	P<.02	295.mg	n.s.s.	0/85	3/48			
lun tum e	no dre	P=1.	909.mg	n.s.s.	0/88	0/48			
2351 M f cd1 wat 52w52 1916m					0	.200mg	1.00mg	4.00mg	Goldenthal;irdc,399-063;1989/pers.comm.
lun a/a ek	28.5mg *	P<.8 -	1.93mg	n.s.s.	2/20	1/20	2/20	2/20	
liv tum ek	no dre	P=1. -	.165mg	n.s.s.	0/20	0/20	0/20	0/20	
--- vsc ek	no dre	P=1. -	.165mg	n.s.s.	0/20	0/20	0/20	0/20	
2352 M f cd1 wat 24m24 1916n					0	.200mg	1.00mg	4.00mg	
lun mix e	4.12mg *	P<.0005	2.41mg	9.38mg	6/50	10/49	13/50	28/50	
lun a/a e	6.46mg *	P<.0005	3.37mg	23.0mg	5/50	9/49	12/50	21/50	

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun a/c e	23.3mg	* P<.005		9.61mg 236.mg	1/50	1/49	1/50	7/50	
liv hes e	54.9mg	* P<.3		13.6mg n.s.s.	3/50	2/50	1/50	5/50	
liv vsc e	68.2mg	* P<.4		14.3mg n.s.s.	4/50	2/50	1/50	5/50	
liv mix e	74.7mg	Z P<.4		15.6mg n.s.s.	5/50	1/50	0/50	5/50	
liv hpa e	98.7mg	* P<.5		17.6mg n.s.s.	4/50	1/50	0/50	4/50	
--- hes e	328.mg	* P<.9		15.5mg n.s.s.	4/50	6/50	2/50	5/50	
liv hpc e	340.mg	* P<.7		30.8mg n.s.s.	1/50	0/50	0/50	1/50	
--- vsc e	no dre	P=1.		15.6mg n.s.s.	7/50	11/50	3/50	7/50	
liv hem e	no dre	P=1.		1.65mg n.s.s.	1/50	0/50	0/50	0/50	
--- hem e	no dre	P=1.		27.5mg n.s.s.	3/50	5/50	1/50	2/50	
2353 M f cd1 wat 52w52 2013m					0	8.00mg	16.0mg		Goldenthal;irdc,399-065;1990/pers.comm.
lun mix eks	3.68mg	* P<.006	+	1.82mg 43.3mg	3/20	10/20	11/20		
lun a/a eks	3.93mg	* P<.007	+	1.92mg 54.2mg	3/20	9/20	11/20		
--- vsc eks	26.0mg	* P<.04	+	7.87mg n.s.s.	0/20	0/20	3/20		
liv vsc eks	26.0mg	* P<.04	+	7.87mg n.s.s.	0/20	0/20	3/20		
liv hem eks	39.7mg	* P<.1		9.77mg n.s.s.	0/20	0/20	2/20		
--- hem eks	39.7mg	* P<.1		9.77mg n.s.s.	0/20	0/20	2/20		
--- hes eks	80.8mg	* P<.3		13.2mg n.s.s.	0/20	0/20	1/20		
liv hes eks	80.8mg	* P<.3		13.2mg n.s.s.	0/20	0/20	1/20		
lun a/c eks	81.5mg	* P=1.		13.3mg n.s.s.	0/20	1/20	0/20		
2354 M f cd1 wat 24m24 2013n					0	8.00mg	16.0mg		
--- vsc es	11.1mg	* P<.0005	+	7.41mg 18.8mg	6/50	18/50	37/50		
--- hes es	11.4mg	* P<.0005	+	7.72mg 18.6mg	4/50	15/50	37/50		
liv vsc es	11.8mg	/ P<.0005	+	8.07mg 18.5mg	2/49	12/50	37/50		
liv hes es	12.2mg	/ P<.0005	+	8.36mg 18.8mg	1/49	10/50	37/50		
lun mix es	27.0mg	* P<.03	+	12.4mg n.s.s.	14/49	25/50	25/50		
lun a/a es	37.1mg	* P<.07	+	15.3mg n.s.s.	13/49	21/50	22/50		
liv hpa es	63.6mg	\ P<.2		19.5mg n.s.s.	2/49	6/50	(1/50)		
lun a/c es	199.mg	* P<.4		55.4mg n.s.s.	1/49	4/50	3/50		
--- hem es	no dre	P=1.		134.mg n.s.s.	2/50	3/50	0/50		
liv hem es	no dre	P=1.		138.mg n.s.s.	1/49	2/50	0/50		
lun msm es	no dre	P=1.		134.mg n.s.s.	0/49	1/50	0/50		
2355 M m cd1 wat 52w52 1916m					0	.167mg	.833mg	1.67mg	Goldenthal;irdc,399-063;1989/pers.comm.
liv hpa ek	26.7mg	* P<.8	-	1.60mg n.s.s.	1/20	0/20	0/20	1/20	
--- vsc ek	no dre	P=1.	-	.132mg n.s.s.	0/20	0/20	0/20	0/20	
liv hpc ek	no dre	P=1.	-	2.06mg n.s.s.	0/20	1/20	0/20	0/20	
liv mix ek	no dre	P=1.	-	1.55mg n.s.s.	1/20	1/20	0/20	1/20	
lun a/a ek	no dre	P=1.	-	1.02mg n.s.s.	3/20	1/20	2/20	2/20	
2356 M m cd1 wat 24m24 1916n					0	.167mg	.833mg	1.67mg	
liv hpc e	11.9mg	* P<.09		4.23mg n.s.s.	5/50	1/50	5/50	8/50	
--- hes e	26.7mg	* P<.09		7.82mg n.s.s.	0/50	1/50	0/50	3/50	
liv mix e	7.22mg	Z P<.2		2.55mg n.s.s.	16/50	6/50	10/50	19/50	
liv hpa e	29.7mg	* P<.6		4.60mg n.s.s.	11/50	5/50	5/50	11/50	
lun mix e	39.6mg	* P<.9		2.67mg n.s.s.	16/50	17/50	24/50	16/50	
liv hes e	44.8mg	* P<.3		9.43mg n.s.s.	0/50	1/50	0/50	2/50	
lun a/c e	89.0mg	* P<.9		5.75mg n.s.s.	4/50	4/50	7/50	4/50	
lun a/a e	116.mg	* P<1.		3.47mg n.s.s.	12/50	13/50	17/50	12/50	
2357 M m cd1 wat 52w52 2013m					0	6.67mg	13.3mg		Goldenthal;irdc,399-065;1990/pers.comm.
lun mix eks	4.33mg	* P<.04	+	1.84mg n.s.s.	4/20	9/20	10/20		
lun a/a eks	5.18mg	* P<.08	+	2.02mg n.s.s.	4/20	9/20	9/20		
liv hpc eks	10.8mg	\ P<.1		2.66mg n.s.s.	0/20	2/20	(0/20)		
--- vsc eks	12.6mg	* P<.02	+	4.79mg n.s.s.	0/20	1/20	4/20		
liv vsc eks	12.6mg	* P<.02	+	4.79mg n.s.s.	0/20	1/20	4/20		
--- hes eks	21.7mg	* P<.04		6.56mg n.s.s.	0/20	0/20	3/20		
liv hes eks	21.7mg	* P<.04		6.56mg n.s.s.	0/20	0/20	3/20		
liv hem eks	33.4mg	* P<.3		8.21mg n.s.s.	0/20	1/20	1/20		
--- hem eks	33.4mg	* P<.3		8.21mg n.s.s.	0/20	1/20	1/20		
lun a/c eks	67.4mg	* P<.3		11.0mg n.s.s.	0/20	0/20	1/20		
liv mix eks	6.28kg	P=1.		7.02mg n.s.s.	1/20	3/20	1/20		
liv hpa eks	no dre	P=1.		9.85mg n.s.s.	1/20	1/20	1/20		
2358 M m cd1 wat 24m24 2013n					0	6.67mg	13.3mg		
--- vsc es	6.13mg	* P<.0005	+	4.28mg 9.51mg	5/50	30/50	39/50		
liv vsc es	6.47mg	* P<.0005	+	4.54mg 10.0mg	4/50	30/50	37/50		
--- hes es	6.53mg	* P<.0005	+	4.54mg 10.3mg	5/50	29/50	38/50		
liv hes es	6.88mg	* P<.0005	+	4.80mg 10.8mg	4/50	29/50	36/50		
liv hpc es	33.4mg	\ P<.07		12.3mg n.s.s.	3/50	9/50	(0/50)		
lun a/c es	33.4mg	\ P<.07		12.3mg n.s.s.	3/50	9/50	(3/50)		
lun mix es	26.4mg	* P<.2		9.70mg n.s.s.	19/50	34/50	26/50		
lun a/a es	34.3mg	* P<.2		12.3mg n.s.s.	16/50	25/50	23/50		
liv hpa es	140.mg	* P<.5		32.9mg n.s.s.	6/50	6/50	9/50		
--- hem es	339.mg	* P<.3		83.4mg n.s.s.	0/50	1/50	1/50		
liv hem es	339.mg	* P<.3		83.4mg n.s.s.	0/50	1/50	1/50		
liv mix es	24.3kg	P=1.		29.8mg n.s.s.	9/50	15/50	9/50		
2359 M f swa wat 72w72 117					0	20.0mg			Toth;jnci,50,181-194;1973
blv ang e	3.57mg	P<.0005	+	2.23mg 5.94mg	0/47	37/44			
blv mix e	3.65mg	P<.0005	+	2.26mg 6.17mg	4/104	37/44			
lun ade e	5.58mg	P<.0005		3.38mg 10.3mg	12/104	32/44			
lun mix e	5.69mg	P<.0005	+	3.41mg 10.7mg	14/104	32/44			
lun adc e	51.6mg	P<.007		19.2mg 1.11gm	2/104	6/44			
kid ade e	148.mg	P<.2		24.1mg n.s.s.	0/32	1/23			
liv tum e	no dre	P=1.		94.8mg n.s.s.	0/109	0/48			
2360 M m swa wat 62w62 117					0	16.7mg			
blv ang e	2.09mg	P<.0005	+	1.33mg 3.37mg	0/50	42/49			
blv mix e	2.11mg	P<.0005	+	1.34mg 3.44mg	2/91	42/49			
lun ade e	2.62mg	P<.0005		1.63mg 4.53mg	10/86	39/48			
lun mix e	2.62mg	P<.0005	+	1.63mg 4.53mg	10/86	39/48			
kid ade e	19.5mg	P<.0005		9.19mg 59.3mg	0/45	9/48			
liv hpt e	30.4mg	P<.005	+	12.4mg 218.mg	0/45	6/48			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun adc e	46.6mg	P<.005		16.1mg 391.mg	0/86	4/48			
2361 M f swi gav 40w55 1095					0	10.4mg			Roe;natu,216,375-376;1967
lun tum	16.0mg	P<.2	+	4.00mg n.s.s.	8/85	5/25			
2362 R f f34 wat 52w52 2012m					0	57.1ug	2.86mg	5.71mg	Goldenthal;irdc,399-062;1989/pers.comm.
liv hem ek	no dre	P=1.	-	57.2ug n.s.s.	1/20	0/20	0/20	0/20	
2363 R f f34 wat 24m24 2012n					0	57.1ug	2.86mg	5.71mg	
liv mix e	30.9mg *	P<.005	-	14.5mg 310.mg	0/50	1/50	5/50	5/50	
liv hpc e	40.7mg *	P<.003	-	17.6mg 197.mg	0/50	0/50	3/50	4/50	
pit ade e	14.8mg *	P<.06	-	5.82mg n.s.s.	15/50	22/50	16/50	28/50	
liv hpa e	184.mg *	P<.5	-	38.9mg n.s.s.	0/50	1/50	2/50	1/50	
2364 R m f34 wat 52w52 2012m					0	50.0ug	2.50mg	5.00mg	
liv tum ek	no dre	P=1.	-	50.0ug n.s.s.	0/20	0/20	0/20	0/20	
2365 R m f34 wat 24m24 2012n					0	50.0ug	2.50mg	5.00mg	
liv mix e	155.mg *	P<.5	-	26.3mg n.s.s.	3/50	0/50	1/50	3/50	
liv hpa e	205.mg *	P<.6	-	30.0mg n.s.s.	2/50	0/50	1/50	2/50	
liv hpc e	650.mg *	P<.8	-	45.5mg n.s.s.	1/50	0/50	0/50	1/50	
1,2-DIMETHYLHYDRAZINE.2HCl 306-37-6									
2366 H f syg wat 67w67 1108					0	1.36mg			Toth;canr,32,804-807;1972/1967a
blv ang e	.156mg	P<.0005	+	94.9ug .258mg	0/32	44/48			
liv ang e	.156mg	P<.0005	+	94.9ug .258mg	0/32	44/48			
lun ang e	.395mg	P<.0005	+	.250mg .670mg	0/32	30/48			
cec mix e	.864mg	P<.0005	+	.487mg 1.76mg	0/32	17/47			
liv mix e	.917mg	P<.0005	+	.444mg 2.51mg	0/25	10/29			
mus ang e	1.03mg	P<.0005	+	.566mg 2.27mg	0/32	15/48			
liv hpt e	1.40mg	P<.003		.604mg 6.57mg	0/25	7/29			
cec pla e	2.08mg	P<.004		.940mg 11.0mg	0/32	8/47			
hea ang e	2.13mg	P<.004	+	.962mg 11.8mg	0/32	8/48			
cec adc e	2.84mg	P<.02		1.16mg n.s.s.	0/32	6/47			
pan ang e	18.4mg	P<.4	+	3.00mg n.s.s.	0/32	1/48			
2367 H m syg wat 71w71 1108					0	1.20mg			
blv ang e	.211mg	P<.0005	+	.135mg .342mg	0/31	41/49			
liv ang e	.211mg	P<.0005	+	.135mg .342mg	0/31	41/49			
lun ang e	.685mg	P<.0005	+	.406mg 1.28mg	0/31	21/49			
mus ang e	1.36mg	P<.0005	+	.701mg 3.69mg	0/31	12/49			
liv mix e	2.05mg	P<.006	+	.883mg 18.3mg	0/28	7/41			
hea ang e	2.49mg	P<.008	+	1.07mg 37.5mg	0/31	7/49			
cec pla e	2.42mg	P<.02	+	.987mg n.s.s.	0/28	6/41			
pan ang e	18.6mg	P<.4	+	3.03mg n.s.s.	0/31	1/49			
2368 M f swa wat 52w52 119					0	2.00mg			Toth;ajpa,64,585-600;1971
blv ang e	noTD50	P<.0005	+	n.s.s. .128mg	4/109	49/49			
lun ade e	.559mg	P<.0005	+	.334mg 1.11mg	0/18	22/48			
liv hpt e	13.9mg	P<.5		2.26mg n.s.s.	0/15	1/41			
2369 M m swa wat 52w52 119					0	1.67mg			
blv ang e	.102mg	P<.0005	+	60.3ug .171mg	0/40	46/49			
prn ang e	.180mg	P<.0005		.116mg .291mg	0/40	39/49			
mus ang e	.203mg	P<.0005		.131mg .330mg	0/40	37/49			
fat ang e	.215mg	P<.0005		.139mg .351mg	0/40	36/49			
pep ang e	.337mg	P<.0005		.211mg .580mg	0/40	28/49			
liv ang e	.377mg	P<.0005		.233mg .662mg	0/40	26/49			
sub ang e	.781mg	P<.0005		.427mg 1.66mg	0/40	15/49			
lyd ang e	1.02mg	P<.0005		.522mg 2.49mg	0/40	12/49			
lun mix e	1.81mg	P<.06	+	.655mg n.s.s.	11/95	12/49			
2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL)THIAZOLE 26049-69-4									
2370 R f sda eat 46w66 200a					0	3.48mg			Cohen;jnci,51,403-417;1973
mgl mix e	noTD50	P<.0005	+	n.s.s. .410mg	2/39	35/35			
mgl adc e	.391mg	P<.0005		.219mg .707mg	0/39	32/35			
--- lbl eh	16.3mg	P<.09	+	4.02mg n.s.s.	0/39	2/35			
liv tum e	no dre	P=1.		10.1mg n.s.s.	0/39	0/35			
tba mix e	noTD50	P<.0005		n.s.s. .410mg	2/39	35/35			
DIMETHYLNITRAMINE 4164-28-7									
2371 R f bdf gav 24m28 1931					0	6.43mg	12.9mg		Scherf;carc,10,1977-1981;1989/pers.comm.
nas ene a	10.4mg *	P<.0005	+	4.98mg 27.4mg	0/10	3/10	8/10		
2372 R m bdf gav 23m28 1931					0	6.43mg	12.9mg		
nas ene a	4.74mg *	P<.0005	+	2.26mg 10.7mg	0/10	6/10	10/10		
2373 R f nzd wat 12m24 119a					0	.860mg			Goodall;clet,1,295-298;1976
liv hpc	.256mg	P<.0005	+	89.8ug .796mg	0/107	9/10			
tba tum	.321mg	P<.002		96.7ug 2.35mg	40/107	9/10			
2374 R m nzd wat 12m24 119a					0	.753mg			
liv hpc	.322mg	P<.0005	+	.126mg 1.02mg	1/107	8/10			
tba tum	.403mg	P<.002		.137mg 3.12mg	30/107	8/10			
DIMETHYLTHIOUREA 61805-96-7									
2375 R m f34 ipj 60w60 2611					0	35.7mg	179.mg		Rao;oncr,6,1285-1288;1999
liv tum er	no dre	P=1.	-	20.4mg n.s.s.	0/10	0/10	0/10		
DIMETHYLVINYL CHLORIDE 513-37-1									
2376 M f b6c gav 24m24 TR316 :					0	71.4mg	142.mg		
for MXA	14.3mg \	P<.0005	c	8.29mg 24.3mg	0/50	41/50	(36/50)		for:adq,can,sqc.
for MXA	14.3mg \	P<.0005	c	8.29mg 24.3mg	0/50	41/50	(38/50)		for:adq,can,sqc,sqp.
for sqc	14.4mg \	P<.0005	c	8.34mg 24.8mg	0/50	40/50	(36/50)		
for MXA	14.4mg \	P<.0005	c	8.34mg 24.8mg	0/50	40/50	(38/50)		for:sqc,sqp.
MXA MXA	124.mg /	P<.004		45.7mg 1.32gm	10/50	2/50	10/50		jej:mlp; liv:mlm; mul:mlh,mlm,mlp; spl:mlm. S
hag ppa	146.mg *	P<.0005		52.9mg 489.mg	0/50	3/50	5/50		S
liv hpa	150.mg *	P<.007		50.0mg 3.68gm	4/50	4/50	4/50		S
lun MXA	186.mg *	P<.003		58.7mg 1.62gm	3/50	1/50	7/50		lun:a/a,a/c. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun	a/a	235.mg	*	P<.004	68.5mg	2.72gm	2/50	1/50	6/50		S
for	sqp	373.mg	*	P<.005	c 83.4mg	5.10gm	0/50	1/50	3/50		
MXA	mlm	229.mg	*	P<.04	64.1mg	n.s.s.	6/50	1/50	5/50	liv:mlm; mul:mlm; spl:mlm.	S
TBA	MXB	14.6mg	*	P<.0005	9.20mg	25.3mg	32/50	45/50	43/50		
liv	MXB	150.mg	*	P<.007	50.0mg	3.68gm	4/50	4/50	4/50	liv:hpa,hpc,nnd.	
lun	MXB	186.mg	*	P<.003	58.7mg	1.62gm	3/50	1/50	7/50	lun:a/a,a/c.	
2377	M m b6c gav 24m24	TR316 :					0	71.4mg	142.mg		
MXB	MXB	15.2mg	*	P<.0005	9.93mg	23.6mg	2/50	44/50	42/50	for:sqc,sqp; pre:sqc.	C
for	MXA	15.5mg	*	P<.0005	c 10.1mg	23.7mg	1/50	43/50	41/50	for:sqc,sqp.	
for	sqc	17.2mg	*	P<.0005	c 11.2mg	26.2mg	0/50	42/50	35/50		
liv	MXA	48.8mg	*	P<.0005	24.0mg	133.mg	11/50	12/50	13/50	liv:hpa,hpc.	S
liv	hpa	87.1mg	*	P<.0005	36.4mg	407.mg	8/50	7/50	8/50		S
lun	MXA	87.7mg	*	P<.0005	37.2mg	355.mg	6/50	9/50	8/50	lun:a/a,a/c.	S
pre	sqc	90.7mg	/	P<.0005	c 41.8mg	213.mg	1/50	3/50	16/50		
liv	hpc	104.mg	*	P<.0005	44.3mg	375.mg	3/50	6/50	7/50		S
lun	a/a	117.mg	*	P<.002	43.2mg	778.mg	3/50	6/50	4/50		S
MXA	MXA	148.mg	*	P<.008	51.1mg	4.32gm	6/50	6/50	6/50	duo:mlm; lyd:mno; mul:grl,mlh,mlm,mlp,mlu; spl:mlm.	S
hag	ppa	149.mg	*	P<.004	50.4mg	1.51gm	2/50	3/50	3/50		S
MXA	MXA	154.mg	*	P<.009	52.0mg	7.57gm	6/50	5/50	6/50	duo:mlm; lyd:mno; mul:mlh,mlm,mlp,mlu; spl:mlm.	S
for	sqp	195.mg	*	P<.0005	c 66.8mg	827.mg	1/50	3/50	8/50		
lun	a/c	199.mg	*	P<.007	65.5mg	3.88gm	3/50	4/50	5/50		S
MXA	MXA	221.mg	*	P<.008	68.2mg	5.79gm	2/50	3/50	4/50	liv:hem,hes; mln:hem; pre:hem; spl:hes.	S
MXA	hes	375.mg	*	P<.03	83.9mg	n.s.s.	1/50	1/50	3/50	liv:hes; spl:hes.	S
TBA	MXB	13.9mg	*	P<.0005	8.92mg	23.2mg	26/50	47/50	44/50		
liv	MXB	48.8mg	*	P<.0005	24.0mg	133.mg	11/50	12/50	13/50	liv:hpa,hpc,nnd.	
lun	MXB	87.7mg	*	P<.0005	37.2mg	355.mg	6/50	9/50	8/50	lun:a/a,a/c.	
2378	R f f34 gav 23m24	TR316 :					0	70.7mg	143.mg		
MXB	MXB	a 25.3mg	/	P<.0005	15.9mg	40.5mg	1/50	25/50	36/50	eso:sqc; for:sqc,sqp; gnv:sqc; nas:adc,adn,can,sqc; orm:sqp; pal:sqc,sqp; ton:sqc.	C
nas	MXA	a 34.3mg	/	P<.0005	c 20.8mg	55.6mg	0/50	17/50	35/50	nas:adc,adn,can,sqc.	
nas	MXA	a 35.2mg	/	P<.0005	c 21.1mg	57.5mg	0/50	16/50	35/50	nas:adc,can,sqc.	
mgl	MXA	a 36.7mg	/	P<.0005	19.1mg	89.9mg	11/50	21/50	5/50	mgl:adc,fba.	S
mgl	fba	a 38.3mg	/	P<.0005	19.5mg	98.1mg	10/50	18/50	5/50		S
nas	MXA	a 46.8mg	/	P<.0005	c 26.9mg	77.7mg	0/50	13/50	29/50	nas:can,sqc.	
nas	can	a 52.7mg	/	P<.0005	c 29.2mg	89.1mg	0/50	11/50	28/50		
pta	MXA	a 68.0mg	*	P<.004	29.5mg	616.mg	17/50	17/50	2/50	pta:adn,cra,crc.	S
pta	MXA	a 71.7mg	*	P<.006	30.3mg	940.mg	17/50	16/50	2/50	pta:cra,crc.	S
ute	MXA	a 84.9mg	*	P<.002	35.3mg	543.mg	8/50	12/50	2/50	ute:esp,ess.	S
ute	esp	a 91.9mg	*	P<.004	36.6mg	801.mg	8/50	11/50	2/50		S
for	MXA	a 95.2mg	*	P<.0005	c 40.2mg	313.mg	1/50	9/50	2/50	for:sqc,sqp.	
thy	MXA	a 131.mg	*	P<.002	44.3mg	994.mg	1/50	5/50	1/50	thy:fca,fcc.	S
thy	fcc	a 136.mg	*	P<.004	44.9mg	1.53gm	1/50	5/50	0/50		S
nas	MXA	a 143.mg	/	P<.0005	c 54.6mg	412.mg	0/50	4/50	6/50	nas:adc,adn.	
nas	adc	a 159.mg	/	P<.0005	c 56.8mg	504.mg	0/50	3/50	6/50		
for	sqc	a 191.mg	*	P<.0005	c 65.9mg	832.mg	0/50	5/50	1/50		
for	sqp	a 209.mg	*	P<.008	c 62.0mg	7.92gm	1/50	4/50	1/50		
lun	MXA	a 218.mg	*	P<.002	70.5mg	1.11gm	0/50	4/50	1/50	lun:a/a,a/c.	S
eso	sqc	a 250.mg	*	P<.003	c 72.5mg	1.89gm	0/50	3/50	1/50		
MXA	MXA	a 318.mg	/	P<.0005	c 117.mg	1.13gm	0/50	2/50	5/50	gnv:sqc; orm:sqp; pal:sqc,sqp; ton:sqc.	
MXA	sqp	a 1.01gm	/	P<.006	c 343.mg	10.5gm	0/50	0/50	4/50	orm:sqp; pal:sqp.	
pta	MXA	a 101.mg	*	P<.03	37.4mg	n.s.s.	16/50	13/50	2/50	pta:adn,cra.	S
pta	cra	a 109.mg	*	P<.04	38.9mg	n.s.s.	16/50	12/50	2/50		S
mul	MXA	a 170.mg	*	P<.02	59.6mg	n.s.s.	5/50	8/50	1/50	mul:lle,mnl.	S
mul	mnl	a 202.mg	*	P<.04	64.5mg	n.s.s.	5/50	7/50	1/50		S
pta	crc	a 222.mg	*	P<.02	64.6mg	n.s.s.	1/50	4/50	0/50		S
thy	cca	a 225.mg	*	P<.04	64.4mg	n.s.s.	3/50	4/50	1/50		S
orm	sqp	a 1.22gm	/	P<.02	c 369.mg	n.s.s.	0/50	0/50	3/50		
TBA	MXB	a 11.9mg	/	P<.0005	7.69mg	19.4mg	33/50	48/50	42/50		
liv	MXB	a no dre		P=1.	n.s.s.	n.s.s.	0/50	0/50	0/50	liv:hpa,hpc,nnd.	
2379	R m f34 gav 22m24	TR316 :					0	70.7mg	143.mg		
tes	ict	a 13.9mg	/	P<.0005	7.93mg	30.9mg	40/50	41/50	6/50		S
MXB	MXB	a 17.5mg	/	P<.0005	10.8mg	28.5mg	0/50	33/50	29/50	eso:sqc,sqp; for:sqc,sqp; lpp:sqc; nas:adc,can,sqc; pal:sqc,sqp; ton:sqc,sqp.	C
nas	MXA	a 29.7mg	/	P<.0005	c 18.2mg	47.1mg	0/50	23/50	28/50	nas:adc,can,sqc.	
for	MXA	a 41.6mg	*	P<.0005	c 19.8mg	98.0mg	0/50	14/50	0/50	for:sqc,sqp.	
nas	MXA	a 52.1mg	/	P<.0005	c 32.0mg	84.8mg	0/50	15/50	24/50	nas:can,sqc.	
nas	can	a 63.4mg	/	P<.0005	c 38.2mg	101.mg	0/50	12/50	24/50		
for	sqp	a 67.1mg	*	P<.0005	c 26.7mg	230.mg	0/50	7/50	0/50		
nas	acn	a 70.1mg	/	P<.0005	29.7mg	185.mg	0/50	8/50	4/50		S
eso	MXA	a 81.6mg	/	P<.0005	c 32.0mg	249.mg	0/50	6/50	4/50	eso:sqc,sqp.	
mul	mnl	a 128.mg	*	P<.006	44.2mg	2.22gm	3/50	6/50	1/50		S
for	sqc	a 135.mg	*	P<.0005	c 50.3mg	463.mg	0/50	7/50	0/50		
eso	sqc	a 143.mg	*	P<.0005	c 44.3mg	770.mg	0/50	4/50	1/50		
MXA	MXA	a 163.mg	*	P<.0005	c 56.5mg	511.mg	0/50	5/50	4/50	lpp:sqc; pal:sqc,sqp; ton:sqc,sqp.	
MXA	sqc	a 178.mg	*	P<.0005	c 58.0mg	708.mg	0/50	5/50	2/50	lpp:sqc; pal:sqc; ton:sqc.	
eso	sqp	a 218.mg	*	P<.002	c 59.8mg	1.31gm	0/50	2/50	3/50		
nas	sqc	a 297.mg	*	P<.009	c 87.7mg	13.1gm	0/50	3/50	0/50		
ton	MXA	a 415.mg	*	P<.002	c 157.mg	2.06gm	0/50	3/50	3/50	ton:sqc,sqp.	
ton	sqc	a 469.mg	*	P<.005	c 165.mg	4.25gm	0/50	3/50	2/50		
MXA	MXA	a 86.7mg	/	P<.02	29.2mg	n.s.s.	13/50	7/50	3/50	adr:phm; amd:phe.	S
TBA	MXB	a 10.2mg	/	P<.0005	6.56mg	17.2mg	40/50	48/50	37/50		
liv	MXB	a 1.03gm	/	P<.3	107.mg	n.s.s.	1/50	0/50	1/50	liv:hpa,hpc,nnd.	
2,4-DINITRO-6-tert-BUTYLPHENYL METHANESULFONATE (HE 166) 29110-68-7											
2380	R f sda eat 52w52	2336					0	1.25mg	5.00mg	Imai;jtxs,9,161-174;1984	
liv	tum	e no dre		P=1.	.491mg	n.s.s.	0/6	0/10	0/8		
tba	mix	e 2.66mg	*	P<.2	.800mg	n.s.s.	0/6	1/10	2/8		

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf | Brkly Code
Path TD_{50} 2Tailpvl LoConf | Cntrl 1 Inc 2 Inc 3 Inc | NCI/NTPPathology

```
2381 R m sda eat 52w52 2336                              0     1.00mg  4.00mg
 liv tum e      no dre    P=1.        .247mg n.s.s.   0/6     0/6     0/6
 tba tum e      no dre    P=1.        .247mg n.s.s.   0/6     0/6     0/6

DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE, COMMERCIAL GRADE (78%)  (karathane) 6119-92-2
2382 M f b6a orl 76w76 1290                              0     .414mg                          Innes;ntis,1968/1969
 liv hpt evx    no dre    P=1.     -  .774mg n.s.s.   0/17    0/17
 lun ade evx    no dre    P=1.     -  .774mg n.s.s.   1/17    0/17
 tba mix evx    no dre    P=1.     -  .774mg n.s.s.   2/17    0/17
2383 M m b6a orl 76w76 1290                              0     .385mg
 liv hpt evx    2.07mg    P<.6     -  .302mg n.s.s.   1/18    2/17
 lun ade evx    19.1mg    P<1.     -  .335mg n.s.s.   2/18    2/17
 tba mix evx    11.9mg    P<1.     -  .280mg n.s.s.   3/18    3/17
2384 M f b6c orl 76w76 1290                              0     .414mg
 liv hpt evx    2.50mg    P<.3     -  .407mg n.s.s.   0/16    1/17
 lun mix evx    no dre    P=1.     -  .774mg n.s.s.   0/16    0/17
 tba mix evx    1.21mg    P<.1     -  .297mg n.s.s.   0/16    2/17
2385 M m b6c orl 76w76 1290                              0     .385mg
 liv hpt evx    2.32mg    P<.3     -  .378mg n.s.s.   0/16    1/17
 lun mix evx    no dre    P=1.     -  .721mg n.s.s.   0/16    0/17
 tba mix evx    .405mg    P<.007   -  .152mg 5.47mg   0/16    5/17

2,4-DINITROPHENOL   51-28-5
2386 M b c51 eat 73w73 257                               0     62.5mg                              King;pseb,112,365-366;1963
 pit ade er     no dre    P=1.        241.mg n.s.s.   0/28    0/38

2,4-DINITROPHENOL, SODIUM   1011-73-0
2387 M f dbx eat 90w90 1652                              0     325.mg                          Tannenbaum;canr,9,403-410;1949
 mgl car er     no dre    P=1.     -  2.38gm n.s.s.  37/50    1/50

1,4-DINITROSO-2,6-DIMETHYLPIPERAZINE   55380-34-2
2388 H m syg gav 35w76 1570                              0     3.68mg                          Lijinsky;carc,4,1165-1167;1983
 for pam        3.10mg    P<.04    +  1.17mg n.s.s.   3/20    9/20
 lun ade        6.04mg    P<.02       2.08mg n.s.s.   0/20    4/20
 liv ang        8.30mg    P<.04       2.50mg n.s.s.   0/20    3/20
 tba mix        .932mg    P<.0005     .448mg 2.63mg   3/20   16/20

DINITROSOCAFFEIDINE   145438-97-7
2389 R b bd9 gav 41w52 2573                              0     1.71mg  9.13mg                  Ivankovic;carc,19,933-937;1998
 for sqc erv    .183mg  * P<.0005 +  .120mg .288mg   0/43   42/42   40/42

DINITROSOHOMOPIPERAZINE   55557-00-1
2390 R f f34 wat  7m31 1375m                             0     10.1ug  26.4ug  72.0ug  .269mg  1.18mg  2.93mg    Lijinsky;eaes,6,513-527;
                                                                                                                 1982/pers.comm.
 ugi car es     .240mg Z P<.0005 +  .144mg .501mg   0/20    1/20    3/20    6/20   13/20  (10/20   14/20)
 eso mix es     .253mg Z P<.0005 +  .151mg .538mg   0/20    1/20    3/20    6/20   13/20  (10/20   14/20)
 ugi mix es     .708mg Z P<.0005 +  .398mg 1.43mg   0/20    1/20    4/20    9/20   16/20   15/20   19/20
 liv mix es     no dre    P=1.     +  29.3mg n.s.s.   1/20    6/20    4/20    1/20    0/20    0/20    0/20
 nas olc es     no dre    P=1.     +  26.8mg n.s.s.   0/20    0/20    0/20    7/20    0/20    0/20    0/20
2391 R f f34 wat 60w82 1375n                             0     .209mg
 ugi mix es     29.7ug    P<.0005 +  12.2ug 68.1ug   0/20   19/20
 ugi car es     46.9ug    P<.0005 +  23.4ug .102mg   0/20   17/20
 eso mix es     55.3ug    P<.0005 +  28.2ug .120mg   0/20   16/20
 nas olc es     .207mg    P<.002  +  88.4ug .783mg   0/20    7/20
2392 R f f34 wat 28m31 1375o                             0     39.9ug  .116mg
 ugi mix es     91.4ug  * P<.0005 +  52.8ug .173mg   0/20    5/20   17/20
 liv mix es     97.3ug  \ P<.006  +  40.6ug 1.20mg   1/20    8/20   (6/20)
 eso mix es     .105mg  * P<.0005 +  59.4ug .203mg   0/20    3/20   17/20
 ton bcp es     .630mg  * P<.004  +  .239mg 4.43mg   0/20    0/20    5/20

N,N-DINITROSOPENTAMETHYLENETETRAMINE   101-25-7
2393 R m cbr ipj  6m23 1258                              0     1.86mg                              Boyland;ejca,4,233-239;1968
 liv hpt e      no dre    P=1.     -  4.93mg n.s.s.   1/22    1/23

DINITROSOPIPERAZINE   140-79-4
2394 M f c17 gav  9m24 1347                              0     3.08mg                                  Pai;carc,2,175-177;1981
 for sqc e      4.66mg    P<.003   +  1.59mg 28.1mg   0/22    4/11
 ute rna e      4.13mg    P<.02       1.36mg n.s.s.   2/22    5/11
2395 M m c17 gav  9m24 1347                              0     2.56mg
 for sqc e      2.01mg    P<.0005 +  .831mg 7.00mg   0/12    7/12
2396 M f swi wat 12m23 1250                              0     10.4mg                          Borzsonyi;canr,40,2925-2927;1980
 lun ade e      no dre    P=1.        11.7mg n.s.s.   7/29    3/14
 liv hpc e      no dre    P=1.        27.8mg n.s.s.   4/29    0/14
 tba mix e      no dre    P=1.     +  5.26mg n.s.s.  25/29   10/14
2397 M m swi wat 12m23 1250                              0     8.67mg
 lun ade e      8.70mg    P<.0005     4.07mg 27.6mg   3/50   11/22
 liv hpc e      51.9mg    P<.2        12.2mg n.s.s.   2/50    3/22
 tba mix e      8.24mg    P<.02    +  3.17mg n.s.s.  19/50   15/22

2,6-DINITROTOLUENE   606-20-2
2398 R m f34 eat 52w52 1834                              0     7.00mg  14.0mg                  Leonard;jnci,79,1313-1319;1987/pers.comm.
 liv hpc er     .574mg  * P<.0005 +  .305mg 1.06mg   0/20   17/20   19/19
 liv thc er     .574mg  * P<.0005    .305mg 1.06mg   0/20   17/20   19/19
 liv nnd er     .964mg  * P<.0005 +  .587mg 1.65mg   0/20   18/20   15/19
 liv clc er     34.2mg  * P<.8       8.41mg n.s.s.   0/20    2/20    0/19
 liv hpd er     68.9mg  * P<.9       11.2mg n.s.s.   0/20    1/20    0/19
2399 R m f34 eat 52w52 2223m                             0     .650mg  3.25mg                  Goldsworthy;carc,7,1909-1915;1986
 liv mix er     .196mg  * P<.0005 +  82.0ug .503mg   0/10    3/10   10/10
```

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
liv nnd er		.504mg *	P<.002 +	.229mg 2.82mg	0/10	3/10	6/10		
liv hpc er		.803mg *	P<.0005 +	.318mg 2.97mg	0/10	0/10	6/10		
2400 R m f34 eat 52w52 2223n					0	.650mg	3.25mg		
liv mix er		no dre	P=1. -	.279mg n.s.s.	0/10	0/10	0/10		
2401 R m f34 eat 52w52 2223o					0	.650mg	3.25mg		
liv mix er		no dre	P=1. -	.279mg n.s.s.	0/10	0/10	0/10		
2,4-DINITROTOLUENE (CONTAINING 0.5% 2,6-DINITROTOLUENE) 121-14-2									
2402 R m f34 eat 52w52 1834					0	27.0mg			Leonard;jnci,79,1313-1319;1987/pers.comm.
liv mix er		90.2mg	P<.3 -	14.7mg n.s.s.	0/20	1/20			
liv nnd er		90.2mg	P<.3 -	14.7mg n.s.s.	0/20	1/20			
2,4-DINITROTOLUENE (CONTAINING 1.0-1.5% 2,6-DINITROTOLUENE) 121-14-2									
2403 M f cd1 eat 52w52 2221m					0	13.0mg	91.0mg	650.mg	Hong;jact,4,257-269;1985
kid tlt ek		no dre	P=1.	4.61mg n.s.s.	0/8	0/8	0/8	0/8	
liv hct ek		no dre	P=1.	4.61mg n.s.s.	0/8	0/8	0/8	0/8	
2404 M f cd1 eat 23m24 2221n					0	13.0mg	91.0mg	650.mg	
kid tlt aes		11.6gm *	P<.2	1.88gm n.s.s.	0/23	0/20	0/22	1/23	
liv hct aes		no dre	P=1.	49.0mg n.s.s.	0/23	0/21	0/23	0/25	
2405 M m cd1 eat 52w52 2221m					0	12.0mg	84.0mg	600.mg	
kid tlt ek		423.mg *	P<.03	103.mg n.s.s.	0/8	0/8	0/8	2/8	
liv hct ek		no dre	P=1.	4.25mg n.s.s.	0/8	0/8	0/8	0/8	
2406 M m cd1 eat 22m24 2221n					0	12.0mg	84.0mg	600.mg	
kid tlt aes		29.4mg Z	P<.0005 +	16.5mg 56.9mg	0/24	6/22	16/19	(10/29)	
liv hct aes		no dre	P=1.	51.8mg n.s.s.	0/25	0/25	0/20	0/32	
2407 R f cdr eat 52w52 2222m					0	.750mg	5.00mg	35.0mg	Lee;jact,4,243-256;1985
liv nnd ek		4.31mg *	P<.0005 +	1.66mg 14.5mg	0/8	0/8	0/8	7/8	
liv hpc ek		52.8mg *	P<.2	8.57mg n.s.s.	0/8	0/8	0/8	1/8	
2408 R f cdr eat 24m24 2222n					0	.750mg	5.00mg	35.0mg	
liv hpc e		52.0mg *	P<.0005 +	25.9mg 128.mg	0/23	0/28	1/26	10/25	
mgl mix e		7.05mg Z	P<.02 +	2.97mg n.s.s.	11/23	1/28	16/26	(21/25)	
liv nnd e		123.mg *	P<.03	46.1mg n.s.s.	0/23	2/28	2/26	5/25	
ski mix e		213.mg *	P<.1	58.5mg n.s.s.	1/23	2/28	0/26	4/25	
2409 R m cdr eat 52w52 2222m					0	.600mg	4.00mg	28.0mg	
liv nnd ek		4.28mg *	P<.0005 +	1.60mg 19.4mg	0/8	1/8	0/8	6/8	
liv hpc ek		no dre	P=1.	.211mg n.s.s.	0/7	0/8	0/8	0/7	
2410 R m cdr eat 24m24 2222n					0	.600mg	4.00mg	28.0mg	
ski mix e		27.7mg *	P<.0005 +	13.9mg 83.0mg	2/25	4/27	3/19	15/27	
liv hpc e		84.7mg *	P<.004 +	33.6mg 747.mg	1/25	0/27	1/19	6/27	
mgl mix e		281.mg *	P<.03	69.1mg n.s.s.	0/25	0/27	0/19	2/27	
liv nnd e		979.mg *	P<.8	72.3mg n.s.s.	1/25	2/27	1/19	2/27	
2,4-DINITROTOLUENE, PRACTICAL GRADE 121-14-2									
2411 M f b6c eat 78w93 TR54 :					0	8.80mg	44.2mg		
TBA MXB		no dre	P=1. -	18.6mg n.s.s.	39/100	14/50	(11/50)		
liv MXB		no dre	P=1.	234.mg n.s.s.	8/100	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB		68.0mg \	P<.2	18.6mg n.s.s.	2/100	4/50	(0/50)		lun:a/a,a/c.
2412 M m b6c eat 78w92 TR54 :					0	8.20mg	40.8mg		
TBA MXB		no dre	P=1. -	86.7mg n.s.s.	40/100	13/50	13/50		
liv MXB		no dre	P=1.	86.7mg n.s.s.	22/100	6/50	9/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	39.4mg n.s.s.	18/100	3/50	(2/50)		lun:a/a,a/c.
2413 R f f34 eat 18m25 TR54 :					0	3.00mg	7.50mg		
mgl fba uv		12.7mg *	P<.02 a	5.78mg n.s.s.	13/75	12/50	23/50		
TBA MXB v		no dre	P=1.	5.97mg n.s.s.	57/75	41/50	40/50		
liv MXB v		no dre	P=1.	35.0mg n.s.s.	3/75	0/50	2/50		liv:hpa,hpc,nnd.
2414 R m f34 eat 18m25 TR54 :					0	2.40mg	6.00mg		
MXA fib uv		9.35mg *	P<.0005 a	5.49mg 19.1mg	0/75	7/50	13/50		ski:fib; sub:fib.
TBA MXB v		43.7mg *	P<.8	4.84mg n.s.s.	40/75	29/50	35/50		
liv MXB v		31.1mg *	P<.04	12.6mg n.s.s.	0/75	3/50	3/50		liv:hpa,hpc,nnd.
DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-) 25321-14-6									
2415 R m f34 eat 52w52 1834					0	35.0mg			Leonard;jnci,79,1313-1319;1987/pers.comm.
liv nnd er		8.02mg	P<.0005 +	3.82mg 20.9mg	0/20	10/19			
liv thc er		9.34mg	P<.0005 +	4.32mg 26.1mg	0/20	9/19			
liv clc er		53.9mg	P<.09	13.2mg n.s.s.	0/20	2/19			
1,4-DIOXANE (p-dioxane) 123-91-1									
2416 M f b6c wat 90w90 TR80 :					0	984.mg	1.99gm		
liv MXA		594.mg *	P<.0005 c	426.mg 861.mg	0/50	21/50	35/50		liv:hpa,hpc.
liv hpc		938.mg /	P<.0005 c	639.mg 1.45gm	0/50	12/50	29/50		
TBA MXB		847.mg *	P<.0005	501.mg 2.19gm	15/50	31/50	35/50		
liv MXB		594.mg *	P<.0005	426.mg 861.mg	0/50	21/50	35/50		liv:hpa,hpc,nnd.
lun MXB		71.9gm *	P<.8	6.34gm n.s.s.	3/50	0/50	3/50		lun:a/a,a/c.
2417 M m b6c wat 90w91 TR80 :					0	820.mg	1.65gm		
liv hpc		1.42gm *	P<.0005 c	863.mg 3.66gm	4/50	18/50	24/50		
liv MXA		1.46gm *	P<.0005 c	833.mg 5.11gm	8/50	19/50	28/50		liv:hpa,hpc.
--- MXA		3.15gm \	P<.005	1.29gm 22.1gm	0/50	6/50	(3/50)		---:hem,hes. S
--- lym		3.93gm \	P<.009	1.49gm 16.3gm	0/50	5/50	(2/50)		S
TBA MXB		1.88gm *	P<.03	841.mg n.s.s.	19/50	28/50	33/50		
liv MXB		1.46gm *	P<.0005	833.mg 5.11gm	8/50	19/50	28/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	8.27gm n.s.s.	8/50	3/50	3/50		lun:a/a,a/c.
2418 M f bd1 wat 24m24 2444					0	99.0mg	396.mg	1.58gm	Yamazaki;icmr,1993,193-198;1994/pers.comm.
liv mix e		65.5mg Z	P<.0005 +	40.8mg 117.mg	4/50	34/50	(41/50	46/50)	
liv hpa e		83.1mg Z	P<.0005 +	50.5mg 159.mg	4/50	30/50	(20/50	2/50)	
liv hpc e		404.mg *	P<.0005 +	292.mg 570.mg	0/50	6/50	30/50	45/50	
nas adc e		72.1gm *	P<.2	11.7gm n.s.s.	0/50	0/50	0/50	1/50	
2419 M m bd1 wat 24m24 2444					0	82.5mg	330.mg	1.32gm	
liv hpa e		519.mg Z	P<.003 +	262.mg 2.99gm	7/50	16/50	22/50	(8/50)	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv mix e	982.mg *	P<.002 +	480.mg 5.39gm	21/50	31/50	37/50	39/50		
liv hpc e	1.04gm *	P<.0005 +	581.mg 2.79gm	15/50	20/50	23/50	36/50		
nas ene e	60.1gm *	P<.2	9.78gm n.s.s.	0/50	0/50	0/50	1/50		
2420 R f osm wat 26m26 TR80 :				0	284.mg	569.mg			
MXB MXB	126.mg *	P<.0005	69.7mg 218.mg	0/35	18/35	18/35			liv:hpa; ntu:sqc. C
liv hpa	160.mg *	P<.0005 c	79.1mg 323.mg	0/35	10/35	11/35			
ntu sqc	476.mg *	P<.0005 c	249.mg 970.mg	0/35	10/35	8/35			
TBA MXB	40.5mg \	P<.0005	20.0mg 108.mg	26/35	28/35	(22/35)			
liv MXB	124.mg *	P<.0005	60.1mg 263.mg	0/35	10/35	12/35			liv:hpa,hpc,nnd.
2421 R m osm wat 26m26 TR80 :				0	250.mg	500.mg			
ntu sqc	168.mg *	P<.0005 c	94.3mg 304.mg	0/35	12/35	16/35			
TBA MXB	114.mg *	P<.0005	59.3mg 339.mg	21/35	18/35	27/35			
liv MXB	796.mg *	P<.2	190.mg n.s.s.	1/35	2/35	1/35			liv:hpa,hpc,nnd.
2422 R m cdr wat 56w69 124				0	305.mg	406.mg	569.mg	731.mg	Hoch-Ligeti;bjca,24,164-167;1969
nas sqc rh	2.95gm *	P<.07 +	1.20gm n.s.s.	0/30	1/30	1/30	2/30	2/30	
2423 R f f3d wat 24m24 2444				0	11.3mg	56.6mg	283.mg		Yamazaki;icmr,1993,193-198;1994/pers.comm.
liv mix e	167.mg Z	P<.0005 +	113.mg 258.mg	1/50	0/50	5/50	40/50		
liv hpa e	182.mg Z	P<.0005 +	123.mg 283.mg	1/50	0/50	5/50	38/50		
mgl ade e	772.mg *	P<.008 +	337.mg 24.1gm	6/50	7/50	10/50	16/50		
liv hpc e	1.12gm *	P<.0005 +	547.mg 2.89gm	0/50	0/50	0/50	10/50		
nas mal e	1.43gm *	P<.0005 +	648.mg 4.19gm	0/50	0/50	0/50	8/50		
nas sqc e	1.65gm *	P<.0005 +	712.mg 5.28gm	0/50	0/50	0/50	7/50		
nas ene e	12.2gm *	P<.2	1.98gm n.s.s.	0/50	0/50	0/50	1/50		
2424 R m f3d wat 24m24 2444				0	9.90mg	49.5mg	248.mg		
liv mix e	189.mg *	P<.0005 +	126.mg 297.mg	0/50	2/50	4/50	33/50		
per mso e	246.mg *	P<.0005 +	157.mg 430.mg	2/50	2/50	5/50	28/50		
liv hpa e	279.mg *	P<.0005 +	179.mg 483.mg	0/50	2/50	4/50	24/50		
liv hpc e	676.mg *	P<.0005 +	363.mg 1.47gm	0/50	0/50	0/50	14/50		
sub fib e	922.mg *	P<.009 +	392.mg 34.7gm	5/50	3/50	5/50	12/50		
nas mal e	1.44gm *	P<.0005 +	623.mg 4.62gm	0/50	0/50	0/50	7/50		
nas sqc e	3.49gm *	P<.009 +	1.06gm 99.6gm	0/50	0/50	0/50	3/50		
mgl fba e	3.07gm *	P<.06 +	906.mg n.s.s.	1/50	1/50	0/50	4/50		
nas srn e	5.27gm *	P<.04	1.30gm n.s.s.	0/50	0/50	0/50	2/50		
nas ene e	10.6gm *	P<.2	1.73gm n.s.s.	0/50	0/50	0/50	1/50		
nas rhb e	10.6gm *	P<.2	1.73gm n.s.s.	0/50	0/50	0/50	1/50		
2425 R b she wat 24m24 125				0	5.29mg	52.9mg	529.mg		Kociba;txap,30,275-286;1974
liv mix e	2.12gm *	P<.0005 +	1.08gm 5.36gm	2/106	0/110	1/106	12/66		
liv hpc e	2.50gm *	P<.0005 +	1.22gm 6.73gm	1/106	0/110	1/106	10/66		
ntu sqc e	15.9gm *	P<.006 +	4.82gm 231.gm	0/120	0/120	0/120	3/120		
tba mix e	no dre	P=1.	4.33gm n.s.s.	31/120	34/120	28/120	21/120		
2426 R b wis wat 63w64 104				0	521.mg				Argus;jnci,35,949-958;1965
liv hpt	515.mg	P<.05 +	209.mg n.s.s.	0/9	6/26				
tba mix	690.mg	P<.4	206.mg n.s.s.	1/9	7/26				
DIOXATHION 78-34-2									
2427 M f b6c eat 78w90 TR125 :				0	52.5mg	105.mg			
TBA MXB v	2.59gm *	P<.9 -	207.mg n.s.s.	2/20	6/50	6/50			
liv MXB v	no dre	P=1.	623.mg n.s.s.	0/20	1/50	0/50			liv:hpa,hpc,nnd.
lun MXB v	1.82gm *	P<.5	447.mg n.s.s.	0/20	1/50	1/50			lun:a/a,a/c.
2428 M m b6c eat 78w90 TR125 :				0	29.5mg	58.8mg			
TBA MXB v	no dre	P=1. -	77.0mg n.s.s.	7/20	10/50	13/50			
liv MXB v	no dre	P=1.	128.mg n.s.s.	4/20	4/50	6/50			liv:hpa,hpc,nnd.
lun MXB v	628.mg *	P<.5	141.mg n.s.s.	1/20	1/50	4/50			lun:a/a,a/c.
2429 R f osm eat 18m26 TR125 :				0	1.60mg	3.00mg			
TBA MXB v	no dre	P=1. -	3.98mg n.s.s.	36/50	27/50	29/50			
liv MXB v	no dre	P=1.	36.3mg n.s.s.	1/50	0/50	0/50			liv:hpa,hpc,nnd.
2430 R m osm eat 18m26 TR125 :				0	2.40mg	4.80mg			
TBA MXB v	no dre	P=1. -	6.81mg n.s.s.	28/50	23/50	21/50			
liv MXB v	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50			liv:hpa,hpc,nnd.
DIPENTAMETHYLENETHIURAM HEXASULFIDE (sulfads) 971-15-3									
2431 M f b6a orl 76w76 1221				0	41.4mg				Innes;ntis,1968/1969
lun ade evx	no dre	P=1. -	49.2mg n.s.s.	1/17	1/18				
liv hpt evx	no dre	P=1. -	82.0mg n.s.s.	0/17	0/18				
tba mix evx	120.mg	P<.5 -	23.9mg n.s.s.	2/17	4/18				
2432 M m b6a orl 76w76 1221				0	38.5mg				
lun ade evx	no dre	P=1. -	47.4mg n.s.s.	2/18	1/17				
liv hpt evx	no dre	P=1. -	72.1mg n.s.s.	1/18	0/17				
tba mix evx	no dre	P=1. -	50.7mg n.s.s.	3/18	1/17				
2433 M f b6c orl 76w76 1221				0	41.4mg				
lun ade evx	83.1mg	P<.05 -	25.1mg n.s.s.	0/16	3/18				
liv hpt evx	no dre	P=1. -	82.0mg n.s.s.	0/16	0/18				
tba mix evx	83.1mg	P<.05 -	25.1mg n.s.s.	0/16	3/18				
2434 M m b6c orl 76w76 1221				0	38.5mg				
liv hpt evx	113.mg	P<.1 -	27.6mg n.s.s.	0/16	2/17				
lun ade evx	113.mg	P<.1 -	27.6mg n.s.s.	0/16	2/17				
tba mix evx	52.5mg	P<.02 -	18.1mg n.s.s.	0/16	4/17				
DIPENTYLNITROSAMINE 13256-06-9									
2435 R f f34 eat 23m24 1824				0	2.50mg	7.50mg	22.5mg		Elashoff;jnci,79,509-526;1987
liv hpc er	7.57mg *	P<.0005 +	4.75mg 12.7mg	0/144	3/24	8/24	24/24		
2436 R m f34 eat 21m24 1824				0	2.00mg	6.00mg	18.0mg		
liv hpc er	2.75mg *	P<.0005 +	1.74mg 4.46mg	1/144	7/24	22/24	23/24		
DIPHENHYDRAMINE.HCl (benadryl) 147-24-0									
2437 M f b6c eat 24m24 TR355 :				0	20.1mg	40.3mg			
TBA MXB	no dre	P=1. -	33.1mg n.s.s.	37/50	39/50	32/50			
liv MXB	363.mg *	P<.5	80.6mg n.s.s.	5/50	5/50	7/50			liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD$_{50}$	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
lun MXB		357.mg * P<.3		98.7mg n.s.s.	3/50	2/50	6/50		lun:a/a,a/c.
2438 M m b6c eat 24m25 TR355 :					0	18.5mg	37.2mg		
liv hpc #		37.3mg \ P<.02	-	16.0mg n.s.s.	4/50	14/50	(5/50)		S
TBA MXB		no dre P=1.		31.3mg n.s.s.	30/50	32/50	22/50		
liv MXB		201.mg * P<.6		34.1mg n.s.s.	12/50	18/50	12/50		liv:hpa,hpc,nnd.
lun MXB		447.mg \ P<.9		31.8mg n.s.s.	6/50	7/50	(0/50)		lun:a/a,a/c.
2439 R f f34 eat 24m24 TR355 :					0	7.62mg	15.4mg		
pta adn		20.5mg * P<.06	e	8.55mg n.s.s.	23/50	26/50	35/50		
TBA MXB		65.1mg * P<.8		8.16mg n.s.s.	47/50	46/50	46/50		
liv MXB		no dre P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
2440 R f f34 eat 25m30 1654					0	82.5mg			Lijinsky;fctx,22,715-720;1984
liv nnd e		no dre P=1.	-	277.mg n.s.s.	4/24	3/24			
2441 R m f34 eat 24m24 TR355 :					0	12.3mg	24.6mg		
lun a/a		66.1mg * P<.009		29.3mg 1.71gm	0/50	5/50	3/50		S
bra ast		140.mg / P<.01		46.0mg 6.01gm	0/50	0/50	4/50		S
lun MXA		57.3mg * P<.02	e	25.0mg n.s.s.	1/50	6/50	5/50		lun:a/a,a/c.
bra MXA		143.mg / P<.05	e	45.5mg n.s.s.	1/50	0/50	5/50		bra:ast,gln.
TBA MXB		17.8mg * P<.07		7.16mg n.s.s.	47/50	49/50	47/50		
liv MXB		243.mg * P<.2		59.7mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
2442 R m f34 eat 25m30 1654					0	66.0mg			Lijinsky;fctx,22,715-720;1984
liv nnd e		no dre P=1.	-	193.mg n.s.s.	5/24	4/24			
DIPHENYL-p-PHENYLENEDIAMINE (agerite DPPD) 74-31-7									
2443 M f b6a orl 76w76 1158					0	462.mg			Innes;ntis,1968/1969
lun ade evx		2.79gm P<.3	-	454.mg n.s.s.	0/18	1/17			
liv hpt evx		no dre P=1.	-	864.mg n.s.s.	0/18	0/17			
tba mix evx		2.79gm P<.3	-	454.mg n.s.s.	0/18	1/17			
2444 M m b6a orl 76w76 1158					0	430.mg			
lun ade evx		1.33gm P<.09	-	328.mg n.s.s.	0/18	2/18			
liv hpt evx		no dre P=1.	-	851.mg n.s.s.	1/18	0/18			
tba mix evx		no dre P=1.	-	401.mg n.s.s.	2/18	2/18			
2445 M f b6c orl 76w76 1158					0	462.mg			
liv hpt evx		no dre P=1.	-	915.mg n.s.s.	0/18	0/18			
lun ade evx		no dre P=1.	-	915.mg n.s.s.	1/18	0/18			
tba mix evx		no dre P=1.	-	915.mg n.s.s.	2/18	0/18			
2446 M m b6c orl 76w76 1158					0	430.mg			
liv hpt evx		no dre P=1.	-	306.mg n.s.s.	3/14	3/16			
lun mix evx		no dre P=1.	-	756.mg n.s.s.	0/14	0/16			
tba mix evx		4.11gm P<.9	-	213.mg n.s.s.	4/14	5/16			
2447 R f f3d eat 24m26 1943					0	232.mg	929.mg		Hasegawa;txcy,54,69-78;1989
liv clc e		44.8gm * P<.2	-	7.30gm n.s.s.	0/47	0/49	1/49		
2448 R m f3d eat 24m26 1943					0	186.mg	743.mg		
liv hnd e		19.5gm * P<.4	-	4.40gm n.s.s.	0/50	1/49	1/49		
DIPHENYLACETONITRILE 86-29-3									
2449 M f b6a orl 76w76 1311					0	78.4mg			Innes;ntis,1968/1969
lun ade evx		no dre P=1.	-	93.2mg n.s.s.	1/17	1/18			
liv hpt evx		no dre P=1.	-	155.mg n.s.s.	0/17	0/18			
tba mix evx		no dre P=1.	-	74.0mg n.s.s.	2/17	2/18			
2450 M m b6a orl 76w76 1311					0	73.0mg			
lun ade evx		3.62gm P<1.	-	63.5mg n.s.s.	2/18	2/17			
liv hpt evx		no dre P=1.	-	137.mg n.s.s.	1/18	0/17			
tba mix evx		no dre P=1.	-	70.3mg n.s.s.	3/18	2/17			
2451 M f b6c orl 76w76 1311					0	78.4mg			
lun mix evx		229.mg P<.1	-	56.3mg n.s.s.	0/16	2/17			
liv hpt evx		no dre P=1.	-	147.mg n.s.s.	0/16	0/17			
tba mix evx		148.mg P<.04	-	44.6mg n.s.s.	0/16	3/17			
2452 M m b6c orl 76w76 1311					0	73.0mg			
lun ade evx		129.mg P<.04	-	38.8mg n.s.s.	0/16	3/16			
liv hpt evx		200.mg P<.09	-	49.1mg n.s.s.	0/16	2/16			
tba mix evx		46.4mg P<.002	-	19.7mg 170.mg	0/16	7/16			
DIPHENYLCARBONATE 102-09-0									
2453 M f b6a orl 76w76 1313					0	36.4mg			Innes;ntis,1968/1969
lun ade evx		206.mg P<.6	-	28.7mg n.s.s.	1/17	2/17			
liv hpt evx		no dre P=1.	-	68.1mg n.s.s.	0/17	0/17			
tba mix evx		no dre P=1.	-	32.0mg n.s.s.	2/17	2/17			
2454 M m b6a orl 76w76 1313					0	33.9mg			
lun ade evx		no dre P=1.	-	38.9mg n.s.s.	2/18	1/16			
liv hpt evx		no dre P=1.	-	59.7mg n.s.s.	1/18	0/16			
tba mix evx		no dre P=1.	-	41.6mg n.s.s.	3/18	1/16			
2455 M f b6c orl 76w76 1313					0	36.4mg			
liv hem evx		233.mg P<.3	-	37.9mg n.s.s.	0/16	1/18			
lun ade evx		233.mg P<.3	-	37.9mg n.s.s.	0/16	1/18			
tba mix evx		73.1mg P<.05	-	22.0mg n.s.s.	0/16	3/18			
2456 M m b6c orl 76w76 1313					0	33.9mg			
liv hpt evx		68.0mg P<.05	-	20.5mg n.s.s.	0/16	3/18			
lun ade evx		217.mg P<.3	-	35.3mg n.s.s.	0/16	1/18			
tba mix evx		25.2mg P<.002	-	10.7mg 103.mg	0/16	7/18			
5,5-DIPHENYLHYDANTOIN (phenytoin) 57-41-0									
2457 M f b6c eat 25m25 TR404 :					0	26.0mg	78.0mg		
liv MXA		59.1mg * P<.0005	c	34.8mg 151.mg	5/50	14/50	30/50		liv:hpa,hpb,hpc.
liv hpa		92.4mg * P<.002	c	48.2mg 496.mg	5/50	13/50	22/50		
liv MXA		148.mg * P<.0005	c	76.5mg 354.mg	0/50	1/50	12/50		liv:hpb,hpc.
liv hpc		165.mg * P<.0005	c	83.1mg 418.mg	0/50	1/50	11/50		
TBA MXB		2.39gm * P<1.		52.8mg n.s.s.	40/50	36/50	42/50		
liv MXB		59.1mg * P<.0005		34.8mg 151.mg	5/50	14/50	30/50		liv:hpa,hpb,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun MXB		no dre	P=1.	385.mg n.s.s.	5/50	3/50	2/50		lun:a/a,a/c.
2458 M f b6c eat 78w86 1887					0	7.07mg	14.1mg		Maeda;jtxe,24,111-119;1988
liv hct e		151.mg *	P<.3	- 45.8mg n.s.s.	0/49	2/49	1/45		
liv hpa e		229.mg *	P<.8	- 56.3mg n.s.s.	0/49	2/49	0/45		
liv hpc e		457.mg *	P<.3	- 74.5mg n.s.s.	0/49	0/49	1/45		
lun act e		2.06gm *	P<1.	- 55.4mg n.s.s.	1/49	2/49	1/45		
liv hem e		no dre	P=1.	- 97.3mg n.s.s.	1/49	1/49	0/45		
2459 M m b6c eat 24m24 TR404 :					0	12.0mg	36.0mg		
TBA MXB		no dre	P=1.	- 26.7mg n.s.s.	43/50	39/50	36/50		
liv MXB		724.mg *	P<.9	33.2mg n.s.s.	29/50	29/50	26/50		liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	91.7mg n.s.s.	10/50	11/50	6/50		lun:a/a,a/c.
2460 M m b6c eat 78w86 1887					0	6.53mg	13.1mg		Maeda;jtxe,24,111-119;1988
liv hem e		321.mg *	P<.7	- 41.0mg n.s.s.	3/47	0/44	4/43		
liv hct e		no dre	P=1.	- 22.3mg n.s.s.	26/47	20/44	16/43		
liv hpa e		no dre	P=1.	- 28.9mg n.s.s.	19/47	12/44	11/43		
liv hpc e		no dre	P=1.	- 28.7mg n.s.s.	7/47	8/44	5/43		
lun act e		no dre	P=1.	- 58.2mg n.s.s.	6/47	3/44	2/43		
2461 M m d2b eat 53w53 2121					0	30.0mg	60.0mg		Diwan;carc,14,2227-2231;1993
liv hpa e		116.mg *	P<.3	28.5mg n.s.s.	0/15	1/15	1/15		
liv mix e		116.mg *	P<.3	28.5mg n.s.s.	0/15	1/15	1/15		
2462 R f f34 eat 24m24 TR404 :					0	40.0mg	120.mg		
TBA MXB		no dre	P=1.	- 37.9mg n.s.s.	45/50	38/50	(39/50)		
liv MXB		2.08gm *	P<.4	512.mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpb,hpc.
2463 R m f34 eat 24m24 TR404 :					0	32.0mg	96.0mg		
liv MXA		351.mg *	P<.02	e 142.mg n.s.s.	0/50	2/50	4/50		liv:hpa,hpc.
liv hpa		429.mg *	P<.02	e 162.mg n.s.s.	0/50	1/50	4/50		
TBA MXB		no dre	P=1.	58.9mg n.s.s.	49/50	46/50	42/50		
liv MXB		351.mg *	P<.02	142.mg n.s.s.	0/50	2/50	4/50		liv:hpa,hpb,hpc.
2464 R m f34 eat 72w72 2657					0	20.0mg	60.0mg		Diwan;ijtx,20,81-87;2001
liv tum		no dre	P=1.	- 26.7mg n.s.s.	0/18	0/18	0/18		
2465 R f f3d eat 24m26 1855					0	11.6mg	23.2mg		Jang;fctx,25,697-702;1987
liv nnd e		47.8gm *	P<1.	- 241.mg n.s.s.	1/50	0/47	1/48		
liv hpc e		no dre	P=1.	- 87.5mg n.s.s.	0/50	0/47	0/48		
tba mal e		110.mg *	P<.2	- 37.0mg n.s.s.	13/50	11/50	19/48		
2466 R m f3d eat 24m26 1855					0	9.29mg	18.6mg		
liv hpc e		1.08gm *	P<.3	- 177.mg n.s.s.	0/50	0/48	1/50		
liv nnd e		no dre	P=1.	- 133.mg n.s.s.	1/50	2/48	1/50		
tba mal e		98.7mg *	P<.5	- 22.8mg n.s.s.	22/50	22/48	26/50		
2467 R f hza eat 60w60 1063					0	100.mg			Morris;canr,29,2145-2156;1969
--- mly es		422.mg	P<.3	- 68.7mg n.s.s.	0/16	1/19			
liv tum es		no dre	P=1.	130.mg n.s.s.	0/16	0/19			
mam tum es		no dre	P=1.	- 93.9mg n.s.s.	3/16	1/19			
N,N-DIPROPYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE ---									
2468 R m sda eat 52w52 1176					0	12.0mg			Brown;jnci,37,365-367;1966
liv tum bfr		no dre	P=1.	6.18mg n.s.s.	0/10	0/10			
DIPROPYLENE GLYCOL 25265-71-8									
2469 M f b6c wat 24m24 TR511 :					0	575.mg	1.04gm	1.95gm	
TBA MXB		no dre	P=1.	- 1.61gm n.s.s.	50/50	35/50	41/50	38/50	
liv MXB		no dre	P=1.	3.40gm n.s.s.	17/50	15/50	14/50	13/50	liv:hpa,hpb,hpc.
lun MXB		31.8gm *	P<.6	5.31gm n.s.s.	3/50	2/50	6/50	3/50	lun:a/a,a/c.
2470 M m b6c wat 24m24 TR511 :					0	735.mg	1.22gm	2.39gm	
TBA MXB		24.5gm *	P<.9	- 1.43gm n.s.s.	43/50	50/50	50/50	39/50	
liv MXB		no dre	P=1.	3.35gm n.s.s.	29/50	25/50	28/50	21/50	liv:hpa,hpb,hpc.
lun MXB		18.1gm *	P<.6	3.23gm n.s.s.	6/50	14/50	13/50	8/50	lun:a/a,a/c.
2471 R f f34 wat 24m24 TR511 :					0	143.mg	571.mg	2.29gm	
TBA MXB		no dre	P=1.	- 1.59gm n.s.s.	50/50	50/50	46/50	47/50	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
2472 R m f34 wat 24m24 TR511 :					0	125.mg	500.mg	1.90gm	
TBA MXB as		274.mg Z	P<.0005	- 158.mg 629.mg	45/50	47/50	49/50	35/50	
liv MXB as		68.2gm *	P<.2	11.1gm n.s.s.	0/50	0/50	0/50	1/50	liv:hpa,hpb,hpc.
DIPYRONE (sulpyrin) 68-89-3									
2473 M f b6c wat 75w86 1545					0	448.mg	1.71gm		Kumagai;jnci,71,1295-1297;1983
liv mix ae		742.mg /	P<.0005	+ 484.mg 1.22gm	3/51	3/47	36/44		
liv hpc ae		7.12gm *	P<.02	2.77gm n.s.s.	1/51	1/47	6/44		
2474 M m b6c wat 77w86 1545					0	189.mg	746.mg		
liv mix ae		547.mg *	P<.0005	+ 300.mg 1.79gm	8/44	16/46	27/48		
2475 R m f3d wat 72w83 2029					0	173.mg			Izumi;carc,12,1221-1225;1991
liv nnd e		400.mg	P<.08	130.mg n.s.s.	1/23	5/24			
liv hpc e		no dre	P=1.	547.mg n.s.s.	0/23	0/24			
kid tum e		no dre	P=1.	547.mg n.s.s.	0/23	0/24			
2476 R f wis eat 24m30 1673					0	40.0mg	120.mg		Donaubauer;txap,81,443-451;1985
mgl ade e		328.mg \	P<.004	- 134.mg 2.04gm	0/49	6/49	(2/49)		
liv lcc e		8.33gm *	P<.3	- 1.36gm n.s.s.	0/49	0/49	1/49		
liv ade e		33.1gm *	P<1.	- 1.07gm n.s.s.	2/49	1/49	2/49		
liv ang e		41.4gm *	P<.9	- 1.51gm n.s.s.	1/49	0/49	1/49		
2477 R m wis eat 24m30 1673					0	32.0mg	96.0mg		
liv ade e		3.34gm *	P<.4	- 822.mg n.s.s.	0/47	1/50	1/49		
liv apc e		no dre	P=1.	- 384.mg n.s.s.	1/47	0/50	0/49		
DISODIUM 5'-RIBONUCLEOTIDE (ribotide) 80702-47-2									
2478 R f wis eat 24m24 2321					0	500.mg	1.00gm		Usui;jtrl,30,614-635;1971
liv tum e		no dre	P=1.	- 700.mg n.s.s.	0/10	0/10	0/10		
tba mix e		no dre	P=1.	- 875.mg n.s.s.	6/10	4/10	4/10		
2479 R m wis eat 24m24 2321					0	400.mg	800.mg		
liv tum e		no dre	P=1.	- 504.mg n.s.s.	0/9	0/9	0/9		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix e	no dre	P=1.	-	666.mg n.s.s.	6/9	3/9	4/9		
2,5-DITHIOBIUREA 142-46-1									
2480 M f b6c eat 94w94 TR132 :					0	1.08gm	2.16gm		
liv hpc	5.67gm	* P<.03	a	2.60gm n.s.s.	2/50	8/50	9/50		
TBA MXB	4.35gm	* P<.2		1.58gm n.s.s.	12/50	24/50	20/50		
liv MXB	5.67gm	* P<.03		2.60gm n.s.s.	2/50	8/50	9/50		liv:hpa,hpc,nnd.
lun MXB	22.9gm	* P<.6		4.47gm n.s.s.	4/50	5/50	6/50		lun:a/a,a/c.
2481 M m b6c eat 94w94 TR132 :					0	996.mg	1.99gm		
TBA MXB	20.0gm	* P<.8	-	1.94gm n.s.s.	20/50	23/50	18/50		
liv MXB	no dre	P=1.		5.70gm n.s.s.	15/50	9/50	7/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		3.98gm n.s.s.	7/50	13/50	4/50		lun:a/a,a/c.
2482 R f f34 eat 25m25 TR132 :					0	215.mg	429.mg		
TBA MXB	842.mg	* P<.3	-	262.mg n.s.s.	31/50	36/50	32/50		
liv MXB	131.gm	* P<1.		3.07gm n.s.s.	1/50	0/50	1/50		liv:hpa,hpc,nnd.
2483 R m f34 eat 25m25 TR132 :					0	172.mg	343.mg		
pit can #	2.62gm	* P<.02	-	905.mg n.s.s.	0/50	0/50	4/50		S
TBA MXB	960.mg	/ P<.4		251.mg n.s.s.	31/50	28/50	30/50		
liv MXB	5.01gm	* P<.09		1.46gm n.s.s.	0/50	1/50	2/50		liv:hpa,hpc,nnd.
DITHIOOXAMIDE 79-40-3									
2484 R f cdr eat 18m24 1112					0	12.0mg	24.0mg		Weisburger;jnci,67,75-88;1981
mgl tum ev	12.6mg	\ P<.02		5.72mg n.s.s.	3/16	15/26	(9/27)		
3-O-DODECYLCARBOMETHYLASCORBIC ACID ---									
2485 R f f3d eat 52w52 2249					0	500.mg			Hirose;carc,16,217-221;1995/pers.comm.
liv tum e	no dre	P=1.		258.mg n.s.s.	0/10	0/10			
n-DODECYLGUANIDINE ACETATE 2439-10-3									
2486 M f b6a orl 76w76 1293					0	11.1mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	22.0mg n.s.s.	0/17	0/18			
lun ade evx	no dre	P=1.	-	22.0mg n.s.s.	1/17	0/18			
tba mix evx	no dre	P=1.	-	10.5mg n.s.s.	2/17	2/18			
2487 M m b6a orl 76w76 1293					0	10.3mg			
lun mix evx	41.9mg	P<.6	-	6.32mg n.s.s.	2/18	3/16			
liv hpt evx	no dre	P=1.	-	18.1mg n.s.s.	1/18	0/16			
tba mix evx	149.mg	P<.9	-	6.90mg n.s.s.	3/18	3/16			
2488 M f b6c orl 76w76 1293					0	11.1mg			
liv hpt evx	54.7mg	P<.3	-	8.90mg n.s.s.	0/16	1/14			
lun mix evx	no dre	P=1.	-	17.1mg n.s.s.	0/16	0/14			
tba mix evx	54.7mg	P<.3	-	8.90mg n.s.s.	0/16	1/14			
2489 M m b6c orl 76w76 1293					0	10.3mg			
liv hpt evx	19.4mg	P<.04	-	5.85mg n.s.s.	0/16	3/17			
lun ade evx	30.1mg	P<.1	-	7.39mg n.s.s.	0/16	2/17			
tba mix evx	10.8mg	P<.007	-	4.07mg 146.mg	0/16	5/17			
DL-DOPA (dl-3,4-dihydroxyphenylalanine) 63-84-3									
2490 R m f3d eat 51w52 2080					0	588.mg			Hirose;carc,13,1825-1828;1992/pers.comm.
for tum e	no dre	P=1.		455.mg n.s.s.	0/15	0/15			
liv tum e	no dre	P=1.		455.mg n.s.s.	0/15	0/15			
DOPAMINE.HCl 62-31-7									
2491 R m f3d eat 51w52 2080					0	588.mg			Hirose;carc,13,1825-1828;1992/pers.comm.
for tum e	no dre	P=1.		455.mg n.s.s.	0/15	0/15			
liv tum e	no dre	P=1.		455.mg n.s.s.	0/15	0/15			
DOXEFAZEPAM 40762-15-0									
2492 R f cdr eat 24m24 1983					0	3.00mg	10.0mg	30.0mg	Borelli;faat,15,82-92;1990
adr phe e	216.mg	* P<.003	-	88.5mg 1.38gm	1/49	0/50	0/49	7/50	
liv hpa e	213.mg	* P<.02	-	84.6mg n.s.s.	1/49	0/50	3/49	5/50	
cns gli e	543.mg	* P<.4	-	124.mg n.s.s.	1/49	0/50	3/49	2/50	
liv hpc e	1.28gm	* P<.6	-	158.mg n.s.s.	0/49	1/50	1/49	1/50	
pit ade e	no dre	P=1.	-	28.9mg n.s.s.	32/49	41/50	33/49	35/50	
tba mal e	no dre	P=1.	-	55.4mg n.s.s.	19/49	21/50	18/49	19/50	
2493 R m cdr eat 24m24 1983					0	3.00mg	10.0mg	30.0mg	
sub mix e	9.04mg	Z P<.002	-	4.30mg 41.2mg	1/48	11/50	(8/47 | 6/50)	
sub fib e	11.8mg	Z P<.002	-	5.33mg 41.1mg	0/48	8/50	(5/47 | 4/50)	
liv hpa e	355.mg	* P<.02	-	122.mg n.s.s.	0/48	0/50	1/47	3/50	
cns gli e	366.mg	* P<.3	-	86.2mg n.s.s.	1/48	3/50	4/47	4/50	
liv cho e	1.44gm	* P<.2	-	235.mg n.s.s.	0/48	0/50	0/47	1/50	
liv hpc e	12.6gm	* P<1.	-	133.mg n.s.s.	1/48	3/50	3/47	2/50	
tba mal e	181.mg	* P<.5	-	39.4mg n.s.s.	17/48	15/50	18/47	20/50	
DOXYLAMINE SUCCINATE 562-10-7									
2494 M f b6c eat 65w65 2268m					0	35.5mg	70.1mg	140.mg	Jackson;jact,12,311-321;1993/NCTR 1991
lun a/a ek	78.7mg	Z P<.3		27.1mg n.s.s.	0/12	3/12	1/12	(0/12)	
liv hpc ek	no dre	P=1.		19.5mg n.s.s.	1/12	0/12	0/12	0/12	
thy fct ek	no dre	P=1.		19.5mg n.s.s.	0/12	0/12	0/12	0/12	
2495 M f b6c eat 24m24 2268n					0	35.5mg	70.1mg	140.mg	
liv hpa e	633.mg	* P<.002	+	326.mg 2.28gm	0/46	3/48	0/48	9/48	
thy fct e	672.mg	* P<.0005	+	337.mg 2.05gm	0/44	1/48	2/45	8/47	
thy fca e	740.mg	* P<.0005	+	361.mg 2.08gm	0/44	0/48	2/45	8/47	
lun mix e	170.mg	Z P<.06		62.5mg n.s.s.	3/48	9/48	(2/48 | 0/48)	
liv hpc e	no dre	P=1.		199.mg n.s.s.	0/46	0/48	0/48	0/48	
lun a/a e	no dre	P=1.		281.mg n.s.s.	3/48	7/48	2/48	(0/48)	
lun a/c e	no dre	P=1.		1.22gm n.s.s.	0/48	2/48	0/48	0/48	
thy fdc e	no dre	P=1.		1.43gm n.s.s.	0/44	1/48	0/45	0/47	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD50 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
2496 M m b6c eat 65w65 2268m	0	32.8mg	64.7mg	129.mg	
liv hpa ek 77.8mg * P<.008 35.1mg 1.39gm	0/12	1/12	3/12	4/12	
lun a/a ek 3.18gm * P<.9 128.mg n.s.s.	1/12	0/12	0/12	1/12	
thy fct ek no dre P=1. 18.0mg n.s.s.	0/12	0/12	0/12	0/12	
2497 M m b6c eat 24m24 2268n	0	32.8mg	64.7mg	129.mg	
liv mix e 125.mg * P<.0005 + 76.6mg 301.mg	9/48	14/48	20/47	29/48	
liv hpa e 144.mg * P<.0005 + 89.8mg 320.mg	6/48	11/48	14/47	27/48	
thy fca e 273.mg Z P<.002 + 130.mg 1.21gm	1/46	0/45	11/45	(5/46)	
liv hpc e no dre P=1. 532.mg n.s.s.	4/48	4/48	6/47	3/48	
lun a/a e no dre P=1. 456.mg n.s.s.	9/48	4/48	7/48	7/48	
lun a/c e no dre P=1. 1.12gm n.s.s.	0/48	2/48	0/48	0/48	
lun mix e no dre P=1. 462.mg n.s.s.	9/48	6/48	7/48	7/48	
2498 R f f34 eat 65w65 2267m	0	35.9mg	71.8mg	144.mg	Jackson;jact,12,1-11;1993/NCTR 1991
liv mix ek no dre P=1. 14.9mg n.s.s.	0/9	0/9	0/9	0/9	
2499 R f f34 eat 24m24 2267n	0	35.9mg	71.8mg	144.mg	
liv mix e no dre P=1. - 203.mg n.s.s.	0/48	0/48	0/48	0/48	
2500 R m f34 eat 65w65 2267m	0	28.7mg	57.5mg	115.mg	
liv hpa ek 469.mg * P<.2 76.3mg n.s.s.	0/9	0/9	0/9	1/9	
liv hpc ek no dre P=1. 11.9mg n.s.s.	0/9	0/9	0/9	0/9	
2501 R m f34 eat 24m24 2267n	0	28.7mg	57.5mg	115.mg	
liv mix e 1.61gm * P<.02 + 558.mg 234.gm	0/48	0/48	0/48	4/48	
liv hpa e 3.27gm * P<.07 804.mg n.s.s.	0/48	0/48	0/48	2/48	
liv hpc e 3.27gm * P<.07 804.mg n.s.s.	0/48	0/48	0/48	2/48	
--- mnl e 271.mg * P<.2 95.2mg n.s.s.	17/48	20/48	29/48	23/48	
alpha-ECDYSONE 3604-87-3					
2502 M f swa gav 95w95 2094	0	10.3ug			El-Mofty;oncr,1,435-438;1994/pers.comm.
mgl adc 26.4ug P<.003 + 13.6ug .117mg	0/25	12/60			
lun adc no dre P=1. .106mg n.s.s.	0/25	0/60			
tba mal 26.4ug P<.003 13.6ug .117mg	0/25	12/60			
2503 M m swa gav 95w95 2094	0	10.3ug			
lun adc 55.8ug P<.05 + 19.3ug n.s.s.	0/25	4/40			
tba mal 55.8ug P<.05 19.3ug n.s.s.	0/25	4/40			
EDIFAS A (methyl ethyl cellulose) 9004-59-5					
2504 M f aps eat 23m23 127a	0	1.30gm	13.0gm		McElligott;fctx,6,449-460;1968
liv tum e no dre P=1. - 5.78gm n.s.s.	0/35	0/25	0/35		
lun ade e no dre P=1. - 38.9gm n.s.s.	1/35	3/25	2/35		
tba mix e no dre P=1. - 12.6gm n.s.s.	16/35	16/25	18/35		
2505 M m aps eat 23m23 127a	0	1.20gm	12.0gm		
liv hpt e 254.gm * P<.9 - 14.8gm n.s.s.	4/29	6/24	4/20		
lun ade e no dre P=1. - 18.3gm n.s.s.	8/29	2/24	4/20		
tba mix e 19.4gm * P<.4 - 4.17gm n.s.s.	18/29	16/24	15/20		
2506 R f aps eat 24m24 127a	0	500.mg	5.00gm		
lun ade e 161.gm * P<.2 - 26.2gm n.s.s.	0/43	0/44	1/43		
liv mix e 375.gm * P<.7 - 28.3gm n.s.s.	1/43	0/44	1/43		
tba mix e 113.gm * P<.9 - 5.18gm n.s.s.	22/43	26/44	24/43		
2507 R m aps eat 24m24 127a	0	400.mg	4.00gm		
liv tum e no dre P=1. - 3.26gm n.s.s.	0/46	0/43	0/49		
lun ade e no dre P=1. - 3.26gm n.s.s.	1/46	0/43	0/49		
tba mix e 27.3gm * P<.4 - 6.71gm n.s.s.	6/46	10/43	12/49		
EDIFAS B (cellulose carboxymethyl ether, sodium) 9004-32-4					
2508 M f aps eat 23m23 127a	0	1.30gm	13.0gm		McElligott;fctx,6,449-460;1968
liv hpt e 538.gm * P<.7 - 42.9gm n.s.s.	0/23	1/32	1/35		
lun ade e no dre P=1. - 44.7gm n.s.s.	1/23	5/32	2/35		
tba mix e no dre P=1. - 17.3gm n.s.s.	12/23	25/32	18/35		
2509 M m aps eat 23m23 127a	0	1.20gm	12.0gm		
lun ade e no dre P=1. - 18.9gm n.s.s.	5/31	9/27	7/31		
liv hpt e no dre P=1. - 51.1gm n.s.s.	3/31	1/27	1/31		
tba mix e 132.gm * P<.9 - 9.17gm n.s.s.	18/31	14/27	18/31		
2510 R f aps eat 24m24 127a	0	500.mg	5.00gm		
liv tum e no dre P=1. - 4.46gm n.s.s.	0/43	0/48	0/44		
tba mix e 7.79gm * P<.2 - 2.57gm n.s.s.	27/43	29/48	33/44		
2511 R m aps eat 24m24 127a	0	400.mg	4.00gm		
liv hpt e 133.gm * P<.2 - 21.7gm n.s.s.	0/49	0/42	1/45		
tba mix e no dre P=1. - 8.70gm n.s.s.	21/49	14/42	15/45		
EDTA, TRISODIUM SALT TRIHYDRATE (EDTA) 150-38-9					
2512 M f b6c eat 24m24 TR11 :	0	483.mg	966.mg		
TBA MXB no dre P=1. - 1.22gm n.s.s.	12/20	24/50	23/50		
liv MXB 18.8gm * P<.5 4.62gm n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB 5.29gm * P<.2 2.29gm n.s.s.	0/20	3/50	4/50		lun:a/a,a/c.
2513 M m b6c eat 24m24 TR11 :	0	446.mg	891.mg		
TBA MXB 4.92gm * P<.7 - 739.mg n.s.s.	9/20	24/50	27/50		
liv MXB 12.3gm * P<.8 1.41gm n.s.s.	3/20	10/50	10/50		liv:hpa,hpc,nnd.
lun MXB 3.19gm * P<.2 1.16gm n.s.s.	2/20	8/50	12/50		lun:a/a,a/c.
2514 R f f34 eat 24m24 TR11 :	0	186.mg	371.mg		
TBA MXB no dre P=1. - 563.mg n.s.s.	14/20	28/50	27/50		
liv MXB no dre P=1. 2.96gm n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
2515 R m f34 eat 24m24 TR11 :	0	149.mg	297.mg		
TBA MXB 1.86gm * P<.7 - 263.mg n.s.s.	9/20	25/50	30/50		
liv MXB 6.59gm * P<.6 1.62gm n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
EFONIDIPINE.HCl ETHANOLATE (NZ-105 ETHANOLATE) 111011-76-8					
2516 M f b6c eat 24m24 2434	0	65.0mg	208.mg	650.mg	Inoue;jjpt,20,1747-1773;1992
lyd mly e 276.mg Z P<.04 - 109.mg n.s.s.	3/50	10/50	(5/50	2/50)	
liv hpc e 7.43gm * P<.3 - 1.78gm n.s.s.	3/50	4/50	4/50	6/50	

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpa e		11.5gm * P<.7	-	1.60gm n.s.s.	5/50	6/50	9/50	7/50	
lun a/c e		12.3gm * P<.5	-	2.22gm n.s.s.	2/50	3/50	3/50	4/50	
lun a/a e		no dre P=1.	-	3.46gm n.s.s.	2/50	2/50	2/50	2/50	
tba mix e		no dre P=1.	-	1.22gm n.s.s.	34/50	36/50	32/50	28/50	
2517 M m b6c eat 24m24 2434					0	60.0mg	192.mg	600.mg	
liv hpa e		no dre P=1.	-	1.52gm n.s.s.	23/50	22/50	26/50	17/50	
liv hpc e		no dre P=1.	-	1.71gm n.s.s.	13/50	10/50	14/50	10/50	
lun a/c e		no dre P=1.	-	3.36gm n.s.s.	5/50	6/50	4/50	3/50	
lun a/a e		no dre P=1.	-	3.66gm n.s.s.	8/50	4/50	5/50	3/50	
tba mix e		no dre P=1.	-	819.mg n.s.s.	42/50	36/50	42/50	34/50	
2518 R f f3d eat 24m24 2435					0	20.0mg	60.0mg	180.mg	Inoue;jjpt,20,1775-1803;1992
liv hpa e		no dre P=1.	-	1.90gm n.s.s.	0/50	1/50	0/50	0/50	
tba mix e		244.mg * P<.2	-	78.7mg n.s.s.	38/50	35/50	38/50	42/50	
2519 R m f3d eat 24m24 2435					0	16.0mg	48.0mg	144.mg	
liv mix e		2.31gm * P<.2	-	646.mg n.s.s.	1/50	0/50	1/50	3/50	
tba mix e		no dre P=1.	-	20.0mg n.s.s.	49/50	50/50	50/50	49/50	
ELLAGIC ACID 476-66-4									
2520 R f f3d eat 52w52 2249					0	50.0mg			Hirose;carc,16,217-221;1995/pers.comm.
liv tum e		no dre P=1.		25.8mg n.s.s.	0/10	0/10			
ELMIRON 37319-17-8									
2521 M f b6c gav 24m24 TR512 :					0	40.0mg	120.mg	360.mg	
liv MXB		663.mg * P<.008		303.mg 16.3gm	10/50	9/50	10/50	21/50	liv:hes,hpa,hpc. P
liv MXA		867.mg * P<.03	p	358.mg n.s.s.	10/50	8/50	9/50	18/50	liv:hpa,hpc.
--- mly		927.mg * P<.02	e	384.mg n.s.s.	7/50	8/50	6/50	16/50	
liv hpa		991.mg * P<.02		424.mg n.s.s.	7/50	5/50	4/50	15/50	S
--- MXA		1.70gm * P<.02		695.mg n.s.s.	1/50	1/50	3/50	6/50	---:hem,hes. S
liv hes		3.16gm * P<.09	p	982.mg n.s.s.	1/50	1/50	1/50	4/50	
--- hem		4.34gm * P<.02		1.31gm n.s.s.	0/50	0/50	0/50	3/50	S
TBA MXB		660.mg * P<.3		191.mg n.s.s.	40/50	34/50	43/50	44/50	
liv MXB		867.mg * P<.03		358.mg n.s.s.	10/50	8/50	9/50	18/50	liv:hpa,hpb,hpc.
lun MXB		no dre P=1.		1.50gm n.s.s.	3/50	4/50	3/50	2/50	lun:a/a,a/c.
2522 M m b6c gav 24m24 TR512 :					0	40.0mg	120.mg	360.mg	
liv hes		1.09gm * P<.002	p	522.mg 5.09gm	2/50	0/50	4/50	9/50	
liv MXA		499.mg * P<.03	e	210.mg n.s.s.	23/50	23/50	26/50	31/50	liv:hpa,hpc.
liv MXA		538.mg * P<.05		217.mg n.s.s.	24/50	24/50	26/50	31/50	liv:hpa,hpb,hpc. S
--- hes		1.34gm Z P<.03		531.mg n.s.s.	6/50	0/50	7/50	9/50	S
TBA MXB		297.mg Z P<.04		125.mg n.s.s.	50/50	32/50	50/50	50/50	
liv MXB		538.mg * P<.05		217.mg n.s.s.	24/50	24/50	26/50	31/50	liv:hpa,hpb,hpc.
lun MXB		8.00gm * P<.9		621.mg n.s.s.	14/50	5/50	13/50	9/50	lun:a/a,a/c.
2523 R f f34 gav 24m24 TR512 :					0	20.0mg	60.0mg	180.mg	
TBA MXB		1.98gm * P<.9	-	93.8mg n.s.s.	50/50	48/50	50/50	46/50	
liv MXB		no dre P=1.		1.54gm n.s.s.	1/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
2524 R m f34 gav 24m24 TR512 :					0	10.0mg	30.0mg	90.0mg	
TBA MXB		no dre P=1.	-	93.3mg n.s.s.	47/50	50/50	47/50	36/50	
liv MXB		no dre P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
EMETINE.2HCl 316-42-7									
2525 M f b6c ipj 40w78 TR43 :					0	.460mg	1.40mg	2.70mg	
TBA MXB as		1.20mg * P<.03	i	.298mg n.s.s.	0/25	2/35	0/35	1/35	
liv MXB as		no dre P=1.		n.s.s. n.s.s.	0/25	0/35	0/35	0/35	liv:hpa,hpc,nnd.
lun MXB as		49.4mg * P<.2		8.05mg n.s.s.	0/25	0/35	0/35	1/35	lun:a/a,a/c.
2526 M m b6c ipj 44w78 TR43 :					0	.460mg	1.00mg	2.70mg	
TBA MXB as		.552mg * P<.09	i	.175mg n.s.s.	3/25	7/35	0/35	0/35	
liv MXB as		1.30mg * P<.3		.293mg n.s.s.	1/25	3/35	0/35	0/35	liv:hpa,hpc,nnd.
lun MXB as		1.19mg * P<.2		.279mg n.s.s.	1/25	3/35	0/35	0/35	lun:a/a,a/c.
2527 R f sda ipj 52w83 TR43 :					0	.130mg	.270mg		
TBA MXB s		.235mg * P<.3	i	71.5ug n.s.s.	6/10	26/35	22/35		
liv MXB s		no dre P=1.		n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
2528 R m sda ipj 52w83 TR43 :					0	.130mg	.270mg		
TBA MXB s		.382mg * P<.5	i	96.7ug n.s.s.	3/10	13/35	5/35		
liv MXB s		no dre P=1.		n.s.s. n.s.s.	0/10	2/35	0/35		liv:hpa,hpc,nnd.
EMODIN 518-82-1									
2529 M f b6c eat 24m24 TR493 :					0	40.6mg	81.2mg	162.mg	
TBA MXB		548.mg * P<.6	-	108.mg n.s.s.	34/50	33/50	43/50	37/50	
liv MXB		no dre P=1.		255.mg n.s.s.	13/50	14/50	21/50	11/50	liv:hpa,hpb,hpc.
lun MXB		65.8gm * P<1.		624.mg n.s.s.	6/50	2/50	3/50	5/50	lun:a/a,a/c.
2530 M m b6c eat 24m24 TR493 :					0	19.2mg	37.4mg	75.0mg	
kid MXA		965.mg * P<.4	e	325.mg n.s.s.	0/50	1/50	2/50	1/50	kid:rua,ruc.
TBA MXB		no dre P=1.		92.3mg n.s.s.	43/50	46/50	43/50	37/50	
liv MXB		no dre P=1.		144.mg n.s.s.	29/50	32/50	31/50	22/50	liv:hpa,hpb,hpc.
lun MXB		no dre P=1.		270.mg n.s.s.	18/50	17/50	12/50	10/50	lun:a/a,a/c.
2531 M m b6c eat 24m24 TR493 with step					0	19.2mg	37.4mg	75.0mg	
kid MXA		885.mg * P<.1	e	336.mg n.s.s.	0/50	1/50	2/50	2/50	kid:rua,ruc.
2532 R f f34 eat 24m24 TR493 :					0	14.0mg	41.5mg	125.mg	
zym car		1.97gm * P<.02	e	596.mg n.s.s.	0/50	0/50	0/50	3/50	
TBA MXB		797.mg * P<.8		71.4mg n.s.s.	48/50	47/50	49/50	47/50	
liv MXB		4.30gm * P<.2		700.mg n.s.s.	0/50	0/50	0/50	1/50	liv:hpa,hpb,hpc.
2533 R m f34 eat 24m24 TR493 :					0	11.2mg	33.2mg	100.mg	
TBA MXB		no dre P=1.	-	88.5mg n.s.s.	47/50	46/50	47/50	43/50	
liv MXB		no dre P=1.		268.mg n.s.s.	1/50	4/50	4/50	2/50	liv:hpa,hpb,hpc.
EMULSIFIER YN 55965-13-4									
2534 M f nss eat 80w80 425					0	2.60gm	7.80gm		Gaunt;fctx,15,1-5;1977
liv tum e		no dre P=1.	-	10.1gm n.s.s.	0/41	0/41	0/47		
lun ade e		no dre P=1.	-	n.s.s. n.s.s.	1/41	0/41	1/47		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
2535 M m nss eat 80w80 425				0	2.40gm	7.20gm			
lun ade e	no dre	P=1.	- 15.8gm n.s.s.	2/25	4/34	2/37			
liv ade e	no dre	P=1.	- 32.5gm n.s.s.	1/25	1/34	0/37			
2536 R f wis eat 24m24 1359				0	1.00gm	3.00gm			Brantom;fctx,11,755-769;1973
pit cra e	5.54gm *	P<.009	- 2.58gm 214.gm	13/47	9/45	23/44			
liv nod e	511.gm *	P<.9	- 21.7gm n.s.s.	1/47	0/45	1/44			
2537 R m wis eat 24m24 1359				0	800.mg	2.40gm			
liv cho e	no dre	P=1.	- 14.7gm n.s.s.	0/41	1/39	0/39			
ENDOSULFAN (thiodan) 115-29-7									
2538 M f b6c eat 78w91 TR62 :				0	.210mg	.430mg			
TBA MXB v	no dre	P=1.	- .250mg n.s.s.	7/20	18/50	(8/50)			
liv MXB v	15.9mg *	P<.4	2.59mg n.s.s.	0/20	0/50	1/50			liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	.497mg n.s.s.	2/20	5/50	(0/50)			lun:a/a,a/c.
2539 M f b6c orl 76w76 283				0	.414mg	.834mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	- .353mg n.s.s.	0/16	0/10	0/17			
lun ade evx	no dre	P=1.	- 1.09mg n.s.s.	0/16	1/10	0/17			
tba mix evx	.425mg \	P<.02	- .127mg n.s.s.	0/16	3/10	(0/17)			
2540 M m b6c eat 78w91 TR62 :				0	.350mg	.700mg			
TBA MXB av	6.36mg *	P<.9	i .364mg n.s.s.	4/20	8/50	7/50			
liv MXB av	no dre	P=1.	.408mg n.s.s.	1/20	6/50	2/50			liv:hpa,hpc,nnd.
lun MXB av	1.70mg *	P<.2	.576mg n.s.s.	0/20	2/50	2/50			lun:a/a,a/c.
2541 M m b6c orl 76w76 283				0	.385mg	.776mg			Innes;ntis,1968/1969
liv hpt evx	.584mg \	P<.03	- .176mg n.s.s.	0/16	3/14	(0/16)			
lun ade evx	.914mg \	P<.08	- .224mg n.s.s.	0/16	2/14	(0/16)			
tba mix evx	.319mg \	P<.004	- .120mg 2.11mg	0/16	5/14	(0/16)			
2542 M f b6a orl 76w76 283				0	.414mg	.834mg			
liv hpt evx	no dre	P=1.	- .506mg n.s.s.	0/17	0/16	0/18			
lun ade evx	no dre	P=1.	- 1.68mg n.s.s.	1/17	1/16	0/18			
tba mix evx	no dre	P=1.	- 1.29mg n.s.s.	2/17	3/16	0/18			
2543 M m b6a orl 76w76 283				0	.385mg	.776mg			
liv hpt evx	no dre	P=1.	- .433mg n.s.s.	1/18	0/16	0/14			
lun ade evx	no dre	P=1.	- .620mg n.s.s.	2/18	4/16	1/14			
tba mix evx	no dre	P=1.	- .637mg n.s.s.	3/18	5/16	1/14			
2544 M f nmo eat 24m24 2230				0	.260mg	.780mg	2.34mg		Hack;fctx,33,941-950;1995
liv hpa	no dre	P=1.	- 2.23mg n.s.s.	0/60	0/60	0/60	0/60		
lun ade	no dre	P=1.	- 16.0mg n.s.s.	2/60	4/60	2/60	2/60		
lun adc	no dre	P=1.	- 25.0mg n.s.s.	1/60	4/60	2/60	0/60		
2545 M m nmo eat 24m24 2230				0	.240mg	.720mg	2.16mg		
liv hpa	63.6mg *	P<.2	- 15.7mg n.s.s.	0/60	0/60	1/60	1/60		
lun adc	83.2mg *	P<.6	- 11.2mg n.s.s.	2/60	2/60	2/60	3/60		
lun ade	no dre	P=1.	- 13.9mg n.s.s.	11/60	5/60	5/60	5/60		
2546 R f osm eat 18m26 TR62 :				0	6.60mg	15.6mg			
TBA MXB dv	no dre	P=1.	- 10.5mg n.s.s.	15/20	30/50	24/50			
liv MXB dv	224.mg *	P<.4	55.0mg n.s.s.	0/20	1/50	1/50			liv:hpa,hpc,nnd.
2547 R m osm eat 70w74 TR62 :				0	15.7mg	32.9mg			
TBA MXB adsv	no dre	P=1.	i 15.3mg n.s.s.	12/20	8/50	(3/50)			
liv MXB adsv	no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50			liv:hpa,hpc,nnd.
2548 R f cdr eat 24m24 2230				0	.150mg	.375mg	.750mg	3.75mg	Hack;fctx,33,941-950;1995
pni isa	7.13mg Z	P<.2	- 2.16mg n.s.s.	0/50	5/50	0/50	5/50	(5/50)	
liv hpc	no dre	P=1.	- .942mg n.s.s.	0/50	0/50	0/50	0/50	0/50	
2549 R m cdr eat 24m24 2230				0	.120mg	.300mg	.600mg	3.00mg	
tyf mix	30.0mg *	P<.1	- 8.45mg n.s.s.	0/50	3/50	4/50	0/50	5/50	
liv hpc	97.1mg *	P<.5	- 14.4mg n.s.s.	1/50	1/50	1/50	1/50	2/50	
ENDRIN 72-20-8									
2550 M f b6c eat 80w90 TR12 :				0	.290mg	.570mg			
TBA MXB	6.88mg *	P<.8	- .956mg n.s.s.	2/10	5/50	8/50			
liv MXB	no dre	P=1.	.973mg n.s.s.	2/10	3/50	(1/50)			liv:hpa,hpc,nnd.
lun MXB	67.0mg *	P<1.	1.83mg n.s.s.	0/10	2/50	1/50			lun:a/a,a/c.
2551 M m b6c eat 80w90 TR12 :				0	.170mg	.340mg			
TBA MXB dsv	.546mg *	P<.04	- .261mg n.s.s.	1/10	3/50	14/50			
liv MXB dsv	.854mg *	P<.2	.335mg n.s.s.	1/10	3/50	10/50			liv:hpa,hpc,nnd.
lun MXB dsv	1.27mg *	P<.08	.520mg n.s.s.	0/10	1/50	5/50			lun:a/a,a/c.
2552 R f osm eat 19m26 TR12 :				0	.110mg	.210mg			
TBA MXB sv	no dre	P=1.	- .214mg n.s.s.	8/10	37/50	33/50			
liv MXB sv	7.44mg *	P<.8	1.21mg n.s.s.	0/10	1/50	1/50			liv:hpa,hpc,nnd.
2553 R f osm eat 19m25 TR12 : pool				0	.110mg	.210mg			
adr MXA sv#	.227mg \	P<.003	- .110mg 1.27mg	4/60	16/50	(6/50)			adr:adn,can. S
pit adn sv	.579mg *	P<.02	.277mg n.s.s.	4/60	11/50	13/50			S
2554 R f osm eat 27m28 1004				0	95.6ug	.287mg	.575mg		Deichmann;imed,39,426-434;1970
liv hem ev	42.3mg *	P<.4	- 6.88mg n.s.s.	0/88	0/48	1/45	0/49		
tba mix ev	no dre	P=1.	- 1.77mg n.s.s.	60/88	37/48	26/45	27/49		
2555 R m osm eat 19m26 TR12 :				0	70.0ug	.140mg			
TBA MXB	.776mg *	P<.8	- .101mg n.s.s.	5/10	25/50	27/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/10	0/50	0/50			liv:hpa,hpc,nnd.
2556 R m osm eat 19m26 TR12 : pool				0	70.0ug	.140mg			
adr MXA #	.553mg *	P<.04	- .233mg n.s.s.	2/60	4/50	8/50			adr:adn,can. S
adr adn	.660mg *	P<.04	.265mg n.s.s.	2/60	2/50	8/50			S
--- hem	.661mg *	P<.03	.298mg n.s.s.	0/60	5/50	3/50			S
pni isc	1.75mg *	P<.04	.529mg n.s.s.	0/60	0/50	3/50			S
2557 R m osm eat 28m29 1004				0	76.5ug	.230mg	.461mg		Deichmann;imed,39,426-434;1970
liv hem ev	no dre	P=1.	- .706mg n.s.s.	1/75	0/47	0/44	0/42		
tba mix ev	no dre	P=1.	- 2.08mg n.s.s.	19/75	11/47	6/44	10/42		
ENFLURANE 13838-16-9									
2558 M f sic inh 52w52 1677m				0	4.74gm				Baden;anes,56,9-13;1982
lun ade ek	8.93gm	P<.4	- 1.84gm n.s.s.	2/25	4/25				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv tum ek	no dre	P=1.	-	6.11gm n.s.s.	0/25	0/25			
2559 M f sic inh 78w82 1677n					0	4.51gm			
lun ade e	18.9gm	P<.2	-	6.69gm n.s.s.	13/98	21/97			
liv mix e	no dre	P=1.	-	56.1gm n.s.s.	2/98	0/97			
2560 M m sic inh 52w52 1677m					0	3.95gm			
liv mix ek	8.12gm	P<.1	-	2.00gm n.s.s.	0/25	2/25			
lun ade ek	no dre	P=1.	-	3.10gm n.s.s.	5/25	2/25			
2561 M m sic inh 78w82 1677n					0	3.76gm			
liv mix e	11.7gm	P<.1	-	4.41gm n.s.s.	18/96	28/96			
lun ade e	60.9gm	P<.8	-	7.07gm n.s.s.	19/96	21/96			
ENOVID (norethynodrel/mestranol [66:1]) 8015-30-3									
2562 M f aah eat 24m24 1367m					0	.650mg			Heston;jnci,51,209-224;1973
lun tum g	4.62mg	P<.6	-	.763mg n.s.s.	28/61	29/57			
liv hpt g	25.2mg	P<.3	-	4.10mg n.s.s.	0/61	1/57			
2563 M f aah eat 24m24 1367n					0	1.30mg			
lun tum	4.31mg	P<.2	-	1.42mg n.s.s.	21/59	30/63			
liv hpt	no dre	P=1.	-	16.9mg n.s.s.	1/59	0/63			
2564 M f aah eat 24m24 1367o					0	2.60mg			
lun tum	no dre	P=1.	-	6.12mg n.s.s.	17/49	16/54			
2565 M f bal eat 86w86 1472					0	.450mg			Munoz;canr,38,1504-1508;1973/Dunn 1969
mix sqc r	2.00mg	P<.1		.492mg n.s.s.	0/20	2/20			
2566 M f bce eat 24m24 1367m					0	.650mg			Heston;jnci,51,209-224;1973
lun tum g	no dre	P=1.	-	4.21mg n.s.s.	18/52	6/55			
2567 M f bce eat 24m24 1367n					0	1.30mg			
lun tum g	no dre	P=1.	-	3.77mg n.s.s.	15/53	11/50			
2568 M f bce eat 24m24 1367o					0	2.60mg			
lun tum	no dre	P=1.	-	19.8mg n.s.s.	12/55	3/55			
2569 M f c7l gav 89w89 230					0	.200mg	2.00mg		Poel;scie,154,402-403;1966
pit tum e	.151mg *	P<.0005	+	52.7ug .995mg	1/8	6/11	7/7		
2570 M f cfl eat 78w78 1453					0	.125mg	1.50mg	5.00mg	Barrows;jtxe,3,219-230;1977
liv hct er	no dre	P=1.	-	23.8mg n.s.s.	0/39	1/40	1/40	0/38	
2571 M m cfl eat 78w78 1453					0	.125mg	1.50mg	5.00mg	
liv hct er	no dre	P=1.	-	17.8mg n.s.s.	6/39	4/40	5/39	1/40	
2572 M f che eat 24m24 1367m					0	.650mg			Heston;jnci,51,209-224;1973
lun tum g	20.7mg	P<.3	-	3.37mg n.s.s.	0/50	1/47			
2573 M f che eat 24m24 1367n					0	1.30mg			
hpl cra	1.75mg	P<.008		.830mg 40.3mg	17/50	32/53			
2574 M f che eat 24m24 1367o					0	2.60mg			
hpl cra	1.82mg	P<.0005	+	1.03mg 4.55mg	15/51	36/49			
liv hpt	no dre	P=1.	-	26.3mg n.s.s.	1/51	0/49			
2575 M f chf eat 24m24 1367m					0	.650mg			
--- fbs g	3.93mg	P<.005	-	1.60mg 26.9mg	0/54	6/56			
lun tum g	27.6mg	P<.8	-	2.21mg n.s.s.	5/54	6/56			
liv hpt g	no dre	P=1.	-	4.36mg n.s.s.	46/54	13/56			
2576 M f chf eat 24m24 1367n					0	1.30mg			
lun tum g	no dre	P=1.	-	10.2mg n.s.s.	3/52	1/53			
liv hpt g	no dre	P=1.	-	11.4mg n.s.s.	34/52	4/53			
2577 M f chf eat 24m24 1367o					0	2.60mg			
lun tum	no dre	P=1.	-	12.5mg n.s.s.	6/50	4/52			
liv hpt	no dre	P=1.	-	24.0mg n.s.s.	37/50	3/52			
2578 M f chh eat 24m24 1367o					0	2.60mg			
liv hpt g	no dre	P=1.	-	28.4mg n.s.s.	2/55	0/53			
2579 M f csc gav 69w69 585m					0	.143mg			Poel;canr,28,845-859;1968
lun tum ek	no dre	P=1.	-	.194mg n.s.s.	0/15	0/15			
tba mix ek	no dre	P=1.	-	83.4ug n.s.s.	4/15	3/15			
2580 M f csc gav 69w82 585n					0	.120mg			
tba mix ek	.332mg	P<.8	-	36.7ug n.s.s.	8/15	9/15			
2581 M f r3m eat 24m24 1463					0	1.95mg			Rudali;gmcr,17,243-252;1975
mam tum Lr	no dre	P=1.		1.93mg n.s.s.	50/73	12/21			
ENOVID-E (norethynodrel/mestranol [25:1]) 8015-30-3									
2582 M f cfl eat 78w78 1453m					0	.130mg	1.56mg	2.60mg	Barrows;jtxe,3,219-230;1977
liv hct er	143.mg *	P<.8	-	9.95mg n.s.s.	0/39	1/39	0/38	1/39	
2583 M m cfl eat 78w78 1453m					0	.130mg	1.56mg	2.60mg	
liv hct er	no dre	P=1.	-	8.87mg n.s.s.	6/39	8/40	7/40	1/39	
2584 M f sww gav 65w80 1453n					0	1.06mg			
liv hct er	20.8mg	P<.6	-	2.84mg n.s.s.	1/50	2/50			
EPHEDRINE SULPHATE 134-72-5									
2585 M f b6c eat 24m24 TR307 :					0	16.1mg	32.2mg		
TBA MXB	259.mg *	P<.9	-	19.8mg n.s.s.	43/50	45/50	41/50		
liv MXB	no dre	P=1.		67.6mg n.s.s.	9/50	3/50	(3/50)		liv:hpa,hpc,nnd.
lun MXB	789.mg *	P<.6		132.mg n.s.s.	1/50	1/50	2/50		lun:a/a,a/c.
2586 M m b6c eat 24m24 TR307 :					0	14.9mg	29.7mg		
MXA mlm #	194.mg *	P<.02	-	79.1mg n.s.s.	0/50	2/50	4/50		mey:mlm; mul:mlm; spl:mlm. S
TBA MXB	no dre	P=1.		27.8mg n.s.s.	38/50	31/50	36/50		
liv MXB	264.mg *	P<.7		37.9mg n.s.s.	19/50	18/50	21/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		98.7mg n.s.s.	9/50	11/50	4/50		lun:a/a,a/c.
2587 R f f34 eat 24m24 TR307 :					0	6.19mg	12.4mg		
TBA MXB	no dre	P=1.	-	13.6mg n.s.s.	45/50	43/50	45/50		
liv MXB	no dre	P=1.		98.6mg n.s.s.	2/50	2/50	0/50		liv:hpa,hpc,nnd.
2588 R m f34 eat 24m24 TR307 :					0	4.95mg	9.90mg		
TBA MXB	no dre	P=1.	-	8.33mg n.s.s.	43/50	47/50	45/50		
liv MXB	166.mg *	P<.7		21.5mg n.s.s.	3/50	5/50	5/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
EPICHLOROHYDRIN 106-89-8								
2589 M f hic ipj 64w64 1143				0	5.71mg			Van Duuren;jnci,53,695-700;1974
lun ptm	28.9mg	P<.8	2.54mg n.s.s.	10/30	11/30			
2590 R m sda inh 13m32 1167m				0	.729mg	2.88mg		Laskin;jnci,65,751-757;1980/Kuschner pers.comm.
nas sqc ajs	421.mg *	P<.2	68.5mg n.s.s.	0/100	0/100	1/100		
liv tum ajs	no dre	P=1.	20.5mg n.s.s.	0/100	0/100	0/100		
2591 R f wis gav 24m24 1727				0	1.43mg	7.14mg		Wester;txcy,36,325-339;1985
for sqc e	2.55mg /	P<.0005 +	1.46mg 4.71mg	0/38	2/27	24/24		
liv nnd e	no dre	P=1. -	72.1mg n.s.s.	1/50		0/49		
tba mix e	no dre	P=1.	10.3mg n.s.s.	33/50		28/49		
2592 R m wis gav 24m24 1727				0	1.43mg	7.14mg		
for sqc e	3.53mg *	P<.0005 +	2.34mg 5.56mg	0/49	6/43	35/43		
liv tum e	218.mg	P<.3 -	35.5mg n.s.s.	0/49		1/45		
liv hpc e	no dre	P=1. -	66.2mg n.s.s.	1/49		0/45		
liv nnd e	no dre	P=1. -	66.2mg n.s.s.	1/49		0/45		
tba mix e	4.83mg	P<.4	.898mg n.s.s.	46/49		44/45		
(-)-EPIGALLOCATECHIN GALLATE (85% (-)-EPIGALLOCATECHIN GALLATE, 10% (-)-EPIGALLOCATECHIN, 5% (-)-EPICATECHIN GALLATE) 989-51-5								
2593 M m cen wat 58w58 2214				0	83.3mg	167.mg		Nishida;gann,85,221-225;1994
liv mix r	no dre	P=1. -	80.5mg n.s.s.	15/20	14/26	12/26		
L-EPINEPHRINE.HCl 55-31-2								
2594 M f b6c inh 24m25 TR380 :				0	.458mg	.920mg		
ute MXA #	6.86mg *	P<.03 i	2.61mg n.s.s.	0/50	1/50	4/50		ute:esp,ess. S
ute esp	8.52mg *	P<.05	2.94mg n.s.s.	0/50	1/50	3/50		S
TBA MXB	no dre	P=1.	1.19mg n.s.s.	36/50	35/50	30/50		
liv MXB	9.74mg *	P<.4	2.42mg n.s.s.	3/50	2/50	6/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	4.44mg n.s.s.	5/50	5/50	2/50		lun:a/a,a/c.
2595 M m b6c inh 24m25 TR380 :				0	.382mg	.774mg		
TBA MXB	no dre	P=1. i	.993mg n.s.s.	38/50	33/50	33/50		
liv MXB	no dre	P=1.	1.93mg n.s.s.	20/50	14/50	15/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	1.34mg n.s.s.	15/50	11/50	16/50		lun:a/a,a/c.
2596 R f f34 inh 24m24 TR380 :				0	.111mg	.368mg		
TBA MXB	no dre	P=1. i	.281mg n.s.s.	49/50	41/50	43/50		
liv MXB	no dre	P=1.	1.96mg n.s.s.	2/50	0/50	1/50		liv:hpa,hpc,nnd.
2597 R m f34 inh 24m24 TR380 :				0	77.1ug	.258mg		
TBA MXB	4.70mg *	P<1. i	.162mg n.s.s.	48/50	40/50	46/50		
liv MXB	no dre	P=1.	1.82mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
1,2-EPOXYBUTANE 106-88-7								
2598 M f b6c inh 24m24 TR329 :				0	45.5mg	90.9mg		
TBA MXB s	141.mg *	P<.4 -	35.3mg n.s.s.	35/50	29/50	20/50		
liv MXB s	445.mg *	P<.3	118.mg n.s.s.	4/50	3/50	5/50		liv:hpa,hpc,nnd.
lun MXB s	834.mg *	P<.6	135.mg n.s.s.	4/50	3/50	3/50		lun:a/a,a/c.
2599 M m b6c inh 24m24 TR329 :				0	37.9mg	75.8mg		
TBA MXB	2.47gm *	P<1. -	81.5mg n.s.s.	28/50	26/50	24/50		
liv MXB	8.60gm *	P<1.	137.mg n.s.s.	14/50	13/50	12/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	228.mg n.s.s.	11/50	9/50	6/50		lun:a/a,a/c.
2600 R f f34 inh 24m24 TR329 :				0	43.3mg	86.6mg		
pta adn	83.8mg *	P<.05	35.2mg n.s.s.	25/50	26/50	32/50		S
thy MXA	509.mg *	P<.03	174.mg n.s.s.	0/50	1/50	3/50		thy:fca,fcc. S
ova MXA	545.mg *	P<.03	181.mg n.s.s.	0/50	1/50	3/50		ova:gcc,gct,tcm. S
nas ppa	1.73gm *	P<.09 e	422.mg n.s.s.	0/50	0/50	2/50		
TBA MXB	78.0mg *	P<.2	27.9mg n.s.s.	45/50	47/50	47/50		
liv MXB	no dre	P=1.	601.mg n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
2601 R m f34 inh 24m24 TR329 :				0	30.3mg	60.6mg		
MXB MXB	106.mg *	P<.0005	56.3mg 241.mg	0/50	2/50	12/50		lun:a/a,a/c; nas:ppa. C
nas ppa	220.mg *	P<.002 c	93.7mg 872.mg	0/50	0/50	7/50		
lun MXA	220.mg *	P<.006 c	92.8mg 684.mg	0/50	2/50	5/50		lun:a/a,a/c.
MXA mnl	30.7mg \	P<.04	12.5mg n.s.s.	25/50	31/50	(22/50)		mul:mnl; spl:mnl. S
lun a/c	314.mg *	P<.02 c	116.mg n.s.s.	0/50	1/50	4/50		
TBA MXB	79.6mg *	P<.3	22.4mg n.s.s.	46/50	48/50	47/50		
liv MXB	622.mg *	P<.5	120.mg n.s.s.	2/50	2/50	3/50		liv:hpa,hpc,nnd.
ERYTHORBATE, SODIUM (isoascorbate) 6381-77-7								
2602 M f b6c wat 22m26 1897				0	4.36gm	8.73gm		Inai;hijm,38,135-139;1989
liv hem e	149.gm *	P<.3 -	45.2gm n.s.s.	0/45	2/44	1/46		
liv hpa e	225.gm *	P<.3 -	55.3gm n.s.s.	0/45	1/44	1/46		
lun a/c e	225.gm *	P<.3 -	55.3gm n.s.s.	0/45	1/44	1/46		
liv hpc e	452.gm *	P<.6 -	60.7gm n.s.s.	1/45	0/44	2/46		
--- lkm e	no dre	P=1. -	30.0gm n.s.s.	5/45	7/44	5/46		
lun a/a e	no dre	P=1. -	29.9gm n.s.s.	1/45	0/44	0/46		
tba mix e	40.9gm *	P<.3 -	12.3gm n.s.s.	10/45	16/44	15/46		
2603 M m b6c wat 22m26 1897				0	1.82gm	3.64gm		
liv hem e	16.9gm \	P<.04 -	5.13gm n.s.s.	0/38	3/38	(0/43)		
liv hpa e	25.1gm *	P<.2 -	9.33gm n.s.s.	1/38	4/38	5/43		
liv hpc e	57.2gm *	P<.5 -	11.6gm n.s.s.	2/38	4/38	4/43		
lun a/c e	85.4gm *	P<.3 -	21.0gm n.s.s.	0/38	1/38	1/43		
lun a/a e	no dre	P=1. -	20.2gm n.s.s.	4/38	0/38	4/43		
tba mix e	8.69gm *	P<.06 -	3.68gm n.s.s.	9/38	14/38	19/43		
2604 R f f3d wat 24m26 1736				0	663.mg	1.33gm		Abe;eamp,41,35-43;1984
liv hpa e	no dre	P=1. -	15.5gm n.s.s.	1/48	1/49	0/45		
tba mix e	no dre	P=1. -	1.69gm n.s.s.	45/48	43/49	35/45		
2605 R m f3d wat 24m26 1736				0	580.mg	1.16gm		
liv hpa e	no dre	P=1. -	12.5gm n.s.s.	1/49	0/48	1/50		
tba mix e	no dre	P=1. -	n.s.s. n.s.s.	49/49	48/48	50/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ERYTHROMYCIN STEARATE 643-22-1								
2606 M f b6c eat 24m24 TR338 :				0	322.mg	644.mg		
TBA MXB	no dre	P=1.	- 634.mg n.s.s.	44/50	41/50	39/50		
liv MXB	no dre	P=1.	2.62gm n.s.s.	4/50	6/50	2/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	3.34gm n.s.s.	4/50	3/50	2/50		lun:a/a,a/c.
2607 M m b6c eat 24m24 TR338 :				0	297.mg	594.mg		
TBA MXB	no dre	P=1.	- 1.02gm n.s.s.	37/50	26/50	29/50		
liv MXB	no dre	P=1.	1.77gm n.s.s.	15/50	8/50	11/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	2.30gm n.s.s.	6/50	5/50	4/50		lun:a/a,a/c.
2608 R f f34 eat 24m24 TR338 :				0	248.mg	495.mg		
TBA MXB	no dre	P=1.	- 153.mg n.s.s.	49/50	48/50	(42/50)		
liv MXB	5.85gm *	P<.2	1.77gm n.s.s.	0/50	1/50	2/50		liv:hpa,hpc,nnd.
2609 R m f34 eat 24m24 TR338 :				0	198.mg	396.mg		
TBA MXB	2.02gm *	P<.8	- 197.mg n.s.s.	45/50	46/50	47/50		
liv MXB	3.95gm *	P<.3	957.mg n.s.s.	1/50	1/50	3/50		liv:hpa,hpc,nnd.
ESTAZOLAM 29975-16-4								
2610 M f b6c eat 24m24 1984				0	.800mg	3.00mg	10.0mg	Kimura;faat,4,827-842;1984
liv agm e	756.mg *	P<.6	- 80.8mg n.s.s.	1/100	0/50	0/50	1/50	
liv hpc e	820.mg *	P<.9	- 40.6mg n.s.s.	2/100	4/50	4/50	2/50	
lun a/a e	1.96gm *	P<.9	- 85.7mg n.s.s.	2/100	0/50	0/50	1/50	
liv ang e	no dre	P=1.	- 102.mg n.s.s.	0/100	1/50	0/50	0/50	
lun a/c e	no dre	P=1.	- 64.4mg n.s.s.	4/100	0/50	3/50	1/50	
tba ben e	70.8mg *	P<.3	- 18.1mg n.s.s.	19/100	6/50	13/50	12/50	
tba mal e	no dre	P=1.	- 21.0mg n.s.s.	32/100	21/50	20/50	16/50	
tba mix e	no dre	P=1.	- 15.1mg n.s.s.	47/100	24/50	28/50	23/50	
2611 M m b6c eat 24m24 1984				0	.800mg	3.00mg	10.0mg	
lun a/a e	89.5mg *	P<.09	- 28.5mg n.s.s.	7/100	1/50	2/50	7/50	
liv agm e	471.mg *	P<.5	- 64.2mg n.s.s.	1/100	0/50	1/50	1/50	
liv hpc e	no dre	P=1.	- 33.9mg n.s.s.	23/100	11/50	12/50	9/50	
lun a/c e	no dre	P=1.	- 35.6mg n.s.s.	13/100	6/50	7/50	6/50	
tba ben e	271.mg *	P<.8	- 24.9mg n.s.s.	21/100	5/50	11/50	10/50	
tba mal e	no dre	P=1.	- 25.2mg n.s.s.	42/100	20/50	28/50	16/50	
tba mix e	no dre	P=1.	- 18.8mg n.s.s.	57/100	23/50	34/50	23/50	
2612 R f cdr eat 24m24 1984				0	.500mg	2.00mg	10.0mg	
liv nnd e	no dre	P=1.	- 73.8mg n.s.s.	5/100	0/50	2/50	1/50	
liv hpc e	no dre	P=1.	- 77.5mg n.s.s.	0/100	1/50	1/50	0/50	
tba mix e	5.81mg *	P<.3	- 1.21mg n.s.s.	95/100	46/50	49/50	49/50	
tba ben e	476.mg *	P<1.	- 4.35mg n.s.s.	91/100	43/50	47/50	45/50	
tba mal e	no dre	P=1.	- 27.3mg n.s.s.	26/100	16/50	17/50	12/50	
2613 R m cdr eat 24m24 1984				0	.500mg	2.00mg	10.0mg	
ski fib e	234.mg *	P<.6	- 33.4mg n.s.s.	3/99	6/49	3/49	4/49	
liv nnd e	854.mg *	P<.8	- 53.3mg n.s.s.	3/100	2/50	1/50	2/50	
liv hpc e	no dre	P=1.	- 76.1mg n.s.s.	4/100	0/50	1/50	1/50	
tba mal e	75.7mg *	P<.3	- 18.3mg n.s.s.	18/100	11/50	9/50	13/50	
tba ben e	no dre	P=1.	- 14.5mg n.s.s.	64/100	36/50	42/50	30/50	
tba mix e	no dre	P=1.	- 15.2mg n.s.s.	76/100	44/50	43/50	34/50	
ESTRADIOL (estradiol-17beta) 50-28-2								
2614 M f c3h eat 24m24 1131				0	56.8ug			Gass;ircs,5,477;1977
mgl adc Lr	.282mg	P<.7	38.1ug n.s.s.	11/23	12/22			
2615 M f c3j eat 52w52 1468				0	13.0ug	.130mg	.650mg	Highman;jept,4,81-95;1980/pers.comm.
mgl adc ek	.904mg *	P<.02	.338mg n.s.s.	2/43	1/34	1/34	7/45	
2616 M f c3j eat 78w78 1468m				0	13.0ug	.130mg	.650mg	
ova tua ek	no dre	P=1.	.525mg n.s.s.	2/14	0/5	2/16	0/7	
2617 M f c3j eat 24m24 1468n				0	13.0ug	.130mg	.650mg	
mgl adc ek	2.75mg *	P<.6	.368mg n.s.s.	4/24	5/23	5/18	2/7	
ESTRADIOL MUSTARD 22966-79-6								
2618 M f b6c gav 52w84 TR59 :				0	3.98mg	8.80mg		
MXB MXB s	.682mg *	P<.0005	.330mg 1.38mg	0/16	21/36	14/35		---:lym; lun:a/a,a/c; myc:srn; sto:sqc. C
lun MXA s	1.14mg *	P<.0005 c	.409mg 5.29mg	0/16	7/36	1/35		lun:a/a,a/c.
--- lym s	2.34mg *	P<.0005 c	.991mg 5.45mg	0/16	9/36	11/35		
myc srn s	3.01mg *	P<.006 c	.925mg 35.0mg	0/16	8/36	1/35		
sto sqc sh	5.17mg *	P<.009 c	1.43mg 178.mg	0/16	2/36	2/35		
mgl MXA s	13.4mg *	P<.02	2.93mg n.s.s.	0/16	0/36	3/35		mgl:acn,can. S
TBA MXB s	.562mg *	P<.0005	.298mg .998mg	0/16	25/36	20/35		
liv MXB s	no dre	P=1.	n.s.s. n.s.s.	0/16	0/36	0/35		liv:hpa,hpc,nnd.
lun MXB s	1.14mg *	P<.0005	.409mg 5.29mg	0/16	7/36	1/35		lun:a/a,a/c.
2619 M f b6c gav 52w82 TR59 : pool				0	3.98mg	8.80mg		
lun MXA s	1.28mg *	P<.0005 c	.442mg 6.82mg	1/31	7/36	1/35		lun:a/a,a/c.
--- lym s	2.23mg *	P<.0005 c	.944mg 4.65mg	0/31	9/36	11/35		
lun a/c s	2.87mg *	P<.002	.807mg 22.7mg	0/31	4/36	0/35		S
myc srn s	3.22mg *	P<.0005 c	1.09mg 11.0mg	0/31	8/36	1/35		
mgl MXA s	12.8mg *	P<.007	2.79mg 272.mg	0/31	0/36	3/35		mgl:acn,can. S
2620 M m b6c gav 52w83 TR59 :				0	3.98mg	8.20mg		
MXB MXB s	4.10mg *	P<.0005	2.41mg 8.00mg	0/14	6/34	18/35		---:leu,lym; sto:sqc. C
--- MXA s	4.39mg *	P<.0005 c	2.56mg 8.90mg	0/14	6/34	17/35		---:leu,lym.
sto sqc sh	29.0mg *	P<.08 c	7.13mg n.s.s.	0/14	0/34	2/35		
TBA MXB s	1.96mg *	P<.0005	1.12mg 6.77mg	4/14	24/34	23/35		
liv MXB s	no dre	P=1.	5.23mg n.s.s.	2/14	5/34	1/35		liv:hpa,hpc,nnd.
lun MXB s	2.34mg \	P<.02	1.01mg n.s.s.	2/14	12/34	(5/35)		lun:a/a,a/c.
2621 M m b6c gav 52w81 TR59 : pool				0	3.98mg	8.20mg		
lun MXA s	1.99mg \	P<.0005 c	.929mg 7.16mg	2/29	12/34	(5/35)		lun:a/a,a/c.
lun a/c s	3.61mg \	P<.0005 c	1.46mg 12.7mg	0/29	6/34	(1/35)		
--- MXA s	4.31mg *	P<.0005 c	2.54mg 7.89mg	0/29	6/34	17/35		---:leu,lym.
myc srn s	5.55mg \	P<.003 c	2.18mg 27.4mg	0/29	6/34	(2/35)		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
2622 R f sda gav 52w85 TR59 :				0	.160mg	.330mg				
TBA MXB	.189mg	* P<.2	- 65.7ug n.s.s.	5/10	27/35	26/35				
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/10	0/35	0/35				liv:hpa,hpc,nnd.
2623 R m sda gav 52w85 TR59 :				0	.160mg	.330mg				
TBA MXB	3.85mg	* P<.9	- .234mg n.s.s.	4/10	10/35	10/35				
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/10	0/35	0/35				liv:hpa,hpc,nnd.
2624 R m sda gav 52w85 TR59 : pool				0	.160mg	.330mg				
mgl fba #	.756mg	* P<.02	- .327mg n.s.s.	0/20	2/35	5/35				s
ESTRAGOLE 140-67-0										
2625 M f cd1 eat 51w86 1582				0	74.2mg	148.mg				Miller;canr,43,1124-1134;1983
liv hpt v	51.8mg	* P<.0005 +	37.3mg 74.3mg	0/50	27/50	35/50				
lun ade v	no dre	P=1.	666.mg n.s.s.	2/50	1/50	2/50				
ETHINYL ESTRADIOL 57-63-6										
2626 R f sls gav 52w52 2247				0	.429mg					Machishi;carc,16,2965-2971;1995
liv hpc Cr	.200mg	P<.04	+ 68.3ug n.s.s.	0/8	4/13					
ETHIONAMIDE 536-33-4										
2627 M f b6c eat 18m24 TR46 :				0	70.2mg	139.mg				
TBA MXB s	450.mg	* P<.5	- 113.mg n.s.s.	4/15	7/35	14/35				
liv MXB s	no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35				liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.	650.mg n.s.s.	1/15	0/35	1/35				lun:a/a,a/c.
2628 M m b6c eat 18m24 TR46 :				0	64.8mg	128.mg				
TBA MXB s	no dre	P=1.	- 101.mg n.s.s.	7/15	16/35	10/34				
liv MXB s	no dre	P=1.	159.mg n.s.s.	3/15	6/35	4/34				liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.	192.mg n.s.s.	2/15	5/35	2/34				lun:a/a,a/c.
2629 M f bal gav 50w69 1014				0	49.7mg					Biancifiori;lapp,24,145-165;1964
thy car e	69.3mg	P<.01	+ 29.9mg 7.42gm	0/20	7/36					
lun ade e	124.mg	P<.4	- 31.8mg n.s.s.	2/18	7/33					
liv ppc e	240.mg	P<.2	- 58.9mg n.s.s.	0/18	2/33					
2630 R f f34 eat 18m24 TR46 :				0	40.0mg	81.0mg				
TBA MXB s	no dre	P=1.	- 49.5mg n.s.s.	12/15	26/35	25/35				
liv MXB s	508.mg	* P<.2	175.mg n.s.s.	0/15	1/35	3/35				liv:hpa,hpc,nnd.
2631 R m f34 eat 18m24 TR46 :				0	32.0mg	64.8mg				
TBA MXB	no dre	P=1.	- 33.4mg n.s.s.	10/15	16/35	(4/34)				
liv MXB	623.mg	* P<.5	153.mg n.s.s.	0/15	1/35	1/34				liv:hpa,hpc,nnd.
ETHIONINE 13073-35-3										
2632 R m wis eat 34w52 1373				0	65.4mg					Argus;zkko,75,201-208;1971
liv car e	noTD50	P<.0005 +	n.s.s. 4.97mg	0/30	30/30					
DL-ETHIONINE 67-21-0										
2633 M f bal eat 24m24 1782n				0	65.0mg	130.mg				Hoover;carc,7,1143-1148;1986
liv mix e	59.7mg	* P<.0005 +	36.2mg 106.mg	0/30	14/29	12/14				
liv hpc e	112.mg	* P<.0005 +	62.6mg 227.mg	0/30	7/29	10/14				
lun adc e	no dre	P=1.	342.mg n.s.s.	7/30	5/29	1/14				
lun ade e	no dre	P=1.	318.mg n.s.s.	6/30	1/29	3/14				
2634 M m bal eat 24m24 1782n				0	120.mg	300.mg				
lun adc e	222.mg	\ P<.04	88.4mg n.s.s.	4/24	12/28	(1/23)				
liv mix e	791.mg	* P<.02	+ 306.mg n.s.s.	1/26	2/24	5/16				
liv hpc e	1.54gm	* P<.02	+ 584.mg n.s.s.	0/26	1/30	4/27				
lun ade e	no dre	P=1.	1.20gm n.s.s.	2/24	1/28	1/23				
2635 M f cen gav 7m24 1782				0	18.7mg	62.4mg				
liv mix	33.8mg	\ P<.05	+ 13.5mg n.s.s.	12/41	20/39	(7/37)				
2636 M f cen eat 68w68 1782m				0	130.mg	308.mg				
liv mix esv	62.5mg	* P<.0005 +	36.4mg 127.mg	1/26	12/24	12/16				
liv hpc esv	128.mg	* P<.0005 +	66.5mg 377.mg	1/26	6/24	9/16				
lun ade esv	1.13gm	* P<.06	278.mg n.s.s.	0/26	0/24	2/16				
2637 M m cen eat 68w68 1782m				0	120.mg	300.mg				
liv mix e	181.mg	* P<.08	+ 69.7mg n.s.s.	8/26	16/30	15/27				
liv hpc e	294.mg	P<.04	+ 119.mg n.s.s.	6/26	3/30	13/27				
lun ade e	no dre	P=1.	573.mg n.s.s.	0/26	1/30	0/27				
2638 M f scd eat 24m24 1782n				0	130.mg	313.mg				
liv mix esv	67.3mg	\ P<.0005 +	37.6mg 132.mg	0/29	20/27	(16/25)				
liv hpc esv	151.mg	* P<.0005 +	97.3mg 251.mg	0/29	18/27	15/25				
lun adc esv	no dre	P=1.	328.mg n.s.s.	13/29	6/27	(4/25)				
lun ade esv	no dre	P=1.	1.87gm n.s.s.	2/29	1/27	0/25				
2639 R m f34 eat 76w78 2535				0	1.20mg	4.00mg	12.0mg	40.0mg	120.mg	Allen;carc,18,1103-1107;1997/ pers.comm.
liv mix ae	13.7mg	Z P<.0005 +	8.42mg 24.1mg	0/28	0/28	0/28	0/28	27/28	(20/21)	
liv hpc ae	16.9mg	Z P<.0005 +	10.2mg 30.5mg	0/28	0/28	0/28	0/28	24/28	(19/21)	
2640 R m f3d eat 24m24 1756				0	4.00mg	20.0mg	100.mg			Ogiso;txpy,13,257-265;1985
liv hpc e	46.0mg	Z P<.0005 +	27.2mg 83.0mg	0/30	0/29	0/27	26/27			
liv thc e	46.0mg	Z P<.0005 +	27.2mg 83.0mg	0/30	0/29	0/27	26/27			
liv ghc e	no dre	P=1.	19.0mg n.s.s.	0/30	0/29	0/27	0/27			
liv clc e	no dre	P=1.	19.0mg n.s.s.	0/30	0/29	0/27	0/27			
2641 R m fis eat 69w69 1491m				0	40.0mg					Leopold;canr,42,4364-4374;1982
liv hpc e	5.24mg	P<.0005 +	2.49mg 11.5mg	0/20	18/20					
liv clc e	235.mg	P<.3	38.3mg n.s.s.	0/20	1/20					
2642 R m fis eat 52w52 1491n				0	100.mg					
liv hpc	12.4mg	P<.0005 +	6.33mg 27.2mg	0/20	15/20					
2643 R m fis eat 39w52 1491o				0	75.0mg					
liv hpc	noTD50	P<.0005 +	n.s.s. 6.85mg	0/20	20/20					
liv clc	250.mg	P<.3	40.8mg n.s.s.	0/20	1/20					

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
4-ETHOXY-PHENYLUREA (dulcin) 150-69-6										
2644 R b osm eat 24m24 2393					0	4.50mg	45.0mg	112.mg	225.mg	450.mg	Fitzhugh;japa,40,583-586;1951
liv mix e	537.mg	* P<.0005	+	281.mg 1.22gm	0/14	0/20	1/15	0/18	2/17	10/14	
o-ETHOXYBENZAMIDE (ethenzamide) 938-73-8										
2645 M f b6c eat 22m23 1797					0	499.mg	1.50gm				Naito;jnci,76,115-118;1986
liv mix er	3.31gm	* P<.4		787.mg n.s.s.	5/19	9/18	7/16				
2646 M m b6c eat 22m23 1797					0	461.mg	1.38gm				
liv mix er	513.mg	* P<.005	+	226.mg 5.10gm	5/10	8/15	17/18				
ETHOXYQUIN 91-53-2										
2647 R f f34 eat 58w58 2307m					0	250.mg					Hard;faat,18,278-287;1992/pers.comm.
kid tum r	no dre	P=1.	-	144.mg n.s.s.	0/19	0/9					
2648 R f f34 eat 78w78 2307n					0	250.mg					
kid tum r	no dre	P=1.	-	377.mg n.s.s.	0/20	0/13					
2649 R m f34 eat 60w60 1640					0	200.mg					Rao;canr,44,1072-1076;1984
liv tum er	no dre	P=1.		343.mg n.s.s.	0/25	0/25					
2650 R m f34 eat 58w58 2307m					0	200.mg					Hard;faat,18,278-287;1992/pers.comm.
kid tum r	no dre	P=1.	-	115.mg n.s.s.	0/18	0/9					
2651 R m f34 eat 78w78 2307n					0	200.mg					
kid tum r	no dre	P=1.	-	440.mg n.s.s.	0/13	0/19					
2652 R m f3d eat 52w52 1900					0	100.mg					Hirose;carc,8,1731-1735;1987/pers.comm.
eso tum er	no dre	P=1.	-	51.5mg n.s.s.	0/10	0/10					
for tum er	no dre	P=1.	-	51.5mg n.s.s.	0/10	0/10					
liv tum er	no dre	P=1.	-	51.5mg n.s.s.	0/10	0/10					
ETHYL ACRYLATE 140-88-5										
2653 M f b6c gav 24m24 TR259 :					0	70.4mg	142.mg				
for MXA	430.mg	* P<.03	c	193.mg n.s.s.	1/50	5/50	7/50				for:sqc,sqp.
TBA MXB	no dre	P=1.		134.mg n.s.s.	32/50	31/50	28/50				
liv MXB	26.3gm	* P<1.		392.mg n.s.s.	3/50	3/50	3/50				liv:hpa,hpc,nnd.
lun MXB	2.81gm	* P<.6		420.mg n.s.s.	2/50	2/50	3/50				lun:a/a,a/c.
2654 M f b6c inh 24m24 1754i					0	6.44mg					Miller;dact,8,1-42;1985
nac tum r	no dre	P=1.	-	119.mg n.s.s.	0/80	0/90					
2655 M f b6c inh 6m27 1754j					0	64.4mg					
lun mix e	4.19gm	P<.8	-	403.mg n.s.s.	6/125	4/66					
liv mix e	no dre	P=1.	-	312.mg n.s.s.	27/125	12/66					
tba ben e	no dre	P=1.	-	155.mg n.s.s.	73/125	35/66					
tba mal e	no dre	P=1.	-	199.mg n.s.s.	90/125	38/66					
tba mix e	no dre	P=1.	-	93.0mg n.s.s.	109/125	53/66					
2656 M f b6c inh 27m27 1754k					0	32.2mg	96.5mg				
lun mix e	1.26gm	* P<.2	-	405.mg n.s.s.	6/125	7/78	8/76				
liv vsc e	no dre	P=1.	-	2.20gm n.s.s.	4/125	1/78	0/76				
liv mix e	no dre	P=1.	-	614.mg n.s.s.	27/125	9/78	13/76				
tba mix e	11.7gm	* P<1.	-	89.5mg n.s.s.	109/125	61/78	66/76				
tba mal e	no dre	P=1.	-	182.mg n.s.s.	90/125	43/78	52/76				
tba ben e	no dre	P=1.	-	308.mg n.s.s.	73/125	38/78	38/76				
2657 M m b6c gav 24m24 TR259 :					0	70.4mg	142.mg				
for MXA	260.mg	* P<.0005	c	147.mg 523.mg	0/50	5/50	12/50				for:sqc,sqp.
for sqp	339.mg	* P<.002	c	178.mg 1.04gm	0/50	4/50	9/50				
for sqc	687.mg	* P<.01	c	296.mg 48.3gm	0/50	2/50	5/50				
TBA MXB	no dre	P=1.		134.mg n.s.s.	30/50	32/50	29/50				
liv MXB	no dre	P=1.		189.mg n.s.s.	17/50	12/50	(6/50)				liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		428.mg n.s.s.	8/50	6/50	5/50				lun:a/a,a/c.
2658 M m b6c inh 24m24 1754i					0	5.36mg					Miller;dact,8,1-42;1985
nac tum r	no dre	P=1.	-	99.5mg n.s.s.	0/80	0/90					
2659 M m b6c inh 6m27 1754j					0	53.6mg					
thy ade e	515.mg	P<.01	-	199.mg 53.5gm	2/121	7/69					
lun mix e	no dre	P=1.	-	302.mg n.s.s.	28/121	12/69					
liv mix e	no dre	P=1.	-	254.mg n.s.s.	44/121	19/69					
tba ben e	no dre	P=1.	-	208.mg n.s.s.	60/121	27/69					
tba mal e	no dre	P=1.	-	160.mg n.s.s.	62/121	31/69					
tba mix e	no dre	P=1.	-	132.mg n.s.s.	90/121	44/69					
2660 M m b6c inh 27m27 1754k					0	26.8mg	80.4mg				
lun mix e	no dre	P=1.	-	215.mg n.s.s.	28/121	10/75	(9/76)				
liv mix e	no dre	P=1.	-	351.mg n.s.s.	44/121	22/75	23/76				
liv vsc e	no dre	P=1.	-	1.17gm n.s.s.	5/121	3/75	1/76				
tba mix e	2.17gm	* P<.9	-	100.mg n.s.s.	90/121	53/75	57/76				
tba mal e	300.mg	* P<.2	-	104.mg n.s.s.	62/121	34/75	47/76				
tba ben e	no dre	P=1.	-	466.mg n.s.s.	60/121	30/75	25/76				
2661 R f f34 gav 24m24 TR259 :					0	70.1mg	141.mg				
for MXA	362.mg	* P<.004	c	188.mg 2.29gm	1/50	6/50	11/50				for:sqc,sqp.
for sqp	420.mg	* P<.01	c	205.mg 37.9gm	1/50	6/50	9/50				
TBA MXB	534.mg	* P<.7		81.4mg n.s.s.	38/50	44/50	44/50				
liv MXB	4.66gm	* P<.3		760.mg n.s.s.	0/50	0/50	1/50				liv:hpa,hpc,nnd.
2662 R f f34 inh 24m24 1754m					0	1.53mg					Miller;dact,8,1-42;1985
nac tum r	no dre	P=1.	-	28.4mg n.s.s.	0/80	0/90					
2663 R f f34 inh 6m27 1754n					0	15.3mg					
liv bht e	no dre	P=1.	-	199.mg n.s.s.	4/121	1/70					
liv sar e	no dre	P=1.	-	280.mg n.s.s.	1/121	0/70					
tyf mix e	no dre	P=1.	-	280.mg n.s.s.	0/121	0/70					
tba mix e	no dre	P=1.	-	11.5mg n.s.s.	114/121	64/70					
tba ben e	no dre	P=1.	-	20.3mg n.s.s.	97/121	54/70					
tba mal e	no dre	P=1.	-	59.0mg n.s.s.	72/121	32/70					
2664 R f f34 inh 27m27 1754o					0	7.66mg	23.0mg				
tyf mix e	1.03gm	* P<.2	-	253.mg n.s.s.	0/121	1/77	1/78				
liv sar e	no dre	P=1.	-	116.mg n.s.s.	1/121	0/77	0/78				
liv bht e	no dre	P=1.	-	299.mg n.s.s.	4/121	1/77	2/78				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba ben e	no dre	P=1.	-	48.7mg n.s.s.	97/121	51/77	56/78		
tba mal e	no dre	P=1.	-	81.1mg n.s.s.	72/121	41/77	38/78		
tba mix e	no dre	P=1.	-	13.7mg n.s.s.	114/121	71/77	73/78		
2665 R m f34 gav 24m24 TR259 :					0	70.1mg	141.mg		
for MXA	71.9mg	* P<.0005	c	50.0mg 111.mg	1/50	18/50	36/50		for:sqc,sqp.
for sqp	92.9mg	* P<.0005	c	62.2mg 152.mg	1/50	15/50	29/50		
for sqc	234.mg	* P<.0005	c	130.mg 488.mg	0/50	5/50	12/50		
mul mle	330.mg	\ P<.03		120.mg n.s.s.	1/50	6/50	(1/50)		S
pan MXA	402.mg	\ P<.02		138.mg n.s.s.	0/50	4/50	(0/50)		pan:acc,ana. S
TBA MXB	94.8mg	* P<.01		45.7mg 9.25gm	38/50	40/50	45/50		
liv MXB	3.29gm	* P<.2		535.mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
2666 R m f34 inh 24m24 1754m					0	1.07mg			Miller;dact,8,1-42;1985
nac tum r	no dre	P=1.	-	19.9mg n.s.s.	0/80	0/90			
2667 R m f34 inh 6m27 1754n					0	10.7mg			
tyf mix e	267.mg	P<.2	-	68.6mg n.s.s.	1/120	3/71			
liv hpc e	no dre	P=1.	-	199.mg n.s.s.	2/120	0/71			
liv bht e	no dre	P=1.	-	199.mg n.s.s.	7/120	0/71			
tba ben e	12.8mg	P<.4	-	2.72mg n.s.s.	113/120	69/71			
tba mal e	no dre	P=1.	-	28.0mg n.s.s.	60/120	33/71			
tba mix e	noTD50	P<.4	-	n.s.s. n.s.s.	116/120	71/71			
2668 R m f34 inh 27m27 1754o					0	5.36mg	16.1mg		
tyf mix e	77.9mg	\ P<.03	-	27.0mg n.s.s.	1/120	5/76	(2/75)		
liv bht e	599.mg	* P<.6	-	94.8mg n.s.s.	7/120	5/76	6/75		
liv hpc e	1.67gm	* P<.6	-	194.mg n.s.s.	2/120	0/76	2/75		
tba mix e	5.76mg	* P<.08	-	1.43mg n.s.s.	116/120	74/76	75/75		
tba ben e	6.27mg	* P<.03	-	2.09mg n.s.s.	113/120	72/76	75/75		
tba mal e	39.0mg	* P<.04	-	16.5mg n.s.s.	60/120	40/76	49/75		
2669 R m f34 gav 26w91 2197m					0	40.8mg			Ghanayem;txpy,22,497-509;1994
for mix C	no dre	P=1.	-	116.mg n.s.s.	0/16	0/18			
liv tum C	no dre	P=1.	-	116.mg n.s.s.	0/16	0/18			
2670 R m f34 gav 52w52 2197n					0	143.mg			
for mix Ck	no dre	P=1.		36.8mg n.s.s.	0/5	0/5			
liv tum Ck	no dre	P=1.		36.8mg n.s.s.	0/5	0/5			
2671 R m f34 gav 52w60 2197o					0	122.mg			
for sqp Ck	54.7mg	P<.08		13.0mg n.s.s.	0/5	2/5			
for sqc Ck	no dre	P=1.		42.0mg n.s.s.	0/5	0/5			
liv tum Ck	no dre	P=1.		42.0mg n.s.s.	0/5	0/5			
2672 R m f34 gav 52w91 2197r					0	81.6mg			
for mix C	116.mg	P<.008	+	39.8mg 2.40gm	0/16	4/13			
for sqc C	163.mg	P<.03		49.1mg n.s.s.	0/16	3/13			
for sqp C	535.mg	P<.2		87.0mg n.s.s.	0/16	1/13			
liv tum C	no dre	P=1.		167.mg n.s.s.	0/16	0/13			
ETHYL ALCOHOL (ethanol) 64-17-5									
2673 H m syg wat 29w78 2345					0	3.29gm	8.23gm		McCoy;clet,33,151-159;1986
trh tum er	no dre	P=1.	-	7.36gm n.s.s.	0/27	0/27	0/27		
2674 M m amm wat 72w72 2081					0	16.7gm			Anderson;carc,13,2107-2111;1992
liv hpa e	127.gm	P<.4		27.8gm n.s.s.	1/47	3/48			
lun ala e	no dre	P=1.		10.4gm n.s.s.	39/47	33/48			
2675 M m bal wat 69w86 2510n					0	1.33gm			Zariwala;ijeb,29,738-743;1991
for sqp	no dre	P=1.	-	5.64gm n.s.s.	1/30	0/30			
2676 M f c3s wat 86w86 1632					0	24.0gm			Schrauzer;jsac,40,240-246;1979
mam adc Lr	no dre	P=1.		15.3gm n.s.s.	23/30	8/15			
2677 M f swi wat 69w86 2510m					0	1.60gm			Zariwala;ijeb,29,738-743;1991
for sqp s	10.9gm	P<.1	-	2.67gm n.s.s.	0/30	2/30			
tba mix s	21.4gm	P<.6	-	2.94gm n.s.s.	1/30	2/30			
2678 M m swi wat 69w86 2510m					0	1.33gm			
lun ade	no dre	P=1.	-	3.40gm n.s.s.	1/30	1/30			
2679 R m aci wat 52w52 2076					0	5.00gm			Watanabe;gann,83,588-593;1992/pers.comm.
for pam er	4.98gm	P<.03		1.50gm n.s.s.	0/22	3/19			
stg adc er	no dre	P=1.		4.89gm n.s.s.	0/22	0/19			
2680 R f cdr wat 24m24 1962					0	2.86gm			Cheever;faat,14,243-261;1990
liv nnd e	no dre	P=1.	-	28.9gm n.s.s.	1/50	0/49			
tba tum e	no dre	P=1.	-	2.70gm n.s.s.	47/50	41/50			
2681 R m cdr wat 24m24 1962					0	2.50gm			
liv nnd e	84.8gm	P<.3	-	13.8gm n.s.s.	0/50	1/50			
liv hpc e	no dre	P=1.	-	25.8gm n.s.s.	1/50	0/50			
tba tum e	no dre	P=1.	-	1.38gm n.s.s.	42/50	42/50			
2682 R m cdr wat 52w52 2074					0	5.00gm			Watanabe;gann,83,1267-1272;1992/pers.comm.
stg adc er	no dre	P=1.		3.86gm n.s.s.	0/12	0/15			
2683 R m f3d wat 51w52 2564					0	4.90gm			Wada;clet,124,127-134;1998
for tum er	no dre	P=1.	-	4.04gm n.s.s.	0/15	0/16			
stg tum er	no dre	P=1.	-	4.04gm n.s.s.	0/15	0/16			
2684 R f nbr wat 64w64 162a					0	5.71gm			Yamamoto;ijcn,2,337-343;1967
liv tum	no dre	P=1.		8.92gm n.s.s.	0/20	0/20			
2685 R m nbr wat 64w64 162a					0	5.00gm			
liv tum	no dre	P=1.		7.80gm n.s.s.	0/20	0/20			
2686 R b sda wat 26m26 1264					0	9.45gm			Schmahl;clet,1,215-218;1976
tba mal e	no dre	P=1.	-	39.9gm n.s.s.	4/48	4/48			
2687 R f sda wat 24m28 2257m					0	1.49gm			Holmberg;txcy,96,133-145;1995/1994
pan ade Ie	21.9gm	P<.04		6.63gm n.s.s.	0/50	3/50			
mgl mix Ie	4.71gm	P<.5		981.mg n.s.s.	38/50	41/50			
mgl ben Ie	6.07gm	P<.4		1.62gm n.s.s.	25/50	30/50			
mgl fba Ie	8.79gm	P<.5		1.98gm n.s.s.	22/50	26/50			
liv hpc Ie	no dre	P=1.		20.4gm n.s.s.	1/50	0/50			
liv mix Ie	no dre	P=1.		20.4gm n.s.s.	2/50	0/50			
mgl car Ie	no dre	P=1.		5.29gm n.s.s.	13/50	11/50			
liv hpa Ie	no dre	P=1.		20.4gm n.s.s.	1/50	0/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba ben Ie	3.15gm	P<.2	1.08gm n.s.s.	30/50	37/50			
tba mal Ie	no dre	P=1.	3.35gm n.s.s.	23/50	21/50			
tba mix Ie	no dre	P=1.	340.mg n.s.s.	50/50	49/50			
2688 R f sda wat 24m28 2257n				0	4.46gm			
pit nen Ie	5.48gm	P<.02	2.40gm n.s.s.	29/50	40/50			
liv hpa Ie	201.gm	P<.3	32.8gm n.s.s.	0/50	1/50			
liv hpc Ie	no dre	P=1.	61.1gm n.s.s.	0/50	0/50			
pan mix Ie	no dre	P=1.	30.0gm n.s.s.	2/50	2/50			
tba mix Ie	5.87gm	P<.6	782.mg n.s.s.	48/50	49/50			
tba ben Ie	12.1gm	P<.3	3.71gm n.s.s.	29/50	35/50			
tba mal Ie	61.0gm	P<.7	7.94gm n.s.s.	19/50	21/50			
2689 R m sda wat 30m30 1440				0	2.50gm			Radike;enhp,41,59-62;1981
liv hnd e	8.26gm	P<.0005	4.47gm 29.0gm	10/80	29/79			
pit tum e	9.11gm	P<.0005 +	4.89gm 32.1gm	8/80	26/79			
adr tum e	13.7gm	P<.0005 +	7.38gm 29.9gm	0/80	14/79			
pan tum e	13.7gm	P<.0005 +	7.38gm 29.9gm	0/80	14/79			
liv hpc e	28.4gm	P<.02 +	11.9gm n.s.s.	1/80	8/79			
tba mix e	2.13gm	P<.0005	1.42gm 3.51gm	16/80	61/79			
2690 R m sda wat 24m28 2257m				0	1.21gm			Holmberg;txcy,96,133-145;1995/1994
pan car Ie	17.5gm	P<.2	4.90gm n.s.s.	1/50	4/50			
liv hpc Ie	no dre	P=1.	16.6gm n.s.s.	2/50	0/50			
liv hpa Ie	no dre	P=1.	16.6gm n.s.s.	0/50	0/50			
tba mix Ie	1.21gm	P<.3	305.mg n.s.s.	45/50	48/50			
tba mal Ie	7.18gm	P<.3	1.95gm n.s.s.	15/50	20/50			
tba ben Ie	no dre	P=1.	1.36gm n.s.s.	35/50	35/50			
2691 R m sda wat 24m28 2257n				0	3.64gm			
pan mix Ie	33.2gm	P<.4	8.52gm n.s.s.	8/50	12/50			
liv hpc Ie	164.gm	P<.3	26.8gm n.s.s.	0/50	1/50			
liv hpa Ie	no dre	P=1.	49.9gm n.s.s.	0/50	0/50			
tba ben Ie	no dre	P=1.	6.88gm n.s.s.	30/50	27/50			
tba mal Ie	no dre	P=1.	8.94gm n.s.s.	16/50	16/50			
tba mix Ie	no dre	P=1.	2.25gm n.s.s.	44/50	44/50			
2692 R m sls wat 28m28 2185				0	2.50gm	10.0gm		Shibayama;extp,45,15-19;1993/pers.comm.
liv mix er	33.8gm *	P<.03 -	14.4gm n.s.s.	3/44	10/41	12/43		
liv hpc er	93.9gm *	P<.07 -	35.7gm n.s.s.	0/44	2/41	3/43		
liv hpa er	56.1gm *	P<.2 -	19.2gm n.s.s.	3/44	8/41	9/43		
2693 R f wis wat 52w52 2028				0	4.08gm			Yamagiwa;gann,82,771-778;1991
liv mix r	no dre	P=1.	2.10gm n.s.s.	0/5	0/10			
2694 R m wis wat 91w91 1800				0	2.50gm			Salmon;carc,7,1447-1450;1986
for sqc r	no dre	P=1.	3.94gm n.s.s.	0/10	0/10			
Z-ETHYL-O,N,N-AZOXYETHANE 16301-26-1								
2695 R m f34 wat 30w55 1723				0	.218mg			Lijinsky;canr,45,76-79;1985
liv mix	noTD50	P<.0005 +	n.s.s. 23.8ug	2/20	20/20			
nas mix	22.0ug	P<.0005 +	11.0ug 47.7ug	0/20	17/20			
eso mix	30.2ug	P<.0005 +	15.4ug 66.5ug	0/20	15/20			
liv hes	34.7ug	P<.0005 +	17.7ug 78.1ug	0/20	14/20			
liv hpc	34.7ug	P<.0005 +	17.7ug 78.1ug	0/20	14/20			
liv nsc	97.1ug	P<.002	41.5ug .368mg	0/20	7/20			
liv nnd	no dre	P=1.	.252mg n.s.s.	2/20	0/20			
Z-ETHYL-O,N,N-AZOXYMETHANE 57497-29-7								
2696 R m f34 wat 30w55 1723				0	.187mg			Lijinsky;canr,45,76-79;1985
liv mix	noTD50	P<.0005 +	n.s.s. 20.4ug	2/20	20/20			
liv hpc	18.9ug	P<.0005 +	9.44ug 40.9ug	0/20	17/20			
liv hes	39.1ug	P<.0005 +	19.5ug 93.3ug	0/20	12/20			
liv nsc	83.2ug	P<.002	35.6ug .315mg	0/20	7/20			
col mix	.125mg	P<.007 +	47.0ug 1.44mg	0/20	5/20			
ilm tum	.221mg	P<.04 +	66.6ug n.s.s.	0/20	3/20			
liv nnd	no dre	P=1.	.216mg n.s.s.	2/20	0/20			
ETHYL BROMOACETATE 105-36-2								
2697 M f hic ipj 64w64 1143				0	.571mg			Van Duuren;jnci,53,695-700;1974
lun ptm	no dre	P=1.	.390mg n.s.s.	12/30	9/30			
S-ETHYL-L-CYSTEINE 2629-59-6								
2698 R m wis eat 58w89 1373				0	116.mg	127.mg		Argus;zkko,75,201-208;1971
abd lps aev	3.63gm *	P<.4 -	592.mg n.s.s.	0/30	0/30	1/30		
liv tum aev	no dre	P=1. -	275.mg n.s.s.	0/30	0/30	0/30		
tba mix aev	3.63gm *	P<.4 -	592.mg n.s.s.	0/30	0/30	1/30		
p,p'-ETHYL-DDD (perthane) 72-56-0								
2699 M f b6c eat 24m24 TR156 :				0	368.mg	806.mg		
liv MXA v	2.67gm *	P<.04 a	1.23gm n.s.s.	1/20	3/50	11/50		liv:hpa,hpc.
liv hpc v	3.16gm *	P<.04 a	1.39gm n.s.s.	1/20	2/50	10/50		
TBA MXB v	2.36gm *	P<.4	617.mg n.s.s.	7/20	24/50	26/50		
liv MXB v	2.67gm *	P<.04	1.23gm n.s.s.	1/20	3/50	11/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	2.94gm n.s.s.	0/20	3/50	1/50		lun:a/a,a/c.
2700 M f b6c orl 76w76 1098				0	110.mg			Innes;ntis,1968/1969
liv hpt evx	665.mg	P<.3	108.mg n.s.s.	0/16	1/17			
lun mix evx	no dre	P=1.	206.mg n.s.s.	0/16	0/17			
tba mix evx	322.mg	P<.1	79.1mg n.s.s.	0/16	2/17			
2701 M m b6c eat 24m24 TR156 :				0	300.mg	600.mg		
lun a/a #	1.64gm *	P<.02 -	866.mg n.s.s.	0/20	4/50	9/50		S
TBA MXB	no dre	P=1.	430.mg n.s.s.	11/20	38/50	33/50		
liv MXB	9.16gm *	P<.9	508.mg n.s.s.	8/20	27/50	25/50		liv:hpa,hpc,nnd.
lun MXB	5.07gm *	P<.6	988.mg n.s.s.	4/20	5/50	12/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2702 M m b6c orl 76w76 1098					0	102.mg			Innes;ntis,1968/1969
liv hpt evx	65.1mg	P<.002	27.6mg	238.mg	0/16	7/16			
lun ade evx	581.mg	P<.3	94.5mg	n.s.s.	0/16	1/16			
tba mix evx	54.1mg	P<.0005	23.9mg	167.mg	0/16	8/16			
2703 M f b6a orl 76w76 1098					0	110.mg			
liv hpt evx	no dre	P=1.	218.mg	n.s.s.	0/17	0/18			
lun ade evx	no dre	P=1.	218.mg	n.s.s.	1/17	0/18			
tba mix evx	no dre	P=1.	104.mg	n.s.s.	2/17	2/18			
2704 M m b6a orl 76w76 1098					0	102.mg			
lun ade evx	581.mg	P<.7	72.9mg	n.s.s.	2/18	3/18			
liv hpt evx	no dre	P=1.	121.mg	n.s.s.	1/18	1/18			
tba mix evx	543.mg	P<.7	63.6mg	n.s.s.	3/18	4/18			
2705 R f f34 eat 24m24 TR156 :					0	175.mg	350.mg		
TBA MXB	no dre	P=1.	- 166.mg	n.s.s.	15/20	32/50	(21/50)		
liv MXB	8.54gm *	P<.8	1.59gm	n.s.s.	0/20	2/50	1/50		liv:hpa,hpc,nnd.
2706 R m f34 eat 24m24 TR156 :					0	140.mg	280.mg		
TBA MXB	no dre	P=1.	- 286.mg	n.s.s.	13/20	36/50	30/50		
liv MXB	no dre	P=1.	1.59gm	n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
N-ETHYL-N-FORMYLHYDRAZINE 74920-78-8									
2707 M f swa wat 61w61 1052					0	40.0mg			Toth;carc,1,61-65;1980
blv mix e	2.49mg	P<.0005 +	1.17mg	4.67mg	8/96	47/48			
lun mix e	2.52mg	P<.0005 +	1.17mg	4.76mg	15/99	49/50			
liv tum e	no dre	P=1.	142.mg	n.s.s.	0/21	0/50			
2708 M m swa wat 60w60 1052					0	33.3mg			
lun mix e	3.19mg	P<.0005 +	1.76mg	6.03mg	22/98	39/42			
blv mix e	3.55mg	P<.0005 +	2.04mg	6.45mg	5/88	32/36			
liv mix e	17.7mg	P<.0005 +	9.07mg	45.6mg	1/52	13/36			
gal mix e	47.4mg	P<.005 +	16.4mg	452.mg	0/44	4/27			
pre mix e	50.8mg	P<.003 +	19.3mg	290.mg	0/52	5/36			
ETHYL METHYLPHENYLGLYCIDATE 77-83-8									
2709 R f wis eat 24m24 1383					0	10.0mg	50.0mg	250.mg	Dunnington;fctx,19,691-699;1981
pit ade e	331.mg *	P<.05 -	126.mg	n.s.s.	18/43	30/44	24/41	31/43	
liv hae e	9.36gm *	P<.2 -	1.52gm	n.s.s.	0/44	0/44	0/42	1/45	
tba ben e	253.mg *	P<.06 -	92.7mg	n.s.s.	24/44	35/44	33/42	37/45	
tba mal e	2.23gm *	P<.2 -	601.mg	n.s.s.	1/44	3/44	3/42	5/45	
2710 R m wis eat 24m24 1383					0	8.00mg	40.0mg	200.mg	
tes ict e	1.15gm Z	P<.2 -	335.mg	n.s.s.	2/38	8/35	1/35	8/36	
liv tum e	no dre	P=1. -	50.8mg	n.s.s.	0/37	0/38	0/39	0/39	
tba ben e	1.15gm *	P<.5 -	230.mg	n.s.s.	10/38	20/39	11/39	17/39	
tba mal e	4.11gm *	P<.7 -	491.mg	n.s.s.	2/38	6/39	4/39	5/39	
N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE 63885-23-4									
2711 M b cbh wat 43w69 600					0	5.48mg			Nakamura;jnci,52,519-522;1974
duo mix e	2.84mg	P<.0005 +	1.64mg	5.50mg	0/38	19/43			
eso mix e	3.85mg	P<.0005 +	2.10mg	8.18mg	0/38	15/43			
duo adc e	4.20mg	P<.0005 +	2.25mg	9.20mg	0/38	14/43			
eso sqc e	5.60mg	P<.0005 +	2.80mg	14.3mg	0/38	11/43			
sto mix e	8.03mg	P<.002	3.63mg	29.5mg	0/38	8/43			
liv hms e	70.3mg	P<.3	11.4mg	n.s.s.	0/38	1/43			
liv hpt e	no dre	P=1.	13.8mg	n.s.s.	19/38	5/43			
lun ade e	no dre	P=1.	21.4mg	n.s.s.	3/38	0/43			
tba mix e	284.mg	P<1.	2.37mg	n.s.s.	22/38	25/43			
1-ETHYL-1-NITROSOUREA (ENU, N-ethyl-N-nitrosourea) 759-73-9									
2712 R f f3d wat 24m26 1614					0	12.0ug	40.2ug	.120mg	.429mg	Maekawa;gann,75,117-125;1984
--- mnl ae	.151mg Z	P<.0005	90.2ug	.351mg	5/52	8/51	18/52	24/50	(27/50)	
ute esp ae	.883mg *	P<.003	.419mg	6.46mg	9/52	10/51	16/52	16/50	22/50	
bra mix ae	.904mg *	P<.0005 +	.544mg	1.66mg	0/52	0/51	0/52	2/50	20/50	
mgl adc ae	2.54mg *	P<.002	1.12mg	12.3mg	1/52	1/51	1/52	1/50	8/50	
dgt mix ae	2.56mg *	P<.003 +	1.10mg	18.2mg	2/52	1/51	1/52	2/50	8/50	
utm sar ae	2.56mg *	P<.003	1.10mg	18.2mg	2/52	1/51	1/52	2/50	8/50	
duo mix ae	7.68mg *	P<.006 +	2.32mg	106.mg	0/52	0/51	0/52	0/50	3/50	
ute ade ae	4.08mg *	P<.1	1.24mg	n.s.s.	0/52	5/51	3/52	3/50	6/50	
tyf ppa ae	8.70mg *	P<.08	2.35mg	n.s.s.	0/52	0/51	1/52	0/50	2/50	
liv nnd ae	no dre	P=1.	4.88mg	n.s.s.	0/52	0/51	1/52	0/50	0/50	
tba mix ae	68.7ug *	P<.0005	32.6ug	.202mg	38/52	39/51	44/52	46/50	50/50	
2713 R m f3d wat 23m26 1614					0	11.2ug	37.5ug	.112mg	.400mg	
per mso ae	.109mg Z	P<.0005	71.0ug	.200mg	1/51	10/52	13/52	28/51	(32/52)	
lun ade ae	.518mg *	P<.0005	.326mg	.976mg	5/51	0/52	6/52	11/51	25/52	
mgl fib ae	.889mg *	P<.0005	.460mg	3.25mg	6/51	5/52	6/52	13/51	18/52	
bra mix ae	.997mg *	P<.0005 +	.588mg	1.90mg	0/51	0/52	2/52	2/51	16/52	
dgt mix ae	1.15mg *	P<.0005 +	.629mg	2.84mg	1/51	2/52	1/52	4/51	14/52	
lun adc ae	2.00mg *	P<.0005	.942mg	7.80mg	1/51	1/52	1/52	2/51	9/52	
sub fib ae	2.42mg *	P<.02	.961mg	n.s.s.	0/51	1/52	2/52	5/51	5/52	
tyf ppa ae	3.90mg *	P<.05 +	1.29mg	n.s.s.	0/51	1/52	4/52	1/51	5/52	
tyf pac ae	8.53mg *	P<.09 +	2.27mg	n.s.s.	0/51	0/52	1/52	0/51	2/52	
pns mix ae	10.2mg *	P<.4 +	2.34mg	n.s.s.	0/51	2/52	0/52	2/51	2/52	
liv nnd ae	16.4mg *	P<.7	1.73mg	n.s.s.	4/51	0/52	6/52	3/51	4/52	
duo mix ae	31.2mg *	P<.5 +	3.55mg	n.s.s.	0/51	1/52	0/52	0/51	1/52	
tba mix ae	25.0ug *	P<.3	n.s.s.	n.s.s.	51/51	51/52	52/52	51/51	52/52	
ETHYL TELLURAC 20941-65-5									
2714 M f b6c eat 25m25 TR152 :					0	277.mg	639.mg		
TBA MXB v	1.03gm *	P<.3 -	325.mg	n.s.s.	8/20	36/50	36/50		
liv MXB v	2.27gm *	P<.2	908.mg	n.s.s.	1/20	7/50	10/50		liv:hpa,hpc,nnd.
lun MXB v	3.40gm *	P<.5	856.mg	n.s.s.	3/20	9/50	12/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2715 M f b6c orl 76w76 132					0	20.4mg			Innes;ntis,1968/1969
lun ade evx		131.mg	P<.3	21.3mg n.s.s.	0/16	1/18			
liv hpt evx		no dre	P=1.	40.5mg n.s.s.	0/16	0/18			
tba mix evx		63.5mg	P<.2	15.6mg n.s.s.	0/16	2/18			
2716 M m b6c eat 25m25 TR152 :					0	151.mg	376.mg		
eye adn v		201.mg	\ P<.002 a	112.mg 617.mg	0/20	16/50	(10/50)		
lun MXA v		228.mg	\ P<.002	127.mg 706.mg	0/20	16/50	(11/50)		lun:a/a,a/c. S
lun a/c v		260.mg	\ P<.003	140.mg 1.02gm	0/20	14/50	(11/50)		S
TBA MXB v		902.mg	* P<.5	198.mg n.s.s.	10/20	39/50	35/50		
liv MXB v		no dre	P=1.	518.mg n.s.s.	8/20	15/50	16/50		liv:hpa,hpc,nnd.
lun MXB v		228.mg	\ P<.002	127.mg 706.mg	0/20	16/50	(11/50)		lun:a/a,a/c.
2717 M m b6c orl 76w76 132					0	19.0mg			Innes;ntis,1968/1969
liv hpt evx		24.2mg	P<.02	8.30mg n.s.s.	0/16	4/16			
lun mix evx		52.1mg	P<.09	12.8mg n.s.s.	0/16	2/16			
lun ade evx		108.mg	P<.3	17.5mg n.s.s.	0/16	1/16			
lun car evx		108.mg	P<.3	17.5mg n.s.s.	0/16	1/16			
tba mix evx		8.41mg	P<.0005	3.84mg 23.6mg	0/16	9/16			
2718 M f b6a orl 76w76 132					0	20.4mg			
lun ade evx		28.2mg	P<.08	9.17mg n.s.s.	1/17	5/18			
liv hpt evx		no dre	P=1.	40.5mg n.s.s.	0/17	0/18			
tba mix evx		26.7mg	P<.2	8.28mg n.s.s.	2/17	6/18			
2719 M m b6a orl 76w76 132					0	19.0mg			
liv hpt evx		55.5mg	P<.3	12.4mg n.s.s.	1/18	3/18			
lun ade evx		no dre	P=1.	17.8mg n.s.s.	2/18	2/18			
tba mix evx		31.2mg	P<.3	8.12mg n.s.s.	3/18	6/18			
2720 R f f34 eat 24m24 TR152 :					0	7.50mg	15.0mg		
pit adn #		12.3mg	\ P<.04 -	5.78mg n.s.s.	2/20	19/50	(9/50)		S
TBA MXB		no dre	P=1.	11.7mg n.s.s.	15/20	40/50	39/50		
liv MXB		650.mg	* P<.4	106.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
2721 R m f34 eat 24m24 TR152 :					0	12.0mg	24.0mg		
--- men		77.6mg	* P<.009 a	37.1mg 2.43gm	0/20	2/50	8/50		
bod men		181.mg	* P<.05 a	61.8mg n.s.s.	0/20	0/50	4/50		
TBA MXB		no dre	P=1.	12.7mg n.s.s.	17/20	43/50	39/50		
liv MXB		no dre	P=1.	119.mg n.s.s.	1/20	2/50	0/50		liv:hpa,hpc,nnd.
3-O-ETHYLASCORBIC ACID 86404-04-8									
2722 R f f3d eat 52w52 2249					0	500.mg			Hirose;carc,16,217-221;1995/pers.comm.
liv tum e		no dre	P=1.	258.mg n.s.s.	0/10	0/10			
ETHYLBENZENE 100-41-4									
2723 M f b6c inh 24m24 TR466 :					0	101.mg	336.mg	1.01gm	
liv MXA		1.88gm	* P<.02 p	809.mg n.s.s.	13/50	12/50	15/50	25/50	liv:hpa,hpc.
liv hpa		2.45gm	* P<.04	978.mg n.s.s.	6/50	9/50	12/50	16/50	S
hag ade		9.07gm	* P<.02	3.13gm n.s.s.	0/50	0/50	1/50	3/50	S
TBA MXB		4.07gm	* P<.6	769.mg n.s.s.	29/50	38/50	31/50	38/50	
liv MXB		1.88gm	* P<.02	809.mg n.s.s.	13/50	12/50	15/50	25/50	liv:hpa,hpb,hpc.
lun MXB		7.95gm	* P<.4	1.91gm n.s.s.	4/50	6/50	5/50	8/50	lun:a/a,a/c.
2724 M m b6c inh 24m24 TR466 :					0	84.3mg	281.mg	843.mg	
lun MXA		1.40gm	* P<.02 p	614.mg n.s.s.	7/50	10/50	15/50	19/50	lun:a/a,a/c.
lun a/a		1.68gm	* P<.02	716.mg n.s.s.	5/50	9/50	10/50	16/50	S
TBA MXB		2.01gm	* P<.4	493.mg n.s.s.	35/50	34/50	40/50	41/50	
liv MXB		9.31gm	* P<.8	787.mg n.s.s.	27/50	24/50	30/50	27/50	liv:hpa,hpb,hpc.
lun MXB		1.40gm	* P<.02	614.mg n.s.s.	7/50	10/50	15/50	19/50	lun:a/a,a/c.
2725 R f f34 inh 24m24 TR466 :					0	24.1mg	80.4mg	242.mg	
kid rua		8.25gm	* P<.2	1.34gm n.s.s.	0/50	0/50	0/50	1/50	
TBA MXB		no dre	P=1.	185.mg n.s.s.	42/50	45/50	43/50	46/50	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
2726 R f f34 inh 24m24 TR466 with step					0	24.1mg	80.4mg	242.mg	
kid rua		1.26gm	* P<.0005 p	595.mg 3.49gm	0/50	0/50	1/50	8/50	
2727 R m f34 inh 24m24 TR466 :					0	16.9mg	56.4mg	169.mg	
tes iab		23.1mg	Z P<.0005	13.8mg 47.2mg	27/50	23/50	32/50	40/50	S
MXB MXB		24.6mg	* P<.0005	14.2mg 55.2mg	36/50	34/50	40/50	45/50	kid:rua,ruc; tes:iab,ica. C
tes MXA		24.8mg	* P<.0005 c	14.3mg 56.3mg	36/50	33/50	40/50	44/50	tes:iab,ica.
amd MXA		106.mg	Z P<.009	42.3mg 3.83gm	13/50	13/50	9/50	14/50	amd:pbb,phm,pob. S
kid MXA		147.mg	* P<.0005 c	64.1mg 612.mg	0/50	3/50	3/50	7/50	kid:rua,ruc.
kid rua		232.mg	* P<.01 c	80.8mg 23.5gm	0/50	3/50	2/50	4/50	
kid ruc		553.mg	* P<.005	137.mg 6.47gm	0/50	0/50	1/50	3/50	S
amd MXA		125.mg	* P<.03	45.4mg n.s.s.	13/50	13/50	9/50	12/50	amd:pbb,pob. S
TBA MXB		53.0mg	* P<.008	23.5mg 1.21gm	48/50	44/50	47/50	38/50	
liv MXB		no dre	P=1.	835.mg n.s.s.	0/50	3/50	0/50	0/50	liv:hpa,hpb,hpc.
2728 R m f34 inh 24m24 TR466 with step					0	16.9mg	56.4mg	169.mg	
kid MXA		255.mg	* P<.0005 c	150.mg 585.mg	3/50	5/50	8/50	21/50	kid:rua,ruc.
kid rua		280.mg	* P<.0005 c	161.mg 680.mg	3/50	5/50	7/50	20/50	
kid ruc		2.03gm	* P<.02	701.mg n.s.s.	0/50	0/50	1/50	3/50	S
2729 R f sda gav 24m29 BT912					0	387.mg			Maltoni;anya,837,15-52;1997
hed car h		4.17gm	P<.2 +	1.24gm n.s.s.	3/50	7/50			
orc car		8.89gm	P<.3	1.96gm n.s.s.	1/50	3/50			
nas car		18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50			
nas ene		18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50			
edu car		no dre	P=1.	3.39gm n.s.s.	1/50	1/50			
zym car		no dre	P=1.	3.39gm n.s.s.	1/50	1/50			
tba mal		1.61gm	P<.08	605.mg n.s.s.	11/50	19/50			
tba mix		no dre	P=1.	769.mg n.s.s.	35/50	30/50			
2730 R f sda gav 24m33 BT905m					0	237.mg			Maltoni;ajim,7,415-446;1985/1997a
tba mal ej		1.21gm	P<.08	433.mg n.s.s.	10/49	14/37			
tba mix j		635.mg	P<.2	211.mg n.s.s.	30/50	30/40			
2731 R m sda gav 24m29 BT912					0	387.mg			Maltoni;anya,837,15-52;1997
hed car h		4.35gm	P<.08 +	1.42gm n.s.s.	1/50	5/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
nas ene	5.99gm	P<.04	1.81gm	n.s.s.	0/50	3/50			
edu car	18.3gm	P<.3	2.99gm	n.s.s.	0/50	1/50			
orc car	18.3gm	P<.3	2.99gm	n.s.s.	0/50	1/50			
zym car	no dre	P=1.	5.57gm	n.s.s.	1/50	0/50			
tba mal	no dre	P=1.	1.20gm	n.s.s.	12/50	12/50			
tba mix	no dre	P=1.	1.04gm	n.s.s.	27/50	22/50			
2732 R m sda gav 24m33 BT905m					0	237.mg			Maltoni;ajim,7,415-446;1985/1997a
tba mix j	1.16gm	P<.4	282.mg	n.s.s.	29/50	27/40			
tba mal ej	1.98gm	P<.3	528.mg	n.s.s.	11/45	14/40			
ETHYLENE GLYCOL 107-21-1									
2733 M f b6c eat 24m24 TR413 :					0	1.59gm	3.19gm	6.37gm	
TBA MXB	no dre	P=1.	- 8.40gm	n.s.s.	39/50	33/50	31/51	36/50	
liv MXB	no dre	P=1.	12.7gm	n.s.s.	10/50	9/50	14/51	10/50	liv:hpa,hpc,nnd.
lun MXB	11.3gm Z	P<.06	4.83gm	n.s.s.	1/50	6/50	6/51	(1/50)	lun:a/a,a/c.
2734 M m b6c eat 24m24 TR413 :					0	740.mg	1.48gm	2.96gm	
hag MXA #	19.2gm *	P<.02	- 7.26gm	n.s.s.	0/54	0/54	2/54	3/54	hag:ade,car. S
TBA MXB	9.98gm *	P<.6	1.83gm	n.s.s.	34/54	36/54	31/54	33/54	
liv MXB	48.1gm *	P<.9	3.13gm	n.s.s.	19/54	23/54	16/54	18/54	liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	6.61gm	n.s.s.	7/54	3/54	9/54	3/54	lun:a/a,a/c.
ETHYLENE GLYCOL, CYCLIC SULFATE (glycol sulfate) 1072-53-3									
2735 M f hic ipj 64w64 1143					0	.286mg			Van Duuren;jnci,53,695-700;1974
lun ptm	no dre	P=1.	.169mg	n.s.s.	10/30	9/30			
ETHYLENE IMINE 151-56-4									
2736 M f b6a orl 76w76 1245					0	1.81mg			Innes;ntis,1968/1969
lun ade evx	.283mg	P<.0005 +	.100mg	.900mg	1/17	10/11			
liv hpt evx	3.29mg	P<.05	.806mg	n.s.s.	0/17	2/11			
tba mix evx	noTD50	P<.003	n.s.s.	.551mg	2/17	11/11			
2737 M m b6a orl 76w76 1245					0	1.68mg			
lun ade evx	.485mg	P<.0005	.219mg	1.59mg	2/18	12/16			
liv hpt evx	.800mg	P<.002 +	.349mg	3.45mg	1/18	9/16			
lun bro evx	2.14mg	P<.02	.734mg	n.s.s.	0/18	4/16			
tba mix evx	noTD50	P<.002	n.s.s.	.419mg	3/18	16/16			
2738 M f b6c orl 76w76 1245					0	1.81mg			
lun ade evx	noTD50	P<.0005 +	n.s.s.	.409mg	0/16	15/15			
liv hpt evx	.500mg	P<.0005	.233mg	1.27mg	0/16	11/15			
tba mix evx	noTD50	P<.0005	n.s.s.	.409mg	0/16	15/15			
2739 M m b6c orl 77w77 1245					0	1.68mg			
liv hpt evx	.295mg	P<.0005 +	.135mg	.688mg	0/16	15/17			
lun mix evx	.295mg	P<.0005 +	.135mg	.688mg	0/16	15/17			
lun ade evx	.364mg	P<.0005	.174mg	.847mg	0/16	14/17			
tba mix evx	.223mg	P<.0005	88.7ug	.540mg	0/16	16/17			
ETHYLENE OXIDE (EO) 75-21-8									
2740 M f b6c inh 24m24 TR326 :					0	27.8mg	55.6mg		
MXB MXB	39.2mg *	P<.002	21.7mg	163.mg	13/50	22/50	43/50		duo:mno; hag:pcy; kid:mno; lun:a/a,a/c; mds:mno; mgl: acn,adq; mln:mno; mul:mlh,mno; spl:mno; ute:acn,adn,mno. M
MXB MXB	45.8mg *	P<.0005	27.3mg	120.mg	3/50	9/50	26/50		hag:pcy; lun:a/a,a/c. C
lun MXA	61.8mg *	P<.0005 c	36.0mg	163.mg	2/50	5/50	22/50		lun:a/a,a/c.
lun a/a	87.5mg *	P<.002 c	47.0mg	362.mg	2/50	4/50	17/50		
lun a/c	200.mg *	P<.004 c	90.3mg	1.25gm	0/50	1/50	7/50		
liv hpa	75.8mg \	P<.02	31.2mg	41.7gm	1/50	8/50	(3/50)		S
mgl MXA	76.3mg \	P<.02 p	31.5mg	n.s.s.	1/50	8/50	(6/50)		mgl:acn,adq.
MXB MXB	79.2mg *	P<.02	38.7mg	n.s.s.	10/50	14/50	29/50		duo:mno; kid:mno; mds:mno; mgl:acn,adq; mln:mno; mul: mlh,mno; spl:mno; ute:acn,adn,mno. P
MXA MXA	139.mg *	P<.06 p	57.8mg	n.s.s.	9/50	6/50	22/50		duo:mno; kid:mno; mds:mno; mln:mno; mul:mlh,mno; spl: mno; ute:mno.
hag pcy	142.mg *	P<.04 c	64.9mg	n.s.s.	1/50	6/50	8/50		
ute MXA	250.mg *	P<.02 p	107.mg	n.s.s.	0/50	2/50	5/50		ute:acn,adn.
ute acn	297.mg *	P<.02 p	120.mg	n.s.s.	0/50	1/50	5/50		
TBA MXB	103.mg *	P<.4	27.6mg	n.s.s.	30/50	33/50	46/50		
liv MXB	149.mg \	P<.4	34.7mg	n.s.s.	6/50	9/50	(3/50)		liv:hpa,hpc,nnd.
lun MXB	61.8mg *	P<.0005	36.0mg	163.mg	2/50	5/50	22/50		lun:a/a,a/c.
2741 M m b6c inh 24m24 TR326 :					0	23.1mg	46.3mg		
MXB MXB	51.2mg *	P<.04	22.5mg	n.s.s.	12/50	26/50	29/50		hag:pcy; lun:a/a,a/c. C
lun MXA	65.7mg *	P<.06 c	27.8mg	n.s.s.	11/50	19/50	26/50		lun:a/a,a/c.
lun a/c	110.mg *	P<.08 c	44.0mg	n.s.s.	6/50	10/50	16/50		
hag pcy	110.mg *	P<.04 c	52.1mg	n.s.s.	1/50	9/50	8/50		
lun a/a	181.mg *	P<.3 c	54.5mg	n.s.s.	5/50	11/50	11/50		
TBA MXB	108.mg *	P<.5	24.4mg	n.s.s.	29/50	38/50	41/50		
liv MXB	273.mg *	P<.6	53.7mg	n.s.s.	15/50	17/50	21/50		liv:hpa,hpc,nnd.
lun MXB	65.7mg *	P<.06	27.8mg	n.s.s.	11/50	19/50	26/50		lun:a/a,a/c.
2742 R m f34 inh 23m24 1624 () pool					0	5.42mg	10.8mg		Lynch;txap,76,69-84;1984
per mso eis	30.8mg *	P<.0005 +	18.3mg	77.8mg	3/78	9/79	21/79		
bra gli eis	121.mg *	P<.01 +	52.3mg	4.81gm	0/76	2/77	5/79		
spl mnl eis	47.3mg *	P<.3 +	14.3mg	n.s.s.	24/77	38/79	30/76		
liv nnd eis	no dre	P=1.	88.2mg	n.s.s.	2/78	3/78	2/79		
2743 R f fmf inh 76w78 1666m () pool					0	13.3mg			Snellings;txap,75,105-117;1984/Garman 1985
pit ade ikr	29.8mg	P<.08 -	8.48mg	n.s.s.	2/40	4/20			
bra mix ikr	237.mg *	P<.6 +	24.7mg	n.s.s.	1/40	0/20	0/20	1/20	
2744 R f fmf inh 23m24 1666o () pool					0	1.31mg	4.32mg	13.2mg	
bra mix ir	143.mg *	P<.02 +	61.7mg	n.s.s.	0/154	1/78	3/79	3/79	
2745 R m fmf inh 76w78 1666m () pool					0	9.29mg			
adr phe ikr	26.1mg	P<.08 -	6.94mg	n.s.s.	1/40	3/20			
bra ast ikr	102.mg *	P<.7 +	16.5mg	n.s.s.	0/40	0/20	1/20	0/20	
pit ade ikr	no dre	P=1. -	9.53mg	n.s.s.	7/40	3/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
tes ict ikr	no dre	P=1.	- 2.56mg n.s.s.	35/40	16/20				
2746 R m fmf inh 24m25 1666o () pool				0	.916mg	3.02mg	9.25mg		
bra mix ir	70.7mg	* P<.002	+ 33.5mg 313.mg	1/156	1/79	4/78	7/79		
2747 R f sda gav 25m35 1486				0	1.53mg	6.11mg		Dunkelberg;bjca,46,924-933;1982	
sto mix e	7.43mg	* P<.0005	+ 5.12mg 11.3mg	0/50	12/50	35/50			
for sqc e	10.6mg	* P<.0005	+ 7.06mg 16.9mg	0/50	8/50	29/50			
mgl adf e	10.0mg	\ P<.02	- 4.33mg n.s.s.	4/50	13/50	(1/50)			
ETHYLENE THIOUREA (ETU) 96-45-7									
2748 M f b6c eat 25m25 TR388 :				0	42.9mg	130.mg			
liv MXA	19.9mg	\ P<.0005	c 12.7mg 38.1mg	4/50	44/50	(48/50)			liv:hpa,hpc.
MXB MXB	26.6mg	\ P<.0005	14.5mg 96.7mg	14/50	47/50	(48/50)		liv:hpa,hpc; pit:pda,pdc; thy:fca,fcc. C	
liv hpa	30.5mg	\ P<.0005	c 19.1mg 59.9mg	2/50	33/50	(14/50)			
liv hpc	39.7mg	* P<.0005	c 28.4mg 62.9mg	2/50	29/50	47/50			
thy MXA	82.0mg	/ P<.0005	c 55.5mg 128.mg	0/50	2/50	38/50			thy:fca,fcc.
thy fca	90.9mg	/ P<.0005	c 60.6mg 144.mg	0/50	2/50	35/50			
pit pda	147.mg	* P<.003	c 74.6mg 973.mg	10/50	19/50	26/50			
pit MXA	155.mg	* P<.005	c 76.7mg 1.57gm	11/50	19/50	26/50			pit:pda,pdc.
thy fcc	546.mg	* P<.0005	c 246.mg 1.69gm	0/50	0/50	8/50			
TBA MXB	120.mg	* P<.08	46.2mg n.s.s.	36/50	49/50	48/50			
liv MXB	19.9mg	\ P<.0005	12.7mg 38.1mg	4/50	44/50	(48/50)			liv:hpa,hpc,nnd.
lun MXB	641.mg	\ P<.7	93.4mg n.s.s.	5/50	8/50	(0/50)			lun:a/a,a/c.
2749 M f b6c orl 81w81 1141				0	88.8mg				Innes;ntis,1968/1969
liv hpt evx	noTD50	P<.0005	n.s.s. 20.7mg	0/16	18/18				
lun ade evx	203.mg	P<.05	61.1mg n.s.s.	0/16	3/18				
tba mix evx	noTD50	P<.0005	n.s.s. 20.7mg	0/16	18/18				
2750 M m b6c eat 25m25 TR388 :				0	39.6mg	120.mg			
liv MXA	54.1mg	* P<.0005	c 30.6mg 158.mg	20/50	32/50	46/50			liv:hpa,hpc.
MXB MXB	54.1mg	* P<.0005	30.6mg 159.mg	21/50	32/50	47/50		liv:hpa,hpc; pit:pda; thy:fca,fcc. C	
liv hpc	54.6mg	/ P<.0005	c 33.5mg 116.mg	13/50	19/50	45/50			
thy MXA	97.1mg	/ P<.0005	c 60.7mg 172.mg	1/50	1/50	29/50			thy:fca,fcc.
thy fca	112.mg	/ P<.0005	c 69.6mg 194.mg	0/50	1/50	26/50			
pit pda	387.mg	* P<.0005	c 173.mg 1.20gm	0/50	0/50	8/50			
thy fcc	730.mg	* P<.04	c 246.mg n.s.s.	1/50	0/50	5/50			
MXA hem	840.mg	* P<.03	284.mg n.s.s.	0/50	1/50	3/50		ear:hem; hea:hem; liv:hem. S	
TBA MXB	89.2mg	* P<.03	38.6mg n.s.s.	35/50	40/50	47/50			
liv MXB	54.1mg	* P<.0005	30.6mg 158.mg	20/50	32/50	46/50			liv:hpa,hpc,nnd.
lun MXB	532.mg	* P<.3	156.mg n.s.s.	5/50	6/50	8/50			lun:a/a,a/c.
2751 M m b6c orl 82w82 1141				0	82.5mg				Innes;ntis,1968/1969
liv hpt evx	16.9mg	P<.0005	+ 7.63mg 40.5mg	0/16	14/16				
lun ade evx	545.mg	P<.3	88.7mg n.s.s.	0/16	1/16				
tba mix evx	16.9mg	P<.0005	7.63mg 40.5mg	0/16	14/16				
2752 M f b6a orl 81w81 1141				0	88.8mg				
liv hpt evx	44.7mg	P<.0005	20.4mg 124.mg	0/17	9/16				
lun ade evx	no dre	P=1.	178.mg n.s.s.	1/17	0/16				
tba mix evx	29.3mg	P<.0005	13.2mg 99.9mg	2/17	12/16				
2753 M m b6a orl 81w81 1141				0	82.6mg				
liv hpt evx	noTD50	P<.0005	n.s.s. 20.0mg	1/18	18/18				
lun ade evx	no dre	P=1.	87.7mg n.s.s.	2/18	2/18				
tba mix evx	noTD50	P<.0005	n.s.s. 21.8mg	3/18	18/18				
2754 R f f34 eat 25m25 TR388 :				0	4.15mg	12.5mg			
thy MXA	7.42mg	/ P<.0005	c 4.74mg 13.2mg	1/50	6/50	28/50			thy:fab,fca.
thy MXA	7.42mg	/ P<.0005	c 4.64mg 14.2mg	3/50	7/50	30/50			thy:fab,fca,fcy,fdc.
thy MXA	39.6mg	/ P<.02	c 15.9mg n.s.s.	2/50	1/50	8/50			thy:fcy,fdc.
TBA MXB	24.6mg	* P<.5	5.13mg n.s.s.	48/50	46/50	49/50			
liv MXB	no dre	P=1.	82.4mg n.s.s.	0/50	1/50	0/50			liv:hpa,hpc,nnd.
2755 R m f34 eat 25m25 TR388 :				0	3.32mg	10.0mg			
thy MXA	3.16mg	* P<.0005	c 2.08mg 5.23mg	1/50	12/50	37/50			thy:fab,fca,fcy,fdc.
thy MXA	5.25mg	* P<.0005	c 3.28mg 9.00mg	0/50	9/50	23/50			thy:fab,fca.
thy MXA	5.50mg	/ P<.0005	c 3.29mg 10.4mg	1/50	3/50	26/50			thy:fcy,fdc.
TBA MXB	17.8mg	* P<.5	3.49mg n.s.s.	43/50	47/50	43/50			
liv MXB	186.mg	* P<.2	30.3mg n.s.s.	0/50	0/50	1/50			liv:hpa,hpc,nnd.
2756 R b cdr eat 24m24 139				0	.225mg	1.13mg	5.63mg	11.3mg 22.5mg	Graham;fctx,13,493-499;1975
--- fbs e	13.2mg	Z P<.003	5.00mg 75.7mg	0/72	0/75	5/73	(4/73	5/69 3/70)	
thy mix e	16.6mg	Z P<.0005	+ 12.5mg 22.9mg	2/72	2/75	1/73	2/73	16/69 62/70	
thy ade e	33.9mg	Z P<.0005	+ 20.0mg 70.6mg	2/72	0/75	5/73	1/73	21/69 (3/70)	
liv hpt e	330.mg	* P<.04	+ 117.mg n.s.s.	1/72	1/75	1/73	2/73	1/69 5/70	
mgl adc e	no dre	P=1.	100.mg n.s.s.	2/72	14/75	4/73	2/73	5/69 (0/70)	
tba mix e	7.23mg	* P<.0005	4.58mg 13.5mg	51/72	49/75	45/73	54/73	61/69 68/70	
tba mal e	13.4mg	Z P<.0005	9.62mg 19.9mg	15/72	23/75	13/73	16/73	31/69 63/70	
2757 R f cdr eat 18m24 141m				0	6.56mg	13.1mg			Ulland;jnci,49,583-584;1972/Weisburger 1981
thy fcc j	39.8mg	* P<.03	+ 18.0mg n.s.s.	0/10	2/26	6/26			
thy ppc j	113.mg	* P<.3	+ 34.2mg n.s.s.	0/10	1/26	2/26			
liv hnd j	no dre	P=1.	59.4mg n.s.s.	0/10	1/26	0/26			
2758 R m cdr eat 18m24 141m				0	5.25mg	10.5mg			
thy fcc j	12.8mg	/ P<.0005	+ 7.21mg 28.7mg	0/10	2/26	15/26			
thy ppc j	90.5mg	* P<.3	+ 27.4mg n.s.s.	0/10	1/26	2/26			
liv hnd j	179.mg	* P<.8	27.7mg n.s.s.	0/10	2/26	1/26			
ETHYLENE UREA (2-imidazolidinone) 120-93-4									
2759 M f b6a orl 76w76 1197				0	89.1mg				Innes;ntis,1968/1969
lun ade evx	505.mg	P<.6	- 70.3mg n.s.s.	1/17	2/17				
liv hpt evx	no dre	P=1.	- 167.mg n.s.s.	0/17	0/17				
tba mix evx	473.mg	P<.7	- 59.5mg n.s.s.	2/17	3/17				
2760 M m b6a orl 76w76 1197				0	82.9mg				
liv hpt evx	500.mg	P<.6	- 69.5mg n.s.s.	1/18	2/18				
lun ade evx	no dre	P=1.	- 109.mg n.s.s.	2/18	1/18				
tba mix evx	no dre	P=1.	- 65.2mg n.s.s.	3/18	3/18				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2761 M f b6c orl 76w76 1197					0	89.1mg			
liv hpt evx	no dre	P=1.	-	167.mg n.s.s.	0/16	0/17			
lun mix evx	no dre	P=1.	-	167.mg n.s.s.	0/16	0/17			
tba tum evx	no dre	P=1.	-	167.mg n.s.s.	0/16	0/17			
2762 M m b6c orl 76w76 1197					0	82.9mg			
liv hpt evx	242.mg	P<.1	-	59.5mg n.s.s.	0/16	2/17			
lun ade evx	242.mg	P<.1	-	59.5mg n.s.s.	0/16	2/17			
tba mix evx	87.1mg	P<.007	-	32.8mg 1.18gm	0/16	5/17			
ETHYLENEBISDITHIOCARBAMATE, DISODIUM (dithane, nabam) 142-59-6									
2763 M f b6a orl 76w76 1215					0	9.96mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	19.7mg n.s.s.	0/17	0/18			
lun mix evx	no dre	P=1.	-	19.7mg n.s.s.	0/17	0/18			
tba mix evx	no dre	P=1.	-	19.7mg n.s.s.	2/17	0/18			
2764 M m b6a orl 76w76 1215					0	9.26mg			
lun ade evx	no dre	P=1.	-	12.2mg n.s.s.	2/18	1/18			
liv hpt evx	no dre	P=1.	-	18.3mg n.s.s.	3/18	0/18			
tba mix evx	no dre	P=1.	-	14.1mg n.s.s.	5/18	1/18			
2765 M f b6c orl 76w76 1215					0	9.96mg			
liv hpt evx	no dre	P=1.	-	17.5mg n.s.s.	0/18	0/16			
lun ade evx	no dre	P=1.	-	17.5mg n.s.s.	1/18	0/16			
tba mix evx	no dre	P=1.	-	17.5mg n.s.s.	3/18	0/16			
2766 M m b6c orl 76w76 1215					0	9.26mg			
liv hpt evx	866.mg	P<1.	-	9.63mg n.s.s.	1/17	1/16			
lun ade evx	no dre	P=1.	-	10.7mg n.s.s.	2/17	1/16			
tba mix evx	no dre	P=1.	-	10.1mg n.s.s.	6/17	2/16			
1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE 106-87-6									
2767 R f esd gav 84w84 55					0	40.8mg			Van Duuren;jnci,37,825-838;1966
sto tum	no dre	P=1.	-	27.4mg n.s.s.	0/5	0/5			
2-ETHYLHEXANOL 104-76-7									
2768 M f b6c gav 80w80 2284					0	35.7mg	143.mg	536.mg	Astill;faat,31,29-41;1996/pers.comm.
liv hpc e	1.68gm *	P<.009	+	727.mg 98.2gm	0/50	1/50	3/50	5/50	
2769 M m b6c gav 80w80 2284					0	35.7mg	143.mg	536.mg	
liv mix e	1.71gm *	P<.09	-	590.mg n.s.s.	6/50	3/50	7/50	10/50	
2770 R f f34 gav 24m24 2284					0	35.7mg	107.mg	357.mg	
liv hpc e	no dre	P=1.	-	3.05gm n.s.s.	1/50	1/50	2/50	0/50	
2771 R m f34 gav 24m24 2284					0	35.7mg	107.mg	357.mg	
liv mix e	no dre	P=1.	-	2.92gm n.s.s.	6/50	3/50	4/50	1/50	
DI(2-ETHYLHEXYL)ADIPATE 103-23-1									
2772 M f b6c eat 24m24 TR212 :					0	1.52gm	3.19gm		
liv hpc	3.05gm \	P<.0005	c	1.57gm 9.40gm	1/50	14/50	(12/50)		
liv MXA	3.84gm *	P<.0005	c	2.29gm 11.3gm	3/50	19/50	18/50		liv:hpa,hpc.
TBA MXB	no dre	P=1.		3.44gm n.s.s.	37/50	33/50	30/50		
liv MXB	3.84gm *	P<.0005		2.29gm 11.3gm	3/50	19/50	18/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		17.8gm n.s.s.	6/50	1/50	3/50		lun:a/a,a/c.
2773 M m b6c eat 24m24 TR212 :					0	1.41gm	2.96gm		
liv MXA	5.33gm *	P<.06	c	2.25gm n.s.s.	13/50	20/50	27/50		liv:hpa,hpc.
liv hpa	9.04gm *	P<.07	c	3.62gm n.s.s.	6/50	8/50	15/50		
TBA MXB	no dre	P=1.		2.99gm n.s.s.	33/50	32/50	34/50		
liv MXB	5.33gm *	P<.06		2.25gm n.s.s.	13/50	20/50	27/50		liv:hpa,hpc,nnd.
lun MXB	11.7gm \	P<.6		2.04gm n.s.s.	8/50	9/50	(3/50)		lun:a/a,a/c.
2774 R f f34 eat 24m24 TR212 :					0	589.mg	1.23gm		
TBA MXB	no dre	P=1.	-	699.mg n.s.s.	44/50	41/50	(34/50)		
liv MXB	14.5gm *	P<.6		4.76gm n.s.s.	0/50	3/50	1/50		liv:hpa,hpc,nnd.
2775 R m f34 eat 24m24 TR212 :					0	466.mg	986.mg		
TBA MXB	no dre	P=1.	-	1.47gm n.s.s.	30/49	32/50	26/50		
liv MXB	no dre	P=1.		4.46gm n.s.s.	2/49	2/50	2/50		liv:hpa,hpc,nnd.
DI(2-ETHYLHEXYL)PHTHALATE (di-sec-octyl phthalate, DEHP) 117-81-7									
2776 M f b6c eat 24m24 TR217 :					0	383.mg	765.mg		
liv MXA	825.mg *	P<.0005	c	513.mg 1.67gm	1/50	12/50	18/50		liv:hpa,hpc.
liv hpc	1.05gm *	P<.0005	c	638.mg 1.89gm	0/50	7/50	17/50		
TBA MXB	350.mg \	P<.003		175.mg 2.07gm	20/50	35/50	(35/50)		
liv MXB	825.mg *	P<.0005		513.mg 1.67gm	1/50	12/50	18/50		liv:hpa,hpc,nnd.
lun MXB	7.26gm *	P<.07		2.20gm n.s.s.	0/50	1/50	2/50		lun:a/a,a/c.
2777 M f b6c eat 78w79 2442m					0	12.8mg	64.2mg	193.mg	770.mg David;faat,50,195-205;1999/2000
liv mix Cekr	650.mg *	P<.004	+	260.mg 5.48gm	0/15	1/10	1/10	1/10	6/15
liv hpa Cekr	1.10gm *	P<.04		363.mg n.s.s.	0/15	1/10	1/10	1/10	4/15
liv hpc Cekr	2.66gm *	P<.03		654.mg n.s.s.	0/15	0/10	0/10	0/10	2/15
2778 M f b6c eat 18m24 2442n					0	579.mg			
liv mix Cer	553.mg	P<.0005	+	341.mg 1.03gm	3/55	30/55			
liv hpc Cer	834.mg	P<.0005		479.mg 1.87gm	3/55	23/55			
liv hpa Cer	1.50gm	P<.0005		790.mg 3.39gm	0/55	13/55			
2779 M f b6c eat 24m24 2442o					0	12.9mg	64.4mg	193.mg	773.mg
liv mix Cer	463.mg *	P<.0005	+	321.mg 723.mg	3/55	3/50	6/55	18/55	38/55
liv hpa Cer	721.mg *	P<.0005		493.mg 1.13gm	0/55	1/50	3/55	8/55	30/55
liv hpc Cer	1.88gm *	P<.0005		986.mg 6.21gm	3/55	2/50	3/55	10/55	14/55
2780 M m b6c eat 24m24 TR217 :					0	353.mg	713.mg		
liv MXA	976.mg *	P<.03	c	440.mg n.s.s.	14/50	25/49	29/50		liv:hpa,hpc.
liv hpc	1.82gm *	P<.08	c	736.mg n.s.s.	9/50	14/49	19/50		
TBA MXB	1.54gm *	P<.4		413.mg n.s.s.	29/50	37/49	38/50		
liv MXB	976.mg *	P<.03		440.mg n.s.s.	14/50	25/49	29/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		1.97gm n.s.s.	10/50	9/49	7/50		lun:a/a,a/c.
2781 M m b6c eat 78w79 2442m					0	11.8mg	59.2mg	178.mg	711.mg David;faat,50,195-205;1999/2000
liv mix Cekr	46.4gm *	P<1.		577.mg n.s.s.	1/15	1/10	3/10	1/10	2/15

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
2782 M m b6c eat 18m24 2442n	0	535.mg			
liv hpc Cer 2.19gm P<.03 898.mg n.s.s.	4/55	12/55			
liv mix Cer 2.37gm P<.09 + 863.mg n.s.s.	7/55	14/55			
2783 M m b6c eat 24m24 2442o	0	11.9mg	59.4mg	178.mg	713.mg
liv mix Cer 546.mg * P<.0005 + 330.mg 1.14gm	7/55	13/50	18/55	26/55	35/55
liv hpc Cer 1.14gm * P<.0005 634.mg 3.07gm	4/55	5/50	8/55	14/55	21/55
liv hpa Cer 1.74gm * P<.004 812.mg 13.6gm	3/55	9/50	11/55	13/55	18/55
2784 R f f34 eat 24m24 TR217 :	0	294.mg	589.mg		
liv MXA 1.11gm * P<.0005 c 644.mg 2.40gm	0/50	6/50	13/50		liv:hpc,nnd.
liv hpc 2.30gm * P<.002 c 1.12gm 5.90gm	0/50	2/50	8/50		
liv nnd 2.35gm * P<.02 1.11gm n.s.s.	0/50	4/50	5/50		s
TBA MXB 1.67gm * P<.6 321.mg n.s.s.	41/50	43/50	49/50		
liv MXB 1.11gm * P<.0005 644.mg 2.40gm	0/50	6/50	13/50		liv:hpa,hpc,nnd.
2785 R f f34 eat 78w79 2442m	0	123.mg	617.mg		David;faat,50,195-205;1999/2000
liv mix Cek 848.mg * P<.02 + 255.mg n.s.s.	0/10	0/10	3/10		
liv hpc Cek 1.34gm * P<.05 328.mg n.s.s.	0/10	0/10	2/10		
2786 R f f34 eat 18m24 2442n	0	464.mg			
liv mix Cer 1.62gm P<.0005 + 787.mg 4.17gm	0/70	10/55			
liv hpa Cer 2.81gm P<.002 1.14gm 12.7gm	0/70	6/55			
liv hpc Cer 4.29gm P<.01 1.48gm 524.gm	0/70	4/55			
2787 R f f34 eat 24m24 2442o	0	4.95mg	24.8mg	124.mg	619.mg
liv mix Ce 1.56gm Z P<.0005 + 888.mg 3.42gm	0/70	4/50	1/55	3/55	19/70
liv hpc Ce 2.59gm * P<.0005 1.35gm 6.39gm	0/70	1/50	0/55	1/55	12/70
liv hpa Ce 5.19gm * P<.02 1.97gm n.s.s.	0/70	3/50	1/55	2/55	7/70
2788 R f f34 eat 24m24 2463	0	15.0mg	50.0mg	600.mg	Cattley;clet,38,15-22;1987/pers.comm.
liv mix Cer 1.16gm * P<.002 + 457.mg 7.23gm	0/20	1/20	1/20	6/20	
liv nnd Cer 1.95gm * P<.03 619.mg n.s.s.	0/20	1/20	1/20	4/20	
liv hpc Cer 4.35gm * P<.03 1.07gm n.s.s.	0/20	0/20	0/20	2/20	
2789 R m f34 eat 24m24 TR217 :	0	235.mg	475.mg		
liv MXA 1.17gm * P<.03 c 526.mg n.s.s.	3/50	6/50	12/50		liv:hpc,nnd.
liv hpc 3.36gm * P<.2 c 1.13gm n.s.s.	1/50	1/50	5/50		
TBA MXB no dre P=1. 455.mg n.s.s.	36/50	35/50	34/50		
liv MXB 1.17gm * P<.03 526.mg n.s.s.	3/50	6/50	12/50		liv:hpa,hpc,nnd.
2790 R m f34 eat 95w95 1823	0	800.mg			Rao;carc,8,1347-1350;1987
liv mix er 499.mg P<.003 + 193.mg 2.61gm	0/8	6/10			
liv hpc er 895.mg P<.02 303.mg n.s.s.	0/8	4/10			
liv hpn er 2.05gm P<.2 501.mg n.s.s.	0/8	2/10			
2791 R m f34 eat 25m25 1982	0	800.mg			Rao;jtxe,30,85-89;1990
liv mix er 412.mg P<.0005 + 178.mg 1.59gm	1/10	11/14			
2792 R m f34 eat 78w79 2442m	0	98.7mg	494.mg		David;faat,50,195-205;1999/2000
liv mix Cek 360.mg * P<.03 + 126.mg n.s.s.	1/10	1/10	5/10		
liv hpc Cek 560.mg * P<.05 171.mg n.s.s.	1/10	0/10	4/10		
2793 R m f34 eat 18m24 2442n	0	371.mg			
liv mix Cer 769.mg P<.0005 + 405.mg 2.24gm	4/70	18/55			
liv hpa Cer 1.39gm P<.008 606.mg 31.8gm	4/70	12/55			
liv hpc Cer 1.91gm P<.002 823.mg 6.76gm	0/70	7/55			
2794 R m f34 eat 24m24 2442o	0	3.96mg	19.8mg	99.0mg	495.mg
liv mix Ce 725.mg * P<.0005 + 444.mg 1.43gm	4/70	5/50	4/55	10/55	29/70
liv hpc Ce 1.05gm * P<.0005 644.mg 1.88gm	0/70	0/50	1/55	3/55	20/70
liv hpa Ce 1.28gm * P<.0005 686.mg 3.67gm	4/70	5/50	3/55	7/55	20/70
pan ana e 3.91gm P<.008 1.48gm 70.5gm	0/60			5/59	
--- mnl e 1.36gm * P<.04 539.mg n.s.s.	15/65	13/50	16/55	32/65	27/65
2795 R m f3d eat 52w52 2161m	0	800.mg			Hayashi;carc,15,2215-2219;1994
liv mix ekr no dre P=1. 412.mg n.s.s.	0/10	0/10			
2796 R m f3d eat 78w78 2161n	0	800.mg			
liv mix er 551.mg P<.03 + 162.mg n.s.s.	0/8	3/7			
ETHYLHYDRAZINE.HCl 18413-14-4					
2797 M f swa wat 82w82 142	0	25.0mg			Shimizu;ijcn,13,500-505;1974
lun mix e 5.22mg P<.0005 + 3.11mg 9.34mg	21/97	44/49			
lun ade e 5.62mg P<.0005 3.40mg 9.90mg	18/97	43/49			
blv mix e 11.6mg P<.0005 + 7.37mg 19.6mg	0/43	30/50			
liv mix e 13.0mg P<.0005 8.13mg 22.3mg	0/43	28/50			
lun adc e 14.0mg P<.0005 8.54mg 25.8mg	4/97	27/49			
blv ang e 27.6mg P<.0005 15.4mg 57.0mg	0/43	16/50			
liv ang e 27.6mg P<.0005 15.4mg 57.0mg	0/43	16/50			
liv agm e 42.9mg P<.0005 21.5mg 111.mg	0/43	11/50			
blv agm e 42.9mg P<.0005 21.5mg 111.mg	0/43	11/50			
2798 M m swa wat 72w72 142	0	20.8mg			
lun ade e 7.82mg P<.0005 4.62mg 15.7mg	15/100	31/48			
lun mix e 8.81mg P<.0005 + 4.93mg 21.1mg	23/100	31/48			
blv mix e 38.6mg P<.09 + 13.7mg n.s.s.	2/28	8/36			
liv ang e 46.9mg P<.08 16.3mg n.s.s.	1/28	6/36			
blv ang e 46.9mg P<.08 16.3mg n.s.s.	1/28	6/36			
liv mix e 48.1mg P<.2 15.4mg n.s.s.	2/28	7/36			
1-ETHYLNITROSO-3-(2-HYDROXYETHYL)UREA 96724-44-6					
2799 H f syg gav 30w75 1956	0	1.87mg			Lijinsky;bmes,2,167-173;1989
cvu tum e 1.04mg P<.002 + .480mg 3.62mg	0/12	9/19			
for ben e 1.76mg P<.01 + .710mg 141.mg	0/12	6/19			
spl vsc e 3.05mg P<.2 + .893mg n.s.s.	1/12	5/19			
liv cho e 27.5mg P<.9 1.69mg n.s.s.	1/12	2/19			
2800 R f f34 wat 7m24 2010	0	.443mg	.885mg		Lijinsky;vivo,4,1-6;1990
ner tum e .714mg * P<.0005 .351mg 2.15mg	0/12	4/12	7/12		
mam car e .748mg * P<.004 + .370mg 3.97mg	0/12	6/12	5/12		
ski tum e .956mg * P<.004 + .445mg 6.16mg	0/12	4/12	5/12		
ute tum e .972mg * P<.07 + .376mg n.s.s.	2/12	6/12	6/12		
liv tum e no dre P=1. .730mg n.s.s.	0/12	0/12	0/12		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2801 R m f34 wat 7m24 2010					0	.310mg	.620mg		
tnv mso e		.226mg	* P<.0005	.121mg .473mg	0/12	9/12	9/12		
lun tum e		.390mg	* P<.0005	.199mg .979mg	0/12	5/12	8/12		
ski tum e		.401mg	* P<.0005 +	.206mg 1.10mg	0/12	6/12	7/12		
ner tum e		.769mg	* P<.005	.345mg 5.53mg	0/12	3/12	5/12		
liv tum e		no dre	P=1.	.511mg n.s.s.	0/12	0/12	0/12		
1-ETHYLNITROSO-3-(2-OXOPROPYL)UREA 110559-84-7									
2802 H f syg gav 30w85 1956					0	.871mg			Lijinsky;bmes,2,167-173;1989
spl vsc e		.394mg	P<.003 +	.159mg 2.42mg	1/12	8/12			
for mix e		.983mg	P<.02 +	.335mg n.s.s.	0/12	4/12			
for car e		2.19mg	P<.09	.536mg n.s.s.	0/12	2/12			
liv cho e		no dre	P=1.	.845mg n.s.s.	1/12	1/12			
2803 H m syg gav 30w85 1956					0	.766mg			
for mix e		.506mg	P<.002 +	.201mg 2.27mg	0/12	6/12			
spl hes e		.865mg	P<.02 +	.295mg n.s.s.	0/12	4/12			
for car e		1.92mg	P<.09	.471mg n.s.s.	0/12	2/12			
liv cho e		1.10mg	P<.2	.313mg n.s.s.	1/12	4/12			
2804 R f f34 gav 7m24 2010m					0	.442mg	.883mg		Lijinsky;vivo,4,1-6;1990
mam car e		.192mg	* P<.0005 +	98.9ug .388mg	0/12	12/12	10/12		
lun tum e		.873mg	* P<.02 +	.383mg n.s.s.	1/12	5/12	6/12		
ner tum e		1.66mg	\ P<.09	.407mg n.s.s.	0/12	2/12	(0/12)		
ute tum e		1.84mg	* P<.4 +	.501mg n.s.s.	2/12	6/12	4/12		
liv tum e		no dre	P=1.	.728mg n.s.s.	0/12	0/12	0/12		
2805 R f f34 wat 7m24 2010n					0	.476mg	.951mg		
ner tum e		.605mg	\ P<.005 +	.225mg 4.85mg	0/12	5/12	(0/12)		
mam car e		.748mg	* P<.0005 +	.366mg 2.03mg	0/12	3/12	8/12		
lun tum e		.885mg	* P<.002 +	.424mg 3.41mg	0/12	4/12	6/12		
thy fct e		.804mg	\ P<.02 +	.274mg n.s.s.	0/12	4/12	(0/12)		
col tum e		1.13mg	\ P<.04 +	.340mg n.s.s.	0/12	3/12	(0/12)		
ute tum e		1.49mg	* P<.09 +	.529mg n.s.s.	2/12	3/12	6/12		
ski tum e		1.79mg	\ P<.09 +	.438mg n.s.s.	0/12	2/12	(0/12)		
liv tum e		5.53mg	* P<.09	1.36mg n.s.s.	0/12	0/12	2/12		
2806 R m f34 gav 7m24 2010m					0	.309mg	.618mg		
lun tum e		noTD50	P<.0005 +	n.s.s. .135mg	0/12	12/12	12/12		
tnv mso e		.225mg	* P<.0005 +	.121mg .472mg	0/12	9/12	9/12		
zym tum e		.499mg	* P<.0005	.245mg 1.50mg	0/12	4/12	7/12		
col tum e		.562mg	* P<.0005 +	.269mg 1.77mg	0/12	3/12	7/12		
thy fct e		.767mg	* P<.005	.344mg 5.51mg	0/12	3/12	5/12		
for tum e		.861mg	* P<.002	.367mg 3.21mg	0/12	0/12	7/12		
ner tum e		1.37mg	* P<.08	.519mg n.s.s.	0/12	3/12	2/12		
liv tum e		3.39mg	* P<.3	.757mg n.s.s.	1/12	0/12	3/12		
2807 R m f34 wat 7m24 2010n					0	.333mg	.666mg		
ner tum e		.127mg	\ P<.0005 +	53.1ug .354mg	0/12	10/12	(5/12)		
lun tum e		.231mg	* P<.0005 +	.123mg .480mg	0/12	8/12	10/12		
tnv mso e		.264mg	* P<.0005 +	.144mg .605mg	0/12	11/12	7/12		
col tum e		.524mg	* P<.0005 +	.256mg 1.42mg	0/12	3/12	8/12		
zym tum e		1.13mg	* P<.003	.455mg 5.71mg	0/12	0/12	6/12		
ski tum e		.982mg	* P<.02 +	.421mg n.s.s.	0/12	3/12	4/12		
liv tum e		no dre	P=1.	.549mg n.s.s.	0/12	0/12	0/12		
ETHYLNITROSOCYANAMIDE (nitrosoethanecarbamonitrile) 38434-77-4									
2808 R f mrw wat 52w90 1246					0	3.40mg			Bulay;jnci,62,1523-1528;1979
res tum		2.91mg	P<.0005 +	1.35mg 8.02mg	0/25	9/20			
liv tum		no dre	P=1.	10.5mg n.s.s.	0/25	0/20			
tba mix		3.17mg	P<.2	.981mg n.s.s.	12/25	14/20			
2809 R m mrw wat 52w90 1246					0	2.97mg			
res tum		4.99mg	P<.005 +	1.88mg 36.2mg	0/22	5/19			
liv tum		no dre	P=1.	8.71mg n.s.s.	0/22	0/19			
tba mix		no dre	P=1.	1.67mg n.s.s.	12/22	10/19			
ETHYLPHENYLACETYLUREA (pheneturide) 90-49-3									
2810 R m f34 eat 71w71 1951					0	17.8mg			Diwan;carc,10,189-194;1989
liv hpt e		no dre	P=1.	25.6mg n.s.s.	0/15	0/15			
4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE 842-00-2									
2811 M f aif eat 23m23 142c					0	13.0mg			Flaks;bjca,28,227-231;1973
ubl car e		34.2mg	P<.0005 +	16.1mg 102.mg	0/40	9/42			
lun ade e		53.4mg	P<.005	21.8mg 360.mg	0/40	6/42			
2812 M f ifc eat 92w92 142a					0	13.0mg			Flaks;bjca,31,585-587;1975
ubl car r		15.3mg	P<.0005 +	8.89mg 31.0mg	0/26	19/52			
ETHYNODIOL DIACETATE (ovulen-50) 297-76-7									
2813 M f crf eat 24m24 1175 pool					0	9.75ug	.130mg		Rudali;jnci,49,813-819;1972
mam tum Ler		no dre	P=1.	.190mg n.s.s.	161/167	30/32	46/56		
2814 R f win gav 60w60 1905					0	4.08mg			Annapurna;ijbb,25,708-713;1988
liv tum er		no dre	P=1. -	1.68mg n.s.s.	0/6	0/6			
ETODOLAC (1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-6]indole-1-acetic acid) 41340-25-4									
2815 M f cd1 eat 78w78 2341					0	3.00mg	9.00mg	15.0mg	Wrenn;phrm,41,113-128;1991
liv hpa		no dre	P=1. -	11.3mg n.s.s.	1/50	0/50	0/50	0/50	
lun a/c		no dre	P=1. -	45.2mg n.s.s.	2/50	3/50	3/50	2/50	
tba mal		336.mg	* P<.9 -	21.4mg n.s.s.	10/50	9/50	11/50	10/50	
tba mix		no dre	P=1. -	25.7mg n.s.s.	15/50	13/50	12/50	12/50	
tba ben		no dre	P=1. -	73.8mg n.s.s.	7/50	4/50	1/50	3/50	
2816 M m cd1 eat 78w78 2341					0	3.00mg	9.00mg	15.0mg	
liv hpc s		no dre	P=1. -	63.5mg n.s.s.	1/50	5/50	1/49	1/49	
liv hpa s		no dre	P=1. -	79.4mg n.s.s.	7/50	0/50	2/49	2/49	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix s	no dre	P=1.	- 43.6mg n.s.s.	13/50	14/50	6/49	8/49	
tba mal s	no dre	P=1.	- 44.1mg n.s.s.	7/50	12/50	5/49	5/49	
tba ben s	no dre	P=1.	- 56.1mg n.s.s.	7/50	3/50	2/49	4/49	
2817 R f cdr eat 24m24 2338				0	3.00mg	9.00mg	15.0mg	Wrenn;phrm,41,129-146;1991
liv nnd	1.01gm *	P<.8	- 85.7mg n.s.s.	0/50	2/50	1/50	1/50	
liv hpc	no dre	P=1.	- 139.mg n.s.s.	1/50	0/50	2/50	0/50	
tba ben	no dre	P=1.	- 31.9mg n.s.s.	43/50	47/50	37/50	33/50	
tba mal	no dre	P=1.	- 52.8mg n.s.s.	12/50	15/50	10/50	10/50	
tba mix	no dre	P=1.	- 24.2mg n.s.s.	47/50	49/50	42/50	38/50	
2818 R m cdr eat 24m24 2338				0	3.00mg	9.00mg	15.0mg	
liv nnd	1.40gm *	P<.8	- 128.mg n.s.s.	1/50	0/50	1/50	1/50	
liv hpc	no dre	P=1.	- 105.mg n.s.s.	1/50	3/50	0/50	2/50	
tba ben	no dre	P=1.	- 9.99mg n.s.s.	26/50	33/50	27/50	(11/50)	
tba mal	no dre	P=1.	- 55.8mg n.s.s.	15/50	16/50	11/50	11/50	
tba mix	no dre	P=1.	- 9.30mg n.s.s.	33/50	39/50	32/50	(19/50)	

EUCALYPTOL 470-82-6

2819 M m cfl gav 19m24 710				0	5.27mg	21.1mg		Roe;jept,2,799-819;1979
lun tum e	no dre	P=1.	38.5mg n.s.s.	102/240	30/52	18/47		
liv tum e	no dre	P=1.	72.8mg n.s.s.	69/240	5/52	12/47		
tba mix e	119.mg *	P<.7	16.2mg n.s.s.	170/240	36/52	35/47		
tba mal e	no dre	P=1.	67.8mg n.s.s.	75/240	18/52	11/47		

EUGENOL (1-allyl-3-methoxy-4-hydroxybenzene) 97-53-0

2820 M f b6c eat 24m24 TR223 :				0	383.mg	773.mg		
liv MXA	2.91gm *	P<.04	e 1.29gm n.s.s.	2/50	7/50	9/50		liv:hpa,hpc.
TBA MXB	no dre	P=1.	1.12gm n.s.s.	27/50	22/50	26/50		
liv MXB	2.91gm *	P<.04	1.29gm n.s.s.	2/50	7/50	9/50		liv:hpa,hpc,nnd.
lun MXB	25.3gm *	P<.8	2.22gm n.s.s.	4/50	6/50	5/50		lun:a/a,a/c.
2821 M m b6c eat 24m24 TR223 :				0	353.mg	713.mg		
liv MXA	451.mg \	P<.02	e 208.mg 124.gm	14/50	28/50	(18/50)		liv:hpa,hpc.
liv hpc	710.mg \	P<.03	e 298.mg n.s.s.	10/50	20/50	(9/50)		
liv hpa	781.mg \	P<.02	e 336.mg n.s.s.	4/50	13/50	(10/50)		
thy fca	8.52gm *	P<.04	2.58gm n.s.s.	0/50	0/50	3/50		S
TBA MXB	1.55gm *	P<.3	464.mg n.s.s.	27/50	36/50	32/50		
liv MXB	451.mg \	P<.02	208.mg 124.gm	14/50	28/50	(18/50)		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	1.77gm n.s.s.	13/50	8/50	9/50		lun:a/a,a/c.
2822 M f cdl eat 50w78 1582				0	176.mg			Miller;canr,43,1124-1134;1983
lun ade v	no dre	P=1.	- 370.mg n.s.s.	1/30	1/30			
liv tum v	no dre	P=1.	- 612.mg n.s.s.	0/30	0/30			
2823 R f f34 eat 24m24 TR223 :				0	294.mg	619.mg		
TBA MXB	no dre	P=1.	- 723.mg n.s.s.	33/40	41/50	38/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/40	0/50	0/50		liv:hpa,hpc,nnd.
2824 R m f34 eat 24m24 TR223 :				0	118.mg	238.mg		
lun MXA #	424.mg \	P<.02	- 158.mg n.s.s.	0/40	5/50	(2/50)		lun:a/a,a/c. S
TBA MXB	293.mg \	P<.5	62.8mg n.s.s.	30/40	40/50	(33/50)		
liv MXB	no dre	P=1.	1.75gm n.s.s.	2/40	0/50	1/50		liv:hpa,hpc,nnd.

FADROZOLE.HCl 102676-31-3

2825 R f sda gav 24m24 2229				0	50.0ug	.250mg	1.25mg	Gunson;bjca,72,72-75;1995/pers.comm.
mgl mix e	no dre	P=1.	- .157mg n.s.s.	29/60	20/60	(7/60	0/60)	
liv mix e	no dre	P=1.	- 13.8mg n.s.s.	4/60	4/60	0/60	1/60	
tba mix e	no dre	P=1.	- 2.10mg n.s.s.	58/60	60/60	52/60	48/60	
2826 R m sda gav 24m24 2229				0	50.0ug	.250mg	1.25mg	
liv mix e	no dre	P=1.	- 9.02mg n.s.s.	10/60	8/60	5/60	4/60	

FENAMINOSULF, FORMULATED (methyl orange B) 140-56-7

2827 M f b6c eat 78w95 TR101 :				0	54.3mg	103.mg		
liv MXA v#	152.mg \	P<.02	- 47.6mg n.s.s.	2/100	4/50	(3/49)		liv:hpa,hpc. S
TBA MXB v	259.mg *	P<.2	82.6mg n.s.s.	26/100	10/50	16/49		
liv MXB v	152.mg \	P<.02	47.6mg n.s.s.	2/100	4/50	(3/49)		liv:hpa,hpc,nnd.
lun MXB v	1.75gm *	P<.7	210.mg n.s.s.	8/100	3/50	4/49		lun:a/a,a/c.
2828 M m b6c eat 78w94 TR101 :				0	94.7mg	189.mg		
TBA MXB v	no dre	P=1.	- 137.mg n.s.s.	20/50	20/50	3/50		
liv MXB v	no dre	P=1.	265.mg n.s.s.	15/50	9/50	2/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	249.mg n.s.s.	7/50	7/50	1/50		lun:a/a,a/c.
2829 R f f34 eat 18m24 TR101 :				0	19.3mg	34.4mg		
TBA MXB v	no dre	P=1.	- 36.7mg n.s.s.	31/50	33/50	30/50		
liv MXB v	no dre	P=1.	325.mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
2830 R m f34 eat 18m24 TR101 :				0	15.4mg	27.5mg		
TBA MXB v	no dre	P=1.	- 19.3mg n.s.s.	31/50	18/50	(17/50)		
liv MXB v	no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.

FENTHION 55-38-9

2831 M f b6c eat 24m24 TR103 :				0	1.30mg	2.60mg		
TBA MXB	17.8mg *	P<.7	- 2.57mg n.s.s.	12/25	22/50	24/50		
liv MXB	no dre	P=1.	11.0mg n.s.s.	2/25	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	11.2mg n.s.s.	3/25	3/50	3/50		lun:a/a,a/c.
2832 M m b6c eat 24m24 TR103 :				0	1.20mg	2.40mg		
MXA MXA	6.12mg *	P<.02	a 3.34mg n.s.s.	0/25	7/50	8/50		ski:fbs,srn; sub:fbs,rhb,srn.
TBA MXB	1.03mg \	P<.02	.500mg n.s.s.	10/25	35/50	(26/50)		
liv MXB	9.44mg *	P<.5	2.37mg n.s.s.	6/25	17/50	17/50		liv:hpa,hpc,nnd.
lun MXB	13.3mg *	P<.3	4.15mg n.s.s.	2/25	5/50	8/50		lun:a/a,a/c.
2833 R f f34 eat 24m24 TR103 :				0	.500mg	1.00mg		
TBA MXB	29.4mg *	P<1.	- .581mg n.s.s.	18/25	44/50	39/50		
liv MXB	no dre	P=1.	9.77mg n.s.s.	1/25	0/50	0/50		liv:hpa,hpc,nnd.
2834 R m f34 eat 24m24 TR103 :				0	.400mg	.800mg		
TBA MXB	no dre	P=1.	- 1.04mg n.s.s.	17/25	32/50	26/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv MXB	10.3mg *	P<.7	2.82mg n.s.s.	0/25	2/50	1/50			liv:hpa,hpc,nnd.
FENVALERATE (cyano-(3-phenoxyphenyl)methyl-4-chloro-alpha-(1-methylethyl)benzene acetate) 51630-58-1									
2835 M f b6c eat 24m24 2177				0	1.30mg	6.50mg	32.5mg	162.mg	Parker;faat,3,114-120;1983/pers.comm.
liv hpa es	no dre	P=1.	- 10.2mg n.s.s.	1/84	0/48	0/45	0/43	0/46	
lun bcd es	no dre	P=1.	- 1.03gm n.s.s.	6/84	2/48	1/45	4/43	1/46	
lun bro es	no dre	P=1.	- 1.46gm n.s.s.	1/84	1/48	2/45	1/43	0/46	
liv hpc es	no dre	P=1.	- 1.82gm n.s.s.	3/84	0/48	1/45	0/43	0/46	
tba tum es	173.mg Z	P<.4	- 39.1mg n.s.s.	28/84	17/48	17/45	18/43	(5/46)	
2836 M m b6c eat 24m24 2177				0	1.20mg	6.00mg	30.0mg	150.mg	
liv hpa es	no dre	P=1.	- 8.85mg n.s.s.	4/94	0/44	0/48	0/46	0/45	
ski fbs es	no dre	P=1.	- 150.mg n.s.s.	2/94	3/44	5/48	1/46	(0/45)	
lun bro es	no dre	P=1.	- 718.mg n.s.s.	9/94	1/44	7/48	3/46	3/45	
lun bcd es	no dre	P=1.	- 754.mg n.s.s.	1/94	1/44	4/48	3/46	1/45	
liv hpc es	no dre	P=1.	- 1.12gm n.s.s.	5/94	3/44	3/48	6/46	0/45	
tba tum es	251.mg Z	P<.6	- 42.6mg n.s.s.	27/94	13/44	21/48	16/46	(5/45)	
2837 M f cb6 gav 24m26 1963				0	26.1mg	52.1mg			Cabral;clet,49,13-18;1990/pers.comm.
--- lym e	384.mg *	P<.6	- 67.5mg n.s.s.	19/49	24/47	18/41			
liv lct e	no dre	P=1.	- 555.mg n.s.s.	2/49	0/47	1/41			
lun ade e	no dre	P=1.	- 193.mg n.s.s.	2/49	0/47	0/41			
tba tum e	435.mg *	P<.7	- 62.6mg n.s.s.	22/49	27/47	20/41			
2838 M m cb6 gav 24m26 1963				0	26.1mg	52.1mg			
liv lct e	328.mg *	P<.09	- 125.mg n.s.s.	4/48	5/47	10/48			
--- lym e	659.mg *	P<.7	- 93.6mg n.s.s.	15/48	17/47	17/48			
lun ade e	no dre	P=1.	- 385.mg n.s.s.	2/48	3/47	1/48			
tba tum e	no dre	P=1.	- 88.7mg n.s.s.	25/48	22/47	24/48			
2839 R f sda eat 24m24 1650m				0	50.0ug	.250mg	1.25mg	12.5mg	Parker;jtxe,13,83-97;1984
mgl fib e	2.55mg Z	P<.02	- .882mg n.s.s.	0/102	1/51	3/51	(1/51	0/48)	
mam ben e	43.7mg *	P<.2	- 14.0mg n.s.s.	25/102	16/51	18/51	21/51	20/48	
mgl fba e	58.0mg *	P<.3	- 15.8mg n.s.s.	25/102	18/51	18/51	19/51	19/48	
mam mal e	150.mg *	P<.5	- 26.2mg n.s.s.	18/102	9/51	11/51	9/51	11/48	
2840 R f sda eat 24m24 1650n				0	50.0mg				
mam ben e	247.mg	P<.4	- 60.6mg n.s.s.	16/50	20/49				
liv rcs e	no dre	P=1.	- 505.mg n.s.s.	1/50	0/49				
mam mal e	no dre	P=1.	- 179.mg n.s.s.	10/50	7/49				
2841 R m sda eat 24m24 1650m				0	40.0ug	.200mg	1.00mg	10.0mg	
sub fbs e	5.04mg Z	P<.003	- 2.18mg 38.3mg	0/103	1/51	3/51	5/51	(0/51)	
2842 R m sda eat 24m24 1650n				0	40.0mg				
sub scs e	266.mg	P<.009	- 101.mg 6.25gm	0/50	5/51				
FERRIC CHLORIDE 7705-08-0									
2843 R f f3d wat 24m26 2090				0	133.mg	265.mg			Sato;fctx,30,837-842;1992
liv nnd e	no dre	P=1.	- 3.10gm n.s.s.	2/50	0/49	1/48			
tba tum e	505.mg *	P<.4	- 132.mg n.s.s.	40/50	39/49	42/48			
2844 R m f3d wat 24m26 2090				0	116.mg	232.mg			
liv nnd e	8.81gm *	P<.7	- 1.23gm n.s.s.	2/50	2/48	3/49			
tba tum e	no dre	P=1.	- 21.1mg n.s.s.	50/50	47/48	49/49			
FERRIC CITRATE TETRAHYDRATE 2338-05-8									
2845 M f b6c wat 22m23 2200				0	115.mg	230.mg			Inai;fctx,32,493-498;1994/pers.comm.
liv hpc e	10.4gm *	P<.3	- 1.69gm n.s.s.	0/47	0/47	1/48			
lun a/a e	10.4gm *	P<.3	- 1.69gm n.s.s.	0/47	0/47	1/48			
liv hpa e	no dre	P=1.	- 2.22gm n.s.s.	1/47	1/47	0/48			
liv hct e	no dre	P=1.	- 1.53gm n.s.s.	1/47	1/47	1/48			
tba mix e	no dre	P=1.	- 375.mg n.s.s.	20/47	18/47	19/48			
2846 M m b6c wat 22m23 2200				0	96.0mg	192.mg			
liv hpa e	no dre	P=1.	- 658.mg n.s.s.	5/28	6/38	3/35			
liv hct e	no dre	P=1.	- 763.mg n.s.s.	8/28	8/38	3/35			
lun a/c e	no dre	P=1.	- 819.mg n.s.s.	0/28	2/38	0/35			
lun a/a e	no dre	P=1.	- 1.09gm n.s.s.	3/28	4/38	0/35			
liv hpc e	no dre	P=1.	- 1.39gm n.s.s.	3/28	2/38	0/35			
tba mix e	no dre	P=1.	- 530.mg n.s.s.	16/28	16/38	9/35			
FERRIC DIMETHYLDITHIOCARBAMATE (ferbam) 14484-64-1									
2847 M f b6a orl 76w76 1209				0	4.39mg				Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	- 8.21mg n.s.s.	0/17	0/17				
lun ade evx	no dre	P=1.	- 8.21mg n.s.s.	1/17	0/17				
tba mix evx	no dre	P=1.	- 5.43mg n.s.s.	2/17	1/17				
2848 M m b6a orl 76w76 1209				0	4.08mg				
lun ade evx	11.2mg	P<.4	- 2.34mg n.s.s.	2/18	4/18				
liv hpt evx	no dre	P=1.	- 4.82mg n.s.s.	1/18	1/18				
tba mix evx	21.6mg	P<.7	- 2.54mg n.s.s.	3/18	4/18				
2849 M f b6c orl 76w76 1209				0	4.39mg				
lun ade evx	24.9mg	P<.3	- 4.05mg n.s.s.	0/16	1/16				
liv hpt evx	no dre	P=1.	- 7.73mg n.s.s.	0/16	0/16				
tba mix evx	12.0mg	P<.09	- 2.95mg n.s.s.	0/16	2/16				
2850 M m b6c orl 76w76 1209				0	4.08mg				
liv hpt evx	5.57mg	P<.02	- 1.91mg n.s.s.	0/16	4/17				
lun ade evx	11.9mg	P<.1	- 2.93mg n.s.s.	0/16	2/17				
tba mix evx	2.81mg	P<.002	- 1.20mg 10.8mg	0/16	7/17				
FINASTERIDE 98319-26-7									
2851 M m cd1 gav 83w83 2206				0	2.50mg	25.0mg	250.mg		Prahalada;faat,22,211-219;1994
tes lya er	326.mg *	P<.0005 +	180.mg 687.mg	1/100	0/50	0/50	16/50		
FLECAINIDE ACETATE (2,5-bis(2,2,2-trifluorethoxyl)-N-(2-piperidylmethyl)benzamide acetate) 54143-56-5									
2852 M f cd1 eat 78w78 1649n				0	15.0mg	30.0mg	60.0mg		Case;txap,73,232-242;1984
lun ade e	938.mg *	P<.7	- 136.mg n.s.s.	5/69	5/69	7/68	6/67		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv ade e		no dre	P=1.	- 68.0mg n.s.s.	1/69	0/69	0/68	0/67	
2853 M m cd1 eat 78w78 1649n					0	15.0mg	30.0mg	60.0mg	
lun ade e		no dre	P=1.	- 165.mg n.s.s.	10/67	7/69	7/69	7/60	
liv ade e		no dre	P=1.	- 269.mg n.s.s.	10/67	4/69	5/69	4/60	
liv hpc e		no dre	P=1.	- 584.mg n.s.s.	2/67	0/69	1/69	0/60	
2854 R f crw eat 24m24 1649m					0	15.0mg	30.0mg	60.0mg	
liv ade e		no dre	P=1.	- 820.mg n.s.s.	2/49	0/50	1/50	0/50	
2855 R m crw eat 24m24 1649m					0	15.0mg	30.0mg	60.0mg	
tes ica e		79.1mg *	P<.004	- 40.8mg 561.mg	19/50	16/50	23/50	32/50	
liv ade e		3.58gm *	P<.2	- 583.mg n.s.s.	0/50	0/50	0/50	1/50	
FLUCONAZOLE 86386-73-4									
2856 M f cd1 eat 24m24 2199					0	2.50mg	5.00mg	10.0mg	Paulus;tcam,14,251-257;1994/pers.comm.
liv hpa e		129.mg *	P<.3	- 37.9mg n.s.s.	1/100	3/50	3/50	2/50	
liv hpc e		no dre	P=1.	- 104.mg n.s.s.	0/100	1/50	0/50	0/50	
tba mix e		no dre	P=1.	- 16.3mg n.s.s.	48/100	24/50	25/50	23/50	
2857 M m cd1 eat 24m24 2199					0	2.50mg	5.00mg	10.0mg	
liv hpa e		144.mg *	P<.7	- 19.4mg n.s.s.	30/100	16/50	11/50	18/50	
liv hpc e		no dre	P=1.	- 40.4mg n.s.s.	15/100	3/50	6/50	7/50	
tba mix e		239.mg *	P<1.	- 10.3mg n.s.s.	66/100	33/50	31/50	34/50	
2858 R f cdr eat 24m24 2199					0	2.50mg	5.00mg	10.0mg	
liv hpa e		298.mg *	P<.3	- 73.2mg n.s.s.	0/99	1/50	0/50	1/50	
mgl ade e		412.mg *	P<.5	- 68.6mg n.s.s.	2/99	0/50	1/50	2/50	
liv hpc e		no dre	P=1.	- 14.7mg n.s.s.	0/99	0/50	0/50	0/50	
mgl car e		no dre	P=1.	- 25.0mg n.s.s.	29/99	15/50	11/50	15/50	
mgl fba e		no dre	P=1.	- 53.5mg n.s.s.	29/99	16/50	9/50	8/50	
mgl mix e		no dre	P=1.	- 32.4mg n.s.s.	50/99	25/50	17/50	19/50	
tba mix e		no dre	P=1.	- 6.24mg n.s.s.	87/99	44/50	41/50	44/50	
2859 R m cdr eat 24m24 2199					0	2.50mg	5.00mg	10.0mg	
liv hpa e		80.7mg *	P<.02	+ 32.8mg n.s.s.	2/100	0/50	4/50	5/50	
amd phe e		no dre	P=1.	- 132.mg n.s.s.	4/100	3/50	0/50	0/50	
liv hpc e		no dre	P=1.	14.7mg n.s.s.	0/100	0/50	0/50	0/50	
tba mix e		no dre	P=1.	- 16.5mg n.s.s.	72/100	37/50	34/50	31/50	
FLUOMETURON 2164-17-2									
2860 M f b6c eat 24m24 TR195 :					0	64.4mg	129.mg		
TBA MXB		369.mg *	P<.2	- 127.mg n.s.s.	9/25	15/50	23/50		
liv MXB		1.23gm *	P<.4	324.mg n.s.s.	1/25	3/50	4/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	636.mg n.s.s.	1/25	2/50	1/50		lun:a/a,a/c.
2861 M m b6c eat 24m24 TR195 :					0	59.4mg	118.mg		
liv MXA		229.mg *	P<.06	a 103.mg n.s.s.	4/25	13/50	21/50		liv:hpa,hpc.
TBA MXB		265.mg *	P<.3	80.2mg n.s.s.	9/25	27/50	29/50		
liv MXB		229.mg *	P<.06	103.mg n.s.s.	4/25	13/50	21/50		liv:hpa,hpc,nnd.
lun MXB		1.42gm *	P<.6	262.mg n.s.s.	2/25	4/50	6/50		lun:a/a,a/c.
2862 R f f34 eat 24m24 TR195 :					0	6.10mg	12.4mg		
TBA MXB v		no dre	P=1.	- 16.0mg n.s.s.	45/50	41/50	42/50		
liv MXB v		no dre	P=1.	77.6mg n.s.s.	3/50	3/50	1/50		liv:hpa,hpc,nnd.
2863 R m f34 eat 24m24 TR195 :					0	5.00mg	9.90mg		
liv nnd v#		55.4mg *	P<.04	- 21.1mg n.s.s.	0/50	1/50	4/50		S
TBA MXB v		no dre	P=1.	9.84mg n.s.s.	30/50	24/50	35/50		
liv MXB v		55.4mg *	P<.04	21.1mg n.s.s.	0/50	1/50	4/50		liv:hpa,hpc,nnd.
N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE 363-17-7									
2864 R f buf eat 53w54 144					0	13.2mg			Morris;jnci,24,149-180;1960
mgl adc e		1.62mg	P<.0005	+ .800mg 3.71mg	0/18	14/18			
liv hpt e		1.90mg	P<.0005	+ .940mg 4.44mg	0/18	13/18			
edu sqc e		4.94mg	P<.002	+ 2.11mg 18.4mg	0/18	7/18			
FLUORIDE, SODIUM 7681-49-4									
2865 M f b6c wat 24m24 TR393 :					0	4.90mg	19.6mg	34.3mg	
TBA MXB		no dre	P=1.	- 38.0mg n.s.s.	72/80	41/52	37/50	61/80	
liv MXB		no dre	P=1.	59.1mg n.s.s.	55/80	33/52	26/50	41/80	liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	138.mg n.s.s.	8/80	6/52	4/50	7/80	lun:a/a,a/c.
2866 M m b6c wat 24m24 TR393 :					0	4.08mg	16.3mg	28.6mg	
TBA MXB		no dre	P=1.	- 33.2mg n.s.s.	71/79	45/50	43/51	69/80	
liv MXB		no dre	P=1.	36.2mg n.s.s.	62/79	39/50	37/51	61/80	liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	96.2mg n.s.s.	23/79	13/50	13/51	18/80	lun:a/a,a/c.
2867 M b cd1 wat 30m30 1036					0	1.75mg			Kanisawa;canr,29,892-895;1969
lun tum e		no dre	P=1.	- 11.0mg n.s.s.	15/71	12/72			
liv tum e		no dre	P=1.	- 15.3mg n.s.s.	4/71	4/72			
tba tum e		no dre	P=1.	- 7.10mg n.s.s.	24/71	22/72			
tba mal e		no dre	P=1.	- 17.4mg n.s.s.	8/71	5/72			
2868 M f dbx eat 90w90 1652					0	117.mg			Tannenbaum;canr,9,403-410;1949
mgl car er		no dre	P=1.	- 276.mg n.s.s.	37/50	20/48			
2869 R f f34 wat 24m24 TR393 :					0	1.41mg	5.63mg	9.86mg	
TBA MXB		73.9mg *	P<.8	- 7.56mg n.s.s.	73/80	41/50	48/50	71/81	
liv MXB		no dre	P=1.	83.0mg n.s.s.	2/80	0/50	1/50	1/81	liv:hpa,hpc,nnd.
2870 R m f34 wat 24m24 TR393 :					0	1.23mg	4.92mg	8.63mg	
MXA ost		82.7mg *	P<.009	30.6mg 2.86gm	0/80	0/51	1/49	4/80	cyx:ost; hum:ost; sub:ost; ver:ost. S
MXA ost		109.mg *	P<.03	e 36.4mg n.s.s.	0/80	0/51	1/49	3/80	cyx:ost; hum:ost; ver:ost.
TBA MXB		147.mg *	P<1.	6.37mg n.s.s.	71/80	48/51	42/49	74/80	
liv MXB		no dre	P=1.	53.0mg n.s.s.	1/80	1/51	1/49	1/80	liv:hpa,hpc,nnd.
4'-FLUORO-4-AMINODIPHENYL 324-93-6									
2871 M f cba gav 6m26 1165					0	1.30mg			Clayson;bjca,19,297-310;1965/Williams 1962
liv hpt e		1.09mg	P<.0005	+ .663mg 1.96mg	0/18	25/40			
2872 M m cba gav 6m24 1165					0	1.19mg			
liv hpt e		1.19mg	P<.005	+ .601mg 8.97mg	2/15	18/32			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv mix e	1.19mg	P<.005		.601mg 8.97mg	2/15	18/32			
N-4-(4'-FLUOROBIPHENYL)ACETAMIDE 398-32-3									
2873 R m f34 eat 52w52 1150					0	16.0mg			Hinton;bect,23,464-469;1979
kid adc ekr	1.01mg	P<.0005	+	.392mg 2.58mg	0/15	14/15			
2-FLUOROETHYL-NITROSOUREA 69112-98-7									
2874 R m f34 gav 9m24 1915					0	74.2ug			Lijinsky;txih,5,925-935;1989
for tum	.125mg	P<.02	+	42.8ug n.s.s.	0/12	4/12			
lun mix	.279mg	P<.09		68.3ug n.s.s.	0/12	2/12			
liv tum	no dre	P=1.		.184mg n.s.s.	1/12	0/12			
5-FLUOROURACIL (fluracil) 51-21-8									
2875 M f b6c wat 82w86 2366					0	5.72mg	11.4mg		Iwagawa;jtxp,4,129-135;1991
lun ade e	331.mg *	P<.7	-	42.4mg n.s.s.	2/51	1/52	3/51		
liv nnd e	no dre	P=1.	-	59.2mg n.s.s.	2/51	2/52	1/51		
lun adc e	no dre	P=1.	-	27.8mg n.s.s.	1/51	0/52	0/51		
liv hpc e	no dre	P=1.	-	87.7mg n.s.s.	1/51	1/52	0/51		
2876 M m b6c wat 82w86 2366					0	4.77mg	9.53mg		
hag ade e	48.7mg *	P<.05	-	18.8mg n.s.s.	2/51	1/50	8/52		
lun ade e	35.7mg *	P<.2	-	13.4mg n.s.s.	3/51	8/50	8/52		
liv hpc e	no dre	P=1.	-	17.1mg n.s.s.	11/51	10/50	11/52		
liv nnd e	no dre	P=1.	-	31.1mg n.s.s.	6/51	1/50	6/52		
lun adc e	no dre	P=1.	-	50.3mg n.s.s.	1/51	1/50	1/52		
2877 M f bal ipj 50w87 1964					0	2.46mg			Cavaliere;tumo,76,179-181;1990
lmr mix e	2.83mg	P<.002	+	1.46mg 11.2mg	6/50	21/50			
lun mix e	7.46mg	P<.2	+	2.43mg n.s.s.	9/50	15/50			
lun sqc e	58.5mg	P<.3		9.52mg n.s.s.	0/50	1/50			
tba tum e	2.19mg	P<.003		1.09mg 14.2mg	14/50	29/50			
2878 M m bal ipj 50w87 1964					0	2.46mg			
lun ade e	3.11mg	P<.02	+	1.42mg n.s.s.	12/50	24/50			
tba tum e	2.73mg	P<.008		1.28mg 69.1mg	13/50	26/50			
2879 R m b46 ivj 12m24 1017					0	2.36mg			Schmahl;arzn,20,1461-1467;1970
liv ade es	34.7mg	P<.1	-	5.65mg n.s.s.	0/65	1/22			
tba ben es	16.3mg	P<.2	-	3.65mg n.s.s.	3/65	3/22			
tba mix es	18.6mg	P<.4	-	3.37mg n.s.s.	7/65	4/22			
tba mal es	no dre	P=1.	-	6.96mg n.s.s.	4/65	1/22			
2880 R f f3d wat 24m26 2635					0	3.32mg	6.69mg		Toyoda;fctx,38,187-193;2000/pers.comm.
adr phe e	36.0mg *	P<.008	-	17.6mg 606.mg	0/49	5/48	5/49		
pit ade e	24.1mg *	P<.2	-	8.52mg n.s.s.	10/49	21/48	16/49		
liv hpa e	53.6gm *	P<1.	-	39.2mg n.s.s.	3/49	2/48	3/49		
tba mix e	10.1mg *	P<.3	-	3.21mg n.s.s.	35/49	41/48	40/49		
2881 R m f3d wat 24m26 2635					0	2.90mg	5.86mg		
liv hpa e	37.7mg *	P<.08	-	14.4mg n.s.s.	4/50	4/49	10/49		
liv hpc e	17.7gm *	P<1.	-	61.4mg n.s.s.	1/50	0/49	1/49		
tba mix e	noTD50	P<.4	-	n.s.s. n.s.s.	49/50	49/49	49/49		
FLUOXETINE.HCl (prozac) 59333-67-4									
2882 M f b6c eat 24m24 2045m					0	1.30mg	5.20mg	13.0mg	Bendele;canr,52,6931-6935;1992/pers.comm.
lun a/a e	no dre	P=1.	-	86.9mg n.s.s.	2/59	2/59	2/60	2/60	
liv mix e	no dre	P=1.	-	101.mg n.s.s.	2/59	2/59	3/60	1/60	
2883 M f b6c eat 24m24 2045n					0	1.30mg	5.20mg	13.0mg	
liv mix e	239.mg *	P<.4	-	54.9mg n.s.s.	4/59	1/60	3/61	5/59	
lun mix e	no dre	P=1.	-	157.mg n.s.s.	3/59	3/60	0/61	1/59	
2884 M m b6c eat 24m24 2045m					0	1.20mg	4.80mg	12.0mg	
lun mix e	19.2mg Z	P<.07	-	7.34mg n.s.s.	9/60	11/60	17/60	(3/59)	
liv mix e	no dre	P=1.	-	51.1mg n.s.s.	16/60	12/60	17/60	9/59	
2885 M m b6c eat 24m24 2045n					0	1.20mg	4.80mg	12.0mg	
lun mix e	37.1mg Z	P<.3	-	10.2mg n.s.s.	5/60	10/60	10/59	(2/61)	
liv mix e	no dre	P=1.	-	66.9mg n.s.s.	16/60	11/60	11/59	8/61	
2886 R f sda eat 24m24 2045m					0	.500mg	2.25mg	10.0mg	
liv hpa e	no dre	P=1.	-	4.86mg n.s.s.	1/60	0/60	0/60	0/60	
2887 R m sda eat 24m24 2045m					0	.400mg	1.80mg	8.00mg	
liv hpa e	207.mg *	P<.04	-	50.9mg n.s.s.	0/60	0/60	0/60	2/60	
FLUVASTATIN 93957-54-1									
2888 R f cdr gav 24m24 2166					0	6.00mg	9.00mg	20.9mg	Robison;faat,23,9-20;1994
liv hpc e	916.mg *	P<.04		225.mg n.s.s.	0/150	0/75	0/75	2/75	
sto pam e	916.mg *	P<.04		225.mg n.s.s.	0/150	0/75	0/75	2/75	
liv hpa e	2.78gm *	P<.9		141.mg n.s.s.	7/150	4/75	3/75	4/75	
2889 R m cdr gav 24m24 2166					0	6.00mg	9.00mg	20.9mg	
thy fca e	125.mg *	P<.002	+	61.6mg 655.mg	4/150	4/75	4/75	11/75	
thy fdc e	258.mg *	P<.04	+	97.2mg n.s.s.	5/150	1/75	2/75	8/75	
sto pam e	610.mg *	P<.03		185.mg n.s.s.	0/150	0/75	1/75	2/75	
sto sqc e	919.mg *	P<.2		226.mg n.s.s.	0/150	1/75	0/75	1/75	
liv hpc e	no dre	P=1.		283.mg n.s.s.	1/150	3/75	0/75	0/75	
liv hpa e	no dre	P=1.		241.mg n.s.s.	4/150	2/75	0/75	2/75	
FORMALDEHYDE 50-00-0									
2890 H m syg inh 94w94 1414m					0	.772mg			Dalbey;txcy,24,9-14;1982
res tum r	no dre	P=1.	-	6.50mg n.s.s.	0/50	0/50			
2891 H m syg inh 25m25 1414n					0	1.29mg			
res tum rs	no dre	P=1.	-	25.6mg n.s.s.	0/132	0/88			
2892 M f b6c inh 52w52 1566a					0	.772mg	2.32mg	5.79mg	Pavkov;ciit;1981/Kerns 1983
nas tum ek	no dre	P=1.		.271mg n.s.s.	0/10	0/10	0/10	0/10	
lun tum ek	no dre	P=1.		2.98mg n.s.s.	0/10			0/10	
liv tum ek	no dre	P=1.		2.98mg n.s.s.	0/10			0/10	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
2893 M f b6c inh 78w78 1566b					0	.772mg	2.32mg	5.79mg			
nas tum ek	no dre	P=1.		1.21mg n.s.s.	0/20	0/20	0/20	0/19			
liv mix ek	no dre	P=1.		8.42mg n.s.s.	2/20			1/19			
lun tum ek	no dre	P=1.		12.8mg n.s.s.	0/20			0/19			
2894 M f b6c inh 24m24 1566c					0	5.79mg					
lun mix ek	47.3mg	P<.3		10.9mg n.s.s.	1/30	3/27					
liv mix ek	98.7mg	P<.6		14.4mg n.s.s.	1/30	2/28					
nas tum ek	no dre	P=1.		3.10mg n.s.s.	0/30	0/26	0/41	0/28			
2895 M f b6c inh 24m27 1566m					0	.686mg	2.06mg	5.15mg			
nas tum e	no dre	P=1.		6.06mg n.s.s.	0/50	0/54	0/39	0/54			
lun mix e	no dre	P=1.		44.5mg n.s.s.	1/50			1/54			
liv tum e	no dre	P=1.		72.5mg n.s.s.	0/50			0/54			
2896 M m b6c inh 52w52 1566a					0	4.83mg					
liv hpc ek	7.85mg	P<.3		1.28mg n.s.s.	0/10	1/10					
lun tum ek	no dre	P=1.		2.49mg n.s.s.	0/10	0/10					
nas tum ek	no dre	P=1.		.226mg n.s.s.	0/10	0/10	0/10	0/10			
2897 M m b6c inh 24m24 1566c					0	.644mg	1.93mg	4.83mg			
ntu sqc es	43.9mg *	P<.04	+	10.8mg n.s.s.	0/20	0/22	0/19	2/17			
liv mix es	34.5mg	P<.2		9.67mg n.s.s.	4/62			6/40			
lun mix es	no dre	P=1.		6.53mg n.s.s.	6/25			4/18			
2898 R f f34 inh 52w52 1566n					0	.184mg	.552mg	1.38mg			
nas tum ek	no dre	P=1.		64.6ug n.s.s.	0/10	0/10	0/10	0/10			
liv tum ek	no dre	P=1.		.710mg n.s.s.	0/10			0/10			
2899 R f f34 inh 78w78 1566o					0	.184mg	.552mg	1.38mg			
ntu sqc ek	3.67mg *	P<.005	+	1.27mg 33.9mg	0/20	0/20	0/20	4/19			
liv nnd ek	192.mg	P<1.		1.81mg n.s.s.	1/20			1/19			
ntu pla ek	no dre	P=1.		3.23mg n.s.s.	0/20	1/20	0/20	0/19			
2900 R f f34 inh 25m25 1566r :					0	.184mg	.552mg	1.38mg			
ntu sqc s	1.37mg Z	P<.0005	+	.952mg 2.06mg	0/78	0/79	1/76	48/73			
ntu pla s	7.95mg Z	P<.4		1.25mg n.s.s.	0/78	3/79	0/76	1/73			
liv nnd es	no dre	P=1.		4.13mg n.s.s.	1/67			0/14			
2901 R m f34 inh 52w52 1566n					0	.129mg	.386mg	.965mg			
nas tum ek	no dre	P=1.		45.2ug n.s.s.	0/10	0/10	0/10	0/10			
liv tum ek	no dre	P=1.		.497mg n.s.s.	0/10			0/10			
2902 R m f34 inh 78w78 1566o					0	.129mg	.386mg	.965mg			
ntu sqc ek	2.57mg *	P<.005	+	.886mg 23.8mg	0/20	0/20	0/20	4/19			
ntu pla ek	5.39mg *	P<.2		1.32mg n.s.s.	0/20	0/20	1/20	1/19			
liv tum ek	no dre	P=1.		2.24mg n.s.s.	0/20			0/20			
2903 R m f34 inh 24m24 1566r :					0	.129mg	.386mg	.965mg			
ntu sqc s	.798mg Z	P<.0005	+	.510mg 1.23mg	0/79	0/80	1/79	47/73			
ntu pla s	3.01mg *	P<.03		1.10mg n.s.s.	1/79	4/80	5/79	3/73			
liv mix es	no dre	P=1.		2.85mg n.s.s.	4/74			1/22			
2904 R m f34 inh 52w52 2279m :					0	45.0ug	.129mg	.386mg	.643mg	.965mg	Monticello;canr,56,1012-1022;1996/ CIIT 1999/pers.comm.
nas sqc Ckr	2.37mg *	P<.06		.582mg n.s.s.	0/12	0/12	0/12	0/12	0/10	2/16	
2905 R m f34 inh 80w80 2279n :					0	45.0ug	.129mg	.386mg	.643mg	.965mg	
nas sqc Ckr	.895mg *	P<.0005	+	.422mg 2.61mg	0/10	0/11	0/12	0/12	3/10	6/11	
2906 R m f34 inh 24m24 2279o :					0	45.0ug	.129mg	.386mg	.643mg	.965mg	
nas sqc Cr	.480mg Z	P<.0005	+	.357mg .656mg	0/46	0/48	0/48	1/48	19/47	71/97	
2907 R m f3d inh 52w52 2445m					0	19.3ug	.129mg	.965mg			Kamata;jtxs,22,239-254;1997/pers.comm.
nas tum ek	no dre	P=1.		4.25ug n.s.s.	0/5	0/5	0/5	0/5			
2908 R m f3d inh 78w78 2445n					0	19.3ug	.129mg	.965mg			
nas mix ek	.874mg *	P<.02		.210mg n.s.s.	0/5	0/5	0/5	2/5			
2909 R m f3d inh 27m28 2445o					0	19.3ug	.129mg	.965mg			
nas mix ae	.980mg *	P<.0005	+	.512mg 2.17mg	0/22	0/22	0/22	14/20			
nas sqc ae	1.24mg *	P<.0005	+	.628mg 2.94mg	0/22	0/22	0/22	12/20			
nas sqp ae	10.0mg *	P<.03		2.46mg n.s.s.	0/22	0/22	0/22	2/20			
2910 R f sda wat 24m34 BT7001					0	.410mg	2.05mg	4.10mg	20.5mg	41.0mg	61.5mg Soffritti;txih,5,699-730; 1989
--- leu er	815.mg *	P<.04	+	316.mg n.s.s.	3/50	2/50	4/50	4/50	4/50	7/50	7/50
--- lls er	996.mg *	P<.03	+	386.mg n.s.s.	1/50	1/50	3/50	2/50	2/50	5/50	5/50
git mix er	2.96gm *	P<.2	+	753.mg n.s.s.	0/50	1/50	2/50	0/50	0/50	1/50	3/50
2911 R f sda inh 24m24 2205					0	1.14mg					Holmstrom;acot,108,274-283;1989
nac sqc er	12.1mg	P<.3		1.97mg n.s.s.	0/15	1/16					
2912 R m sda wat 24m34 BT7001					0	.359mg	1.79mg	3.59mg	17.9mg	35.9mg	53.8mg Soffritti;txih,5,699-730; 1989
--- lls er	424.mg *	P<.0005	+	213.mg 1.73gm	4/50	0/50	2/50	4/50	4/50	6/50	11/50
--- leu er	480.mg *	P<.01	+	213.mg 63.8gm	5/50	1/50	5/50	5/50	8/50	6/50	11/50
git mix er	1.41gm *	P<.02	+	517.mg n.s.s.	0/50	2/50	0/50	0/50	0/50	1/50	5/50
2913 R m sda inh 28m28 1674					0	.952mg					Sellakumar;txap,81,401-406;1985
nac sqc e	1.82mg	P<.0005	+	1.22mg 2.86mg	0/99	38/100					
nac car e	86.4mg	P<.3	+	14.1mg n.s.s.	0/99	1/100					
nac fbs e	86.4mg	P<.3	+	14.1mg n.s.s.	0/99	1/100					
liv hpc e	no dre	P=1.		16.0mg n.s.s.	1/99	1/100					
2914 R f wal wat 24m24 1918					0	1.80mg	21.0mg	109.mg			Til;fctx,27,77-87;1989
for exp e	no dre	P=1.	-	16.7mg n.s.s.	1/48	0/49	0/47	0/48			
stg tum e	no dre	P=1.	-	16.7mg n.s.s.	0/48	0/49	0/47	0/48			
liv hpc	no dre	P=1.	-	17.2mg n.s.s.	0/50	0/50	0/50	0/50			
pit het	no dre	P=1.	-	410.mg n.s.s.	6/50	11/50	3/50	7/50			
tba mix	no dre	P=1.	-	136.mg n.s.s.	37/50	38/50	32/50	34/50			
tba ben	no dre	P=1.	-	144.mg n.s.s.	34/50	37/50	25/50	32/50			
tba mal	no dre	P=1.	-	418.mg n.s.s.	9/50	9/50	7/50	7/50			
2915 R m wal wat 24m24 1918					0	1.20mg	15.0mg	82.0mg			
stg tum e	no dre	P=1.	-	10.4mg n.s.s.	0/47	0/45	0/44	0/47			
for exp e	no dre	P=1.	-	913.mg n.s.s.	0/47	1/45	0/44	0/47			
liv hpc	no dre	P=1.	-	981.mg n.s.s.	0/50	1/50	0/50	0/50			
tba mix	no dre	P=1.	-	182.mg n.s.s.	33/50	27/50	30/50	24/50			
tba ben	no dre	P=1.	-	242.mg n.s.s.	28/50	22/50	26/50	18/50			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
tba mal		no dre	P=1.	- 263.mg n.s.s.	8/50	6/50	8/50	7/50	
2916 R m wal inh 28m29 1926					0	6.21ug	62.1ug	.621mg	Woutersen;japt,9,39-46;1989
nac sqc r		42.9mg	* P<.7	- 4.83mg n.s.s.	0/30	1/30	1/30	1/30	
FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL]HYDRAZIDE 31873-81-1									
2917 R f sda eat 46w64 1073					0	29.5mg			Erturk;jnci,47,437-445;1971/1970a
liv tum ev		no dre	P=1.	52.9mg n.s.s.	0/29	0/23			
tba mix ev		no dre	P=1.	- 52.9mg n.s.s.	2/29	0/23			
FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE 32852-21-4									
2918 R f sda eat 46w64 1073					0	14.7mg			Erturk;jnci,47,437-445;1971/1970a
mgl adf ev		14.4mg	P<.03	+ 5.54mg n.s.s.	2/29	8/28			
liv tum ev		no dre	P=1.	32.1mg n.s.s.	0/29	0/28			
tba mix ev		14.4mg	P<.03	5.54mg n.s.s.	2/29	8/28			
FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZIDE (FNT) 3570-75-0									
2919 H m syg eat 48w70 1077					0	63.1mg			Croft;jnci,51,941-949;1973
ubl tcc e		16.6mg	P<.0005	+ 7.32mg 46.9mg	0/17	9/13			
for sqp e		25.1mg	P<.0005	+ 12.9mg 57.3mg	0/24	13/24			
liv tum e		no dre	P=1.	141.mg n.s.s.	0/24	0/24			
lun tum e		no dre	P=1.	141.mg n.s.s.	0/24	0/24			
2920 M f swi eat 33w52 1076					0	41.3mg			Cohen;canr,33,1593-1597;1973
for sqp e		8.85mg	P<.0005	+ 4.33mg 21.9mg	0/29	11/20			
--- lle e		11.4mg	P<.0005	+ 5.09mg 47.4mg	2/29	10/20			
lun alc e		67.1mg	P<.06	16.5mg n.s.s.	0/29	2/20			
liv tum e		no dre	P=1.	42.5mg n.s.s.	0/29	0/20			
tba mix e		2.42mg	P<.0005	.980mg 5.76mg	2/29	19/20			
2921 M f swi eat 33w52 1118					0	41.3mg			Cohen;canr,38,1398-1405;1978
for pam		13.8mg	P<.0005	+ 7.06mg 32.6mg	0/30	12/30			
--- leu		25.6mg	P<.008	10.7mg 639.mg	1/30	8/30			
liv tum		no dre	P=1.	63.8mg n.s.s.	0/30	0/30			
lun tum		no dre	P=1.	63.8mg n.s.s.	0/30	0/30			
2922 R f buf eat 46w64 1073					0	71.9mg			Erturk;jnci,47,437-445;1971/1970a
mgl mix e		5.54mg	P<.0005	+ 2.43mg 11.4mg	0/30	28/29			
mgl adc e		13.1mg	P<.0005	+ 7.48mg 25.0mg	0/30	22/29			
kid mix e		17.5mg	P<.0005	+ 9.87mg 34.5mg	0/30	19/29			
liv cye e		39.1mg	P<.0005	+ 19.5mg 96.4mg	0/30	11/29			
kid uac e		44.1mg	P<.0005	+ 21.3mg 116.mg	0/30	10/29			
mgl adf e		80.5mg	P<.003	+ 32.7mg 434.mg	0/30	6/29			
kid tua e		98.6mg	P<.007	+ 37.3mg 1.20gm	0/30	5/29			
tba mix e		noTD50	P<.0005	n.s.s. 8.39mg	0/30	29/29			
2923 R f hza eat 44w60 1063					0	73.6mg			Morris;canr,29,2145-2156;1969
mam tum es		5.50mg	P<.0005	+ 2.28mg 13.1mg	3/16	25/26			
kid ade es		17.6mg	P<.0005	+ 9.51mg 37.0mg	0/16	16/26			
kid car es		78.5mg	P<.03	+ 29.7mg n.s.s.	0/16	5/26			
smi adc es		78.5mg	P<.03	+ 29.7mg n.s.s.	0/16	5/26			
eac sqc esh		100.mg	P<.05	+ 34.6mg n.s.s.	0/16	4/26			
cec adc es		210.mg	P<.2	+ 51.5mg n.s.s.	0/16	2/26			
liv hms es		428.mg	P<.4	- 69.6mg n.s.s.	0/16	1/26			
2924 R f sda eat 45w75 200a					0	31.3mg			Cohen;jnci,51,403-417;1973
mgl adc ev		3.54mg	P<.0005	+ 1.95mg 6.19mg	6/71	49/51			
for sqp ev		65.4mg	P<.0005	29.6mg 196.mg	0/71	8/51			
kid rcc ev		65.4mg	P<.0005	29.6mg 196.mg	0/71	8/51			
k/p tcc evh		137.mg	P<.008	+ 47.2mg 3.07gm	0/71	4/51			
--- lbl evh		184.mg	P<.03	+ 55.7mg n.s.s.	0/71	3/51			
liv tum ev		no dre	P=1.	- 171.mg n.s.s.	0/71	0/51			
tba mix ev		3.79mg	P<.0005	2.02mg 7.04mg	18/71	49/51			
2925 R f sda eat 46w64 1073					0	71.9mg			Erturk;jnci,47,437-445;1971/1970a
mgl mix e		5.85mg	P<.0005	+ 2.49mg 12.8mg	2/29	25/26			
kid mix e		9.96mg	P<.0005	+ 5.42mg 19.5mg	0/29	22/26			
mgl adc e		19.5mg	P<.0005	+ 10.6mg 41.0mg	0/29	16/26			
liv mix e		30.1mg	P<.0005	+ 15.3mg 71.1mg	0/29	12/26			
kid uac e		33.9mg	P<.0005	+ 16.8mg 83.4mg	0/29	11/26			
liv cye e		43.9mg	P<.0005	+ 20.5mg 123.mg	0/29	9/26			
kid tua e		50.7mg	P<.0005	+ 22.8mg 157.mg	0/29	8/26			
mgl adf e		52.8mg	P<.009	+ 22.0mg 2.37gm	2/29	9/26			
tba mix e		noTD50	P<.0005	n.s.s. 9.13mg	2/29	26/26			
2926 R m sda eat 46w64 1073					0	57.5mg			
kid mix er		5.82mg	P<.0005	+ 2.92mg 11.7mg	0/28	24/26			
kid uac er		19.3mg	P<.0005	+ 10.2mg 42.6mg	0/28	14/26			
liv cye e		35.3mg	P<.0005	+ 17.1mg 92.9mg	0/29	10/29			
mgl adf eh		46.2mg	P<.0005	+ 20.8mg 151.mg	0/29	8/29			
kid tua er		47.6mg	P<.002	+ 20.4mg 177.mg	0/28	7/26			
k/p tcc er		69.9mg	P<.006	+ 26.4mg 690.mg	0/28	5/26			
tba mix e		noTD50	P<.0005	n.s.s. 6.71mg	0/29	29/29			
1-FORMYL-3-THIOSEMICARBAZIDE 2302-84-3									
2927 R f sda eat 46w64 1073					0	71.9mg			Erturk;jnci,47,437-445;1971/1970a
liv tum e		no dre	P=1.	151.mg n.s.s.	0/29	0/27			
tba mix e		140.mg	P<.2	- 38.6mg n.s.s.	2/29	5/27			
FORMYLHYDRAZINE 624-84-0									
2928 M f swa wat 83w83 397					0	250.mg			Toth;bjca,37,960-964;1978
lun mix e		36.0mg	P<.0005	+ 19.5mg 64.9mg	15/96	47/49			
liv mix e		6.86gm	P<.9	292.mg n.s.s.	3/33	2/19			
2929 M m swa wat 83w83 397					0	208.mg			
lun mix e		noTD50	P<.0005	+ n.s.s. 36.9mg	22/92	50/50			
liv mix e		1.15gm	P<.2	316.mg n.s.s.	3/69	5/43			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
FOSETYL Al (aliette) 39148-24-8									
2930 R f cd1 eat 24m24 2138					0	100.mg	400.mg	1.51gm	Quest;rtxp,14,3-11;1991/Environmental Protection Agency 1993/pers.comm.
k/p mix v		14.6gm *	P<.005	6.04gm 163.gm	1/80	1/80	1/80	7/80	
k/p tcc v		17.8gm *	P<.0005	7.28gm 65.1gm	0/80	0/80	0/80	6/80	
ubl mix v		17.6gm Z	P<.02	6.25gm n.s.s.	0/80	3/80	0/80	6/80	
ubl tcc v		23.9gm *	P<.02	8.23gm n.s.s.	0/80	1/78	0/79	4/80	
k/p tpp v		80.4gm *	P<.5	12.1gm n.s.s.	1/80	1/80	1/80	2/80	
ubl adq v		110.gm *	P<.2	17.9gm n.s.s.	0/80	0/80	0/80	1/80	
ubl tpp v		452.gm *	P<.9	16.9gm n.s.s.	0/80	2/78	0/79	1/80	
2931 R m cd1 eat 24m24 2138					0	80.0mg	320.mg	1.21gm	
ubl mix ev		3.66gm *	P<.0005 +	2.10gm 8.15gm	3/80	3/78	2/79	21/80	
ubl tcc ev		5.00gm *	P<.0005	2.69gm 12.7gm	2/80	2/78	1/79	16/80	
ubl tpp ev		17.2gm *	P<.04	5.94gm n.s.s.	1/80	1/78	1/79	5/80	
k/p tpp v		31.8gm *	P<.3	7.40gm n.s.s.	1/80	3/80	0/80	4/80	
k/p mix v		36.4gm *	P<.4	7.07gm n.s.s.	1/80	4/80	1/80	4/80	
k/p tcc v		no dre	P=1.	19.5gm n.s.s.	1/80	1/80	1/80	0/80	
amd mix ev		no dre	P=1.	5.89gm n.s.s.	6/80	5/78	10/79	6/80	
FUMONISIN B1 116355-83-0									
2932 M f b6c eat 24m24 TR496 :					0	.650mg	1.95mg	6.50mg	10.4mg
liv MXA		6.79mg Z	P<.0005 c	4.75mg 10.6mg	5/48	3/52	1/48	19/48	39/48 liv:hpa,hpc.
liv hpa		8.68mg Z	P<.0005 c	5.79mg 14.6mg	5/48	3/52	1/48	16/48	31/48
liv hpc		24.2mg *	P<.0005 c	14.1mg 46.7mg	0/48	0/52	0/48	10/48	9/48
TBA MXB		8.19mg Z	P<.0005	4.67mg 23.6mg	32/48	17/52	22/48	30/48	44/48
liv MXB		6.79mg Z	P<.0005	4.75mg 10.6mg	5/48	3/52	1/48	19/48	39/48 liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	99.6mg n.s.s.	2/48	0/52	0/48	1/48	0/48 lun:a/a,a/c.
2933 M m b6c eat 24m24 TR496 :					0	.600mg	1.80mg	9.60mg	18.0mg
hag ade #		182.mg *	P<.02 -	64.2mg n.s.s.	1/48	0/48	0/48	0/48	5/48 S
hag MXA		195.mg *	P<.04	64.1mg n.s.s.	1/48	1/48	0/48	0/48	5/48 hag:ade,car. S
TBA MXB		no dre	P=1.	32.4mg n.s.s.	37/48	19/48	34/48	24/48	27/48
liv MXB		no dre	P=1.	48.0mg n.s.s.	12/48	9/48	9/48	9/48	10/48 liv:hpa,hpb,hpc.
lun MXB		276.mg Z	P<.3	68.4mg n.s.s.	6/48	0/48	0/48	0/48	6/48 lun:a/a,a/c.
2934 R f f34 eat 24m24 TR496 :					0	.248mg	.745mg	2.49mg	4.97mg
TBA MXB		no dre	P=1. -	4.12mg n.s.s.	45/48	35/40	45/48	43/48	46/48
liv MXB		no dre	P=1.	35.0mg n.s.s.	0/48	0/40	1/48	0/48	0/48 liv:hpa,hpb,hpc.
2935 R m f34 eat 24m24 TR496 :					0	.199mg	.596mg	1.99mg	5.96mg
kid MXA		3.73mg Z	P<.0005 c	1.75mg 10.2mg	0/48	0/40	0/48	9/48	(15/48) kid:rua,ruc.
kid ruc		5.05mg Z	P<.0005 c	2.17mg 16.7mg	0/48	0/40	0/48	7/48	(10/48)
kid rua		19.2mg *	P<.002 c	8.29mg 87.9mg	0/48	0/40	0/48	2/48	5/48
TBA MXB		no dre	P=1.	5.75mg n.s.s.	48/48	35/40	44/48	43/48	43/48
liv MXB		no dre	P=1.	28.7mg n.s.s.	0/48	3/40	3/48	0/48	1/48 liv:hpa,hpb,hpc.
2936 R m bd9 eat 52w52 2018m					0	2.00mg			Gelderblom;carc,12,1247-1251;1991
liv hpc k		no dre	P=1.	.515mg n.s.s.	0/5	0/5			
2937 R m bd9 eat 86w86 2018n					0	2.00mg			
liv hpc k		1.02mg	P<.02 +	.285mg n.s.s.	0/5	3/5			
2938 R m bd9 eat 26m26 2018o					0	2.00mg			
liv hpc		1.34mg	P<.005 +	.534mg 8.70mg	0/5	7/10			
2939 R m bd9 eat 24m24 2652					0	40.0ug	.400mg	1.00mg	Gelderblom;txcy,161,39-51;2001
liv hpc		no dre	P=1.	.145mg n.s.s.	0/20	0/20	0/20	0/20	
tba mix		5.68mg *	P<.3	1.56mg n.s.s.	1/20	0/20	3/20	2/20	
2-FURALDEHYDE SEMICARBAZONE 2411-74-7									
2940 R f sda eat 46w66 1120					0	26.8mg			Erturk;canr,30,1409-1412;1970
mgl fba er		48.8mg	P<.2 -	15.1mg n.s.s.	2/29	6/30			
FURAN 110-00-9									
2941 M f b6c gav 24m24 TR402 :					0	5.64mg	10.6mg		
liv MXA		2.19mg /	P<.0005 c	1.52mg 3.36mg	7/50	34/50	50/50		liv:hpa,hpc.
liv hpa		2.26mg /	P<.0005	1.57mg 3.44mg	5/50	31/50	48/50		S
MXB MXB		2.26mg /	P<.0005	1.56mg 3.53mg	9/50	34/50	50/50		amd:pob; liv:hpa,hpc. C
liv MXA		6.85mg /	P<.0005	4.20mg 12.4mg	2/50	7/50	27/50		liv:car,hpc. S
for sqp		23.8mg *	P<.04	8.90mg n.s.s.	2/50	6/50	3/50		S
amd pob		36.0mg /	P<.03 c	12.6mg n.s.s.	2/50	1/50	6/50		
TBA MXB		2.81mg /	P<.0005	1.65mg 6.99mg	43/50	43/50	50/50		
liv MXB		2.19mg /	P<.0005	1.52mg 3.36mg	7/50	34/50	50/50		liv:hpa,hpc,nnd.
lun MXB		38.5mg *	P<.2	11.3mg n.s.s.	4/50	6/50	4/50		lun:a/a,a/c.
2942 M m b6c gav 24m24 TR402 :					0	5.65mg	10.6mg		
liv MXA		3.60mg *	P<.0005 c	2.17mg 8.50mg	26/50	44/50	50/50		liv:hpa,hpc.
MXB MXB		3.60mg *	P<.0005	2.17mg 8.50mg	26/50	44/50	50/50		amd:pob; liv:hpa,hpc. C
liv hpa		4.02mg *	P<.0005	2.40mg 9.61mg	20/50	33/50	42/50		S
liv hpc		5.13mg *	P<.0005	3.37mg 9.50mg	7/50	32/50	34/50		S
amd pob		20.1mg *	P<.002 c	10.3mg 72.7mg	1/50	6/50	10/50		
mul MXA		11.0mg \	P<.02	4.46mg n.s.s.	5/50	12/50	(1/50)		mul:mlh,mlm. S
lun a/a		18.2mg *	P<.02	7.89mg n.s.s.	9/50	7/50	16/50		S
for sqp		64.6mg *	P<.03	21.4mg n.s.s.	0/50	1/50	3/50		S
TBA MXB		5.43mg *	P<.008	2.65mg 106.mg	43/50	45/50	50/50		
liv MXB		3.60mg *	P<.0005	2.17mg 8.50mg	26/50	44/50	50/50		liv:hpa,hpc,nnd.
lun MXB		21.5mg *	P<.08	8.12mg n.s.s.	12/50	9/50	16/50		lun:a/a,a/c.
2943 R f f34 gav 24m24 TR402 :					0	1.40mg	2.81mg	5.64mg	
liv clc		.395mg Z	P<.0005 c	.273mg .598mg	0/50	49/50	(50/50	48/50)	
MXB MXB		.543mg Z	P<.0005	.342mg 1.04mg	8/50	49/50	(50/50	50/50)	liv:clc,hpa,hpc; mul:mnl. C
mul mnl		5.84mg *	P<.0005 c	3.31mg 18.0mg	8/50	9/50	17/50	21/50	
liv MXA		11.2mg *	P<.0005 c	6.00mg 28.1mg	0/50	2/50	4/50	8/50	liv:hpa,hpc.
liv hpa		11.8mg *	P<.0005	6.20mg 32.8mg	0/50	2/50	4/50	7/50	S
ubl tpp		50.7mg *	P<.02	15.4mg n.s.s.	0/50	0/50	0/50	3/50	S
TBA MXB		2.83mg *	P<.008	1.38mg 67.0mg	45/50	50/50	50/50	50/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB		11.2mg *	P<.0005	6.00mg 28.1mg	0/50	2/50	4/50	8/50	liv:hpa,hpc,nnd.
2944 R m f34 gav 24m24 TR402 :					0	1.41mg	2.82mg	5.64mg	
liv clc		.398mg Z	P<.0005 c	.268mg .620mg	0/50	43/50	(48/50	49/50)	
MXB MXB		.529mg Z	P<.0005	.323mg 1.06mg	8/50	44/50	(48/50	49/50)	liv:clc,hpa,hpc; mul:mnl. C
liv MXA		2.31mg *	P<.0005 c	1.65mg 3.45mg	1/50	5/50	22/50	35/50	liv:hpa,hpc.
liv hpa		3.10mg *	P<.0005	2.13mg 4.94mg	1/50	4/50	18/50	27/50	S
mul mnl		4.64mg *	P<.0005 c	2.71mg 12.3mg	8/50	11/50	17/50	25/50	
liv hpc		6.18mg Z	P<.0005	3.79mg 10.9mg	0/50	1/50	6/50	18/50	S
tes MXA		3.14mg *	P<.03	1.42mg n.s.s.	45/50	38/50	40/50	45/50	tes:ica,ica. S
amd pob		12.7mg *	P<.05	4.99mg n.s.s.	8/50	4/50	9/50	10/50	S
ski ker		16.4mg *	P<.05	7.84mg n.s.s.	0/50	3/50	5/50	2/50	S
sub fib		18.1mg *	P<.03	8.52mg n.s.s.	0/50	3/50	4/50	3/50	S
pre MXA		21.5mg *	P<.04	8.50mg n.s.s.	1/50	2/50	4/50	4/50	pre:ade,anb. S
TBA MXB		1.96mg *	P<.0005	1.11mg 6.22mg	31/50	45/50	48/50	49/50	
liv MXB		2.31mg *	P<.0005	1.65mg 3.45mg	1/50	5/50	22/50	35/50	liv:hpa,hpc,nnd.
FURFURAL 98-01-1									
2945 H f syg inh 52w81 1078					0	123.mg			Feron;txcy,11,127-144;1978
liv tum ev		no dre	P=1. -	92.4mg n.s.s.	0/6	0/6			
lun tum ev		no dre	P=1. -	216.mg n.s.s.	0/14	0/14			
2946 H m syg inh 52w81 1078					0	108.mg			
liv tum ev		no dre	P=1. -	81.3mg n.s.s.	0/6	0/6			
lun tum ev		no dre	P=1. -	203.mg n.s.s.	0/15	0/15			
2947 M f b6c gav 24m24 TR382 :					0	35.1mg	70.5mg	123.mg	
liv hpa		364.mg *	P<.01 p	177.mg 26.3gm	1/50	3/50	5/50	8/50	
liv MXA		377.mg *	P<.04	160.mg n.s.s.	5/50	3/50	7/50	12/50	liv:hpa,hpc. S
for sqp		920.mg *	P<.03 e	355.mg n.s.s.	1/50	0/50	1/50	6/50	
TBA MXB		no dre	P=1.	118.mg n.s.s.	33/50	26/50	24/50	31/50	
liv MXB		377.mg *	P<.04	160.mg n.s.s.	5/50	3/50	7/50	12/50	liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	585.mg n.s.s.	5/50	2/50	1/50	3/50	lun:a/a,a/c.
2948 M m b6c gav 24m24 TR382 :					0	35.1mg	70.7mg	123.mg	
liv MXA		135.mg *	P<.008 c	65.9mg 3.47gm	16/50	22/50	17/50	32/50	liv:hpa,hpc.
liv hpc		219.mg *	P<.007 c	107.mg 3.10gm	7/50	12/50	6/50	21/50	
sub MXA		169.mg Z	P<.02	75.6mg n.s.s.	5/50	7/50	13/50	(3/50)	sub:fbs,fib,sar. S
sub MXA		187.mg Z	P<.02	86.4mg n.s.s.	3/50	6/50	11/50	(2/50)	sub:fbs,sar. S
sub MXA		190.mg Z	P<.04	80.9mg n.s.s.	5/50	7/50	12/50	(3/50)	sub:fbs,fib. S
liv hpa		207.mg *	P<.03 c	91.8mg n.s.s.	9/50	13/50	11/50	19/50	
sub fbs		212.mg Z	P<.03	93.6mg n.s.s.	3/50	6/50	10/50	(2/50)	S
kcx MXA		1.40gm *	P<.3 e	425.mg n.s.s.	0/50	1/50	1/50	1/50	kcx:ade,car.
TBA MXB		165.mg *	P<.3	52.4mg n.s.s.	38/50	41/50	42/50	42/50	
liv MXB		135.mg *	P<.008	65.9mg 3.47gm	16/50	22/50	17/50	32/50	liv:hpa,hpc,nnd.
lun MXB		662.mg *	P<.4	166.mg n.s.s.	10/50	8/50	5/50	13/50	lun:a/a,a/c.
2949 R f f34 gav 24m24 TR382 :					0	21.1mg	42.4mg		
TBA MXB		194.mg *	P<.8 -	20.4mg n.s.s.	43/50	44/50	33/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
2950 R m f34 gav 24m24 TR382 :					0	21.1mg	42.3mg		
liv clc		683.mg *	P<.09 p	162.mg n.s.s.	0/50	0/50	2/50		
TBA MXB		150.mg *	P<.7	20.9mg n.s.s.	43/50	39/50	40/50		
liv MXB		no dre	P=1.	345.mg n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
FURFURYL ALCOHOL 98-00-0									
2951 M f b6c inh 24m24 TR482 :					0	2.52mg	10.1mg	40.3mg	
TBA MXB		no dre	P=1. -	48.8mg n.s.s.	36/50	37/50	39/50	36/50	
liv MXB		no dre	P=1.	113.mg n.s.s.	14/50	19/50	12/50	12/50	liv:hpa,hpb,hpc.
lun MXB		41.8mg Z	P<.2	12.5mg n.s.s.	6/50	8/50	11/50	(1/50)	lun:a/a,a/c.
2952 M m b6c inh 24m24 TR482 :					0	2.10mg	8.41mg	33.6mg	
kid MXA		263.mg *	P<.005 p	91.0mg 2.22gm	0/50	0/50	0/50	4/50	kid:rua,ruc.
kid ruc		538.mg *	P<.04	132.mg n.s.s.	0/50	0/50	0/50	2/50	S
kid rua		538.mg *	P<.04	132.mg n.s.s.	0/50	0/50	0/50	2/50	S
TBA MXB		no dre	P=1.	39.5mg n.s.s.	42/50	44/50	41/50	39/50	
liv MXB		no dre	P=1.	70.7mg n.s.s.	28/50	27/50	23/50	22/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	51.0mg n.s.s.	20/50	23/50	17/50	20/50	lun:a/a,a/c.
2953 M m b6c inh 24m24 TR482 with step					0	2.10mg	8.41mg	33.6mg	
kid MXA		291.mg *	P<.002 p	110.mg 1.30gm	0/50	0/50	0/50	5/50	kid:rua,ruc.
kid rua		492.mg *	P<.01	149.mg 48.0gm	0/50	0/50	0/50	3/50	S
kid ruc		744.mg *	P<.04	183.mg n.s.s.	0/50	0/50	0/50	2/50	S
2954 R f f34 inh 24m24 TR482 :					0	.600mg	2.40mg	9.60mg	
--- mnl		10.1mg *	P<.01	4.44mg 662.mg	21/50	19/50	18/50	29/50	S
cli MXA		27.8mg *	P<.05	9.68mg n.s.s.	7/50	2/50	4/50	9/50	cli:ade,anb,car,cnb. S
cli MXA		35.7mg *	P<.05	12.0mg n.s.s.	4/50	2/50	2/50	7/50	cli:ade,anb. S
kid rua		113.mg *	P<.03	27.7mg n.s.s.	0/50	0/50	0/50	2/50	S
kid MXA		110.mg *	P<.2	24.4mg n.s.s.	0/50	1/50	0/50	2/50	kid:rua,ruc.
nre ade		161.mg *	P<.2 e	26.1mg n.s.s.	0/50	0/50	0/50	1/50	
kid ruc		no dre	P=1.	58.8mg n.s.s.	0/50	1/50	0/50	0/50	
nlw ade		no dre	P=1. e	63.3mg n.s.s.	0/50	0/50	1/50	0/50	
TBA MXB		7.57mg *	P<.1	2.70mg n.s.s.	49/50	50/50	49/50	50/50	
liv MXB		no dre	P=1.	50.2mg n.s.s.	1/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
2955 R f f34 inh 24m24 TR482 with step					0	.600mg	2.40mg	9.60mg	
kid rua		108.mg *	P<.07	37.3mg n.s.s.	0/50	0/50	2/50	2/50	
kid MXA		161.mg *	P<.3 e	35.4mg n.s.s.	0/50	1/50	2/50	2/50	kid:rua,ruc.
kid ruc		no dre	P=1.	107.mg n.s.s.	0/50	1/50	0/50	0/50	
2956 R m f34 inh 24m24 TR482 :					0	.420mg	1.68mg	6.73mg	
MXA MXA as		9.60mg *	P<.005 p	2.19mg 199.mg	0/50	1/50	1/50	4/50	nlw:ade; nre:ade,car,sqc.
nre sqc as		46.4mg *	P<.007	13.8mg 846.mg	0/50	0/50	0/50	3/50	S
zym MXA as		17.4mg *	P<.05	2.58mg n.s.s.	1/50	0/50	1/50	3/50	zym:ade,car. S
TBA MXB as		1.46mg *	P<.003	.655mg 9.20mg	50/50	49/50	49/50	47/50	
liv MXB as		no dre	P=1.	25.8mg n.s.s.	1/50	1/50	0/50	0/50	liv:hpa,hpb,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
FUROSEMIDE 54-31-9									
2957 M f b6c eat 24m24 TR356 :				0	89.3mg	180.mg			
mgl MXA	732.mg	* P<.004	p 310.mg 4.35gm	0/50	2/50	5/50		mgl:acc,mtm.	
mgl mtm	845.mg	* P<.004	337.mg 5.57gm	0/50	1/50	5/50			S
thy fca	703.mg	* P<.02	292.mg n.s.s.	0/50	4/50	3/50			S
TBA MXB	136.mg	* P<.02	62.7mg n.s.s.	34/50	35/50	39/50			
liv MXB	3.97gm	* P<.8	380.mg n.s.s.	6/50	4/50	5/50		liv:hpa,hpc,nnd.	
lun MXB	2.71gm	* P<.6	416.mg n.s.s.	3/50	2/50	3/50		lun:a/a,a/c.	
2958 M m b6c eat 24m24 TR356 :				0	82.4mg	166.mg			
TBA MXB	393.mg	* P<.5	- 89.7mg n.s.s.	33/50	34/50	34/50			
liv MXB	405.mg	* P<.2	133.mg n.s.s.	15/50	16/50	20/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	471.mg n.s.s.	5/50	3/50	4/50		lun:a/a,a/c.	
2959 R f f34 eat 24m24 TR356 :				0	17.2mg	34.5mg			
thy MXA #	47.1mg	* P<.003	- 22.2mg 296.mg	4/50	7/50	11/50		thy:cca,ccr.	S
thy cca	51.4mg	* P<.004	23.6mg 375.mg	4/50	6/50	11/50			S
TBA MXB	20.9mg	/ P<.04	8.91mg n.s.s.	48/50	45/50	46/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.	
2960 R m f34 eat 24m24 TR356 :				0	13.7mg	27.7mg			
pta adn	27.0mg	\ P<.05	10.0mg n.s.s.	4/50	11/50	(8/50)			S
kid MXA	370.mg	* P<.7	e 48.3mg n.s.s.	1/50	4/50	2/50		kid:tla,uac.	
brm mng	no dre	P=1.	e n.s.s. n.s.s.	0/50	3/50	0/50			
TBA MXB	no dre	P=1.	15.6mg n.s.s.	47/50	44/50	46/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.	
2961 R m f34 eat 24m24 TR356 with step				0	13.7mg	27.7mg			
kid MXA	277.mg	* P<.3	e 76.9mg n.s.s.	3/50	5/50	6/50		kid:tla,uac.	
FUSARENON-X 23255-69-8									
2962 R m don eat 24m24 1748m				0	.100mg	.210mg		Saito;jjem,50,293-302;1980/Ohtsubo pers.comm.	
liv hnd e	no dre	P=1.	.319mg n.s.s.	1/19	0/22	0/25			
tba mix e	no dre	P=1.	.684mg n.s.s.	4/19	3/22	2/25			
2963 R m don eat 18m24 1748n				0	.100mg	.105mg			
liv hnd ae	no dre	P=1.	.218mg n.s.s.	0/23	0/24	0/18			
tba mix ae	no dre	P=1.	.464mg n.s.s.	4/23	2/24	1/18			
GALLIC ACID 149-91-7									
2964 R m f3d eat 52w52 2098				0	800.mg			Shibata;carc,14,275-280;1993	
for tum er	no dre	P=1.	412.mg n.s.s.	0/10	0/10				
2965 R m f3d eat 60w60 2134				0	800.mg			Ito;anti,183-194;1990/pers.comm.	
for sqc er	no dre	P=1.	- 1.10gm n.s.s.	0/19	0/20				
for sqp er	no dre	P=1.	- 1.10gm n.s.s.	0/19	0/20				
GEMCADIOL (2,2,9,9-tetramethyl-1,10-decanediol) 35449-36-6									
2966 R f cdr eat 52w52 1768				0	30.0mg	150.mg	300.mg	Fitzgerald;faat,6,520-531;1986	
liv hpa k	no dre	P=1.	186.mg n.s.s.	0/10	1/10	0/10	0/10		
2967 R m cdr eat 52w52 1768				0	30.0mg	150.mg	300.mg		
liv hpa k	no dre	P=1.	185.mg n.s.s.	0/10	2/10	0/10	0/10		
GEMFIBROZIL 25812-30-0									
2968 M f cd1 eat 78w78 1518n				0	30.0mg	300.mg		Fitzgerald;jnci,67,1105-1115;1981/pers.comm.	
liv hpa ej	6.60gm	* P<.6	- 922.mg n.s.s.	4/72	1/72	4/72			
lun mix ej	11.8gm	* P<.9	- 606.mg n.s.s.	9/72	10/72	10/72			
tba mix ej	1.69gm	* P<.6	- 309.mg n.s.s.	21/72	23/72	25/72			
2969 M m cd1 eat 78w78 1518n				0	30.0mg	300.mg			
liv mix ej	1.66gm	* P<.5	- 350.mg n.s.s.	16/72	17/72	20/72			
lun mix ej	no dre	P=1.	- 893.mg n.s.s.	23/72	17/72	13/72			
tba mix ej	no dre	P=1.	- 237.mg n.s.s.	47/72	46/72	45/72			
2970 R f cdr eat 24m24 1518m				0	30.0mg	300.mg			
liv hpc ej	504.mg	\ P<.1	- 124.mg n.s.s.	0/50	2/50	(0/50)			
tba mix ej	no dre	P=1.	- 224.mg n.s.s.	47/50	50/50	44/50			
2971 R m cdr eat 24m24 1518m				0	30.0mg	300.mg			
adr phe ej	85.9mg	\ P<.006	39.5mg 974.mg	3/50	13/50	(9/50)			
pan mix ej	161.mg	\ P<.004	65.6mg 1.00gm	0/50	6/50	(2/50)			
tes ict ej	516.mg	* P<.0005	268.mg 1.61gm	1/50	8/50	17/50			
liv hpc ej	247.mg	\ P<.02	+ 85.1mg n.s.s.	0/50	4/50	(5/50)			
tba ben ej	196.mg	* P<.02	80.4mg n.s.s.	35/50	39/50	45/50			
tba mix ej	202.mg	* P<.08	65.4mg n.s.s.	41/50	44/50	47/50			
GENTIAN VIOLET 548-62-9									
2972 M f b6c eat 52w52 1680m				0	13.0mg	39.0mg	78.0mg	Littlefield;faat,5,902-912;1985	
liv tum	no dre	P=1.	- 10.7mg n.s.s.	0/48	0/24	0/24	0/24		
2973 M f b6c eat 78w78 1680n				0	13.0mg	39.0mg	78.0mg		
liv hpa e	115.mg	* P<.003	+ 51.5mg 734.mg	3/47	0/22	3/24	8/24		
liv hpc e	343.mg	* P<.07	+ 103.mg n.s.s.	1/47	0/22	1/24	3/24		
2974 M f b6c eat 25m25 1680o				0	13.0mg	39.0mg	78.0mg		
liv hpc e	57.9mg	Z P<.0005	+ 44.7mg 77.0mg	7/185	5/93	30/93	73/95		
liv hpa e	75.5mg	Z P<.0005	+ 49.8mg 128.mg	8/185	8/93	36/93	(20/95)		
hag ade e	305.mg	* P<.0005	+ 166.mg 1.13gm	8/186	11/93	18/89	15/94		
ute rta e	413.mg	* P<.0005	+ 244.mg 786.mg	0/188	2/95	6/90	12/93		
vag rta e	668.mg	* P<.0005	+ 335.mg 2.14gm	1/182	1/90	4/88	8/87		
ubl rta e	834.mg	* P<.002	+ 407.mg 3.57gm	0/188	2/92	3/89	5/91		
ova rta e	912.mg	* P<.0005	+ 430.mg 3.27gm	0/178	1/90	3/89	5/89		
2975 M m b6c eat 52w52 1680m				0	12.0mg	36.0mg	72.0mg		
liv hpa	no dre	P=1.	- 79.4mg n.s.s.	0/48	2/24	0/24	0/24		
2976 M m b6c eat 78w78 1680n				0	12.0mg	36.0mg	72.0mg		
liv hpa e	636.mg	* P<.5	- 106.mg n.s.s.	3/48	0/24	2/24	2/22		
liv hpc e	no dre	P=1.	- 119.mg n.s.s.	5/48	1/24	2/24	2/22		
2977 M m b6c eat 25m25 1680o				0	12.0mg	36.0mg	72.0mg		
liv hpa e	139.mg	* P<.0005	+ 90.3mg 260.mg	17/183	14/92	20/93	37/93		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc e	222.mg *	P<.0005 +	123.mg 742.mg	27/183	15/92	17/93	33/93	
hag ade e	615.mg *	P<.03 +	255.mg n.s.s.	7/187	7/92	10/94	9/89	
GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE) (CAS# 105-87-3 and 150-84-5) mixture								
2978 M f b6c gav 23m24 TR252 :				0	354.mg	714.mg		
TBA MXB as	353.mg *	P<.02 -	146.mg n.s.s.	20/50	20/50	6/50		
liv MXB as	2.73gm *	P<.4	520.mg n.s.s.	5/50	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB as	5.30gm *	P<.4	779.mg n.s.s.	1/50	1/50	1/50		lun:a/a,a/c.
2979 M m b6c gav 23m24 TR252 :				0	354.mg	714.mg		
TBA MXB as	485.mg /	P<.04 -	197.mg n.s.s.	33/50	33/50	21/50		
liv MXB as	647.mg /	P<.005	296.mg 7.59gm	13/50	17/50	15/50		liv:hpa,hpc,nnd.
lun MXB as	5.26gm *	P<.6	766.mg n.s.s.	6/50	6/50	3/50		lun:a/a,a/c.
2980 R f f34 gav 24m24 TR252 :				0	707.mg	1.41gm		
TBA MXB	no dre	P=1. -	1.61gm n.s.s.	38/50	31/50	28/50		
liv MXB	45.1gm *	P<.3	7.34gm n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
2981 R m f34 gav 24m24 TR252 :				0	707.mg	1.41gm		
tes ict s	772.mg *	P<.03	353.mg n.s.s.	43/50	44/50	44/50		S
ski MXA s	5.05gm *	P<.05	2.06gm n.s.s.	0/50	5/50	1/50		ski:sqc,sqp. S
ski sqp s	6.12gm *	P<.06 e	2.32gm n.s.s.	0/50	4/50	1/50		
kid tla s	20.2gm *	P<.5 e	4.71gm n.s.s.	0/50	2/50	0/50		
TBA MXB s	9.26gm *	P<.8	867.mg n.s.s.	36/50	33/50	23/50		
liv MXB s	15.4gm *	P<.2	3.79gm n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
GERMANATE, SODIUM 12025-19-3								
2982 M b cd1 wat 24m24 1512				0	.877mg			Kanisawa;canr,27,1192-1195;1967
lun mix e	no dre	P=1. -	7.48mg n.s.s.	26/170	14/131			
liv mix e	no dre	P=1. -	10.5mg n.s.s.	7/170	4/131			
tba mix e	no dre	P=1. -	7.84mg n.s.s.	55/170	25/131			
tba ben e	no dre	P=1. -	8.97mg n.s.s.	29/170	13/131			
tba mal e	no dre	P=1. -	10.0mg n.s.s.	15/170	7/131			
2983 R b leb wat 35m35 1036				0	.265mg			Kanisawa;canr,29,892-895;1969
liv tum e	no dre	P=1. -	6.82mg n.s.s.	1/82	1/98			
tba tum e	no dre	P=1. -	2.70mg n.s.s.	31/82	25/98			
tba mal e	no dre	P=1. -	8.11mg n.s.s.	9/82	2/98			
GIBBERELLIC ACID 77-06-5								
2984 M f b6a orl 76w76 1281				0	180.mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1. -	318.mg n.s.s.	0/17	0/16			
lun ade evx	no dre	P=1. -	318.mg n.s.s.	1/17	0/16			
tba mix evx	no dre	P=1. -	208.mg n.s.s.	2/17	1/16			
2985 M m b6a orl 76w76 1281				0	168.mg			
liv hpt evx	316.mg	P<.2 -	89.6mg n.s.s.	1/18	4/18			
lun mix evx	460.mg	P<.4 -	96.2mg n.s.s.	2/18	4/18			
tba mix evx	151.mg	P<.07 -	52.6mg n.s.s.	3/18	8/18			
2986 M f b6c orl 76w76 1281				0	180.mg			
liv hpt evx	no dre	P=1. -	357.mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1. -	357.mg n.s.s.	0/16	0/18			
tba mix evx	1.15gm	P<.3 -	188.mg n.s.s.	0/16	1/18			
2987 M m b6c orl 76w76 1281				0	168.mg			
liv hpt evx	460.mg	P<.09 -	113.mg n.s.s.	0/16	2/16			
lun ade evx	952.mg	P<.3 -	155.mg n.s.s.	0/16	1/16			
tba mix evx	214.mg	P<.02 -	73.3mg n.s.s.	0/16	4/16			
Glu-P-1 (2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole) 67730-11-4								
2988 M f cdf eat 67w67 1616				0	65.0mg			Ohgaki;carc,5,815-819;1984
liv mix e	5.08mg	P<.0005 +	2.33mg 9.78mg	0/40	37/38			
blv mix e	10.9mg	P<.0005 +	6.63mg 18.9mg	0/40	31/38			
blv hms e	13.8mg	P<.0005	8.44mg 24.3mg	0/40	28/38			
liv hpc e	18.5mg	P<.0005	11.1mg 33.6mg	0/40	24/38			
liv hpa e	44.1mg	P<.0005	23.1mg 99.8mg	0/40	13/38			
lun ade e	166.mg	P<.02	57.4mg n.s.s.	0/40	4/38			
lun mix e	308.mg	P<.4	65.6mg n.s.s.	2/40	4/38			
2989 M m cdf eat 57w57 1616				0	60.0mg			
blv mix e	5.77mg	P<.0005 +	3.31mg 10.4mg	0/39	30/34			
blv hms e	7.81mg	P<.0005	4.63mg 14.0mg	0/39	27/34			
blv hae e	98.7mg	P<.02	34.1mg n.s.s.	0/39	4/34			
liv hpa e	98.7mg	P<.02 +	34.1mg n.s.s.	0/39	4/34			
lun ade e	1.00gm	P<.9	50.9mg n.s.s.	3/39	3/34			
lun mix e	no dre	P=1.	50.5mg n.s.s.	11/39	6/34			
2990 R f f3d eat 67w67 1619m				0	25.0mg			Takayama;gann,75,207-213;1984/Masuda;expl,26,123-129;1984
liv mix e	8.39mg	P<.0005 +	5.07mg 15.1mg	0/50	24/42			
zym sqc e	12.7mg	P<.0005 +	7.24mg 25.1mg	0/50	18/42			
smi mix e	26.1mg	P<.0005 +	12.7mg 67.7mg	0/50	10/42			
col mix e	39.0mg	P<.002 +	16.8mg 142.mg	0/50	7/42			
cli tum e	56.1mg	P<.005 +	21.3mg 463.mg	0/50	5/42			
smi adc e	56.1mg	P<.005 +	21.3mg 463.mg	0/50	5/42			
col ade e	71.0mg	P<.02 +	24.5mg n.s.s.	0/50	4/42			
smi mcc e	71.0mg	P<.02 +	24.5mg n.s.s.	0/50	4/42			
col adc e	95.9mg	P<.03 +	29.0mg n.s.s.	0/50	3/42			
bra ast e	95.9mg	P<.03 +	29.0mg n.s.s.	0/50	3/42			
smi ade e	146.mg	P<.08 +	35.8mg n.s.s.	0/50	2/42			
2991 R m f3d eat 67w67 1619m				0	20.0mg			
liv mix e	3.25mg	P<.0005 +	1.99mg 5.58mg	2/50	35/42			
smi mix e	5.89mg	P<.0005 +	3.61mg 10.4mg	0/50	26/42			
smi adc e	6.71mg	P<.0005 +	4.06mg 12.1mg	0/50	24/42			
smi ade e	8.21mg	P<.0005 +	4.84mg 15.4mg	0/50	21/42			
col mix e	9.45mg	P<.0005 +	5.45mg 18.3mg	0/50	19/42			
zym sqc e	10.2mg	P<.0005 +	5.80mg 20.1mg	0/50	18/42			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
col ade e		15.4mg	P<.0005 +	8.06mg 34.7mg	0/50	13/42			
col adc e		16.9mg	P<.0005 +	8.68mg 39.6mg	0/50	12/42			
smi mcc e		236.mg	P<.3 +	38.4mg n.s.s.	0/50	1/42			
Glu-P-2 (2-aminodipyrido[1,2-a:3',2'-d]imidazole) 67730-10-3									
2992 M f cdf eat 82w82 1616					0	65.0mg			Ohgaki;carc,5,815-819;1984
liv mix		12.0mg	P<.0005 +	7.10mg 20.7mg	0/40	36/40			
liv hpc		20.0mg	P<.0005	12.3mg 34.4mg	0/40	30/40			
blv mix		39.9mg	P<.0005 +	23.3mg 76.3mg	0/40	20/40			
blv hms		43.0mg	P<.0005	24.8mg 83.5mg	0/40	19/40			
liv hpa		170.mg	P<.004	69.4mg 1.03gm	0/40	6/40			
lun ade		1.09gm	P<.3	178.mg n.s.s.	0/40	1/40			
lun mix		no dre	P=1.	224.mg n.s.s.	2/40	1/40			
2993 M m cdf eat 84w84 1616					0	60.0mg			
blv mix		23.9mg	P<.0005 +	14.6mg 41.9mg	0/40	27/40			
blv hms		27.3mg	P<.0005	16.6mg 48.9mg	0/40	25/40			
liv mix		93.2mg	P<.0005 +	45.3mg 248.mg	0/40	10/40			
liv hpa		201.mg	P<.008	76.2mg 3.49gm	0/40	5/40			
liv hpc		255.mg	P<.02	87.9mg n.s.s.	0/40	4/40			
lun ade		483.mg	P<.5	92.2mg n.s.s.	3/40	5/40			
lun mix		no dre	P=1.	105.mg n.s.s.	11/40	8/40			
2994 R f f3d eat 24m24 1619					0	25.0mg			Takayama;gann,75,207-213;1984
cli tum		56.4mg	P<.0005 +	28.2mg 138.mg	0/50	11/42			
col mix		81.1mg	P<.0005 +	36.6mg 252.mg	0/50	8/42			
smi mix		81.1mg	P<.0005 +	36.6mg 252.mg	0/50	8/42			
zym sqc		94.0mg	P<.002 +	40.5mg 341.mg	0/50	7/42			
col ade		111.mg	P<.003 +	45.3mg 525.mg	0/50	6/42			
smi adc		135.mg	P<.005 +	51.3mg 1.12gm	0/50	5/42			
smi ade		171.mg	P<.02 +	59.1mg n.s.s.	0/50	4/42			
col adc		351.mg	P<.08 +	86.3mg n.s.s.	0/50	2/42			
liv mix		351.mg	P<.08 +	86.3mg n.s.s.	0/50	2/42			
smi mcc		711.mg	P<.3 +	116.mg n.s.s.	0/50	1/42			
2995 R m f3d eat 24m24 1619					0	20.0mg			
smi mix		33.8mg	P<.0005 +	18.1mg 73.9mg	0/50	14/42			
smi adc		45.1mg	P<.0005 +	22.6mg 111.mg	0/50	11/42			
liv mix		52.1mg	P<.003 +	24.0mg 290.mg	2/50	11/42			
col mix		88.9mg	P<.003 +	36.2mg 420.mg	0/50	6/42			
smi ade		137.mg	P<.02 +	47.3mg n.s.s.	0/50	4/42			
col adc		185.mg	P<.03 +	56.0mg n.s.s.	0/50	3/42			
col ade		185.mg	P<.03 +	56.0mg n.s.s.	0/50	3/42			
smi mcc		281.mg	P<.08 +	69.1mg n.s.s.	0/50	2/42			
bra ast		281.mg	P<.08 +	69.1mg n.s.s.	0/50	2/42			
zym sqc		569.mg	P<.3 +	92.6mg n.s.s.	0/50	1/42			
L-GLUTAMIC ACID 56-86-0									
2996 M m cbl eat 24m24 1631					0	1.20gm	4.80gm		Ebert;txlt,3,65-70;1979
liv tum e		no dre	P=1. -	4.06gm n.s.s.	0/55	0/20	0/29		
lun tum e		no dre	P=1. -	4.06gm n.s.s.	0/55	0/20	0/29		
tba tum e		no dre	P=1. -	4.06gm n.s.s.	0/55	0/20	0/29		
N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID (N2-[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE) 69644-85-5									
2997 M f swa gav 12m31 1832					0	78.2mg			Toth;acnr,6,917-920;1986
liv mix e		41.4gm	P<1.	666.mg n.s.s.	1/46	1/42			
lun mix e		no dre	P=1.	264.mg n.s.s.	12/47	12/47			
sub mix e		no dre	P=1.	585.mg n.s.s.	3/43	1/32			
2998 M m swa gav 12m31 1832					0	78.2mg			
sub fbs e		277.mg	P<.0005 +	146.mg 632.mg	0/43	13/48			
lun mix e		250.mg	P<.05	101.mg n.s.s.	15/49	23/45			
liv mix e		no dre	P=1.	443.mg n.s.s.	7/40	3/32			
beta-N-[gamma-L(+)-GLUTAMYL]-4-HYDROXYMETHYLPHENYLHYDRAZINE (agaritine) 2757-90-6									
2999 M f swa wat 28m28 1584					0	125.mg			Toth;acnr,1,255-258;1981/1982a
liv ang e		2.72gm	P<.4	500.mg n.s.s.	1/56	2/34			
lun ade e		3.29gm	P<.8	362.mg n.s.s.	20/94	12/50			
lun mix e		no dre	P=1. -	458.mg n.s.s.	29/94	13/50			
3000 M m swa wat 28m28 1584					0	104.mg			
liv ang aes		2.04gm	P<.4	311.mg n.s.s.	3/83	2/25			
liv hpt aes		3.31gm	P<.5 -	396.mg n.s.s.	1/83	1/25			
lun ade aes		no dre	P=1.	643.mg n.s.s.	13/100	4/47			
lun mix aes		no dre	P=1. -	567.mg n.s.s.	19/100	6/47			
GLUTARALDEHYDE 111-30-8									
3001 M f b6c inh 24m24 TR490 :					0	79.6ug	.159mg	.318mg	
TBA MXB		3.08mg *	P<.9 -	.203mg n.s.s.	41/50	44/50	41/50	40/50	
liv MXB		no dre	P=1.	.977mg n.s.s.	14/50	17/50	11/50	7/50	liv:hpa,hpb,hpc.
lun MXB		17.4mg *	P<1.	.674mg n.s.s.	3/50	8/50	7/50	4/50	lun:a/a,a/c.
3002 M f b6c inh 52w52 2584m					0	.129mg			Zissu;txlt,95,131-139;1998
lun adc		.540mg	P<.1 -	.133mg n.s.s.	0/50	2/50			
liv tum		no dre	P=1. -	.332mg n.s.s.	0/50	0/50			
3003 M f b6c inh 78w78 2584n					0	.129mg			
lun adc		.347mg	P<.02 -	.120mg n.s.s.	0/30	4/30			
liv tum		no dre	P=1. -	.448mg n.s.s.	0/30	0/30			
3004 M m b6c inh 24m24 TR490 :					0	66.5ug	.133mg	.266mg	
TBA MXB		no dre	P=1. -	.160mg n.s.s.	44/50	42/50	39/50	(33/50)	
liv MXB		no dre	P=1.	.242mg n.s.s.	32/50	24/50	26/50	(21/50)	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	.677mg n.s.s.	18/50	15/50	15/50	14/50	lun:a/a,a/c.
3005 M m b6c inh 52w52 2584m					0	.107mg			Zissu;txlt,95,131-139;1998
lun adc		no dre	P=1. -	.136mg n.s.s.	2/50	2/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc		no dre	P=1.	- .208mg n.s.s.	4/50	1/50			
3006 M m b6c inh 78w78 2584n					0	.107mg			
lun adc		1.14mg	P<.7	- .140mg n.s.s.	2/30	3/30			
liv hpc		no dre	P=1.	- .169mg n.s.s.	4/30	3/30			
3007 R f f34 inh 24m24 TR490 :					0	76.3ug	.153mg	.229mg	
TBA MXB		.125mg	Z P<.2	- 46.8ug n.s.s.	49/50	46/50	49/50	(36/50)	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
3008 R m f34 inh 24m24 TR490 :					0	53.6ug	.107mg	.161mg	
TBA MXB		.239mg	* P<.5	- 49.3ug n.s.s.	43/50	49/50	44/50	35/50	
liv MXB		no dre	P=1.	.623mg n.s.s.	0/50	1/50	0/50	0/50	liv:hpa,hpb,hpc.
GLYCERIN, NATURAL 56-81-5									
3009 R b lev eat 24m24 2389					0	2.25gm	4.50gm		Hine;aihm,7,282-291;1953
tba mix		38.3gm	* P<.6	- 6.59gm n.s.s.	5/26	3/22	6/22		
GLYCERIN, SYNTHETIC 56-81-5									
3010 R b lev eat 24m24 2389					0	2.25gm	4.50gm		Hine;aihm,7,282-291;1953
tba mix		12.3gm	* P<.2	- 4.24gm n.s.s.	5/26	4/21	9/22		
GLYCEROL alpha-MONOCHLOROHYDRIN 96-24-2									
3011 R f cdr gav 17m24 1112					0	6.79mg	13.6mg		Weisburger;jnci,67,75-88;1981
pty ade ev		no dre	P=1.	- 24.2mg n.s.s.	0/20	0/26	0/26		
3012 R m cdr gav 17m24 1112					0	6.79mg	13.6mg		
pty ade ev		116.mg	* P<.06	35.1mg n.s.s.	0/20	0/26	3/26		
GLYCIDALDEHYDE 765-34-4									
3013 R f esd gav 70w70 55					0	13.5mg			Van Duuren;jnci,37,825-838;1966
sto tum		no dre	P=1.	- 6.29mg n.s.s.	0/5	0/5			
GLYCIDOL 556-52-5									
3014 H f syg gav 14m24 2042					0	17.9mg			Lijinsky;txih,8,267-271;1992
spl hes eh		56.1mg	P<.05	+ 19.3mg n.s.s.	0/12	4/20			
liv hcs e		244.mg	P<.4	39.8mg n.s.s.	0/12	1/20			
liv cho e		244.mg	P<.4	39.8mg n.s.s.	0/12	1/20			
lun adc e		no dre	P=1.	75.3mg n.s.s.	1/12	0/20			
tba tum e		71.8mg	P<.8	8.94mg n.s.s.	7/12	13/20			
3015 H m syg gav 14m24 2042					0	15.8mg			
for mal e		64.1mg	P<.08	19.4mg n.s.s.	0/12	3/19			
spl hes eh		99.1mg	P<.2	+ 24.3mg n.s.s.	0/12	2/19			
liv hes e		204.mg	P<.4	33.2mg n.s.s.	0/12	1/19			
tba tum e		no dre	P=1.	14.0mg n.s.s.	7/12	9/19			
3016 M f b6c gav 24m24 TR374 :					0	17.7mg	35.4mg		
MXB MXB		15.3mg	* P<.0005	10.2mg 26.6mg	5/50	21/50	37/50	hag:acn,adn; mgl:acn,adn,fba; ski:sqc,sqp; sub:fbs,srn; ute:acn,can.	C
hag MXA		32.9mg	* P<.0005 c	18.2mg 103.mg	4/50	11/50	17/50	hag:acn,adn.	
hag adn		36.0mg	* P<.0005	19.4mg 128.mg	4/50	10/50	16/50		S
mgl acn		56.6mg	* P<.0005	31.5mg 138.mg	1/50	5/50	15/50		S
mgl MXA		56.9mg	* P<.0005 c	31.0mg 170.mg	2/50	6/50	15/50	mgl:acn,adn,fba.	
sub MXA		86.4mg	* P<.0005 c	43.1mg 229.mg	0/50	3/50	9/50	sub:fbs,srn.	
sub srn		145.mg	* P<.003	60.9mg 702.mg	0/50	1/50	6/50		S
ute MXA		127.mg	* P<.02 c	51.3mg n.s.s.	0/50	3/50	3/50	ute:acn,can.	
MXA MXA		137.mg	* P<.04	52.6mg n.s.s.	1/50	3/50	5/50	liv:hem,hes; ova:hem; pec:hes; sub:hes; ute:hem,hes.	S
ute acn		144.mg	* P<.04	54.8mg n.s.s.	0/50	3/50	2/50		S
sub fbs		217.mg	* P<.03	78.1mg n.s.s.	0/50	2/50	3/50		S
ski MXA		417.mg	* P<.07 c	102.mg n.s.s.	0/50	0/50	2/50	ski:sqc,sqp.	
TBA MXB		27.5mg	* P<.08	10.9mg n.s.s.	45/50	46/50	47/50		
liv MXB		76.0mg	* P<.07	29.1mg n.s.s.	9/50	7/50	14/50	liv:hpa,hpc,nnd.	
lun MXB		96.7mg	* P<.2	32.3mg n.s.s.	6/50	10/50	8/50	lun:a/a,a/c.	
3017 M m b6c gav 24m24 TR374 :					0	17.7mg	35.4mg		
hag MXA		41.7mg	* P<.003 c	21.5mg 270.mg	8/50	12/50	22/50	hag:acn,adn.	
for sqp		97.5mg	* P<.0005	48.3mg 274.mg	0/50	2/50	9/50		S
for MXA		100.mg	* P<.003 c	47.7mg 533.mg	1/50	2/50	10/50	for:sqc,sqp.	
MXB MXB		29.2mg	* P<.05	12.3mg n.s.s.	35/50	41/50	46/50	for:sqc,sqp; hag:acn,adn; liv:hpa,hpc; lun:a/a,a/c; ski:sqp.	C
liv MXA		36.6mg	* P<.04 c	15.8mg n.s.s.	24/50	31/50	35/50	liv:hpa,hpc.	
MXA MXA		38.8mg	\ P<.03	15.4mg n.s.s.	5/50	12/50	(7/50)	mul:mlh,mlm,mlp; thm:mlm.	S
liv hpa		41.2mg	* P<.03	18.4mg n.s.s.	18/50	16/50	30/50		S
hag adn		60.4mg	* P<.03	27.2mg n.s.s.	7/50	10/50	16/50		S
lun MXA		66.2mg	* P<.07 c	26.2mg n.s.s.	13/50	11/50	21/50	lun:a/a,a/c.	
hag acn		148.mg	* P<.02	61.5mg n.s.s.	1/50	2/50	7/50		S
ski sqp		253.mg	* P<.02 c	86.5mg n.s.s.	0/50	0/50	4/50		
mul mlh		297.mg	* P<.04	100.mg n.s.s.	0/50	1/50	3/50		S
epy srn		473.mg	* P<.09 e	116.mg n.s.s.	0/50	0/50	2/50		
ubl tcc		761.mg	* P<.3 e	186.mg n.s.s.	0/50	1/50	1/50		
TBA MXB		34.6mg	* P<.2	12.6mg n.s.s.	42/50	47/50	49/50		
liv MXB		36.6mg	* P<.04	15.8mg n.s.s.	24/50	31/50	35/50	liv:hpa,hpc,nnd.	
lun MXB		66.2mg	* P<.07	26.2mg n.s.s.	13/50	11/50	21/50	lun:a/a,a/c.	
3018 R f f34 gav 23m24 TR374 :					0	26.5mg	53.6mg		
MXB MXB a		4.13mg	/ P<.0005	2.43mg 7.45mg	25/50	39/50	42/50	bra:gln; cli:acn,adn,can; for:sqc,sqp; mgl:acn,fba; mth:sqc,sqp; mul:mnl; thy:fca,fcc; ton:sqp.	C
mgl MXA a		4.15mg	/ P<.0005 c	2.40mg 7.58mg	14/50	34/50	37/50	mgl:acn,fba.	
mgl fba a		4.55mg	* P<.0005 c	2.52mg 8.70mg	14/50	32/50	29/50		
cli MXA a		12.5mg	/ P<.0005 c	5.27mg 36.5mg	5/50	9/50	12/50	cli:acn,adn,can.	
ute esp a		13.5mg	* P<.0005	6.57mg 39.2mg	19/50	21/50	14/50		S
mul mnl a		14.0mg	/ P<.0005 c	7.12mg 32.9mg	13/50	14/50	20/50		
cli adn a		16.7mg	* P<.0005	6.73mg 56.7mg	3/50	7/50	7/50		S
mgl acn a		23.0mg	* P<.0005 c	11.9mg 46.8mg	1/50	11/50	16/50		
for MXA a		28.5mg	/ P<.0005 c	11.0mg 62.5mg	0/50	4/50	11/50	for:sqc,sqp.	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
for sqp a	31.4mg /	P<.0005		11.3mg 77.8mg	0/50	4/50	8/50		S
bra gln a	43.6mg *	P<.0005	c	12.3mg 174.mg	0/50	4/50	4/50		
MXA MXA a	44.7mg *	P<.0005	c	14.1mg 181.mg	1/50	3/50	7/50		mth:sqc,sqp; ton:sqp.
MXA sqp a	46.7mg *	P<.0005		14.4mg 212.mg	1/50	3/50	6/50		mth:sqp; ton:sqp. S
ton sqp a	53.7mg *	P<.0005		15.1mg 319.mg	1/50	3/50	5/50		S
cli MXA a	62.7mg *	P<.008		14.0mg 2.21gm	2/50	2/50	5/50		cli:acn,can. S
cli can a	64.1mg *	P<.008		14.1mg 2.38gm	2/50	1/50	5/50		S
thy MXA a	68.2mg *	P<.003	c	13.1mg 878.mg	0/50	1/50	3/50		thy:fca,fcc.
pta adn a	30.6mg *	P<.03		10.0mg n.s.s.	18/50	14/50	6/50		S
sub MXA a	71.1mg *	P<.02		15.8mg n.s.s.	1/50	4/50	2/50		sub:fbs,fib. S
adr MXA a	91.1mg /	P<.04		17.7mg n.s.s.	2/50	0/50	3/50		adr:con,crn. S
ute MXA a	130.mg /	P<.02		20.1mg n.s.s.	1/50	0/50	4/50		ute:acn,adn. S
for sqc a	317.mg *	P<.02		94.6mg n.s.s.	0/50	0/50	3/50		S
thy fcc a	411.mg *	P<.02		109.mg n.s.s.	0/50	0/50	3/50		S
stg fbs a	752.mg *	P<.07	e	164.mg n.s.s.	0/50	0/50	2/50		
TBA MXB a	3.88mg /	P<.0005		2.29mg 7.16mg	43/50	43/50	47/50		
liv MXB a	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
3019 R m f34 gav 93w98 TR374 :					0	26.8mg	53.6mg		
tes ict a	1.49mg /	P<.0005		.818mg 2.82mg	46/50	50/50	49/50		S
MXB MXB a	2.30mg /	P<.0005		1.04mg 4.74mg	8/50	40/50	46/50	bra:gln; col:adc,adp; for:sqc,sqp; mgl:fba; ski:bct,sea, sec; smi:mua; thy:fca,fcc; tnv:men,msm; zym:can.	C
mul mnl a	3.14mg /	P<.0005		1.49mg 6.95mg	25/50	33/50	21/50		S
tnv MXA a	4.42mg /	P<.0005	c	1.75mg 8.36mg	3/50	34/50	39/50		tnv:men,msm.
tnv msm a	5.68mg /	P<.0005		1.94mg 12.1mg	3/50	24/50	31/50		S
ski sqp a	7.00mg *	P<.0005		1.31mg 80.1mg	0/50	3/50	3/50		S
bra gln a	7.32mg *	P<.0005	c	1.31mg 74.5mg	0/50	5/50	6/50		
mgl fba a	7.97mg /	P<.0005	c	2.65mg 27.8mg	3/50	8/50	7/50		
lun MXA a	10.7mg *	P<.0005		2.61mg 70.1mg	2/50	5/50	4/50		lun:a/a,a/c. S
pre adn a	10.8mg *	P<.002		2.87mg 85.3mg	5/50	7/50	1/50		S
pre MXA a	11.2mg /	P<.0005		3.43mg 68.2mg	10/50	7/50	5/50		pre:acn,adn. S
pta MXA a	11.9mg *	P<.005		2.94mg 205.mg	8/50	8/50	2/50		pta:adn,can. S
pta adn a	13.1mg *	P<.009		3.08mg 767.mg	8/50	7/50	2/50		S
thy MXA a	16.5mg /	P<.0005	c	3.45mg 81.4mg	1/50	4/50	6/50		thy:fca,fcc.
lun a/a a	17.0mg *	P<.003		3.07mg 344.mg	1/50	3/50	2/50		S
thy fcc a	19.7mg /	P<.0005		3.46mg 147.mg	1/50	2/50	5/50		S
ski ker a	21.6mg *	P<.003		3.55mg 333.mg	1/50	4/50	1/50		S
sub MXA a	25.3mg /	P<.0005		6.08mg 160.mg	4/50	5/50	5/50		sub:fbs,fib,nfm. S
for MXA a	25.6mg /	P<.0005	c	3.64mg 194.mg	1/50	2/50	6/50		for:sqc,sqp.
tnv men a	25.8mg *	P<.0005		10.8mg 61.5mg	0/50	10/50	8/50		S
ski MXA a	29.5mg /	P<.0005	c	10.2mg 87.2mg	0/50	5/50	4/50		ski:bct,sea,sec.
sub MXA a	30.0mg /	P<.002		6.33mg 248.mg	4/50	4/50	5/50		sub:fbs,fib. S
ski MXA a	30.6mg *	P<.0005		10.3mg 98.1mg	0/50	5/50	3/50		ski:bct,sea. S
ton MXA a	37.8mg *	P<.006		3.94mg 1.42gm	1/50	1/50	4/50		ton:sqc,sqp. S
ski bct a	38.8mg *	P<.0005		11.1mg 176.mg	0/50	4/50	2/50		S
thy cca a	42.8mg /	P<.005		7.41mg 651.mg	2/50	3/50	3/50		S
sub MXA a	42.9mg /	P<.002		8.90mg 377.mg	2/50	3/50	4/50		sub:fib,nfm. S
zym can a	49.8mg /	P<.0005	c	14.7mg 235.mg	1/50	3/50	6/50		
sub fib a	55.9mg /	P<.005		9.83mg 942.mg	2/50	2/50	4/50		S
for sqp a	101.mg /	P<.0005		35.5mg 395.mg	0/50	1/50	5/50		S
MXA MXA a	244.mg *	P<.004	c	89.0mg 1.88gm	0/50	1/50	4/50		col:adc,adp; smi:mua.
MXA MXA a	72.3mg *	P<.03		8.91mg n.s.s.	3/50	2/50	5/50		mth:sqc,sqp; ton:sqc,sqp. S
TBA MXB a	1.66mg /	P<.0005		.903mg 3.17mg	43/50	50/50	48/50		
liv MXB a	101.mg *	P<.2		16.6mg n.s.s.	1/50	1/50	1/50		liv:hpa,hpc,nnd.
GLYCINE 56-40-6									
3020 R f f3d wat 25m25 2352					0	1.43gm	2.86gm		Kitahori;jtxp,7,471-480;1994
ute esp e	3.10gm \	P<.003		1.53gm 16.5gm	5/50	18/50	(12/50)		
k/p tpp eh	25.7gm *	P<.1	+	10.5gm n.s.s.	0/50	4/50	2/50		
liv nnd e	157.gm *	P<.3		25.6gm n.s.s.	0/50	0/50	1/50		
tba mix e	7.55gm \	P<.6		1.37gm n.s.s.	27/50	30/50	(12/50)		
3021 R m f3d wat 25m25 2352					0	1.25gm	2.50gm		
liv nnd e	no dre	P=1.		9.26gm n.s.s.	1/50	0/50	0/50		
tba mix e	no dre	P=1.		1.84gm n.s.s.	36/50	44/50	36/50		
GLYCOL SULFITE 3741-38-6									
3022 M f hic ipj 64w64 1143					0	1.71mg			Van Duuren;jnci,53,695-700;1974
lun ptm	1.03mg	P<.07		.385mg n.s.s.	10/30	17/30			
GLYCYRRHETINIC ACID 471-53-4									
3023 R m f34 eat 54w54 2078					0	96.0mg			Reddy;carc,13,1019-1023;1992
col mix er	no dre	P=1.		64.0mg n.s.s.	0/12	0/12			
GLYCYRRHIZINATE, DISODIUM 71277-79-7									
3024 M f b6c wat 22m26 1685					0	140.mg	262.mg	524.mg	Kobuke;fctx,23,979-983;1985
lun ade e	14.4gm *	P<.2	-	3.54gm n.s.s.	0/44	0/47	1/46	1/37	
liv hpa e	28.9gm *	P<.2	-	4.71gm n.s.s.	0/44	0/47	0/46	1/37	
liv hpc e	29.0gm *	P<.6	-	4.73gm n.s.s.	0/44	0/47	1/46	0/37	
lun adc e	no dre	P=1.	-	3.72gm n.s.s.	0/44	1/47	1/46	0/37	
liv hem e	no dre	P=1.	-	5.96gm n.s.s.	1/44	0/47	1/46	0/37	
tba mix e	no dre	P=1.	-	1.33gm n.s.s.	12/44	12/47	11/46	9/37	
3025 M m b6c wat 22m26 1685					0	58.2mg	116.mg	218.mg	
liv hem e	no dre	P=1.	-	1.22gm n.s.s.	3/37	0/38	3/37	2/40	
liv hpc e	no dre	P=1.	-	1.23gm n.s.s.	5/37	0/38	3/37	3/40	
liv hpa e	no dre	P=1.	-	1.41gm n.s.s.	4/37	3/38	2/37	2/40	
lun ade e	no dre	P=1.	-	1.53gm n.s.s.	0/37	1/38	1/37	0/40	
lun adc e	no dre	P=1.	-	1.88gm n.s.s.	2/37	0/38	1/37	1/40	
tba mix e	3.17gm *	P<.8	-	377.mg n.s.s.	14/37	7/38	14/37	14/40	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
FD & C GREEN NO. 1 (guinea green B) 4680-78-8									
3026 M f cbj eat 24m24 143				0	1.30gm	2.60gm			Hansen;fctx,4,389-410;1966
liv mix	146.gm	* P<.6	- 18.2gm n.s.s.	1/101	1/53	1/49			
lun ade	146.gm	* P<.6	- 18.2gm n.s.s.	1/101	1/53	1/49			
tba mal	18.4gm	\ P<.1	- 4.84gm n.s.s.	1/101	3/53	(0/49)			
tba mix	no dre	P=1.	- 16.5gm n.s.s.	6/101	3/53	2/49			
3027 M m cbj eat 24m24 143				0	1.20gm	2.40gm			
liv mix	26.1gm	* P<.5	- 5.50gm n.s.s.	12/101	13/50	7/51			
lun mix	59.2gm	* P<.3	13.4gm n.s.s.	1/101	1/50	2/51			
tba mix	20.8gm	* P<.4	- 4.84gm n.s.s.	15/101	15/50	9/51			
tba mal	no dre	P=1.	- 9.44gm n.s.s.	11/101	9/50	4/51			
3028 R f osm eat 24m24 143				0	250.mg	500.mg	1.00gm	2.50gm	
liv mix e	13.8gm	* P<.003	+ 5.23gm 85.1gm	0/25	0/25	0/25	1/25	4/25	
tba mix e	97.5gm	* P<1.	2.54gm n.s.s.	12/25	10/25	13/25	9/25	12/25	
tba mal e	no dre	P=1.	- 5.09gm n.s.s.	6/25	5/25	8/25	4/25	5/25	
3029 R m osm eat 24m24 143				0	200.mg	400.mg	800.mg	2.00gm	
liv mix e	5.98gm	* P<.003	+ 2.82gm 31.6gm	0/25	0/25	2/25	2/25	5/25	
tba mix e	11.4gm	* P<.4	2.59gm n.s.s.	4/25	7/25	2/25	5/25	7/25	
tba mal e	no dre	P=1.	- 4.77gm n.s.s.	2/25	5/25	1/25	5/25	2/25	
3030 R b wis eat 93w93 1136				0	1.80gm				Willheim;gaga,23,1-19;1953
mix mly er	3.92gm	P<.006	+ 958.mg 76.8gm	0/50	2/9				
mds mly er	8.37gm	P<.05	+ 1.36gm n.s.s.	0/50	1/9				
abd mly er	8.37gm	P<.05	+ 1.36gm n.s.s.	0/50	1/9				
FD & C GREEN NO. 2 (light green SF yellowish) 5141-20-8									
3031 M f cbj eat 24m24 143				0	1.30gm	2.60gm			Hansen;fctx,4,389-410;1966
lun mix	43.8gm	* P<.04	13.3gm n.s.s.	0/100	1/50	2/50			
liv mix	no dre	P=1.	22.3gm n.s.s.	3/100	1/50	1/50			
tba mix	148.gm	* P<.9	11.0gm n.s.s.	7/100	4/50	4/50			
tba mal	152.gm	* P<.8	- 14.5gm n.s.s.	3/100	2/50	2/50			
3032 M m cbj eat 24m24 143				0	1.20gm	2.40gm			
liv mix	18.9gm	\ P<.4	3.68gm n.s.s.	6/100	5/50	(0/50)			
lun mix	58.2gm	* P<.3	13.2gm n.s.s.	1/100	1/50	2/50			
tba mal	49.3gm	* P<.5	- 9.39gm n.s.s.	3/100	5/50	2/50			
tba mix	318.gm	* P<1.	9.31gm n.s.s.	7/100	7/50	3/50			
3033 R m nss eat 65w65 176a				0	12.0mg	1.20gm			Allmark;jphp,8,417-424;1956
liv tum e	no dre	P=1.	5.75mg n.s.s.	0/5	0/6	0/8			
tba tum e	no dre	P=1.	- 5.75mg n.s.s.	0/5	0/6	0/8			
3034 R f osm eat 24m24 143				0	250.mg	500.mg	1.00gm	2.50gm	Hansen;fctx,4,389-410;1966
liv tum e	no dre	P=1.	- 696.mg n.s.s.	0/25	0/25	0/25	0/25	0/25	
tba mix e	no dre	P=1.	- 4.73gm n.s.s.	10/25	15/25	16/25	10/25	8/25	
tba mal e	no dre	P=1.	- 4.81gm n.s.s.	6/25	6/25	9/25	6/25	5/25	
3035 R m osm eat 24m24 143				0	200.mg	400.mg	800.mg	2.00gm	
liv hpa e	no dre	P=1.	- 557.mg n.s.s.	1/25	0/25	0/25	0/25	0/25	
tba mix e	no dre	P=1.	- 4.57gm n.s.s.	8/25	7/25	10/25	6/25	5/25	
tba mal e	no dre	P=1.	- 4.99gm n.s.s.	4/25	3/25	4/25	3/25	3/25	
3036 R b wis eat 95w95 1136				0	1.80gm				Willheim;gaga,23,1-19;1953
cec mly er	5.64gm	P<.04	+ 913.mg n.s.s.	0/50	1/6				
FD & C GREEN NO. 3 (fast green FCF) 2353-45-9									
3037 M f cbj eat 24m24 143				0	1.30gm	2.60gm			Hansen;fctx,4,389-410;1966
lun ade	133.gm	* P<.5	- 21.7gm n.s.s.	0/100	1/50	0/50			
liv hpa	no dre	P=1.	- 25.6gm n.s.s.	2/100	0/50	1/50			
tba mal	no dre	P=1.	- 25.4gm n.s.s.	3/100	2/50	0/50			
tba mix	no dre	P=1.	- 19.2gm n.s.s.	5/100	3/50	1/50			
3038 M m cbj eat 24m24 143				0	1.20gm	2.40gm			
liv mix	no dre	P=1.	19.1gm n.s.s.	8/100	4/50	1/50			
lun ade	no dre	P=1.	- 21.3gm n.s.s.	2/100	2/50	0/50			
tba mix	18.1gm	\ P<.5	- 3.21gm n.s.s.	10/100	7/50	(1/50)			
tba mal	no dre	P=1.	- 23.5gm n.s.s.	8/100	2/50	1/50			
3039 R f osm eat 24m24 143				0	250.mg	500.mg	1.00gm	2.50gm	
liv tum e	no dre	P=1.	- 696.mg n.s.s.	0/25	0/25	0/25	0/25	0/25	
mgl fba e	no dre	P=1.	- 2.70gm n.s.s.	6/25	6/25	10/25	15/25	6/25	
tba mix e	18.5gm	* P<.8	- 1.90gm n.s.s.	13/25	10/25	11/25	18/25	12/25	
tba mal e	46.7gm	* P<.9	- 3.30gm n.s.s.	7/25	6/25	3/25	11/25	6/25	
3040 R m osm eat 24m24 143				0	200.mg	400.mg	800.mg	2.00gm	
liv hpa e	no dre	P=1.	- 10.6gm n.s.s.	0/25	0/25	1/25	0/25	0/25	
tba mix e	no dre	P=1.	- 5.03gm n.s.s.	2/25	3/25	5/25	3/25	2/25	
tba mal e	no dre	P=1.	- 5.37gm n.s.s.	1/25	2/25	3/25	3/25	1/25	
GRISEOFULVIN 126-07-8									
3041 H f syg eat 23m23 402				0	314.mg	1.57gm	3.14gm		Rustia;bjca,38,237-249;1978
lun tum ae	no dre	P=1.	1.01gm n.s.s.	0/29	0/21	0/24	0/22		
liv clc ae	no dre	P=1.	- 3.34gm n.s.s.	0/16	1/9	0/5	0/5		
liv mix ae	no dre	P=1.	4.25gm n.s.s.	1/16	1/9	0/5	0/5		
3042 H m syg eat 29m30 402				0	276.mg	1.38gm	2.76gm		
liv tum ae	no dre	P=1.	- 1.13gm n.s.s.	0/22	0/16	0/23	0/24		
lun tum ae	no dre	P=1.	1.13gm n.s.s.	0/22	0/16	0/23	0/24		
3043 M f swa gav 52w52 2408				0	10.0mg				El-Mofty;oncr,1,1079-1081;1994
mgl idc er	13.8mg	P<.03	+ 5.96mg n.s.s.	0/25	7/60				
3044 M f swi eat 27m27 402				0	130.mg				Rustia;bjca,38,237-249;1978
lun tum e	no dre	P=1.	- 471.mg n.s.s.	19/89	6/37				
liv hem e	no dre	P=1.	- 845.mg n.s.s.	5/76	1/36				
3045 M m swi eat 27m27 402				0	120.mg				
liv hpt e	1.66gm	P<.2	+ 270.mg n.s.s.	0/32	1/17				
liv hem e	no dre	P=1.	- 525.mg n.s.s.	6/86	2/33				
lun tum e	no dre	P=1.	- 326.mg n.s.s.	16/79	6/32				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
GUAR GUM 9000-30-0								
3046 M f b6c eat 24m25 TR229 :				0	3.16gm	6.32gm		
TBA MXB	no dre	P=1.	- 8.80gm n.s.s.	32/50	26/50	27/50		
liv MXB	no dre	P=1.	27.4gm n.s.s.	5/50	2/50	4/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	33.9gm n.s.s.	5/50	1/50	3/50		lun:a/a,a/c.
3047 M m b6c eat 24m24 TR229 :				0	2.92gm	5.89gm		
TBA MXB	no dre	P=1.	- 8.14gm n.s.s.	32/50	33/50	32/50		
liv MXB	no dre	P=1.	7.71gm n.s.s.	16/50	12/50	(7/50)		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	21.6gm n.s.s.	12/50	9/50	8/50		lun:a/a,a/c.
3048 R f f34 eat 24m24 TR229 :				0	1.24gm	2.48gm		
TBA MXB	no dre	P=1.	- 2.53gm n.s.s.	46/50	47/50	46/50		
liv MXB	no dre	P=1.	18.5gm n.s.s.	2/50	1/50	1/50		liv:hpa,hpc,nnd.
3049 R m f34 eat 24m24 TR229 :				0	990.mg	1.98gm		
sub fib #	13.4gm *	P<.03	- 5.10gm n.s.s.	0/50	1/50	4/50		S
TBA MXB	16.5gm *	P<.9	1.29gm n.s.s.	39/50	41/50	42/50		
liv MXB	no dre	P=1.	16.4gm n.s.s.	3/50	0/50	1/50		liv:hpa,hpc,nnd.
GUM ARABIC (gum acacia) 9000-01-5								
3050 M f b6c eat 24m24 TR227 :				0	3.19gm	6.38gm		
TBA MXB	no dre	P=1.	- 6.45gm n.s.s.	30/50	33/50	31/50		
liv MXB	31.1gm *	P<.06	12.2gm n.s.s.	3/50	2/50	10/50		liv:hpa,hpc,nnd.
lun MXB	24.7gm \	P<.3	6.59gm n.s.s.	3/50	7/50	(1/50)		lun:a/a,a/c.
3051 M m b6c eat 24m24 TR227 :				0	2.94gm	5.89gm		
--- hem #	80.8gm *	P<.05	- 24.5gm n.s.s.	0/50	0/50	3/50		S
TBA MXB	46.0gm /	P<.8	5.01gm n.s.s.	36/50	28/50	40/50		
liv MXB	no dre	P=1.	12.4gm n.s.s.	16/50	11/50	15/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	12.1gm n.s.s.	12/50	10/50	12/50		lun:a/a,a/c.
3052 R f f34 eat 24m24 TR227 :				0	1.23gm	2.45gm		
TBA MXB	8.31gm *	P<.7	- 1.29gm n.s.s.	45/50	46/50	47/50		
liv MXB	no dre	P=1.	10.2gm n.s.s.	3/50	3/50	2/50		liv:hpa,hpc,nnd.
3053 R m f34 eat 24m24 TR227 :				0	981.mg	1.96gm		
TBA MXB	7.97gm *	P<.7	- 1.08gm n.s.s.	40/50	45/50	42/50		
liv MXB	33.5gm *	P<.7	4.15gm n.s.s.	4/50	5/50	5/50		liv:hpa,hpc,nnd.
HCDD MIXTURE (1,2,3,7,8,9-hexachlorodibenzo-p-dioxin and 1,2,3,6,7,8-isomer. CAS# 19408-74-3 and 57653-85-7) mixture								
3054 M f b6c gav 24m24 TR198 :				0	344.ng	688.ng	1.39ug	
liv MXA	3.87ug *	P<.005	c 1.86ug 36.0ug	3/75	4/50	6/50	10/50	liv:hpa,hpc.
liv hpa	4.31ug *	P<.005	c 2.05ug 42.4ug	2/75	4/50	4/50	9/50	
TBA MXB	6.60ug *	P<.5	1.42ug n.s.s.	36/75	24/50	22/50	28/50	
liv MXB	3.87ug *	P<.005	1.86ug 36.0ug	3/75	4/50	6/50	10/50	liv:hpa,hpc,nnd.
lun MXB	63.0ug *	P<.9	4.57ug n.s.s.	2/75	2/50	5/50	1/50	lun:a/a,a/c.
3055 M m b6c gav 24m24 TR198 :				0	172.ng	347.ng	688.ng	
liv MXA	876.ng *	P<.007	c 420.ng 16.6ug	15/75	14/50	14/50	24/50	liv:hpa,hpc.
liv hpa	1.26ug *	P<.005	c 612.ng 11.9ug	7/75	5/50	9/50	15/50	
TBA MXB	1.02ug *	P<.2	350.ng n.s.s.	40/75	33/50	29/50	38/50	
liv MXB	876.ng *	P<.007	420.ng 16.6ug	15/75	14/50	14/50	24/50	liv:hpa,hpc,nnd.
lun MXB	40.1ug *	P<1.	1.04ug n.s.s.	10/75	11/50	10/50	7/50	lun:a/a,a/c.
3056 R f osm gav 24m24 TR198 :				0	174.ng	347.ng	694.ng	
liv MXA	596.ng *	P<.0005	c 369.ng 1.33ug	5/75	10/50	12/50	30/50	liv:hpc,nnd.
TBA MXB	no dre	P=1.	756.ng n.s.s.	54/75	36/50	33/50	41/50	
liv MXB	596.ng *	P<.0005	369.ng 1.33ug	5/75	10/50	12/50	30/50	liv:hpa,hpc,nnd.
3057 R m osm gav 24m25 TR198 :				0	175.ng	347.ng	694.ng	
liv MXA #	2.30ug *	P<.02	- 842.ng n.s.s.	0/75	0/50	1/50	4/50	liv:hpc,nnd. S
TBA MXB	no dre	P=1.	807.ng n.s.s.	40/75	22/50	22/50	25/50	
liv MXB	2.30ug *	P<.02	842.ng n.s.s.	0/75	0/50	1/50	4/50	liv:hpa,hpc,nnd.
HEMATOXYLIN 517-28-2								
3058 R b wis eat 78w78 1136				0	1.80gm			Willheim;gaga,23,1-19;1953
mix mly er	1.00gm	P<.002	+ 231.mg 13.6gm	0/50	2/4			
fhd mly er	2.41gm	P<.02	+ 386.mg n.s.s.	0/50	1/4			
abd mly er	2.41gm	P<.02	+ 386.mg n.s.s.	0/50	1/4			
HEPTACHLOR 76-44-8								
3059 M f b6c eat 80w89 TR9 :				0	1.00mg	2.10mg		
liv hpc v	1.47mg /	P<.0005	c .887mg 3.94mg	2/10	3/50	30/50		
TBA MXB v	1.46mg /	P<.007	.779mg 24.9mg	4/10	12/50	31/50		
liv MXB v	1.47mg /	P<.0005	.887mg 3.94mg	2/10	3/50	30/50		liv:hpa,hpc,nnd.
lun MXB v	26.5mg *	P<.6	6.52mg n.s.s.	0/10	1/50	1/50		lun:a/a,a/c.
3060 M f b6c eat 80w89 TR9 : pool				0	1.00mg	2.10mg		
liv hpc v	1.37mg /	P<.0005	c .866mg 2.47mg	3/80	3/50	30/50		
3061 M m b6c eat 73w89 TR9 :				0	.650mg	1.30mg		
liv hpc av	1.09mg /	P<.006	c .586mg 12.2mg	5/20	11/50	34/48		
TBA MXB av	1.35mg /	P<.03	.645mg n.s.s.	7/20	11/50	34/48		
liv MXB av	1.09mg /	P<.006	.586mg 12.2mg	5/20	11/50	34/48		liv:hpa,hpc,nnd.
lun MXB av	7.15mg *	P<.2	2.51mg n.s.s.	1/20	1/50	7/48		lun:a/a,a/c.
3062 M m b6c eat 73w89 TR9 : pool				0	.650mg	1.30mg		
liv hpc av	1.09mg /	P<.0005	c .628mg 2.83mg	17/95	11/50	34/48		
3063 R f osm eat 19m26 TR9 :				0	.920mg	1.85mg		
thy MXA v#	4.11mg /	P<.02	- 2.03mg n.s.s.	1/10	3/49	14/50		thy:fca,fcc. S
TBA MXB v	125.mg *	P<1.	.998mg n.s.s.	9/10	37/49	33/50		
liv MXB v	no dre	P=1.	3.28mg n.s.s.	1/10	9/49	5/50		liv:hpa,hpc,nnd.
3064 R f osm eat 19m25 TR9 : pool				0	.920mg	1.85mg		
thy MXA v#	4.05mg /	P<.002	- 2.05mg 16.1mg	3/60	3/49	14/50		thy:fca,fcc. S
thy fcc v	10.5mg *	P<.04	4.01mg n.s.s.	1/60	2/49	5/50		S
3065 R m osm eat 19m26 TR9 :				0	1.10mg	2.20mg		
TBA MXB v	no dre	P=1.	- 2.33mg n.s.s.	7/10	24/50	20/50		
liv MXB v	18.1mg *	P<.5	4.46mg n.s.s.	1/10	3/50	6/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc			Brkly Code / NCI/NTPPathology
3066 R f cfr eat 26m26 66b	0	75.0ug	.150mg	.250mg	.350mg	.500mg	Epstein(review) {S Witherup}; stev,6,103-154;1976
tba tum r 1.25mg * P<.2 - .426mg n.s.s.	6/20	7/20	7/20	6/20	11/20	9/20	
tba mal r 1.87mg * P<.2 - .695mg n.s.s.	1/20	3/20	2/20	4/20	6/20	3/20	
tba ben r 3.07mg * P<.4 - .728mg n.s.s.	5/20	4/20	5/20	2/20	6/20	7/20	
3067 R m cfr eat 26m26 66b	0	60.0ug	.120mg	.200mg	.280mg	.400mg	
tba tum r no dre P=1. - 1.34mg n.s.s.	10/20	2/20	6/20	6/20	4/20	3/20	
tba mal r no dre P=1. - 1.46mg n.s.s.	5/20	1/20	5/20	2/20	1/20	3/20	
tba ben r no dre P=1. - 1.82mg n.s.s.	5/20	1/20	1/20	4/20	3/20	0/20	
HEPTAMETHYLENEIMINE 1121-92-2							
3068 R f mrc wat 17m24 216	0	7.36mg					Garcia;zkko,79,141-144;1973
liv tum e no dre P=1. 22.7mg n.s.s.	0/15	0/15					
tba mix e 15.8mg P<.3 4.09mg n.s.s.	4/15	7/15					
3069 R m mrc wat 17m24 216	0	6.44mg					
liv tum e no dre P=1. 19.9mg n.s.s.	0/15	0/15					
tba mix e 6.37mg P<.07 2.17mg n.s.s.	5/15	10/15					
HEPTYLAMINE 111-68-2							
3070 R m wis wat 61w61 104	0	1.92mg					Argus;jnci,35,949-958;1965
liv tum e no dre P=1. 2.72mg n.s.s.	0/9	0/20					
tba mix e no dre P=1. - 1.74mg n.s.s.	1/9	1/20					
HEXACHLOROBENZENE 118-74-1							
3071 H f syg eat 24m24 151a	0	5.23mg	10.5mg	20.9mg			Cabral;natu,269,510-511;1977
liv hpt 7.42mg * P<.0005 + 5.47mg 10.3mg	0/40	14/30	17/30	51/60			
liv hae 125.mg * P<.003 + 58.8mg 577.mg	0/40	0/30	2/30	7/60			
tba mix 7.68mg * P<.0005 + 5.41mg 11.9mg	5/40	16/30	18/30	52/60			
3072 H m syg eat 24m24 151a	0	4.60mg	9.20mg	18.4mg			
liv hpt 5.48mg * P<.0005 + 4.05mg 7.55mg	0/40	14/30	26/30	49/59			
liv hae 32.3mg * P<.0005 + 20.4mg 56.1mg	0/40	1/30	6/30	20/59			
thy ald 108.mg * P<.002 + 50.9mg 382.mg	0/40	0/30	1/30	8/59			
tba mix 3.72mg * P<.0005 + 2.62mg 5.40mg	3/40	18/30	27/30	56/59			
3073 M m c5c eat 52w52 1938m	0	12.0mg					Smith;ijcn,43,492-496;1989/pers.comm.
liv hnd ekr 17.5mg P<.3 2.83mg n.s.s.	0/9	1/9					
liv hpc ekr no dre P=1. 5.56mg n.s.s.	0/9	0/9					
3074 M m c5c eat 78w78 1938n	0	12.0mg					
liv tum er no dre P=1. - 15.3mg n.s.s.	0/11	0/11					
3075 M f swi eat 86w93 384	0	6.50mg	13.0mg	26.0mg			Cabral;ijcn,23,47-51;1979
liv lct aes 46.4mg * P<.0005 + 26.3mg 93.4mg	0/49	0/30	3/30	14/41			
lun tum aes no dre P=1. 32.2mg n.s.s.	14/49	4/30	6/30	(2/41)			
tba mix aes no dre P=1. 63.5mg n.s.s.	39/49	21/30	13/30	19/41			
3076 M m swi eat 23m25 384	0	6.00mg	12.0mg	24.0mg			
liv lct aes 109.mg * P<.0005 + 53.3mg 329.mg	0/47	0/30	3/29	7/44			
lun tum aes no dre P=1. 189.mg n.s.s.	13/47	4/30	0/29	4/44			
tba mix aes no dre P=1. 86.7mg n.s.s.	22/47	15/30	10/29	12/44			
3077 R f agu eat 90w90 1180	0	5.00mg					Smith;clet,11,169-172;1980
liv lct r noTD50 P<.0005 + n.s.s. 1.65mg	0/12	14/14					
3078 R m cdr eat 28m28 1833m	0	1.60mg					Arnold;fctx,23,779-793;1985
liv nnd be 27.3mg P<.1 6.71mg n.s.s.	0/39	2/39					
liv hpc be 55.3mg P<.3 9.00mg n.s.s.	0/39	1/39					
liv blc be 55.3mg P<.3 9.00mg n.s.s.	0/39	1/39					
3079 R m cdr eat 28m28 1833n	0	1.60mg					
liv nnd e 17.9mg P<.05 5.43mg n.s.s.	0/38	3/39					
liv kcs e 55.3mg P<.3 9.00mg n.s.s.	0/38	1/39					
3080 R f f34 eat 90w90 1708	0	10.0mg					Smith;carc,6,631-636;1985
liv mix r 4.67mg P<.0005 + 2.16mg 12.4mg	0/15	10/15					
liv hpc r 12.7mg P<.006 + 4.75mg 120.mg	0/15	5/15					
liv nnd r 12.7mg P<.006 + 4.75mg 120.mg	0/15	5/15					
3081 R f f34 eat 64w64 2118	0	10.0mg					Smith;carc,14,1381-1387;1993
liv tum er 5.52mg P<.03 + 1.64mg n.s.s.	0/8	3/8					
3082 R m f34 eat 90w90 1708	0	8.00mg					Smith;carc,6,631-636;1985
liv mix r 28.7mg P<.09 + 7.04mg n.s.s.	0/15	2/15					
HEXACHLOROBUTADIENE 87-68-3							
3083 R f sss eat 24m24 373	0	.200mg	2.00mg	20.0mg			Kociba;amih,38,589-602;1977
kid mix e 94.4mg * P<.0005 + 38.5mg 338.mg	0/90	0/40	0/40	6/40			
liv mht e no dre P=1. - 1.49mg n.s.s.	1/90	0/40	0/40	0/40			
tba mix e 9.84mg * P<.1 2.42mg n.s.s.	82/90	35/40	37/40	39/40			
3084 R m sss eat 95w95 373	0	.200mg	2.00mg	20.0mg			
kid mix es 50.5mg * P<.0005 + 23.4mg 148.mg	1/90	0/40	0/40	9/39			
liv hpc es no dre P=1. - 1.24mg n.s.s.	1/90	0/40	0/40	0/39			
tba mix es no dre P=1. 34.8mg n.s.s.	39/90	24/40	13/40	15/39			
alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (alpha-lindane) 319-84-6							
3085 M m ddy eat 36w72 1149n	0	30.0mg					Ito;canr,36,2227-2234;1976
liv mix ekr noTD50 P<.0005 + n.s.s. 6.62mg	0/18	13/13					
3086 R m buf eat 35w65 1071	0	10.8mg					Angsubhakorn;bjca,43,881-883;1981
liv mix ekr no dre P=1. - 6.07mg n.s.s.	0/8	0/7					
3087 R m wis eat 72w72 45a	0	40.0mg	60.0mg				Ito;jnci,54,801-804;1975
liv nod ekr 11.2mg * P<.0005 + 6.37mg 23.3mg	0/8	12/16	10/13				
liv hpc ekr 107.mg * P<.09 + 37.0mg n.s.s.	0/8	1/16	3/13				
beta-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (beta-lindane) 319-85-7							
3088 M f cf1 eat 26m26 89	0	26.0mg					Thorpe;fctx,11,433-442;1973
liv lct e 139.mg P<.007 + 48.1mg 1.92gm	0/44	4/30					
liv mix e 64.3mg P<.07 + 23.2mg n.s.s.	10/44	13/30					
lun tum e no dre P=1. - 116.mg n.s.s.	27/44	5/30					

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3089 M m cf1 eat 26m26 89					0	24.0mg			
liv mix e		17.7mg	P<.0005 +	9.03mg 51.0mg	11/45	22/30			
liv lct e		51.1mg	P<.002 +	23.1mg 231.mg	2/45	10/30			
lun tum e		no dre	P=1. -	79.6mg n.s.s.	27/45	8/30			
gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (lindane) 58-89-9									
3090 M f b6c eat 80w90 TR14 :					0	9.20mg	18.5mg		
TBA MXB		no dre	P=1. -	46.4mg n.s.s.	4/10	7/50	8/50		
liv MXB		no dre	P=1.	56.9mg n.s.s.	1/10	4/50	3/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	86.0mg n.s.s.	1/10	1/50	2/50		lun:a/a,a/c.
3091 M m b6c eat 80w90 TR14 :					0	8.50mg	17.0mg		
TBA MXB		no dre	P=1. -	19.9mg n.s.s.	4/10	21/50	15/50		
liv MXB		no dre	P=1.	25.8mg n.s.s.	3/10	19/50	10/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	65.5mg n.s.s.	2/10	2/50	3/50		lun:a/a,a/c.
3092 M m b6c eat 80w90 TR14 : pool					0	8.50mg	17.0mg		
liv hpc #		12.0mg \	P<.004 -	5.84mg 95.4mg	5/50	19/50	(9/50)		S
liv MXA		15.3mg \	P<.04	6.39mg n.s.s.	8/50	19/50	(10/50)		liv:hpc,nnd. S
3093 M f baa eat 26w52 1828m					0	10.4mg			Wolff;carc,8,1889-1897;1987
lun tum er		1.26gm	P<1.	14.6mg n.s.s.	1/48	1/45			
liv hpc er		no dre	P=1. -	24.1mg n.s.s.	0/48	0/45			
liv hpa er		no dre	P=1. -	24.1mg n.s.s.	0/48	0/45			
3094 M f baa eat 6m24 1828n					0	5.20mg			
lun tum er		15.9gm	P<1.	50.4mg n.s.s.	2/96	2/95			
liv hpc er		no dre	P=1. -	55.5mg n.s.s.	3/96	2/95			
liv hpa er		no dre	P=1. -	54.8mg n.s.s.	6/96	3/95			
3095 M f baa eat 52w52 1828o					0	20.8mg			
liv hpa er		no dre	P=1. -	51.4mg n.s.s.	0/48	0/48			
liv hpc er		no dre	P=1. -	51.4mg n.s.s.	0/48	0/48			
lun tum er		no dre	P=1.	51.4mg n.s.s.	1/48	0/48			
3096 M f baa eat 24m24 1828r					0	20.8mg			
lun tum er		1.33gm	P<.7 -	160.mg n.s.s.	2/96	3/96			
liv hpc er		no dre	P=1. -	297.mg n.s.s.	3/96	1/96			
liv mix er		no dre	P=1. -	219.mg n.s.s.	9/96	4/96			
liv hpa er		no dre	P=1. -	222.mg n.s.s.	6/96	3/96			
3097 M f cf1 eat 26m26 89					0	52.0mg			Thorpe;fctx,11,433-442;1973
liv mix e		43.7mg	P<.0005 +	21.9mg 140.mg	10/44	20/29			
liv lct e		94.3mg	P<.0005 +	45.6mg 243.mg	0/44	10/29			
lun tum e		no dre	P=1. -	133.mg n.s.s.	27/44	10/29			
3098 M m cf1 eat 26m26 89					0	48.0mg			
liv mix e		15.4mg	P<.0005 +	7.43mg 34.4mg	11/45	27/29			
liv lct e		48.6mg	P<.0005 +	25.8mg 114.mg	2/45	16/29			
lun tum e		no dre	P=1. -	95.0mg n.s.s.	27/45	12/29			
3099 M f nmr eat 80w80 1119					0	1.63mg	3.25mg	6.50mg	Herbst;txcy,4,91-96;1975
liv mix r		803.mg *	P<1. -	16.7mg n.s.s.	6/100	7/50	2/50	4/50	
3100 M m nmr eat 80w80 1119					0	1.50mg	3.00mg	6.00mg	
liv mix r		no dre	P=1. -	22.9mg n.s.s.	7/100	5/50	1/50	3/50	
liv ret r		no dre	P=1. -	25.2mg n.s.s.	0/100	3/50	0/50	0/50	
3101 M f pva eat 52w52 1828o					0	20.8mg			Wolff;carc,8,1889-1897;1987
lun tum er		no dre	P=1.	49.3mg n.s.s.	1/46	0/46			
liv hpc er		no dre	P=1. -	51.4mg n.s.s.	0/48	0/48			
liv hpa er		no dre	P=1. -	51.4mg n.s.s.	0/46	0/48			
3102 M f pva eat 24m24 1828r					0	20.8mg			
liv mix er		132.mg	P<.05 +	53.5mg n.s.s.	7/95	16/95			
lun tum er		170.mg	P<.09 +	62.5mg n.s.s.	6/95	13/94			
liv hpa er		207.mg	P<.2	71.0mg n.s.s.	5/95	11/95			
liv hpc er		435.mg	P<.3	113.mg n.s.s.	2/95	5/95			
3103 M f yva eat 26w52 1828m					0	10.4mg			
lun tum er		84.6mg	P<.3	13.8mg n.s.s.	0/48	1/48			
liv hpc er		no dre	P=1. -	25.7mg n.s.s.	0/48	0/48			
liv hpa er		no dre	P=1. -	25.7mg n.s.s.	2/48	0/48			
3104 M f yva eat 6m24 1828n					0	5.20mg			
lun tum er		52.2mg	P<.1	18.4mg n.s.s.	4/95	10/95			
liv hpa er		62.3mg	P<.3 -	17.4mg n.s.s.	8/93	13/95			
liv hpc er		396.mg	P<.9 -	21.5mg n.s.s.	12/93	13/95			
3105 M f yva eat 52w52 1828o					0	20.8mg			
liv hpa er		162.mg	P<.7	19.7mg n.s.s.	2/48	3/48			
lun tum er		169.mg	P<.3	27.6mg n.s.s.	0/48	1/48			
liv hpc er		no dre	P=1.	51.4mg n.s.s.	0/48	0/48			
3106 M f yva eat 24m24 1828r					0	20.8mg			
liv mix er		28.8mg	P<.0005 +	17.1mg 71.0mg	20/93	49/94			
liv hpa er		41.6mg	P<.0005 +	24.6mg 97.7mg	8/93	33/94			
lun tum er		85.3mg	P<.002 +	43.3mg 383.mg	4/95	18/95			
liv hpc er		294.mg	P<.5 -	65.1mg n.s.s.	12/93	16/94			
3107 R f osm eat 19m25 TR14 :					0	4.90mg	9.80mg		
TBA MXB sv		no dre	P=1. -	3.27mg n.s.s.	9/10	44/50	(34/50)		
liv MXB sv		no dre	P=1.	24.7mg n.s.s.	0/10	4/50	2/50		liv:hpa,hpc,nnd.
3108 R m osm eat 19m25 TR14 :					0	6.90mg	13.6mg		
TBA MXB v		38.4mg *	P<.6 -	7.29mg n.s.s.	3/10	21/50	19/50		
liv MXB v		143.mg *	P<.8	27.8mg n.s.s.	0/10	3/50	2/50		liv:hpa,hpc,nnd.
3109 R m osm eat 19m25 TR14 : pool					0	6.90mg	13.6mg		
--- hem v#		131.mg *	P<.03 -	39.5mg n.s.s.	0/55	0/50	3/50		S
HEXACHLOROCYCLOHEXANE, TECHNICAL GRADE 608-73-1									
3110 M f swi eat 66w66 2164					0	65.0mg			Munir;tumo,69,383-386;1983
liv mix r		noTD50	P<.0005 +	n.s.s. 12.0mg	1/20	14/14			
3111 M m swi eat 52w52 1744					0	60.0mg			Kandarkar;ijmr,78,155-161;1983
liv hpc r		25.3mg	P<.05 +	10.9mg n.s.s.	0/6	7/21			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3112 M m swi eat 66w66 2164					0	60.0mg			Munir;tumo,69,383-386;1983
liv mix r	noTD50	P<.002	+	n.s.s. 12.6mg	2/22	12/12			
HEXACHLOROCYCLOPENTADIENE 77-47-4									
3113 M f b6c inh 24m24 TR437 :					0	34.5ug	.173mg	.691mg	
TBA MXB	no dre	P=1.	-	.796mg n.s.s.	34/50	37/50	33/50	20/50	
liv MXB	no dre	P=1.		1.18mg n.s.s.	9/50	12/50	10/50	6/50	liv:hpa,hpb,hpc.
lun MXB	10.3mg *	P<.7		1.17mg n.s.s.	7/50	4/50	5/50	5/50	lun:a/a,a/c.
3114 M m b6c inh 24m24 TR437 :					0	28.9ug	.145mg	.580mg	
TBA MXB	no dre	P=1.	-	.535mg n.s.s.	35/50	32/50	39/50	33/50	
liv MXB	no dre	P=1.		.866mg n.s.s.	24/50	21/50	28/50	20/50	liv:hpa,hpb,hpc.
lun MXB	2.45mg *	P<.3		.649mg n.s.s.	11/50	11/50	14/50	16/50	lun:a/a,a/c.
3115 M m b6c inh 15m24 TR437a :					0	.371mg			
lun MXA	1.05mg	P<.2		.323mg n.s.s.	11/50	17/50			lun:a/a,a/c.
lun MXB	1.05mg	P<.2		.323mg n.s.s.	11/50	17/50			lun:a/a,a/c.
3116 M m b6c inh 10m24 TR437b :					0	.590mg			
lun a/c	2.21mg	P<.004		.899mg 13.4mg	0/50	6/50			S
lun MXB	3.11mg	P<.5		.668mg n.s.s.	11/50	14/50			lun:a/a,a/c.
3117 M m b6c inh 8m24 TR437c :					0	.185mg			
lun a/c	1.15mg	P<.02		.392mg n.s.s.	0/50	4/50			S
lun MXB	2.04mg	P<.7		.262mg n.s.s.	11/50	13/50			lun:a/a,a/c.
3118 M m b6c inh 6m24 TR437d :					0	.365mg			
lun a/c	1.98mg	P<.02		.750mg n.s.s.	0/50	5/50			S
lun MXB	10.9mg	P<.9		.577mg n.s.s.	11/50	14/50			lun:a/a,a/c.
3119 R f f34 inh 24m24 TR437 :					0	8.26ug	41.4ug	.166mg	
thy ccr #	.838mg *	P<.05	-	.291mg n.s.s.	0/50	1/50	3/50	4/50	S
TBA MXB	1.81mg *	P<.9		.101mg n.s.s.	47/50	48/50	41/50	49/50	
liv MXB	no dre	P=1.		.725mg n.s.s.	1/50	1/50	1/50	1/50	liv:hpa,hpb,hpc.
3120 R m f34 inh 24m24 TR437 :					0	5.78ug	29.0ug	.116mg	
pit pda #	.121mg *	P<.05	-	47.1ug n.s.s.	23/50	23/50	23/50	33/50	S
TBA MXB	.188mg *	P<.4		44.4ug n.s.s.	47/50	45/50	43/50	49/50	
liv MXB	.932mg *	P<.2		.225mg n.s.s.	1/50	1/50	1/50	3/50	liv:hpa,hpb,hpc.
HEXACHLOROETHANE 67-72-1									
3121 M f b6c gav 78w90 TR68 :					0	361.mg	722.mg		
liv hpc v	873.mg *	P<.2	c	362.mg n.s.s.	2/20	20/50	15/50		
TBA MXB v	1.19gm *	P<.4		313.mg n.s.s.	8/20	32/50	26/50		
liv MXB v	873.mg *	P<.2		362.mg n.s.s.	2/20	20/50	15/50		liv:hpa,hpc,nnd.
lun MXB v	6.95gm *	P<.4		1.65gm n.s.s.	1/20	1/50	4/50		lun:a/a,a/c.
3122 M f b6c gav 78w90 TR68 : pool					0	361.mg	722.mg		
liv hpc v	319.mg \	P<.0005	c	178.mg 760.mg	2/60	20/50	(15/50)		
3123 M m b6c gav 78w90 TR68 :					0	361.mg	722.mg		
liv hpc v	585.mg *	P<.2	c	236.mg n.s.s.	3/20	15/50	31/50		
TBA MXB v	675.mg *	P<.4		216.mg n.s.s.	4/20	17/50	34/50		
liv MXB v	585.mg *	P<.2		236.mg n.s.s.	3/20	15/50	31/50		liv:hpa,hpc,nnd.
lun MXB v	23.6gm *	P<1.		883.mg n.s.s.	0/20	2/50	3/50		lun:a/a,a/c.
3124 M m b6c gav 78w90 TR68 : pool					0	361.mg	722.mg		
liv hpc v	359.mg *	P<.0005	c	213.mg 958.mg	6/60	15/50	31/50		
3125 R f f34 gav 24m24 TR361 :					0	56.1mg	111.mg		
TBA MXB	no dre	P=1.	-	89.8mg n.s.s.	50/50	44/50	43/50		
liv MXB	276.gm *	P<1.		384.mg n.s.s.	1/50	3/50	1/50		liv:hpa,hpc,nnd.
3126 R f osm gav 18m26 TR68 :					0	105.mg	210.mg		
TBA MXB dv	no dre	P=1.	-	169.mg n.s.s.	14/20	33/50	20/50		
liv MXB dv	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
3127 R m f34 gav 24m24 TR361 :					0	7.01mg	14.0mg		
MXA MXA	8.02mg \	P<.03	e	3.35mg n.s.s.	15/50	28/50	(21/50)		adr:pob; amd:pbb,phc,phm,pob.
MXA MXA	9.05mg \	P<.04		3.70mg n.s.s.	14/50	26/50	(19/50)		adr:pob; amd:pbb,pob. S
kid MXA	55.4mg *	P<.02	c	23.3mg n.s.s.	1/50	2/50	7/50		kid:ade,rua,ruc.
kid ruc	159.mg *	P<.04		47.3mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	28.0mg *	P<.5		6.04mg n.s.s.	45/50	48/50	45/50		
liv MXB	1.34gm *	P<.9		53.9mg n.s.s.	2/50	1/50	2/50		liv:hpa,hpc,nnd.
3128 R m osm gav 18m26 TR68 :					0	105.mg	210.mg		
TBA MXB dv	no dre	P=1.	-	118.mg n.s.s.	9/20	17/50	11/50		
liv MXB dv	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
HEXACHLOROPHENE 70-30-4									
3129 M f c51 eat 24m24 706					0	19.5mg			Rudali;clet,5,325-332;1978
liv hpt	434.mg	P<.3	-	70.7mg n.s.s.	0/25	1/33			
tba mix	no dre	P=1.	-	31.2mg n.s.s.	7/25	9/33			
3130 M m c51 eat 24m24 706					0	18.0mg			
liv tum	no dre	P=1.	-	130.mg n.s.s.	0/25	0/35			
lun tum	no dre	P=1.	-	130.mg n.s.s.	1/25	0/35			
tba mix	900.mg	P<1.	-	37.0mg n.s.s.	4/25	6/35			
3131 M f xvi eat 24m24 706					0	19.5mg			
lun tum	33.4mg	P<.2	-	10.7mg n.s.s.	21/38	28/40			
liv tum	no dre	P=1.	-	161.mg n.s.s.	0/38	0/40			
tba mix	39.4mg	P<.3	-	11.1mg n.s.s.	22/38	28/40			
3132 M m xvi eat 24m24 706					0	18.0mg			
lun tum	17.8mg	P<.07	-	6.56mg n.s.s.	23/37	30/37			
liv ade	450.mg	P<.3	-	73.3mg n.s.s.	0/37	1/37			
tba mix	17.8mg	P<.07	-	6.56mg n.s.s.	23/37	30/37			
3133 R f f34 eat 25m25 TR40 :					0	.850mg	2.50mg	7.50mg	
TBA MXB	no dre	P=1.	-	9.82mg n.s.s.	21/24	17/24	21/24	13/24	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/24	0/24	0/24	0/24	liv:hpa,hpc,nnd.
3134 R m f34 eat 25m25 TR40 :					0	.680mg	2.00mg	6.00mg	
sub fbs #	41.3mg *	P<.02	-	12.4mg n.s.s.	0/24	0/24	0/24	3/24	S
tnv men	57.5mg *	P<.05		14.1mg n.s.s.	0/24	0/24	0/24	2/24	S
TBA MXB	30.4mg *	P<.5		5.68mg n.s.s.	11/24	5/24	7/24	11/24	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/24	0/24	0/24	0/24	liv:hpa,hpc,nnd.
2,4-HEXADIENAL (89% trans,trans-, 11% cis,trans-)					**142-83-6**				
3135 M f b6c gav 24m24 TR509 :					0	21.4mg	42.9mg	85.7mg	
for MXA	129.mg *	P<.0005 c	78.2mg	297.mg	2/50	2/50	11/50	18/50	for:sqc,sqp.
for sqp	165.mg *	P<.0005 c	92.7mg	555.mg	2/50	2/50	11/50	13/50	
ski MXA	218.mg Z	P<.008	98.3mg	3.38gm	0/50	3/50	5/50	(0/50)	ski:fbs,fih. S
for sqc	580.mg *	P<.002 c	250.mg	2.12gm	0/50	0/50	0/50	7/50	
TBA MXB	no dre	P=1.	116.mg	n.s.s.	39/50	41/50	38/50	29/50	
liv MXB	no dre	P=1.	186.mg	n.s.s.	13/50	7/50	14/50	10/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	422.mg	n.s.s.	2/50	3/50	1/50	2/50	lun:a/a,a/c.
3136 M m b6c gav 24m24 TR509 :					0	21.4mg	42.9mg	85.7mg	
for MXA	279.mg *	P<.009 c	132.mg	12.5gm	2/50	4/50	5/50	10/50	for:sqc,sqp.
for sqp	354.mg *	P<.04	150.mg	n.s.s.	2/50	4/50	5/50	8/50	S
ton sqc	2.08gm *	P<.07 e	511.mg	n.s.s.	0/50	0/50	0/50	2/50	
TBA MXB	279.mg *	P<.6	46.3mg	n.s.s.	47/50	46/50	46/50	48/50	
liv MXB	211.mg *	P<.4	55.1mg	n.s.s.	31/50	36/50	35/50	37/50	liv:hpa,hpb,hpc.
lun MXB	1.98gm *	P<.9	140.mg	n.s.s.	19/50	12/50	15/50	17/50	lun:a/a,a/c.
3137 R f f34 gav 24m24 TR509 :					0	16.1mg	32.1mg	64.2mg	
for sqp	102.mg Z	P<.0005 c	62.1mg	184.mg	0/50	1/50	5/50	17/50	
TBA MXB	112.mg *	P<.4	28.3mg	n.s.s.	48/50	48/50	48/50	48/50	
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
3138 R m f34 gav 24m24 TR509 :					0	16.1mg	32.1mg	64.2mg	
for MXA	44.7mg Z	P<.0005 c	30.8mg	68.4mg	0/50	3/50	11/50	29/50	for:sqc,sqp.
for sqp	46.1mg Z	P<.0005	31.6mg	70.9mg	0/50	3/50	10/50	29/50	S
amd phm	415.mg *	P<.02	168.mg	n.s.s.	0/50	1/50	1/50	4/50	S
TBA MXB	107.mg *	P<.4	27.5mg	n.s.s.	47/50	48/50	47/50	48/50	
liv MXB	no dre	P=1.	437.mg	n.s.s.	0/50	1/50	0/50	0/50	liv:hpa,hpb,hpc.
3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA (hercules-7531) 2163-79-3									
3139 M f b6a orl 76w76 1277					0	205.mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	383.mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	-	383.mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	-	253.mg n.s.s.	2/17	1/17			
3140 M m b6a orl 76w76 1277					0	190.mg			
lun ade evx	no dre	P=1.	-	250.mg n.s.s.	2/18	1/18			
liv hpt evx	no dre	P=1.	-	377.mg n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	-	197.mg n.s.s.	3/18	2/18			
3141 M f b6c orl 76w76 1277					0	205.mg			
lun ade evx	1.23gm	P<.3	-	201.mg n.s.s.	0/16	1/17			
liv hpt evx	no dre	P=1.	-	383.mg n.s.s.	0/16	0/17			
tba mix evx	1.23gm	P<.3	-	201.mg n.s.s.	0/16	1/17			
3142 M m b6c orl 76w76 1277					0	190.mg			
liv hpt evx	359.mg	P<.04	-	108.mg n.s.s.	0/16	3/17			
lun mix evx	no dre	P=1.	-	356.mg n.s.s.	0/16	0/17			
tba mix evx	259.mg	P<.02	-	89.2mg n.s.s.	0/16	4/17			
HEXAMETHYLENETETRAMINE 100-97-0									
3143 M f c3d wat 14m24 155m					0	1.14gm			Della Porta;fctx,6,707-715;1968
liv agm e	51.9gm	P<.7	-	4.76gm n.s.s.	2/63	2/43			
liv hpt e	no dre	P=1.	-	5.98gm n.s.s.	15/63	4/43			
lun ade e	no dre	P=1.	-	6.38gm n.s.s.	12/63	3/43			
tba mix e	no dre	P=1.	-	3.01gm n.s.s.	46/63	20/43			
3144 M m c3d wat 14m24 155m					0	952.mg			
liv agm e	32.3gm	P<.4	-	5.25gm n.s.s.	0/30	1/49			
lun ade e	293.gm	P<1.	-	3.16gm n.s.s.	3/30	5/49			
liv hpt e	no dre	P=1.	-	3.24gm n.s.s.	20/30	16/49			
tba mix e	no dre	P=1.	-	2.21gm n.s.s.	21/30	22/49			
3145 M f ctn wat 12m23 155m					0	600.mg	1.20gm	3.00gm	
mix tum ae	20.9gm *	P<.02	-	9.06gm n.s.s.	1/99	1/48	6/102	4/50	
hag tum ae	26.3gm Z	P<.05	-	9.65gm n.s.s.	3/99	4/48	1/102	7/50	
liv agm ae	no dre	P=1.	-	14.7gm n.s.s.	3/99	2/48	7/102	1/50	
lun ade ae	no dre	P=1.	-	8.34gm n.s.s.	17/99	10/48	21/102	8/50	
tba mix ae	11.6gm *	P<.6	-	1.97gm n.s.s.	67/99	36/48	77/102	36/50	
3146 M m ctn wat 12m23 155m					0	500.mg	1.00gm	2.50gm	
lun ade ae	no dre	P=1.	-	10.3gm n.s.s.	19/99	10/50	19/94	1/29	
liv agm ae	no dre	P=1.	-	12.6gm n.s.s.	9/99	3/50	10/94	0/29	
tba mix ae	no dre	P=1.	-	5.51gm n.s.s.	55/99	27/50	57/94	8/29	
3147 M f swr wat 14m24 155m					0	1.17gm			
lun ade e	no dre	P=1.	-	1.77gm n.s.s.	15/30	10/27			
liv tum e	no dre	P=1.	-	6.36gm n.s.s.	0/30	0/27			
tba mix e	no dre	P=1.	-	1.61gm n.s.s.	18/30	12/27			
3148 M m swr wat 14m24 155m					0	971.mg			
lun ade e	no dre	P=1.	-	1.33gm n.s.s.	19/45	11/29			
liv agm e	no dre	P=1.	-	5.69gm n.s.s.	1/45	0/29			
tba mix e	no dre	P=1.	-	1.34gm n.s.s.	22/45	12/29			
3149 R f wis wat 24m34 155n					0	407.mg			
liv tum e	no dre	P=1.	-	7.94gm n.s.s.	0/48	0/48			
tba mix e	no dre	P=1.	-	1.56gm n.s.s.	37/48	27/48			
3150 R m wis wat 24m34 155n					0	356.mg			
liv lcc e	no dre	P=1.	-	6.94gm n.s.s.	1/48	0/48			
tba mix e	no dre	P=1.	-	627.mg n.s.s.	39/48	36/48			
HEXAMETHYLMELAMINE 531-18-0									
3151 R f sda eat 44w66 200a					0	10.6mg			Cohen;jnci,51,403-417;1973
mgl adc ev	10.2mg	P<.003	+	4.13mg 52.4mg	0/25	6/24			
mgl mix ev	11.9mg	P<.03	+	4.33mg n.s.s.	1/25	6/24			
k/p tcc evh	33.6mg	P<.09	+	8.27mg n.s.s.	0/25	2/24			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv tum ev	no dre	P=1.	21.1mg n.s.s.	0/25	0/24			
tba mix ev	6.82mg	P<.003	3.01mg 40.7mg	1/25	9/24			
HEXAMETHYLPHOSPHORAMIDE 680-31-9								
3152 R b cdr inh 12m24 2462m				0	16.9ug	75.3ug	.678mg	Lee;jnci,68,157-164;1982/1982a/1984/pers.comm.
nas mix aemr	34.5ug	Z P<.0005 +	28.7ug 41.8ug	0/196	39/194	180/219	(179/215)	
nas mal aemr	41.6ug	Z P<.0005 +	34.4ug 50.8ug	0/196	30/194	167/219	(168/215)	
nas epc aemr	58.1ug	Z P<.0005 +	47.5ug 72.1ug	0/196	24/194	137/219	(120/215)	
nsa sqc aemr	.519mg	Z P<.0005 +	.323mg .928mg	0/196	4/194	21/219	(41/215)	
3153 R b cdr inh 17m24 2462n				0	4.52ug	17.9ug		
nas mix aemr	34.4ug	/ P<.0005 +	25.9ug 47.2ug	0/200	0/200	75/200		
nas mal aemr	38.7ug	/ P<.0005 +	28.7ug 53.9ug	0/200	0/200	68/200		
nas epc aemr	45.6ug	/ P<.0005 +	33.2ug 65.2ug	0/200	0/200	59/200		
nsa sqc aemr	.608mg	* P<.004 +	.231mg 4.00mg	0/200	0/200	5/200		
HEXANAL METHYLFORMYLHYDRAZONE 57590-22-4								
3154 M f swi gav 12m28 2019				0	3.03mg	6.52mg		Toth;myco,115,65-71;1991
lun mix e	2.96mg	* P<.0005 +	1.97mg 4.96mg	13/48	37/50	45/50		
lun ade e	4.68mg	* P<.0005	3.17mg 7.81mg	7/48	26/50	39/50		
lun adc e	8.73mg	* P<.0005	5.41mg 20.0mg	6/48	21/50	27/50		
liv mix e	19.9mg	* P<.0005 +	11.1mg 41.5mg	0/41	2/36	14/43		
liv bhp e	23.3mg	* P<.0005	12.5mg 52.5mg	0/41	2/36	12/43		
liv hpc e	180.mg	* P<.1	44.4mg n.s.s.	0/41	0/36	2/43		
3155 M m swi gav 12m30 2019				0	2.90mg	6.69mg		
lun mix es	1.92mg	\ P<.0005 +	1.12mg 3.86mg	13/48	39/46	(35/50)		
lun adc es	5.52mg	\ P<.0005	3.09mg 13.0mg	3/48	21/46	(15/50)		
pre mix es	6.51mg	/ P<.0005 +	4.47mg 9.92mg	0/47	3/44	43/50		
lun ade es	6.63mg	* P<.0005	4.02mg 16.1mg	12/48	31/46	34/50		
pre sqc es	8.03mg	/ P<.0005	5.40mg 12.6mg	0/47	0/44	40/50		
liv mix es	31.4mg	* P<.007 +	13.5mg 413.mg	0/36	4/37	3/18		
liv bhp es	45.4mg	* P<.08	17.2mg n.s.s.	0/36	4/37	1/18		
pre sqp es	93.3mg	* P<.05	35.4mg n.s.s.	0/47	2/44	3/50		
liv hpc es	115.mg	* P<.05	28.2mg n.s.s.	0/36	0/37	2/18		
pre ade es	no dre	P=1.	79.8mg n.s.s.	0/47	1/44	0/50		
HEXANAMIDE 628-02-4								
3156 M f cb6 eat 52w69 1343 pool				0	978.mg	1.47gm		Fleischman;jept,3,149-170;1980
sto sqp e	8.90gm	* P<.07	2.69gm n.s.s.	0/86	3/41	0/34		
lun a/a e	37.2gm	* P<.7 -	3.94gm n.s.s.	2/89	0/41	2/37		
liv hpc e	no dre	P=1. -	2.09gm n.s.s.	1/89	0/41	0/37		
3157 M m cb6 eat 52w69 1343 pool				0	903.mg	1.35gm		
--- mix e	1.95gm	* P<.0005 +	1.00gm 4.56gm	0/95	6/35	6/39		
--- mlh e	2.14gm	* P<.0005	1.08gm 5.28gm	0/95	6/35	5/39		
mul mlh e	2.66gm	* P<.0005	1.25gm 7.72gm	0/91	5/35	4/39		
lun a/a e	3.49gm	\ P<.06 -	952.mg n.s.s.	1/87	3/35	(0/39)		
liv hes e	25.3gm	* P<.2 -	4.11gm n.s.s.	0/91	0/35	1/39		
liv mlh e	25.3gm	* P<.2	4.11gm n.s.s.	0/91	0/35	1/39		
3158 R f f34 eat 52w69 1343				0	564.mg			
liv tum e	no dre	P=1. -	1.89gm n.s.s.	0/49	0/37			
3159 R m f34 eat 52w69 1343				0	452.mg			
liv tum e	no dre	P=1. -	655.mg n.s.s.	0/50	0/16			
HEXANE, COMMERCIAL GRADE (52% n-HEXANE, 16% 3-METHYLPENTANE, 16% METHYLCYCLOPENTANE) 110-54-3								
3160 M f b6c inh 24m24 2613				0	992.mg	3.31gm	9.92gm	Daughtrey;faat,48,21-29;1999
pit mix e	9.46gm	Z P<.003	5.09gm 58.6gm	0/45	6/48	8/48	(5/49)	
pit ade e	10.3gm	Z P<.007	5.42gm 186.gm	0/45	6/48	7/48	(5/49)	
liv mix e	30.3gm	* P<.02 +	13.0gm n.s.s.	7/50	8/50	9/49	16/50	
liv hpc e	84.8gm	* P<.2	25.6gm n.s.s.	3/50	2/50	5/49	6/50	
3161 M m b6c inh 24m24 2613				0	827.mg	2.76gm	8.27gm	
liv mix e	no dre	P=1. -	23.7gm n.s.s.	17/49	16/50	17/50	13/50	
3162 R f f34 inh 24m24 2613				0	236.mg	788.mg	2.36gm	
nac tum e	no dre	P=1. -	1.74gm n.s.s.	0/50	0/49	0/49	0/50	
3163 R m f34 inh 24m24 2613				0	165.mg	551.mg	1.65gm	
nac tum e	no dre	P=1. -	1.24gm n.s.s.	0/48	0/50	0/50	0/50	
1-O-HEXYL-2,3,5-TRIMETHYLHYDROQUINONE 148081-72-5								
3164 R f f3d eat 52w52 2249				0	250.mg			Hirose;carc,16,217-221;1995/pers.comm.
liv tum e	no dre	P=1.	129.mg n.s.s.	0/10	0/10			
N-HEXYLNITROSOUREA 18774-85-1								
3165 R f f34 gav 12m24 1915				0	1.36mg			Lijinsky;txih,5,925-935;1989
ute mix	.579mg	P<.002 +	.226mg 2.72mg	2/12	10/12			
for tum	.848mg	P<.0005 +	.361mg 2.59mg	0/12	8/12			
mgl adc	1.73mg	P<.005 +	.644mg 13.9mg	0/12	5/12			
lun mix	2.06mg	P<.06 +	.677mg n.s.s.	1/12	5/12			
liv tum	no dre	P=1.	3.36mg n.s.s.	0/12	0/12			
3166 R m f34 gav 12m24 1915				0	.952mg			
for tum	noTD50	P<.0005 +	n.s.s. .460mg	0/12	12/12			
lun mix	noTD50	P<.0005 +	n.s.s. .460mg	0/12	12/12			
--- mso	.745mg	P<.0005	.308mg 2.60mg	0/12	7/12			
col tum	2.27mg	P<.04 +	.681mg n.s.s.	0/12	3/12			
liv tum	no dre	P=1.	1.38mg n.s.s.	1/12	1/12			
4-HEXYLRESORCINOL 136-77-6								
3167 M f b6c gav 24m24 TR330 :				0	43.8mg	87.6mg		
TBA MXB	no dre	P=1. -	124.mg n.s.s.	39/50	22/50	31/50		
liv MXB	no dre	P=1.	699.mg n.s.s.	3/50	0/50	1/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	585.mg n.s.s.	5/50	0/50	2/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3168 M m b6c gav 24m24 TR330 :					0	43.8mg	87.6mg		
hag MXA	368.mg	* P<.03	e	158.mg n.s.s.	0/50	4/50	3/50		hag:adn,can.
amd phe	519.mg	* P<.07	e	187.mg n.s.s.	1/50	2/50	5/50		
TBA MXB	no dre	P=1.		72.4mg n.s.s.	36/50	34/50	30/50		
liv MXB	no dre	P=1.		115.mg n.s.s.	21/50	9/50	(9/50)		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		225.mg n.s.s.	10/50	9/50	5/50		lun:a/a,a/c.
3169 R f f34 gav 24m24 TR330 :					0	44.2mg	88.4mg		
TBA MXB	no dre	P=1.	-	76.1mg n.s.s.	44/50	39/50	35/50		
liv MXB	128.gm	* P<1.		548.mg n.s.s.	1/50	0/50	1/50		liv:hpa,hpc,nnd.
3170 R m f34 gav 24m24 TR330 :					0	44.2mg	88.4mg		
TBA MXB	615.mg	\ P<1.	-	22.8mg n.s.s.	44/50	44/50	(36/50)		
liv MXB	1.53gm	* P<.3		376.mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
L-HISTIDINE.HCl 645-35-2									
3171 R f f3d eat 24m25 2285					0	607.mg	1.21gm		Ikezaki;fctx,34,687-691;1996
liv hpa e	no dre	P=1.	-	4.42gm n.s.s.	0/50	0/50	0/50		
3172 R m f3d eat 24m25 2285					0	486.mg	972.mg		
liv hpa e	52.2gm	* P<.3	-	8.50gm n.s.s.	0/50	0/49	1/50		
HUMIC ACIDS, COMMERCIAL GRADE 1415-93-6									
3173 M f b6c wat 24m24 1806					0	100.mg			Van Duuren;enhp,69,109-117;1986
liv hem e	1.24gm	P<.2		305.mg n.s.s.	3/96	4/48			
liv hnd e	3.19gm	P<.5		442.mg n.s.s.	2/96	2/48			
lun ptm e	5.65gm	P<.9		289.mg n.s.s.	13/96	7/48			
tba mix e	169.mg	P<.5		32.4mg n.s.s.	84/96	44/48			
3174 M m b6c wat 24m24 1806					0	83.3mg			
lun ptm e	348.mg	P<.2		113.mg n.s.s.	22/99	17/50			
liv hpt e	2.64gm	P<.8		242.mg n.s.s.	12/99	7/50			
tba mix e	153.mg	P<.3		38.8mg n.s.s.	76/99	42/50			
HYDRAZINE 302-01-2									
3175 H m syg inh 12m24 1679n					0	20.6ug	82.4ug	.412mg	Vernot;faat,5,1050-1064;1985
nas adp es	4.16mg	* P<.0005	+	2.32mg 8.95mg	1/200	0/200	1/200	16/200	
thy pfa es	17.5mg	* P<.003	+	6.05mg 115.mg	0/200	0/200	0/200	4/200	
col adc es	14.0mg	* P<.03	+	5.33mg n.s.s.	0/200	0/200	2/200	3/200	
sto bcc es	37.6mg	* P<.4	+	7.19mg n.s.s.	0/200	0/200	2/200	1/200	
col ley es	70.5mg	* P<.2	+	11.5mg n.s.s.	0/200	0/200	0/200	1/200	
col pam es	70.5mg	* P<.2	+	11.5mg n.s.s.	0/200	0/200	0/200	1/200	
3176 M f cb6 inh 12m27 1679n					0	.183mg			
lun ade e	7.78mg	P<.04		3.12mg n.s.s.	4/400	12/400			
3177 M f nmb wat 24m24 1960					0	.400mg	2.00mg	10.0mg	Steinhoff;expl,39,1-9;1990
tba ben	58.5mg	* P<.5	-	12.0mg n.s.s.	21/50	18/50	21/50	23/50	
tba mal	no dre	P=1.	-	17.1mg n.s.s.	27/50	37/50	27/50	27/50	
3178 M m nmb wat 24m24 1960					0	.333mg	1.67mg	8.33mg	
tba mal	no dre	P=1.	-	20.7mg n.s.s.	17/50	26/50	22/50	17/50	
tba ben	no dre	P=1.	-	28.3mg n.s.s.	26/50	24/50	22/50	16/50	
3179 M f swi gav 40w55 1095					0	5.19mg			Roe;natu,216,375-376;1967
lun tum	5.67mg	P<.08	+	1.71mg n.s.s.	8/85	6/25			
3180 M f swi wat 26m26 1117					0	2.00mg			Toth;ijcn,9,109-118;1972/1969a
lun mix e	2.54mg	P<.0005	+	1.45mg 5.59mg	14/108	27/50			
lun ade e	2.81mg	P<.0005		1.59mg 6.34mg	12/108	25/50			
lun adc e	9.00mg	P<.0005		4.00mg 37.2mg	2/108	9/50			
liv mix e	no dre	P=1.		13.1mg n.s.s.	3/88	1/41			
3181 M m swi wat 26m26 1117					0	1.67mg			
lun mix e	2.20mg	P<.0005	+	1.23mg 5.11mg	10/86	24/46			
lun ade e	2.77mg	P<.0005		1.47mg 7.69mg	10/86	21/46			
lun adc e	6.19mg	P<.0005		2.91mg 16.9mg	0/86	9/46			
--- mly e	9.52mg	P<.007		3.73mg 180.mg	2/86	7/46			
liv mix e	29.8mg	P<.5		4.90mg n.s.s.	2/41	3/33			
3182 R f f34 inh 12m30 1679m					0	1.96ug	9.81ug	39.3ug	.196mg	Vernot;faat,5,1050-1064;1985
nas adp e	.758mg	Z P<.0005	+	.485mg 1.29mg	0/150	2/100	0/100	2/100	28/100	
nas sqp e	8.72mg	* P<.004	+	2.64mg 79.3mg	0/150	0/100	0/100	0/100	3/100	
nas vlp e	6.56mg	* P<.03	+	2.27mg n.s.s.	0/150	0/100	0/100	2/100	2/100	
nas adc e	9.20mg	* P<.03	+	2.72mg n.s.s.	0/150	1/100	0/100	0/100	3/100	
nas sqc e	13.1mg	* P<.02	+	3.23mg n.s.s.	0/150	0/100	0/100	0/100	2/100	
lun bcd e	26.4mg	* P<.09	+	4.30mg n.s.s.	0/150	0/100	0/100	0/100	1/100	
3183 R m f34 inh 12m30 1679m					0	1.37ug	6.87ug	27.5ug	.137mg	
nas adp e	.194mg	* P<.0005	+	.144mg .271mg	0/150	2/100	1/100	9/100	58/100	
nas vlp e	1.36mg	* P<.0005	+	.715mg 3.05mg	0/150	0/100	0/100	1/100	12/100	
lun bcd e	6.10mg	* P<.004	+	1.85mg 55.5mg	0/150	0/100	0/100	0/100	3/100	
nas sqp e	6.10mg	* P<.004	+	1.85mg 55.5mg	0/150	0/100	0/100	0/100	3/100	
thy car e	1.60mg	* P<.02		.658mg n.s.s.	7/150	6/100	5/100	9/100	13/100	
nas sqc e	6.12mg	* P<.02	+	1.85mg n.s.s.	0/150	0/100	0/100	1/100	2/100	
nas adc e	no dre	P=1.	+	5.33mg n.s.s.	0/150	1/100	0/100	0/100	0/100	
3184 R f wis wat 36m36 2390					0	.114mg	.571mg	2.86mg	Steinhoff;expl,33,133-143;1988
liv mix e	41.6mg	* P<.0005	+	17.0mg 149.mg	0/50	0/50	0/50	6/47	
mgl mal e	1.13mg	Z P<.03		.459mg n.s.s.	2/50	9/50	(2/50	1/47)	
liv hpc e	129.mg	* P<.03		31.8mg n.s.s.	0/50	0/50	0/50	2/47	
tba mix e	no dre	P=1.		5.27mg n.s.s.	39/50	44/50	41/50	37/47	
3185 R m wis wat 36m36 2390					0	.100mg	.500mg	2.50mg	
liv mix e	43.7mg	* P<.03	+	14.9mg n.s.s.	0/50	1/49	2/50	4/49	
liv hpc e	no dre	P=1.		42.3mg n.s.s.	0/50	0/49	1/50	0/49	
tba mix e	9.64mg	* P<.3		2.77mg n.s.s.	37/50	35/49	36/50	40/49	
HYDRAZINE SULFATE 10034-93-2									
3186 H f syg wat 25m25 1108					0	16.4mg			Toth;canr,32,804-807;1972/1967a
cec tum e	115.mg	P<.004	-	39.6mg 813.mg	0/79	4/40			
thy ade e	124.mg	P<.004	-	42.8mg 895.mg	0/84	4/43			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv tum e		no dre	P=1.	156.mg n.s.s.	0/84	0/43			
lun tum e		no dre	P=1.	156.mg n.s.s.	0/84	0/43			
3187 H m syg wat 28m28 1108					0	14.4mg			
cec tum e		136.mg	P<.02 -	41.0mg 241.gm	0/64	3/33			
liv hem e		no dre	P=1. -	23.3mg n.s.s.	1/22	0/6			
lun tum e		no dre	P=1.	194.mg n.s.s.	0/86	0/50			
3188 H m syg wat 24m24 1821					0	20.4mg	40.8mg	61.2mg	Bosan;carc,8,439-444;1987
liv hpc er		181.mg *	P<.0005 +	95.1mg 431.mg	0/31	0/31	4/31	9/31	
liv mhs er		2.58gm *	P<.3	420.mg n.s.s.	0/31	0/31	0/31	1/31	
liv hpa er		2.59gm *	P<.5	421.mg n.s.s.	0/31	0/31	1/31	0/31	
liv rts er		2.59gm *	P<.5	421.mg n.s.s.	0/31	0/31	1/31	0/31	
3189 H m syg wat 91w91 2324					0	20.4mg	40.8mg	61.2mg	FitzGerald;carc,17,2703-2709;1996/pers.comm.
liv hpa Cer		87.5mg *	P<.002	47.0mg 336.mg	0/8	1/17	3/24	10/23	
liv mix Cer		87.5mg *	P<.002 +	47.0mg 336.mg	0/8	1/17	3/24	10/23	
liv hpc Cer		464.mg *	P<.2	140.mg n.s.s.	0/8	0/17	1/24	2/23	
3190 M f akr wat 69w69 158					0	24.0mg			Toth;jnci,42,469-475;1969a/1966a
liv tum e		no dre	P=1. -	87.1mg n.s.s.	0/30	0/40			
lun tum e		no dre	P=1. -	87.1mg n.s.s.	0/30	0/40			
3191 M m akr wat 69w69 158					0	20.0mg			
lun ade e		no dre	P=1. -	22.9mg n.s.s.	1/11	1/20			
liv hem e		no dre	P=1. -	52.6mg n.s.s.	1/16	0/29			
3192 M f c3h wat 92w92 158					0	24.0mg			
lun ade e		109.mg	P<.05 +	37.7mg n.s.s.	0/22	4/36			
3193 M f cbc gav 36w74 1074					0	21.8mg			Biancifiori;bjca,18,543-550;1964
lun mix e		3.35mg	P<.0005 +	1.58mg 7.60mg	4/47	19/21			
liv hpt e		6.27mg	P<.0005 +	3.19mg 14.5mg	2/47	15/21			
3194 M m cbc gav 36w84 1074					0	16.0mg			
lun mix e		5.10mg	P<.0005 +	2.62mg 11.3mg	1/37	16/21			
liv hpt e		8.43mg	P<.0005 +	4.01mg 26.7mg	4/37	13/21			
3195 M f ic3 gav 73w73 156					0	37.7mg			Bhide;ijcn,18,530-535;1976
lun adc		10.3mg	P<.0005 +	5.58mg 21.6mg	0/12	17/24			
liv tum		no dre	P=1. -	91.9mg n.s.s.	0/12	0/24			
3196 M m ic3 gav 73w73 156					0	31.4mg			
lun adc		79.5mg	P<.2 +	19.5mg n.s.s.	0/12	2/16			
liv tum		no dre	P=1. -	51.1mg n.s.s.	0/12	0/16			
3197 M f swa wat 95w95 158					0	24.0mg			Toth;jnci,42,469-475;1969a/1966a
lun mix e		23.8mg	P<.0005 +	13.1mg 57.1mg	14/109	24/47			
lun ade e		26.7mg	P<.0005	14.5mg 66.4mg	12/109	22/47			
lun adc e		146.mg	P<.03	49.0mg n.s.s.	2/109	5/47			
liv hem e		no dre	P=1. -	97.1mg n.s.s.	3/78	1/36			
3198 M m swa wat 94w94 158					0	20.0mg			
lun mix e		18.7mg	P<.0005 +	10.8mg 39.8mg	10/110	25/50			
lun ade e		23.1mg	P<.0005	12.7mg 55.2mg	10/110	22/50			
lun adc e		74.2mg	P<.0005	32.0mg 237.mg	0/110	7/50			
liv mix e		78.4mg	P<.2	18.7mg n.s.s.	2/40	3/17			
3199 M b swi gav 54w54 1525					0	27.6mg			Maru;clet,17,75-80;1982
lun tum r		3.92mg	P<.0005 +	2.23mg 7.57mg	1/47	22/30			
liv tum r		no dre	P=1.	28.4mg n.s.s.	7/47	2/30			
3200 M b swi gav 95w95 1552					0	27.6mg			Menon;zkko,105,258-261;1983
lun adc r		9.81mg	P<.0005 +	6.55mg 15.7mg	1/20	51/63			
3201 R f cbs gav 68w94 157					0	24.7mg			Severi;jnci,41,331-349;1968
lun mix		42.4mg	P<.004 +	16.0mg 274.mg	0/22	5/18			
liv mix e		no dre	P=1.	54.0mg n.s.s.	0/22	0/13			
3202 R m cbs gav 68w94 157					0	25.9mg			
liv mix eh		39.4mg	P<.002 +	13.5mg 231.mg	0/28	4/13			
lun mix		60.1mg	P<.009 +	18.1mg 1.95gm	0/28	3/14			
2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE 26049-71-8									
3203 M f swi eat 46w66 1076					0	9.06mg			Cohen;canr,33,1593-1597;1973
--- lle e		11.3mg	P<.04 +	3.84mg n.s.s.	1/28	5/22			
liv tum e		no dre	P=1.	16.5mg n.s.s.	0/28	0/22			
lun tum e		no dre	P=1.	16.5mg n.s.s.	0/28	0/22			
tba mix e		11.3mg	P<.04	3.84mg n.s.s.	1/28	5/22			
3204 R f sda eat 46w75 200a					0	3.07mg			Cohen;jnci,51,403-417;1973
mgl adc e		1.02mg	P<.0005	.587mg 2.05mg	6/71	24/35			
mgl mix e		1.03mg	P<.0005 +	.548mg 2.56mg	18/71	26/35			
--- lbl eh		7.09mg	P<.002 +	2.69mg 31.4mg	0/71	5/35			
liv tum e		no dre	P=1.	11.5mg n.s.s.	0/71	0/35			
tba mix e		.582mg	P<.0005	.315mg 1.21mg	18/71	31/35			
2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE (HNT) 26049-68-3									
3205 M f swi eat 46w55 1076					0	54.4mg			Cohen;canr,33,1593-1597;1973
for sqp e		16.4mg	P<.0005 +	7.27mg 48.5mg	0/29	8/17			
liv tum e		no dre	P=1.	53.3mg n.s.s.	0/29	0/17			
lun tum e		no dre	P=1.	53.3mg n.s.s.	0/29	0/17			
tba mix e		7.57mg	P<.0005	3.58mg 20.0mg	2/29	13/17			
3206 R f sda eat 46w57 1073					0	37.1mg			Erturk;jnci,47,437-445;1971/1970a
mgl mix ev		2.83mg	P<.0005 +	1.09mg 7.37mg	2/29	15/16			
mgl adc ev		7.79mg	P<.0005	3.64mg 20.5mg	0/29	10/16			
mgl adf ev		25.2mg	P<.04	8.18mg n.s.s.	2/29	5/16			
kid mix ev		36.8mg	P<.02 +	11.1mg n.s.s.	0/29	3/16			
liv tum ev		no dre	P=1.	36.8mg n.s.s.	0/29	0/16			
tba mix ev		2.83mg	P<.0005	1.09mg 7.37mg	2/29	15/16			
3207 R f sda eat 46w66 1121					0	31.0mg			Cohen;canr,30,897-901;1970
mgl mix e		3.66mg	P<.0005 +	2.00mg 7.00mg	4/35	32/35			
mgl adc e		10.9mg	P<.0005 +	6.26mg 21.3mg	0/35	19/35			
slg adc e		145.mg	P<.1	35.8mg n.s.s.	0/35	2/35			
liv cye e		295.mg	P<.3	48.1mg n.s.s.	0/35	1/35			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix e		noTD50	P<.0005	n.s.s. 3.77mg	4/35	35/35			
2-HYDRAZINO-4-(p-NITROPHENYL)THIAZOLE 26049-70-7									
3208 M f swi eat 46w66 1076					0	9.06mg			Cohen;canr,33,1593-1597;1973
--- lle e		10.6mg	P<.03 +	3.63mg n.s.s.	1/28	5/21			
lun alc e		25.0mg	P<.07	6.14mg n.s.s.	0/28	2/21			
liv tum e		no dre	P=1.	15.8mg n.s.s.	0/28	0/21			
tba mix e		8.33mg	P<.02	3.13mg n.s.s.	1/28	6/21			
3209 R f sda eat 46w75 200a					0	3.07mg			Cohen;jnci,51,403-417;1973
mgl mix e		1.97mg	P<.002 +	.917mg 11.6mg	18/71	20/35			
mgl adc e		3.78mg	P<.004	1.62mg 34.6mg	6/71	11/35			
for sqp e		9.00mg	P<.003	3.11mg 61.2mg	0/71	4/35			
liv tum e		no dre	P=1.	11.5mg n.s.s.	0/71	0/35			
tba mix e		.743mg	P<.0005	.406mg 1.62mg	18/71	29/35			
3210 R f sda eat 45w52 1121					0	73.8mg			Cohen;canr,30,897-901;1970
mgl mix ev		8.66mg	P<.0005 +	4.95mg 17.3mg	4/35	27/34			
mgl adc ev		9.51mg	P<.0005 +	5.64mg 17.3mg	0/35	25/34			
slg adc ev		21.7mg	P<.0005	11.8mg 46.3mg	0/35	15/34			
liv tum ev		no dre	P=1.	129.mg n.s.s.	0/35	0/34			
tba mix ev		noTD50	P<.0005	n.s.s. 5.63mg	4/35	34/34			
2-HYDRAZINO-4-PHENYLTHIAZOLE 34176-52-8									
3211 R f sda eat 46w66 200a					0	26.7mg			Cohen;jnci,51,403-417;1973
liv tum ev		no dre	P=1.	70.9mg n.s.s.	0/25	0/32			
tba mix ev		311.mg	P<.8 -	31.5mg n.s.s.	1/25	2/32			
p-HYDRAZINOBENZOIC ACID 619-67-0									
3212 M f swi gav 40w55 1095					0	20.8mg			Roe;natu,216,375-376;1967
lun tum		no dre	P=1. -	21.7mg n.s.s.	8/85	1/25			
p-HYDRAZINOBENZOIC ACID.HCl 24589-77-3									
3213 M f swa wat 28m28 1741					0	250.mg			McManus;livt,57,78-85;1987
aol mix e		1.07gm	P<.0005 +	462.mg 3.77gm	0/45	7/36			
aol lei e		1.97gm	P<.01 +	680.mg 212.gm	0/45	4/36			
lun ade e		1.17gm	P<.04	469.mg n.s.s.	5/48	13/49			
aol ley e		2.66gm	P<.03 +	806.mg n.s.s.	0/45	3/36			
lun mix e		1.14gm	P<.2	385.mg n.s.s.	12/48	19/49			
lun adc e		11.2gm	P<.9	865.mg n.s.s.	7/48	8/49			
3214 M m swa wat 28m28 1741					0	208.mg			
aol mix e		380.mg	P<.0005 +	216.mg 862.mg	2/46	21/50			
aol lei e		609.mg	P<.002 +	309.mg 2.24gm	2/46	15/50			
aol ley e		1.49gm	P<.005 +	606.mg 11.3gm	0/46	6/50			
lun ade e		597.mg	P<.07	219.mg n.s.s.	10/40	15/33			
lun mix e		675.mg	P<.3	191.mg n.s.s.	15/39	15/28			
lun adc e		no dre	P=1.	652.mg n.s.s.	9/40	6/33			
HYDRAZOBENZENE 122-66-7									
3215 M f b6c eat 78w95 TR92 :					0	4.30mg	42.2mg		
liv MXA		26.0mg *	P<.0005 c	15.2mg 53.2mg	3/100	4/47	22/50		liv:hpa,hpc.
liv hpc		29.7mg *	P<.0005 c	16.9mg 63.7mg	3/100	4/47	20/50		
TBA MXB		31.5mg *	P<.0005	15.7mg 126.mg	29/100	19/47	29/50		
liv MXB		26.0mg *	P<.0005	15.2mg 53.2mg	3/100	4/47	22/50		liv:hpa,hpc,nnd.
lun MXB		8.76gm *	P<1.	100.mg n.s.s.	5/100	3/47	2/50		lun:a/a,a/c.
3216 M m b6c eat 78w95 TR92 :					0	7.90mg	39.4mg		
TBA MXB v		no dre	P=1. -	49.6mg n.s.s.	45/100	18/50	17/50		
liv MXB v		1.09gm *	P<.9	61.0mg n.s.s.	20/100	11/50	9/50		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	148.mg n.s.s.	15/100	2/50	3/50		lun:a/a,a/c.
3217 R f f34 eat 18m25 TR92 :					0	1.40mg	3.60mg		
MXB MXB		6.74mg *	P<.0005	3.58mg 15.9mg	1/100	3/50	12/50		liv:nnd; mgl:acn. C
mgl acn		11.4mg *	P<.002 c	5.11mg 50.7mg	1/100	3/50	6/50		
liv nnd		18.1mg *	P<.0005 c	7.27mg 64.9mg	0/100	0/50	6/50		
TBA MXB		4.50mg *	P<.2	1.61mg n.s.s.	80/100	39/50	36/50		
liv MXB		18.1mg *	P<.0005	7.27mg 64.9mg	0/100	0/50	6/50		liv:hpa,hpc,nnd.
3218 R m f34 eat 18m25 TR92 :					0	2.30mg	8.80mg		
MXB MXB v		3.55mg *	P<.0005	2.37mg 5.97mg	6/99	14/50	38/50		liv:hpc,nnd; zym:sqc. C
liv MXA v		3.70mg *	P<.0005 c	2.44mg 6.30mg	6/99	13/50	37/50		liv:hpc,nnd.
liv hpc v		4.67mg /	P<.0005 c	3.05mg 7.77mg	1/99	5/50	31/50		
adr phe v		16.2mg *	P<.007	7.08mg 323.mg	15/99	7/50	16/50		S
MXA MXA v		35.8mg *	P<.003	14.8mg 258.mg	1/99	2/50	6/50		eac:sqc,sqp; zym:sqc. S
zym sqc v		38.5mg *	P<.0005 c	15.5mg 157.mg	0/99	1/50	5/50		
TBA MXB v		6.85mg *	P<.01	3.13mg 342.mg	62/99	36/50	43/50		
liv MXB v		3.70mg *	P<.0005	2.44mg 6.30mg	6/99	13/50	37/50		liv:hpa,hpc,nnd.
HYDROCHLORIC ACID (hydrogen chloride) 7647-01-0									
3219 R m sda inh 30m30 1674					0	.781mg			Sellakumar;txap,81,401-406;1985
liv hpc e		no dre	P=1. -	14.8mg n.s.s.	1/99	1/99			
nac tum e		no dre	P=1. -	24.1mg n.s.s.	0/99	0/99			
HYDROCHLOROFLUOROCARBON 123 306-83-2									
3220 R f cdr inh 24m24 2240					0	140.mg	468.mg	2.34gm	Malley;faat,25,101-114;1995
liv cgf Ce		22.7gm *	P<.0005 +	9.27gm 82.2gm	0/65	0/67	0/67	6/69	
liv hpa Ce		20.3gm *	P<.04 +	9.07gm n.s.s.	0/65	5/67	2/67	7/69	
pan ana e		92.1gm *	P<.4	15.4gm n.s.s.	0/65	2/67	0/67	2/69	
3221 R m cdr inh 24m24 2240					0	98.3mg	328.mg	1.64gm	
pan ana e		1.26gm Z	P<.0005 +	661.mg 4.43gm	1/67	4/66	12/66	(14/66)	
tes ica e		9.05gm *	P<.07 +	3.20gm n.s.s.	4/67	12/66	9/66	14/66	
liv hpa Ce		13.1gm *	P<.03 +	4.93gm n.s.s.	3/67	2/66	2/66	8/66	
pan acc e		60.8gm *	P<.3	12.1gm n.s.s.	1/67	0/66	0/66	2/66	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

HYDROCHLOROTHIAZIDE 58-93-5
3222 M f b6c eat 24m24 TR357 : 0 320.mg 638.mg
TBA MXB no dre P=1. - 846.mg n.s.s. 36/50 35/50 27/50
liv MXB no dre P=1. 2.74gm n.s.s. 3/50 5/50 1/50 liv:hpa,hpc,nnd.
lun MXB no dre P=1. 3.18gm n.s.s. 4/50 3/50 2/50 lun:a/a,a/c.
3223 M m b6c eat 24m24 TR357 : 0 296.mg 589.mg
liv MXA 1.23gm * P<.008 e 612.mg 24.4gm 7/50 10/50 21/50 liv:hpa,hpc.
liv hpa 1.49gm * P<.007 747.mg 20.3gm 3/50 8/50 14/50 S
TBA MXB 3.82gm / P<.7 610.mg n.s.s. 30/50 20/50 34/50
liv MXB 1.23gm * P<.008 612.mg 24.4gm 7/50 10/50 21/50 liv:hpa,hpc,nnd.
lun MXB 19.8gm * P<.9 1.59gm n.s.s. 8/50 4/50 9/50 lun:a/a,a/c.
3224 R f f34 eat 24m25 TR357 : 0 12.4mg 24.6mg 99.1mg
TBA MXB no dre P=1. - 88.0mg n.s.s. 49/50 39/50 39/50 37/50
liv MXB no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 0/50 liv:hpa,hpc,nnd.
3225 R f f34 eat 24m30 1854 0 44.0mg Lijinsky;txih,3,413-422;1987/pers.comm.
pit mix 33.9mg P<.0005 18.4mg 69.4mg 0/24 18/24
adr phe 100.mg P<.0005 46.7mg 285.mg 0/24 9/24
liv hpc 1.11gm P<.3 180.mg n.s.s. 0/24 1/24
liv mix no dre P=1. 152.mg n.s.s. 4/24 3/24
liv nnd no dre P=1. 194.mg n.s.s. 4/24 2/24
3226 R m f34 eat 24m25 TR357 : 0 9.91mg 19.8mg 79.2mg
TBA MXB 214.mg * P<.7 - 29.2mg n.s.s. 50/50 43/50 44/50 45/50
liv MXB 771.mg * P<.3 143.mg n.s.s. 1/50 0/50 1/50 2/50 liv:hpa,hpc,nnd.
3227 R m f34 eat 24m30 1854 0 46.2mg Lijinsky;txih,3,413-422;1987/pers.comm.
tes car 35.6mg P<.0005 19.3mg 72.9mg 0/24 18/24
pit mix 71.3mg P<.0005 36.1mg 169.mg 0/24 12/24
adr phe 271.mg P<.4 64.1mg n.s.s. 6/24 9/24
liv hpc no dre P=1. 357.mg n.s.s. 1/24 0/24
liv mix no dre P=1. 357.mg n.s.s. 3/24 0/24
liv nnd no dre P=1. 357.mg n.s.s. 2/24 0/24

HYDROCORTISONE (cortisol) 50-23-7
3228 R f sda gav 26m26 1134 0 5.36mg Schmahl;zkko,86,77-84;1976
tba mal e no dre P=1. - 27.5mg n.s.s. 3/33 2/40
3229 R m sda gav 24m24 1134 0 5.36mg
liv hae e no dre P=1. 32.0mg n.s.s. 1/36 0/29
tba mal e no dre P=1. - 32.0mg n.s.s. 1/36 0/29

HYDROGEN PEROXIDE 7722-84-1
3230 M f c56 wat 23m23 1381m 0 200.mg 800.mg Ito;gann,72,174-175;1981/1981a/pers.comm.
duo car ej 7.54gm * P<.008 + 2.60gm 151.gm 0/50 0/50 4/49
duo ade ej 2.01gm \ P<.2 561.mg n.s.s. 1/50 4/50 (0/49)
duo mix ej 7.83gm * P<.3 2.02gm n.s.s. 1/50 4/50 4/49
liv tum ej no dre P=1. 1.52gm n.s.s. 0/50 0/50 0/49
3231 M m c56 wat 23m23 1381m 0 167.mg 667.mg
duo mix ej 4.80gm * P<.2 1.75gm n.s.s. 0/48 3/51 3/50
duo ade ej 7.35gm * P<.3 2.25gm n.s.s. 0/48 2/51 2/50
duo car ej 15.0gm * P<.4 3.23gm n.s.s. 0/48 1/51 1/50
liv hem ej no dre P=1. 4.80gm n.s.s. 0/48 1/51 0/50

HYDROQUINONE 123-31-9
3232 M f b6c gav 24m24 TR366 : 0 35.0mg 70.0mg
liv hpa 65.0mg \ P<.002 32.3mg 305.mg 2/55 15/55 (12/55) S
liv MXA 122.mg * P<.009 p 62.8mg 4.53gm 3/55 16/55 13/55 liv:hpa,hpc.
TBA MXB no dre P=1. 63.5mg n.s.s. 43/55 42/55 39/55
liv MXB 122.mg * P<.009 62.8mg 4.53gm 3/55 16/55 13/55 liv:hpa,hpc,nnd.
lun MXB 19.2gm * P<1. 203.mg n.s.s. 4/55 6/55 4/55 lun:a/a,a/c.
3233 M f b6c eat 96w96 1929 0 1.04gm Shibata;gann,82,1211-1219;1991
liv hpa e 17.9gm P<.3 2.92gm n.s.s. 0/29 1/30
kid ade e no dre P=1. 5.48gm n.s.s. 0/29 0/30
liv hpc e no dre P=1. 5.48gm n.s.s. 1/29 0/30
3234 M m b6c gav 24m24 TR366 : 0 35.3mg 70.5mg
TBA MXB 497.mg * P<.8 - 45.4mg n.s.s. 39/55 46/55 44/55
liv MXB 383.mg * P<.7 63.4mg n.s.s. 20/55 29/55 25/55 liv:hpa,hpc,nnd.
lun MXB no dre P=1. 183.mg n.s.s. 14/55 11/55 10/55 lun:a/a,a/c.
3235 M m b6c eat 96w96 1929 0 960.mg Shibata;gann,82,1211-1219;1991
liv hpa e 1.45gm P<.05 + 572.mg n.s.s. 6/28 14/30
kid ade e 5.32gm P<.05 + 1.61gm n.s.s. 0/28 3/30
liv hpc e no dre P=1. 1.69gm n.s.s. 7/28 6/30
3236 R f f34 gav 24m24 TR366 : 0 17.6mg 35.3mg
--- mnl 55.8mg * P<.006 p 27.9mg 747.mg 9/55 15/55 22/55
TBA MXB 51.6mg * P<.3 15.6mg n.s.s. 47/55 49/55 50/55
liv MXB no dre P=1. n.s.s. n.s.s. 0/55 0/55 0/55 liv:hpa,hpc,nnd.
3237 R m f34 gav 24m24 TR366 : 0 17.6mg 35.2mg
kid rua 64.7mg * P<.0005 p 32.1mg 181.mg 0/55 4/55 8/55
amd MXA 40.4mg * P<.03 17.7mg n.s.s. 14/55 19/55 21/55 amd:pbb,phm,pob. S
amd MXA 48.2mg * P<.05 19.9mg n.s.s. 13/55 17/55 19/55 amd:pbb,pob. S
TBA MXB 41.8mg * P<.3 12.7mg n.s.s. 49/55 46/55 48/55
liv MXB 5.71gm * P<1. 82.6mg n.s.s. 3/55 2/55 2/55 liv:hpa,hpc,nnd.
3238 R f f3d eat 24m24 1929 0 400.mg Shibata;gann,82,1211-1219;1991
liv hpc e 8.08gm P<.3 1.32gm n.s.s. 0/30 1/30
liv hnd e no dre P=1. 1.20gm n.s.s. 2/30 2/30
kid ade e no dre P=1. 2.47gm n.s.s. 0/30 0/30
3239 R m f3d eat 24m24 1929 0 320.mg
kid ade e 349.mg P<.0005 + 185.mg 766.mg 0/30 14/30
liv hnd e no dre P=1. 1.32gm n.s.s. 2/30 1/30
liv hpc e no dre P=1. 1.19gm n.s.s. 1/30 1/30

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf | Brkly Code
Path TD_{50} 2Tailpvl LoConf | Cntrl 1 Inc 2 Inc 3 Inc | NCI/NTPPathology

HYDROQUINONE MONOBENZYL ETHER (agerite alba) 103-16-2

3240 M f b6a orl 76w76 1308					0	205.mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	383.mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	-	383.mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	-	180.mg n.s.s.	2/17	2/17			
3241 M m b6a orl 76w76 1308					0	190.mg			
lun ade evx	no dre	P=1.	-	178.mg n.s.s.	2/18	2/18			
liv hpt evx	no dre	P=1.	-	225.mg n.s.s.	1/18	1/18			
tba mix evx	no dre	P=1.	-	150.mg n.s.s.	3/18	3/18			
3242 M f b6c orl 76w76 1308					0	205.mg			
liv hpt evx	no dre	P=1.	-	383.mg n.s.s.	0/16	0/17			
lun mix evx	no dre	P=1.	-	383.mg n.s.s.	0/16	0/17			
tba mix evx	1.23gm	P<.3	-	201.mg n.s.s.	0/16	1/17			
3243 M m b6c orl 76w76 1308					0	190.mg			
liv hpt evx	382.mg	P<.05	-	115.mg n.s.s.	0/16	3/18			
lun ade evx	382.mg	P<.05	-	115.mg n.s.s.	0/16	3/18			
tba mix evx	141.mg	P<.002	-	60.3mg 576.mg	0/16	7/18			

3-HYDROXY-4-ACETYLAMINOBIPHENYL 4463-22-3

3244 R f nss eat 43w65 1424					0	12.3mg			Miller;jnci,15,1571-1590;1955
liv tum	no dre	P=1.	-	7.94mg n.s.s.	0/15	0/8			

N-HYDROXY-2-ACETYLAMINOFLUORENE (hydroxy-N-2-fluorenylacetamide) 53-95-2

3245 H m nss eat 32w56 308m					0	17.0mg			Miller;canr,24,2018-2026;1964
for mix	2.10mg	P<.0005	+	1.07mg 4.56mg	0/17	16/20			
liv bda	20.8mg	P<.05	+	6.27mg n.s.s.	0/17	3/20			
3246 H m nss ipj 34w69 308n					0	3.43mg			
per fbs	2.20mg	P<.03		.652mg n.s.s.	0/8	3/8			
for pam	no dre	P=1.		2.49mg n.s.s.	0/8	0/8			
smi adc	no dre	P=1.		2.49mg n.s.s.	0/8	0/8			
3247 M f ddd eat 30w76 1628					0	25.6mg			Enomoto;jjem,44,37-54;1974
for mix e	6.23mg	P<.0005	+	3.08mg 14.3mg	0/16	14/18			
ubl mix e	7.32mg	P<.0005	+	3.62mg 17.1mg	0/16	13/18			
liv hpt e	16.0mg	P<.0005	+	7.10mg 52.5mg	0/16	8/18			
ubl epc e	16.0mg	P<.0005		7.10mg 52.5mg	0/16	8/18			
eso ept e	28.8mg	P<.009	+	10.9mg 632.mg	0/16	5/18			
k/p ept e	164.mg	P<.3	+	26.7mg n.s.s.	0/16	1/18			
lun ade e	no dre	P=1.	-	34.0mg n.s.s.	2/16	1/18			
3248 R f nbr eat 64w64 162a					0	4.00mg			Yamamoto;ijcn,2,337-343;1967
liv mix	1.74mg	P<.0005	+	.805mg 4.90mg	0/20	9/20			
liv cho	2.03mg	P<.0005	+	.908mg 6.43mg	0/20	8/20			
3249 R m nbr eat 64w64 162a					0	3.20mg			
liv mix	.690mg	P<.0005	+	.352mg 1.55mg	0/20	14/20			
liv cho	16.2mg	P<.3		2.64mg n.s.s.	0/20	1/20			

3-HYDROXY-4-AMINOBIPHENYL (4-amino-3-hydroxybiphenyl) 4363-03-5

3250 R f nss eat 43w65 1424					0	9.67mg			Miller;jnci,15,1571-1590;1955
liv tum	no dre	P=1.	-	5.45mg n.s.s.	0/15	0/7			

3-HYDROXY-p-BUTYROPHENETIDIDE (betadid, bucetin) 1083-57-4

3251 M f b6c eat 72w84 1835					0	795.mg	1.76gm		Togei;jnci,79,1151-1158;1987
liv hpa ae	4.00gm \	P<.02		1.38gm n.s.s.	0/46	4/47	(0/46)		
lun act ae	11.3gm *	P<.4		3.06gm n.s.s.	1/46	6/47	3/46		
liv hpc ae	no dre	P=1.		8.72gm n.s.s.	0/46	1/47	0/46		
3252 M m b6c eat 70w84 1835					0	745.mg	1.54gm		
kid rcc ae	5.53gm *	P<.004	+	2.50gm 32.0gm	0/47	2/45	6/46		
--- lkm ae	2.74gm \	P<.04		997.mg n.s.s.	1/47	6/45	(1/46)		
kid rca ae	5.58gm *	P<.02	+	2.53gm n.s.s.	0/47	4/45	4/46		
lun act ae	5.28gm *	P<.3		1.60gm n.s.s.	6/47	12/45	10/46		
liv hpa ae	17.5gm \	P<.9		833.mg n.s.s.	14/47	14/45	(0/46)		
ubl pam ae	46.4gm *	P<.3		7.55gm n.s.s.	0/47	0/45	1/46		
liv hem ae	406.gm *	P<1.		5.29gm n.s.s.	3/47	1/45	3/46		
liv hpc ae	no dre	P=1.		6.91gm n.s.s.	7/47	4/45	2/46		

1-HYDROXYANTHRAQUINONE 129-43-1

3253 R m ain eat 68w68 1937					0	400.mg			Mori;carc,11,799-802;1990
lgi mix e	59.2mg	P<.0005	+	32.9mg 112.mg	0/30	25/29			
col ade e	219.mg	P<.0005	+	112.mg 517.mg	0/30	12/29			
liv mix e	219.mg	P<.0005	+	112.mg 517.mg	0/30	12/29			
liv nnd e	219.mg	P<.0005		112.mg 517.mg	0/30	12/29			
col adc e	246.mg	P<.0005	+	122.mg 605.mg	0/30	11/29			
cec ade e	277.mg	P<.0005	+	134.mg 726.mg	0/30	10/29			
cec adc e	619.mg	P<.007	+	235.mg 7.54gm	0/30	5/29			
sto mix e	619.mg	P<.007	+	235.mg 7.54gm	0/30	5/29			
for pam e	789.mg	P<.02		272.mg n.s.s.	0/30	4/29			
liv hpc e	789.mg	P<.02		272.mg n.s.s.	0/30	4/29			
stg ade e	3.34gm	P<.3		544.mg n.s.s.	0/30	1/29			
3254 R m f34 eat 78w78 2235					0	400.mg			Yoshimi;clet,97,75-82;1995/pers.comm.
lgi mix er	222.mg	P<.004	+	81.7mg 1.56gm	0/10	5/10			
col adc er	432.mg	P<.04		129.mg n.s.s.	0/10	3/10			
col mix er	432.mg	P<.04	+	129.mg n.s.s.	0/10	3/10			
cec adc er	432.mg	P<.04	+	129.mg n.s.s.	0/10	3/10			

1'-HYDROXYESTRAGOLE 51410-44-7

3255 M f cd1 eat 51w86 1582					0	80.7mg			Miller;canr,43,1124-1134;1983
liv hpt v	57.8mg	P<.0005	+	35.2mg 104.mg	0/50	24/50			
lun ade v	no dre	P=1.		383.mg n.s.s.	2/50	1/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | NCI/NTPPathology

1-(2-HYDROXYETHYL)-3-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE 5036-03-3
3256 R f sda eat 46w66 200a 0 34.8mg Cohen;jnci,51,403-417;1973
mgl adc e 16.7mg P<.0005 + 8.90mg 36.9mg 0/25 14/32
liv tum e no dre P=1. 92.6mg n.s.s. 0/25 0/32
tba mix e 18.0mg P<.0005 9.19mg 56.5mg 1/25 14/32

1-(2-HYDROXYETHYL)-NITROSO-3-ETHYLUREA 96724-45-7
3257 R f f34 wat 7m24 2010 0 .443mg .885mg Lijinsky;vivo,4,1-6;1990
mam car e .501mg * P<.0005 + .261mg 1.22mg 0/12 6/12 8/12
liv tum e no dre P=1. .730mg n.s.s. 0/12 0/12 0/12
3258 R m f34 wat 7m24 2010 0 .310mg .620mg
lun tum e .446mg * P<.0005 .224mg 1.28mg 0/12 5/12 7/12
tnv mso e .576mg * P<.002 .276mg 2.22mg 0/12 4/12 6/12
ski tum e .641mg * P<.002 + .297mg 2.13mg 0/12 2/12 7/12
ner tum e .754mg * P<.003 .337mg 3.30mg 0/12 2/12 6/12
liv tum e 1.09mg * P<.02 .440mg n.s.s. 0/12 2/12 4/12

1-(2-HYDROXYETHYL)-1-NITROSOUREA (N-nitroso-2-hydroxethylurea) 13743-07-2
3259 M f swi wat 50w51 1967 () 0 4.29mg 8.57mg Mirvish;clet,54,101-106;1990/pers.comm.
--- lym e .603mg * P<.0005 + .327mg 1.28mg 1/15 11/14 13/15
lun ade e 1.97mg * P<.0005 1.00mg 6.03mg 0/15 5/14 7/15
tba tum e noTD50 P<.0005 n.s.s. .453mg 2/15 14/14 15/15
3260 M m swi wat 50w51 1967 () 0 3.57mg 7.14mg
lun ade e .382mg \ P<.0005 .173mg .988mg 0/12 11/14 (6/15)
--- lym e 1.27mg * P<.0005 + .671mg 3.06mg 0/12 4/14 10/15
tba tum e .353mg * P<.0005 .170mg .832mg 2/12 11/14 15/15
3261 R f f34 gav 37w60 1792m 0 .707mg Lijinsky;gann,79,181-186;1988/1986
mgl adc j .452mg P<.003 + .183mg 2.36mg 0/20 6/20
col ade j 1.53mg P<.1 .376mg n.s.s. 0/20 2/20
for sqc j 3.15mg P<.3 .512mg n.s.s. 0/20 1/20
zym car j 3.15mg P<.3 .512mg n.s.s. 0/20 1/20
for mix j no dre P=1. .461mg n.s.s. 2/20 2/20
lun a/a j no dre P=1. .581mg n.s.s. 1/20 1/20
3262 R m f34 gav 37w55 1792m 0 .540mg
lun mix j 77.6ug P<.0005 + 38.9ug .188mg 1/20 15/20
for mix j .203mg P<.0005 + 90.6ug .641mg 0/20 8/20
col mix j .240mg P<.002 + .103mg .910mg 0/20 7/20
for sqc j .637mg P<.04 .192mg n.s.s. 0/20 3/20
col adc j .983mg P<.1 .241mg n.s.s. 0/20 2/20
zym mix j .568mg P<.3 .153mg n.s.s. 2/20 5/20
lun mal j .602mg P<.2 .170mg n.s.s. 1/20 4/20
zym car j .879mg P<.4 .183mg n.s.s. 2/20 4/20
3263 R f mrw wat 39w85 2038m 0 1.12mg Mirvish;jtxe,32,59-74;1991/pers.comm.
--- bly 3.16mg P<.2 + .956mg n.s.s. 0/10 3/20
--- mye 3.16mg P<.2 - .956mg n.s.s. 0/10 3/20
liv tum 10.0mg P<.4 1.63mg n.s.s. 0/10 1/20
tba tum .320mg P<.0005 .163mg .696mg 0/10 16/20
3264 R m mrw wat 52w70 1246 0 2.10mg Bulay;jnci,62,1523-1528;1979
bon ost 1.52mg P<.002 + .786mg 5.40mg 1/26 15/40
--- mly 2.03mg P<.0005 + 1.02mg 5.89mg 0/26 11/40
--- lcl 2.03mg P<.0005 1.02mg 5.89mg 0/26 11/40
tba mix .360mg P<.0005 .190mg .903mg 10/26 36/40
3265 R m mrw wat 39w85 2038m 0 .983mg Mirvish;jtxe,32,59-74;1991/pers.comm.
--- bly 1.56mg P<.2 + .591mg n.s.s. 0/5 5/20
bon ost 1.56mg P<.2 + .591mg n.s.s. 0/5 5/20
--- mye 2.02mg P<.2 - .694mg n.s.s. 0/5 4/20
liv tum 2.77mg P<.3 .836mg n.s.s. 0/5 3/20
tba tum .195mg P<.0005 92.9ug .450mg 0/5 18/20
3266 R m wis wat 90w90 2038n 0 2.14mg
lun tum 1.59mg P<.002 + .857mg 4.69mg 0/10 15/30
mgl adc 4.14mg P<.04 + 1.78mg n.s.s. 0/10 7/30
kid tum 4.93mg P<.06 + 2.00mg n.s.s. 0/10 6/30
--- mye 3.66mg P<.2 + 1.43mg n.s.s. 1/10 10/30
--- bly 15.9mg P<.3 3.92mg n.s.s. 0/10 2/30
liv tum no dre P=1. 9.92mg n.s.s. 0/10 0/30
tba tum .576mg P<.0005 .314mg 1.27mg 1/10 26/30

4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL)QUINAZOLINE 33389-36-5
3267 R f sda eat 46w66 1390 0 17.4mg Cohen;jnci,57,277-282;1976
itn lei e 3.84mg P<.0005 2.16mg 7.49mg 0/84 20/28
liv bda e 132.mg P<.1 21.5mg n.s.s. 0/84 1/28
tba mix e 1.87mg P<.0005 + .939mg 3.79mg 6/84 26/28

2-HYDROXYETHYLHYDRAZINE (BOH) 109-84-2
3268 H f syg wat 84w84 160 0 20.5mg Shimizu;jnci,52,903-906;1974
liv hpt s 148.mg P<.02 - 44.7mg 28.1gm 0/100 3/50
lun tum s no dre P=1. 137.mg n.s.s. 0/100 0/50
3269 H m syg wat 84w84 160 0 18.0mg
liv hpt s 84.4mg P<.02 - 29.9mg 49.0gm 1/100 5/50
lun tum s no dre P=1. 121.mg n.s.s. 0/100 0/50
3270 M f b6a orl 78w78 159 0 .708mg Innes;ntis,1968/1969
lun ade evx no dre P=1. .670mg n.s.s. 2/15 2/17
liv hpt evx no dre P=1. 1.39mg n.s.s. 1/15 0/17
tba mix evx 5.34mg P<.8 .508mg n.s.s. 2/15 3/17
3271 M m b6a orl 78w78 159 0 .660mg
liv hpt evx .314mg P<.0005 + .148mg .820mg 0/18 10/18
lun ade evx no dre P=1. .912mg n.s.s. 2/18 1/18

Chemical / Synonym / CAS number	Spe	Strain	Xpo+Xpt	Sex	Route	Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference

Site	Notes	DR	AuOp	UpConf						Brkly Code
	Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun	mix evx	no dre	P=1.		.975mg n.s.s.	3/18	1/18			
tba	mix evx	.404mg	P<.02		.163mg n.s.s.	3/18	10/18			
3272	M f b6c orl 78w78 159					0	.708mg			
liv	hpt evx	4.77mg	P<.3		.777mg n.s.s.	0/17	1/18			
lun	ade evx	4.77mg	P<.3		.777mg n.s.s.	0/17	1/18			
tba	mix evx	4.77mg	P<.6		.628mg n.s.s.	1/17	2/18			
3273	M m b6c orl 78w78 159					0	.660mg			
liv	hpt evx	.541mg	P<.02	+	.212mg n.s.s.	1/17	7/17			
lun	ade evx	no dre	P=1.		.774mg n.s.s.	1/17	1/17			
tba	mix evx	.713mg	P<.4		.177mg n.s.s.	7/17	10/17			
3274	M f swi wat 75w75 160					0	30.0mg			Shimizu;jnci,52,903-906;1974
lun	tum s	no dre	P=1.	-	65.1mg n.s.s.	21/100	7/50			
liv	mix s	no dre	P=1.		107.mg n.s.s.	3/100	1/50			
3275	M m swi wat 75w75 160					0	25.0mg			
lun	tum s	no dre	P=1.	-	84.2mg n.s.s.	23/100	4/50			
liv	mix s	no dre	P=1.	-	100.mg n.s.s.	6/100	1/50			
1-(3-HYDROXYPROPYL)-1-NITROSOUREA		71752-70-0								
3276	R f f34 gav 7m24 1915m					0	.751mg			Lijinsky;txih,5,925-935;1989
for	tum	1.27mg	P<.02	+	.433mg n.s.s.	0/12	4/12			
liv	tum	1.27mg	P<.02		.433mg n.s.s.	0/12	4/12			
lun	mix	no dre	P=1.		1.86mg n.s.s.	1/12	0/12			
3277	R f f34 gav 9m24 1915n					0	.520mg			
liv	tum	no dre	P=1.		1.29mg n.s.s.	0/12	0/12			
3278	R m f34 gav 7m24 1915m					0	.526mg			
ski	mix	.668mg	P<.005		.249mg 5.36mg	0/12	5/12			
stg	tum	.888mg	P<.02	+	.303mg n.s.s.	0/12	4/12			
for	tum	1.98mg	P<.09	+	.484mg n.s.s.	0/12	2/12			
lun	mix	1.79mg	P<.3		.405mg n.s.s.	1/12	3/12			
liv	tum	3.78mg	P<.6		.531mg n.s.s.	1/12	2/12			
3279	R m f34 gav 9m24 1915n					0	.364mg			
for	tum	.866mg	P<.04	+	.260mg n.s.s.	0/12	3/12			
liv	tum	1.24mg	P<.3		.280mg n.s.s.	1/12	3/12			
8-HYDROXYQUINOLINE (8-quinolinol)		148-24-3								
3280	M f b6c eat 24m24 TR276 :					0	193.mg	386.mg		
---	MXA #	819.mg \	P<.02	-	305.mg n.s.s.	0/50	5/50	(1/50)		---:hem,hes. S
TBA	MXB	no dre	P=1.		172.mg n.s.s.	33/50	30/50	(25/50)		
liv	MXB	no dre	P=1.		1.36gm n.s.s.	5/50	2/50	4/50		liv:hpa,hpc,nnd.
lun	MXB	2.98gm *	P<.5		713.mg n.s.s.	2/50	5/50	5/50		lun:a/a,a/c.
3281	M m b6c eat 24m24 TR276 :					0	178.mg	357.mg		
TBA	MXB	no dre	P=1.	-	373.mg n.s.s.	35/50	35/50	35/50		
liv	MXB	17.7gm *	P<1.		478.mg n.s.s.	14/50	15/50	17/50		liv:hpa,hpc,nnd.
lun	MXB	2.77gm *	P<.6		550.mg n.s.s.	6/50	10/50	10/50		lun:a/a,a/c.
3282	R f f34 eat 24m24 TR276 :					0	74.3mg	149.mg		
TBA	MXB	434.mg *	P<.6	-	84.9mg n.s.s.	40/50	44/50	45/50		
liv	MXB	no dre	P=1.		552.mg n.s.s.	4/50	2/50	4/50		liv:hpa,hpc,nnd.
3283	R f f34 eat 24m24 1529					0	50.0mg			Fukushima;clet,14,115-123;1981
liv	hnd e	no dre	P=1.	-	285.mg n.s.s.	3/44	1/39			
3284	R m f34 eat 24m24 TR276 :					0	59.4mg	119.mg		
lun	MXA #	651.mg *	P<.03	-	277.mg n.s.s.	0/50	3/50	4/50		lun:a/a,a/c. S
thy	ccr	1.06gm *	P<.03		362.mg n.s.s.	0/50	0/50	4/50		S
TBA	MXB	no dre	P=1.		141.mg n.s.s.	43/50	42/50	36/50		
liv	MXB	no dre	P=1.		693.mg n.s.s.	7/50	1/50	3/50		liv:hpa,hpc,nnd.
3285	R m f34 eat 52w52 166m					0	320.mg			Yamamoto;txap,19,687-698;1971
liv	tum e	no dre	P=1.	-	165.mg n.s.s.	0/10	0/10			
3286	R m f34 eat 78w78 166n					0	320.mg			
tes	ldc	398.mg	P<.02	-	136.mg n.s.s.	0/15	4/15			
liv	tum	no dre	P=1.	-	556.mg n.s.s.	0/15	0/15			
3287	R m f34 eat 24m24 1529					0	40.0mg			Fukushima;clet,14,115-123;1981
liv	hnd e	269.mg	P<.04	-	81.4mg n.s.s.	0/31	3/31			
1'-HYDROXYSAFROLE		5208-87-7								
3288	M f b6b eat 52w69 1581n					0	135.mg	260.mg		Boberg;canr,43,5163-5173;1983
liv	hpt ev	1.53gm *	P<.3		404.mg n.s.s.	1/44	2/41	3/42		
3289	M f b6n eat 52w69 1581n					0	135.mg	260.mg		
liv	hpt ev	53.3mg *	P<.0005	+	36.6mg 81.6mg	1/49	24/38	27/38		
3290	M f cd1 eat 51w73 1035c					0	483.mg			Wislocki;canr,37,1883-1891;1977
liv	hpc ev	68.0mg	P<.0005	+	37.7mg 125.mg	0/53	30/33			
sub	ang ev	1.55gm	P<.007		587.mg 17.2gm	0/55	5/50			
lun	tum ev	no dre	P=1.		2.45gm n.s.s.	0/55	0/50			
3291	M f cd1 eat 52w69 1581m					0	135.mg	260.mg		Boberg;canr,43,5163-5173;1983
liv	hpt ev	49.1mg *	P<.0005	+	32.7mg 77.2mg	0/32	17/29	25/32		
lun	ade ev	3.67gm *	P<.9		597.mg n.s.s.	0/32	1/29	0/32		
3292	M m cd1 eat 51w73 1035c					0	446.mg			Wislocki;canr,37,1883-1891;1977
liv	car ev	no dre	P=1.		1.13gm n.s.s.	0/44	0/25			
lun	tum ev	no dre	P=1.		2.04gm n.s.s.	0/55	0/45			
3293	M m cd1 eat 56w69 1042a					0	429.mg	536.mg		Borchert;canr,33,590-600;1973
isp	ang	429.mg *	P<.0005	+	245.mg 972.mg	1/50	7/25	13/40		
lun	ade	5.47gm *	P<.5		1.05gm n.s.s.	1/50	1/25	2/40		
liv	car	18.9gm *	P<.9		872.mg n.s.s.	4/50	3/25	3/40		
3294	R m cdr eat 58w95 1035c					0	77.3mg	100.mg		Wislocki;canr,37,1883-1891;1977
liv	hpc ae	47.8mg *	P<.0005	+	28.2mg 88.3mg	0/18	7/18	16/18		
3295	R m cdr eat 43w69 1042a					0	138.mg			Borchert;canr,33,590-600;1973
liv	car	16.7mg	P<.0005	+	6.14mg 47.1mg	0/12	11/12			
for	pam	59.8mg	P<.002	+	23.7mg 269.mg	0/12	6/12			
3296	R m cdr eat 36w52 1042c					0	156.mg			
liv	car	12.1mg	P<.0005	+	5.64mg 27.7mg	0/18	16/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
for pam	65.8mg	P<.003	+	26.6mg 334.mg	0/18	6/18			
IBUPROFEN 15687-27-1									
3297 R m f34 eat 54w54 2078					0	16.0mg			Reddy;carc,13,1019-1023;1992
col mix er	no dre	P=1.		10.7mg n.s.s.	0/12	0/12			
ICRF-159 21416-87-5									
3298 M f b6c ipj 52w86 TR78 :					0	10.0mg	21.0mg		
--- MXA	23.7mg	* P<.005	c	12.7mg 187.mg	0/15	5/35	9/35		---:leu,lym.
--- MXB	23.7mg	* P<.005		12.7mg 187.mg	0/15	5/35	9/35		---:leu,lhc,lym. C
--- lhc	53.7mg	* P<.03	c	21.9mg n.s.s.	0/15	1/35	5/35		
TBA MXB	16.8mg	* P<.003		9.72mg 86.4mg	0/15	8/35	11/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		lun:a/a,a/c.
3299 M f b6c ipj 52w86 TR78 : pool					0	10.0mg	21.0mg		
--- MXA	25.9mg	* P<.0005		13.2mg 90.5mg	1/45	5/35	9/35		---:leu,lym. S
--- lhc	53.7mg	* P<.003	c	21.9mg 268.mg	0/45	1/35	5/35		
3300 M m b6c ipj 52w86 TR78 :					0	10.0mg	21.0mg		
TBA MXB	262.mg	* P<.8	-	23.0mg n.s.s.	2/15	2/35	3/35		
liv MXB	no dre	P=1.		65.8mg n.s.s.	2/15	0/35	0/35		liv:hpa,hpc,nnd.
lun MXB	212.mg	* P<.3		34.5mg n.s.s.	0/15	0/35	1/35		lun:a/a,a/c.
3301 R f sda ipj 52w81 TR78 :					0	13.0mg	26.0mg		
ute acn	11.3mg	* P<.002	c	6.67mg 34.9mg	0/10	10/34	11/35		
TBA MXB	6.48mg	* P<.005		3.48mg 66.8mg	4/10	24/34	22/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/10	0/34	0/35		liv:hpa,hpc,nnd.
3302 R f sda ipj 52w79 TR78 : pool					0	13.0mg	26.0mg		
ute acn	10.7mg	* P<.0005	c	6.34mg 20.1mg	0/40	10/34	11/35		
3303 R m sda ipj 52w81 TR78 :					0	13.0mg	26.0mg		
TBA MXB s	9.55mg	* P<.03	-	4.34mg n.s.s.	1/10	11/36	4/35		
liv MXB s	105.mg	* P<.5		17.2mg n.s.s.	0/10	1/36	0/35		liv:hpa,hpc,nnd.
3-((IMINO((2,2,2-TRIFLUOROETHYL)AMINO)METHYL)AMINO)-1H-PYRAZOLE-1-PENTAMIDE (ICI 162846) 84545-30-2									
3304 M f b6c eat 91w91 1896					0	20.0mg	100.mg	500.mg	Streett;txpy,16,299-304;1988
gam cnd er	956.mg	* P<.0005	+	524.mg 2.04gm	0/100	1/50	0/50	14/50	
3305 M m b6c eat 91w91 1896					0	20.0mg	100.mg	500.mg	
gam cnd er	401.mg	Z P<.0005	+	257.mg 674.mg	0/100	1/50	0/50	29/50	
3306 R f sda eat 24m24 1896					0	20.0mg	100.mg	500.mg	
gam cnd er	1.35gm	* P<.0005	+	686.mg 3.83gm	0/104	3/52	3/52	11/52	
3307 R m sda eat 24m24 1896					0	20.0mg	100.mg	500.mg	
gam cnd er	1.03gm	Z P<.003	+	357.mg 6.30gm	0/104	0/52	4/52	(4/52)	
3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE(ESTER).HCl (IPD) 3458-22-8									
3308 M f b6c ipj 52w86 TR18 :					0	5.20mg	11.6mg		
TBA MXB e	1.17mg	* P<.0005	-	.541mg 3.20mg	3/15	13/36	14/35		
liv MXB e	no dre	P=1.		n.s.s. n.s.s.	0/15	0/36	0/35		liv:hpa,hpc,nnd.
lun MXB e	6.88mg	* P<.04		1.77mg n.s.s.	1/15	2/36	2/35		lun:a/a,a/c.
3309 M m b6c ipj 52w78 TR18 :					0	5.80mg	14.0mg		
--- lym #	37.7mg	* P<.04	-	9.01mg n.s.s.	0/15	0/34	3/35		S
TBA MXB	2.07mg	/ P<.0005		.728mg 7.51mg	1/15	6/34	4/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/34	0/35		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/34	0/35		lun:a/a,a/c.
3310 R f sda ipj 36w80 TR18 :					0	3.30mg	4.90mg	21.0mg	
per MXA as	2.74mg	Z P<.003	a	.722mg 27.7mg	0/20	0/35	3/35	0/35	per:fbs,srn.
TBA MXB as	.616mg	* P<.006		.228mg 9.06mg	12/20	8/35	3/35	0/35	
liv MXB as	5.01mg	* P<.05		.816mg n.s.s.	0/20	0/35	1/35	0/35	liv:hpa,hpc,nnd.
3311 R m sda ipj 36w80 TR18 :					0	4.90mg	21.0mg		
per MXA as	.915mg	* P<.003	a	.160mg 23.9mg	0/20	3/70	0/35		per:fbs,fib,srn.
TBA MXB as	1.30mg	* P<.0005		.226mg 11.1mg	5/20	7/70	1/35		
liv MXB as	no dre	P=1.		n.s.s. n.s.s.	0/20	0/70	0/35		liv:hpa,hpc,nnd.
IMINODIACETIC ACID, MONOSODIUM 32607-00-4									
3312 R f mrc wat 20m24 213					0	165.mg			Lijinsky;jnci,50,1061-1063;1973
tba mix e	143.mg	P<.03	-	53.5mg n.s.s.	4/15	10/15			
3313 R m mrc wat 20m24 213					0	115.mg			
tba mix e	no dre	P=1.	-	134.mg n.s.s.	8/15	5/15			
INDOLE 120-72-9									
3314 M f swa eat 70w70 2401					0	1.30gm			El-Aaser;ejca,14,645-648;1978
ubl car r	no dre	P=1.	-	3.03gm n.s.s.	0/45	0/25			
INDOLE-3-ACETIC ACID (heteroauxin) 87-51-4									
3315 M f b6a orl 76w76 1280					0	89.1mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	-	99.3mg n.s.s.	1/17	1/17			
liv hpt evx	no dre	P=1.	-	167.mg n.s.s.	0/17	0/17			
tba mix evx	no dre	P=1.	-	78.3mg n.s.s.	2/17	2/17			
3316 M m b6a orl 76w76 1280					0	82.9mg			
liv hpt evx	no dre	P=1.	-	98.0mg n.s.s.	1/18	1/18			
lun ade evx	no dre	P=1.	-	109.mg n.s.s.	2/18	1/18			
tba mix evx	no dre	P=1.	-	65.2mg n.s.s.	3/18	3/18			
3317 M f b6c orl 76w76 1280					0	89.1mg			
lun ade evx	538.mg	P<.3	-	87.5mg n.s.s.	0/16	1/17			
liv hpt evx	no dre	P=1.	-	167.mg n.s.s.	0/16	0/17			
tba mix evx	538.mg	P<.3	-	87.5mg n.s.s.	0/16	1/17			
3318 M m b6c orl 76w76 1280					0	82.9mg			
liv hpt evx	113.mg	P<.02	-	38.9mg n.s.s.	0/16	4/17			
lun ade evx	500.mg	P<.3	-	81.5mg n.s.s.	0/16	1/17			
tba mix evx	40.3mg	P<.0005	-	18.5mg 114.mg	0/16	9/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
INDOLIDAN 100643-96-7									
3319 R f f34 eat 24m24 2033					0	.125mg	.375mg	1.25mg	Sandusky;faat,16,198-209;1991/pers.comm.
amd mix e		4.82mg	* P<.0005	+ 2.38mg 19.9mg	3/60	2/59	3/58	13/60	
amd pob e		5.05mg	* P<.0005	2.48mg 20.6mg	3/60	2/59	2/58	13/60	
amd phm e		no dre	P=1.	12.0mg n.s.s.	0/60	0/59	1/58	0/60	
3320 R m f34 eat 95w95 2033					0	.100mg	.300mg	1.00mg	
amd mix es		1.27mg	* P<.0005	+ .737mg 3.15mg	4/60	9/60	13/60	24/60	
amd pob es		1.38mg	* P<.0005	.784mg 3.64mg	4/60	9/60	12/60	23/60	
amd phm es		23.8mg	* P<.2	5.86mg n.s.s.	0/60	0/60	1/60	1/60	
INDOMETHACIN 53-86-1									
3321 R m f3d eat 52w52 2192					0	2.00mg			Shibata;carc,14,1265-1269;1993/pers.comm.
for tum er		no dre	P=1.	1.03mg n.s.s.	0/10	0/10			
3322 R f sda wat 92w92 2251					0	.887mg			Holmang;carc,16,1493-1498;1995
mgl mix e		1.15mg	P<.01	+ .533mg 75.3mg	12/49	24/48			
mgl adc e		5.32mg	P<.08	+ 1.74mg n.s.s.	1/49	5/48			
liv tum e		no dre	P=1.	6.87mg n.s.s.	0/49	0/48			
IODINATED GLYCEROL (organidin) 5634-39-9									
3323 M f b6c gav 24m24 TR340 :					0	43.4mg	87.6mg		
MXB MXB		92.4mg	* P<.005	47.4mg 806.mg	15/50	21/50	34/50		hag:adn,can; pta:adn. P
pta adn		138.mg	* P<.02	p 67.0mg n.s.s.	10/50	15/50	24/50		
hag MXA		263.mg	* P<.06	p 107.mg n.s.s.	6/50	8/50	14/50		hag:adn,can.
liv MXA		373.mg	* P<.02	175.mg n.s.s.	0/50	5/50	4/50		liv:hpa,hpc. S
liv hpa		471.mg	* P<.04	203.mg n.s.s.	0/50	4/50	3/50		S
for sqp		608.mg	* P<.08	e 218.mg n.s.s.	1/50	2/50	5/50		
TBA MXB		172.mg	* P<.3	50.0mg n.s.s.	37/50	30/50	45/50		
liv MXB		373.mg	* P<.02	175.mg n.s.s.	0/50	5/50	4/50		liv:hpa,hpc,nnd.
lun MXB		2.74gm	/ P<.7	315.mg n.s.s.	4/50	0/50	5/50		lun:a/a,a/c.
3324 M m b6c gav 24m24 TR340 :					0	87.6mg	176.mg		
TBA MXB		no dre	P=1.	- 184.mg n.s.s.	33/50	29/50	29/50		
liv MXB		1.10gm	* P<.4	273.mg n.s.s.	10/50	9/50	13/50		liv:hpa,hpc,nnd.
lun MXB		2.41gm	* P<.7	341.mg n.s.s.	9/50	6/50	10/50		lun:a/a,a/c.
3325 R f f34 gav 24m24 TR340 :					0	43.9mg	87.6mg		
TBA MXB		214.mg	* P<.6	- 41.1mg n.s.s.	44/50	46/50	47/50		
liv MXB		2.49gm	* P<.3	406.mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
3326 R m f34 gav 24m24 TR340 :					0	88.4mg	175.mg		
tes ict		40.6mg	* P<.0005	23.1mg 110.mg	46/50	49/50	48/50		S
MXB MXB		84.1mg	* P<.0005	47.3mg 223.mg	14/50	31/50	25/50		mul:mnl; thy:fcc. P
mul mnl		101.mg	* P<.0005	p 55.2mg 303.mg	14/50	29/50	24/50		
thy fcc		280.mg	* P<.005	p 111.mg 2.52gm	0/50	5/50	1/50		
nas adn		1.21gm	* P<.04	e 259.mg n.s.s.	0/50	0/50	2/50		
TBA MXB		52.1mg	* P<.0005	27.5mg 198.mg	45/50	46/50	42/50		
liv MXB		571.mg	* P<.02	182.mg n.s.s.	0/50	2/50	2/50		liv:hpa,hpc,nnd.
IODOACETAMIDE 144-48-9									
3327 R m wis wat 74w75 1759					0	9.87mg			Shirai;acpj,35,35-43;1985
sto car r		no dre	P=1.	- 21.1mg n.s.s.	0/20	0/20			
IODOFORM (triiodomethane) 75-47-8									
3328 M f b6c gav 78w90 TR110 :					0	28.5mg	56.3mg		
TBA MXB v		no dre	P=1.	- 40.2mg n.s.s.	7/20	14/50	(5/50)		
liv MXB v		no dre	P=1.	418.mg n.s.s.	1/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	418.mg n.s.s.	1/20	1/50	0/50		lun:a/a,a/c.
3329 M m b6c gav 78w90 TR110 :					0	28.5mg	56.9mg		
TBA MXB v		73.8mg	* P<.2	- 30.0mg n.s.s.	5/20	14/50	23/50		
liv MXB v		1.66gm	* P<.9	81.1mg n.s.s.	3/20	5/50	7/50		liv:hpa,hpc,nnd.
lun MXB v		630.mg	* P<.7	91.4mg n.s.s.	1/20	4/50	4/50		lun:a/a,a/c.
3330 R f osm gav 18m26 TR110 :					0	13.6mg	27.1mg		
TBA MXB v		11.3mg	\ P<.05	- 4.66mg n.s.s.	10/20	27/50	(23/50)		
liv MXB v		no dre	P=1.	241.mg n.s.s.	1/20	0/50	0/50		liv:hpa,hpc,nnd.
3331 R m osm gav 18m26 TR110 :					0	35.2mg	70.4mg		
thy MXA v#		82.2mg	* P<.02	- 40.8mg n.s.s.	0/20	8/50	4/50		thy:fca,fcc. S
TBA MXB v		113.mg	* P<.4	28.4mg n.s.s.	7/20	17/50	10/50		
liv MXB v		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
3332 R m osm gav 18m26 TR110 : pool					0	35.2mg	70.4mg		
thy MXA v#		116.mg	* P<.05	- 46.2mg n.s.s.	2/40	8/50	4/50		thy:fca,fcc. S
IPAZILIDE FUMARATE (WIN 54177-4) 115436-74-3									
3333 R f cdr gav 52w52 2189					0	26.0mg	104.mg	208.mg	Greener;faat,20,147-154;1993
liv tum		no dre	P=1.	- 14.6mg n.s.s.	0/15	0/15	0/15	0/15	
3334 R m cdr gav 52w52 2189					0	26.0mg	104.mg	208.mg	
liv tum		no dre	P=1.	- 14.6mg n.s.s.	0/15	0/15	0/15	0/15	
IQ (2-amino-3-methylimidazo[4,5-f]quinoline) 76180-96-6									
3335 M f cdf eat 96w96 1617					0	39.0mg			Ohgaki;carc,5,921-924;1984
liv mix e		17.5mg	P<.0005	+ 10.2mg 33.6mg	3/38	27/36			
liv hpc e		24.1mg	P<.0005	14.2mg 44.9mg	0/38	22/36			
for mix e		62.4mg	P<.0005	+ 31.2mg 154.mg	0/38	11/36			
lun mix e		67.9mg	P<.03	+ 27.9mg n.s.s.	7/38	15/36			
3336 M m cdf eat 96w96 1617					0	36.0mg			
lun mix e		22.4mg	P<.0005	+ 12.2mg 60.4mg	7/33	27/39			
for mix e		42.3mg	P<.0005	+ 22.6mg 109.mg	1/33	16/39			
liv mix e		48.6mg	P<.002	+ 24.0mg 241.mg	3/33	16/39			
lun adc e		60.2mg	P<.007	27.9mg 811.mg	3/33	14/39			
liv hpc e		91.6mg	P<.002	41.4mg 347.mg	0/33	8/39			
for sqc e		153.mg	P<.02	58.1mg n.s.s.	0/33	5/39			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes / Path	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
3337 P b cym gav 9y9 2007 : ()				0	7.14mg	14.3mg		Adamson;enhp,102,190-193;1994/Dalgard 1997/Thorgeirsson pers.comm.
liv hpc jw	.374mg	* P<.0005	+ .175mg .743mg	0/10	15/18	18/18		
tba mal jw	.374mg	* P<.0005	.175mg .743mg	0/10	15/18	18/18		
3338 R f f34 eat 53w78 2148				0	2.55mg			Weisburger;pseb,205,347-352;1994/pers.comm.
zym tum	2.26mg	P<.002	+ 1.15mg 7.85mg	0/15	12/34			
pre tum	3.19mg	P<.007	+ 1.50mg 37.3mg	0/15	9/34			
mgl tum	3.52mg	P<.06	+ 1.47mg n.s.s.	1/15	10/34			
liv hpc	5.06mg	P<.03	+ 2.06mg n.s.s.	0/15	6/34			
lun ade	16.2mg	P<.3	3.98mg n.s.s.	0/15	2/34			
sbg mix	32.9mg	P<.4	5.36mg n.s.s.	0/15	1/34			
3339 R m f34 eat 53w63 2148				0	2.52mg			
sbg mix	.998mg	P<.0005	+ .550mg 2.31mg	0/15	16/34			
zym tum	1.20mg	P<.0005	+ .638mg 3.22mg	0/15	14/34			
pre tum	6.87mg	P<.2	2.08mg n.s.s.	0/15	3/34			
liv hpc	10.5mg	P<.3	2.57mg n.s.s.	0/15	2/34			
col tum	10.5mg	P<.3	2.57mg n.s.s.	0/15	2/34			
lun mix	27.1mg	P<.8	2.41mg n.s.s.	1/15	3/34			
3340 R m f34 gav 35w52 2263				0	2.02mg			Guo;clet,95,161-165;1995/pers.comm.
zym sqc e	.287mg	P<.0005	+ .147mg .646mg	0/20	14/20			
liv hpc e	.579mg	P<.0005	+ .268mg 1.63mg	0/20	9/20			
ski sqc e	.579mg	P<.0005	+ .268mg 1.63mg	0/20	9/20			
col adc e	.803mg	P<.002	+ .343mg 3.04mg	0/20	7/20			
smi adc e	1.55mg	P<.02	+ .534mg n.s.s.	0/20	4/20			
tba mix e	.287mg	P<.0005	.147mg .646mg	0/20	14/20			
3341 R f f3d eat 72w72 1767m				0	15.0mg			Ohgaki;enhp,67,129-134;1986/1991
zym sqc j	4.38mg	P<.0005	+ 2.68mg 7.70mg	0/50	27/40			
cli sqc j	7.11mg	P<.0005	+ 4.14mg 13.6mg	0/50	20/40			
liv hpc j	8.24mg	P<.0005	+ 4.69mg 16.3mg	0/50	18/40			
lgi adc j	19.3mg	P<.0005	+ 9.08mg 53.5mg	0/50	9/40			
ski sqc j	63.2mg	P<.03	+ 19.1mg n.s.s.	0/50	3/40			
orc sqc j	195.mg	P<.3	+ 31.7mg n.s.s.	0/50	1/40			
smi adc j	195.mg	P<.3	+ 31.7mg n.s.s.	0/50	1/40			
3342 R m f3d eat 55w55 1767m				0	12.0mg			
zym sqc j	.999mg	P<.0005	+ .590mg 1.72mg	0/50	36/40			
liv hpc j	2.08mg	P<.0005	+ 1.27mg 3.74mg	1/50	27/40			
lgi adc j	2.34mg	P<.0005	+ 1.42mg 4.19mg	0/50	25/40			
ski sqc j	4.16mg	P<.0005	+ 2.34mg 8.41mg	0/50	17/40			
smi adc j	6.45mg	P<.0005	+ 3.31mg 15.1mg	0/50	12/40			
orc sqc j	44.8mg	P<.07	+ 11.0mg n.s.s.	0/50	2/40			
IQ.HCl (2-amino-3-methylimidazo[4,5-f]quinoline.HCl) ---								
3343 R f sda gav 31w52 1721				0	11.1mg			Tanaka;gann,76,570-576;1985/pers.comm.
mgl car ev	3.29mg	P<.0005	+ 1.75mg 7.23mg	0/27	14/32			
mgl mix ev	3.80mg	P<.002	+ 1.86mg 16.6mg	2/27	14/32			
zym epc ev	4.50mg	P<.0005	+ 2.24mg 11.5mg	0/27	11/32			
liv mix ev	9.12mg	P<.006	+ 3.71mg 81.0mg	0/27	6/32			
liv nnd ev	19.2mg	P<.06	+ 5.82mg n.s.s.	0/27	3/32			
liv hpc ev	29.3mg	P<.2	+ 7.22mg n.s.s.	0/27	2/32			
liv hae ev	29.3mg	P<.2	+ 7.22mg n.s.s.	0/27	2/32			
pan ana ev	59.7mg	P<.3	+ 9.71mg n.s.s.	0/27	1/32			
unt tpp ev	59.7mg	P<.3	+ 9.71mg n.s.s.	0/27	1/32			
tba mix ev	1.59mg	P<.0005	.900mg 3.30mg	2/27	23/32			
IRSOGLADINE MALEATE 84504-69-8								
3344 R m wis eat 55w55 2663				0	4.00mg			Sugie;txcy,166,53-61;2001
liv tum	no dre	P=1.	- 2.31mg n.s.s.	0/10	0/10			
ISATIDINE 15503-86-3								
3345 R f wis wat 24m24 1871				0	.816mg			Schoental;bjca,8,458-465;1954
liv hpt rv	1.27mg	P<.03	+ .474mg n.s.s.	0/7	5/14			
3346 R m wis wat 24m24 1871				0	.714mg			
liv hpt rv	.499mg	P<.005	+ .177mg 3.68mg	0/7	5/8			
ISOBUTENE 115-11-7								
3347 M f b6c inh 24m24 TR487 :				0	360.mg	1.44gm	5.76gm	
TBA MXB	no dre	P=1.	- 3.76gm n.s.s.	47/50	45/50	49/50	48/50	
liv MXB	47.8gm	* P<.8	5.54gm n.s.s.	23/50	28/50	22/50	28/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	24.9gm n.s.s.	6/50	4/50	4/50	3/50	lun:a/a,a/c.
3348 M m b6c inh 24m24 TR487 :				0	300.mg	1.20gm	4.81gm	
TBA MXB	8.84gm	* P<.4	- 2.11gm n.s.s.	41/50	50/50	43/50	50/50	
liv MXB	no dre	P=1.	4.53gm n.s.s.	30/50	32/50	28/50	29/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	10.8gm n.s.s.	17/50	13/50	9/50	9/50	lun:a/a,a/c.
3349 R f f34 inh 24m24 TR487 :				0	85.9mg	344.mg	1.37gm	
TBA MXB	no dre	P=1.	- 760.mg n.s.s.	50/50	48/50	50/50	48/50	
liv MXB	30.1gm	* P<.2	4.90gm n.s.s.	0/50	0/50	0/50	1/50	liv:hpa,hpb,hpc.
3350 R m f34 inh 24m24 TR487 :				0	60.1mg	240.mg	962.mg	
thy fcc	3.55gm	* P<.02	p 1.17gm n.s.s.	1/50	0/50	0/50	5/50	
TBA MXB	no dre	P=1.	497.mg n.s.s.	50/50	48/50	50/50	50/50	
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
ISOBUTYL p-HYDROXYBENZOATE 4247-02-3								
3351 M f icr eat 24m25 1688				0	188.mg	375.mg	751.mg	Inai;fctx,23,575-578;1985
lun tum	37.2gm	* P<.8	- 3.62gm n.s.s.	2/50	3/50	2/50	3/50	
liv tum	no dre	P=1.	- 1.15gm n.s.s.	0/50	0/50	0/50	0/50	
tba mix	12.3gm	* P<.7	- 1.61gm n.s.s.	12/50	10/50	12/50	13/50	
3352 M m icr eat 24m24 1688				0	177.mg	353.mg	706.mg	
liv tum	26.3gm	Z P<.7	- 3.08gm n.s.s.	0/50	4/50	0/50	2/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun tum	no dre	P=1.	-	2.84gm n.s.s.	3/50	6/50	3/50	4/50	
tba mix	6.57gm	* P<.5	-	1.38gm n.s.s.	8/50	12/50	9/50	12/50	
ISOBUTYL NITRITE 542-56-3									
3353 M f b6c inh 24m24 TR448 :					0	49.1mg	98.2mg	196.mg	
lun MXA	417.mg	* P<.04	p	177.mg n.s.s.	6/51	15/51	9/50	19/50	lun:a/a,a/c,ade.
lun MXA	423.mg	* P<.03	p	186.mg n.s.s.	4/51	14/51	7/50	17/50	lun:a/a,ade.
TBA MXB	no dre	P=1.		151.mg n.s.s.	37/51	45/51	37/50	40/50	
liv MXB	no dre	P=1.		464.mg n.s.s.	10/51	13/51	7/50	10/50	liv:hpa,hpb,hpc.
lun MXB	428.mg	* P<.04		180.mg n.s.s.	6/51	15/51	8/50	19/50	lun:a/a,a/c.
3354 M m b6c inh 24m24 TR448 :					0	41.1mg	82.1mg	164.mg	
lun MXA	247.mg	* P<.03	p	112.mg n.s.s.	8/50	16/50	16/50	19/53	lun:a/a,a/c.
lun a/a	279.mg	* P<.02	p	127.mg n.s.s.	7/50	12/50	13/50	17/53	
thy MXA	1.45gm	* P<.04	e	495.mg n.s.s.	1/50	0/50	0/50	5/53	thy:fab,fca.
TBA MXB	258.mg	* P<.2		83.9mg n.s.s.	33/50	35/50	38/50	39/53	
liv MXB	no dre	P=1.		294.mg n.s.s.	24/50	19/50	20/50	16/53	liv:hpa,hpb,hpc.
lun MXB	247.mg	* P<.03		112.mg n.s.s.	8/50	16/50	16/50	19/53	lun:a/a,a/c.
3355 R f f34 inh 24m24 TR448 :					0	11.6mg	23.2mg	46.5mg	
lun MXA	112.mg	* P<.0005	c	62.2mg 230.mg	0/46	3/46	2/46	11/46	lun:a/a,a/c.
lun a/a	128.mg	* P<.0005	c	68.5mg 354.mg	0/46	2/46	2/46	10/46	
TBA MXB	no dre	P=1.		44.6mg n.s.s.	40/46	34/46	37/46	35/46	
liv MXB	no dre	P=1.		342.mg n.s.s.	0/46	1/46	0/46	0/46	liv:hpa,hpb,hpc.
3356 R m f34 inh 24m24 TR448 :					0	8.19mg	16.4mg	32.8mg	
lun a/a	35.7mg	* P<.0005	c	22.7mg 96.9mg	0/46	3/46	12/46	13/46	
lun MXA	38.8mg	* P<.002	c	22.2mg 192.mg	1/46	5/46	13/46	15/46	lun:a/a,a/c.
TBA MXB	no dre	P=1.		37.5mg n.s.s.	45/46	40/46	40/46	42/46	
liv MXB	no dre	P=1.		171.mg n.s.s.	1/46	1/46	1/46	1/46	liv:hpa,hpb,hpc.
N-ISOBUTYL-N'-NITRO-N-NITROSOGUANIDINE 5461-85-8									
3357 R m wis wat 52w78 1082					0	2.14mg			Matsukura;gann,70,181-185;1979
stg tum er	no dre	P=1.	-	2.24mg n.s.s.	0/9	0/9			
ISOBUTYRALDEHYDE 78-84-2									
3358 M f b6c inh 24m24 TR472 :					0	463.mg	926.mg	1.85gm	
TBA MXB	no dre	P=1.	-	2.03gm n.s.s.	38/50	45/50	37/50	40/50	
liv MXB	no dre	P=1.		4.23gm n.s.s.	12/50	20/50	15/50	12/50	liv:hpa,hpb,hpc.
lun MXB	48.6gm	* P<.7		6.38gm n.s.s.	3/50	1/50	3/50	4/50	lun:a/a,a/c.
3359 M m b6c inh 24m24 TR472 :					0	386.mg	772.mg	1.54gm	
TBA MXB	8.81gm	* P<.7	-	1.12gm n.s.s.	40/50	36/50	39/50	34/50	
liv MXB	no dre	P=1.		2.31gm n.s.s.	27/50	25/50	26/50	18/50	liv:hpa,hpb,hpc.
lun MXB	26.3gm	* P<.8		2.72gm n.s.s.	12/50	8/50	10/50	10/50	lun:a/a,a/c.
3360 R f f34 inh 24m24 TR472 :					0	110.mg	221.mg	441.mg	
TBA MXB	no dre	P=1.	-	301.mg n.s.s.	48/50	49/50	50/50	49/50	
liv MXB	no dre	P=1.		1.63gm n.s.s.	0/50	1/50	2/50	0/50	liv:hpa,hpb,hpc.
3361 R m f34 inh 24m24 TR472 :					0	77.3mg	154.mg	309.mg	
TBA MXB	235.mg	* P<.2	-	77.1mg n.s.s.	49/50	48/50	49/50	49/50	
liv MXB	no dre	P=1.		960.mg n.s.s.	0/50	2/50	0/50	0/50	liv:hpa,hpb,hpc.
ISOFLURANE 26675-46-7									
3362 M f sww inh 78w81 1879					0	1.52gm	6.09gm		Baden;anes,69,750-753;1988
lun ala	30.0gm	* P<.3	-	8.67gm n.s.s.	15/92	14/83	19/83		
liv bsa	no dre	P=1.	-	36.0gm n.s.s.	1/92	2/83	1/83		
3363 M m sww inh 78w81 1879					0	1.27gm	5.08gm		
lun ala	no dre	P=1.	-	16.1gm n.s.s.	18/89	23/84	12/82		
liv bsa	no dre	P=1.	-	27.2gm n.s.s.	4/89	7/84	2/82		
ISOMALT 64519-82-0									
3364 M f scp eat 24m24 1979					0	3.25gm	6.50gm	13.0gm	Smits-van Prooije;fctx,28,243-251;1990
lun act e	92.6gm	* P<.4	-	22.5gm n.s.s.	3/44	10/43	9/49	7/42	
liv tum e	no dre	P=1.	-	16.9gm n.s.s.	0/44	0/44	0/45	0/44	
tba tum e	83.4gm	* P<.7	-	11.8gm n.s.s.	28/46	28/48	27/50	30/46	
3365 M m scp eat 94w94 1979					0	3.00gm	6.00gm	12.0gm	
lun act e	26.2gm	Z P<.3	-	8.30gm n.s.s.	5/49	13/49	9/49	(3/50)	
liv nnd e	no dre	P=1.	-	48.6gm n.s.s.	4/48	4/49	4/47	3/50	
liv hpc e	no dre	P=1.	-	90.4gm n.s.s.	1/48	1/49	0/47	1/50	
tba tum e	no dre	P=1.	-	22.2gm n.s.s.	20/50	22/50	19/50	17/50	
ISOMAZOLE 86315-52-8									
3366 R f f34 eat 24m24 2033					0	12.5mg	25.0mg	50.0mg	Sandusky;faat,16,198-209;1991/pers.comm.
amd mix e	385.mg	* P<.02	+	169.mg n.s.s.	1/60	1/60	4/60	6/60	
amd pob e	450.mg	* P<.02		192.mg n.s.s.	1/60	0/60	3/60	6/60	
amd phm e	no dre	P=1.		474.mg n.s.s.	0/60	1/60	1/60	0/60	
3367 R m f34 eat 24m24 2033					0	10.0mg	20.0mg	40.0mg	
amd mix es	38.8mg	* P<.0005	+	25.7mg 70.8mg	10/60	13/60	18/60	40/60	
amd pob es	45.4mg	* P<.0005		29.3mg 89.6mg	9/60	13/60	16/60	36/60	
amd phm es	481.mg	* P<.04		183.mg n.s.s.	1/60	0/60	2/60	5/60	
ISONIAZID (INH) 54-85-3									
3368 H f syg wat 28m28 170					0	136.mg			Toth;ejca,5,165-171;1969
for pam e	575.mg	P<.02	-	195.mg n.s.s.	2/54	5/22			
liv tum e	no dre	P=1.		1.37gm n.s.s.	0/72	0/36			
lun tum e	no dre	P=1.		1.37gm n.s.s.	0/72	0/36			
3369 H m syg wat 30m30 170					0	120.mg			
liv hem e	no dre	P=1.	-	425.mg n.s.s.	2/25	0/11			
lun tum e	no dre	P=1.		1.51gm n.s.s.	0/67	0/39			
3370 M f akr wat 70w70 169					0	200.mg			Toth;ijcn,2,413-420;1967
lun tum e	89.6mg	P<.4	-	13.2mg n.s.s.	0/1	1/2			
liv tum	no dre	P=1.		560.mg n.s.s.	0/30	0/30			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3371 M m akr wat 59w59 169					0	167.mg			
lun tum e	202.mg	P<.2	-	32.6mg n.s.s.	0/9	1/6			
liv hem e	no dre	P=1.	-	155.mg n.s.s.	1/14	0/14			
3372 M m amm gav 79w79 584m					0	31.4mg	62.9mg		Bhide;ijcn,21,381-386;1978
liv car r	159.mg \	P<.2		48.2mg n.s.s.	0/20	3/40	(0/40)		
lun car r	206.mg *	P<.4		64.0mg n.s.s.	1/20	7/40	6/40		
mix car r	219.mg *	P<.5	+	55.8mg n.s.s.	1/20	10/40	6/40		
3373 M f c3h wat 72w72 1115					0	200.mg			Toth;scie,152,1376-1377;1966a
lun ade e	755.mg	P<.5		123.mg n.s.s.	0/4	1/12			
3374 M m c3h wat 72w72 1115					0	167.mg			
lun ade e	219.mg	P<.2		71.3mg n.s.s.	1/12	6/21			
3375 M f cbc gav 36w84 1074					0	34.1mg			Biancifiori;bjca,18,543-550;1964
lun mix e	11.2mg	P<.0005	+	5.26mg 29.8mg	4/47	13/17			
liv hpt e	187.mg	P<.4	-	32.3mg n.s.s.	2/47	2/17			
3376 M m cbc gav 36w74 1074					0	32.2mg			
lun mix e	12.2mg	P<.0005	+	5.80mg 32.7mg	1/37	11/18			
liv hpt e	165.mg	P<.6	-	22.1mg n.s.s.	4/37	3/18			
3377 M b nss gav 52w52 1425					0	30.1mg			Pershin;vopr,XVIII,50-53;1972
lun ade e	19.3mg	P<.0005	+	11.1mg 47.4mg	5/94	27/98			
mgl adc e	80.9mg	P<.06	+	30.1mg n.s.s.	2/94	8/98			
tba mix e	14.1mg	P<.0005	+	8.62mg 29.9mg	7/94	35/98			
3378 M f swa wat 23m25 169					0	100.mg	300.mg		Toth;ijcn,2,413-420;1967
lun ade ae	386.mg *	P<.0005	+	201.mg 1.37gm	14/108	17/39	13/32		
liv hem ae	no dre	P=1.	-	413.mg n.s.s.	3/88	0/30	0/18		
3379 M f swa wat 80w80 1127					0	200.mg			Toth;canr,26,1473-1475;1966
lun mix e	153.mg	P<.0005	+	82.3mg 426.mg	9/68	23/47			
lun ade e	189.mg	P<.0005	+	97.3mg 635.mg	8/68	20/47			
lun adc e	435.mg	P<.01		165.mg 27.1gm	1/48	6/32			
liv hem e	no dre	P=1.	-	534.mg n.s.s.	3/48	1/32			
3380 M m swa wat 86w87 169					0	83.3mg	250.mg		Toth;ijcn,2,413-420;1967
lun ade aes	104.mg \	P<.0005	+	49.2mg 437.mg	10/90	15/38	(3/14)		
liv mix aes	no dre	P=1.		555.mg n.s.s.	2/85	1/38	0/10		
3381 M m swa wat 80w80 1127					0	167.mg			Toth;canr,26,1473-1475;1966
lun ade e	124.mg	P<.0005	+	67.5mg 311.mg	8/80	21/44			
liv hem e	no dre	P=1.	-	203.mg n.s.s.	2/35	0/10			
3382 M b swi gav 97w97 1525					0	27.6mg			Maru;clet,17,75-80;1982
lun tum r	24.5mg	P<.0005	+	13.0mg 55.8mg	1/47	15/30			
liv tum r	no dre	P=1.		116.mg n.s.s.	7/47	1/30			
3383 M b swi gav 95w95 1552					0	27.6mg			Menon;zkko,105,258-261;1983
lun adc r	28.8mg	P<.0005	+	17.2mg 80.7mg	1/20	27/60			
3384 M f swi gav 83w83 584m					0	37.7mg			Bhide;ijcn,21,381-386;1978
lun car r	53.1mg	P<.0005		23.9mg 174.mg	0/30	8/30			
mix car r	53.1mg	P<.0005	+	23.9mg 174.mg	0/30	8/30			
liv car r	no dre	P=1.		149.mg n.s.s.	0/30	0/30			
3385 M f swi gav 81w83 584n					0	37.0mg			
mix car gr	39.9mg	P<.0005	+	19.3mg 105.mg	0/30	10/30			
lun car gr	88.6mg	P<.008		33.6mg 1.32gm	0/30	5/30			
liv car gr	88.6mg	P<.008		33.6mg 1.32gm	0/30	5/30			
3386 M m swi gav 85w85 584m					0	15.7mg	31.4mg		
mix car r	24.0mg *	P<.0005	+	13.9mg 53.4mg	1/30	6/30	16/30		
lun car r	28.9mg *	P<.0005		16.2mg 70.0mg	1/30	4/30	15/30		
liv car r	211.mg *	P<.3		63.8mg n.s.s.	0/30	2/30	1/30		
3387 M m swi gav 79w79 584o					0	15.7mg	31.4mg		
mix car fr	25.7mg *	P<.003	+	14.1mg 107.mg	0/15	6/25	9/25		
lun car fr	41.1mg *	P<.007		20.0mg 420.mg	0/15	3/25	7/25		
liv car fr	88.8mg *	P<.3		33.7mg n.s.s.	0/15	3/25	2/25		
3388 M m swi gav 79w79 584r					0	31.4mg			
mix car br	21.2mg	P<.005	+	10.1mg 158.mg	1/15	12/25			
lun car br	39.2mg	P<.05		15.4mg n.s.s.	1/15	8/25			
liv car br	71.3mg	P<.05		24.6mg n.s.s.	0/15	4/25			
3389 R f cbs wat 48w64 157					0	149.mg			Severi;jnci,41,331-349;1968
mgl fba s	120.mg	P<.002	+	60.1mg 399.mg	0/22	11/40			
lun tum s	no dre	P=1.		465.mg n.s.s.	0/22	0/40			
liv tum s	no dre	P=1.		465.mg n.s.s.	0/22	0/40			
3390 R m cbs wat 48w84 157					0	99.4mg			
liv tum es	199.mg	P<.07	+	32.1mg n.s.s.	0/21	1/5			
lun mix s	1.07gm	P<.2	+	262.mg n.s.s.	0/28	2/49			
ISONICOTINAMIDE 1453-82-3									
3391 M f swa wat 28m28 1732					0	2.00gm			Toth;onco,40,72-75;1983/1979
liv hpt e	21.3gm	P<.2	-	3.47gm n.s.s.	0/28	1/12			
lun mix e	no dre	P=1.	-	6.83gm n.s.s.	15/91	5/33			
3392 M m swa wat 27m27 1732					0	1.67gm			
lun mix e	no dre	P=1.	-	5.77gm n.s.s.	22/88	9/43			
liv mix e	no dre	P=1.		13.9gm n.s.s.	2/62	0/32			
ISONICOTINIC ACID 55-22-1									
3393 H f syg wat 28m28 1108					0	682.mg			Toth;canr,32,804-807;1972/1967a
cec tum e	8.08gm	P<.03	-	1.99gm n.s.s.	0/66	2/27			
liv tum e	no dre	P=1.		6.36gm n.s.s.	0/72	0/34			
lun tum e	no dre	P=1.		6.36gm n.s.s.	0/72	0/34			
3394 H m syg wat 28m28 1108					0	600.mg			
liv lcc e	6.95gm	P<.1	-	1.13gm n.s.s.	0/39	1/13			
liv mix e	10.3gm	P<.5		1.19gm n.s.s.	1/39	1/13			
lun tum e	no dre	P=1.		4.85gm n.s.s.	0/64	0/29			
3395 M f cbc gav 36w89 1074					0	20.9mg			Biancifiori;bjca,18,543-550;1964
liv hpt e	612.mg	P<.8	-	31.4mg n.s.s.	2/47	1/17			
lun ade e	no dre	P=1.	-	32.6mg n.s.s.	4/47	1/16			

Chemical / Spe Strain Xpo+Xpt / Sex Route Paper Num	Synonym	CAS number	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
Site Path	**Notes TD$_{50}$**	**DR 2Tailpvl**	**AuOp LoConf**	**UpConf**	**Cntrl**	**1 Inc**	**2 Inc**	**3 Inc**	**Brkly Code NCI/NTPPathology**
3396 M m cbc gav 36w89 1074					0	17.4mg			
lun ade e	101.mg	P<.3	-	16.3mg n.s.s.	0/13	1/12			
liv hpt e	no dre	P=1.	-	24.6mg n.s.s.	4/27	2/18			
ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE (phthivazid) 149-17-7									
3397 M b nss gav 52w52 1425					0	30.1mg			Pershin;vopr,XVIII,50-53;1972
lun adc e	45.0mg	P<.03	+	19.2mg n.s.s.	5/94	14/90			
mgl adc e	86.6mg	P<.07	+	30.3mg n.s.s.	2/94	7/90			
tba mix e	27.4mg	P<.003	+	13.6mg 174.mg	7/94	21/90			
ISOPHORONE 78-59-1									
3398 M f b6c gav 24m24 TR291 :					0	175.mg	354.mg		
TBA MXB	no dre	P=1.	-	136.mg n.s.s.	36/50	41/50	(28/50)		
liv MXB	2.74gm *	P<.5		604.mg n.s.s.	4/50	6/50	8/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		1.88gm n.s.s.	3/50	1/50	2/50		lun:a/a,a/c.
3399 M m b6c gav 24m24 TR291 :					0	177.mg	354.mg		
--- mlh s	244.mg \	P<.002	e	109.mg 928.mg	0/50	9/50	(4/50)		
--- MXA s	203.mg \	P<.06	e	80.2mg n.s.s.	7/50	19/50	(5/50)		---:mlh,mlm,mlp.
--- MXA s	236.mg \	P<.1	e	85.7mg n.s.s.	8/50	19/50	(5/50)		---:lkn,mlh,mlm,mlp.
sub MXA s	654.mg *	P<.03	e	293.mg n.s.s.	3/50	6/50	13/50		sub:fbs,fib.
sub MXA s	703.mg *	P<.04	e	301.mg n.s.s.	4/50	6/50	14/50		sub:fbs,fib,nfs,sar.
sub fbs s	1.17gm *	P<.09	e	444.mg n.s.s.	3/50	4/50	10/50		
sub fib s	1.21gm *	P<.06	e	460.mg n.s.s.	0/50	2/50	3/50		
liv MXA s	573.mg *	P<.3	e	162.mg n.s.s.	18/50	18/50	29/50		liv:hpa,hpc.
MXA MXA s	840.mg *	P<.2	e	308.mg n.s.s.	5/50	7/50	13/50		ski:fib; sub:fbs,fib.
MXA MXA s	882.mg *	P<.2	e	309.mg n.s.s.	6/50	8/50	14/50		ski:fib,nfs; sub:fbs,fib,nfs,sar.
MXA MXA s	1.21gm *	P<.2	e	434.mg n.s.s.	4/50	5/50	11/50		ski:nfs; sub:fbs,nfs,sar.
sub MXA s	1.26gm *	P<.2	e	451.mg n.s.s.	4/50	4/50	11/50		sub:fbs,nfs,sar.
TBA MXB s	no dre	P=1.		174.mg n.s.s.	35/50	40/50	40/50		
liv MXB s	573.mg *	P<.3		162.mg n.s.s.	18/50	18/50	29/50		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.		1.39gm n.s.s.	7/50	1/50	3/50		lun:a/a,a/c.
3400 R f f34 gav 24m24 TR291 :					0	175.mg	350.mg		
TBA MXB s	16.6gm *	P<1.	-	192.mg n.s.s.	43/50	36/50	30/50		
liv MXB s	no dre	P=1.		1.45gm n.s.s.	3/50	1/50	1/50		liv:hpa,hpc,nnd.
3401 R m f34 gav 24m24 TR291 :					0	175.mg	350.mg		
MXB MXB	774.mg *	P<.0005		378.mg 2.07gm	0/50	3/50	8/50		kid:tla,uac; pre:can. P
kid MXA	1.21gm *	P<.008	p	492.mg 21.4gm	0/50	3/50	3/50		kid:tla,uac.
pre can	2.25gm *	P<.005	p	818.mg 19.3gm	0/50	0/50	5/50		
TBA MXB	237.mg *	P<.05		99.5mg n.s.s.	38/50	42/50	33/50		
liv MXB	9.08gm *	P<.9		522.mg n.s.s.	5/50	9/50	2/50		liv:hpa,hpc,nnd.
ISOPHOSPHAMIDE 3778-73-2									
3402 M f b6c ipj 52w79 TR32 :					0	2.80mg	5.60mg		
--- lhc s	5.06mg *	P<.0005	c	2.81mg 14.1mg	0/15	3/35	13/35		
TBA MXB s	3.63mg *	P<.0005		2.18mg 9.48mg	0/15	7/35	15/35		
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	0/15	1/35	0/35		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		lun:a/a,a/c.
3403 M f b6c ipj 52w79 TR32 : pool					0	2.80mg	5.60mg		
--- lhc s	5.06mg *	P<.0005	c	2.81mg 10.9mg	0/30	3/35	13/35		
3404 M m b6c ipj 52w79 TR32 :					0	2.80mg	5.60mg		
TBA MXB s	no dre	P=1.	-	1.85mg n.s.s.	0/15	6/35	4/35		
liv MXB s	no dre	P=1.		2.70mg n.s.s.	0/15	5/35	2/35		liv:hpa,hpc,nnd.
lun MXB s	37.6mg *	P<.5		6.13mg n.s.s.	0/15	0/35	1/35		lun:a/a,a/c.
3405 M m b6c ipj 52w79 TR32 : pool					0	2.80mg	5.60mg		
liv MXA s#	2.42mg \	P<.02	-	.900mg n.s.s.	0/30	5/35	(2/35)		liv:hpa,hpc. S
3406 R f sda ipj 52w83 TR32 :					0	1.60mg	3.30mg		
mgl fba s	.301mg *	P<.0005	a	.158mg 1.01mg	3/10	28/35	6/35		
ute lei s	.739mg *	P<.003	c	.375mg 3.07mg	0/10	15/35	1/35		
TBA MXB s	.383mg /	P<.009		.175mg 17.4mg	9/10	32/35	9/35		
liv MXB s	17.2mg *	P<.5		2.79mg n.s.s.	0/10	1/35	0/35		liv:hpa,hpc,nnd.
3407 R f sda ipj 52w80 TR32 : pool					0	1.60mg	3.30mg		
mgl fba s	.358mg *	P<.0005	a	.199mg .841mg	8/30	28/35	6/35		
ute lei s	.814mg *	P<.0005	c	.429mg 1.76mg	0/30	15/35	1/35		
mgl MXA s	2.96mg *	P<.007		.977mg 49.3mg	0/30	3/35	1/35		mgl:ccn,cyn. S
3408 R m sda ipj 52w79 TR32 :					0	1.60mg	3.30mg		
TBA MXB s	1.01mg /	P<.02	-	.476mg n.s.s.	5/10	17/35	12/35		
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
3409 R m sda ipj 52w79 TR32 : pool					0	1.60mg	3.30mg		
--- MXA s#	3.23mg *	P<.0005	-	1.37mg 11.2mg	0/30	3/35	5/35		---:leu,lym. S
ISOPRENE (2-methyl-1,3-butadiene) 78-79-5									
3410 M f b6c inh 19m24 2258o					0	8.89mg	62.3mg		Placke;txcy,113,253-262;1996
pit pda e	247.mg *	P<.03	+	97.1mg n.s.s.	1/49	6/46	9/49		
hag ade e	319.mg *	P<.03	+	122.mg n.s.s.	2/49	3/49	8/49		
spl hes eh	682.mg *	P<.1	+	201.mg n.s.s.	1/50	1/49	4/50		
liv hpa e	no dre	P=1.		310.mg n.s.s.	4/50	6/50	3/50		
liv hpc e	no dre	P=1.		322.mg n.s.s.	2/50	4/50	2/50		
lun a/a e	no dre	P=1.		227.mg n.s.s.	5/50	6/50	5/50		
3411 M m b6c inh 26w53 TX31 :					0	24.9mg	78.6mg	250.mg	787.mg	2.51gm	
hag ade	96.8mg Z	P<.003	c	45.4mg 603.mg	2/30	6/30	4/30	14/30	(13/30	12/30)	
hag MXA	96.8mg Z	P<.003	c	45.4mg 603.mg	2/30	6/30	4/30	14/30	(13/30	12/30)	hag:ade,car.
liv hpa	150.mg Z	P<.0005		82.0mg 425.mg	4/30	2/30	6/30	15/30	18/30	(16/30)	S
liv MXA	183.mg Z	P<.0005	c	92.0mg 753.mg	7/30	3/30	7/30	15/30	18/30	(17/30)	liv:hpa,hpc.
MXB MXB	355.mg Z	P<.0005		176.mg 1.45gm	11/30	10/30	10/30	23/30	25/30	23/30	for:sqc,sqp; hag:ade,car; liv: hpa,hpc; lun:a/a,a/c. C
lun MXA	752.mg *	P<.0005	c	371.mg 2.96gm	2/30	2/30	1/30	5/30	10/30	9/30	lun:a/a,a/c.
lun a/a	836.mg *	P<.0005		403.mg 3.79gm	2/30	2/30	1/30	4/30	10/30	8/30	S
liv hpc	1.27gm *	P<.006		523.mg 17.8gm	4/30	1/30	3/30	5/30	4/30	9/30	S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
for MXA		1.31gm *	P<.0005 c	657.mg 3.48gm	0/30	0/30	0/30	1/30	4/30	6/30	for:sqc,sqp.
for sqp		1.86gm *	P<.0005	838.mg 6.55gm	0/30	0/30	0/30	1/30	2/30	5/30	S
lun a/c		2.79gm *	P<.004	1.06gm 29.6gm	0/30	0/30	0/30	1/30	1/30	3/30	S
for sqc		4.85gm *	P<.04	1.47gm n.s.s.	0/30	0/30	0/30	0/30	2/30	1/30	S
hag car		14.7gm *	P<.4	2.39gm n.s.s.	0/30	0/30	0/30	0/30	1/30	0/30	
TBA MXB		348.mg Z	P<.0005	175.mg 1.37gm	12/30	10/30	11/30	23/30	26/30	24/30	
liv MXB		183.mg Z	P<.0005	92.0mg 753.mg	7/30	3/30	7/30	15/30	18/30	(17/30)	liv:hpa,hpb,hpc.
lun MXB		752.mg *	P<.0005	371.mg 2.96gm	2/30	2/30	1/30	5/30	10/30	9/30	lun:a/a,a/c.
3412 M m b6c inh 9m24 2258m					0	25.9mg	51.9mg	892.mg			Placke;txcy,113,253-262;1996
hag ade e		739.mg *	P<.0005 +	426.mg 1.59gm	4/47	13/48	12/50	31/49			
lun a/a e		908.mg *	P<.0005 +	510.mg 2.12gm	11/50	8/50	10/50	29/49			
liv hpa e		1.07gm *	P<.0005 +	530.mg 4.46gm	11/50	14/49	22/50	28/47			
lmr hcs e		4.43gm *	P<.003 +	1.80gm 30.8gm	0/50	2/50	1/50	7/50			
liv hpc e		2.33gm *	P<.02 +	958.mg n.s.s.	9/50	11/49	10/50	18/47			
lun a/c e		9.23gm *	P<.03 +	2.82gm n.s.s.	0/50	0/50	1/50	3/49			
for sqp e		15.6gm *	P<.03	3.85gm n.s.s.	0/50	0/47	0/49	2/47			
hea hes e		32.9gm *	P<.2	5.36gm n.s.s.	0/49	0/49	0/50	1/49			
hag car e		no dre	P=1.	7.87gm n.s.s.	0/47	0/48	2/50	0/49			
spl hes e		no dre	P=1.	8.16gm n.s.s.	1/49	1/47	3/50	0/47			
3413 M m b6c inh 80w96 2258n					0	892.mg					
hag ade e		711.mg	P<.0005 +	423.mg 1.46gm	4/47	28/50					
lmr hcs e		3.45gm	P<.002 +	1.49gm 14.5gm	0/50	7/50					
liv hpa e		1.76gm	P<.04 +	739.mg n.s.s.	11/50	21/50					
lun a/c e		8.41gm	P<.04 +	2.55gm n.s.s.	0/50	3/50					
liv hpc e		3.29gm	P<.2 +	1.07gm n.s.s.	9/50	15/50					
lun a/a e		4.81gm	P<.4	1.17gm n.s.s.	11/50	15/50					
hag car e		12.8gm	P<.2	3.14gm n.s.s.	0/47	2/50					
for sqp e		25.8gm	P<.3	4.20gm n.s.s.	0/50	1/50					
for sqc e		25.8gm	P<.3	4.20gm n.s.s.	0/50	1/50					
hea hes e		25.8gm	P<.3	4.20gm n.s.s.	0/49	1/50					
spl hes e		25.8gm	P<.6	3.46gm n.s.s.	1/49	2/50					
3414 M m b6c inh 19m24 2258o					0	7.41mg	51.9mg	227.mg	568.mg	1.78gm	
hag ade e		881.mg *	P<.0005 +	601.mg 1.43gm	4/47	4/49	9/50	17/50	26/49	35/50	
liv hpa e		1.57gm *	P<.0005 +	891.mg 4.07gm	11/50	12/50	15/50	24/50	27/48	30/50	
lun a/a e		1.66gm *	P<.0005 +	997.mg 3.62gm	11/50	16/50	4/50	13/50	23/50	30/50	
lun a/c e		6.68gm *	P<.0005 +	4.02gm 28.8gm	0/50	1/50	2/50	1/50	7/50	7/50	
for sqc e		22.2gm *	P<.008 +	7.68gm 740.gm	0/50	0/48	0/50	1/50	0/47	3/50	
liv hpc e		4.85gm *	P<.03 +	2.00gm n.s.s.	9/50	6/50	9/50	16/50	17/48	16/50	
hag car e		15.0gm *	P<.02 +	6.10gm n.s.s.	0/47	0/49	0/50	1/50	3/49	2/50	
for sqp e		45.0gm *	P<.07	11.1gm n.s.s.	0/50	0/48	0/50	0/50	1/47	1/50	
hea hes eh		39.0gm *	P<.4 +	8.07gm n.s.s.	0/49	0/50	0/50	2/50	1/50	1/50	
lmr hcs e		150.gm *	P<.9	8.45gm n.s.s.	0/50	2/50	2/50	4/50	2/50	2/50	
spl hes e		no dre	P=1.	13.5gm n.s.s.	1/49	3/48	2/50	1/50	2/48	1/49	
3415 R f f34 inh 24m24 TR486 :					0	45.9mg	146.mg	1.46gm			
mgl fbm		206.mg Z	P<.02 p	93.9mg n.s.s.	7/50	12/50	19/50	(17/50)			
mgl MXA		3.34gm Z	P<.4 p	833.mg n.s.s.	19/50	35/50	32/50	32/50			mgl:fba,fbm.
bra mag		30.8gm *	P<.2 e	5.02gm n.s.s.	0/50	0/50	0/50	1/50			
brm grb		40.6gm *	P<.5 e	4.69gm n.s.s.	0/50	1/50	0/50	1/50			
brm sar		50.8gm *	P<.5 e	5.83gm n.s.s.	0/50	1/50	0/50	1/50			
bra mbm		52.8gm *	P<.2 e	8.61gm n.s.s.	0/50	0/50	0/50	1/50			
bra asb		no dre	P=1. e	6.35gm n.s.s.	0/50	0/50	1/50	0/50			
TBA MXB		6.94gm *	P<.8	752.mg n.s.s.	49/50	48/50	49/50	48/50			
liv MXB		25.3gm *	P<.4	3.90gm n.s.s.	0/50	0/50	1/50	1/50			liv:hpa,hpb,hpc.
3416 R m f34 inh 24m24 TR486 :					0	32.1mg	102.mg	1.02gm			
mgl fba		655.mg *	P<.0005 c	345.mg 1.70gm	2/50	4/50	6/50	21/50			
mgl MXA		655.mg *	P<.0005 c	345.mg 1.70gm	2/50	4/50	6/50	21/50			mgl:fba,fbm.
mgl MXA		670.mg *	P<.0005 c	347.mg 1.86gm	2/50	5/50	7/50	21/50			mgl:car,fba.
mgl fbm		2.22gm *	P<.003 c	870.mg 15.0gm	1/50	1/50	0/50	7/50			
kid MXA		3.15gm *	P<.02	1.10gm n.s.s.	0/50	2/50	2/50	6/50			kid:rua,ruc. S
kid rua		3.15gm *	P<.02 c	1.10gm n.s.s.	0/50	2/50	2/50	6/50			
tes MXA		914.mg *	P<.2 c	299.mg n.s.s.	33/50	37/50	44/50	48/50			tes:iab,ica.
MXB MXB		988.mg *	P<.2	308.mg n.s.s.	33/50	39/50	44/50	48/50			kid:rua; mgl:car,fba,fbm; tes:iab,ica. C
mgl car		7.88gm *	P<.3 c	1.50gm n.s.s.	0/50	1/50	1/50	2/50			
TBA MXB		no dre	P=1.	541.mg n.s.s.	49/50	50/50	49/50	47/50			
liv MXB		no dre	P=1.	4.74gm n.s.s.	0/50	3/50	0/50	0/50			liv:hpa,hpb,hpc.
3417 R m f34 inh 26w52 TX31					0	5.11mg	16.1mg	51.1mg	161.mg	511.mg	
tes ica		316.mg *	P<.03 e	122.mg n.s.s.	3/30	3/30	4/30	7/30	8/30	9/30	
liv MXB		no dre	P=1.	5.41mg n.s.s.	0/30	0/30	0/30	0/30	0/30	0/30	liv:hpa,hpc.
3418 R m f34 inh 24m24 TR486 with step					0	31.9mg	102.mg	1.01gm			
kid rua		2.29gm *	P<.0005 c	1.10gm 9.34gm	2/50	4/50	8/50	15/50			
kid MXA		2.29gm *	P<.0005	1.10gm 9.34gm	2/50	4/50	8/50	15/50			kid:rua,ruc. S
ISOPROPANOL 67-63-0											
3419 M f cd1 inh 54w54 2574m					0	386.mg	1.93gm	3.86gm			Burleigh-Flayer;faat,36,95-111;1997
kid tum k		no dre	P=1. -	165.mg n.s.s.	0/10	0/10	0/10	0/10			
3420 M f cd1 inh 78w78 2574n					0	386.mg	1.93gm	3.86gm			
kid tum a		no dre	P=1. -	1.89gm n.s.s.	0/55	0/55	0/55	0/55			
3421 M m cd1 inh 54w54 2574m					0	322.mg	1.61gm	3.22gm			
kid tum k		no dre	P=1. -	138.mg n.s.s.	0/10	0/10	0/10	0/10			
3422 M m cd1 inh 78w78 2574n					0	322.mg	1.61gm	3.22gm			
kid tum a		no dre	P=1. -	1.58gm n.s.s.	0/55	0/55	0/55	0/55			
3423 R f f34 inh 72w73 2574m					0	90.7mg	454.mg	907.mg			
kid tum k		no dre	P=1. -	70.9mg n.s.s.	0/10	0/10	0/10	0/10			
3424 R f f34 inh 24m24 2574n					0	92.0mg	460.mg	920.mg			
kid tum a		no dre	P=1. -	948.mg n.s.s.	0/65	0/65	0/65	0/65			
3425 R m f34 inh 72w73 2574m					0	63.5mg	318.mg	635.mg			
tes ica k		456.mg *	P<.0005 -	184.mg 1.72gm	0/10	0/10	0/10	6/10			
kid tum k		no dre	P=1. -	49.6mg n.s.s.	0/10	0/10	0/10	0/10			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3426 R m f34 inh 24m24 2574n					0	64.4mg	322.mg	644.mg	
tes ica a		46.4mg	* P<.0005	- 21.1mg 129.mg	49/65	58/65	65/65	65/65	
kid tum a		no dre	P=1.	- 663.mg n.s.s.	0/65	0/65	0/65	0/65	
p-ISOPROPOXYDIPHENYLAMINE (agerite 150) 101-73-5									
3427 M f b6a orl 76w76 1306					0	414.mg			Innes;ntis,1968/1969
liv agm evx		2.65gm	P<.3	- 431.mg n.s.s.	0/17	1/18			
lun ade evx		no dre	P=1.	- 492.mg n.s.s.	1/17	1/18			
tba mix evx		1.20gm	P<.5	- 239.mg n.s.s.	2/17	4/18			
3428 M m b6a orl 76w76 1306					0	385.mg			
liv hpt evx		1.13gm	P<.3	- 252.mg n.s.s.	1/18	3/18			
lun ade evx		2.18gm	P<.7	- 274.mg n.s.s.	2/18	3/18			
tba mix evx		985.mg	P<.5	- 196.mg n.s.s.	3/18	5/18			
3429 M f b6c orl 76w76 1306					0	414.mg			
liv hpt evx		2.65gm	P<.3	- 431.mg n.s.s.	0/16	1/18			
lun mix evx		no dre	P=1.	- 820.mg n.s.s.	0/16	0/18			
tba mix evx		1.29gm	P<.2	- 316.mg n.s.s.	0/16	2/18			
3430 M m b6c orl 76w76 1306					0	385.mg			
liv hpt evx		679.mg	P<.04	- 205.mg n.s.s.	0/16	3/16			
lun ade evx		2.18gm	P<.3	- 355.mg n.s.s.	0/16	1/16			
tba mix evx		300.mg	P<.003	- 121.mg 1.47gm	0/16	6/16			
ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE (CIPC, chlorpropham) 101-21-3									
3431 H f syg eat 33m33 171a					0	209.mg			Van Esch;fctx,10,373-381;1972
liv tum e		no dre	P=1.	2.12gm n.s.s.	0/27	0/26			
lun sqc e		no dre	P=1.	- 2.12gm n.s.s.	1/27	0/26			
3432 H m syg eat 33m33 171a					0	184.mg			
liv hpc e		no dre	P=1.	- 1.65gm n.s.s.	1/22	0/23			
3433 M f b6a orl 76w76 1196					0	157.mg			Innes;ntis,1968/1969
lun ade evx		no dre	P=1.	- 175.mg n.s.s.	1/17	1/17			
liv hpt evx		no dre	P=1.	- 294.mg n.s.s.	0/17	0/17			
tba mix evx		no dre	P=1.	- 138.mg n.s.s.	2/17	2/17			
3434 M m b6a orl 76w76 1196					0	146.mg			
liv hpt evx		no dre	P=1.	- 258.mg n.s.s.	1/18	0/16			
lun ade evx		no dre	P=1.	- 258.mg n.s.s.	2/18	0/16			
tba mix evx		no dre	P=1.	- 180.mg n.s.s.	3/18	1/16			
3435 M f b6c orl 76w76 1196					0	157.mg			
liv hpt evx		no dre	P=1.	- 311.mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1.	- 311.mg n.s.s.	0/16	0/18			
tba tum evx		no dre	P=1.	- 311.mg n.s.s.	0/16	0/18			
3436 M m b6c orl 76w76 1196					0	146.mg			
liv hpt evx		258.mg	P<.04	- 77.8mg n.s.s.	0/16	3/16			
lun ade evx		830.mg	P<.3	- 135.mg n.s.s.	0/16	1/16			
tba mix evx		114.mg	P<.003	- 45.9mg 559.mg	0/16	6/16			
3437 M b swi eat 27m27 171a					0	125.mg			Van Esch;fctx,10,373-381;1972
lun ade e		682.mg	P<.2	- 209.mg n.s.s.	10/49	15/47			
lun adc e		4.95gm	P<.3	- 807.mg n.s.s.	0/49	1/47			
liv tum e		no dre	P=1.	1.51gm n.s.s.	0/49	0/47			
3438 R f alb eat 24m24 170a					0	10.0mg	100.mg	1.00gm	Larson;txap,2,659-673;1960
mix mly		no dre	P=1.	- 4.86gm n.s.s.	1/25	0/25	1/25	0/25	
3439 R m alb eat 24m24 170a					0	8.00mg	80.0mg	800.mg	
liv tum s		no dre	P=1.	37.1mg n.s.s.	0/25	0/25	0/25	0/25	
mds mly s		no dre	P=1.	- 3.11gm n.s.s.	0/25	0/25	1/25	0/25	
1-ISOPROPYL-3-METHYL-s-PYRAZOLYLDIMETHYL CARBAMATE (isolan) 119-38-0									
3440 M f b6a orl 76w76 1247					0	8.38ug			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1.	- 14.7ug n.s.s.	0/18	0/16			
lun mix evx		no dre	P=1.	- 14.7ug n.s.s.	0/18	0/16			
tba mix evx		23.0ug	P<.08	- 5.63ug n.s.s.	0/18	2/16			
3441 M m b6a orl 76w76 1247					0	7.80ug			
lun ade evx		14.7ug	P<.04	- 4.43ug n.s.s.	0/18	3/17			
liv hpt evx		41.9ug	P<.6	- 6.12ug n.s.s.	1/18	2/17			
tba mix evx		12.4ug	P<.2	- 3.44ug n.s.s.	2/18	5/17			
3442 M f b6c orl 76w76 1247					0	8.38ug			
liv hpt evx		no dre	P=1.	- 14.7ug n.s.s.	0/18	0/16			
lun ade evx		no dre	P=1.	- 14.7ug n.s.s.	1/18	0/16			
tba mix evx		no dre	P=1.	- 14.7ug n.s.s.	2/18	0/16			
3443 M m b6c orl 76w76 1247					0	7.80ug			
lun ade evx		15.6ug	P<.06	- 4.72ug n.s.s.	0/14	3/18			
liv hpt evx		no dre	P=1.	- 11.2ug n.s.s.	3/14	1/18			
tba mix evx		41.3ug	P<.8	- 3.81ug n.s.s.	4/14	6/18			
ISOPROPYL-N-PHENYL CARBAMATE (IPC) 122-42-9									
3444 H f syg eat 33m33 171a					0	209.mg			Van Esch;fctx,10,373-381;1972
liv tum e		no dre	P=1.	2.12gm n.s.s.	0/27	0/26			
lun sqc e		no dre	P=1.	- 2.12gm n.s.s.	1/27	0/26			
3445 H m syg eat 33m33 171a					0	184.mg			
liv hpc e		no dre	P=1.	- 995.mg n.s.s.	1/22	1/23			
3446 M f b6a orl 76w76 171					0	78.4mg			Innes;ntis,1968/1969
lun ade evx		444.mg	P<.6	- 61.8mg n.s.s.	1/17	2/17			
liv hpt evx		no dre	P=1.	- 147.mg n.s.s.	0/17	0/17			
tba mix evx		416.mg	P<.7	- 52.4mg n.s.s.	2/17	3/17			
3447 M m b6a orl 76w76 171					0	73.0mg			
liv hpt evx		350.mg	P<.5	- 53.4mg n.s.s.	1/18	2/16			
lun ade evx		1.70gm	P<1.	- 58.9mg n.s.s.	2/18	2/16			
tba mix evx		254.mg	P<.6	- 38.6mg n.s.s.	3/18	4/16			
3448 M f b6c orl 76w76 171					0	78.4mg			
lun ade evx		244.mg	P<.2	- 59.8mg n.s.s.	0/16	2/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpt evx	502.mg	P<.3	-	81.7mg n.s.s.	0/16	1/18			
tba mix evx	88.1mg	P<.009	-	33.2mg 1.93gm	0/16	5/18			
3449 M m b6c orl 76w76 171					0	73.0mg			
liv hpt evx	120.mg	P<.04	-	36.1mg n.s.s.	0/16	3/15			
lun ade evx	387.mg	P<.3	-	63.0mg n.s.s.	0/16	1/15			
tba mix evx	52.3mg	P<.002	-	21.0mg 236.mg	0/16	6/15			
ISOSAFROLE 120-58-1									
3450 M f b6a orl 81w81 172					0	72.7mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.		145.mg n.s.s.	1/15	0/16			
lun ade evx	no dre	P=1.		145.mg n.s.s.	2/15	0/16			
tba mix evx	no dre	P=1.		145.mg n.s.s.	2/15	0/16			
3451 M m b6a orl 81w81 172					0	67.7mg			
liv hpt evx	225.mg	P<.09		55.2mg n.s.s.	0/18	2/17			
lun mix evx	no dre	P=1.		144.mg n.s.s.	3/18	0/17			
tba mix evx	327.mg	P<.7		44.2mg n.s.s.	3/18	4/17			
3452 M f b6c orl 81w81 172					0	72.7mg			
liv hpt evx	468.mg	P<.3		76.2mg n.s.s.	0/17	1/16			
lun ade evx	468.mg	P<.3		76.2mg n.s.s.	0/17	1/16			
tba mix evx	414.mg	P<.6		60.7mg n.s.s.	1/17	2/16			
3453 M m b6c orl 81w81 172					0	67.7mg			
liv hpt evx	106.mg	P<.08		34.5mg n.s.s.	1/17	5/18			
lun ade evx	231.mg	P<.4		50.4mg n.s.s.	1/17	3/18			
tba mix evx	492.mg	P<.9		31.4mg n.s.s.	7/17	8/18			
IVERMECTIN 70288-86-7									
3454 R m wis eat 52w52 2660					0	.200mg			O'Connor;jepo,20,223-227;2001/pers.comm.
for tum er	no dre	P=1.	-	.206mg n.s.s.	0/19	0/20			
JOSAMYCIN 16846-24-5									
3455 R f f3d eat 24m25 2604					0	613.mg	1.23gm		Kasahara;fctx,37,61-67;1999
liv hpa e	no dre	P=1.	-	4.38gm n.s.s.	7/50	0/50	0/50		
3456 R f f3d eat 52w52 2664					0	10.0mg	50.0mg	250.mg 1.25gm	Kasahara;fctx,40,1017-1022;2002
liv tum e	no dre	P=1.	-	4.13mg n.s.s.	0/10	0/10	0/10	0/10 0/10	
3457 R m f3d eat 24m25 2604					0	491.mg	981.mg		Kasahara;fctx,37,61-67;1999
liv hpc e	51.3gm *	P<.6	-	6.99gm n.s.s.	1/50	0/50	2/50		
liv hpa e	no dre	P=1.	-	2.96gm n.s.s.	7/50	3/50	(1/50)		
3458 R m f3d eat 52w52 2664					0	8.00mg	40.0mg	200.mg 1.00gm	Kasahara;fctx,40,1017-1022;2002
liv tum e	no dre	P=1.	-	3.30mg n.s.s.	0/10	0/10	0/10	0/10 0/10	
KAEMPFEROL 520-18-3									
3459 R f aci eat 77w77 1662					0	20.0mg			Takanashi;jfds,5,55-60;1983
tba mix e	55.3mg	P<.4	-	6.92mg n.s.s.	1/22	1/6			
3460 R m aci eat 77w77 1662					0	16.0mg			
adr coa e	17.9mg	P<.1	-	3.71mg n.s.s.	2/30	2/6			
KANECHLOR 400 (PCBs, polychlorinated biphenyls) 12737-87-0									
3461 R f don eat 26w84 1762					0	6.19mg			Kimura;zkko,87,257-266;1976
liv tum e	no dre	P=1.	-	20.8mg n.s.s.	0/10	0/25			
KEPONE (chlordecone) 143-50-0									
3462 M f b6c eat 80w90 TR-B :					0	2.30mg	4.70mg		
liv hpc v	1.62mg \	P<.003	c	1.01mg 6.36mg	0/10	26/50	(23/50)		
TBA MXB v	1.57mg \	P<.003		.992mg 5.65mg	0/10	27/50	(25/50)		
liv MXB v	1.62mg \	P<.003		1.01mg 6.36mg	0/10	26/50	(23/50)		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		n.s.s. n.s.s.	0/10	0/50	0/50		lun:a/a,a/c.
3463 M m b6c eat 80w89 TR-B :					0	2.40mg	2.20mg		
liv hpc dv	.705mg *	P<.0005	c	.462mg 1.59mg	6/20	43/50	39/50		
TBA MXB dv	.705mg *	P<.0005		.462mg 1.59mg	6/20	43/50	39/50		
liv MXB dv	.705mg *	P<.0005		.462mg 1.59mg	6/20	43/50	39/50		liv:hpa,hpc,nnd.
lun MXB dv	29.3mg *	P<.3		7.21mg n.s.s.	0/20	2/50	0/50		lun:a/a,a/c.
3464 R f osm eat 19m25 TR-B :					0	.640mg	.930mg		
TBA MXB v	1.83mg *	P<.5	-	.469mg n.s.s.	7/10	29/50	29/50		
liv MXB v	2.96mg /	P<.08		1.30mg n.s.s.	1/10	1/50	12/50		liv:hpa,hpc,nnd.
3465 R m osm eat 19m25 TR-B :					0	.230mg	.690mg		
TBA MXB v	1.42mg *	P<.4	-	.459mg n.s.s.	3/15	24/50	16/50		
liv MXB v	2.49mg *	P<.2		1.22mg n.s.s.	0/15	3/50	3/50		liv:hpa,hpc,nnd.
3466 R m sda eat 91w91 1160					0	40.0ug			Chu;txap,59,268-278;1981
liv nnd	.199mg	P<.3		32.4ug n.s.s.	0/10	1/10			
KETOPROFEN 22071-15-4									
3467 R m f34 eat 54w54 2078					0	8.00mg			Reddy;carc,13,1019-1023;1992
col mix er	no dre	P=1.		5.33mg n.s.s.	0/12	0/12			
KOJIC ACID (5-hydroxy-2(hydroxymethyl)-4-pyrone) 501-30-4									
3468 M f b6c eat 84w88 2588n					0	1.88gm	3.76gm		Fujimoto;fctx,36,697-703;1998
thy fca	2.61gm /	P<.0005	+	1.77gm 4.09gm	1/55	4/55	39/55		
liv hpa	20.9gm *	P<.008		9.04gm 429.gm	0/55	2/55	5/55		
lun tum	no dre	P=1.		10.2gm n.s.s.	1/55	0/55	0/55		
3469 M m b6c eat 52w52 2588m					0	1.80gm	3.60gm		
thy fca k	323.mg *	P<.002	+	119.mg 1.32gm	0/5	2/5	5/5		
3470 M m b6c eat 84w88 2588n					0	1.73gm	3.47gm		
thy fca	927.mg *	P<.0005	+	679.mg 1.30gm	1/55	34/55	46/55		
liv hpa	19.7gm *	P<.7		2.69gm n.s.s.	23/55	36/55	25/55		
lun tum	no dre	P=1.		9.38gm n.s.s.	1/55	0/55	0/55		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
LASIOCARPINE	**303-34-4**								
3471 R f f34 eat 21m24 TR39 :					0	.350mg	.750mg	1.50mg	
MXB MXB as	.141mg	Z P<.0005		85.9ug .247mg	2/24	17/24	19/24	8/24	liv:adn,ang,hpc; mul:grl,leu,lle,lym,ule. C
mul MXA as	.325mg	* P<.0005	c	.165mg .822mg	2/24	9/24	11/24	1/24	mul:leu,lym.
liv ang as	.355mg	* P<.0005	c	.183mg .741mg	0/24	8/24	7/24	2/24	
mul MXA as	.387mg	* P<.0005	c	.186mg 1.04mg	1/24	7/24	8/24	1/24	mul:grl,lle,ule.
liv MXA as	.453mg	Z P<.0005	c	.195mg 1.26mg	0/24	5/24	1/24	7/24	liv:adn,hpc.
TBA MXB as	.102mg	Z P<.0005		60.1ug .205mg	18/24	22/24	22/24	8/24	
liv MXB as	22.7mg	* P<.2		3.70mg n.s.s.	0/24	0/24	0/24	1/24	liv:hpa,hpc,nnd.
3472 R m f34 eat 23m24 TR39 :					0	.280mg	.600mg	1.20mg	
liv MXB as	.250mg	Z P<.0005		.149mg .428mg	0/24	5/24	14/24	17/24	liv:adn,ang,hpc. C
liv ang as	.355mg	Z P<.0005	c	.208mg .621mg	0/24	5/24	11/24	13/24	
--- MXA as	.514mg	Z P<.0005		.256mg 1.45mg	4/24	3/24	11/24	7/24	---:leu,lym. S
liv MXA as	.908mg	Z P<.0005	c	.329mg 3.21mg	0/24	0/24	3/24	5/24	liv:adn,hpc.
TBA MXB as	.152mg	Z P<.0005		97.2ug .257mg	7/24	14/24	22/24	23/24	
liv MXB as	7.43mg	Z P<.03		1.82mg n.s.s.	0/24	0/24	0/24	2/24	liv:hpa,hpc,nnd.
3473 R m f34 eat 55w59 390					0	1.86mg			Rao;bjca,37,289-293;1978
liv ang e	.688mg	P<.004	+	.319mg 3.32mg	0/10	9/20			
liv car e	.954mg	P<.02	+	.408mg 170.mg	0/10	7/20			
tba mix e	.217mg	P<.0005		.108mg .469mg	0/10	17/20			
3474 R m f34 ipj 56w76 1013					0	.880mg			Svoboda;canr,32,908-911;1972
liv mix ev	.341mg	P<.0005	+	.165mg .851mg	0/25	11/18			
liv hpc ev	.397mg	P<.0005	+	.188mg 1.04mg	0/25	10/18			
ski sqc ev	.794mg	P<.002	+	.321mg 3.10mg	0/25	6/18			
lun ade ev	1.33mg	P<.09		.406mg n.s.s.	2/25	5/18			
smi adc evh	2.73mg	P<.06	+	.671mg n.s.s.	0/25	2/18			
tba mix ev	.152mg	P<.0005		69.2ug .372mg	2/25	16/18			
LEAD ACETATE	**301-04-2**								
3475 M f cd1 wat 30m30 56					0	1.00mg			Schroeder;jnut,83,239-250;1964
lun tum e	no dre	P=1.	-	3.58mg n.s.s.	9/60	4/29			
tba tum e	51.5mg	P<1.	-	1.90mg n.s.s.	22/60	11/29			
3476 M f cd1 wat 28m28 1395					0	1.00mg			Schroeder;jnut,105,452-458;1975
lun tum e	7.56mg	P<.05	-	2.54mg n.s.s.	1/45	5/37			
tba mix e	45.3mg	P<.9	-	2.62mg n.s.s.	9/45	8/37			
tba mal e	no dre	P=1.	-	3.06mg n.s.s.	9/45	7/37			
3477 M m cd1 wat 30m30 56					0	.833mg			Schroeder;jnut,83,239-250;1964
lun tum e	no dre	P=1.	-	8.23mg n.s.s.	8/44	1/39			
liv sar e	no dre	P=1.	-	9.99mg n.s.s.	1/44	0/39			
tba mix e	no dre	P=1.	-	8.57mg n.s.s.	11/44	1/39			
3478 M m cd1 wat 25m25 1395					0	.833mg			Schroeder;jnut,105,452-458;1975
lun tum e	7.78mg	P<.4	-	1.98mg n.s.s.	4/43	8/49			
tba mal e	4.04mg	P<.04	-	1.59mg n.s.s.	2/43	9/49			
tba mix e	6.22mg	P<.5	-	1.39mg n.s.s.	10/43	15/49			
3479 R f f34 eat 24m24 1947					0	25.0mg	100.mg	400.mg	Fears;txih,5,1-23;1989
kid mal e	1.58gm	* P<.0005	-	598.mg 6.55gm	0/214	0/24	1/24	4/24	
liv hpc e	no dre	P=1.		92.4mg n.s.s.	0/214	0/24	0/24	0/24	
3480 R m f34 eat 52w52 1150					0	400.mg			Hinton;bect,23,464-469;1979
kid adc ekr	993.mg	P<.3		162.mg n.s.s.	0/15	1/15			
liv hpc ekr	no dre	P=1.		309.mg n.s.s.	0/15	0/15			
3481 R m f34 eat 24m24 1947					0	20.0mg	80.0mg	320.mg	Fears;txih,5,1-23;1989
kid mal e	129.mg	* P<.0005	+	80.1mg 222.mg	0/213	0/24	11/24	19/24	
liv hpc e	no dre	P=1.		73.8mg n.s.s.	0/214	0/24	0/24	0/23	
3482 R b leb wat 41m41 1036					0	.265mg			Kanisawa;canr,29,892-895;1969
liv tum es	no dre	P=1.	-	5.00mg n.s.s.	1/34	0/32			
tba tum es	no dre	P=1.	-	1.67mg n.s.s.	10/34	7/32			
tba mal es	133.mg	P<1.	-	2.40mg n.s.s.	2/34	2/32			
3483 R m sda wat 76w76 1755					0	130.mg			Koller;txpy,13,50-57;1985
kid tcc e	28.4mg	P<.0005	+	13.4mg 68.2mg	0/10	13/16			
liv tum e	no dre	P=1.		229.mg n.s.s.	0/10	0/16			
tba mix e	28.4mg	P<.0005	+	13.4mg 68.2mg	0/10	13/16			
LEAD ACETATE, BASIC	**1335-32-6**								
3484 H f syg eat 23m25 176					0	105.mg	523.mg		Van Esch;bjca,23,765-771;1969
liv tum as	no dre	P=1.		456.mg n.s.s.	0/23	0/24	0/24		
3485 H m syg eat 24m24 176					0	92.0mg	460.mg		
liv tum s	no dre	P=1.		348.mg n.s.s.	0/22	0/22	0/22		
3486 M f swi eat 24m24 176					0	130.mg	751.mg		
kid car sv	14.8gm	* P<.2	+	2.42gm n.s.s.	0/25	0/25	1/25		
kid ade sv	no dre	P=1.	+	2.93gm n.s.s.	0/25	1/25	0/25		
liv hpt sv	no dre	P=1.		2.93gm n.s.s.	0/25	1/25	0/25		
lun ade sv	no dre	P=1.		2.58gm n.s.s.	3/25	5/25	1/25		
3487 M m swi eat 20m24 176					0	120.mg	713.mg		
kid car asv	472.mg	\ P<.02	+	163.mg n.s.s.	0/25	4/25	(0/25)		
kid ade asv	986.mg	\ P<.1	+	242.mg n.s.s.	0/25	2/25	(0/25)		
liv hpt asv	no dre	P=1.		529.mg n.s.s.	0/25	0/25	0/25		
lun ade asv	no dre	P=1.		2.75gm n.s.s.	3/25	1/25	1/25		
3488 R m sda eat 79w79 1709					0	400.mg			Kasprzak;carc,6,279-282;1985
kid mix e	266.mg	P<.0005	+	138.mg 604.mg	0/30	13/29			
liv tum e	no dre	P=1.	-	1.38gm n.s.s.	0/30	0/29			
3489 R f wis eat 29m29 175m					0	50.0mg			Van Esch;bjca,16,289-297;1962
kid mix e	107.mg	P<.003	+	43.1mg 571.mg	0/15	6/16			
3490 R f wis eat 24m24 175n					0	500.mg			
kid mix e	339.mg	P<.0005	+	138.mg 1.13gm	0/13	7/11			
3491 R m wis eat 29m29 175m					0	40.0mg			
kid mix e	107.mg	P<.008	+	40.4mg 2.21gm	0/14	5/16			
3492 R m wis eat 24m24 175n					0	400.mg			
kid mix e	443.mg	P<.002	+	176.mg 2.04gm	0/13	6/13			

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
LEAD DIMETHYLDITHIOCARBAMATE (ledate) 19010-66-3									
3493 M f b6c eat 24m24 TR151 :					0	3.25mg	6.50mg		
TBA MXB		no dre	P=1.	- 11.9mg n.s.s.	9/20	18/50	18/50		
liv MXB		149.mg *	P<.6	36.6mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	23.0mg n.s.s.	3/20	4/50	5/50		lun:a/a,a/c.
3494 M f b6c orl 76w76 1093					0	18.1mg			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1.	35.8mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1.	35.8mg n.s.s.	0/16	0/18			
tba mix evx		116.mg	P<.3	18.8mg n.s.s.	0/16	1/18			
3495 M m b6c eat 24m24 TR151 :					0	3.00mg	6.00mg		
TBA MXB		no dre	P=1.	- 5.92mg n.s.s.	12/20	32/50	28/50		
liv MXB		no dre	P=1.	16.0mg n.s.s.	4/20	11/50	7/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	12.0mg n.s.s.	9/20	14/50	15/50		lun:a/a,a/c.
3496 M m b6c orl 76w76 1093					0	16.8mg			Innes;ntis,1968/1969
--- rts evx		16.4mg	P<.006	6.17mg 162.mg	0/16	5/16			
liv hpt evx		95.3mg	P<.3	15.5mg n.s.s.	0/16	1/16			
lun mix evx		no dre	P=1.	29.6mg n.s.s.	0/16	0/16			
tba mix evx		10.7mg	P<.002	4.54mg 39.0mg	0/16	7/16			
3497 M f b6a orl 76w76 1093					0	18.1mg			
liv hpt evx		no dre	P=1.	35.8mg n.s.s.	0/17	0/18			
lun ade evx		no dre	P=1.	35.8mg n.s.s.	1/17	0/18			
tba mix evx		no dre	P=1.	35.8mg n.s.s.	2/17	0/18			
3498 M m b6a orl 76w76 1093					0	16.8mg			
lun ade evx		833.mg	P<1.	14.6mg n.s.s.	2/18	2/17			
liv hpt evx		no dre	P=1.	31.4mg n.s.s.	1/18	0/17			
tba mix evx		no dre	P=1.	16.2mg n.s.s.	3/18	2/17			
3499 R f f34 eat 24m24 TR151 :					0	1.25mg	2.50mg		
TBA MXB		27.8mg *	P<.9	- 1.82mg n.s.s.	15/20	33/50	36/50		
liv MXB		no dre	P=1.	16.3mg n.s.s.	1/20	1/50	1/50		liv:hpa,hpc,nnd.
3500 R m f34 eat 24m24 TR151 :					0	1.00mg	2.00mg		
TBA MXB		no dre	P=1.	- 1.40mg n.s.s.	17/20	40/50	37/50		
liv MXB		72.6mg *	P<.4	11.8mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
LEUPEPTIN 24365-47-7									
3501 M f ajj eat 68w68 1432					0	130.mg			Hosaka;gann,71,913-917;1980
lun mix e		229.mg	P<.3	- 59.6mg n.s.s.	3/20	7/25			
liv lpb e		933.mg	P<.3	- 152.mg n.s.s.	0/20	1/25			
3502 M m ajj eat 68w68 1432					0	120.mg			
liv mix e		55.8mg	P<.006	+ 25.2mg 641.mg	4/23	14/25			
lun mix e		422.mg	P<.9	- 29.0mg n.s.s.	15/23	17/25			
LEVOBUNOLOL.HCl 27912-14-7									
3503 M f cf1 eat 78w78 2067m					0	12.0mg	50.0mg	200.mg	Rothwell;faat,18,353-359;1992/pers.comm.
ute ley e		1.22gm *	P<.002	423.mg 6.69gm	0/100	0/50	0/50	4/50	
lun agc e		2.50gm *	P<.7	288.mg n.s.s.	18/100	8/50	7/50	10/50	
liv hpt e		5.01gm *	P<.2	816.mg n.s.s.	0/100	0/50	0/50	1/50	
3504 M m cf1 eat 78w78 2067m					0	12.0mg	50.0mg	200.mg	
lun agc e		no dre	P=1.	495.mg n.s.s.	22/100	6/50	6/50	7/50	
liv bhp e		no dre	P=1.	594.mg n.s.s.	9/100	1/50	3/50	3/50	
3505 R f wal eat 78w78 2067m					0	5.00mg	30.0mg	180.mg	
liv hct ek		no dre	P=1.	4.85mg n.s.s.	0/10	0/10	0/10	0/10	
3506 R f wal eat 24m24 2067n					0	5.00mg	30.0mg	180.mg	
mgl fba e		71.0mg Z	P<.05	27.0mg n.s.s.	27/100	24/50	23/50	(15/50)	
liv bhp e		2.36gm *	P<.3	554.mg n.s.s.	4/100	4/50	2/50	5/50	
3507 R f wal eat 52w52 2067o					0	.500mg	2.00mg	5.00mg	
liv bhp ek		no dre	P=1.	2.85mg n.s.s.	0/10	1/10	0/10	0/10	
3508 R f wal eat 78w78 2067r					0	.500mg	2.00mg	5.00mg	
liv tum ek		no dre	P=1.	.429mg n.s.s.	0/10	0/10	0/10	0/10	
3509 R f wal eat 24m24 2067s					0	.500mg	2.00mg	5.00mg	
liv bhp e		no dre	P=1.	3.05mg n.s.s.	2/80	0/40	0/40	0/40	
--- lyt e		no dre	P=1.	26.5mg n.s.s.	1/80	4/40	1/40	1/40	
liv mhp e		no dre	P=1.	29.1mg n.s.s.	0/80	1/40	1/40	0/40	
3510 R m wal eat 78w78 2067m					0	5.00mg	30.0mg	180.mg	
liv hct ek		no dre	P=1.	4.85mg n.s.s.	0/10	0/10	0/10	0/10	
3511 R m wal eat 24m24 2067n					0	5.00mg	30.0mg	180.mg	
liv bhp e		982.mg *	P<.005	388.mg 12.9gm	2/100	2/50	2/50	7/50	
liv mhp e		no dre	P=1.	43.1mg n.s.s.	1/100	0/50	0/50	0/50	
3512 R m wal eat 52w52 2067o					0	.500mg	2.00mg	5.00mg	
liv tum ek		no dre	P=1.	.191mg n.s.s.	0/10	0/10	0/10	0/10	
3513 R m wal eat 78w78 2067r					0	.500mg	2.00mg	5.00mg	
liv tum ek		no dre	P=1.	.429mg n.s.s.	0/10	0/10	0/10	0/10	
3514 R m wal eat 24m24 2067s					0	.500mg	2.00mg	5.00mg	
pit ade e		71.9mg *	P<.7	9.99mg n.s.s.	10/80	7/40	11/40	6/40	
liv bhp e		no dre	P=1.	41.1mg n.s.s.	1/80	0/40	1/40	0/40	
D-LIMONENE 5989-27-5									
3515 M f b6c gav 24m24 TR347 :					0	354.mg	707.mg		
liv hpc #		10.5gm *	P<.05	- 3.18gm n.s.s.	0/50	0/50	3/50		S
TBA MXB		no dre	P=1.	532.mg n.s.s.	41/50	31/50	(26/50)		
liv MXB		6.44gm *	P<.3	1.84gm n.s.s.	4/50	2/50	8/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	4.74gm n.s.s.	5/50	2/50	2/50		lun:a/a,a/c.
3516 M m b6c gav 24m24 TR347 :					0	177.mg	354.mg		
TBA MXB		no dre	P=1.	- 134.mg n.s.s.	43/50	29/50	(35/50)		
liv MXB		no dre	P=1.	862.mg n.s.s.	22/50	14/50	15/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	1.01gm n.s.s.	15/50	9/50	10/50		lun:a/a,a/c.
3517 R f f34 gav 24m24 TR347 :					0	211.mg	424.mg		
ute esp #		533.mg \	P<.009	- 240.mg 14.6gm	3/50	13/50	(5/50)		S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TBA MXB		1.33gm * P<.6		224.mg n.s.s.	37/50	44/50	26/50		
liv MXB		no dre	P=1.	4.07gm n.s.s.	2/50	0/50	0/50		liv:hpa,hpc,nnd.
3518 R m f34 gav 24m24 TR347 :					0	53.1mg	106.mg		
kid MXA		204.mg * P<.002	c	119.mg 644.mg	0/50	8/50	11/50		kid:tla,uac.
kid tla		325.mg * P<.004	c	167.mg 1.90gm	0/50	4/50	8/50		
kid uac		595.mg * P<.1	c	257.mg n.s.s.	0/50	4/50	3/50		
TBA MXB		no dre	P=1.	102.mg n.s.s.	43/50	40/50	45/50		
liv MXB		no dre	P=1.	504.mg n.s.s.	2/50	2/50	2/50		liv:hpa,hpc,nnd.
LITHOCHOLIC ACID 434-13-9									
3519 M f b6c gav 24m24 TR175 :					0	52.5mg	105.mg		
TBA MXB		960.mg * P<.8	-	111.mg n.s.s.	6/20	20/50	23/50		
liv MXB		1.14gm * P<.2		392.mg n.s.s.	0/20	1/50	3/50		liv:hpa,hpc,nnd.
lun MXB		1.03gm * P<.2		357.mg n.s.s.	0/20	1/50	3/50		lun:a/a,a/c.
3520 M m b6c gav 24m24 TR175 :					0	52.5mg	105.mg		
TBA MXB		no dre	P=1.	132.mg n.s.s.	12/20	26/50	20/50		
liv MXB		no dre	P=1.	187.mg n.s.s.	6/20	17/50	9/50		liv:hpa,hpc,nnd.
lun MXB		834.mg * P<.6		180.mg n.s.s.	1/20	7/50	5/50		lun:a/a,a/c.
3521 R f f34 gav 24m24 TR175 :					0	106.mg	212.mg		
TBA MXB		686.mg * P<.6	-	129.mg n.s.s.	14/20	35/49	35/50		
liv MXB		1.89gm * P<.3		653.mg n.s.s.	0/20	2/49	2/50		liv:hpa,hpc,nnd.
3522 R m f34 gav 24m24 TR175 :					0	106.mg	212.mg		
TBA MXB		501.mg * P<.3	-	150.mg n.s.s.	9/20	26/50	30/50		
liv MXB		2.25gm * P<.2		778.mg n.s.s.	0/20	1/50	3/50		liv:hpa,hpc,nnd.
LOCUST BEAN GUM (carob seed gum) 9000-40-2									
3523 M f b6c eat 24m24 TR221 :					0	3.19gm	6.44gm		
pit adn #		20.2gm \ P<.03	-	6.98gm n.s.s.	0/50	4/50	(1/50)		S
ute esp		86.5gm * P<.05		26.2gm n.s.s.	0/50	0/50	3/50		S
TBA MXB		no dre	P=1.	4.02gm n.s.s.	45/50	36/50	(30/50)		
liv MXB		no dre	P=1.	34.8gm n.s.s.	3/50	2/50	2/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	29.4gm n.s.s.	5/50	2/50	4/50		lun:a/a,a/c.
3524 M m b6c eat 24m24 TR221 :					0	2.94gm	5.94gm		
lun a/a #		7.16gm \ P<.05	-	2.90gm n.s.s.	7/50	17/50	(11/50)		S
TBA MXB		no dre	P=1.	5.06gm n.s.s.	36/50	41/50	38/50		
liv MXB		no dre	P=1.	14.0gm n.s.s.	18/50	16/50	14/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	9.89gm n.s.s.	14/50	21/50	14/50		lun:a/a,a/c.
3525 R f f34 eat 24m24 TR221 :					0	1.23gm	2.45gm		
adr coa #		11.9gm * P<.04	-	4.97gm n.s.s.	1/50	4/50	6/50		S
TBA MXB		29.5gm * P<.9		1.74gm n.s.s.	44/50	43/50	42/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
3526 R m f34 eat 24m24 TR221 :					0	981.mg	1.96gm		
TBA MXB		no dre	P=1.	1.78gm n.s.s.	37/50	35/50	35/50		
liv MXB		516.gm * P<1.		9.23gm n.s.s.	1/50	2/50	1/50		liv:hpa,hpc,nnd.
LOFEXIDINE.HCl (2-[1-(2,6-dichlorphenoxy)-ethyl]-2-imidazoline.HCl) 21498-08-8									
3527 R f lev eat 52w52 1668					0	3.00mg	8.00mg		Tsai;arzn,31,955-962;1982
tba tum e		2.30mg \ P<.09	-	.563mg n.s.s.	0/10	2/10	(0/20)		
3528 R m lev eat 52w52 1668					0	3.00mg	8.00mg		
tba tum e		2.30mg \ P<.09	-	.563mg n.s.s.	0/10	2/10	(0/20)		
LONIDAMINE 50264-69-2									
3529 R f sda eat 24m24 2055					0	20.0mg	60.0mg	180.mg	Patton;txlt,62,209-214;1992/pers.comm.
tba ben		no dre	P=1.	228.mg n.s.s.	87/100	44/50	36/50	39/50	
tba mix		no dre	P=1.	239.mg n.s.s.	92/100	45/50	38/50	40/50	
tba mal		no dre	P=1.	902.mg n.s.s.	14/100	7/50	8/50	4/50	
3530 R m sda eat 24m24 2055					0	20.0mg	60.0mg	180.mg	
tba mix		190.mg * P<.2		54.0mg n.s.s.	90/100	42/50	40/50	48/50	
tba ben		866.mg * P<.7		108.mg n.s.s.	83/100	37/50	38/50	42/50	
tba mal		no dre	P=1.	677.mg n.s.s.	18/100	11/50	6/50	8/50	
LORNOXICAM 70374-39-9									
3531 R f sda gav 52w52 2532m					0	60.0ug	.160mg	.400mg	Pohlmeyer-Esch;fctx,35,909-922;1997
kid tum		no dre	P=1.	40.5ug n.s.s.	0/20	0/20	0/20	0/20	
3532 R f sda gav 52w52 2532n					0	10.0ug	60.0ug		
kid tum		no dre	P=1.	8.83ug n.s.s.	0/20	0/20	0/20		
3533 R f sda gav 24m24 2532o					0	62.5ug	.125mg	.199mg	
liv hpa esv		13.2mg * P<.2	-	2.14mg n.s.s.	0/100	0/50	0/50	1/50	
tba mix esv		no dre	P=1.	- .252mg n.s.s.	89/100	44/50	33/50	(24/50)	
3534 R m sda gav 52w52 2532m					0	60.0ug	.160mg	.400mg	
kid tum		no dre	P=1.	40.5ug n.s.s.	0/20	0/20	0/20	0/20	
3535 R m sda gav 52w52 2532n					0	10.0ug	60.0ug		
kid tum		no dre	P=1.	8.83ug n.s.s.	0/20	0/20	0/20		
3536 R m sda gav 24m24 2532o					0	62.5ug	.125mg	.250mg	
liv mix e		no dre	P=1.	2.79mg n.s.s.	5/100	0/50	1/50	1/50	
tba mix e		no dre	P=1.	- .204mg n.s.s.	78/100	39/50	41/50	38/50	
LOVASTATIN (Mevacor) 75330-75-5									
3537 M f cd1 gav 92w92 2365					0	20.0mg	100.mg	500.mg	MacDonald;amjc,62,16J-27J;1988/FDA 1987/ pers.comm.
liv mix		623.mg * P<.0005	+	374.mg 1.14gm	0/100	0/50	2/50	20/50	
for sqp		1.02gm * P<.0005	+	544.mg 2.68gm	1/100	0/50	6/50	10/50	
lun ala		1.22gm * P<.008	+	520.mg 27.9gm	7/100	8/50	9/50	13/50	
liv hpc		2.24gm * P<.0005		966.mg 7.16gm	0/100	0/50	0/50	7/50	
for sqc		38.4gm * P<.7		2.74gm n.s.s.	1/100	1/50	0/50	1/50	
lun adc		57.4gm * P<1.		1.88gm n.s.s.	4/100	5/50	1/50	3/50	
3538 M m cd1 gav 92w92 2365					0	20.0mg	100.mg	500.mg	
liv mix		439.mg * P<.0005	+	254.mg 985.mg	16/100	6/50	12/50	27/50	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes / Path	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
liv hpc	708.mg *	P<.0005	382.mg 1.88gm	8/100	5/50	6/50	19/50	
for sqp	8.55gm *	P<.4	1.56gm n.s.s.	2/100	0/50	3/50	2/50	
for sqc	no dre	P=1.	130.mg n.s.s.	1/100	0/50	0/50	0/50	
lun adc	no dre	P=1.	3.81gm n.s.s.	3/100	3/50	2/50	0/50	
lun ala	no dre	P=1.	1.20gm n.s.s.	17/100	7/50	8/50	8/50	
3539 R f cdr gav 24m24 2365				0	5.00mg	30.0mg	180.mg	
liv hpa	19.9gm *	P<.8 -	1.33gm n.s.s.	2/100	0/50	0/50	1/50	
3540 R m cdr gav 24m24 2365				0	5.00mg	30.0mg	180.mg	
liv hpc	2.33gm *	P<.08 -	650.mg n.s.s.	0/100	2/50	1/50	3/50	
liv hpa	no dre	P=1. -	1.47gm n.s.s.	4/100	0/50	0/50	1/50	
LOXTIDINE 76956-02-0								
3541 R f cdr eat 27m27 2450				0	50.0mg	185.mg	685.mg	Poynter;guts,26,1284-1295;1985
stf cnd	272.mg Z	P<.0005 +	128.mg 741.mg	0/114	9/63	(8/63	10/63)	
liv hpa	no dre	P=1.	10.8gm n.s.s.	0/114	1/63	0/63	0/63	
3542 R m cdr eat 27m27 2450				0	50.0mg	185.mg	685.mg	
stf cnd	2.01gm Z	P<.005 +	819.mg 20.2gm	0/114	2/63	4/63	(1/63)	
liv mix	no dre	P=1.	6.67gm n.s.s.	2/114	2/63	2/63	1/63	
LUPITIDINE.3HCl (SK&F 93479-A3) 72716-75-7								
3543 M f ssk gav 91w91 2451				0	1.00gm			Betton;txpy,16,288-298;1988/pers.comm.
gam cnd er	no dre	P=1. -	7.42gm n.s.s.	0/50	0/47			
3544 M m ssk gav 91w91 2451				0	1.00gm			
gam cnd er	no dre	P=1. -	7.42gm n.s.s.	0/42	0/47			
3545 R f wsk gav 23m23 2451				0	40.0mg	200.mg	1.00gm	
gam cnd er	2.99gm *	P<.0005 +	1.35gm 8.75gm	0/40	0/36	0/17	8/37	
3546 R m wsk gav 23m23 2451				0	40.0mg	200.mg	1.00gm	
gam cnd er	3.83gm *	P<.0005 +	1.56gm 13.8gm	0/40	0/23	0/22	6/34	
LUTEOSKYRIN 21884-44-6								
3547 M f ddn eat 37m37 1346m				0	6.00mg			Uraguchi;fctx,10,193-207;1972
liv mix e	79.4mg	P<.3 +	24.0mg n.s.s.	0/7	3/26			
liv lca e	122.mg	P<.4 +	29.9mg n.s.s.	0/7	2/26			
liv lcc e	248.mg	P<.5 +	40.4mg n.s.s.	0/7	1/26			
3548 M m ddn eat 37m37 1346m				0	1.67mg	5.00mg	16.7mg	
liv mix e	14.8mg Z	P<.0005 +	7.71mg 45.5mg	0/10	2/18	11/24	(11/29)	
liv lca e	83.7mg *	P<.03 +	42.0mg n.s.s.	0/10	0/18	5/24	6/29	
liv hpt e	89.5mg *	P<.08 +	34.0mg n.s.s.	0/10	1/18	7/24	7/29	
liv lcc e	332.mg *	P<.2 +	100.mg n.s.s.	0/10	0/18	1/24	2/29	
liv akt e	no dre	P=1. +	108.mg n.s.s.	0/10	1/18	3/24	1/29	
3549 M m ddn eat 37m37 1346n				0	5.00mg			
liv lca e	25.1mg	P<.03 +	11.3mg n.s.s.	0/9	8/29			
liv hpt e	74.3mg	P<.2 +	22.5mg n.s.s.	0/9	3/29			
liv akt e	113.mg	P<.3 +	27.9mg n.s.s.	0/9	2/29			
3550 M m ddn eat 37m37 1346o				0	5.00mg			
liv hpt e	113.mg	P<.3 +	27.9mg n.s.s.	0/10	2/29			
liv lca e	231.mg	P<.5 +	37.6mg n.s.s.	0/10	1/29			
LUTESTRAL 8065-91-6								
3551 M f c3h eat 24m24 1175				0	1.04mg			Rudali;jnci,49,813-819;1972
mam tum Ler	5.98mg	P<.7	.759mg n.s.s.	54/92	19/30			
3552 M f crf eat 24m24 1175 pool				0	1.04mg			
mam tum Ler	no dre	P=1.	.487mg n.s.s.	161/167	28/31			
3553 M m crf eat 24m24 1463				0	.960mg			Rudali;gmcr,17,243-252;1975
mam tum r	1.76mg	P<.0005	.851mg 4.52mg	0/76	10/32			
3554 M f r3m eat 24m24 1175				0	1.04mg			Rudali;jnci,49,813-819;1972
mam tum Ler	2.12mg	P<.4	.531mg n.s.s.	50/73	31/40			
LYNESTRENOL 52-76-6								
3555 D f beg eat 85m85 2168				0	78.1ug	.391mg	.977mg	Misdorp;aenc,125,27-31;1991/pers.comm.
mgl car er	.580mg *	P<.002 +	.265mg 2.68mg	1/16	0/16	3/16	7/16	
MAGNESIUM CHLORIDE HEXAHYDRATE 7791-18-6								
3556 M f b6c eat 22m24 1945				0	600.mg	2.40gm		Kurata;fctx,27,559-563;1989
liv hes e	57.5gm *	P<.4 -	12.5gm n.s.s.	0/49	1/50	1/50		
liv hnd e	60.5gm *	P<.7 -	7.51gm n.s.s.	1/50	5/50	3/50		
lun ade e	100.gm *	P<.2 -	16.3gm n.s.s.	0/49	0/50	1/49		
lun adc e	260.gm *	P<.9 -	9.45gm n.s.s.	0/49	3/50	1/49		
liv hem e	no dre	P=1. -	15.8gm n.s.s.	1/49	1/50	1/50		
--- lkm e	no dre	P=1. -	5.08gm n.s.s.	9/49	17/50	11/50		
liv hpc e	no dre	P=1. -	18.6gm n.s.s.	0/49	1/50	0/50		
3557 M m b6c eat 22m24 1945				0	554.mg	2.22gm		
--- lkm e	10.7gm *	P<.1 -	3.73gm n.s.s.	5/50	7/50	11/50		
liv hes e	46.7gm *	P<.07 -	11.5gm n.s.s.	0/50	0/50	2/50		
liv hem e	24.4gm *	P<.3 -	6.05gm n.s.s.	2/50	4/50	5/50		
lun ade e	87.6gm *	P<.7 -	9.95gm n.s.s.	1/49	2/50	2/50		
liv hnd e	no dre	P=1. -	8.24gm n.s.s.	17/50	11/50	10/50		
liv hpc e	no dre	P=1. -	2.72gm n.s.s.	13/50	6/50	(4/50)		
lun adc e	no dre	P=1. -	11.5gm n.s.s.	2/49	2/50	2/50		
MALAOXON (malathion-O-analog) 1634-78-2								
3558 M f b6c eat 24m24 TR135 :				0	65.0mg	130.mg		
TBA MXB	no dre	P=1. -	265.mg n.s.s.	15/50	15/50	15/50		
liv MXB	no dre	P=1.	263.mg n.s.s.	6/50	3/50	(1/50)		liv:hpa,hpc,nnd.
lun MXB	2.76gm *	P<.3	680.mg n.s.s.	0/50	1/50	1/50		lun:a/a,a/c.
3559 M m b6c eat 24m24 TR135 :				0	59.4mg	119.mg		
TBA MXB	472.mg *	P<.4 -	127.mg n.s.s.	23/50	18/50	26/50		
liv MXB	579.mg /	P<.2	183.mg n.s.s.	12/50	5/50	17/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun MXB		3.23gm *	P<.8	315.mg n.s.s.	6/50	5/50	6/50		lun:a/a,a/c.
3560 R f f34 eat 24m24 TR135 :					0	25.0mg	49.5mg		
thy MXA #		296.mg *	P<.02 -	120.mg n.s.s.	0/50	1/50	5/50		thy:cca,ccr. S
TBA MXB		no dre	P=1.	41.9mg n.s.s.	45/50	44/50	44/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	3/50	0/50		liv:hpa,hpc,nnd.
3561 R m f34 eat 24m24 TR135 :					0	20.0mg	40.0mg		
TBA MXB		no dre	P=1. -	27.7mg n.s.s.	44/50	43/50	40/50		
liv MXB		1.56gm *	P<.3	254.mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
MALATHION 121-75-5									
3562 M f b6c eat 80w94 TR24 :					0	884.mg	1.75gm		
TBA MXB		no dre	P=1. -	4.12gm n.s.s.	1/10	5/50	5/50		
liv MXB		31.7gm *	P<.3	7.80gm n.s.s.	0/10	0/50	2/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	n.s.s. n.s.s.	0/10	0/50	0/50		lun:a/a,a/c.
3563 M m b6c eat 80w94 TR24 :					0	816.mg	1.62gm		
liv nnd #		10.2gm *	P<.04 -	4.17gm n.s.s.	0/10	0/50	6/50		S
TBA MXB		5.19gm *	P<.3	1.66gm n.s.s.	3/10	9/50	19/50		
liv MXB		4.40gm *	P<.2	1.74gm n.s.s.	2/10	7/50	17/50		liv:hpa,hpc,nnd.
lun MXB		44.7gm *	P<.8	7.80gm n.s.s.	0/10	1/50	1/50		lun:a/a,a/c.
3564 R f f34 eat 24m24 TR192 :					0	97.2mg	194.mg		
TBA MXB		293.mg *	P<.3 -	82.4mg n.s.s.	43/50	45/50	45/50		
liv MXB		no dre	P=1.	1.16gm n.s.s.	2/50	0/50	1/50		liv:hpa,hpc,nnd.
3565 R f osm eat 19m25 TR24 :					0	166.mg	299.mg		
TBA MXB v		434.mg *	P<.2 -	175.mg n.s.s.	7/15	28/50	32/50		
liv MXB v		3.87gm *	P<.2	1.17gm n.s.s.	0/15	0/50	3/50		liv:hpa,hpc,nnd.
3566 R f osm eat 19m25 TR24 : pool					0	166.mg	299.mg		
thy MXA v#		2.96gm *	P<.03 -	1.02gm n.s.s.	0/55	0/50	4/50		thy:fca,fcc. S
3567 R m f34 eat 24m24 TR192 :					0	78.5mg	157.mg		
adr phe #		145.mg *	P<.0005 -	64.8mg 587.mg	2/50	11/50	6/49		S
TBA MXB		66.6mg *	P<.002	32.0mg 340.mg	32/50	30/50	26/49		
liv MXB		411.mg *	P<.05	101.mg n.s.s.	0/50	2/50	0/49		liv:hpa,hpc,nnd.
3568 R m osm eat 19m25 TR24 :					0	133.mg	239.mg		
TBA MXB v		335.mg *	P<.2 -	139.mg n.s.s.	4/15	23/50	25/50		
liv MXB v		3.07gm *	P<.7	851.mg n.s.s.	0/15	2/50	1/50		liv:hpa,hpc,nnd.
MALEIC HYDRAZIDE (1,2-dihydro-3,6-pyridazinedione) 123-33-1									
3569 M f b6a orl 76w76 1193					0	414.mg			Innes;ntis,1968/1969
liv hpt evx		2.35gm	P<.3 -	382.mg n.s.s.	0/17	1/16			
lun ade evx		38.7gm	P<1. -	431.mg n.s.s.	1/17	1/16			
tba mix evx		932.mg	P<.4 -	205.mg n.s.s.	2/17	4/16			
3570 M m b6a orl 76w76 1193					0	385.mg			
liv hpt evx		2.07gm	P<.6 -	302.mg n.s.s.	1/18	2/17			
lun ade evx		no dre	P=1. -	721.mg n.s.s.	2/18	0/17			
tba mix evx		11.9gm	P<1. -	280.mg n.s.s.	3/18	3/17			
3571 M f b6c orl 76w76 1193					0	414.mg			
liv hpt evx		no dre	P=1. -	774.mg n.s.s.	0/16	0/17			
lun mix evx		no dre	P=1. -	774.mg n.s.s.	0/16	0/17			
tba mix evx		no dre	P=1. -	774.mg n.s.s.	0/16	0/17			
3572 M m b6c orl 76w76 1193					0	385.mg			
liv hpt evx		1.06gm	P<.09 -	259.mg n.s.s.	0/16	2/16			
lun mix evx		no dre	P=1. -	678.mg n.s.s.	0/16	0/16			
tba mix evx		679.mg	P<.04 -	205.mg n.s.s.	0/16	3/16			
3573 M f cb6 gav 28m28 1520					0	72.9mg			Cabral;txcy,24,169-173;1982
liv tum e		no dre	P=1. -	340.mg n.s.s.	1/12	2/35			
lun tum e		no dre	P=1. -	394.mg n.s.s.	2/12	2/35			
tba tum e		147.mg	P<.3 -	51.4mg n.s.s.	5/12	22/35			
3574 M m cb6 gav 28m28 1520					0	72.9mg			
lun tum e		2.43gm	P<.5 -	395.mg n.s.s.	0/11	1/37			
liv tum e		3.48gm	P<.9 -	237.mg n.s.s.	1/11	4/37			
tba tum e		no dre	P=1. -	112.mg n.s.s.	7/11	18/37			
3575 R f nss eat 23m23 1109					0	500.mg			Barnes;natu,180,62-64;1957
liv hpt e		no dre	P=1. -	1.33gm n.s.s.	0/9	0/14			
tba mix e		3.72gm	P<.8 -	393.mg n.s.s.	2/9	4/14			
3576 R m nss eat 23m23 1109					0	400.mg			
liv hpt e		no dre	P=1. -	1.07gm n.s.s.	0/8	0/14			
tba mix e		12.3gm	P<1. -	467.mg n.s.s.	1/8	2/14			
MALONALDEHYDE, SODIUM SALT (3-hydroxy-2-propenal, sodium salt) 24382-04-5									
3577 M f b6c gav 24m24 TR331 :					0	42.0mg	84.9mg		
TBA MXB		274.mg *	P<.5 -	64.5mg n.s.s.	27/50	31/50	26/50		
liv MXB		568.mg *	P<.2	184.mg n.s.s.	2/50	3/50	5/50		liv:hpa,hpc,nnd.
lun MXB		4.41gm *	P<.9	200.mg n.s.s.	5/50	7/50	4/50		lun:a/a,a/c.
3578 M m b6c gav 24m24 TR331 :					0	42.4mg	84.9mg		
TBA MXB		217.mg *	P<.6 -	36.0mg n.s.s.	39/50	37/50	31/50		
liv MXB		230.mg *	P<.4	55.8mg n.s.s.	17/50	21/50	17/50		liv:hpa,hpc,nnd.
lun MXB		1.13gm *	P<.8	102.mg n.s.s.	10/50	5/50	8/50		lun:a/a,a/c.
3579 M f swi wat 52w52 1521 pool					0	.100mg	1.00mg	10.0mg	Bird;jtxe,10,897-905;1982
liv hpt e		4.62mg Z	P<.03	1.14mg n.s.s.	0/97	0/49	2/50	(0/48)	
liv mix e		14.1mg *	P<.02 +	5.07mg n.s.s.	1/97	2/49	4/50	6/48	
liv hem e		24.8mg *	P<.02	7.78mg n.s.s.	1/97	1/49	0/50	4/48	
liv hnd e		44.3mg *	P<.3	10.3mg n.s.s.	0/97	1/49	2/50	2/48	
lun ade e		no dre	P=1. -	14.3mg n.s.s.	6/97	4/49	5/50	2/48	
3580 R f f34 gav 24m24 TR331 :					0	35.0mg	70.7mg		
thy MXA		252.mg /	P<.02 c	98.7mg n.s.s.	2/50	1/50	7/50		thy:fca,fcc.
TBA MXB		164.mg *	P<.5	34.5mg n.s.s.	37/50	37/50	21/50		
liv MXB		1.95gm *	P<.2	318.mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
3581 R m f34 gav 24m24 TR331 :					0	35.4mg	70.7mg		
MXB MXB		67.7mg *	P<.0005	37.4mg 216.mg	4/50	17/50	13/50		pni:isa; thy:fca,fcc. C

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
pni isa		80.5mg \	P<.0005 c	37.9mg 219.mg	0/50	9/50	(1/50)		
pni MXA		90.3mg \	P<.005	39.6mg 876.mg	1/50	9/50	(1/50)		pni:isa,isc. S
thy MXA		113.mg *	P<.002 c	56.2mg 545.mg	4/50	8/50	13/50		thy:fca,fcc.
tes ict		39.8mg *	P<.02	18.5mg n.s.s.	40/50	45/50	36/50		S
amd phe		184.mg *	P<.05	70.8mg n.s.s.	5/50	6/50	8/50		S
sub MXA		195.mg *	P<.04	81.3mg n.s.s.	1/50	7/50	3/50		sub:fbs,fib. S
thy fca		206.mg *	P<.02	86.5mg n.s.s.	3/50	3/50	9/50		S
thy fcc		236.mg *	P<.02	98.2mg n.s.s.	1/50	5/50	5/50		S
adr coa		566.mg *	P<.03	186.mg n.s.s.	0/50	1/50	3/50		S
TBA MXB		41.8mg /	P<.008	20.2mg 889.mg	40/50	40/50	41/50		
liv MXB		665.mg *	P<.4	133.mg n.s.s.	3/50	2/50	3/50		liv:hpa,hpc,nnd.
MANGANESE ETHYLENEBISTHIOCARBAMATE (maneb) 12427-38-2									
3582 M f b6a orl 76w76 1214					0	21.6mg			Innes;ntis,1968/1969
lun ade evx		no dre	P=1.	- 25.6mg n.s.s.	1/17	1/18			
liv hpt evx		no dre	P=1.	- 42.7mg n.s.s.	0/17	0/18			
tba mix evx		138.mg	P<.7	- 15.5mg n.s.s.	2/17	3/18			
3583 M m b6a orl 76w76 1214					0	20.0mg			
lun ade evx		54.9mg	P<.4	- 11.5mg n.s.s.	2/18	4/18			
liv hpt evx		no dre	P=1.	- 39.7mg n.s.s.	1/18	0/18			
tba mix evx		106.mg	P<.7	- 12.4mg n.s.s.	3/18	4/18			
3584 M f b6c orl 76w76 1214					0	21.6mg			
liv hpt evx		no dre	P=1.	- 40.3mg n.s.s.	0/16	0/17			
lun mix evx		no dre	P=1.	- 40.3mg n.s.s.	0/16	0/17			
tba tum evx		no dre	P=1.	- 40.3mg n.s.s.	0/16	0/17			
3585 M m b6c orl 76w76 1214					0	20.0mg			
liv hpt evx		128.mg	P<.3	- 20.9mg n.s.s.	0/16	1/18			
lun ade evx		128.mg	P<.3	- 20.9mg n.s.s.	0/16	1/18			
tba mix evx		62.3mg	P<.2	- 15.3mg n.s.s.	0/16	2/18			
3586 R b mgr gav 22m24 1426					0	88.0mg			Andrianova;vpit,29,71-74;1970
liv tum e		no dre	P=1.	109.mg n.s.s.	0/46	0/6			
tba mix e		157.mg	P<.02	+ 36.3mg n.s.s.	1/46	2/6			
MANGANESE (II) SULFATE MONOHYDRATE 10034-96-5									
3587 M f b6c eat 24m24 TR428 :					0	192.mg	641.mg	1.92gm	
thy fca		20.5gm *	P<.1	e 6.11gm n.s.s.	2/51	1/50	0/51	5/51	
TBA MXB		no dre	P=1.	1.89gm n.s.s.	37/51	37/50	37/51	36/51	
liv MXB		no dre	P=1.	4.20gm n.s.s.	13/51	15/50	7/51	13/51	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	7.11gm n.s.s.	6/51	4/50	6/51	4/51	lun:a/a,a/c.
3588 M m b6c eat 24m24 TR428 :					0	178.mg	592.mg	1.78gm	
hag adc		23.2gm *	P<.05	7.20gm n.s.s.	1/50	0/50	0/51	4/51	S
thy fca		26.2gm *	P<.02	e 7.93gm n.s.s.	0/50	0/50	0/51	3/51	
TBA MXB		no dre	P=1.	2.01gm n.s.s.	46/50	44/50	40/51	39/51	
liv MXB		no dre	P=1.	182.mg n.s.s.	34/50	31/50	(24/51	22/51)	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	4.17gm n.s.s.	12/50	13/50	9/51	12/51	lun:a/a,a/c.
3589 R f f34 eat 24m24 TR428 :					0	74.0mg	247.mg	740.mg	
TBA MXB		no dre	P=1.	- 557.mg n.s.s.	45/50	47/50	49/51	42/50	
liv MXB		no dre	P=1.	4.29gm n.s.s.	0/50	1/50	1/51	0/50	liv:hpa,hpb,hpc.
3590 R m f34 eat 24m24 TR428 :					0	59.2mg	197.mg	591.mg	
pni MXA #		1.46gm *	P<.04	- 513.mg n.s.s.	0/52	3/51	4/51	4/52	pni:isa,isc. S
TBA MXB		386.mg *	P<.07	147.mg n.s.s.	44/52	46/51	46/51	44/52	
liv MXB		no dre	P=1.	1.46gm n.s.s.	0/52	1/51	1/51	0/52	liv:hpa,hpb,hpc.
MANIDIPINE.2HCl (CV-4093.2HCl) 89226-75-5									
3591 M f icm eat 78w78 2430					0	1.20mg	4.00mg	12.0mg	40.0mg Osheroff;jjpt,17,1205-1216;1989
lun a/a e		438.mg *	P<.5	- 81.5mg n.s.s.	3/50	2/50	2/50	3/50	4/50
liv hpa e		545.mg *	P<.2	- 134.mg n.s.s.	0/50	0/50	0/49	1/50	1/50
3592 M m icm eat 78w78 2430					0	1.20mg	4.00mg	12.0mg	40.0mg
liv hpa e		no dre	P=1.	- 32.8mg n.s.s.	5/50	9/50	1/49	5/50	(1/50)
lun a/a e		no dre	P=1.	- 94.1mg n.s.s.	10/50	6/50	9/50	8/50	6/50
liv hpc e		no dre	P=1.	- 183.mg n.s.s.	2/50	2/50	0/49	1/50	1/50
3593 R f cdr eat 24m24 2431					0	.600mg	2.00mg	6.00mg	Osheroff;jjpt,17,1217-1231;1989
liv hpa e		157.mg *	P<.5	- 25.5mg n.s.s.	3/49	2/49	1/50	4/50	
liv hpc e		no dre	P=1.	- 4.35mg n.s.s.	1/49	0/49	0/50	0/50	
3594 R m cdr eat 24m24 2431					0	.600mg	2.00mg	6.00mg	
liv hpc e		405.mg *	P<.8	- 35.2mg n.s.s.	1/50	0/50	2/50	1/50	
liv hpa e		8.24gm Z	P<1.	- 30.3mg n.s.s.	1/50	6/50	0/50	3/50	
D-MANNITOL 69-65-8									
3595 M f b6c eat 24m24 TR236 :					0	3.19gm	6.38gm		
--- hes #		46.7gm *	P<.04	- 17.7gm n.s.s.	0/50	2/50	3/50		S
--- lle		48.0gm *	P<.02	19.5gm n.s.s.	0/50	2/50	4/50		S
TBA MXB		no dre	P=1.	11.2gm n.s.s.	26/50	24/50	18/50		
liv MXB		no dre	P=1.	25.7gm n.s.s.	3/50	3/50	2/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	36.9gm n.s.s.	3/50	2/50	1/50		lun:a/a,a/c.
3596 M m b6c eat 24m24 TR236 :					0	2.94gm	5.89gm		
TBA MXB		no dre	P=1.	- 10.6gm n.s.s.	33/50	26/50	26/50		
liv MXB		no dre	P=1.	14.5gm n.s.s.	14/50	14/50	11/50		liv:hpa,hpc,nnd.
lun MXB		98.1gm *	P<.8	10.7gm n.s.s.	9/50	12/50	11/50		lun:a/a,a/c.
3597 R f f34 eat 24m24 TR236 :					0	1.23gm	2.45gm		
TBA MXB		5.00gm \	P<.7	- 686.mg n.s.s.	45/50	44/50	(36/50)		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
3598 R m f34 eat 24m24 TR236 :					0	981.mg	1.96gm		
TBA MXB		no dre	P=1.	- 1.77gm n.s.s.	40/50	40/50	36/50		
liv MXB		18.0gm *	P<.1	6.18gm n.s.s.	0/50	2/50	2/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
MANNITOL NITROGEN MUSTARD (degranol) 576-68-1								
3599 R m b46 ivj 12m24 1017				0	.286mg			Schmahl;arzn,20,1461-1467;1970
tba mix es	3.11mg	P<.5	.583mg n.s.s.	7/65	6/37			
tba mal es	3.85mg	P<.5	.706mg n.s.s.	4/65	4/37			
tba ben es	23.5mg	P<.9	1.05mg n.s.s.	3/65	2/37			
MeA-alpha-C ACETATE (2-amino-3-methyl-9H-pyrido-[2,3-b]-indole acetate) 117831-29-5								
3600 M f cdf eat 84w84 1616				0	104.mg			Ohgaki;carc,5,815-819;1984
blv hms	38.6mg	P<.0005 +	23.7mg 67.3mg	0/40	28/40			
liv mix	38.6mg	P<.0005 +	23.7mg 67.3mg	0/40	28/40			
liv hpc	98.9mg	P<.0005	53.9mg 210.mg	0/40	15/40			
liv hpa	118.mg	P<.0005	62.1mg 267.mg	0/40	13/40			
lun ade	1.84gm	P<.3	299.mg n.s.s.	0/40	1/40			
lun mix	no dre	P=1.	273.mg n.s.s.	2/40	2/40			
3601 M m cdf eat 73w73 1616				0	96.0mg			
blv hms	15.6mg	P<.0005 +	9.38mg 26.7mg	0/40	35/40			
liv mix	43.5mg	P<.0005 +	25.6mg 81.9mg	0/40	21/40			
liv hpa	90.9mg	P<.0005	46.6mg 214.mg	0/40	12/40			
liv hpc	127.mg	P<.0005	59.7mg 372.mg	0/40	9/40			
lun ade	1.18gm	P<.7	132.mg n.s.s.	3/40	4/40			
lun mix	no dre	P=1.	192.mg n.s.s.	11/40	5/40			
3602 R m f3d eat 23m23 2064				0	4.00mg	8.00mg		Tamano;carc,15,2009-2015;1994
sub fib e	6.70mg *	P<.0005 +	3.53mg 20.3mg	2/20	4/20	14/20		
pan ana e	8.70mg *	P<.0005 +	4.65mg 23.5mg	0/20	6/20	8/20		
liv hpc Ce	11.7mg *	P<.003 +	5.87mg 52.8mg	0/20	5/20	6/20		
ubl tcc eh	28.6mg *	P<.09 +	10.8mg n.s.s.	0/20	3/20	2/20		
pni isa e	48.1mg *	P<.04	14.5mg n.s.s.	0/20	0/20	3/20		
slg fbs eh	73.5mg *	P<.1 +	18.1mg n.s.s.	0/20	0/20	2/20		
MeIQ (2-amino-3,4-dimethylimidazo[4,5-f]quinoline) 77094-11-2								
3603 M f cdf eat 91w91 1798				0	13.0mg	52.0mg		Ohgaki;carc,7,1889-1893;1986
for mix e	10.7mg *	P<.0005 +	7.18mg 16.5mg	0/40	19/36	34/38		
for sqc e	24.5mg *	P<.0005 +	16.0mg 39.7mg	0/40	11/36	24/38		
liv mix e	27.1mg *	P<.0005 +	17.2mg 45.4mg	0/40	4/36	27/38		
liv hpc e	65.6mg /	P<.0005 +	36.4mg 135.mg	0/40	0/36	16/38		
lun mix e	25.1mg \	P<.03 -	10.1mg n.s.s.	5/40	12/36	(7/38)		
3604 M m cdf eat 91w91 1798				0	12.0mg	48.0mg		
for mix e	14.5mg *	P<.0005 +	9.53mg 23.1mg	0/29	7/38	35/38		
for sqc e	22.4mg /	P<.0005 +	14.4mg 37.1mg	0/29	3/38	30/38		
lun mix e	148.mg *	P<.2 -	46.8mg n.s.s.	6/29	6/38	12/38		
liv hpc e	no dre	P=1.	163.mg n.s.s.	1/29	3/38	1/38		
liv mix e	no dre	P=1.	70.6mg n.s.s.	4/29	11/38	7/38		
3605 M f cj5 eat 85w85 2617				0	39.0mg			Fujita;gann,90,1203-1206;1999
liv fbs e	20.7mg	P<.0005	11.2mg 59.8mg	9/39	27/40			
lgi adc e	32.3mg	P<.0005 +	18.1mg 65.2mg	0/39	17/40			
cec adc e	50.0mg	P<.0005 +	25.7mg 118.mg	0/39	12/40			
liv hpc e	62.1mg	P<.0005 +	30.1mg 166.mg	0/39	10/40			
liv hpa e	80.0mg	P<.002	36.1mg 272.mg	0/39	8/40			
col adc e	92.8mg	P<.002 +	40.0mg 393.mg	0/39	7/40			
MeIQx (2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline) 77500-04-0								
3606 M f cdf eat 84w84 1820m				0	78.0mg			Ohgaki;carc,8,665-668;1987/Wakabayashi 1992
liv hpa ej	14.2mg	P<.0005	7.95mg 25.6mg	0/39	32/35			
liv mix ej	14.2mg	P<.0005 +	7.95mg 25.6mg	0/39	32/35			
liv hpc ej	27.8mg	P<.0005	16.6mg 50.3mg	0/39	25/35			
lun mix ej	77.2mg	P<.002 +	37.2mg 370.mg	4/39	15/35			
lun ade ej	143.mg	P<.02	59.2mg n.s.s.	2/39	9/35			
lun adc ej	257.mg	P<.1	83.2mg n.s.s.	2/39	6/35			
--- lkm ej	6.82gm	P<1.	83.2mg n.s.s.	11/39	10/35			
3607 M m cdf eat 84w84 1820m				0	72.0mg			
liv hpa ej	86.9mg	P<.01	38.8mg 10.9gm	5/36	15/37			
liv hpc ej	102.mg	P<.0005	49.6mg 273.mg	0/36	10/37			
--- lkm ej	109.mg	P<.006 +	48.9mg 1.23gm	2/36	11/37			
liv mix ej	83.8mg	P<.02 +	37.0mg n.s.s.	6/36	16/37			
lun mix ej	134.mg	P<.2	42.9mg n.s.s.	10/36	16/37			
lun adc ej	236.mg	P<.4	60.9mg n.s.s.	7/36	11/37			
lun ade ej	262.mg	P<.2	77.2mg n.s.s.	3/36	7/37			
3608 R f f3d eat 61w61 1867				0	20.0mg			Kato;carc,9,71-73;1988/pers.comm.
cli sqc e	4.72mg	P<.0005 +	2.34mg 11.3mg	0/20	12/19			
liv nnd e	6.31mg	P<.0005 +	3.00mg 16.4mg	0/20	10/19			
zym sqc e	6.31mg	P<.0005 +	3.00mg 16.4mg	0/20	10/19			
ski sqc e	87.2mg	P<.3	14.2mg n.s.s.	0/20	1/19			
3609 R m f3d eat 61w61 1867				0	16.0mg			
liv mix e	noTD50	P<.0005 +	n.s.s. 2.01mg	0/19	20/20			
liv hpc e	1.26mg	P<.0005 +	.518mg 2.88mg	0/19	19/20			
zym mix e	2.72mg	P<.0005 +	1.39mg 6.00mg	0/19	15/20			
zym sqc e	3.59mg	P<.0005 +	1.82mg 8.30mg	0/19	13/20			
ski mix e	8.76mg	P<.002 +	3.75mg 34.5mg	0/19	7/20			
ski sqc e	13.1mg	P<.008 +	4.95mg 197.mg	0/19	5/20			
zym sqp e	35.8mg	P<.1	8.79mg n.s.s.	0/19	2/20			
liv nnd e	73.5mg	P<.3	12.0mg n.s.s.	0/19	1/20			
ski bcc e	73.5mg	P<.3	12.0mg n.s.s.	0/19	1/20			
ski sqp e	73.5mg	P<.3	12.0mg n.s.s.	0/19	1/20			
3610 R m f3d eat 56w56 2093				0	4.00mg	8.00mg	16.0mg	Kushida;clet,83,31-35;1994
liv mix e	1.24mg Z	P<.0005 +	.827mg 1.93mg	0/15	5/30	26/29	16/16	
liv hpc e	2.91mg Z	P<.0005 +	1.82mg 5.01mg	0/15	0/30	13/29	15/16	
liv hpa e	3.15mg Z	P<.0005	1.80mg 7.67mg	0/15	5/30	13/29	(1/16)	
zym mix e	4.91mg Z	P<.0005 +	2.84mg 9.53mg	0/15	1/30	5/29	13/16	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
zym sqc e		8.60mg	Z P<.0005 +	4.41mg 20.5mg	0/15	0/30	3/29	9/16	
ski mix e		12.0mg	* P<.0005 +	5.66mg 39.2mg	0/15	0/30	3/29	6/16	
zym sqp e		29.1mg	* P<.1	10.0mg n.s.s.	0/15	1/30	1/29	2/16	
ski tri e		38.9mg	* P<.05	11.8mg n.s.s.	0/15	0/30	1/29	2/16	
zym sea e		38.9mg	* P<.05	11.8mg n.s.s.	0/15	0/30	1/29	2/16	
ski sea e		58.8mg	* P<.07	14.5mg n.s.s.	0/15	0/30	0/29	2/16	
ski sqc e		59.2mg	* P<.2	14.6mg n.s.s.	0/15	0/30	1/29	1/16	
ski sqp e		59.2mg	* P<.2	14.6mg n.s.s.	0/15	0/30	1/29	1/16	
MELAMINE 108-78-1									
3611 M f b6c eat 24m24 TR245 :					0	287.mg	574.mg		
TBA MXB		no dre	P=1.	- 804.mg n.s.s.	28/50	33/50	26/50		
liv MXB		no dre	P=1.	2.61gm n.s.s.	4/50	6/50	2/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.53gm n.s.s.	5/50	1/50	3/50		lun:a/a,a/c.
3612 M m b6c eat 24m24 TR245 :					0	265.mg	530.mg		
TBA MXB		3.20gm	* P<.7	- 525.mg n.s.s.	23/50	22/50	20/50		
liv MXB		4.37gm	* P<.6	820.mg n.s.s.	12/50	8/50	12/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	2.37gm n.s.s.	5/50	4/50	1/50		lun:a/a,a/c.
3613 R f f34 eat 24m24 TR245 :					0	221.mg	441.mg		
thy MXA #		2.47gm	* P<.03	- 937.mg n.s.s.	0/50	2/50	3/50		thy:cca,ccr. S
thy ccr		4.16gm	* P<.04	1.26gm n.s.s.	0/50	0/50	3/50		S
TBA MXB		3.93gm	* P<.9	273.mg n.s.s.	42/50	43/50	37/50		
liv MXB		4.41gm	* P<.2	1.33gm n.s.s.	0/50	2/50	1/50		liv:hpa,hpc,nnd.
3614 R m f34 eat 24m24 TR245 :					0	88.3mg	177.mg		
ubl MXA		679.mg	/ P<.0005	308.mg 2.04gm	0/50	0/50	9/50		ubl:tcc,tpp. S
ubl tcc		735.mg	/ P<.002 c	322.mg 2.51gm	0/50	0/50	8/50		
TBA MXB		149.mg	* P<.04	65.3mg n.s.s.	30/50	36/50	38/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
MELOXICAM 71125-38-7									
3615 R f wis gav 52w52 2537					0	.200mg	.400mg	.800mg	Yabe;phrm,53,29-49;1997/pers.comm.
sto tum		no dre	P=1.	- .113mg n.s.s.	0/16	0/20	0/18	0/19	
3616 R m wis gav 52w52 2537					0	.200mg	.400mg	.800mg	
sto tum		no dre	P=1.	- .110mg n.s.s.	0/18	0/18	0/20	0/19	
MELPHALAN (L-sarcolysin) 148-82-3									
3617 M f swi ipj 26w79 1336m					0	.106mg	.212mg	Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.	
lun mix e		.165mg	* P<.007 +	61.7ug 4.11mg	20/154	6/15	3/8		
mgl ade e		.617mg	* P<.004	.152mg 10.1mg	0/154	1/15	1/8		
--- lys e		.702mg	* P<.06	.154mg n.s.s.	3/154	0/15	2/8		
adr fbs e		1.26mg	* P<.03	.204mg n.s.s.	0/154	0/15	1/8		
liv lys e		no dre	P=1.	97.5ug n.s.s.	1/154	0/15	0/8		
tba mix e		51.0ug	* P<.0005	23.3ug .167mg	42/154	10/15	7/8		
tba mal e		.104mg	* P<.002	43.4ug .617mg	29/154	7/15	5/8		
tba ben e		.365mg	* P<.08	.100mg n.s.s.	13/154	3/15	2/8		
3618 M m swi ipj 26w77 1336m					0	.108mg			
lun mix e		.137mg	P<.005 +	54.6ug 1.57mg	9/101	9/28			
--- lys e		.302mg	P<.02 +	94.4ug n.s.s.	2/101	4/28			
liv mix e		no dre	P=1.	.341mg n.s.s.	2/101	0/28			
tba mix e		91.4ug	P<.02	36.2ug n.s.s.	28/101	15/28			
tba mal e		.115mg	P<.02	44.9ug n.s.s.	19/101	12/28			
tba ben e		2.02mg	P<.8	.140mg n.s.s.	9/101	3/28			
3619 P b cym gav 16y18 2003 :					0	63.0ug		Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.	
kid rca w		.100mg	P<.04	24.1ug n.s.s.	0/12	2/7			
pnm ngs w		.207mg	P<.03	50.8ug n.s.s.	0/33	2/12			
ute mix w		86.0ug	P<.2	20.5ug n.s.s.	1/15	3/10			
ute ena w		.170mg	P<.2	27.6ug n.s.s.	0/11	1/5			
ute ley w		.172mg	P<.3	30.1ug n.s.s.	1/15	2/10			
ski pam w		.245mg	P<.2	39.9ug n.s.s.	0/12	1/7			
pal sqc w		.358mg	P<.2	58.3ug n.s.s.	0/13	1/10			
pro car w		.358mg	P<.2	58.3ug n.s.s.	0/13	1/10			
scl ecc w		.358mg	P<.2	58.3ug n.s.s.	0/13	1/10			
tba mix Ww		40.3ug	P<.005	15.7ug .389mg	2/33	8/12			
tba mal Ww		70.1ug	P<.02 +	23.2ug n.s.s.	1/33	5/12			
tba ben w		.157mg	P<.3	30.3ug n.s.s.	2/20	3/10			
3620 P b rhe gav 16y19 2003 :					0	64.0ug			
ute ley Ww		32.2ug	P<.02	4.56ug n.s.s.	1/29	2/5			
lun ade w		.290mg	P<.08	47.2ug n.s.s.	0/31	1/8			
tba ben Ww		84.9ug	P<.1	15.1ug n.s.s.	6/108	3/8			
3621 R f cdr ipj 26w78 1336n					0	.129mg	.304mg	Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.	
per sar e		.135mg	* P<.0005 +	63.2ug .371mg	0/182	8/16	1/6		
lun a/a e		1.44mg	* P<.02	.234mg n.s.s.	0/182	0/16	1/6		
pan adc e		1.44mg	* P<.02	.234mg n.s.s.	0/182	0/16	1/6		
--- lys e		1.54mg	* P<.09	.236mg n.s.s.	1/182	0/16	1/6		
liv tum e		no dre	P=1.	.112mg n.s.s.	0/182	0/16	0/6		
tba mal e		78.1ug	* P<.0005	35.2ug .310mg	44/182	13/16	3/6		
tba mix e		.106mg	* P<.07	33.1ug n.s.s.	103/182	14/16	4/6		
tba ben e		no dre	P=1.	.319mg n.s.s.	59/182	1/16	1/6		
3622 R m cdr ipj 26w67 1336n					0	.149mg			
per mix e		71.9ug	P<.0005 +	32.0ug .212mg	0/177	8/18			
--- lys e		.359mg	P<.003	88.1ug 4.84mg	0/177	2/18			
liv tum e		no dre	P=1.	.229mg n.s.s.	0/177	0/18			
tba mix e		23.6ug	P<.0005	9.76ug 77.1ug	59/177	16/18			
tba mal e		47.0ug	P<.0005	20.7ug .171mg	32/177	12/18			
tba ben e		.493mg	P<.5	74.1ug n.s.s.	27/177	4/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
DL-MENTHOL 15356-70-4									
3623 M f b6c eat 24m24 TR98 :				0	257.mg	515.mg			
TBA MXB	no dre	P=1.	- 723.mg n.s.s.	30/50	20/50	24/50			
liv MXB	5.19gm *	P<.3	1.54gm n.s.s.	1/50	3/50	3/50		liv:hpa,hpc,nnd.	
lun MXB	3.17gm *	P<.06	1.22gm n.s.s.	1/50	3/50	5/50		lun:a/a,a/c.	
3624 M m b6c eat 24m24 TR98 :				0	238.mg	475.mg			
TBA MXB	2.75gm *	P<.7	- 357.mg n.s.s.	29/50	28/50	33/50			
liv MXB	1.96gm *	P<.3	601.mg n.s.s.	8/50	8/50	14/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	1.10gm n.s.s.	6/50	7/50	6/50		lun:a/a,a/c.	
3625 R f f34 eat 24m24 TR98 :				0	184.mg	368.mg			
TBA MXB	no dre	P=1.	- 462.mg n.s.s.	41/50	36/50	32/50			
liv MXB	no dre	P=1.	2.11gm n.s.s.	1/50	1/50	1/50		liv:hpa,hpc,nnd.	
3626 R m f34 eat 24m24 TR98 :				0	147.mg	294.mg			
TBA MXB	1.41gm *	P<.7	- 200.mg n.s.s.	32/50	41/50	37/50			
liv MXB	5.69gm *	P<.6	932.mg n.s.s.	1/50	3/50	2/50		liv:hpa,hpc,nnd.	
MER-25 67-98-1									
3627 R f nss gav 52w52 481				0	12.2mg			Shay;mpoc,305-318;1962	
mam tum er	no dre	P=1.	- 13.9mg n.s.s.	0/9	0/22				
2-MERCAPTOBENZOTHIAZOLE (captax, rotax) 149-30-4									
3628 M f b6c gav 24m24 TR332 :				0	265.mg	531.mg			
liv MXA	2.16gm *	P<.3	e 629.mg n.s.s.	4/50	12/50	4/50		liv:hpa,hpc.	
TBA MXB	no dre	P=1.	697.mg n.s.s.	38/50	33/50	15/50			
liv MXB	2.16gm *	P<.3	629.mg n.s.s.	4/50	12/50	4/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	2.14gm n.s.s.	3/50	1/50	2/50		lun:a/a,a/c.	
3629 M f b6c orl 76w76 1302				0	44.3mg			Innes;ntis,1968/1969	
lun ade evx	283.mg	P<.3	- 46.1mg n.s.s.	0/16	1/18				
liv hpt evx	no dre	P=1.	- 87.7mg n.s.s.	0/16	0/18				
tba mix evx	283.mg	P<.3	- 46.1mg n.s.s.	0/16	1/18				
3630 M m b6c gav 24m24 TR332 :				0	265.mg	531.mg			
TBA MXB	3.33gm *	P<.8	- 359.mg n.s.s.	31/50	39/50	25/50			
liv MXB	3.70gm *	P<.7	557.mg n.s.s.	16/50	21/50	14/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	1.06gm n.s.s.	7/50	9/50	5/50		lun:a/a,a/c.	
3631 M m b6c orl 76w76 1302				0	41.2mg			Innes;ntis,1968/1969	
liv hpt evx	56.2mg	P<.02	- 19.3mg n.s.s.	0/16	4/17				
lun ade evx	120.mg	P<.1	- 29.5mg n.s.s.	0/16	2/17				
tba mix evx	17.0mg	P<.0005	- 7.99mg 44.6mg	0/16	10/17				
3632 M f b6a orl 76w76 1302				0	44.3mg				
lun ade evx	no dre	P=1.	- 49.3mg n.s.s.	1/17	1/17				
liv hpt evx	no dre	P=1.	- 82.8mg n.s.s.	0/17	0/17				
tba mix evx	no dre	P=1.	- 54.8mg n.s.s.	2/17	1/17				
3633 M m b6a orl 76w76 1302				0	41.2mg				
lun ade evx	no dre	P=1.	- 38.5mg n.s.s.	2/18	2/18				
liv hpt evx	no dre	P=1.	- 48.7mg n.s.s.	1/18	1/18				
tba mix evx	105.mg	P<.5	- 21.0mg n.s.s.	3/18	5/18				
3634 R f f34 gav 24m24 TR332 :				0	133.mg	265.mg			
MXB MXB	247.mg *	P<.03	112.mg n.s.s.	16/50	28/50	29/50		amd:phe; pta:adn.	P
pta adn	343.mg *	P<.07	p 140.mg n.s.s.	15/50	24/50	25/50			
amd phe	805.mg *	P<.04	p 347.mg n.s.s.	1/50	5/50	6/50			
TBA MXB	576.mg *	P<.6	116.mg n.s.s.	37/50	46/50	40/50			
liv MXB	no dre	P=1.	3.30gm n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.	
3635 R m f34 gav 24m24 TR332 :				0	265.mg	531.mg			
MXB MXB	157.mg \	P<.0005	82.2mg 543.mg	24/50	38/50	(31/50)		amd:phe,phm; mul:mnl; pan:ana; pre:adn,can.	P
tes ict	240.mg *	P<.005	121.mg 2.27gm	48/50	48/50	48/50			S
pta adn	333.mg \	P<.009	146.mg 13.6gm	14/50	21/50	(12/50)			S
pan ana	345.mg \	P<.0005	p 167.mg 1.10gm	2/50	13/50	(6/50)			
amd MXA	394.mg *	P<.003	p 203.mg 2.31gm	18/50	27/50	24/50		amd:phe,phm.	
mul mnl	401.mg \	P<.004	p 183.mg 2.99gm	7/50	16/50	(3/50)			
pre adn	1.71gm *	P<.004	749.mg 10.5gm	0/50	4/50	4/50			S
pre MXA	1.58gm *	P<.02	p 684.mg n.s.s.	1/50	6/50	5/50		pre:adn,can.	
sub MXA	1.73gm *	P<.04	686.mg n.s.s.	3/50	6/50	7/50		sub:fbs,fib,nfm,srn.	S
sub MXA	1.90gm *	P<.03	744.mg n.s.s.	2/50	4/50	6/50		sub:fib,nfm.	S
sub fib	2.20gm *	P<.04	822.mg n.s.s.	2/50	3/50	6/50			S
MXA MXA	3.20gm *	P<.02	1.14gm n.s.s.	0/50	2/50	3/50		mul:msm; tna:men.	S
TBA MXB	136.mg \	P<.002	69.9mg 617.mg	37/50	47/50	(41/50)			
liv MXB	no dre	P=1.	1.94gm n.s.s.	3/50	2/50	1/50		liv:hpa,hpc,nnd.	
2-MERCAPTOBENZOTHIAZOLE, ZINC (zetax) 155-04-4									
3636 M f b6a orl 76w76 1300				0	462.mg			Innes;ntis,1968/1969	
lun ade evx	no dre	P=1.	- 515.mg n.s.s.	1/17	1/17				
liv hpt evx	no dre	P=1.	- 864.mg n.s.s.	0/17	0/17				
tba mix evx	no dre	P=1.	- 572.mg n.s.s.	2/17	1/17				
3637 M m b6a orl 76w76 1300				0	430.mg				
lun ade evx	no dre	P=1.	- 564.mg n.s.s.	2/18	1/18				
liv hpt evx	no dre	P=1.	- 851.mg n.s.s.	1/18	0/18				
tba mix evx	no dre	P=1.	- 603.mg n.s.s.	3/18	1/18				
3638 M f b6c orl 76w76 1300				0	462.mg				
liv hpt evx	no dre	P=1.	- 864.mg n.s.s.	0/16	0/17				
lun mix evx	no dre	P=1.	- 864.mg n.s.s.	0/16	0/17				
tba mix evx	2.79gm	P<.3	- 454.mg n.s.s.	0/16	1/17				
3639 M m b6c orl 76w76 1300				0	430.mg				
liv hpt evx	388.mg	P<.004	- 157.mg 2.37gm	0/16	6/18				
lun ade evx	2.75gm	P<.3	- 448.mg n.s.s.	0/16	1/18				
tba mix evx	319.mg	P<.002	- 136.mg 1.30gm	0/16	7/18				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
2-MERCAPTOETHANESULFONATE, SODIUM		**19767-45-4**							
3640 R m sda wat	9m24 1637				0	87.0mg			Tacchi;clet,22,89-94;1984
liv tum	no dre	P=1.		717.mg n.s.s.	0/40	0/40			
lun tum	no dre	P=1.		717.mg n.s.s.	0/40	0/40			
ubl tum	no dre	P=1.		717.mg n.s.s.	0/40	0/40			
6-MERCAPTOPURINE		**50-44-2**							
3641 R m b46 ivj	12m24 1017				0	1.18mg			Schmahl;arzn,20,1461-1467;1970
tba mix es	58.1mg	P<.9	-	2.51mg n.s.s.	7/65	3/25			
3642 R f f3d eat	24m26 1980				0	1.15mg	2.30mg		Maekawa;zkko,116,245-250;1990/pers.comm.
adr phe	22.5mg	* P<.02		9.17mg n.s.s.	0/50	2/50	4/50		
cns mix	34.1mg	* P<.04		11.8mg n.s.s.	0/50	1/50	3/50		
ute adc	34.1mg	* P<.04		11.8mg n.s.s.	0/50	1/50	3/50		
liv hpc	139.mg	* P<.3		22.6mg n.s.s.	0/50	0/50	1/50		
liv hpa	no dre	P=1.		9.33mg n.s.s.	1/50	0/50	0/50		
tba mix	4.74mg	* P<.4		1.27mg n.s.s.	39/50	38/50	43/50		
tba mal	10.3mg	* P<.3		3.31mg n.s.s.	14/50	17/50	20/50		
3643 R m f3d eat	24m26 1980				0	.920mg	1.84mg		
liv hpa	no dre	P=1.		20.6mg n.s.s.	3/50	1/50	1/50		
tba mix	no dre	P=1.		.616mg n.s.s.	50/50	50/50	48/50		
tba mal	no dre	P=1.		4.44mg n.s.s.	20/50	17/50	18/50		
MERCURIC CHLORIDE		**7487-94-7**							
3644 M f b6c gav	24m24 TR408 :				0	3.53mg	7.07mg		
TBA MXB	5.83mg	\ P<.09	-	2.18mg n.s.s.	23/50	32/50	(19/50)		
liv MXB	no dre	P=1.		33.4mg n.s.s.	3/50	1/50	2/50		liv:hpa,hpc,nnd.
lun MXB	40.8mg	* P<.3		12.4mg n.s.s.	3/50	8/50	5/50		lun:a/a,a/c.
3645 M m b6c gav	24m24 TR408 :				0	3.53mg	7.07mg		
kid MXA	81.6mg	* P<.04	e	24.7mg n.s.s.	0/50	0/50	3/50		kid:rua,uac.
kid rua	125.mg	* P<.09	e	30.7mg n.s.s.	0/50	0/50	2/50		
kid uac	240.mg	* P<.3	e	39.0mg n.s.s.	0/50	0/50	1/50		
TBA MXB	no dre	P=1.		12.2mg n.s.s.	28/50	20/50	17/50		
liv MXB	no dre	P=1.		18.5mg n.s.s.	7/50	4/50	6/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		18.4mg n.s.s.	10/50	8/50	6/50		lun:a/a,a/c.
3646 M f cd1 wat	27m27 1395				0	1.00mg			Schroeder;jnut,105,452-458;1975
--- lkm e	3.58mg	P<.009	-	1.55mg 105.mg	3/47	11/41			
lun tum e	no dre	P=1.	-	3.36mg n.s.s.	9/47	7/41			
tba mix e	2.42mg	P<.05	-	.973mg n.s.s.	14/47	21/41			
tba mal e	5.55mg	P<.08	-	1.95mg n.s.s.	4/47	9/41			
3647 M m cd1 wat	28m28 1395				0	.833mg			
lun tum e	11.2mg	P<.5	-	2.25mg n.s.s.	5/38	9/48			
tba mix e	3.20mg	P<.2	-	1.09mg n.s.s.	11/38	21/48			
tba mal e	no dre	P=1.	-	7.43mg n.s.s.	2/38	1/48			
3648 R f f34 gav	24m24 TR408 :				0	1.76mg	3.51mg		
for sqp	51.8mg	* P<.09	e	12.7mg n.s.s.	0/50	0/50	2/50		
TBA MXB	no dre	P=1.		2.12mg n.s.s.	46/50	42/50	39/50		
liv MXB	105.mg	* P<.8		17.2mg n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
3649 R m f34 gav	24m24 TR408 :				0	1.75mg	3.51mg		
tes MXA	.825mg	* P<.0005		.437mg 2.88mg	45/50	37/50	39/50		tes:iab,ica. S
amd MXA	1.56mg	* P<.0005		.770mg 6.42mg	21/50	18/50	23/50		amd:pbb,pob. S
amd MXA	1.60mg	* P<.002		.767mg 8.98mg	24/50	18/50	23/50		amd:pbb,phc,phm,pmb,pob. S
for sqp	3.12mg	* P<.0005	p	1.48mg 7.20mg	0/50	3/50	12/50		
thy MXA	5.25mg	* P<.006	e	2.14mg 68.4mg	2/50	6/50	6/50		thy:fca,fcc.
thy fcc	7.32mg	* P<.005	e	2.71mg 71.8mg	1/50	2/50	6/50		
thy fca	5.98mg	\ P<.05	e	1.65mg n.s.s.	1/50	4/50	(0/50)		
TBA MXB	1.04mg	* P<.002		.521mg 4.77mg	45/50	34/50	39/50		
liv MXB	10.3mg	* P<.02		2.91mg n.s.s.	0/50	1/50	2/50		liv:hpa,hpc,nnd.
MERCUROUS CHLORIDE (Calomel)		**7546-30-7**							
3650 M m bal eat	14m24 2498				0	21.1mg			O'Gara;canr,28,2272-2275;1968
lun tum	no dre	P=1.	-	27.1mg n.s.s.	9/33	3/14			
liv tum	no dre	P=1.	-	60.8mg n.s.s.	0/33	0/14			
MERCURYMETHYL CHLORIDE (methylmercuric chloride)		**115-09-3**							
3651 M f b6c eat	24m24 1961				0	52.0ug	.260mg	1.30mg	Mitsumori;faat,14,179-190;1990
kid rca er	65.8mg	* P<.2		10.7mg n.s.s.	0/60	0/60	0/60	1/60	
3652 M m b6c eat	24m24 1961				0	48.0ug	.240mg	1.20mg	
kid mix ers	3.19mg	* P<.0005	+	1.81mg 6.42mg	0/60	0/60	1/60	16/60	
kid rcc ers	4.28mg	* P<.0005		2.26mg 9.65mg	0/60	0/60	0/60	13/60	
kid rca ers	9.83mg	* P<.002		4.01mg 45.6mg	0/60	0/60	1/60	5/60	
3653 M f cd1 wat	33m35 1395				0	.200mg	.253mg		Schroeder;jnut,105,452-458;1975
lun tum esv	no dre	P=1.	-	3.28mg n.s.s.	9/47	3/31	3/40		
tba mix esv	2.13mg	\ P<.5	-	.446mg n.s.s.	14/47	12/31	(4/40)		
tba mal esv	no dre	P=1.	-	4.64mg n.s.s.	4/47	2/31	0/40		
3654 M m cd1 wat	31m37 1395				0	.167mg	.208mg		
lun tum esv	no dre	P=1.	-	1.57mg n.s.s.	5/38	4/25	3/32		
tba mix esv	5.63mg	* P<.8	-	.727mg n.s.s.	11/38	9/25	10/32		
tba mal esv	9.64mg	* P<.6	-	1.53mg n.s.s.	2/38	3/25	2/32		
3655 M f icm eat	52w52 2035m				0	52.0ug	.260mg	1.30mg	Hirano;jjvs,48,127-135;1986/pers.comm.
kid tum k	no dre	P=1.	-	13.0ug n.s.s.	0/6	0/6	0/6	0/6	
3656 M f icm eat	78w78 2035n				0	52.0ug	.260mg	1.30mg	
kid tum k	no dre	P=1.	-	29.2ug n.s.s.	0/6	0/6	0/6	0/6	
3657 M f icm eat	24m24 2035o				0	52.0ug	.260mg	1.30mg	
kid tum	no dre	P=1.	-	.363mg n.s.s.	0/42	0/42	0/42	0/42	
3658 M f icm eat	80w80 2041				0	1.30mg			Hirano;jjvs,50,886-893;1988
lun adc e	11.6mg	P<.6	-	1.99mg n.s.s.	5/50	7/50			
liv hem e	26.1mg	P<.3	-	4.25mg n.s.s.	0/50	1/50			
liv hpa e	no dre	P=1.	-	7.93mg n.s.s.	5/50	0/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc e		no dre	P=1.	- 7.93mg n.s.s.	1/50	0/50			
kid ade e		no dre	P=1.	- 7.93mg n.s.s.	1/50	0/50			
lun ade e		no dre	P=1.	- 5.70mg n.s.s.	3/50	1/50			
3659 M m icm eat 52w52 2035m					0	48.0ug	.240mg	1.20mg	Hirano;jjvs,48,127-135;1986/pers.comm.
kid tum k		no dre	P=1.	12.0ug n.s.s.	0/6	0/6	0/6	0/6	
3660 M m icm eat 78w78 2035n					0	48.0ug	.240mg	1.20mg	
kid mix k		.896mg	* P<.006	+ .264mg 10.9mg	0/6	0/6	0/6	3/6	
kid adc k		3.20mg	* P<.2	.520mg n.s.s.	0/6	0/6	0/6	1/6	
3661 M m icm eat 24m24 2035o					0	48.0ug	.240mg	1.20mg	
kid mix ae		1.69mg	* P<.0005	+ .802mg 4.78mg	1/26	0/19	0/23	10/20	
kid adc ae		1.88mg	* P<.0005	.876mg 5.14mg	0/26	0/19	0/23	9/20	
3662 M m icm eat 80w80 2041					0	1.20mg			Hirano;jjvs,50,886-893;1988
kid mix e		1.36mg	P<.0005	+ .746mg 2.89mg	0/50	15/50			
kid adc e		1.48mg	P<.0005	.795mg 3.23mg	0/50	14/50			
lun adc e		5.10mg	P<.3	1.37mg n.s.s.	6/50	10/50			
kid ade e		24.1mg	P<.3	3.92mg n.s.s.	0/50	1/50			
liv hpa e		no dre	P=1.	3.33mg n.s.s.	12/50	6/50			
liv hpb e		no dre	P=1.	7.32mg n.s.s.	2/50	0/50			
liv hpc e		no dre	P=1.	3.45mg n.s.s.	7/50	4/50			
lun ade e		no dre	P=1.	2.48mg n.s.s.	7/50	6/50			
3663 R f sda eat 52w52 2541m					0	20.0ug	.100mg	.500mg	Mitsumori;jjvs,46,549-557;1984/pers.comm.
liv tum k		no dre	P=1.	- 4.99ug n.s.s.	0/6	0/6	0/6	0/6	
3664 R f sda eat 78w78 2541n					0	20.0ug	.100mg	.500mg	
liv tum k		no dre	P=1.	- 11.2ug n.s.s.	0/6	0/6	0/6	0/6	
3665 R f sda eat 30m30 2541o					0	20.0ug	.100mg	.500mg	
kid ade		15.7mg	* P<.2	- 2.55mg n.s.s.	0/24	0/24	0/24	1/24	
liv tum		no dre	P=1.	- .125mg n.s.s.	0/24	0/24	0/24	0/24	
3666 R m sda eat 52w52 2541m					0	16.0ug	80.0ug	.400mg	
liv tum k		no dre	P=1.	- 3.99ug n.s.s.	0/6	0/6	0/6	0/6	
3667 R m sda eat 78w78 2541n					0	16.0ug	80.0ug	.400mg	
liv tum k		no dre	P=1.	- 8.97ug n.s.s.	0/6	0/6	0/6	0/6	
3668 R m sda eat 30m30 2541o					0	16.0ug	80.0ug	.400mg	
liv tum		no dre	P=1.	- 99.7ug n.s.s.	0/24	0/24	0/24	0/24	
3669 R f wis eat 24m24 2303					0	5.00ug	25.0ug	.125mg	Verschuuren;txcy,6,107-123;1976/1974/pers.comm.
liv tum eg		no dre	P=1.	- 20.1ug n.s.s.	0/25	0/24	0/25	0/25	
3670 R m wis eat 24m24 2303					0	4.00ug	20.0ug	.100mg	
liv tum e		no dre	P=1.	- 15.9ug n.s.s.	0/23	0/25	0/20	0/23	
MESTRANOL 72-33-3									
3671 M f cfl eat 78w78 1453					0	5.00ug	30.0ug	60.0ug	.200mg Barrows;jtxe,3,219-230;1977
liv hct er		6.27mg	* P<.7	- .551mg n.s.s.	1/40	0/40	1/40	1/39	1/39
3672 M m cfl eat 78w78 1453					0	5.00ug	30.0ug	60.0ug	.200mg
liv hct er		1.81mg	* P<.5	- .335mg n.s.s.	2/40	4/40	4/40	0/40	5/40
3673 M f crf eat 24m24 1174					0	.130mg			Rudali;reec,16,425-429;1971
mam tum Lr		no dre	P=1.	60.3ug n.s.s.	145/160	30/34			
3674 M f r3m eat 24m24 1174					0	13.0ug			
mam tum Lr		no dre	P=1.	12.2ug n.s.s.	12/15	26/40			
METEPA 57-39-6									
3675 R m she gav 60w60 179					0	.625mg	2.50mg		Gaines;bwho,34,317-320;1966
--- lyk e		4.46mg	* P<.02	+ 1.35mg n.s.s.	0/20	0/20	3/20		
METHACRYLONITRILE 126-98-7									
3676 M f b6c gav 24m24 TR497 :					0	1.07mg	2.14mg	4.29mg	
TBA MXB		no dre	P=1.	- 5.04mg n.s.s.	34/50	28/50	29/50	21/50	
liv MXB		no dre	P=1.	7.46mg n.s.s.	10/50	11/50	14/50	6/50	liv:hpa,hpb,hpc.
lun MXB		178.mg	* P<.9	12.9mg n.s.s.	6/50	3/50	2/50	5/50	lun:a/a,a/c.
3677 M m b6c gav 24m24 TR497 :					0	1.07mg	2.14mg	4.29mg	
TBA MXB		no dre	P=1.	- 3.55mg n.s.s.	40/50	41/50	39/50	24/50	
liv MXB		no dre	P=1.	4.50mg n.s.s.	24/50	29/50	28/50	15/50	liv:hpa,hpb,hpc.
lun MXB		160.mg	* P<.9	6.93mg n.s.s.	6/50	13/50	9/50	5/50	lun:a/a,a/c.
3678 R f f34 gav 24m24 TR497 :					0	2.14mg	7.14mg	21.4mg	
TBA MXB		323.mg	* P<1.	- 14.1mg n.s.s.	45/50	45/50	42/50	46/50	
liv MXB		no dre	P=1.	285.mg n.s.s.	1/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
3679 R m f34 gav 24m24 TR497 :					0	2.14mg	7.14mg	21.4mg	
sub MXA #		205.mg	* P<.02	- 70.2mg n.s.s.	0/50	0/50	1/50	3/50	sub:fbs,fih,sar. S
TBA MXB		no dre	P=1.	18.9mg n.s.s.	43/50	48/50	42/50	42/50	
liv MXB		no dre	P=1.	174.mg n.s.s.	1/50	2/50	0/50	0/50	liv:hpa,hpb,hpc.
METHAFURYLENE 531-06-6									
3680 R f f34 wat 22m30 1790					0	29.5mg			Lijinsky;zkko,112,57-60;1986
tyf mix e		559.mg	P<.6	- 80.6mg n.s.s.	1/21	2/20			
liv mix e		no dre	P=1.	- 77.7mg n.s.s.	6/21	4/20			
3681 R m f34 wat 22m27 1790					0	23.4mg			
liv mix e		no dre	P=1.	- 88.0mg n.s.s.	4/19	1/20			
METHAPHENILENE 493-78-7									
3682 R f f34 wat 19m30 1790					0	25.7mg			Lijinsky;zkko,112,57-60;1986
tyf mix e		487.mg	P<.6	- 70.3mg n.s.s.	1/21	2/20			
liv mix e		no dre	P=1.	- 83.9mg n.s.s.	6/21	3/20			
3683 R m f34 wat 19m30 1790					0	18.0mg			
liv mix e		no dre	P=1.	- 66.5mg n.s.s.	4/19	2/20			
tyf mix e		no dre	P=1.	- 77.5mg n.s.s.	2/19	1/20			
METHAPYRILENE.HCl (base CAS# is 91-80-5) 135-23-9									
3684 H m syg gav 58w61 1572					0	32.6mg			Lijinsky;jtxe,12,653-657;1983
liv nnd		150.mg	P<.4	24.4mg n.s.s.	0/12	1/20			
tba tum		no dre	P=1.	23.8mg n.s.s.	2/12	2/20			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
3685 R f f34 eat 26m31 1644	0	5.17mg	10.3mg		Lijinsky;fctx,22,27-30;1984
liv mix 7.65mg * P<.0005 + 4.54mg 15.6mg	3/20	12/30	20/20		
liv nnd 11.8mg * P<.0005 6.62mg 35.1mg	3/20	12/30	15/20		
liv hpc 61.6mg / P<.004 + 25.1mg 363.mg	0/20	0/30	6/20		
3686 R m f34 eat 73w73 1618	0	40.0mg			Ohshima;jnci,72,759-768;1984
liv bsa ekr noTD50 P<.009 + n.s.s. 18.7mg	0/5	5/5			
liv esa ekr noTD50 P<.009 + n.s.s. 18.7mg	0/5	5/5			
liv hpc ekr 14.7mg P<.02 + 4.11mg n.s.s.	0/5	3/5			
liv hps ekr 26.4mg P<.08 + 6.29mg n.s.s.	0/5	2/5			
liv thc ekr 26.4mg P<.08 + 6.29mg n.s.s.	0/5	2/5			
3687 R m f34 eat 26m31 1644	0	4.14mg	8.27mg		Lijinsky;fctx,22,27-30;1984
liv mix 7.70mg * P<.0005 + 4.27mg 22.2mg	5/20	13/30	18/20		
liv nnd 11.1mg * P<.003 5.69mg 68.0mg	5/20	12/30	15/20		
liv hpc 77.0mg * P<.04 + 26.6mg n.s.s.	0/20	1/30	3/20		
liv clc 400.mg * P<.3 65.1mg n.s.s.	0/20	0/30	1/20		
METHIDATHION 950-37-8					
3688 M f cd1 eat 23m23 2130	0	.390mg	1.30mg	6.50mg 13.0mg	Quest;rtxp,12,117-126;1990
liv hpc e 184.mg * P<.3 - 45.1mg n.s.s.	2/50	3/50	2/50	2/50 5/50	
liv mix e 16.2gm * P<1. - 48.8mg n.s.s.	5/50	10/50	5/50	2/50 8/50	
liv hpa e no dre P=1. - 97.6mg n.s.s.	3/50	9/50	3/50	1/50 3/50	
3689 M m cd1 eat 23m23 2130	0	.360mg	1.20mg	6.00mg 12.0mg	
liv mix es 6.04mg * P<.0005 + 3.92mg 10.6mg	9/46	15/45	11/47	21/43 38/45	
liv hpa es 17.2mg * P<.0005 + 9.67mg 43.9mg	1/46	9/45	7/47	8/43 21/45	
liv hpc es 21.8mg * P<.0005 + 11.4mg 83.6mg	8/46	6/45	4/47	13/43 17/45	
METHIMAZOLE 60-56-0					
3690 R f hrl eat 24m24 180	0	.250mg	1.50mg	9.00mg	Owen;fctx,11,649-653;1973
thy fca es 1.57mg Z P<.0005 + .834mg 3.46mg	0/50	0/25	14/25	(12/25)	
thy fdc es 9.47mg Z P<.007 + 2.86mg 150.mg	0/50	0/25	3/25	(2/25)	
3691 R m hrl eat 24m24 180	0	.200mg	1.20mg	7.20mg	
thy fca es .900mg Z P<.0005 + .500mg 1.85mg	1/50	1/25	17/25	(5/25)	
thy fdc es 37.6mg * P<.05 + 11.5mg n.s.s.	1/50	0/25	2/25	3/25	
DL-METHIONINE 59-51-8					
3692 M m cen eat 52w52 1992	0	1.80gm			Fullerton;carc,11,1301-1305;1990
liv hpc r 4.47gm P<.1 1.10gm n.s.s.	0/30	2/30			
liv mix r 2.00gm P<.2 625.mg n.s.s.	2/30	6/30			
liv hpa r 4.16gm P<.4 854.mg n.s.s.	2/30	4/30			
lun mix r no dre P=1. 1.86gm n.s.s.	2/30	1/30			
3693 R m f34 eat 17m24 1803	0	419.mg			Shivapurkar;carc,7,547-550;1986
liv nnd e no dre P=1. - 1.15gm n.s.s.	2/28	2/28			
METHOTREXATE 59-05-2					
3694 H f syg eat 23m24 1324	0	.261mg	.523mg	1.05mg	Rustia;txap,26,329-338;1973
liv hpa as 51.1mg * P<.2 - 8.32mg n.s.s.	0/49	0/42	0/42	1/39	
liv mix as 167.mg * P<.8 9.14mg n.s.s.	1/49	0/42	0/42	1/39	
lun tum as no dre P=1. 1.30mg n.s.s.	0/49	0/42	0/42	0/39	
tba mix as no dre P=1. - 6.01mg n.s.s.	7/49	4/42	2/42	3/39	
3695 H m syg eat 25m27 1324	0	.230mg	.460mg	.920mg	
liv tum as no dre P=1. - 1.38mg n.s.s.	0/49	0/42	0/42	0/40	
lun tum as no dre P=1. 1.38mg n.s.s.	0/49	0/42	0/42	0/40	
tba mix as no dre P=1. - 12.8mg n.s.s.	8/49	1/42	0/42	1/40	
3696 M f swi eat 28m28 1324	0	.195mg	.325mg	.520mg .650mg	
liv hpc 65.2mg * P<.4 - 10.6mg n.s.s.	0/70	0/36	0/36	1/42 0/48	
lun mix no dre P=1. - 3.57mg n.s.s.	14/70	8/36	8/36	6/42 8/48	
tba mix 48.0mg * P<1. - 1.35mg n.s.s.	34/70	21/36	13/36	19/42 26/48	
3697 M m swi eat 27m28 1324	0	.180mg	.300mg	.480mg .600mg	
liv hem a no dre P=1. - 3.20mg n.s.s.	6/70	2/36	6/36	1/42 (0/48)	
lun mix a no dre P=1. - 3.45mg n.s.s.	13/70	6/36	3/36	9/42 6/48	
tba mix a no dre P=1. - 1.99mg n.s.s.	29/70	15/36	17/36	18/42 15/48	
3698 R m b46 ivj 12m24 1017	0	71.4ug			Schmahl;arzn,20,1461-1467;1970
tba ben es .409mg P<.1 - .111mg n.s.s.	3/65	4/26			
tba mix es .330mg P<.2 - 90.2ug n.s.s.	7/65	6/26			
tba mal es 2.96mg P<.8 - .181mg n.s.s.	4/65	2/26			
3699 R f sda ipj 24m24 1134	0	89.3ug			Schmahl;zkko,86,77-84;1976
tba mal e no dre P=1. - .406mg n.s.s.	3/33	1/31			
3700 R m sda ipj 24m24 1134	0	89.3ug			
liv hae e no dre P=1. .552mg n.s.s.	1/36	0/30			
tba mal e no dre P=1. - .552mg n.s.s.	1/36	0/30			
2-METHOXY-4-AMINOAZOBENZENE 80830-39-3					
3701 M f b6c eat 56w56 1500	0	117.mg			Watanabe;gann,73,136-140;1982
liv tum r no dre P=1. - 90.9mg n.s.s.	0/13	0/13			
3702 M m b6c eat 56w56 1500	0	108.mg			
liv tum r no dre P=1. - 83.9mg n.s.s.	0/13	0/13			
3-METHOXY-4-AMINOAZOBENZENE 3544-23-8					
3703 M f b6c eat 56w56 1500	0	78.0mg	117.mg		Watanabe;gann,73,136-140;1982
liv hpa r 60.2mg * P<.005 + 25.8mg 388.mg	0/13	1/13	6/13		
3704 M m b6c eat 56w56 1500	0	72.0mg	108.mg		
liv tum r no dre P=1. - 27.7mg n.s.s.	0/13	0/10	0/12		
2-METHOXY-3-AMINODIBENZOFURAN 5834-17-3					
3705 R f fis eat 75w75 183n	0	50.0mg			Radomski;jnci,39,1069-1080;1967
ubl mix e 25.7mg P<.002 + 10.2mg 115.mg	0/12	6/12			
auc sqc e 43.9mg P<.02 + 15.0mg n.s.s.	0/12	4/12			
ubl tcc e 43.9mg P<.02 + 15.0mg n.s.s.	0/12	4/12			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
mgl adc e		205.mg	P<.3	+ 33.3mg n.s.s.	0/12	1/12			
liv tum e		no dre	P=1.	64.3mg n.s.s.	0/12	0/12			
tba mal e		33.1mg	P<.005	12.3mg 265.mg	0/12	5/12			
3706 R m fis eat 75w75 183n					0	40.0mg			
ubl mix e		26.4mg	P<.005	+ 9.84mg 212.mg	0/12	5/12			
auc sqc e		78.2mg	P<.09	+ 19.2mg n.s.s.	0/12	2/12			
ubl tcc e		78.2mg	P<.09	+ 19.2mg n.s.s.	0/12	2/12			
liv tum e		no dre	P=1.	51.4mg n.s.s.	0/12	0/12			
tba mal e		78.2mg	P<.09	19.2mg n.s.s.	0/12	2/12			
3707 R f sda eat 75w75 183m					0	50.0mg			
ubl mix e		43.9mg	P<.02	+ 15.0mg n.s.s.	0/12	4/12			
mgl adc e		61.9mg	P<.04	+ 18.6mg n.s.s.	0/12	3/12			
auc sqc e		61.9mg	P<.04	+ 18.6mg n.s.s.	0/12	3/12			
ubl tcc e		205.mg	P<.3	+ 33.3mg n.s.s.	0/12	1/12			
liv tum e		no dre	P=1.	64.3mg n.s.s.	0/12	0/12			
tba mal e		25.7mg	P<.002	10.2mg 115.mg	0/12	6/12			
3708 R m sda eat 75w75 183m					0	40.0mg			
kid sqc e		164.mg	P<.3	+ 26.6mg n.s.s.	0/12	1/12			
ubl tpp e		164.mg	P<.3	+ 26.6mg n.s.s.	0/12	1/12			
liv tum e		no dre	P=1.	51.4mg n.s.s.	0/12	0/12			
tba mal e		78.2mg	P<.09	19.2mg n.s.s.	0/12	2/12			
3709 R f wis eat 75w75 183n					0	50.0mg			
ubl mix e		43.9mg	P<.02	+ 15.0mg n.s.s.	0/12	4/12			
mgl adc e		97.7mg	P<.09	+ 23.9mg n.s.s.	0/12	2/12			
ubl tcc e		97.7mg	P<.09	+ 23.9mg n.s.s.	0/12	2/12			
liv cye e		205.mg	P<.3	33.3mg n.s.s.	0/12	1/12			
tba mal e		43.9mg	P<.02	15.0mg n.s.s.	0/12	4/12			
3710 R m wis eat 75w75 183n					0	40.0mg			
ubl mix e		35.2mg	P<.02	+ 12.0mg n.s.s.	0/12	4/12			
auc sqc e		78.2mg	P<.09	+ 19.2mg n.s.s.	0/12	2/12			
ubl tcc e		78.2mg	P<.09	+ 19.2mg n.s.s.	0/12	2/12			
kid sqc e		164.mg	P<.3	+ 26.6mg n.s.s.	0/12	1/12			
liv tum e		no dre	P=1.	51.4mg n.s.s.	0/12	0/12			
tba mal e		26.4mg	P<.005	9.84mg 212.mg	0/12	5/12			
3711 R m wis eat 84w84 1420					0	34.3mg			Hackmann;zkko,61,45-54;1956
ubl mix e		noTD50	P<.004	+ n.s.s. 17.9mg	0/7	6/6			
tba mal e		noTD50	P<.004	+ n.s.s. 17.9mg	0/7	6/6			
tba ben e		53.3mg	P<.07	13.0mg n.s.s.	0/9	2/8			
3-METHOXYCATECHOL 934-00-9									
3712 R m f3d eat 51w51 2162 ()					0	800.mg			Kawabe;gann,85,17-25;1994
stg ade Cer		48.7mg	P<.0005	+ 18.9mg 124.mg	0/15	14/15			
for sqp er		425.mg	P<.02	146.mg n.s.s.	0/15	4/15			
stg adc Cer		no dre	P=1.	595.mg n.s.s.	0/15	0/15			
for sqc er		no dre	P=1.	595.mg n.s.s.	0/15	0/15			
METHOXYCHLOR 72-43-5									
3713 M f b6c eat 78w92 TR35 :					0	109.mg	217.mg		
TBA MXB v		no dre	P=1.	- 828.mg n.s.s.	3/20	6/50	3/50		
liv MXB v		no dre	P=1.	1.41gm n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		lun:a/a,a/c.
3714 M m b6c eat 78w91 TR35 :					0	178.mg	352.mg		
TBA MXB v		no dre	P=1.	- 466.mg n.s.s.	3/20	5/50	9/50		
liv MXB v		no dre	P=1.	664.mg n.s.s.	3/20	3/50	6/50		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		lun:a/a,a/c.
3715 R f osm eat 18m26 TR35 :					0	26.4mg	48.2mg		
TBA MXB dv		no dre	P=1.	- 63.8mg n.s.s.	12/20	30/50	30/50		
liv MXB dv		no dre	P=1.	329.mg n.s.s.	1/20	1/50	2/50		liv:hpa,hpc,nnd.
3716 R f osm eat 27m27 21					0	50.0mg			Deichmann;txap,11,88-103;1967
liv tum		no dre	P=1.	391.mg n.s.s.	0/30	0/30			
tba mix		no dre	P=1.	181.mg n.s.s.	13/30	6/30			
3717 R f osm eat 24m24 84a					0	4.00mg			Radomski;txap,7,652-656;1965
liv tum		no dre	P=1.	- 24.7mg n.s.s.	1/30	0/30			
tba ben		no dre	P=1.	- 7.36mg n.s.s.	6/30	6/30			
tba mal		no dre	P=1.	- 8.82mg n.s.s.	6/30	5/30			
3718 R m osm eat 18m26 TR35 :					0	12.6mg	23.8mg		
TBA MXB dv		no dre	P=1.	- 44.6mg n.s.s.	11/20	23/50	21/50		
liv MXB dv		no dre	P=1.	145.mg n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
3719 R m osm eat 27m27 21					0	40.0mg			Deichmann;txap,11,88-103;1967
liv tum		no dre	P=1.	313.mg n.s.s.	0/30	0/30			
tba mix		234.mg	P<.08	76.3mg n.s.s.	1/30	5/30			
3720 R m osm eat 24m24 84a					0	3.20mg			Radomski;txap,7,652-656;1965
liv tum		no dre	P=1.	- 19.8mg n.s.s.	0/30	0/30			
tba ben		31.8mg	P<.1	- 7.81mg n.s.s.	0/30	2/30			
tba mal		no dre	P=1.	- 19.8mg n.s.s.	3/30	0/30			
4-METHOXYPHENOL 150-76-5									
3721 R f f3d eat 24m24 2202					0	1.00gm			Asakawa;ijcn,56,146-152;1994
for sqp e		2.58gm	P<.002	+ 1.11gm 10.3gm	0/30	7/30			
for sqc e		3.07gm	P<.004	+ 1.25gm 17.6gm	0/30	6/30			
liv hnd e		no dre	P=1.	3.73gm n.s.s.	1/30	1/30			
stg tum e		no dre	P=1.	6.18gm n.s.s.	0/30	0/30			
3722 R m f3d eat 51w52 1950					0	588.mg			Hirose;canr,48,5310-5315;1988/pers.comm.
for pam		1.46gm	P<.4	238.mg n.s.s.	0/10	1/15			
stg tum		no dre	P=1.	455.mg n.s.s.	0/10	0/15			
3723 R m f3d eat 51w52 1990					0	98.1mg	196.mg	392.mg	785.mg	Wada;carc,11,1891-1894;1990
for tum er		no dre	P=1.	- 29.6mg n.s.s.	0/10	0/11	0/11	0/11	0/11	
stg tum er		no dre	P=1.	- 29.6mg n.s.s.	0/10	0/11	0/11	0/11	0/11	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3724 R m f3d eat 24m24 2202				0	800.mg			Asakawa;ijcn,56,146-152;1994
for sqc e	377.mg	P<.0005 +	217.mg 707.mg	0/30	23/30			
for sqp e	832.mg	P<.0005 +	437.mg 2.07gm	1/30	15/30			
stg ade e	16.2gm	P<.3	2.63gm n.s.s.	0/30	1/30			
liv hnd e	no dre	P=1.	2.99gm n.s.s.	1/30	1/30			
METHOXYPHENYLACETIC ACID 1701-77-5								
3725 M f b6a orl 76w76 1312				0	78.4mg			Innes;ntis,1968/1969
lun ade evx	236.mg	P<.4 -	51.4mg n.s.s.	1/17	3/18			
liv hpt evx	no dre	P=1. -	155.mg n.s.s.	0/17	0/18			
tba mix evx	227.mg	P<.5 -	45.2mg n.s.s.	2/17	4/18			
3726 M m b6a orl 76w76 1312				0	73.0mg			
lun ade evx	157.mg	P<.3 -	35.9mg n.s.s.	2/18	4/16			
liv hpt evx	3.62gm	P<1. -	n.s.s. n.s.s.	1/18	1/16			
tba mix evx	139.mg	P<.4 -	31.5mg n.s.s.	3/18	5/16			
3727 M f b6c orl 76w76 1312				0	78.4mg			
lun ade evx	244.mg	P<.2 -	59.8mg n.s.s.	0/16	2/18			
liv hpt evx	no dre	P=1. -	155.mg n.s.s.	0/16	0/18			
tba mix evx	157.mg	P<.05 -	47.5mg n.s.s.	0/16	3/18			
3728 M m b6c orl 76w76 1312				0	73.0mg			
--- rts evx	82.1mg	P<.009 -	30.9mg 1.80gm	0/16	5/18			
liv hpt evx	227.mg	P<.2 -	55.7mg n.s.s.	0/16	2/18			
lun mix evx	no dre	P=1. -	145.mg n.s.s.	0/16	0/18			
tba mix evx	54.2mg	P<.002 -	23.1mg 221.mg	0/16	7/18			
8-METHOXYPSORALEN (8-MOP) 298-81-7								
3729 M f hra eat 52w80 2032				0	.836mg	1.95mg	7.43mg	Dunnick;faat,16,92-102;1991/pers.comm.
ski sqc r	48.9mg *	P<.3 -	14.8mg n.s.s.	0/36	0/36	2/36	1/36	
ski mix r	56.8mg *	P<.4 -	10.8mg n.s.s.	1/36	2/36	3/36	3/36	
ski sqp r	151.mg *	P<.7 -	15.4mg n.s.s.	1/36	2/36	1/36	2/36	
3730 M m hra eat 52w80 2032				0	.836mg	1.95mg	7.43mg	
ski sqp r	137.mg *	P<.6 -	15.9mg n.s.s.	0/36	1/36	1/36	1/36	
ski sqc r	no dre	P=1. -	31.2mg n.s.s.	0/36	1/36	0/36	0/36	
ski sqn r	no dre	P=1. -	2.38mg n.s.s.	1/36	0/36	0/36	0/36	
ski mix r	no dre	P=1. -	20.9mg n.s.s.	1/36	2/36	1/36	1/36	
3731 R f f34 gav 24m24 TR359 :				0	26.3mg	52.8mg		
MXA sqp #	333.mg *	P<.02 -	108.mg n.s.s.	0/50	1/50	3/50		pal:sqp; ton:sqp. S
TBA MXB	45.6mg *	P<.09	17.5mg n.s.s.	46/50	43/50	37/50		
liv MXB	5.14gm *	P<.9	240.mg n.s.s.	1/50	0/50	1/50		liv:hpa,hpc,nnd.
3732 R m f34 gav 24m24 TR359 :				0	26.3mg	52.8mg		
tes ict	14.6mg *	P<.0005	8.08mg 43.1mg	38/50	44/50	43/50		S
MXB MXB	27.3mg *	P<.0005	15.5mg 59.4mg	2/50	16/50	14/50		kid:tla,uac; zym:can,sqc. C
kid MXA	32.4mg *	P<.0005 c	17.6mg 73.7mg	1/50	12/50	11/50		kid:tla,uac.
kid tla	43.2mg *	P<.0005 c	22.2mg 120.mg	1/50	11/50	8/50		
lun a/a	57.1mg *	P<.003 e	25.5mg 397.mg	4/50	9/50	9/50		
lun MXA	57.1mg *	P<.003	25.5mg 397.mg	4/50	9/50	9/50		lun:a/a,a/c. S
sub MXA	70.2mg *	P<.0005	32.1mg 265.mg	1/50	5/50	8/50		sub:fib,srn. S
sub fib	72.6mg *	P<.002 e	32.6mg 316.mg	1/50	5/50	7/50		
kid uac	167.mg *	P<.008 c	52.4mg 3.38gm	0/50	1/50	3/50		
zym MXA	101.mg *	P<.02 c	41.2mg n.s.s.	1/50	7/50	4/50		zym:can,sqc.
pan ana	113.mg *	P<.04	39.2mg n.s.s.	2/50	3/50	4/50		S
lun a/c	488.mg *	P<.3	79.4mg n.s.s.	0/50	1/50	0/50		
TBA MXB	16.1mg *	P<.002	8.23mg 76.0mg	44/50	41/50	41/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
Z-METHYL-O,N,N-AZOXYETHANE 57497-34-4								
3733 R m f34 wat 30w95 1723				0	16.2mg	72.6mg		Lijinsky;canr,45,76-79;1985
liv mix	11.5mg \	P<.002 +	5.32mg 46.7mg	2/20	12/20	(10/20)		
liv hpc	18.2mg \	P<.0005 +	8.13mg 57.5mg	0/20	8/20	(6/20)		
kid mix	123.mg *	P<.0005 +	52.9mg 405.mg	0/20	0/20	7/20		
liv hes	302.mg *	P<.3	83.6mg n.s.s.	0/20	2/20	2/20		
liv nnd	664.mg *	P<.8	67.4mg n.s.s.	2/20	6/20	4/20		
METHYL BROMIDE 74-83-9								
3734 M f b6c inh 17m24 TR385 :				0	12.0mg	39.7mg	23.4mg	
TBA MXB as	no dre	P=1. -	65.4mg n.s.s.	27/50	29/50	27/50	27/60	
liv MXB as	no dre	P=1.	149.mg n.s.s.	10/50	11/50	8/50	6/60	liv:hpa,hpc,nnd.
lun MXB as	no dre	P=1.	202.mg n.s.s.	4/50	4/50	1/50	7/60	lun:a/a,a/c.
3735 M m b6c inh 17m24 TR385 :				0	10.0mg	33.1mg	19.5mg	
TBA MXB as	no dre	P=1. -	27.7mg n.s.s.	37/50	41/49	38/50	16/70	
liv MXB as	no dre	P=1.	45.0mg n.s.s.	28/50	31/49	26/50	9/70	liv:hpa,hpc,nnd.
lun MXB as	no dre	P=1.	60.1mg n.s.s.	14/50	14/49	14/50	5/70	lun:a/a,a/c.
3736 M f bdj inh 24m24 2378				0	4.84mg	19.3mg	77.4mg	Nagano;apor,741-746;1998/pers.comm.
lyd mly e	845.mg *	P<.6 -	150.mg n.s.s.	6/50	15/50	9/50	12/49	
lun a/a e	6.42gm *	P<.8 -	433.mg n.s.s.	1/50	0/50	2/50	1/49	
liv hpc e	23.9gm *	P<1. -	589.mg n.s.s.	1/50	1/50	0/50	1/49	
lun a/c e	no dre	P=1. -	577.mg n.s.s.	1/50	4/50	1/50	1/49	
liv hpa e	no dre	P=1. -	374.mg n.s.s.	2/50	10/50	1/50	4/49	
3737 M m bdj inh 24m24 2378				0	4.03mg	16.1mg	64.5mg	
liv hpa e	no dre	P=1. -	156.mg n.s.s.	15/50	16/50	13/50	14/50	
liv hpc e	no dre	P=1. -	230.mg n.s.s.	19/50	15/50	9/50	12/50	
lun a/c e	no dre	P=1. -	253.mg n.s.s.	9/50	8/50	3/50	7/50	
lun a/a e	no dre	P=1. -	436.mg n.s.s.	4/50	4/50	2/50	2/50	
3738 R f f3d inh 24m24 2378				0	1.15mg	5.76mg	28.8mg	
adr phe e	805.mg Z	P<.8 -	77.7mg n.s.s.	0/49	13/49	6/49	7/49	
liv hpa e	no dre	P=1. -	221.mg n.s.s.	3/50	2/50	2/50	1/50	
liv hpc e	no dre	P=1. -	289.mg n.s.s.	1/50	0/50	1/50	0/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3739 R m f3d inh 24m24 2378					0	.806mg	4.03mg	20.2mg	
pit ade e	31.8mg	* P<.01	-	14.1mg 4.58gm	16/50	23/50	19/50	30/50	
per msm e	40.8mg	Z P<.007	-	14.1mg 599.mg	0/50	0/50	4/50	(1/50)	
liv hpc e	no dre	P=1.	-	246.mg n.s.s.	1/50	1/50	0/50	0/50	
liv hpa e	no dre	P=1.	-	229.mg n.s.s.	0/50	3/50	0/50	0/50	
3740 R f wsr inh 30m30 2017					0	.872mg	8.72mg	26.2mg	Reuzel;fctx,29,31-39;1991/pers.comm.
liv nnd e	2.24gm	* P<.2	-	365.mg n.s.s.	0/60	0/60	0/59	1/60	
liv clc e	no dre	P=1.	-	611.mg n.s.s.	0/60	1/60	0/59	0/60	
nof tum e	no dre	P=1.	-	14.2mg n.s.s.	0/58	0/58	0/59	0/59	
nre tum e	no dre	P=1.	-	14.2mg n.s.s.	0/58	0/58	0/59	0/59	
tba mal e	no dre	P=1.	-	141.mg n.s.s.	17/60	11/60	13/60	12/60	
tba tum e	no dre	P=1.	-	56.5mg n.s.s.	52/60	54/60	52/60	46/60	
3741 R m wsr inh 30m30 2017					0	.610mg	6.10mg	18.3mg	
nof tum e	no dre	P=1.	-	8.08mg n.s.s.	0/46	0/48	0/49	0/48	
pit het e	no dre	P=1.	-	19.8mg n.s.s.	10/47	21/50	14/50	(7/44)	
nre fbs e	no dre	P=1.	-	205.mg n.s.s.	0/46	0/48	1/49	0/48	
nre ost e	no dre	P=1.	-	341.mg n.s.s.	0/46	1/48	0/49	0/48	
liv hpc e	no dre	P=1.	-	346.mg n.s.s.	0/48	1/48	0/49	0/49	
liv nnd e	no dre	P=1.	-	346.mg n.s.s.	0/48	1/48	0/49	0/49	
liv clc e	no dre	P=1.	-	346.mg n.s.s.	0/48	1/48	0/49	0/49	
nre sqc e	no dre	P=1.	-	353.mg n.s.s.	1/46	2/48	0/49	0/48	
tba tum e	no dre	P=1.	-	94.8mg n.s.s.	31/48	40/50	30/50	21/49	
tba mal e	no dre	P=1.	-	154.mg n.s.s.	11/48	16/50	14/50	5/49	
METHYL tert-BUTYL ETHER (MTBE) 1634-04-4									
3742 M f cd1 inh 80w80 2243 :					0	453.mg	3.40gm	9.07gm	Bird;japt,17,S45-S55;1997/pers.comm.
liv mix C	6.55gm	* P<.0005	+	3.08gm 21.9gm	2/50	2/50	2/50	13/50	
liv hpa C	8.26gm	* P<.0005	+	3.62gm 36.7gm	2/50	1/50	2/50	10/50	
lun ala	43.6gm	Z P<.2		10.0gm n.s.s.	3/50	0/50	0/50	4/50	
liv hpc C	239.gm	* P<.6		24.9gm n.s.s.	0/50	1/50	0/50	1/50	
3743 M m cd1 inh 79w79 2243 :					0	378.mg	2.83gm	7.56gm	
liv mix Cs	10.6gm	* P<.09		3.73gm n.s.s.	12/50	12/50	12/50	16/50	
liv hpc Cs	15.7gm	* P<.03		6.06gm n.s.s.	2/50	4/50	3/50	8/50	
liv hpa Cs	21.3gm	* P<.4		5.07gm n.s.s.	11/50	11/50	9/50	12/50	
lun a/c s	no dre	P=1.		41.4gm n.s.s.	1/50	0/50	0/50	0/50	
3744 R f f34 inh 24m24 2243 :					0	108.mg	810.mg	2.16gm	
liv hpa	24.2gm	* P<.3		5.81gm n.s.s.	2/50	1/49	0/50	4/50	
kid rua C	60.7gm	* P<.7		9.89gm n.s.s.	0/50	0/49	1/50	0/50	
3745 R m f34 inh 22m24 2243 :					0	75.6mg	567.mg	1.51gm	
tes ica as	30.7mg	Z P<.0005		16.8mg 58.4mg	32/50	35/50	42/51	47/50	
kid mix Cas	297.mg	* P<.0005	+	69.4mg 1.27gm	1/50	0/50	8/51	3/50	
kid rua Cas	433.mg	* P<.0005	+	76.8mg 3.15gm	1/50	0/50	5/51	3/50	
kid ruc Cas	1.29gm	* P<.003	+	344.mg 13.2gm	0/50	0/50	3/51	0/50	
liv mix as	2.48gm	* P<.08		485.mg n.s.s.	0/50	2/50	1/51	1/50	
3746 R f sda gav 24m35 BT958					0	97.7mg	437.mg		Belpoggi;txih,11,119-149;1995/1997
--- lkm e	2.35gm	* P<.002	+	1.17gm 10.8gm	2/58	6/51	12/47		
ute sar	2.69gm	\ P<.3		706.mg n.s.s.	2/60	5/60	(0/60)		
liv hct	no dre	P=1.		2.11gm n.s.s.	0/60	0/60	0/60		
tba ben	no dre	P=1.		1.54gm n.s.s.	49/60	43/60	40/60		
tba mal	no dre	P=1.		3.01gm n.s.s.	22/60	19/60	16/60		
3747 R m sda gav 24m39 BT958					0	124.mg	358.mg		
tes ldc e	2.07gm	* P<.007	+	950.mg 29.3gm	2/26	2/25	11/32		
liv hpc	18.0gm	* P<.5		5.04gm n.s.s.	0/60	2/60	1/60		
--- lkm e	no dre	P=1.		3.91gm n.s.s.	10/59	9/59	7/58		
tba ben	2.31gm	* P<.2		829.mg n.s.s.	26/60	26/60	34/60		
tba mal	no dre	P=1.		2.38gm n.s.s.	25/60	23/60	20/60		
METHYL CARBAMATE 598-55-0									
3748 M f b6c gav 24m24 TR328 :					0	354.mg	707.mg		
TBA MXB	no dre	P=1.	-	700.mg n.s.s.	32/50	28/50	27/50		
liv MXB	4.70gm	* P<.4		1.20gm n.s.s.	4/50	7/50	6/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		2.30gm n.s.s.	7/50	5/50	4/50		lun:a/a,a/c.
3749 M m b6c gav 24m24 TR328 :					0	354.mg	707.mg		
TBA MXB	5.22gm	* P<.8	-	495.mg n.s.s.	27/50	35/50	28/50		
liv MXB	5.08gm	* P<.7		780.mg n.s.s.	14/50	17/50	16/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		1.61gm n.s.s.	11/50	8/50	8/50		lun:a/a,a/c.
3750 R f f34 gav 24m24 TR328 :					0	70.7mg	142.mg		
liv MXA	839.mg	* P<.006	p	342.mg 8.57gm	0/50	0/50	6/50		liv:hpc,nnd.
liv nnd	979.mg	* P<.02		372.mg n.s.s.	0/50	0/50	5/50		S
TBA MXB	no dre	P=1.		146.mg n.s.s.	47/50	43/50	42/50		
liv MXB	839.mg	* P<.006		342.mg 8.57gm	0/50	0/50	6/50		liv:hpa,hpc,nnd.
3751 R f f34 gav 52w52 TR328a					0	286.mg			
liv nnd	21.3mg	P<.0005		7.46mg 66.1mg	0/10	9/10			S
liv hpc	53.4mg	P<.002	c	20.7mg 226.mg	0/10	6/10			
3752 R f f34 gav 78w78 TR328b					0	286.mg			
liv hpc	68.4mg	P<.0005	c	26.9mg 215.mg	0/10	8/10			
liv nnd	159.mg	P<.004		58.4mg 1.11gm	0/10	5/10			S
3753 R m f34 gav 24m24 TR328 :					0	70.7mg	142.mg		
liv MXA	2.03gm	/ P<.6		357.mg n.s.s.	4/50	0/50	7/50		liv:hpc,nnd.
TBA MXB	no dre	P=1.		56.6mg n.s.s.	47/50	45/50	(40/50)		
liv MXB	2.03gm	/ P<.6		357.mg n.s.s.	4/50	0/50	7/50		liv:hpa,hpc,nnd.
3754 R m f34 gav 52w52 TR328a					0	286.mg			
liv hpc	30.4mg	P<.0005	c	11.9mg 95.4mg	0/10	8/10			
liv nnd	40.7mg	P<.0005		16.2mg 139.mg	0/10	7/10			S
3755 R m f34 gav 78w78 TR328b					0	286.mg			
liv hpc	47.8mg	P<.0005	c	16.8mg 149.mg	0/10	9/10			
liv nnd	494.mg	P<.09		121.mg n.s.s.	0/10	2/10			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

METHYL CARBAZATE 6294-89-9

3756 R f wis eat 24m24 1389				0	2.50mg	5.00mg	10.0mg	Truhaut;txcy,22,219-221;1981
tba tum	no dre	P=1.	- 8.26mg n.s.s.	16/24	11/24	15/24	14/24	
3757 R m wis eat 24m24 1389				0	2.50mg	5.00mg	10.0mg	
tba tum	no dre	P=1.	- 17.5mg n.s.s.	7/24	6/24	8/24	5/24	

2-METHYL-4-CHLOROPHENOXYACETIC ACID 94-74-6

3758 M f b6c eat 52w52 2618m				0	2.60mg	13.0mg	65.0mg	Bellet;rtxp,30,223-232;1999/pers.comm.
liv tum ek	no dre	P=1.	- 1.08mg n.s.s.	0/10	0/10	0/10	0/10	
3759 M f b6c eat 24m24 2618n				0	2.60mg	13.0mg	65.0mg	
liv hpc e	1.02gm *	P<.3	- 219.mg n.s.s.	1/50	1/50	3/50	3/50	
lun adc e	2.74gm *	P<.2	- 446.mg n.s.s.	0/50	0/50	0/50	1/50	
lun ade e	34.0gm *	P<1.	- 325.mg n.s.s.	1/50	3/50	2/50	2/50	
liv hpa e	no dre	P=1.	- 381.mg n.s.s.	1/50	5/50	1/50	2/50	
3760 M m b6c eat 52w52 2618m				0	2.40mg	12.0mg	60.0mg	
liv tum ek	no dre	P=1.	- .997mg n.s.s.	0/10	0/10	0/10	0/10	
3761 M m b6c eat 24m24 2618n				0	2.40mg	12.0mg	60.0mg	
liv hpa e	614.mg *	P<.3	- 144.mg n.s.s.	4/50	4/50	6/50	7/50	
lun adc e	1.78gm *	P<.6	259.mg n.s.s.	2/50	2/50	1/50	3/50	
liv hpc e	no dre	P=1.	- 250.mg n.s.s.	11/50	10/50	7/50	7/50	
lun ade e	no dre	P=1.	564.mg n.s.s.	5/50	3/50	5/50	0/50	
3762 R f wis eat 52w52 2618m				0	1.00mg	4.00mg	16.0mg	
liv tum ek	no dre	P=1.	- .393mg n.s.s.	0/10	0/10	0/10	0/10	
3763 R f wis eat 24m24 2618n				0	1.00mg	4.00mg	16.0mg	
liv hpa e	6.30gm *	P<1.	- 59.4mg n.s.s.	5/50	2/50	6/50	4/50	
liv hpc e	no dre	P=1.	- 124.mg n.s.s.	0/50	0/50	1/50	0/50	
3764 R f wis eat 24m24 2618o				0	1.00mg	4.00mg	16.0mg	
liv hpa e	no dre	P=1.	- 2.36mg n.s.s.	1/15	0/15	0/15	0/15	
3765 R m wis eat 52w52 2618m				0	.800mg	3.20mg	12.8mg	
liv tum ek	no dre	P=1.	- .314mg n.s.s.	0/10	0/10	0/10	0/10	
3766 R m wis eat 24m24 2618n				0	.800mg	3.20mg	12.8mg	
liv hpa e	231.mg *	P<.8	- 24.2mg n.s.s.	13/50	15/50	12/50	15/50	
liv hpc e	233.mg *	P<.4	- 50.0mg n.s.s.	3/50	1/50	1/50	4/50	
3767 R m wis eat 24m24 2618o				0	.800mg	3.20mg	12.8mg	
liv mix e	no dre	P=1.	- 38.6mg n.s.s.	1/15	1/15	1/15	0/15	

METHYL CLOFENAPATE 21340-68-1

3768 M f aps eat 26w78 2242m				0	4.33mg			Tucker;cthf,39-53;1995
liv mix r	no dre	P=1.	2.33mg n.s.s.	5/25	2/10			
3769 M f aps eat 52w78 2242n				0	8.67mg			
liv mix r	25.0mg	P<.6	3.36mg n.s.s.	5/25	3/10			
3770 M f aps eat 78w78 2242o				0	1.30mg	6.50mg	13.0mg	
liv hpa r	2.27mg Z	P<.0005 +	1.23mg 5.44mg	5/25	3/25	20/25	(2/25)	
liv hpc r	8.30mg *	P<.0005 +	4.81mg 16.3mg	0/25	1/25	5/25	13/25	
3771 M f aps mix 78w78 2242r				0	1.34mg	15.7mg		
liv hpc	13.4mg *	P<.0005 +	6.50mg 38.4mg	0/25	1/25	9/25		
liv hpa	48.5mg *	P<.2	12.6mg n.s.s.	1/25	2/25	4/25		
lun ade	890.mg *	P<1.	22.9mg n.s.s.	0/25	2/25	1/25		
3772 M m aps eat 26w78 2242m				0	4.00mg			
liv mix r	2.08mg	P<.02 +	.700mg n.s.s.	4/25	6/10			
3773 M m aps eat 52w78 2242n				0	8.00mg			
liv mix r	5.94mg	P<.05 +	1.79mg n.s.s.	4/25	5/10			
3774 M m aps eat 78w78 2242o				0	1.20mg	6.00mg	12.0mg	
liv hpc r	.858mg Z	P<.0005 +	.407mg 3.14mg	1/25	11/25	(9/25	10/25)	
liv hpa r	2.75mg Z	P<.0005 +	1.38mg 11.6mg	3/25	9/25	15/25	(4/25)	
3775 M m aps mix 78w78 2242r				0	1.27mg	14.9mg		
liv hpc	16.8mg *	P<.0005 +	7.55mg 66.9mg	0/25	1/25	7/25		
liv hpa	no dre	P=1.	20.2mg n.s.s.	5/25	2/25	3/25		
lun ade	no dre	P=1.	28.8mg n.s.s.	2/25	1/25	1/25		
3776 R f aap eat 6m24 2242m				0	.125mg	.625mg	3.12mg	
liv tum	no dre	P=1.	.208mg n.s.s.	0/25	0/10	0/10	0/10	
3777 R f aap eat 12m24 2242n				0	.250mg	1.25mg	6.25mg	
liv tum	no dre	P=1.	13.1mg n.s.s.	0/25	1/10	0/10	0/10	
3778 R f aap eat 24m24 2242o				0	.500mg	2.50mg	12.5mg	
liv hpc e	5.88mg *	P<.0005 +	3.50mg 10.7mg	0/24	1/24	4/25	20/24	
liv hpa e	460.mg *	P<.8	29.0mg n.s.s.	0/24	1/24	2/25	1/24	
3779 R m aap eat 6m24 2242m				0	.100mg	.500mg	2.50mg	
liv tum	no dre	P=1.	.166mg n.s.s.	0/25	0/10	0/10	0/10	
3780 R m aap eat 12m24 2242n				0	.200mg	1.00mg	5.00mg	
pae ade	1.44mg Z	P<.007	.493mg 31.2mg	2/25	0/10	5/10	(2/10)	
liv tum	no dre	P=1.	.332mg n.s.s.	0/25	0/10	0/10	0/10	
3781 R m aap eat 24m24 2242o				0	.400mg	2.00mg	10.0mg	
liv hpc e	2.87mg *	P<.0005 +	1.70mg 5.05mg	0/24	0/24	9/25	22/23	
tes lya e	2.93mg Z	P<.002 +	1.41mg 13.4mg	1/24	3/24	10/25	(9/23)	
liv hpa e	17.4mg *	P<.0005	8.44mg 68.7mg	0/24	0/24	4/25	6/23	
pae ade e	18.5mg *	P<.03 +	6.99mg n.s.s.	2/24	5/24	6/25	9/23	
3782 R m f34 eat 75w75 1478				0	40.0mg			Reddy;canr,42,259-266;1982
liv hpc er	noTD50	P<.0005 +	n.s.s. 9.17mg	0/10	14/14			

1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM 29676-95-7

3783 M b icr eat 54w54 211				0	12.5mg			Matsuzaki;gann,66,259-267;1975
lun ade s	8.03mg	P<.0005 +	4.40mg 19.9mg	0/30	15/60			
for sqc s	10.3mg	P<.002 +	5.33mg 34.8mg	0/30	12/60			
lun car s	21.9mg	P<.03 +	8.94mg n.s.s.	0/30	6/60			
thm lyk s	26.5mg	P<.05 +	10.1mg n.s.s.	0/30	5/60			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

3'-METHYL-4-DIMETHYLAMINOAZOBENZENE 55-80-1

3784 P b rhe eat 5y24 2004 : 0 18.5mg Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.

liv hpc jw	67.1mg	P<.06		10.9mg n.s.s.	0/23	1/4		
--- hem jw	49.5mg	P<.3		3.37mg n.s.s.	2/108	1/12		
tba mal Wjw	436.mg	P<.9		12.7mg n.s.s.	6/74	1/8		
tba ben Wjw	no dre	P=1.		6.93mg n.s.s.	12/108	1/12		
tba mix Wjw	no dre	P=1.		6.59mg n.s.s.	17/108	2/12		

3785 R m aap gav 52w52 1710 0 2.50mg Styles;carc,6,21-28;1985

liv hpc bekr	3.64mg	P<.4	+	.590mg n.s.s.	0/5	1/9		

3786 R m f3d eat 24m24 1756 0 .960mg 4.80mg 24.0mg Ogiso;txpy,13,257-265;1985

liv hpc e	3.28mg *	P<.0005	+	2.04mg 5.42mg	0/30	4/27	21/23	26/28
liv thc e	4.94mg *	P<.0005		3.06mg 8.18mg	0/30	3/27	14/23	26/28
liv ghc e	10.1mg Z	P<.0005		4.56mg 32.2mg	0/30	1/27	7/23	(0/28)
liv clc e	46.7mg *	P<.0005		22.6mg 120.mg	0/30	0/27	0/23	10/28

N-METHYL-N,4-DINITROSOANILINE 99-80-9

3787 R m cbr ipj 26w86 1258 0 .429mg Boyland;ejca,4,233-239;1968

pec mix e	1.30mg	P<.2	+	.319mg n.s.s.	0/10	2/14		
liv hpt e	1.50mg	P<.3	-	.244mg n.s.s.	0/7	1/8		

N-METHYL-N-FORMYLHYDRAZINE 758-17-8

3788 H f syg wat 24m24 716 0 10.6mg Toth;zkko,93,109-121;1979

--- mhs e	4.71mg	P<.0005	+	2.73mg 8.73mg	0/13	24/31		
liv mix e	11.3mg	P<.0005	+	6.50mg 21.9mg	0/79	19/41		
liv lcc e	25.1mg	P<.0005		12.2mg 64.5mg	0/79	10/41		
liv hpt e	28.3mg	P<.0005		13.3mg 77.2mg	0/79	9/41		
gal mix e	29.1mg	P<.5	+	8.75mg n.s.s.	0/1	3/14		
lun tum e	no dre	P=1.		92.8mg n.s.s.	0/100	0/44		
tba mix e	6.04mg	P<.0005		3.63mg 11.3mg	13/100	32/44		

3789 H m syg wat 24m24 716 0 9.36mg

liv mix e	7.55mg	P<.0005	+	4.57mg 13.6mg	0/65	24/43		
--- mhs e	12.7mg	P<.002	+	6.13mg 41.1mg	0/16	10/26		
liv hpt e	13.3mg	P<.0005		7.35mg 27.4mg	0/65	16/43		
bil mix e	19.7mg	P<.007	+	8.45mg 218.mg	0/16	7/26		
gal mix e	25.3mg	P<.002	+	11.4mg 89.1mg	0/34	8/37		
liv lcc e	30.0mg	P<.0005		13.5mg 88.4mg	0/65	8/43		
gal ppa e	42.5mg	P<.01		16.1mg 1.95gm	0/34	5/37		
lun tum e	no dre	P=1.		85.4mg n.s.s.	0/88	0/46		
tba mix e	4.89mg	P<.0005		3.04mg 8.58mg	7/88	34/46		

3790 M f swa wat 65w73 1110 0 15.6mg 31.2mg Toth;jnci,60,201-204;1978

lun mix aes	6.44mg \	P<.0005	+	3.77mg 13.3mg	15/100	30/48	(9/37)	
liv mix aes	10.4mg *	P<.0005	+	6.44mg 18.8mg	0/33	22/43	3/11	
liv hpt aes	19.5mg *	P<.0005	+	10.7mg 47.2mg	0/33	12/43	3/11	
liv lcc aes	19.9mg \	P<.0005	+	9.67mg 59.0mg	0/33	10/43	(0/11)	
gal ade aes	31.5mg *	P<.008	+	11.9mg 510.mg	0/29	4/23	1/5	

3791 M f swa wat 23m23 1265 0 2.00mg 4.00mg Toth;nplm,27,25-31;1980

lun mix aes	.921mg *	P<.0005	+	.636mg 1.37mg	15/99	39/49	47/50	
blv mix aes	6.04mg *	P<.0005	+	3.49mg 14.5mg	8/95	10/44	20/48	
gal mix aes	57.9mg *	P<.02		17.5mg n.s.s.	0/82	0/44	3/48	
liv bhp aes	24.7mg *	P<.2		4.02mg n.s.s.	0/32	1/10	0/5	

3792 M f swa wat 23m24 1266 0 .500mg 1.00mg Toth;myco,78,11-16;1982a

lun mix aes	.745mg *	P<.0005	+	.444mg 1.77mg	29/94	31/48	32/48	
lun adc aes	1.12mg *	P<.0005		.665mg 2.72mg	14/94	23/48	22/48	
lun ade aes	1.50mg *	P<.002		.779mg 7.82mg	20/94	23/48	21/48	
liv hpt aes	9.23mg *	P<.2	-	2.27mg n.s.s.	0/50	2/23	0/17	
liv agm aes	23.8mg *	P<.5	-	4.03mg n.s.s.	3/77	1/45	3/38	

3793 M f swa wat 92w92 1314 0 7.80mg Toth;myco,68,121-128;1979

lun mix es	2.16mg	P<.0005	+	1.32mg 3.73mg	15/99	43/49		
liv mix es	8.66mg	P<.0005	+	4.95mg 17.1mg	0/68	18/47		
blv mix es	12.2mg	P<.0005	+	6.17mg 39.7mg	8/99	17/49		
liv bhp es	17.5mg	P<.0005		8.50mg 45.0mg	0/68	10/47		
liv lcc es	22.4mg	P<.0005		10.1mg 66.6mg	0/68	8/47		
gal mix es	31.3mg	P<.003	+	11.9mg 164.mg	0/63	5/40		
gal ade es	39.7mg	P<.006		13.7mg 449.mg	0/63	4/40		

3794 M m swa wat 65w72 1110 0 13.0mg 26.0mg Toth;jnci,60,201-204;1978

liv mix aes	16.8mg \	P<.0005	+	8.19mg 48.2mg	1/81	11/47	(3/26)	
bil mix aes	36.2mg *	P<.003	+	13.8mg 203.mg	0/75	5/29	0/8	
gal ade aes	38.0mg \	P<.002	+	14.4mg 186.mg	0/81	5/47	(0/26)	
lun mix aes	14.2mg \	P<.02	+	6.00mg n.s.s.	22/98	20/47	(4/26)	

3795 M m swa wat 22m23 1265 0 1.67mg 3.33mg Toth;nplm,27,25-31;1980

lun mix ae	1.72mg *	P<.0005	+	1.12mg 3.09mg	22/98	36/49	31/46	
blv mix ae	3.47mg \	P<.0005	+	1.64mg 14.5mg	5/78	13/42	(7/36)	
liv mix ae	5.47mg *	P<.0005	+	3.10mg 12.2mg	2/78	6/42	14/36	
gal mix ae	9.10mg *	P<.0005	+	4.90mg 20.0mg	0/90	6/46	8/43	
gal ade ae	9.88mg *	P<.0005		5.21mg 22.8mg	0/90	6/46	7/43	

3796 M m swa wat 23m24 1266 0 .417mg .833mg Toth;myco,78,11-16;1982a

lun mix aes	.865mg *	P<.0005	+	.488mg 2.69mg	19/83	27/45	24/47	
lun ade aes	1.30mg *	P<.002		.686mg 5.95mg	13/83	20/45	18/47	
stg pla aes	3.43mg \	P<.01	-	1.04mg 215.mg	0/80	3/39	(0/43)	
lun adc aes	2.48mg *	P<.03		1.08mg n.s.s.	9/83	14/45	11/47	
sub fbs aes	2.60mg \	P<.02	-	.916mg n.s.s.	1/83	5/45	(0/47)	
for sqp aes	11.2mg *	P<.02	-	3.38mg n.s.s.	0/80	0/39	3/43	
liv mix aes	no dre	P=1.		3.97mg n.s.s.	5/80	3/39	2/43	

3797 M m swa wat 82w82 1314 0 6.50mg Toth;myco,68,121-128;1979

liv mix es	1.03mg	P<.0005	+	.527mg 1.99mg	1/69	28/30		
lun mix es	1.87mg	P<.0005	+	1.07mg 3.78mg	22/88	34/41		
bil cho es	12.4mg	P<.0005	+	5.05mg 44.5mg	0/69	6/30		

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
gal ade es		15.2mg	P<.0005 +	5.75mg 64.6mg	0/69	5/30			
sev ade es		20.7mg	P<.009 -	6.27mg 618.mg	0/51	3/24			
METHYL HESPERIDIN 11013-97-1									
3798 M f b6c eat 22m24 1987					0	1.50gm	6.00gm		Kurata;fctx,28,613-618;1990
liv hpc e		194.gm *	P<.6 -	29.5gm n.s.s.	1/50	1/50	2/50		
liv hnd e		379.gm *	P<.8 -	28.8gm n.s.s.	3/50	1/50	3/50		
liv hes e		887.gm *	P<.9 -	45.7gm n.s.s.	1/50	0/50	1/50		
liv hem e		no dre	P=1. -	65.1gm n.s.s.	2/50	1/50	0/50		
lun ade e		no dre	P=1. -	45.5gm n.s.s.	3/50	2/50	1/50		
3799 M m b6c eat 22m24 1987					0	1.38gm	5.54gm		
liv hpc e		146.gm *	P<.9 -	10.8gm n.s.s.	10/50	14/50	12/50		
liv hnd e		416.gm *	P<1. -	9.74gm n.s.s.	17/50	16/50	17/50		
liv hem e		no dre	P=1. -	32.1gm n.s.s.	3/50	2/50	2/50		
lun adc e		no dre	P=1. -	45.2gm n.s.s.	5/50	3/50	1/50		
lun ade e		no dre	P=1. -	32.6gm n.s.s.	6/50	2/50	3/50		
METHYL LINOLEATE HYDROPEROXIDE 27323-65-5									
3800 R m wis gav 30w87 1475					0	9.61mg			Arffmann;jnci,67,1071-1075;1981
git mix e		no dre	P=1. -	41.6mg n.s.s.	0/30	0/30			
liv tum e		no dre	P=1. -	41.6mg n.s.s.	0/30	0/30			
METHYL LINOLEATE, NATIVE 112-63-0									
3801 R m wis gav 30w87 1475					0	9.71mg			Arffmann;jnci,67,1071-1075;1981
git mix e		no dre	P=1. -	42.0mg n.s.s.	0/30	0/30			
liv tum e		no dre	P=1. -	42.0mg n.s.s.	0/30	0/30			
METHYL METHACRYLATE 80-62-6									
3802 H f syg inh 73w73 2544					0	234.mg			Lomax;fctx,35,393-407;1997
liv tum e		no dre	P=1. -	1.24gm n.s.s.	0/46	0/52			
lun tum e		no dre	P=1. -	1.24gm n.s.s.	0/46	0/52			
3803 H m syg inh 78w78 2544					0	206.mg			
lun pcy e		3.29gm	P<.3 -	536.mg n.s.s.	0/48	1/42			
liv tum e		no dre	P=1. -	1.00gm n.s.s.	0/48	0/42			
3804 M f b6c inh 24m24 TR314 :					0	631.mg	1.26gm		
TBA MXB		no dre	P=1. -	1.08gm n.s.s.	34/50	19/50	(19/50)		
liv MXB		no dre	P=1.	1.82gm n.s.s.	7/50	4/50	(2/50)		liv:hpa,hpc,nnd.
lun MXB		4.01gm \	P<.3	1.04gm n.s.s.	2/50	5/50	(0/50)		lun:a/a,a/c.
3805 M m b6c inh 24m24 TR314 :					0	526.mg	1.05gm		
TBA MXB		no dre	P=1. -	1.32gm n.s.s.	30/50	17/50	(17/50)		
liv MXB		no dre	P=1.	2.07gm n.s.s.	16/50	7/50	(7/50)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	7.86gm n.s.s.	11/50	1/50	4/50		lun:a/a,a/c.
3806 R f f34 inh 24m24 TR314 :					0	75.1mg	150.mg		
TBA MXB		500.mg *	P<.7 -	78.2mg n.s.s.	40/50	46/50	44/50		
liv MXB		2.14gm *	P<.1	526.mg n.s.s.	0/50	0/50	2/50		liv:hpa,hpc,nnd.
3807 R f f34 inh 24m24 2544					0	123.mg			Lomax;fctx,35,393-407;1997
liv mix e		4.15gm	P<.3 -	676.mg n.s.s.	0/44	1/49			
nre tum e		no dre	P=1. -	54.0mg n.s.s.	0/45	0/45	0/41	0/42	
3808 R m f34 inh 24m24 TR314 :					0	105.mg	210.mg		
TBA MXB		no dre	P=1. -	139.mg n.s.s.	44/50	46/50	45/50		
liv MXB		1.27gm *	P<.2	477.mg n.s.s.	0/50	3/50	2/50		liv:hpa,hpc,nnd.
3809 R m f34 inh 24m24 2544					0	5.36mg	21.5mg	85.8mg	Lomax;fctx,35,393-407;1997
nre ade e		1.69gm *	P<.2 -	415.mg n.s.s.	0/44	0/47	1/48	1/42	
liv mix e		no dre	P=1. -	528.mg n.s.s.	4/49			2/50	
METHYL METHANESULFONATE (MMS) 66-27-3									
3810 M m rfm wat 24m24 195					0	33.3mg			Clapp;scie,161,913-914;1968
lun ade e		31.8mg	P<.0005 +	16.0mg 113.mg	63/162	33/47			
thm lym e		185.mg	P<.02 +	67.5mg n.s.s.	6/162	7/47			
liv tum e		3.98gm	P<.9 -	160.mg n.s.s.	6/162	2/47			
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE (MNNG) 70-25-7									
3811 M f cb6 wat 27w52 2226m					0	10.4mg			Ho;clet,91,177-183;1995/pers.comm.
smi adc e		2.03mg	P<.004 +	.841mg 12.1mg	0/7	7/12			
3812 M f cb6 wat 52w52 2226n					0	10.0mg			
smi adc e		no dre	P=1.	6.70mg n.s.s.	0/7	0/13			
3813 P b rhe eat 23y23 2004 :					0	.964mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
liv hpa jw		3.03mg	P<.06	.493mg n.s.s.	0/23	1/4			
tba ben Wjw		no dre	P=1.	1.07mg n.s.s.	8/108	1/18			
3814 R b alb wat 78w78 1571					0	13.2mg			Tsung-Hsien;jnci,70,1067-1069;1983
for pam r		22.9mg	P<.02	7.87mg n.s.s.	0/23	4/20			
stg adc r		22.9mg	P<.02	7.87mg n.s.s.	0/23	4/20			
3815 R m alb wat 34w52 1778					0	2.83mg			Gurkalo;bexb,101,833-837;1986
gam adc er		.403mg	P<.003 +	.160mg 1.90mg	0/6	7/10			
3816 R m bfm wat 52w52 196					0	4.15mg			Bralow;onco,27,168-180;1973
stg ivc er		no dre	P=1. -	10.7mg n.s.s.	0/20	0/50			
stg pvc er		no dre	P=1. -	10.7mg n.s.s.	0/20	0/50			
3817 R f f34 eat 24m24 1954					0	1.00mg	2.00mg	4.00mg	Fears;txih,4,221-255;1988
sto car es		1.44mg *	P<.0005 +	.961mg 2.25mg	1/119	8/24	16/24	20/24	
liv hpc es		17.8mg *	P<.0005	7.25mg 64.3mg	0/120	0/24	3/24	3/24	
3818 R m f34 wat 12m29 1611m					0	.857mg			Lijinsky;canr,44,447-449;1984
stg mix		1.42mg	P<.0005 +	.658mg 4.00mg	0/20	9/20			
stg ade		2.38mg	P<.003 +	.963mg 12.4mg	0/20	6/20			
stg adc		5.22mg	P<.04 +	1.58mg n.s.s.	0/20	3/20			
stg sar		16.5mg	P<.3 +	2.69mg n.s.s.	0/20	1/20			
liv nnd		no dre	P=1.	3.94mg n.s.s.	5/20	1/20			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD50 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
3819 R m f34 wat 12m24 1611n	0	1.02mg			
stg mix .592mg P<.0005 + .302mg 1.33mg	0/20	14/20			
stg ade 1.65mg P<.002 + .708mg 6.27mg	0/20	7/20			
stg sar 2.48mg P<.007 + .936mg 28.6mg	0/20	5/20			
stg adc 3.19mg P<.02 + 1.10mg n.s.s.	0/20	4/20			
liv nnd no dre P=1. 3.31mg n.s.s.	5/20	1/20			
3820 R m f34 eat 24m24 1954	0	.800mg	1.60mg	3.20mg	Fears;txih,4,221-255;1988
sto car es .724mg * P<.0005 + .486mg 1.11mg	0/119	14/24	18/23	22/24	
liv hpc es no dre P=1. 2.19mg n.s.s.	1/120	0/24	0/23	0/24	
3821 R m f3d wat 30w70 2278	0	2.14mg			Tatematsu;jnci,78,771-777;1987/pers.comm.
sto ade er 1.37mg P<.02 + .661mg n.s.s.	0/8	10/26			
sto adc er 1.81mg P<.03 + .814mg n.s.s.	0/8	8/26			
3822 R m sda wat 30w52 2141m	0	3.46mg			Basso;zkko,118,441-446;1992
stg adc er 1.61mg P<.03 + .551mg n.s.s.	0/10	4/13			
3823 R m sda wat 52w52 2141n	0	6.00mg			
stg adc er 1.12mg P<.0005 + .508mg 3.53mg	0/10	9/15			
3824 R f wis wat 35w60 1105	0	2.33mg			Tahara;zkko,100,1-12;1981
bil cye er .178mg P<.0005 73.1ug .411mg	0/5	19/20			
stg cnd er 2.38mg P<.2 + .821mg n.s.s.	0/5	4/20			
3825 R f wis wat 32w57 1726	0	1.59mg			Yasui;canr,45,4763-4767;1985
duo adc r 6.38mg P<.5 + 1.04mg n.s.s.	0/5	1/20			
stg adc r 6.38mg P<.5 + 1.04mg n.s.s.	0/5	1/20			
3826 R m wis wat 77w77 199	0	3.30mg			Sugimura;canr,30,455-465;1970
stg mix e .693mg P<.0005 + .289mg 2.05mg	0/6	10/12			
stg ade e 1.13mg P<.003 + .480mg 5.31mg	0/6	8/12			
stg adc e 3.06mg P<.06 + 1.04mg n.s.s.	0/6	4/12			
liv hpa e 14.3mg P<.4 2.32mg n.s.s.	0/6	1/12			
3827 R m wis wat 30w65 435	0	1.92mg			Matsukura;jnci,61,141-143;1978
stg adc er .523mg P<.002 + .186mg 2.54mg	0/10	5/8			
3828 R m wis wat 35w60 1105	0	2.04mg			Tahara;zkko,100,1-12;1981
stg cnd er 2.09mg P<.2 + .510mg n.s.s.	0/5	2/10			
bil cye er no dre P=1. 1.40mg n.s.s.	0/5	0/10			
3829 R m wis wat 32w87 1475	0	.366mg	1.52mg		Arffmann;jnci,67,1071-1075;1981
git mix e .581mg * P<.0005 + .366mg 1.00mg	0/30	10/30	20/30		
liv tum e no dre P=1. 1.28mg n.s.s.	0/30	0/30	0/30		
3830 R m wis wat 28w58 1678	0	2.90mg			Domellof;ajsu,142,551-554;1981
git adc r .810mg P<.0005 + .444mg 1.92mg	0/12	16/30			
smi adc r 1.21mg P<.003 .617mg 4.60mg	0/12	12/30			
stg adc r 4.31mg P<.1 1.49mg n.s.s.	0/12	4/30			
3831 R m wis wat 30w54 1724m	0	4.68mg			Morishita;clet,17,347-352;1983/pers.comm.
duo tum er 3.44mg P<.1 + .839mg n.s.s.	0/8	2/9			
3832 R m wis wat 26w52 1724n	0	2.50mg			
git mix er 1.60mg P<.04 + .549mg n.s.s.	0/12	4/17			
duo tum er 2.21mg P<.07 .665mg n.s.s.	0/12	3/17			
stg tum er 7.06mg P<.3 + 1.15mg n.s.s.	0/12	1/17			
3833 R m wis wat 26w52 1724o	0	2.50mg			
git mix er 1.92mg P<.04 + .827mg n.s.s.	0/12	7/35			
stg mix er 2.28mg P<.06 + .927mg n.s.s.	0/12	6/35			
duo tum er 7.28mg P<.3 1.79mg n.s.s.	0/12	2/35			
3834 R m wis wat 32w57 1726	0	1.39mg			Yasui;canr,45,4763-4767;1985
duo adc r 2.72mg P<.4 + .668mg n.s.s.	0/5	2/20			
3835 R m wis wat 75w75 1822	0	2.13mg			Fujii;nutc,9,185-193;1987
duo adc e .910mg P<.0005 + .505mg 1.85mg	0/30	17/30			
gam adc e 5.31mg P<.02 + 1.83mg n.s.s.	0/30	4/30			
eso sqc e 11.0mg P<.1 + 2.71mg n.s.s.	0/30	2/30			
liv tum e no dre P=1. 6.86mg n.s.s.	0/30	0/30			
tba mix e no dre P=1. .764mg n.s.s.	20/30	20/30			
3836 R m wis wat 28w52 2124	0	1.08mg	2.15mg	2.77mg	Zaidi;carc,14,1561-1567;1993
pyl mix sv .284mg * P<.0005 + .195mg .709mg	0/10	16/25	20/24	13/22	
pyl mal sv .410mg * P<.0005 + .274mg .955mg	0/10	10/25	18/24	11/22	
pyl adc sv .428mg * P<.0005 + .285mg 1.06mg	0/10	10/25	17/24	11/22	
duo mal sv .516mg * P<.01 + .339mg 33.9mg	0/10	11/25	15/24	8/22	
duo adc sv .584mg * P<.007 + .376mg 8.58mg	0/10	9/25	15/24	7/22	
liv ccy sv 4.58mg * P<.2 1.74mg n.s.s.	0/10	1/25	1/24	3/22	
for mix sv 5.79mg * P<.3 2.00mg n.s.s.	0/10	1/25	1/24	2/22	
duo lei sv 22.8mg * P<.8 2.92mg n.s.s.	0/10	1/25	0/24	1/22	
duo ade sv 23.7mg * P<.4 3.85mg n.s.s.	0/10	0/25	0/24	1/22	
duo cas sv no dre P=1. 4.27mg n.s.s.	0/10	1/25	0/24	0/22	
pyl ade sv no dre P=1. 1.29mg n.s.s.	0/10	6/25	2/24	2/22	
3837 R m wky wat 30w60 2122	0	1.25mg			Tatematsu;carc,14,1415-1419;1993
gam adc er .895mg P<.04 + .268mg n.s.s.	0/10	3/11			
3838 R m wmf wat 52w52 196	0	4.15mg			Bralow;onco,27,168-180;1973
stg ivc er 6.75mg P<.2 1.66mg n.s.s.	0/16	2/20			
3839 R m wsr wat 52w52 196	0	4.15mg			
stg ivc er 1.03mg P<.0005 + .684mg 1.63mg	0/40	37/74			
stg pvc er 2.72mg P<.0005 + 1.54mg 5.91mg	0/40	17/74			
2-METHYL-1-NITROANTHRAQUINONE 129-15-7					
3840 M f b6c eat 49w49 TR29 : ()	0	32.0mg	64.0mg		
sub hes 1.88mg * P<.0005 c 1.12mg 3.17mg	0/50	29/50	38/50		
TBA MXB 1.76mg * P<.0005 1.07mg 2.85mg	10/50	34/50	44/50		
liv MXB no dre P=1. n.s.s. n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB 97.3mg * P<.06 15.9mg n.s.s.	3/50	0/50	1/50		lun:a/a,a/c.
3841 M m b6c eat 46w46 TR29 : ()	0	29.5mg	59.0mg		
sub hes 1.34mg / P<.0005 c .780mg 2.31mg	0/50	25/50	36/50		
TBA MXB 1.02mg / P<.0005 .621mg 1.65mg	22/50	42/50	46/50		
liv MXB no dre P=1. n.s.s. n.s.s.	8/50	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB 45.5mg * P<.08 7.41mg n.s.s.	10/50	1/50	0/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
3842 R f f34 eat 18m25 TR29 :					0	21.0mg	43.0mg		
sub fib s		131.mg /	P<.0005 a	66.1mg 403.mg	1/50	0/50	13/50		
ubl MXA s		224.mg *	P<.01 a	96.4mg 28.3gm	0/50	3/50	4/50		ubl:ppn,srn,tpp.
pit ade s		63.4mg *	P<.04	27.4mg n.s.s.	17/50	26/50	25/50		s
liv MXA s		324.mg *	P<.02 c	123.mg n.s.s.	0/50	1/50	4/50		liv:hpc,nnd.
sto sqc s		507.mg *	P<.03 a	154.mg n.s.s.	0/50	0/50	3/50		
liv hpc s		547.mg *	P<.04 c	165.mg n.s.s.	0/50	0/50	3/50		
TBA MXB s		47.1mg *	P<.08	18.6mg n.s.s.	38/50	43/50	44/50		
liv MXB s		324.mg *	P<.02	123.mg n.s.s.	0/50	1/50	4/50		liv:hpa,hpc,nnd.
3843 R m f34 eat 18m25 TR29 :					0	16.8mg	34.4mg		
sub fib		25.8mg /	P<.0005 a	16.8mg 47.4mg	3/49	10/50	34/50		
liv MXA		48.8mg *	P<.0005 c	28.0mg 130.mg	1/49	7/50	15/50		liv:hpc,nnd.
liv hpc		89.2mg *	P<.005 c	43.8mg 879.mg	1/49	5/50	9/50		
liv nnd		133.mg *	P<.004	60.2mg 779.mg	0/49	2/50	6/50		s
TBA MXB		31.9mg *	P<.05	13.6mg n.s.s.	32/49	41/50	47/50		
liv MXB		48.8mg *	P<.0005	28.0mg 130.mg	1/49	7/50	15/50		liv:hpa,hpc,nnd.
4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE 21638-36-8									
3844 R f sda eat 46w66 200a					0	17.4mg			Cohen;jnci,51,403-417;1973
mgl adc e		5.34mg	P<.0005 +	3.04mg 10.5mg	0/25	19/32			
liv tum e		no dre	P=1.	46.3mg n.s.s.	0/25	0/32			
tba mix e		5.59mg	P<.0005	3.11mg 12.4mg	1/25	19/32			
4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE 16699-10-8									
3845 R f fis eat 34w52 1162					0	1.63mg			Yamamoto;jnci,51,1313-1315;1973
liv hnd		.468mg	P<.0005 +	.217mg 1.32mg	0/20	9/20			
3846 R m fis eat 34w52 1162					0	1.31mg			
liv hnd		1.38mg	P<.04 +	.416mg n.s.s.	0/20	3/20			
liv car		4.37mg	P<.3 +	.711mg n.s.s.	0/20	1/20			
N-METHYL-N-NITROSOBENZAMIDE 63412-06-6									
3847 R f mrw wat 12m30 1246					0	3.59mg			Bulay;jnci,62,1523-1528;1979
liv tum		no dre	P=1. -	22.0mg n.s.s.	0/25	0/19			
tba mix		11.2mg	P<.4 +	2.67mg n.s.s.	12/25	12/19			
3848 R m mrw wat 12m30 1246					0	3.14mg			
for mix		3.23mg	P<.0005 +	1.55mg 8.10mg	0/22	11/17			
for sqp		7.73mg	P<.002	3.12mg 31.1mg	0/22	6/17			
for sqc		9.66mg	P<.003	3.64mg 56.4mg	0/22	5/17			
liv tum		no dre	P=1. -	17.2mg n.s.s.	0/22	0/17			
tba mix		2.49mg	P<.02	.856mg n.s.s.	12/22	15/17			
N-(N-METHYL-N-NITROSOCARBAMOYL)-L-ORNITHINE (nitrosourea amino acid) 63642-17-1									
3849 R f wal ipj 26w52 1317					0	5.12mg			Longnecker;jept,4,117-129;1980
kid epn es		.633mg	P<.0005 +	.271mg 1.81mg	0/14	9/12			
kid mnp es		.633mg	P<.0005 +	.271mg 1.81mg	0/14	9/12			
ski neo es		1.42mg	P<.002 +	.565mg 6.13mg	0/14	6/13			
pan aca es		11.0mg	P<.3 +	1.78mg n.s.s.	0/14	1/13			
mam mix es		no dre	P=1. +	1.88mg n.s.s.	5/14	3/15			
3850 R m wal ipj 26w52 1317					0	5.12mg			
kid epn es		1.04mg	P<.02 +	.452mg n.s.s.	0/4	8/14			
ski neo es		1.04mg	P<.02 +	.452mg n.s.s.	0/4	8/14			
kid mnp es		1.57mg	P<.06 +	.628mg n.s.s.	0/4	6/14			
pan mix es		5.25mg	P<.3 +	1.29mg n.s.s.	0/4	2/13			
pan adc es		11.0mg	P<.5 +	1.78mg n.s.s.	0/4	1/13			
zym car es		11.8mg	P<.5 +	1.93mg n.s.s.	0/4	1/14			
R(-)-2-METHYL-N-NITROSOPIPERIDINE 14026-03-0									
3851 R b sda wat 24m24 1418					0	25.7mg			Wiessler;zkko,79,118-122;1973
nol epd		22.1mg	P<.0005 +	10.8mg 54.7mg	0/20	11/20			
liv hpa		108.mg	P<.04	32.7mg n.s.s.	0/20	3/20			
tba mal		20.4mg	P<.0005 +	9.83mg 61.1mg	1/20	12/20			
S(+)-2-METHYL-N-NITROSOPIPERIDINE 36702-44-0									
3852 R b sda wat 24m24 1418					0	25.7mg			Wiessler;zkko,79,118-122;1973
mix epd		34.5mg	P<.0005 +	15.4mg 109.mg	0/20	8/20			
liv mix		49.4mg	P<.003	20.0mg 258.mg	0/20	6/20			
liv lcc		61.2mg	P<.007	23.1mg 706.mg	0/20	5/20			
tba mal		13.2mg	P<.0005 +	6.62mg 31.9mg	1/20	15/20			
METHYL 12-OXO-trans-10-OCTADECENOATE 21308-79-2									
3853 M b stm eat 42w84 1627					0	239.mg			Kiaer;apms,83,550-558;1975
--- mly e		2.94gm	P<.7 -	361.mg n.s.s.	2/30	3/30			
METHYL PARATHION 298-00-0									
3854 M f b6c eat 24m24 TR157 :					0	8.10mg	16.2mg		
TBA MXB		no dre	P=1. -	7.79mg n.s.s.	14/20	30/50	(20/50)		
liv MXB		no dre	P=1.	58.5mg n.s.s.	1/20	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB		125.mg *	P<.5	47.3mg n.s.s.	0/20	3/50	2/50		lun:a/a,a/c.
3855 M m b6c eat 24m24 TR157 :					0	4.20mg	9.20mg		
TBA MXB v		no dre	P=1. -	10.0mg n.s.s.	13/20	31/50	28/50		
liv MXB v		no dre	P=1.	8.86mg n.s.s.	10/20	14/50	(12/50)		liv:hpa,hpc,nnd.
lun MXB v		58.1mg *	P<.5	13.9mg n.s.s.	1/20	10/50	8/50		lun:a/a,a/c.
3856 R f f34 eat 24m24 TR157 :					0	1.00mg	2.00mg		
TBA MXB s		no dre	P=1. -	1.49mg n.s.s.	18/20	33/50	20/50		
liv MXB s		no dre	P=1.	7.80mg n.s.s.	2/20	5/50	0/50		liv:hpa,hpc,nnd.
3857 R m f34 eat 24m24 TR157 :					0	.800mg	1.60mg		
TBA MXB		no dre	P=1. -	1.52mg n.s.s.	16/20	37/50	32/50		
liv MXB		no dre	P=1.	19.7mg n.s.s.	2/20	0/50	0/50		liv:hpa,hpc,nnd.

Chemical / Synonym / CAS number / Spe Strain Xpo+Xpt / Sex Route Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
N-METHYL-2-PYRROLIDONE* 872-50-4**					
3858 M f b6c eat 78w78 2653	0	78.0mg	156.mg	936.mg	Malley;dact,24,315-338;2001
liv hpc e 7.33gm * P<.009 2.22gm 231.gm	0/50	0/50	0/50	3/50	
liv hpa e 3.32gm * P<.02 + 1.24gm n.s.s.	2/50	2/50	1/50	7/50	
tba ben e 3.44gm * P<.2 994.mg n.s.s.	10/50	6/50	5/50	12/50	
tba mal e 14.9gm * P<.8 1.30gm n.s.s.	12/50	5/50	9/50	10/50	
3859 M m b6c eat 78w78 2653	0	72.0mg	144.mg	864.mg	
liv hpc e 1.48gm * P<.0005 + 714.mg 5.92gm	4/50	1/50	3/50	13/50	
liv hpa e 1.76gm * P<.005 + 767.mg 21.2gm	5/50	2/50	4/50	12/50	
lun ade e 4.08gm * P<.1 1.23gm n.s.s.	1/50	2/50	3/50	5/50	
lun adc e no dre P=1. 2.30gm n.s.s.	1/50	4/50	6/50	2/50	
tba ben e 1.63gm Z P<.04 633.mg n.s.s.	15/50	5/50	8/50	18/50	
tba mal e 2.27gm * P<.2 725.mg n.s.s.	9/50	7/50	11/50	14/50	
3860 R f cdr inh 24m24 1818	0	30.4mg			Lee;faat,9,222-235;1987/pers.comm.
liv tum e no dre P=1. - 513.mg n.s.s.	0/83	0/82			
3861 R f cdr eat 24m24 2653	0	80.0mg	250.mg	750.mg	Malley;dact,24,315-338;2001
liv mix e no dre P=1. - 7.57gm n.s.s.	0/62	0/62	1/62	0/62	
tba mix e no dre P=1. - 313.mg n.s.s.	62/62	60/62	61/62	59/62	
3862 R m cdr inh 24m24 1818	0	21.2mg			Lee;faat,9,222-235;1987/pers.comm.
liv tum e no dre P=1. - 372.mg n.s.s.	0/82	0/85			
3863 R m cdr eat 24m24 2653	0	64.0mg	200.mg	600.mg	Malley;dact,24,315-338;2001
liv mix e 58.5gm * P<.9 - 2.81gm n.s.s.	2/62	6/62	3/62	4/62	
tba mix e 6.06gm * P<.9 - 276.mg n.s.s.	56/62	55/62	56/62	56/62	
(N-6)-METHYLADENINE 443-72-1					
3864 M f scd wat 6m24 1255	0	4.33mg			Anderson;ijcn,24,319-322;1979
lun tum s no dre P=1. - 6.08mg n.s.s.	3/16	3/17			
liv hct s no dre P=1. - 15.2mg n.s.s.	1/16	0/17			
3865 M m scd wat 6m25 1255	0	3.52mg			
liv hct s no dre P=1. - 5.70mg n.s.s.	5/21	3/17			
lun tum s no dre P=1. - 6.92mg n.s.s.	4/21	2/17			
(N-6)-METHYLADENOSINE 1867-73-8					
3866 M f scd wat 8m27 1255	0	9.76mg			Anderson;ijcn,24,319-322;1979
liv mix s 364.mg P<.9 - 16.9mg n.s.s.	1/16	1/12			
lun tum s no dre P=1. - 14.1mg n.s.s.	3/16	2/12			
3867 M m scd wat 8m27 1255	0	7.89mg			
lun tum s 55.6mg P<.6 - 8.65mg n.s.s.	4/21	4/14			
liv mix s 108.mg P<.8 - 9.22mg n.s.s.	5/21	4/14			
alpha-METHYLBENZYL ALCOHOL 98-85-1					
3868 M f b6c gav 24m24 TR369 :	0	265.mg	531.mg		
TBA MXB no dre P=1. - 870.mg n.s.s.	33/50	23/50	24/50		
liv MXB no dre P=1. 4.97gm n.s.s.	2/50	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 2.76gm n.s.s.	7/50	1/50	4/50		lun:a/a,a/c.
3869 M m b6c gav 24m24 TR369 :	0	265.mg	531.mg		
TBA MXB 2.23gm * P<.7 - 321.mg n.s.s.	39/50	40/50	32/50		
liv MXB no dre P=1. 711.mg n.s.s.	20/50	22/50	13/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 1.07gm n.s.s.	17/50	14/50	9/50		lun:a/a,a/c.
3870 R f f34 gav 24m24 TR369 :	0	265.mg	531.mg		
pni isa s# 2.30gm * P<.009 - 791.mg 60.5gm	0/50	1/50	3/50		S
TBA MXB s 826.mg * P<.5 190.mg n.s.s.	46/50	40/50	22/50		
liv MXB s 8.63gm * P<.4 1.41gm n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
3871 R m f34 gav 24m24 TR369 :	0	265.mg	531.mg		
tes ict s 51.5mg / P<.0005 31.1mg 98.0mg	46/50	36/50	35/50		S
amd MXA s 135.mg * P<.0005 62.4mg 508.mg	16/50	20/50	4/50		amd:phe,phm. S
kid MXA s 458.mg / P<.0005 p 161.mg 1.70gm	0/50	2/50	5/50		kid:tla,uac.
kid tla s 564.mg / P<.0005 176.mg 2.50gm	0/50	1/50	5/50		S
lun MXA s 1.05gm * P<.04 243.mg n.s.s.	1/50	3/50	1/50		lun:a/a,a/c. S
pre can s 1.27gm * P<.03 276.mg n.s.s.	0/50	3/50	0/50		S
TBA MXB s 88.6mg * P<.0005 46.3mg 249.mg	43/50	32/50	18/50		
liv MXB s 4.80gm * P<.7 456.mg n.s.s.	2/50	2/50	0/50		liv:hpa,hpc,nnd.
3872 R m f34 gav 24m24 TR369 with step	0	265.mg	531.mg		
kid MXA 944.mg * P<.0005 p 567.mg 2.38gm	1/50	13/50	14/50		kid:tla,uac.
kid tla 984.mg * P<.0005 587.mg 2.50gm	1/50	12/50	14/50		S
3-METHYLBUTANAL METHYLFORMYLHYDRAZONE 57590-21-3					
3873 M f swa gav 12m30 1966	0	2.98mg			Toth;vivo,4,283-288;1990
lun mix e 1.99mg P<.0005 + 1.19mg 3.85mg	13/50	42/50			
lun ade e 2.39mg P<.0005 1.48mg 4.33mg	7/50	38/50			
liv mix e 7.90mg P<.0005 + 4.39mg 16.3mg	0/50	16/50			
lun adc e 8.70mg P<.003 4.26mg 54.6mg	6/50	19/50			
liv hpt e 9.27mg P<.0005 4.98mg 20.2mg	0/50	14/50			
gal mix e 28.9mg P<.008 + 11.0mg 559.mg	0/50	5/50			
gal ade e 36.5mg P<.02 12.6mg n.s.s.	0/50	4/50			
liv hpc e 74.6mg P<.1 18.4mg n.s.s.	0/50	2/50			
gal adc e 151.mg P<.3 24.6mg n.s.s.	0/50	1/50			
3874 M m swa gav 12m28 1966	0	3.18mg			
lun mix e 2.53mg P<.0005 + 1.48mg 5.47mg	13/50	38/50			
lun ade e 3.30mg P<.0005 1.88mg 8.11mg	12/50	34/50			
pre mix e 4.36mg P<.0005 + 2.66mg 7.83mg	0/50	24/50			
pre sqc e 5.59mg P<.0005 3.28mg 10.6mg	0/50	20/50			
liv mix e 5.97mg P<.0005 + 3.46mg 11.6mg	0/50	19/50			
liv hpt e 8.00mg P<.0005 4.37mg 17.0mg	0/50	15/50			
lun adc e 10.7mg P<.003 5.10mg 69.2mg	3/50	14/50			
liv hpc e 34.2mg P<.02 11.8mg n.s.s.	0/50	4/50			
pre sqp e 34.2mg P<.02 11.8mg n.s.s.	0/50	4/50			

Site / Notes / DR / AuOp / UpConf / Path / TD_{50} / 2Tailpvl / LoConf / Cntrl / 1 Inc / 2 Inc / 3 Inc / Brkly Code / NCI/NTPPathology

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
gal ade e	46.1mg	P<.04	+	14.0mg n.s.s.	0/50	3/50			
4-METHYLCATECHOL 452-86-8									
3875 R f f3d eat 24m24 2202					0	1.00gm			Asakawa;ijcn,56,146-152;1994
stg ade e	noTD50	P<.0005	+	n.s.s. 304.mg	0/30	30/30			
for sqp e	253.mg	P<.0005	+	130.mg 487.mg	0/30	28/30			
stg adc e	1.09gm	P<.0005	+	579.mg 2.40gm	0/30	14/30			
for sqc e	1.50gm	P<.0005	+	747.mg 3.71gm	0/30	11/30			
stg sar e	6.50gm	P<.04		1.97gm n.s.s.	0/30	3/30			
liv hnd e	no dre	P=1.		3.73gm n.s.s.	1/30	1/30			
3876 R m f3d eat 24m24 2202					0	800.mg			
stg ade e	noTD50	P<.0005	+	n.s.s. 243.mg	0/30	30/30			
for sqp e	468.mg	P<.0005	+	265.mg 941.mg	1/30	21/30			
stg adc e	656.mg	P<.0005	+	364.mg 1.34gm	0/30	17/30			
for sqc e	719.mg	P<.0005	+	394.mg 1.50gm	0/30	16/30			
stg sar e	3.83gm	P<.02		1.32gm n.s.s.	0/30	4/30			
liv hnd e	no dre	P=1.		2.99gm n.s.s.	1/30	1/30			
3-METHYLCHOLANTHRENE 56-49-5									
3877 P b cym eat 5y27 2004 :					0	8.37mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
tba mal jw	no dre	P=1.		9.22mg n.s.s.	3/15	0/3			
3878 P b rhe eat 5y26 2004 :					0	10.7mg			
tba mal Wjw	no dre	P=1.		7.38mg n.s.s.	6/74	0/7			
3879 R m lee eat 26w65 1484m					0	1.07mg			Flaks;carc,3,981-991;1982
liv tum	no dre	P=1.	-	.518mg n.s.s.	0/40	0/6			
3880 R m lee eat 39w65 1484n					0	1.61mg			
liv tum	no dre	P=1.	-	1.94mg n.s.s.	0/40	0/15			
3881 R m lee eat 65w65 1484o					0	2.68mg			
liv tum	no dre	P=1.	-	3.24mg n.s.s.	0/40	0/15			
3882 R f nss gav 52w52 481					0	4.90mg			Shay;mpoc,305-318;1962
mam tum er	.506mg	P<.0005	+	.261mg 1.08mg	0/9	17/21			
3883 R f wis gav 52w52 188BT					0	9.80mg			Shay;jnci,27,503-513;1961
mgl adc r	.714mg	P<.0005	+	.343mg 1.53mg	0/20	19/21			
3884 R f wis gav 26w52 188bm					0	2.46mg			
mgl adc r	.202mg	P<.0005	+	91.4ug .485mg	0/20	14/16			
3885 R f wis gav 39w52 188bn					0	3.69mg			
mgl adc r	.304mg	P<.0005	+	.137mg .727mg	0/20	14/16			
3886 R f wis gav 52w52 188bo					0	4.90mg			
mgl adc r	.764mg	P<.0005	+	.375mg 1.84mg	0/20	12/18			
3887 R f wis gav 52w52 188br					0	4.90mg			
mgl adc r	.506mg	P<.0005	+	.261mg 1.08mg	0/20	17/21			
3888 R f wis gav 52w52 188bs					0	4.90mg			
mgl adc r	noTD50	P<.0005	+	n.s.s. .486mg	0/20	17/17			
3889 R f wis gav 52w52 188bu					0	12.2mg			
mgl adc r	.689mg	P<.0005	+	.286mg 1.55mg	0/20	20/21			
3890 R f wis gav 52w52 188bv					0	4.90mg			
mgl adc r	.590mg	P<.0005	+	.336mg 1.12mg	0/20	22/29			
3891 R f wis gav 52w52 1130m					0	8.57mg			Gruenstein;canr,24,1656-1658;1964
mgl adc m	1.25mg	P<.0005	+	.808mg 2.04mg	1/54	37/53			
3892 R f wis gav 52w52 1130n					0	4.90mg			
mam tum r	.669mg	P<.0005	+	.363mg 1.39mg	1/54	18/25			
alpha-METHYLDOPA SESQUIHYDRATE 41372-08-1									
3893 M f b6c eat 24m24 TR348 :					0	811.mg	1.61gm		
TBA MXB	no dre	P=1.	-	3.22gm n.s.s.	33/50	22/50	21/50		
liv MXB	no dre	P=1.		5.13gm n.s.s.	4/50	1/50	(0/50)		liv:hpa,hpc,nnd.
lun MXB	25.0gm *	P<.5		4.97gm n.s.s.	4/50	1/50	6/50		lun:a/a,a/c.
3894 M m b6c eat 24m24 TR348 :					0	749.mg	1.49gm		
kid MXA	20.1gm *	P<.2	e	6.08gm n.s.s.	0/50	2/50	1/50		kid:tla,uac.
TBA MXB	no dre	P=1.		4.11gm n.s.s.	32/50	15/50	17/50		
liv MXB	no dre	P=1.		7.29gm n.s.s.	15/50	5/50	6/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		4.94gm n.s.s.	10/50	5/50	7/50		lun:a/a,a/c.
3895 R f f34 eat 24m24 TR348 :					0	154.mg	312.mg		
TBA MXB	592.mg *	P<.5	-	140.mg n.s.s.	45/50	47/50	47/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
3896 R m f34 eat 24m24 TR348 :					0	123.mg	250.mg		
TBA MXB	no dre	P=1.	-	216.mg n.s.s.	46/50	31/50	42/50		
liv MXB	no dre	P=1.		351.mg n.s.s.	6/50	3/50	(1/50)		liv:hpa,hpc,nnd.
N-METHYLDOPAMINE,O,O'-DIISOBUTYROYL ESTER.HCl (ibopamine.HCl) 75011-65-3									
3897 R f cdr gav 24m24 1875					0	30.0mg	90.0mg	180.mg	Walker;neag,9,291-301;1988/pers.comm.
adr coa	no dre	P=1.	-	164.mg n.s.s.	71/200	26/100	(22/100 | 19/100)	
pit ade	no dre	P=1.	-	249.mg n.s.s.	163/200	83/100	92/100	75/100	
mgl adc	no dre	P=1.	-	626.mg n.s.s.	31/200	17/100	11/100	(1/100)	
mgl ade	no dre	P=1.	-	1.22gm n.s.s.	67/200	30/100	27/100	23/100	
adr phm	no dre	P=1.	-	2.59gm n.s.s.	11/200	1/100	3/100	3/100	
3898 R m cdr gav 24m24 1875					0	30.0mg	90.0mg	180.mg	
pit ade	30.2mg Z	P<.002	-	15.5mg 142.mg	125/200	81/100	(59/100 | 41/100)	
adr phm	no dre	P=1.	-	850.mg n.s.s.	45/200	11/100	13/100	(7/100)	
adr coa	no dre	P=1.	-	145.mg n.s.s.	50/200	21/100	(11/100 | 10/100)	
4,4'-METHYLENE-BIS(2-CHLOROANILINE) (3,3'-dichloro-4,4'-diaminodiphenylmethane, MOCA) 101-14-4									
3899 D f beg eat 9y9 1030					0	7.31mg			Stula;jept,1,31-50;1977
ubl ptc emv	2.12mg	P<.003	+	.586mg 14.8mg	0/6	4/5			
liv hnd emv	3.72mg	P<.02	+	1.04mg n.s.s.	0/6	3/5			
mgl mix emv	no dre	P=1.	-	2.29mg n.s.s.	4/6	2/5			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
3900 R f cdr eat 67w67 192m					0	50.0mg			Stula;txap,31,159-176;1975/pers.comm.
lun adc ef		42.3mg	P<.003 +	17.1mg 223.mg	0/21	6/21			
mgl adc ef		42.3mg	P<.003 +	17.1mg 223.mg	0/21	6/21			
liv hpa ef		142.mg	P<.1 -	34.9mg n.s.s.	0/21	2/21			
liv hpc ef		291.mg	P<.3 -	47.4mg n.s.s.	0/21	1/21			
3901 R f cdr eat 24m24 192n					0	50.0mg			
lun adc e		34.7mg	P<.0005 +	21.4mg 60.5mg	0/44	27/44			
liv hpc e		467.mg	P<.04 -	141.mg n.s.s.	0/44	3/44			
liv hpa e		708.mg	P<.1 -	174.mg n.s.s.	0/44	2/44			
liv cho e		1.43gm	P<.3 -	233.mg n.s.s.	0/44	1/44			
3902 R m cdr eat 67w67 192m					0	40.0mg			
liv hpc ef		15.3mg	P<.0005 +	7.53mg 38.0mg	0/21	11/21			
liv hpa ef		41.8mg	P<.007 +	15.8mg 498.mg	0/21	5/21			
lun adc ef		41.8mg	P<.007 +	15.8mg 498.mg	0/21	5/21			
3903 R m cdr eat 24m24 192n					0	40.0mg			
lun adc e		42.3mg	P<.0005 +	25.0mg 79.2mg	0/44	21/44			
liv hpc e		388.mg	P<.04 -	117.mg n.s.s.	0/44	3/44			
liv hpa e		388.mg	P<.04 -	117.mg n.s.s.	0/44	3/44			
3904 R m cdr eat 18m24 1031m					0	7.53mg	15.1mg	34.0mg	Kommineni;jept,2,149-171;1979
lun neo es		20.8mg *	P<.0005 +	15.7mg 28.6mg	1/100	23/100	28/75	35/50	
lun mix es		29.2mg *	P<.0005 +	21.5mg 41.1mg	0/100	14/100	20/75	31/50	
mgl adc es		87.6mg *	P<.0005 +	53.7mg 174.mg	1/100	5/100	8/75	14/50	
liv hpc es		92.2mg Z	P<.0005 +	56.8mg 164.mg	0/100	3/100	3/75	18/50	
zym car es		107.mg *	P<.0005 +	61.4mg 288.mg	1/100	8/100	5/75	11/50	
--- ker es		144.mg Z	P<.01	63.9mg 6.58gm	1/100	3/100	7/75	(1/50)	
ski sqc es		286.mg *	P<.2	109.mg n.s.s.	1/100	4/100	7/75	2/50	
tba mix es		10.4mg *	P<.0005	6.48mg 21.1mg	58/100	80/100	61/75	48/50	
3905 R m cdr eat 18m24 1031n					0	3.76mg	7.53mg	15.1mg	
lun neo efs		35.1mg *	P<.0005 +	22.7mg 58.9mg	0/100	6/100	11/75	13/50	
lun mix efs		60.9mg *	P<.0005 +	35.0mg 127.mg	0/100	3/100	7/75	8/50	
zym car efs		112.mg *	P<.0005 +	54.5mg 298.mg	0/100	0/100	4/75	6/50	
liv hpc efs		124.mg Z	P<.0005 +	58.3mg 337.mg	0/100	0/100	0/75	9/50	
mgl adc efs		162.mg *	P<.006 +	70.1mg 1.51gm	0/100	1/100	3/75	3/50	
--- hes efs		138.mg *	P<.02 +	58.8mg n.s.s.	1/100	2/100	4/75	4/50	
ski sqc efs		263.mg *	P<.03	90.3mg n.s.s.	1/100	0/100	1/75	4/50	
tba mix efs		14.8mg *	P<.0005	8.87mg 37.5mg	37/100	34/100	40/75	36/50	
3906 R f wi2 eat 16m28 1018					0	29.9mg			Grundmann;zkko,74,28-39;1970
liv mix e		15.8mg	P<.0005 +	8.23mg 32.9mg	0/25	18/22			
mgl mix e		51.4mg	P<.003	22.5mg 352.mg	2/25	10/22			
lun mix e		104.mg	P<.005 +	39.4mg 827.mg	0/25	5/22			
tba mix e		11.6mg	P<.0005 +	5.53mg 25.9mg	2/25	20/22			
3907 R m wi2 eat 16m30 1018					0	22.5mg			
liv mix e		10.8mg	P<.0005 +	5.69mg 21.6mg	0/25	22/25			
lun mix e		59.5mg	P<.0005 +	26.8mg 192.mg	0/25	8/25			
tba mix e		9.09mg	P<.0005 +	4.52mg 18.4mg	0/25	23/25			
4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCl 64049-29-2									
3908 M f chi eat 77w90 191 :					0	117.mg	246.mg		Russfield;txap,31,47-54;1975
liv hpt		66.6mg /	P<.0005 +	35.3mg 147.mg	0/20	9/21	7/14		
liv mix		66.6mg /	P<.0005 +	35.3mg 147.mg	0/20	9/21	7/14		
lun mix		556.mg *	P<.4 -	108.mg n.s.s.	6/20	3/21	2/14		
tba mix		52.8mg /	P<.0005	26.1mg 196.mg	17/20	16/21	12/14		
3909 M m chi eat 77w94 191 :					0	108.mg	206.mg		
lun mix		342.mg *	P<.2 -	86.4mg n.s.s.	5/18	3/13	4/20		
liv mix		471.mg *	P<.4	112.mg n.s.s.	3/18	4/13	4/20		
tba mix		97.9mg *	P<.02	28.0mg n.s.s.	12/18	7/13	16/20		
3910 R m cdr eat 77w98 191 :					0	18.0mg	31.3mg		
liv mix		70.1mg *	P<.2	18.6mg n.s.s.	1/22	1/22	4/19		
tba mix		33.4mg *	P<.5	6.57mg n.s.s.	14/22	13/22	14/19		
4,4'-METHYLENE-BIS(2-METHYLANILINE) 838-88-0									
3911 R f cdr eat 82w82 192					0	10.5mg			Stula;txap,31,159-176;1975/pers.comm.
liv hpc v		7.92mg	P<.0005 +	4.58mg 15.4mg	0/44	19/44			
liv hpa v		30.5mg	P<.004	12.4mg 187.mg	0/44	6/44			
liv clc v		96.3mg	P<.1	23.7mg n.s.s.	0/44	2/44			
3912 R m cdr eat 68w68 192					0	8.49mg			
mgl fba v		6.91mg	P<.0005 +	3.58mg 19.2mg	1/44	14/44			
ski fib v		8.19mg	P<.002 +	3.97mg 37.4mg	2/44	13/44			
liv hpc v		12.4mg	P<.002 +	5.61mg 41.8mg	0/44	8/44			
liv hpa v		17.0mg	P<.004	6.92mg 104.mg	0/44	6/44			
liv hem v		35.2mg	P<.04	10.7mg n.s.s.	0/44	3/44			
METHYLENE CHLORIDE (dichloromethane, Freon 30) 75-09-2									
3913 M f b6c inh 24m24 TR306 :					0	2.14gm	4.28gm		
MXB MXB		817.mg *	P<.0005	568.mg 1.28gm	5/50	36/50	46/50		liv:hpa,hpc; lun:a/a,a/c. C
lun MXA		917.mg *	P<.0005 c	635.mg 1.43gm	3/50	30/50	41/50		lun:a/a,a/c.
lun a/a		1.42gm *	P<.0005 c	938.mg 2.39gm	2/50	23/50	28/50		
liv MXA		1.43gm /	P<.0005 c	956.mg 2.31gm	3/50	16/50	40/50		liv:hpa,hpc.
lun a/c		1.69gm /	P<.0005 c	1.10gm 2.81gm	1/50	13/50	29/50		
liv hpc		1.85gm /	P<.0005 c	1.20gm 3.04gm	1/50	11/50	32/50		
liv hpa		3.17gm /	P<.0005 c	1.85gm 6.50gm	2/50	6/50	22/50		
thy fca		15.8gm *	P<.05	5.11gm n.s.s.	1/50	1/50	4/50		S
TBA MXB		1.02gm *	P<.0005	652.mg 1.93gm	18/50	41/50	47/50		
liv MXB		1.43gm /	P<.0005	956.mg 2.31gm	3/50	16/50	40/50		liv:hpa,hpc,nnd.
lun MXB		917.mg *	P<.0005	635.mg 1.43gm	3/50	30/50	41/50		lun:a/a,a/c.
3914 M f b6c inh 6m24 2117m					0	546.mg			Kari;carc,14,819-826;1993
lun mix er		1.28gm	P<.0005 +	676.mg 4.60gm	5/67	21/68			
lun car er		1.65gm	P<.003	820.mg 8.84gm	4/67	17/68			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv mix er	1.84gm	P<.1	681.mg n.s.s.	18/67	27/67				
liv hpa er	2.57gm	P<.07	978.mg n.s.s.	8/67	16/67				
lun ade er	3.40gm	P<.02	1.41gm n.s.s.	1/67	8/68				
liv hpc er	6.79gm	P<.6	1.30gm n.s.s.	11/67	14/67				
3915 M f b6c inh 12m24 2117n				0	1.09gm				
lun mix er	804.mg	P<.0005 +	521.mg 1.37gm	5/67	40/63				
lun car er	952.mg	P<.0005	609.mg 1.66gm	4/67	36/63				
lun ade er	3.81gm	P<.0005	1.88gm 13.1gm	1/67	12/63				
liv mix er	2.85gm	P<.05 +	1.18gm n.s.s.	18/67	28/64				
liv hpc er	4.96gm	P<.2	1.77gm n.s.s.	11/67	18/64				
liv hpa er	6.25gm	P<.2	2.12gm n.s.s.	8/67	14/64				
3916 M f b6c inh 18m24 2117o				0	1.64gm				
lun mix er	1.52gm	P<.0005 +	971.mg 2.68gm	5/67	38/68				
liv mix er	1.73gm	P<.0005 +	986.mg 4.73gm	18/67	42/68				
liv hpa er	2.78gm	P<.0005	1.54gm 8.13gm	8/67	28/68				
lun car er	2.83gm	P<.0005	1.63gm 6.56gm	4/67	25/68				
lun ade er	3.59gm	P<.0005	2.04gm 7.83gm	1/67	19/68				
liv hpc er	4.02gm	P<.008	1.92gm 87.8gm	11/67	25/68				
3917 M f b6c inh 24m24 2117r				0	2.18gm				
lun mix er	1.65gm	P<.0005 +	1.08gm 2.77gm	5/67	42/67				
liv mix er	1.74gm	P<.0005 +	1.05gm 3.74gm	18/67	47/68				
lun a/c er	2.67gm	P<.0005	1.65gm 5.13gm	4/67	31/67				
liv hpc er	2.75gm	P<.0005	1.60gm 6.83gm	11/67	35/68				
liv hpa er	4.86gm	P<.002	2.50gm 23.3gm	8/67	24/68				
lun a/a er	5.02gm	P<.0005	2.81gm 11.3gm	1/67	18/67				
3918 M m b6c inh 24m24 TR306 :				0	1.79gm	3.57gm			
lun MXA	920.mg *	P<.0005 c	630.mg 1.46gm	5/50	27/50	40/50			lun:a/a,a/c.
MXB MXB	1.09gm *	P<.0005	672.mg 2.27gm	27/50	35/50	45/50			liv:hpa,hpc; lun:a/a,a/c. C
lun a/a	1.68gm *	P<.0005 c	1.08gm 2.98gm	3/50	19/50	24/50			
lun a/c	1.71gm /	P<.0005 c	1.09gm 2.95gm	2/50	10/50	28/50			
liv MXA	1.80gm *	P<.0005 c	1.01gm 4.99gm	22/50	24/50	33/50			liv:hpa,hpc.
liv hpc	2.69gm *	P<.0005 c	1.49gm 7.70gm	13/50	15/50	26/50			
liv hpa	3.48gm *	P<.003 c	1.68gm 23.5gm	10/50	14/50	14/50			
--- hes	12.9gm *	P<.02	4.78gm n.s.s.	1/50	2/50	5/50			S
--- MXA	13.2gm *	P<.03	4.82gm n.s.s.	2/50	2/50	6/50			---:hem,hes. S
TBA MXB	1.16gm *	P<.0005	688.mg 2.76gm	34/50	37/50	46/50			
liv MXB	1.80gm *	P<.0005	1.01gm 4.99gm	22/50	24/50	33/50			liv:hpa,hpc,nnd.
lun MXB	920.mg *	P<.0005	630.mg 1.46gm	5/50	27/50	40/50			lun:a/a,a/c.
3919 M m b6c wat 24m24 1802				0	60.0mg	125.mg	185.mg	250.mg	Serota;fctx,24,959-963;1986
liv mix e	1.31gm *	P<.07 -	540.mg n.s.s.	24/125	51/200	30/100	31/99	35/125	
liv hpc e	2.35gm *	P<.2 -	815.mg n.s.s.	14/125	33/200	18/100	17/99	23/125	
liv hpa e	2.90gm *	P<.2 -	1.01gm n.s.s.	10/125	20/200	14/100	14/99	15/125	
thy tum e	no dre	P=1. -	825.mg n.s.s.	0/125	0/200	0/100	0/99	0/125	
3920 M f swi gav 15m24 BT3003				0	39.6mg	198.mg			Maltoni;anya,534,352-366;1988
lun ade s	7.05gm *	P<.9	502.mg n.s.s.	10/60	8/50	9/50			
liv hpt s	no dre	P=1.	340.mg n.s.s.	0/60	0/50	0/50			
tba mal s	no dre	P=1.	586.mg n.s.s.	15/60	8/50	10/50			
tba mix s	no dre	P=1.	427.mg n.s.s.	31/60	17/50	20/50			
3921 M m swi gav 15m24 BT3003				0	39.6mg	198.mg			
lun ade s	916.mg *	P<.05	345.mg n.s.s.	3/60	6/50	9/50			
liv hpt s	no dre	P=1.	1.27gm n.s.s.	5/60	2/50	2/50			
tba mal s	no dre	P=1.	1.18gm n.s.s.	12/60	4/50	4/50			
tba mix s	no dre	P=1.	477.mg n.s.s.	18/60	10/50	13/50			
3922 R f f34 inh 24m24 TR306 :				0	255.mg	510.mg	1.02gm		
mgl MXA	598.mg *	P<.0005 c	361.mg 1.36gm	5/50	11/50	13/50	23/50		mgl:adn,fba.
mgl MXA	630.mg *	P<.0005	371.mg 1.57gm	6/50	13/50	14/50	23/50		mgl:acn,adn,fba. S
mgl fba	632.mg *	P<.0005 c	378.mg 1.49gm	5/50	11/50	13/50	22/50		
mgl MXA	670.mg *	P<.0005	385.mg 1.80gm	7/50	13/50	14/50	23/50		mgl:acn,adn,fba,mtm. S
--- mnl	1.28gm *	P<.02	578.mg n.s.s.	17/50	17/50	23/50	23/50		S
liv MXA	4.27gm *	P<.05	1.56gm n.s.s.	2/50	1/50	4/50	5/50		liv:hpc,nnd. S
TBA MXB	501.mg *	P<.007	244.mg 8.34gm	41/50	46/50	48/50	48/50		
liv MXB	4.27gm *	P<.05	1.56gm n.s.s.	2/50	1/50	4/50	5/50		liv:hpa,hpc,nnd.
3923 R f f34 wat 78w78 1801m				0	5.00mg	50.0mg	125.mg	250.mg	Serota;fctx,24,951-958;1986
liv nnd ek	no dre	P=1. -	9.99mg n.s.s.	0/20	0/20	0/20	0/20	0/20	
3924 R f f34 wat 18m24 1801n				0	188.mg				
liv mix e	1.54gm	P<.02 -	379.mg n.s.s.	0/100	2/25				
liv nnd e	1.54gm	P<.02 -	379.mg n.s.s.	0/100	2/25				
liv hpc e	no dre	P=1. -	966.mg n.s.s.	0/100	0/25				
3925 R f f34 wat 24m24 1801o				0	5.00mg	50.0mg	125.mg	250.mg	
liv mix e	1.43gm *	P<.003 -	638.mg 10.1gm	0/100	1/50	4/50	1/50	6/50	
liv nnd e	2.34gm *	P<.02 -	880.mg n.s.s.	0/100	1/50	2/50	1/50	4/50	
liv hpc e	3.63gm *	P<.06 -	1.25gm n.s.s.	0/100	0/50	2/50	0/50	2/50	
3926 R m f34 inh 24m24 TR306 :				0	179.mg	357.mg	714.mg		
MXA MXA	917.mg *	P<.0005 p	477.mg 2.17gm	0/50	1/50	4/50	9/50		mgl:adn,fba; sub:fib.
MXA MXA	1.44gm *	P<.006	686.mg 16.1gm	0/50	2/50	5/50	4/50		mul:men,msm; tnv:men,msm. S
mgl MXA	1.64gm *	P<.002 p	693.mg 7.00gm	0/50	0/50	2/50	5/50		mgl:adn,fba.
tnv MXA	1.64gm *	P<.005	739.mg 12.2gm	0/50	1/50	4/50	4/50		tnv:men,msm. S
mgl fba	1.77gm *	P<.004 p	716.mg 11.2gm	0/50	0/50	2/50	4/50		
sub MXA	1.99gm *	P<.003	853.mg 11.1gm	0/50	1/50	2/50	5/50		sub:fib,srn. S
sub fib	2.18gm *	P<.007	892.mg 28.3gm	0/50	1/50	2/50	4/50		S
tnv msm	4.31gm *	P<.04	1.34gm n.s.s.	0/50	1/50	0/50	3/50		S
TBA MXB	539.mg *	P<.2	186.mg n.s.s.	46/50	48/50	49/50	48/50		
liv MXB	no dre	P=1.	1.43gm n.s.s.	2/50	2/50	4/50	1/50		liv:hpa,hpc,nnd.
3927 R m f34 wat 78w78 1801m				0	5.00mg	50.0mg	125.mg	250.mg	Serota;fctx,24,951-958;1986
liv nnd ek	no dre	P=1. -	489.mg n.s.s.	0/20	1/20	2/20	1/20	0/20	
3928 R m f34 wat 18m24 1801n				0	188.mg				
liv nnd e	1.61gm	P<.4 -	307.mg n.s.s.	9/100	4/25				
liv mix e	3.66gm	P<.8 -	341.mg n.s.s.	13/100	4/25				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv hpc e	no dre	P=1.	- 966.mg n.s.s.	4/100	0/25				
3929 R m f34 wat 24m24 1801o				0	5.00mg	50.0mg	125.mg	250.mg	
liv mix e	no dre	P=1.	- 2.41gm n.s.s.	13/100	1/50	1/50	2/50	2/50	
liv nnd e	no dre	P=1.	- 2.58gm n.s.s.	9/100	1/50	1/50	2/50	1/50	
liv hpc e	no dre	P=1.	- 3.01gm n.s.s.	4/100	0/50	0/50	0/50	1/50	
3930 R f sda gav 15m24 BT3002				0	39.6mg	198.mg			Maltoni;anya,534,352-366;1988
mam mal s	1.13gm *	P<.07	403.mg n.s.s.	4/50	3/50	9/50			
mam mix s	1.03gm *	P<.7	151.mg n.s.s.	28/50	37/50	33/50			
tba mal s	1.74gm *	P<.6	320.mg n.s.s.	14/50	12/50	16/50			
tba mix s	no dre	P=1.	141.mg n.s.s.	39/50	41/50	39/50			
3931 R f sda inh 24m24 BT4005				0	29.4mg				
mam mix gv	37.8mg	P<.009	17.7mg 1.23gm	24/60	35/54				
tba mix gv	32.1mg	P<.03	13.6mg n.s.s.	35/60	42/54				
tba mal gv	477.mg	P<.7	70.6mg n.s.s.	9/60	10/54				
3932 R m sda gav 15m24 BT3002				0	39.6mg	198.mg			
tba mix s	no dre	P=1.	47.0mg n.s.s.	37/50	33/50	(22/50)			
tba mal s	935.mg \	P<.9	68.6mg n.s.s.	15/50	16/50	(6/50)			
3933 R f sss inh 24m24 1600				0	130.mg	390.mg	910.mg		Burek;faat,4,30-47;1984/pers.comm.
mgl ben e	4.43gm *	P<.7	627.mg n.s.s.	79/96	81/95	80/96	83/97		
pit ade e	no dre	P=1.	1.25gm n.s.s.	34/96	24/95	30/96	(16/97)		
3934 R f sss inh 24m24 1890m				0	13.0mg	52.0mg	130.mg		Nitschke;faat,11,48-59;1988/pers.comm.
mgl fba e	631.mg *	P<.7	84.1mg n.s.s.	51/69	57/69	60/69	55/69		
mgl ben e	1.55gm *	P<.9	93.8mg n.s.s.	52/70	58/70	61/70	55/70		
liv kcs e	9.34gm *	P<.8	- 1.52gm n.s.s.	0/70	0/70	1/70	0/70		
liv hpc e	9.52gm *	P<.7	- 1.09gm n.s.s.	1/70	0/70	2/70	1/70		
liv nnd e	no dre	P=1.	- 813.mg n.s.s.	4/70	4/70	3/70	4/70		
mgl adc e	no dre	P=1.	- 859.mg n.s.s.	3/69	5/69	4/69	3/69		
3935 R f sss inh 12m24 1890n				0	65.0mg				
mgl fba e	37.7mg	P<.05	11.8mg n.s.s.	51/69	23/25				
mgl ben e	38.1mg	P<.05	11.9mg n.s.s.	52/70	23/25				
mgl adc e	1.14gm	P<.6	- 149.mg n.s.s.	3/69	2/25				
liv nnd e	no dre	P=1.	- 220.mg n.s.s.	4/70	1/25				
liv hpc e	no dre	P=1.	- 335.mg n.s.s.	1/70	0/25				
3936 R m sss inh 24m24 1600				0	91.0mg	273.mg	637.mg		Burek;faat,4,30-47;1984/pers.comm.
slg mix e	4.26gm *	P<.0005	2.28gm 12.1gm	1/92	0/95	5/95	11/97		
mgl ben e	5.08gm *	P<.03	2.17gm n.s.s.	7/92	3/95	7/95	14/97		
3937 R m sss inh 86w86 1890m				0	9.10mg	36.4mg	91.0mg		Nitschke;faat,11,48-59;1988/pers.comm.
liv tum e	no dre	P=1.	- 66.5mg n.s.s.	0/70	0/70	0/70	0/70		
4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE 101-61-1									
3938 M f b6c eat 78w91 TR186 :				0	139.mg	278.mg			
liv MXA	207.mg *	P<.003	c 126.mg 1.14gm	1/20	19/50	23/50			liv:hpa,hpc.
TBA MXB	280.mg *	P<.07	122.mg n.s.s.	6/20	26/50	30/50			
liv MXB	207.mg *	P<.003	126.mg 1.14gm	1/20	19/50	23/50			liv:hpa,hpc,nnd.
lun MXB	1.08gm \	P<.2	328.mg n.s.s.	0/20	3/50	(0/50)			lun:a/a,a/c.
3939 M m b6c eat 78w91 TR186 :				0	128.mg	257.mg			
TBA MXB	367.mg *	P<.2	- 140.mg n.s.s.	7/20	24/50	31/50			
liv MXB	558.mg *	P<.2	216.mg n.s.s.	5/20	12/50	22/50			liv:hpa,hpc,nnd.
lun MXB	1.41gm *	P<.4	437.mg n.s.s.	1/20	6/50	7/50			lun:a/a,a/c.
3940 R f f34 eat 14m24 TR186 :				0	11.0mg	21.0mg			
thy MXA	16.4mg /	P<.0005	c 11.2mg 25.8mg	0/20	4/50	36/50			thy:fca,fcc.
thy fcc	27.7mg /	P<.0005	c 17.4mg 51.4mg	0/20	3/50	23/50			
liv nnd	203.mg *	P<.05	70.2mg n.s.s.	0/20	0/50	4/50			S
TBA MXB	41.7mg /	P<.4	10.8mg n.s.s.	17/20	33/50	44/50			
liv MXB	203.mg *	P<.05	70.2mg n.s.s.	0/20	0/50	4/50			liv:hpa,hpc,nnd.
3941 R m f34 eat 14m24 TR186 :				0	8.80mg	16.8mg			
thy MXA	16.5mg /	P<.0005	c 10.7mg 33.5mg	1/20	4/50	34/50			thy:fca,fcc.
thy fcc	28.6mg /	P<.002	c 16.5mg 117.mg	1/20	4/50	21/50			
TBA MXB	42.9mg *	P<.5	10.2mg n.s.s.	14/20	29/50	44/50			
liv MXB	no dre	P=1.	76.0mg n.s.s.	3/20	5/50	3/50			liv:hpa,hpc,nnd.
2,2'-METHYLENEBIS(4-METHYL-6-tert-BUTYLPHENOL) 119-47-1									
3942 R f wis eat 52w52 2335m				0	5.00mg	15.0mg	50.0mg		Takagi;jtxs,19,77-89;1994/pers.comm.
liv tum ek	no dre	P=1.	- .899mg n.s.s.	0/5	0/5	0/5	0/5		
3943 R f wis eat 78w78 2335n				0	5.00mg	15.0mg	50.0mg		
liv tum e	no dre	P=1.	- 7.71mg n.s.s.	0/20	0/19	0/19	0/20		
3944 R m wis eat 52w52 2335m				0	4.00mg	12.0mg	40.0mg		
tes ict ek	44.5mg *	P<.2	- 7.20mg n.s.s.	0/5	0/5	0/5	1/5		
liv tum ek	no dre	P=1.	- .719mg n.s.s.	0/5	0/5	0/5	0/5		
3945 R m wis eat 78w78 2335n				0	4.00mg	12.0mg	40.0mg		
tes ict e	36.6mg Z	P<.8	- 3.30mg n.s.s.	15/20	11/20	15/20	(0/20)		
liv hpa e	no dre	P=1.	- 114.mg n.s.s.	1/20	1/20	0/20	0/20		
4,4'-METHYLENEDIANILINE.2HCl 13552-44-8									
3946 M f b6c wat 24m24 TR248 :				0	29.4mg	59.1mg			
MXB MXB	32.6mg *	P<.0005	19.1mg 95.5mg	16/50	36/50	44/50			---:mlh,mlm,mlu,mno; liv:hpa,hpc; thy:fca. C
liv MXA	59.3mg *	P<.0005	c 35.2mg 162.mg	4/50	15/50	23/50			liv:hpa,hpc.
--- MXA	64.7mg *	P<.007	c 32.7mg 1.16gm	13/50	28/50	29/50			---:mlh,mlm,mlu,mno.
thy MXA	128.mg /	P<.0005	71.6mg 265.mg	0/50	1/50	15/50			thy:fca,fcc. S
liv hpc	137.mg *	P<.002	c 72.0mg 611.mg	1/50	6/50	11/50			
thy fca	150.mg /	P<.0005	c 80.7mg 338.mg	0/50	1/50	13/50			
liv hpa	135.mg *	P<.02	c 65.1mg n.s.s.	3/50	9/50	12/50			
lun MXA	268.mg *	P<.04	109.mg n.s.s.	2/50	3/50	8/50			lun:a/a,a/c. S
lun a/a	327.mg *	P<.04	129.mg n.s.s.	1/50	2/50	6/50			S
TBA MXB	52.1mg *	P<.05	22.1mg n.s.s.	32/50	47/50	47/50			
liv MXB	59.3mg *	P<.0005	35.2mg 162.mg	4/50	15/50	23/50			liv:hpa,hpc,nnd.
lun MXB	268.mg *	P<.04	109.mg n.s.s.	2/50	3/50	8/50			lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3947 M m b6c wat 24m24 TR248 :					0	24.5mg	49.5mg		
liv MXA		17.0mg	\ P<.0005	9.07mg 65.8mg	17/50	43/50	(37/50)		liv:hpa,hpc. S
liv hpc		22.3mg	\ P<.0005 c	12.1mg 75.5mg	10/50	33/50	(29/50)		
MXB MXB		28.7mg	* P<.0005	17.1mg 78.7mg	12/50	36/50	34/50		adr:phe; liv:hpc; thy:fca. C
adr phe		70.0mg	* P<.0005 c	39.7mg 231.mg	2/50	12/50	14/50		
thy fca		88.4mg	/ P<.0005 c	51.4mg 172.mg	0/50	3/50	16/50		
TBA MXB		47.4mg	* P<.07	19.1mg n.s.s.	37/50	47/50	45/50		
liv MXB		17.0mg	\ P<.0005	9.07mg 65.8mg	17/50	43/50	(37/50)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	168.mg n.s.s.	13/50	12/50	4/50		lun:a/a,a/c.
3948 R f f34 wat 24m24 TR248 :					0	8.41mg	16.7mg		
thy MXB		22.0mg	* P<.0005	13.9mg 38.4mg	0/50	5/50	22/50		thy:cca,fca. C
thy MXA		27.2mg	* P<.0005	16.6mg 50.3mg	0/50	4/50	19/50		thy:fca,fcc. S
thy fca		33.5mg	/ P<.0005 c	19.5mg 66.1mg	0/50	2/50	17/50		
thy cca		73.7mg	* P<.007 c	34.7mg 873.mg	0/50	3/50	6/50		
thy MXA		70.0mg	* P<.04	30.6mg n.s.s.	1/50	5/50	7/50		thy:cca,ccr. S
TBA MXB		277.mg	* P<1.	10.6mg n.s.s.	43/50	48/50	49/50		
liv MXB		118.mg	* P<.4	31.5mg n.s.s.	4/50	8/50	8/50		liv:hpa,hpc,nnd.
3949 R m f34 wat 24m24 TR248 :					0	7.36mg	14.7mg		
MXB MXB		12.5mg	* P<.0005	8.33mg 22.0mg	1/50	12/50	29/50		liv:nnd; thy:fcc. C
liv nnd		14.3mg	* P<.0005 c	9.35mg 27.1mg	1/50	12/50	25/50		
thy MXA		49.5mg	* P<.006	24.4mg 535.mg	1/50	4/50	10/50		thy:fca,fcc. S
thy fcc		85.4mg	* P<.003 c	36.9mg 422.mg	0/50	0/50	7/50		
TBA MXB		no dre	P=1.	15.3mg n.s.s.	45/50	42/50	40/50		
liv MXB		14.1mg	* P<.0005	9.22mg 26.6mg	1/50	13/50	25/50		liv:hpa,hpc,nnd.
METHYLETHYLKETOXIME 96-29-7									
3950 M f cd1 inh 78w78 2654					0	16.8mg	84.0mg	419.mg	Newton;intx,13,1093-1116;2001
liv hpa e		2.44gm	* P<.02	843.mg n.s.s.	0/50	0/50	1/50	3/50	
lun ade e		5.88gm	* P<.7	633.mg n.s.s.	6/50	5/50	8/50	7/50	
3951 M m cd1 inh 78w78 2654					0	14.0mg	70.0mg	349.mg	
liv hpc e		810.mg	* P<.002 +	362.mg 4.35gm	2/50	2/50	1/50	10/50	
liv mix e		534.mg	* P<.02 +	220.mg n.s.s.	6/50	13/50	11/50	18/50	
lun ade e		1.10gm	* P<.3	315.mg n.s.s.	9/50	10/50	10/50	14/50	
liv hpa e		1.46gm	* P<.3	356.mg n.s.s.	4/50	11/50	10/50	11/50	
3952 R f f34 inh 26m26 2654					0	4.00mg	20.0mg	99.7mg	
liv hpa e		804.mg	* P<.006	328.mg 10.7gm	0/50	0/50	2/50	4/50	
3953 R m f34 inh 26m26 2654					0	2.80mg	14.0mg	69.8mg	
liv mix e		74.5mg	* P<.0005 +	49.2mg 122.mg	0/50	2/50	6/50	27/50	
liv hpa e		118.mg	* P<.0005 +	72.4mg 243.mg	0/50	2/50	5/50	18/50	
liv hpc e		242.mg	* P<.0005 +	127.mg 546.mg	0/50	0/50	1/50	12/50	
mgl fba e		346.mg	* P<.007	146.mg 6.16gm	2/50	2/50	4/50	9/50	
ski fib e		84.8mg	Z P<.02	34.1mg n.s.s.	1/50	3/50	7/50	(2/50)	
METHYLEUGENOL 93-15-2									
3954 M f b6c gav 24m24 TR491 :					0	26.4mg	53.6mg	107.mg	
liv MXA		14.6mg	* P<.0005	10.5mg 21.7mg	7/50	38/50	48/50	49/50	liv:hpb,hpc. S
liv hpc		14.9mg	* P<.0005 c	10.7mg 22.4mg	7/50	37/50	47/50	47/50	
liv MXA		15.9mg	Z P<.0005 c	10.6mg 27.7mg	25/50	50/50	49/50	49/50	liv:hpa,hpb,hpc.
liv MXA		15.9mg	Z P<.0005 c	10.6mg 27.7mg	25/50	50/50	49/50	49/50	liv:hpa,hpc.
liv MXB		15.9mg	Z P<.0005	10.6mg 27.7mg	25/50	50/50	49/50	49/50	liv:hcc,hpa,hpb,hpc. C
liv MXA		15.9mg	Z P<.0005	10.6mg 27.7mg	25/50	50/50	49/50	49/50	liv:hpa,hpb,hpc. S
liv hpa		18.2mg	Z P<.0005 c	11.9mg 32.7mg	20/50	48/50	46/50	41/50	
liv hpb		54.1mg	* P<.0005 c	33.2mg 93.6mg	0/50	6/50	11/50	15/50	
sub fbs		89.7mg	Z P<.004	32.2mg 611.mg	0/50	5/50	(1/50	0/50)	S
liv hcc		1.62gm	* P<.05 c	399.mg n.s.s.	0/50	0/50	0/50	2/50	
TBA MXB		21.2mg	* P<.0005	13.0mg 45.4mg	41/50	50/50	49/50	49/50	
liv MXB		15.9mg	Z P<.0005	10.6mg 27.7mg	25/50	50/50	49/50	49/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	298.mg n.s.s.	7/50	4/50	1/50	2/50	lun:a/a,a/c.
3955 M m b6c gav 24m24 TR491 :					0	26.4mg	53.6mg	107.mg	
liv hpa C		24.7mg	Z P<.04	10.3mg n.s.s.	26/50	43/50	(38/50	39/50)	S
liv MXA C		27.3mg	Z P<.07 c	10.6mg n.s.s.	31/50	47/50	(46/50	40/50)	liv:hpa,hpc.
liv MXB C		27.3mg	Z P<.07	10.6mg n.s.s.	31/50	47/50	(46/50	41/50)	liv:hpa,hpb,hpc. C
MXB MXB C		27.3mg	Z P<.07	10.6mg n.s.s.	31/50	47/50	(46/50	41/50)	liv:hpa,hpb,hpc; stg:nem. M
liv hpb C		1.28gm	* P<.03 c	438.mg n.s.s.	0/50	0/50	1/50	3/50	
stg nem C		2.30gm	* P<.07 p	566.mg n.s.s.	0/50	0/50	0/50	2/50	
TBA MXB		338.mg	* P<.6	55.3mg n.s.s.	41/50	48/50	49/50	45/50	
liv MXB C		27.3mg	Z P<.07	10.6mg n.s.s.	31/50	47/50	(46/50	41/50)	liv:hpa,hpb,hpc.
lun MXB		275.mg	* P<.2	93.4mg n.s.s.	15/50	13/50	25/50	20/50	lun:a/a,a/c.
3956 R f f34 gav 24m24 TR491 :					0	26.4mg	53.6mg	107.mg	
MXB MXB C		25.2mg	Z P<.0005	18.4mg 36.1mg	1/50	9/50	29/50	44/50	liv:hpa,hpc; stg:neb,nem. C
stg MXA C		34.3mg	Z P<.0005 c	24.3mg 50.0mg	0/50	1/50	25/50	34/50	stg:neb,nem.
liv MXA C		40.3mg	Z P<.0005 c	27.7mg 63.2mg	1/50	8/50	14/50	34/50	liv:hpa,hpc.
liv hpa C		44.2mg	Z P<.0005 c	30.1mg 70.9mg	1/50	8/50	11/50	33/50	
stg nem C		54.8mg	Z P<.0005 c	36.3mg 87.2mg	0/50	1/50	12/50	26/50	
stg neb C		100.mg	Z P<.0005 c	52.4mg 233.mg	0/50	0/50	13/50	(9/50)	
liv hpc C		197.mg	* P<.0005 c	97.7mg 489.mg	0/50	0/50	4/50	8/50	
for MXA		557.mg	* P<.02 e	188.mg 93.5gm	0/50	0/50	1/50	3/50	for:sqc,sqp.
liv MXA C		852.mg	* P<.02	237.mg n.s.s.	0/50	0/50	0/50	3/50	liv:hcc,hch. S
TBA MXB		67.1mg	* P<.06	27.0mg n.s.s.	47/50	49/50	48/50	47/50	
liv MXB C		40.3mg	Z P<.0005	27.7mg 63.2mg	1/50	8/50	14/50	34/50	liv:hpa,hpb,hpc.
3957 R f f34 gav 12m24 TR491a :					0	109.mg			
liv hpa C		25.5mg	P<.0005 c	16.4mg 42.9mg	1/50	43/50			
liv MXA C		25.5mg	P<.0005 c	16.4mg 42.9mg	1/50	43/50			liv:hpa,hpc.
stg MXA C		25.5mg	P<.0005 c	16.4mg 41.7mg	0/50	41/50			stg:neb,nem.
MXB MXB C		25.5mg	P<.0005	16.4mg 42.9mg	1/50	43/50			liv:hcc,hch,hpa,hpc; stg:neb,nem. C
stg nem C		26.9mg	P<.0005 c	16.9mg 45.1mg	0/50	36/50			
liv hpc C		63.8mg	P<.0005 c	36.6mg 120.mg	0/50	22/50			
liv MXA C		86.4mg	P<.0005 c	46.8mg 176.mg	0/50	17/50			liv:hcc,hch.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hcc C	171.mg	P<.0005	c	77.5mg 503.mg	0/50	9/50			
liv hch C	199.mg	P<.0005	c	85.0mg 673.mg	0/50	8/50			
stg neb C	528.mg	P<.009	c	197.mg 12.3gm	0/50	5/50			
amd pob	262.mg	P<.03		92.1mg n.s.s.	1/50	6/50			S
TBA MXB	152.mg	P<.4		35.6mg n.s.s.	47/50	47/50			
liv MXB C	25.5mg	P<.0005		16.4mg 42.9mg	1/50	43/50			liv:hpa,hpb,hpc.
3958 R m f34 gav 24m24 TR491 :					0	26.4mg	53.6mg	107.mg	
MXB MXB	14.1mg	Z P<.0005		9.63mg 22.1mg	12/50	28/50	39/50	47/50	---:msm; liv:hcc,hch,hpa,hpc; mgl:fba; stg:neb, nem; sub:fbs,fib. C
liv MXA	21.1mg	Z P<.0005	c	14.4mg 32.8mg	7/50	14/50	28/50	43/50	liv:hpa,hpc.
liv hpa	24.6mg	Z P<.0005	c	16.6mg 38.8mg	5/50	12/50	23/50	38/50	
liv hpc	45.2mg	Z P<.0005	c	27.8mg 78.8mg	2/50	3/50	14/50	25/50	
mgl MXA	46.9mg	Z P<.0005		26.0mg 109.mg	5/50	5/50	16/50	13/50	mgl:ade,car,fba. S
mgl fba	50.6mg	* P<.0005	c	27.8mg 121.mg	5/50	5/50	15/50	13/50	
sub MXA	59.1mg	Z P<.0005		32.3mg 174.mg	1/50	13/50	8/50	8/50	sub:fbs,fib,fih. S
sub MXA	60.1mg	* P<.0005	c	32.7mg 173.mg	1/50	12/50	8/50	8/50	sub:fbs,fib.
sub fib	79.7mg	* P<.002	c	40.0mg 351.mg	1/50	9/50	8/50	5/50	
kid MXA	110.mg	Z P<.002		49.2mg 544.mg	3/50	2/50	6/50	6/50	kid:rab,rua. S
kid MXA	115.mg	Z P<.003		49.4mg 808.mg	4/50	2/50	6/50	6/50	kid:rab,rua,ruc. S
--- msm	172.mg	* P<.0005	c	85.8mg 469.mg	1/50	3/50	5/50	12/50	
stg MXA	352.mg	Z P<.0005	c	143.mg 1.14gm	0/50	0/50	0/50	7/50	stg:neb,nem.
stg nem	520.mg	Z P<.003		169.mg 3.58gm	0/50	0/50	0/50	4/50	S
stg neb	1.11gm	* P<.02		334.mg n.s.s.	0/50	0/50	0/50	3/50	S
liv MXA	1.64gm	* P<.05	c	488.mg n.s.s.	0/50	0/50	1/50	2/50	liv:hcc,hch.
liv hcc	2.80gm	* P<.2		685.mg n.s.s.	0/50	0/50	1/50	1/50	
liv hch	3.97gm	* P<.2		647.mg n.s.s.	0/50	0/50	0/50	1/50	
TBA MXB	19.1mg	Z P<.0005		11.4mg 43.0mg	48/50	48/50	48/50	49/50	
liv MXB	21.1mg	Z P<.0005		14.4mg 32.8mg	7/50	14/50	28/50	43/50	liv:hpa,hpb,hpc.
3959 R m f34 gav 24m24 TR491 with step					0	26.4mg	53.6mg	107.mg	
kid MXA	237.mg	* P<.004		124.mg 1.95gm	4/50	6/50	17/50	13/50	kid:rab,rua. S
kid MXA	263.mg	* P<.01	c	130.mg 15.1gm	5/50	6/50	17/50	13/50	kid:rab,rua,ruc.
3960 R m f34 gav 53w97 TR491a :					0	116.mg			
liv MXA	11.4mg	P<.0005	c	5.53mg 23.7mg	7/50	45/50			liv:hpa,hpc.
MXB MXB	11.7mg	P<.0005		5.77mg 24.4mg	9/50	45/50			---:msm; liv:hcc,hch,hpa,hpc; stg:neb,nem; sub:fib. C
liv hpc	15.8mg	P<.0005	c	6.89mg 34.2mg	2/50	36/50			
liv hpa	16.7mg	P<.0005	c	8.00mg 36.8mg	5/50	32/50			
kid MXA	27.2mg	P<.0005		8.27mg 138.mg	4/50	8/50			kid:rua,ruc. S
kid rua	27.3mg	P<.0005		8.21mg 137.mg	3/50	8/50			S
stg MXA	33.6mg	P<.0005	c	8.47mg 430.mg	0/50	4/50			stg:neb,nem.
liv MXA	54.0mg	P<.0005	c	15.6mg 155.mg	0/50	13/50			liv:hcc,hch.
liv hcc	65.2mg	P<.0005	c	16.2mg 298.mg	0/50	7/50			
mgl fba	86.3mg	P<.007		23.0mg 2.44gm	5/50	6/50			S
stg neb	98.7mg	P<.007		16.8mg 1.64gm	0/50	2/50			S
stg nem	100.mg	P<.008		16.9mg 2.04gm	0/50	2/50			S
sub fib	164.mg	P<.009	c	30.6mg 9.96gm	1/50	4/50			
liv hch	313.mg	P<.002	c	124.mg 1.27gm	0/50	6/50			
--- msm	364.mg	P<.02	c	127.mg n.s.s.	1/50	5/50			
TBA MXB	9.61mg	P<.0005		5.11mg 21.0mg	48/50	46/50			
liv MXB	11.4mg	P<.0005		5.53mg 23.7mg	7/50	45/50			liv:hpa,hpb,hpc.
3961 R m f34 gav 53w97 TR491a with step					0	116.mg			
kid rua	162.mg	P<.0005		86.7mg 485.mg	4/50	20/50			S
kid MXA	171.mg	P<.0005	c	88.8mg 620.mg	5/50	20/50			kid:rua,ruc.

METHYLGUANIDINE 471-29-4

3962 R m wis eat 68w68 1471					0	64.0mg			Matsukura;zkko,90,87-94;1977
liv hem e	84.0mg	P<.2		13.5mg n.s.s.	0/10	1/5			

7-METHYLGUANINE 578-76-7

3963 R b b46 ivj 25m29 1443					0	.565mg			Kruger;zkko,75,253-254;1971
tba mal	8.24mg	P<.2	-	2.03mg n.s.s.	0/20	2/30			

METHYLHYDRAZINE 60-34-4

3964 H f syg wat 86w86 194					0	13.6mg			Toth;canr,33,2744-2753;1973
liv mhs e	15.4mg	P<.0005	+	8.53mg 31.7mg	0/85	16/47			
cec mix e	25.8mg	P<.0005	+	11.7mg 93.3mg	1/67	9/39			
cec pla e	29.8mg	P<.002		12.9mg 132.mg	1/67	8/39			
liv mix e	30.8mg	P<.006		9.28mg 418.mg	0/39	3/16			
lun ang e	297.mg	P<.2	-	48.4mg n.s.s.	0/85	1/47			
3965 H m syg wat 23m23 194					0	12.0mg			
liv mhs e	9.20mg	P<.0005	+	5.72mg 16.0mg	0/72	27/48			
cec mix e	42.1mg	P<.004	+	17.1mg 359.mg	1/59	7/39			
cec pla e	50.7mg	P<.01		19.2mg 4.28gm	1/59	6/39			
lun tum e	no dre	P=1.		110.mg n.s.s.	0/87	0/48			
3966 M f swi wat 62w62 1117					0	20.0mg			Toth;ijcn,9,109-118;1972/1969a
lun ade es	19.6mg	P<.008		8.03mg 558.mg	12/107	12/39			
bil mix es	24.6mg	P<.003	+	10.6mg 119.mg	0/34	7/39			
bil cho es	29.2mg	P<.006		11.9mg 247.mg	0/34	6/39			
lun mix es	21.4mg	P<.02	+	8.30mg n.s.s.	14/107	12/39			
liv hpt es	51.1mg	P<.05	+	15.5mg n.s.s.	0/31	3/33			
3967 M m swi wat 69w69 1117					0	16.7mg			
liv mix es	4.58mg	P<.0005	+	1.43mg 24.5mg	0/45	4/6			
liv hpt es	7.25mg	P<.0005		2.10mg 52.8mg	0/45	3/6			
lun ade es	10.1mg	P<.0005		4.45mg 44.8mg	10/91	11/24			
bil mix es	22.5mg	P<.002	+	6.79mg 167.mg	0/64	3/15			

METHYLHYDRAZINE SULFATE 302-15-8

3968 M f swi gav 40w55 1095					0	10.4mg			Roe;natu,216,375-376;1967
lun tum	no dre	P=1.	-	10.8mg n.s.s.	8/85	1/25			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3969 M f swi wat 26m26 1117					0	2.00mg			Toth;ijcn,9,109-118;1972/1969a
lun mix e	2.98mg	P<.0005	+	1.58mg 8.60mg	14/88	23/45			
lun ade e	4.02mg	P<.0005		1.99mg 15.7mg	12/88	19/45			
lun adc e	5.63mg	P<.0005		2.78mg 16.3mg	2/88	12/45			
liv mix e	47.2mg	P<.5		8.16mg n.s.s.	3/88	3/45			
3970 M m swi wat 26m26 1117					0	1.67mg			
lun mix e	2.51mg	P<.0005	+	1.37mg 6.32mg	10/86	23/48			
lun ade e	2.93mg	P<.0005		1.54mg 8.52mg	10/86	21/48			
lun adc e	12.0mg	P<.002		4.57mg 57.4mg	0/86	5/48			
--- mly e	7.85mg	P<.02		3.12mg n.s.s.	2/55	8/43			
liv mix e	no dre	P=1.		7.98mg n.s.s.	2/41	2/41			
METHYLHYDROQUINONE 95-71-6									
3971 R m f3d eat 51w52 1950					0	588.mg			Hirose;canr,48,5310-5315;1988/pers.comm.
for tum	no dre	P=1.		455.mg n.s.s.	0/10	0/15			
stg tum	no dre	P=1.		455.mg n.s.s.	0/10	0/15			
2-METHYLIMIDAZOLE 693-98-1									
3972 M f b6c eat 24m24 TR516 :					0	81.3mg	163.mg	325.mg	
liv hpa	1.38gm	* P<.04	p	589.mg n.s.s.	3/50	4/49	6/49	10/50	
TBA MXB	729.mg	Z P<.3		201.mg n.s.s.	23/50	49/49	33/49	39/50	
liv MXB	1.62gm	* P<.08		626.mg n.s.s.	4/50	4/49	6/49	10/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		3.12gm n.s.s.	4/50	4/49	0/49	1/50	lun:a/a,a/c.
3973 M m b6c eat 24m24 TR516 :					0	75.0mg	150.mg	325.mg	
liv hpc	378.mg	Z P<.007		186.mg 6.01gm	4/50	8/50	14/50	(6/50)	S
MXB MXB	378.mg	* P<.004		189.mg 3.41gm	10/50	22/50	22/50	27/50	liv:hpa,hpc; thy:fca. P
thy fca	1.81gm	* P<.002	p	819.mg 7.08gm	0/50	1/50	0/50	7/50	
liv MXA	546.mg	* P<.04	p	231.mg n.s.s.	10/50	22/50	22/50	22/50	liv:hpa,hpc.
liv hpa	648.mg	* P<.02		289.mg n.s.s.	7/50	14/50	13/50	18/50	S
TBA MXB	866.mg	Z P<.5		180.mg n.s.s.	50/50	34/50	50/50	46/50	
liv MXB	546.mg	* P<.04		231.mg n.s.s.	10/50	22/50	22/50	22/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		863.mg n.s.s.	14/50	9/50	10/50	9/50	lun:a/a,a/c.
3974 R f f34 eat 24m24 TR516 :					0	50.0mg	125.mg	250.mg	
thy MXA	882.mg	* P<.0005	c	437.mg 3.20gm	1/50	1/50	1/50	11/50	thy:fca,fcc.
thy fcc	1.38gm	* P<.01	c	580.mg 149.gm	1/50	1/50	1/50	7/50	
thy fca	2.10gm	* P<.004	c	793.mg 13.8gm	0/50	0/50	0/50	5/50	
liv hpa	2.00gm	* P<.05	e	707.mg n.s.s.	1/50	0/50	2/50	4/50	
TBA MXB	131.mg	Z P<.2		47.5mg n.s.s.	48/50	45/50	49/50	(38/50)	
liv MXB	2.00gm	* P<.05		707.mg n.s.s.	1/50	0/50	2/50	4/50	liv:hpa,hpb,hpc.
3975 R m f34 eat 24m24 TR516 :					0	12.0mg	40.0mg	120.mg	
ski MXA	624.mg	* P<.04		233.mg n.s.s.	2/50	2/50	2/50	7/50	ski:bcc,ker,tri. S
liv MXA	663.mg	* P<.06	e	258.mg n.s.s.	0/50	1/50	3/50	3/50	liv:hpa,hpc.
thy MXA	854.mg	* P<.07	p	279.mg n.s.s.	1/50	2/50	1/50	5/50	thy:fca,fcc.
pni isa	1.01gm	* P<.02		350.mg n.s.s.	0/50	0/50	1/50	3/50	S
TBA MXB	303.mg	* P<.5		65.4mg n.s.s.	41/50	45/50	44/50	46/50	
liv MXB	663.mg	* P<.06		258.mg n.s.s.	0/50	1/50	3/50	3/50	liv:hpa,hpb,hpc.
1-METHYLNAPHTHALENE 90-12-0									
3976 M f b6c eat 81w81 2115					0	97.5mg	195.mg		Murata;faat,21,44-51;1993/pers.comm.
liv hpa	979.mg	* P<.02		399.mg n.s.s.	0/50	2/50	4/50		
liv hpc	6.04gm	* P<.3		983.mg n.s.s.	0/50	0/50	1/50		
lun a/a	no dre	P=1.		581.mg n.s.s.	4/50	2/50	4/50		
lun a/c	no dre	P=1.		1.12gm n.s.s.	1/50	0/50	1/50		
lun mix	no dre	P=1.		543.mg n.s.s.	5/50	2/50	5/50		
tba tum	no dre	P=1.		333.mg n.s.s.	14/50	7/50	13/50		
3977 M m b6c eat 81w81 2115					0	90.0mg	180.mg		
lun mix	201.mg	* P<.0005		116.mg 610.mg	2/50	13/50	15/50		
lun a/a	244.mg	* P<.003		133.mg 1.38gm	2/50	13/50	12/50		
lun a/c	1.83gm	* P<.05		555.mg n.s.s.	0/50	0/50	3/50		
liv hpc	no dre	P=1.		244.mg n.s.s.	11/50	6/50	(3/50)		
liv hpa	no dre	P=1.		1.31gm n.s.s.	9/50	1/50	1/50		
tba tum	2.26gm	* P<.9		170.mg n.s.s.	17/50	20/50	18/50		
2-METHYLNAPHTHALENE 91-57-6									
3978 M f b6c eat 81w81 2531					0	97.5mg	195.mg		Murata;faat,36,90-93;1997/1993/pers.comm.
lun mix e	4.01gm	* P<.8		414.mg n.s.s.	5/50	4/50	6/50		
liv hpa e	6.06gm	* P=1.		987.mg n.s.s.	0/50	1/50	0/50		
tba mix e	no dre	P=1.		290.mg n.s.s.	12/50	10/50	12/50		
3979 M m b6c eat 81w81 2531					0	90.0mg	180.mg		
lun mix e	205.mg	\ P<.02		88.0mg n.s.s.	2/50	10/50	(6/50)		
lun a/a e	735.mg	* P<.3		243.mg n.s.s.	2/50	9/50	5/50		
lun a/c e	2.78gm	* P<.3		683.mg n.s.s.	0/50	1/50	1/50		
liv hpc e	no dre	P=1.		524.mg n.s.s.	10/50	6/50	6/50		
liv hpa e	no dre	P=1.		1.05gm n.s.s.	9/50	2/50	2/50		
tba mix e	no dre	P=1.		379.mg n.s.s.	22/50	18/50	13/50		
METHYLNITRAMINE (N-nitromethylamine) 598-57-2									
3980 R f bdf gav 27m30 1931					0	5.43mg	10.9mg		Scherf;carc,10,1977-1981;1989/pers.comm.
spd nim a	28.7mg	* P<.006	+	10.8mg 271.mg	0/10	0/10	5/10		
spn nim a	39.8mg	* P<.3	+	13.7mg n.s.s.	0/10	3/10	1/10		
pnr nim a	171.mg	* P<1.	+	27.9mg n.s.s.	0/10	1/10	0/10		
3981 R m bdf gav 26m29 1931					0	5.43mg	10.9mg		
spd nim a	12.5mg	* P<.0005	+	5.72mg 39.8mg	0/10	2/10	7/10		
spn nim a	13.6mg	* P<.008	+	6.31mg 265.mg	0/10	5/10	4/10		
pnr nim a	50.1mg	* P<.3	+	15.1mg n.s.s.	0/10	2/10	1/10		

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf | Brkly Code
Path TD_{50} 2Tailpvl LoConf | Cntrl 1 Inc 2 Inc 3 Inc | NCI/NTPPathology

METHYLNITROSAMINO-N,N-DIMETHYLETHYLAMINE 23834-30-2

3982 H f syg gav 14m25 2111					0	5.38mg			Lijinsky;clet,63,101-107;1992
nac mix e	2.76mg	P<.0005	+	1.18mg 7.91mg	0/12	9/12			
lun a/a e	9.45mg	P<.02	+	3.22mg n.s.s.	0/12	4/12			
nac mal e	9.45mg	P<.02		3.22mg n.s.s.	0/12	4/12			
col mix e	21.0mg	P<.09		5.15mg n.s.s.	0/12	2/12			
liv hct e	44.0mg	P<.3		7.16mg n.s.s.	0/12	1/12			
3983 H m syg gav 14m25 2111					0	4.74mg			
nac mix e	6.25mg	P<.005	+	2.33mg 50.2mg	0/12	5/12			
liv hct e	11.7mg	P<.04	+	3.52mg n.s.s.	0/12	3/12			
nac mal e	38.7mg	P<.3		6.30mg n.s.s.	0/12	1/12			
col adc e	38.7mg	P<.3		6.30mg n.s.s.	0/12	1/12			
lun tum e	no dre	P=1.		12.2mg n.s.s.	0/12	0/12			

4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANOL 76014-81-8

3984 R m f34 wat 26m26 1866					0	.250mg			Rivenson;canr,48,6912-6917;1988/pers.comm.
lun mix	.103mg	P<.0005	+	56.5ug .199mg	6/80	26/30			
lun adc	.409mg	P<.0005		.203mg 1.07mg	2/80	12/30			
lun adq	.577mg	P<.0005		.265mg 1.76mg	1/80	9/30			
pae mix	.668mg	P<.0005	+	.294mg 2.29mg	1/80	8/30			
pae aod	1.09mg	P<.0005		.413mg 4.54mg	0/80	5/30			
amd tum	1.39mg	P<.002		.479mg 7.65mg	0/80	4/30			
lun ade	1.38mg	P<.04		.445mg n.s.s.	3/80	5/30			
pae ana	2.14mg	P<.05		.589mg n.s.s.	1/80	3/30			
liv hpt	5.86mg	P<.2		.954mg n.s.s.	0/80	1/30			
liv mix	7.25mg	P<.7		.712mg n.s.s.	6/80	3/30			
liv ade	no dre	P=1.		.935mg n.s.s.	6/80	2/30			

4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-(BUTANONE) (NNK) 64091-91-4

3985 H f syg wat 87w87 2209					0	.136mg	.409mg		Furukawa;clet,86,75-82;1994
liv hpc	5.13mg *	P<.3	-	.836mg n.s.s.	0/10	0/20	1/20		
lun mix	no dre	P=1.	-	.295mg n.s.s.	0/10	0/20	0/20		
pan adc	no dre	P=1.	-	.295mg n.s.s.	0/10	0/20	0/20		
pni isa	no dre	P=1.	-	.824mg n.s.s.	1/10	1/20	1/20		
3986 R m f34 wat 27m30 1866					0	25.0ug	50.0ug	.250mg	Rivenson;canr,48,6912-6917;1988/pers.comm.
lun mix	.182mg *	P<.0005	+	.123mg .297mg	6/80	9/80	20/80	27/30	
lun ade	.343mg Z	P<.002		.181mg 1.52mg	3/80	5/80	16/80	(2/30)	
pae mix	.490mg Z	P<.006	+	.241mg 5.70mg	1/80	5/80	9/80	(2/30)	
liv mix	.651mg *	P<.0005	+	.345mg 1.90mg	6/80	3/80	11/80	12/30	
lun adc	.672mg *	P<.0005		.375mg 1.53mg	2/80	3/80	4/80	13/30	
liv ade	.871mg *	P<.0005		.427mg 3.37mg	6/80	2/80	9/80	10/30	
lun adq	1.46mg Z	P<.0005		.677mg 4.26mg	1/80	0/80	0/80	9/30	
nas mix	1.66mg *	P<.0005		.751mg 5.90mg	0/80	1/80	2/80	5/30	
lun sqc	3.40mg *	P<.005		1.17mg 42.2mg	0/80	1/80	0/80	3/30	
--- mix	.140mg Z	P<.02		63.5ug n.s.s.	9/80	21/80	(10/80	2/30)	
liv hpt	2.74mg *	P<.03		1.04mg n.s.s.	0/80	1/80	2/80	2/30	
pae aod	6.93mg *	P<.08		1.70mg n.s.s.	0/80	0/80	1/80	1/30	
pae ana	29.2mg *	P<1.		.859mg n.s.s.	1/80	5/80	8/80	1/30	
3987 R m f34 wat 26m26 2232					0	.100mg			Hecht;cebp,5,645-652;1996
lun mix e	68.8ug	P<.0005	+	44.3ug .124mg	1/18	39/56			
lun adc e	.148mg	P<.0005	+	89.4ug .304mg	0/18	23/56			
lun ade e	.279mg	P<.03		.138mg n.s.s.	1/18	16/56			
pae mal e	.975mg	P<.2		.337mg n.s.s.	0/16	4/52			
liv mix e	2.97mg	P<.8		.364mg n.s.s.	1/15	5/55			
pae ana e	no dre	P=1.		.951mg n.s.s.	3/16	1/52			
pae mix e	no dre	P=1.		.463mg n.s.s.	3/16	5/52			

(N-6)-(METHYLNITROSO)ADENINE ---

3988 M f scd wat 24m24 1255					0	20.6mg			Anderson;ijcn,24,319-322;1979
liv mix	63.2mg	P<.2		19.8mg n.s.s.	1/16	5/20			
lun tum	909.mg	P<1.		28.5mg n.s.s.	3/16	4/20			
3989 M m scd wat 24m24 1255					0	17.1mg			
lun tum	18.0mg	P<.02	+	7.37mg n.s.s.	4/21	11/19			
liv mix	62.6mg	P<.4		13.8mg n.s.s.	5/21	7/19			

(N-6)-(METHYLNITROSO)ADENOSINE 21928-82-5

3990 M f scd wat 24m24 1255					0	35.7mg			Anderson;ijcn,24,319-322;1979
rep mix	15.8mg	P<.0005	+	7.88mg 38.3mg	1/16	16/20			
lun tum	17.4mg	P<.0005	+	8.22mg 58.0mg	3/16	16/20			
mgl car	28.7mg	P<.0005	+	13.7mg 101.mg	1/16	12/20			
ute tum	84.9mg	P<.02	+	32.1mg n.s.s.	0/16	5/20			
liv mix	no dre	P=1.		89.9mg n.s.s.	1/16	1/20			
3991 M m scd wat 24m24 1255					0	29.7mg			
lun tum	21.6mg	P<.002	+	9.65mg 115.mg	4/21	13/19			
liv mix	no dre	P=1.		54.0mg n.s.s.	5/21	3/19			

METHYLNITROSOCYANAMIDE 33868-17-6

3992 R f sda wat 60w95 1733					0	.573mg	1.08mg	2.23mg 4.39mg	Endo;pjpa,50,497-502;1974/pers.comm.
for mix er	.480mg *	P<.0005	+	.283mg .828mg	0/9	2/12	12/15	15/15 14/14	
for car er	1.17mg *	P<.0005	+	.713mg 2.02mg	0/9	0/12	5/15	12/15 13/14	

N-METHYLOLACRYLAMIDE (N-(hydroxymethyl)-acrylamide) 924-42-5

3993 M f b6c gav 24m24 TR352 :					0	17.5mg	35.0mg		
MXB MXB	27.8mg *	P<.0005		15.8mg 89.4mg	14/50	20/50	37/50		hag:ade,anb; liv:hpa; lun:a/a,a/c; ova:gcb. C
hag MXA	44.6mg *	P<.0005		25.3mg 141.mg	5/50	11/50	22/50		hag:ade,anb,car. S
hag MXA	55.5mg *	P<.002	c	29.9mg 222.mg	5/50	8/50	20/50		hag:ade,anb.
liv hpa	66.9mg /	P<.0005	c	35.6mg 241.mg	3/50	4/50	17/50		
liv MXA	74.8mg *	P<.009		35.7mg 2.08gm	6/50	7/50	17/50		liv:hpa,hpc. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
ova gcb	119.mg * P<.006	c	58.1mg 996.mg	0/50	5/50	5/50			
lun MXA	111.mg * P<.06	c	45.2mg n.s.s.	6/50	8/50	13/50		lun:a/a,a/c.	
TBA MXB	30.9mg * P<.03		13.9mg n.s.s.	33/50	41/50	47/50			
liv MXB	74.8mg * P<.009		35.7mg 2.08gm	6/50	7/50	17/50		liv:hpa,hpc,nnd.	
lun MXB	111.mg * P<.06		45.2mg n.s.s.	6/50	8/50	13/50		lun:a/a,a/c.	
3994 M m b6c gav 24m24 TR352 :				0	17.5mg	35.0mg			
MXB MXB	13.3mg * P<.0005		8.07mg 32.0mg	16/50	30/50	43/50		hag:ade; liv:hpa,hpc; lun:a/a,a/c.	C
hag MXA	17.4mg * P<.0005		11.4mg 30.6mg	2/50	14/50	30/50		hag:ade,car.	S
hag ade	17.5mg * P<.0005	c	11.7mg 29.4mg	1/50	14/50	29/50			
liv MXA	29.4mg * P<.003	c	15.2mg 186.mg	12/50	17/50	26/50		liv:hpa,hpc.	
lun MXA	38.5mg * P<.002	c	20.4mg 163.mg	5/50	10/50	18/50		lun:a/a,a/c.	
liv hpa	50.2mg / P<.008		23.3mg 1.15gm	8/50	4/50	19/50			S
lun a/a	66.0mg * P<.009		30.7mg 2.27gm	3/50	6/50	11/50			S
lun a/c	75.1mg * P<.006		35.1mg 897.mg	2/50	4/50	10/50			S
liv hpc	63.4mg * P<.05		27.1mg n.s.s.	6/50	13/50	12/50			S
TBA MXB	22.3mg * P<.02		10.2mg n.s.s.	35/50	39/50	47/50			
liv MXB	29.4mg * P<.003		15.2mg 186.mg	12/50	17/50	26/50		liv:hpa,hpc,nnd.	
lun MXB	38.5mg * P<.002		20.4mg 163.mg	5/50	10/50	18/50		lun:a/a,a/c.	
3995 R f f34 gav 24m24 TR352 :				0	4.20mg	8.41mg			
TBA MXB	no dre P=1.	-	6.33mg n.s.s.	45/50	36/50	42/50			
liv MXB	no dre P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.	
3996 R m f34 gav 24m24 TR352 :				0	4.20mg	8.41mg			
ski ker #	13.0mg \ P<.03	-	4.72mg n.s.s.	1/50	6/50	(3/50)			S
TBA MXB	3.12gm * P<1.		5.39mg n.s.s.	45/50	40/50	45/50			
liv MXB	no dre P=1.		11.0mg n.s.s.	4/50	2/50	(0/50)		liv:hpa,hpc,nnd.	

METHYLPHENIDATE.HCl (ritalin) 298-59-9

3997 M f b6c eat 24m24 TR439 :				0	6.41mg	32.2mg	64.4mg		
liv hpa	91.6mg * P<.002	p	48.4mg 380.mg	6/49	10/50	10/50	28/50		
liv MXA	97.0mg * P<.003	p	49.0mg 607.mg	9/49	11/50	11/50	30/50	liv:hpa,hpc.	
lun MXA	256.mg * P<.02		119.mg n.s.s.	1/49	1/50	6/50	7/50	lun:a/a,a/c.	S
lun a/a	349.mg * P<.03		144.mg n.s.s.	1/49	1/50	4/50	6/50		S
TBA MXB	6.67gm * P<1.		55.9mg n.s.s.	34/49	35/50	40/50	41/50		
liv MXB	97.0mg * P<.003		49.0mg 607.mg	9/49	11/50	11/50	30/50	liv:hpa,hpb,hpc.	
lun MXB	256.mg * P<.02		119.mg n.s.s.	1/49	1/50	6/50	7/50	lun:a/a,a/c.	
3998 M m b6c eat 24m24 TR439 :				0	5.90mg	29.6mg	59.5mg		
liv hpb	376.mg * P<.008	p	162.mg 8.06gm	0/50	1/50	1/50	5/50		
liv MXA	110.mg * P<.06	p	43.9mg n.s.s.	24/50	23/50	26/50	34/50	liv:hpa,hpc.	
liv MXA	110.mg * P<.06	p	43.9mg n.s.s.	24/50	23/50	26/50	34/50	liv:hpa,hpb,hpc.	
liv hpa	126.mg * P<.05	p	51.5mg n.s.s.	18/50	18/50	16/50	29/50		
liv MXA	236.mg * P<.2	p	78.4mg n.s.s.	10/50	10/50	18/50	14/50	liv:hpb,hpc.	
TBA MXB	187.mg * P<.5		43.7mg n.s.s.	41/50	35/50	33/50	43/50		
liv MXB	110.mg * P<.06		43.9mg n.s.s.	24/50	23/50	26/50	34/50	liv:hpa,hpb,hpc.	
lun MXB	no dre P=1.		269.mg n.s.s.	16/50	10/50	9/50	6/50	lun:a/a,a/c.	
3999 R f f34 eat 24m24 TR439 :				0	4.93mg	24.7mg	49.6mg		
TBA MXB	no dre P=1.	-	58.6mg n.s.s.	46/50	47/50	45/50	43/50		
liv MXB	no dre P=1.		483.mg n.s.s.	0/50	1/50	0/50	0/50	liv:hpa,hpb,hpc.	
4000 R m f34 eat 24m24 TR439 :				0	3.97mg	19.9mg	39.9mg		
TBA MXB	no dre P=1.	-	37.3mg n.s.s.	43/50	36/50	36/50	41/51		
liv MXB	no dre P=1.		369.mg n.s.s.	0/50	2/50	0/50	0/51	liv:hpa,hpb,hpc.	

6-METHYLQUINOLINE 91-62-3

4001 R f f34 eat 24m24 1529				0	25.0mg			Fukushima;clet,14,115-123;1981	
liv hnd e	230.mg P<.4	-	52.6mg n.s.s.	3/44	5/37				
4002 R m f34 eat 24m24 1529				0	20.0mg				
liv hnd e	123.mg P<.03	-	42.5mg n.s.s.	0/31	4/38				

8-METHYLQUINOLINE 611-32-5

4003 R f f34 eat 24m24 1529				0	25.0mg			Fukushima;clet,14,115-123;1981	
liv hnd e	no dre P=1.	-	175.mg n.s.s.	3/44	0/34				
4004 R m f34 eat 24m24 1529				0	20.0mg				
liv hnd e	no dre P=1.	-	78.3mg n.s.s.	0/31	0/19				

p-METHYLSTYRENE 622-97-9

4005 M f swi gav 78w83 BT107				0	6.71mg	33.6mg	168.mg	Conti;anya,534,203-234;1988	
lun ade	616.mg * P<.2	-	200.mg n.s.s.	13/60	5/60	10/60	15/60		
liv hpt	no dre P=1.	-	42.6mg n.s.s.	0/60	0/60	0/60	0/60		
tba mix	343.mg * P<.2	-	104.mg n.s.s.	33/60	18/60	33/60	33/60		
tba mal	no dre P=1.	-	343.mg n.s.s.	19/60	10/60	20/60	13/60		
4006 M m swi gav 78w83 BT107				0	6.71mg	33.6mg	168.mg		
lun ade	962.mg * P<.3	-	262.mg n.s.s.	7/60	5/60	7/60	10/60		
liv hpt	no dre P=1.	-	793.mg n.s.s.	5/60	4/60	6/60	2/60		
tba mal	no dre P=1.	-	583.mg n.s.s.	12/60	7/60	9/60	6/60		
tba mix	no dre P=1.	-	320.mg n.s.s.	20/60	14/60	18/60	15/60		

METHYLTHIOURACIL 56-04-2

4007 H f nss wat 52w52 1385				0	273.mg			Christov;zkko,77,171-179;1972	
thy mix ekr	53.4mg P<.006	+	22.1mg 507.mg	0/6	7/12				
4008 M b cfi eat 51w78 1630				0	375.mg			Jemec;canc,40,2188-2202;1977	
liv hpt erv	1.37gm P<.3		337.mg n.s.s.	0/9	2/20				
thy tum erv	no dre P=1.		869.mg n.s.s.	0/9	0/20				

METIAPINE 5800-19-1

4009 R f alb eat 78w78 200				0	3.00mg	10.0mg	30.0mg	Gibson;txap,25,220-229;1973	
mgl fba e	no dre P=1.	-	38.9mg n.s.s.	1/22	6/20	1/21	2/20		
4010 R m alb eat 78w78 200				0	3.00mg	10.0mg	30.0mg		
pit ade e	no dre P=1.	-	8.00mg n.s.s.	3/18	7/20	3/19	(0/20)		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
METIRAM, TECHNICAL GRADE (WITH 2% ADDED ETHYLENETHIOUREA)				9006-42-2					
4011 M f cfl eat 92w94 2636				0	13.0mg	39.0mg	130.mg		Charles;faat,54,481-492;2000
liv hpa ae	1.73gm	* P<.05	- 524.mg n.s.s.	0/52	0/52	1/51	2/52		
lun adc ae	6.49gm	* P<.9	- 355.mg n.s.s.	4/52	5/52	6/51	5/52		
liv hpc ae	12.6gm	* P<1.	- 377.mg n.s.s.	2/52	6/52	5/51	4/52		
lun ade ae	no dre	P=1.	- 307.mg n.s.s.	7/52	7/52	12/51	7/52		
tba mix ae	no dre	P=1.	- 112.mg n.s.s.	32/52	32/52	36/51	32/52		
4012 M m cfl eat 96w96 2636				0	12.0mg	36.0mg	120.mg		
liv hpa e	420.mg	* P<.01	- 181.mg 30.3gm	3/51	4/52	4/51	11/52		
lun ade e	932.mg	* P<.5	- 175.mg n.s.s.	9/51	14/52	14/51	14/52		
liv hpc e	3.70gm	* P<1.	- 139.mg n.s.s.	21/51	29/52	23/51	25/52		
lun adc e	no dre	P=1.	- 351.mg n.s.s.	14/51	13/52	14/51	10/52		
tba mix e	no dre	P=1.	- 106.mg n.s.s.	49/51	46/52	39/51	43/52		
4013 R f cdr eat 26m26 2636				0	.250mg	1.00mg	4.00mg	16.0mg	
pit ade e	27.9mg	* P<.1	- 9.74mg n.s.s.	29/50	32/50	31/50	39/50	37/50	
liv hpc e	1.19gm	* P<.5	- 149.mg n.s.s.	0/50	1/50	0/50	0/50	1/50	
liv hpa e	no dre	P=1.	- 165.mg n.s.s.	3/50	1/50	1/50	0/50	1/50	
4014 R m cdr eat 28m28 2636				0	.200mg	.800mg	3.20mg	12.8mg	
liv hpc e	1.08gm	* P<.5	- 135.mg n.s.s.	0/50	1/50	0/50	0/50	1/50	
liv hpa e	no dre	P=1.	- 149.mg n.s.s.	2/50	0/50	0/50	2/50	0/50	
pit ade e	no dre	P=1.	- 28.8mg n.s.s.	17/50	19/50	27/50	22/50	20/50	
METRONIDAZOLE 443-48-1									
4015 M f swi eat 28m30 201				0	78.0mg	195.mg	390.mg	650.mg	Rustia;jnci,48,721-729;1972
lun mix e	937.mg	* P<.0005	+ 498.mg 3.54gm	14/65	4/10	10/20	14/19	16/32	
--- mly e	1.30gm	* P<.002	+ 654.mg 6.48gm	16/68	3/10	5/20	10/19	18/34	
liv mix e	24.2gm	* P<.6	- 3.34gm n.s.s.	2/53	0/10	0/18	2/19	1/25	
4016 M m swi eat 27m29 201				0	72.0mg	180.mg	360.mg	600.mg	
lun mix e	347.mg	* P<.0005	+ 217.mg 635.mg	13/67	3/8	11/15	12/16	27/34	
liv mix e	20.7gm	* P<.8	- 2.06gm n.s.s.	6/64	0/8	3/14	3/16	3/32	
4017 R f sda eat 66w75 200a				0	59.4mg				Cohen;jnci,51,403-417;1973
ute amy e	180.mg	P<.004	- 62.0mg 1.27gm	0/71	4/36				
liv tum e	no dre	P=1.	229.mg n.s.s.	0/71	0/36				
tba mix e	61.1mg	P<.03	- 24.3mg n.s.s.	18/71	17/36				
4018 R f smw eat 34m35 1064				0	30.0mg	150.mg	300.mg		Rustia;jnci,63,863-868;1979
mgl fba ae	431.mg	* P<.0005	+ 231.mg 1.25gm	30/95	17/29	14/28	23/29		
mgl mix ae	446.mg	* P<.0005	+ 232.mg 1.46gm	34/95	17/29	15/28	23/29		
liv hpc ae	1.86gm	* P<.0005	+ 842.mg 5.46gm	0/58	0/28	1/21	7/25		
sub mix a	4.05gm	* P<.03	1.54gm n.s.s.	0/100	1/30	3/30	1/30		
ute mix a	2.97gm	* P<.2	- 855.mg n.s.s.	13/100	9/30	8/30	7/30		
pit mix a	no dre	P=1.	- 761.mg n.s.s.	61/100	24/30	19/30	17/30		
tba mix a	139.mg	* P<.0005	53.2mg 720.mg	80/100	27/30	28/30	30/30		
4019 R m smw eat 33m33 1064				0	24.0mg	120.mg	240.mg		
pit mix a	731.mg	* P<.004	+ 338.mg 6.36gm	20/100	11/30	10/30	15/30		
tes mix a	993.mg	* P<.01	+ 424.mg 178.gm	18/100	9/30	6/30	14/30		
sub mix a	2.36gm	* P<.06	816.mg n.s.s.	5/100	2/30	5/30	4/30		
mgl fba a	2.49gm	Z P<.02	989.mg n.s.s.	0/100	2/30	1/30	3/30		
liv hpc a	45.9gm	* P<.8	2.70gm n.s.s.	2/100	0/30	0/30	1/30		
tba mix a	211.mg	* P<.0005	112.mg 592.mg	47/100	22/30	21/30	27/30		
MEXACARBATE (zectran) 315-18-4									
4020 M f b6c eat 78w92 TR147 :				0	7.50mg	14.9mg			
TBA MXB v	no dre	P=1.	- 11.2mg n.s.s.	5/20	16/50	(13/50)			
liv MXB v	no dre	P=1.	57.7mg n.s.s.	1/20	1/50	3/50			liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	28.4mg n.s.s.	1/20	2/50	(1/50)			lun:a/a,a/c.
4021 M f b6c orl 76w76 1102				0	1.56mg				Innes;ntis,1968/1969
lun ade evx	2.93mg	P<.04	.885mg n.s.s.	0/16	3/17				
liv hpt evx	no dre	P=1.	2.91mg n.s.s.	0/16	0/17				
tba mix evx	2.12mg	P<.02	.729mg n.s.s.	0/16	4/17				
4022 M m b6c eat 78w91 TR147 :				0	33.6mg	66.0mg			
liv MXA esv#	76.4mg	* P<.03	- 45.5mg n.s.s.	0/20	6/50	15/50			liv:hpa,hpc. S
liv hpc esv	85.5mg	* P<.02	49.8mg n.s.s.	0/20	4/50	15/50			S
TBA MXB esv	53.2mg	* P<.3	20.2mg n.s.s.	0/20	24/50	28/50			
liv MXB esv	76.4mg	* P<.03	45.5mg n.s.s.	0/20	6/50	15/50			liv:hpa,hpc,nnd.
lun MXB esv	391.mg	* P<.6	109.mg n.s.s.	0/20	3/50	4/50			lun:a/a,a/c.
4023 M m b6c eat 78w90 TR147 : pool				0	33.6mg	66.0mg			
sub fbs esv#	137.mg	* P<.05	- 72.2mg n.s.s.	0/40	6/50	7/50			S
ski fib esv	242.mg	* P<.03	105.mg n.s.s.	0/40	1/50	6/50			S
4024 M m b6c orl 76w76 1102				0	1.45mg				Innes;ntis,1968/1969
liv hpt evx	1.42mg	P<.006	.533mg 14.0mg	0/16	5/16				
lun ade evx	1.84mg	P<.02	.633mg n.s.s.	0/16	4/16				
tba mix evx	.642mg	P<.0005	.293mg 1.80mg	0/16	9/16				
4025 M f b6a orl 76w76 1102				0	1.56mg				
liv hpt evx	no dre	P=1.	2.91mg n.s.s.	0/17	0/17				
lun ade evx	no dre	P=1.	2.91mg n.s.s.	1/17	0/17				
tba mix evx	no dre	P=1.	1.93mg n.s.s.	2/17	1/17				
4026 M m b6a orl 76w76 1102				0	1.45mg				
liv hpt evx	7.80mg	P<.6	1.14mg n.s.s.	1/18	2/17				
lun ade evx	no dre	P=1.	1.78mg n.s.s.	2/18	1/17				
tba mix evx	44.8mg	P<1.	1.06mg n.s.s.	3/18	3/17				
4027 R f osm eat 18m26 TR147 :				0	11.9mg	23.6mg			
TBA MXB v	no dre	P=1.	- 23.7mg n.s.s.	12/20	33/50	28/50			
liv MXB v	1.06gm	* P<.4	173.mg n.s.s.	0/20	0/50	1/50			liv:hpa,hpc,nnd.
4028 R m osm eat 18m26 TR147 :				0	5.80mg	11.8mg			
TBA MXB v	24.7mg	\ P<.8	- 3.26mg n.s.s.	6/20	21/50	(16/50)			
liv MXB v	no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50			liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
MICHLER'S KETONE 90-94-8									
4029 M f b6c eat 78w91 TR181 :				0	139.mg	278.mg			
liv MXA	53.0mg *	P<.0005 c	40.5mg 77.0mg	0/20	41/50	49/50			liv:hpa,hpc.
liv hpc	111.mg /	P<.0005 c	79.2mg 168.mg	0/20	16/50	38/50			
TBA MXB	69.1mg *	P<.0005	45.6mg 159.mg	4/20	43/50	49/50			
liv MXB	53.0mg *	P<.0005	40.5mg 77.0mg	0/20	41/50	49/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50			lun:a/a,a/c.
4030 M m b6c eat 78w91 TR181 :				0	128.mg	257.mg			
--- MXA	203.mg /	P<.0005 c	126.mg 349.mg	0/20	5/50	23/50			---:hem,hes.
--- hes	233.mg /	P<.0005 c	141.mg 425.mg	0/20	5/50	20/50			
MXA MXA	753.mg *	P<.008	331.mg 13.1gm	0/20	2/50	6/50			ski:fbs; sub:fbs,srn. S
TBA MXB	99.3mg /	P<.0005	63.1mg 207.mg	7/20	21/50	39/50			
liv MXB	459.mg *	P<.07	183.mg n.s.s.	3/20	8/50	9/50			liv:hpa,hpc,nnd.
lun MXB	1.14gm /	P<.3	310.mg n.s.s.	2/20	2/50	4/50			lun:a/a,a/c.
4031 R f f34 eat 18m25 TR181 :				0	18.0mg	37.0mg			
liv MXA	4.87mg /	P<.0005 c	3.53mg 6.86mg	0/20	46/50	48/50			liv:hpc,nnd.
liv hpc	5.47mg /	P<.0005 c	3.93mg 7.81mg	0/20	41/50	44/50			
TBA MXB	5.97mg /	P<.0005	4.06mg 10.1mg	7/20	47/50	48/50			
liv MXB	4.87mg /	P<.0005	3.53mg 6.86mg	0/20	46/50	48/50			liv:hpa,hpc,nnd.
4032 R m f34 eat 18m25 TR181 :				0	7.40mg	14.4mg			
liv MXA	6.69mg /	P<.0005 c	4.85mg 9.78mg	0/20	17/50	43/50			liv:hpc,nnd.
liv hpc	8.86mg /	P<.0005 c	6.24mg 13.3mg	0/20	9/50	40/50			
TBA MXB	7.29mg /	P<.0005	4.74mg 16.3mg	5/20	26/50	48/50			
liv MXB	6.69mg /	P<.0005	4.85mg 9.78mg	0/20	17/50	43/50			liv:hpa,hpc,nnd.
MIREX (1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-1,3,4-metheno-1H-cyclobuta[cd]pentalene) 2385-85-5									
4033 M f b6a orl 68w68 202				0	3.67mg				Innes;ntis,1968/1969
liv hpt evx	1.10mg	P<.0005 +	.512mg 2.89mg	0/17	10/16				
lun ade evx	no dre	P=1.	5.18mg n.s.s.	1/17	0/16				
tba mix evx	1.26mg	P<.003	.540mg 7.45mg	2/17	10/16				
4034 M m b6a orl 58w58 202				0	3.48mg				
liv hpt evx	2.13mg	P<.04 +	.718mg n.s.s.	1/18	5/15				
lun ade evx	no dre	P=1.	3.34mg n.s.s.	2/18	0/15				
tba mix evx	3.32mg	P<.3	.797mg n.s.s.	3/18	5/15				
4035 M f b6c orl 69w69 202				0	3.67mg				
liv hpt evx	1.60mg	P<.0005	.705mg 4.95mg	0/16	8/16				
lun mix evx	no dre	P=1.	5.32mg n.s.s.	0/16	0/16				
tba mix evx	1.60mg	P<.0005	.705mg 4.95mg	0/16	8/16				
4036 M m b6c orl 58w58 202				0	3.48mg				
liv mix evx	1.50mg	P<.002	.641mg 6.13mg	0/16	7/18				
liv hpt evx	1.83mg	P<.004	.738mg 11.2mg	0/16	6/18				
lun mix evx	no dre	P=1.	4.01mg n.s.s.	0/16	0/18				
tba mix evx	1.50mg	P<.002	.641mg 6.13mg	0/16	7/18				
4037 R f f34 eat 24m25 TR313 :				0	4.77ug	47.9ug	.481mg	1.21mg	2.41mg
MXA mnl	5.97mg *	P<.02 c	2.69mg n.s.s.	8/52	8/52	11/52	14/52	18/52	18/52	mul:mnl; spl:mnl.
TBA MXB	22.4mg *	P<.9	1.75mg n.s.s.	48/52	48/52	49/52	47/52	50/52	49/52	
liv MXB	16.5mg *	P<.3	4.54mg n.s.s.	10/52	5/52	4/52	5/52	10/52	9/52	liv:hpa,hpc,nnd.
4038 R f f34 eat 24m24 TR313a :				0	2.45mg	4.95mg			
liv MXA	3.17mg *	P<.0005 c	2.17mg 5.50mg	2/52	23/52	31/52			liv:hpc,nnd.
liv nnd	3.22mg *	P<.0005 c	2.19mg 5.67mg	2/52	23/52	30/52			
MXB MXB	3.34mg *	P<.0005	2.11mg 7.24mg	8/52	25/52	37/52			liv:hpc,nnd; mul:mnl; spl:mnl. C
MXA mnl	15.7mg *	P<.05 c	6.61mg n.s.s.	6/52	9/52	14/52			mul:mnl; spl:mnl.
TBA MXB	21.9mg *	P<.7	2.93mg n.s.s.	49/52	47/52	48/52			
liv MXB	3.17mg *	P<.0005	2.17mg 5.50mg	2/52	23/52	31/52			liv:hpa,hpc,nnd.
4039 R m f34 eat 24m24 TR313 :				0	3.89ug	39.1ug	.392mg	1.00mg	1.96mg
MXB MXB	.669mg *	P<.0005	.443mg 1.14mg	16/52	11/52	17/52	23/52	27/52	37/52	adr:phe,phm; k/p:tpp; liv:hpc, nnd. C
tes ict	.708mg *	P<.0005	.392mg 2.25mg	50/52	51/52	43/52	48/52	39/52	42/52	S
liv MXA	.825mg *	P<.0005 c	.545mg 1.39mg	6/52	5/52	6/52	15/52	16/52	28/52	liv:hpc,nnd.
liv nnd	.870mg *	P<.0005 c	.574mg 1.47mg	3/52	5/52	5/52	14/52	15/52	26/52	
adr MXA	1.43mg *	P<.0005 c	.840mg 3.18mg	10/52	7/52	13/52	12/52	18/52	20/52	adr:phe,phm.
liv hpc	7.09mg *	P<.009	2.70mg 356.mg	3/52	0/52	2/52	2/52	3/52	4/52	S
thy MXA	10.4mg *	P<.003	3.67mg 100.mg	0/52	1/52	0/52	1/52	0/52	4/52	thy:fca,fcc. S
thy fca	12.7mg *	P<.003	4.33mg 88.7mg	0/52	0/52	0/52	1/52	0/52	3/52	S
k/p tpp	13.5mg *	P<.002 c	4.58mg 72.4mg	0/52	0/52	0/52	0/52	1/52	3/52	
TBA MXB	.618mg *	P<.0005	.374mg 1.39mg	45/52	46/52	40/52	45/52	48/52	45/52	
liv MXB	.825mg *	P<.0005	.545mg 1.39mg	6/52	5/52	6/52	15/52	16/52	28/52	liv:hpa,hpc,nnd.
4040 R m sda eat 91w91 1160				0	40.0ug	.200mg			Chu;txap,59,268-278;1981
liv nnd	no dre	P=1.	52.6ug n.s.s.	0/10	0/10	0/10			
MIREX, PHOTO- 39801-14-4									
4041 R m sda eat 91w91 1160				0	8.00ug	40.0ug	.200mg	1.00mg	Chu;txap,59,268-278;1981
thy ade	1.46mg *	P<.007 +	.474mg 28.7mg	1/10	0/10	0/10	0/10	4/10	
liv nnd	6.68mg *	P<.5	1.06mg n.s.s.	0/10	1/10	0/10	1/10	1/10	
MISOPROSTOL 59122-46-2									
4042 M f cd1 gav 91w91 1841				0	.160mg	1.60mg	16.0mg		Port;txpy,15,134-142;1987/pers.comm.
lun ala e	2.35gm *	P<.9 -	106.mg n.s.s.	1/64	1/64	0/64	1/64		
liv hpa e	no dre	P=1. -	110.mg n.s.s.	0/64	3/64	0/64	1/64		
liv hem e	no dre	P=1. -	176.mg n.s.s.	2/64	2/64	0/64	0/64		
lun alc e	no dre	P=1. -	96.2mg n.s.s.	0/64	2/64	2/64	1/64		
tba mix e	.130mg Z	P<.0005 -	69.7ug .481mg	22/64	42/64	(21/64	18/64)		
4043 M m cd1 gav 91w91 1841				0	.160mg	1.60mg	16.0mg		
liv hpa e	no dre	P=1. -	5.97mg n.s.s.	15/64	11/64	9/64	(2/64)		
liv hpc e	no dre	P=1. -	109.mg n.s.s.	2/64	1/64	1/64	1/64		
lun ala e	no dre	P=1. -	148.mg n.s.s.	0/64	1/64	1/64	0/64		
lun alc e	no dre	P=1. -	167.mg n.s.s.	2/64	4/64	1/64	0/64		
liv hem e	no dre	P=1. -	176.mg n.s.s.	1/64	1/64	0/64	0/64		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix e	no dre	P=1.	-	2.86mg n.s.s.	34/64	27/64	27/64	(15/64)	
4044 R f cdr gav 24m24 1840					0	24.0ug	.240mg	2.40mg	Dodd;txpy,15,125-133;1987/pers.comm.
liv hcs e	9.53gm *	P<1.	-	18.1mg n.s.s.	0/60	2/60	1/59	1/60	
liv hpc e	no dre	P=1.	-	22.4mg n.s.s.	0/60	0/60	1/59	0/60	
mgl fba e	no dre	P=1.	-	5.70mg n.s.s.	23/60	27/60	37/59	24/60	
tba mix e	no dre	P=1.	-	2.28mg n.s.s.	56/60	58/60	54/59	52/60	
4045 R m cdr gav 24m24 1840					0	24.0ug	.240mg	2.40mg	
liv hcs e	no dre	P=1.	-	18.8mg n.s.s.	2/60	0/60	1/60	1/60	
tba mix e	no dre	P=1.	-	.350mg n.s.s.	47/60	49/60	42/60	(24/60)	
MITOMYCIN-C 50-07-7									
4046 R f cdr ipj 26w78 1336					0	5.40ug			Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.
per sar e	981.ng	P<.0005	+	516.ng 1.95ug	0/182	22/25			
liv tum e	no dre	P=1.		15.6ug n.s.s.	0/182	0/25			
tba mal e	1.13ug	P<.0005		553.ng 2.67ug	44/182	22/25			
tba mix e	1.23ug	P<.0005		490.ng 5.41ug	103/182	23/25			
tba ben e	no dre	P=1.		13.8ug n.s.s.	59/182	1/25			
4047 R m cdr ipj 26w63 1336					0	6.65ug			
per sar e	1.07ug	P<.0005	+	575.ng 2.16ug	0/177	19/24			
liv lys e	39.3ug	P<.04		6.40ug n.s.s.	0/177	1/24			
tba mal e	732.ng	P<.0005		346.ng 1.66ug	32/177	22/24			
tba mix e	805.ng	P<.0005		361.ng 2.11ug	59/177	22/24			
tba ben e	no dre	P=1.		12.1ug n.s.s.	27/177	0/24			
MOLYBDENUM TRIOXIDE 1313-27-5									
4048 M f b6c inh 24m24 TR462 :					0	3.15mg	9.44mg	31.5mg	
lun MXA	68.3mg *	P<.02	p	29.9mg n.s.s.	3/50	6/50	8/50	15/50	lun:a/a,a/c.
lun a/a	97.8mg *	P<.06	p	36.5mg n.s.s.	1/50	4/50	8/50	9/50	
sub sar	162.mg *	P<.05		64.7mg n.s.s.	0/50	1/50	3/50	4/50	S
TBA MXB	no dre	P=1.		32.8mg n.s.s.	40/50	39/50	43/50	40/50	
liv MXB	4.45gm *	P<1.		33.4mg n.s.s.	23/50	22/50	25/50	27/50	liv:hpa,hpb,hpc.
lun MXB	68.3mg *	P<.02		29.9mg n.s.s.	3/50	6/50	8/50	15/50	lun:a/a,a/c.
4049 M m b6c inh 24m24 TR462 :					0	2.62mg	7.87mg	26.2mg	
lun MXA	3.21mg Z	P<.007	p	1.52mg 51.2mg	11/50	27/50	(21/50	18/50)	lun:a/a,a/c.
lun a/c	4.15mg Z	P<.0005	p	2.13mg 14.5mg	2/50	16/50	(14/50	10/50)	
liv hpc	14.8mg Z	P<.04		6.23mg n.s.s.	12/50	18/50	21/50	(13/50)	S
TBA MXB	no dre	P=1.		22.2mg n.s.s.	40/50	44/50	45/50	42/50	
liv MXB	11.7mg Z	P<.1		4.28mg n.s.s.	30/50	27/50	34/50	(28/50)	liv:hpa,hpb,hpc.
lun MXB	3.21mg Z	P<.007		1.52mg 51.2mg	11/50	27/50	(21/50	18/50)	lun:a/a,a/c.
4050 R f f34 inh 24m24 TR462 :					0	.749mg	2.25mg	7.49mg	
mgl MXA #	.770mg Z	P<.05	-	.312mg n.s.s.	22/50	33/50	(29/50	19/50)	mgl:ade,fba. S
cli MXA	5.04mg Z	P<.04		2.07mg n.s.s.	3/50	7/50	10/50	(3/50)	cli:ade,car. S
TBA MXB	14.0mg *	P<.5		2.96mg n.s.s.	48/50	50/50	49/50	49/50	
liv MXB	no dre	P=1.		52.4mg n.s.s.	1/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
4051 R m f34 inh 24m24 TR462 :					0	.524mg	1.57mg	5.24mg	
lun MXA	21.8mg *	P<.05	e	7.76mg n.s.s.	0/50	1/50	1/50	4/50	lun:a/a,a/c.
lun a/a	31.6mg *	P<.02		9.53mg n.s.s.	0/50	0/50	0/50	3/50	S
TBA MXB	no dre	P=1.		3.97mg n.s.s.	50/50	49/50	50/50	49/50	
liv MXB	128.mg *	P<.8		9.85mg n.s.s.	2/50	2/50	1/50	3/50	liv:hpa,hpb,hpc.
MONOACETYL HYDRAZINE 1068-57-1									
4052 M f swi gav 95w95 1661m					0	22.9mg			Bhide;clet,23,235-240;1984/pers.comm.
lun mix rs	53.8mg	P<.3	+	13.9mg n.s.s.	3/20	5/15			
4053 M f swi gav 34w95 1661n					0	11.4mg			
lun mix rs	18.8mg	P<.1	+	5.77mg n.s.s.	3/20	6/15			
4054 M m swi gav 95w95 1661m					0	19.0mg	26.2mg		
lun mix rs	35.6mg *	P<.02	+	15.2mg n.s.s.	2/20	4/15	7/15		
4055 M m swi gav 34w95 1661n					0	9.52mg			
lun mix rs	4.48mg	P<.0005	+	1.98mg 15.0mg	2/20	11/15			
MONOCHLOROACETIC ACID 79-11-8									
4056 M f b6c gav 24m24 TR396 :					0	35.6mg	71.2mg		
TBA MXB	no dre	P=1.	-	49.7mg n.s.s.	41/60	33/60	(27/60)		
liv MXB	2.05gm *	P<.7		312.mg n.s.s.	1/60	2/60	2/60		liv:hpa,hpc,nnd.
lun MXB	640.mg *	P<.2		243.mg n.s.s.	0/60	3/60	2/60		lun:a/a,a/c.
4057 M f b6c orl 76w76 1263					0	20.4mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	38.2mg n.s.s.	0/18	0/17			
lun ade evx	no dre	P=1.	-	38.2mg n.s.s.	1/18	0/17			
tba mix evx	1.01gm	P<1.	-	17.8mg n.s.s.	2/18	2/17			
4058 M m b6c gav 24m24 TR396 :					0	35.6mg	71.2mg		
TBA MXB	159.mg *	P<.3	-	46.4mg n.s.s.	31/60	32/60	21/60		
liv MXB	no dre	P=1.		150.mg n.s.s.	12/60	8/60	6/60		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		135.mg n.s.s.	12/60	10/60	5/60		lun:a/a,a/c.
4059 M m b6c orl 76w76 1263					0	19.0mg			Innes;ntis,1968/1969
lun ade evx	122.mg	P<.3	-	19.8mg n.s.s.	0/14	1/18			
liv hpt evx	no dre	P=1.	-	20.5mg n.s.s.	3/14	2/18			
tba mix evx	no dre	P=1.	-	11.3mg n.s.s.	4/14	5/18			
4060 M f b6a orl 76w76 1263					0	20.4mg			
lun ade evx	59.7mg	P<.09	-	14.7mg n.s.s.	0/18	2/17			
liv hpt evx	no dre	P=1.	-	38.2mg n.s.s.	0/18	0/17			
tba mix evx	38.5mg	P<.04	-	11.6mg n.s.s.	0/18	3/17			
4061 M m b6a orl 76w76 1263					0	19.0mg			
lun ade evx	115.mg	P<.3	-	18.7mg n.s.s.	0/18	1/17			
liv hpt evx	2.01gm	P<1.	-	21.0mg n.s.s.	1/18	1/17			
tba mix evx	942.mg	P<1.	-	16.5mg n.s.s.	2/18	2/17			
4062 R f f34 gav 24m24 TR396 :					0	10.7mg	21.3mg		
ute esp #	41.7mg *	P<.002	-	21.4mg 193.mg	1/53	7/53	9/53		S
ute MXA	47.3mg *	P<.007		22.5mg 816.mg	2/53	7/53	9/53		ute:esp,ess. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TBA MXB	85.4mg *	P<.8		10.4mg n.s.s.	50/53	45/53	39/53		
liv MXB	no dre	P=1.		161.mg n.s.s.	1/53	0/53	0/53		liv:hpa,hpc,nnd.
4063 R m f34 gav 24m24 TR396 :					0	10.7mg	21.3mg		
TBA MXB	53.3mg *	P<.7	-	8.54mg n.s.s.	49/53	45/53	34/53		
liv MXB	623.mg *	P<.7		60.9mg n.s.s.	1/53	1/53	1/53		liv:hpa,hpc,nnd.
4064 R m f34 wat 24m24 2327					0	2.50mg	25.0mg	57.2mg	DeAngelo;jtxe,52,425-445;1997
liv hpc C	no dre	P=1.	-	14.4mg n.s.s.	0/29	0/32	0/32	0/29	
liv hpa C	no dre	P=1.	-	322.mg n.s.s.	1/29	2/32	0/32	1/29	
MONOCROTALINE 315-22-0									
4065 R m cdr gav 42w71 1719m					0	.813mg			Newberne;pffm,1,23-31;1973
liv hpc erv	1.16mg	P<.02	+	.566mg n.s.s.	0/15	10/50			
4066 R m cdr gav 42w71 1719n					0	.813mg			
liv hpc cerv	.790mg	P<.005	+	.424mg 4.36mg	0/15	14/50			
MONOMETHYLARSONIC ACID 124-58-3									
4067 M f b6c eat 24m24 2632					0	1.30mg	6.50mg	26.0mg 52.0mg	Arnold;txcy,190,197-219;2003
liv hpa e	751.mg *	P<.02	-	259.mg n.s.s.	0/52	0/52	0/52	2/52 2/52	
lun a/a e	2.19gm *	P<.7	-	244.mg n.s.s.	2/52	7/52	1/52	2/52 5/52	
liv hpc e	no dre	P=1.	-	326.mg n.s.s.	1/52	4/52	6/52	1/52 3/52	
lun a/c e	no dre	P=1.	-	337.mg n.s.s.	0/52	2/52	3/52	2/52 1/52	
4068 M m b6c eat 24m24 2632					0	1.20mg	6.00mg	24.0mg 48.0mg	
lun a/a e	1.36gm *	P<.7	-	169.mg n.s.s.	6/52	4/51	3/52	7/52 5/51	
liv hpc e	no dre	P=1.	-	280.mg n.s.s.	6/52	2/52	6/52	6/52 2/51	
liv hpa e	no dre	P=1.	-	280.mg n.s.s.	6/52	9/52	6/52	6/52 4/51	
lun a/c e	no dre	P=1.	-	493.mg n.s.s.	7/52	5/51	4/52	3/52 1/51	
4069 R f f34 eat 24m24 2632					0	2.50mg	20.0mg	53.2mg	
liv tum esv	no dre	P=1.	-	26.4mg n.s.s.	0/60	0/60	0/60	0/60	
4070 R m f34 eat 24m24 2632					0	2.00mg	16.0mg	42.5mg	
--- mnl esv	139.mg Z	P<.9	-	9.91mg n.s.s.	45/60	53/60	49/60	(20/60)	
liv hpc esv	no dre	P=1.	-	21.1mg n.s.s.	1/60	0/60	0/60	0/60	
4071 R m f3d wat 24m24 2631					0	2.50mg	10.0mg		Shen;txap,193,335-345;2003
tes ict e	3.36mg *	P<.02	-	1.22mg n.s.s.	35/42	38/42	44/45		
liv hpa e	72.4mg *	P<.5	-	15.2mg n.s.s.	6/42	12/42	11/45		
ubl tcc Ce	no dre	P=1.	-	69.2mg n.s.s.	0/42	1/42	0/45		
tba mix e	5.91mg *	P<.7	-	.396mg n.s.s.	42/42	41/42	45/45		
MONONITROSOCAFFEIDINE 145438-96-6									
4072 R b bd9 wat 73w79 2573					0	2.14mg	3.57mg	10.7mg	Ivankovic;carc,19,933-937;1998
nas mix er	1.00mg Z	P<.0005	+	.713mg 1.45mg	0/66	31/41	28/45	(32/43)	
nof nue er	1.03mg Z	P<.0005	+	.617mg 1.88mg	0/66	23/41	(20/45	24/43)	
nas sqc er	5.56mg Z	P<.0005	+	3.10mg 12.0mg	0/66	8/41	8/45	(8/43)	
MONOSODIUM ASPARTATE 3792-50-5									
4073 R f f3d wat 23m23 2353					0	1.43gm	2.86gm		Kitahori;jtxp,9,161-168;1996
liv tum	no dre	P=1.	-	9.07gm n.s.s.	0/50	0/50	0/50		
tba mix	8.34gm *	P<.3	-	2.68gm n.s.s.	17/50	23/50	23/50		
4074 R m f3d wat 23m23 2353					0	1.25gm	2.50gm		
liv tum	no dre	P=1.	-	7.94gm n.s.s.	0/50	0/50	0/50		
tba mix	2.72gm *	P<.1	-	1.03gm n.s.s.	31/50	42/50	38/50		
DL-MONOSODIUM GLUTAMATE 32221-81-1									
4075 M m cbl eat 24m24 1631					0	1.20gm	4.80gm		Ebert;txlt,3,65-70;1979
liv tum e	no dre	P=1.	-	4.51gm n.s.s.	0/55	0/23	0/27		
lun ade e	no dre	P=1.	-	17.6gm n.s.s.	0/55	1/23	0/27		
tba mix e	no dre	P=1.	-	17.6gm n.s.s.	0/55	1/23	0/27		
L-MONOSODIUM GLUTAMATE 142-47-2									
4076 M m cbl eat 24m24 1631					0	1.20gm	4.80gm		Ebert;txlt,3,65-70;1979
liv tum e	no dre	P=1.	-	4.68gm n.s.s.	0/55	0/25	0/23		
lun tum e	no dre	P=1.	-	4.68gm n.s.s.	0/55	0/25	0/23		
tba tum e	no dre	P=1.	-	4.68gm n.s.s.	0/55	0/25	0/23		
4077 R f f3d eat 24m24 2236					0	300.mg	625.mg	1.25gm 2.50gm	Shibata;fctx,33,383-391;1995
liv hpa e	no dre	P=1.	-	30.8gm n.s.s.	1/50	1/50	2/50	0/50 0/50	
4078 R m f3d eat 24m24 2236					0	240.mg	500.mg	1.00gm 2.00gm	
liv hpa e	no dre	P=1.	-	1.34gm n.s.s.	1/50	0/50	0/50	0/50 0/50	
MONOSODIUM SUCCINATE 2922-54-5									
4079 R f f3d wat 24m26 1977					0	526.mg	1.05gm		Maekawa;fctx,28,235-241;1990
liv tum e	no dre	P=1.	-	4.12gm n.s.s.	0/49	0/48	0/49		
tba tum e	4.82gm *	P<.7	-	655.mg n.s.s.	40/49	37/48	40/47		
4080 R m f3d wat 24m26 1977					0	460.mg	920.mg		
liv hpc e	54.7gm *	P<.3	-	8.91gm n.s.s.	0/50	0/48	1/50		
liv hpa e	no dre	P=1.	-	6.14gm n.s.s.	2/50	4/48	1/50		
tba tum e	noTD50	P=1.	-	n.s.s. n.s.s.	50/50	48/48	50/50		
4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE 58139-48-3									
4081 R f sda eat 46w66 1390					0	17.4mg			Cohen;jnci,57,277-282;1976
tba mix e	5.03mg	P<.0005	+	2.70mg 11.2mg	6/84	18/28			
L-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE)AMINO]-2-OXAZOLIDINONE.HCl 3031-51-4									
4082 R f sda eat 46w66 200a					0	34.8mg			Cohen;jnci,51,403-417;1973
mgl mix e	2.81mg	P<.0005		1.25mg 5.71mg	1/25	31/32			
mgl adc e	6.33mg	P<.0005	+	3.70mg 11.6mg	0/25	25/32			
--- lbl eh	39.0mg	P<.004	+	16.8mg 219.mg	0/25	7/32			
k/p tcc eh	149.mg	P<.2	+	36.6mg n.s.s.	0/25	2/32			
liv tum e	no dre	P=1.		92.6mg n.s.s.	0/25	0/32			
tba mix e	2.81mg	P<.0005		1.25mg 5.71mg	1/25	31/32			

Chemical / Spe Strain Xpo+Xpt / Sex Route Paper Num	Synonym	CAS number	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
MYLERAN	(busulfan)	55-98-1					
4083 R m b46 gav 12m24 1017			0	9.29ug			Schmahl;arzn,20,1461-1467;1970
tba mix es	93.1ug	P<.6	12.7ug n.s.s.	7/65	3/18		
tba mal es	.117mg	P<.5	15.1ug n.s.s.	4/65	2/18		
tba ben es	.642mg	P<.9	20.6ug n.s.s.	3/65	1/18		
NAFENOPIN		3771-19-5					
4084 H m smb eat 60w60 2190			0	230.mg			Lake;enhp,101(Supp5),241-247;1993/pers.comm.
liv mix Cr	no dre	P=1. -	126.mg n.s.s.	0/9	0/8		
4085 R m f34 eat 25m25 2271			0	40.0mg			Reddy;jnci,59,1645-1650;1977/pers.comm.
liv hpc er	22.4mg	P<.0005 +	10.4mg 57.7mg	0/10	11/15		
pan mix er	132.mg	P<.07 +	39.9mg n.s.s.	0/10	3/15		
pan ana er	207.mg	P<.2	50.7mg n.s.s.	0/10	2/15		
pan acc er	428.mg	P<.4	69.7mg n.s.s.	0/10	1/15		
4086 R m sda eat 60w60 2190			0	20.0mg			Lake;enhp,101(Supp5),241-247;1993/pers.comm.
liv mix Cr	3.51mg	P<.0005 +	1.45mg 11.5mg	0/8	8/11		
4087 R f wis eat 55w55 2180m			0	100.mg			Kraupp-Grasl;canr,50,3701-3708;1990/pers.comm.
liv hpc kr	163.mg	P<.3	26.4mg n.s.s.	0/9	1/9		
liv mix kr	163.mg	P<.3	26.4mg n.s.s.	0/9	1/9		
liv hpa kr	no dre	P=1.	51.9mg n.s.s.	0/9	0/9		
4088 R f wis eat 70w70 2180o			0	100.mg			
liv mix r	36.6mg	P<.0005 +	16.0mg 123.mg	0/11	8/14		
liv hpa r	55.5mg	P<.005 +	22.2mg 383.mg	0/11	6/14		
liv hpc r	92.3mg	P<.03 +	31.6mg n.s.s.	0/11	4/14		
4089 R m wis eat 59w59 2155			0	100.mg			Kraupp-Grasl;canr,51,666-671;1991/pers.comm.
liv mix e	22.1mg	P<.0005 +	10.9mg 52.9mg	0/18	12/19		
liv hpa e	48.0mg	P<.002	20.5mg 187.mg	0/18	7/19		
liv hpc e	58.1mg	P<.004 +	23.5mg 324.mg	0/18	6/19		
tba tum e	12.3mg	P<.0005	5.98mg 29.2mg	1/18	16/19		
4090 R m wis eat 57w57 2180n			0	100.mg			Kraupp-Grasl;canr,50,3701-3708;1990/pers.comm.
liv mix r	19.8mg	P<.0005 +	9.48mg 49.6mg	0/18	11/17		
liv hpa r	38.8mg	P<.002 +	16.5mg 139.mg	0/18	7/17		
liv hpc r	59.1mg	P<.005 +	22.3mg 507.mg	0/18	5/17		
NALIDIXIC ACID		389-08-2					
4091 M f b6c eat 24m24 TR368 :			0	258.mg	515.mg		
amd phe #	3.63gm *	P<.03 -	1.38gm n.s.s.	0/50	2/50	3/50	S
TBA MXB	1.69gm *	P<.6	344.mg n.s.s.	36/50	39/50	35/50	
liv MXB	3.16gm *	P<.3	963.mg n.s.s.	4/50	6/50	7/50	liv:hpa,hpc,nnd.
lun MXB	4.90gm *	P<.4	1.27gm n.s.s.	1/50	5/50	2/50	lun:a/a,a/c.
4092 M m b6c eat 24m24 TR368 :			0	238.mg	475.mg		
sub MXA	1.21gm *	P<.04 e	536.mg n.s.s.	5/50	9/50	14/50	sub:fbs,fib.
TBA MXB	1.33gm *	P<.4	342.mg n.s.s.	26/50	24/50	32/50	
liv MXB	no dre	P=1.	1.07gm n.s.s.	10/50	12/50	7/50	liv:hpa,hpc,nnd.
lun MXB	4.60gm *	P<.6	848.mg n.s.s.	6/50	5/50	8/50	lun:a/a,a/c.
4093 M f cdf eat 76w85 2294			0	93.0mg	186.mg		Kurokawa;fctx,24,319-323;1986
lun adc e	1.77gm *	P<.3 -	478.mg n.s.s.	1/51	3/50	3/51	
liv hpa e	6.45gm *	P<1. -	1.05gm n.s.s.	0/51	1/50	0/51	
lun mix e	no dre	P=1. -	476.mg n.s.s.	7/51	6/50	6/51	
tba tum e	no dre	P=1. -	130.mg n.s.s.	36/51	35/50	34/51	
4094 M m cdf eat 76w85 2294			0	85.8mg	172.mg		
liv hpc e	1.94gm *	P<.3 -	587.mg n.s.s.	0/49	2/50	1/50	
liv mix e	3.10gm *	P<.8 -	332.mg n.s.s.	4/49	8/50	5/50	
lun adc e	3.98gm *	P<.9 -	305.mg n.s.s.	8/49	8/50	9/50	
liv hpa e	no dre	P=1. -	426.mg n.s.s.	4/49	6/50	4/50	
lun mix e	no dre	P=1. -	284.mg n.s.s.	15/49	11/50	14/50	
tba tum e	no dre	P=1. -	202.mg n.s.s.	39/49	32/50	31/50	
4095 R f f34 eat 24m24 TR368 :			0	99.0mg	198.mg		
cli MXA	372.mg *	P<.05 c	165.mg n.s.s.	5/50	15/50	16/50	cli:adn,can,ppc,ppn.
TBA MXB	no dre	P=1.	102.mg n.s.s.	47/50	43/50	(41/50)	
liv MXB	no dre	P=1.	1.14gm n.s.s.	1/50	0/50	1/50	liv:hpa,hpc,nnd.
4096 R m f34 eat 24m24 TR368 :			0	79.2mg	159.mg		
pre MXA	138.mg *	P<.0005 c	82.0mg 416.mg	3/50	19/50	20/50	pre:adn,can,ppn.
pre can	211.mg *	P<.0005	126.mg 458.mg	0/50	10/50	12/50	S
pre adn	301.mg *	P<.02	145.mg n.s.s.	2/50	10/50	10/50	S
pre MXA	358.mg *	P<.05	155.mg n.s.s.	3/50	10/50	10/50	pre:adn,ppn. S
TBA MXB	7.60gm *	P<1.	94.9mg n.s.s.	44/50	45/50	44/50	
liv MXB	no dre	P=1.	746.mg n.s.s.	2/50	1/50	1/50	liv:hpa,hpc,nnd.
NAPHTHALENE		91-20-3					
4097 M f b6c inh 24m24 TR410 :			0	16.0mg	48.3mg		
lun MXA	163.mg /	P<.0005 p	91.2mg 572.mg	5/70	2/68	29/138	lun:a/a,a/c.
lun a/a	171.mg /	P<.002 p	94.4mg 662.mg	5/70	2/68	28/138	
lun a/c	4.02gm *	P<.3 p	654.mg n.s.s.	0/70	0/68	1/138	
TBA MXB	128.mg *	P<.04	58.4mg n.s.s.	23/70	22/68	63/138	
liv MXB	no dre	P=1.	457.mg n.s.s.	2/70	2/68	3/138	liv:hpa,hpc,nnd.
lun MXB	163.mg /	P<.0005	91.2mg 572.mg	5/70	2/68	29/138	lun:a/a,a/c.
4098 M m b6c inh 24m24 TR410 :			0	13.3mg	40.3mg		
TBA MXB	no dre	P=1. -	30.0mg n.s.s.	36/70	36/70	(66/137)	
liv MXB	no dre	P=1.	182.mg n.s.s.	8/70	14/70	23/137	liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	116.mg n.s.s.	7/70	17/70	31/137	lun:a/a,a/c.
4099 R f f34 inh 24m24 TR500 :			0	3.92mg	11.8mg	23.5mg	
MXB MXB	37.3mg *	P<.0005	22.1mg 75.0mg	0/49	2/49	7/49	13/49 nof:neu; nre:ade. C
nof neu	52.9mg *	P<.0005 c	29.5mg 106.mg	0/49	2/49	3/49	12/49
nre ade	121.mg *	P<.03 c	48.6mg n.s.s.	0/49	0/49	4/49	2/49
TBA MXB	no dre	P=1.	13.4mg n.s.s.	48/49	48/49	47/49	44/49
liv MXB	no dre	P=1.	103.mg n.s.s.	0/49	1/49	1/49	0/49 liv:hpa,hpb,hpc.

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4100 R m f34 inh 24m24 TR500 :					0	2.75mg	8.24mg	16.5mg	
MXB MXB		12.3mg	* P<.0005	8.06mg 23.6mg	0/49	6/49	11/49	18/49	nof:neu; nre:ade. C
nre ade		14.0mg	* P<.0005 c	8.89mg 32.9mg	0/49	6/49	8/49	15/49	
nof neu		88.0mg	* P<.008 c	36.1mg 1.97gm	0/49	0/49	4/49	3/49	
mgl fba		133.mg	* P<.02	40.3mg n.s.s.	0/49	0/49	0/49	3/49	S
TBA MXB		27.5mg	* P<.5	6.30mg n.s.s.	48/49	48/49	46/49	49/49	
liv MXB		171.mg	* P<.2	43.3mg n.s.s.	2/49	0/49	0/49	4/49	liv:hpa,hpb,hpc.
1-NAPHTHALENE ACETAMIDE 86-86-2									
4101 M f b6a orl 76w76 1156					0	180.mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	-	337.mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	-	337.mg n.s.s.	1/17	0/17			
tba mix evx	956.mg	P<.7	-	120.mg n.s.s.	2/17	3/17			
4102 M m b6a orl 76w76 1156					0	168.mg			
liv hpt evx	no dre	P=1.	-	314.mg n.s.s.	1/18	0/17			
lun ade evx	no dre	P=1.	-	314.mg n.s.s.	2/18	0/17			
tba mix evx	no dre	P=1.	-	314.mg n.s.s.	3/18	0/17			
4103 M f b6c orl 76w76 1156					0	180.mg			
lun ade evx	461.mg	P<.09	-	113.mg n.s.s.	0/16	2/15			
liv hpt evx	956.mg	P<.3	-	156.mg n.s.s.	0/16	1/15			
tba mix evx	213.mg	P<.02	-	73.0mg n.s.s.	0/16	4/15			
4104 M m b6c orl 76w76 1156					0	168.mg			
liv hpt evx	316.mg	P<.04	-	95.4mg n.s.s.	0/16	3/17			
lun ade evx	1.01gm	P<.3	-	165.mg n.s.s.	0/16	1/17			
tba mix evx	141.mg	P<.003	-	56.9mg 765.mg	0/16	6/17			
1-NAPHTHALENE ACETIC ACID (planofix) 86-87-3									
4105 M f b6a orl 76w76 1157					0	73.0mg			Innes;ntis,1968/1969
liv agm evx	213.mg	P<.09	-	52.4mg n.s.s.	0/17	2/17			
lun ade evx	no dre	P=1.	-	81.4mg n.s.s.	1/17	1/17			
tba mix evx	387.mg	P<.7	-	48.8mg n.s.s.	2/17	3/17			
4106 M m b6a orl 76w76 1157					0	68.0mg			
liv hpt evx	no dre	P=1.	-	80.4mg n.s.s.	1/18	1/18			
lun ade evx	no dre	P=1.	-	89.3mg n.s.s.	2/18	1/18			
tba mix evx	no dre	P=1.	-	53.5mg n.s.s.	3/18	3/18			
4107 M f b6c orl 76w76 1157					0	73.0mg			
liv hpt evx	no dre	P=1.	-	129.mg n.s.s.	0/16	0/16			
lun mix evx	no dre	P=1.	-	129.mg n.s.s.	0/16	0/16			
tba tum evx	no dre	P=1.	-	129.mg n.s.s.	0/16	0/16			
4108 M m b6c orl 76w76 1157					0	68.0mg			
liv hpt evx	199.mg	P<.1	-	48.8mg n.s.s.	0/16	2/17			
lun mix evx	no dre	P=1.	-	127.mg n.s.s.	0/16	0/17			
tba mix evx	71.5mg	P<.007	-	26.9mg 966.mg	0/16	5/17			
1,5-NAPHTHALENEDIAMINE (1,5-diaminonaphthalene) 2243-62-1									
4109 M f b6c eat 24m24 TR143 :					0	127.mg	253.mg		
MXB MXB		66.6mg	\ P<.0005	42.1mg 129.mg	3/50	38/50	(34/50)		liv:hpa,hpc; lun:a/a,a/c; thy:cca,ccr,fca,pcy,ppa. C
liv hpc		115.mg	\ P<.0005 c	69.5mg 236.mg	1/50	25/50	(16/50)		
liv MXA		129.mg	* P<.0005 c	89.8mg 223.mg	1/50	28/50	27/50		liv:hpa,hpc.
thy MXA		327.mg	* P<.002 c	186.mg 1.46gm	2/50	17/50	14/50		thy:fca,pcy,ppa.
lun MXA		331.mg	\ P<.0005 c	161.mg 1.00gm	0/50	10/50	(5/50)		lun:a/a,a/c.
thy MXA		936.mg	* P<.002 c	455.mg 3.26gm	0/50	2/50	8/50		thy:cca,ccr.
thy ccr		1.32gm	* P<.005 c	571.mg 9.23gm	0/50	1/50	6/50		
TBA MXB		223.mg	* P<.03	102.mg n.s.s.	21/50	41/50	37/50		
liv MXB		129.mg	* P<.0005	89.8mg 223.mg	1/50	28/50	27/50		liv:hpa,hpc,nnd.
lun MXB		331.mg	\ P<.0005	161.mg 1.00gm	0/50	10/50	(5/50)		lun:a/a,a/c.
4110 M m b6c eat 24m24 TR143 :					0	118.mg	235.mg		
thy MXB		217.mg	* P<.0005	139.mg 373.mg	0/50	10/50	19/50		thy:cca,ccr,fca,pcy,ppa. C
thy MXA		276.mg	* P<.0005 c	170.mg 510.mg	0/50	8/50	16/50		thy:fca,pcy,ppa.
thy MXA		1.26gm	* P<.02 c	515.mg n.s.s.	0/50	2/50	4/50		thy:cca,ccr.
thy ccr		1.91gm	* P<.02 c	661.mg n.s.s.	0/50	0/50	4/50		
TBA MXB		583.mg	* P<.5	131.mg n.s.s.	24/50	40/50	25/50		
liv MXB		1.64gm	* P<.6	291.mg n.s.s.	12/50	13/50	13/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	607.mg n.s.s.	4/50	9/50	2/50		lun:a/a,a/c.
4111 R f f34 eat 24m25 TR143 :					0	24.3mg	48.1mg		
MXB MXB		50.8mg	* P<.002	29.5mg 242.mg	3/25	16/50	28/50		cli:adn,can; ute:esp. C
ute esp		69.6mg	* P<.009 c	37.7mg 2.04gm	2/25	14/50	20/50		
cli MXA		137.mg	* P<.009 c	69.1mg 4.53gm	1/25	3/50	13/50		cli:adn,can.
thy MXA		57.6mg	\ P<.03	26.2mg n.s.s.	1/25	12/50	(4/50)		thy:cca,ccr. S
TBA MXB		55.8mg	* P<.2	19.7mg n.s.s.	17/25	41/50	49/50		
liv MXB		236.mg	* P<.2	107.mg n.s.s.	0/25	4/50	4/50		liv:hpa,hpc,nnd.
4112 R m f34 eat 24m25 TR143 :					0	19.4mg	38.9mg		
TBA MXB		48.1mg	* P<.2	19.2mg n.s.s.	10/25	32/50	38/50		
liv MXB		1.04gm	* P<.9	86.4mg n.s.s.	1/25	7/50	4/50		liv:hpa,hpc,nnd.
N-(1-NAPHTHYL)ETHYLENEDIAMINE.2HCl 1465-25-4									
4113 M f b6c eat 24m25 TR168 :					0	253.mg	392.mg		
TBA MXB sv	no dre	P=1.	-	851.mg n.s.s.	21/50	15/50	9/50		
liv MXB sv	25.6gm	* P<.8		1.94gm n.s.s.	1/50	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB sv	4.39gm	* P<.2		1.33gm n.s.s.	0/50	2/50	1/50		lun:a/a,a/c.
4114 M m b6c eat 24m24 TR168 :					0	60.0mg	120.mg		
TBA MXB	no dre	P=1.	-	119.mg n.s.s.	24/50	19/50	(16/50)		
liv MXB	no dre	P=1.		368.mg n.s.s.	12/50	5/50	9/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		384.mg n.s.s.	4/50	7/50	3/50		lun:a/a,a/c.
4115 R f f34 eat 24m25 TR168 :					0	25.0mg	50.0mg		
liv MXA #	93.5mg	\ P<.02	-	42.3mg n.s.s.	0/25	8/50	(1/50)		liv:hpc,nnd. S
TBA MXB	no dre	P=1.		69.2mg n.s.s.	17/25	36/50	30/50		
liv MXB	93.5mg	\ P<.02		42.3mg n.s.s.	0/25	8/50	(1/50)		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD50 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
4116 R m f34 eat 24m25 TR168 :	0	20.0mg	40.0mg		
TBA MXB 41.6mg \ P<.3 - 12.5mg n.s.s.	10/25	35/50	(27/50)		
liv MXB no dre P=1. 265.mg n.s.s.	1/25	2/50	1/50		liv:hpa,hpc,nnd.
sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE (agerite white) 93-46-9					
4117 M f b6a orl 76w76 1305	0	38.9mg			Innes;ntis,1968/1969
lun ade evx 221.mg P<.6 - 30.7mg n.s.s.	1/17	2/17			
liv hpt evx no dre P=1. - 72.8mg n.s.s.	0/17	0/17			
tba mix evx 63.8mg P<.2 - 17.3mg n.s.s.	2/17	5/17			
4118 M m b6a orl 76w76 1305	0	36.2mg			
lun ade evx no dre P=1. - 47.5mg n.s.s.	2/18	1/18			
liv hpt evx no dre P=1. - 71.7mg n.s.s.	1/18	0/18			
tba mix evx no dre P=1. - 37.5mg n.s.s.	3/18	2/18			
4119 M f b6c orl 76w76 1305	0	38.9mg			
liv hpt evx no dre P=1. - 72.8mg n.s.s.	0/16	0/17			
lun mix evx no dre P=1. - 72.8mg n.s.s.	0/16	0/17			
tba mix evx 235.mg P<.3 - 38.2mg n.s.s.	0/16	1/17			
4120 M m b6c orl 76w76 1305	0	36.2mg			
liv hpt evx 59.4mg P<.04 - 17.9mg n.s.s.	0/16	3/15			
lun ade evx 192.mg P<.3 - 31.2mg n.s.s.	0/16	1/15			
tba mix evx 25.9mg P<.002 - 10.4mg 117.mg	0/16	6/15			
1-(1-NAPHTHYL)-2-THIOUREA (ANTU) 86-88-4					
4121 M f b6a orl 76w76 1155	0	.834mg			Innes;ntis,1968/1969
lun ade evx no dre P=1. - .991mg n.s.s.	1/17	1/18			
liv hpt evx no dre P=1. - 1.65mg n.s.s.	0/17	0/18			
tba mix evx no dre P=1. - 1.10mg n.s.s.	2/17	1/18			
4122 M m b6a orl 76w76 1155	0	.776mg			
lun ade evx no dre P=1. - 1.02mg n.s.s.	2/18	1/18			
liv hpt evx no dre P=1. - 1.54mg n.s.s.	1/18	0/18			
tba mix evx no dre P=1. - .803mg n.s.s.	3/18	2/18			
4123 M f b6c orl 76w76 1155	0	.834mg			
liv hpt evx no dre P=1. - 1.65mg n.s.s.	0/16	0/18			
lun mix evx no dre P=1. - 1.65mg n.s.s.	0/16	0/18			
tba mix evx 5.34mg P<.3 - .869mg n.s.s.	0/16	1/18			
4124 M m b6c orl 76w76 1155	0	.776mg			
lun ade evx 1.27mg P<.04 - .383mg n.s.s.	0/16	3/15			
liv hpt evx no dre P=1. - 1.28mg n.s.s.	0/16	0/15			
tba mix evx .700mg P<.005 - .263mg 5.52mg	0/16	5/15			
1-NAPHTHYLAMINE 134-32-7					
4125 M m icr eat 52w52 2594	0	120.mg			Osanai;jsol,52,179-201;1976
liv hpt e 67.3mg P<.07 + 22.3mg n.s.s.	2/21	6/18			
2-NAPHTHYLAMINE 91-59-8					
4126 M f bal eat 40w55 1446	0	189.mg			Yoshida;gann,70,645-652;1979
liv hnd er 17.4mg P<.0005 7.87mg 41.7mg	0/17	14/16			
liv ade er 36.9mg P<.0005 17.2mg 97.2mg	0/17	10/16			
liv mix er 63.0mg P<.0005 26.7mg 223.mg	0/17	7/16			
liv hpt er 175.mg P<.04 + 52.6mg n.s.s.	0/17	3/16			
ubl tum er no dre P=1. - 174.mg n.s.s.	0/17	0/16			
4127 M b cba gav 79w79 207	0	50.1mg			Bonser;bjca,6,412-424;1952
liv hpt e 20.5mg P<.002 + 10.5mg 67.5mg	0/7	13/21			
4128 M m icr eat 52w52 2594	0	120.mg			Osanai;jsol,52,179-201;1976
liv hpt e 46.0mg P<.02 + 18.0mg n.s.s.	2/21	8/19			
4129 P f rhe mix 60m60 1470 ()	0	90.5mg			Conzelman;jnci,42,825-831;1969
ubl mix emrv 5.74mg P<.06 + 2.42mg n.s.s.	0/3	7/14			
ubl pam emrv 25.8mg P<.4 + 6.34mg n.s.s.	0/3	2/14			
ubl ppa emrv 25.8mg P<.4 + 6.34mg n.s.s.	0/3	2/14			
ubl tcc emrv 25.8mg P<.4 + 6.34mg n.s.s.	0/3	2/14			
ubl car emrv 53.7mg P<.6 + 8.74mg n.s.s.	0/3	1/14			
ubl ppc emrv 53.7mg P<.6 + 8.74mg n.s.s.	0/3	1/14			
4130 R b alb eat 24m24 207m	0	4.50mg			Bonser;bjca,6,412-424;1952
ubl pam r no dre P=1. 15.8mg n.s.s.	0/17	0/17			
4131 R b alb eat 24m24 207n	0	4.50mg			
ubl pam er 9.68mg P<.2 2.90mg n.s.s.	0/5	3/11			
4132 R b alb eat 24m24 207o	0	4.50mg			
ubl pam efr 35.4mg P<.4 5.76mg n.s.s.	0/5	1/12			
4133 R f wis gav 13m23 1564	0	24.4mg			Hicks;bjca,46,646-661;1982
ubl mix er 61.6mg P<.02 + 21.2mg n.s.s.	0/20	4/18			
2-NAPHTHYLAMINO,1-SULFONIC ACID 81-16-3					
4134 M f bld eat 15m33 1488	0	306.mg			Della Porta;carc,3,647-649;1982
lun mix e 9.96gm P<.8 - 942.mg n.s.s.	14/49	15/48			
liv mix e 876.gm P<1. - 3.33gm n.s.s.	1/49	1/48			
4135 M m bld eat 15m33 1488	0	283.mg			
lun mix e 4.92gm P<.7 - 765.mg n.s.s.	14/48	16/47			
liv mix e 379.gm P<1. - 2.42gm n.s.s.	2/48	2/47			
NEFIRACETAM 77191-36-7					
4136 M f b6c eat 24m24 2203	0	270.mg			Kajimura;arzn,44(I),254-259;1994
liv hpa e 4.25gm P<.5 - 807.mg n.s.s.	3/50	5/50			
liv hpc e no dre P=1. - 2.78gm n.s.s.	2/50	0/50			
lun a/a e no dre P=1. - 1.29gm n.s.s.	4/50	3/50			
lun a/c e no dre P=1. - 2.78gm n.s.s.	2/50	0/50			
4137 M m b6c eat 24m24 2203	0	270.mg			
liv hpa e 2.68gm P<.4 - 616.mg n.s.s.	5/50	8/50			
liv hpc e 8.42gm P<.8 - 871.mg n.s.s.	4/50	5/50			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
lun a/a e		no dre P=1.	-	1.03gm n.s.s.	6/50	5/50			
lun a/c e		no dre P=1.	-	1.87gm n.s.s.	2/50	1/50			
4138 R f f3d eat 24m24 2203					0	90.0mg			
liv hct e		no dre P=1.	-	927.mg n.s.s.	0/50	0/50			
4139 R m f3d eat 24m24 2203					0	72.0mg			
liv hpa e		2.39gm P<.6	-	327.mg n.s.s.	1/50	2/50			
NEOSUGAR 88385-81-3									
4140 R f f3d eat 24m24 1880					0	400.mg	1.00gm	2.50gm	Clevenger;jact,7,643-662;1988
spl leu		25.5gm * P<.5	-	5.05gm n.s.s.	4/50	7/50	12/50	7/50	
pit ade		no dre P=1.	-	8.67gm n.s.s.	24/50	19/50	19/50	14/50	
4141 R m f3d eat 24m24 1880					0	320.mg	800.mg	2.00gm	
pit ade		3.55gm * P<.007	-	1.71gm 59.6gm	10/50	13/50	19/50	22/50	
NICKEL 7440-02-0									
4142 R f leb wat 43m43 1464					0	.286mg			Schroeder;jnut,104,239-243;1974
tba mix e		no dre P=1.	-	1.29mg n.s.s.	10/26	9/27			
tba mal e		no dre P=1.	-	2.83mg n.s.s.	7/26	3/27			
4143 R m leb wat 37m37 1464					0	.250mg			
tba mix e		no dre P=1.	-	.919mg n.s.s.	9/23	4/17			
tba mal e		no dre P=1.	-	1.10mg n.s.s.	4/23	2/17			
NICKEL (II) ACETATE 373-02-4									
4144 M f cd1 wat 33m33 56					0	1.00mg			Schroeder;jnut,83,239-250;1964
lun tum e		no dre P=1.	-	6.58mg n.s.s.	9/60	3/33			
liv car e		no dre P=1.	-	12.7mg n.s.s.	1/60	0/33			
tba mix e		no dre P=1.	-	8.98mg n.s.s.	22/60	3/33			
4145 M f cd1 wat 29m29 1395					0	1.00mg			Schroeder;jnut,105,452-458;1975
tba mix e		29.0mg P<.8	-	2.89mg n.s.s.	9/45	10/44			
4146 M m cd1 wat 32m32 56					0	.833mg			Schroeder;jnut,83,239-250;1964
lun tum e		no dre P=1.	-	4.94mg n.s.s.	8/44	5/41			
tba tum e		no dre P=1.	-	4.36mg n.s.s.	11/44	7/41			
4147 M m cd1 wat 32m32 1395					0	.833mg			Schroeder;jnut,105,452-458;1975
tba mix e		no dre P=1.	-	5.82mg n.s.s.	10/43	4/37			
NICKEL DIBUTYLDITHIOCARBAMATE (vanguard N) 13927-77-0									
4148 M f b6a orl 76w76 1357					0	28.9ug			Innes;ntis,1968/1969
lun ade evx		86.9ug P<.4	-	19.0ug n.s.s.	1/17	3/18			
liv hpt evx		no dre P=1.	-	57.3ug n.s.s.	0/17	0/18			
tba mix evx		.185mg P<.7	-	20.8ug n.s.s.	2/17	3/18			
4149 M m b6a orl 76w76 1357					0	27.0ug			
lun ade evx		.153mg P<.7	-	19.2ug n.s.s.	2/18	3/18			
liv hpt evx		no dre P=1.	-	53.5ug n.s.s.	1/18	0/18			
tba mix evx		no dre P=1.	-	21.2ug n.s.s.	3/18	3/18			
4150 M f b6c orl 76w76 1357					0	28.9ug			
lun ade evx		.174mg P<.3	-	28.4ug n.s.s.	0/16	1/17			
liv hpt evx		no dre P=1.	-	54.1ug n.s.s.	0/16	0/17			
tba mix evx		.174mg P<.3	-	28.4ug n.s.s.	0/16	1/17			
4151 M m b6c orl 76w76 1357					0	27.0ug			
liv hpt evx		50.9ug P<.04	-	15.3ug n.s.s.	0/16	3/17			
lun ade evx		.163mg P<.3	-	26.5ug n.s.s.	0/16	1/17			
tba mix evx		28.3ug P<.007	-	10.7ug .383mg	0/16	5/17			
NICKEL (II) SULFATE HEXAHYDRATE 10101-97-0									
4152 M f b6c inh 24m24 TR454 :					0	77.2ug	.158mg	.312mg	
TBA MXB		no dre P=1.	-	.407mg n.s.s.	41/61	45/60	40/60	36/60	
liv MXB		no dre P=1.		.573mg n.s.s.	18/61	28/60	15/60	19/60	liv:hpa,hpb,hpc.
lun MXB		3.10mg Z P<.8		.378mg n.s.s.	7/61	6/60	10/60	(1/60)	lun:a/a,a/c.
4153 M m b6c inh 24m24 TR454 :					0	63.9ug	.131mg	.258mg	
TBA MXB		no dre P=1.	-	.328mg n.s.s.	38/61	35/61	41/62	27/62	
liv MXB		no dre P=1.		.398mg n.s.s.	26/61	18/61	29/62	19/62	liv:hpa,hpb,hpc.
lun MXB		no dre P=1.		.621mg n.s.s.	13/61	18/61	7/62	8/62	lun:a/a,a/c.
4154 R f f34 inh 24m24 TR454 :					0	8.82ug	18.4ug	37.7ug	
TBA MXB		no dre P=1.	-	31.3ug n.s.s.	49/53	52/53	50/54	48/55	
liv MXB		no dre P=1.		n.s.s. n.s.s.	0/53	0/53	0/54	0/55	liv:hpa,hpb,hpc.
4155 R m f34 inh 24m24 TR454 :					0	6.13ug	12.8ug	26.2ug	
TBA MXB		no dre P=1.	-	16.9ug n.s.s.	50/54	50/53	51/53	49/53	
liv MXB		2.08mg * P<.9		98.5ug n.s.s.	2/54	1/53	2/53	2/53	liv:hpa,hpb,hpc.
NICOTINAMIDE 98-92-0									
4156 M f swa wat 26m26 1732					0	2.00gm			Toth;onco,40,72-75;1983/1979
lun mix e		no dre P=1.	-	7.03gm n.s.s.	15/89	7/45			
liv tum e		no dre P=1.		23.8gm n.s.s.	0/98	0/49			
4157 M m swa wat 25m25 1732					0	1.67gm			
lun mix e		no dre P=1.	-	9.34gm n.s.s.	21/87	6/50			
liv mix e		no dre P=1.		15.8gm n.s.s.	2/61	0/42			
NICOTINE 54-11-5									
4158 R f sda ipj 24m24 1134					0	.286mg			Schmahl;zkko,86,77-84;1976
tba mal es		no dre P=1.	-	1.00mg n.s.s.	3/33	2/32			
4159 R m sda ipj 24m24 1134					0	.286mg			
liv hae es		no dre P=1.		2.06mg n.s.s.	1/36	0/35			
tba mal es		6.38mg P<.6	-	.898mg n.s.s.	1/36	2/35			
NICOTINE.HCl 2820-51-1									
4160 M f swa wat 28m29 1530					0	125.mg	188.mg		Toth;acnr,2,71-74;1982/1979
lun tum e		11.1gm * P<.9	-	834.mg n.s.s.	15/95	6/46	9/48		
liv mix e		no dre P=1.	-	1.06gm n.s.s.	0/99	0/50	0/48		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4161 M m swa wat 26m28 1530					0	104.mg	156.mg		
liv mix e	no dre	P=1.	-	606.mg n.s.s.	2/62	0/38	0/32		
lun tum e	no dre	P=1.	-	1.41gm n.s.s.	22/88	6/50	6/48		
NICOTINIC ACID (niacin) 59-67-6									
4162 M f swa wat 32m32 1530					0	2.00gm			Toth;acnr,2,71-74;1982/1979
lun tum e	17.0gm	P<.2	-	5.50gm n.s.s.	15/95	13/48			
liv mix e	no dre	P=1.	-	36.8gm n.s.s.	0/99	0/50			
4163 M m swa wat 28m28 1530					0	1.67gm			
lun tum e	no dre	P=1.	-	7.84gm n.s.s.	22/88	9/50			
liv mix e	no dre	P=1.	-	9.24gm n.s.s.	2/62	1/33			
NICOTINIC ACID HYDRAZIDE (3-pyridoyl hydrazine) 553-53-7									
4164 M f swa wat 24m24 1084					0	250.mg			Toth;onco,38,106-109;1981
lun mix e	145.mg	P<.0005	+	85.8mg 294.mg	25/98	38/50			
lun ade e	181.mg	P<.0005		106.mg 376.mg	20/98	34/50			
lun adc e	511.mg	P<.0005		259.mg 1.57gm	6/98	16/50			
liv ang e	no dre	P=1.	-	1.41gm n.s.s.	3/71	1/42			
liv agm e	no dre	P=1.	-	1.54gm n.s.s.	5/71	1/42			
4165 M m swa wat 23m23 1084					0	208.mg			
lun ade e	428.mg	P<.004		197.mg 3.49gm	16/99	19/49			
lun mix e	528.mg	P<.05	+	203.mg n.s.s.	26/99	21/49			
liv hpt e	1.41gm	P<.08	-	230.mg n.s.s.	0/43	1/11			
liv ang e	no dre	P=1.	-	1.30gm n.s.s.	4/90	0/32			
liv agm e	no dre	P=1.	-	1.01gm n.s.s.	8/80	0/25			
NIGROSINE 8005-03-6									
4166 R f nss eat 64w64 1372					0	150.mg	1.50gm		Allmark;jphp,9,622-628;1957
liv tum e	no dre	P=1.	-	89.3mg n.s.s.	0/7	0/9	0/5		
tba mix e	no dre	P=1.	-	586.mg n.s.s.	1/7	1/9	0/5		
4167 R m nss eat 64w64 1372					0	12.0mg	120.mg		
liv tum e	no dre	P=1.	-	4.26mg n.s.s.	0/5	0/5	0/5		
tba mix e	no dre	P=1.	-	4.26mg n.s.s.	0/5	0/5	0/5		
NIOBATE, SODIUM 12034-09-2									
4168 M b cd1 wat 31m31 1036					0	.877mg			Kanisawa;canr,29,892-895;1969
lun tum e	no dre	P=1.	-	7.82mg n.s.s.	15/71	11/79			
liv tum e	no dre	P=1.	-	24.1mg n.s.s.	4/71	0/79			
tba tum e	no dre	P=1.	-	6.56mg n.s.s.	24/71	18/79			
tba mal e	no dre	P=1.	-	10.8mg n.s.s.	8/71	5/79			
NITHIAZIDE 139-94-6									
4169 M f b6c eat 22m24 TR146 :					0	294.mg	587.mg		
TBA MXB v	1.40gm *	P<.2	-	522.mg n.s.s.	6/20	13/50	23/50		
liv MXB v	2.72gm *	P<.3		924.mg n.s.s.	3/20	4/50	12/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		3.71gm n.s.s.	3/20	1/50	2/50		lun:a/a,a/c.
4170 M m b6c eat 22m24 TR146 :					0	271.mg	542.mg		
liv MXA v	758.mg *	P<.05	c	349.mg n.s.s.	4/20	15/50	25/50		liv:hpa,hpc.
liv hpc v	1.90gm *	P<.2	c	721.mg n.s.s.	2/20	6/50	12/50		
TBA MXB v	4.75gm *	P<.9		415.mg n.s.s.	10/20	27/50	28/50		
liv MXB v	758.mg *	P<.05		349.mg n.s.s.	4/20	15/50	25/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		874.mg n.s.s.	3/20	4/50	(1/50)		lun:a/a,a/c.
4171 R f f34 eat 22m24 TR146 :					0	28.2mg	56.5mg		
MXA MXA v	131.mg *	P<.02	c	68.2mg n.s.s.	1/20	5/50	15/50		mgl:cyn,fba; ski:fba; sub:fba.
TBA MXB v	175.mg *	P<.6		36.5mg n.s.s.	13/20	28/50	38/50		
liv MXB v	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
4172 R m f34 eat 22m24 TR146 :					0	22.6mg	45.2mg		
TBA MXB v	no dre	P=1.	-	48.5mg n.s.s.	11/20	25/50	24/50		
liv MXB v	508.mg *	P<.3		154.mg n.s.s.	0/20	1/50	2/50		liv:hpa,hpc,nnd.
NITRATE, SODIUM 7631-99-4									
4173 R f f34 eat 24m29 1490					0	1.06gm	2.11gm		Maekawa;fctx,20,25-33;1982
liv mix e	no dre	P=1.	-	10.1gm n.s.s.	2/50	0/50	0/49		
tba mix e	no dre	P=1.	-	2.99gm n.s.s.	46/50	43/50	39/49		
4174 R m f34 eat 24m29 1490					0	846.mg	1.69gm		
liv mix e	no dre	P=1.	-	10.2gm n.s.s.	6/50	7/50	4/50		
tba mix e	2.62gm *	P<.6	-	409.mg n.s.s.	47/50	50/50	48/50		
4175 R f mrc wat 20m24 213					0	165.mg			Lijinsky;jnci,50,1061-1063;1973
pit tum e	103.mg	P<.004	-	42.8mg 764.mg	3/15	11/15			
tba mix e	86.9mg	P<.004	-	35.3mg 665.mg	4/15	12/15			
4176 R m mrc wat 20m24 213					0	115.mg			
tba mix e	750.mg	P<.8	-	83.5mg n.s.s.	5/15	6/15			
NITRIC OXIDE 10102-43-9									
4177 M f icr inh 29m29 1388					0	5.19mg			Oda;envr,22,254-263;1980
lun ade	no dre	P=1.	-	38.4mg n.s.s.	6/64	5/65			
NITRILOTRIACETIC ACID 139-13-9									
4178 M f b6c eat 77w91 TR6 :					0	836.mg	1.67gm		
kid uac	13.8gm *	P<.06	c	4.77gm n.s.s.	0/20	0/50	4/50		
TBA MXB	3.95gm *	P<.3		1.33gm n.s.s.	4/20	13/50	19/50		
liv MXB	no dre	P=1.		9.71gm n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB	9.31gm *	P<.2		3.80gm n.s.s.	0/20	2/50	4/50		lun:a/a,a/c.
4179 M m b6c eat 77w91 TR6 :					0	771.mg	1.54gm		
MXA MXA	1.47gm /	P<.0005	c	1.04gm 2.17gm	0/20	5/50	24/50		k/p:pam; kid:tla,uac.
TBA MXB	2.21gm /	P<.09		1.06gm n.s.s.	10/20	14/50	31/50		
liv MXB	no dre	P=1.		9.66gm n.s.s.	3/20	3/50	2/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		4.68gm n.s.s.	4/20	5/50	6/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
4180 R f f34 eat 77w99 TR6 :	0	281.mg	562.mg		
liv nnd 810.mg * P<.004 508.mg 2.19gm	2/20	8/50	22/50		S
MXA MXA 1.45gm * P<.002 c 908.mg 2.72gm	0/20	2/50	13/50		kid:tla,tpp; ubl:sqc,tcc.
ubl MXA 1.57gm * P<.002 c 967.mg 3.08gm	0/20	2/50	12/50		ubl:sqc,tcc.
adr phe 1.71gm / P<.005 984.mg 4.86gm	1/20	0/50	14/50		S
lun a/c 2.25gm * P<.03 1.28gm 10.1gm	0/20	3/50	7/50		S
TBA MXB 631.mg * P<.2 278.mg n.s.s.	14/20	33/50	47/50		
liv MXB 810.mg * P<.004 508.mg 2.19gm	2/20	8/50	22/50		liv:hpa,hpc,nnd.
4181 R m f34 eat 18m24 TR6 :	0	225.mg	450.mg		
MXA MXA 446.mg \ P<.05 234.mg 10.6gm	2/20	16/50	(8/50)		adr:phe; pit:bsa,cra; pni:isa; thy:fca,fcc. S
MXA MXA 2.26gm * P<.02 c 1.21gm 7.43gm	0/20	1/50	7/50		kid:tla,uac; ure:pam,ppa.
TBA MXB 7.12gm * P<.9 442.mg n.s.s.	8/20	26/50	22/50		
liv MXB no dre P=1. 3.30gm n.s.s.	3/20	5/50	2/50		liv:hpa,hpc,nnd.
4182 R f mrc wat 20m24 213	0	165.mg			Lijinsky;jnci,50,1061-1063;1973
tba mix 221.mg P<.2 - 67.2mg n.s.s.	5/15	9/15			
4183 R m mrc wat 20m24 213	0	115.mg			
tba mix 248.mg P<.3 - 64.2mg n.s.s.	4/15	7/15			
NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE 18662-53-8					
4184 M f b6c eat 78w91 TR6a :	0	279.mg	557.mg		
TBA MXB 5.31gm * P<.8 - 667.mg n.s.s.	6/20	11/50	16/50		
liv MXB no dre P=1. 2.31gm n.s.s.	2/20	3/50	2/50		liv:hpa,hpc,nnd.
lun MXB 61.8gm * P<.9 2.72gm n.s.s.	1/20	0/50	2/50		lun:a/a,a/c.
4185 M m b6c eat 78w91 TR6a :	0	257.mg	514.mg		
--- MXA # 1.55gm * P<.02 - 778.mg n.s.s.	0/20	3/49	8/50		---:leu,lym. S
TBA MXB no dre P=1. 730.mg n.s.s.	7/20	17/49	14/50		
liv MXB no dre P=1. 2.12gm n.s.s.	4/20	4/49	3/50		liv:hpa,hpc,nnd.
lun MXB 1.99gm \ P<.6 409.mg n.s.s.	2/20	7/49	(0/50)		lun:a/a,a/c.
4186 R f f34 eat 24m24 TR6 :	0	10.0mg	100.mg	1.00gm	
MXA MXA 783.mg * P<.0005 c 417.mg 1.73gm	0/24	0/24	1/24	13/24	kid:tla,uac; ubl:pam,tcc; ure:tcc.
ubl MXA 1.99gm * P<.002 c 808.mg 10.9gm	0/24	0/24	1/24	5/24	ubl:pam,tcc.
ure tcc 2.28gm * P<.0005 c 919.mg 8.10gm	0/24	0/24	0/24	6/24	
kid MXA 2.88gm * P<.002 c 994.mg 17.1gm	0/24	0/24	0/24	4/24	kid:tla,uac.
TBA MXB 2.99gm * P<.6 481.mg n.s.s.	18/24	19/24	17/24	20/24	
liv MXB no dre P=1. 2.37gm n.s.s.	1/24	3/24	1/24	1/24	liv:hpa,hpc,nnd.
4187 R f f34 eat 18m25 TR6a :	0	276.mg	552.mg		
TBA MXB no dre P=1. - 559.mg n.s.s.	13/20	36/50	26/49		
liv MXB 12.0gm * P<.5 2.96gm n.s.s.	0/20	1/50	1/49		liv:hpa,hpc,nnd.
4188 R m f34 eat 24m24 TR6 :	0	8.00mg	80.0mg	800.mg	
MXA MXA 511.mg * P<.0005 c 261.mg 1.10gm	0/24	0/24	0/24	14/24	kid:hem,tcc,tla,uac; ubl:tcc; ure:tcc.
kid MXA 826.mg * P<.0005 c 367.mg 2.13gm	0/24	0/24	0/24	9/24	kid:hem,tcc,tla,uac.
ure tcc 965.mg * P<.0005 c 412.mg 2.66gm	0/24	0/24	0/24	8/24	
kid tcc 2.53gm * P<.002 c 830.mg 13.7gm	0/24	0/24	0/24	4/24	
TBA MXB 329.mg Z P<.0005 157.mg 1.21gm	8/24	15/24	10/24	18/24	
liv MXB 2.20gm * P<.05 579.mg n.s.s.	2/24	0/24	1/24	3/24	liv:hpa,hpc,nnd.
4189 R m f34 eat 18m25 TR6a :	0	221.mg	441.mg		
TBA MXB 2.63gm * P<.7 - 409.mg n.s.s.	10/20	26/50	24/50		
liv MXB no dre P=1. 3.59gm n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.
4190 R m cdr wat 24m24 1089m	0	50.0mg			Goyer;jnci,66,869-880;1981/pers.comm.
kid ade e 320.mg P<.02 + 139.mg n.s.s.	4/101	13/96			
tba mix e 88.4mg P<.07 35.5mg n.s.s.	61/101	70/96			
4191 R m cdr wat 24m24 1089n	0	50.0mg			
kid ade e 224.mg P<.0005 + 113.mg 748.mg	1/85	13/87			
tba mix e 105.mg P<.2 37.9mg n.s.s.	50/85	61/87			
NITRITE, SODIUM 7632-00-0					
4192 H f syg eat 97w97 1831	0	149.mg			Ernst;carc,8,1843-1845;1987/pers.comm.
liv cgf e no dre P=1. 402.mg n.s.s.	1/14	0/15			
tba tum e 477.mg P<.6 78.7mg n.s.s.	5/14	7/15			
4193 H m syg eat 24m24 1831	0	131.mg			
liv tum e no dre P=1. 391.mg n.s.s.	0/16	0/15			
tba tum e no dre P=1. 134.mg n.s.s.	10/16	6/15			
4194 M f b6c wat 24m24 TR495 :	0	45.0mg	90.0mg	165.mg	
for MXA 1.61gm * P<.06 e 572.mg n.s.s.	1/50	0/50	1/50	5/50	for:sqc,sqp.
TBA MXB 459.mg * P<.4 124.mg n.s.s.	21/50	32/50	31/50	32/50	
liv MXB no dre P=1. 553.mg n.s.s.	10/50	8/50	7/50	7/50	liv:hpa,hpb,hpc.
lun MXB 843.mg * P<.2 300.mg n.s.s.	1/50	6/50	5/50	6/50	lun:a/a,a/c.
4195 M m b6c wat 24m24 TR495 :	0	60.0mg	120.mg	220.mg	
TBA MXB 9.19gm * P<1. - 196.mg n.s.s.	40/50	35/50	36/50	38/50	
liv MXB no dre P=1. 324.mg n.s.s.	26/50	25/50	17/50	25/50	liv:hpa,hpb,hpc.
lun MXB 990.mg Z P<.2 316.mg n.s.s.	13/50	6/50	12/50	17/50	lun:a/a,a/c.
4196 M f cb6 eat 52w69 1361	0	489.mg			Murthy;ijcn,23,253-259;1979
liv hpc e no dre P=1. - 532.mg n.s.s.	1/92	0/12			
lun ade e no dre P=1. - 532.mg n.s.s.	2/92	0/12			
tba mix e no dre P=1. - 268.mg n.s.s.	17/92	2/12			
4197 M f cb6 wat 27m29 1925	0	36.8mg	368.mg		Anderson;canr,45,3561-3566;1985
lun tum g 5.20gm * P<.5 - 788.mg n.s.s.	1/20	1/15	2/17		
liv mix g no dre P=1. - 1.33gm n.s.s.	3/20	1/15	1/17		
4198 M m cb6 eat 52w69 1361	0	452.mg			Murthy;ijcn,23,253-259;1979
lun ade e 1.61gm P<.2 - 236.mg n.s.s.	1/95	1/11			
liv hpc e no dre P=1. - 451.mg n.s.s.	2/95	0/11			
tba mix e 1.21gm P<.4 - 185.mg n.s.s.	8/95	2/11			
4199 M f icr wat 25m25 2328	0	173.mg	244.mg	471.mg	Inai;gann,70,203-208;1979/pers.comm.
lun tum 7.23gm * P<.5 - 1.71gm n.s.s.	3/20	3/50	2/50	8/50	
liv tum no dre P=1. - 6.27gm n.s.s.	1/20	0/50	0/50	1/50	
tba mix no dre P=1. - 708.mg n.s.s.	10/20	19/50	21/50	22/50	
4200 M m icr wat 25m25 2328	0	241.mg	429.mg	702.mg	
lun tum 16.3gm * P<.7 - 2.29gm n.s.s.	2/20	6/50	4/50	7/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv tum		25.0gm *	P<.7	- 5.18gm n.s.s.	0/20	1/50	1/50	1/50	
tba mix		no dre	P=1.	- 1.67gm n.s.s.	9/20	23/50	16/50	18/50	
4201 M f scd wat		8m29 1255			0	30.7mg			Anderson;ijcn,24,319-322;1979
liv hct s		744.mg	P<.7	- 79.3mg n.s.s.	1/16	2/20			
lun tum s		no dre	P=1.	- 132.mg n.s.s.	3/16	1/20			
4202 M m scd wat		8m27 1255			0	27.7mg			
lun tum s		103.mg	P<.3	- 25.7mg n.s.s.	4/21	6/17			
liv hct s		no dre	P=1.	- 52.8mg n.s.s.	5/21	3/17			
4203 M f vms wat		31m31 2320			0	400.mg			Hawkes;huet,11,279-281;1992
bra gli r		no dre	P=1.	- 8.36gm n.s.s.	1/100	1/100			
4204 M m vms wat		26m26 2320			0	333.mg			
bra gli r		no dre	P=1.	- 8.11gm n.s.s.	0/100	0/100			
4205 R f f34 wat		24m24 TR495 :			0	42.9mg	85.7mg	171.mg	
TBA MXB		74.4gm *	P<1.	- 108.mg n.s.s.	45/50	45/50	49/50	45/50	
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
4206 R f f34 eat		52w69 1361			0	188.mg			Murthy;ijcn,23,253-259;1979
liv tum e		no dre	P=1.	- 273.mg n.s.s.	0/44	0/16			
tba mix e		no dre	P=1.	- 88.4mg n.s.s.	20/44	6/16			
4207 R f f34 wat		24m28 1490			0	51.0mg	85.0mg		Maekawa;fctx,20,25-33;1982
liv mix e		no dre	P=1.	- 420.mg n.s.s.	1/49	0/48	0/48		
tba mix e		no dre	P=1.	- 154.mg n.s.s.	45/49	41/48	35/48		
4208 R f f34 eat		24m30 1645m			0	80.0mg			Lijinsky;jtxe,13,609-614;1984/1983a
liv mix e		124.mg	P<.003	+ 56.7mg 817.mg	4/24	14/24			
liv nnd e		199.mg	P<.03	78.9mg n.s.s.	4/24	11/24			
liv car e		470.mg	P<.02	162.mg n.s.s.	0/24	4/24			
4209 R f f34 eat		24m30 1654m			0	80.9mg			Lijinsky;fctx,22,715-720;1984/1983a
liv mix e		141.mg	P<.007	+ 62.0mg 2.04gm	4/24	13/24			
liv nnd e		164.mg	P<.02	69.2mg n.s.s.	4/24	12/24			
liv hpc e		629.mg	P<.04	190.mg n.s.s.	0/24	3/24			
4210 R f f34 wat		24m30 1654n			0	63.5mg			
adr mdt e		163.mg	P<.0005	73.1mg 523.mg	0/24	8/24			
thy car e		163.mg	P<.0005	73.1mg 523.mg	0/24	8/24			
mam tum e		115.mg	P<.05	44.1mg n.s.s.	8/24	15/24			
liv mix e		153.mg	P<.03	+ 60.7mg n.s.s.	4/24	11/24			
liv nnd e		185.mg	P<.06	68.2mg n.s.s.	4/24	10/24			
ute pol e		218.mg	P<.02	85.8mg n.s.s.	1/24	7/24			
liv hpc e		1.55gm	P<.3	252.mg n.s.s.	0/24	1/24			
4211 R f f34 eat		24m30 1854			0	87.9mg			Lijinsky;txih,3,413-422;1987/pers.comm.
liv mix		136.mg	P<.003	62.3mg 897.mg	4/24	14/24			
liv nnd		218.mg	P<.03	86.7mg n.s.s.	4/24	11/24			
liv hpc		516.mg	P<.02	178.mg n.s.s.	0/24	4/24			
4212 R m f34 wat		24m24 TR495 :			0	37.5mg	75.0mg	150.mg	
ski fib #		667.mg *	P<.04	- 325.mg n.s.s.	0/50	1/50	6/50	3/50	s
TBA MXB		no dre	P=1.	81.2mg n.s.s.	45/50	39/50	44/50	(37/50)	
liv MXB		6.55gm *	P<.7	1.07gm n.s.s.	0/50	0/50	1/50	0/50	liv:hpa,hpb,hpc.
4213 R m f34 eat		52w69 1361			0	151.mg			Murthy;ijcn,23,253-259;1979
liv tum e		no dre	P=1.	- 218.mg n.s.s.	0/50	0/16			
tba mix e		no dre	P=1.	- 58.8mg n.s.s.	30/50	8/16			
4214 R m f34 wat		24m28 1490			0	45.2mg	81.0mg		Maekawa;fctx,20,25-33;1982
liv mix e		1.31gm *	P<.5	- 306.mg n.s.s.	4/46	5/49	7/50		
tba mix e		noTD50	P=1.	- n.s.s. n.s.s.	46/46	49/49	50/50		
4215 R m f34 eat		24m30 1645m			0	64.0mg			Lijinsky;jtxe,13,609-614;1984/1983a
liv mix e		445.mg	P<.3	114.mg n.s.s.	3/24	6/24			
liv nnd e		467.mg	P<.3	125.mg n.s.s.	2/24	5/24			
liv car e		no dre	P=1.	297.mg n.s.s.	1/24	1/24			
4216 R m f34 eat		24m30 1654m			0	64.7mg			Lijinsky;fctx,22,715-720;1984/1983a
liv nnd e		no dre	P=1.	235.mg n.s.s.	5/24	3/24			
4217 R m f34 wat		24m30 1654n			0	44.5mg			
liv mix e		946.mg	P<.7	109.mg n.s.s.	3/24	4/24			
liv hpc e		1.04gm	P<.6	143.mg n.s.s.	1/24	2/24			
liv nnd e		no dre	P=1.	160.mg n.s.s.	2/24	2/24			
4218 R m f34 eat		24m30 1854			0	92.3mg			Lijinsky;txih,3,413-422;1987/pers.comm.
liv mix		641.mg	P<.3	164.mg n.s.s.	3/24	6/24			
liv nnd		674.mg	P<.3	180.mg n.s.s.	2/24	5/24			
liv hpc		no dre	P=1.	429.mg n.s.s.	1/24	1/24			
4219 R m f34 eat		27m27 1920			0	80.0mg	200.mg		Grant;fctx,27,565-571;1989
tes ict ef		no dre	P=1.	- 109.mg n.s.s.	16/20	31/48	(7/50)		
--- mnl ef		no dre	P=1.	- 348.mg n.s.s.	9/18	7/39	(3/40)		
mix lym ef		no dre	P=1.	- 371.mg n.s.s.	15/20	14/50	(10/49)		
--- grl ef		no dre	P=1.	- 1.63gm n.s.s.	0/18	1/39	0/40		
tba tum ef		no dre	P=1.	- 389.mg n.s.s.	20/20	45/50	34/50		
4220 R b cdr eat		29m29 471			0	45.0mg			Newberne;scie,204,1079-1081;1979
--- mly		539.mg	P<.03	+ 231.mg n.s.s.	6/136	16/136			
spl lym		601.mg	P<.04	246.mg n.s.s.	6/136	15/136			
liv ang		5.84gm	P<.3	952.mg n.s.s.	0/136	1/136			
liv mix		no dre	P=1.	1.08gm n.s.s.	1/136	1/136			
4221 R m f3d wat		51w51 2162 ()			0	100.mg			Kawabe;gann,85,17-25;1994
for tum er		no dre	P=1.	- 74.3mg n.s.s.	0/15	0/15			
stg tum Cer		no dre	P=1.	- 74.3mg n.s.s.	0/15	0/15			
4222 R f mrc wat		20m24 213			0	65.9mg			Lijinsky;jnci,50,1061-1063;1973
tba mix e		57.3mg	P<.03	- 21.4mg n.s.s.	4/15	10/15			
4223 R f mrc wat		16m28 1189			0	11.2mg			Greenblatt;jnci,50,799-802;1973
liv tum e		no dre	P=1.	- 41.3mg n.s.s.	0/20	0/13			
tba tum e		no dre	P=1.	- 6.48mg n.s.s.	14/20	9/13			
4224 R m mrc wat		20m24 213			0	46.2mg			Lijinsky;jnci,50,1061-1063;1973
tba mix e		61.9mg	P<.2	- 18.8mg n.s.s.	5/15	9/15			
4225 R m mrc wat		16m28 1189			0	7.85mg			Greenblatt;jnci,50,799-802;1973
liv tum e		no dre	P=1.	- 33.4mg n.s.s.	0/20	0/15			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba tum e	no dre	P=1.	-	12.9mg n.s.s.	7/20	4/15			
4226 R m wis eat 92w92 1352					0	32.0mg	64.0mg		Aoyagi;jnci,65,411-414;1980
liv mix e	155.mg *	P<.007	+	63.2mg 2.04gm	0/19	1/22	5/19		
4227 R m wis wat 24m24 1910m					0	75.0mg	150.mg		Yamamoto;clet,45,221-225;1989/1996/pers.comm.
liv tum ej	no dre	P=1.	-	168.mg n.s.s.	0/17	0/17	0/17		
4228 R m wis wat 94w94 1914					0	75.0mg	150.mg		Yamamoto;carc,10,1607-1611;1989
liv hpc	no dre	P=1.	-	168.mg n.s.s.	0/20	0/20	0/20		
lun tum	no dre	P=1.	-	168.mg n.s.s.	0/20	0/20	0/20		
nas tum	no dre	P=1.	-	168.mg n.s.s.	0/20	0/20	0/20		
3-NITRO-p-ACETOPHENETIDE 1777-84-0									
4229 M f b6c eat 78w97 TR133 :					0	763.mg	1.53gm		
TBA MXB v	no dre	P=1.	-	1.44gm n.s.s.	22/50	17/50	(15/50)		
liv MXB v	no dre	P=1.		8.86gm n.s.s.	4/50	3/50	1/50		liv:hpa,hpc,nnd.
lun MXB v	30.8gm *	P<.7		4.33gm n.s.s.	1/50	4/50	2/50		lun:a/a,a/c.
4230 M m b6c eat 78w98 TR133 :					0	697.mg	1.39gm		
liv MXA v	2.27gm *	P<.03	c	1.02gm n.s.s.	10/50	13/49	23/50		liv:hpa,hpc.
TBA MXB v	3.49gm *	P<.3		989.mg n.s.s.	21/50	20/49	29/50		
liv MXB v	2.27gm *	P<.03		1.02gm n.s.s.	10/50	13/49	23/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		5.73gm n.s.s.	11/50	2/49	6/50		lun:a/a,a/c.
4231 R f f34 eat 18m25 TR133 :					0	66.0mg	130.mg		
TBA MXB v	no dre	P=1.	-	649.mg n.s.s.	45/50	12/50	15/50		
liv MXB v	6.24gm *	P<.7		692.mg n.s.s.	2/50	0/50	3/50		liv:hpa,hpc,nnd.
4232 R m f34 eat 18m24 TR133 :					0	52.8mg	105.mg		
TBA MXB v	no dre	P=1.	-	118.mg n.s.s.	26/50	19/50	(13/50)		
liv MXB v	no dre	P=1.		1.38gm n.s.s.	3/50	0/50	0/50		liv:hpa,hpc,nnd.
5-NITRO-o-ANISIDINE 99-59-2									
4233 M f b6c eat 78w96 TR127 :					0	836.mg	666.mg		
--- MXA v	2.33gm *	P<.04		917.mg n.s.s.	9/100	5/50	10/50		---:leu,lym. S
liv hpc v	3.72gm /	P<.06	c	1.32gm n.s.s.	3/100	0/50	8/50		
TBA MXB v	1.82gm *	P<.2		632.mg n.s.s.	29/100	9/50	22/50		
liv MXB v	3.72gm /	P<.06		1.32gm n.s.s.	3/100	0/50	8/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		3.87gm n.s.s.	5/100	0/50	2/50		lun:a/a,a/c.
4234 M m b6c eat 78w95 TR127 :					0	780.mg	615.mg		
liv hpc v#	1.05gm \	P<.003	-	504.mg 6.19gm	18/100	25/50	(3/50)		S
liv MXA v	1.12gm \	P<.005		518.mg 11.3gm	20/100	25/50	(3/50)		liv:hpa,hpc. S
TBA MXB v	1.69gm \	P<.2		516.mg n.s.s.	45/100	32/50	(17/50)		
liv MXB v	1.12gm \	P<.005		518.mg 11.3gm	20/100	25/50	(3/50)		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.		2.53gm n.s.s.	15/100	5/50	(2/50)		lun:a/a,a/c.
4235 R f f34 eat 18m25 TR127 :					0	147.mg	294.mg		
MXB MXB	170.mg *	P<.0005		107.mg 292.mg	3/100	17/50	22/50		cli:adn,can,ppa,sqc; ski:sec,sqc; zym:sec,sqc. C
mgl MXA	222.mg \	P<.0005		102.mg 642.mg	2/100	11/50	(4/50)		mgl:acn,adn,pac. S
cli MXA	230.mg *	P<.0005	c	133.mg 454.mg	3/100	12/50	14/50		cli:adn,can,ppa,sqc.
mgl acn	254.mg \	P<.0005		117.mg 609.mg	0/100	10/50	(4/50)		S
lun MXA	280.mg \	P<.0005		99.1mg 1.63gm	1/100	5/50	(1/50)		lun:a/a,a/c. S
MXA MXA	602.mg *	P<.0005	c	306.mg 1.23gm	0/100	5/50	10/50		ski:sec,sqc; zym:sec,sqc.
cli MXA	966.mg *	P<.0005	c	458.mg 2.42gm	0/100	1/50	9/50		cli:can,sqc.
cli can	1.26gm /	P<.0005	c	529.mg 3.95gm	0/100	0/50	7/50		
TBA MXB	73.4mg *	P<.0005		44.8mg 154.mg	83/100	45/50	41/50		
liv MXB	3.20gm *	P<.2		589.mg n.s.s.	2/100	0/50	2/50		liv:hpa,hpc,nnd.
4236 R m f34 eat 18m25 TR127 :					0	118.mg	235.mg		
MXB MXB	28.1mg *	P<.0005		16.4mg 43.8mg	2/99	36/50	45/50		ski:bcc,cuc,sea,sec,sgc,sqc,tri; zym:cuc,sec,sqc. C
ski MXA	30.5mg *	P<.0005	c	17.3mg 49.6mg	2/99	30/50	42/50		ski:bcc,sec,sgc,sqc,tri.
ski tri	43.7mg *	P<.0005	c	21.5mg 78.8mg	0/99	20/50	9/50		
ski bcc	52.0mg /	P<.0005	c	22.7mg 105.mg	1/99	7/50	30/50		
ski MXA	66.0mg *	P<.0005	c	27.1mg 113.mg	0/99	14/50	26/50		ski:sea,sec.
MXA MXA	105.mg /	P<.0005	c	61.3mg 176.mg	1/99	10/50	29/50		ski:cuc,sec,sqc; zym:cuc,sec,sqc.
pit adn	115.mg *	P<.0005		38.0mg 528.mg	10/99	8/50	5/50		S
ski sec	162.mg /	P<.0005	c	87.7mg 286.mg	0/99	5/50	21/50		
pre MXA	196.mg *	P<.0005		45.7mg 1.17gm	2/99	2/50	5/50		pre:adn,can. S
ski sqc	252.mg /	P<.0005	c	107.mg 627.mg	1/99	3/50	12/50		
adr MXA	345.mg *	P<.0005		55.5mg 2.47gm	1/99	1/50	5/50		adr:coa,coc. S
TBA MXB	12.8mg *	P<.0005		7.94mg 21.3mg	58/99	44/50	48/50		
liv MXB	194.mg *	P<.002		49.9mg 1.68gm	4/99	3/50	3/50		liv:hpa,hpc,nnd.
5-NITRO-2-FURALDEHYDE SEMICARBAZONE (nitrofurazone) 59-87-0									
4237 M f b6c eat 24m24 TR337 :					0	19.3mg	39.9mg		
ova MXB	22.4mg *	P<.0005		15.4mg 37.7mg	1/50	20/50	29/50		ova:gct,mtb. C
ova MXA	29.8mg *	P<.0005		20.1mg 48.8mg	0/50	18/50	20/50		ova:mtb,tua. S
ova mtb	30.8mg *	P<.0005	c	20.7mg 50.6mg	0/50	17/50	20/50		
ova gct	124.mg *	P<.005	c	60.2mg 1.14gm	1/50	4/50	9/50		
TBA MXB	66.2mg *	P<.3		19.9mg n.s.s.	36/50	43/50	42/50		
liv MXB	no dre	P=1.		214.mg n.s.s.	3/50	3/50	1/50		liv:hpa,hpc,nnd.
lun MXB	241.mg *	P<.3		73.0mg n.s.s.	3/50	7/50	6/50		lun:a/a,a/c.
4238 M m b6c eat 24m24 TR337 :					0	17.8mg	36.8mg		
sub MXA #	154.mg *	P<.05	-	60.1mg n.s.s.	3/50	3/50	8/50		sub:fbs,fib,nfs,srn. S
TBA MXB	89.3mg *	P<.4		23.9mg n.s.s.	28/50	26/50	26/50		
liv MXB	152.mg \	P<.7		20.2mg n.s.s.	16/50	15/50	(5/50)		liv:hpa,hpc,nnd.
lun MXB	1.38gm *	P<.9		69.1mg n.s.s.	8/50	7/50	6/50		lun:a/a,a/c.
4239 R f f34 eat 24m24 TR337 :					0	15.4mg	30.7mg		
mgl fba	15.7mg *	P<.0005	c	9.47mg 44.2mg	8/50	36/50	36/50		
TBA MXB	no dre	P=1.		20.3mg n.s.s.	44/50	47/50	46/50		
liv MXB	253.mg *	P<.2		87.3mg n.s.s.	0/50	2/50	2/50		liv:hpa,hpc,nnd.
4240 R m f34 eat 24m24 TR337 :					0	12.3mg	24.6mg		
tnv MXA	44.0mg \	P<.003	e	18.8mg 195.mg	0/50	7/50	(2/50)		tnv:men,msm.
ski MXA	151.mg *	P<.006	e	55.2mg 548.mg	0/50	0/50	5/50		ski:sea,tri.
pre can	65.5mg *	P<.03	e	29.4mg n.s.s.	1/50	8/50	5/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ski sea	177.mg *	P<.02	59.1mg n.s.s.	0/50	0/50	4/50		s
TBA MXB	33.8mg *	P<.3	9.75mg n.s.s.	47/50	46/50	40/50		
liv MXB	no dre	P=1.	73.2mg n.s.s.	7/50	4/50	3/50		liv:hpa,hpc,nnd.
4241 R f hza eat 36w54 1063m				0	33.3mg			Morris;canr,29,2145-2156;1969
mgl fba es	6.52mg	P<.006 +	3.15mg 54.3mg	0/5	11/18			
liv tum es	no dre	P=1.	33.3mg n.s.s.	0/5	0/18			
4242 R f hza eat 44w60 1063n				0	36.8mg			
mam tum es	noTD50	P<.0005 +	n.s.s. 4.64mg	3/16	24/24			
liv tum es	no dre	P=1.	60.5mg n.s.s.	0/16	0/24			
4243 R f sda eat 46w66 1120				0	34.8mg			Erturk;canr,30,1409-1412;1970
mam tum er	7.12mg	P<.0005 +	3.96mg 14.7mg	2/29	22/29			
5-NITRO-2-FURAMIDOXIME 772-43-0								
4244 R f sda eat 46w66 200a				0	6.97mg			Cohen;jnci,51,403-417;1973
liv tum e	no dre	P=1.	18.5mg n.s.s.	0/39	0/32			
tba mix e	42.0mg	P<.5 -	6.78mg n.s.s.	2/39	3/32			
5-NITRO-2-FURANMETHANEDIOL DIACETATE 92-55-7								
4245 R f hza eat 36w54 1063m				0	66.7mg			Morris;canr,29,2145-2156;1969
liv tum es	no dre	P=1.	18.5mg n.s.s.	0/5	0/5			
mam tum es	no dre	P=1. -	18.5mg n.s.s.	0/5	0/5			
4246 R f hza eat 44w60 1063n				0	73.6mg			
mam tum es	105.mg	P<.5 -	18.5mg n.s.s.	3/16	4/13			
liv tum es	no dre	P=1.	65.6mg n.s.s.	0/16	0/13			
3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE (NFIP) 75198-31-1								
4247 M f ctn eat 40w79 1163				0	65.8mg	160.mg	371.mg	Cabral;tumo,66,131-144;1980
mix car es	21.6mg Z	P<.0005 +	13.3mg 37.7mg	0/39	28/40	(23/36	35/44)	
mix pam es	117.mg Z	P<.0005 +	68.0mg 329.mg	2/39	12/40	16/39	(15/50)	
thy lys es	781.mg *	P<.0005	412.mg 2.15gm	0/39	0/40	5/40	8/50	
lun tum es	no dre	P=1. -	704.mg n.s.s.	6/39	6/40	3/35	6/43	
liv hpt es	no dre	P=1. -	138.mg n.s.s.	1/37	0/36	0/23	0/16	
tba mix es	noTD50	P<.0005 +	n.s.s. 20.3mg	28/39	40/40	40/40	50/50	
4248 M m ctn eat 40w73 1163				0	65.8mg	143.mg	409.mg	
mix car es	40.1mg Z	P<.0005 +	26.8mg 63.3mg	0/39	19/35	20/33	(18/30)	
mix pam es	65.8mg Z	P<.0005 +	39.4mg 174.mg	3/39	19/38	17/37	(18/30)	
lun tum es	763.mg *	P<.2 -	248.mg n.s.s.	5/39	5/36	8/35	8/31	
liv hpt es	no dre	P=1. -	765.mg n.s.s.	7/37	1/33	1/28	1/15	
tba mix es	57.1mg *	P<.002 +	26.0mg 338.mg	21/39	38/38	37/37	38/42	
4249 R f wis eat 40w89 1163				0	89.9mg			
mix pam es	27.5mg	P<.0005 +	15.9mg 50.7mg	0/32	25/31			
mam tum es	33.3mg	P<.0005 +	17.5mg 85.0mg	8/32	25/31			
kid tum es	116.mg	P<.0005 +	56.1mg 304.mg	0/32	10/31			
mix car es	443.mg	P<.04 +	134.mg n.s.s.	0/32	3/31			
liv hpt es	644.mg	P<.3	145.mg n.s.s.	1/32	3/31			
tba mix es	15.8mg	P<.0005 +	6.29mg 43.0mg	14/32	30/31			
4250 R m wis eat 40w83 1163				0	77.1mg			
kid tum es	21.4mg	P<.0005 +	12.1mg 40.4mg	0/31	23/29			
mix pam es	43.7mg	P<.0005 +	23.4mg 101.mg	1/31	16/29			
mix car es	104.mg	P<.0005 +	47.0mg 331.mg	0/31	8/29			
liv hpt es	959.mg	P<.3	156.mg n.s.s.	0/31	1/29			
tba mix es	11.9mg	P<.0005 +	4.72mg 32.9mg	13/31	28/29			
5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL 2122-86-3								
4251 R f sda eat 46w66 1126				0	17.4mg			Cohen;jnci,54,841-850;1975
mgl mix e	8.61mg	P<.0005	4.53mg 22.7mg	2/39	16/35			
mgl adc e	31.2mg	P<.006	11.8mg 302.mg	0/39	5/35			
liv tum e	no dre	P=1.	50.6mg n.s.s.	0/39	0/35			
tba mix e	8.61mg	P<.0005 +	4.53mg 22.7mg	2/39	16/35			
N-{[3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYL}ACETAMIDE 36133-88-7								
4252 R f sda eat 46w66 1126				0	13.9mg			Cohen;jnci,54,841-850;1975
mgl mix e	6.35mg	P<.0005	3.24mg 22.9mg	2/24	16/32			
mgl adc e	10.3mg	P<.0005	4.98mg 30.0mg	0/24	10/32			
lun alc e	59.6mg	P<.2 +	14.7mg n.s.s.	0/24	2/32			
k/p tcc eh	59.6mg	P<.2 +	14.7mg n.s.s.	0/24	2/32			
liv tum e	no dre	P=1.	37.0mg n.s.s.	0/24	0/32			
tba mix e	5.20mg	P<.0005	2.76mg 14.7mg	2/24	18/32			
N-[5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOL-2-YL]ACETAMIDE 2578-75-8								
4253 M f swi eat 46w55 1076				0	109.mg			Cohen;canr,33,1593-1597;1973
for mix e	6.74mg	P<.0005 +	2.82mg 15.0mg	0/29	21/22			
for sqp e	14.1mg	P<.0005	7.41mg 29.6mg	0/29	17/22			
for sqc e	104.mg	P<.008	35.8mg 2.28gm	0/29	4/22			
liv tum e	no dre	P=1.	138.mg n.s.s.	0/29	0/22			
lun tum e	no dre	P=1.	138.mg n.s.s.	0/29	0/22			
tba mix e	6.90mg	P<.0005	2.85mg 15.9mg	2/29	21/22			
4254 R f sda eat 40w59 1126				0	53.0mg			Cohen;jnci,54,841-850;1975
for mix ev	8.84mg	P<.0005 +	5.08mg 16.7mg	0/24	22/30			
mix hms ev	10.6mg	P<.0005 +	6.06mg 20.6mg	0/24	20/30			
for sqp ev	11.6mg	P<.0005	6.59mg 22.9mg	0/24	19/30			
lun alc ev	15.3mg	P<.0005 +	8.40mg 31.9mg	0/24	16/30			
k/p tcc evh	16.9mg	P<.0005 +	9.10mg 36.0mg	0/24	15/30			
itn hms ev	18.6mg	P<.0005 +	9.87mg 40.9mg	0/24	14/30			
liv hms ev	22.9mg	P<.0005 +	11.7mg 55.1mg	0/24	12/30			
mgl adc ev	37.7mg	P<.002	17.0mg 145.mg	0/24	8/30			
lun hms ev	52.3mg	P<.007 +	21.3mg 561.mg	0/24	6/30			
mgl mix ev	43.3mg	P<.05	16.9mg n.s.s.	2/24	9/30			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
pan hms ev		81.6mg	P<.03 +	28.2mg n.s.s.	0/24	4/30			
--- lbl ev		111.mg	P<.06 +	33.5mg n.s.s.	0/24	3/30			
smi adc ev		111.mg	P<.06 +	33.5mg n.s.s.	0/24	3/30			
smi lei ev		111.mg	P<.06 +	33.5mg n.s.s.	0/24	3/30			
tba mix ev		noTD50	P<.0005	n.s.s. 5.41mg	2/24	30/30			
4-(5-NITRO-2-FURYL)THIAZOLE 53757-28-1									
4255 R f asd eat 46w68 1411					0	52.1mg			Swaminathan;canr,41,2648-2653;1981
mgl fba e		15.6mg	P<.0005 +	8.56mg 38.6mg	6/36	24/35			
for sqc e		19.5mg	P<.0005 +	11.2mg 38.0mg	0/36	19/35			
liv tum e		no dre	P=1.	161.mg n.s.s.	0/36	0/35			
tba mix e		7.68mg	P<.0005 +	4.26mg 15.2mg	6/36	31/35			
N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE (NFTA) 531-82-8									
4256 H m syg eat 48w70 1077					0	63.1mg			Croft;jnci,51,941-949;1973
ubl mix e		8.91mg	P<.0005 +	4.14mg 20.3mg	0/22	16/18			
ubl sqc e		60.2mg	P<.004 +	22.7mg 388.mg	0/22	5/18			
for sqp e		68.1mg	P<.003 +	27.6mg 372.mg	0/24	6/24			
liv tum e		no dre	P=1.	141.mg n.s.s.	0/24	0/24			
lun tum e		no dre	P=1.	141.mg n.s.s.	0/24	0/24			
4257 R f sda eat 46w66 1122					0	69.3mg			Erturk;canr,30,936-941;1970
mam mix e		10.5mg	P<.0005 +	6.89mg 16.4mg	0/28	47/56			
mgl adc e		36.2mg	P<.0005 +	21.9mg 66.4mg	0/28	23/56			
mgl fba e		56.9mg	P<.0005	31.7mg 132.mg	0/28	16/56			
liv tum e		no dre	P=1.	322.mg n.s.s.	0/28	0/56			
tba mix e		7.25mg	P<.0005	4.51mg 11.6mg	0/28	52/56			
4258 R f sda eat 46w66 1126m					0	69.3mg			Cohen;jnci,54,841-850;1975
mgl fba e		25.0mg	P<.0005 +	13.4mg 66.1mg	4/35	20/34			
k/p tcc e		316.mg	P<.09	77.6mg n.s.s.	0/35	2/34			
liv tum e		no dre	P=1.	196.mg n.s.s.	0/35	0/34			
tba mix e		22.8mg	P<.0005	12.4mg 56.4mg	4/35	21/34			
4259 R f sda eat 46w66 1126n					0	69.3mg			
mgl fba e		30.2mg	P<.0005 +	16.5mg 70.4mg	1/32	17/35			
k/p tcc e		660.mg	P<.3	108.mg n.s.s.	0/32	1/35			
liv tum e		no dre	P=1.	201.mg n.s.s.	0/32	0/35			
tba mix e		27.7mg	P<.0005	15.3mg 61.8mg	1/32	18/35			
N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE (FANFT) 24554-26-5									
4260 H m syg eat 48w70 1077					0	63.1mg			Croft;jnci,51,941-949;1973
ubl mix e		noTD50	P<.0005 +	n.s.s. 9.77mg	0/20	23/23			
ubl sqc e		54.0mg	P<.003 +	23.2mg 238.mg	0/20	7/23			
for sqp e		83.8mg	P<.007 +	31.7mg 1.09gm	0/24	5/24			
liv tum e		no dre	P=1.	141.mg n.s.s.	0/24	0/24			
lun tum e		no dre	P=1.	141.mg n.s.s.	0/24	0/24			
4261 M f cd1 eat 36w68 1601					0	68.8mg			Dunsford;jnci,73,151-160;1984
ubl tcc e		33.3mg	P<.0005 +	20.5mg 58.9mg	0/53	25/55			
ubl spt e		128.mg	P<.002 +	58.0mg 449.mg	0/53	8/55			
ubl sqc e		128.mg	P<.002 +	58.0mg 449.mg	0/53	8/55			
lun ade e		1.12gm	P<.6	148.mg n.s.s.	1/53	2/55			
liv tum e		no dre	P=1.	333.mg n.s.s.	0/53	0/55			
tba mix e		18.7mg	P<.0005	10.6mg 45.9mg	19/53	43/55			
4262 M m cd1 eat 40w77 1601					0	62.3mg			
ubl tcc e		30.5mg	P<.0005 +	19.5mg 51.4mg	0/55	30/56			
ubl spt e		97.1mg	P<.0005 +	49.9mg 230.mg	0/55	12/56			
ubl sqc e		250.mg	P<.009 +	95.0mg 6.08gm	0/55	5/56			
lun ade e		no dre	P=1.	298.mg n.s.s.	4/55	1/56			
liv hpc e		no dre	P=1.	298.mg n.s.s.	4/55	1/56			
tba mix e		21.5mg	P<.0005	12.6mg 47.6mg	17/55	43/56			
4263 M f nmr gav 68w75 1771					0	114.mg	115.mg	118.mg	Berger;clet,31,311-318;1986
for sqc esv		139.mg *	P<.0005 +	89.7mg 232.mg	0/100	14/60	4/13	12/44	
for pam esv		164.mg *	P<.0005 +	103.mg 285.mg	0/100	18/60	1/13	7/44	
stg mal esv		944.mg *	P<.02	358.mg n.s.s.	0/100	5/60	0/13	0/44	
liv mal esv		2.39gm *	P<.2	588.mg n.s.s.	0/100	0/60	0/13	2/44	
lun adc esv		no dre	P=1.	106.mg n.s.s.	1/100	0/60	0/13	0/44	
tba mal esv		59.5mg *	P<.0005	40.0mg 103.mg	18/100	35/60	7/13	27/44	
tba ben esv		69.4mg *	P<.0005	48.4mg 107.mg	4/100	32/60	5/13	18/44	
4264 M f swi eat 46w53 1068					0	106.mg			Erturk;canr,30,1309-1311;1970
ubl tum		18.2mg	P<.0005 +	11.5mg 30.6mg	0/56	31/48			
--- leu		55.4mg	P<.03 +	23.4mg n.s.s.	15/56	23/48			
lun car		163.mg	P<.03 +	60.3mg n.s.s.	1/56	6/48			
4265 M f swi eat 46w66 1076					0	85.2mg			Cohen;canr,33,1593-1597;1973
ubl tcc e		7.72mg	P<.0005 +	3.21mg 17.4mg	0/28	20/21			
lun alc e		86.4mg	P<.003	32.7mg 508.mg	0/28	5/21			
--- lle e		78.3mg	P<.02 +	29.4mg n.s.s.	1/28	6/21			
for sqp e		235.mg	P<.07 +	57.7mg n.s.s.	0/28	2/21			
liv tum e		no dre	P=1.	148.mg n.s.s.	0/28	0/21			
tba mix e		noTD50	P<.0005	n.s.s. 12.5mg	1/28	21/21			
4266 M f swi eat 33w52 1118					0	41.3mg			Cohen;canr,38,1398-1405;1978
ubl car		19.8mg	P<.0005 +	9.28mg 57.1mg	0/30	9/30			
--- leu		47.6mg	P<.08	15.6mg n.s.s.	1/30	5/30			
lun ala		208.mg	P<.3	33.9mg n.s.s.	0/30	1/30			
liv tum		no dre	P=1.	63.8mg n.s.s.	0/30	0/30			
4267 R m f34 eat 30w52 727					0	.115mg	.231mg	1.15mg	2.31mg	11.5mg	23.1mg	Arai;jnci,62,1013-1016;1979
ubl mix e		1.31mg *	P<.0005 +	.739mg 2.38mg	0/20	0/16	0/15	0/16	1/15	13/14	16/16	
ubl ppc e		5.92mg *	P<.0005	3.09mg 13.4mg	0/20	0/16	0/15	0/16	0/15	4/14	9/16	
liv tum e		no dre	P=1.	55.8ug n.s.s.	0/20	0/16	0/15	0/16	0/15	0/14	0/16	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc			Brkly Code NCI/NTPPathology
4268 R m f34 eat 7m24 1575					0	.115mg	.577mg	1.15mg	5.77mg	11.5mg	23.1mg Arai;clet,18,261-269;1983
ubl car		3.18mg	Z P<.0005 +	2.25mg 4.56mg	0/40	0/40	0/40	0/40	34/40	39/40	(36/40)
4269 R m fis eat 72w72 1430					0	80.0mg					Fukushima;canr,41,3100-3103;1981
ubl car		noTD50	P<.0005 +	n.s.s. 24.4mg	0/27	8/8					
4270 R m fis eat 24m24 1574					0	2.00mg					Murasaki;carc,4,97-99;1983
liv tum		no dre	P=1.	8.24mg n.s.s.	0/30	0/20					
ubl tum		no dre	P=1.	8.24mg n.s.s.	0/30	0/20					
4271 R m fis eat 36w74 1657m					0	38.9mg					Cohen;canr,39,1207-1217;1979
ubl car		4.51mg	P<.0005 +	1.85mg 10.3mg	0/42	19/20					
ubl ivc		9.74mg	P<.0005	4.99mg 21.5mg	0/42	15/20					
ubl nvc		60.5mg	P<.003	20.8mg 378.mg	0/42	4/20					
liv hnd		263.mg	P<.2	42.8mg n.s.s.	0/42	1/20					
4272 R m fis eat 77w77 1657n					0	80.0mg					
ubl car		9.87mg	P<.0005 +	5.36mg 17.5mg	0/42	40/42					
ubl ivc		18.1mg	P<.0005	11.3mg 30.5mg	0/42	34/42					
ubl nvc		195.mg	P<.004	79.4mg 1.19gm	0/42	6/42					
liv tum		no dre	P=1.	380.mg n.s.s.	0/42	0/42					
4273 R f sda eat 46w63 1124					0	68.6mg					Erturk;canr,27,1998-2002;1967
ubl mix		5.07mg	P<.0005 +	2.24mg 10.3mg	0/30	29/30					
4274 R f sda eat 26w70 1125m					0	34.9mg					Erturk;canr,29,2219-2228;1969
ubl mix er		noTD50	P<.0005 +	n.s.s. 4.81mg	0/34	30/30					
ubl tcc er		noTD50	P<.0005 +	n.s.s. 5.30mg	0/27	24/24					
ubl ppc er		48.6mg	P<.003 +	19.8mg 234.mg	0/34	6/30					
4275 R f sda eat 46w70 1125n					0	61.8mg					
ubl mix er		noTD50	P<.0005 +	n.s.s. 8.63mg	0/34	29/29					
ubl tcc er		noTD50	P<.0005 +	n.s.s. 9.56mg	0/27	23/23					
ubl ppc er		82.7mg	P<.003 +	33.6mg 383.mg	0/34	6/29					
4276 R m sda eat 26w52 1125m					0	37.6mg					
ubl tcc er		noTD50	P<.0005 +	n.s.s. 3.99mg	0/30	15/15					
4277 R m sda eat 46w52 1125n					0	66.5mg					
ubl tcc er		noTD50	P<.0005 +	n.s.s. 6.07mg	0/30	20/20					
4278 R f wis eat 34w52 1123					0	62.7mg					Adolphs;urre,6,19-27;1978
ubl tcc er		noTD50	P<.0005 +	n.s.s. 4.76mg	0/15	30/30					
N,N'-[6-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL]BISACETAMIDE 51325-35-0											
4279 R f sda eat 46w66 200a					0	69.7mg					Cohen;jnci,51,403-417;1973
mgl mix e		14.1mg	P<.0005 +	8.17mg 27.0mg	2/39	25/33					
mgl adc e		29.0mg	P<.0005	16.0mg 60.3mg	0/39	16/33					
liv tum e		no dre	P=1.	191.mg n.s.s.	0/39	0/33					
tba mix e		12.8mg	P<.0005	7.44mg 24.3mg	2/39	26/33					
3-NITRO-3-HEXENE 4812-22-0											
4280 M b swi inh 62w62 1360					0	.291mg					Deichmann;imed,34,800-807;1965
lun adc		.346mg	P<.02 +	.131mg n.s.s.	0/21	5/27					
4281 M f sww inh 62w62 1366m					0	.332mg					Deichmann;txap,5,445-456;1963
lun adc r		.363mg	P<.09	88.6ug n.s.s.	0/10	2/10					
lun mix r		.687mg	P<.6	97.1ug n.s.s.	1/10	2/10					
4282 M f sww inh 62w62 1366n					0	.332mg					
lun adc r		.768mg	P<.3	.125mg n.s.s.	0/10	1/10					
4283 R b cfn inh 37m37 1360					0	.326mg	.651mg				Deichmann;imed,34,800-807;1965
lun ulc e		8.66mg *	P<.0005 +	4.91mg 19.8mg	0/100	6/100	11/100				
3-NITRO-4-HYDROXYPHENYLARSONIC ACID (roxarsone) 121-19-7											
4284 M f b6c eat 24m24 TR345 :					0	12.8mg	25.5mg				
TBA MXB		no dre	P=1.	- 32.7mg n.s.s.	24/50	11/50	18/50				
liv MXB		no dre	P=1.	196.mg n.s.s.	3/50	0/50	0/50				liv:hpa,hpc,nnd.
lun MXB		193.mg *	P<.6	34.8mg n.s.s.	3/50	4/50	5/50				lun:a/a,a/c.
4285 M m b6c eat 24m24 TR345 :					0	11.8mg	23.5mg				
adr MXA #		138.mg *	P<.03	- 56.5mg n.s.s.	0/50	2/50	4/50				adr:csa,coa. S
TBA MXB		no dre	P=1.	29.5mg n.s.s.	35/50	30/50	34/50				
liv MXB		no dre	P=1.	71.9mg n.s.s.	12/50	15/50	7/50				liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	63.0mg n.s.s.	11/50	5/50	10/50				lun:a/a,a/c.
4286 M f asw eat 24m24 213b					0	6.50mg	13.0mg				Prier;txap,5,526-542;1963
tba tum e		no dre	P=1.	- 6.88mg n.s.s.	14/16	20/30	27/33				
tba mal e		93.6mg *	P<.8	- 10.9mg n.s.s.	6/16	16/30	15/33				
4287 M m asw eat 24m24 213b					0	6.00mg	12.0mg				
liv hpt e		185.mg *	P<.3	- 30.1mg n.s.s.	0/10	0/22	1/12				
tba mal e		85.6mg *	P<.7	- 12.5mg n.s.s.	1/10	5/22	2/12				
tba tum e		no dre	P=1.	- 12.6mg n.s.s.	4/10	6/22	4/12				
4288 R f f34 eat 24m24 TR345 :					0	2.45mg	4.93mg				
TBA MXB		no dre	P=1.	- 4.18mg n.s.s.	48/50	47/50	46/50				
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50				liv:hpa,hpc,nnd.
4289 R m f34 eat 24m24 TR345 :					0	1.96mg	3.92mg				
pit pda		3.40mg \	P<.05	1.28mg n.s.s.	6/50	13/50	(8/50)				S
pni isa		16.5mg *	P<.02	6.87mg n.s.s.	0/50	3/50	4/50				S
pan ade		19.0mg *	P<.07 e	6.46mg n.s.s.	1/50	1/50	5/50				
TBA MXB		7.20mg *	P<.5	1.58mg n.s.s.	46/50	48/50	47/50				
liv MXB		no dre	P=1.	18.5mg n.s.s.	2/50	2/50	1/50				liv:hpa,hpc,nnd.
4290 R f asd eat 24m24 213b					0	2.50mg	10.0mg				Prier;txap,5,526-542;1963
tba tum e		no dre	P=1.	- 15.2mg n.s.s.	14/27	18/28	11/28				
tba mal e		no dre	P=1.	- 45.4mg n.s.s.	4/27	2/28	1/28				
4291 R m asd eat 24m24 213b					0	2.00mg	8.00mg				
tba tum e		no dre	P=1.	- 21.7mg n.s.s.	4/24	2/24	2/22				
tba mal e		1.30gm *	P<1.	- 22.9mg n.s.s.	1/24	1/24	1/22				
2-NITRO-p-PHENYLENEDIAMINE 5307-14-2											
4292 M f b6c eat 78w90 TR169 :					0	248.mg	490.mg				
liv MXA		614.mg *	P<.006 c	346.mg 6.17gm	1/20	10/50	17/50				liv:hpa,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TBA MXB		468.mg *	P<.02	244.mg n.s.s.	4/20	18/50	27/50		
liv MXB		614.mg *	P<.006	346.mg 6.17gm	1/20	10/50	17/50		liv:hpa,hpc,nnd.
lun MXB		1.98gm *	P<.3	898.mg n.s.s.	0/20	5/50	3/50		lun:a/a,a/c.
4293 M m b6c eat 78w90 TR169 :					0	229.mg	457.mg		
TBA MXB		no dre	P=1.	- 326.mg n.s.s.	9/20	17/50	(7/50)		
liv MXB		no dre	P=1.	1.60gm n.s.s.	3/20	7/50	3/50		liv:hpa,hpc,nnd.
lun MXB		945.mg \	P<.3	318.mg n.s.s.	1/20	8/50	(2/50)		lun:a/a,a/c.
4294 R f f34 eat 18m24 TR169 :					0	41.0mg	82.0mg		
--- MXA #		892.mg *	P<.05	- 308.mg n.s.s.	0/20	0/50	4/50		---:leu,lym. S
TBA MXB		no dre	P=1.	153.mg n.s.s.	11/20	12/50	17/50		
liv MXB		no dre	P=1.	666.mg n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.
4295 R m f34 eat 18m24 TR169 :					0	16.0mg	32.8mg		
thy MXA #		224.mg *	P<.03	- 96.6mg n.s.s.	0/20	1/50	6/50		thy:cca,ccr. S
TBA MXB		no dre	P=1.	90.8mg n.s.s.	9/20	15/50	13/50		
liv MXB		no dre	P=1.	489.mg n.s.s.	1/20	0/50	0/50		liv:hpa,hpc,nnd.
4-NITRO-o-PHENYLENEDIAMINE 99-56-9									
4296 M f b6c eat 24m24 TR180 :					0	478.mg	956.mg		
TBA MXB		no dre	P=1.	- 924.mg n.s.s.	8/20	18/50	(11/50)		
liv MXB		no dre	P=1.	2.64gm n.s.s.	1/20	9/50	3/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.79gm n.s.s.	3/20	5/50	4/50		lun:a/a,a/c.
4297 M m b6c eat 24m24 TR180 :					0	441.mg	883.mg		
TBA MXB		no dre	P=1.	- 539.mg n.s.s.	12/20	25/50	(12/50)		
liv MXB		no dre	P=1.	3.51gm n.s.s.	4/20	5/50	4/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	1.96gm n.s.s.	3/20	13/50	6/50		lun:a/a,a/c.
4298 R f f34 eat 24m24 TR180 :					0	18.4mg	36.8mg		
TBA MXB		no dre	P=1.	- 36.0mg n.s.s.	15/20	31/50	33/50		
liv MXB		no dre	P=1.	217.mg n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
4299 R m f34 eat 24m24 TR180 :					0	14.7mg	29.4mg		
TBA MXB		no dre	P=1.	- 47.2mg n.s.s.	9/20	26/50	19/50		
liv MXB		no dre	P=1.	147.mg n.s.s.	1/20	2/50	2/50		liv:hpa,hpc,nnd.
5-NITRO-o-TOLUIDINE 99-55-8									
4300 M f b6c eat 78w96 TR107 :					0	125.mg	240.mg		
MXB MXB v		242.mg *	P<.0005	142.mg 698.mg	3/50	12/50	22/50		---:hes; liv:hpc. C
liv hpc v		288.mg /	P<.0005 c	168.mg 787.mg	2/50	7/50	20/50		
--- hes vh		1.86gm *	P<.4 c	529.mg n.s.s.	1/50	5/50	3/50		
TBA MXB v		989.mg *	P<.5	205.mg n.s.s.	19/50	19/50	25/50		
liv MXB v		288.mg /	P<.0005	168.mg 787.mg	2/50	7/50	20/50		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	1.36gm n.s.s.	2/50	3/50	0/50		lun:a/a,a/c.
4301 M m b6c eat 78w95 TR107 :					0	115.mg	224.mg		
liv hpc v		266.mg /	P<.005 c	135.mg 2.35gm	12/50	12/49	29/50		
MXB MXB v		269.mg /	P<.005	135.mg 2.90gm	13/50	12/49	30/50		---:hem,hes; liv:hpc. C
--- MXA vh		2.55gm *	P<.2 c	718.mg n.s.s.	1/50	0/49	4/50		---:hem,hes.
TBA MXB v		431.mg *	P<.2	146.mg n.s.s.	23/50	20/49	31/50		
liv MXB v		266.mg /	P<.005	135.mg 2.35gm	12/50	12/49	29/50		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	1.03gm n.s.s.	5/50	3/49	2/50		lun:a/a,a/c.
4302 R f f34 eat 18m25 TR107 :					0	1.80mg	3.60mg		
TBA MXB v		no dre	P=1.	- 3.72mg n.s.s.	42/50	33/50	35/50		
liv MXB v		43.0mg *	P<.3	13.0mg n.s.s.	0/50	2/50	1/50		liv:hpa,hpc,nnd.
4303 R m f34 eat 18m25 TR107 :					0	1.40mg	2.90mg		
liv hpc v#		27.7mg *	P<.04	- 8.39mg n.s.s.	0/50	0/50	3/50		S
TBA MXB v		43.7mg *	P<.9	2.67mg n.s.s.	30/50	20/50	27/50		
liv MXB v		no dre	P=1.	9.23mg n.s.s.	5/50	1/50	4/50		liv:hpa,hpc,nnd.
5-NITROACENAPHTHENE 602-87-9									
4304 H f syg eat 26w71 1091					0	382.mg			Takemura;bjca,30,481-483;1974
bil cho		354.mg	P<.003	152.mg 1.66gm	0/20	7/24			
4305 M f b6c eat 78w96 TR118 :					0	53.3mg	127.mg		
MXB MXB ev		45.3mg *	P<.0005	29.3mg 87.4mg	2/50	23/50	19/50		liv:hpc; ova:gct,lut,tua. C
liv hpc ev		45.8mg *	P<.0005 c	29.5mg 90.3mg	2/50	23/50	18/50		
ova MXA ev		217.mg *	P<.0005 c	108.mg 623.mg	0/50	4/50	7/50		ova:gct,lut,tua.
ova tua ev		395.mg *	P<.005 c	161.mg 3.08gm	0/50	2/50	4/50		
TBA MXB ev		90.4mg *	P<.02	40.3mg n.s.s.	19/50	29/50	21/50		
liv MXB ev		45.8mg *	P<.0005	29.5mg 90.3mg	2/50	23/50	18/50		liv:hpa,hpc,nnd.
lun MXB ev		1.32gm *	P<.5	232.mg n.s.s.	2/50	3/50	2/50		lun:a/a,a/c.
4306 M m b6c eat 78w95 TR118 :					0	58.8mg	140.mg		
TBA MXB es		no dre	P=1.	- 74.6mg n.s.s.	23/50	15/50	1/50		
liv MXB es		no dre	P=1.	132.mg n.s.s.	12/50	7/50	0/50		liv:hpa,hpc,nnd.
lun MXB es		no dre	P=1.	152.mg n.s.s.	5/50	4/50	0/50		lun:a/a,a/c.
4307 R f f34 eat 18m23 TR118 :					0	43.0mg	87.0mg		
MXB MXB e		5.98mg /	P<.0005	1.96mg 11.3mg	1/100	37/50	38/50		cli:can; eac:cas,cuc,sqc; lun:a/a,a/c; mgl:acn,pcn. C
lun MXA e		9.63mg *	P<.0005 c	2.18mg 44.5mg	1/100	8/50	3/50		lun:a/a,a/c.
eac MXA e		14.9mg /	P<.0005 c	7.28mg 24.8mg	0/100	27/50	35/50		eac:cas,cuc,sqc.
eac cuc e		17.4mg *	P<.0005 c	7.85mg 30.9mg	0/100	25/50	26/50		
cli can e		52.2mg *	P<.0005 c	18.7mg 143.mg	0/100	6/50	5/50		
mgl MXA e		77.9mg *	P<.0005 c	31.5mg 198.mg	0/100	6/50	5/50		mgl:acn,pcn.
mgl acn e		81.7mg *	P<.0005 c	32.1mg 220.mg	0/100	5/50	5/50		
eac sqc e		90.5mg /	P<.0005 c	29.9mg 230.mg	0/100	3/50	9/50		
TBA MXB e		6.44mg /	P<.0005	3.78mg 10.5mg	83/100	46/50	45/50		
liv MXB e		no dre	P=1.	n.s.s. n.s.s.	2/100	0/50	0/50		liv:hpa,hpc,nnd.
4308 R m f34 eat 17m23 TR118 :					0	34.4mg	62.4mg		
MXB MXB ae		6.45mg /	P<.0005	1.67mg 17.7mg	1/99	25/50	21/50		eac:cuc,sqc; lun:a/a,a/c. C
eac MXA ae		7.88mg *	P<.0005 c	1.71mg 27.8mg	0/99	21/50	20/50		eac:cuc,sqc.
eac cuc ae		8.92mg *	P<.0005 c	1.75mg 45.1mg	0/99	14/50	18/50		
lun MXA ae		29.9mg *	P<.0005 c	9.96mg 93.8mg	1/99	7/50	3/50		lun:a/a,a/c.
lun a/c ae		35.1mg *	P<.0005 c	10.4mg 171.mg	1/99	5/50	0/50		
thy MXA ae		37.7mg /	P<.0005	10.6mg 210.mg	0/99	4/50	1/50		thy:fcc,pac. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
kid MXA ae	42.9mg	* P<.0005		13.5mg 204.mg	0/99	4/50	0/50		kid:tla,uac. S
thy MXA ae	58.5mg	* P<.0005		15.4mg 323.mg	0/99	4/50	0/50		thy:fca,ppa. S
eac sqc ae	68.2mg	* P<.0005	c	27.4mg 188.mg	0/99	7/50	2/50		
TBA MXB ae	5.58mg	/ P<.0005		2.91mg 10.1mg	58/99	39/50	30/50		
liv MXB ae	71.4mg	* P<.08		5.92mg n.s.s.	4/99	1/50	0/50		liv:hpa,hpc,nnd.
p-NITROANILINE 100-01-6									
4309 M f b6c gav 24m24 TR418 :					0	2.11mg	21.1mg	70.3mg	
TBA MXB	487.mg	* P<.8	-	57.7mg n.s.s.	35/50	33/50	34/49	36/50	
liv MXB	no dre	P=1.		104.mg n.s.s.	17/50	17/50	21/49	16/50	liv:hpa,hpc,nnd.
lun MXB	2.37gm	* P<.8		178.mg n.s.s.	2/50	5/50	5/49	4/50	lun:a/a,a/c.
4310 M m b6c gav 24m24 TR418 :					0	2.11mg	21.1mg	70.5mg	
--- MXA	374.mg	* P<.1	e	126.mg n.s.s.	5/50	3/50	4/50	10/50	---:hem,hes.
liv hes	501.mg	* P<.05	e	171.mg n.s.s.	0/50	1/50	2/50	4/50	
TBA MXB	no dre	P=1.		135.mg n.s.s.	33/50	38/50	36/50	28/50	
liv MXB	no dre	P=1.		28.9mg n.s.s.	25/50	26/50	25/50	(13/50)	liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		193.mg n.s.s.	9/50	10/50	9/50	9/50	lun:a/a,a/c.
4311 R f cdr gav 24m24 1985					0	.250mg	1.50mg	9.00mg	Nair;faat,15,607-621;1990
liv nnd e	no dre	P=1.	-	29.9mg n.s.s.	17/60	14/59	10/60	13/60	
liv hpc e	no dre	P=1.	-	115.mg n.s.s.	2/60	2/59	1/60	0/60	
tba mix e	9.05mg	* P<.2	-	2.90mg n.s.s.	55/60	50/60	45/60	56/60	
tba ben e	9.72mg	* P<.2	-	3.15mg n.s.s.	53/60	49/60	45/60	55/60	
tba mal e	47.0mg	* P<.3	-	13.6mg n.s.s.	22/60	15/60	13/60	23/60	
4312 R m cdr gav 24m24 1985					0	.250mg	1.50mg	9.00mg	
liv hpc e	129.mg	* P<.3	-	30.7mg n.s.s.	0/60	1/60	4/60	3/60	
liv nnd e	no dre	P=1.	-	49.9mg n.s.s.	16/60	7/60	3/60	7/60	
tba mix e	12.2mg	* P<.08	-	4.41mg n.s.s.	51/60	36/60	39/60	50/60	
tba mal e	41.6mg	* P<.09	-	14.6mg n.s.s.	12/60	8/60	12/60	17/60	
tba ben e	16.2mg	* P<.2	-	5.47mg n.s.s.	50/60	33/60	34/60	47/60	
o-NITROANISOLE 91-23-6									
4313 M f b6c eat 24m24 TR416 :					0	85.7mg	255.mg	767.mg	
--- MXA	153.mg	Z P<.008		67.1mg 3.07gm	5/50	14/50	(14/50	5/50)	---:mlh,mlm,mlp,mlu. S
liv hpa	179.mg	Z P<.0005	p	96.6mg 695.mg	14/50	20/50	36/50	(18/50)	
liv MXA	194.mg	Z P<.003	p	99.4mg 1.09gm	17/50	21/50	37/50	(20/50)	liv:hpa,hpc.
TBA MXB	350.mg	Z P<.3		104.mg n.s.s.	39/50	44/50	47/50	(28/50)	
liv MXB	194.mg	Z P<.003		99.1mg 1.13gm	17/50	22/50	37/50	(20/50)	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		1.02gm n.s.s.	6/50	3/50	3/50	(0/50)	lun:a/a,a/c.
4314 M m b6c eat 24m24 TR416 :					0	79.2mg	237.mg	710.mg	
liv hpa	177.mg	Z P<.002	c	95.4mg 724.mg	14/50	26/50	41/50	(29/50)	
liv MXB	198.mg	Z P<.006		97.0mg 2.44gm	21/50	33/50	46/50	(34/50)	liv:hpa,hpb,hpc. C
liv MXA	208.mg	Z P<.007	c	101.mg 3.82gm	21/50	32/50	45/50	(32/50)	liv:hpa,hpc.
liv MXA	391.mg	Z P<.005	c	194.mg 4.17gm	7/50	14/50	23/50	(15/50)	liv:hpb,hpc.
liv hpb	428.mg	Z P<.0005	c	251.mg 825.mg	0/50	3/50	17/50	(9/50)	
liv hpc	no dre	P=1.		1.99gm n.s.s.	7/50	12/50	11/50	7/50	
TBA MXB	43.5gm	* P<1.		531.mg n.s.s.	38/50	41/50	49/50	41/50	
liv MXB	198.mg	Z P<.006		97.0mg 2.44gm	21/50	33/50	46/50	(34/50)	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		3.36gm n.s.s.	6/50	12/50	4/50	4/50	lun:a/a,a/c.
4315 R f f34 eat 24m24 TR416 :					0	11.0mg	32.9mg	98.9mg	
--- mnl	152.mg	* P<.006	p	71.8mg 1.85gm	14/50	11/50	14/50	26/50	
lun a/a	666.mg	* P<.02		251.mg n.s.s.	0/50	0/50	2/50	3/50	S
liv hpa	1.01gm	* P<.02		307.mg n.s.s.	0/50	0/50	0/50	3/50	S
for MXA	1.27gm	* P<.2	e	313.mg n.s.s.	0/50	1/50	0/50	2/50	for:sqc,sqp.
for sqp	3.27gm	* P<.5	e	404.mg n.s.s.	0/50	1/50	0/50	1/50	
TBA MXB	336.mg	* P<.7		52.3mg n.s.s.	46/50	46/50	46/50	46/50	
liv MXB	1.01gm	* P<.02		307.mg n.s.s.	0/50	0/50	0/50	3/50	liv:hpa,hpb,hpc.
4316 R f f34 eat 6m24 TR416a :					0	77.9mg	234.mg		
MXB MXB	12.9mg	/ P<.0005		6.72mg 23.8mg	0/22	20/20	32/34	kid:tcc,tpp; lgi:adp,car; ubl:sar,sqc,sqp,tcc,tpp. C	
ubl MXA	13.0mg	/ P<.0005	c	6.74mg 24.0mg	0/22	19/20	32/34		ubl:tcc,tpp.
ubl tcc	13.2mg	/ P<.0005	c	6.81mg 24.8mg	0/22	18/20	32/34		
lgi adp	55.0mg	/ P<.0005	c	24.6mg 114.mg	0/22	5/20	17/34		
lgi MXA	55.0mg	/ P<.0005	c	24.6mg 114.mg	0/22	5/20	17/34		lgi:adp,car.
col adp	60.9mg	/ P<.0005		26.0mg 130.mg	0/22	4/20	17/34		S
ubl sar	192.mg	/ P<.0005	c	73.8mg 544.mg	0/22	1/20	9/34		
ubl MXA	588.mg	* P<.003	c	208.mg 3.24gm	0/22	0/20	5/34		ubl:sqc,sqp.
ubl sqp	751.mg	* P<.006	c	236.mg 9.40gm	0/22	0/20	4/34		
ubl tpp	543.mg	* P<.07	c	99.4mg n.s.s.	0/22	1/20	1/34		
kid MXA	1.24gm	* P<.04	c	287.mg n.s.s.	0/22	0/20	2/34		kid:tcc,tpp.
col car	1.30gm	* P<.04		317.mg n.s.s.	0/22	0/20	2/34		S
lgi car	1.30gm	* P<.04	c	317.mg n.s.s.	0/22	0/20	2/34		
rec adp	560.mg	* P<.2		91.3mg n.s.s.	0/22	1/20	0/34		
kid tpp	1.89gm	* P<.2	c	309.mg n.s.s.	0/22	0/20	1/34		
ubl sqc	2.70gm	* P<.2	c	439.mg n.s.s.	0/22	0/20	1/34		
kid tcc	3.55gm	* P<.2	c	578.mg n.s.s.	0/22	0/20	1/34		
TBA MXB	10.7mg	/ P<.0005		5.84mg 22.2mg	19/22	20/20	32/34		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/22	0/20	0/34		liv:hpa,hpb,hpc.
4317 R m f34 eat 24m24 TR416 :					0	8.75mg	26.2mg	79.0mg	
tes MXA	21.3mg	* P<.0005		11.8mg 63.4mg	48/50	45/50	45/50	45/51	tes:iab,ica. S
--- mnl	25.9mg	* P<.0005	p	15.1mg 62.1mg	26/50	25/50	42/50	34/51	
amd MXA	89.6mg	* P<.004		39.4mg 767.mg	7/50	7/50	8/50	10/51	amd:pbb,pob. S
kid MXA	251.mg	* P<.005	e	93.2mg 3.11gm	0/50	1/50	1/50	3/51	kid:rua,ruc.
for MXA	304.mg	* P<.007	e	102.mg 5.23gm	0/50	0/50	2/50	2/51	for:sqc,sqp.
amd MXA	109.mg	* P<.04		40.9mg n.s.s.	12/50	10/50	10/50	10/51	amd:pbb,phm,pob. S
pre MXA	195.mg	* P<.04		68.6mg n.s.s.	7/50	4/50	3/50	8/51	pre:car,cnb. S
for sqp	543.mg	* P<.05	e	134.mg n.s.s.	0/50	0/50	1/50	1/51	
kid ruc	612.mg	* P<.02	e	149.mg n.s.s.	0/50	0/50	0/50	2/51	
for sqc	715.mg	* P<.07	e	167.mg n.s.s.	0/50	0/50	1/50	1/51	
kid rua	435.mg	* P<.2	e	127.mg n.s.s.	0/50	1/50	1/50	1/51	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TBA MXB	21.4mg *	P<.0005		12.1mg 59.4mg	48/50	44/50	48/50	47/51	
liv MXB	330.mg *	P<.2		78.5mg n.s.s.	0/50	4/50	1/50	2/51	liv:hpa,hpb,hpc.
4318 R m f34 eat 6m24 TR416a :					0	62.3mg	187.mg		
MXB MXB	7.47mg /	P<.0005		2.84mg 14.0mg	0/21	26/27	34/34		kid:tcc,tpp; lgi:adp,car; ubl:sar,sqc,sqp,tcc,tpp. C
ubl MXA	7.48mg /	P<.0005	c	2.84mg 14.1mg	0/21	26/27	33/34		ubl:tcc,tpp.
ubl tcc	8.28mg /	P<.0005	c	2.93mg 16.4mg	0/21	23/27	33/34		
lgi MXA	8.54mg /	P<.0005	c	2.96mg 17.9mg	0/21	21/27	25/34		lgi:adp,car.
lgi adp	8.58mg /	P<.0005	c	2.96mg 18.0mg	0/21	21/27	24/34		
col adp	17.2mg /	P<.0005		7.65mg 29.1mg	0/21	18/27	24/34		S
rec adp	51.8mg *	P<.0005		15.7mg 212.mg	0/21	6/27	1/34		S
ubl tpp	75.6mg *	P<.004	c	17.0mg 965.mg	0/21	3/27	1/34		
kid MXA	83.6mg *	P<.0005	c	16.8mg 468.mg	0/21	1/27	9/34		kid:tcc,tpp.
kid tcc	90.9mg *	P<.0005	c	17.0mg 806.mg	0/21	1/27	6/34		
ubl MXA	273.mg /	P<.0005	c	117.mg 801.mg	0/21	0/27	8/34		ubl:sqc,sqp.
ubl sar	292.mg *	P<.0005	c	117.mg 994.mg	0/21	1/27	7/34		
ubl sqc	422.mg /	P<.002	c	147.mg 2.04gm	0/21	0/27	5/34		
ubl sqp	482.mg /	P<.003	c	155.mg 3.27gm	0/21	0/27	4/34		
lgi car	573.mg *	P<.004	c	194.mg 4.36gm	0/21	0/27	4/34		
col car	573.mg *	P<.004		194.mg 4.36gm	0/21	0/27	4/34		S
cec adp	21.3mg *	P<.03		3.48mg n.s.s.	0/21	1/27	0/34		S
kid tpp	1.04gm *	P<.03	c	291.mg n.s.s.	0/21	0/27	3/34		
TBA MXB	3.97mg /	P<.0005		1.92mg 8.76mg	19/21	27/27	34/34		
liv MXB	no dre	P=1.		12.8mg n.s.s.	1/21	0/27	0/34		liv:hpa,hpb,hpc.
4-NITROANTHRANILIC ACID 619-17-0									
4319 M f b6c eat 78w93 TR109 :					0	502.mg	1.09gm		
TBA MXB	no dre	P=1.	-	1.35gm n.s.s.	39/100	18/50	18/50		
liv MXB	no dre	P=1.		6.86gm n.s.s.	8/100	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB	2.56gm \	P<.05		824.mg n.s.s.	2/100	5/50	(1/50)		lun:a/a,a/c.
4320 M m b6c eat 78w93 TR109 :					0	463.mg	1.01gm		
--- MXA #	12.6gm *	P<.02	-	3.81gm n.s.s.	0/100	0/50	3/50		---:hem,hes. S
TBA MXB	1.66gm \	P<.4		381.mg n.s.s.	40/100	30/50	(15/50)		
liv MXB	no dre	P=1.		2.25gm n.s.s.	22/100	16/50	9/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		4.11gm n.s.s.	18/100	10/50	4/50		lun:a/a,a/c.
4321 R f f34 eat 18m24 TR109 :					0	170.mg	557.mg		
TBA MXB v	no dre	P=1.	-	411.mg n.s.s.	57/75	35/50	22/50		
liv MXB v	11.8gm *	P<.6		1.31gm n.s.s.	3/75	0/50	2/50		liv:hpa,hpc,nnd.
4322 R m f34 eat 18m24 TR109 :					0	136.mg	446.mg		
TBA MXB v	no dre	P=1.	-	353.mg n.s.s.	40/75	24/50	15/50		
liv MXB v	3.71gm *	P<.09		911.mg n.s.s.	0/75	1/50	1/50		liv:hpa,hpc,nnd.
NITROBENZENE 98-95-3									
4323 M f b6c inh 25m25 2213m					0	7.91mg	39.6mg	79.1mg	Cattley;faat,22,328-340;1994/pers.comm.
lun a/a e	46.3mg Z	P<.09		16.9mg n.s.s.	4/53	11/60	(3/64	2/62)	
liv hpa e	572.mg *	P<.09	+	210.mg n.s.s.	6/51	5/61	5/64	13/62	
mgl adc e	660.mg	P<.02	+	250.mg n.s.s.	0/48			5/60	
liv mix e	578.mg *	P<.2		196.mg n.s.s.	7/51	7/61	7/64	14/62	
lun a/c e	1.10gm *	P<.2		361.mg n.s.s.	2/53	0/60	4/64	4/62	
thy fca e	3.37gm *	P<.6		513.mg n.s.s.	2/49	0/59	3/61	2/61	
liv hpc e	no dre	P=1.		615.mg n.s.s.	1/51	2/61	3/64	1/62	
lun mix e	no dre	P=1.		493.mg n.s.s.	6/53	11/60	6/64	6/62	
4324 M m b6c inh 25m25 2213m					0	6.60mg	33.0mg	66.0mg	
lun mix e	200.mg *	P<.03	+	88.0mg n.s.s.	9/68	21/67	21/65	23/66	
lun a/a e	238.mg *	P<.02	+	108.mg n.s.s.	7/68	12/67	15/65	18/66	
thy fca e	616.mg Z	P<.03	+	226.mg n.s.s.	0/65	4/65	1/65	7/64	
lun a/c e	1.40gm *	P<.6		231.mg n.s.s.	4/68	10/67	8/65	8/66	
liv hpc e	no dre	P=1.		345.mg n.s.s.	12/68	13/65	12/65	8/64	
liv mix e	no dre	P=1.		225.mg n.s.s.	25/68	30/65	22/65	21/64	
liv hpa e	no dre	P=1.		218.mg n.s.s.	14/68	18/65	15/65	14/64	
4325 R m cdr inh 65w65 2213r					0	.264mg	1.32mg	6.60mg	
liv hpc ek	no dre	P=1.		.171mg n.s.s.	0/10	0/10	0/10	0/10	
liv hpa ek	no dre	P=1.		3.87mg n.s.s.	0/10	0/10	1/10	0/10	
kid tla ek	no dre	P=1.		3.87mg n.s.s.	0/10	0/10	1/10	0/10	
4326 R m cdr inh 25m25 2213s					0	.264mg	1.32mg	6.60mg	
liv mix e	32.5mg *	P<.003	+	14.4mg 226.mg	2/53	1/57	3/60	9/55	
liv hpa e	44.1mg *	P<.004	+	18.1mg 385.mg	1/53	1/57	1/60	7/55	
liv hpc e	295.mg *	P<.6		36.6mg n.s.s.	2/53	0/57	2/60	2/55	
thy mix e	519.mg *	P<.9		29.3mg n.s.s.	5/53	5/54	2/58	5/54	
thy fca e	1.08gm *	P<1.		34.4mg n.s.s.	2/53	4/54	2/58	3/54	
kid tla e	no dre	P=1.		83.0mg n.s.s.	2/53	0/57	1/60	0/55	
kid tlc e	no dre	P=1.		86.7mg n.s.s.	0/53	1/57	0/60	0/55	
kid mix e	no dre	P=1.		83.2mg n.s.s.	2/53	1/57	1/60	0/55	
thy fcc e	no dre	P=1.		49.9mg n.s.s.	4/53	1/54	0/58	2/54	
4327 R f f34 inh 65w65 2213n					0	.377mg	1.88mg	9.42mg	
ute esp ek	5.87mg *	P<.05		1.79mg n.s.s.	0/10	2/10	1/10	4/10	
liv mix ek	no dre	P=1.		.245mg n.s.s.	0/10	0/10	0/10	0/10	
thy fct ek	no dre	P=1.		7.59mg n.s.s.	0/10			0/10	
kid mix ek	no dre	P=1.		.245mg n.s.s.	0/10	0/10	0/10	0/10	
4328 R f f34 inh 25m25 2213o					0	.377mg	1.88mg	9.42mg	
ute esp e	35.9mg *	P<.07	+	13.1mg n.s.s.	11/59	15/55	14/55	21/59	
thy mix e	129.mg	P<.04		38.9mg n.s.s.	0/59			3/58	
liv mix e	132.mg *	P<.06	+	39.7mg n.s.s.	0/60	2/56	0/56	4/60	
thy fca e	195.mg	P<.1		47.9mg n.s.s.	0/59			2/58	
liv hpc e	248.mg *	P<.04		60.9mg n.s.s.	0/60	0/56	0/56	2/60	
liv hpa e	194.mg *	P<.2		48.3mg n.s.s.	0/60	2/56	0/56	3/60	
thy fdc e	393.mg	P<.3		64.0mg n.s.s.	0/59			1/58	
kid mix e	no dre	P=1.		3.72mg n.s.s.	0/60	0/56	0/56	0/60	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
4329 R m f34 inh 65w65 2213n	0	.264mg	1.32mg	6.60mg	
kid mix ek no dre P=1. .171mg n.s.s.	0/10	0/10	0/10	0/10	
liv mix ek no dre P=1. .171mg n.s.s.	0/10	0/10	0/10	0/10	
thy fct ek no dre P=1. .171mg n.s.s.	0/10	0/10	0/10	0/10	
4330 R m f34 inh 25m25 2213o	0	.264mg	1.32mg	6.60mg	
liv mix e 17.0mg * P<.0005 + 9.08mg 46.8mg	1/59	4/59	5/60	16/60	
liv hpa e 19.0mg * P<.0005 + 10.1mg 50.9mg	1/59	3/59	3/60	15/60	
kid mix e 56.8mg * P<.0005 + 23.2mg 205.mg	0/59	0/58	0/60	6/60	
kid tla e 68.7mg * P<.002 + 26.1mg 300.mg	0/59	0/58	0/60	5/60	
thy mix e 38.2mg * P<.02 + 15.6mg n.s.s.	2/59	1/59	5/60	8/60	
thy fdc e 59.5mg * P<.05 + 20.5mg n.s.s.	2/59	1/59	3/60	6/60	
liv hpc e 66.7mg * P<.04 22.5mg n.s.s.	0/59	1/59	2/60	4/60	
thy fca e 87.5mg * P<.09 30.2mg n.s.s.	0/59	0/59	2/60	2/60	
kid tlc e 353.mg * P<.2 57.5mg n.s.s.	0/59	0/58	0/60	1/60	
6-NITROBENZIMIDAZOLE 94-52-0					
4331 M f b6c eat 78w95 TR117 :	0	127.mg	253.mg		
liv MXA v 354.mg / P<.0005 c 206.mg 769.mg	3/100	4/50	20/50		liv:hpa,hpc.
liv hpc v 762.mg * P<.002 c 359.mg 3.92gm	3/100	2/50	11/50		
pit MXA v 335.mg \ P<.03 131.mg n.s.s.	8/100	12/50	(0/50)		pit:adn,cra. S
TBA MXB v 429.mg * P<.05 176.mg n.s.s.	29/100	22/50	25/50		
liv MXB v 354.mg / P<.0005 206.mg 769.mg	3/100	4/50	20/50		liv:hpa,hpc,nnd.
lun MXB v no dre P=1. 870.mg n.s.s.	5/100	4/50	2/50		lun:a/a,a/c.
4332 M m b6c eat 78w95 TR117 :	0	118.mg	234.mg		
liv MXA v 392.mg * P<.02 c 180.mg n.s.s.	20/100	19/50	22/50		liv:hpa,hpc.
liv hpc v 423.mg * P<.02 194.mg n.s.s.	18/100	16/50	21/50		S
TBA MXB v 1.98gm * P<.8 229.mg n.s.s.	45/100	29/50	25/50		
liv MXB v 392.mg * P<.02 180.mg n.s.s.	20/100	19/50	22/50		liv:hpa,hpc,nnd.
lun MXB v no dre P=1. 901.mg n.s.s.	15/100	8/50	4/50		lun:a/a,a/c.
4333 R f f34 eat 18m24 TR117 :	0	45.0mg	182.mg		
TBA MXB v no dre P=1. - 55.8mg n.s.s.	70/100	31/50	(26/50)		
liv MXB v no dre P=1. 1.92gm n.s.s.	2/100	0/50	0/50		liv:hpa,hpc,nnd.
4334 R m f34 eat 18m24 TR117 :	0	36.0mg	146.mg		
TBA MXB v no dre P=1. - 247.mg n.s.s.	54/102	22/50	22/50		
liv MXB v 8.83gm * P<.7 797.mg n.s.s.	1/102	0/50	1/50		liv:hpa,hpc,nnd.
p-NITROBENZOIC ACID 62-23-7					
4335 M f b6c eat 24m24 TR442 :	0	160.mg	321.mg	641.mg	
TBA MXB 3.16gm * P<.7 - 445.mg n.s.s.	36/50	38/50	35/50	32/50	
liv MXB no dre P=1. 1.01gm n.s.s.	15/50	16/50	15/50	11/50	liv:hpa,hpb,hpc.
lun MXB 2.33gm * P<.1 839.mg n.s.s.	3/50	10/50	4/50	9/50	lun:a/a,a/c.
4336 M m b6c eat 24m24 TR442 :	0	148.mg	297.mg	594.mg	
TBA MXB no dre P=1. - 787.mg n.s.s.	33/50	36/50	35/50	30/50	
liv MXB no dre P=1. 1.14gm n.s.s.	22/50	26/50	23/50	19/50	liv:hpa,hpb,hpc.
lun MXB 4.35gm * P<.5 887.mg n.s.s.	7/50	14/50	10/50	13/50	lun:a/a,a/c.
4337 R f f34 eat 24m24 TR442 :	0	61.7mg	123.mg	247.mg	
cli MXA 287.mg * P<.007 p 141.mg 5.60gm	4/50	14/50	15/50	15/50	cli:ade,anb,car,cnb.
ute MXA 197.mg Z P<.02 92.4mg n.s.s.	5/50	12/50	13/50	(5/50)	ute:esp,ess. S
ute esp 220.mg Z P<.03 97.5mg n.s.s.	5/50	11/50	12/50	(5/50)	S
cli MXA 439.mg * P<.04 p 182.mg n.s.s.	4/50	12/50	10/50	12/50	cli:ade,anb.
cli MXA 1.08gm * P<.08 p 411.mg n.s.s.	1/50	2/50	5/50	4/50	cli:car,cnb.
TBA MXB 373.mg * P<.4 95.8mg n.s.s.	44/50	48/50	50/50	45/50	
liv MXB no dre P=1. 1.93gm n.s.s.	2/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
4338 R m f34 eat 24m24 TR442 :	0	49.5mg	98.9mg	198.mg	
pre MXA # 926.mg * P<.04 - 386.mg n.s.s.	1/50	1/50	4/50	6/50	pre:car,cnb. S
TBA MXB no dre P=1. 215.mg n.s.s.	46/50	48/50	47/50	41/50	
liv MXB no dre P=1. 509.mg n.s.s.	4/50	4/50	1/50	4/50	liv:hpa,hpb,hpc.
1-NITROBUTANE 627-05-4					
4339 R m f34 gav 50w83 2265	0	17.8mg			Fiala;txcy,99,89-97;1995/pers.comm.
liv tum er no dre P=1. - 69.9mg n.s.s.	0/30	0/30			
2-NITROBUTANE 600-24-8					
4340 R m f34 gav 50w83 2265	0	17.8mg			Fiala;txcy,99,89-97;1995/pers.comm.
liv hpc er 2.86mg P<.0005 + 1.47mg 5.50mg	0/30	28/30			
NITROETHANE 79-24-3					
4341 R f leb inh 24m24 2289	0	26.8mg	53.6mg		Griffin;eaes,16,11-24;1988
liv hpc e 2.19gm * P<.3 - 357.mg n.s.s.	0/40	0/40	1/39		
4342 R m leb inh 24m24 2289	0	18.8mg	37.5mg		
liv tum e no dre P=1. - 106.mg n.s.s.	0/40	0/40	0/41		
NITROFEN 1836-75-5					
4343 M f b6c eat 78w91 TR184 :	0	334.mg	668.mg		
liv MXA 406.mg * P<.0005 c 282.mg 942.mg	0/20	14/50	30/50		liv:hpa,hpc.
liv hpc 1.20gm * P<.008 c 692.mg 20.6gm	0/20	5/50	13/50		
TBA MXB 606.mg * P<.05 287.mg n.s.s.	3/20	23/50	33/50		
liv MXB 406.mg * P<.0005 282.mg 942.mg	0/20	14/50	30/50		liv:hpa,hpc,nnd.
lun MXB 4.73gm * P<.3 1.80gm n.s.s.	0/20	2/50	3/50		lun:a/a,a/c.
4344 M f b6c eat 78w92 TR26 :	0	264.mg	529.mg		
liv hpc v 64.2mg \ P<.0005 c 42.8mg 102.mg	0/20	42/50	(44/50)		
TBA MXB v 74.6mg \ P<.0005 46.4mg 157.mg	3/20	43/50	(44/50)		
liv MXB v 64.2mg \ P<.0005 42.8mg 102.mg	0/20	42/50	(44/50)		liv:hpa,hpc,nnd.
lun MXB v no dre P=1. n.s.s. n.s.s.	0/20	1/50	0/50		lun:a/a,a/c.
4345 M f b6c eat 78w90 TR26 : pool	0	264.mg	529.mg		
liv hpc v 67.7mg \ P<.0005 c 45.2mg 108.mg	1/80	42/50	(44/50)		
--- hes v 2.84gm * P<.02 a 993.mg n.s.s.	1/80	0/50	5/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4346 M m b6c eat 78w91 TR184 :					0	308.mg	617.mg		
liv MXA	204.mg	* P<.0005	c 144.mg	401.mg	1/20	31/50	40/50		liv:hpa,hpc.
liv hpc	540.mg	* P<.0005	c 355.mg	1.20gm	0/20	13/50	20/50		
TBA MXB	310.mg	* P<.003	175.mg	1.70gm	7/20	31/50	43/50		
liv MXB	204.mg	* P<.0005	144.mg	401.mg	1/20	31/50	40/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	2.90gm	n.s.s.	3/20	0/50	3/50		lun:a/a,a/c.
4347 M m b6c eat 78w92 TR26 :					0	244.mg	488.mg		
liv hpc v	133.mg	* P<.007	c 73.0mg	1.86gm	4/20	38/50	46/50		
TBA MXB v	167.mg	* P<.04	78.7mg	n.s.s.	6/20	40/50	46/50		
liv MXB v	133.mg	* P<.007	73.0mg	1.86gm	4/20	38/50	46/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	1.40gm	n.s.s.	1/20	1/50	1/50		lun:a/a,a/c.
4348 M m b6c eat 78w90 TR26 : pool					0	244.mg	488.mg		
liv hpc v	85.3mg	* P<.0005	c 60.9mg	129.mg	5/80	38/50	46/50		
--- hes v	1.49gm	* P<.005	c 566.mg	13.6gm	0/80	1/50	4/50		
sub MXA v	481.mg	\ P<.03	193.mg	n.s.s.	3/80	10/50	(0/50)		sub:fbs,fib. S
4349 R f f34 eat 18m24 TR184 :					0	113.mg	225.mg		
TBA MXB	no dre	P=1.	- 206.mg	n.s.s.	15/20	21/50	(15/50)		
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
4350 R f osm eat 18m26 TR26 :					0	46.1mg	92.0mg		
pan can #	459.mg	* P<.02	- 215.mg	n.s.s.	0/20	2/50	7/50		S
ova gct	827.mg	* P<.04	286.mg	n.s.s.	0/20	0/50	4/50		S
--- lym	934.mg	* P<.05	320.mg	n.s.s.	0/20	0/50	4/50		S
TBA MXB	100.mg	/ P<.07	42.4mg	n.s.s.	14/20	31/50	42/50		
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
4351 R f osm eat 18m24 TR26 : pool					0	46.1mg	92.0mg		
pan can	420.mg	* P<.0005	c 197.mg	1.17gm	0/110	2/50	7/50		
ova MXA	820.mg	* P<.03	281.mg	n.s.s.	1/110	1/50	4/50		ova:gcc,gct. S
ova gct	1.02gm	* P<.04	321.mg	n.s.s.	1/110	0/50	4/50		S
--- lym	1.06gm	* P<.04	333.mg	n.s.s.	1/110	0/50	4/50		S
4352 R m f34 eat 18m24 TR184 :					0	90.4mg	180.mg		
TBA MXB	no dre	P=1.	- 441.mg	n.s.s.	10/20	20/50	14/50		
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
4353 R m osm eat 18m26 TR26 :					0	65.3mg	136.mg		
TBA MXB sv	202.mg	* P<.5	i 45.9mg	n.s.s.	10/20	30/50	4/50		
liv MXB sv	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.

2-NITROFLUORENE 607-57-8

4354 R m wis eat 11m24 2248					0	.917mg	3.83mg	16.3mg	Cui;carc,16,2135-2141;1995
for mix e	.285mg	* P<.0005	+ .133mg	.626mg	0/20	16/18	19/19	20/20	
for sqc e	1.12mg	Z P<.0005	+ .650mg	2.08mg	0/20	10/18	16/19	(11/20)	
liv hpc e	2.10mg	* P<.0005	+ 1.17mg	3.90mg	0/20	2/18	15/19	20/20	
kid coc e	2.35mg	Z P<.0005	+ 1.26mg	4.95mg	0/20	1/18	15/19	(10/20)	
kid mix e	3.00mg	* P<.0005	+ 1.85mg	5.60mg	0/20	4/18	17/19	17/20	

1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN (macrodantin, nitrofurantoin) 67-20-9

4355 M f b6c eat 24m24 TR341 :					0	166.mg	319.mg		
ova MXB s	866.mg	* P<.003	466.mg	3.57gm	0/50	3/50	11/50		ova:gcb,gcm,mtb,tua. C
ova MXA s	1.40gm	/ P<.004	c 660.mg	3.82gm	0/50	0/50	9/50		ova:mtb,tua.
ova tua s	2.53gm	* P<.03	c 960.mg	n.s.s.	0/50	0/50	5/50		
ova mtb s	3.38gm	* P<.05	c 1.16gm	n.s.s.	0/50	0/50	4/50		
ova MXA sh	2.56gm	* P<.4	c 972.mg	n.s.s.	0/50	3/50	2/50		ova:gcb,gcm.
ova gcb sh	8.47gm	* P<.9	c 1.12gm	n.s.s.	0/50	3/50	1/50		
TBA MXB s	no dre	P=1.	368.mg	n.s.s.	30/50	35/50	41/50		
liv MXB s	2.33gm	* P<.2	764.mg	n.s.s.	2/50	2/50	8/50		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.	822.mg	n.s.s.	3/50	2/50	(0/50)		lun:a/a,a/c.
4356 M f b6c eat 64w64 1923					0	350.mg	500.mg		Stitzel;txpy,17,774-781;1989
cvu lei er	4.00gm	* P<.3	- 651.mg	n.s.s.	0/20	0/19	1/18		
ova gct er	4.02gm	* P<.5	- 654.mg	n.s.s.	0/20	1/19	0/18		
4357 M m b6c eat 24m24 TR341 :					0	153.mg	294.mg		
TBA MXB	no dre	P=1.	- 357.mg	n.s.s.	31/50	27/50	33/50		
liv MXB	no dre	P=1.	567.mg	n.s.s.	10/50	12/50	11/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	787.mg	n.s.s.	6/50	4/50	7/50		lun:a/a,a/c.
4358 M f bd1 eat 24m24 1747					0	97.5mg	390.mg		Ito;hijm,32,99-102;1983
lun adc	no dre	P=1.	- 3.26gm	n.s.s.	0/54	1/54	0/54		
liv hem	no dre	P=1.	- 3.65gm	n.s.s.	1/54	2/54	0/54		
tba mix	no dre	P=1.	- 956.mg	n.s.s.	16/54	9/54	14/54		
4359 M m bd1 eat 24m24 1747					0	90.0mg	360.mg		
lun ade	53.9gm	* P<.9	- 2.85gm	n.s.s.	1/53	0/52	1/52		
liv hem	no dre	P=1.	- 2.45gm	n.s.s.	3/53	0/52	2/52		
liv mix	no dre	P=1.	3.17gm	n.s.s.	9/53	1/52	2/52		
liv ade	no dre	P=1.	- 771.mg	n.s.s.	6/53	1/52	(0/52)		
tba mix	no dre	P=1.	- 2.54gm	n.s.s.	12/53	1/52	4/52		
4360 M f cd1 eat 22m23 1972					0	40.2mg	78.4mg	167.mg	Butler;fctx,28,49-54;1990
liv hem e	4.46gm	* P<.07	- 1.10gm	n.s.s.	0/50	0/49	0/50	2/50	
liv hes e	no dre	P=1.	- 1.16gm	n.s.s.	2/50	1/49	2/50	1/50	
liv hpa e	no dre	P=1.	- 1.66gm	n.s.s.	0/50	1/49	0/50	0/50	
lun ala e	no dre	P=1.	- 869.mg	n.s.s.	1/50	5/50	0/50	2/50	
lun alc e	no dre	P=1.	- 1.09gm	n.s.s.	1/50	2/50	1/50	1/50	
4361 M m cd1 eat 22m23 1972					0	37.1mg	72.4mg	152.mg	
--- myl e	588.mg	* P<.02	- 263.mg	n.s.s.	2/50	6/50	4/49	10/50	
lun ala e	833.mg	* P<.05	- 350.mg	n.s.s.	1/50	2/50	6/49	5/50	
liv hpa e	1.20gm	* P<.2	- 412.mg	n.s.s.	3/50	2/50	3/49	7/50	
lun alc e	17.0gm	* P<.9	- 945.mg	n.s.s.	3/50	1/50	0/49	3/50	
liv hes e	no dre	P=1.	- 955.mg	n.s.s.	1/50	3/50	3/49	0/50	
liv hpc e	no dre	P=1.	- 446.mg	n.s.s.	4/50	7/50	9/49	4/50	
4362 R f f34 eat 24m24 TR341 :					0	29.4mg	63.8mg		
cli ade #	93.7mg	\ P<.03	- 36.2mg	n.s.s.	1/50	7/50	(4/50)		S
TBA MXB	no dre	P=1.	45.2mg	n.s.s.	49/50	48/50	46/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
4363 R m f34 eat 24m24 TR341 :					0	51.3mg	98.1mg		
sub fib	303.mg *	P<.02	142.mg	n.s.s.	0/50	5/50	4/50		S
kid MXA h	698.mg *	P<.05 p	240.mg	n.s.s.	0/50	1/50	3/50		kid:rua,ruc.
TBA MXB	no dre	P=1.	62.1mg	n.s.s.	48/50	47/50	45/50		
liv MXB	332.mg \	P<.2	90.0mg	n.s.s.	1/50	4/50	(0/50)		liv:hpa,hpc,nnd.
4364 R m f34 eat 24m24 TR341 with step					0	51.3mg	98.1mg		
kid MXA	163.mg *	P<.0005 p	97.1mg	401.mg	3/50	11/50	20/50		kid:rua,ruc.
4365 R m f34 eat 24m24 1986					0	74.8mg			Hasegawa;txcy,62,333-347;1990
ubl tum r	no dre	P=1. -	370.mg	n.s.s.	0/30	0/24			
4366 R f cdr eat 24m24 1978					0	16.8mg	31.0mg	55.8mg	Butler;fctx,28,269-277;1990
mgl mix e	no dre	P=1. -	137.mg	n.s.s.	17/50	17/50	17/50	14/50	
tba tum e	no dre	P=1. -	35.4mg	n.s.s.	48/50	45/50	47/50	44/50	
tba mal e	no dre	P=1. -	205.mg	n.s.s.	5/50	7/50	8/50	4/50	
4367 R m cdr eat 24m24 1978					0	12.4mg	22.3mg	43.1mg	
mgl fba e	878.mg *	P<.2 -	266.mg	n.s.s.	0/50	0/50	2/50	1/50	
tba mal e	1.20gm *	P<.8 -	132.mg	n.s.s.	7/50	8/50	3/50	9/50	
tba tum e	no dre	P=1. -	97.2mg	n.s.s.	39/50	38/50	32/50	28/50	
4368 R f hza eat 36w54 1063m					0	100.mg			Morris;canr,29,2145-2156;1969
mgl fba es	120.mg	P<.3 -	19.4mg	n.s.s.	0/5	1/7			
liv tum es	no dre	P=1.	38.9mg	n.s.s.	0/5	0/7			
4369 R f hza eat 44w60 1063n					0	110.mg			
mam tum es	214.mg	P<.6 -	35.8mg	n.s.s.	3/16	5/18			
liv tum es	no dre	P=1.	136.mg	n.s.s.	0/16	0/18			
4370 R f sda eat 75w80 200a					0	55.6mg			Cohen;jnci,51,403-417;1973
liv tum ev	no dre	P=1.	244.mg	n.s.s.	0/30	0/36			
tba mix ev	185.mg	P<.7 -	28.6mg	n.s.s.	14/30	19/36			
4371 R f sda eat 24m24 1622					0	94.0mg			Wang;clet,21,303-308;1984
mgl fba	54.3mg	P<.006	21.1mg	675.mg	2/11	9/12			
tba mix	64.2mg	P<.2	17.9mg	n.s.s.	6/11	10/12			
1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE 555-84-0									
4372 R f sda eat 46w66 200a					0	52.3mg			Cohen;jnci,51,403-417;1973
mgl mix e	noTD50	P<.0005	n.s.s.	6.44mg	1/25	31/31			
mgl adc e	5.26mg	P<.0005 +	2.72mg	10.0mg	0/25	29/31			
--- lbl eh	82.0mg	P<.02 +	31.1mg	n.s.s.	0/25	5/31			
liv tum e	no dre	P=1.	134.mg	n.s.s.	0/25	0/31			
tba mix e	noTD50	P<.0005	n.s.s.	6.44mg	1/25	31/31			
NITROGEN DIOXIDE 10102-44-0									
4373 R m wis inh 73w73 2325					0	22.1ug	.221mg	2.21mg	Ichinose;txcy,67,211-225;1991
lun mix er	no dre	P=1.	20.2ug	n.s.s.	0/10	0/10	0/10	0/10	
NITROGEN MUSTARD (2,2'-dichloro-N-methyldiethylamine) 51-75-2									
4374 R m b46 ivj 12m24 1017					0	7.86ug			Schmahl;arzn,20,1461-1467;1970
tba mix es	11.4ug	P<.0005 +	5.13ug	51.5ug	7/65	12/27			
tba mal es	22.8ug	P<.02 +	8.41ug	n.s.s.	4/65	7/27			
tba ben es	34.2ug	P<.05	10.8ug	n.s.s.	3/65	5/27			
NITROGEN MUSTARD N-OXIDE (mitomen) 126-85-2									
4375 R m b46 ivj 12m24 1017					0	.300mg			Schmahl;arzn,20,1461-1467;1970
--- mix es	1.40mg	P<.002	.571mg	5.62mg	0/65	6/44			
tba mix es	.764mg	P<.008 +	.335mg	15.9mg	7/65	14/44			
tba mal es	.806mg	P<.003 +	.364mg	5.46mg	4/65	12/44			
tba ben es	no dre	P=1.	1.36mg	n.s.s.	3/65	2/44			
NITROMETHANE 75-52-5									
4376 M f b6c inh 24m24 TR461 :					0	145.mg	288.mg	577.mg	
hag MXA	876.mg *	P<.02 c	415.mg	n.s.s.	6/50	9/50	20/50	21/50	hag:ade,car.
hag ade	968.mg *	P<.02 c	469.mg	n.s.s.	5/50	7/50	16/50	19/50	
lun MXA	1.97gm *	P<.07 p	782.mg	n.s.s.	3/50	6/50	6/50	12/50	lun:a/a,a/c.
liv hpa	935.mg *	P<.2 c	343.mg	n.s.s.	14/50	25/50	17/50	35/50	
liv MXA	1.25gm Z	P<.3 c	347.mg	n.s.s.	19/50	34/50	22/50	40/50	liv:hpa,hpc.
MXB MXB	1.81gm *	P<.6	340.mg	n.s.s.	24/50	36/50	33/50	42/50	hag:ade,car; liv:hpa,hpc. C
MXB MXB	2.74gm *	P<.7	356.mg	n.s.s.	25/50	38/50	33/50	42/50	hag:ade,car; liv:hpa,hpc; lun:a/a,a/c. M
TBA MXB	no dre	P=1.	472.mg	n.s.s.	38/50	45/50	43/50	46/50	
liv MXB	1.25gm Z	P<.3	347.mg	n.s.s.	19/50	34/50	22/50	40/50	liv:hpa,hpb,hpc.
lun MXB	1.97gm *	P<.07	782.mg	n.s.s.	3/50	6/50	6/50	12/50	lun:a/a,a/c.
4377 M m b6c inh 24m24 TR461 :					0	120.mg	240.mg	481.mg	
hag MXA	320.mg *	P<.0005 c	201.mg	697.mg	10/50	11/50	25/50	37/50	hag:ade,car.
MXB MXB	399.mg *	P<.003	206.mg	2.77gm	21/50	21/50	31/50	39/50	hag:ade,car; lun:a/a,a/c. M
hag ade	403.mg *	P<.0005 c	243.mg	1.00gm	9/50	10/50	19/50	32/50	
lun a/c	1.37gm *	P<.005	665.mg	12.1gm	2/50	3/50	3/50	11/50	S
hag car	2.11gm *	P<.03 c	916.mg	n.s.s.	1/50	1/50	6/50	5/50	
lun MXA	1.22gm *	P<.2 p	436.mg	n.s.s.	13/50	13/50	12/50	20/50	lun:a/a,a/c.
TBA MXB	788.mg *	P<.3	231.mg	n.s.s.	40/50	39/50	43/50	46/50	
liv MXB	no dre	P=1.	581.mg	n.s.s.	29/50	24/50	22/50	26/50	liv:hpa,hpb,hpc.
lun MXB	1.22gm *	P<.2	436.mg	n.s.s.	13/50	13/50	12/50	20/50	lun:a/a,a/c.
4378 R f f34 inh 24m24 TR461 :					0	17.2mg	34.5mg	68.8mg	
mgl MXA	40.4mg *	P<.002 c	21.3mg	216.mg	21/50	25/50	34/50	41/50	mgl:ade,car,fba.
mgl fba	44.1mg *	P<.003 c	22.8mg	293.mg	19/50	21/50	33/50	36/50	
mgl MXA	45.9mg *	P<.004	23.2mg	397.mg	20/50	21/50	33/50	36/50	mgl:ade,fba. S
mgl MXA	196.mg Z	P<.03	81.2mg	n.s.s.	4/50	7/50	1/50	13/50	mgl:ade,car. S
mgl car	197.mg Z	P<.02 c	85.3mg	n.s.s.	2/50	7/50	1/50	11/50	
TBA MXB	168.mg *	P<.6	28.5mg	n.s.s.	49/50	50/50	50/50	50/50	
liv MXB	no dre	P=1.	727.mg	n.s.s.	1/50	1/50	0/50	0/50	liv:hpa,hpb,hpc.
4379 R m f34 inh 24m24 TR461 :					0	12.1mg	24.1mg	48.1mg	
pni isc #	138.mg *	P<.03 -	53.0mg	n.s.s.	1/50	1/50	3/50	5/50	S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ski sqp		409.mg	* P<.03	122.mg n.s.s.	0/50	0/50	0/50	3/50	s
TBA MXB		59.1mg	* P<.4	14.1mg n.s.s.	50/50	47/50	49/50	49/50	
liv MXB		520.mg	* P<.5	105.mg n.s.s.	1/50	1/50	3/50	2/50	liv:hpa,hpb,hpc.
4380 R f leb inh 24m24 2297					0	21.8mg	43.6mg		Griffin;eaes,34,109-117;1996/pers.comm.
liv hpc e	no dre	P=1.	-	120.mg n.s.s.	0/40	0/40	0/40		
4381 R m leb inh 24m24 2297					0	15.3mg	30.5mg		
liv hpc e	no dre	P=1.	-	266.mg n.s.s.	1/40	1/40	0/40		
1-NITRONAPHTHALENE 86-57-7									
4382 M f b6c eat 78w96 TR64 :					0	63.7mg	127.mg		
TBA MXB	no dre	P=1.	-	230.mg n.s.s.	42/100	12/50	20/50		
liv MXB	no dre	P=1.		1.01gm n.s.s.	5/100	0/50	1/50		liv:hpa,hpc,nnd.
lun MXB	682.mg	* P<.2		231.mg n.s.s.	5/100	4/50	7/50		lun:a/a,a/c.
4383 M m b6c eat 78w96 TR64 :					0	58.8mg	118.mg		
TBA MXB	no dre	P=1.	-	168.mg n.s.s.	38/100	19/50	21/50		
liv MXB	no dre	P=1.		323.mg n.s.s.	17/100	8/50	8/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		290.mg n.s.s.	17/100	8/50	9/50		lun:a/a,a/c.
4384 R f f34 eat 18m25 TR64 :					0	21.0mg	66.0mg		
TBA MXB v	no dre	P=1.	-	72.0mg n.s.s.	51/75	32/50	34/50		
liv MXB v	no dre	P=1.		346.mg n.s.s.	4/75	0/50	2/50		liv:hpa,hpc,nnd.
4385 R m f34 eat 18m25 TR64 :					0	16.8mg	52.8mg		
TBA MXB v	no dre	P=1.	-	23.4mg n.s.s.	36/75	21/50	(19/50)		
liv MXB v	509.mg	* P<.2		175.mg n.s.s.	0/75	2/50	2/50		liv:hpa,hpc,nnd.
3-NITROPENTANE 551-88-2									
4386 R m f34 gav 50w83 2265					0	12.5mg			Fiala;txcy,99,89-97;1995/pers.comm.
liv mix ersv	2.37mg	P<.0005	+	1.29mg 4.46mg	0/30	27/30			
liv hpc ersv	3.05mg	P<.0005	+	1.73mg 5.67mg	0/30	25/30			
1-NITROPROPANE 108-03-2									
4387 R f leb inh 52w52 1670m					0	31.8mg			Griffin;eaes,6,268-282;1982
liv hpc ekr	no dre	P=1.	-	16.4mg n.s.s.	0/10	0/10			
4388 R f leb inh 78w78 1670n					0	31.8mg			
liv hpc ekr	no dre	P=1.	-	36.9mg n.s.s.	0/10	0/10			
4389 R f leb inh 93w93 1670o					0	31.8mg			
liv hpc ekr	no dre	P=1.	-	147.mg n.s.s.	0/59	0/28			
4390 R f leb inh 52w93 1670r					0	17.8mg			
liv hpc ekr	no dre	P=1.	-	23.4mg n.s.s.	0/59	0/8			
4391 R m leb inh 52w52 1670m					0	22.3mg			
liv hpc ekr	no dre	P=1.	-	11.5mg n.s.s.	0/10	0/10			
4392 R m leb inh 78w78 1670n					0	22.3mg			
liv hpc ekr	no dre	P=1.	-	25.8mg n.s.s.	0/10	0/10			
4393 R m leb inh 93w93 1670o					0	22.3mg			
liv hpc ekr	no dre	P=1.	-	99.1mg n.s.s.	0/60	0/27			
4394 R m leb inh 52w93 1670r					0	12.4mg			
liv hpc ekr	no dre	P=1.	-	12.3mg n.s.s.	0/60	0/6			
4395 R m sda gav 26w77 1837					0	9.59ug			Fiala;carc,8,1947-1949;1987/pers.comm.
liv hpa ev	.872mg	P<1.	-	16.8ug n.s.s.	1/29	1/26			
2-NITROPROPANE 79-46-9									
4396 R f sda inh 95w95 1444					0	7.96mg			Griffin;eaes,5,194-201;1981
liv tum e	293.mg	P<.2	-	47.8mg n.s.s.	0/85	1/65			
tba ben e	no dre	P=1.	-	24.1mg n.s.s.	66/85	32/65			
tba mal e	no dre	P=1.	-	45.9mg n.s.s.	18/85	6/65			
4397 R f sda inh 52w52 1444m					0	7.96mg			
liv tum ek	no dre	P=1.	-	4.10mg n.s.s.	0/10	0/10			
tba ben ek	no dre	P=1.	-	2.38mg n.s.s.	1/10	1/10			
tba mal ek	no dre	P=1.	-	4.10mg n.s.s.	0/10	0/10			
4398 R f sda inh 52w95 1444n					0	4.34mg			
liv tum ek	no dre	P=1.	-	7.46mg n.s.s.	0/48	0/10			
tba ben ek	no dre	P=1.	-	1.43mg n.s.s.	36/48	7/10			
tba mal ek	no dre	P=1.	-	4.83mg n.s.s.	7/48	1/10			
4399 R m sda inh 95w95 1444					0	5.57mg			
liv agm e	no dre	P=1.	-	62.2mg n.s.s.	1/85	0/65			
tba ben e	no dre	P=1.	-	12.2mg n.s.s.	42/85	26/65			
tba mal e	no dre	P=1.	-	21.1mg n.s.s.	11/85	7/65			
4400 R m sda inh 52w52 1444m					0	5.57mg			
liv tum ek	no dre	P=1.	-	2.87mg n.s.s.	0/10	0/10			
tba ben ek	9.06mg	P<.3	-	1.47mg n.s.s.	0/10	1/10			
tba mal ek	no dre	P=1.	-	2.87mg n.s.s.	0/10	0/10			
4401 R m sda inh 52w95 1444n					0	3.04mg			
liv agm ek	no dre	P=1.	-	5.22mg n.s.s.	1/64	0/10			
tba ben ek	7.78mg	P<.6	-	1.02mg n.s.s.	32/64	6/10			
tba mal ek	23.6mg	P<.4	-	2.81mg n.s.s.	2/64	1/10			
3-NITROPROPIONIC ACID 504-88-1									
4402 M f b6c gav 24m24 TR52 :					0	8.80mg	17.7mg		
TBA MXB	no dre	P=1.	-	22.1mg n.s.s.	26/50	32/50	26/50		
liv MXB	337.mg	* P<.5		65.8mg n.s.s.	2/50	1/50	4/50		liv:hpa,hpc,nnd.
lun MXB	499.mg	* P<.8		49.0mg n.s.s.	2/50	6/50	3/50		lun:a/a,a/c.
4403 M m b6c gav 24m24 TR52 :					0	8.80mg	17.7mg		
TBA MXB	no dre	P=1.	-	17.9mg n.s.s.	39/50	28/50	38/50		
liv MXB	no dre	P=1.		39.7mg n.s.s.	20/50	10/50	16/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		49.1mg n.s.s.	14/50	8/50	10/50		lun:a/a,a/c.
4404 R f f34 gav 26m26 TR52 :					0	.850mg	1.70mg		
TBA MXB	43.8mg	* P<1.	-	1.43mg n.s.s.	40/50	30/50	39/50		
liv MXB	29.0mg	* P<.3		7.14mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4405 R m f34 gav 26m26 TR52 :					0	.600mg	1.20mg		
liv MXA	4.41mg	* P<.004	a	2.08mg 27.1mg	0/50	3/50	6/50		liv:hpc,nnd.
liv nnd	5.03mg	* P<.008	a	2.28mg 87.3mg	0/50	3/50	5/50		
pni isa	4.53mg	* P<.06	a	1.85mg n.s.s.	4/50	6/50	11/50		
TBA MXB	7.02mg	* P<.7		.998mg n.s.s.	36/50	31/50	38/50		
liv MXB	4.41mg	* P<.004		2.08mg 27.1mg	0/50	3/50	6/50		liv:hpa,hpc,nnd.
1-NITROPYRENE 5522-43-0									
4406 R f f3j gav 13m24 2329					0	.755mg	1.51mg	3.02mg	Odagiri;cmde,291-307;1986
mgl mix	3.33mg	* P<.002	+	1.85mg 16.7mg	4/30	13/40	21/40	22/46	
mgl adc	4.82mg	* P<.0005	+	3.06mg 9.19mg	0/30	2/40	12/40	14/46	
cli sqc	6.08mg	* P<.0005	+	3.70mg 16.4mg	0/30	3/40	9/40	11/46	
cli mix	6.16mg	* P<.003	+	3.44mg 34.5mg	1/30	4/40	11/40	12/46	
--- mnl	4.33mg	* P<.06	+	1.81mg n.s.s.	9/30	23/40	22/40	27/46	
mgl ade	51.4mg	* P<.04		15.6mg n.s.s.	0/30	0/40	0/40	3/46	
ute esp	13.1mg	* P<.3		3.82mg n.s.s.	4/30	10/40	14/40	12/46	
mgl fba	39.6mg	* P<.7		5.05mg n.s.s.	4/30	11/40	11/40	10/46	
cli adc	157.mg	* P<.9		25.5mg n.s.s.	0/30	0/40	1/40	0/46	
cli ade	no dre	P=1.		21.1mg n.s.s.	1/30	1/40	1/40	1/46	
6-NITROQUINOLINE 613-50-3									
4407 R f f34 eat 24m24 1529					0	25.0mg			Fukushima;clet,14,115-123;1981
liv hnd e	no dre	P=1.	-	185.mg n.s.s.	3/44	0/36			
4408 R m f34 eat 24m24 1529					0	20.0mg			
liv hnd e	267.mg	P<.2	-	65.7mg n.s.s.	0/31	2/40			
8-NITROQUINOLINE 607-35-2									
4409 R f f34 eat 24m24 1529					0	50.0mg			Fukushima;clet,14,115-123;1981
for sqp e	9.55mg	P<.0005	+	4.34mg 18.6mg	1/44	36/37			
for sqc e	32.8mg	P<.0005	+	19.6mg 59.5mg	0/44	24/37			
liv hnd e	no dre	P=1.	-	381.mg n.s.s.	3/44	0/37			
4410 R m f34 eat 24m24 1529					0	40.0mg			
for sqp e	10.1mg	P<.0005	+	5.21mg 19.5mg	0/31	28/30			
for sqc e	24.9mg	P<.0005	+	14.2mg 48.3mg	0/31	20/30			
liv hnd e	no dre	P=1.	-	247.mg n.s.s.	0/31	0/30			
NITROSO-BAYGON 38777-13-8									
4411 R m sda gav 31w90 1409					0	.984mg			Lijinsky;eaes,2,413-419;1978
for tum erv	.364mg	P<.0005	+	.173mg .891mg	0/40	12/16			
for car erv	.434mg	P<.0005	+	.206mg 1.10mg	0/40	11/16			
N-NITROSO-BIS-(4,4,4-TRIFLUORO-N-BUTYL)AMINE 83335-32-4									
4412 R f sda gav 7m23 1489					0	1.35mg			Preussmann;carc,3,1219-1222;1982
liv hpc	.707mg	P<.0005	+	.382mg 1.47mg	0/24	17/24			
lun mix	1.12mg	P<.0005	+	.576mg 2.55mg	0/24	13/24			
tba mal	.291mg	P<.0005		.120mg .693mg	4/24	23/24			
4413 R m sda gav 7m23 1489					0	1.35mg			
liv hpc	.793mg	P<.0005	+	.425mg 1.68mg	0/24	16/24			
lun mix	.793mg	P<.0005	+	.425mg 1.68mg	0/24	16/24			
tba mal	.363mg	P<.0005		.176mg .788mg	2/24	22/24			
1-NITROSO-5,6-DIHYDROTHYMINE 62641-67-2									
4414 R f mrw wat 12m30 1607					0	3.21mg			Lawson;jnci,73,515-519;1984
liv mix e	31.2mg	P<.1		7.66mg n.s.s.	0/20	2/20			
tba mix e	no dre	P=1.	-	2.67mg n.s.s.	15/20	14/20			
4415 R m mrw wat 12m30 1607					0	2.25mg			
liv tum e	no dre	P=1.	-	13.1mg n.s.s.	0/23	0/19			
tba mix e	no dre	P=1.	-	7.43mg n.s.s.	9/23	3/19			
1-NITROSO-5,6-DIHYDROURACIL 16813-36-8									
4416 R f mrw wat 41w70 1246					0	1.08mg			Bulay;jnci,62,1523-1528;1979
liv hpc	.104mg	P<.0005	+	44.5ug .222mg	0/25	24/25			
liv mix	.104mg	P<.0005	+	44.5ug .222mg	0/25	24/25			
tba mix	.130mg	P<.0005		48.6ug .458mg	12/25	24/25			
4417 R m mrw wat 41w70 1246					0	.941mg			
liv hpc	93.2ug	P<.0005	+	39.4ug .204mg	0/22	22/23			
liv mix	93.2ug	P<.0005	+	39.4ug .204mg	0/22	22/23			
tba mix	.125mg	P<.002		43.9ug .639mg	12/22	22/23			
N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE 89911-79-5									
4418 H f syg gav 41w75 1682					0	4.69mg			Lijinsky;jnci,74,923-926;1985
for mix e	1.59mg	P<.0005	+	.804mg 3.67mg	0/20	13/20			
for sqp e	1.59mg	P<.0005	+	.804mg 3.67mg	0/20	13/20			
liv cad e	32.6mg	P<.3		5.30mg n.s.s.	0/20	1/20			
lun tum e	no dre	P=1.		10.0mg n.s.s.	0/20	0/20			
4419 R f f34 wat 37w85 1612					0	.269mg			Lijinsky;carc,5,167-170;1984
eso mix	53.5ug	P<.0005	+	25.4ug .117mg	0/20	18/20			
ton mix	88.8ug	P<.0005	+	45.5ug .196mg	0/20	15/20			
eso car	.117mg	P<.0005		59.3ug .271mg	0/20	13/20			
for mix	.178mg	P<.0005	+	84.8ug .464mg	0/20	10/20			
ton sqc	.241mg	P<.0005		.108mg .762mg	0/20	8/20			
liv hpc	2.40mg	P<.3		.391mg n.s.s.	0/20	1/20			
liv mix	no dre	P=1.		.526mg n.s.s.	3/20	1/20			
NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE 92177-50-9									
4420 H f syg gav 35w55 1682					0	5.45mg			Lijinsky;jnci,74,923-926;1985
for mix e	.754mg	P<.0005	+	.386mg 1.66mg	0/20	15/20			
for sqp e	.868mg	P<.0005	+	.443mg 1.95mg	0/20	14/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
pdu mix e		3.63mg	P<.007 +	1.37mg 41.9mg	0/20	5/20			
liv hpa e		9.92mg	P<.1	2.44mg n.s.s.	0/20	2/20			
liv mix e		9.92mg	P<.1	2.44mg n.s.s.	0/20	2/20			
liv hpc e		20.4mg	P<.3	3.32mg n.s.s.	0/20	1/20			
lun car e		20.4mg	P<.3	3.32mg n.s.s.	0/20	1/20			
4421 R f f34 wat 31w55 1639					0	.349mg			Lijinsky;zkko,107,178-182;1984
eso mix		35.2ug	P<.0005 +	17.6ug 76.3ug	0/20	17/20			
for mix		48.2ug	P<.0005 +	24.7ug .106mg	0/20	15/20			
ton mix		55.5ug	P<.0005 +	28.3ug .125mg	0/20	14/20			
eso car		63.7ug	P<.0005 +	32.2ug .147mg	0/20	13/20			
ton car		96.4ug	P<.0005 +	46.0ug .252mg	0/20	10/20			
for car		.155mg	P<.002 +	66.4ug .588mg	0/20	7/20			
liv hpc		1.30mg	P<.3 -	.212mg n.s.s.	0/20	1/20			
N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE 89911-78-4									
4422 H f syg gav 12m24 1682					0	12.5mg			Lijinsky;jnci,74,923-926;1985
trh ade e		52.7mg	P<.04	15.9mg n.s.s.	0/20	3/20			
lun tum e		no dre	P=1.	51.5mg n.s.s.	0/20	0/20			
liv tum e		no dre	P=1.	51.5mg n.s.s.	0/20	0/20			
4423 R f f34 wat 17m28 1612					0	1.87mg	3.74mg		Lijinsky;carc,5,167-170;1984
liv mix		5.98mg *	P<.02 +	2.75mg n.s.s.	3/20	8/20	10/20		
liv nnd		8.69mg *	P<.04 +	3.59mg n.s.s.	3/20	5/20	9/20		
liv hpc		11.5mg *	P<.02 +	5.18mg n.s.s.	0/20	4/20	4/20		
1-NITROSO-3,5-DIMETHYL-4-BENZOYLPIPERAZINE 61034-40-0									
4424 R f f34 wat 12m29 1208					0	2.81mg			Singer;canr,41,1034-1038;1981
for pam e		9.66mg	P<.007 +	3.65mg 111.mg	0/20	5/20			
liv tum e		9.10mg	P<.04	3.31mg n.s.s.	1/20	6/20			
for bcc e		26.4mg	P<.1 +	6.48mg n.s.s.	0/20	2/20			
tba mix e		no dre	P=1. +	.701mg n.s.s.	20/20	19/20			
NITROSO-2,6-DIMETHYLMORPHOLINE 1456-28-6									
4425 H f syg gav 59w83 430					0	1.31mg	2.63mg	5.24mg 10.5mg	Reznik;jnci,60,371-378;1978
trh ppp a		6.40mg *	P<.0005 +	3.54mg 21.8mg	0/15	2/15	3/15	3/15 8/15	
mix mix a		9.17mg *	P<.0005	4.70mg 27.7mg	0/15	0/15	1/15	7/15 4/15	
liv mix a		11.0mg *	P<.0005	5.34mg 32.0mg	0/15	0/15	1/15	3/15 6/15	
mix mix a		16.9mg *	P<.008	7.29mg 279.mg	0/15	0/15	0/15	5/15 2/15	
pan mix a		5.75mg *	P<.02 +	2.77mg n.s.s.	0/15	3/15	7/15	6/15 6/15	
pdu ade a		6.99mg *	P<.02	3.39mg n.s.s.	0/15	2/15	6/15	5/15 5/15	
for mix a		9.45mg *	P<.03	4.86mg n.s.s.	0/15	1/15	3/15	5/15 3/15	
gal mix a		12.9mg Z	P<.04	6.07mg n.s.s.	0/15	0/15	5/15	0/15 4/15	
pdu car a		32.1mg *	P<.3 +	8.48mg n.s.s.	0/15	1/15	2/15	1/15 2/15	
lun mix a		34.6mg *	P<.6 +	5.06mg n.s.s.	0/15	3/15	5/15	5/15 2/15	
lar sqp a		no dre	P=1. +	16.5mg n.s.s.	0/15	3/15	2/15	0/15 1/15	
tba mix a		1.55mg *	P<.0005	.987mg 4.99mg	0/15	8/15	12/15	14/15 10/15	
4426 H m syg gav 66w87 430					0	1.31mg	2.63mg	5.24mg 10.5mg	
lun mix a		1.21mg Z	P<.0005 +	.659mg 2.72mg	0/15	7/15	9/15	(5/15 5/15)	
pan mix a		2.78mg Z	P<.0005 +	1.58mg 7.41mg	0/15	2/15	10/15	6/15 (9/15)	
for mix a		2.91mg Z	P<.002	1.31mg 10.6mg	0/15	1/15	7/15	(3/15 4/15)	
pdu car a		6.67mg *	P<.0005 +	3.75mg 18.8mg	0/15	0/15	5/15	6/15 6/15	
liv mix a		10.1mg *	P<.002	5.16mg 38.4mg	0/15	0/15	3/15	4/15 5/15	
trh ppp a		10.5mg *	P<.03 +	4.25mg n.s.s.	0/15	4/15	3/15	3/15 6/15	
pdu ade a		21.2mg Z	P<.3	5.29mg n.s.s.	0/15	2/15	7/15	1/15 4/15	
lar sqp a		27.3mg *	P<.3 +	7.74mg n.s.s.	0/15	2/15	1/15	3/15 2/15	
tba mix a		1.68mg *	P<.0005	1.07mg 2.90mg	0/15	5/15	10/15	12/15 13/15	
1-NITROSO-1-HYDROXYETHYL-3-CHLOROETHYLUREA (1-(2-hydroxyethyl)-nitroso-3-chloroethylurea) 96806-34-7									
4427 R f f34 gav 9m27 1792					0	.582mg			Lijinsky;zkko,112,221-228;1986
liv mix e		.488mg	P<.0005 +	.242mg 1.17mg	0/20	12/19			
liv nnd e		.564mg	P<.0005 +	.274mg 1.40mg	0/20	11/19			
liv hpc e		.653mg	P<.0005 +	.310mg 1.70mg	0/20	10/19			
--- mnl e		.760mg	P<.02	.308mg n.s.s.	4/20	11/19			
ktu mix e		4.38mg	P<.09 +	1.08mg n.s.s.	0/20	2/19			
liv clc e		4.38mg	P<.09 +	1.08mg n.s.s.	0/20	2/19			
4428 R f f34 wat 7m24 2010					0	.499mg			Lijinsky;vivo,4,1-6;1990
ute tum e		.669mg	P<.08	.214mg n.s.s.	2/12	6/12			
liv tum e		1.19mg	P<.04 +	.357mg n.s.s.	0/12	3/12			
4429 R m f34 gav 8m28 1792					0	.390mg	.758mg		Lijinsky;zkko,112,221-228;1986
liv mix e		.150mg *	P<.0005 +	73.4ug .298mg	2/20	18/20	20/20		
liv hpc e		.233mg *	P<.0005 +	.135mg .412mg	0/20	14/20	20/20		
ktu mix e		.663mg *	P<.0005 +	.387mg 1.25mg	0/20	7/20	14/20		
liv clc e		.926mg *	P<.0005 +	.519mg 2.01mg	0/20	7/20	10/20		
liv nnd e		1.19mg *	P<.02 +	.564mg n.s.s.	2/20	10/20	8/20		
4430 R m f34 wat 7m24 2010					0	.349mg			Lijinsky;vivo,4,1-6;1990
liv tum e		.590mg	P<.02 +	.201mg n.s.s.	0/12	4/12			
N-NITROSO-2-HYDROXYMORPHOLINE 67587-52-4									
4431 R f f34 wat 12m28 1928					0	.265mg	.530mg		Hecht;carc,10,1475-1477;1989/pers.comm.
liv hpc e		14.9mg *	P<1. -	2.42mg n.s.s.	0/20	1/20	0/20		
1-NITROSO-1-(2-HYDROXYPROPYL)-3-CHLOROETHYLUREA (1-(2-hydroxypropyl)-nitroso-3-chloroethylurea) 96806-35-8									
4432 R f f34 gav 40w95 1792					0	.791mg			Lijinsky;zkko,112,221-228;1986
liv mix e		.885mg	P<.0005 +	.396mg 2.80mg	0/20	8/20			
liv nnd e		.885mg	P<.0005 +	.396mg 2.80mg	0/20	8/20			
--- mnl e		.962mg	P<.05	.358mg n.s.s.	4/20	10/20			
liv hpc e		8.81mg	P<.3 +	1.43mg n.s.s.	0/20	1/20			
4433 R f f34 wat 7m24 2010					0	.535mg			Lijinsky;vivo,4,1-6;1990
liv tum e		no dre	P=1.	1.32mg n.s.s.	0/12	0/12			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4434 R m f34 gav 8m28 1792					0	.438mg	.751mg		Lijinsky;zkko,112,221-228;1986
liv mix e	.861mg	* P<.0005	+	.462mg 2.43mg	2/20	4/19	15/20		
liv nnd e	1.17mg	* P<.002	+	.587mg 5.55mg	2/20	4/19	12/20		
liv hpc e	2.71mg	* P<.004	+	1.17mg 16.8mg	0/20	1/19	6/20		
lun abt e	2.39mg	* P<.02		1.01mg n.s.s.	1/20	2/19	7/20		
4435 R m f34 wat 7m24 2010					0	.374mg			Lijinsky;vivo,4,1-6;1990
liv tum e	no dre	P=1.		.926mg n.s.s.	0/12	0/12			
N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE 75896-33-2									
4436 R f f34 wat 50w75 1612					0	5.44mg			Lijinsky;carc,5,167-170;1984
liv hpc	1.02mg	P<.0005	+	.511mg 2.21mg	0/20	17/20			
liv mix	1.12mg	P<.0005	+	.532mg 2.94mg	3/20	17/20			
liv ang	4.50mg	P<.002	+	1.93mg 17.0mg	0/20	7/20			
nas olc	5.44mg	P<.003		2.20mg 28.4mg	0/20	6/20			
eso mix	6.74mg	P<.007	+	2.55mg 77.7mg	0/20	5/20			
liv nnd	no dre	P=1.		11.7mg n.s.s.	3/20	0/20			
N-NITROSO-3-HYDROXYPYRROLIDINE 56222-35-6									
4437 R b sda wat 26m26 1634					0	2.50mg			Eisenbrand;iarc,657-663;1980
liv hpc	8.11mg	P<.006		3.07mg 85.1mg	0/24	5/23			
tba mal	7.65mg	P<.03	+	2.80mg n.s.s.	1/24	6/23			
N-NITROSO-N-ISOBUTYLUREA (N-isobutyl-N-nitrosourea) 760-60-1									
4438 R f don wat 76w76 1549					0	5.71mg	11.4mg	22.9mg	Ogiu;gann,74,342-350;1983
dgt mix e	4.73mg	* P<.0005	+	3.18mg 7.32mg	0/17	6/25	14/24	25/28	
duo mix e	7.22mg	* P<.0005	+	4.72mg 11.7mg	0/17	2/25	12/24	21/28	
stg mix e	23.1mg	* P<.05		12.7mg n.s.s.	0/17	3/25	7/24	5/28	
liv mix e	1.22gm	* P<1.		30.4mg n.s.s.	1/17	2/25	3/24	2/28	
tba mix e	4.70mg	* P<.02		2.04mg n.s.s.	12/17	20/25	20/24	27/28	
N-NITROSO-N-METHYL-N-DODECYLAMINE 55090-44-3									
4439 R f f34 gav 30w65 1561					0	4.52mg			Lijinsky;fctx,21,601-605;1983
ubl tum	.656mg	P<.0005	+	.323mg 1.50mg	1/20	17/20			
lun tum	1.32mg	P<.0005		.658mg 3.15mg	0/20	12/20			
liv tum	no dre	P=1.		7.28mg n.s.s.	0/20	0/20			
tba tum	noTD50	P=1.		n.s.s. n.s.s.	20/20	20/20			
4440 R m f34 gav 7m26 1206					0	1.84mg			Lijinsky;canr,41,1288-1292;1981
ubl tcc e	.487mg	P<.0005	+	.200mg 1.12mg	0/20	19/20			
for car e	5.07mg	P<.007	+	1.92mg 58.5mg	0/20	5/20			
--- leu e	.970mg	P<.02		.356mg n.s.s.	11/20	18/20			
pni isc e	2.75mg	P<.02		1.11mg n.s.s.	3/20	10/20			
lun adc e	6.54mg	P<.02	+	2.25mg n.s.s.	0/20	4/20			
liv hpc e	8.98mg	P<.04	+	2.71mg n.s.s.	0/20	3/20			
for pam e	13.9mg	P<.1	+	3.40mg n.s.s.	0/20	2/20			
lun ade e	28.5mg	P<.3	+	4.63mg n.s.s.	0/20	1/20			
tba mix e	noTD50	P<.6	+	n.s.s. n.s.s.	19/20	20/20			
4441 R m f34 gav 28w66 1912					0	2.91mg			Reznik;acnr,1,389-392;1981
ubl tcc er	noTD50	P<.0005	+	n.s.s. .497mg	0/5	15/15			
N-NITROSO-N-METHYL-4-FLUOROANILINE 937-25-7									
4442 R m f34 wat 12m26 1544					0	.714mg			Kroeger-Koepke;carc,4,157-160;1983
eso mix	.255mg	P<.0005	+	.121mg .558mg	0/20	18/20			
liv hnd	10.3mg	P<.7		1.29mg n.s.s.	2/20	3/20			
tba mix	no dre	P=1.		.234mg n.s.s.	19/20	18/20			
N-NITROSO-N-METHYL-4-NITROANILINE 943-41-9									
4443 R m f34 wat 12m26 1544					0	.840mg			Kroeger-Koepke;carc,4,157-160;1983
liv hnd	5.87mg	P<.4	-	1.22mg n.s.s.	2/20	4/20			
tba mix	no dre	P=1.	-	.149mg n.s.s.	19/20	19/20			
NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE 13256-11-6									
4444 R m f34 wat 7m30 1374m					0	2.92ug	8.10ug	44.6ug	.197mg .600mg	Lijinsky;fctx,20,393-399;1982
ugi mix e	7.88ug Z	P<.0005	+	4.57ug 17.1ug	0/20	9/20	11/20	(16/20 | 19/20 19/20)	
eso mix e	40.1ug Z	P<.0005	+	22.3ug 80.6ug	0/20	1/20	2/20	15/20	(13/20 16/20)	
for bcp e	2.21mg Z	P<.4		.424mg n.s.s.	0/20	6/20	1/20	1/20	4/20 (5/20)	
for bcc e	2.57mg Z	P<.3	+	.666mg n.s.s.	0/20	4/20	7/20	15/20	4/20 9/20	
liv hnd e	no dre	P=1.		4.94mg n.s.s.	0/20	0/20	5/20	0/20	0/20 0/20	
mul mle e	no dre	P=1.		4.81mg n.s.s.	9/20	16/20	13/20	9/20	0/20 0/20	
ton bcc e	no dre	P=1.	+	3.60mg n.s.s.	0/20	0/20	0/20	6/20	0/20 0/20	
4445 R m f34 wat 24m30 1374n					0	9.22ug				
ugi mix e	13.6ug	P<.0005	+	6.49ug 35.5ug	0/20	10/20				
for bcc e	42.2ug	P<.02	+	14.5ug n.s.s.	0/20	4/20				
eso mix e	42.2ug	P<.02	+	14.5ug n.s.s.	0/20	4/20				
liv hnd e	.184mg	P<.3		29.9ug n.s.s.	0/20	1/20				
ton bcc e	.184mg	P<.3	+	29.9ug n.s.s.	0/20	1/20				
N-NITROSO-N-METHYL-N-TETRADECYLAMINE 75881-20-8									
4446 R m f34 gav 7m24 1206					0	4.71mg			Lijinsky;canr,41,1288-1292;1981
ubl tcc e	noTD50	P<.0005	+	n.s.s. 1.65mg	0/20	20/20			
lun ade e	29.4mg	P<.1	+	7.23mg n.s.s.	0/20	2/20			
lun adc e	60.5mg	P<.3	+	9.84mg n.s.s.	0/20	1/20			
liv tum e	no dre	P=1.		18.7mg n.s.s.	0/20	0/20			
tba mix e	noTD50	P<.6	+	n.s.s. n.s.s.	19/20	20/20			
N-NITROSO-N-METHYLDECYLAMINE 75881-22-0									
4447 R m f34 gav 7m24 1206					0	3.63mg			Lijinsky;canr,41,1288-1292;1981
ubl tcc e	1.26mg	P<.0005	+	.630mg 2.73mg	0/20	17/20			
lun adc e	8.32mg	P<.007	+	3.14mg 95.9mg	0/20	5/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun ade e	14.7mg	P<.04	+	4.45mg n.s.s.	0/20	3/20			
liv hpc e	22.7mg	P<.1	+	5.58mg n.s.s.	0/20	2/20			
for pam e	46.6mg	P<.3	+	7.59mg n.s.s.	0/20	1/20			
nas mix e	46.6mg	P<.3	+	7.59mg n.s.s.	0/20	1/20			
for car e	46.6mg	P<.3	+	7.59mg n.s.s.	0/20	1/20			
tba mix e	no dre	P=1.	+	.953mg n.s.s.	19/20	18/20			
NITROSO-5-METHYLOXAZOLIDONE	**79624-33-2**								
4448 H f syg gav 28w60 1672					0	1.70mg			Lijinsky;canr,45,542-545;1985
for mix e	.172mg	P<.0005	+	80.7ug .391mg	1/20	18/20			
N-NITROSO-N-METHYLUREA	**684-93-5**								
4449 M m c3h wat 30w54 2182					0	2.78mg	5.56mg	11.1mg	Tatematsu;gann,84,1258-1264;1993/pers.comm.
lun ade e	.794mg Z	P<.003		.380mg 3.14mg	0/10	10/21	(6/21	4/22)	
spl hms e	1.23mg *	P<.0005	+	.814mg 3.95mg	0/10	8/21	18/21	13/22	
stg adc e	6.19mg *	P<.004	+	3.10mg 36.2mg	0/10	1/21	3/21	7/22	
liv nnd e	2.53mg Z	P<.5		.538mg n.s.s.	3/10	9/21	(2/21	1/22)	
liv hpc e	no dre	P=1.		16.7mg n.s.s.	1/10	2/21	0/21	0/22	
4450 P b cym eat 18y22 2004 :					0	6.32mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
ugi sqc jw	4.52mg	P<.0005	+	1.22mg 18.6mg	0/63	6/16			
eso mix jw	7.71mg	P<.0005	+	2.95mg 27.9mg	0/63	6/16			
eso sqc jw	10.5mg	P<.002	+	3.75mg 46.0mg	0/63	5/16			
orc mix jw	2.65mg	P<.04		.652mg n.s.s.	0/4	2/2			
phr sqc jw	82.2mg	P<.08		13.4mg n.s.s.	0/63	1/16			
pls sqc jw	7.95mg	P<.2		1.29mg n.s.s.	0/4	1/2			
ton sqp jw	7.95mg	P<.2		1.29mg n.s.s.	0/4	1/2			
sku rhb jw	23.9mg	P<.2		3.88mg n.s.s.	0/10	1/5			
eso sqp jw	29.2mg	P<.2		4.75mg n.s.s.	0/12	1/6			
col lei jw	34.5mg	P<.2		5.61mg n.s.s.	0/14	1/7			
hea rhm jw	66.3mg	P<.2		10.8mg n.s.s.	0/26	1/13			
sto adc jw	66.3mg	P<.2		10.8mg n.s.s.	0/26	1/13			
tba mix jw	2.64mg	P<.005		.839mg 35.0mg	4/63	9/16			
tba mal jw	4.00mg	P<.02		1.26mg n.s.s.	3/63	7/16			
tba ben jw	19.1mg	P<.5		2.14mg n.s.s.	2/20	2/8			
4451 P b rhe eat 18y22 2004 :					0	7.80mg			
ugi sqc jw	7.18mg	P<.0005	+	3.23mg 21.0mg	1/72	9/16			
eso sqc jw	8.20mg	P<.0005	+	3.58mg 22.4mg	0/72	8/16			
orc mix jw	15.7mg	P<.003		4.90mg 143.mg	1/72	4/16			
phr sqc jw	44.2mg	P<.008		10.8mg 1.52gm	0/72	2/15			
epg sqc jw	42.8mg	P<.06		6.98mg n.s.s.	0/37	1/7			
sto adc jw	42.8mg	P<.06		6.98mg n.s.s.	0/37	1/7			
gnv sqc jw	62.6mg	P<.07		10.2mg n.s.s.	0/47	1/10			
lar sqc jw	95.6mg	P<.07		15.6mg n.s.s.	0/72	1/15			
chp sqc jw	95.6mg	P<.07		15.6mg n.s.s.	0/72	1/15			
pls sqc jw	102.mg	P<.07		16.6mg n.s.s.	0/72	1/16			
ton sqc jw	72.9mg	P<.3		8.84mg n.s.s.	1/72	1/16			
tba mal Wjw	6.75mg	P<.0005		2.79mg 26.2mg	5/74	9/16			
4452 R m f34 gav 6m24 1915					0	.312mg			Lijinsky;txih,5,925-935;1989
for tum	92.7ug	P<.0005	+	44.1ug .203mg	0/12	18/20			
lun mix	.357mg	P<.002	+	.165mg 1.33mg	0/12	9/20			
ner mix	2.03mg	P<.2	+	.498mg n.s.s.	0/12	2/20			
liv tum	11.6mg	P<.9		.574mg n.s.s.	1/12	2/20			
N-NITROSO-N-METHYLURETHAN	**615-53-2**								
4453 H b syg gav 27w73 1181					0	.629mg			Herrold;jnci,37,389-394;1966
for epc ev	noTD50	P<.0005	+	n.s.s. .127mg	0/16	16/16			
eso epc ev	.127mg	P<.0005	+	59.7ug .305mg	0/16	13/16			
N-NITROSO-1,3-OXAZOLIDINE	**(nitrosooxazolidone) 39884-52-1**								
4454 H f syg gav 7m24 1672					0	.899mg			Lijinsky;canr,45,542-545;1985
for mix e	2.61mg	P<.07	+	.855mg n.s.s.	1/20	5/20			
liv tum e	no dre	P=1.		3.71mg n.s.s.	0/20	0/20			
4455 H m syg gav 35w65 1608					0	2.83mg			Lijinsky;carc,5,875-878;1984
liv clc	.471mg	P<.0005	+	.240mg 1.02mg	0/20	16/20			
liv hpa	.949mg	P<.0005	+	.464mg 2.35mg	0/20	11/20			
liv hpc	2.63mg	P<.007	+	.995mg 30.4mg	0/20	5/20			
lun car	14.8mg	P<.3		2.40mg n.s.s.	0/20	1/20			
tba mix	.267mg	P<.0005		.106mg .681mg	3/20	19/20			
3-NITROSO-2-OXAZOLIDINONE	**38347-74-9**								
4456 R m mrw wat 64w64 1813m					0	2.14mg			Mirvish;jnci,78,387-393;1987/pers.comm.
itn mix e	noTD50	P<.0005	+	n.s.s. .262mg	0/17	26/26			
liv mix e	.582mg	P<.0005	+	.315mg 1.22mg	0/17	16/26			
tba tum e	noTD50	P<.0005		n.s.s. .281mg	2/17	26/26			
4457 R m mrw wat 70w70 1813n					0	2.15mg			
itn mix ev	.729mg	P<.0005	+	.389mg 1.57mg	0/17	15/25			
liv mix ev	1.15mg	P<.0005	+	.571mg 3.09mg	0/17	11/25			
tba tum ev	.335mg	P<.0005		.171mg .750mg	2/17	22/25			
NITROSO-2-OXOPROPYLETHANOLAMINE	**92177-49-6**								
4458 H f syg gav 50w65 1682					0	5.99mg			Lijinsky;jnci,74,923-926;1985
liv mix e	.997mg	P<.0005	+	.508mg 2.17mg	0/20	16/20			
pdu mix e	2.31mg	P<.0005	+	1.10mg 6.05mg	0/20	10/20			
liv caa e	2.68mg	P<.0005	+	1.24mg 7.57mg	0/20	9/20			
liv hca e	3.72mg	P<.002	+	1.59mg 14.1mg	0/20	7/20			
pdu car e	3.72mg	P<.002		1.59mg 14.1mg	0/20	7/20			
liv clc e	5.58mg	P<.007		2.11mg 64.3mg	0/20	5/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path		TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv hpa e		5.58mg	P<.007		2.11mg 64.3mg	0/20	5/20				
lun ade e		31.3mg	P<.3		5.09mg n.s.s.	0/20	1/20				
4459 R f f34 wat 12m28 1639						0	.850mg				Lijinsky;zkko,107,178-182;1984
liv mix		1.80mg	P<.002	+	.770mg 6.82mg	0/20	7/20				
liv hpc		2.70mg	P<.007	+	1.02mg 31.1mg	0/20	5/20				
liv nnd		2.70mg	P<.007	+	1.02mg 31.1mg	0/20	5/20				
DI(N-NITROSO)-PERHYDROPYRIMIDINE 15973-99-6											
4460 R m sda ipj 24m24 1538						0	10.0ug	28.6ug			Habs;zkko,105,191-193;1983
pnl sqc rs		.166mg *	P<.003	+	67.8ug .778mg	0/40	0/40	6/40			
N-NITROSO-2-PHENYLETHYLUREA 777-79-7											
4461 H f syg gav 30w75 1956						0	2.08mg				Lijinsky;bmes,2,167-173;1989
spl vsc e		.801mg	P<.005	+	.308mg 7.43mg	1/12	7/11				
for mix e		.939mg	P<.002	+	.369mg 3.87mg	0/12	6/11				
liv cho e		6.51mg	P<.5		.984mg n.s.s.	1/12	2/11				
for car e		7.77mg	P<.3		1.26mg n.s.s.	0/12	1/11				
4462 H m syg gav 30w75 1956						0	1.83mg				
for mix e		1.21mg	P<.005	+	.450mg 9.70mg	0/12	5/12				
for car e		2.27mg	P<.04		.680mg n.s.s.	0/12	3/12				
spl hes e		2.27mg	P<.04	+	.680mg n.s.s.	0/12	3/12				
liv cho e		3.25mg	P<.3		.732mg n.s.s.	1/12	3/12				
NITROSO-1,2,3,6-TETRAHYDROPYRIDINE 55556-92-8											
4463 R f f34 wat 6m30 1375m ()						0	7.94ug	20.6ug	50.8ug	.140mg	.785mg 2.83mg Lijinsky;eaes,6,513-527; 1982/pers.comm.
ugi mix esy		.142mg Z	P<.0005	+	76.3ug .350mg	0/20	6/20	1/20	4/20	15/20	(17/20 15/20)
eso mix esy		.216mg Z	P<.0005	+	.129mg .378mg	0/20	0/20	0/20	1/20	16/20	19/20 (15/20)
ugi car esy		.271mg Z	P<.0005	+	.141mg .614mg	0/20	0/20	0/20	0/20	13/20	(10/20 8/20)
liv hes esy		4.04mg *	P<.0005	+	2.14mg 8.91mg	0/20	0/20	0/20	0/20	0/20	0/20 14/20
liv hpc esy		no dre	P=1.	+	12.8mg n.s.s.	0/20	2/20	6/20	4/20	2/20	0/20 2/20
liv mix esy		no dre	P=1.	+	8.09mg n.s.s.	1/20	4/20	9/20	6/20	5/20	0/20 5/20
stn bcp esy		no dre	P=1.	+	14.4mg n.s.s.	0/20	6/20	0/20	2/20	4/20	1/20 1/20
4464 R f f34 wat 16m23 1375n						0	.184mg				
ugi mix es		noTD50	P<.0005	+	n.s.s. 62.0ug	0/20	20/20				
ugi car es		96.6ug	P<.0005	+	49.3ug .217mg	0/20	14/20				
eso mix es		.127mg	P<.0005	+	63.3ug .303mg	0/20	12/20				
liv hnd es		2.15mg	P<.6	+	.298mg n.s.s.	1/20	2/20				
4465 R f f34 wat 23m30 1375o						0	31.8ug	82.6ug			
ugi mix e		37.4ug *	P<.0005	+	22.0ug 66.7ug	0/20	10/20	19/20			
stn bcp e		55.1ug \	P<.0005	+	25.6ug .156mg	0/20	9/20	(3/20)			
eso mix e		66.9ug /	P<.0005	+	37.6ug .131mg	0/20	0/20	20/20			
ugi car e		85.6ug /	P<.0005	+	47.9ug .171mg	0/20	2/20	16/20			
liv mix e		.132mg *	P<.003	+	66.5ug .852mg	1/20	7/20	9/20			
eso sqc e		.430mg *	P<.005	+	.163mg 3.43mg	0/20	0/20	5/20			
liv hnd e		.284mg *	P<.03	+	.115mg n.s.s.	1/20	3/20	6/20			
N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE 82018-90-4											
4466 R m sda gav 88w88 1554						0	2.14mg	4.29mg	8.57mg	17.1mg	Preussmann;carc,4,755-757;1983
eso ppc		2.52mg *	P<.0005	+	1.73mg 4.45mg	0/20	9/20	18/20	14/20	17/20	
nas mix		7.34mg Z	P<.007	+	4.14mg 120.mg	0/20	4/20	8/20	5/20	(3/20)	
liv hes		no dre	P=1.		65.7mg n.s.s.	0/20	1/20	0/20	0/20	0/20	
N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE POLYMER 29929-77-9											
4467 R m cbr ipj 6m23 1258						0	1.86mg				Boyland;ejca,4,233-239;1968
pec sar e		3.31mg	P<.003	+	1.34mg 15.4mg	0/22	6/20				
1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE 75881-18-4											
4468 H m syg gav 46w69 1570						0	4.57mg				Lijinsky;carc,4,1165-1167;1983
for pam		1.32mg	P<.0005	+	.623mg 4.85mg	3/20	14/20				
lun ade		1.73mg	P<.0005	+	.844mg 4.28mg	0/20	11/20				
lun car		3.20mg	P<.002	+	1.37mg 12.1mg	0/20	7/20				
liv ang		6.18mg	P<.02		2.13mg n.s.s.	0/20	4/20				
tba mix		noTD50	P<.0005		n.s.s. .813mg	3/20	20/20				
4469 R f f34 wat 30w85 1570						0	.259mg	.980mg			
nas olc		.151mg *	P<.0005	+	88.2ug .270mg	0/20	13/20	18/20			
liv nnd		no dre	P=1.		.564mg n.s.s.	2/20	0/20	0/20			
tba mix		no dre	P=1.		.184mg n.s.s.	19/20	17/20	18/20			
N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE 88208-16-6											
4470 R f f34 wat 50w55 1613						0	8.16mg				Lijinsky;clet,22,281-288;1984
eso mix		.825mg	P<.0005	+	.412mg 1.78mg	0/20	17/20				
nas mix		.972mg	P<.0005	+	.495mg 2.11mg	0/20	16/20				
eso car		1.13mg	P<.0005	+	.578mg 2.49mg	0/20	15/20				
liv nnd		no dre	P=1.	-	9.41mg n.s.s.	2/20	0/20				
N-NITROSOALLYL-2-HYDROXYPROPYLAMINE 91308-70-2											
4471 R f f34 wat 50w65 1613						0	6.22mg				Lijinsky;clet,22,281-288;1984
nas mix		.877mg	P<.0005	+	.438mg 1.90mg	0/20	17/20				
liv hpc		1.38mg	P<.0005	+	.705mg 3.11mg	0/20	14/20				
eso mix		4.67mg	P<.003	+	1.89mg 24.4mg	0/20	6/20				
N-NITROSOALLYL-2-OXOPROPYLAMINE 91308-71-3											
4472 H f syg gav 40w55 1682						0	5.67mg				Lijinsky;jnci,74,923-926;1985
nac mix e		1.19mg	P<.0005	+	.591mg 2.83mg	0/20	12/20				
nac car e		1.36mg	P<.0005		.665mg 3.37mg	0/20	11/20				
liv mix e		3.78mg	P<.007		1.43mg 43.5mg	0/20	5/20				
liv hpa e		4.87mg	P<.02	+	1.68mg n.s.s.	0/20	4/20				

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
liv clc e 21.2mg P<.3 3.45mg n.s.s.	0/20	1/20			
lun tum e no dre P=1. 6.53mg n.s.s.	0/20	0/20			
4473 R f f34 wat 50w85 1613	0	1.18mg			Lijinsky;clet,22,281-288;1984
liv hpc .335mg P<.0005 + .170mg .728mg	0/20	16/20			
eso mix 1.25mg P<.002 + .535mg 4.73mg	0/20	7/20			
N-NITROSOALLYLETHANOLAMINE 91308-69-9					
4474 R f f34 wat 50w65 1613	0	5.49mg			Lijinsky;clet,22,281-288;1984
nas mix .491mg P<.0005 + .202mg 1.12mg	0/20	19/20			
liv hpc 4.12mg P<.003 + 1.67mg 21.5mg	0/20	6/20			
NITROSOAMYLURETHAN (1-amyl-1-nitrosourethan) 64005-62-5					
4475 R f don wat 52w60 1494	0	2.86mg	5.71mg	11.4mg	Onodera;gann,73,48-54;1982
eso sqc ae 1.01mg Z P<.0005 + .664mg 1.63mg	0/37	19/29	17/29	(18/27)	
mix sqc ae 1.09mg * P<.0005 + .769mg 1.59mg	0/37	19/29	21/29	21/27	
eso pam ae 1.46mg * P<.0005 + 1.02mg 2.18mg	0/37	16/29	19/29	18/27	
for pam ae 1.54mg Z P<.0005 .746mg 3.98mg	0/37	10/29	(3/29	2/27)	
mix pam ae 1.70mg Z P<.0005 + 1.05mg 3.02mg	0/37	11/29	14/29	(8/27)	
for sqc ae 2.81mg Z P<.002 1.14mg 12.1mg	0/37	6/29	(1/29	0/27)	
tba mix ae .336mg * P<.0005 .187mg .626mg	11/37	29/29	29/29	26/27	
NITROSOANABASINE (NAB) 1133-64-8					
4476 R f cbt wat 73w73 1260	0	98.0mg			Boyland;bjca,18,265-270;1964
eso mix e 12.9mg P<.0005 + 4.84mg 35.9mg	0/5	12/13			
eso ben e 17.7mg P<.0005 + 7.54mg 53.0mg	0/5	11/13			
eso sqc e 413.mg P<.5 + 67.2mg n.s.s.	0/5	1/13			
liv tum e no dre P=1. 129.mg n.s.s.	0/5	0/13			
4477 R m cbt wat 73w73 1260	0	85.7mg			
eso mix e 11.0mg P<.002 + 4.19mg 37.0mg	0/3	13/14			
eso ben e 28.1mg P<.03 + 12.6mg n.s.s.	0/3	9/14			
eso sqc e 86.0mg P<.2 + 29.5mg n.s.s.	0/3	4/14			
liv tum e no dre P=1. 122.mg n.s.s.	0/3	0/14			
N-NITROSOAZETIDINE 15216-10-1					
4478 H m syg gav 50w85 1608	0	6.72mg			Lijinsky;carc,5,875-878;1984
liv mix 7.14mg P<.002 + 3.06mg 27.1mg	0/20	7/20			
liv hpa 10.7mg P<.007 4.04mg 123.mg	0/20	5/20			
lun tum no dre P=1. 18.5mg n.s.s.	0/20	0/20			
tba mix 8.83mg P<.08 3.05mg n.s.s.	3/20	8/20			
N-NITROSOBENZTHIAZURON (1-(2'-benzothiazolyl)-3-methyl-3-nitrosourea) 51542-33-7					
4479 R b wis gav 51w58 1422	0	7.14mg	14.3mg		Ungerer;zkko,81,217-224;1974
for mix 1.13mg * P<.0005 + .746mg 1.74mg	0/22	27/30	25/30		
for sqc 1.48mg * P<.0005 + .984mg 2.31mg	0/22	21/30	25/30		
for pam 3.75mg \ P<.0005 1.82mg 11.0mg	0/22	10/30	(4/30)		
liv mix 11.3mg * P<.03 5.67mg n.s.s.	0/22	6/30	5/30		
N-NITROSOBIS(2-HYDROXYPROPYL)AMINE (N-bis(2-hydroxypropyl)nitrosamine) 53609-64-6					
4480 R f f34 wat 42w55 1612	0	6.83mg			Lijinsky;carc,5,167-170;1984
eso mix .813mg P<.0005 + .414mg 1.77mg	0/20	16/20			
eso car 1.25mg P<.0005 .630mg 2.88mg	0/20	13/20			
nas olc 3.04mg P<.002 + 1.30mg 11.5mg	0/20	7/20			
liv nnd no dre P=1. 7.87mg n.s.s.	3/20	0/20			
4481 R m mrw gav 74w74 1553	0	17.9mg	35.7mg	71.4mg	Pour;carc,4,49-55;1983
pro car er 437.mg * P<.7 + 55.4mg n.s.s.	0/15	2/14	1/15	1/15	
4482 R m wis wat 45w52 1191	0	5.00mg	25.0mg		Konishi;gann,69,573-577;1978
lun ade es .881mg * P<.0005 + .358mg 2.34mg	0/12	6/10	9/9		
lun adc es 3.36mg * P<.0005 1.51mg 12.6mg	0/12	3/10	6/9		
liv hem es 4.55mg * P<.0005 1.88mg 15.8mg	0/12	1/10	6/9		
lun crt es 9.48mg * P<.003 3.22mg 61.8mg	0/12	0/10	4/9		
liv hpc es 2.40mg \ P<.03 .718mg n.s.s.	0/12	3/10	(1/9)		
N-NITROSOBIS(2-OXOPROPYL)AMINE 60599-38-4					
4483 R f f34 gav 30w95 1551	0	.644mg			Lijinsky;clet,19,207-213;1983
liv hpc .684mg P<.002 + .254mg 3.08mg	0/20	5/12			
tba mix noTD50 P<.6 n.s.s. n.s.s.	18/20	12/12			
4484 R f f34 wat 50w75 1639	0	1.50mg			Lijinsky;zkko,107,178-182;1984
liv mix .232mg P<.0005 + .110mg .506mg	0/20	18/20			
lun mix .399mg P<.0005 + .200mg .967mg	1/20	15/20			
liv hpc .582mg P<.0005 + .290mg 1.39mg	0/20	12/20			
liv hes .892mg P<.0005 + .413mg 2.52mg	0/20	9/20			
4485 R f mrc gav 73w77 1911	0	.357mg	.714mg	1.43mg	Pour;clet,45,49-57;1989
liv mix as .283mg Z P<.0005 + .167mg .511mg	0/15	0/15	12/15	14/15	
thy mix as 1.39mg * P<.02 .651mg n.s.s.	0/15	1/15	5/15	3/15	
lun ade as 14.0mg * P<.7 2.27mg n.s.s.	0/15	0/15	1/15	0/15	
npc mix as 14.0mg * P<.7 2.27mg n.s.s.	0/15	0/15	1/15	0/15	
tba tum as .171mg * P<.0005 90.5ug .399mg	5/15	5/15	15/15	15/15	
4486 R m mrc gav 72w80 1911	0	.357mg	.714mg	1.43mg	
urt pam as .878mg * P<.0005 + .458mg 2.02mg	0/15	0/15	4/14	9/15	
liv mix as .989mg * P<.005 + .476mg 9.48mg	1/15	2/15	5/14	7/15	
lun mix as 1.10mg * P<.0005 + .548mg 2.94mg	0/15	0/15	4/14	7/15	
npc mix as 1.23mg * P<.0005 + .594mg 3.45mg	0/15	0/15	3/14	7/15	
col mix as 1.60mg * P<.002 + .719mg 5.63mg	0/15	0/15	2/14	6/15	
pro sqc as 2.21mg * P<.003 .898mg 12.1mg	0/15	0/15	1/14	5/15	
thy mix as .968mg * P<.04 .508mg n.s.s.	0/15	4/15	5/14	4/15	
tba tum as 99.5ug * P<.0005 49.8ug .217mg	3/15	11/15	14/14	15/15	
4487 R m mrw gav 24m24 1393	0	1.43mg			Pour;clet,13,303-308;1981
urt mix .891mg P<.0005 + .411mg 2.36mg	0/15	10/15			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv tum	1.56mg	P<.002	+	.658mg 5.63mg	0/15	7/15			
nas tum	1.56mg	P<.002	+	.658mg 5.63mg	0/15	7/15			
clr tum	1.56mg	P<.002	+	.658mg 5.63mg	0/15	7/15			
lun tum	1.92mg	P<.003	+	.770mg 9.22mg	0/15	6/15			
pro sqk	2.41mg	P<.006	+	.907mg 22.8mg	0/15	5/15			
thy tum	3.16mg	P<.02	+	1.08mg n.s.s.	0/15	4/15			
4488 R m mrw gav 74w74 1553					0	.357mg	.714mg	1.43mg	Pour;carc,4,49-55;1983
pro car er	1.53mg *	P<.003	+	.658mg 7.19mg	0/15	0/15	2/12	5/15	
N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)AMINE (6-F-DEN) 625-89-8									
4489 R f f34 wat 7m30 1342					0	.610mg			Preussmann;carc,2,753-756;1981
liv mal e	4.98mg	P<.3	-	.931mg n.s.s.	1/20	2/12			
4490 R m sda wat 7m26 1342					0	.561mg			
mix mal e	no dre	P=1.	-	2.36mg n.s.s.	2/35	2/35			
liv tum e	no dre	P=1.		4.86mg n.s.s.	0/35	0/35			
NITROSOCHLORDIAZEPOXIDE 51715-17-4									
4491 M f c7b wat 17m25 1257					0	4.02mg			Giner-Sorolla;fctx,18,81-83;1980
lun tum	no dre	P=1.	-	5.85mg n.s.s.	14/43	6/21			
liv tum	no dre	P=1.	-	18.1mg n.s.s.	0/43	0/21			
tba mix	no dre	P=1.	-	8.43mg n.s.s.	24/43	6/21			
4492 M m c7b wat 17m25 1257					0	3.35mg			
lun tum	no dre	P=1.	-	3.32mg n.s.s.	15/18	14/23			
tba mix	no dre	P=1.	-	3.12mg n.s.s.	16/18	15/23			
N-NITROSOCIMETIDINE 73785-40-7									
4493 M f cb6 wat 24m24 1925					0	22.6mg	226.mg		Anderson;canr,45,3561-3566;1985
liv mix g	no dre	P=1.	-	558.mg n.s.s.	3/20	1/17	1/17		
lun tum g	no dre	P=1.	-	714.mg n.s.s.	1/20	2/17	0/17		
4494 R f f34 wat 25m30 1611					0	4.99mg			Lijinsky;canr,44,447-449;1984
thy tum	18.8mg	P<.007	-	7.11mg 217.mg	0/20	5/20			
pit tum	3.60mg	P<.02	-	1.32mg n.s.s.	11/20	18/20			
liv nnd	43.3mg	P<.5	-	8.56mg n.s.s.	3/20	5/20			
4495 R m f34 wat 25m30 1611					0	3.49mg			
liv nnd	no dre	P=1.	-	7.07mg n.s.s.	5/20	5/20			
4496 R f sda gav 12m24 1699					0	7.17mg	71.7mg		Habs;hepg,29,265-266;1982
tba mix	no dre	P=1.	-	142.mg n.s.s.	10/50	1/20	3/20		
tba mal	no dre	P=1.	-	232.mg n.s.s.	7/50	0/20	1/20		
4497 R m sda gav 12m24 1699					0	7.17mg	71.7mg		
tba mix	no dre	P=1.	-	136.mg n.s.s.	9/50	1/20	3/20		
tba mal	4.82gm *	P<.9	-	149.mg n.s.s.	5/50	1/20	2/20		
NITROSODIBUTYLAMINE 924-16-3									
4498 M m icr eat 52w65 1434					0	4.80mg			Takayama;gann,60,353;1969
for mix	.686mg	P<.0005		.416mg 1.18mg	0/30	33/39			
for sqc	1.09mg	P<.0005	+	.666mg 1.92mg	0/30	27/39			
liv mix	2.65mg	P<.0005	+	1.44mg 5.65mg	0/30	15/39			
liv ade	4.34mg	P<.0005		2.11mg 12.7mg	0/30	10/39			
for sqp	7.69mg	P<.008		3.13mg 122.mg	0/30	6/39			
lun ade	8.00mg	P<.1	+	2.82mg n.s.s.	2/30	8/39			
eso pam	11.9mg	P<.03	+	4.10mg n.s.s.	0/30	4/39			
4499 R m f34 gav 7m25 1551					0	.857mg			Lijinsky;clet,19,207-213;1983
liv hpc	.691mg	P<.0005	+	.345mg 1.65mg	0/20	12/20			
for car	.914mg	P<.0005	+	.436mg 2.39mg	0/20	10/20			
lun car	1.16mg	P<.003	+	.508mg 6.79mg	1/20	9/20			
ubl tcc	1.47mg	P<.002	+	.629mg 5.57mg	0/20	7/20			
tba mix	no dre	P=1.		.136mg n.s.s.	19/20	19/20			
N-NITROSODIETHANOLAMINE 1116-54-7									
4500 R f f34 wat 13m24 1610					0	7.77mg	14.4mg	31.4mg	99.8mg Lijinsky;fctx,22,23-26;1984/pers.comm.
liv hpc a	3.27mg *	P<.0005	+	1.86mg 5.75mg	0/40	15/16	16/16	19/20	20/20
nas adc a	44.1mg Z	P<.0005	+	23.1mg 106.mg	0/40	3/16	2/16	8/20	(1/20)
nas olc a	128.mg Z	P<.005	+	48.4mg 1.12gm	0/40	1/16	0/16	4/20	(1/20)
liv clc a	197.mg *	P<.007	+	81.3mg 3.82gm	0/40	3/16	1/16	3/20	5/20
kid tum a	327.mg *	P<.009	+	133.mg 13.1gm	0/40	0/16	0/16	4/20	2/20
eso pam a	2.05gm *	P<.2	+	333.mg n.s.s.	0/40	0/16	0/16	0/20	1/20
nas sqc a	4.32gm *	P<.9	+	190.mg n.s.s.	0/40	3/16	1/16	2/20	1/20
4501 R f f34 wat 17m30 1707					0	.879mg	1.00mg	2.01mg	2.51mg Lijinsky;carc,6,1679-1681;1985
liv mix a	1.90mg *	P<.0005	+	1.32mg 2.92mg	1/20	10/39	5/20	14/20	27/27
liv nnd a	2.93mg *	P<.0005	+	1.96mg 5.05mg	1/20	8/39	4/20	13/20	19/27
liv hpc a	4.05mg *	P<.0005	+	2.65mg 6.65mg	0/20	5/39	2/20	7/20	19/27
kid mix a	42.2mg *	P<.03	+	14.6mg n.s.s.	0/20	0/39	0/20	1/20	3/27
liv caa a	56.8mg *	P<.08		17.2mg n.s.s.	0/20	0/39	0/20	2/20	1/27
4502 R f f34 wat 12m28 1928					0	2.56mg			Hecht;carc,10,1475-1477;1989/pers.comm.
liv hpc e	1.94mg	P<.0005	+	.988mg 4.36mg	0/20	14/20			
liv hes e	45.4mg	P<.3		7.40mg n.s.s.	0/20	1/20			
4503 R m f34 wat 48w95 1610					0	6.02mg	9.02mg	16.8mg	48.4mg Lijinsky;fctx,22,23-26;1984/pers.comm.
liv hpc a	2.77mg *	P<.0005	+	1.72mg 4.60mg	1/28	14/16	14/16	18/20	20/20
nas adc a	15.5mg *	P<.0005	+	10.1mg 32.1mg	0/28	5/16	9/16	8/20	14/20
liv clc a	23.9mg Z	P<.002	+	12.3mg 89.9mg	0/28	4/16	2/16	6/20	(4/20)
nas olc a	50.4mg Z	P<.003	+	20.5mg 265.mg	0/28	0/16	1/16	5/20	(2/20)
kid tum a	99.7mg *	P<.002	+	45.1mg 409.mg	0/28	0/16	1/16	2/20	5/20
eso pam a	207.mg *	P<.003	+	71.3mg 1.32gm	0/28	0/16	0/16	0/20	4/20
nas sqc a	280.mg *	P<.009	+	84.7mg 9.40gm	0/28	0/16	0/16	0/20	3/20
eso car a	432.mg *	P<.2	+	106.mg n.s.s.	0/28	0/16	0/16	1/20	1/20
4504 R m f34 wat 17m29 1707					0	.640mg	.795mg	1.46mg	1.83mg Lijinsky;carc,6,1679-1681;1985
liv mix a	2.84mg Z	P<.0005	+	1.72mg 6.81mg	4/20	6/39	2/20	11/20	19/27
liv nnd a	3.93mg *	P<.002	+	2.19mg 15.1mg	4/20	6/39	2/20	7/20	17/27

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv hpc a		9.03mg *	P<.0005 +	4.65mg 24.9mg	0/20	0/39	1/20	4/20	7/27	
kid mix a		19.0mg *	P<.07 +	7.77mg n.s.s.	0/20	1/39	1/20	2/20	2/27	
liv caa a		38.6mg *	P<.06	11.7mg n.s.s.	0/20	0/39	0/20	1/20	2/27	
4505 R m f3d wat 40w78 2565					0	1.47mg				Hasegawa;clet,123,185-191;1998/pers.comm.
liv tum e		no dre	P=1. -	2.55mg n.s.s.	0/10	0/15				
4506 R m sda wat 27m34 1483					0	1.07mg	4.29mg	17.9mg	71.4mg	286.mg Preussmann;canr,42,5167-5171;1982
liv mix ae		8.23mg Z	P<.0005 +	6.04mg 11.5mg	0/88	7/72	43/72	33/36	(32/36	31/36)
liv hpd ae		9.51mg Z	P<.0005 +	6.94mg 13.3mg	0/88	5/72	40/72	32/36	(31/36	31/36)
nas mix ae		168.mg Z	P<.0005 +	75.3mg 795.mg	0/88	2/72	0/72	6/36	(6/36	1/36)
nas olp ae		679.mg Z	P<.002	276.mg 4.62gm	0/88	1/72	0/72	4/36	3/36	(0/36)
nas sqc ae		954.mg Z	P<.004	339.mg 11.0gm	0/88	1/72	0/72	2/36	3/36	(1/36)
liv cgd ae		10.7gm *	P<.2	2.17gm n.s.s.	0/88	0/72	1/72	0/36	1/36	1/36
4507 R m sda wat 38m39 1838					0	.143mg	.450mg	1.43mg		Berger;carc,8,1635-1643;1987/pers.comm.
liv mix a		38.4mg *	P<.0005 +	16.0mg 201.mg	3/500	2/80	1/80	6/80		
liv hpc a		70.4mg *	P<.0005 +	24.3mg 368.mg	0/500	0/80	1/80	3/80		
liv hmb a		126.mg *	P<.06 +	30.8mg n.s.s.	1/500	1/80	0/80	2/80		
ner tum a		42.5mg *	P<.3 +	11.5mg n.s.s.	54/500	8/80	16/80	11/80		
--- tum a		55.6mg *	P<.2 +	15.3mg n.s.s.	23/500	8/80	5/80	7/80		
git mix a		143.mg *	P<.6 +	20.7mg n.s.s.	26/500	7/80	3/80	6/80		
liv hpa a		347.mg *	P<.3 +	47.6mg n.s.s.	1/500	0/80	0/80	1/80		
tba ben a		7.93mg *	P<.2	2.58mg n.s.s.	362/500	61/80	60/80	64/80		
tba mal a		23.5mg *	P<.3 +	6.85mg n.s.s.	144/500	29/80	29/80	28/80		
N-NITROSODIETHYLAMINE (DEN) 55-18-5										
4508 N b bbb ipj 32m32 2001s : ()					0	.897mg				Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
nac mec jw		12.2ug	P<.0005 +	3.36ug 46.0ug	0/9	10/13				
liv hpc jw		18.4ug	P<.008	3.57ug 1.03mg	0/9	2/3				
tba mal Wjw		12.2ug	P<.0005	3.36ug 46.0ug	0/9	10/13				
4509 P b cym ipj 16y16 2004m :					0	6.30ug	.322mg	.910mg	1.35mg	2.29mg
liv hpc jw		3.63ug *	P<.0005 +	944.ng 22.0ug	0/105	2/7	3/3	5/5	5/5	38/40
tba mal Wjw		3.63ug *	P<.0005	944.ng 22.0ug	0/105	2/7	3/3	5/5	5/5	38/40
4510 P b cym eat 16y16 2004n :					0	8.07mg				
liv hpc jw		2.08mg	P<.0005 +	1.01mg 4.45mg	0/104	13/16				
tba mal Wjw		2.08mg	P<.0005	1.01mg 4.45mg	0/104	13/16				
4511 P b rhe ipj 20y20 2004m :					0	7.40ug	80.0ug	.340mg	.650mg	1.59mg 2.09mg
liv hpc jw		27.1ug *	P<.0005 +	10.1ug 59.9ug	0/120	0/4	4/8	6/6	5/5	6/6 51/53
liv bda jw		27.0ug *	P<.02	4.40ug n.s.s.	0/23	-/-	1/1	-/-	-/-	-/- -/-
tba mix Wjw		21.6ug *	P<.0005	8.79ug 43.7ug	9/120	0/4	5/8	6/6	5/5	6/6 51/53
tba mal Wjw		24.7ug *	P<.0005	9.66ug 55.5ug	4/120	0/4	4/8	6/6	5/5	6/6 51/53
tba ben Wjw		no dre	P=1.	.130mg n.s.s.	6/108	0/4	1/8	0/6	0/5	0/6 0/45
4512 P b rhe eat 22y22 2004n :					0	6.87mg				
liv hpc jw		2.62mg	P<.0005 +	1.04mg 5.88mg	0/102	11/14				
tba mal Wjw		1.59mg	P<.0005	.620mg 4.89mg	5/102	11/14				
4513 R f clw wat 41m41 2259 :					0	2.00ug	4.00ug	9.00ug	18.0ug	36.0ug 72.0ug .107mg .143mg .179mg .215mg .287mg .358mg .430mg .573mg 1.15mg Peto;canr,51,6415-5451;1991a/Peto 1991b
liv mxp		49.8ug Z	P<.0005 +	37.5ug 64.7ug	16/240	6/60	4/60	4/60	7/60	12/60 35/60 44/60 47/66 47/60 46/60 49/60 52/60 52/60 57/60 50/54
liv hct		61.5ug Z	P<.0005 +	46.6ug 80.8ug	11/240	4/60	4/60	3/60	4/60	10/60 31/60 42/60 45/66 45/60 45/60 48/60 50/60 52/60 57/60 45/54
liv hpc		.105mg Z	P<.0005 +	75.3ug .139mg	2/240	0/60	2/60	1/60	3/60	3/60 22/60 39/60 37/66 44/60 43/60 46/60 47/60 50/60 56/60 44/54
eso mix		.203mg Z	P<.0005 +	.162mg .250mg	0/240	0/60	0/60	0/60	0/60	3/60 19/60 21/60 32/66 29/60 42/60 37/60 44/60 41/60 36/60 26/54
liv bdh		.561mg *	P<.0005	.200mg 2.73mg	4/240	2/60	0/60	1/60	2/60	1/60 2/60 2/60 2/66 0/60 0/60 0/60 1/60 0/60 0/60 0/54
liv bdb		.562mg *	P<.0005	.210mg 2.63mg	3/240	2/60	0/60	1/60	2/60	1/60 2/60 2/60 2/66 0/60 0/60 0/60 1/60 0/60 0/60 0/54
eso mal		.729mg Z	P<.0005 +	.531mg .992mg	0/240	0/60	0/60	0/60	0/60	0/60 2/60 8/60 16/66 11/60 15/60 11/60 18/60 13/60 12/60 11/54
liv bdm		no dre	P=1.	.657mg n.s.s.	1/240	0/60	0/60	0/60	0/60	0/60 0/60 0/60 0/66 0/60 0/60 0/60 0/60 0/60 0/60 0/54
4514 R m clw wat 40m40 2259 :					0	1.00ug	3.00ug	5.00ug	10.0ug	20.0ug 41.0ug 61.0ug 82.0ug .102mg .122mg .163mg .204mg .245mg .326mg .653mg
liv mxp		52.0ug Z	P<.0005 +	37.3ug 72.1ug	13/240	4/60	2/60	9/60	4/60	7/60 15/60 25/60 15/60 25/60 26/60 31/60 29/60 35/60 30/60 48/60
liv hct		92.4ug Z	P<.0005 +	62.4ug .133mg	10/240	1/60	2/60	3/60	0/60	5/60 9/60 18/60 10/60 21/60 20/60 23/60 27/60 28/60 28/60 47/60
eso mix		94.9ug Z	P<.0005 +	77.7ug .115mg	0/240	0/60	0/60	0/60	0/60	3/60 16/60 32/60 37/60 45/60 48/60 41/60 49/60 46/60 47/60 46/60
liv hpc		.136mg Z	P<.0005 +	89.6ug .198mg	4/240	0/60	0/60	1/60	0/60	5/60 7/60 16/60 8/60 18/60 20/60 21/60 27/60 28/60 28/60 47/60
eso mal		.236mg Z	P<.0005 +	.185mg .300mg	0/240	0/60	0/60	0/60	0/60	0/60 3/60 14/60 23/60 25/60 30/60 20/60 25/60 21/60 25/60 20/60
liv bdh		.372mg *	P<.0005	.150mg 1.15mg	3/240	2/60	0/60	1/60	2/60	0/60 4/60 3/60 1/60 2/60 2/60 2/60 1/60 0/60 0/60 0/60
liv bdb		.419mg *	P<.0005	.160mg 1.50mg	3/240	2/60	0/60	1/60	2/60	0/60 3/60 2/60 1/60 2/60 2/60 2/60 1/60 0/60 0/60 0/60
nsp mix		2.74mg *	P<.0005	.967mg 9.63mg	0/240	0/60	0/60	0/60	0/60	0/60 2/60 1/60 1/60 1/60 0/60 1/60 1/60 0/60 0/60 0/60
liv bdm		5.87mg *	P<.02	1.38mg n.s.s.	0/240	0/60	0/60	0/60	0/60	0/60 1/60 1/60 0/60 0/60 0/60 0/60 0/60 0/60 0/60 0/60
4515 R f f34 wat 7m30 1173m					0	4.40ug	10.4ug	26.4ug	.119mg	.538mg Lijinsky;canr,41,4997-5003;1981/ pers.comm.
eso mix		25.5ug Z	P<.0005 +	14.7ug 48.3ug	0/20	0/20	3/20	18/19	(13/20	10/12)
liv hpc		no dre	P=1. +	1.53mg n.s.s.	0/20	1/20	5/20	5/19	1/20	1/12
ton bcc		no dre	P=1. +	2.24mg n.s.s.	0/20	0/20	1/20	6/19	0/20	0/12

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
4516 R f f34 wat 14m30 1173n				0	8.48ug	20.7ug			
liv mix	7.87ug \	P<.0005 +	3.92ug 20.0ug	1/20	14/20	(5/20)			
eso mix	20.7ug /	P<.0005 +	11.7ug 40.8ug	0/20	2/20	17/20			
4517 R f f34 wat 24m30 1173o				0	14.8ug				
mix mix	13.1ug	P<.0005 +	6.70ug 29.5ug	0/20	14/20				
eso mix	15.0ug	P<.0005 +	7.61ug 34.8ug	0/20	13/20				
for bcp	54.9ug	P<.007 +	20.7ug .633mg	0/20	5/20				
liv mix	41.6ug	P<.02 +	16.4ug n.s.s.	1/20	7/20				
4518 R f f34 wat 30w65 1561				0	.132mg				Lijinsky;fctx,21,601-605;1983
eso tum	21.9ug	P<.0005 +	11.2ug 47.7ug	0/20	16/20				
liv tum	no dre	P=1.	.127mg n.s.s.	1/20	1/20				
tba tum	no dre	P=1.	16.1ug n.s.s.	20/20	18/20				
4519 R f fis wat 86w86 1041				0	51.6ug				Nixon;jnci,53,453-458;1974
liv hpt e	no dre	P=1. -	.109mg n.s.s.	0/15	0/15				
tba mix e	no dre	P=1. -	.109mg n.s.s.	3/15	0/15				
4520 R m fis wat 86w86 1041				0	46.0ug				
liv hpt e	no dre	P=1. -	84.3ug n.s.s.	0/16	0/13				
tba tum e	no dre	P=1. -	84.3ug n.s.s.	0/16	0/13				
4521 R m sda wat 27m27 1303				0	71.4ug				Habs;onco,37,259-265;1980
mix tum	70.6ug	P<.0005 +	49.8ug .104mg	0/90	52/90				
liv tum	.119mg	P<.0005 +	79.4ug .190mg	0/90	36/90				
eso tum	.133mg	P<.0005 +	87.4ug .217mg	0/90	33/90				
4522 R m sda wat 35m37 1838				0	7.14ug	22.9ug	71.4ug		Berger;carc,8,1635-1643;1987/pers.comm.
liv mix a	.270mg Z	P<.0005 +	.183mg .422mg	3/500	2/80	3/80	36/80		
git mix a	.401mg *	P<.0005 +	.241mg .807mg	26/500	9/80	7/80	25/80		
liv hpc a	.541mg Z	P<.0005 +	.326mg .991mg	0/500	1/80	0/80	21/80		
eso pam a	.715mg Z	P<.0005 +	.405mg 1.44mg	0/500	0/80	0/80	17/80		
liv hmm a	.719mg *	P<.0005 +	.408mg 1.45mg	0/500	0/80	2/80	15/80		
eso sqc a	3.38mg *	P<.002 +	1.13mg 26.3mg	1/500	0/80	0/80	4/80		
unt tum a	6.51mg *	P<.3 +	1.32mg n.s.s.	1/500	2/80	1/80	1/80		
tba mal a	.188mg *	P<.0005 +	.118mg .370mg	144/500	23/80	27/80	52/80		
tba ben a	no dre	P=1.	.368mg n.s.s.	362/500	58/80	54/80	53/80		
4523 R f wio wat 60w63 1041				0	.136mg				Nixon;jnci,53,453-458;1974
liv hpt e	49.3ug	P<.0005 +	23.5ug .131mg	0/18	10/20				
tba mix e	53.7ug	P<.002	24.3ug .262mg	1/18	10/20				
4524 R m wio wat 60w63 1041				0	.104mg				
liv hpt e	.104mg	P<.02 +	35.9ug n.s.s.	0/17	4/18				
tba mix e	.104mg	P<.02	35.9ug n.s.s.	0/17	4/18				
4525 R f wis gav 28m28 1399				0	10.2ug				Kroes;fctx,12,671-679;1974
mgl adc e	.127mg	P<.08 -	41.5ug n.s.s.	1/59	5/58				
liv hnd e	31.3mg	P<1. -	98.7ug n.s.s.	1/59	1/58				
tba ben e	35.5ug	P<.08 -	13.6ug n.s.s.	18/59	27/58				
tba mal e	4.01mg	P<1. -	47.3ug n.s.s.	7/59	7/58				
4526 R m wis gav 28m28 1399				0	7.14ug				
liv tum e	no dre	P=1. -	78.4ug n.s.s.	0/39	0/40				
tba mal e	77.4ug	P<.4 -	18.1ug n.s.s.	4/39	7/40				
tba ben e	.257mg	P<.9 -	18.2ug n.s.s.	8/39	9/40				
N-NITROSODIMETHYLAMINE (DMN) 62-75-9									
4527 M m amm wat 72w72 2081				0	.167mg				Anderson;carc,13,2107-2111;1992
lun ala e	.177mg	P<.6	31.8ug n.s.s.	39/47	42/48				
liv hpa e	no dre	P=1.	.790mg n.s.s.	1/47	0/48				
4528 M f bal wat 85w85 88				0	.600mg				Terracini;ijcn,11,747-764;1973
lun ade gs	.324mg	P<.0005 +	.186mg .824mg	20/62	44/62				
tba mix gs	.396mg	P<.3	97.8ug n.s.s.	56/62	59/62				
4529 M f cbl gav 50w72 1522				0	.238mg				Griciute;clet,13,345-351;1981
frb olp e	.153mg	P<.0005 +	78.1ug .360mg	0/32	12/30				
liv ben e	.350mg	P<.003	.143mg 1.82mg	0/32	6/30				
liv mal e	.429mg	P<.006	.163mg 4.64mg	0/32	5/30				
lun tum e	no dre	P=1.	.706mg n.s.s.	0/32	0/30				
tba mix e	96.4ug	P<.002	46.8ug .441mg	8/32	20/30				
4530 M m cbl gav 50w72 1522				0	.198mg				
frb olp e	.161mg	P<.0005 +	82.3ug .377mg	0/38	12/36				
liv mal e	.179mg	P<.0005 +	89.3ug .440mg	0/38	11/36				
liv ben e	.508mg	P<.2 +	.161mg n.s.s.	2/38	6/36				
lun ade e	21.1mg	P<1.	.340mg n.s.s.	2/38	2/36				
tba mix e	60.0ug	P<.0005	30.8ug .196mg	13/38	28/36				
4531 P b rhe ipj 10y10 2004 : ()				0	1.01mg				Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
tba mal Wjw	no dre	P=1.	.109mg n.s.s.	1/74	0/2				
4532 R m buf eat 26w52 1664				0	.500mg				Angsubhakorn;ijcn,28,621-626;1981
liv hpc ekr	1.76mg	P<.4 +	.286mg n.s.s.	0/14	1/21				
4533 R f clw wat 41m41 2259 :				0	1.00ug	3.00ug	5.00ug	10.0ug	20.0ug 41.0ug 61.0ug 82.0ug .102mg .122mg .163mg .204mg .245mg .326mg .653mg						Peto;canr,51,6415-5451;1991a/Peto 1991b
liv mxp	42.4ug Z	P<.0005 +	34.1ug 52.8ug	16/240	4/60	6/60	5/60	7/60	12/60 18/60 42/60 43/60 51/60 55/60 56/60 58/60 59/60 57/60 58/60
liv bdh	75.2ug Z	P<.0005 +	59.0ug 96.8ug	4/240	1/60	4/60	1/60	4/60	4/60 9/60 39/60 33/60 44/60 48/60 46/60 44/60 38/60 10/60 1/60
liv bdb	76.3ug Z	P<.0005 +	58.5ug 97.6ug	3/240	1/60	4/60	1/60	4/60	4/60 9/60 39/60 33/60 44/60 48/60 46/60 44/60 38/60 10/60 1/60
liv hct	.145mg Z	P<.0005 +	92.8ug .226mg	11/240	2/60	2/60	4/60	2/60	6/60 6/60 3/60 7/60 7/60 4/60 7/60 13/60 20/60 40/60 41/60
liv hpc	.237mg Z	P<.0005 +	.135mg .396mg	2/240	0/60	0/60	2/60	1/60	5/60 3/60 2/60 6/60 4/60 4/60 7/60 13/60 20/60 40/60 41/60
liv mmx	.914mg Z	P<.0005 +	.356mg 2.01mg	0/240	1/60	0/60	0/60	1/60	1/60 2/60 0/60 3/60 1/60 3/60 2/60 0/60 2/60 5/60 12/60
liv bdm	no dre	P=1.	.881mg n.s.s.	1/240	0/60	0/60	0/60	0/60	0/60 0/60 0/60 0/60 0/60 0/60 0/60 0/60 0/60

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
4534 R m clw wat 41m41 2259 :					0	1.00ug	3.00ug	5.00ug	10.0ug 20.0ug 41.0ug 61.0ug 82.0ug .102mg .122mg .163mg .204mg .245mg .326mg .653mg
liv mxp		86.7ug	Z P<.0005 +	68.4ug .111mg	13/240	5/60	7/60	5/60	6/60 5/60 9/60 12/60 19/60 35/60 38/60 41/60 48/60 56/60 56/60 59/60
liv hct		.157mg	Z P<.0005 +	.110mg .224mg	10/240	4/60	3/60	2/60	4/60 4/60 5/60 8/60 7/60 13/60 14/60 19/60 27/60 32/60 44/60 46/60
liv hpc		.218mg	Z P<.0005 +	.149mg .303mg	4/240	1/60	2/60	1/60	1/60 3/60 5/60 6/60 6/60 13/60 13/60 18/60 27/60 32/60 44/60 46/60
liv bdh		.308mg	Z P<.0005 +	.188mg .470mg	3/240	2/60	3/60	2/60	2/60 1/60 1/60 4/60 7/60 13/60 12/60 12/60 16/60 18/60 8/60 0/60
liv bdb		.313mg	Z P<.0005 +	.191mg .479mg	3/240	2/60	3/60	2/60	2/60 1/60 1/60 4/60 7/60 12/60 12/60 11/60 16/60 18/60 8/60 0/60
liv mmx		.712mg	Z P<.0005 +	.377mg 1.04mg	0/240	0/60	0/60	1/60	1/60 0/60 1/60 0/60 6/60 5/60 12/60 10/60 3/60 7/60 4/60 10/60
lun mix		1.64mg	* P<.0005	.529mg 5.24mg	0/240	0/60	0/60	0/60	1/60 0/60 2/60 1/60 2/60 0/60 0/60 0/60 0/60 0/60 1/60 0/60
liv bdm		23.6mg	* P<.02	5.66mg n.s.s.	0/240	0/60	0/60	0/60	0/60 0/60 0/60 0/60 0/60 1/60 0/60 1/60 0/60 0/60 0/60 0/60
4535 R f f34 wat 7m26 1609					0	63.1ug	.168mg		Lijinsky;clet,22,83-88;1984
liv mix		58.7ug	* P<.0005 +	33.8ug .123mg	2/20	14/20	17/20		
liv hpc		.135mg	* P<.0005 +	77.5ug .316mg	0/20	9/20	10/20		
liv hes		.438mg	* P<.002 +	.188mg 1.56mg	0/20	0/20	7/20		
liv nnd		no dre	P=1.	.309mg n.s.s.	2/20	5/20	2/20		
4536 R m f34 gav 30w65 1864					0	.527mg			Lijinsky;canr,47,3968-3972;1987/pers.comm.
lun mix e		76.5ug	P<.0005 +	37.7ug .169mg	0/19	16/19			
lun a/a e		.106mg	P<.0005 +	53.3ug .240mg	0/19	14/19			
liv mix e		.189mg	P<.0005 +	89.9ug .494mg	0/19	10/19			
kid mnp e		.189mg	P<.0005 +	89.9ug .494mg	0/19	10/19			
liv bht e		.372mg	P<.003	.151mg 1.92mg	0/19	6/19			
lun sqc e		.372mg	P<.003	.151mg 1.92mg	0/19	6/19			
liv cab e		.822mg	P<.04	.248mg n.s.s.	0/19	3/19			
liv hes e		.822mg	P<.04	.248mg n.s.s.	0/19	3/19			
4537 R f por eat 25m28 122m					0	.100mg	.250mg	.500mg 1.00mg 2.50mg	Terracini;bjca,20,559-565;1967
liv tum ar		1.40mg	* P<.0005 +	.893mg 2.36mg	0/29	0/18	4/62	2/5 15/23 10/12	
4538 R f por eat 12m28 122n					0	.108mg			
liv tum r		.443mg	P<.01	.133mg 23.7mg	0/29	3/15			
4539 R m por eat 28m28 122m					0	80.0ug	.200mg		
liv tum r		1.18mg	* P<.2 +	.289mg n.s.s.	0/12	1/19	1/6		
4540 R f wis eat 96w96 1201					0	5.00ug	50.0ug	.500mg	Arai;gann,70,549-558;1979
liv nod		.113mg	Z P<.002 +	46.0ug .439mg	0/18	0/24	6/24	(4/24)	
--- leu		1.46mg	* P<.005	.546mg 16.3mg	0/18	1/24	0/24	5/24	
liv hae		1.83mg	* P<.03 +	.631mg n.s.s.	0/18	0/24	1/24	3/24	
liv hpc		4.10mg	* P<.4 +	.666mg n.s.s.	0/18	0/24	3/24	2/24	
4541 R m wis eat 54w69 707					0	.313mg			Terao;fctx,16,591-596;1978
tes ldc er		.136mg	P<.0005 +	57.3ug .441mg	0/29	7/14			
liv car er		no dre	P=1. -	.398mg n.s.s.	0/29	0/14			
4542 R m wis eat 96w96 1201					0	4.00ug	40.0ug	.400mg	Arai;gann,70,549-558;1979
liv nod		.782mg	* P<.0005 +	.337mg 3.05mg	0/18	0/24	1/24	6/24	
liv hae		1.95mg	* P<.007 +	.591mg 32.7mg	0/18	0/24	0/24	3/24	
liv hpc		5.52mg	* P<.4 +	.780mg n.s.s.	0/18	0/24	1/24	1/24	
N-NITROSODIPHENYLAMINE (redax, diphenylnitrosamine) 86-30-6									
4543 M f b6c eat 23m23 TR164 :					0	322.mg	798.mg		
TBA MXB v		no dre	P=1. -	912.mg n.s.s.	9/20	24/50	15/50		
liv MXB v		no dre	P=1.	1.89gm n.s.s.	3/20	7/50	4/50		liv:hpa,hpc,nnd.
lun MXB v		no dre	P=1.	1.48gm n.s.s.	3/20	11/50	5/50		lun:a/a,a/c.
4544 M f b6c orl 76w76 1094					0	510.mg			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1.	842.mg n.s.s.	0/18	0/15			
lun ade evx		no dre	P=1.	842.mg n.s.s.	1/18	0/15			
tba mix evx		no dre	P=1.	582.mg n.s.s.	3/18	1/15			
4545 M m b6c eat 23m23 TR164 :					0	1.20gm	2.40gm		
TBA MXB		no dre	P=1. -	2.44gm n.s.s.	10/20	29/50	22/50		
liv MXB		no dre	P=1.	6.54gm n.s.s.	6/20	12/50	7/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	5.78gm n.s.s.	4/20	9/50	7/50		lun:a/a,a/c.
4546 M m b6c orl 76w76 1094					0	474.mg			Innes;ntis,1968/1969
liv hpt evx		385.mg	P<.02	142.mg n.s.s.	1/17	6/15			
lun ade evx		9.67gm	P<.9	356.mg n.s.s.	2/17	2/15			
tba mix evx		897.mg	P<.6	154.mg n.s.s.	6/17	7/15			
4547 M f b6a orl 76w76 1094					0	510.mg			
lun ade evx		1.02gm	P<.04	309.mg n.s.s.	0/17	3/18			
liv hpt evx		no dre	P=1.	1.01gm n.s.s.	0/17	0/18			
tba mix evx		3.26gm	P<.7	366.mg n.s.s.	2/17	3/18			
4548 M m b6a orl 76w76 1094					0	474.mg			
lun ade evx		no dre	P=1.	443.mg n.s.s.	2/18	2/18			
liv hpt evx		no dre	P=1.	939.mg n.s.s.	3/18	0/18			
tba mix evx		no dre	P=1.	445.mg n.s.s.	5/18	3/18			
4549 R f f34 eat 23m23 TR164 :					0	50.0mg	200.mg		
ubl tcc		116.mg	/ P<.0005 c	78.4mg 181.mg	0/20	0/50	40/50		
TBA MXB		159.mg	/ P<.008	76.7mg 3.27gm	13/20	23/50	43/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
4550 R m f34 eat 23m23 TR164 :					0	40.0mg	160.mg		
ubl tcc		299.mg	/ P<.0005 c	167.mg 616.mg	0/20	0/50	16/50		
--- fib		537.mg	* P<.01	242.mg 24.5gm	1/20	1/50	10/50		s
TBA MXB		136.gm	* P<1.	137.mg n.s.s.	16/20	29/50	33/50		
liv MXB		5.45gm	* P<.3	887.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
4551 R m cbr ipj 6m23 1258					0	.186mg			Boyland;ejca,4,233-239;1968
liv hpt e		18.9mg	P<1. -	.441mg n.s.s.	1/24	1/21			

Chemical / Spe Strain Xpo+Xpt / Sex Route Paper Num	Synonym / CAS number	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf		Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
p-NITROSODIPHENYLAMINE	**156-10-5**					
4552 M f b6c eat 53w92 TR190 :		0	343.mg	636.mg		
TBA MXB asv 2.17gm * P<.5 - 493.mg n.s.s.		4/20	16/50	9/50		
liv MXB asv 2.25gm * P<.2 974.mg n.s.s.		0/20	5/50	2/50		liv:hpa,hpc,nnd.
lun MXB asv 5.41gm * P<.4 1.64gm n.s.s.		0/20	2/50	1/50		lun:a/a,a/c.
4553 M m b6c eat 53w92 TR190 :		0	316.mg	587.mg		
liv MXA asv 340.mg \ P<.02 c 172.mg n.s.s.		2/20	22/50	(12/50)		liv:hpa,hpc.
liv hpc asv 661.mg \ P<.02 c 323.mg n.s.s.		0/20	10/50	(1/50)		
TBA MXB asv 260.mg \ P<.03 128.mg n.s.s.		4/20	30/50	(17/50)		
liv MXB asv 340.mg \ P<.02 172.mg n.s.s.		2/20	22/50	(12/50)		liv:hpa,hpc,nnd.
lun MXB asv 3.52gm * P<.7 711.mg n.s.s.		1/20	10/50	4/50		lun:a/a,a/c.
4554 R f f34 eat 18m24 TR190 :		0	92.9mg	186.mg		
TBA MXB no dre P=1. - 195.mg n.s.s.		11/20	36/50	28/50		
liv MXB 1.21gm * P<.06 522.mg n.s.s.		0/20	2/50	5/50		liv:hpa,hpc,nnd.
4555 R m f34 eat 18m24 TR190 :		0	74.3mg	149.mg		
liv MXA 201.mg * P<.0005 c 129.mg 547.mg		0/20	10/50	19/50		liv:hpc,nnd.
TBA MXB no dre P=1. 129.mg n.s.s.		13/20	34/50	33/50		
liv MXB 201.mg * P<.0005 129.mg 547.mg		0/20	10/50	19/50		liv:hpa,hpc,nnd.
N-NITROSODIPROPYLAMINE	**621-64-7**					
4556 P b rhe ipj 31m31 2004 : ()		0	3.52mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
liv hpc jw 12.1ug P<.0005 + 3.14ug 59.5ug		0/102	4/4			
tba mal Wjw 12.1ug P<.0005 3.14ug 59.5ug		0/102	4/4			
4557 R f f34 gav 30w60 1551		0	.898mg			Lijinsky;clet,19,207-213;1983
liv hpc .186mg P<.0005 + 79.3ug .564mg		0/20	8/12			
nas car .186mg P<.0005 + 79.3ug .564mg		0/20	8/12			
eso mix .505mg P<.004 + .172mg 3.75mg		0/20	4/12			
tba mix noTD50 P<.6 n.s.s. n.s.s.		18/20	12/12			
N-NITROSODITHIAZINE	**114282-83-6**					
4558 R f f34 gav 11m26 1884		0	.702mg			Lijinsky;fctx,26,3-7;1988
nac car e 5.11mg P<.1 1.25mg n.s.s.		0/20	2/20			
liv hpc e 10.5mg P<.3 - 1.71mg n.s.s.		0/20	1/20			
NITROSODODECAMETHYLENEIMINE	**40580-89-0**					
4559 R f nzd gav 12m40 1603		0	.619mg			Goodall;carc,5,537-540;1984
liv hct e 10.9mg P<.007 + 2.67mg 255.mg		0/109	2/20			
lun mix e 7.96mg P<.03 2.20mg n.s.s.		2/109	3/20			
4560 R m nzd gav 12m35 1603		0	.495mg			
hea tum e 2.15mg P<.03 .730mg n.s.s.		18/108	8/20			
lun mix e 14.6mg P<.5 1.88mg n.s.s.		6/108	2/20			
liv hct e 16.8mg P<.3 + 2.30mg n.s.s.		1/108	1/20			
N-NITROSOEPHEDRINE	**17608-59-2**					
4561 R m sda gav 24m24 1259		0	34.3mg			Eisenbrand;clet,5,103-106;1978
liv mix 95.2mg P<.0005 + 41.0mg 332.mg		0/40	7/32			
liv hpc 138.mg P<.004 52.4mg 974.mg		0/40	5/32			
lun mix 217.mg P<.1 + 64.1mg n.s.s.		1/40	4/32			
for pam 239.mg P<.03 + 72.2mg n.s.s.		0/40	3/32			
for sqc 740.mg P<.3 + 120.mg n.s.s.		0/40	1/32			
tba mix 40.0mg P<.0005 20.1mg 129.mg		4/40	16/32			
NITROSOETHYLMETHYLAMINE (N-nitrosomethylethylamine)	**10595-95-6**					
4562 R f f34 wat 7m27 1561		0	63.9ug			Lijinsky;fctx,21,601-605;1983
--- tum 38.6ug P<.03 13.4ug n.s.s.		12/20	18/20			
liv tum no dre P=1. .322mg n.s.s.		1/20	0/20			
tba tum no dre P=1. 13.5ug n.s.s.		20/20	19/20			
4563 R m f34 gav 30w55 1864		0	.727mg			Lijinsky;canr,47,3968-3972;1987/pers.comm.
liv bht e 50.3ug P<.0005 19.8ug .125mg		0/19	15/16			
liv mix e 50.3ug P<.0005 + 19.8ug .125mg		0/19	15/16			
liv hes e .120mg P<.0005 56.8ug .302mg		0/19	11/16			
nac tum e .201mg P<.0005 + 88.9ug .602mg		0/19	8/16			
lun a/a e .242mg P<.0005 + .103mg .821mg		0/19	7/16			
NITROSOETHYLURETHAN (1-ethyl-1-nitrosourethan)	**614-95-9**					
4564 R f don wat 51w60 1494		0	.714mg	1.43mg	2.86mg	Onodera;gann,73,48-54;1982
mix sqc ae .164mg Z P<.0005 .108mg .260mg		0/37	21/26	21/28	(11/24)	
for sqc ae .248mg * P<.0005 + .170mg .375mg		0/37	11/26	22/28	22/24	
mix pam ae .339mg Z P<.0005 .213mg .581mg		0/37	14/26	14/28	(9/24)	
eso pam ae .473mg Z P<.0005 .284mg .884mg		0/37	11/26	11/28	(7/24)	
for pam ae .508mg * P<.0005 + .338mg .807mg		0/37	6/26	16/28	16/24	
eso sqc ae .540mg Z P<.0005 .317mg 1.08mg		0/37	11/26	9/28	(4/24)	
duo adc ae .555mg * P<.0005 + .364mg .900mg		0/37	5/26	12/28	18/24	
tba mix ae 78.4ug * P<.0005 41.3ug .151mg		11/37	25/26	27/28	24/24	
4565 R f f3d wat 23m26 1939		0	7.96ug	31.8ug	.133mg	.571mg Maekawa;gann,80,632-636;1989/pers.comm.
ugi mix es 55.3ug * P<.0005 + 37.8ug 83.4ug		1/40	0/39	16/38	38/39	37/38
for pam es 79.6ug Z P<.0005 + 41.9ug .180mg		0/40	0/39	13/38	(14/39	19/38)
eso sqc es .139mg Z P<.0005 + 87.0ug .242mg		0/40	0/39	1/38	26/39	(23/38)
for sqc es .213mg Z P<.0005 + .125mg .405mg		0/40	0/39	2/38	18/39	(9/38)
eso pam es .514mg Z P<.0005 + .241mg 1.72mg		1/40	0/39	1/38	9/39	(6/38)
orc sqc es .784mg * P<.0005 + .475mg 1.42mg		0/40	0/39	0/38	6/39	17/38
orc pam es 3.02mg * P<.0005 + 1.30mg 9.75mg		0/40	0/39	0/38	1/39	6/38
tba tum es .135mg * P<.002 49.0ug .868mg		33/40	30/39	31/38	39/39	37/38
N-NITROSOGUVACOLINE	**55557-02-3**					
4566 R m f34 wat 30m30 1866		0	1.00mg			Rivenson;canr,48,6912-6917;1988/pers.comm.
pae ana 7.95mg P<.02 2.57mg n.s.s.		1/80	4/30			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv ade	no dre	P=1.		9.37mg n.s.s.	6/80	0/30			
NITROSOHEPTAMETHYLENEIMINE 20917-49-1									
4567 R m f34 wat 6m27 1376m ()					0	39.8ug	.197mg	.733mg	Lijinsky;jnci,69,1127-1133;1982/pers.comm.
ugi car esy	36.3ug	Z P<.0005	+	18.1ug 86.7ug	0/20	12/20	(11/20 | 10/20)	
ugi mix esy	51.2ug	Z P<.0005	+	30.3ug 96.3ug	0/20	15/20	17/20	(15/20)	
eso mix esy	.118mg	Z P<.0005	+	66.9ug .233mg	0/20	5/20	15/20	(12/20)	
liv hem esy	no dre	P=1.		.160mg n.s.s.	1/20	0/20	0/20	0/20	
4568 R m f34 wat 12m29 1376n					0	11.4ug	31.5ug	.125mg	
ugi mix es	57.1ug	* P<.0005	+	35.3ug 99.6ug	0/20	2/20	13/20	16/20	
eso bcc es	.159mg	* P<.0005	+	85.8ug .340mg	0/20	0/20	2/20	13/20	
ton bcc es	.171mg	* P<.0005	+	92.7ug .410mg	0/20	1/20	4/20	10/20	
liv hpc es	no dre	P=1.	+	.729mg n.s.s.	0/20	5/20	0/20	0/20	
4569 R m f34 wat 23m27 1376o					0	24.8ug	64.6ug		
ugi mix e	29.2ug	* P<.0005	+	17.4ug 52.1ug	0/20	10/20	17/20		
eso mix e	73.5ug	* P<.0005	+	39.7ug .158mg	0/20	3/20	12/20		
ton bcc e	.105mg	* P<.004	+	53.7ug .736mg	0/20	6/20	6/20		
liv mix e	.198mg	\ P<.1	+	48.5ug n.s.s.	0/20	2/20	(0/20)		
N-NITROSOHEXAMETHYLENEIMINE 932-83-2									
4570 M f bal gav 30w49 2207o ()					0	7.00mg			Strickland;clet,41,139-146;1988
liv mix e	.797mg	P<.0005	+	.402mg 1.81mg	0/19	14/19			
nac mix e	4.50mg	P<.02	+	1.55mg n.s.s.	0/19	4/19			
lun mix e	7.44mg	P<.5		1.42mg n.s.s.	4/19	6/19			
eso sqp e	19.7mg	P<.3		3.20mg n.s.s.	0/19	1/19			
for mix e	no dre	P=1.		4.03mg n.s.s.	2/19	1/19			
4571 M f cd1 gav 30w62 2207m					0	5.49mg			
liv mix e	.746mg	P<.0005	+	.361mg 1.82mg	2/20	17/20			
lun mix e	2.71mg	P<.02	+	1.11mg n.s.s.	2/20	9/20			
for mix e	5.65mg	P<.07	+	1.85mg n.s.s.	1/20	5/20			
eso sqp e	12.7mg	P<.1		3.11mg n.s.s.	0/20	2/20			
nac tum e	26.0mg	P<.3		4.24mg n.s.s.	0/20	1/20			
4572 M f nzb wat 32w74 1738					0	3.07mg			Goodall;txcy,33,251-259;1984
ssq mix	.415mg	P<.0005	+	.156mg 1.13mg	0/113	12/13			
eso mix	.725mg	P<.0005	+	.320mg 1.96mg	0/113	10/13			
liv hpc	3.21mg	P<.004	+	1.02mg 40.6mg	4/113	4/13			
stg mix	4.05mg	P<.0005	+	1.22mg 29.1mg	0/113	3/13			
opx mix	6.37mg	P<.003	+	1.56mg 88.1mg	0/113	2/13			
lun mix	no dre	P=1.		1.58mg n.s.s.	39/113	4/13			
4573 M m nzb wat 32w60 1738					0	3.16mg			
eso mix	.313mg	P<.0005	+	.110mg .974mg	0/194	9/10			
ssq mix	.448mg	P<.0005	+	.176mg 1.40mg	0/194	8/10			
opx mix	1.41mg	P<.0005	+	.477mg 7.31mg	0/194	4/10			
stg mix	3.23mg	P<.0005	+	.789mg 43.0mg	0/194	2/10			
lun mix	1.93mg	P<.2		.458mg n.s.s.	53/194	5/10			
liv hpc	8.03mg	P<.2	+	1.14mg n.s.s.	3/194	1/10			
4574 M f sen gav 30w67 2207n					0	5.08mg			Strickland;clet,41,139-146;1988
lun mix e	.783mg	P<.0005	+	.385mg 1.79mg	1/20	17/20			
liv mix e	1.92mg	P<.004	+	.851mg 13.4mg	3/20	12/20			
for mix e	2.25mg	P<.002	+	1.03mg 9.43mg	1/20	10/20			
eso sqp e	6.47mg	P<.02	+	2.23mg n.s.s.	0/20	4/20			
nac mix e	6.47mg	P<.02	+	2.23mg n.s.s.	0/20	4/20			
1-NITROSOHYDANTOIN 42579-28-2									
4575 R f mrw wat 12m26 1246					0	11.4mg			Bulay;jnci,62,1523-1528;1979
liv tum	no dre	P=1.		63.0mg n.s.s.	0/25	0/24			
tba mix	19.6mg	P<.2	+	5.90mg n.s.s.	12/25	16/24			
4576 R m mrw wat 12m26 1246					0	9.96mg			
for sqp	27.8mg	P<.005		11.3mg 198.mg	0/22	6/25			
phr sqc	43.8mg	P<.03	+	15.1mg n.s.s.	0/22	4/25			
liv tum	no dre	P=1.		57.4mg n.s.s.	0/22	0/25			
tba mix	7.31mg	P<.03		2.84mg n.s.s.	12/22	21/25			
NITROSOHYDROXYPROLINE 30310-80-6									
4577 R f mrc wat 17m24 216					0	4.42mg			Garcia;zkko,79,141-144;1973
liv tum	no dre	P=1.		13.6mg n.s.s.	0/15	0/15			
tba mix	3.84mg	P<.03	-	1.43mg n.s.s.	4/15	10/15			
4578 R m mrc wat 17m24 216					0	3.86mg			
liv tum	no dre	P=1.		11.9mg n.s.s.	0/15	0/15			
tba mix	no dre	P=1.	-	3.47mg n.s.s.	5/15	5/15			
NITROSOIMINODIACETIC ACID 25081-31-6									
4579 R f mrc wat 17m24 213					0	56.5mg			Lijinsky;jnci,50,1061-1063;1973
tba mix e	63.9mg	P<.07	-	22.0mg n.s.s.	4/15	9/15			
4580 R m mrc wat 17m24 213					0	39.6mg			
pit tum e	66.9mg	P<.006	-	25.1mg 631.mg	0/15	5/15			
tba mix e	76.0mg	P<.3	-	19.4mg n.s.s.	5/15	8/15			
NITROSOMETHYL-3-CARBOXYPROPYLAMINE (NMCOPA) 61445-55-4									
4581 R m f3d wat 40w78 2565					0	1.47mg			Hasegawa;clet,123,185-191;1998/pers.comm.
ubr mix e	.982mg	P<.005	+	.416mg 6.61mg	0/10	7/16			
ubr tcc e	4.23mg	P<.2	+	1.04mg n.s.s.	0/10	2/16			
liv tum e	no dre	P=1.		2.72mg n.s.s.	0/10	0/16			
N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE 86451-37-8									
4582 H f syg gav 41w81 1715					0	1.57mg			Lijinsky;zkko,109,1-4;1985
nac mix	.940mg	P<.0005	+	.449mg 2.46mg	0/20	10/20			
nac car	1.51mg	P<.002		.647mg 5.73mg	0/20	7/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv vsc		12.7mg	P<.3	- 2.07mg n.s.s.	0/20	1/20			
tba mix		.509mg	P<.0005	.250mg 1.38mg	2/20	15/20			
4583 R f f34 wat		9m26 1609			0	.430mg			Lijinsky;clet,22,83-88;1984
lun mix		.646mg	P<.0005	+ .289mg 2.04mg	0/20	8/20			
liv mix		.670mg	P<.02	.275mg n.s.s.	2/20	9/20			
liv nnd		1.01mg	P<.06	+ .358mg n.s.s.	2/20	7/20			
eso mix		1.48mg	P<.02	+ .509mg n.s.s.	0/20	4/20			
nas mix		1.48mg	P<.02	+ .509mg n.s.s.	0/20	4/20			
liv hpc		3.13mg	P<.1	.769mg n.s.s.	0/20	2/20			
N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE 26921-68-6									
4584 R m f34 gav		69w69 1904			0	1.53mg			Koepke;canr,48,1533-1536;1988/pers.comm.
liv hpc	es	1.29mg	P<.003	+ .522mg 6.74mg	0/20	6/20			
nas sqc	es	2.06mg	P<.02	+ .710mg n.s.s.	0/20	4/20			
liv hes	es	8.97mg	P<.3	1.46mg n.s.s.	0/20	1/20			
nas sqp	es	8.97mg	P<.3	1.46mg n.s.s.	0/20	1/20			
liv nnd	es	no dre	P=1.	1.45mg n.s.s.	3/20	2/20			
N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE 70415-59-7									
4585 R f f34 gav		30m30 1904			0	2.45mg			Koepke;canr,48,1533-1536;1988/pers.comm.
liv nnd	e	3.48mg	P<.004	+ 1.55mg 24.4mg	3/20	12/20			
lun mix	e	8.06mg	P<.06	+ 2.85mg n.s.s.	2/20	7/20			
lun a/c	e	24.9mg	P<.1	+ 6.11mg n.s.s.	0/20	2/20			
lun a/a	e	14.4mg	P<.3	3.87mg n.s.s.	2/20	5/20			
4586 R m f34 gav		30m30 1904			0	1.71mg			
lun mix	e	1.09mg	P<.0005	+ .511mg 2.98mg	3/20	16/19			
tes ict	e	2.26mg	P<.0005	1.06mg 7.37mg	1/20	11/19			
lun a/c	e	2.46mg	P<.0005	+ 1.17mg 6.40mg	0/20	10/19			
liv nnd	e	4.78mg	P<.06	+ 1.69mg n.s.s.	3/20	8/19			
lun a/a	e	8.46mg	P<.3	2.28mg n.s.s.	3/20	6/19			
N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE 75411-83-5									
4587 R f f34 wat		30w75 1609			0	.408mg			Lijinsky;clet,22,83-88;1984
nas mix		48.6ug	P<.0005	+ 20.0ug .111mg	0/20	19/20			
eso mix		.105mg	P<.0005	+ 53.7ug .231mg	0/20	15/20			
lun mix		.408mg	P<.003	.165mg 2.13mg	0/20	6/20			
eso car		.408mg	P<.003	.165mg 2.13mg	0/20	6/20			
liv hpc		.895mg	P<.04	.270mg n.s.s.	0/20	3/20			
liv mix		.798mg	P<.3	.215mg n.s.s.	2/20	5/20			
liv nnd		2.54mg	P<.7	.318mg n.s.s.	2/20	3/20			
4588 R m f34 wat		30w75 1609			0	.286mg			
nas mix		44.2ug	P<.0005	+ 21.0ug 96.7ug	0/20	18/20			
eso mix		.170mg	P<.0005	+ 78.9ug .480mg	0/20	9/20			
liv mix		no dre	P=1.	.291mg n.s.s.	2/20	2/20			
liv nnd		no dre	P=1.	.407mg n.s.s.	2/20	1/20			
4589 R m f3d wat		40w78 2565			0	.293mg			Hasegawa;clet,123,185-191;1998/pers.comm.
liv tum	es	no dre	P=1.	- .510mg n.s.s.	0/10	0/15			
N-NITROSOMETHYL(2-OXOPROPYL)AMINE 55984-51-5									
4590 R f mrc gav		67w76 1911			0	.129mg	.257mg	.500mg	Pour;clet,45,49-57;1989
npc mix	as	16.7ug Z	P<.0005	+ 6.68ug 36.8ug	0/15	14/15	15/15	(9/14)	
phr mix	as	75.8ug *	P<.0005	+ 47.6ug .149mg	0/15	10/15	14/15	9/14	
eso mix	as	.160mg *	P<.0005	+ 90.8ug .314mg	0/15	1/15	6/15	12/14	
liv mix	as	.268mg *	P<.002	+ .143mg 1.05mg	0/15	3/15	5/15	6/14	
lun ade	as	no dre	P=1.	1.09mg n.s.s.	6/15	0/15	0/15	1/14	
nsp pam	as	no dre	P=1.	.618mg n.s.s.	0/15	3/15	0/15	0/14	
tba tum	as	noTD50	P<.0005	n.s.s. 34.9ug	5/15	15/15	15/15	14/14	
4591 R m mrc gav		51w58 1911			0	.129mg	.257mg	.500mg	
npc mix	as	17.8ug *	P<.0005	+ 9.79ug 32.5ug	0/15	12/13	15/15	14/15	
phr mix	as	23.0ug Z	P<.0005	+ 12.7ug 44.4ug	0/15	10/13	13/15	(8/15)	
eso mix	as	64.2ug *	P<.0005	+ 38.9ug .120mg	0/15	4/13	12/15	10/15	
liv mix	as	.252mg Z	P<.07	+ 82.7ug n.s.s.	1/15	0/13	5/15	(1/15)	
nsp pam	as	.942mg *	P<.4	.270mg n.s.s.	0/15	1/13	1/15	1/15	
lun ade	as	no dre	P=1.	64.7ug n.s.s.	0/15	0/13	0/15	0/15	
tba tum	as	noTD50	P<.0005	n.s.s. 19.0ug	3/15	13/13	15/15	15/15	
N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE ---									
4592 R f f34 gav		28m28 1904			0	5.22mg			Koepke;canr,48,1533-1536;1988/pers.comm.
liv mix	e	3.47mg	P<.0005	+ 1.64mg 10.3mg	3/20	15/19			
liv hpc	e	7.55mg	P<.0005	+ 3.49mg 21.1mg	0/20	9/19			
liv hes	e	12.8mg	P<.003	+ 5.17mg 61.8mg	0/20	6/19			
liv nnd	e	22.3mg	P<.3	6.01mg n.s.s.	3/20	6/19			
4593 R m f34 gav		28m28 1904			0	3.66mg			
liv hes	e	11.8mg	P<.007	+ 4.45mg 136.mg	0/20	5/20			
liv mix	e	7.79mg	P<.04	+ 2.94mg n.s.s.	3/20	9/20			
pit ade	e	11.1mg	P<.04	4.04mg n.s.s.	1/20	6/20			
tes ict	e	11.1mg	P<.04	4.04mg n.s.s.	1/20	6/20			
liv hpc	e	32.2mg	P<.1	+ 7.91mg n.s.s.	0/20	2/20			
liv nnd	e	12.6mg	P<.2	3.88mg n.s.s.	3/20	7/20			
2-NITROSOMETHYLAMINOPYRIDINE 16219-98-0									
4594 R f bdf gav		72w72 1261			0	.714mg			Preussmann;jnci,62,153-156;1979
eso mix	e	.214mg	P<.003	+ .118mg .826mg	0/5	18/27			
liv mix	e	no dre	P=1.	.964mg n.s.s.	1/5	2/27			
tba mal	e	.668mg	P<.08	.301mg n.s.s.	0/5	8/27			
tba mix	e	.280mg	P<.2	.112mg n.s.s.	2/5	20/27			
tba ben	e	3.05mg	P<.9	.263mg n.s.s.	2/5	12/27			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
3-NITROSOMETHYLAMINOPYRIDINE 69658-91-9									
4595 R f bdf gav 27m27 1261					0	.571mg			Preussmann;jnci,62,153-156;1979
liv mix e	no dre	P=1.	-	1.92mg n.s.s.	1/5	2/26			
tba mix e	no dre	P=1.	-	1.10mg n.s.s.	2/5	6/26			
tba mal e	6.09mg	P<.4	-	1.50mg n.s.s.	0/5	2/26			
tba ben e	no dre	P=1.	-	1.51mg n.s.s.	2/5	4/26			
4-NITROSOMETHYLAMINOPYRIDINE 16219-99-1									
4596 R f bdf gav 23m23 1261					0	2.86mg			Preussmann;jnci,62,153-156;1979
liv mix e	no dre	P=1.	-	8.33mg n.s.s.	1/5	0/15			
tba mix e	no dre	P=1.	-	2.85mg n.s.s.	2/5	4/15			
tba ben e	no dre	P=1.	-	3.56mg n.s.s.	2/5	3/15			
tba mal e	26.8mg	P<.5	-	4.35mg n.s.s.	0/5	1/15			
NITROSOMETHYLANILINE 614-00-6									
4597 R f cbt wat 67w67 1260					0	70.7mg			Boyland;bjca,18,265-270;1964
eso mix ev	noTD50	P<.0005	+	n.s.s. 12.4mg	0/5	15/15			
eso sqc ev	26.4mg	P<.02	+	11.6mg n.s.s.	0/5	8/15			
eso ben ev	32.0mg	P<.03	+	13.5mg n.s.s.	0/5	7/15			
liv tum ev	no dre	P=1.	-	90.7mg n.s.s.	0/5	0/15			
4598 R m cbt wat 60w60 1260					0	64.1mg			
eso mix ev	5.27mg	P<.002	+	2.07mg 16.2mg	0/3	15/16			
eso sqc ev	10.5mg	P<.009	+	5.02mg 241.mg	0/3	12/16			
eso ben ev	70.4mg	P<.3	+	21.2mg n.s.s.	0/3	3/16			
liv tum ev	no dre	P=1.	-	70.4mg n.s.s.	0/3	0/16			
4599 R f f34 wat 12m26 1544					0	.895mg			Kroeger-Koepke;carc,4,157-160;1983
eso car	.458mg	P<.0005	+	.233mg .996mg	0/20	16/20			
liv car	no dre	P=1.		3.30mg n.s.s.	4/20	1/20			
tba mix	no dre	P=1.		.258mg n.s.s.	18/20	18/20			
4600 R m f34 wat 12m26 1544					0	.627mg			
eso mix	.272mg	P<.0005	+	.136mg .588mg	0/20	17/20			
liv car	no dre	P=1.		2.20mg n.s.s.	3/20	1/20			
tba mix	no dre	P=1.		.205mg n.s.s.	19/20	18/20			
4601 R b sda wat 24m24 1264					0	83.8ug	.319mg		Schmahl;clet,1,215-218;1976
eso mix e	34.3ug \	P<.0005	+	22.0ug 55.7ug	0/48	39/48	(42/48)		
NITROSOMETHYLPHENIDATE 55557-03-4									
4602 M f c7b wat 17m25 1257					0	8.05mg			Giner-Sorolla;fctx,18,81-83;1980
lun tum	no dre	P=1.	-	19.3mg n.s.s.	14/43	7/31			
liv tum	no dre	P=1.	-	53.4mg n.s.s.	0/43	0/31			
tba mix	no dre	P=1.	-	10.6mg n.s.s.	24/43	15/31			
4603 M m c7b wat 17m25 1257					0	6.70mg			
lun tum	no dre	P=1.	-	4.69mg n.s.s.	15/18	17/24			
tba mix	no dre	P=1.	-	3.59mg n.s.s.	16/18	19/24			
NITROSOMETHYLUNDECYLAMINE 68107-26-6									
4604 R m f34 gav 30w65 1207					0	6.07mg			Lijinsky;clet,5,209-213;1978
lun sqc	2.37mg	P<.0005	+	1.12mg 6.28mg	2/260	10/20			
liv hpc	2.38mg	P<.0005	+	1.13mg 6.38mg	3/260	10/20			
lun ald	2.41mg	P<.0005	+	1.13mg 6.59mg	5/260	10/20			
liv clc	3.18mg	P<.0005	+	1.42mg 9.37mg	0/260	8/20			
lun ala	4.99mg	P<.0005		1.91mg 24.9mg	8/260	6/20			
eso sqc	15.4mg	P<.002		3.79mg 205.mg	0/260	2/20			
stn pam	15.4mg	P<.002		3.79mg 205.mg	0/260	2/20			
N-NITROSOMORPHOLINE 59-89-2									
4605 H f syg wat 24m24 1543					0	1.36mg	6.82mg	13.6mg	Ketkar;clet,17,333-338;1983/pers.comm.
res mix e	1.35mg Z	P<.0005	+	.714mg 2.97mg	0/50	14/28	(16/30	22/30)	
liv mix e	51.6mg *	P<.0005	+	23.4mg 156.mg	0/50	0/28	2/30	6/30	
tba mix e	1.48mg Z	P<.0005		.746mg 4.02mg	3/50	14/28	(17/30	23/30)	
4606 H f syg wat 24m24 1998					0	1.36mg	6.82mg	13.6mg	Cardesa;expl,401,267-281;1990
trh mem er	11.3mg *	P<.0005	+	6.50mg 29.0mg	0/25	7/28	11/30	16/30	
lar mix er	15.4mg *	P<.0005	+	8.95mg 44.7mg	0/25	4/28	9/30	12/30	
4607 H m syg wat 24m24 1543					0	1.20mg	6.00mg	12.0mg	Ketkar;clet,17,333-338;1983/pers.comm.
res mix e	5.98mg *	P<.0005	+	4.03mg 9.71mg	0/50	8/29	13/29	21/30	
liv mix e	9.14mg *	P<.0005	+	5.87mg 15.4mg	0/50	4/29	9/29	18/30	
tba mix e	5.56mg *	P<.0005		3.40mg 10.8mg	8/50	12/29	14/29	26/30	
4608 H m syg wat 24m24 1998					0	1.20mg	6.00mg	12.0mg	Cardesa;expl,401,267-281;1990
trh mem er	7.98mg *	P<.0005	+	5.21mg 14.9mg	0/25	5/29	9/29	20/30	
lar mix er	11.5mg *	P<.0005	+	7.14mg 20.2mg	0/25	1/29	10/29	15/30	
4609 R f f34 wat 10m29 1886m					0	7.29ug	17.8ug	42.1ug	.104mg .338mg 1.06mg 2.83mg Lijinsky; canr,48,2089-2095;1988
liv mix e	.140mg *	P<.0005	+	95.6ug .222mg	1/80	6/48	7/48	15/48	14/24 22/23 23/24 24/24
amd phe e	.325mg Z	P<.007		.146mg 6.40mg	8/80	10/48	3/48	15/48	7/24 (5/24 2/24 0/24)
thy ccr e	.363mg Z	P<.0005		.185mg 1.38mg	2/80	1/48	4/48	8/48	5/24 (2/24 2/24 0/24)
liv hpc e	.564mg Z	P<.0005	+	.382mg .871mg	0/80	0/48	1/48	5/48	7/24 15/23 16/24 (15/24)
liv hes e	.666mg *	P<.0005	+	.432mg 1.05mg	0/80	0/48	0/48	1/48	0/24 8/23 23/24 24/24
liv nnd e	1.28mg Z	P<.0005	+	.793mg 2.31mg	1/80	6/48	6/48	11/48	9/24 15/23 11/24 20/24
eso mix e	1.97mg Z	P<.0005		1.09mg 4.07mg	0/80	0/48	0/48	0/48	0/24 3/24 13/24 (5/24)
eso sqp e	2.53mg Z	P<.0005		1.33mg 5.72mg	0/80	0/48	0/48	0/48	0/24 2/24 11/24 (5/24)
ton mix e	6.54mg Z	P<.003		2.44mg 63.6mg	2/80	2/48	0/48	0/48	1/24 2/24 4/24 (0/24)
ton sqp e	50.2mg *	P<.3		14.1mg n.s.s.	0/80	1/48	0/48	0/48	0/24 1/24 2/24 0/24
thy fca e	no dre	P=1.		20.0mg n.s.s.	0/80	1/48	0/48	4/48	1/24 3/24 0/24 0/24
4610 R f f34 wat 23m29 1886n					0	2.27ug	5.83ug	14.6ug	35.6ug 84.2ug .249mg
liv mix e	.127mg *	P<.0005	+	89.3ug .192mg	1/80	6/100	5/99	7/47	9/48 22/48 23/24
liv nnd e	.239mg *	P<.0005	+	.156mg .411mg	1/80	5/100	5/99	6/47	8/48 15/48 15/24
liv hpc e	.431mg *	P<.0005	+	.266mg .761mg	0/80	1/100	0/99	0/47	1/48 7/48 16/24
thy fca e	.581mg Z	P<.0005		.299mg 1.95mg	0/80	0/100	2/100	3/48	0/48 7/48 (2/24)

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf								Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc				NCI/NTPPathology
liv hes e	.630mg *	P<.0005 +	.361mg	1.24mg	0/80	0/100	0/99	0/47	0/48	5/48	13/24	
amd phe e	1.07mg *	P<.06	.377mg	n.s.s.	8/80	22/100	18/100	8/48	12/48	13/48	7/24	
ton sqp e	3.49mg *	P<.02	1.08mg	n.s.s.	0/80	1/100	1/100	0/48	1/48	1/48	2/24	
4611 R f f34 wat 50w73 1928					0	.714mg						Hecht;carc,10,1475-1477;1989/pers.comm.
liv mix e	noTD50	P<.0005 +	n.s.s.	.129mg	0/20	20/20						
liv hpc e	80.5ug	P<.0005 +	33.1ug	.184mg	0/20	19/20						
liv hes e	.348mg	P<.0005 +	.166mg	.909mg	0/20	10/20						
N'-NITROSONORNICOTINE (NNN) 53759-22-1												
4612 H f syg wat 31w96 1539					0	7.05mg						Hecht;clet,20,333-340;1983
res pam	11.5mg	P<.04 +	3.45mg	n.s.s.	0/10	3/10						
liv tum	no dre	P=1.	12.4mg	n.s.s.	0/10	0/10						
4613 H m syg wat 31w96 1539					0	6.20mg						
res pam	10.1mg	P<.04 +	3.03mg	n.s.s.	0/10	3/10						
liv ang	34.4mg	P<.3	5.58mg	n.s.s.	0/10	1/10						
4614 R m f34 wat 87w87 2563					0	.250mg						Stoner;carc,19,2139-2143;1998/pers.comm.
eso sqp er	95.7ug	P<.0005 +	43.4ug	.267mg	0/9	10/14						
N'-NITROSONORNICOTINE-1-N-OXIDE 78246-24-9												
4615 H f syg wat 31w96 1539n					0	7.05mg						Hecht;clet,20,333-340;1983
liv ang	39.0mg	P<.3 -	6.34mg	n.s.s.	0/10	1/10						
4616 H m syg wat 31w96 1539n					0	6.20mg						
liv tum	no dre	P=1.	10.9mg	n.s.s.	0/10	0/10						
4617 R f f34 wat 8m24 1539m					0	2.37mg						
nas mix	1.86mg	P<.0005 +	.769mg	6.48mg	0/12	7/12						
eso mix	5.65mg	P<.04 +	1.70mg	n.s.s.	0/12	3/12						
4618 R m f34 wat 8m24 1539m					0	2.08mg						
nas mix	.573mg	P<.0005 +	.211mg	1.62mg	0/12	11/12						
nas mal	1.63mg	P<.0005	.673mg	5.67mg	0/12	7/12						
eso mix	1.63mg	P<.0005 +	.673mg	5.67mg	0/12	7/12						
eso pam	2.64mg	P<.005	.983mg	21.2mg	0/12	5/12						
nas pam	2.64mg	P<.005	.983mg	21.2mg	0/12	5/12						
NITROSOPIPECOLIC ACID 4515-18-8												
4619 R f mrc wat 17m24 216					0	4.42mg						Garcia;zkko,79,141-144;1973
liv tum e	no dre	P=1.	13.6mg	n.s.s.	0/15	0/15						
tba mix e	4.99mg	P<.07 -	1.72mg	n.s.s.	4/15	9/15						
4620 R m mrc wat 17m24 216					0	3.86mg						
liv tum e	no dre	P=1.	11.9mg	n.s.s.	0/15	0/15						
tba mix e	3.82mg	P<.07 -	1.30mg	n.s.s.	5/15	10/15						
N-NITROSOPIPERAZINE 5632-47-3												
4621 R f mrc wat 14m30 229					0	.964mg	4.90mg					Garcia;zkko,74,179-184;1970
liv tum e	no dre	P=1.	2.48mg	n.s.s.	0/13	0/10	0/10					
tba mix e	5.51mg *	P<.2 +	1.55mg	n.s.s.	4/13	8/10	7/10					
4622 R m mrc wat 14m30 229					0	.672mg	3.30mg					
liv hpt e	6.52mg \	P<.05	1.06mg	n.s.s.	0/57	1/10	(0/10)					
tba mix e	21.6mg *	P<.5 +	3.16mg	n.s.s.	12/57	4/10	3/10					
N-NITROSOPIPERIDINE 100-75-4												
4623 H f syg wat 24m24 1541					0	8.18mg	34.1mg	68.2mg				Ketkar;clet,21,219-224;1983
res mix	96.7mg *	P<.0005 +	56.9mg	240.mg	0/50	4/30	6/30	10/30				
dgt mix	132.mg *	P<.002 +	70.6mg	624.mg	0/50	4/30	5/30	7/30				
liv mix	307.mg *	P<.005 +	133.mg	3.08gm	0/50	1/30	2/30	4/30				
tba mix	9.89mg Z	P<.0005	4.97mg	27.9mg	3/50	14/30	(12/30	16/30)				
4624 H f syg wat 24m24 1998					0	8.18mg	34.1mg	68.2mg				Cardesa;expl,401,267-281;1990
trh mem er	205.mg *	P<.005 +	99.9mg	1.93gm	0/25	1/30	4/28	5/30				
lar mix er	258.mg *	P<.002 +	117.mg	1.10gm	0/25	0/30	3/28	5/30				
4625 H m syg wat 24m24 1541					0	7.20mg	30.0mg	60.0mg				Ketkar;clet,21,219-224;1983
res mix	50.9mg *	P<.0005 +	32.6mg	90.0mg	0/50	5/30	10/30	15/30				
dgt mix	98.2mg *	P<.0005 +	55.5mg	198.mg	0/50	0/30	4/30	13/30				
liv mix	135.mg *	P<.0005 +	71.2mg	312.mg	0/50	1/30	2/30	10/30				
tba mix	52.9mg *	P<.0005	29.6mg	142.mg	8/50	9/30	12/30	19/30				
4626 H m syg wat 24m24 1998					0	7.20mg	30.0mg	60.0mg				Cardesa;expl,401,267-281;1990
lar mix er	76.1mg *	P<.0005 +	45.2mg	146.mg	0/25	1/28	7/29	13/30				
trh mem er	180.mg *	P<.0005 +	87.5mg	569.mg	0/25	0/28	4/29	6/30				
4627 M m icm eat 52w52 225					0	6.00mg						Takayama;nawi,56,142;1969
for sqc	1.30mg	P<.0005 +	.736mg	2.60mg	0/30	18/33						
liv mix	2.53mg	P<.0005 +	1.26mg	6.36mg	0/30	11/33						
liv ade	5.12mg	P<.005	2.09mg	36.6mg	0/30	6/33						
lun ade	3.52mg	P<.02 +	1.49mg	n.s.s.	2/30	10/33						
4628 P b cym eat 12y12 2004 :					0	176.mg						Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
liv hpc jw	12.1mg	P<.0005 +	3.30mg	56.7mg	0/62	5/5						
liv hes jw	21.7mg	P<.008	3.53mg	5.75gm	0/35	1/1						
tba mal Wjw	12.1mg	P<.0005	3.30mg	56.7mg	0/62	5/5						
4629 P b rhe eat 12y12 2004 :					0	123.mg						
liv hpc jw	8.36mg	P<.0005 +	2.35mg	29.5mg	0/94	6/7						
tba mal Wjw	10.3mg	P<.0005	3.04mg	46.4mg	2/94	6/7						
4630 P b rhe ipj 20y20 2004m :					0	3.10mg						
liv hpc jw	1.65mg	P<.0005 +	.454mg	11.7mg	0/69	3/5						
bil hmt jw	1.07mg	P<.02	.174mg	n.s.s.	0/23	1/1						
tba mix Wjw	1.01mg	P<.003	.279mg	11.5mg	9/108	4/6						
tba mal Wjw	1.40mg	P<.003	.353mg	20.4mg	4/74	3/6						
tba ben Wjw	4.27mg	P<.3	.460mg	n.s.s.	6/108	1/6						
4631 R b clw wat 30m30 1958					0	11.0ug	22.0ug	44.0ug	87.0ug	.174mg	.349mg	.523mg .698mg .872mg
1.05mg 1.39mg 1.74mg 2.09mg 2.79mg 5.58mg												Gray;canr,51,6470-6491;1991
eso mix e	1.31mg *	P<.0005 +	.970mg	1.82mg	0/246	0/12	0/12	1/12	0/12	1/12	3/12 8/12 4/12 10/12	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf									Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc					NCI/NTPPathology
	10/12	8/12	8/12	10/12	12/12	9/12							
liv hct e	1.41mg	*	P<.0005	+	1.04mg	2.00mg	8/246	0/12	1/12	1/12	3/12	3/12	5/12	9/12	7/12	9/12
	11/12	8/12	8/12	10/12	9/12	8/12										
liv hpc e	1.51mg	*	P<.0005	+	1.11mg	2.10mg	2/246	0/12	1/12	1/12	3/12	2/12	4/12	9/12	5/12	7/12
	10/12	8/12	8/12	10/12	9/12	8/12										
eso mal e	10.3mg	*	P<.0005	+	6.07mg	19.5mg	0/246	0/12	0/12	0/12	0/12	1/12	1/12	2/12	0/12	3/12
	3/12	1/12	1/12	4/12	3/12	1/12										
nsp mix e	27.4mg	Z	P<.0005	+	12.0mg	110.mg	0/246	0/12	1/12	0/12	0/12	0/12	0/12	0/12	0/12	2/12
	1/12	1/12	2/12	1/12	0/12	1/12										
nsp mal e	77.1mg	Z	P<.02	+	22.7mg	n.s.s.	0/246	0/12	1/12	0/12	0/12	0/12	0/12	0/12	0/12	0/12
	0/12	1/12	1/12	0/12	0/12	1/12										
ski mal e	222.mg	*	P<.07		36.2mg	n.s.s.	0/246	0/12	0/12	0/12	0/12	0/12	0/12	0/12	0/12	0/12
	0/12	0/12	0/12	0/12	1/12	0/12										
lgi mal e	224.mg	Z	P<.8		36.4mg	n.s.s.	0/246	0/12	0/12	0/12	0/12	0/12	0/12	1/12	0/12	0/12
	0/12	0/12	0/12	0/12	0/12	0/12										
4632 R b sda wat 27m33 1634							0	17.1ug	85.7ug	.429mg	2.14mg			Eisenbrand;iarc,657-663;1980		
liv mix a	.963mg	Z	P<.0005		.590mg	1.96mg	0/40	3/78	5/75	16/34	(11/34)					
mix mix a	2.32mg	*	P<.0005		1.51mg	3.80mg	0/40	0/78	2/75	8/34	24/34					
tba mal a	1.57mg	*	P<.0005	+	.998mg	2.69mg	4/40	7/78	7/75	14/34	28/34					
NITROSOPROLINE 7519-36-0																
4633 R f mrc wat 17m24 216							0	4.42mg						Garcia;zkko,79,141-144;1973		
liv tum e	no dre		P=1.		13.6mg	n.s.s.	0/15	0/15								
tba mix e	6.69mg		P<.2	-	2.05mg	n.s.s.	4/15	8/15								
4634 R m mrc wat 17m24 216							0	3.86mg								
liv tum e	no dre		P=1.		11.9mg	n.s.s.	0/15	0/15								
tba mix e	no dre		P=1.	-	4.39mg	n.s.s.	5/15	4/15								
N-NITROSOPYRROLIDINE 930-55-2																
4635 H f syg wat 24m24 1503							0	.573mg	2.18mg	4.50mg				Ketkar;zkko,104,75-79;1982		
liv hct	35.9mg	*	P<.008	+	12.4mg	770.mg	0/50	0/30	1/30	3/30						
tba mix	8.44mg	*	P<.002		4.27mg	39.7mg	3/50	2/30	10/30	8/30						
4636 H m syg wat 24m24 1503							0	.504mg	1.92mg	3.96mg						
liv hct	8.88mg	*	P<.0005	+	4.67mg	20.4mg	0/50	1/30	2/30	10/30						
liv hae	130.mg	*	P<.2		21.2mg	n.s.s.	0/50	0/30	0/30	1/30						
tba mix	9.26mg	*	P<.007		4.14mg	159.mg	8/50	3/30	4/30	13/30						
4637 M m swi gav 76w76 1713							0	1.19mg						Shah;zkko,109,203-207;1985		
tba mix e	.679mg		P<.002	+	.309mg	2.84mg	1/20	10/20								
4638 R m chm wat 84w84 1774							0	3.00mg						Chung;canr,46,1285-1289;1986		
liv hpc	.659mg		P<.0005	+	.340mg	1.35mg	0/23	20/23								
liv nnd	1.13mg		P<.0005	+	.601mg	2.40mg	0/23	16/23								
liv clc	14.8mg		P<.1	+	3.63mg	n.s.s.	0/23	2/23								
4639 R b clw wat 30m30 1958							0	34.0ug	69.0ug	.137mg	.275mg	.550mg	1.10mg	1.65mg	2.20mg	2.75mg
3.30mg	4.40mg	5.50mg	6.60mg	8.80mg	17.6mg									Gray;canr,51,6470-6491;1991		
liv hct e	1.70mg	*	P<.0005	+	1.24mg	2.36mg	8/246	0/12	0/12	1/12	5/12	6/12	9/12	12/12	12/12	11/12
	10/12	12/12	9/12	10/12	11/12	12/12										
liv hpc e	2.20mg	*	P<.0005	+	1.63mg	3.03mg	2/246	0/12	0/12	1/12	5/12	4/12	7/12	10/12	11/12	10/12
	9/12	11/12	9/12	9/12	11/12	12/12										
bil ben e	99.7mg	*	P<.003	+	40.1mg	814.mg	2/246	0/12	0/12	0/12	1/12	0/12	1/12	0/12	0/12	0/12
	1/12	0/12	2/12	2/12	2/12	0/12										
nsp tum e	350.mg	*	P<.04		86.1mg	n.s.s.	0/246	0/12	0/12	0/12	0/12	0/12	0/12	0/12	0/12	1/12
	0/12	0/12	0/12	0/12	1/12	0/12										
4640 R f f34 wat 7m26 1795							0	1.00mg						Michejda;canr,46,2252-2256;1986/pers.comm.		
liv hpc e	noTD50		P<.0005	+	n.s.s.	.409mg	0/20	20/20								
liv nnd e	2.51mg		P<.04	+	.915mg	n.s.s.	1/20	6/20								
liv hes e	15.0mg		P<.3	+	2.44mg	n.s.s.	0/20	1/20								
liv clc e	15.0mg		P<.3	+	2.44mg	n.s.s.	0/20	1/20								
tba mix e	noTD50		P<.6	+	n.s.s.	n.s.s.	19/20	20/20								
4641 R f f34 wat 12m26 2022							0	1.65mg						Lijinsky;clet,12,99-103;1981		
liv hpc e	.439mg		P<.0005	+	.179mg	1.04mg	1/20	19/20								
liv mix e	.439mg		P<.0005	+	.179mg	1.04mg	1/20	19/20								
liv clc e	4.49mg		P<.007	+	1.70mg	51.8mg	0/20	5/20								
liv cho e	7.95mg		P<.04		2.40mg	n.s.s.	0/20	3/20								
liv lyp e	7.95mg		P<.04		2.40mg	n.s.s.	0/20	3/20								
liv sar e	25.2mg		P<.3		4.10mg	n.s.s.	0/20	1/20								
tba tum e	no dre		P=1.		.326mg	n.s.s.	20/20	19/20								
4642 R f mrw wat 16m24 228							0	5.21mg						Greenblatt;jnci,48,1687-1696;1972/1973		
liv hpc e	1.81mg		P<.0005	+	.802mg	4.45mg	0/20	13/15								
tba mix e	4.49mg		P<.3		1.06mg	n.s.s.	14/20	13/15								
4643 R m mrw wat 16m24 228							0	3.65mg								
liv hpc e	1.58mg		P<.0005	+	.731mg	3.93mg	0/20	12/15								
tes pms e	8.21mg		P<.007		2.82mg	123.mg	0/20	4/15								
tba mix e	2.03mg		P<.004		.807mg	16.5mg	6/20	12/15								
4644 R b sda wat 23m30 371							0	.300mg	1.00mg	3.00mg	10.0mg			Preussmann;zkko,90,161-166;1977		
liv hpc as	3.26mg	Z	P<.0005		2.23mg	5.01mg	0/61	0/60	13/62	30/38	(9/24)					
liv hpa as	55.5mg	*	P<.005		20.9mg	857.mg	0/61	3/60	4/62	1/38	5/24					
tba mal as	2.37mg	Z	P<.0005	+	1.60mg	3.90mg	6/61	12/60	20/62	32/38	(11/24)					
tba ben as	71.1mg	*	P<.2		20.9mg	n.s.s.	5/61	7/60	9/62	3/38	6/24					
4645 R m sda wat 20m30 1717m							0	.657mg							Hoos;clet,26,77-82;1985	
liv hpc	.648mg		P<.0005	+	.454mg	.958mg	0/80	53/80								
tba mal	.631mg		P<.0005		.412mg	1.10mg	19/80	60/80								
4646 R m sda wat 10m30 1717n							0	.657mg								
liv hpc	.489mg		P<.0005	+	.346mg	.712mg	0/80	61/80								
tba mal	.501mg		P<.0005		.333mg	.826mg	19/80	65/80								
4647 R m sda wat 37m38 1838							0	28.6ug	95.0ug	.286mg				Berger;carc,8,1635-1643;1987/pers.comm.		
liv mix a	2.43mg	*	P<.0005	+	1.44mg	4.68mg	3/500	1/80	4/80	17/80						
liv hpc a	4.06mg	*	P<.0005	+	2.14mg	9.15mg	0/500	1/80	0/80	12/80						
liv hpa a	8.13mg	*	P<.0005	+	3.42mg	31.2mg	1/500	0/80	2/80	5/80						

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
unt tum a		7.03mg Z	P<.1 +	1.78mg n.s.s.	1/500	2/80	1/80	(0/80)	
git mix a		14.9mg *	P<.4 +	3.25mg n.s.s.	26/500	6/80	7/80	6/80	
liv hmm a		55.7mg *	P<.3	9.07mg n.s.s.	0/500	0/80	1/80	0/80	
tba mal a		2.03mg *	P<.007 +	.933mg 38.1mg	144/500	23/80	28/80	35/80	
tba ben a		no dre	P=1.	1.18mg n.s.s.	362/500	63/80	59/80	55/80	
N-NITROSOTHIALDINE 81795-07-5									
4648 R f f34 gav 43w90 1884					0	1.13mg			Lijinsky;fctx,26,3-7;1988
eso sqa e		.483mg	P<.0005 +	.247mg 1.09mg	0/20	14/20			
eso sqc e		1.63mg	P<.003	.661mg 8.52mg	0/20	6/20			
ton sqa e		1.53mg	P<.02 +	.603mg n.s.s.	1/20	7/20			
liv hpa e		2.61mg	P<.02 +	.897mg n.s.s.	0/20	4/20			
liv cho e		3.58mg	P<.04 +	1.08mg n.s.s.	0/20	3/20			
ton sqc e		no dre	P=1.	2.09mg n.s.s.	1/20	1/20			
N-NITROSOTHIOMORPHOLINE 26541-51-5									
4649 R f mrc wat 9m24 229					0	.739mg	4.25mg		Garcia;zkko,74,179-184;1970
eso mix e		7.69mg *	P<.002 +	3.11mg 34.4mg	0/13	0/10	6/17		
ton sqc e		22.0mg *	P<.3 +	5.31mg n.s.s.	0/13	1/10	2/17		
liv tum e		no dre	P=1.	1.41mg n.s.s.	0/13	0/10	0/17		
tba mix e		7.38mg *	P<.2	2.22mg n.s.s.	4/13	3/10	9/17		
4650 R m mrc wat 38w95 229					0	.571mg	2.90mg		
eso mix e		4.15mg *	P<.0005 +	1.42mg 21.5mg	0/57	0/11	4/10		
liv tum e		no dre	P=1.	.888mg n.s.s.	0/57	0/11	0/10		
tba mix e		2.29mg *	P<.02	.794mg n.s.s.	12/57	4/11	6/10		
o-NITROSOTOLUENE 611-23-4									
4651 R m f34 eat 72w93 1487					0	105.mg			Hecht;clet,16,103-108;1982
liv mix e		50.7mg	P<.0005 +	28.3mg 105.mg	1/27	20/29			
ski fib e		55.8mg	P<.0005 +	30.9mg 119.mg	1/27	19/29			
liv hpt e		59.2mg	P<.0005 +	33.1mg 119.mg	0/27	18/29			
ubl mix e		71.5mg	P<.0005 +	39.1mg 149.mg	0/27	16/29			
ubl pam e		78.8mg	P<.0005 +	42.5mg 168.mg	0/27	15/29			
spl fib e		87.0mg	P<.0005 +	46.1mg 191.mg	0/27	14/29			
pec scs e		303.mg	P<.009	115.mg 8.01gm	0/27	5/29			
pec mso e		195.mg	P<.03	78.5mg n.s.s.	2/27	9/29			
o-NITROTOLUENE 88-72-2									
4652 M f b6c eat 24m24 TR504 :					0	162.mg	325.mg	650.mg	
MXB MXB		230.mg Z	P<.0005	169.mg 330.mg	9/60	11/60	30/60	55/60	---:hes; cec:car; liv:hpa,hpc. C
liv MXA		303.mg Z	P<.0005 c	212.mg 471.mg	9/60	9/60	24/60	39/60	liv:hpa,hpc.
liv hpa		409.mg Z	P<.0005 c	273.mg 687.mg	7/60	5/60	19/60	29/60	
--- MXA		480.mg Z	P<.0005	336.mg 722.mg	3/60	4/60	3/60	50/60	---:hem,hes. S
--- hes		501.mg Z	P<.0005 c	354.mg 734.mg	0/60	2/60	3/60	50/60	
mey hes		858.mg Z	P<.0005	550.mg 1.42gm	0/60	0/60	0/60	32/60	S
liv hpc		975.mg Z	P<.0005 c	573.mg 2.04gm	2/60	4/60	6/60	16/60	
sub hes		1.18gm Z	P<.0005	692.mg 2.21gm	0/60	0/60	2/60	19/60	S
mus hes		1.86gm Z	P<.0005	1.02gm 3.81gm	0/60	0/60	0/60	16/60	S
cec car		2.50gm *	P<.002 c	1.11gm 9.77gm	0/60	1/60	4/60	3/60	
ute hes		6.74gm *	P<.02	2.21gm n.s.s.	0/60	1/60	0/60	3/60	S
TBA MXB		228.mg Z	P<.0005	147.mg 449.mg	56/60	37/60	46/60	56/60	
liv MXB		303.mg Z	P<.0005	212.mg 471.mg	9/60	9/60	24/60	39/60	liv:hpa,hpb,hpc.
lun MXB		2.62gm *	P<.06	951.mg n.s.s.	5/60	6/60	4/60	6/60	lun:a/a,a/c.
4653 M m b6c eat 21m24 TR504 :					0	150.mg	300.mg	600.mg	
MXB MXB a		65.6mg Z	P<.0005	49.2mg 88.0mg	4/60	29/60	57/60	60/60	---:hes; cec:car. C
--- MXA a		78.2mg Z	P<.0005	58.7mg 107.mg	5/60	18/60	55/60	60/60	---:hem,hes. S
--- hes a		80.9mg Z	P<.0005 c	60.1mg 109.mg	4/60	17/60	55/60	60/60	
mey hes a		136.mg Z	P<.0005	95.4mg 195.mg	0/60	8/60	38/60	38/60	S
mus hes a		152.mg Z	P<.0005	107.mg 216.mg	0/60	6/60	33/60	45/60	S
cec car a		292.mg *	P<.0005 c	163.mg 571.mg	0/60	12/60	9/60	0/60	
sub hes a		366.mg Z	P<.0005	204.mg 662.mg	0/60	4/60	8/60	20/60	S
pro hes a		2.30gm *	P<.005	752.mg 21.4gm	0/60	0/60	4/60	0/60	S
lun hes a		6.95gm Z	P<.005	2.28gm 60.2gm	0/60	0/60	0/60	4/60	S
TBA MXB a		33.4mg Z	P<.0005	24.7mg 47.0mg	57/60	59/60	59/60	60/60	
liv MXB a		183.mg Z	P<.002	88.3mg 1.09gm	28/60	29/60	7/60	2/60	liv:hpa,hpb,hpc.
lun MXB a		1.01gm Z	P<.3	267.mg n.s.s.	14/60	7/60	6/60	(0/60)	lun:a/a,a/c.
4654 R f f34 eat 24m24 TR504 :					0	31.2mg	62.5mg	100.mg	
mgl MXA		37.5mg *	P<.0005	24.6mg 73.5mg	23/60	47/60	52/60	57/60	mgl:car,fba. S
MXB MXB		37.6mg *	P<.0005	24.6mg 75.4mg	25/60	47/60	56/60	57/60	liv:hpa; mgl:fba; sub:fbs,fib. M
mgl fba		38.0mg *	P<.0005 c	24.8mg 75.6mg	23/60	47/60	52/60	56/60	
MXB MXB		38.2mg *	P<.0005	24.8mg 77.8mg	25/60	47/60	56/60	56/60	mgl:fba; sub:fbs,fib. C
sub MXA		108.mg Z	P<.0005 c	71.2mg 195.mg	3/60	3/60	21/60	22/60	sub:fbs,fib.
sub fib		124.mg Z	P<.0005 c	79.5mg 239.mg	3/60	3/60	18/60	20/60	
sub fbs		757.mg *	P<.007	323.mg 8.72gm	0/60	0/60	4/60	3/60	S
ute MXA		241.mg *	P<.02	111.mg n.s.s.	11/60	8/60	15/60	17/60	ute:esp,ess. S
ute esp		263.mg *	P<.03	118.mg n.s.s.	11/60	7/60	15/60	16/60	S
liv hpa		836.mg *	P<.02 p	328.mg n.s.s.	1/60	0/60	1/60	6/60	
TBA MXB		90.6mg *	P<.08	36.7mg n.s.s.	60/60	60/60	60/60	60/60	
liv MXB		836.mg *	P<.02	328.mg n.s.s.	1/60	0/60	1/60	6/60	liv:hpa,hpb,hpc.
4655 R m f34 eat 23m24 TR504 :					0	25.0mg	50.0mg	80.0mg	
MXB MXB a		6.29mg Z	P<.0005	4.55mg 8.84mg	10/60	52/60	56/60	60/60	---:msm; liv:hcc,hpa,hpc; mgl:fba; sub:fbs,fib, lip. C
sub MXA a		6.57mg Z	P<.0005 c	4.79mg 9.20mg	5/60	47/60	55/60	59/60	sub:fbs,fib.
sub fib a		6.67mg Z	P<.0005 c	4.84mg 9.37mg	5/60	46/60	52/60	59/60	
--- msm a		17.6mg Z	P<.0005 c	12.0mg 25.9mg	2/60	20/60	29/60	44/60	
sub fbs a		35.0mg Z	P<.0005 c	21.3mg 57.8mg	0/60	7/60	17/60	20/60	
mgl fba a		47.3mg *	P<.0005 c	24.2mg 97.9mg	0/60	7/60	10/60	2/60	
sub lip a		53.0mg Z	P<.0005 c	29.2mg 93.1mg	0/60	4/60	13/60	13/60	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
liv MXA a	106.mg Z	P<.0005 c	42.2mg 436.mg	3/60	3/60	3/60	8/60	liv:hpa,hpc.	
amd pob a	111.mg *	P<.002	44.2mg 689.mg	2/60	4/60	6/60	2/60		S
liv hpa a	113.mg Z	P<.0005 c	44.9mg 457.mg	2/60	3/60	3/60	7/60		
lun MXA a	116.mg *	P<.02	39.1mg n.s.s.	2/60	5/60	1/60	2/60	lun:a/a,a/c.	S
liv hcc a	1.82gm *	P<.3 c	438.mg n.s.s.	0/60	1/60	0/60	1/60		
TBA MXB a	6.56mg Z	P<.0005	4.61mg 9.80mg	50/60	60/60	60/60	60/60		
liv MXB a	106.mg Z	P<.0005	42.2mg 436.mg	3/60	3/60	3/60	8/60	liv:hpa,hpb,hpc.	
4656 R m f34 eat 3m24 TR504a : ()				0	10.7mg	28.4mg			
MXB MXB	1.83mg /	P<.0005	1.20mg 2.82mg	11/60	57/60	60/60	---:msm; liv:clc,hpa,hpc; lun:a/a,a/c; mgl:fba; ski:sar; sub:fbs,fib,lip.		M
MXB MXB	1.84mg /	P<.0005	1.22mg 2.83mg	10/60	57/60	60/60	---:msm; liv:clc,hpa,hpc; mgl:fba; ski:sar; sub:fbs,fib, lip.		C
MXA MXA	2.15mg /	P<.0005 c	1.42mg 3.33mg	5/60	47/60	53/60	ski:sar; sub:fbs,fib.		
MXA MXA	2.17mg /	P<.0005	1.44mg 3.38mg	5/60	45/60	52/60	ski:sar; sub:fib.		S
sub fib	2.17mg /	P<.0005 c	1.44mg 3.38mg	5/60	45/60	52/60			
--- msm	2.48mg /	P<.0005 c	1.54mg 4.03mg	2/60	44/60	54/60			
mgl fba	7.13mg /	P<.0005 c	3.66mg 14.2mg	0/60	13/60	20/60			
sub lip	10.2mg *	P<.0005 c	4.90mg 21.9mg	0/60	10/60	12/60			
sub fbs	13.6mg /	P<.0005 c	6.31mg 28.3mg	0/60	8/60	12/60			
lun MXA	22.0mg /	P<.0005 p	8.39mg 69.3mg	2/60	3/60	11/60		lun:a/a,a/c.	
lun a/a	26.9mg /	P<.0005	9.43mg 94.1mg	1/60	3/60	8/60			S
liv MXA	30.8mg /	P<.002 c	9.86mg 197.mg	3/60	3/60	6/60		liv:hpa,hpc.	
--- ost	98.0mg *	P<.05	17.4mg n.s.s.	1/60	3/60	3/60			S
bon ost	101.mg *	P<.04	17.5mg n.s.s.	1/60	2/60	3/60			S
--- MXA	110.mg /	P<.02	17.6mg n.s.s.	1/60	0/60	4/60		---:hem,hes.	S
--- hem	304.mg *	P<.02	89.9mg n.s.s.	0/60	0/60	3/60			S
liv clc	327.mg *	P<.02 c	92.7mg n.s.s.	0/60	0/60	3/60			
TBA MXB	1.89mg /	P<.0005	1.25mg 3.03mg	50/60	60/60	60/60			
liv MXB	30.8mg /	P<.002	9.86mg 197.mg	3/60	3/60	6/60		liv:hpa,hpb,hpc.	
p-NITROTOLUENE 99-99-0									
4657 M f b6c eat 24m24 TR498 :				0	162.mg	325.mg	650.mg		
TBA MXB	4.76gm *	P<.7 -	730.mg n.s.s.	21/50	23/50	29/50	25/50		
liv MXB	no dre	P=1.	3.15gm n.s.s.	8/50	6/50	2/50	6/50	liv:hpa,hpb,hpc.	
lun MXB	8.64gm *	P<.4	1.96gm n.s.s.	6/50	2/50	4/50	8/50	lun:a/a,a/c.	
4658 M m b6c eat 24m24 TR498 :				0	150.mg	300.mg	600.mg		
lun MXA	1.48gm *	P<.03 e	648.mg n.s.s.	8/50	14/50	12/50	19/50	lun:a/a,a/c.	
TBA MXB	741.mg *	P<.07	299.mg n.s.s.	31/50	38/50	41/50	44/50		
liv MXB	2.08gm *	P<.4	560.mg n.s.s.	20/50	24/50	25/50	25/50	liv:hpa,hpb,hpc.	
lun MXB	1.48gm *	P<.03	648.mg n.s.s.	8/50	14/50	12/50	19/50	lun:a/a,a/c.	
4659 R f f34 eat 24m24 TR498 :				0	62.4mg	125.mg	250.mg		
cli MXA	257.mg Z	P<.03 p	115.mg n.s.s.	8/50	12/50	20/50	(8/50)	cli:ade,car.	
TBA MXB	679.mg *	P<.6	129.mg n.s.s.	44/50	46/50	49/50	50/50		
liv MXB	13.2gm *	P<.7	2.15gm n.s.s.	0/50	0/50	1/50	0/50	liv:hpa,hpb,hpc.	
4660 R m f34 eat 24m24 TR498 :				0	50.0mg	100.mg	200.mg		
sub MXA	414.mg Z	P<.02 e	189.mg n.s.s.	1/50	2/50	9/50	(1/50)	sub:fbs,fib.	
MXA MXA	488.mg Z	P<.05	199.mg n.s.s.	2/50	2/50	9/50	(1/50)	ski:fih; sub:fbs,fib.	S
TBA MXB	no dre	P=1.	313.mg n.s.s.	48/50	41/50	34/50	38/50		
liv MXB	no dre	P=1.	3.05gm n.s.s.	1/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.	
NITROUS OXIDE (nitrogen oxide) 10024-97-2									
4661 M f sww inh 78w83 1769				0	35.5gm	142.gm		Baden;anes,64,747-750;1986	
lun ade	309.gm *	P<.08 -	118.gm n.s.s.	25/88	24/77	31/75			
liv tum	no dre	P=1. -	841.gm n.s.s.	4/88	2/77	2/75			
mix tum	no dre	P=1. -	465.gm n.s.s.	19/88	11/77	11/75			
4662 M m sww inh 78w83 1769				0	29.5gm	118.gm			
lun ade s	no dre	P=1. -	39.7gm n.s.s.	34/91	28/75	(16/76)			
mix tum s	no dre	P=1. -	320.gm n.s.s.	9/91	10/75	8/76			
liv tum s	no dre	P=1. -	483.gm n.s.s.	11/91	8/75	6/76			
NIVALENOL 23282-20-4									
4663 M f c6s eat 24m24 1946				0	.780mg	1.56mg	3.90mg	Ohtsubo;fctx,27,591-598;1989/pers.comm.	
liv mfh e	no dre	P=1. -	28.3mg n.s.s.	0/38	2/38	0/41	0/41		
lun mix e	no dre	P=1. -	45.3mg n.s.s.	2/38	1/38	0/41	0/41		
tba tum e	no dre	P=1. -	4.58mg n.s.s.	22/38	25/38	23/41	23/41		
NONABROMOBIPHENYL (bromkal 80-9D) 27753-52-2									
4664 M f b6c eat 78w78 2436				0	13.0mg	39.0mg		Momma;jjpt,14,5541-5563;1986	
liv nnd e	4.89mg *	P<.0005 +	3.44mg 7.05mg	0/49	33/46	45/49			
liv hpc e	13.7mg *	P<.0005 +	9.39mg 21.0mg	0/49	8/46	37/49			
lun ade e	no dre	P=1.	182.mg n.s.s.	3/49	1/46	1/49			
tba mix e	4.90mg *	P<.0005	3.37mg 7.40mg	4/49	35/46	45/49			
4665 M m b6c eat 78w78 2436				0	12.0mg	36.0mg			
liv nnd es	2.86mg *	P<.0005 +	1.70mg 5.29mg	19/50	48/49	44/46			
liv hpc es	3.44mg \	P<.0005 +	2.13mg 6.22mg	7/50	38/49	(13/46)			
liv hpb es	35.4mg \	P<.004 +	14.4mg 212.mg	0/50	6/49	(1/46)			
lun ade es	no dre	P=1.	42.1mg n.s.s.	5/50	2/49	(0/46)			
tba mix es	2.07mg *	P<.0005	1.11mg 4.18mg	23/50	49/49	45/46			
NORETHYNODREL 68-23-5									
4666 M f c3h eat 24m24 1175				0	1.76mg			Rudali;jnci,49,813-819;1972	
mam tum Ler	no dre	P=1.	2.48mg n.s.s.	54/92	45/77				
4667 M f cfl eat 78w78 1453m				0	.125mg	1.50mg	5.00mg	Barrows;jtxe,3,219-230;1977	
liv hct er	49.1mg *	P<.04 -	12.1mg n.s.s.	0/39	0/39	0/40	2/39		
4668 M m cfl eat 78w78 1453m				0	.125mg	1.50mg	5.00mg		
liv hct er	no dre	P=1. -	16.3mg n.s.s.	6/39	7/40	1/40	3/40		
4669 M f crf eat 24m24 1175 pool				0	1.76mg			Rudali;jnci,49,813-819;1972	
mam tum Ler	2.13mg	P<.6	.243mg n.s.s.	161/167	48/49				

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf Brkly Code
Path TD_{50} 2Tailpvl LoConf Cntrl 1 Inc 2 Inc 3 Inc NCI/NTPPathology

4670 M f r3m eat 24m24 1175 0 1.76mg
mam tum Ler no dre P=1. 1.86mg n.s.s. 50/73 19/31
4671 M f sww gav 65w80 1453 0 1.02mg Barrows;jtxe,3,219-230;1977
liv hct er no dre P=1. - 6.19mg n.s.s. 1/50 0/50

NORHARMAN (9H-pyrido(3,4-b)indole) 244-63-3
4672 R m wis eat 80w80 1460 0 20.0mg Hagiwara;txlt,6,71-75;1980
for pam 191.mg P<.3 - 31.0mg n.s.s. 0/28 1/24
ubl tum no dre P=1. - 58.5mg n.s.s. 0/28 0/24

NORLESTRIN 8015-12-1
4673 M f c7l gav 89w89 230 0 .200mg 2.00mg Poel;scie,154,402-403;1966
pit tum e 1.34mg * P<.2 + .347mg n.s.s. 1/8 7/15 5/8
4674 M f csc gav 69w69 585m 0 .143mg Poel;canr,28,845-859;1968
lun tum ek no dre P=1. - .194mg n.s.s. 0/15 0/15
tba mix ek no dre P=1. - 83.4ug n.s.s. 4/15 3/15
4675 M f csc gav 69w82 585n 0 .120mg
tba mix ek no dre P=1. - 57.2ug n.s.s. 8/15 7/15
4676 P f rhe eat 8y10 1441 0 37.5ug .383mg 1.91mg Fitzgerald;jtxe,10,879-896;1982
ute ley e 6.42mg * P<.2 - 1.05mg n.s.s. 0/16 0/16 0/16 1/16
ski pam e 10.1mg * P<.6 - 1.13mg n.s.s. 0/16 1/16 0/16 1/16
lun tum e no dre P=1. 28.5ug n.s.s. 0/16 0/16 0/16 0/16
pdu ade e no dre P=1. - 1.86mg n.s.s. 0/16 1/16 0/16 0/16
liv tum e no dre P=1. 28.5ug n.s.s. 0/16 0/16 0/16 0/16
4677 R b asd eat 24m24 1403 0 .338mg 3.38mg Schardein;txap,16,10-23;1970
liv hnd e 1.94mg \ P<.0005 + .941mg 6.88mg 4/200 13/100 (10/100)
pit cra e 5.31mg / P<.0005 + 3.07mg 13.3mg 64/200 19/100 55/100
mgl mix e 6.66mg * P<.0005 + 3.47mg 27.9mg 61/200 34/100 51/100
mgl ade e 14.8mg * P<.0005 + 7.91mg 37.3mg 5/200 2/100 17/100
ute aep e 27.4mg * P<.002 + 12.0mg 164.mg 4/200 2/100 10/100
liv hpa e 7.59mg \ P<.02 + 2.30mg 37.2gm 0/200 3/100 (4/100)
mgl adc e 76.8mg * P<.05 + 22.9mg n.s.s. 2/200 0/100 4/100
mgl fep e 21.0mg * P<.2 + 6.38mg n.s.s. 58/200 33/100 37/100
tba mix e 14.2mg * P<.6 2.59mg n.s.s. 159/200 82/100 83/100

NOVADELOX (18% BENZOYL PEROXIDE, 78% CALCIUM SULPHATE, 4% MAGNESIUM CARBONATE) 94-36-0
4678 M b alb eat 80w80 1345 0 19.6mg 196.mg 1.96gm Sharratt;fctx,2,527-538;1964
lun ade e no dre P=1. - 9.23gm n.s.s. 0/41 1/42 1/42 0/42
lun mix e no dre P=1. 9.85gm n.s.s. 1/41 1/42 1/42 0/42
liv hpt e no dre P=1. - 11.0gm n.s.s. 1/41 1/42 0/42 0/42
4679 R b alb eat 28m28 1345 0 7.07mg 70.7mg 707.mg
liv mhp e no dre P=1. - 6.57gm n.s.s. 0/46 0/47 1/47 0/45
tba ben e 6.48gm * P<.04 - 2.16gm n.s.s. 3/46 1/47 1/47 6/45
tba mal e 15.6gm * P<.5 - 2.84gm n.s.s. 6/46 2/47 1/47 5/45

OCHRATOXIN A 303-47-9
4680 M f b6c eat 24m24 1691 0 .130mg 5.20mg Bendele;jnci,75,733-739;1985
liv hpc er 34.8mg * P<.02 + 12.3mg n.s.s. 0/47 1/45 5/49
liv hpa er 109.mg * P<.3 21.7mg n.s.s. 0/47 1/45 2/49
kid mix er no dre P=1. 1.18mg n.s.s. 0/47 0/45 0/49
4681 M m b6c eat 24m24 1691 0 .120mg 4.80mg
kid mix er 3.53mg * P<.0005 + 2.25mg 5.92mg 0/50 0/47 31/50
kid ade er 4.64mg * P<.0005 2.87mg 8.13mg 0/50 0/47 26/50
kid car er 10.3mg * P<.0005 5.52mg 22.5mg 0/50 0/47 14/50
liv hpa er 48.1mg * P<.3 12.2mg n.s.s. 1/50 5/47 6/50
liv hpc er 58.7mg * P<.2 14.5mg n.s.s. 0/50 3/47 4/50
4682 R f f34 gav 24m24 TR358 : 0 14.8ug 49.4ug .148mg
kid MXA .485mg * P<.0005 c .235mg 1.40mg 0/50 0/51 2/50 8/50 kid:rua,ruc.
kid rua .813mg * P<.003 c .331mg 4.82mg 0/50 0/51 1/50 5/50
kid ruc 1.31mg * P<.02 c .448mg n.s.s. 0/50 0/51 1/50 3/50
MXB MXB .386mg * P<.3 .103mg n.s.s. 17/50 23/51 24/50 30/50 kid:rua,ruc; mgl:fba. C
mgl fba .550mg * P<.5 c .116mg n.s.s. 17/50 23/51 22/50 28/50
TBA MXB no dre P=1. .117mg n.s.s. 39/50 44/51 40/50 45/50
liv MXB no dre P=1. n.s.s. n.s.s. 0/50 0/51 0/50 0/50 liv:hpa,hpc,nnd.
4683 R m f34 gav 24m24 TR358 : 0 14.8ug 49.3ug .148mg
kid MXA 57.9ug * P<.0005 c 40.6ug 87.9ug 1/50 1/51 20/51 36/50 kid:rua,ruc,rue,tcb.
kid MXA 75.6ug * P<.0005 c 51.8ug .115mg 0/50 0/51 16/51 30/50 kid:ruc,tcb.
kid MXA .241mg * P<.0005 c .127mg .729mg 1/50 1/51 6/51 10/50 kid:rua,rue.
TBA MXB 86.3ug * P<.007 40.9ug 1.42mg 43/50 38/51 44/51 50/50
liv MXB 2.50mg * P<.3 .495mg n.s.s. 1/50 0/51 0/51 2/50 liv:hpa,hpc,nnd.
4684 R f dah gav 26m26 2585m 0 .171mg Castegnaro;ijcn,77,70-75;1998
kid tum r no dre P=1. - 1.58mg n.s.s. 0/10 0/40
4685 R m dah gav 26m26 2585m 0 .171mg
kid adc r .368mg P<.02 + .149mg n.s.s. 0/10 6/20
ubl tcc er 1.18mg P<.2 + .290mg n.s.s. 0/10 2/19
4686 R f lew gav 26m26 2585n 0 .171mg
kid adc r 2.56mg P<.4 .417mg n.s.s. 0/10 1/20
4687 R m lew gav 26m26 2585n 0 .171mg
kid adc r 1.25mg P<.2 + .306mg n.s.s. 0/10 2/20
4688 R b wis gav 12m26 1365 0 76.4ug .229mg Purchase;fctx,9,681-682;1971
liv tum e no dre P=1. .132mg n.s.s. 0/10 0/10 0/10
tba tum e no dre P=1. - .132mg n.s.s. 0/10 0/10 0/10

OCTACHLOROSTYRENE 29082-74-4
4689 M m c5c eat 78w78 2212 0 12.0mg Smith;clet,81,145-150;1994
liv hnd r no dre P=1. 13.9mg n.s.s. 0/8 0/10
4690 R f sda eat 52w52 1773 0 250.ng 2.50ug 25.0ug .250mg 2.50mg Chu;faat,6,69-77;1986
liv tum no dre P=1. n.s.s. n.s.s. 0/20 0/20 0/20 0/20 0/20 0/20

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
4691 R m sda eat 52w52 1773	0	200.ng	2.00ug	20.0ug .200mg 2.00mg	
liv tum no dre P=1. n.s.s. n.s.s.	0/20	0/20	0/20	0/20 0/20 0/20	
OIL, CORN (Zea mays) 8001-30-7					
4692 R m f34 gav 24m24 TR426 :	0	1.61gm	3.22gm	6.47gm	
pan MXA 6.94gm * P<.0005 + 4.35gm 18.0gm	1/50	8/50	11/50	23/50	pan:acc,ana.
pan ana 7.15gm * P<.0005 + 4.46gm 18.5gm	1/50	8/50	10/50	23/50	
TBA MXB no dre P=1. 9.15gm n.s.s.	44/50	42/50	38/50	42/50	
liv MXB no dre P=1. 75.3gm n.s.s.	4/50	3/50	0/50	0/50	liv:hpa,hpb,hpc.
OIL, SAFFLOWER (Carthamus tinctorius) 8001-23-8					
4693 R m f34 gav 24m24 TR426 :	0	1.63gm	3.26gm	6.55gm	
pan MXA 4.85gm * P<.0005 + 3.31gm 8.77gm	1/50	7/50	15/50	29/51	pan:acc,ana.
pan ana 4.94gm * P<.0005 + 3.35gm 9.14gm	1/50	7/50	15/50	28/51	
TBA MXB no dre P=1. 7.70gm n.s.s.	47/50	46/50	41/50	42/51	
liv MXB no dre P=1. 54.2gm n.s.s.	3/50	2/50	2/50	0/51	liv:hpa,hpb,hpc.
OLEATE, SODIUM 143-19-1					
4694 R f f3d wat 25m25 1687	0	1.43gm	2.86gm		Hiasa;fctx,23,619-623;1985
liv hnd e no dre P=1. - 22.2gm n.s.s.	0/43	1/39	0/45		
tba mix e no dre P=1. - 2.99gm n.s.s.	24/43	28/39	25/45		
4695 R m f3d wat 25m25 1687	0	1.25gm	2.50gm		
pan mix e 10.1gm * P<.003 - 5.09gm 45.3gm	0/41	4/40	7/45		
pan ism e 12.6gm * P<.005 - 5.91gm 94.5gm	0/41	3/40	6/45		
liv hnd e 29.1gm * P<.03 - 10.0gm n.s.s.	0/41	0/40	4/45		
liv mix e 39.3gm * P<.2 - 10.8gm n.s.s.	1/41	0/40	4/45		
tba mix e no dre P=1. - 625.mg n.s.s.	40/41	40/40	43/45		
OLESTRA 121854-29-3					
4696 M f cd1 eat 24m24 2154m	0	3.25gm	6.50gm	13.0gm	Lafranconi;fctx,32,789-798;1994/pers.comm.
liv hpa e 259.gm * P<.3 - 65.5gm n.s.s.	1/50	1/49	1/51	3/50	
lun mix e 661.gm * P<.9 - 29.4gm n.s.s.	7/50	13/50	11/50	9/50	
4697 M f cd1 eat 24m24 2154n	0	13.0gm			
lun mix e 196.gm P<.6 - 33.6gm n.s.s.	5/50	7/50			
liv hpa e 214.gm P<.3 - 47.1gm n.s.s.	1/50	3/50			
4698 M m cd1 eat 24m24 2154m	0	3.00gm	6.00gm	12.0gm	
lun mix e 50.9gm * P<.1 - 18.9gm n.s.s.	9/50	8/49	10/50	15/49	
liv mix e 266.gm * P<.8 - 25.1gm n.s.s.	13/50	14/50	9/50	15/50	
4699 M m cd1 eat 24m24 2154n	0	12.0gm			
liv mix e 116.gm P<.4 - 25.8gm n.s.s.	6/50	9/50			
lun mix e 341.gm P<.8 - 29.3gm n.s.s.	8/50	9/50			
4700 R f f34 eat 24m24 2037m	0	495.mg	2.38gm	4.54gm	Wood;fctx,29,223-230;1991
pit ade e 6.66gm * P<.04 - 2.84gm n.s.s.	18/51	29/48	35/52	30/50	
liv hpa e 50.3gm P<.04 - 15.2gm n.s.s.	0/51			3/50	
4701 R f f34 eat 24m24 2037n	0	4.54gm			
liv hpa e 58.6gm P<.05 - 17.7gm n.s.s.	0/58	3/58			
4702 R m f34 eat 24m24 2037m	0	396.mg	1.90gm	3.64gm	
pit ade e 10.1gm * P<.08 - 3.88gm n.s.s.	18/50	17/50	14/50	27/50	
liv hpa e 123.gm P<.3 - 20.1gm n.s.s.	0/50			1/50	
4703 R m f34 eat 24m24 2037n	0	3.64gm			
liv hpa e no dre P=1. - 18.4gm n.s.s.	2/50	2/50			
OLTIPRAZ (5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione) 64224-21-1					
4704 R f cdr gav 52w52 2523	0	10.0mg	30.0mg	60.0mg	Crowell;faat,35,9-21;1997
liv tum e no dre P=1. - 8.59mg n.s.s.	0/25	0/25	0/25	0/25	
4705 R m cdr gav 52w52 2523	0	10.0mg	30.0mg	60.0mg	
liv tum e no dre P=1. - 8.59mg n.s.s.	0/25	0/25	0/25	0/25	
4706 R m f34 eat 52w52 2300	0	16.0mg			Rao;canr,56,3395-3398;1996/pers.comm.
--- lym er no dre P=1. 9.89mg n.s.s.	0/12	0/12			
OMEPRAZOLE 73590-58-6					
4707 M f cd1 gav 78w78 1781m	0	14.1mg	44.0mg	141.mg	Havu;dgsn,35,42-55;1986/pers.comm.
gam cnd er no dre P=1. 63.3mg n.s.s.	0/109	0/55	0/55	0/55	
4708 M m cd1 gav 78w78 1781m	0	14.1mg	44.0mg	141.mg	
gam cnd er no dre P=1. 63.3mg n.s.s.	0/109	0/55	0/55	0/55	
4709 R f sda gav 24m24 1781n	0	14.1mg	44.0mg	141.mg	
gam cnd er 63.0mg Z P<.0005 + 41.1mg 103.mg	0/120	13/60	19/60	(24/60)	
4710 R m sda gav 24m24 1781n	0	14.1mg	44.0mg	141.mg	
gam cnd er 1.12gm * P<.0005 + 486.mg 3.65gm	0/119	0/60	1/60	6/60	
C.I. ACID ORANGE 3 6373-74-6					
4711 M f b6c gav 24m24 TR335 :	0	177.mg	354.mg		
lun a/a # 2.59gm * P<.05 - 868.mg n.s.s.	0/50	1/50	3/50		S
TBA MXB no dre P=1. 165.mg n.s.s.	35/50	27/50	(23/50)		
liv MXB 7.55gm * P<.8 707.mg n.s.s.	3/50	4/50	4/50		liv:hpa,hpc,nnd.
lun MXB 11.6gm * P<.8 1.10gm n.s.s.	2/50	2/50	3/50		lun:a/a,a/c.
4712 M m b6c gav 24m24 TR335 :	0	88.4mg	177.mg		
liv hpc # 184.mg \ P<.02 - 79.4mg n.s.s.	7/50	16/50	(10/50)		S
TBA MXB 372.mg * P<.4 96.8mg n.s.s.	42/50	36/50	39/50		
liv MXB no dre P=1. 224.mg n.s.s.	21/50	20/50	15/50		liv:hpa,hpc,nnd.
lun MXB 5.86gm * P<.9 266.mg n.s.s.	13/50	9/50	10/50		lun:a/a,a/c.
4713 R f f34 gav 24m24 TR335 :	0	264.mg	531.mg		
kid tcc s 1.71gm / P<.0005 c 683.mg 6.26gm	0/50	0/50	6/50		
TBA MXB s 361.mg * P<.05 149.mg n.s.s.	45/50	44/50	19/50		
liv MXB s 5.09gm * P<.5 945.mg n.s.s.	1/50	3/50	0/50		liv:hpa,hpc,nnd.
4714 R m f34 gav 23m24 TR335 :	0	265.mg	536.mg		
TBA MXB ans 270.mg / P<.03 - 113.mg n.s.s.	42/50	33/50	13/50		
liv MXB ans no dre P=1. 1.65gm n.s.s.	2/50	0/50	0/50		liv:hpa,hpc,nnd.

Chemical / Synonym / CAS number	Spe Strain Xpo+Xpt / Sex Route Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
C.I. ACID ORANGE 10 1936-15-8						
4715 M f b6c eat 24m24 TR211 :		0	386.mg	773.mg		
TBA MXB	no dre P=1. - 709.mg n.s.s.	25/50	27/50	(19/50)		
liv MXB	no dre P=1. 3.72gm n.s.s.	3/50	3/50	3/50		liv:hpa,hpc,nnd.
lun MXB	no dre P=1. 2.15gm n.s.s.	2/50	1/50	(0/50)		lun:a/a,a/c.
4716 M m b6c eat 24m24 TR211 :		0	360.mg	720.mg		
TBA MXB	no dre P=1. - 1.45gm n.s.s.	30/50	19/50	25/50		
liv MXB	no dre P=1. 2.09gm n.s.s.	15/50	7/50	12/50		liv:hpa,hpc,nnd.
lun MXB	22.0gm * P<.8 2.56gm n.s.s.	1/50	3/50	2/50		lun:a/a,a/c.
4717 R f f34 eat 24m24 TR211 :		0	49.5mg	149.mg		
TBA MXB	no dre P=1. - 89.9mg n.s.s.	68/90	33/50	(31/50)		
liv MXB	no dre P=1. 967.mg n.s.s.	3/90	2/50	1/50		liv:hpa,hpc,nnd.
4718 R m f34 eat 24m24 TR211 :		0	39.6mg	119.mg		
tnv MXA #	915.mg * P<.05 - 346.mg n.s.s.	0/90	3/50	2/50		tnv:men,msm. S
TBA MXB	2.71gm * P<.9 125.mg n.s.s.	61/90	31/50	34/50		
liv MXB	620.mg * P<.06 223.mg n.s.s.	5/90	3/50	8/50		liv:hpa,hpc,nnd.
OROTIC ACID, MONOSODIUM SALT 154-85-8						
4719 R m f34 eat 52w52 2126m		0	400.mg			Laconi;carc,14,1901-1905;1993/pers.comm.
liv hpa ek	925.mg P<.4 150.mg n.s.s.	0/8	1/14			
4720 R m f34 eat 24m24 2126n		0	400.mg			
liv hpa e	395.mg P<.002 189.mg 1.31gm	0/11	10/20			
--- leu e	1.69gm P<.1 509.mg n.s.s.	0/11	3/20			
zym tum e	2.60gm P<.2 639.mg n.s.s.	0/11	2/20			
gamma-ORYZANOL 11042-64-1						
4721 M f b6c eat 78w79 2092		0	197.mg	592.mg	1.97gm	Tamagawa;fctx,30,49-56;1992
--- mly e	5.97gm * P<.05 - 2.23gm n.s.s.	2/46	5/48	3/47	9/50	
liv hpc e	no dre P=1. - 11.7gm n.s.s.	2/50			0/50	
liv nnd e	no dre P=1. - 5.44gm n.s.s.	4/50			3/50	
lun a/a e	no dre P=1. - 8.44gm n.s.s.	3/50			1/50	
4722 M m b6c eat 78w79 2092		0	197.mg	592.mg	1.97gm	
--- mly e	15.9gm * P<.3 - 3.97gm n.s.s.	0/45	1/46	2/45	2/48	
liv hpc e	no dre P=1. - 7.14gm n.s.s.	1/50			1/50	
liv nnd e	no dre P=1. - 3.02gm n.s.s.	11/50			10/50	
lun a/a e	no dre P=1. - 6.36gm n.s.s.	3/50			2/50	
lun acb e	no dre P=1. - 7.14gm n.s.s.	1/50			1/50	
4723 R f f3d eat 24m24 2091		0	1.98gm			Tamagawa;fctx,30,41-48;1992
liv nnd e	no dre P=1. - 20.8gm n.s.s.	2/50	0/50			
4724 R m f3d eat 24m24 2091		0	1.98gm			
liv nnd e	68.5gm P<.3 - 11.2gm n.s.s.	0/50	1/50			
OSUTIDINE 140695-21-2						
4725 R f sjd gav 52w52 2577m		0	2.00gm			Nagai;phrm,55,149-168;1998/pers.comm.
liv tum e	no dre P=1. - 1.75gm n.s.s.	0/19	0/17			
4726 R f sjd gav 52w56 2577n		0	1.85gm			
liv tum e	no dre P=1. - 993.mg n.s.s.	0/10	0/9			
4727 R m sjd gav 52w52 2577m		0	2.00gm			
liv tum e	no dre P=1. - 1.85gm n.s.s.	0/16	0/18			
4728 R m sjd gav 52w56 2577n		0	1.85gm			
liv tum e	no dre P=1. - 993.mg n.s.s.	0/8	0/9			
OVULEN (ethynodiol diacetate/ethinyl estradiol [10:1]) 8056-92-6						
4729 M f crf eat 24m24 1463		0	.390mg			Rudali;gmcr,17,243-252;1975
mam tum Lr	.858mg P<.8 57.0ug n.s.s.	161/167	37/38			
4730 M m crf eat 24m24 1463		0	.360mg			
mam tum r	.300mg P<.0005 .158mg .664mg	0/76	14/25			
OXAMYL 23135-22-0						
4731 M f cd1 eat 24m24 1788		0	3.25mg	6.50mg	9.94mg	Kennedy;faat,7,106-118;1986/pers.comm.
tba mix v	no dre P=1. - 35.8mg n.s.s.	32/80	42/79	28/79	27/80	
4732 M m cd1 eat 24m24 1788		0	3.00mg	6.00mg	9.17mg	
tba mix v	no dre P=1. - 30.7mg n.s.s.	35/80	36/79	28/80	29/78	
4733 R f cdr eat 24m24 1788		0	7.50mg			
liv hph eg	no dre P=1. - 46.4mg n.s.s.	1/60	0/30			
4734 R m cdr eat 24m24 1788		0	6.00mg			
liv tum e	no dre P=1. - 37.1mg n.s.s.	0/60	0/30			
OXAZEPAM 604-75-1						
4735 M f b6c eat 23m24 TR443 :		0	16.2mg	325.mg	650.mg	
liv MXA a	19.8mg Z P<.0005 c 12.7mg 32.6mg	28/50	36/50	50/50	47/50	liv:hpa,hpb,hpc.
MXB MXB a	19.8mg Z P<.0005 12.7mg 32.6mg	28/50	36/50	50/50	47/50	liv:hpa,hpb,hpc; thy:fca. M
liv hpa a	27.2mg Z P<.0005 c 16.8mg 47.7mg	25/50	35/50	35/50	36/50	
liv hpc a	47.2mg Z P<.0005 c 30.0mg 76.0mg	9/50	5/50	49/50	44/50	
thy fca a	160.mg Z P<.0005 p 68.3mg 573.mg	0/50	4/50	5/50	6/50	
liv hpb a	476.mg Z P<.0005 c 221.mg 1.07gm	0/50	1/50	8/50	8/50	
TBA MXB a	20.2mg Z P<.0005 12.9mg 33.4mg	37/50	43/50	50/50	47/50	
liv MXB a	19.8mg Z P<.0005 12.7mg 32.6mg	28/50	36/50	50/50	47/50	liv:hpa,hpb,hpc.
lun MXB a	811.mg * P<.2 121.mg n.s.s.	5/50	4/50	1/50	1/50	lun:a/a,a/c.
4736 M f sww eat 57w57 TR443 :		0	325.mg	650.mg		
liv MXA s	64.8mg * P<.0005 c 46.4mg 94.0mg	1/60	23/60	47/60		liv:hpa,hpc.
liv hpa s	65.8mg * P<.0005 c 47.3mg 94.1mg	0/60	22/60	47/60		
liv hpc s	360.mg / P<.0005 c 176.mg 1.06gm	1/60	1/60	11/60		
TBA MXB s	79.9mg * P<.0005 50.9mg 155.mg	24/60	37/60	49/60		
liv MXB s	64.8mg * P<.0005 46.4mg 94.0mg	1/60	23/60	47/60		liv:hpa,hpb,hpc.
lun MXB s	1.48gm * P<.5 273.mg n.s.s.	11/60	6/60	7/60		lun:a/a,a/c.

Site / Notes / DR / AuOp / UpConf / Cntrl / 1 Inc / 2 Inc / 3 Inc / Brkly Code
Path / TD_{50} / 2Tailpvl / LoConf / NCI/NTPPathology

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4737 M m b6c eat 23m24 TR443 :					0	15.0mg	300.mg	600.mg	
liv MXA a	59.0mg	Z P<.0005	c	40.5mg 89.4mg	23/50	19/50	50/50	50/50	liv:hpa,hpb,hpc.
liv MXA a	68.3mg	Z P<.0005	c	47.6mg 101.mg	9/50	6/50	47/50	50/50	liv:hpb,hpc.
liv hpc a	73.5mg	Z P<.0005	c	51.1mg 109.mg	9/50	5/50	45/50	50/50	
liv hpa a	93.7mg	Z P<.0005	c	60.0mg 157.mg	17/50	18/50	34/50	32/50	
liv hpb a	205.mg	* P<.0005	c	126.mg 347.mg	0/50	2/50	21/50	13/50	
TBA MXB a	54.0mg	Z P<.0005		37.0mg 83.5mg	37/50	35/50	50/50	50/50	
liv MXB a	59.0mg	Z P<.0005		40.5mg 89.4mg	23/50	19/50	50/50	50/50	liv:hpa,hpb,hpc.
lun MXB a	no dre	P=1.		407.mg n.s.s.	13/50	18/50	5/50	1/50	lun:a/a,a/c.
4738 M m sww eat 57w57 TR443 :					0	300.mg	600.mg		
liv MXA s	34.6mg	* P<.0005	c	24.7mg 49.6mg	1/60	35/60	52/60		liv:hpa,hpc.
liv hpa s	35.0mg	* P<.0005	c	25.0mg 50.6mg	1/60	35/60	50/60		
liv hpc s	139.mg	/ P<.0005	c	80.4mg 257.mg	0/60	5/60	19/60		
TBA MXB s	47.0mg	* P<.0005		30.3mg 83.5mg	26/60	42/60	54/60		
liv MXB s	34.6mg	* P<.0005		24.7mg 49.6mg	1/60	35/60	52/60		liv:hpa,hpb,hpc.
lun MXB s	755.mg	* P<.4		163.mg n.s.s.	14/60	9/60	7/60		lun:a/a,a/c.
4739 R f f34 eat 24m24 TR468 :					0	31.3mg	125.mg	250.mg	
--- mnl #	114.mg	Z P<.002	-	57.8mg 575.mg	14/50	19/50	29/50	(18/50)	S
TBA MXB	170.mg	Z P<.3		46.2mg n.s.s.	49/50	49/50	45/50	(38/50)	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpb,hpc.
4740 R f f34 eat 6m24 TR468a :					0	124.mg			
TBA MXB	no dre	P=1.	-	75.0mg n.s.s.	49/50	43/50			
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50			liv:hpa,hpb,hpc.
4741 R m f34 eat 23m23 TR468 :					0	25.0mg	100.mg	200.mg	
tes MXA #	27.4mg	* P<.0005	-	16.6mg 56.3mg	45/50	48/50	49/50	47/50	tes:iab,ica. S
--- mnl	79.1mg	* P<.005		36.1mg 926.mg	27/50	36/50	33/50	19/50	S
thy MXA	336.mg	* P<.02		116.mg n.s.s.	4/50	3/50	4/50	6/50	thy:fca,fcc. S
kid rua	500.mg	* P<.05		142.mg n.s.s.	1/50	0/50	3/50	1/50	S
TBA MXB	50.4mg	* P<.002		25.5mg 225.mg	47/50	45/50	44/50	32/50	
liv MXB C	1.79gm	* P<.2		293.mg n.s.s.	2/50	0/50	0/50	3/50	liv:hpa,hpb,hpc.
4742 R m f34 eat 23m23 TR468 with step					0	25.0mg	100.mg	200.mg	
kid rua	1.01gm	* P<.03	e	434.mg n.s.s.	2/50	1/50	7/50	6/50	
4743 R m f34 eat 6m24 TR468a :					0	101.mg			
tes MXA #	16.9mg	P<.0005	-	8.32mg 52.9mg	45/50	48/50			tes:iab,ica. S
--- mnl	31.0mg	P<.0005		14.3mg 115.mg	27/50	34/50			S
kid rua	no dre	P=1.		62.0mg n.s.s.	1/50	0/50			
TBA MXB	27.5mg	P<.004		11.8mg 237.mg	47/50	42/50			
liv MXB C	no dre	P=1.		91.6mg n.s.s.	2/50	1/50			liv:hpa,hpb,hpc.
4744 R m f34 eat 6m24 TR468a with step					0	101.mg			
kid rua	779.mg	P<.2	e	241.mg n.s.s.	2/50	6/50			
N-(9-OXO-2-FLUORENYL)ACETAMIDE 3096-50-2									
4745 R f buf eat 86w86 144					0	12.4mg			Morris;jnci,24,149-180;1960
mgl adc e	6.17mg	P<.0005	+	2.98mg 15.4mg	0/18	11/18			
edu sqc e	32.0mg	P<.04	+	9.65mg n.s.s.	0/18	3/18			
liv hpt e	102.mg	P<.3	+	16.6mg n.s.s.	0/18	1/18			
OXOLINIC ACID 14698-29-4									
4746 M f icm eat 78w78 2151o					0	6.50mg	19.5mg	65.0mg	Yamada;fctx,32,397-408;1994
lun ade e	55.1mg	Z P<.07		20.8mg n.s.s.	4/50	5/50	10/50	(1/50)	
liv hpa e	572.mg	* P<.02		173.mg n.s.s.	0/50	0/50	0/50	3/50	
lun adc e	no dre	P=1.		141.mg n.s.s.	5/50	6/50	4/50	5/50	
tba ben e	no dre	P=1.		132.mg n.s.s.	14/50	8/50	15/50	8/50	
tba mal e	no dre	P=1.		76.4mg n.s.s.	19/50	16/50	11/50	17/50	
tba mix e	no dre	P=1.		66.0mg n.s.s.	27/50	21/50	25/50	22/50	
4747 M m icm eat 78w78 2151o					0	6.00mg	18.0mg	60.0mg	
liv hpa e	no dre	P=1.		118.mg n.s.s.	18/50	18/50	14/50	12/50	
lun adc e	no dre	P=1.		134.mg n.s.s.	6/50	3/50	8/50	4/50	
lun ade e	no dre	P=1.		147.mg n.s.s.	11/50	8/50	10/50	6/50	
liv hpc e	no dre	P=1.		337.mg n.s.s.	1/50	2/50	1/50	0/50	
tba mix e	no dre	P=1.		108.mg n.s.s.	37/50	34/50	31/50	22/50	
tba ben e	no dre	P=1.		119.mg n.s.s.	28/50	24/50	22/50	16/50	
tba mal e	no dre	P=1.		138.mg n.s.s.	15/50	14/50	19/50	8/50	
4748 R f wis eat 24m24 2151o					0	1.50mg	5.00mg	15.0mg	50.0mg
liv hpc e	2.44gm	* P<.8		398.mg n.s.s.	0/50	0/50	0/50	1/50	0/50
tba mix e	68.5mg	* P<.3		18.6mg n.s.s.	37/50	42/50	44/50	42/50	44/50
tba ben e	589.mg	* P<.9		34.0mg n.s.s.	34/50	40/50	43/50	39/50	39/50
tba mal e	1.04gm	* P<.7		129.mg n.s.s.	5/50	11/50	7/50	7/50	9/50
4749 R m wis eat 52w52 2151m					0	1.20mg	4.00mg	12.0mg	40.0mg
tes lya er	no dre	P=1.		.432mg n.s.s.	0/10	0/10	0/10	0/10	0/10
4750 R m wis eat 78w78 2151n					0	1.20mg	4.00mg	12.0mg	40.0mg
tes lya er	no dre	P=1.		.973mg n.s.s.	0/10	0/10	0/10	0/10	0/10
4751 R m wis eat 24m24 2151o					0	1.20mg	4.00mg	12.0mg	40.0mg
tes lya e	167.mg	* P<.004	+	73.4mg 1.39gm	2/50	4/50	3/50	2/50	11/50
liv nnd e	no dre	P=1.		178.mg n.s.s.	4/50	2/50	3/50	4/50	3/50
tba mal e	1.79gm	* P<.9		87.1mg n.s.s.	14/50	8/50	9/50	17/50	11/50
tba ben e	no dre	P=1.		58.4mg n.s.s.	29/50	27/50	28/50	25/50	27/50
tba mix e	no dre	P=1.		44.3mg n.s.s.	40/50	32/50	34/50	36/50	34/50
1-(2-OXOPROPYL)NITROSO-3-(2-CHLOROETHYL)UREA 110559-85-8									
4752 H f syg gav 43w75 1956					0	1.71mg			Lijinsky;bmes,2,167-173;1989
spl vsc e	.774mg	P<.008	+	.299mg 15.1mg	1/12	7/12			
liv cho e	no dre	P=1.		2.20mg n.s.s.	1/12	0/12			
4753 H m syg gav 43w75 1956					0	1.51mg			
spl hes e	.216mg	P<.0005	+	79.5ug .610mg	0/12	11/12			
liv cho e	no dre	P=1.		1.94mg n.s.s.	1/12	0/12			
4754 R f f34 gav 7m24 2010m					0	.570mg			Lijinsky;vivo,4,1-6;1990
liv tum e	1.36mg	P<.04		.408mg n.s.s.	0/12	3/12			

Chemical / Synonym / CAS number	Spe Strain Xpo+Xpt / Sex Route Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
Site Notes DR AuOp UpConf	Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
ner tum e	4.49mg P<.3 .730mg n.s.s.	0/12	1/12			
4755 R f f34 wat 7m24 2010n		0	.570mg			
lun tum e	4.49mg P<.3 .730mg n.s.s.	0/12	1/12			
ner tum e	4.49mg P<.3 .730mg n.s.s.	0/12	1/12			
liv tum e	no dre P=1. 1.41mg n.s.s.	0/12	0/12			
4756 R m f34 gav 7m24 2010m		0	.399mg			
ner tum e	.951mg P<.04 .286mg n.s.s.	0/12	3/12			
lun tum e	3.14mg P<.3 .511mg n.s.s.	0/12	1/12			
liv tum e	no dre P=1. .987mg n.s.s.	1/12	0/12			
4757 R m f34 wat 7m24 2010n		0	.399mg			
lun tum e	1.50mg P<.09 .368mg n.s.s.	0/12	2/12			
liv tum e	3.14mg P<.3 .511mg n.s.s.	0/12	1/12			
ner tum e	3.14mg P<.3 .511mg n.s.s.	0/12	1/12			
2-OXOPROPYLNITROSOUREA 89837-93-4						
4758 H f syg gav 40w55 1956		0	1.51mg			Lijinsky;bmes,2,167-173;1989
spl vsc e	.121mg P<.0005 + 43.4ug .384mg	1/12	11/12			
liv cho e	no dre P=1. 1.05mg n.s.s.	1/12	0/12			
4759 H m syg gav 40w75 1956		0	.975mg			
spl hes e	.140mg P<.0005 + 51.5ug .394mg	0/12	11/12			
liv cho e	no dre P=1. .737mg n.s.s.	1/12	1/12			
4760 R f f34 gav 7m24 2010		0	.513mg			Lijinsky;vivo,4,1-6;1990
kid mnp e	.320mg P<.0005 .136mg .977mg	0/12	8/12			
liv tum e	4.04mg P<.3 .656mg n.s.s.	0/12	1/12			
4761 R m f34 gav 7m24 2010		0	.359mg			
kid mnp e	.456mg P<.005 .170mg 3.66mg	0/12	5/12			
liv tum e	no dre P=1. .887mg n.s.s.	1/12	0/12			
1'-OXOSAFROLE 30418-53-2						
4762 R m cdr eat 73w95 1035d		0	77.3mg			Wislocki;canr,37,1883-1891;1977
liv car e	no dre P=1. - 239.mg n.s.s.	0/18	0/18			
OXPRENOLOL.HCl 6452-73-9						
4763 M f cf1 eat 78w91 469m		0	12.9mg	42.9mg	129.mg	Newberne;txap,41,535-546;1977
liv car e	2.40gm * P<.2 - 391.mg n.s.s.	0/24	0/28	0/28	1/24	
lun ade e	no dre P=1. - 464.mg n.s.s.	5/49	6/49	4/49	4/50	
lun nfs e	no dre P=1. - 529.mg n.s.s.	0/24	1/28	0/28	0/24	
4764 M f cf1 eat 78w78 469n		0	150.mg			
lun car e	425.mg P<.2 - 143.mg n.s.s.	1/25	6/37			
liv tum e	no dre P=1. - 939.mg n.s.s.	0/40	0/54			
4765 M m cf1 eat 78w91 469m		0	12.9mg	42.9mg	129.mg	
liv pca e	2.12gm * P<.5 - 366.mg n.s.s.	0/49	4/49	1/49	3/49	
lun ade e	no dre P=1. - 453.mg n.s.s.	4/49	7/49	3/49	4/49	
4766 M m cf1 eat 78w78 469n		0	150.mg			
liv car e	2.62gm P<.7 - 279.mg n.s.s.	1/29	2/36			
lun ade e	no dre P=1. - 316.mg n.s.s.	2/29	2/36			
lun car e	no dre P=1. - 291.mg n.s.s.	9/44	7/48			
4767 R f cdr eat 78w78 469m		0	15.0mg	50.0mg	150.mg	
liv tum e	no dre P=1. - 37.3mg n.s.s.	0/30	0/30	0/30	0/30	
4768 R m cdr eat 78w78 469m		0	15.0mg	50.0mg	150.mg	
liv hpa e	1.68gm * P<.3 - 317.mg n.s.s.	1/29	0/30	0/30	2/30	
4,4'-OXYDIANILINE 101-80-4						
4769 M f b6c eat 24m24 TR205 :		0	19.1mg	38.3mg	102.mg	
MXB MXB s	19.7mg Z P<.002 9.78mg 97.5mg	10/50	25/50	(23/50	35/50)	hag:adn; liv:hpa,hpc; thy:fca. C
hag adn s	46.8mg Z P<.0005 c 27.4mg 135.mg	2/50	15/50	14/50	(12/50)	
liv MXA s	108.mg * P<.0005 c 58.1mg 413.mg	8/50	13/50	15/50	29/50	liv:hpa,hpc.
liv hpc s	252.mg * P<.01 c 115.mg 17.8gm	4/50	7/50	6/50	15/50	
thy fca s	598.mg * P<.0005 c 258.mg 2.04gm	0/50	0/50	0/50	7/50	
liv hpa s	244.mg * P<.02 c 109.mg n.s.s.	4/50	6/50	9/50	14/50	
TBA MXB s	32.9mg Z P<.02 15.9mg 4.65gm	28/50	37/50	40/50	(42/50)	
liv MXB s	108.mg * P<.0005 58.1mg 413.mg	8/50	13/50	15/50	29/50	liv:hpa,hpc,nnd.
lun MXB s	156.mg Z P<.08 58.4mg n.s.s.	5/50	5/50	10/50	(3/50)	lun:a/a,a/c.
4770 M m b6c eat 24m24 TR205 :		0	17.7mg	35.3mg	94.2mg	
hag adn	26.2mg Z P<.0005 c 14.2mg 73.2mg	1/50	17/50	(13/50	17/50)	
--- hem	379.mg * P<.003 183.mg 2.05gm	0/50	0/50	5/50	5/50	S
pit adn	568.mg * P<.004 231.mg 4.96gm	1/50	0/50	0/50	7/50	S
MXB MXB	167.mg * P<.3 44.8mg n.s.s.	30/50	42/50	36/50	39/50	hag:adn; liv:hpa,hpc. C
liv MXA	225.mg * P<.5 c 50.7mg n.s.s.	29/50	40/50	34/50	36/50	liv:hpa,hpc.
TBA MXB	318.mg * P<.7 50.1mg n.s.s.	39/50	45/50	40/50	42/50	
liv MXB	225.mg * P<.5 50.7mg n.s.s.	29/50	40/50	34/50	36/50	liv:hpa,hpc,nnd.
lun MXB	no dre P=1. 381.mg n.s.s.	13/50	10/50	8/50	4/50	lun:a/a,a/c.
4771 R f f34 eat 24m24 TR205 :		0	9.80mg	19.6mg	24.5mg	
MXB MXB s	12.1mg Z P<.0005 8.62mg 18.3mg	3/50	4/50	37/50	26/50	liv:hpc,nnd; thy:fca,fcc. C
thy MXA s	14.3mg Z P<.0005 c 10.2mg 20.8mg	0/50	4/50	29/50	23/50	thy:fca,fcc.
liv MXA s	20.1mg Z P<.0005 c 13.2mg 35.5mg	3/50	0/50	24/50	17/50	liv:hpc,nnd.
thy fca s	27.5mg Z P<.0005 c 18.1mg 44.4mg	0/50	2/50	17/50	16/50	
liv nnd s	29.5mg Z P<.0005 c 18.1mg 61.1mg	3/50	0/50	20/50	11/50	
thy fcc s	41.2mg * P<.0005 c 24.6mg 77.8mg	0/50	2/50	12/50	7/50	
liv hpc s	93.7mg Z P<.0005 c 45.6mg 260.mg	0/50	0/50	4/50	6/50	
TBA MXB s	20.6mg Z P<.02 9.60mg n.s.s.	42/50	36/50	45/50	31/50	
liv MXB s	20.1mg Z P<.0005 13.2mg 35.5mg	3/50	0/50	24/50	17/50	liv:hpa,hpc,nnd.
4772 R m f34 eat 24m24 TR205 :		0	7.80mg	15.7mg	19.6mg	
MXB MXB	6.65mg * P<.0005 5.00mg 9.96mg	2/50	18/50	43/50	43/50	liv:hpc,nnd; thy:fca,fcc. C
liv MXA	7.12mg Z P<.0005 c 5.38mg 10.3mg	1/50	13/50	41/50	39/50	liv:hpc,nnd.
liv hpc	15.7mg Z P<.0005 c 11.1mg 23.7mg	0/50	4/50	23/50	22/50	
thy MXA	17.7mg Z P<.0005 c 12.2mg 30.1mg	1/50	6/50	17/50	28/50	thy:fca,fcc.
liv nnd	22.5mg * P<.0005 c 14.7mg 50.7mg	1/50	9/50	18/50	17/50	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes Path	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
thy fcc	32.1mg *	P<.0005 c	20.6mg 63.2mg	0/50	5/50	9/50	15/50	
thy fca	47.4mg *	P<.0005 c	27.0mg 143.mg	1/50	1/50	8/50	13/50	
TBA MXB	no dre	P=1.	15.2mg n.s.s.	45/50	38/50	48/50	46/50	
liv MXB	7.12mg Z	P<.0005	5.38mg 10.3mg	1/50	13/50	41/50	39/50	liv:hpa,hpc,nnd.
N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE SULFENAMIDE (OTOS) 13752-51-7								
4773 R f sda eat 52w52 1765m				0	1.00mg	3.00mg	10.0mg 30.0mg	Hinderer;txap,82,521-531;1986/pers.comm.
unt tum ek	no dre	P=1.	.351mg n.s.s.	0/10	0/10	0/10	0/10 0/10	
4774 R f sda eat 26m26 1765n				0	1.00mg	3.00mg	10.0mg 30.0mg	
unt mix e	96.9mg Z	P<.0005 +	54.0mg 200.mg	0/50	0/50	0/50	0/50 16/50	
ubl mix e	206.mg *	P<.0005 +	93.4mg 604.mg	0/50	0/50	0/50	0/50 8/50	
kid mix e	338.mg *	P<.0005 +	128.mg 1.44gm	0/50	0/50	0/50	0/50 5/50	
kid sqc e	571.mg *	P<.007	173.mg 10.6gm	0/50	0/50	0/50	0/50 3/50	
kid utc e	571.mg *	P<.007	173.mg 10.6gm	0/50	0/50	0/50	0/50 3/50	
ubl utp e	571.mg *	P<.007 +	173.mg 10.6gm	0/50	0/50	0/50	0/50 3/50	
ubl sqp e	862.mg *	P<.03 +	212.mg n.s.s.	0/50	0/50	0/50	0/50 2/50	
ubl utc e	862.mg *	P<.03 +	212.mg n.s.s.	0/50	0/50	0/50	0/50 2/50	
kid utp e	1.74gm *	P<.2	283.mg n.s.s.	0/50	0/50	0/50	0/50 1/50	
ubl sqc e	1.74gm *	P<.2 +	283.mg n.s.s.	0/50	0/50	0/50	0/50 1/50	
4775 R m sda eat 52w52 1765m				0	.800mg	2.40mg	8.00mg 24.0mg	
unt tum ek	no dre	P=1.	.281mg n.s.s.	0/10	0/10	0/10	0/10 0/10	
4776 R m sda eat 26m26 1765n				0	.800mg	2.40mg	8.00mg 24.0mg	
unt mix e	85.5mg Z	P<.0005 +	46.3mg 189.mg	1/50	0/50	0/50	0/50 15/50	
ubl mix e	130.mg *	P<.0005 +	63.4mg 334.mg	0/50	0/50	0/50	0/50 10/50	
ubl utc e	340.mg *	P<.003 +	117.mg 2.03gm	0/50	0/50	0/50	0/50 4/50	
ubl utp e	457.mg *	P<.007 +	138.mg 8.46gm	0/50	0/50	0/50	0/50 3/50	
kid mix e	528.mg *	P<.06 +	143.mg n.s.s.	1/50	0/50	0/50	0/50 3/50	
kid utc e	690.mg *	P<.03	170.mg n.s.s.	0/50	0/50	0/50	0/50 2/50	
ubl sqc e	690.mg *	P<.03 +	170.mg n.s.s.	0/50	0/50	0/50	0/50 2/50	
kid sqc e	1.39gm *	P<.2	226.mg n.s.s.	0/50	0/50	0/50	0/50 1/50	
ubl sqp e	1.39gm *	P<.2 +	226.mg n.s.s.	0/50	0/50	0/50	0/50 1/50	
kid utp e	no dre	P=1.	6.52mg n.s.s.	1/50	0/50	0/50	0/50 0/50	
N-OXYDIETHYLENEBENZOTHIAZOLE-2-SULFENAMIDE (amax) 102-77-2								
4777 M f b6a orl 76w76 1298				0	205.mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1. -	243.mg n.s.s.	1/17	1/18			
liv hpt evx	no dre	P=1. -	405.mg n.s.s.	0/17	0/18			
tba mix evx	1.31gm	P<.7 -	147.mg n.s.s.	2/17	3/18			
4778 M m b6a orl 76w76 1298				0	190.mg			
liv hpt evx	20.1gm	P<1. -	211.mg n.s.s.	1/18	1/17			
lun ade evx	no dre	P=1. -	356.mg n.s.s.	2/18	0/17			
tba mix evx	no dre	P=1. -	250.mg n.s.s.	3/18	1/17			
4779 M f b6c orl 76w76 1298				0	205.mg			
lun ade evx	598.mg	P<.1 -	147.mg n.s.s.	0/16	2/17			
liv hpt evx	1.23gm	P<.3 -	201.mg n.s.s.	0/16	1/17			
tba mix evx	386.mg	P<.04 -	116.mg n.s.s.	0/16	3/17			
4780 M m b6c orl 76w76 1298				0	190.mg			
liv hpt evx	359.mg	P<.04 -	108.mg n.s.s.	0/16	3/17			
lun ade evx	556.mg	P<.1 -	137.mg n.s.s.	0/16	2/17			
tba mix evx	200.mg	P<.007 -	75.3mg 2.70gm	0/16	5/17			
OXYMETHOLONE 434-07-1								
4781 R f f34 gav 24m24 TR485 :				0	2.14mg	21.4mg	71.4mg	
lun MXA	66.9mg Z	P<.0005 c	28.6mg 229.mg	0/50	0/50	7/50	(1/50)	lun:a/a,a/c.
lun a/a	80.1mg Z	P<.002 c	32.3mg 328.mg	0/50	0/50	6/50	(1/50)	
MXB MXB	81.4mg *	P<.0005	45.8mg 223.mg	1/50	1/50	9/50	15/50	liv:hpa,hpc; lun:a/a,a/c; ski:bca,ker,sgc,sqc, sqp. C
liv MXA	190.mg *	P<.002 c	87.9mg 857.mg	1/50	1/50	1/50	10/50	liv:hpa,hpc.
ski MXA	211.mg *	P<.004 c	99.4mg 1.52gm	0/50	0/50	4/50	5/50	ski:bca,ker,sgc,sqc,sqp.
liv hpa	248.mg *	P<.005 c	105.mg 2.58gm	1/50	1/50	1/50	8/50	
ski MXA	278.mg *	P<.03	120.mg n.s.s.	0/50	0/50	4/50	3/50	ski:ker,sqc,sqp. S
TBA MXB	no dre	P=1.	91.5mg n.s.s.	45/50	45/50	37/50	37/50	
liv MXB	190.mg *	P<.002	87.9mg 857.mg	1/50	1/50	1/50	10/50	liv:hpa,hpb,hpc.
4782 R m f34 gav 24m24 TR485 :				0	2.14mg	21.4mg	107.mg	
sub MXA	4.79mg Z	P<.004 e	1.91mg 25.7mg	0/51	7/50	(2/50	2/51)	sub:fbs,fib.
amd MXA	427.mg *	P<.7 e	57.9mg n.s.s.	19/51	25/50	21/50	29/51	amd:phm,pob.
amd pob	427.mg *	P<.7 e	57.9mg n.s.s.	19/51	25/50	21/50	29/51	
kid rua	1.26gm *	P<.3 e	236.mg n.s.s.	0/51	1/50	0/50	2/51	
sub fib	no dre	P=1. e	295.mg n.s.s.	0/51	5/50	2/50	2/51	
TBA MXB	no dre	P=1.	106.mg n.s.s.	48/51	48/50	44/50	40/51	
liv MXB	no dre	P=1.	516.mg n.s.s.	1/51	2/50	1/50	0/51	liv:hpa,hpb,hpc.
4783 R m f34 gav 24m24 TR485 with step				0	2.14mg	21.4mg	107.mg	
kid rua	no dre	P=1. e	482.mg n.s.s.	4/51	13/50	1/50	6/51	
OXYTETRACYCLINE.HCl 2058-46-0								
4784 M f b6c eat 24m24 TR315 :				0	811.mg	1.61gm		
TBA MXB	no dre	P=1. -	2.12gm n.s.s.	43/50	34/50	36/50		
liv MXB	no dre	P=1.	12.4gm n.s.s.	6/50	0/50	2/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	6.10gm n.s.s.	3/50	3/50	3/50		lun:a/a,a/c.
4785 M m b6c eat 24m24 TR315 :				0	749.mg	1.49gm		
TBA MXB	no dre	P=1. -	1.58gm n.s.s.	36/50	32/50	33/50		
liv MXB	no dre	P=1.	2.37gm n.s.s.	18/50	15/50	17/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	4.32gm n.s.s.	10/50	9/50	6/50		lun:a/a,a/c.
4786 R f f34 eat 24m24 TR315 :				0	1.24gm	2.48gm		
ute ess	24.0gm *	P<.05	8.10gm n.s.s.	0/50	1/50	3/50		S
pta adn	5.23gm *	P<.2 e	1.79gm n.s.s.	19/50	17/50	30/50		
TBA MXB	no dre	P=1.	1.60gm n.s.s.	49/50	44/50	49/50		
liv MXB	76.2gm *	P<.9	6.17gm n.s.s.	5/50	4/50	6/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
4787 R m f34 eat 24m24 TR315 :				0	990.mg	1.98gm			
amd MXA	10.9gm *	P<.6	e 1.91gm n.s.s.	12/50	19/50	24/50		amd:phe,phm.	
TBA MXB	no dre	P=1.	723.mg n.s.s.	48/50	48/50	(42/50)			
liv MXB	no dre	P=1.	4.52gm n.s.s.	6/50	5/50	9/50		liv:hpa,hpc,nnd.	
OZONE 10028-15-6									
4788 M f b6c inh 30m30 TR440a :				0	.308mg	.616mg			
lun a/a	1.78mg *	P<.04	.702mg n.s.s.	3/50	3/50	11/50			S
lun MXA	2.09mg *	P<.2	p .655mg n.s.s.	6/50	8/50	12/50		lun:a/a,a/c.	
TBA MXB	no dre	P=1.	.375mg n.s.s.	48/50	49/50	47/50			
liv MXB	no dre	P=1.	.668mg n.s.s.	27/50	28/50	21/50		liv:hpa,hpb,hpc.	
lun MXB	2.09mg *	P<.2	.655mg n.s.s.	6/50	8/50	12/50		lun:a/a,a/c.	
4789 M f b6c inh 24m24 TR440b :				0	74.0ug	.308mg	.617mg		
lun MXA	1.88mg *	P<.06	p .741mg n.s.s.	6/50	7/50	9/50	16/50	lun:a/a,a/c.	
lun a/c	2.75mg *	P<.05	1.11mg n.s.s.	2/50	2/50	5/50	8/50		S
ute esp	6.49mg *	P<.05	2.20mg n.s.s.	1/50	0/50	0/50	5/50		S
TBA MXB	no dre	P=1.	.835mg n.s.s.	47/50	44/50	42/50	40/50		
liv MXB	no dre	P=1.	.132mg n.s.s.	27/50	22/50	(20/50	11/50)	liv:hpa,hpb,hpc.	
lun MXB	1.88mg *	P<.06	.741mg n.s.s.	6/50	7/50	9/50	16/50	lun:a/a,a/c.	
4790 M m b6c inh 30m30 TR440a :				0	.257mg	.513mg			
lun a/c	.633mg *	P<.02	.293mg n.s.s.	8/50	15/50	18/50			S
lun MXA	.961mg *	P<.2	e .318mg n.s.s.	16/50	22/50	21/50		lun:a/a,a/c.	
TBA MXB	1.54mg *	P<.6	.282mg n.s.s.	43/50	50/50	42/50			
liv MXB	2.02mg *	P<.6	.365mg n.s.s.	31/50	34/50	31/50		liv:hpa,hpb,hpc.	
lun MXB	.961mg *	P<.2	.318mg n.s.s.	16/50	22/50	21/50		lun:a/a,a/c.	
4791 M m b6c inh 24m24 TR440b :				0	61.7ug	.257mg	.514mg		
MXA hes	.314mg Z	P<.02	.118mg n.s.s.	0/50	5/50	(1/50	0/50)	liv:hes; mey:hes; spl:hes.	S
lun MXA	.894mg *	P<.07	e .340mg n.s.s.	14/50	13/50	18/50	19/50	lun:a/a,a/c.	
TBA MXB	.997mg *	P<.4	.246mg n.s.s.	39/50	43/50	42/50	40/50		
liv MXB	1.68mg *	P<.5	.376mg n.s.s.	30/50	27/50	29/50	29/50	liv:hpa,hpb,hpc.	
lun MXB	.894mg *	P<.07	.340mg n.s.s.	14/50	13/50	18/50	19/50	lun:a/a,a/c.	
4792 R f f34 inh 29m29 TR440a :				0	73.5ug	.147mg			
TBA MXB	no dre	P=1.	- 86.8ug n.s.s.	49/56	48/56	50/56			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/56	0/56	0/56		liv:hpa,hpb,hpc.	
4793 R f f34 inh 24m24 TR440b :				0	17.6ug	73.5ug	.147mg		
TBA MXB	no dre	P=1.	- 92.5ug n.s.s.	48/56	48/56	48/56	46/56		
liv MXB	no dre	P=1.	1.47mg n.s.s.	0/56	1/56	0/56	0/56	liv:hpa,hpb,hpc.	
4794 R m f34 inh 28m29 TR440a :				0	51.4ug	.103mg			
TBA MXB a	.138mg \	P<.7	- 15.9ug n.s.s.	50/56	47/56	(49/56)			
liv MXB a	2.41mg *	P<.8	.164mg n.s.s.	1/56	1/56	2/56		liv:hpa,hpb,hpc.	
4795 R m f34 inh 24m24 TR440b :				0	12.3ug	51.4ug	.103mg		
thy MXA #	15.6ug Z	P<.009	- 5.62ug .729mg	2/56	11/56	(4/56	2/56)	thy:cca,ccr.	S
thy cca	19.0ug Z	P<.02	5.78ug n.s.s.	1/56	8/56	(2/56	1/56)		S
TBA MXB	1.20mg *	P<1.	35.5ug n.s.s.	49/56	49/56	49/56	49/56		
liv MXB	no dre	P=1.	.354mg n.s.s.	2/56	1/56	1/56	1/56	liv:hpa,hpb,hpc.	
4796 R m sda inh 86w86 2160				0	30.0ug			Ito;extp,46,1-6;1994	
lun ade Cr	.204mg	P<.3	33.1ug n.s.s.	0/15	1/15				
4797 R m wis inh 13m24 2317				0	6.50ug			Ichinose;txcy,74,173-184;1992	
lun mix er	no dre	P=1.	48.2ug n.s.s.	0/35	0/36				
PALONIDIPINE.HCl (TC-81) 96515-74-1									
4798 R f f34 eat 24m24 2440				0	.670mg	2.00mg	6.00mg	Hamada;clnr,26,3075-3096;1992	
liv tum e	no dre	P=1.	- 4.77mg n.s.s.	0/50	0/50	0/50	0/50		
4799 R m f34 eat 24m24 2440				0	.670mg	2.00mg	6.00mg		
--- mnl e	no dre	P=1.	- 9.51mg n.s.s.	18/50	22/50	28/50	19/50		
liv hpa e	no dre	P=1.	- 51.5mg n.s.s.	2/50	2/50	3/50	0/50		
PARATHION 56-38-2									
4800 M f b6c eat 80w89 TR70 :				0	9.40mg	18.5mg			
TBA MXB	no dre	P=1.	- 33.0mg n.s.s.	3/10	12/50	9/50			
liv MXB	no dre	P=1.	107.mg n.s.s.	1/10	1/50	1/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	94.0mg n.s.s.	1/10	0/50	2/50		lun:a/a,a/c.	
4801 M m b6c eat 67w89 TR70 :				0	7.70mg	13.2mg			
TBA MXB a	75.1mg *	P<.7	- 12.6mg n.s.s.	2/10	14/50	12/50			
liv MXB a	111.mg *	P<.7	19.6mg n.s.s.	2/10	6/50	9/50		liv:hpa,hpc,nnd.	
lun MXB a	52.5mg *	P<.2	23.8mg n.s.s.	0/10	3/50	5/50		lun:a/a,a/c.	
4802 R f osm eat 19m26 TR70 :				0	.820mg	1.60mg			
TBA MXB v	no dre	P=1.	- 1.57mg n.s.s.	10/10	34/50	32/50			
liv MXB v	16.4mg *	P<.2	5.67mg n.s.s.	0/10	1/50	3/50		liv:hpa,hpc,nnd.	
4803 R f osm eat 19m25 TR70 : pool				0	.820mg	1.60mg			
mgl fba v	2.07mg \	P<.004	.947mg 16.4mg	9/90	16/50	(8/50)			S
adr MXA v	3.93mg *	P<.0005 a	2.01mg 15.0mg	4/90	6/50	13/50		adr:coa,coc.	
adr coa v	5.31mg *	P<.004 a	2.48mg 38.8mg	4/90	4/50	11/50			
4804 R m osm eat 19m26 TR70 :				0	.900mg	1.80mg			
TBA MXB v	3.65mg *	P<.4	- 1.03mg n.s.s.	5/10	25/50	35/50			
liv MXB v	17.7mg *	P<.09	6.12mg n.s.s.	0/10	0/50	4/50		liv:hpa,hpc,nnd.	
4805 R m osm eat 19m25 TR70 : pool				0	.900mg	1.80mg			
adr MXA v	5.22mg *	P<.005 a	2.54mg 54.3mg	3/90	7/50	11/50		adr:coa,coc.	
adr coa v	6.39mg *	P<.007 a	2.99mg 111.mg	2/90	5/50	9/50			
pni isc v	19.2mg *	P<.03	6.62mg n.s.s.	0/90	1/50	3/50			S
PATULIN 149-29-1									
4806 R f sda gav 17m37 393				0	.316mg			Osswald;fctx,16,243-247;1978	
liv mhs v	no dre	P=1.	- 7.80mg n.s.s.	1/50	0/50				
tba mix v	no dre	P=1.	- .809mg n.s.s.	42/50	37/50				
tba ben v	no dre	P=1.	- 1.23mg n.s.s.	29/50	25/50				
tba mal v	no dre	P=1.	- 1.80mg n.s.s.	13/50	12/50				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
PENICILLIN VK 132-98-9										
4807 M f b6c gav 24m24 TR336 :					0	357.mg	714.mg			
TBA MXB	no dre	P=1.	-	754.mg n.s.s.	38/50	26/50	30/50			
liv MXB	10.2gm *	P<.6		1.66gm n.s.s.	3/50	4/50	4/50		liv:hpa,hpc,nnd.	
lun MXB	16.6gm *	P<.7		2.19gm n.s.s.	4/50	1/50	5/50		lun:a/a,a/c.	
4808 M m b6c gav 24m24 TR336 :					0	357.mg	714.mg			
TBA MXB	no dre	P=1.	-	719.mg n.s.s.	36/50	35/50	29/50			
liv MXB	no dre	P=1.		657.mg n.s.s.	19/50	18/50	(8/50)		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.		1.81gm n.s.s.	10/50	9/50	6/50		lun:a/a,a/c.	
4809 R f f34 gav 24m24 TR336 :					0	354.mg	707.mg			
thy MXA s#	1.36gm *	P<.03	-	576.mg n.s.s.	6/50	7/50	11/50		thy:cca,ccr.	S
thy cca s	1.62gm *	P<.05		638.mg n.s.s.	6/50	6/50	10/50			S
cli adn s	3.65gm *	P<.02		1.25gm n.s.s.	0/50	1/50	3/50			S
TBA MXB s	503.mg *	P<.08		197.mg n.s.s.	44/50	45/50	38/50			
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.	
4810 R m f34 gav 24m24 TR336 :					0	354.mg	707.mg			
pta MXA s#	874.mg *	P<.02	-	390.mg n.s.s.	10/50	11/50	14/50		pta:adn,can.	S
pta adn s	949.mg *	P<.03		406.mg n.s.s.	10/50	11/50	13/50			S
TBA MXB s	544.mg *	P<.08		210.mg n.s.s.	42/50	40/50	31/50			
liv MXB s	12.2gm *	P<.5		1.99gm n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.	
PENTACHLOROANISOLE 1825-21-4										
4811 M f b6c gav 24m24 TR414 :					0	14.1mg	28.2mg			
TBA MXB	47.5mg *	P<.4	-	11.7mg n.s.s.	32/50	31/50	30/50			
liv MXB	63.0mg *	P<.2		19.8mg n.s.s.	11/50	10/50	14/50		liv:hpa,hpc,nnd.	
lun MXB	776.mg *	P<.8		66.1mg n.s.s.	2/50	2/50	2/50		lun:a/a,a/c.	
4812 M m b6c gav 24m24 TR414 :					0	14.1mg	28.3mg			
MXB MXB	38.3mg *	P<.0005		21.8mg 124.mg	2/50	11/50	16/50		amd:pob; liv:hes.	P
amd pob	77.4mg *	P<.002	p	38.5mg 189.mg	0/50	4/50	7/50			
liv hes	68.0mg *	P<.02	p	32.6mg n.s.s.	2/50	8/50	10/50			
TBA MXB	40.2mg *	P<.3		11.9mg n.s.s.	38/50	47/50	46/50			
liv MXB	no dre	P=1.		25.8mg n.s.s.	26/50	34/50	24/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.		50.9mg n.s.s.	11/50	12/50	8/50		lun:a/a,a/c.	
4813 R f f34 gav 24m24 TR414 :					0	14.0mg	28.2mg			
amd pob	174.mg *	P<.4	e	50.8mg n.s.s.	3/50	7/50	9/50			
TBA MXB	no dre	P=1.		14.7mg n.s.s.	45/50	41/50	(41/50)			
liv MXB	1.18gm *	P<.3		192.mg n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.	
4814 R m f34 gav 24m24 TR414 :					0	6.99mg	14.0mg	28.2mg		
amd pob s	24.8mg *	P<.03	p	10.8mg n.s.s.	12/50	17/50	23/50	15/50		
amd MXA s	30.0mg *	P<.08	p	11.5mg n.s.s.	15/50	18/50	25/50	15/50	amd:phm,pob.	
TBA MXB s	no dre	P=1.		15.0mg n.s.s.	47/50	49/50	44/50	23/50		
liv MXB s	6.46gm *	P<1.		86.3mg n.s.s.	0/50	1/50	1/50	0/50	liv:hpa,hpc,nnd.	
PENTACHLOROETHANE (pentalin) 76-01-7										
4815 M f b6c gav 24m24 TR232 :					0	177.mg	357.mg			
liv MXA as	39.8mg /	P<.0005	c	24.0mg 68.0mg	3/50	36/50	32/50		liv:hpa,hpc.	
liv hpc as	66.6mg *	P<.0005	c	38.3mg 118.mg	1/50	28/50	13/50			
liv hpa as	153.mg /	P<.0005	c	69.1mg 367.mg	2/50	8/50	19/50			
TBA MXB as	39.5mg /	P<.0005		24.1mg 69.1mg	22/50	38/50	33/50			
liv MXB as	39.8mg /	P<.0005		24.0mg 68.0mg	3/50	36/50	32/50		liv:hpa,hpc,nnd.	
lun MXB as	1.03gm /	P<.2		193.mg n.s.s.	4/50	0/50	3/50		lun:a/a,a/c.	
4816 M m b6c gav 24m24 TR232 :					0	177.mg	357.mg			
liv hpc as	102.mg /	P<.0005	c	59.1mg 234.mg	4/50	26/50	7/50			
liv MXA as	107.mg /	P<.0005		58.4mg 304.mg	14/50	30/50	14/50		liv:hpa,hpc.	S
TBA MXB as	85.6mg /	P<.0005		46.5mg 278.mg	20/50	38/50	14/50			
liv MXB as	107.mg /	P<.0005		58.4mg 304.mg	14/50	30/50	14/50		liv:hpa,hpc,nnd.	
lun MXB as	no dre	P=1.		389.mg n.s.s.	6/50	5/50	0/50		lun:a/a,a/c.	
4817 R f f34 gav 24m24 TR232 :					0	53.1mg	106.mg			
TBA MXB s	1.66gm *	P<.9	-	79.4mg n.s.s.	37/50	36/50	26/50			
liv MXB s	no dre	P=1.		409.mg n.s.s.	1/50	3/50	0/50		liv:hpa,hpc,nnd.	
4818 R m f34 gav 24m24 TR232 :					0	53.1mg	106.mg			
kid tla sh	635.mg *	P<.009	a	240.mg 14.6gm	0/50	1/50	4/50			
kid MXA sh	662.mg *	P<.07	a	229.mg n.s.s.	1/50	2/50	4/50		kid:tla,uac.	
TBA MXB s	no dre	P=1.		107.mg n.s.s.	36/50	26/50	22/50			
liv MXB s	no dre	P=1.		500.mg n.s.s.	2/50	1/50	1/50		liv:hpa,hpc,nnd.	
PENTACHLORONITROBENZENE (PCNB) 82-68-8										
4819 M f b6c eat 24m24 TR325 :					0	322.mg	644.mg			
lun a/a s#	2.00gm *	P<.04	-	770.mg n.s.s.	1/50	4/50	4/50			S
MXA mlm s	2.34gm *	P<.03		881.mg n.s.s.	0/50	3/50	2/50		mln:mlm; mul:mlm.	S
TBA MXB s	1.01gm *	P<.3		284.mg n.s.s.	27/50	24/50	21/50			
liv MXB s	2.50gm *	P<.2		720.mg n.s.s.	3/50	4/50	4/50		liv:hpa,hpc,nnd.	
lun MXB s	3.44gm *	P<.3		896.mg n.s.s.	3/50	4/50	4/50		lun:a/a,a/c.	
4820 M f b6c eat 78w91 TR61 :					0	446.mg	893.mg			
TBA MXB v	3.32gm *	P<.2	-	1.22gm n.s.s.	2/20	5/50	10/50			
liv MXB v	9.69gm *	P<.09		2.93gm n.s.s.	0/20	0/50	3/50		liv:hpa,hpc,nnd.	
lun MXB v	30.7gm *	P<.4		5.00gm n.s.s.	0/20	0/50	1/50		lun:a/a,a/c.	
4821 M f b6c orl 77w77 1101					0	169.mg			Innes;ntis,1968/1969	
liv hpt evx	252.mg	P<.02		86.7mg n.s.s.	0/16	4/18				
lun ade evx	1.11gm	P<.3		180.mg n.s.s.	0/16	1/18				
tba mix evx	195.mg	P<.009		73.4mg 4.27gm	0/16	5/18				
4822 M m b6c eat 24m24 TR325 :					0	297.mg	594.mg			
TBA MXB	13.0gm *	P<1.	-	527.mg n.s.s.	31/50	34/50	29/50			
liv MXB	23.1gm *	P<1.		804.mg n.s.s.	17/50	18/50	16/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.		1.90gm n.s.s.	9/50	4/50	6/50		lun:a/a,a/c.	
4823 M m b6c eat 78w91 TR61 :					0	265.mg	530.mg			
TBA MXB v	no dre	P=1.	-	498.mg n.s.s.	6/20	11/50	12/50			
liv MXB v	no dre	P=1.		669.mg n.s.s.	2/20	8/50	4/50		liv:hpa,hpc,nnd.	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	Brkly Code
lun MXB	v	no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		lun:a/a,a/c.	
4824 M m b6c orl 77w77 1101					0	157.mg			Innes;ntis,1968/1969	
liv hpt evx		501.mg	P<.2	123.mg n.s.s.	0/16	2/18				
lun ade evx		501.mg	P<.2	123.mg n.s.s.	0/16	2/18				
tba mix evx		181.mg	P<.009	68.4mg 3.98gm	0/16	5/18				
4825 M f b6a orl 77w77 1101					0	169.mg				
liv hpt evx		1.05gm	P<.3	170.mg n.s.s.	0/17	1/17				
lun ade evx		no dre	P=1.	324.mg n.s.s.	1/17	0/17				
tba mix evx		no dre	P=1.	152.mg n.s.s.	2/17	2/17				
4826 M m b6a orl 77w77 1101					0	157.mg				
liv hpt evx		71.1mg	P<.0005 +	32.2mg 264.mg	1/18	10/17				
lun ade evx		no dre	P=1.	198.mg n.s.s.	2/18	1/17				
tba mix evx		68.7mg	P<.004	29.4mg 544.mg	3/18	11/17				
4827 R f osm eat 18m26 TR61 :					0	272.mg	514.mg			
TBA MXB dv		no dre	P=1. -	322.mg n.s.s.	14/20	34/50	(20/50)			
liv MXB dv		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.	
4828 R m osm eat 18m26 TR61 :					0	152.mg	280.mg			
TBA MXB dv		no dre	P=1. -	409.mg n.s.s.	8/20	20/50	18/50			
liv MXB dv		no dre	P=1.	1.67gm n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.	
2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7) 87-86-5										
4829 M f b6c eat 24m24 TR349 :					0	12.8mg	25.6mg	76.9mg		
MXB MXB		28.7mg *	P<.0005	19.4mg 47.8mg	1/35	6/50	9/50	42/50	---:hes; amd:pbb,phm,pob; liv:hpa,hpc.	C
liv MXA		38.3mg *	P<.0005 c	24.4mg 71.6mg	1/35	4/50	6/50	31/50	liv:hpa,hpc.	
amd MXA		38.8mg Z	P<.0005 c	25.7mg 61.2mg	0/35	2/50	2/50	38/50	amd:pbb,phm,pob.	
amd MXA		40.3mg Z	P<.0005	26.6mg 64.0mg	0/35	1/50	2/50	38/50	amd:pbb,pob.	S
liv hpa		40.6mg *	P<.0005	25.8mg 75.3mg	1/35	3/50	6/50	30/50		S
--- MXA		187.mg *	P<.0005	93.8mg 646.mg	0/35	1/50	3/50	9/50	---:hem,hes.	S
--- hes		200.mg *	P<.002 c	97.8mg 878.mg	0/35	1/50	3/50	8/50		
TBA MXB		86.1mg Z	P<.2	29.6mg n.s.s.	24/35	29/50	25/50	46/50		
liv MXB		38.3mg *	P<.0005	24.4mg 71.6mg	1/35	4/50	6/50	31/50	liv:hpa,hpc,nnd.	
lun MXB		12.8gm *	P<1.	221.mg n.s.s.	2/35	3/50	1/50	3/50	lun:a/a,a/c.	
4830 M f b6c orl 76w76 1285					0	18.1mg			Innes;ntis,1968/1969	
lun ade evx		56.1mg	P<.2 -	13.8mg n.s.s.	0/16	2/18				
liv hpt evx		no dre	P=1. -	35.8mg n.s.s.	0/16	0/18				
tba mix evx		26.3mg	P<.02 -	9.04mg n.s.s.	0/16	4/18				
4831 M m b6c eat 24m24 TR349 :					0	11.8mg	23.7mg	71.0mg		
amd MXA		17.4mg *	P<.0005	12.4mg 25.6mg	0/35	4/50	21/50	44/50	amd:pbb,pob.	S
amd MXA		17.5mg *	P<.0005 c	12.2mg 28.2mg	1/35	4/50	21/50	45/50	amd:pbb,phm,pmb,pob.	
MXB MXB		24.9mg Z	P<.0005	13.9mg 72.0mg	7/35	21/50	27/50	45/50	amd:pbb,phm,pmb,pob; liv:hpa,hpc.	C
liv hpa		36.2mg *	P<.0005	19.2mg 128.mg	5/35	13/50	17/50	32/50		S
liv MXA		38.3mg Z	P<.003 c	18.8mg 224.mg	6/35	19/50	21/50	34/50	liv:hpa,hpc.	
TBA MXB		57.8mg *	P<.09	21.2mg n.s.s.	20/35	32/50	33/50	46/50		
liv MXB		38.3mg Z	P<.003	18.8mg 224.mg	6/35	19/50	21/50	34/50	liv:hpa,hpc,nnd.	
lun MXB		1.94gm *	P<.9	143.mg n.s.s.	5/35	1/50	2/50	5/50	lun:a/a,a/c.	
4832 M m b6c orl 76w76 1285					0	16.8mg			Innes;ntis,1968/1969	
liv hpt evx		108.mg	P<.3 -	17.5mg n.s.s.	0/16	1/18				
lun ade evx		108.mg	P<.3 -	17.5mg n.s.s.	0/16	1/18				
tba mix evx		33.7mg	P<.05 -	10.2mg n.s.s.	0/16	3/18				
4833 M f b6a orl 76w76 1285					0	18.1mg				
liv hpt evx		no dre	P=1. -	35.8mg n.s.s.	0/17	0/18				
lun ade evx		no dre	P=1. -	35.8mg n.s.s.	1/17	0/18				
tba mix evx		no dre	P=1. -	17.0mg n.s.s.	2/17	2/18				
4834 M m b6a orl 76w76 1285					0	16.8mg				
liv mix evx		90.4mg	P<.6 -	13.2mg n.s.s.	1/18	2/17				
lun ade evx		no dre	P=1. -	20.7mg n.s.s.	2/18	1/17				
tba mix evx		520.mg	P<1. -	12.2mg n.s.s.	3/18	3/17				
4835 R f sss eat 24m24 1401					0	1.00mg	3.00mg	10.0mg 30.0mg	Schwetz;pcpl,301-309;1978	
tba tum e		no dre	P=1. -	10.0mg n.s.s.	27/27	26/27	25/27	25/27 25/27		
4836 R m sss eat 95w95 1401					0	1.00mg	3.00mg	10.0mg 30.0mg		
tba tum e		no dre	P=1. -	33.4mg n.s.s.	11/27	13/26	13/27	12/27 11/27		
2,3,4,5,6-PENTACHLOROPHENOL (penta, PCP) 87-86-5										
4837 M f cd1 eat 52w69 1581					0	48.8mg			Boberg;canr,43,5163-5173;1983	
lun ade e		448.mg	P<.3	73.0mg n.s.s.	0/32	1/31				
liv tum e		no dre	P=1.	137.mg n.s.s.	0/32	0/31				
4838 R f f34 eat 24m24 TR483 :					0	10.0mg	20.0mg	30.0mg		
TBA MXB		no dre	P=1. -	23.3mg n.s.s.	45/60	43/50	42/50	43/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/60	0/50	0/50	0/50	liv:hpa,hpb,hpc.	
4839 R f f34 eat 12m24 TR483a :					0	24.6mg				
TBA MXB		no dre	P=1. -	18.1mg n.s.s.	45/50	42/50				
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50			liv:hpa,hpb,hpc.	
4840 R m f34 eat 24m24 TR483 :					0	8.00mg	16.0mg	24.0mg		
pre car #		19.3mg Z	P<.04 -	7.03mg n.s.s.	1/60	7/50	(1/50	0/50)		S
TBA MXB		no dre	P=1.	8.49mg n.s.s.	46/60	46/50	50/50	(45/50)		
liv MXB		no dre	P=1.	147.mg n.s.s.	0/60	1/50	1/50	0/50	liv:hpa,hpb,hpc.	
4841 R m f34 eat 12m24 TR483a :					0	19.8mg				
MXB MXB		48.9mg	P<.03	21.0mg n.s.s.	2/50	12/50			---:msm; nse:sqc.	P
ski ker		52.8mg	P<.02	22.8mg n.s.s.	0/50	7/50				S
--- msm		59.0mg	P<.03 p	24.4mg n.s.s.	1/50	9/50				
nse sqc h		129.mg	P<.2 p	37.9mg n.s.s.	1/50	5/50				
TBA MXB		no dre	P=1.	22.8mg n.s.s.	46/50	44/50				
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50			liv:hpa,hpb,hpc.	
2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE (penta, PCP) 87-86-5										
4842 M f b6c eat 24m24 TR349 :					0	12.8mg	25.5mg			
--- hes		106.mg *	P<.007 p	49.9mg 1.32gm	0/35	3/50	6/50			
MXB MXB		50.4mg *	P<.02	25.0mg n.s.s.	3/35	11/50	14/50		---:hes; liv:hpa,hpc.	P

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXA	90.1mg *	P<.2	p	34.1mg n.s.s.	3/35	9/50	9/50		liv:hpa,hpc.
TBA MXB	79.3mg /	P<.5		17.5mg n.s.s.	27/35	30/50	37/50		
liv MXB	90.1mg *	P<.2		34.1mg n.s.s.	3/35	9/50	9/50		liv:hpa,hpc,nnd.
lun MXB	395.mg *	P<.4		89.9mg n.s.s.	1/35	1/50	3/50		lun:a/a,a/c.
4843 M m b6c eat 24m24 TR349 :					0	11.8mg	23.5mg		
MXB MXB	10.5mg *	P<.002		5.89mg 51.5mg	7/35	29/50	41/50		amd:pbb,pob; liv:hpa,hpc. C
amd MXA	12.9mg *	P<.0005	c	8.42mg 24.2mg	0/35	10/50	23/50		amd:pbb,pob.
liv hpa	13.5mg *	P<.002		7.57mg 66.9mg	5/35	20/50	33/50		S
liv MXA	13.7mg *	P<.005	c	7.30mg 123.mg	7/35	26/50	37/50		liv:hpa,hpc.
TBA MXB	22.6mg *	P<.2		7.67mg n.s.s.	17/35	38/50	45/50		
liv MXB	13.7mg *	P<.005		7.30mg 123.mg	7/35	26/50	37/50		liv:hpa,hpc,nnd.
lun MXB	154.mg *	P<.5		36.5mg n.s.s.	2/35	2/50	6/50		lun:a/a,a/c.
4844 R f mrw eat 87w87 2038					0	25.0mg			Mirvish;jtxe,32,59-74;1991/pers.comm.
liv hpa	13.1mg	P<.002	+	5.07mg 55.4mg	0/10	6/10			
tba tum	9.96mg	P<.0005		3.96mg 34.1mg	0/10	7/10			
4845 R m mrw eat 87w87 2038					0	20.0mg			
tba tum	43.0mg	P<.3		6.93mg n.s.s.	0/5	1/5			
PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE (PETN, NF) 78-11-5									
4846 M f b6c eat 24m24 TR365 :					0	3.19gm	6.38gm		
TBA MXB	no dre	P=1.	-	9.43gm n.s.s.	37/50	29/50	28/50		
liv MXB	no dre	P=1.		13.6gm n.s.s.	6/50	2/50	(1/50)		liv:hpa,hpc,nnd.
lun MXB	82.0gm *	P<.5		17.0gm n.s.s.	3/50	3/50	5/50		lun:a/a,a/c.
4847 M m b6c eat 24m24 TR365 :					0	2.94gm	5.89gm		
TBA MXB	no dre	P=1.	-	10.4gm n.s.s.	36/50	28/50	32/50		
liv MXB	no dre	P=1.		14.5gm n.s.s.	11/50	11/50	11/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		9.00gm n.s.s.	11/50	8/50	(7/50)		lun:a/a,a/c.
4848 R f f34 eat 24m25 TR365 :					0	304.mg	616.mg		
zym MXA	5.03gm *	P<.04	e	1.66gm n.s.s.	0/50	1/50	3/50		zym:ade,car.
thy MXA	5.80gm *	P<.03		1.71gm n.s.s.	0/50	0/50	3/50		thy:fca,fcc. S
zym ade	11.1gm *	P<.1	e	2.72gm n.s.s.	0/50	0/50	2/50		
zym car	9.20gm *	P<.2	e	2.10gm n.s.s.	0/50	1/50	1/50		
TBA MXB	416.mg *	P<.04		182.mg n.s.s.	46/50	47/50	50/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
4849 R m f34 eat 24m25 TR365 :					0	981.mg	1.97gm		
amd phm	12.2gm *	P<.04		4.24gm n.s.s.	0/50	2/50	3/50		S
zym MXA	13.6gm *	P<.2	e	4.84gm n.s.s.	0/50	3/50	2/50		zym:ade,car.
zym car	20.6gm *	P<.2	e	7.00gm n.s.s.	0/50	2/50	2/50		
zym ade	no dre	P=1.	e	n.s.s. n.s.s.	0/50	1/50	0/50		
TBA MXB	24.0gm /	P<1.		1.02gm n.s.s.	47/50	43/50	48/50		
liv MXB	no dre	P=1.		11.4gm n.s.s.	3/50	0/50	1/50		liv:hpa,hpc,nnd.
PENTANAL METHYLFORMYLHYDRAZONE 57590-20-2									
4850 M f swa gav 12m33 1859					0	2.58mg			Toth;myco,98,83-89;1987/pers.comm.
lun mix e	3.12mg	P<.0005	+	1.80mg 6.98mg	13/50	36/48			
lun ade e	5.64mg	P<.0005		2.94mg 22.1mg	12/50	28/48			
lun adc e	9.29mg	P<.0005		4.88mg 26.7mg	2/50	16/48			
liv bhp e	11.8mg	P<.003	+	5.31mg 52.3mg	0/23	8/32			
4851 M m swa gav 12m31 1859					0	2.77mg			
lun mix e	3.79mg	P<.0005	+	2.04mg 11.7mg	11/41	30/44			
lun ade e	5.52mg	P<.002		2.84mg 23.2mg	8/41	24/44			
pre mix e	16.2mg	P<.007	+	6.61mg 193.mg	0/27	6/34			
lun adc e	11.0mg	P<.02		4.82mg n.s.s.	5/41	15/44			
pre sqc e	19.8mg	P<.02		7.52mg n.s.s.	0/27	5/34			
liv hpt e	33.1mg	P<.3	+	5.38mg n.s.s.	0/8	1/11			
pre sqp e	106.mg	P<.3		17.2mg n.s.s.	0/27	1/34			
N-PENTYL-N'-NITRO-N-NITROSOGUANIDINE 13010-10-1									
4852 R m wis wat 52w78 1082					0	2.30mg			Matsukura;gann,70,181-185;1979
stg tum er	no dre	P=1.	-	1.60mg n.s.s.	0/9	0/6			
n-PENTYLHYDRAZINE.HCl 1119-68-2									
4853 M f swa wat 94w94 36					0	12.5mg			Shimizu;bjca,31,492-496;1975
lun mix	5.87mg	P<.0005	+	3.54mg 11.2mg	21/100	38/50			
lun ade	7.95mg	P<.0005		4.69mg 16.3mg	18/100	33/50			
lun adc	18.7mg	P<.0005		10.0mg 45.4mg	4/100	17/50			
blv mix	35.5mg	P<.003	+	15.6mg 245.mg	5/100	11/50			
blv agm	71.9mg	P<.04		24.4mg n.s.s.	3/100	6/50			
blv ang	82.2mg	P<.04		26.9mg n.s.s.	2/100	5/50			
liv mix	223.mg	P<.4		39.3mg n.s.s.	3/100	3/50			
4854 M m swa wat 94w94 36					0	10.4mg			
lun ade	30.0mg	P<.04		11.6mg n.s.s.	15/100	15/50			
lun mix	46.9mg	P<.3		12.8mg n.s.s.	23/100	16/50			
blv mix	65.6mg	P<.2		19.8mg n.s.s.	6/100	7/50			
liv mix	271.mg	P<.7		31.1mg n.s.s.	6/100	4/50			
PEPPERMINT OIL 8006-90-4									
4855 M m cfl gav 19m24 710					0	2.64mg	10.5mg		Roe;jept,2,799-819;1979
lun tum e	no dre	P=1.		21.1mg n.s.s.	102/240	19/51	20/49		
liv tum e	no dre	P=1.		25.3mg n.s.s.	69/240	13/51	14/49		
tba mix e	no dre	P=1.		11.0mg n.s.s.	170/240	37/51	34/49		
tba mal e	112.mg *	P<.6		17.3mg n.s.s.	75/240	20/51	17/49		
PERHEXILINE MALEATE (2-(2-DICYCLOHEXYLETHYL) PIPERIDINE MALEATE) 6724-53-4									
4856 R f sda eat 52w52 2404m					0	50.0mg	100.mg	200.mg	Nagata;phrm,20,541-566;1980
liv tum e	no dre	P=1.	-	23.6mg n.s.s.	0/16	0/16	0/16	0/16	
4857 R f sda eat 52w56 2404n					0	46.2mg	92.3mg	185.mg	
liv tum e	no dre	P=1.	-	12.6mg n.s.s.	0/8	0/8	0/8	0/8	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
4858 R m sda eat 52w52 2404m	0	50.0mg	100.mg	200.mg	
liv tum e no dre P=1. - 23.6mg n.s.s.	0/16	0/16	0/16	0/16	
4859 R m sda eat 52w56 2404n	0	46.2mg	92.3mg	185.mg	
liv tum e no dre P=1. - 12.6mg n.s.s.	0/8	0/8	0/8	0/8	
PETASITENINE 60102-37-6					
4860 R f aci wat 68w68 427	0	5.71mg			Hirono;jnci,58,1155-1157;1977
liv hms erh 1.52mg P<.003 + .477mg 9.69mg	0/9	4/6			
liv mix erh 1.52mg P<.003 + .477mg 9.69mg	0/9	4/6			
liv lca erh 4.13mg P<.05 + .994mg n.s.s.	0/9	2/6			
4861 R m aci wat 58w58 427	0	5.00mg			
liv mix erh .662mg P<.0005 + .183mg 3.71mg	0/10	4/5			
liv lca erh 1.16mg P<.005 + .324mg 13.1mg	0/10	3/5			
liv hms erh 4.78mg P<.2 + .770mg n.s.s.	0/10	1/5			
PHENACETIN 62-44-2					
4862 M f b6c eat 22m24 1501	0	720.mg	1.50gm		Nakanishi;ijcn,29,439-444;1982
lun ade e 6.89gm * P<.1 - 2.60gm n.s.s.	7/48	6/50	14/49		
ubl pam e 37.0gm * P<.1 + 9.10gm n.s.s.	0/48	0/50	2/49		
ubl tcc e 37.0gm * P<.1 + 9.10gm n.s.s.	0/48	0/50	2/49		
lun adc e 8.83gm * P<.2 - 3.23gm n.s.s.	3/48	6/50	8/49		
liv hnd e 14.0gm * P<.3 - 4.15gm n.s.s.	2/48	5/50	5/49		
liv hem e 29.2gm * P<.4 - 6.97gm n.s.s.	1/48	1/50	3/49		
liv hpc e 47.7gm * P<.7 - 6.28gm n.s.s.	2/48	3/50	3/49		
4863 M m b6c eat 22m24 1501	0	665.mg	1.38gm		
kid rca e 1.10gm * P<.0005 + 754.mg 1.69gm	0/48	11/48	32/48		
lun adc e 3.80gm * P<.006 - 1.90gm 41.0gm	3/48	8/48	13/48		
kid rcc e 4.02gm / P<.0005 2.20gm 8.53gm	0/48	1/48	14/48		
lun ade e 5.28gm * P<.2 - 1.87gm n.s.s.	8/48	14/48	14/48		
liv hpc e 17.1gm \ P<.9 - 1.39gm n.s.s.	10/48	11/48	(3/48)		
liv hem e no dre P=1. - 10.5gm n.s.s.	4/48	1/48	2/48		
liv hnd e no dre P=1. - 4.58gm n.s.s.	14/48	10/48	10/48		
4864 M f cb6 eat 77w77 1028	0	268.mg	754.mg		Macklin;dact,3,135-163;1980
liv tum e no dre P=1. - 848.mg n.s.s.	0/36	0/37	0/41		
4865 M m cb6 eat 77w77 1028	0	268.mg	754.mg		
liv hnd e 12.9gm * P<.2 - 2.11gm n.s.s.	0/35	0/40	1/32		
4866 R f sda eat 18m24 708	0	469.mg	938.mg		Isaka;gann,70,29-36;1979
--- myl 2.56gm * P<.0005 - 1.45gm 5.32gm	0/65	6/50	11/50		
mix mix 2.73gm * P<.0005 + 1.52gm 5.79gm	0/65	5/50	11/50		
nas adc 7.73gm * P<.005 + 3.15gm 58.5gm	0/65	1/50	5/50		
ubl tcc 11.7gm * P<.02 + 4.05gm n.s.s.	0/65	0/50	4/50		
ubl pam 23.8gm * P<.08 + 5.85gm n.s.s.	0/65	0/50	2/50		
nas tcc 23.8gm * P<.2 + 5.87gm n.s.s.	0/65	1/50	1/50		
nas sqc 48.0gm * P<.7 + 7.82gm n.s.s.	0/65	1/50	0/50		
liv tum no dre P=1. 3.22gm n.s.s.	0/65	0/50	0/50		
tba mix 1.21gm * P<.0005 728.mg 2.89gm	6/65	19/50	21/50		
4867 R f sda eat 26m26 1449	0	268.mg			Johansson;apms,84,375-383;1976
mgl adc e 1.38gm P<.08 + 451.mg n.s.s.	1/30	5/30			
edu sqc e 1.43gm P<.02 + 494.mg n.s.s.	0/30	4/30			
4868 R m sda eat 18m24 708	0	375.mg	750.mg		Isaka;gann,70,29-36;1979
mix mix 741.mg * P<.0005 + 503.mg 1.15gm	0/65	17/50	23/50		
--- myl 2.38gm * P<.0005 - 1.30gm 6.32gm	0/65	8/50	7/50		
nas adc 2.38gm * P<.0005 + 1.30gm 6.32gm	0/65	8/50	7/50		
ubl tcc 2.71gm / P<.0005 + 1.43gm 6.12gm	0/65	1/50	12/50		
nas tcc 4.05gm * P<.002 + 1.91gm 13.5gm	0/65	2/50	7/50		
nas sqc 7.53gm * P<.06 + 2.86gm n.s.s.	0/65	3/50	2/50		
k/p rcc 38.3gm * P<.3 + 6.24gm n.s.s.	0/65	0/50	1/50		
liv tum no dre P=1. 2.58gm n.s.s.	0/65	0/50	0/50		
tba mix 631.mg * P<.0005 432.mg 990.mg	1/65	20/50	26/50		
4869 R m sda eat 27m27 1459	0	214.mg			Johansson;ijcn,27,521-529;1981
kcx rct h 1.30gm P<.02 + 447.mg n.s.s.	0/30	4/30			
for sqp h 2.69gm P<.1 + 661.mg n.s.s.	0/30	2/30			
ubl tum 1.64gm P<.3 + 435.mg n.s.s.	2/30	5/30			
k/p tum h 5.47gm P<.3 + 891.mg n.s.s.	0/30	1/30			
liv hem 5.47gm P<.3 891.mg n.s.s.	0/30	1/30			
4870 R f wis eat 69w69 1740	0	500.mg			Kunze;zkko,105,38-47;1983
unt tum er no dre P=1. - 1.86gm n.s.s.	0/30	0/41			
PHENAZONE 60-80-0					
4871 R m sda eat 26m26 1459	0	214.mg			Johansson;ijcn,27,521-529;1981
k/p mix 1.23gm P<.02 + 425.mg n.s.s.	0/30	4/30			
liv ccy 2.55gm P<.1 628.mg n.s.s.	0/30	2/30			
ubl tum 1.55gm P<.3 + 413.mg n.s.s.	2/30	5/30			
4872 R m sda eat 88w88 2211	0	214.mg			Johansson;carc,9,783-787;1988
k/p mix e no dre P=1. 821.mg n.s.s.	0/30	0/26			
liv tum e no dre P=1. 821.mg n.s.s.	0/30	0/26			
ubl mix e no dre P=1. 821.mg n.s.s.	0/30	0/26			
PHENAZOPYRIDINE.HCl 136-40-3					
4873 M f b6c eat 19m24 TR99 :	0	41.6mg	84.5mg		
liv MXA 71.1mg * P<.007 c 38.0mg 991.mg	2/15	11/35	19/35		liv:hpa,hpc.
liv hpc 132.mg * P<.03 c 61.6mg n.s.s.	2/15	6/35	14/35		
TBA MXB 89.7mg * P<.2 34.1mg n.s.s.	8/15	20/35	27/35		
liv MXB 71.1mg * P<.007 38.0mg 991.mg	2/15	11/35	19/35		liv:hpa,hpc,nnd.
lun MXB 4.65gm * P<.9 252.mg n.s.s.	1/15	1/35	2/35		lun:a/a,a/c.
4874 M m b6c eat 19m24 TR99 :	0	39.6mg	78.0mg		
TBA MXB 496.mg * P<.8 - 51.8mg n.s.s.	7/15	17/35	20/35		
liv MXB 811.mg * P<.9 62.1mg n.s.s.	5/15	15/35	15/35		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun MXB	1.30gm * P<.8			144.mg n.s.s.	1/15	4/35	4/35		lun:a/a,a/c.
4875 R f f34 eat 18m24 TR99 :					0	98.0mg	199.mg		
col acn h	687.mg * P<.2		c	311.mg n.s.s.	0/15	3/34	5/35		
TBA MXB	no dre	P=1.		232.mg n.s.s.	5/15	10/34	13/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/34	0/35		liv:hpa,hpc,nnd.
4876 R m f34 eat 18m24 TR99 :					0	78.4mg	161.mg		
MXA MXA	303.mg * P<.02		c	160.mg 43.4gm	0/15	4/35	9/35		col:acn,adn; rec:acn.
MXA acn	333.mg * P<.02		c	172.mg n.s.s.	0/15	4/35	8/35		col:acn; rec:acn.
TBA MXB	no dre	P=1.		210.mg n.s.s.	9/15	19/35	14/35		
liv MXB	2.17gm * P<.5			535.mg n.s.s.	0/15	1/35	1/35		liv:hpa,hpc,nnd.
PHENESTERIN 3546-10-9									
4877 M f b6c gav 70w83 TR60 :					0	3.00mg	5.40mg	10.8mg	
MXB MXB aes	.211mg Z P<.0005			.103mg .440mg	7/35	30/40	16/35	21/35	---:leu,lym; lun:a/a,a/c; myc:srn. C
lun MXA aes	.416mg * P<.0005		c	.152mg 1.25mg	2/35	15/40	1/35	1/35	lun:a/a,a/c.
--- MXA aes	.652mg Z P<.0005		c	.288mg 1.65mg	5/35	12/40	14/35	17/35	---:leu,lym.
ova tua aes	.912mg * P<.0005			.273mg 3.43mg	0/35	8/40	0/35	0/35	S
myc srn aes	.951mg * P<.0005		c	.288mg 2.78mg	0/35	8/40	2/35	3/35	
--- hes aes	1.52mg * P<.0005			.465mg 6.27mg	0/35	4/40	1/35	2/35	S
TBA MXB aes	.183mg Z P<.0005			96.1ug .368mg	11/35	33/40	17/35	21/35	
liv MXB aes	no dre	P=1.		n.s.s. n.s.s.	3/35	1/40	0/35	0/35	liv:hpa,hpc,nnd.
lun MXB aes	.416mg * P<.0005			.152mg 1.25mg	2/35	15/40	1/35	1/35	lun:a/a,a/c.
4878 M f b6c gav 70w82 TR60 : pool					0	5.40mg	10.8mg		
--- MXA aes	2.07mg * P<.0005		c	.862mg 3.97mg	0/31	14/35	17/35		---:leu,lym.
4879 M m b6c gav 64w81 TR60 :					0	3.00mg	4.10mg	9.00mg	
MXB MXB a	.757mg * P<.0005			.491mg 1.30mg	3/35	25/40	19/35	15/35	---:leu,lym; lun:a/a,a/c; myc:srn. C
lun MXA a	1.19mg * P<.0005		c	.684mg 2.84mg	2/35	18/40	6/35	2/35	lun:a/a,a/c.
lun a/c a	2.05mg Z P<.0005		c	1.08mg 5.57mg	0/35	14/40	0/35	0/35	
--- MXA a	2.13mg * P<.0005		c	1.20mg 4.46mg	1/35	11/40	9/35	11/35	---:leu,lym.
myc srn a	3.87mg * P<.0005		c	1.85mg 11.2mg	0/35	5/40	7/35	2/35	
TBA MXB a	.728mg * P<.0005			.446mg 1.43mg	11/35	29/40	20/35	17/35	
liv MXB a	32.9mg * P<.9			2.07mg n.s.s.	7/35	10/40	2/35	0/35	liv:hpa,hpc,nnd.
lun MXB a	1.19mg * P<.0005			.684mg 2.84mg	2/35	18/40	6/35	2/35	lun:a/a,a/c.
4880 M m b6c gav 64w81 TR60 : pool					0	4.10mg	9.00mg		
--- MXA a	1.89mg * P<.0005		c	.784mg 4.46mg	0/29	9/35	11/35		---:leu,lym.
--- hes a	6.15mg * P<.002			1.99mg 36.3mg	0/29	1/35	3/35		S
myc srn a	6.28mg * P<.003		c	2.64mg 30.5mg	0/29	7/35	2/35		
4881 R f sda gav 52w85 TR60 :					0	1.30mg	2.60mg		
TBA MXB	.271mg * P<.0005		-	.137mg .880mg	7/10	28/35	22/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
4882 R f sda gav 52w85 TR60 : pool					0	1.30mg	2.60mg		
mgl acn	.523mg * P<.0005		c	.251mg 1.30mg	1/20	12/35	12/35		
4883 R m sda gav 52w84 TR60 :					0	1.30mg	2.60mg		
TBA MXB	.481mg * P<.002		-	.258mg 2.10mg	1/10	18/35	11/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
4884 R m sda gav 52w84 TR60 : pool					0	1.30mg	2.60mg		
--- MXA #	2.73mg * P<.003		-	1.07mg 8.49mg	0/20	2/35	5/35		---:leu,lym. S
PHENETHYL ISOTHIOCYANATE 2257-09-2									
4885 H f syg eat 51w52 2615					0	50.1mg	100.mg		Nishikawa;clet,141,109-115;1999
liv tum e	no dre	P=1.	-	17.2mg n.s.s.	0/10	0/10	0/10		
lun tum e	no dre	P=1.	-	17.2mg n.s.s.	0/10	0/10	0/10		
4886 R m f34 eat 26m26 2232					0	19.6mg			Hecht;cebp,5,645-652;1996
pae mix e	93.0mg	P<.5	-	18.7mg n.s.s.	3/16	5/16			
pae ana e	194.mg	P<.7	-	23.0mg n.s.s.	3/16	4/16			
pae mal e	241.mg	P<.3	-	39.2mg n.s.s.	0/16	1/16			
liv mix e	no dre	P=1.	-	51.1mg n.s.s.	1/15	1/18			
pni isa e	no dre	P=1.	-	74.8mg n.s.s.	1/16	0/16			
PHENFORMIN.HCl 834-28-6									
4887 M f b6c eat 18m24 TR7 :					0	117.mg	244.mg		
TBA MXB	no dre	P=1.	-	203.mg n.s.s.	7/15	13/35	(9/35)		
liv MXB	no dre	P=1.		701.mg n.s.s.	1/15	3/35	2/35		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		lun:a/a,a/c.
4888 M m b6c eat 18m24 TR7 :					0	108.mg	226.mg		
TBA MXB s	no dre	P=1.	-	266.mg n.s.s.	8/15	10/35	11/35		
liv MXB s	no dre	P=1.		262.mg n.s.s.	1/15	6/35	4/35		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.		376.mg n.s.s.	1/15	4/35	1/35		lun:a/a,a/c.
4889 R f f34 eat 18m24 TR7 :					0	15.0mg	30.0mg		
TBA MXB	no dre	P=1.	-	39.3mg n.s.s.	14/15	28/35	26/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
4890 R m f34 eat 18m24 TR7 :					0	12.0mg	24.0mg		
TBA MXB	36.4mg / P<.2		-	13.0mg n.s.s.	7/15	14/35	24/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
PHENOBARBITAL (phenobarbitone) 50-06-6									
4891 H m syg eat 52w52 1804					0	46.0mg			Stenback;jnci,76,327-333;1986
liv mix er	no dre	P=1.	-	23.7mg n.s.s.	0/5	0/10			
4892 M m b6c wat 52w52 1477m					0	83.3mg			Becker;canr,42,3918-3923;1982
liv mix r	noTD50	P<.006	+	n.s.s. 11.5mg	5/16	16/16			
4893 M m b6c eat 96w96 2398					0	60.0mg			Nitta;jtxp,4,55-61;1991/pers.comm.
liv hpc	20.4mg	P<.0005	+	12.3mg 37.4mg	10/46	43/50			
liv mix	21.1mg	P<.0005	+	12.5mg 40.2mg	12/46	43/50			
lun mix	no dre	P=1.		184.mg n.s.s.	9/46	7/50			
4894 M f c3l eat 52w52 235m					0	65.0mg			Peraino;jnci,51,1349-1350;1973
liv tum r	noTD50	P<.0005	+	n.s.s. 5.36mg	5/39	29/29			
4895 M f c3l eat 52w52 235n					0	65.0mg			
liv tum r	12.2mg	P<.0005	+	5.45mg 46.2mg	1/16	10/16			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
4896 M m c3l eat 52w52 235m					0	60.0mg			
liv tum r		4.18mg	P<.0005 +	1.52mg 19.0mg	25/37	35/36			
4897 M m c3l eat 52w52 235n					0	60.0mg			
liv tum r		4.46mg	P<.0005 +	1.56mg 21.4mg	7/17	16/17			
4898 M m c5n wat 78w78 1477n					0	83.3mg			Becker;canr,42,3918-3923;1982
liv tum r		no dre	P=1. -	155.mg n.s.s.	0/16	0/16			
4899 M m cb6 eat 53w53 2084m					0	60.0mg			Diwan;carc,13,1893-1901;1992
liv hct r		no dre	P=1.	80.3mg n.s.s.	0/25	0/25			
4900 M f cd1 wat 78w78 1582					0	100.mg			Miller;canr,43,1124-1134;1983
liv hpt		559.mg	P<.1	137.mg n.s.s.	0/30	2/30			
lun ade		no dre	P=1.	210.mg n.s.s.	1/30	1/30			
4901 M m cen wat 52w52 1477o					0	83.3mg			Becker;canr,42,3918-3923;1982
liv mix kr		noTD50	P<.3	n.s.s. n.s.s.	5/8	8/8			
4902 M m cen wat 52w52 1477r					0	83.3mg			
liv mix r		noTD50	P<.09 +	n.s.s. n.s.s.	10/16	16/16			
4903 M m cen eat 52w52 1992					0	60.0mg			Fullerton;carc,11,1301-1305;1990
liv mix r		6.67mg	P<.0005 +	3.75mg 13.3mg	2/30	24/30			
liv hpc r		7.78mg	P<.0005 +	4.47mg 14.7mg	0/30	22/30			
lun mix r		139.mg	P<.4	28.5mg n.s.s.	2/30	4/30			
liv hpa r		no dre	P=1.	44.9mg n.s.s.	2/30	2/30			
4904 M m chg eat 52w52 1891					0	24.0mg			Mizutani;clet,39,233-237;1988
liv tum r		5.56mg	P<.002 +	2.31mg 38.5mg	42/139	14/21			
4905 M m chh eat 52w52 1891					0	24.0mg			
liv tum r		noTD50	P<.09	n.s.s. n.s.s.	42/56	31/31			
4906 M m d2b eat 26m26 2227					0	60.0mg			Diwan;clet,89,29-35;1995/pers.comm.
liv hpa er		42.4mg	P<.0005 +	21.0mg 161.mg	9/29	23/30			
liv mix er		42.4mg	P<.0005 +	21.0mg 161.mg	9/29	23/30			
liv hpb er		101.mg	P<.0005 +	50.1mg 250.mg	0/29	11/30			
liv hpc er		199.mg	P<.02 +	78.1mg n.s.s.	1/29	7/30			
4907 M m dba eat 53w53 2084n					0	60.0mg			Diwan;carc,13,1893-1901;1992
liv hpa r		61.2mg	P<.02	21.1mg n.s.s.	0/25	4/25			
4908 R f aci eat 67w67 1448					0	25.0mg			Uchida;zkko,100,231-238;1981
liv tum		no dre	P=1. -	25.7mg n.s.s.	0/10	0/12			
tba mix		81.7mg	P<.3	13.3mg n.s.s.	0/10	1/12			
4909 R m aci eat 67w67 1448					0	20.0mg			
liv tum		no dre	P=1. -	20.5mg n.s.s.	0/10	0/12			
tba mix		no dre	P=1.	15.3mg n.s.s.	4/10	1/12			
4910 R f f34 wat 76w76 1689					0	28.6mg			Diwan;jnci,75,1099-1105;1985
liv hpa er		99.2mg	P<.3	16.1mg n.s.s.	0/10	1/10			
4911 R f f34 eat 89w91 2219					0	24.4mg			Zavanella;carc,15,2531-2539;1994/pers.comm.
liv hct r		46.5mg	P<.06	12.5mg n.s.s.	1/24	3/11			
4912 R m f34 wat 76w76 1689					0	25.0mg			Diwan;jnci,75,1099-1105;1985
liv hpa er		86.8mg	P<.3	14.1mg n.s.s.	0/10	1/10			
4913 R m f34 wat 72w72 1690					0	25.0mg			Diwan;jnci,74,509-516;1985
liv hpa e		45.0mg	P<.08	11.0mg n.s.s.	0/13	2/12			
4914 R m f34 eat 17m24 1803					0	14.0mg			Shivapurkar;carc,7,547-550;1986
liv nnd e		no dre	P=1. -	38.2mg n.s.s.	2/28	2/28			
4915 R m f34 eat 52w52 1834					0	20.0mg			Leonard;jnci,79,1313-1319;1987/pers.comm.
liv mix er		no dre	P=1. -	20.6mg n.s.s.	0/20	0/20			
4916 R m f34 eat 71w71 1951					0	20.0mg			Diwan;carc,10,189-194;1989
liv hpt e		no dre	P=1.	28.8mg n.s.s.	0/15	0/15			
4917 R m f34 eat 71w71 2084m					0	20.0mg			Diwan;carc,13,1893-1901;1992
liv hpa		76.6mg	P<.1	18.8mg n.s.s.	0/25	2/25			
4918 R m f34 eat 71w71 2109					0	20.0mg			Diwan;artx,66,413-422;1992
liv hpa e		44.6mg	P<.04	11.0mg n.s.s.	0/27	2/15			
4919 R m f34 eat 89w91 2219					0	19.6mg			Zavanella;carc,15,2531-2539;1994/pers.comm.
liv hct r		328.mg	P<.8	22.7mg n.s.s.	1/21	1/13			
4920 R m f34 eat 72w72 2322					0	20.0mg			Diwan;carc,17,37-43;1996
liv hpa		115.mg	P<.3	18.7mg n.s.s.	0/18	1/18			
4921 R m f34 eat 78w78 2535					0	20.0mg			Allen;carc,18,1103-1107;1997/pers.comm.
liv tum e		no dre	P=1. -	64.9mg n.s.s.	0/28	0/28			
4922 R m f34 eat 72w72 2657					0	20.0mg			Diwan;ijtx,20,81-87;2001
liv hpa		75.5mg	P<.3 -	12.3mg n.s.s.	0/12	1/12			
4923 R m f3d wat 40w78 2565					0	14.7mg			Hasegawa;clet,123,185-191;1998/pers.comm.
liv tum e		no dre	P=1. -	25.5mg n.s.s.	0/10	0/15			
4924 R m fis eat 39w78 1653					0	10.0mg			Carr;carc,5,1583-1590;1984
liv tum e		no dre	P=1. -	6.96mg n.s.s.	0/12	0/6			
tba tum e		no dre	P=1. -	6.96mg n.s.s.	0/12	0/6			
4925 R f sda ipj 24m24 1134					0	.286mg			Schmahl;zkko,86,77-84;1976
tba mal es		no dre	P=1. -	1.25mg n.s.s.	3/33	1/30			
4926 R m sda ipj 24m24 1134					0	.286mg			
liv hae es		no dre	P=1.	1.88mg n.s.s.	1/36	0/32			
tba mal es		54.7mg	P<1. -	n.s.s. n.s.s.	1/36	1/32			
4927 R m wis eat 59w59 2155					0	50.0mg			Kraupp-Grasl;canr,51,666-671;1991/pers.comm.
liv mix e		303.mg	P<.4	49.4mg n.s.s.	0/18	1/28			
tba tum e		9.22mg	P<.0005	5.07mg 20.4mg	1/18	20/28			
4928 R f wsh wat 56w56 2659					0	57.1mg			White;carc,22,553-557;2001
liv tum Cr		no dre	P=1. -	34.1mg n.s.s.	0/10	0/10			
PHENOBARBITAL, SODIUM (phenobarbitone, sodium) 57-30-7									
4929 M m b6c wat 61w61 2071					0	83.3mg			Herren-Freund;txap,90,183-189;1987
liv hpa er		no dre	P=1. -	62.0mg n.s.s.	2/22	2/22			
liv hpc er		no dre	P=1. -	130.mg n.s.s.	0/22	0/22			
4930 M f bal wat 27m28 1772					0	95.8mg			Cavaliere;tumo,72,125-128;1986
lun ade		1.21gm	P<.5 -	209.mg n.s.s.	7/50	6/30			
liv hpc		no dre	P=1. -	789.mg n.s.s.	0/50	0/30			
tba mix		no dre	P=1. -	274.mg n.s.s.	12/50	6/30			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD50 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
4931 M m bal wat 27m27 1772	0	83.3mg			
lun ade no dre P=1. - 219.mg n.s.s.	19/50	8/30			
liv hpc no dre P=1. - 630.mg n.s.s.	0/50	0/30			
tba mix no dre P=1. - 246.mg n.s.s.	22/50	8/30			
4932 M m cb6 eat 60w60 2186n	0	85.0mg			Evans;txpy,20,585-594;1992/pers.comm.
liv esn kr 184.mg P<.1 45.2mg n.s.s.	0/20	2/20			
liv bsn kr no dre P=1. 117.mg n.s.s.	0/20	0/20			
liv hpc kr no dre P=1. 117.mg n.s.s.	0/20	0/20			
4933 M m cb6 eat 80w80 2186r	0	85.0mg			
liv bsn kr 154.mg P<.3 24.9mg n.s.s.	0/5	1/5			
liv esn kr 154.mg P<.3 24.9mg n.s.s.	0/5	1/5			
liv hpc kr no dre P=1. 51.8mg n.s.s.	0/5	0/5			
4934 M m cb6 eat 14m23 2186u	0	51.0mg			
liv esn er 290.mg P<.09 71.3mg n.s.s.	0/20	2/19			
liv hpc er 2.92gm P<.9 111.mg n.s.s.	8/190	1/19			
liv bsn er no dre P=1. 104.mg n.s.s.	4/20	2/19			
4935 M m cb6 eat 23m23 2186w	0	85.0mg			
liv esn er 77.7mg P<.0005 + 37.1mg 203.mg	0/20	10/20			
liv bsn er 834.mg P<.8 91.9mg n.s.s.	4/20	5/20			
liv hpc er 8.72gm P<.9 640.mg n.s.s.	8/190	6/125			
4936 M f cf1 eat 26m26 89	0	65.0mg			Thorpe;fctx,11,433-442;1973
liv mix e 44.2mg P<.0005 + 22.5mg 122.mg	10/44	21/28			
liv lct e 128.mg P<.0005 + 60.1mg 352.mg	0/44	9/28			
lun tum e no dre P=1. - 175.mg n.s.s.	27/44	9/28			
4937 M f cf1 wat 28m28 237	0	100.mg			Ponomarkov;clet,1,165-172;1976
liv hpt e 95.2mg P<.0005 + 65.2mg 145.mg	0/47	45/73			
lun ade e no dre P=1. - 338.mg n.s.s.	15/47	21/73			
tba mix e no dre P=1. 93.4mg n.s.s.	45/47	65/73			
4938 M m cf1 eat 26m26 89	0	60.0mg			Thorpe;fctx,11,433-442;1973
liv mix e 34.6mg P<.0005 + 18.1mg 86.1mg	11/45	24/30			
liv lct e 174.mg P<.006 + 70.9mg 2.46gm	2/45	8/30			
lun tum e no dre P=1. - 86.7mg n.s.s.	27/45	15/30			
4939 M m cf1 wat 28m28 237	0	83.3mg			Ponomarkov;clet,1,165-172;1976
liv hpt e 62.2mg P<.0005 + 41.6mg 109.mg	12/44	77/98			
lun ade e no dre P=1. - 244.mg n.s.s.	20/44	40/98			
tba mix e 132.mg P<.4 33.0mg n.s.s.	40/44	93/98			
4940 M m chh eat 55w55 1776m	0	85.0mg			Evans;carc,7,627-631;1986/pers.comm.
liv esn ejkr noTD50 P<.009 + n.s.s. 22.6mg	0/5	5/5			
liv bsn ejkr 56.6mg P<.5 8.26mg n.s.s.	1/5	2/5			
liv hpc ejkr no dre P=1. 24.5mg n.s.s.	0/5	0/5			
4941 M m chh eat 65w65 1776n	0	85.0mg			
liv esn ejkr 49.8mg P<.0005 + 24.8mg 123.mg	0/30	11/30			
liv bsn ejkr no dre P=1. 68.8mg n.s.s.	12/30	8/30			
liv hpc ejkr no dre P=1. 205.mg n.s.s.	0/30	0/30			
4942 M m chh eat 23m23 1776o	0	85.0mg			
liv esn ejr 30.5mg P<.0005 + 18.8mg 51.6mg	0/65	34/41			
liv bsn ejr no dre P=1. 143.mg n.s.s.	24/65	14/41			
liv hpc ejr no dre P=1. 493.mg n.s.s.	5/65	1/41			
4943 M m chh eat 60w60 2186m	0	85.0mg			Evans;txpy,20,585-594;1992/pers.comm.
liv esn kr 8.42mg P<.0005 + 4.00mg 18.4mg	0/20	18/20			
liv hpc kr 184.mg P<.1 45.2mg n.s.s.	0/20	2/20			
liv bsn kr no dre P=1. 52.0mg n.s.s.	10/20	5/20			
4944 M m chh eat 80w80 2186o	0	85.0mg			
liv esn kr noTD50 P<.009 + n.s.s. 47.7mg	0/5	5/5			
liv hpc kr 21.4mg P<.005 5.93mg 191.mg	0/5	4/5			
liv bsn kr no dre P=1. 17.1mg n.s.s.	5/5	3/5			
4945 M m chh eat 60w91 2186s	0	56.0mg			
liv esn er 9.51mg P<.0005 3.98mg 21.1mg	0/20	21/22			
liv bsn er no dre P=1. 80.8mg n.s.s.	16/20	8/22			
liv hpc er no dre P=1. 94.8mg n.s.s.	52/190	4/22			
4946 M m chh eat 91w91 2186v	0	85.0mg			
liv esn er noTD50 P<.0005 + n.s.s. 23.8mg	0/20	20/20			
liv hpc er 2.11gm P<.8 179.mg n.s.s.	52/190	26/90			
liv bsn er no dre P=1. 104.mg n.s.s.	16/20	8/20			
4947 R m cdr wat 95w95 1035	0	50.0mg			Wislocki;canr,37,1883-1891;1977
liv sad e 500.mg P<.3 81.4mg n.s.s.	0/15	1/18			
4948 R m f34 eat 95w95 1783	0	20.0mg	60.0mg		Imaida;canr,46,6160-6164;1986
liv nnd 120.mg * P<.004 60.5mg 908.mg	1/42	7/42	10/42		
thy cca 31.7mg \ P<.03 13.7mg n.s.s.	9/42	19/42	(11/42)		
4949 R m f34 eat 56w56 1942	0	40.0mg			Diwan;txap,98,269-277;1989
ubl tum e no dre P=1. - 35.9mg n.s.s.	0/15	0/15			
4950 R m f3d eat 24m24 2610	0	.320mg	1.20mg	5.00mg 20.0mg	Hagiwara;fctx,37,869-879;1999
liv hpc e no dre P=1. - 100.mg n.s.s.	0/19	1/20	0/20	1/20 0/20	
4951 R m fis eat 24m24 389	0	39.8mg			Butler;bjca,37,418-423;1978
liv hnd ev 67.3mg P<.0005 33.6mg 177.mg	0/25	11/33			
4952 R f wis wat 34m34 85	0	28.6mg			Rossi;ijcn,19,179-185;1977
liv hpt e 102.mg P<.0005 + 48.0mg 287.mg	0/32	9/29			
tba tum e 73.1mg P<.2 22.5mg n.s.s.	19/32	22/29			
4953 R m wis wat 34m34 85	0	25.0mg			
liv hpt e 74.3mg P<.0005 + 38.9mg 168.mg	0/35	13/36			
tba tum e 206.mg P<.6 35.8mg n.s.s.	19/35	22/36			
PHENOL 108-95-2					
4954 M f b6c wat 24m24 TR203 :	0	491.mg	981.mg		
TBA MXB no dre P=1. - 1.71gm n.s.s.	27/50	21/50	21/50		
liv MXB no dre P=1. 7.62gm n.s.s.	3/50	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB 18.5gm * P<.6 3.60gm n.s.s.	1/50	3/50	2/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
4955 M m b6c wat 24m24 TR203 :				0	409.mg	818.mg		
TBA MXB	no dre	P=1.	- 1.48gm n.s.s.	30/50	28/50	25/50		
liv MXB	2.45gm \	P<.5	523.mg n.s.s.	14/50	19/50	(9/50)		liv:hpa,hpc,nnd.
lun MXB	8.29gm *	P<.5	1.91gm n.s.s.	6/50	5/50	10/50		lun:a/a,a/c.
4956 R f f34 wat 24m24 TR203 :				0	140.mg	280.mg		
TBA MXB	no dre	P=1.	- 257.mg n.s.s.	45/50	45/50	38/50		
liv MXB	no dre	P=1.	866.mg n.s.s.	4/50	1/50	(0/50)		liv:hpa,hpc,nnd.
4957 R m f34 wat 24m24 TR203 :				0	123.mg	245.mg		
thy ccr #	420.mg \	P<.007	- 158.mg 5.60gm	0/50	5/50	(1/50)		S
--- MXA	133.mg \	P<.03	57.0mg n.s.s.	18/50	31/50	(25/50)		---:leu,lym. S
--- mle	143.mg \	P<.04	59.1mg n.s.s.	18/50	30/50	(24/50)		S
--- leu	143.mg \	P<.04	59.1mg n.s.s.	18/50	30/50	(25/50)		S
TBA MXB	no dre	P=1.	189.mg n.s.s.	40/50	44/50	38/50		
liv MXB	no dre	P=1.	716.mg n.s.s.	5/50	4/50	4/50		liv:hpa,hpc,nnd.
PHENOLPHTHALEIN 77-09-8								
4958 M f b6c eat 24m24 TR465 :				0	388.mg	777.mg	1.55gm	
MXB MXB	508.mg Z	P<.0005	296.mg 1.53gm	15/50	33/50	40/50	(36/50)	---:hcs,lmt,mly; ova:sxb,sxs. C
--- mly	748.mg Z	P<.003 c	394.mg 4.88gm	15/50	28/50	33/50	(25/50)	
--- lmt	1.61gm Z	P<.003 c	859.mg 8.28gm	1/50	9/50	10/50	(7/50)	
ova MXA	1.90gm Z	P<.003 c	1.00gm 8.68gm	0/50	7/50	6/50	(5/50)	ova:sxb,sxs.
--- hcs	4.08gm *	P<.0005 c	2.27gm 11.7gm	0/50	2/50	7/50	7/50	
TBA MXB	1.74gm *	P<.2	642.mg n.s.s.	40/50	39/50	47/50	43/50	
liv MXB	no dre	P=1.	3.96gm n.s.s.	21/50	3/50	6/50	(2/50)	liv:hpa,hpb,hpc.
lun MXB	9.19gm *	P<.3	2.56gm n.s.s.	6/50	5/50	6/50	8/50	lun:a/a,a/c.
4959 M m b6c eat 24m24 TR465 :				0	359.mg	719.mg	1.44gm	
--- MXB	1.15gm Z	P<.0005	689.mg 2.53gm	1/50	7/50	18/50	(12/50)	---:hcs,lmt. C
spl hes	1.64gm Z	P<.006	621.mg 16.2gm	0/50	5/50	(1/50	1/50)	S
--- hcs	2.68gm *	P<.0005 c	1.57gm 7.81gm	1/50	3/50	11/50	12/50	
--- lmt	2.74gm Z	P<.002 c	1.37gm 11.1gm	0/50	4/50	7/50	(2/50)	
TBA MXB	32.2gm *	P<1.	1.07gm n.s.s.	40/50	40/50	42/50	38/50	
liv MXB	no dre	P=1.	3.89gm n.s.s.	27/50	20/50	11/50	16/50	liv:hpa,hpb,hpc.
lun MXB	8.06gm *	P<.4	1.88gm n.s.s.	11/50	15/50	8/50	16/50	lun:a/a,a/c.
4960 M m bal eat 14m24 2498m				0	2.25gm			O'Gara;canr,28,2272-2275;1968
liv hpt	20.8gm	P<.2	- 3.38gm n.s.s.	0/33	1/14			
lun tum	no dre	P=1.	- 2.89gm n.s.s.	9/33	3/14			
4961 M m c56 gav 16m24 2498n				0	637.mg			
liv hpt	no dre	P=1.	- 1.97gm n.s.s.	2/26	0/15			
lun tum	no dre	P=1.	- 1.97gm n.s.s.	0/26	0/15			
4962 R f f34 eat 24m24 TR465 :				0	599.mg	1.25gm	2.50gm	
amd MXA	3.53gm Z	P<.08 p	1.47gm n.s.s.	3/50	12/50	10/50	(2/50)	amd:pbb,phm,pob.
amd MXA	4.16gm Z	P<.2 p	1.60gm n.s.s.	3/50	11/50	9/50	(2/50)	amd:pbb,pob.
TBA MXB	no dre	P=1.	1.91gm n.s.s.	49/50	50/50	50/50	49/50	
liv MXB	no dre	P=1.	9.90gm n.s.s.	0/50	3/50	1/50	1/50	liv:hpa,hpb,hpc.
4963 R m f34 eat 24m24 TR465 :				0	480.mg	999.mg	2.00gm	
MXB MXB	250.mg Z	P<.003	123.mg 1.42gm	17/50	35/50	(34/50	35/50)	amd:pbb,pob; kid:rua,ruc. C
amd MXA	517.mg Z	P<.006 c	257.mg 5.97gm	17/50	34/50	34/50	(34/50)	amd:pbb,pob.
amd MXA	533.mg Z	P<.007	261.mg 8.35gm	18/50	35/50	35/50	(35/50)	amd:pbb,phm,pmb,pob. S
kid MXA	3.22gm *	P<.005 c	1.68gm 35.5gm	0/50	5/50	3/50	7/50	kid:rua,ruc.
kid rua	4.05gm *	P<.009 c	1.97gm 134.gm	0/50	4/50	2/50	6/50	
thy MXA	6.99gm *	P<.03	2.74gm n.s.s.	0/50	1/50	2/50	3/50	thy:fab,fca. S
TBA MXB	3.54gm *	P<.5	703.mg n.s.s.	47/50	47/50	47/50	47/50	
liv MXB	118.gm *	P<.9	5.67gm n.s.s.	1/50	3/50	0/50	2/50	liv:hpa,hpb,hpc.
4964 R m f34 eat 24m24 TR465 : with step				0	480.mg	999.mg	2.00gm	
kid MXA	975.mg *	P<.0005 c	609.mg 2.29gm	1/50	10/50	16/50	16/50	kid:rua,ruc.
kid rua	1.04gm *	P<.0005 c	641.mg 2.65gm	1/50	10/50	15/50	15/50	
PHENOTHIAZINE 92-84-2								
4965 M f b6a orl 76w76 1254				0	78.4mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- 87.3mg n.s.s.	1/17	1/17			
liv hpt evx	no dre	P=1.	- 147.mg n.s.s.	0/17	0/17			
tba mix evx	no dre	P=1.	- 68.9mg n.s.s.	2/17	2/17			
4966 M m b6a orl 76w76 1254				0	73.0mg			
liv hpt evx	393.mg	P<.6	- 57.3mg n.s.s.	1/18	2/17			
lun ade evx	no dre	P=1.	- 89.8mg n.s.s.	2/18	1/17			
tba mix evx	311.mg	P<.7	- 41.9mg n.s.s.	3/18	4/17			
4967 M f b6c orl 76w76 1254				0	78.4mg			
liv hpt evx	no dre	P=1.	- 155.mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	- 155.mg n.s.s.	0/16	0/18			
tba tum evx	no dre	P=1.	- 155.mg n.s.s.	0/16	0/18			
4968 M m b6c orl 76w76 1254				0	73.0mg			
liv hpt evx	414.mg	P<.3	- 67.4mg n.s.s.	0/16	1/16			
lun mix evx	no dre	P=1.	- 129.mg n.s.s.	0/16	0/16			
tba mix evx	200.mg	P<.09	- 49.1mg n.s.s.	0/16	2/16			
PHENOXYBENZAMINE.HCl 63-92-3								
4969 M f b6c ipj 52w84 TR72 :				0	3.30mg	10.3mg		
abc srn s	5.85mg /	P<.0005 c	3.11mg 12.0mg	0/15	0/35	16/35		
TBA MXB s	3.08mg /	P<.0005	1.59mg 8.85mg	5/15	7/35	16/35		
liv MXB s	no dre	P=1.	7.21mg n.s.s.	1/15	1/35	0/35		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.	7.21mg n.s.s.	1/15	1/35	0/35		lun:a/a,a/c.
4970 M m b6c ipj 51w83 TR72 :				0	3.40mg	10.7mg		
abc srn as	4.95mg /	P<.0005 c	2.63mg 9.91mg	0/15	0/35	17/35		
TBA MXB as	2.17mg /	P<.0005	1.17mg 4.88mg	3/15	7/35	18/35		
liv MXB as	5.84mg *	P<.2	1.98mg n.s.s.	1/15	6/35	0/35		liv:hpa,hpc,nnd.
lun MXB as	63.0mg *	P<.9	3.24mg n.s.s.	2/15	3/35	0/35		lun:a/a,a/c.
4971 R f sda ipj 52w83 TR72 :				0	1.30mg	2.70mg		
per srn	2.36mg /	P<.0005 c	1.30mg 5.16mg	0/10	0/35	16/35		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TBA MXB		1.34mg *	P<.05	.610mg n.s.s.	5/10	20/35	20/35		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
4972 R m sda ipj 52w83 TR72 :					0	1.30mg	3.80mg		
per srn s		.710mg /	P<.0005 c	.403mg 1.31mg	0/10	11/35	16/35		
TBA MXB s		.555mg /	P<.0005	.303mg 1.35mg	3/10	15/35	16/35		
liv MXB s		no dre	P=1.	n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
1-PHENYL-3,3-DIMETHYLTRIAZENE 7227-91-0									
4973 R b bdr gav 24m24 1467					0	3.57mg	7.14mg		Preussmann;zkko,81,285-310;1974
bra mix		5.81mg *	P<.0005 +	2.65mg 16.1mg	0/120	1/7	8/12		
tba mal		2.31mg *	P<.0005 +	1.10mg 5.34mg	2/120	4/7	11/12		
PHENYL ISOTHIOCYANATE 103-72-0									
4974 M f b6a orl 76w76 1304					0	21.6mg			Innes;ntis,1968/1969
liv hem evx		138.mg	P<.3	- 22.5mg n.s.s.	0/17	1/18			
lun ade evx		no dre	P=1.	- 25.6mg n.s.s.	1/17	1/18			
tba mix evx		39.4mg	P<.3	- 10.3mg n.s.s.	2/17	5/18			
4975 M m b6a orl 76w76 1304					0	20.0mg			
lun ade evx		no dre	P=1.	- 21.4mg n.s.s.	2/18	1/15			
liv hpt evx		no dre	P=1.	- 33.1mg n.s.s.	1/18	0/15			
tba mix evx		no dre	P=1.	- 22.9mg n.s.s.	3/18	1/15			
4976 M f b6c orl 76w76 1304					0	21.6mg			
liv hpt evx		no dre	P=1.	- 42.7mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1.	- 42.7mg n.s.s.	0/16	0/18			
tba tum evx		no dre	P=1.	- 42.7mg n.s.s.	0/16	0/18			
4977 M m b6c orl 76w76 1304					0	20.0mg			
liv hpt evx		128.mg	P<.3	- 20.9mg n.s.s.	0/16	1/18			
lun ade evx		128.mg	P<.3	- 20.9mg n.s.s.	0/16	1/18			
tba mix evx		40.2mg	P<.05	- 12.1mg n.s.s.	0/16	3/18			
1-PHENYL-3-METHYL-5-PYRAZOLONE 89-25-8									
4978 M f b6c eat 24m24 TR141 :					0	956.mg	1.91gm		
TBA MXB		no dre	P=1.	- 2.85gm n.s.s.	9/20	19/50	15/50		
liv MXB		no dre	P=1.	14.2gm n.s.s.	2/20	2/50	0/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	8.43gm n.s.s.	1/20	3/50	1/50		lun:a/a,a/c.
4979 M m b6c eat 24m24 TR141 :					0	883.mg	1.77gm		
TBA MXB		no dre	P=1.	- 1.38gm n.s.s.	11/20	20/50	(14/50)		
liv MXB		no dre	P=1.	2.85gm n.s.s.	8/20	8/50	(6/50)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.62gm n.s.s.	3/20	3/50	(0/50)		lun:a/a,a/c.
4980 R f f34 eat 24m24 TR141 :					0	123.mg	245.mg		
TBA MXB		no dre	P=1.	- 115.mg n.s.s.	12/20	36/50	(25/50)		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
4981 R m f34 eat 24m24 TR141 :					0	98.1mg	196.mg		
TBA MXB		no dre	P=1.	- 192.mg n.s.s.	14/20	32/49	31/50		
liv MXB		3.70gm *	P<.5	907.mg n.s.s.	0/20	1/49	1/50		liv:hpa,hpc,nnd.
PHENYL-beta-NAPHTHYLAMINE (agerite powder, N-phenyl-2-naphthylamine) 135-88-6									
4982 H f syg gav 84w84 1151					0	37.5mg			Green;zkko,95,51-55;1979
liv tum e		no dre	P=1.	202.mg n.s.s.	0/40	0/40			
lun tum e		no dre	P=1.	202.mg n.s.s.	0/40	0/40			
tba mix e		no dre	P=1.	- 72.3mg n.s.s.	8/40	6/40			
4983 H m syg gav 84w84 1151					0	37.5mg			
liv tum e		no dre	P=1.	202.mg n.s.s.	0/40	0/40			
lun tum e		no dre	P=1.	202.mg n.s.s.	0/40	0/40			
tba mix e		no dre	P=1.	- 84.5mg n.s.s.	3/40	3/40			
4984 M f b6c eat 24m24 TR333 :					0	322.mg	644.mg		
kid MXA		10.8gm *	P<.1	e 2.66gm n.s.s.	0/50	0/50	2/50		kid:tla,uac.
TBA MXB		no dre	P=1.	830.mg n.s.s.	42/50	23/50	33/50		
liv MXB		5.63gm *	P<.4	1.41gm n.s.s.	4/50	3/50	7/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.31gm n.s.s.	5/50	1/50	3/50		lun:a/a,a/c.
4985 M f b6c orl 76w76 1153					0	169.mg			Innes;ntis,1968/1969
liv hpt evx		1.08gm	P<.3	176.mg n.s.s.	0/16	1/18			
lun mix evx		no dre	P=1.	334.mg n.s.s.	0/16	0/18			
tba mix evx		1.08gm	P<.3	176.mg n.s.s.	0/16	1/18			
4986 M m b6c eat 24m24 TR333 :					0	297.mg	594.mg		
sub MXA #		2.38gm *	P<.04	- 992.mg n.s.s.	2/50	4/50	8/50		sub:fbs,nfs,srn. S
TBA MXB		4.51gm *	P<.8	437.mg n.s.s.	34/50	30/50	32/50		
liv MXB		1.35gm *	P<.2	487.mg n.s.s.	11/50	16/50	17/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	1.36gm n.s.s.	11/50	9/50	7/50		lun:a/a,a/c.
4987 M m b6c orl 76w76 1153					0	157.mg			Innes;ntis,1968/1969
liv hpt evx		165.mg	P<.007	62.2mg 2.23gm	0/16	5/17			
lun mix evx		no dre	P=1.	294.mg n.s.s.	0/16	0/17			
tba mix evx		108.mg	P<.002	46.1mg 417.mg	0/16	7/17			
4988 M f b6a orl 76w76 1153					0	169.mg			
lun ade evx		no dre	P=1.	201.mg n.s.s.	1/17	1/18			
liv hpt evx		no dre	P=1.	334.mg n.s.s.	0/17	0/18			
tba mix evx		1.08gm	P<.7	121.mg n.s.s.	2/17	3/18			
4989 M m b6a orl 76w76 1153					0	157.mg			
lun ade evx		431.mg	P<.4	90.1mg n.s.s.	2/18	4/18			
liv hpt evx		460.mg	P<.3	103.mg n.s.s.	1/18	3/18			
tba mix evx		186.mg	P<.2	57.2mg n.s.s.	3/18	7/18			
4990 R f f34 eat 24m24 TR333 :					0	124.mg	248.mg		
TBA MXB		no dre	P=1.	- 175.mg n.s.s.	46/50	38/50	(33/50)		
liv MXB		no dre	P=1.	3.10gm n.s.s.	2/50	0/50	0/50		liv:hpa,hpc,nnd.
4991 R m f34 eat 24m24 TR333 :					0	99.0mg	198.mg		
TBA MXB		no dre	P=1.	- 108.mg n.s.s.	48/50	40/50	(42/50)		
liv MXB		no dre	P=1.	1.11gm n.s.s.	2/50	3/50	0/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

```
4992 R f sda gav 32m32 1524                                0     171.mg                                  Ketkar;clet,16,203-206;1982
 liv tum e       no dre    P=1.       2.42gm n.s.s.   0/40    0/40
 tba mix e       no dre    P=1.    -  2.00gm n.s.s.  30/40    3/40
4993 R m sda gav 37m37 1524                                0     171.mg
 liv tum e       no dre    P=1.       3.34gm n.s.s.   0/40    0/40
 tba mix e       no dre    P=1.    -  1.80gm n.s.s.  24/40    8/40

N-PHENYL-p-PHENYLENEDIAMINE.HCl   2198-59-6
4994 M f b6c eat 48w91 TR82 :                              0     252.mg  478.mg
 TBA MXB sv      no dre    P=1.    -  648.mg n.s.s.   5/20    4/50   (2/50)
 liv MXB sv      no dre    P=1.       1.53gm n.s.s.   1/20    2/50    1/50                           liv:hpa,hpc,nnd.
 lun MXB sv      no dre    P=1.       n.s.s. n.s.s.   0/20    0/50    0/50                               lun:a/a,a/c.
4995 M m b6c eat 48w91 TR82 :                              0     131.mg  260.mg
 TBA MXB sv      no dre    P=1.    -  404.mg n.s.s.  10/20   25/49   15/50
 liv MXB sv      213.mg \  P<.06      96.5mg n.s.s.   2/20   18/49  (10/50)                           liv:hpa,hpc,nnd.
 lun MXB sv      no dre    P=1.       818.mg n.s.s.   4/20    4/49    5/50                               lun:a/a,a/c.
4996 R f f34 eat 18m24 TR82 :                              0    22.5mg  45.0mg
 TBA MXB         no dre    P=1.    -  68.6mg n.s.s.  13/20   26/50   24/50
 liv MXB         no dre    P=1.       n.s.s. n.s.s.   0/20    0/50    0/50                           liv:hpa,hpc,nnd.
4997 R m f34 eat 18m24 TR82 :                              0    18.0mg  36.0mg
 TBA MXB         161.mg *  P<.5    -  40.5mg n.s.s.   6/20   17/50   20/50
 liv MXB         no dre    P=1.       n.s.s. n.s.s.   0/20    0/50    0/50                           liv:hpa,hpc,nnd.

2-PHENYL-1,3-PROPANEDIOL DICARBAMATE  (Felbamate) 25451-15-4
4998 M f cd1 eat 92w92 2569                                0     100.mg  600.mg  1.20gm          McGee;faat,45,146-151;1998/pers.comm.
 liv mix e       10.2gm Z  P<.06      3.55gm n.s.s.   7/120   1/60    0/60    9/60
 liv hpa e       10.4gm Z  P<.02  +   3.92gm n.s.s.   3/120   0/60    0/60    7/60
 liv hpc e       no dre    P=1.       9.25gm n.s.s.   4/120   1/60    0/60    2/60
4999 M m cd1 eat 92w92 2569                                0     100.mg  600.mg  1.20gm
 liv hpa e       5.77gm *  P<.06  +   2.16gm n.s.s.   9/120   7/60    9/60   10/59
 liv hpc e       no dre    P=1.       9.11gm n.s.s.  18/120   9/60    7/60    2/59
 liv mix e       no dre    P=1.       3.05gm n.s.s.  27/120  16/60   16/60   12/59
5000 R f cdr eat 24m24 2569                                0    10.0mg  30.0mg  100.mg
 liv hpa e       934.mg *  P<.005 +   355.mg 10.1gm   0/100   0/50    2/50    3/50
 liv hpc e       no dre    P=1.       71.9mg n.s.s.   0/100   0/50    0/50    0/50
5001 R f cdr eat 52w52 2570                                0    30.0mg  150.mg  300.mg          McGee;faat,45,225-232;1998/pers.comm.
 liv tum er      no dre    P=1.    -  28.7mg n.s.s.   0/24    0/24    0/25    0/24
5002 R m cdr eat 24m24 2569                                0    30.0mg  100.mg  300.mg          McGee;faat,45,146-151;1998/pers.comm.
 tes ict e       1.31gm *  P<.0005 +  623.mg 4.72gm   1/100   2/50    1/50    9/50
 liv mix e       9.78gm *  P<.5       1.49gm n.s.s.   4/100   1/50    1/50    3/50
5003 R m cdr eat 52w52 2570                                0    30.0mg  150.mg  600.mg          McGee;faat,45,225-232;1998/pers.comm.
 liv tum er      no dre    P=1.    -  28.9mg n.s.s.   0/23    0/23    0/25    0/25

(E)-7-PHENYL-7-(3-PYRIDYL)-6-HEPTENOIC ACID  (CV-4151, isbogrel) 89667-40-3
5004 M f cd1 eat 24m24 2438                                0     300.mg                        Chatani;jjpt,23,1205-1223;1995/pers.comm.
 liv hpa e       4.93gm    P<.3     -  1.09gm n.s.s.   1/50    3/50
 lun a/a e       no dre    P=1.     -  722.mg n.s.s.  15/50   13/50
 lun a/c e       no dre    P=1.     -  1.88gm n.s.s.   1/50    1/50
 tba mix e       no dre    P=1.     -  410.mg n.s.s.  36/50   31/50
5005 M m cd1 eat 24m24 2438                                0     300.mg
 lun a/a e       1.22gm    P<.06    -  460.mg n.s.s.   5/50   12/50
 liv hpa e       2.05gm    P<.4     -  527.mg n.s.s.   8/50   12/50
 liv hpc e       10.2gm    P<.3     -  1.66gm n.s.s.   0/50    1/50
 lun a/c e       no dre    P=1.     -  1.52gm n.s.s.   2/50    2/50
 tba mix e       1.09gm    P<.4     -  288.mg n.s.s.  21/50   26/50
5006 R f cdr eat 24m24 2437                                0     100.mg                        Chatani;jjpt,23,1225-1238;1995/pers.comm.
 liv hpa e       no dre    P=1.     -  1.03gm n.s.s.   0/50    0/50
5007 R m cdr eat 24m24 2437                                0     100.mg
 liv hpa e       no dre    P=1.     -  1.03gm n.s.s.   3/50    0/50

1-PHENYL-2-THIOUREA   103-85-5
5008 M f b6c eat 78w91 TR148 :                             0    16.9mg  33.8mg
 TBA MXB         133.mg *  P<.4     -  35.3mg n.s.s.   4/20   11/50   15/50
 liv MXB         268.mg *  P<.06      92.7mg n.s.s.   0/20    0/50    4/50                           liv:hpa,hpc,nnd.
 lun MXB         134.mg *  P<.07      60.5mg n.s.s.   0/20    3/50    5/50                               lun:a/a,a/c.
5009 M m b6c eat 78w91 TR148 :                             0    15.6mg  31.2mg
 TBA MXB         no dre    P=1.     -  49.0mg n.s.s.   6/20   16/50   12/50
 liv MXB         no dre    P=1.       74.6mg n.s.s.   1/20    7/50    3/50                           liv:hpa,hpc,nnd.
 lun MXB         no dre    P=1.       73.7mg n.s.s.   3/20    6/50    6/50                               lun:a/a,a/c.
5010 R f f34 eat 18m24 TR148 :                             0    2.30mg  4.50mg
 TBA MXB         no dre    P=1.     -  2.46mg n.s.s.  12/20   37/50  (30/50)
 liv MXB         no dre    P=1.       n.s.s. n.s.s.   0/20    0/50    0/50                           liv:hpa,hpc,nnd.
5011 R m f34 eat 18m24 TR148 :                             0    1.80mg  3.60mg
 TBA MXB         no dre    P=1.     -  2.71mg n.s.s.   7/20   22/50  (22/50)
 liv MXB         no dre    P=1.       17.3mg n.s.s.   0/20    2/50    1/50                           liv:hpa,hpc,nnd.

1-PHENYLAZO-2-NAPHTHOL  (C.I. solvent yellow 14) 842-07-9
5012 M f b6c eat 24m24 TR226 :                             0    63.8mg  128.mg
 --- lym #       128.mg \  P<.03    -  55.6mg n.s.s.   9/50   23/50  (17/50)                                                                  S
 TBA MXB         391.mg *  P<.4       96.1mg n.s.s.  28/50   34/50   36/50
 liv MXB         833.mg *  P<.2      279.mg n.s.s.   2/50    4/50    6/50                           liv:hpa,hpc,nnd.
 lun MXB         3.03gm *  P<.8       342.mg n.s.s.   3/50    6/50    4/50                               lun:a/a,a/c.
5013 M m b6c eat 24m24 TR226 :                             0    58.9mg  118.mg
 TBA MXB         154.mg *  P<.04    -  68.5mg n.s.s.  24/50   30/50   37/50
 liv MXB         587.mg *  P<.4       159.mg n.s.s.  15/50   11/50   19/50                           liv:hpa,hpc,nnd.
 lun MXB         1.08gm *  P<.5       250.mg n.s.s.   5/50    7/50    7/50                               lun:a/a,a/c.
5014 M f cba eat 12m24 1165                                0    64.9mg                        Clayson;bjca,19,297-310;1965/Williams 1962
 liv hpt         no dre    P=1.     -  348.mg n.s.s.   0/18    0/26
```

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
5015 M m cba eat 12m24 1165					0	59.9mg			
liv hpt		no dre	P=1.	- 150.mg n.s.s.	2/15	1/18			
5016 R f f34 eat 24m24 TR226 :					0	12.4mg	24.8mg		
liv MXA		86.5mg	* P<.01	c 40.2mg 4.20gm	2/50	3/49	11/50		liv:hpc,nnd.
liv nnd		96.6mg	* P<.02	c 43.2mg n.s.s.	2/50	3/49	10/50		
sub fib		346.mg	* P<.05	104.mg n.s.s.	0/50	0/49	3/50		S
TBA MXB		no dre	P=1.	24.4mg n.s.s.	44/50	41/49	38/50		
liv MXB		86.5mg	* P<.01	40.2mg 4.20gm	2/50	3/49	11/50		liv:hpa,hpc,nnd.
5017 R m f34 eat 24m24 TR226 :					0	9.90mg	19.8mg		
liv nnd		17.7mg	/ P<.0005	c 10.4mg 50.0mg	5/50	10/50	30/50		
liv MXA		17.9mg	/ P<.0005	c 10.3mg 55.3mg	6/50	10/50	31/50		liv:hpc,nnd.
TBA MXB		106.mg	* P<.8	13.5mg n.s.s.	36/50	33/50	45/50		
liv MXB		17.9mg	/ P<.0005	10.3mg 55.3mg	6/50	10/50	31/50		liv:hpa,hpc,nnd.
PHENYLBUTAZONE 50-33-9									
5018 M f b6c gav 24m24 TR367 :					0	105.mg	210.mg		
TBA MXB		no dre	P=1.	- 323.mg n.s.s.	31/50	20/50	25/50		
liv MXB		6.01gm	* P<.9	405.mg n.s.s.	5/50	5/50	7/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	704.mg n.s.s.	3/50	3/50	3/50		lun:a/a,a/c.
5019 M m b6c gav 24m24 TR367 :					0	105.mg	210.mg		
liv hpa		323.mg	* P<.007	160.mg 4.75gm	8/50	12/50	23/50		S
liv MXA		353.mg	/ P<.03	p 157.mg n.s.s.	16/50	14/50	31/50		liv:hpa,hpc.
TBA MXB		434.mg	* P<.3	136.mg n.s.s.	30/50	28/50	40/50		
liv MXB		353.mg	/ P<.03	157.mg n.s.s.	16/50	14/50	31/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	616.mg n.s.s.	6/50	6/50	5/50		lun:a/a,a/c.
5020 R f f34 gav 24m24 TR367 :					0	34.9mg	69.7mg		
kid tcc h		1.16gm	* P<.09	p 276.mg n.s.s.	0/50	0/50	2/50		
TBA MXB		1.58gm	* P<1.	40.3mg n.s.s.	46/50	46/50	36/50		
liv MXB		no dre	P=1.	339.mg n.s.s.	1/50	2/50	0/50		liv:hpa,hpc,nnd.
5021 R m f34 gav 24m24 TR367 :					0	35.0mg	70.1mg		
kid MXA		458.mg	* P<.04	e 158.mg n.s.s.	0/50	1/50	3/50		kid:rab,rua,ruc.
kid MXA		621.mg	* P<.04	187.mg n.s.s.	0/50	0/50	3/50		kid:rab,rua. S
TBA MXB		121.mg	* P<.4	31.1mg n.s.s.	41/50	42/50	44/50		
liv MXB		1.09gm	* P<.3	261.mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
5022 R m f34 gav 24m24 TR367 with step					0	35.0mg	70.1mg		
kid MXA		382.mg	* P<.02	e 180.mg n.s.s.	0/50	5/50	4/50		kid:rab,rua,ruc.
5023 R f don eat 24m26 1815					0	59.1mg	118.mg		Maekawa;jnci,79,577-584;1987/pers.comm.
adr phe e		707.mg	* P<.03	- 283.mg n.s.s.	4/96	6/50	6/42		
liv nnd e		1.14gm	* P<.06	- 396.mg n.s.s.	2/96	3/50	4/42		
kid tum e		no dre	P=1.	- 427.mg n.s.s.	0/96	0/50	0/42		
tba mix e		no dre	P=1.	- 151.mg n.s.s.	85/96	43/50	32/42		
5024 R m don eat 24m26 1815					0	47.3mg	95.4mg		
kid tum e		no dre	P=1.	- 335.mg n.s.s.	0/93	0/47	0/44		
liv hpc e		no dre	P=1.	- 335.mg n.s.s.	1/93	0/47	0/44		
liv nnd e		no dre	P=1.	- 778.mg n.s.s.	4/93	0/47	2/44		
tba mix e		no dre	P=1.	- 159.mg n.s.s.	69/93	36/47	27/44		
m-PHENYLENEDIAMINE 108-45-2									
5025 M f b6c wat 78w84 1888					0	37.1mg	74.3mg		Amo;fctx,26,893-897;1988
liv hem e		916.mg	* P<.2	- 277.mg n.s.s.	0/50	1/50	2/59		
liv hct e		no dre	P=1.	- 175.mg n.s.s.	3/50	0/50	0/59		
liv hnd e		no dre	P=1.	- 175.mg n.s.s.	0/50	0/50	0/59		
lun ade e		no dre	P=1.	- 406.mg n.s.s.	4/50	2/50	2/59		
5026 M m b6c wat 78w84 1888					0	31.0mg	61.9mg		
liv hem e		2.73gm	* P<.9	- 165.mg n.s.s.	4/50	4/50	5/56		
liv hct e		no dre	P=1.	- 112.mg n.s.s.	20/50	7/50	(3/56)		
liv hnd e		no dre	P=1.	- 98.2mg n.s.s.	7/50	4/50	(1/56)		
lun ade e		no dre	P=1.	- 123.mg n.s.s.	8/50	3/50	(1/56)		
p-PHENYLENEDIAMINE 106-50-3									
5027 R f f34 eat 80w80 1542					0	25.0mg	50.0mg		Imaida;txlt,16,259-269;1983
adr phe e		4.28gm	* P<1.	- 146.mg n.s.s.	1/21	1/37	2/42		
liv tum e		no dre	P=1.	78.3mg n.s.s.	0/21	0/37	0/42		
5028 R m f34 eat 80w80 1542					0	20.0mg	40.0mg		
adr phe e		no dre	P=1.	- 42.8mg n.s.s.	6/19	8/35	10/36		
liv tum e		no dre	P=1.	57.4mg n.s.s.	0/19	0/35	0/36		
m-PHENYLENEDIAMINE.2HCl 541-69-5									
5029 M f chi eat 64w77 381 :					0	260.mg	520.mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
lun mix a		253.mg	* P<.03	- 87.6mg n.s.s.	3/13	4/13	6/16		
liv mix a		1.17gm	* P<.3	- 190.mg n.s.s.	0/13	1/13	0/16		
tba mix a		370.mg	* P<.3	- 93.9mg n.s.s.	9/13	5/13	1/16		
5030 M m chi eat 64w77 381 :					0	240.mg	480.mg		
lun mix a		421.mg	* P<.08	- 104.mg n.s.s.	2/16	2/15	0/10		
liv mix a		889.mg	* P<.3	- 145.mg n.s.s.	2/16	1/15	0/10		
tba mix a		307.mg	* P<.3	- 77.9mg n.s.s.	9/16	5/15	0/10		
5031 R m cdr eat 18m25 381 :					0	30.0mg	60.0mg		
liv mix		1.69gm	* P<.9	- 87.6mg n.s.s.	1/17	1/17	1/15		
tba mix		114.mg	* P<.3	- 31.5mg n.s.s.	13/17	7/17	6/15		
o-PHENYLENEDIAMINE.2HCl 615-28-1									
5032 M f chi eat 77w90 381 :					0	806.mg	1.70gm		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv mix v		507.mg	* P<.002	236.mg 1.83gm	1/15	7/18	6/15		
liv hpt v		611.mg	* P<.002	+ 276.mg 2.46gm	1/15	6/18	6/15		
lun mix v		2.26gm	* P<.3	- 522.mg n.s.s.	5/15	3/18	4/15		
tba mix v		676.mg	* P<.07	233.mg n.s.s.	10/15	13/18	10/15		
5033 M f chi eat 77w90 381 : pool					0	806.mg	1.70gm		
liv hpt v		611.mg	* P<.0005	+ 276.mg 1.49gm	1/102	6/18	6/15		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
5034 M m chi eat 77w86 381 :					0	783.mg	1.57gm		
liv hpt v		921.mg	* P<.04	+ 406.mg n.s.s.	0/14	5/17	3/14		
liv mix v		921.mg	* P<.04	+ 406.mg n.s.s.	1/14	5/17	3/14		
lun mix v		3.21gm	* P<.6	- 643.mg n.s.s.	3/14	4/17	2/14		
tba mix v		1.97gm	* P<.5	381.mg n.s.s.	7/14	10/17	6/14		
5035 M m chi eat 77w86 381 : pool					0	783.mg	1.57gm		
liv hpt v		1.11gm	* P<.0005	+ 456.mg 4.81gm	7/99	5/17	3/14		
5036 R m cdr eat 18m25 381 :					0	57.6mg	115.mg		
liv hpt		248.mg	* P<.02	+ 92.5mg n.s.s.	0/16	0/14	5/16		
liv mix		248.mg	* P<.02	+ 92.5mg n.s.s.	0/16	0/14	5/16		
tba mix		no dre	P=1.	67.7mg n.s.s.	10/16	9/14	12/16		
5037 R m cdr eat 18m25 381 : pool					0	57.6mg	115.mg		
liv hpt		315.mg	* P<.02	+ 105.mg n.s.s.	2/111	0/14	5/16		
p-PHENYLENEDIAMINE.2HCl 624-18-0									
5038 M f b6c eat 24m24 TR174 :					0	80.5mg	161.mg		
TBA MXB		1.50gm	* P<.8	- 198.mg n.s.s.	8/20	17/50	21/49		
liv MXB		1.37gm	* P<.5	325.mg n.s.s.	2/20	6/50	8/49		liv:hpa,hpc,nnd.
lun MXB		1.39gm	* P<.2	527.mg n.s.s.	0/20	2/50	3/49		lun:a/a,a/c.
5039 M m b6c eat 24m24 TR174 :					0	74.3mg	149.mg		
TBA MXB		no dre	P=1.	- 167.mg n.s.s.	15/20	35/50	31/50		
liv MXB		no dre	P=1.	193.mg n.s.s.	9/20	18/50	21/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	346.mg n.s.s.	4/20	10/50	8/50		lun:a/a,a/c.
5040 R f f34 eat 24m27 TR174 :					0	30.6mg	61.3mg		
TBA MXB		247.mg	* P<.6	- 44.0mg n.s.s.	10/20	37/50	36/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
5041 R m f34 eat 24m27 TR174 :					0	24.5mg	49.0mg		
TBA MXB		no dre	P=1.	- 65.7mg n.s.s.	14/20	34/50	29/50		
liv MXB		2.23gm	* P<.4	364.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
PHENYLEPHRINE.HCl 61-76-7									
5042 M f b6c eat 24m24 TR322 :					0	161.mg	322.mg		
TBA MXB		911.mg	* P<.4	- 236.mg n.s.s.	22/50	31/50	27/50		
liv MXB		7.85gm	* P<.7	1.01gm n.s.s.	3/50	2/50	4/50		liv:hpa,hpc,nnd.
lun MXB		1.61gm	* P<.2	579.mg n.s.s.	2/50	6/50	6/50		lun:a/a,a/c.
5043 M m b6c eat 24m24 TR322 :					0	149.mg	297.mg		
sub fbs #		1.64gm	* P<.04	- 744.mg n.s.s.	0/50	4/50	4/50		S
MXA mlm		1.72gm	* P<.02	742.mg n.s.s.	0/50	2/50	5/50		mul:mlm; spl:mlm. S
TBA MXB		6.33gm	* P<1.	274.mg n.s.s.	27/50	30/50	34/50		
liv MXB		4.27gm	* P<.8	409.mg n.s.s.	15/50	15/50	20/50		liv:hpa,hpc,nnd.
lun MXB		2.13gm	* P<.5	485.mg n.s.s.	6/50	11/50	11/50		lun:a/a,a/c.
5044 R f f34 eat 24m24 TR322 :					0	30.7mg	61.9mg		
TBA MXB		272.mg	* P<.7	- 37.9mg n.s.s.	44/50	45/50	42/50		
liv MXB		no dre	P=1.	714.mg n.s.s.	2/50	0/50	0/50		liv:hpa,hpc,nnd.
5045 R m f34 eat 24m24 TR322 :					0	24.6mg	49.5mg		
TBA MXB		no dre	P=1.	- 20.1mg n.s.s.	45/50	42/50	(29/50)		
liv MXB		no dre	P=1.	348.mg n.s.s.	5/50	1/50	2/50		liv:hpa,hpc,nnd.
PHENYLETHYL-3-METHYLCAFFEATE 71835-85-3									
5046 R m f34 eat 55w55 2413					0	30.0mg			Rao;canr,55,2310-2315;1995
col tum r		no dre	P=1.	- 20.7mg n.s.s.	0/12	0/12			
PHENYLETHYLHYDRAZINE SULFATE 156-51-4									
5047 M f swa wat 93w93 239					0	30.0mg			Toth;canr,36,917-921;1976/1974
blv mix e		14.6mg	P<.0005	+ 8.37mg 28.7mg	2/52	22/32			
sub ang e		19.9mg	P<.0005	11.2mg 39.6mg	0/52	18/32			
blv ang e		20.4mg	P<.0005	11.3mg 42.2mg	1/52	18/32			
mus ang e		21.7mg	P<.0005	12.1mg 44.1mg	0/52	17/32			
fat ang e		23.7mg	P<.0005	13.0mg 49.3mg	0/52	16/32			
lun ade e		25.8mg	P<.0005	14.2mg 65.5mg	18/95	28/49			
lun mix e		27.5mg	P<.0005	+ 14.7mg 80.1mg	21/95	28/49			
lun ang e		123.mg	P<.006	42.5mg 1.22gm	0/52	4/32			
liv mix e		278.mg	P<.4	56.2mg n.s.s.	2/52	3/32			
5048 M m swa wat 99w99 239					0	25.0mg			
lun ade e		30.0mg	P<.0005	- 14.5mg 113.mg	15/93	17/34			
lun mix e		33.1mg	P<.004	- 14.6mg 304.mg	23/93	18/34			
liv mix e		no dre	P=1.	- 136.mg n.s.s.	6/88	2/50			
PHENYLGLYCIDYL ETHER 122-60-1									
5049 R f cdr inh 24m24 1737					0	.460mg	5.52mg		Lee;ajpa,111,140-148;1983
nas epc r		90.2mg	* P<.005	+ 31.2mg 812.mg	0/90	0/90	4/90		
5050 R m cdr inh 24m24 1737					0	.322mg	3.86mg		
nas mix r		29.1mg	* P<.0005	+ 13.2mg 108.mg	1/90	0/90	9/90		
6-PHENYLHEXYL ISOTHIOCYANATE 133920-06-6									
5051 R m f34 eat 26m26 2287					0	8.76mg			Hecht;carc,17,2061-2067;1996
pae ana e		no dre	P=1.	- 14.3mg n.s.s.	3/16	3/17			
pni isa e		no dre	P=1.	- 21.3mg n.s.s.	1/16	1/17			
liv hpc e		no dre	P=1.	- 41.9mg n.s.s.	0/15	0/20			
liv hpa e		no dre	P=1.	- 41.9mg n.s.s.	1/15	0/20			
5052 R m f34 eat 55w55 2412					0	25.6mg			Rao;canr,55,4311-4318;1995
col tum r		no dre	P=1.	- 17.7mg n.s.s.	0/12	0/12			
PHENYLHYDRAZINE 100-63-0									
5053 M f swi gav 39w55 1095					0	5.91mg			Roe;natu,216,375-376;1967
lun tum v		no dre	P=1.	- 8.51mg n.s.s.	8/85	0/25			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
PHENYLHYDRAZINE.HCl 59-88-1									
5054 M f swa wat 26m26 1056				0	20.0mg				Toth;zkko,87,267-273;1976/1974
liv mix e	68.6mg	P<.0005	32.6mg 229.mg	2/90	11/49				
blv mix e	72.1mg	P<.0005 +	33.3mg 301.mg	3/90	11/49				
blv agm e	147.mg	P<.02	52.8mg n.s.s.	2/90	6/49				
blv ang e	165.mg	P<.02	58.0mg n.s.s.	1/90	5/49				
liv agm e	165.mg	P<.02	58.0mg n.s.s.	1/90	5/49				
liv ang e	165.mg	P<.02	58.0mg n.s.s.	1/90	5/49				
lun mix e	no dre	P=1. -	56.9mg n.s.s.	21/87	8/38				
5055 M m swa wat 26m26 1056				0	16.7mg				
blv mix e	70.6mg	P<.02 +	27.8mg n.s.s.	6/81	10/43				
liv mix e	83.9mg	P<.04	30.7mg n.s.s.	6/81	9/43				
lun mix e	no dre	P=1. -	94.2mg n.s.s.	23/87	5/43				
beta-PHENYLISOPROPYLHYDRAZINE.HCl 66-05-7									
5056 M f swa wat 28m30 1675				0	31.2mg	62.4mg			Toth;faat,2,173-176;1982/1980
liv hpt aes	no dre	P=1. -	23.0mg n.s.s.	1/15	0/4	0/3			
lun tum aes	no dre	P=1. -	145.mg n.s.s.	25/99	10/49	(2/45)			
5057 M m swa wat 23m26 1675				0	26.0mg	52.0mg			
liv hpt aes	no dre	P=1. -	65.2mg n.s.s.	0/99	0/42	0/7			
lun tum aes	no dre	P=1. -	143.mg n.s.s.	26/100	5/42	(0/7)			
PHENYLMERCURIC ACETATE 62-38-4									
5058 M f b6a orl 76w76 1286				0	3.39mg				Innes;ntis,1968/1969
liv hpt evx	no dre	P=1. -	6.34mg n.s.s.	0/17	0/17				
lun ade evx	no dre	P=1. -	6.34mg n.s.s.	1/17	0/17				
tba mix evx	no dre	P=1. -	6.34mg n.s.s.	2/17	0/17				
5059 M m b6a orl 76w76 1286				0	3.16mg				
lun ade evx	no dre	P=1. -	3.89mg n.s.s.	2/18	1/17				
liv hpt evx	no dre	P=1. -	5.91mg n.s.s.	1/18	0/17				
tba mix evx	no dre	P=1. -	3.04mg n.s.s.	3/18	2/17				
5060 M f b6c orl 76w76 1286				0	3.39mg				
liv hpt evx	21.7mg	P<.3 -	3.53mg n.s.s.	0/16	1/18				
lun ade evx	21.7mg	P<.3 -	3.53mg n.s.s.	0/16	1/18				
tba mix evx	10.5mg	P<.2 -	2.59mg n.s.s.	0/16	2/18				
5061 M m b6c orl 76w76 1286				0	3.16mg				
lun ade evx	9.24mg	P<.1 -	2.27mg n.s.s.	0/16	2/17				
liv hpt evx	no dre	P=1. -	5.91mg n.s.s.	0/16	0/17				
tba mix evx	9.24mg	P<.1 -	2.27mg n.s.s.	0/16	2/17				
o-PHENYLPHENOL (orthoxenol, Dowicide 1) 90-43-7									
5062 M f b6a orl 76w76 1310				0	38.9mg				Innes;ntis,1968/1969
liv hpt evx	no dre	P=1. -	64.2mg n.s.s.	0/17	0/15				
lun ade evx	no dre	P=1. -	64.2mg n.s.s.	1/17	0/15				
tba mix evx	no dre	P=1. -	41.7mg n.s.s.	2/17	1/15				
5063 M m b6a orl 76w76 1310				0	36.2mg				
liv hpt evx	1.80gm	P<1. -	n.s.s. n.s.s.	1/18	1/16				
lun ade evx	no dre	P=1. -	41.5mg n.s.s.	2/18	1/16				
tba mix evx	no dre	P=1. -	32.3mg n.s.s.	3/18	2/16				
5064 M f b6c orl 76w76 1310				0	38.9mg				
lun ade evx	221.mg	P<.3 -	35.9mg n.s.s.	0/16	1/16				
liv hpt evx	no dre	P=1. -	68.5mg n.s.s.	0/16	0/16				
tba mix evx	107.mg	P<.09 -	26.2mg n.s.s.	0/16	2/16				
5065 M m b6c orl 76w76 1310				0	36.2mg				
liv hpt evx	46.1mg	P<.02 -	15.8mg n.s.s.	0/16	4/16				
lun ade evx	205.mg	P<.3 -	33.4mg n.s.s.	0/16	1/16				
tba mix evx	35.4mg	P<.006 -	13.3mg 350.mg	0/16	5/16				
5066 M m b6c eat 52w52 2454				0	780.mg	1.56gm	3.12gm		Mikuriya;tmrl,40,281-288;1989/pers.comm.
liv hpa e	4.52gm *	P<.3 -	1.56gm n.s.s.	0/20	1/20	2/20	1/20		
kid tum e	no dre	P=1. -	459.mg n.s.s.	0/20	0/20	0/20	0/20		
lun ade e	no dre	P=1. -	459.mg n.s.s.	1/20	0/20	0/20	0/20		
5067 R m f3d eat 91w91 1646				0	250.mg	500.mg	1.00gm		Hiraga;fctx,22,865-870;1984
ubl mix ers	232.mg Z	P<.0005 +	137.mg 430.mg	0/24	0/20	23/24	(4/23)		
ubl tcc ers	296.mg Z	P<.0005 +	171.mg 568.mg	0/24	0/20	20/24	(2/23)		
ubl nvt ers	451.mg Z	P<.0005 +	245.mg 960.mg	0/24	0/20	15/24	(2/23)		
ubl ivt ers	1.65gm Z	P<.008 +	625.mg 26.3gm	0/24	0/20	5/24	(0/23)		
5068 R m f3d eat 24m24 1930				0	500.mg				Fukushima;carc,10,1635-1640;1989
ubl tum r	no dre	P=1. -	3.19gm n.s.s.	0/30	0/31				
p-PHENYLPHENOL (paraxenol) 92-69-3									
5069 M f b6a orl 76w76 1309				0	193.mg				Innes;ntis,1968/1969
lun ade evx	no dre	P=1. -	215.mg n.s.s.	1/17	1/17				
liv hpt evx	no dre	P=1. -	361.mg n.s.s.	0/17	0/17				
tba mix evx	no dre	P=1. -	170.mg n.s.s.	2/17	2/17				
5070 M m b6a orl 76w76 1309				0	180.mg				
liv hpt evx	no dre	P=1. -	212.mg n.s.s.	1/18	1/18				
lun ade evx	no dre	P=1. -	356.mg n.s.s.	2/18	0/18				
tba mix evx	953.mg	P<.7 -	112.mg n.s.s.	3/18	4/18				
5071 M f b6c orl 76w76 1309				0	193.mg				
liv hpt evx	no dre	P=1. -	361.mg n.s.s.	0/16	0/17				
lun mix evx	no dre	P=1. -	361.mg n.s.s.	0/16	0/17				
tba tum evx	no dre	P=1. -	361.mg n.s.s.	0/16	0/17				
5072 M m b6c orl 76w76 1309				0	180.mg				
lun ade evx	426.mg	P<.08 -	105.mg n.s.s.	0/16	2/14				
liv hpt evx	no dre	P=1. -	277.mg n.s.s.	0/16	0/14				
tba mix evx	195.mg	P<.01 -	66.9mg 13.2gm	0/16	4/14				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf								Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc					NCI/NTPPathology
o-PHENYLPHENOL, SODIUM (o-phenylphenate, sodium) 132-27-4												
5073 M f b6c eat 22m24 1647				0	600.mg	1.20gm	2.40gm					Hagiwara;fctx,22,809-814;1984
liv hpc e	13.0gm	Z P<.4	- 3.28gm n.s.s.	4/49	5/50	7/50	(0/50)					
lun ade e	143.gm	* P<.3	- 23.2gm n.s.s.	0/49	0/49	0/50	1/50					
liv hnd e	no dre	P=1.	- 9.85gm n.s.s.	5/49	6/50	9/50	3/50					
5074 M m b6c eat 22m24 1647				0	554.mg	1.11gm	2.22gm					
liv hpc e	5.42gm	* P<.009	- 2.68gm 188.gm	4/49	9/50	13/50	14/50					
liv hes e	11.6gm	* P<.09	- 5.84gm n.s.s.	0/49	3/50	5/50	3/50					
liv fbs e	132.gm	* P<.7	- 21.6gm n.s.s.	0/49	0/50	1/50	0/50					
liv hem e	no dre	P=1.	- 13.3gm n.s.s.	1/49	3/50	2/50	1/50					
liv hnd e	no dre	P=1.	- 5.00gm n.s.s.	16/49	19/50	16/50	15/50					
lun adc e	no dre	P=1.	- 14.4gm n.s.s.	3/49	3/50	2/50	2/50					
lun ade e	no dre	P=1.	- 10.3gm n.s.s.	4/49	4/50	5/50	3/50					
5075 R f f3d eat 65w65 1777				0	500.mg	1.00gm						Fujii;fctx,24,207-211;1986
ubl mix er	2.88gm	* P<.1	+ 707.mg n.s.s.	0/15	0/15	2/15						
ubl tcc er	5.89gm	* P<.3	+ 958.mg n.s.s.	0/15	0/15	1/15						
ubl tpp er	5.89gm	* P<.3	+ 958.mg n.s.s.	0/15	0/15	1/15						
5076 R f f3d eat 24m25 2457m				0	245.mg	491.mg						Fujii;jsms,12,277-287;1985
ubl mix e	5.08gm	* P<.02	+ 1.93gm n.s.s.	0/50	1/50	4/50						
ubl tcc e	26.0gm	* P<.3	4.24gm n.s.s.	0/50	0/50	1/50						
5077 R f f3d eat 24m29 2457n				0	117.mg	222.mg	423.mg					
ubl mix e	8.82gm	* P<.08	+ 2.17gm n.s.s.	0/25	0/25	0/24	2/25					
ubl tcc e	17.8gm	* P<.3	2.91gm n.s.s.	0/25	0/25	0/24	1/25					
5078 R m f3d eat 91w91 1378				0	50.0mg	100.mg	200.mg	400.mg	800.mg	1.60gm		Hiraga;fctx,19,303-310;1981
unt mix er	414.mg	* P<.0005	+ 279.mg 642.mg	0/20	0/20	0/20	1/21	7/21	20/21	17/20		
ubl mix er	470.mg	Z P<.0005	287.mg 836.mg	0/20	0/20	0/20	0/21	6/21	19/21	(8/20)		
kpp tcc er	2.42gm	* P<.0005	1.24gm 5.68gm	0/20	0/20	0/20	1/21	0/21	1/21	10/20		
5079 R m f3d eat 24m24 1752				0	100.mg	200.mg	400.mg	800.mg				Fukushima;onco,42,304-311;1985
ubl can er	3.18gm	* P<.04	+ 779.mg n.s.s.	0/7	0/9	0/8	0/9	2/5				
ubl pam er	3.18gm	* P<.04	+ 779.mg n.s.s.	0/7	0/9	0/8	0/9	2/5				
5080 R m f3d eat 65w65 1777				0	400.mg	800.mg						Fujii;fctx,24,207-211;1986
ubl mix er	195.mg	/ P<.0005	+ 103.mg 423.mg	0/14	0/15	15/15						
ubl tcc er	364.mg	/ P<.0005	+ 175.mg 959.mg	0/14	0/15	10/15						
ubl tpp er	852.mg	* P<.008	+ 322.mg 13.7gm	0/14	0/15	5/15						
5081 R m f3d eat 24m24 1930				0	800.mg							Fukushima;carc,10,1635-1640;1989
ubl car er	1.03gm	P<.0005	+ 523.mg 2.42gm	0/27	12/29							
ubl pam er	5.02gm	P<.05	1.52gm n.s.s.	0/27	3/29							
5082 R m f3d eat 24m25 2457m				0	275.mg	785.mg						Fujii;jsms,12,277-287;1985
ubl mix e	442.mg	/ P<.0005	+ 304.mg 669.mg	0/50	2/50	47/50						
ubl tcc e	461.mg	/ P<.0005	316.mg 699.mg	0/50	2/50	46/50						
5083 R m f3d eat 24m28 2457n				0	86.0mg	255.mg	800.mg					
ubl mix e	610.mg	Z P<.0005	+ 370.mg 1.09gm	0/25	0/25	3/25	23/25					
ubl tcc e	789.mg	Z P<.0005	465.mg 1.47gm	0/25	0/25	1/25	21/25					
3-PHENYLPROPYL ISOTHIOCYNATE 2627-27-2												
5084 R m f34 eat 89w89 2563				0	17.7mg							Stoner;carc,19,2139-2143;1998/pers.comm.
tes ict e	4.34mg	P<.01	1.40mg 349.mg	4/9	13/14							
PhIP.HCl (2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine.HCl) ---												
5085 M f cdf eat 82w82 1872				0	52.0mg							Esumi;gann,80,1176-1178;1989/pers.comm.
--- lym e	22.4mg	P<.0005	+ 12.6mg 50.4mg	6/40	26/38							
5086 M m cdf eat 82w82 1872				0	48.0mg							
--- lym e	63.9mg	P<.004	+ 28.9mg 513.mg	2/36	11/35							
5087 R m f34 eat 52w52 2300				0	6.38mg							Rao;canr,56,3395-3398;1996/pers.comm.
--- lym ersv	.789mg	P<.0005	+ .475mg 1.41mg	0/12	27/36							
thm lym ersv	1.07mg	P<.0005	+ .637mg 2.06mg	0/12	23/36							
itn mix ersv	3.36mg	P<.02	+ 1.63mg n.s.s.	0/12	10/36							
smi tum ersv	5.06mg	P<.04	2.18mg n.s.s.	0/12	7/36							
col tum ersv	12.6mg	P<.2	3.80mg n.s.s.	0/12	3/36							
5088 R f f3d eat 52w52 1922m				0	20.0mg							Ito;carc,12,1503-1506;1991/Shirai 1997/pers.comm.
mgl adc ej	5.45mg	P<.0005	+ 2.90mg 12.0mg	0/40	14/30							
col adc ej	49.7mg	P<.07	12.2mg n.s.s.	0/40	2/30							
liv tum ej	no dre	P=1.	30.9mg n.s.s.	0/40	0/30							
5089 R f f3d eat 24m24 2062m				0	1.25mg	5.00mg						Hasegawa;carc,14,2553-2557;1993/Shirai 1999/pers.comm.
mgl adc ej	6.34mg	* P<.0005	+ 3.51mg 13.1mg	0/30	2/30	14/30						
col adc ej	30.4mg	* P<.008	10.5mg 584.mg	0/30	0/30	4/30						
liv nnd ej	no dre	P=1.	28.8mg n.s.s.	2/30	2/30	0/30						
mgl ade ej	no dre	P=1.	20.3mg n.s.s.	3/30	4/30	1/30						
mgl fba ej	no dre	P=1.	3.19mg n.s.s.	8/30	5/30	(1/30)						
5090 R f f3d eat 54w54 2195				0	10.0mg							Hasegawa;carc,16,2243-2246;1995/pers.comm.
mgl adc er	3.62mg	P<.0005	+ 1.62mg 11.4mg	0/20	8/20							
col ade er	17.5mg	P<.1	4.31mg n.s.s.	0/20	2/20							
mgl fba er	17.5mg	P<.1	4.31mg n.s.s.	0/20	2/20							
5091 R f f3d eat 52w52 2249				0	10.0mg							Hirose;carc,16,217-221;1995/pers.comm.
mgl mix e	2.87mg	P<.004	+ 1.33mg 13.8mg	0/10	9/20							
mgl adc e	3.35mg	P<.006	+ 1.50mg 28.0mg	0/10	8/20							
lgi mix e	16.3mg	P<.2	3.99mg n.s.s.	0/10	2/20							
mgl fba e	16.3mg	P<.2	3.99mg n.s.s.	0/10	2/20							
lgi car e	30.0mg	P<.4	4.88mg n.s.s.	0/10	1/18							
lgi ade e	30.0mg	P<.4	4.88mg n.s.s.	0/10	1/18							
liv tum e	no dre	P=1.	10.3mg n.s.s.	0/10	0/20							
5092 R f f3d eat 54w54 2612				0	10.0mg							Hagiwara;gann,90,399-405;1999
mgl adc e	3.62mg	P<.006	+ 1.62mg 30.2mg	0/10	8/20							
mgl mix e	3.62mg	P<.006	+ 1.62mg 30.2mg	0/10	8/20							
col mix e	11.4mg	P<.2	+ 3.43mg n.s.s.	0/10	3/20							
col adc e	17.5mg	P<.2	+ 4.31mg n.s.s.	0/10	2/20							

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
5093 R m f3d eat 52w52 1922m					0	16.0mg			Ito;carc,12,1503-1506;1991/Shirai 1997/pers.comm.
pro car Cej		2.49mg	P<.0005 +	1.38mg 5.03mg	0/37	18/27			
col adc ej		3.42mg	P<.0005 +	1.87mg 7.13mg	0/40	16/29			
liv tum ej		no dre	P=1.	23.9mg n.s.s.	0/40	0/29			
5094 R m f3d eat 24m24 2062m					0	1.00mg	4.00mg		Hasegawa;carc,14,2553-2557;1993/Shirai 1999/pers.comm.
--- lle ej		5.92mg	* P<.003 +	2.85mg 38.2mg	3/30	6/30	13/30		
col adc ej		6.44mg	* P<.0005 +	3.37mg 14.6mg	0/30	0/30	13/30		
liv nnd ej		4.62mg	\ P<.08	1.51mg n.s.s.	1/30	5/30	(1/30)		
pro car ej		18.5mg	* P<.6	2.75mg n.s.s.	10/25	13/25	11/22		
mgl fba ej		no dre	P=1.	12.2mg n.s.s.	2/30	2/30	2/30		
5095 R f sdf eat 52w52 2525					0	5.53mg			Weisburger;jepo,16,329-334;1997
mgl mix v		.826mg	P<.0005 +	.462mg 1.80mg	1/18	21/30			
col adc v		13.7mg	P<.2	3.38mg n.s.s.	0/18	2/30			
5096 R f sdj eat 48w48 2233m ()					0	1.25mg	5.00mg	10.0mg	Imaida;gann,87,1116-1120;1996/pers.comm.
mgl mix Cer		1.54mg	* P<.0005 +	.882mg 3.26mg	1/20	1/21	7/20	13/18	
mgl adc Cer		1.67mg	* P<.0005 +	.960mg 3.26mg	0/20	1/21	5/20	13/18	
mgl dpp Cer		44.3mg	* P<.5	7.22mg n.s.s.	0/20	0/21	1/20	0/18	
mgl fba Cer		no dre	P=1.	8.97mg n.s.s.	1/20	0/21	1/20	0/18	
5097 R f sdj eat 48w48 2233n ()					0	.625mg	2.50mg		
mgl mix Cer		.797mg	* P<.005 +	.356mg 8.02mg	1/20	3/20	8/20		
mgl adc Cer		.851mg	* P<.002 +	.399mg 3.21mg	0/20	2/20	7/20		
mgl fba Cer		4.86mg	* P<.4	1.09mg n.s.s.	0/20	1/20	1/20		
mgl dpp Cer		no dre	P=1.	.439mg n.s.s.	1/20	0/20	0/20		
PHORBOL 17673-25-5									
5098 M f aks ipj 24m24 1415					0	4.16mg			Armuth;bjca,34,516-522;1976
lmr lyk er		no dre	P=1.	- 1.35mg n.s.s.	15/15	11/13			
5099 M m aks ipj 24m24 1415					0	3.47mg			
lmr lyk er		8.26mg	P<.7	- 1.01mg n.s.s.	10/14	11/14			
5100 M f bal ipj 24m24 1415					0	4.16mg			
lmr tum er		no dre	P=1.	- 58.3mg n.s.s.	0/53	0/68			
5101 M m bal ipj 24m24 1415					0	3.47mg			
lmr tum er		no dre	P=1.	- 29.3mg n.s.s.	0/58	0/41			
5102 M f c3p ipj 24m24 1415					0	4.16mg			
lmr tum er		no dre	P=1.	- 39.4mg n.s.s.	0/61	0/46			
5103 M m c3p ipj 24m24 1415					0	3.47mg			
lmr tum er		no dre	P=1.	- 42.2mg n.s.s.	0/41	0/59			
5104 M f c5l ipj 24m24 1415					0	4.16mg			
lmr tum er		no dre	P=1.	- 25.7mg n.s.s.	0/20	0/30			
5105 M f sjs ipj 24m24 1415					0	4.16mg			
lmr rtb er		92.6mg	P<1.	1.95mg n.s.s.	26/32	27/33			
5106 M f swr ipj 24m24 1415					0	4.16mg			
lmr lyk er		2.21mg	P<.0005 +	1.32mg 4.07mg	3/45	29/39			
PHOSPHAMIDON 13171-21-6									
5107 M f b6c eat 80w90 TR16 :					0	9.10mg	18.3mg		
TBA MXB		215.mg	* P<.8	- 22.4mg n.s.s.	1/10	11/50	9/50		
liv MXB		34.2mg	\ P<.2	14.0mg n.s.s.	0/10	6/50	(1/50)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	81.7mg n.s.s.	1/10	3/50	1/50		lun:a/a,a/c.
5108 M m b6c eat 66w90 TR16 :					0	7.60mg	13.2mg		
TBA MXB		no dre	P=1.	- 18.4mg n.s.s.	3/10	14/50	11/50		
liv MXB		no dre	P=1.	23.5mg n.s.s.	2/10	9/50	7/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	47.9mg n.s.s.	1/10	3/50	2/50		lun:a/a,a/c.
5109 R f osm eat 19m26 TR16 :					0	2.90mg	5.80mg		
TBA MXB		no dre	P=1.	i 6.09mg n.s.s.	7/10	29/50	26/50		
liv MXB		no dre	P=1.	47.0mg n.s.s.	0/10	1/50	0/50		liv:hpa,hpc,nnd.
5110 R f osm eat 19m25 TR16 : pool					0	2.90mg	5.80mg		
thy MXA #		19.0mg	* P<.008 i	9.26mg 361.mg	2/95	9/50	8/50		thy:cca,ccr. S
5111 R m osm eat 19m26 TR16 :					0	2.30mg	4.60mg		
TBA MXB		no dre	P=1.	i 5.55mg n.s.s.	4/10	26/50	20/50		
liv MXB		185.mg	* P<.5	30.2mg n.s.s.	0/10	0/50	1/50		liv:hpa,hpc,nnd.
5112 R m osm eat 19m25 TR16 : pool					0	2.30mg	4.60mg		
spl MXA #		26.9mg	* P<.02 i	10.9mg n.s.s.	1/95	3/50	5/50		spl:hem,hes. S
PHOSPHINE 7803-51-2									
5113 R f f34 inh 52w52 2602m					0	31.2ug	.104mg	.312mg	Newton;intx,11,639-708;1999/pers.comm.
liv tum ek		no dre	P=1.	- 11.5ug n.s.s.	0/10	0/10	0/10	0/10	
5114 R f f34 inh 24m24 2602n					0	31.2ug	.104mg	.312mg	
liv hpa e		53.1mg	* P<.9	- 1.70mg n.s.s.	0/50	2/50	1/50	1/50	
5115 R m f34 inh 52w52 2602m					0	21.9ug	72.9ug	.219mg	
liv tum ek		no dre	P=1.	- 8.04ug n.s.s.	0/10	0/10	0/10	0/10	
5116 R m f34 inh 24m24 2602n					0	21.9ug	72.9ug	.219mg	
liv hpa e		5.69mg	* P<.6	- .929mg n.s.s.	3/50	0/50	3/50	3/50	
liv hpc e		no dre	P=1.	- 1.98mg n.s.s.	2/50	1/50	0/50	1/50	
5117 R f sda eat 52w52 1692m					0	250.ng			Cabrol Telle;fctx,23,1001-1009;1985
tba tum ek		no dre	P=1.	- 245.ng n.s.s.	0/20	0/19			
5118 R f sda eat 24m24 1692n					0	250.ng			
tba mix e		no dre	P=1.	- 43.1ng n.s.s.	10/10	10/11			
5119 R m sda eat 52w52 1692m					0	200.ng			
tba tum ek		no dre	P=1.	- 206.ng n.s.s.	0/19	0/20			
5120 R m sda eat 24m24 1692n					0	200.ng			
tba mix e		no dre	P=1.	- 264.ng n.s.s.	2/11	1/10			
PHTHALAMIDE 88-96-0									
5121 M f b6c eat 24m24 TR161 :					0	806.mg	1.62gm	3.25gm	
TBA MXB as		no dre	P=1.	- 3.07gm n.s.s.	19/40	29/50	27/50	8/50	
liv MXB as		no dre	P=1.	17.3gm n.s.s.	4/40	2/50	2/50	0/50	liv:hpa,hpc,nnd.
lun MXB as		no dre	P=1.	15.8gm n.s.s.	3/40	5/50	1/50	0/50	lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
5122 M m b6c eat 24m24 TR161 :				0	3.00gm	6.00gm			
TBA MXB	1.09kg	P<1.	- 4.34gm n.s.s.	15/20	33/50	32/50			
liv MXB	no dre	P=1.	10.8gm n.s.s.	9/20	17/50	13/50			liv:hpa,hpc,nnd.
lun MXB	35.8gm *	P<.5	9.09gm n.s.s.	3/20	7/50	10/50			lun:a/a,a/c.
5123 R f f34 eat 25m25 TR161 :				0	250.mg	500.mg			
TBA MXB	722.mg *	P<.3	- 217.mg n.s.s.	14/20	39/50	39/50			
liv MXB	5.39gm *	P<.5	1.25gm n.s.s.	2/20	2/50	6/50			liv:hpa,hpc,nnd.
5124 R m f34 eat 25m25 TR161 :				0	600.mg	1.20gm			
TBA MXB	no dre	P=1.	- 1.06gm n.s.s.	17/20	43/50	34/50			
liv MXB	16.6gm *	P<.3	5.02gm n.s.s.	0/20	1/50	2/50			liv:hpa,hpc,nnd.
PHTHALIC ANHYDRIDE 85-44-9									
5125 M f b6c eat 24m24 TR159 :				0	1.56gm	3.12gm			
TBA MXB v	no dre	P=1.	- 5.42gm n.s.s.	10/20	21/50	17/50			
liv MXB v	no dre	P=1.	25.9gm n.s.s.	1/20	0/50	1/50			liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	10.7gm n.s.s.	1/20	6/50	2/50			lun:a/a,a/c.
5126 M m b6c eat 24m24 TR159 :				0	1.96gm	3.92gm			
TBA MXB v	no dre	P=1.	- 7.76gm n.s.s.	11/20	22/50	18/50			
liv MXB v	7.46gm \	P<.3	2.27gm n.s.s.	3/20	12/50	(7/50)			liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	13.3gm n.s.s.	7/20	6/50	9/50			lun:a/a,a/c.
5127 R f f34 eat 24m24 TR159 :				0	375.mg	750.mg			
lun a/a #	6.23gm *	P<.03	- 2.37gm n.s.s.	0/20	0/50	5/50			S
TBA MXB	4.50gm *	P<.8	511.mg n.s.s.	13/20	37/50	36/50			
liv MXB	no dre	P=1.	5.50gm n.s.s.	0/20	1/50	0/50			liv:hpa,hpc,nnd.
5128 R m f34 eat 24m24 TR159 :				0	300.mg	600.mg			
TBA MXB	no dre	P=1.	- 451.mg n.s.s.	15/20	37/50	36/50			
liv MXB	no dre	P=1.	4.79gm n.s.s.	1/20	2/50	0/50			liv:hpa,hpc,nnd.
PICLORAM, TECHNICAL GRADE 1918-02-1									
5129 M f b6c eat 80w90 TR23 :				0	292.mg	585.mg			
TBA MXB v	no dre	P=1.	- 1.57gm n.s.s.	1/10	6/50	3/50			
liv MXB v	20.1gm *	P<.4	3.28gm n.s.s.	0/10	0/50	1/50			liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	1.25gm n.s.s.	1/10	1/50	(0/50)			lun:a/a,a/c.
5130 M m b6c eat 80w90 TR23 :				0	270.mg	540.mg			
TBA MXB v	no dre	P=1.	- 688.mg n.s.s.	5/10	18/50	14/50			
liv MXB v	no dre	P=1.	398.mg n.s.s.	5/10	13/50	(8/50)			liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	1.33gm n.s.s.	1/10	5/50	3/50			lun:a/a,a/c.
5131 R f osm eat 19m26 TR23 :				0	263.mg	527.mg			
TBA MXB v	no dre	P=1.	- 397.mg n.s.s.	7/10	32/50	33/50			
liv MXB v	1.64gm *	P<.09	864.mg n.s.s.	0/10	5/50	8/50			liv:hpa,hpc,nnd.
5132 R f osm eat 19m26 TR23 : pool				0	263.mg	527.mg			
liv nnd v	1.70gm *	P<.007 a	873.mg 23.4gm	0/40	5/50	7/50			
5133 R m osm eat 19m26 TR23 :				0	210.mg	422.mg			
TBA MXB v	2.93gm *	P<.8	- 290.mg n.s.s.	3/10	28/50	22/50			
liv MXB v	1.32gm \	P<.3	456.mg n.s.s.	0/10	4/50	(0/50)			liv:hpa,hpc,nnd.
5134 R f f34 eat 24m24 1981				0	20.0mg	60.0mg	200.mg		Stott;jtxe,30,91-104;1990
liv hpa	15.8gm *	P<.8	- 1.27gm n.s.s.	2/50	1/50	0/50	2/50		
thy pfa	no dre	P=1.	- 909.mg n.s.s.	3/50	10/50	4/50	4/50		
5135 R m f34 eat 24m24 1981				0	20.0mg	60.0mg	200.mg		
liv hpa	5.56gm *	P<.6	- 759.mg n.s.s.	1/50	1/50	4/50	2/50		
liv hpc	8.71gm *	P<.6	- 1.04gm n.s.s.	0/50	1/50	1/50	1/50		
PILDRALAZINE.2HCl 56393-22-7									
5136 M f b6c wat 19m29 1567				0	13.0mg	25.9mg	51.8mg		Della Porta;zkko,106,97-101;1983
liv mix e	503.mg *	P<.2	- 160.mg n.s.s.	6/49	5/48	5/49	10/46		
lun mix e	no dre	P=1.	- 475.mg n.s.s.	4/49	4/48	2/49	2/46		
5137 M m b6c wat 19m29 1567				0	10.8mg	21.6mg	43.2mg		
liv mix e	922.mg Z	P<.6	- 171.mg n.s.s.	11/50	0/48	8/50	10/49		
lun mix e	no dre	P=1.	- 232.mg n.s.s.	5/50	10/48	5/50	5/49		
5138 M f bld wat 19m29 1567				0	13.0mg	25.9mg	51.8mg		
--- lym e	408.mg *	P<.6	- 72.9mg n.s.s.	16/46	31/49	23/50	23/47		
liv hpa e	no dre	P=1.	- 765.mg n.s.s.	0/46	1/49	0/50	0/47		
lun mix e	no dre	P=1.	- 149.mg n.s.s.	14/46	12/49	16/50	13/47		
PILOCARPINE 92-13-7									
5139 R f sda ipj 24m24 1134				0	4.29mg				Schmahl;zkko,86,77-84;1976
tba mal e	98.4mg	P<.8	- 10.1mg n.s.s.	3/33	4/34				
5140 R m sda ipj 24m24 1134				0	4.29mg				
liv hae e	no dre	P=1.	30.0mg n.s.s.	1/36	0/34				
tba mal e	1.75gm	P<1.	- 18.1mg n.s.s.	1/36	1/34				
PIMARICIN 7681-93-8									
5141 R f cfn eat 24m24 240				0	6.25mg	12.5mg	25.0mg	50.0mg	Levinskas;txap,8,97-109;1966
liv mhp	no dre	P=1.	- 639.mg n.s.s.	1/40	1/35	0/35	0/35	0/40	
5142 R m cfn eat 24m24 240				0	5.00mg	10.0mg	20.0mg	40.0mg	
lun lys	1.97gm *	P<.5	- 320.mg n.s.s.	0/40	0/35	0/35	1/35	0/40	
thm tma	no dre	P=1.	- 350.mg n.s.s.	0/40	0/35	1/35	0/35	0/40	
PIPERAZINE 110-85-0									
5143 R f mrc wat 17m24 216				0	7.36mg				Garcia;zkko,79,141-144;1973
liv tum e	no dre	P=1.	22.7mg n.s.s.	0/15	0/15				
tba mix e	11.2mg	P<.2	3.42mg n.s.s.	4/15	8/15				
5144 R m mrc wat 17m24 216				0	6.44mg				
liv tum e	no dre	P=1.	19.9mg n.s.s.	0/15	0/15				
tba mix e	no dre	P=1.	5.79mg n.s.s.	5/15	5/15				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
PIPERIDINE 110-89-4									
5145 R f mrc wat 17m24 216					0	29.4mg			Garcia;zkko,79,141-144;1973
liv tum e	no dre	P=1.	91.0mg	n.s.s.	0/15	0/15			
tba mix e	63.3mg	P<.3	16.4mg	n.s.s.	4/15	7/15			
5146 R m mrc wat 17m24 216					0	25.8mg			
liv tum e	no dre	P=1.	79.6mg	n.s.s.	0/15	0/15			
tba mix e	no dre	P=1.	29.2mg	n.s.s.	5/15	4/15			
PIPERONYL BUTOXIDE 51-03-6									
5147 M f b6c eat 26m26 TR120 :					0	135.mg	364.mg		
TBA MXB v	no dre	P=1.	- 241.mg	n.s.s.	15/20	22/50	(20/50)		
liv MXB v	3.26gm *	P<.3	929.mg	n.s.s.	1/20	2/50	5/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	1.49gm	n.s.s.	2/20	6/50	2/50		lun:a/a,a/c.
5148 M f b6c orl 76w76 1096					0	41.4mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	82.0mg	n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	82.0mg	n.s.s.	0/16	0/18			
tba mix evx	83.1mg	P<.05	25.1mg	n.s.s.	0/16	3/18			
5149 M m b6c eat 26m26 TR120 :					0	124.mg	336.mg		
TBA MXB v	no dre	P=1.	- 406.mg	n.s.s.	16/20	32/50	31/50		
liv MXB v	no dre	P=1.	528.mg	n.s.s.	10/20	17/50	20/50		liv:hpa,hpc,nnd.
lun MXB v	no dre	P=1.	998.mg	n.s.s.	5/20	6/50	8/50		lun:a/a,a/c.
5150 M m b6c orl 76w76 1096					0	38.5mg			Innes;ntis,1968/1969
--- rts evx	34.8mg	P<.005	13.1mg	274.mg	0/16	5/15			
liv hpt evx	98.5mg	P<.09	24.2mg	n.s.s.	0/16	2/15			
lun mix evx	no dre	P=1.	63.6mg	n.s.s.	0/16	0/15			
tba mix evx	22.4mg	P<.0005	9.48mg	78.6mg	0/16	7/15			
5151 M f b6a orl 76w76 1096					0	41.4mg			
lun ade evx	265.mg	P<.6	34.8mg	n.s.s.	1/17	2/18			
liv hpt evx	no dre	P=1.	82.0mg	n.s.s.	0/17	0/18			
tba mix evx	265.mg	P<.7	29.7mg	n.s.s.	2/17	3/18			
5152 M m b6a orl 76w76 1096					0	38.5mg			
lun ade evx	no dre	P=1.	50.5mg	n.s.s.	2/18	1/18			
liv hpt evx	no dre	P=1.	76.3mg	n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	54.0mg	n.s.s.	3/18	1/18			
5153 M f cd1 eat 52w52 2144					0	780.mg	1.56gm		Takahashi;artx,68,467-469;1994/1997/pers.comm.
liv mix e	516.mg /	P<.0005 +	347.mg	812.mg	0/51	0/52	38/68		
liv hpc e	756.mg /	P<.0005 +	480.mg	1.29gm	0/51	0/52	28/68		
liv hpa e	2.38gm /	P<.0005	1.16gm	7.07gm	0/51	0/52	10/68		
5154 M f cd1 eat 79w79 2566					0	30.0mg	100.mg	300.mg	Butler;huet,17,323-330;1998
liv hpa e	825.mg *	P<.0005 +	400.mg	2.89gm	4/120	1/60	1/60	12/60	
liv esa e	1.12gm *	P<.0005 +	515.mg	3.56gm	1/120	0/60	0/60	9/60	
liv bsa e	4.54gm *	P<.3	1.00gm	n.s.s.	3/120	0/60	1/60	3/60	
liv mxc e	no dre	P=1.	2.10gm	n.s.s.	0/120	1/60	0/60	0/60	
5155 M m cd1 eat 52w52 2144					0	720.mg	1.44gm		Takahashi;artx,68,467-469;1994/1997/pers.comm.
liv mix e	229.mg /	P<.0005 +	172.mg	313.mg	1/52	13/53	74/100		
liv hpc e	410.mg /	P<.0005 +	296.mg	589.mg	0/52	6/53	52/100		
liv hpa e	1.06gm *	P<.0005	645.mg	2.92gm	1/52	7/53	22/100		
5156 M m cd1 eat 79w79 2566					0	30.0mg	100.mg	300.mg	Butler;huet,17,323-330;1998
liv hpa e	160.mg *	P<.0005 +	103.mg	296.mg	15/120	13/60	21/60	34/60	
liv esa e	355.mg *	P<.0005 +	219.mg	648.mg	1/120	0/60	9/60	17/60	
liv bsa e	844.mg *	P<.06	314.mg	n.s.s.	13/120	11/60	10/60	14/60	
liv mxc e	2.63gm *	P<.2	735.mg	n.s.s.	1/120	2/60	2/60	3/60	
liv hpc e	3.47gm *	P<.4	757.mg	n.s.s.	6/120	2/60	2/60	5/60	
5157 R f f34 eat 25m25 TR120 :					0	250.mg	500.mg		
--- lym #	1.18gm *	P<.008	- 631.mg	27.1gm	1/20	7/50	15/50		S
TBA MXB	7.82gm *	P<.9	422.mg	n.s.s.	15/20	33/50	33/50		
liv MXB	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
5158 R m f34 eat 25m25 TR120 :					0	200.mg	400.mg		
TBA MXB	no dre	P=1.	- 384.mg	n.s.s.	14/20	34/50	32/50		
liv MXB	no dre	P=1.	5.20gm	n.s.s.	2/20	0/50	0/50		liv:hpa,hpc,nnd.
5159 R f cdr eat 24m24 2566					0	30.0mg	100.mg	500.mg	Butler;huet,17,323-330;1998
liv hpc e	12.8gm *	P<.2	- 3.16gm	n.s.s.	0/120	0/60	1/60	1/60	
5160 R m cdr eat 24m24 2566					0	30.0mg	100.mg	500.mg	
liv hpa e	12.8gm *	P<.02	- 3.14gm	n.s.s.	0/120	0/60	0/60	2/60	
liv hpc e	78.5gm *	P<.8	- 4.64gm	n.s.s.	2/120	0/60	0/60	1/60	
5161 R f f3d eat 24m26 1686					0	236.mg	473.mg		Maekawa;fctx,23,675-682;1985
liv nnd e	no dre	P=1.	- 4.33gm	n.s.s.	0/47	1/49	0/49		
tba mix e	no dre	P=1.	- 726.mg	n.s.s.	35/47	39/49	30/49		
5162 R f f3d eat 96w96 2143					0	300.mg	600.mg	1.20gm	Takahashi;faat,22,293-303;1994/pers.comm.
liv hct e	977.mg Z	P<.0005 +	621.mg	1.66gm	0/30	0/30	4/30	25/33	
liv hpc e	2.22gm Z	P<.0005 +	1.22gm	4.71gm	0/30	0/30	0/30	15/33	
liv hpa e	2.46gm *	P<.0005	1.32gm	5.56gm	0/30	0/30	4/30	10/33	
liv ccy e	19.1gm *	P<.08	4.70gm	n.s.s.	0/30	0/30	0/30	2/33	
5163 R m f3d eat 24m26 1686					0	189.mg	378.mg		Maekawa;fctx,23,675-682;1985
liv nnd e	7.69gm *	P<.3	- 1.88gm	n.s.s.	1/48	1/48	3/46		
liv hpc e	20.1gm *	P<.3	- 3.28gm	n.s.s.	0/48	0/48	1/46		
tba mix e	no dre	P=1.	- 267.mg	n.s.s.	48/48	48/48	41/46		
5164 R m f3d eat 95w95 2143					0	240.mg	480.mg	960.mg	Takahashi;faat,22,293-303;1994/pers.comm.
liv hct e	468.mg Z	P<.0005 +	314.mg	731.mg	0/30	0/30	12/30	29/33	
liv hpc e	806.mg Z	P<.0005 +	508.mg	1.38gm	0/30	0/30	4/30	24/33	
liv hpa e	1.40gm Z	P<.002	634.mg	4.73gm	0/30	0/30	8/30	(5/33)	
liv ccy e	30.2gm *	P<.3	4.92gm	n.s.s.	0/30	0/30	0/30	1/33	
5165 R b wis eat 22m24 241					0	4.50mg	45.0mg	450.mg 1.11gm	Sarles;atmh,1,862-883;1952
liv hpt sv	22.5gm *	P<.5	- 3.48gm	n.s.s.	1/24	0/24	0/24	1/24 1/24	
liv hpc sv	26.1gm *	P<.2	- 4.25gm	n.s.s.	0/24	0/24	0/24	0/24 1/24	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
PIPERONYL BUTOXIDE IN SOLVENT (butacide) 51-03-6								
5166 M f b6a orl 76w76 1097				0	157.mg			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- 187.mg n.s.s.	1/17	1/18			
liv hpt evx	no dre	P=1.	- 311.mg n.s.s.	0/17	0/18			
tba mix evx	1.01gm	P<.7	- 113.mg n.s.s.	2/17	3/18			
5167 M m b6a orl 76w76 1097				0	146.mg			
liv hpt evx	no dre	P=1.	- 173.mg n.s.s.	1/18	1/18			
lun ade evx	no dre	P=1.	- 192.mg n.s.s.	2/18	1/18			
tba mix evx	no dre	P=1.	- 115.mg n.s.s.	3/18	3/18			
5168 M f b6c orl 76w76 1097				0	157.mg			
liv hpt evx	no dre	P=1.	- 311.mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	- 311.mg n.s.s.	0/16	0/18			
tba tum evx	no dre	P=1.	- 311.mg n.s.s.	0/16	0/18			
5169 M m b6c orl 76w76 1097				0	146.mg			
liv hpt evx	186.mg	P<.02	- 63.9mg n.s.s.	0/16	4/16			
lun mix evx	no dre	P=1.	- 258.mg n.s.s.	0/16	0/16			
tba mix evx	93.1mg	P<.002	- 39.5mg 340.mg	0/16	7/16			
PIPERONYL SULFOXIDE 120-62-7								
5170 M f b6c eat 24m24 TR124 :				0	38.3mg	98.0mg		
TBA MXB av	no dre	P=1.	- 110.mg n.s.s.	10/20	23/50	25/50		
liv MXB av	725.mg *	P<.3	215.mg n.s.s.	1/20	3/50	6/50		liv:hpa,hpc,nnd.
lun MXB av	no dre	P=1.	523.mg n.s.s.	2/20	2/50	2/50		lun:a/a,a/c.
5171 M f b6c orl 76w76 1099				0	15.7mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	31.1mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	31.1mg n.s.s.	0/16	0/18			
tba mix evx	100.mg	P<.3	16.3mg n.s.s.	0/16	1/18			
5172 M m b6c eat 24m24 TR124 :				0	42.2mg	84.0mg		
liv hpc a	62.2mg *	P<.02	c 31.0mg n.s.s.	6/20	31/50	46/50		
TBA MXB a	423.mg *	P<.8	46.4mg n.s.s.	14/20	39/50	47/50		
liv MXB a	62.2mg *	P<.02	31.0mg n.s.s.	6/20	31/50	46/50		liv:hpa,hpc,nnd.
lun MXB a	no dre	P=1.	106.mg n.s.s.	6/20	10/50	(7/50)		lun:a/a,a/c.
5173 M m b6c orl 76w76 1099				0	14.6mg			Innes;ntis,1968/1969
--- rts evx	9.10mg	P<.0005	4.05mg 29.9mg	0/16	8/18			
liv hpt evx	45.4mg	P<.2	11.2mg n.s.s.	0/16	2/18			
lun mix evx	no dre	P=1.	29.0mg n.s.s.	0/16	0/18			
tba mix evx	7.72mg	P<.0005	3.56mg 22.2mg	0/16	9/18			
5174 M f b6a orl 76w76 1099				0	15.7mg			
lun ade evx	no dre	P=1.	17.5mg n.s.s.	1/17	1/17			
liv hpt evx	no dre	P=1.	29.3mg n.s.s.	0/17	0/17			
tba mix evx	no dre	P=1.	13.8mg n.s.s.	2/17	2/17			
5175 M m b6a orl 76w76 1099				0	14.6mg			
liv hpt evx	88.2mg	P<.6	12.3mg n.s.s.	1/18	2/18			
lun ade evx	no dre	P=1.	29.0mg n.s.s.	2/18	0/18			
tba mix evx	no dre	P=1.	15.1mg n.s.s.	3/18	2/18			
5176 R f f34 eat 24m24 TR124 :				0	150.mg	300.mg		
TBA MXB	2.30gm *	P<.8	- 283.mg n.s.s.	12/20	24/50	27/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
5177 R m f34 eat 24m24 TR124 :				0	60.0mg	120.mg		
TBA MXB	no dre	P=1.	- 60.1mg n.s.s.	15/20	32/50	(22/50)		
liv MXB	2.65gm *	P<.6	651.mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
PIRMENOL.HCl (cis-(+-)-alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-alpha-phenyl-2-pyridinemethanol.HCl) 61477-94-9								
5178 M f b6c eat 24m24 2414				0	11.1mg	27.7mg	55.4mg	Macallum;drug,3,278-289;1991/pers.comm.
--- lym e	94.6mg Z	P<.009	- 46.6mg 3.02gm	3/65	11/65	13/65	(3/65)	
liv hpc e	978.mg *	P<.3	- 255.mg n.s.s.	2/65	3/65	2/65	5/65	
liv hpa e	1.56gm *	P<.6	- 254.mg n.s.s.	5/65	3/65	4/65	6/65	
lun ade e	1.98gm *	P<.6	- 312.mg n.s.s.	2/65	2/65	3/65	3/65	
lun car e	no dre	P=1.	- 611.mg n.s.s.	4/65	0/65	1/65	2/65	
tba mix e	no dre	P=1.	- 81.7mg n.s.s.	36/65	36/65	41/65	34/65	
5179 M m b6c eat 24m24 2414				0	11.1mg	27.7mg	55.4mg	
lun ade e	947.mg *	P<.6	- 156.mg n.s.s.	8/65	11/65	10/65	11/65	
lun car e	4.04gm *	P<.7	- 484.mg n.s.s.	1/65	0/65	2/65	1/65	
liv hpc e	no dre	P=1.	- 318.mg n.s.s.	15/65	15/65	13/65	8/65	
liv hpa e	no dre	P=1.	- 189.mg n.s.s.	14/65	18/65	21/65	11/65	
tba mix e	no dre	P=1.	- 64.9mg n.s.s.	46/65	45/65	50/65	43/65	
5180 R f wis eat 24m24 2414				0	11.1mg	27.7mg	55.4mg	
pit ade e	15.9mg Z	P<.0005	- 9.66mg 37.9mg	14/50	36/50	36/50	(32/50)	
liv tum e	no dre	P=1.	- 617.mg n.s.s.	0/50	1/50	0/50	0/50	
tba mix e	440.mg *	P<.9	- 28.1mg n.s.s.	40/50	43/50	46/50	41/50	
5181 R m wis eat 24m24 2414				0	11.1mg	27.7mg	55.4mg	
adr coa e	104.mg Z	P<.05	- 44.2mg n.s.s.	3/50	9/50	10/50	(3/50)	
liv tum e	no dre	P=1.	- 239.mg n.s.s.	1/50	3/50	5/50	1/50	
tba mix e	no dre	P=1.	- 113.mg n.s.s.	33/50	36/50	36/50	25/50	
PIROXICAM 36322-90-4								
5182 R m f34 eat 54w54 2078				0	16.0mg			Reddy;carc,13,1019-1023;1992
col mix er	no dre	P=1.	10.7mg n.s.s.	0/12	0/12			
PIVALOLACTONE 1955-45-9								
5183 M f b6c gav 24m24 TR140 :				0	31.8mg	63.7mg		
TBA MXB	179.mg *	P<.3	- 55.7mg n.s.s.	6/20	20/50	22/50		
liv MXB	no dre	P=1.	340.mg n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
lun MXB	482.mg *	P<.6	161.mg n.s.s.	0/20	4/50	2/50		lun:a/a,a/c.
5184 M m b6c gav 24m24 TR140 :				0	31.8mg	63.7mg		
TBA MXB	no dre	P=1.	- 97.0mg n.s.s.	12/20	24/50	25/50		
liv MXB	no dre	P=1.	64.1mg n.s.s.	4/20	10/50	(4/50)		liv:hpa,hpc,nnd.
lun MXB	435.mg *	P<.5	114.mg n.s.s.	2/20	6/50	10/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
5185 R f f34 gav 24m24 TR140 :					0	63.1mg	126.mg			
sto MXA		333.mg /	P<.002	c 175.mg 1.03gm	0/20	2/50	11/50			sto:sqc,sqp.
TBA MXB		200.mg *	P<.3	62.5mg n.s.s.	14/20	35/50	34/50			
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50			liv:hpa,hpc,nnd.
5186 R m f34 gav 24m24 TR140 :					0	63.1mg	126.mg			
sto MXA		154.mg *	P<.0005	c 96.7mg 293.mg	0/20	6/50	21/50			sto:sqc,sqp.
sto sqc		532.mg *	P<.009	c 241.mg 12.5gm	0/20	1/50	7/50			
TBA MXB		181.mg *	P<.2	66.4mg n.s.s.	11/20	29/50	34/50			
liv MXB		850.mg *	P<.3	323.mg n.s.s.	0/20	3/50	2/50			liv:hpa,hpc,nnd.
POLICOSANOL (ateromixol) 142583-61-7										
5187 M f swi gav 78w78 2347					0	50.0mg	500.mg			Aleman;fctx,33,573-578;1995/pers.comm.
liv hpa e		no dre	P=1.	- 406.mg n.s.s.	1/79	0/77	0/78			
lun ade e		no dre	P=1.	- 2.37gm n.s.s.	2/79	5/77	2/78			
lun adc e		no dre	P=1.	- 3.15gm n.s.s.	2/79	0/77	1/78			
liv hpc e		no dre	P=1.	- 3.64gm n.s.s.	0/79	1/77	0/78			
liv mix e		no dre	P=1.	- 4.37gm n.s.s.	1/79	1/77	0/78			
5188 M m swi gav 78w78 2347					0	50.0mg	500.mg			
liv hpc e		752.mg \	P<.1	- 185.mg n.s.s.	0/78	2/79	(0/77)			
lun adc e		10.6gm *	P<.6	- 1.57gm n.s.s.	1/78	3/79	3/77			
lun ade e		252.gm *	P<1.	- 1.91gm n.s.s.	3/78	3/79	3/77			
liv hpa e		no dre	P=1.	- 415.mg n.s.s.	1/78	0/79	0/77			
liv mix e		no dre	P=1.	- 4.08gm n.s.s.	1/78	2/79	0/77			
5189 R f sda gav 24m24 2193					0	50.0mg	500.mg			Aleman;tcam,14,239-249;1994/pers.comm.
liv hct e		no dre	P=1.	- 476.mg n.s.s.	0/48	0/51	0/49			
5190 R f sda gav 52w52 2196					0	.500mg	5.00mg	50.0mg	500.mg	Aleman;txlt,70,77-87;1994/pers.comm.
liv tum		no dre	P=1.	- .464mg n.s.s.	0/20	0/20	0/20	0/20	0/20	
tba tum		no dre	P=1.	- .464mg n.s.s.	0/20	0/20	0/20	0/20	0/20	
5191 R m sda gav 24m24 2193					0	50.0mg	500.mg			Aleman;tcam,14,239-249;1994/pers.comm.
tyf mca e		19.1gm *	P<.2	- 3.11gm n.s.s.	0/51	0/53	1/51			
liv hct e		no dre	P=1.	- 495.mg n.s.s.	0/51	0/53	0/51			
5192 R m sda gav 52w52 2196					0	.500mg	5.00mg	50.0mg	500.mg	Aleman;txlt,70,77-87;1994/pers.comm.
liv tum		no dre	P=1.	- .464mg n.s.s.	0/20	0/20	0/20	0/20	0/20	
tba tum		no dre	P=1.	- .464mg n.s.s.	0/20	0/20	0/20	0/20	0/20	
POLYBROMINATED BIPHENYL MIXTURE (firemaster FF-1) 67774-32-7										
5193 M f b6c gav 6m30 TR244 :					0	14.2ug	42.5ug	.142mg	.425mg	1.45mg
liv hpc		.534mg *	P<.0005	c .250mg 1.66mg	0/13	0/19	2/15	2/11	3/17	7/8
TBA MXB		.338mg *	P<.003	.141mg 2.97mg	12/13	13/19	12/15	9/11	16/17	8/8
liv MXB		.402mg *	P<.0005	.180mg 1.22mg	0/13	2/19	2/15	3/11	4/17	8/8
lun MXB		.915mg *	P<.02	.285mg n.s.s.	0/13	1/19	1/15	1/11	3/17	1/8
5194 M f b6c eat 24m24 TR398 :					0	1.30mg	3.90mg			
liv MXA		.307mg /	P<.0005	c .204mg .477mg	5/50	42/50	47/50			liv:hpa,hpc.
liv hpa		.367mg /	P<.0005	c .245mg .562mg	4/50	39/50	46/50			
liv hpc		.588mg /	P<.0005	c .364mg .975mg	1/50	22/50	35/50			
TBA MXB		.362mg /	P<.0005	.234mg .601mg	25/50	46/50	47/50			
liv MXB		.307mg /	P<.0005	.204mg .477mg	5/50	42/50	47/50			liv:hpa,hpb,hpc.
lun MXB		19.1mg *	P<.3	3.06mg n.s.s.	1/50	2/50	1/50			lun:a/a,a/c.
5195 M m b6c gav 6m30 TR244 :					0	14.2ug	42.5ug	.142mg	.425mg	1.47mg
liv hpc		.381mg *	P<.0005	c .200mg .899mg	12/25	8/27	8/24	12/25	15/23	21/22
TBA MXB		.418mg *	P<.0005	.190mg 1.87mg	20/25	23/27	22/24	23/25	21/23	22/22
liv MXB		.285mg *	P<.0005	.147mg .685mg	14/25	9/27	12/24	14/25	17/23	22/22
lun MXB		no dre	P=1.	.471mg n.s.s.	1/25	1/27	3/24	4/25	3/23	0/22
5196 M m b6c eat 24m24 TR398 :					0	1.20mg	3.60mg			
liv hpa		.233mg /	P<.0005	c .139mg .401mg	9/50	48/50	42/50			
liv MXA		.262mg /	P<.0005	c .156mg .453mg	16/50	48/50	48/50			liv:hpa,hpc.
liv hpc		.540mg /	P<.0005	c .319mg .922mg	8/50	30/50	36/50			
TBA MXB		.349mg /	P<.0005	.203mg .660mg	37/50	48/50	48/50			
liv MXB		.262mg /	P<.0005	.156mg .453mg	16/50	48/50	48/50			liv:hpa,hpb,hpc.
lun MXB		54.9mg *	P<.9	1.92mg n.s.s.	13/50	10/50	2/50			lun:a/a,a/c.
5197 R f f34 gav 6m29 TR244 : ()					0	14.4ug	43.2ug	.144mg	.432mg	1.51mg
liv MXA y		.596mg *	P<.0005	c .323mg 1.22mg	0/20	2/21	0/21	2/11	7/19	16/20
liv nnd y		1.10mg *	P<.0005	c .505mg 3.47mg	0/20	2/21	0/21	2/11	5/19	8/20
liv hpc y		1.65mg *	P<.0005	c .619mg 4.21mg	0/20	0/21	0/21	0/11	3/19	7/20
liv clc y		2.10mg *	P<.0005	c .800mg 6.40mg	0/20	0/21	0/21	0/11	0/19	7/20
TBA MXB y		.365mg *	P<.009	.136mg 13.7mg	18/20	18/21	17/21	11/11	19/19	17/20
liv MXB y		.645mg *	P<.0005	.343mg 1.35mg	0/20	2/21	0/21	2/11	7/19	15/20
5198 R f f34 eat 24m24 TR398 :					0	.500mg	1.50mg			
liv MXA		.656mg *	P<.0005	c .464mg .970mg	0/50	12/50	39/50			liv:hpa,hpc.
liv hpa		.700mg *	P<.0005	c .490mg 1.05mg	0/50	10/50	38/50			
mgl fba		1.59mg \	P<.05	.616mg n.s.s.	4/50	11/50	(2/50)			s
liv hpc		8.22mg *	P<.02	c 3.34mg n.s.s.	0/50	2/50	4/50			
TBA MXB		2.38mg *	P<.3	.699mg n.s.s.	40/50	42/50	47/50			
liv MXB		.656mg *	P<.0005	.464mg .970mg	0/50	12/50	39/50			liv:hpa,hpb,hpc.
5199 R m f34 gav 6m27 TR244 : ()					0	15.1ug	46.2ug	.151mg	.478mg	1.73mg
liv MXA y		.148mg *	P<.0005	c 45.7ug .491mg	0/33	2/39	1/40	5/31	10/33	10/32
liv nnd y		.168mg *	P<.0005	c 47.2ug .608mg	0/33	0/39	1/40	4/31	4/33	1/32
liv hpc y		1.30mg *	P<.0005	c .484mg 3.70mg	0/33	2/39	0/40	1/31	7/33	7/32
liv clc y		14.4mg *	P<.006	c 3.45mg 286.mg	0/33	0/39	0/40	0/31	0/33	2/32
TBA MXB y		64.5ug *	P<.0005	29.8ug .163mg	30/33	34/39	34/40	24/31	25/33	18/32
liv MXB y		.151mg *	P<.0005	45.9ug .619mg	0/33	2/39	1/40	5/31	10/33	8/32
5200 R m f34 eat 24m24 TR398 :					0	.400mg	1.20mg			
liv MXA		.408mg *	P<.0005	c .282mg .646mg	1/50	12/50	41/50			liv:hpa,hpc.
liv hpa		.461mg *	P<.0005	c .313mg .745mg	1/50	10/50	38/50			
liv hpc		1.19mg *	P<.0005	c .700mg 2.25mg	0/50	2/50	19/50			
TBA MXB		1.56mg *	P<.3	.429mg n.s.s.	45/50	48/50	50/50			
liv MXB		.408mg *	P<.0005	.282mg .646mg	1/50	12/50	41/50			liv:hpa,hpb,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

POLYBROMINATED BIPHENYLS (firemaster BP-6) 59536-65-1

5201 R f sss eat 57w57 1061					0	2.50mg			Schwartz;jnci,64,63-67;1980
liv tum	no dre	P=1.	-	1.86mg n.s.s.	0/8	0/12			
tba mix	5.91mg	P<.4	-	.962mg n.s.s.	0/8	1/12			

POLYDEXTROSE, ACID FORM 68424-04-4

5202 M f cd1 eat 80w80 2126					0	6.50gm	13.0gm		Burdock;fctx,37,233-264;1999/pers.comm.
liv tum e	no dre	P=1.	-	25.7gm n.s.s.	0/49	0/49	0/48		
5203 M m cd1 eat 80w80 2126					0	6.00gm	12.0gm		
liv hpa e	46.3gm	* P<.3	-	13.9gm n.s.s.	5/49	10/50	9/50		

POLYOXYETHYLENE(10)NONYLPHENYL ETHER (NP-10) 26027-38-3

5204 M f b6c eat 24m24 2620					0	65.0mg	195.mg	585.mg	Inoue;jtxs,24,149-166;1999
liv hpa e	8.67gm	* P<.6	-	1.34gm n.s.s.	5/50	8/50	9/50	8/50	
liv hpc e	no dre	P=1.	-	3.92gm n.s.s.	5/50	3/50	3/50	2/50	
5205 R f f3d eat 52w52 2614m					0	450.mg			Inoue;jtxs,24,167-193;1999/pers.comm.
liv tum ek	no dre	P=1.	-	464.mg n.s.s.	0/20	0/20			
5206 R f f3d eat 24m24 2614n					0	450.mg			
liv hpa e	no dre	P=1.	-	4.64gm n.s.s.	3/50	0/50			

POLYSORBATE 80 9005-65-6

5207 M f b6c eat 24m24 TR415 :					0	3.19gm	6.42gm		
TBA MXB	42.9gm	/ P<.8	-	5.34gm n.s.s.	30/51	16/50	29/50		
liv MXB	no dre	P=1.		23.6gm n.s.s.	3/51	2/50	2/50		liv:hpa,hpc,nnd.
lun MXB	332.gm	* P<.9		18.1gm n.s.s.	3/51	2/50	3/50		lun:a/a,a/c.
5208 M m b6c eat 24m24 TR415 :					0	2.95gm	5.92gm		
TBA MXB	no dre	P=1.	-	5.33gm n.s.s.	32/53	34/53	31/50		
liv MXB	no dre	P=1.		12.5gm n.s.s.	15/53	13/53	11/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		15.7gm n.s.s.	6/53	6/53	5/50		lun:a/a,a/c.
5209 R f f34 eat 24m24 TR415 :					0	1.23gm	2.47gm		
liv hpa #	15.8gm	* P<.05	-	5.46gm n.s.s.	0/50	1/50	3/50		S
TBA MXB	no dre	P=1.		1.41gm n.s.s.	49/50	48/50	48/50		
liv MXB	15.8gm	* P<.05		5.46gm n.s.s.	0/50	1/50	3/50		liv:hpa,hpc,nnd.
5210 R m f34 eat 99w99 TR415 :					0	1.00gm	2.00gm		
amd MXA	2.58gm	* P<.07	e	1.02gm n.s.s.	21/50	19/50	29/50		amd:pbb,phm,pob.
TBA MXB	3.29gm	* P<.5		781.mg n.s.s.	47/50	46/50	46/50		
liv MXB	217.gm	* P<.9		8.20gm n.s.s.	2/50	0/50	2/50		liv:hpa,hpc,nnd.

POLYVINYLPYRIDINE-N-OXIDE 9045-81-2

5211 M f ici ivj 17m24 1419					0	8.24mg			Schmahl;arzn,19,1313-1314;1969
lun ade	no dre	P=1.	-	48.0mg n.s.s.	3/39	2/50			
tba mal	no dre	P=1.	-	14.9mg n.s.s.	14/39	17/50			
tba ben	1.69gm	P<1.	-	30.9mg n.s.s.	3/39	4/50			
5212 R f wis ivj 17m24 1419					0	5.89mg			
tba mal	175.mg	P<.8	-	18.2mg n.s.s.	4/48	5/48			
tba ben	no dre	P=1.	-	21.8mg n.s.s.	4/48	4/48			

POTASSIUM BICARBONATE 298-14-6

5213 R f wsr eat 78w78 2095m					0	1.00gm	2.00gm		Lina;carc,15,523-527;1994/pers.comm.
ubl tpp ekr	8.28gm	* P<.1		2.03gm n.s.s.	0/15	0/15	2/15		
ubl tcc ekr	no dre	P=1.		1.16gm n.s.s.	0/15	0/15	0/15		
5214 R f wsr eat 30m30 2095n					0	1.00gm	2.00gm		
ubl mix erh	12.8gm	* P<.0005	+	6.43gm 36.1gm	0/48	2/48	9/47		
ubl tpp erh	20.7gm	* P<.004	+	8.94gm 126.gm	0/48	1/48	6/47		
ubl tcc erh	37.1gm	* P<.04	+	12.8gm n.s.s.	0/48	1/48	3/47		
5215 R m wsr eat 78w78 2095m					0	800.mg	1.60gm		
ubl mix ekr	6.40gm	* P<.3		1.57gm n.s.s.	0/15	1/13	1/15		
ubl tcc ekr	12.9gm	* P<.3		2.11gm n.s.s.	0/15	0/13	1/15		
ubl tpp ekr	13.1gm	* P=1.		2.13gm n.s.s.	0/15	1/13	0/15		
5216 R m wsr eat 28m28 2095n					0	800.mg	1.60gm		
ubl mix erh	13.2gm	* P<.05	+	5.98gm n.s.s.	0/48	5/50	3/49		
ubl tpp erh	17.8gm	* P<.1	+	7.26gm n.s.s.	0/48	4/50	2/49		
ubl tcc erh	54.4gm	* P<.3	+	13.4gm n.s.s.	0/48	1/50	1/49		

POTASSIUM CHLORIDE 7447-40-7

5217 R m f34 eat 24m24 1807					0	100.mg	400.mg	1.60gm	Imai;jnma,37,115-127;1986
amd phe	6.21gm	* P<.2	-	1.84gm n.s.s.	11/50	16/50	20/50	19/50	
mgl fba	33.5gm	Z P<.5	-	5.60gm n.s.s.	0/50	6/50	1/50	4/50	
5218 R f wsr eat 78w78 2095m					0	1.50gm			Lina;carc,15,523-527;1994/pers.comm.
ubl mix ekr	no dre	P=1.		2.61gm n.s.s.	0/15	0/15			
5219 R f wsr eat 30m30 2095n					0	1.50gm			
ubl tpp er	79.5gm	P<.3		12.9gm n.s.s.	0/48	1/50			
ubl tcc er	no dre	P=1.		24.2gm n.s.s.	0/48	0/50			
5220 R m wsr eat 78w78 2095m					0	1.20gm			
ubl mix ekr	no dre	P=1.		1.95gm n.s.s.	0/15	0/14			
5221 R m wsr eat 28m28 2095n					0	1.20gm			
ubl mix er	no dre	P=1.		16.4gm n.s.s.	0/48	0/49			

POTASSIUM IODIDE 7681-11-0

5222 R f f3d wat 24m24 2520					0	.571mg	5.71mg	57.1mg	Takegawa;gann,89,105-109;1998/2000
slm sqc Ceh	560.mg	* P<.006	+	169.mg 7.59gm	0/40	0/40	0/40	3/40	
ute esp e	204.mg	Z P<.02	-	79.4mg n.s.s.	1/40	7/40	2/40	10/40	
liv tum e	no dre	P=1.		4.24mg n.s.s.	0/40	0/40	0/40	0/40	
5223 R m f3d wat 24m24 2520					0	.500mg	5.00mg	50.0mg	
slm sqc Ceh	363.mg	* P<.002	+	125.mg 2.04gm	0/40	0/40	0/40	4/40	
liv hpa e	no dre	P=1.		389.mg n.s.s.	1/40	0/40	1/40	0/40	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
PRACTOLOL (eraldin) 6673-35-4									
5224 M f aps mix 78w78 2358m					0	20.0mg	100.mg		Cruickshank;stnd,93-123;1984
lun tum e	no dre	P=1.	-	104.mg n.s.s.	2/24	5/24	3/25		
liv tum e	no dre	P=1.	-	217.mg n.s.s.	0/24	1/24	0/25		
5225 M m aps mix 78w78 2358m					0	20.0mg	100.mg		
lun tum e	383.mg *	P<.4	-	85.7mg n.s.s.	2/25	2/23	4/24		
liv tum e	24.3gm *	P<1.	-	130.mg n.s.s.	4/25	1/23	3/24		
5226 R f aap eat 24m24 2358n					0	20.0mg	100.mg		
liv tum e	no dre	P=1.	-	68.1mg n.s.s.	0/20	0/20	0/19		
5227 R m aap eat 24m24 2358n					0	16.0mg	80.0mg		
pit tum e	23.9mg \	P<.006	-	9.97mg 293.mg	1/20	8/20	(1/20)		
tes tum e	194.mg *	P<.004	-	79.0mg 1.55gm	0/20	1/20	5/20		
liv tum e	no dre	P=1.	-	55.0mg n.s.s.	0/20	0/20	0/20		
PRANLUKAST HYDRATE (ONO-1078 HYDRATE) 150821-03-7									
5228 R f sjd gav 52w52 2388m					0	1.00gm			Yonezawa;phrm,44,219-242;1992
liv tum e	no dre	P=1.	-	1.03gm n.s.s.	0/19	0/20			
5229 R f sjd gav 52w56 2388n					0	923.mg			
liv tum e	no dre	P=1.	-	276.mg n.s.s.	0/5	0/5			
5230 R m sjd gav 52w52 2388m					0	1.00gm			
liv tum e	no dre	P=1.	-	979.mg n.s.s.	0/19	0/19			
5231 R m sjd gav 52w56 2388n					0	923.mg			
liv nnd e	no dre	P=1.	-	276.mg n.s.s.	1/5	0/5			
PRAZEPAM 2955-38-6									
5232 M f cf1 eat 80w80 2139					0	8.00mg	25.0mg	75.0mg	de la Iglesia;txap,57,39-54;1981/pers.comm.
bon otm e	264.mg *	P<.01	-	108.mg 15.3gm	5/100	0/50	3/50	8/50	
--- lyt e	146.mg *	P<.07	-	54.5mg n.s.s.	21/100	11/50	17/50	17/50	
lun agt e	15.4gm *	P<1.	-	142.mg n.s.s.	16/100	4/50	9/50	7/50	
liv hpa e	no dre	P=1.	-	338.mg n.s.s.	1/100	1/50	2/50	0/50	
liv hpc e	no dre	P=1.	-	452.mg n.s.s.	1/100	0/50	1/50	0/50	
tba mal e	108.mg *	P<.07	-	40.6mg n.s.s.	41/100	16/50	22/50	27/50	
tba ben e	251.mg *	P<.09	-	86.2mg n.s.s.	11/100	4/50	8/50	10/50	
tba mix e	139.mg *	P<.3	-	41.5mg n.s.s.	49/100	18/50	27/50	28/50	
5233 M m cf1 eat 80w80 2139					0	8.00mg	25.0mg	75.0mg	
liv hpa e	2.15gm *	P<.5	-	296.mg n.s.s.	1/100	0/50	1/50	1/50	
liv hpc e	8.96gm *	P<1.	-	179.mg n.s.s.	7/100	5/50	4/50	4/50	
--- lyt e	no dre	P=1.	-	135.mg n.s.s.	10/100	7/50	11/50	5/50	
lun agt e	no dre	P=1.	-	175.mg n.s.s.	19/100	4/50	7/50	7/50	
tba ben e	639.mg *	P<.3	-	164.mg n.s.s.	6/100	0/50	2/50	5/50	
tba mix e	6.41gm *	P<1.	-	80.2mg n.s.s.	38/100	15/50	21/50	18/50	
tba mal e	no dre	P=1.	-	89.6mg n.s.s.	35/100	15/50	21/50	16/50	
5234 R f wal eat 24m24 2139					0	8.00mg	25.0mg	75.0mg	
mgl mix e	207.mg *	P<.06	-	80.4mg n.s.s.	41/115	26/65	25/65	33/65	
liv hpa e	1.45gm *	P<.06	-	431.mg n.s.s.	1/115	0/65	1/65	3/65	
pit cra e	no dre	P=1.	-	314.mg n.s.s.	34/115	18/65	23/65	13/65	
tba mal e	415.mg *	P<.1	-	145.mg n.s.s.	18/115	9/65	13/65	16/65	
tba mix e	230.mg *	P<.4	-	55.1mg n.s.s.	80/115	42/65	50/65	48/65	
tba ben e	67.5gm *	P<1.	-	91.5mg n.s.s.	72/115	39/65	46/65	40/65	
5235 R m wal eat 24m24 2139					0	8.00mg	25.0mg	75.0mg	
liv hpc e	2.39gm *	P<.2	-	587.mg n.s.s.	0/115	0/65	1/65	1/65	
liv hpa e	3.54gm *	P<.5	-	548.mg n.s.s.	1/115	0/65	2/65	1/65	
pit cra e	no dre	P=1.	-	385.mg n.s.s.	17/115	2/65	6/65	7/65	
tba ben e	1.51gm Z	P<.7	-	183.mg n.s.s.	37/115	7/65	16/65	19/65	
tba mix e	3.08gm *	P<.9	-	137.mg n.s.s.	57/115	21/65	26/65	30/65	
tba mal e	no dre	P=1.	-	254.mg n.s.s.	23/115	16/65	12/65	13/65	
PRAZIQUANTEL (embay 8440, droncit) 55268-74-1									
5236 H f syg gav 80w80 1519m					0	14.3mg	35.7mg		Ketkar;txcy,24,345-350;1982
tba mix e	250.mg *	P<.5	-	50.3mg n.s.s.	12/99	9/50	8/49		
5237 H m syg gav 80w80 1519m					0	14.3mg	35.7mg		
tba mix e	no dre	P=1.	-	79.5mg n.s.s.	23/99	16/49	7/50		
5238 R f sda gav 24m30 1519n					0	11.4mg	28.6mg		
tba mix e	no dre	P=1.	-	57.7mg n.s.s.	76/97	37/50	35/50		
5239 R m sda gav 24m30 1519n					0	11.4mg	28.6mg		
tba mix e	no dre	P=1.	-	106.mg n.s.s.	61/103	27/50	23/50		
PREDNIMUSTINE 29069-24-7									
5240 R f sda gav 18m24 1770					0	1.29mg	2.58mg		Berger;smon,13,8-13;1986
auc sqc	19.2mg *	P<.005	+	6.64mg 167.mg	0/120	2/30	2/30		
tba ben	14.0mg *	P<.5	-	2.92mg n.s.s.	43/120	12/30	13/30		
tba mal	21.6mg *	P<.3	-	5.23mg n.s.s.	13/120	3/30	6/30		
PREDNISOLONE 50-24-8									
5241 R m cdr wat 24m24 2059					0	.400mg			Ryrfeldt;txpy,20,115-117;1992
liv mix ers	1.53mg	P<.0005	+	.799mg 4.81mg	11/200	21/100			
liv hpa ers	2.16mg	P<.002		1.04mg 9.22mg	7/200	15/100			
liv hpc ers	6.58mg	P<.08		2.05mg n.s.s.	4/200	6/100			
5242 R f sda gav 18m24 1770					0	.323mg	.645mg		Berger;smon,13,8-13;1986
tba ben	1.96mg *	P<.2	-	.599mg n.s.s.	43/120	12/30	15/30		
tba mal	no dre	P=1.	-	2.37mg n.s.s.	13/120	4/30	2/30		
PREDNISONE 53-03-2									
5243 M f cd1 eat 78w78 2104					0	.250mg	.500mg	1.00mg	5.00mg Dillberger;txpy,20,18-26;1992
lun abt es	no dre	P=1.	-	19.7mg n.s.s.	6/48	4/50	3/50	2/50	2/49
lun ulc es	no dre	P=1.	-	22.1mg n.s.s.	0/48	0/50	0/50	1/50	0/49
liv mix es	no dre	P=1.	-	31.0mg n.s.s.	3/47	3/50	1/50	1/50	0/49

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
5244 M m cd1 eat 78w78 2104				0	.250mg	.500mg	1.00mg	5.00mg	
liv mix es	no dre	P=1.	- 3.52mg n.s.s.	12/50	7/50	8/50	4/50	(1/50)	
lun abt es	no dre	P=1.	- 17.7mg n.s.s.	9/50	6/50	4/50	6/50	3/50	
PREMARIN (conjugated equine estrogens) 12126-59-9									
5245 R f cdr eat 24m24 108				0	70.0ug	.700mg			Gibson;txap,11,489-510;1967
liv tum e	no dre	P=1.	- .262mg n.s.s.	0/20	0/20	0/20			
5246 R m cdr eat 24m24 108				0	70.0ug	.700mg			
liv hpt e	no dre	P=1.	- 2.32mg n.s.s.	0/20	1/20	0/20			
PRIMIDOLOL.HCl 40778-40-3									
5247 M f cd1 eat 78w78 1669				0	12.5mg	25.0mg	50.0mg		Faccini;txcy,21,279-290;1981
lun ade e	449.mg *	P<.4	95.9mg n.s.s.	8/100	5/50	2/49	7/50		
lun adc e	1.67gm *	P<.4	272.mg n.s.s.	0/100	0/50	1/49	0/50		
liv hpc e	1.67gm *	P<.2	271.mg n.s.s.	0/100	0/50	0/49	1/50		
tba mix e	52.3mg *	P<.005	25.5mg 595.mg	24/100	19/50	17/49	24/50		
5248 M m cd1 eat 78w78 1669				0	50.0mg				
liv hpc e	935.mg	P<.5	130.mg n.s.s.	2/100	2/50				
liv cho e	no dre	P=1.	290.mg n.s.s.	1/100	0/50				
liv ade e	no dre	P=1.	290.mg n.s.s.	8/100	0/50				
lun adc e	no dre	P=1.	290.mg n.s.s.	1/100	0/50				
lun ade e	no dre	P=1.	121.mg n.s.s.	22/100	7/50				
tba mix e	no dre	P=1.	101.mg n.s.s.	48/100	15/50				
PRIMIDONE 125-33-7									
5249 M f b6c eat 23m24 TR476 :				0	37.9mg	75.8mg	164.mg		
liv hpa	27.7mg Z	P<.002 c	14.6mg 115.mg	15/50	42/50	(45/50	47/50)		
liv MXA	28.9mg Z	P<.002 c	14.9mg 142.mg	16/50	42/50	(45/50	50/50)		liv:hpa,hpc.
liv MXA	42.8mg Z	P<.0005 c	24.2mg 157.mg	16/50	42/50	46/50	(50/50)		liv:hpa,hpb,hpc.
liv hpc	97.3mg *	P<.0005 c	67.2mg 167.mg	3/50	11/50	19/50	38/50		
liv MXA	98.7mg *	P<.0005 c	67.3mg 175.mg	4/50	12/50	20/50	39/50		liv:hpb,hpc.
liv hpb	1.39gm *	P<.3	399.mg n.s.s.	1/50	4/50	4/50	4/50		
TBA MXB	163.mg *	P<.08	63.2mg n.s.s.	34/50	47/50	47/50	50/50		
liv MXB	42.8mg Z	P<.0005	24.2mg 157.mg	16/50	42/50	46/50	(50/50)		liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	844.mg n.s.s.	7/50	5/50	4/50	3/50		lun:a/a,a/c.
5250 M m b6c eat 23m24 TR476 :				0	35.0mg	70.1mg	152.mg		
liv MXA	24.7mg Z	P<.0005 c	13.6mg 76.5mg	12/50	39/50	(40/50	39/50)		liv:hpb,hpc.
liv hpb	52.5mg Z	P<.0005	35.9mg 80.7mg	0/50	17/50	26/50	(7/50)		S
liv hpc	55.0mg *	P<.0005	34.3mg 119.mg	12/50	31/50	35/50	38/50		S
liv MXA	60.2mg *	P<.002 c	32.2mg 264.mg	31/50	49/50	49/50	46/50		liv:hpa,hpb,hpc.
MXB MXB	60.2mg *	P<.002	32.2mg 264.mg	31/50	49/50	49/50	46/50		liv:hpa,hpb,hpc; thy:fca. M
liv MXA	60.4mg *	P<.002 c	32.4mg 261.mg	31/50	48/50	47/50	46/50		liv:hpa,hpc.
thy fca	349.mg *	P<.002 p	179.mg 1.43gm	0/50	3/50	3/50	6/50		
liv hpa	46.8mg Z	P<.02	22.8mg 34.3gm	22/50	41/50	39/50	(32/50)		S
--- hcs	1.15gm Z	P<.03	391.mg n.s.s.	1/50	0/50	0/50	5/50		S
TBA MXB	77.6mg *	P<.01	36.9mg 3.75gm	40/50	50/50	50/50	47/50		
liv MXB	60.2mg *	P<.002	32.2mg 264.mg	31/50	49/50	49/50	46/50		liv:hpa,hpb,hpc.
lun MXB	1.76gm *	P<.7	229.mg n.s.s.	11/50	9/50	6/50	9/50		lun:a/a,a/c.
5251 R f f34 eat 23m24 TR476 :				0	29.3mg	63.6mg	122.mg		
TBA MXB	no dre	P=1.	- 104.mg n.s.s.	47/50	44/50	41/50	46/50		
liv MXB	4.05gm *	P<.6	631.mg n.s.s.	0/50	1/50	0/50	1/50		liv:hpa,hpb,hpc.
5252 R m f34 eat 23m24 TR476 :				0	23.5mg	50.8mg	100.mg		
tes MXA as	8.15mg Z	P<.0005	4.97mg 15.2mg	41/50	44/50	42/50	43/50		tes:iab,ica. S
amd MXA as	20.8mg *	P<.0005	10.4mg 75.6mg	23/50	28/50	24/50	12/50		amd:pbb,phm,pob. S
amd MXA as	20.8mg *	P<.0005	10.4mg 75.6mg	23/50	28/50	24/50	12/50		amd:pbb,pob. S
thy MXA as	80.2mg *	P<.003 e	29.4mg 557.mg	2/50	4/50	7/50	4/50		thy:fca,fcc.
thy fca as	174.mg *	P<.005	63.2mg 2.02gm	1/50	1/50	6/50	3/50		S
kid MXA as	522.mg *	P<.3	69.1mg n.s.s.	2/50	1/50	1/50	2/50		kid:rua,ruc.
kid rua as	1.28gm *	P<.7	80.1mg n.s.s.	2/50	1/50	1/50	1/50		
TBA MXB as	15.4mg *	P<.0005	7.98mg 50.2mg	49/50	45/50	46/50	26/50		
liv MXB as	138.mg Z	P<.09	32.3mg n.s.s.	1/50	1/50	1/50	1/50		liv:hpa,hpb,hpc.
5253 R m f34 eat 23m24 TR476 with step				0	23.5mg	50.8mg	100.mg		
kid MXA a	967.mg *	P<.2 e	295.mg n.s.s.	4/50	2/50	4/50	7/50		kid:rua,ruc.
kid rua a	1.29gm *	P<.4	325.mg n.s.s.	4/50	2/50	4/50	6/50		
PROBENECID 57-66-9									
5254 M f b6c gav 24m24 TR395 :				0	70.4mg	282.mg			
liv MXA	540.mg *	P<.003 p	256.mg 3.80gm	5/50	3/50	16/50			liv:hpa,hpc.
liv hpa	561.mg *	P<.002 p	273.mg 2.65gm	3/50	2/50	14/50			
TBA MXB	498.mg *	P<.2	161.mg n.s.s.	23/50	21/50	31/50			
liv MXB	540.mg *	P<.003	256.mg 3.80gm	5/50	3/50	16/50			liv:hpa,hpc,nnd.
lun MXB	1.98gm *	P<.3	488.mg n.s.s.	3/50	4/50	6/50			lun:a/a,a/c.
5255 M m b6c gav 24m24 TR395 :				0	70.5mg	282.mg			
sub fib #	2.13gm *	P<.02 -	643.mg n.s.s.	0/50	0/50	3/50			S
TBA MXB	276.mg *	P<.02	122.mg n.s.s.	25/50	26/50	36/50			
liv MXB	731.mg *	P<.2	241.mg n.s.s.	15/50	12/50	19/50			liv:hpa,hpc,nnd.
lun MXB	2.32gm *	P<.5	466.mg n.s.s.	5/50	4/50	6/50			lun:a/a,a/c.
5256 R f f34 gav 24m24 TR395 :				0	70.1mg	280.mg			
TBA MXB	1.54gm *	P<.8 -	129.mg n.s.s.	48/50	46/50	37/50			
liv MXB	1.79gm *	P<.07	543.mg n.s.s.	0/50	1/50	2/50			liv:hpa,hpc,nnd.
5257 R m f34 gav 24m24 TR395 :				0	70.0mg	281.mg			
tes MXA #	212.mg *	P<.05 -	85.3mg n.s.s.	45/50	39/50	44/50			tes:iab,ica. S
TBA MXB	296.mg *	P<.1	107.mg n.s.s.	42/50	41/50	41/50			
liv MXB	no dre	P=1.	1.13gm n.s.s.	1/50	2/50	0/50			liv:hpa,hpc,nnd.
PROCARBAZINE 671-16-9									
5258 R m b46 ivj 12m24 1017				0	1.71mg				Schmahl;arzn,20,1461-1467;1970
tba mix	4.01mg	P<.002 +	1.92mg 17.2mg	7/89	15/48				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mal		3.93mg	P<.0005	1.95mg 12.4mg	4/89	14/48			
tba ben		no dre	P=1.	11.4mg n.s.s.	3/89	1/48			
PROCARBAZINE.HCl		366-70-1							
5259 M f b6c ipj 52w85 TR19 :					0	2.00mg	5.20mg		
MXB MXB s		.194mg	/ P<.0005	65.1ug .432mg	0/15	19/35	18/35		---:leu,lym; bra:oln; lun:a/a; ute:acn. C
ute acn s		.253mg	/ P<.0005 c	68.9ug .728mg	0/15	14/35	8/35		
--- MXA s		.758mg	* P<.0005 c	.289mg 2.96mg	0/15	8/35	2/35		---:leu,lym.
--- lym s		.908mg	* P<.002 c	.308mg 5.34mg	0/15	6/35	2/35		
lun a/a s		3.83mg	/ P<.002 c	1.05mg 19.5mg	0/15	1/35	6/35		
bra oln s		6.34mg	/ P<.0005 c	2.93mg 16.6mg	0/15	0/35	11/35		
TBA MXB s		.193mg	/ P<.0005	65.0ug .422mg	0/15	19/35	20/35		
liv MXB s		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
lun MXB s		3.83mg	/ P<.002	1.05mg 19.5mg	0/15	1/35	6/35		lun:a/a,a/c.
5260 M f b6c ipj 52w80 TR19 : pool					0	2.00mg	5.20mg		
ute acn s		.411mg	/ P<.0005 c	.203mg .834mg	0/45	14/35	8/35		
--- MXA s		.690mg	* P<.0005 c	.258mg 2.69mg	1/45	8/35	2/35		---:leu,lym.
--- lym s		.855mg	* P<.0005 c	.283mg 4.57mg	1/45	6/35	2/35		
lun a/a s		3.39mg	/ P<.0005 c	.927mg 13.6mg	0/45	1/35	6/35		
bra oln s		5.62mg	/ P<.0005 c	2.60mg 13.2mg	0/45	0/35	11/35		
5261 M m b6c ipj 52w85 TR19 :					0	1.90mg	4.80mg		
MXB MXB s		.511mg	/ P<.0005	.289mg .947mg	0/15	14/35	19/35		---:leu,lym; bra:oln,ulc; lun:a/a,a/c. C
lun MXA s		.623mg	/ P<.0005 c	.323mg 1.39mg	0/15	11/35	10/35		lun:a/a,a/c.
lun a/a s		.721mg	/ P<.0005 c	.369mg 1.63mg	0/15	10/35	10/35		
--- MXA s		3.34mg	* P<.009 c	1.36mg 135.mg	0/15	4/35	4/35		---:leu,lym.
bra MXA s		4.51mg	/ P<.0005 c	2.07mg 13.1mg	0/15	0/35	10/35		bra:oln,ulc.
bra oln s		5.19mg	/ P<.0005 c	2.28mg 17.1mg	0/15	0/35	9/35		
TBA MXB s		.464mg	/ P<.0005	.271mg .821mg	0/15	18/35	20/35		
liv MXB s		3.28mg	/ P<.01	1.27mg 222.mg	0/15	3/35	3/35		liv:hpa,hpc,nnd.
lun MXB s		.623mg	/ P<.0005	.323mg 1.39mg	0/15	11/35	10/35		lun:a/a,a/c.
5262 M m b6c ipj 52w85 TR19 : pool					0	1.90mg	4.80mg		
lun MXA s		.623mg	/ P<.0005 c	.323mg 1.31mg	0/45	11/35	10/35		lun:a/a,a/c.
lun a/a s		.721mg	/ P<.0005 c	.369mg 1.53mg	0/45	10/35	10/35		
--- MXA s		3.34mg	* P<.002 c	1.36mg 13.8mg	0/45	4/35	4/35		---:leu,lym.
bra MXA s		4.51mg	/ P<.0005 c	2.07mg 11.7mg	0/45	0/35	10/35		bra:oln,ulc.
bra oln s		5.19mg	/ P<.0005 c	2.28mg 14.6mg	0/45	0/35	9/35		
5263 M f swi ipj 26w76 1336					0	1.75mg		Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.	
lun mix e		1.05mg	P<.0005 +	.446mg 4.68mg	20/154	10/19			
--- leu e		3.72mg	P<.0005	1.12mg 26.7mg	0/154	3/19			
ute car e		5.75mg	P<.004	1.41mg 82.8mg	0/154	2/19			
ute sar e		6.11mg	P<.03	1.43mg n.s.s.	1/154	2/19			
--- lys e		6.99mg	P<.09 +	1.47mg n.s.s.	3/154	2/19			
liv lys e		no dre	P=1.	3.66mg n.s.s.	1/154	0/19			
tba mix e		.244mg	P<.0005	92.6ug .683mg	42/154	18/19			
tba mal e		.391mg	P<.0005	.181mg 1.03mg	29/154	16/19			
tba ben e		27.8mg	P<.8	1.74mg n.s.s.	13/154	2/19			
5264 M m swi ipj 26w78 1336					0	1.71mg			
lun mix e		1.53mg	P<.0005 +	.683mg 6.43mg	9/101	11/27			
liv mix e		no dre	P=1.	5.35mg n.s.s.	2/101	0/27			
tba mix e		1.15mg	P<.004	.492mg 9.99mg	28/101	16/27			
tba mal e		1.74mg	P<.009	.689mg 94.8mg	19/101	12/27			
tba ben e		9.84mg	P<.4	1.74mg n.s.s.	9/101	4/27			
5265 P b cym mix 16y19 2004 :					0	3.96mg		Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.	
bon ost jmw		5.91mg	P<.005	1.34mg 109.mg	0/49	2/8			
--- anl jmw		14.8mg	P<.008 +	3.65mg 544.mg	0/67	2/13			
bra ast jmw		6.19mg	P<.06	1.01mg n.s.s.	0/16	1/3			
--- lcl jmw		21.1mg	P<.06	3.43mg n.s.s.	0/49	1/9			
kid hes jmw		23.5mg	P<.06	3.83mg n.s.s.	0/50	1/10			
tba mal Wjmw		1.73mg	P<.0005	.622mg 6.53mg	1/67	7/13			
5266 P b rhe mix 16y23 2004 :					0	3.78mg			
--- anl jmw		4.21mg	P<.0005 +	1.48mg 14.4mg	0/105	6/22			
cec adc jmw		5.16mg	P<.04	.840mg n.s.s.	0/18	1/2			
hum ost jmw		32.7mg	P<.05	5.32mg n.s.s.	0/64	1/10			
kid hes jmw		39.6mg	P<.06	6.44mg n.s.s.	0/68	1/12			
tba mal Wjmw		1.90mg	P<.0005	.722mg 7.08mg	5/105	9/22			
5267 R f sda ipj 26w86 TR19 :					0	3.15mg	10.8mg		
MXB MXB s		.337mg	/ P<.0005	.106mg .701mg	0/10	25/36	30/35		---:lym; bra:oln; crb:mua; mgl:acn,adn. C
MXA MXA s		.416mg	* P<.0005 c	.112mg 1.47mg	0/10	17/36	3/35		bra:oln; crb:mua.
bra oln s		.418mg	* P<.0005 c	.112mg 1.51mg	0/10	17/36	2/35		
mgl MXA s		.458mg	/ P<.0005 c	.112mg 1.37mg	0/10	17/36	25/35		mgl:acn,adn.
mgl acn s		.459mg	/ P<.0005 c	.112mg 1.37mg	0/10	16/36	25/35		
--- lym s		5.18mg	/ P<.0005 c	2.79mg 9.68mg	0/10	0/36	20/35		
TBA MXB s		.329mg	/ P<.0005	.105mg .668mg	4/10	27/36	30/35		
liv MXB s		no dre	P=1.	n.s.s. n.s.s.	0/10	0/36	0/35		liv:hpa,hpc,nnd.
5268 R f sda ipj 26w80 TR19 : pool					0	3.15mg	10.8mg		
MXA MXA s		.360mg	* P<.0005 c	96.8ug 1.10mg	0/40	17/36	3/35		bra:oln; crb:mua.
bra oln s		.361mg	* P<.0005 c	96.9ug 1.11mg	0/40	17/36	2/35		
mgl MXA s		.396mg	/ P<.0005 c	96.7ug 1.14mg	3/40	17/36	25/35		mgl:acn,adn.
mgl acn s		.397mg	/ P<.0005 c	96.8ug 1.15mg	2/40	16/36	25/35		
--- lym s		4.48mg	/ P<.0005 c	2.41mg 8.16mg	0/40	0/36	20/35		
5269 R m sda ipj 26w61 TR19 :					0	2.20mg	6.20mg		
MXB MXB s		.284mg	* P<.0005	.104mg .627mg	1/10	16/34	24/35		---:leu,lym; bra:can,oln; mgl:acn,adn; olb:acn. C
MXA MXA s		.343mg	* P<.0005 c	.110mg 1.13mg	0/10	12/34	9/35		bra:can,oln; olb:acn.
--- MXA s		2.10mg	* P<.0005 c	1.00mg 5.59mg	1/10	3/34	12/35		---:leu,lym.
mgl MXA s		4.50mg	* P<.003 c	1.93mg 20.1mg	0/10	1/34	8/35		mgl:acn,adn.
mgl acn s		4.85mg	* P<.004 c	2.00mg 29.1mg	0/10	1/34	7/35		
TBA MXB s		.186mg	/ P<.0005	84.2ug .361mg	4/10	19/34	30/35		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB s	no dre	P=1.	n.s.s. n.s.s.	0/10	0/34	0/35		liv:hpa,hpc,nnd.
5270 R m sda ipj 26w61 TR19 : pool				0	2.20mg	6.20mg		
MXA MXA s	.343mg	* P<.0005	c .110mg .885mg	0/40	12/34	9/35		bra:can,oln; olb:acn.
--- MXA s	2.10mg	* P<.0005	c 1.00mg 4.63mg	1/40	3/34	12/35		---:leu,lym.
--- lym s	2.51mg	* P<.0005	c 1.10mg 6.37mg	1/40	3/34	9/35		
mgl MXA s	4.50mg	* P<.0005	c 1.93mg 12.8mg	1/40	1/34	8/35		mgl:acn,adn.
olb acn s	4.67mg	* P<.003	1.22mg 50.7mg	0/40	0/34	3/35		S
mgl acn s	4.85mg	* P<.0005	c 2.00mg 15.3mg	1/40	1/34	7/35		
--- leu s	13.3mg	* P<.02	3.78mg n.s.s.	0/40	0/34	3/35		S
PROFLAVINE.HCl HEMIHYDRATE 952-23-8								
5271 M f b6c eat 24m24 TR5 :				0	26.0mg	52.0mg		
liv MXA #	26.4mg	\ P<.0005	i 13.6mg 89.3mg	5/49	20/50	(22/50)		liv:hpa,hpc. S
TBA MXB	86.2mg	* P<.3	26.0mg n.s.s.	36/49	37/50	41/50		
liv MXB	26.4mg	\ P<.0005	13.6mg 89.3mg	5/49	20/50	(22/50)		liv:hpa,hpc,nnd.
lun MXB	487.mg	* P<.5	107.mg n.s.s.	4/49	3/50	6/50		lun:a/a,a/c.
5272 M m b6c eat 24m24 TR5 :				0	24.0mg	48.0mg		
TBA MXB	no dre	P=1.	i 35.5mg n.s.s.	39/50	38/50	39/50		
liv MXB	248.mg	* P<.7	34.1mg n.s.s.	26/50	28/50	30/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	95.5mg n.s.s.	9/50	11/50	8/50		lun:a/a,a/c.
5273 R f f34 eat 25m25 TR5 :				0	15.0mg	30.0mg		
TBA MXB	no dre	P=1.	i 21.2mg n.s.s.	48/50	42/50	(35/50)		
liv MXB	no dre	P=1.	157.mg n.s.s.	1/50	2/50	1/50		liv:hpa,hpc,nnd.
5274 R m f34 eat 25m25 TR5 :				0	12.0mg	24.0mg		
MXA MXA #	213.mg	* P<.02	i 80.8mg 25.0gm	0/50	0/50	5/50		lgi:srn; smi:acn,lei. S
liv MXA	254.mg	* P<.05	87.8mg n.s.s.	0/50	1/50	3/50		liv:hpc,nnd. S
TBA MXB	no dre	P=1.	35.6mg n.s.s.	36/50	30/50	32/50		
liv MXB	254.mg	* P<.05	87.8mg n.s.s.	0/50	1/50	3/50		liv:hpa,hpc,nnd.
PROMETHAZINE.HCl 58-33-3								
5275 M f b6c gav 24m24 TR425 :				0	2.63mg	5.28mg	10.6mg	
TBA MXB	no dre	P=1.	- 17.0mg n.s.s.	31/50	33/50	29/51	26/51	
liv MXB	47.8mg	* P<.08	18.6mg n.s.s.	4/50	4/50	7/51	10/51	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	102.mg n.s.s.	8/50	2/50	0/51	2/51	lun:a/a,a/c.
5276 M m b6c gav 24m24 TR425 :				0	7.90mg	15.9mg	31.8mg	
TBA MXB	393.mg	* P<.9	- 31.1mg n.s.s.	31/50	35/50	29/50	37/50	
liv MXB	157.mg	* P<.4	37.8mg n.s.s.	18/50	18/50	17/50	25/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	111.mg n.s.s.	11/50	9/50	7/50	8/50	lun:a/a,a/c.
5277 R f f34 gav 24m24 TR425 :				0	5.81mg	11.6mg	23.4mg	
TBA MXB	no dre	P=1.	- 16.7mg n.s.s.	46/50	42/50	39/50	32/53	
liv MXB	418.mg	* P<.2	102.mg n.s.s.	0/50	0/50	1/50	1/53	liv:hpa,hpb,hpc.
5278 R m f34 gav 24m24 TR425 :				0	5.85mg	11.8mg	23.7mg	
tes MXA #	10.3mg	* P<.02	- 4.68mg n.s.s.	47/50	44/50	44/50	43/51	tes:iab,ica. S
TBA MXB	24.6mg	* P<.3	6.85mg n.s.s.	44/50	46/50	47/50	31/51	
liv MXB	no dre	P=1.	49.7mg n.s.s.	4/50	2/50	3/50	1/51	liv:hpa,hpb,hpc.
PRONETHALOL (alderlin) 54-80-8								
5279 M f nss eat 64w64 20				0	65.0mg	130.mg	260.mg	Howe;natu,207,594-595;1965
thm tum r	408.mg	* P<.3	147.mg n.s.s.	0/25	3/25	4/25	2/25	
5280 M m nss eat 64w64 20				0	60.0mg	120.mg	240.mg	
thm tum r	1.93gm	* P<.7	266.mg n.s.s.	1/25	0/25	3/25	1/25	
PRONETHALOL.HCl (alderlin.HCl) 51-02-5								
5281 M f cf1 eat 78w78 469				0	150.mg			Newberne;txap,41,535-546;1977
lun ade e	1.30gm	P<.6	- 239.mg n.s.s.	3/40	6/52			
liv tum e	no dre	P=1.	- 904.mg n.s.s.	0/40	0/52			
5282 M m cf1 eat 78w78 469				0	150.mg			
lun ade e	931.mg	P<.5	- 174.mg n.s.s.	2/29	4/32			
liv ade e	1.82gm	P<.3	- 297.mg n.s.s.	0/29	1/32			
liv car e	no dre	P=1.	- 340.mg n.s.s.	1/29	1/32			
PROPANE SULTONE 1120-71-4								
5283 R f cdr gav 46w60 1112				0	8.00mg	8.53mg		Weisburger;jnci,67,75-88;1981
crb mag aes	4.06mg	* P<.1	+ 2.02mg n.s.s.	1/7	12/26	12/26		
mgl adc aes	4.13mg	* P<.02	+ 2.40mg n.s.s.	0/7	6/26	13/26		
crl mag aes	7.20mg	* P<.08	+ 3.70mg n.s.s.	0/7	8/26	4/26		
--- grl aesh	18.6mg	* P<.3	+ 7.07mg n.s.s.	0/7	2/26	3/26		
smi adc aesh	31.7mg	* P<.5	+ 9.60mg n.s.s.	0/7	2/26	1/26		
5284 R m cdr gav 46w60 1112				0	8.00mg	8.53mg		
crb mag aes	3.64mg	* P<.02	+ 2.16mg n.s.s.	0/6	10/26	11/26		
crl mag aes	4.75mg	* P<.03	+ 2.68mg n.s.s.	0/6	6/26	11/26		
smi adc aesh	15.4mg	* P<.3	+ 6.27mg n.s.s.	0/6	3/26	3/26		
--- grl aesh	23.5mg	* P<.3	+ 8.12mg n.s.s.	0/6	0/26	4/26		
PROPAZINE (gesamil) 139-40-2								
5285 M f b6a orl 76w76 1242				0	14.6mg			Innes;ntis,1968/1969
lun ade evx	82.6mg	P<.6	- 11.5mg n.s.s.	1/17	2/17			
liv hpt evx	no dre	P=1.	- 27.2mg n.s.s.	0/17	0/17			
tba mix evx	37.2mg	P<.4	- 7.81mg n.s.s.	2/17	4/17			
5286 M m b6a orl 76w76 1242				0	13.6mg			
liv hpt evx	73.1mg	P<.6	- 10.7mg n.s.s.	1/18	2/17			
lun ade evx	673.mg	P<1.	- 11.8mg n.s.s.	2/18	2/17			
tba mix evx	57.8mg	P<.7	- 7.80mg n.s.s.	3/18	4/17			
5287 M f b6c orl 76w76 1242				0	14.6mg			
liv hpt evx	no dre	P=1.	- 28.8mg n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1.	- 28.8mg n.s.s.	0/16	0/18			
tba mix evx	93.2mg	P<.3	- 15.2mg n.s.s.	0/16	1/18			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes / Path	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
5288 M m b6c orl 76w76 1242				0	13.6mg			
liv hpt evx	39.7mg	P<.1	- 9.75mg n.s.s.	0/16	2/17			
lun ade evx	82.0mg	P<.3	- 13.3mg n.s.s.	0/16	1/17			
tba mix evx	11.4mg	P<.003	- 4.61mg 61.9mg	0/16	6/17			
beta-PROPIOLACTONE 57-57-8								
5289 M f hic gav 77w77 1011				0	5.71mg			Van Duuren;jnci,63,1433-1439;1979
for tum	1.33mg	P<.0005	+ .765mg 2.49mg	0/30	24/30			
for sqc	1.47mg	P<.0005	.848mg 2.77mg	0/30	23/30			
5290 M m hic gav 83w83 1011				0	4.76mg			
for tum	1.16mg	P<.0005	+ .660mg 2.16mg	0/30	25/30			
for sqc	1.43mg	P<.0005	.821mg 2.68mg	0/30	23/30			
5291 R f esd gav 69w69 55				0	4.08mg			Van Duuren;jnci,37,825-838;1966
sto sqc	1.34mg	P<.02	+ .374mg n.s.s.	0/5	3/5			
5292 R f sda gav 12m35 1486				0	2.86mg			Dunkelberg;bjca,46,924-933;1982
sto tum e	1.61mg	P<.0005	+ .986mg 2.65mg	0/50	46/50			
PROPRANOLOL.HCl 318-98-9								
5293 M f cd1 eat 78w92 1635				0	84.8mg			Weikel;jcph,19,591-604;1979
lun ade e	2.12gm	P<.7	- 267.mg n.s.s.	3/60	4/57			
liv tum e	no dre	P=1.	- 779.mg n.s.s.	0/60	0/57			
tba ben e	1.99gm	P<.7	- 243.mg n.s.s.	4/60	5/57			
tba mal e	no dre	P=1.	- 323.mg n.s.s.	13/60	7/57			
tba mix e	no dre	P=1.	- 211.mg n.s.s.	16/60	12/57			
5294 M m cd1 eat 78w92 1635				0	84.8mg			
liv car e	2.91gm	P<.6	- 371.mg n.s.s.	1/57	2/61			
liv ade e	no dre	P=1.	- 672.mg n.s.s.	6/57	1/61			
lun ade e	no dre	P=1.	- 228.mg n.s.s.	11/57	10/61			
lun car e	no dre	P=1.	- 512.mg n.s.s.	1/57	1/61			
tba mal e	670.mg	P<.4	- 171.mg n.s.s.	5/57	9/61			
tba ben e	no dre	P=1.	- 314.mg n.s.s.	19/57	11/61			
tba mix e	no dre	P=1.	- 203.mg n.s.s.	23/57	18/61			
5295 R f f34 gav 88w91 2219				0	70.9mg			Zavanella;carc,15,2531-2539;1994/pers.comm.
liv mix rsv	no dre	P=1.	- 146.mg n.s.s.	1/24	0/13			
5296 R m f34 gav 88w91 2219				0	70.9mg			
liv mix rsv	no dre	P=1.	- 134.mg n.s.s.	1/21	0/12			
5297 R f lev eat 18m24 1635				0	28.0mg			Weikel;jcph,19,591-604;1979
liv tum e	no dre	P=1.	- 347.mg n.s.s.	0/60	0/60			
tba mix e	144.mg	P<.7	- 19.4mg n.s.s.	44/60	46/60			
tba ben e	no dre	P=1.	- 33.5mg n.s.s.	43/60	40/60			
tba mal e	342.mg	P<.4	- 78.0mg n.s.s.	5/60	8/60			
5298 R m lev eat 18m24 1635				0	28.0mg			
liv hpa e	no dre	P=1.	- 347.mg n.s.s.	1/60	0/60			
tba mix e	no dre	P=1.	- 39.0mg n.s.s.	44/60	39/60			
tba ben e	no dre	P=1.	- 59.6mg n.s.s.	41/60	32/60			
tba mal e	no dre	P=1.	- 76.7mg n.s.s.	12/60	12/60			
PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE, COMMERCIAL GRADE (78%) (tillam-6-E) 1114-71-2								
5299 M f b6a orl 76w76 1223				0	44.3mg			Innes;ntis,1968/1969
lun ade evx	113.mg	P<.09	- 27.8mg n.s.s.	0/15	2/15			
liv hpt evx	no dre	P=1.	- 73.1mg n.s.s.	0/15	0/15			
tba mix evx	219.mg	P<.6	- 30.5mg n.s.s.	1/15	2/15			
5300 M m b6a orl 76w76 1223				0	41.2mg			
lun ade evx	no dre	P=1.	- 33.8mg n.s.s.	3/18	2/15			
liv hpt evx	no dre	P=1.	- 68.0mg n.s.s.	0/18	0/15			
tba mix evx	no dre	P=1.	- 33.8mg n.s.s.	3/18	2/15			
5301 M f b6c orl 76w76 1223				0	44.3mg			
lun ade evx	267.mg	P<.6	- 37.1mg n.s.s.	1/18	2/18			
liv hpt evx	no dre	P=1.	- 87.7mg n.s.s.	0/18	0/18			
tba mix evx	251.mg	P<.7	- 31.5mg n.s.s.	2/18	3/18			
5302 M m b6c orl 76w76 1223				0	41.2mg			
lun ade evx	no dre	P=1.	- 48.2mg n.s.s.	2/15	1/16			
liv hpt evx	no dre	P=1.	- 51.5mg n.s.s.	3/15	1/16			
tba mix evx	no dre	P=1.	- 43.8mg n.s.s.	5/15	2/16			
N-N'-PROPYL-N-FORMYLHYDRAZINE 77337-54-3								
5303 M f swa wat 75w79 1053				0	80.0mg	160.mg		Toth;bjca,42,922-928;1980
lun mix ae	8.74mg	\ P<.0005	+ 3.99mg 17.1mg	25/99	49/50	(22/49)		
liv mix ae	215.mg	* P<.0005	+ 108.mg 653.mg	0/38	6/45	5/19		
gal mix ae	444.mg	* P<.006	+ 216.mg 3.77gm	0/54	5/50	5/49		
gal ade ae	497.mg	* P<.02	234.mg n.s.s.	0/54	5/50	4/49		
5304 M m swa wat 51w61 1053				0	66.7mg	133.mg		
lun mix aes	8.84mg	\ P<.0005	+ 5.21mg 16.5mg	26/100	42/48	(6/37)		
pre mix aes	60.4mg	\ P<.0005	+ 30.2mg 172.mg	0/33	11/48	(1/37)		
pre sqc aes	75.7mg	\ P<.002	35.6mg 294.mg	0/33	9/48	(1/37)		
liv hpt aes	no dre	P=1.	304.mg n.s.s.	0/28	2/50	0/50		
PROPYL GALLATE 121-79-9								
5305 M f b6c eat 24m24 TR240 :				0	758.mg	1.52gm		
liv hpa #	8.26gm	* P<.01	- 3.56gm 370.gm	0/50	2/50	5/50		S
TBA MXB	no dre	P=1.	2.54gm n.s.s.	25/50	17/50	22/50		
liv MXB	21.4gm	* P<.5	4.17gm n.s.s.	3/50	3/50	5/50		liv:hpa,hpc,nnd.
lun MXB	44.3gm	* P<.6	6.71gm n.s.s.	1/50	1/50	2/50		lun:a/a,a/c.
5306 M m b6c eat 24m24 TR240 :				0	700.mg	1.40gm		
--- lym #	6.54gm	* P<.02	- 2.92gm n.s.s.	1/50	3/50	8/50		S
--- mly	12.1gm	* P<.03	4.60gm n.s.s.	0/50	1/50	4/50		S
--- lhc	15.1gm	* P<.03	5.22gm n.s.s.	0/50	0/50	4/50		S
TBA MXB	3.64gm	\ P<.6	604.mg n.s.s.	29/50	31/50	(22/50)		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB		no dre	P=1.	4.54gm n.s.s.	17/50	15/50	10/50		liv:hpa,hpc,nnd.
lun MXB		55.6gm	* P<.9	4.19gm n.s.s.	4/50	5/50	5/50		lun:a/a,a/c.
5307 R f f34 eat 24m24 TR240 :					0	292.mg	583.mg		
mgl ade	#	8.08gm	* P<.05	- 2.44gm n.s.s.	0/50	0/50	3/50		S
TBA MXB		no dre	P=1.	663.mg n.s.s.	38/50	34/50	36/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
5308 R m f34 eat 24m24 TR240 :					0	233.mg	466.mg		
pni isa	#	749.mg	\ P<.002	- 338.mg 2.74gm	0/50	8/50	(2/50)		S
adr MXA		613.mg	\ P<.03	256.mg n.s.s.	4/50	13/50	(8/50)		adr:phe,phm. S
adr phe		613.mg	\ P<.03	256.mg n.s.s.	4/50	13/50	(8/50)		S
pni MXA		840.mg	\ P<.03	335.mg n.s.s.	2/50	9/50	(4/50)		pni:isa,isc. S
pre MXA		1.04gm	\ P<.03	404.mg n.s.s.	1/50	7/50	(0/50)		pre:adc,ade,car. S
thy MXA		6.87gm	* P<.05	2.08gm n.s.s.	0/50	0/50	3/50		thy:fca,fcc. S
TBA MXB		no dre	P=1.	581.mg n.s.s.	33/50	37/50	32/50		
liv MXB		no dre	P=1.	3.51gm n.s.s.	2/50	1/50	1/50		liv:hpa,hpc,nnd.
5309 R m f3d eat 52w52 1900					0	400.mg			Hirose;carc,8,1731-1735;1987/pers.comm.
eso tum er		no dre	P=1.	- 206.mg n.s.s.	0/10	0/10			
for tum er		no dre	P=1.	- 206.mg n.s.s.	0/10	0/10			
liv tum er		no dre	P=1.	- 206.mg n.s.s.	0/10	0/10			
n-PROPYL ISOME 83-59-0									
5310 M f b6a orl 76w76 1252					0	828.mg			Innes;ntis,1968/1969
lun ade evx		4.69gm	P<.6	- 653.mg n.s.s.	1/17	2/17			
liv hpt evx		no dre	P=1.	- 1.55gm n.s.s.	0/17	0/17			
tba mix evx		4.39gm	P<.7	- 553.mg n.s.s.	2/17	3/17			
5311 M m b6a orl 76w76 1252					0	770.mg			
lun ade evx		no dre	P=1.	- 720.mg n.s.s.	2/18	2/18			
liv hpt evx		no dre	P=1.	- 1.53gm n.s.s.	1/18	0/18			
tba mix evx		no dre	P=1.	- 797.mg n.s.s.	3/18	2/18			
5312 M f b6c orl 76w76 1252					0	828.mg			
liv hpt evx		no dre	P=1.	- 1.64gm n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1.	- 1.64gm n.s.s.	0/16	0/18			
tba tum evx		no dre	P=1.	- 1.64gm n.s.s.	0/16	0/18			
5313 M m b6c orl 76w76 1252					0	770.mg			
liv hpt evx		1.05gm	P<.02	- 361.mg n.s.s.	0/16	4/17			
lun ade evx		4.65gm	P<.3	- 757.mg n.s.s.	0/16	1/17			
tba mix evx		374.mg	P<.0005	- 172.mg 1.06gm	0/16	9/17			
N-PROPYL-N'-NITRO-N-NITROSOGUANIDINE 13010-07-6									
5314 R m wis wat 34w65 1081m					0	1.59mg			Sasajima;zkko,94,201-206;1979
stg ade er		1.90mg	P<.04	.573mg n.s.s.	0/15	3/15			
5315 R m wis wat 52w65 1081n					0	2.38mg			
stg ade er		.919mg	P<.002	+ .338mg 4.24mg	0/15	5/10			
stg adc er		2.85mg	P<.05	+ .698mg n.s.s.	0/15	2/10			
5316 R m wis wat 52w78 1082					0	1.98mg			Matsukura;gann,70,181-185;1979
stg adc er		2.27mg	P<.06	+ .551mg n.s.s.	0/9	2/7			
stg ade er		2.27mg	P<.06	.551mg n.s.s.	0/9	2/7			
N-PROPYL-N-NITROSOUREA 816-57-9									
5317 R f f3d wat 70w70 2112m					0	22.9mg			Ogiu;thym,20,249-258;1992
thm lym e		noTD50	P<.0005	+ n.s.s. 3.78mg	0/20	20/20			
tba tum e		noTD50	P<.02	n.s.s. n.s.s.	10/20	20/20			
5318 R f f3d wat 75w75 2112n					0	22.9mg			
thm lym e		noTD50	P<.0005	+ n.s.s. 4.34mg	0/20	20/20			
tba tum e		noTD50	P<.02	n.s.s. n.s.s.	10/20	20/20			
5319 R m f3d wat 70w70 2112m					0	20.0mg			
thm lym e		noTD50	P<.0005	+ n.s.s. 3.31mg	0/20	20/20			
tba tum e		noTD50	P<.4	n.s.s. n.s.s.	18/20	20/20			
5320 R m f3d wat 75w75 2112n					0	20.0mg			
thm lym e		noTD50	P<.0005	+ n.s.s. 3.80mg	0/20	20/20			
tba tum e		noTD50	P<.4	n.s.s. n.s.s.	18/20	20/20			
PROPYLENE 115-07-1									
5321 M f b6c inh 24m24 TR272 :					0	2.65gm	5.31gm		
TBA MXB		no dre	P=1.	- 7.47gm n.s.s.	31/50	35/50	39/50		
liv MXB		no dre	P=1.	15.3gm n.s.s.	2/50	3/50	5/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	17.1gm n.s.s.	6/50	4/50	7/50		lun:a/a,a/c.
5322 M m b6c inh 24m24 TR272 :					0	2.21gm	4.42gm		
TBA MXB		no dre	P=1.	- 12.7gm n.s.s.	37/50	25/50	28/50		
liv MXB		no dre	P=1.	13.2gm n.s.s.	14/50	11/50	14/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	25.7gm n.s.s.	16/50	4/50	7/50		lun:a/a,a/c.
5323 M f swi inh 18m24 BT702					0	94.7mg	474.mg	2.37gm	Ciliberti;anya,534,235-245;1988
lun ade		19.8gm	* P<.09	- 6.88gm n.s.s.	6/100	10/100	13/100	15/100	
liv hpt		286.gm	* P<.6	- 30.2gm n.s.s.	0/100	1/100	0/100	1/100	
lun adc		1.17kg	P<.9	- 34.8gm n.s.s.	1/100	1/100	0/100	1/100	
tba mix		10.1gm	* P<.08	- 3.79gm n.s.s.	24/100	34/100	31/100	39/100	
tba mal		20.1gm	* P<.3	- 5.89gm n.s.s.	18/100	20/100	19/100	25/100	
5324 M m swi inh 18m24 BT702					0	78.9mg	395.mg	1.97gm	
lun ade		no dre	P=1.	- 26.0gm n.s.s.	10/100	8/100	9/100	3/100	
lun adc		no dre	P=1.	- 29.9gm n.s.s.	0/100	0/100	1/100	0/100	
liv hpt		no dre	P=1.	- 44.5gm n.s.s.	4/100	2/100	1/100	0/100	
tba mix		no dre	P=1.	- 1.99gm n.s.s.	26/100	17/100	19/100	(6/100)	
tba mal		no dre	P=1.	- 2.63gm n.s.s.	14/100	11/100	10/100	(2/100)	
5325 R f f34 inh 24m24 TR272 :					0	638.mg	1.28gm		
TBA MXB		no dre	P=1.	- 915.mg n.s.s.	37/50	42/50	40/50		
liv MXB		20.5gm	* P<.2	5.05gm n.s.s.	0/50	0/50	2/50		liv:hpa,hpc,nnd.
5326 R m f34 inh 24m24 TR272 :					0	447.mg	893.mg		
TBA MXB		15.5gm	* P<1.	- 704.mg n.s.s.	36/50	38/50	41/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB	4.61gm *	P<.06		1.99gm n.s.s.	0/50	4/50	3/50		liv:hpa,hpc,nnd.
PROPYLENE GLYCOL 57-55-6									
5327 R f cdr eat 24m24 1351					0	313.mg	625.mg	1.25gm 2.50gm	Gaunt;fctx,10,151-162;1972
liv nod e	no dre	P=1.	-	8.74gm n.s.s.	4/28	5/25	2/27	4/28 2/27	
5328 R m cdr eat 24m24 1351					0	250.mg	500.mg	1.00gm 2.00gm	
liv nod e	no dre	P=1.	-	9.11gm n.s.s.	2/26	4/27	3/27	0/23 1/24	
PROPYLENE GLYCOL MONO-t-BUTYL ETHER 57018-52-7									
5329 M f b6c inh 24m24 TR515 :					0	131.mg	524.mg	2.10gm	
liv hpa	1.78gm	Z P<.0005		1.02gm 4.38gm	14/50	8/50	10/50	37/50	S
liv MXA	1.78gm	Z P<.0005	c	974.mg 5.23gm	18/50	14/50	16/50	41/50	liv:hpa,hpc.
liv MXA	1.78gm	Z P<.0005		974.mg 5.23gm	18/50	14/50	16/50	41/50	liv:hpa,hpb,hpc. S
TBA MXB	8.12gm *	P<.7		1.19gm n.s.s.	43/50	50/50	43/50	49/50	
liv MXB	1.78gm	Z P<.0005		974.mg 5.23gm	18/50	14/50	16/50	41/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		12.8gm n.s.s.	3/50	5/50	3/50	1/50	lun:a/a,a/c.
5330 M m b6c inh 24m24 TR515 :					0	109.mg	436.mg	1.74gm	
liv hpb	9.32gm *	P<.002	c	3.80gm 45.1gm	0/50	0/50	1/50	5/50	
liv hpa	1.97gm *	P<.02		877.mg n.s.s.	18/50	23/50	26/50	36/50	S
liv MXA	1.98gm *	P<.03	c	842.mg n.s.s.	25/50	26/50	33/50	41/50	liv:hpa,hpc.
liv MXA	1.98gm *	P<.03		842.mg n.s.s.	25/50	26/50	33/50	41/50	liv:hpa,hpb,hpc. S
liv MXB	1.98gm *	P<.03		842.mg n.s.s.	25/50	26/50	33/50	41/50	liv:hpa,hpb,hpc. C
TBA MXB	7.93gm *	P<.7		971.mg n.s.s.	46/50	50/50	47/50	50/50	
liv MXB	1.98gm *	P<.03		842.mg n.s.s.	25/50	26/50	33/50	41/50	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		5.14gm n.s.s.	17/50	10/50	1/50	10/50	lun:a/a,a/c.
5331 R f f34 inh 24m24 TR515 :					0	31.2mg	125.mg	499.mg	
TBA MXB	no dre	P=1.	-	347.mg n.s.s.	50/50	49/50	50/50	50/50	
liv MXB	10.5gm *	P<.3		2.03gm n.s.s.	1/50	0/50	0/50	2/50	liv:hpa,hpb,hpc.
5332 R m f34 inh 24m24 TR515 :					0	21.9mg	87.6mg	350.mg	
liv hpa	1.45gm *	P<.04	e	508.mg n.s.s.	3/50	0/50	2/50	6/50	
ski MXA	1.51gm *	P<.02		532.mg n.s.s.	0/50	1/50	0/50	4/50	ski:bca,bcc. S
ski bca	2.07gm *	P<.04		608.mg n.s.s.	0/50	1/50	0/50	3/50	S
kid MXA	2.28gm *	P<.2	e	574.mg n.s.s.	1/50	1/50	3/50	3/50	kid:rua,ruc.
kid rua	4.48gm *	P<.5		700.mg n.s.s.	1/50	1/50	3/50	2/50	
TBA MXB	683.mg *	P<.5		136.mg n.s.s.	50/50	49/50	50/50	50/50	
liv MXB	1.45gm *	P<.04		508.mg n.s.s.	3/50	0/50	2/50	6/50	liv:hpa,hpb,hpc.
5333 R m f34 inh 24m24 TR515 with step					0	21.9mg	87.6mg	350.mg	
kid MXA	2.65gm *	P<.2	e	826.mg n.s.s.	1/50	2/50	5/50	5/50	kid:rua,ruc.
kid rua	3.80gm *	P<.3		938.mg n.s.s.	1/50	2/50	5/50	4/50	
1,2-PROPYLENE OXIDE (1,2-epoxypropane) 75-56-9									
5334 M f b6c inh 24m24 TR267 :					0	148.mg	296.mg		
--- MXA	863.mg /	P<.003		360.mg 5.43gm	1/50	1/50	7/50		---:hem,hes. S
nas MXA	1.21gm /	P<.002	c	451.mg 4.63gm	0/50	0/50	5/50		nas:hem,hes.
mgl MXA	1.26gm *	P<.01		475.mg 80.3gm	0/50	3/50	3/50		mgl:adc,adq. S
lun a/a	588.mg *	P<.02		243.mg n.s.s.	4/50	7/50	6/50		S
--- hes	1.61gm *	P<.02		522.mg n.s.s.	0/50	1/50	3/50		S
--- hem	1.81gm /	P<.05		554.mg n.s.s.	1/50	0/50	4/50		S
nas hem	2.02gm *	P<.02		606.mg n.s.s.	0/50	0/50	3/50		S
mgl adq	2.77gm *	P<.03		732.mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	226.mg *	P<.01		107.mg 15.0gm	28/50	35/50	23/50		
liv MXB	979.mg *	P<.2		320.mg n.s.s.	3/50	7/50	3/50		liv:hpa,hpc,nnd.
lun MXB	588.mg *	P<.02		243.mg n.s.s.	4/50	7/50	6/50		lun:a/a,a/c.
5335 M m b6c inh 24m24 TR267 :					0	123.mg	247.mg		
nas MXA	732.mg /	P<.0005	c	355.mg 1.95gm	0/50	0/50	10/50		nas:hem,hes.
--- MXA	753.mg *	P<.006		342.mg 8.20gm	2/50	2/50	10/50		---:hem,hes. S
nas hem	1.47gm *	P<.005		558.mg 12.1gm	0/50	0/50	5/50		S
nas hes	1.61gm *	P<.006		604.mg 15.1gm	0/50	0/50	5/50		S
TBA MXB	722.mg *	P<.4		173.mg n.s.s.	29/50	31/50	27/50		
liv MXB	no dre	P=1.		425.mg n.s.s.	14/50	16/50	9/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		469.mg n.s.s.	15/50	14/50	8/50		lun:a/a,a/c.
5336 R f f34 inh 24m24 TR267 :					0	35.2mg	70.4mg		
MXA MXA	156.mg *	P<.04		71.3mg n.s.s.	3/50	12/50	10/50		cvu:esp; ute:esp,ess. S
nas ppa	732.mg *	P<.04	p	221.mg n.s.s.	0/50	0/50	3/50		
TBA MXB	124.mg *	P<.4		32.8mg n.s.s.	38/50	46/50	44/50		
liv MXB	no dre	P=1.		1.01gm n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
5337 R m f34 inh 24m24 TR267 :					0	24.7mg	49.3mg		
nas ppa	826.mg *	P<.1	p	202.mg n.s.s.	0/50	0/50	2/50		
TBA MXB	220.mg *	P<.8		27.8mg n.s.s.	40/50	41/50	45/50		
liv MXB	528.mg *	P<.4		133.mg n.s.s.	1/50	2/50	3/50		liv:hpa,hpc,nnd.
5338 R m f34 inh 23m24 1624 () pool					0	14.2mg	42.4mg		Lynch;txap,76,69-84;1984
adr phe eis	35.1mg \	P<.002	+	18.4mg 144.mg	8/78	25/78	(22/80)		
liv hpc eis	2.96gm *	P<.3		482.mg n.s.s.	0/78	0/78	1/76		
liv nnd eis	no dre	P=1.		509.mg n.s.s.	2/78	1/78	1/76		
5339 R f sda gav 25m35 1486					0	3.13mg	12.5mg		Dunkelberg;bjca,46,924-933;1982
sto mix e	39.5mg *	P<.0005	+	24.0mg 71.6mg	0/50	2/50	21/50		
for sqc e	44.3mg *	P<.0005	+	26.3mg 82.6mg	0/50	2/50	19/50		
5340 R f wsr inh 29m29 1830					0	5.33mg	17.8mg	53.3mg	Kuper;fctx,26,159-167;1988
mgl fba e	92.6mg *	P<.003	+	46.7mg 602.mg	32/69	30/71	39/69	47/70	
mgl adc e	813.mg *	P<.2		235.mg n.s.s.	3/69	6/71	5/69	8/70	
liv cho	2.46gm *	P<.5		447.mg n.s.s.	2/69	1/71	2/69	3/70	
res car e	no dre	P=1.		77.4mg n.s.s.	0/69	0/71	0/69	0/70	
tba tum e	25.7mg *	P<.0005		14.0mg 69.4mg	52/69	49/71	61/69	67/70	
tba mal e	150.mg *	P<.0005		81.1mg 510.mg	6/69	15/71	14/69	26/70	
5341 R m wsr inh 29m29 1830					0	3.73mg	12.4mg	37.3mg	
res car eh	896.mg *	P<.005		310.mg 7.93gm	0/70	0/69	0/71	4/70	
liv nnd	no dre	P=1.		604.mg n.s.s.	0/70	0/69	1/71	0/70	
liv clc	no dre	P=1.		630.mg n.s.s.	1/70	0/69	2/71	0/70	

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
tba mal e		101.mg *	P<.002	51.3mg 569.mg	19/70	17/69	22/71	34/70	
tba tum e		79.3mg Z	P<.02	35.9mg n.s.s.	49/70	28/69	34/71	53/70	
PROPYLHYDRAZINE.HCl 56795-66-5									
5342 M f swa wat 99w99 252					0	50.0mg			Nagel;ejca,11,473-478;1975/Toth 1974
lun mix e		41.4mg	P<.0005 +	22.6mg 104.mg	21/99	27/43			
lun ade e		42.7mg	P<.0005	23.5mg 103.mg	18/99	26/43			
lun adc e		109.mg	P<.0005	51.8mg 367.mg	4/99	12/43			
liv mix e		no dre	P=1.	18.7mg n.s.s.	2/43	0/2			
5343 M m swa wat 93w93 252					0	41.7mg			
lun ade e		41.3mg	P<.0005	21.8mg 116.mg	15/99	22/43			
lun mix e		50.5mg	P<.002 +	23.9mg 281.mg	23/99	22/43			
liv lcc e		102.mg	P<.006 -	25.0mg 2.02gm	0/56	2/10			
liv mix e		80.8mg	P<.06	20.3mg n.s.s.	4/56	3/10			
PROPYLTHIOURACIL 51-52-5									
5344 M b c5l eat 73w73 257					0	1.25gm	1.50gm		King;pseb,112,365-366;1963
pit ade er		409.mg *	P<.0005 +	266.mg 663.mg	0/28	15/24	21/29		
5345 R m lev eat 52w52 254					0	40.0mg			Lindsay;arpa,81,308-316;1966
thy ade ers		10.3mg	P<.0005 +	5.69mg 21.5mg	0/68	16/33			
5346 R f wal wat 78w78 256					0	42.9mg			Willis;jpat,82,23-27;1961
thy ade erv		15.8mg	P<.0005 +	8.77mg 34.7mg	1/20	20/30			
thy car erv		115.mg	P<.04 +	39.8mg n.s.s.	0/20	4/30			
5347 R m wal wat 78w78 256					0	37.5mg			
thy ade erv		17.2mg	P<.002 +	7.77mg 73.3mg	2/20	11/18			
thy car erv		79.3mg	P<.03 +	23.9mg n.s.s.	0/20	3/18			
5348 R m wis wat 6m24 1273					0	7.50mg			Stoll;bdca,50,389-398;1963
thy ade rs		noTD50	P<.2 -	n.s.s. n.s.s.	3/8	5/5			
PROQUAZONE (1-isopropyl-7-methyl-4-phenyl-2(1H)-quinazolinone) 22760-18-5									
5349 M f cd1 eat 86w86 1667					0	60.0mg	180.mg	360.mg	Van Ryzin;dact,3,361-379;1980
liv hem		48.7gm *	P<.9 -	2.50gm n.s.s.	1/50	0/50	0/50	1/50	
liv hms		no dre	P=1. -	2.88gm n.s.s.	1/50	0/50	1/50	0/50	
liv hpc		no dre	P=1. -	1.65gm n.s.s.	0/50	3/50	0/50	1/50	
lun a/a		no dre	P=1. -	866.mg n.s.s.	4/50	6/50	10/50	3/50	
lun a/c		no dre	P=1. -	284.mg n.s.s.	12/50	3/50	(2/50	1/50)	
5350 M m cd1 eat 86w86 1667					0	60.0mg	180.mg	360.mg	
liv hpc		4.35gm *	P<.6 -	762.mg n.s.s.	4/50	2/50	8/50	4/50	
lun a/a		5.45gm *	P<.7 -	666.mg n.s.s.	5/50	6/50	9/50	6/50	
liv hem		14.0gm *	P<.2 -	2.28gm n.s.s.	0/50	0/50	0/50	1/50	
lun a/c		no dre	P=1. -	861.mg n.s.s.	12/50	11/50	7/50	10/50	
PRORESID 1508-45-8									
5351 R m b46 ivj 12m24 1017					0	.714mg			Schmahl;arzn,20,1461-1467;1970
tba mix es		no dre	P=1. -	2.58mg n.s.s.	7/65	1/24			
PROTOCATECHUIC ACID (3,4-dihydroxybenzoic acid) 99-50-3									
5352 H f syg eat 49w52 2638					0	49.3mg	98.5mg		Nakamura;acnr,20,3423-3428;2000/pers.comm.
liv tum e		no dre	P=1. -	16.9mg n.s.s.	0/10	0/10	0/10		
lun tum e		no dre	P=1. -	16.9mg n.s.s.	0/10	0/10	0/10		
5353 R m f3d eat 51w52 2080					0	588.mg			Hirose;carc,13,1825-1828;1992/pers.comm.
for tum e		no dre	P=1.	455.mg n.s.s.	0/15	0/15			
liv tum e		no dre	P=1.	455.mg n.s.s.	0/15	0/15			
SX PURPLE (ponceau 4R, food red no. 102) 2611-82-7									
5354 R b non eat 33m33 1429					0	771.mg			Andrianova;vpit,29,61-65;1970
liv tum		no dre	P=1.	15.0gm n.s.s.	0/50	0/50			
tba mix		24.5gm	P<.1 +	6.02gm n.s.s.	0/50	2/50			
5355 R f nss eat 64w64 1372					0	1.50gm			Allmark;jphp,9,622-628;1957
liv tum e		no dre	P=1. -	819.mg n.s.s.	0/7	0/7			
5356 R m nss eat 64w64 1372					0	1.20gm			
liv tum e		no dre	P=1. -	562.mg n.s.s.	0/5	0/6			
tba tum e		no dre	P=1. -	562.mg n.s.s.	0/5	0/6			
5357 R f sls eat 52w52 2601					0	1.00gm			Sekigawa;jnma,30,179-191;1979
liv tum e		no dre	P=1. -	1.03gm n.s.s.	0/20	0/20			
tba mix e		no dre	P=1. -	617.mg n.s.s.	1/20	1/20			
5358 R m sls eat 52w52 2601					0	800.mg			
liv tum e		no dre	P=1. -	824.mg n.s.s.	0/20	0/20			
tba mix e		no dre	P=1. -	824.mg n.s.s.	1/20	0/20			
PURPURIN 81-54-9									
5359 R m f34 eat 74w74 2264					0	400.mg			Mori;clet,102,193-198;1996/pers.comm.
ubl mal e		678.mg	P<.007 +	257.mg 7.89gm	0/28	5/27			
ubl tcc e		865.mg	P<.02 +	298.mg n.s.s.	0/28	4/27			
ubl sqc e		3.68gm	P<.3	599.mg n.s.s.	0/28	1/27			
PYRAZINAMIDE 98-96-4									
5360 M f b6c eat 18m24 TR48 :					0	348.mg	697.mg		
TBA MXB s		3.43gm *	P<.7 i	575.mg n.s.s.	1/15	5/35	9/35		
liv MXB s		10.7gm *	P<.5	1.75gm n.s.s.	0/15	0/35	1/35		liv:hpa,hpc,nnd.
lun MXB s		no dre	P=1.	2.62gm n.s.s.	1/15	0/35	1/35		lun:a/a,a/c.
5361 M m b6c eat 18m24 TR48 :					0	322.mg	726.mg		
TBA MXB s		546.mg *	P<.2 -	105.mg n.s.s.	2/15	5/35	6/35		
liv MXB s		5.18gm *	P<.4	956.mg n.s.s.	1/15	0/35	3/35		liv:hpa,hpc,nnd.
lun MXB s		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		lun:a/a,a/c.
5362 R f f34 eat 18m24 TR48 :					0	134.mg	268.mg		
pit MXA #		178.mg \	P<.03 -	78.9mg n.s.s.	2/15	14/35	(7/34)		pit:cra,crc. S
TBA MXB		182.mg \	P<.4	50.4mg n.s.s.	11/15	26/35	(19/34)		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/34		liv:hpa,hpc,nnd.
5363 R m f34 eat 18m24 TR48 :					0	107.mg	214.mg		
TBA MXB		284.mg	\ P<.4	- 79.4mg n.s.s.	4/15	17/35	(8/36)		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/36		liv:hpa,hpc,nnd.
PYRIDINE 110-86-1									
5364 M f b6c wat 24m24 TR470 :					0	25.0mg	50.0mg	100.mg	
liv MXA		27.2mg	Z P<.0005	c 15.9mg 73.2mg	13/50	23/50	36/50	(43/50)	liv:hpb,hpc.
liv hpc		41.6mg	* P<.0005	c 25.0mg 103.mg	13/50	23/50	33/50	41/50	
liv hpb		132.mg	* P<.0005	c 79.8mg 287.mg	1/50	2/50	9/50	16/50	
liv hpa		41.9mg	Z P<.08	16.5mg n.s.s.	37/50	39/50	43/50	(34/50)	
--- MXA		690.mg	* P<.02	260.mg n.s.s.	0/50	0/50	2/50	3/50	---:hem,hes. S
--- hem		868.mg	* P<.02	297.mg n.s.s.	0/50	0/50	1/50	3/50	S
TBA MXB		338.mg	* P<.7	44.9mg n.s.s.	47/50	45/50	45/50	45/50	
liv MXB		150.mg	* P<.4	38.6mg n.s.s.	41/50	42/50	45/50	44/50	liv:hpa,hpb,hpc.
lun MXB		1.99gm	* P<.7	250.mg n.s.s.	4/50	4/50	2/50	5/50	lun:a/a,a/c.
5365 M m b6c wat 24m24 TR470 :					0	41.7mg	83.3mg	167.mg	
liv MXA		22.1mg	Z P<.0005	c 12.0mg 67.3mg	17/50	42/50	(45/50	42/50)	liv:hpb,hpc.
liv hpc		28.6mg	Z P<.0005	c 14.8mg 116.mg	15/50	35/50	(41/50	40/50)	
liv hpb		68.1mg	Z P<.0005	c 42.9mg 153.mg	2/50	18/50	22/50	(15/50)	
liv hpa		488.mg	Z P<.6	91.0mg n.s.s.	29/50	40/50	34/50	39/50	
TBA MXB		25.7gm	* P<1.	94.1mg n.s.s.	43/50	49/50	48/50	47/50	
liv MXB		496.mg	* P<.7	79.3mg n.s.s.	38/50	47/50	46/50	47/50	liv:hpa,hpb,hpc.
lun MXB		no dre	P=1.	476.mg n.s.s.	13/50	7/50	9/50	8/50	lun:a/a,a/c.
5366 R f f34 wat 24m24 TR470 :					0	5.71mg	11.4mg	22.9mg	
--- mnl		31.2mg	* P<.008	e 15.3mg 795.mg	12/50	16/50	22/50	23/50	
TBA MXB		32.9mg	* P<.3	9.85mg n.s.s.	45/50	42/50	45/50	44/50	
liv MXB		no dre	P=1.	161.mg n.s.s.	1/50	0/50	1/50	0/50	liv:hpa,hpb,hpc.
5367 R m f34 wat 24m24 TR470 :					0	5.00mg	10.0mg	20.0mg	
kid rua		73.7mg	* P<.009	p 30.4mg 2.01gm	1/50	0/50	2/50	6/50	
kid MXA		67.3mg	* P<.02	p 28.1mg n.s.s.	1/50	1/50	2/50	6/50	kid:rua,ruc.
TBA MXB		31.0mg	* P<.4	7.65mg n.s.s.	46/50	45/50	46/50	43/50	
liv MXB		160.mg	* P<.2	44.1mg n.s.s.	1/50	1/50	1/50	3/50	liv:hpa,hpb,hpc.
5368 R m f34 wat 24m24 TR470 with step					0	5.00mg	9.99mg	20.0mg	
kid MXA		74.6mg	* P<.008	p 36.2mg 1.92gm	2/50	4/50	6/50	10/50	kid:rua,ruc.
kid rua		75.6mg	* P<.006	p 37.1mg 920.mg	2/50	3/50	6/50	10/50	
5369 R m wis wat 24m24 TR470a :					0	5.00mg	10.0mg	20.0mg	
tes MXA		22.4mg	* P<.003	e 10.2mg 157.mg	5/50	6/50	4/50	12/50	tes:iab,ica.
thy MXA		38.4mg	Z P<.005	13.9mg 318.mg	0/50	0/50	5/50	(0/50)	thy:fab,fca. S
TBA MXB		7.14mg	* P<.005	3.50mg 64.7mg	43/50	38/50	32/50	39/50	
liv MXB		no dre	P=1.	55.8mg n.s.s.	2/50	0/50	1/50	0/50	liv:hpa,hpb,hpc.
PYRILAMINE MALEATE 59-33-6									
5370 M f b6c eat 65w65 2326m					0	274.mg			Greenman;jact,14,148-157;1995/NCTR 1991
liv mix ek		no dre	P=1.	265.mg n.s.s.	0/12	0/12			
lun mix ek		no dre	P=1.	265.mg n.s.s.	0/12	0/12			
tba mix ek		no dre	P=1.	265.mg n.s.s.	1/12	0/12			
5371 M f b6c eat 24m24 2326n					0	27.2mg	136.mg	272.mg	
lun a/a e		6.68gm	* P<.5	- 1.24gm n.s.s.	1/48	2/47	1/48	3/48	
liv hpc e		no dre	P=1.	- 3.18gm n.s.s.	0/47	2/47	0/48	0/47	
liv mix e		no dre	P=1.	- 2.14gm n.s.s.	1/47	4/47	1/48	1/47	
liv hpa e		no dre	P=1.	- 1.99gm n.s.s.	1/47	2/47	1/48	1/47	
tba ben e		2.44gm	* P<.4	- 615.mg n.s.s.	7/48	7/47	5/48	11/48	
tba mal e		no dre	P=1.	- 698.mg n.s.s.	14/48	14/47	6/48	15/48	
tba mix e		no dre	P=1.	- 542.mg n.s.s.	19/48	22/47	11/48	21/48	
5372 M m b6c eat 65w65 2326m					0	253.mg			
liv hpa ek		no dre	P=1.	160.mg n.s.s.	2/12	1/12			
lun a/a ek		no dre	P=1.	245.mg n.s.s.	1/12	0/12			
tba ben ek		no dre	P=1.	171.mg n.s.s.	3/12	1/12			
tba mix ek		no dre	P=1.	171.mg n.s.s.	3/12	1/12			
5373 M m b6c eat 24m24 2326n					0	25.1mg	125.mg	251.mg	
lun a/a e		11.3gm	* P<.9	- 896.mg n.s.s.	5/47	2/48	6/47	4/48	
liv hpc e		no dre	P=1.	- 1.19gm n.s.s.	3/46	3/47	5/47	2/48	
liv mix e		no dre	P=1.	- 893.mg n.s.s.	13/46	4/47	8/47	8/48	
liv hpa e		no dre	P=1.	- 1.04gm n.s.s.	10/46	2/47	3/47	7/48	
tba ben e		no dre	P=1.	- 807.mg n.s.s.	18/48	7/48	8/48	12/48	
tba mal e		no dre	P=1.	- 1.02gm n.s.s.	6/48	9/48	10/48	4/48	
tba mix e		no dre	P=1.	- 733.mg n.s.s.	23/47	15/48	16/47	15/48	
5374 R f f34 eat 26m31 1644					0	82.7mg			Lijinsky;fctx,22,27-30;1984
liv mix		175.mg	P<.02	+ 70.5mg n.s.s.	3/20	10/20			
liv nnd		266.mg	P<.08	91.9mg n.s.s.	3/20	8/20			
liv hpc		880.mg	P<.1	+ 216.mg n.s.s.	0/20	2/20			
5375 R f f34 wat 26m31 1644m					0	67.5mg			
liv nnd		1.25gm	P<.7	145.mg n.s.s.	3/20	4/20			
5376 R f f34 eat 65w65 2256m					0	211.mg			Greenman;faat,25,1-8;1995/NCTR 1991
liv mix ek		no dre	P=1.	153.mg n.s.s.	0/9	0/9			
tba ben ek		no dre	P=1.	53.8mg n.s.s.	3/9	3/9			
tba mal ek		no dre	P=1.	153.mg n.s.s.	0/9	0/9			
5377 R f f34 eat 24m24 2256n					0	20.9mg	104.mg	209.mg	
ova gcb e		5.43gm	* P<.06	- 1.33gm n.s.s.	0/48	0/48	0/48	2/48	
liv hpc e		no dre	P=1.	- 159.mg n.s.s.	0/48	0/48	0/48	0/48	
liv hpa e		no dre	P=1.	- 2.48gm n.s.s.	0/48	1/48	0/48	0/48	
tba mal e		3.21gm	* P<.8	- 331.mg n.s.s.	15/48	16/48	20/48	16/48	
tba ben e		no dre	P=1.	- 591.mg n.s.s.	39/48	41/48	29/48	27/48	
tba mix e		no dre	P=1.	- 303.mg n.s.s.	44/48	45/48	42/48	36/48	
5378 R m f34 eat 26m31 1644					0	66.2mg			Lijinsky;fctx,22,27-30;1984
liv hpc		704.mg	P<.1	+ 173.mg n.s.s.	0/20	2/20			
liv mix		518.mg	P<.5	95.7mg n.s.s.	5/20	7/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv nnd	no dre	P=1.		138.mg n.s.s.	5/20	5/20			
5379 R m f34 wat 26m31 1644m					0	47.3mg			
liv nnd	no dre	P=1.		98.7mg n.s.s.	5/20	5/20			
5380 R m f34 eat 65w65 2256m					0	169.mg			Greenman;faat,25,1-8;1995/NCTR 1991
liv mix ek	no dre	P=1.		122.mg n.s.s.	0/9	0/9			
tba ben ek	65.2mg	P<.4		13.8mg n.s.s.	5/9	7/9			
tba mix ek	111.mg	P<.6		14.8mg n.s.s.	6/9	7/9			
tba mal ek	no dre	P=1.		122.mg n.s.s.	1/9	0/9			
5381 R m f34 eat 24m24 2256n					0	16.7mg	83.6mg	167.mg	
liv hpc e	no dre	P=1.	-	127.mg n.s.s.	0/48	0/48	0/48	0/48	
liv hpa e	no dre	P=1.	-	1.98gm n.s.s.	0/48	3/48	0/48	0/48	
tba mix e	69.7mg *	P<.4	-	11.3mg n.s.s.	47/48	47/48	47/48	48/48	
tba ben e	no dre	P=1.	-	28.4mg n.s.s.	47/48	47/48	47/48	47/48	
tba mal e	17.0gm *	P<1.	-	235.mg n.s.s.	19/48	23/48	26/48	20/48	
PYRIMETHAMINE (daraprin) 58-14-0									
5382 M f b6c eat 18m24 TR77 :					0	34.7mg	69.5mg		
TBA MXB	315.mg *	P<.8	-	44.2mg n.s.s.	1/15	5/35	9/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
lun MXB	405.mg *	P<.4		99.6mg n.s.s.	0/15	0/35	2/35		lun:a/a,a/c.
5383 M m b6c eat 18m24 TR77 :					0	32.0mg	64.2mg		
TBA MXB s	419.mg *	P<.9	i	30.1mg n.s.s.	0/15	1/35	1/35		
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		lun:a/a,a/c.
5384 R f f34 eat 18m24 TR77 :					0	5.30mg	10.7mg		
TBA MXB	27.8mg *	P<.5	-	7.01mg n.s.s.	7/15	16/35	26/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
5385 R m f34 eat 18m24 TR77 :					0	4.20mg	8.60mg		
TBA MXB	no dre	P=1.	-	14.9mg n.s.s.	8/15	17/35	11/35		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
QUERCETIN 117-39-5									
5386 M f ddy eat 28m28 1146					0	2.60gm			Saito;tcam,1,213-221;1980
lun mix e	4.24gm	P<.05	-	1.82gm n.s.s.	4/15	18/31			
liv tum e	no dre	P=1.	-	23.5gm n.s.s.	0/15	0/33			
5387 M m ddy eat 27m27 1146					0	2.40gm			
liv mix e	15.1gm	P<.09	-	5.20gm n.s.s.	0/14	4/32			
lun mix e	5.46gm	P<.2	-	1.87gm n.s.s.	6/16	21/37			
hea scs e	73.4gm	P<.4	-	12.0gm n.s.s.	0/16	1/37			
5388 R f f34 eat 24m24 TR409 :					0	50.0mg	500.mg	2.00gm	
ton sqc #	36.5gm *	P<.04	-	8.92gm n.s.s.	0/50	0/50	0/50	2/50	S
TBA MXB	no dre	P=1.		1.27gm n.s.s.	49/50	48/50	43/50	44/50	
liv MXB	75.7gm *	P<.6		7.97gm n.s.s.	0/50	1/50	0/50	1/50	liv:hpa,hpc,nnd.
5389 R f f34 eat 64w64 1648					0	50.0mg	100.mg		Stoewsand;jtxe,14,105-114;1984
tba mix fg	no dre	P=1.	-	69.1mg n.s.s.	0/10	1/11	0/11		
5390 R m f34 eat 24m24 TR409 :					0	40.0mg	400.mg	1.60gm	
kid MXA	8.99gm *	P<.003		3.06gm 58.8gm	0/50	0/50	0/50	4/50	kid:rua,uac. S
kid rua	12.5gm *	P<.009	p	3.72gm 393.gm	0/50	0/50	0/50	3/50	
TBA MXB	no dre	P=1.		1.19gm n.s.s.	46/50	40/50	46/50	39/50	
liv MXB	no dre	P=1.		5.34gm n.s.s.	3/50	4/50	4/50	1/50	liv:hpa,hpc,nnd.
5391 R m f34 eat 24m24 TR409 with step					0	40.0mg	400.mg	1.60gm	
kid MXA	5.25gm *	P<.004		2.40gm 45.6gm	1/50	2/50	7/50	9/50	kid:rua,uac. S
kid rua	6.03gm *	P<.009	p	2.59gm 305.gm	1/50	2/50	7/50	8/50	
5392 R m f34 eat 64w64 1648					0	40.0mg	80.0mg		Stoewsand;jtxe,14,105-114;1984
tba mix	no dre	P=1.	-	59.8mg n.s.s.	1/10	0/10	1/11		
5393 R f f3d eat 24m26 1934					0	580.mg	2.32gm		Ito;gann,80,317-325;1989
--- lkm e	7.86gm *	P<.06	-	3.04gm n.s.s.	8/50	14/50	17/50		
ute esp e	19.3gm *	P<.4	-	4.71gm n.s.s.	8/50	10/50	12/50		
liv hnd e	no dre	P=1.	-	5.55gm n.s.s.	2/50	0/50	0/50		
5394 R m f3d eat 24m26 1934					0	464.mg	1.86gm		
--- lkm e	1.16gm \	P<.005	-	550.mg 11.6gm	6/50	18/50	(14/50)		
liv hnd e	66.8gm *	P<.7	-	8.86gm n.s.s.	2/50	2/50	3/50		
5395 R f nra eat 58w58 1392					0	50.0mg			Pamukcu;canr,40,3468-3472;1980
ilm mix er	5.12mg	P<.0005	+	2.31mg 12.3mg	0/9	14/16			
ilm adc er	15.4mg	P<.003		6.79mg 76.3mg	0/9	8/16			
ubl mix er	51.3mg	P<.09	+	15.5mg n.s.s.	0/9	3/16			
5396 R m nra eat 58w58 1392					0	40.0mg			
ilm mix er	noTD50	P<.004	+	n.s.s. 9.97mg	0/8	6/6			
ubl tcc er	21.0mg	P<.06	+	5.06mg n.s.s.	0/8	2/6			
QUERCETIN DIHYDRATE 6151-25-3									
5397 H f syg eat 24m24 1144m					0	10.5gm			Morino;carc,3,93-97;1982
ilm adc	140.gm	P<.3	-	22.7gm n.s.s.	0/20	1/20			
for pam	no dre	P=1.	-	20.5gm n.s.s.	2/20	2/20			
5398 H f syg eat 23m23 1144n					0	4.18gm			
for pam	18.9gm	P<.2	-	4.63gm n.s.s.	0/8	2/15			
ute ley	39.2gm	P<.4	-	6.37gm n.s.s.	0/8	1/15			
5399 H f syg eat 12m23 1144o					0	523.mg			
for pam	no dre	P=1.	-	698.mg n.s.s.	0/8	0/7			
5400 H m syg eat 24m24 1144m					0	9.20gm			
for pam	56.7gm	P<.3	-	12.6gm n.s.s.	1/20	3/20			
adr coa	no dre	P=1.	-	18.0gm n.s.s.	2/20	2/20			
5401 H m syg eat 23m23 1144n					0	3.68gm			
for pam	no dre	P=1.	-	10.7gm n.s.s.	1/8	0/15			
adr coa	no dre	P=1.	-	12.2gm n.s.s.	1/8	0/15			
5402 H m syg eat 12m23 1144o					0	461.mg			
for pam	1.44gm	P<.5	-	228.mg n.s.s.	1/8	2/7			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
5403 R f aci eat 77w77 1145m					0	500.mg	2.50gm		Hirono;clet,13,15-21;1981
adr coa		no dre	P=1.	- 462.mg n.s.s.	0/22	0/10	0/9		
pit ade		no dre	P=1.	- 462.mg n.s.s.	0/22	0/10	0/9		
5404 R f aci eat 28m28 1145n					0	5.00gm			
thi sar		90.4gm	P<.2	- 14.7gm n.s.s.	0/33	1/20			
adr coa		226.gm	P<.8	- 16.0gm n.s.s.	1/33	1/20			
pit ade		461.gm	P<1.	- 13.2gm n.s.s.	3/33	2/20			
5405 R m aci eat 77w77 1145m					0	400.mg	2.00gm		
tes ict		2.29gm *	P<.09	- 593.mg n.s.s.	3/30	1/10	3/8		
cec ade		7.13gm *	P<.08	- 1.16gm n.s.s.	0/30	0/10	1/8		
adr phe		7.13gm *	P<.08	- 1.16gm n.s.s.	0/30	0/10	1/8		
5406 R m aci eat 28m28 1145n					0	4.00gm			
cec adc		35.2gm	P<.05	- 8.65gm n.s.s.	0/33	2/20			
cec ade		72.3gm	P<.2	- 11.8gm n.s.s.	0/33	1/20			
pan exa		72.3gm	P<.2	- 11.8gm n.s.s.	0/33	1/20			
5407 R f f34 eat 77w77 1662					0	50.0mg			Takanashi;jfds,5,55-60;1983
adr coa	e	118.mg	P<.3	- 27.2mg n.s.s.	1/16	3/15			
5408 R m f34 eat 77w77 1662					0	40.0mg			
tba mix	e	noTD50	P<.6	- n.s.s. n.s.s.	15/16	15/15			
QUILLAIA EXTRACT (spray-dried aqueous extract of Quillaia sp. bark) 68990-67-0									
5409 M f the eat 84w84 1404					0	130.mg	650.mg	1.95gm	Phillips;fctx,17,23-27;1979
lun ppa	e	no dre	P=1.	- 5.84gm n.s.s.	9/44	5/43	4/43	5/46	
liv hnd	e	no dre	P=1.	- 12.1gm n.s.s.	1/44	2/43	1/43	0/46	
5410 M m the eat 84w84 1404					0	120.mg	600.mg	1.80gm	
lun ppa	e	4.09gm *	P<.03	- 1.64gm n.s.s.	7/45	3/42	7/41	12/43	
liv mhp	e	no dre	P=1.	- 8.58gm n.s.s.	5/45	1/42	2/41	1/43	
liv hnd	e	no dre	P=1.	- 3.93gm n.s.s.	8/45	4/42	3/41	6/43	
5411 R f wis eat 25m25 1527					0	150.mg	500.mg	1.50gm	Drake;fctx,20,15-23;1982
thy ade	e	8.70gm *	P<.09	- 3.06gm n.s.s.	0/39	2/40	5/45	4/42	
liv ade	e	72.4gm *	P<.2	- 11.8gm n.s.s.	0/42	0/45	0/46	1/46	
5412 R m wis eat 25m25 1527					0	120.mg	400.mg	1.20gm	
liv ade	e	no dre	P=1.	- 605.mg n.s.s.	0/40	0/33	0/26	0/44	
QUINAPRIL.HCl 82586-55-8									
5413 M f b6c gav 24m24 2330					0	5.00mg	35.0mg	75.0mg	McGuire;jtxs,21,207-214;1996/pers.comm.
pit ade		128.mg Z	P<.01	- 54.5mg 12.2gm	3/50	4/50	11/50	(2/50)	
liv hpc		966.mg *	P<.04	- 334.mg n.s.s.	0/50	0/50	2/50	2/50	
lun ade		5.07gm *	P<.8	- 435.mg n.s.s.	4/50	0/50	1/50	3/50	
liv hpa		no dre	P=1.	- 631.mg n.s.s.	3/50	6/50	3/50	1/50	
tba mix		8.16gm *	P<1.	- 89.7mg n.s.s.	26/50	29/50	31/50	27/50	
5414 M m b6c gav 24m24 2330					0	5.00mg	35.0mg	75.0mg	
liv hpa	s	623.mg *	P<.3	- 175.mg n.s.s.	8/50	5/50	5/50	11/50	
liv hpc	s	1.64gm *	P<.6	- 265.mg n.s.s.	4/50	3/50	4/50	5/50	
lun ade	s	2.79gm *	P<.9	- 203.mg n.s.s.	3/50	11/50	9/50	7/50	
lun car	s	2.81gm *	P<.4	- 510.mg n.s.s.	1/50	0/50	0/50	2/50	
tba mix	s	221.mg *	P<.3	- 67.3mg n.s.s.	24/50	26/50	23/50	31/50	
5415 R f wis gav 24m24 2330					0	10.0mg	50.0mg	100.mg	
liv mix	s	no dre	P=1.	- 103.mg n.s.s.	0/65	0/65	0/65	0/65	
tba mix	s	no dre	P=1.	- 98.2mg n.s.s.	55/65	53/65	52/65	52/65	
5416 R m wis gav 24m24 2330					0	10.0mg	50.0mg	100.mg	
liv mix	s	no dre	P=1.	- 1.22gm n.s.s.	1/65	1/65	0/65	1/65	
tba mix	s	no dre	P=1.	- 334.mg n.s.s.	43/65	41/65	40/65	29/65	
p-QUINONE DIOXIME 105-11-3									
5417 M f b6c eat 24m24 TR179 :					0	96.6mg	193.mg		
TBA MXB		6.71gm *	P<1.	- 252.mg n.s.s.	7/20	14/50	17/50		
liv MXB		656.mg *	P<.02	329.mg n.s.s.	0/20	3/50	8/50		liv:hpa,hpc,nnd.
lun MXB		6.66gm *	P<.8	664.mg n.s.s.	1/20	2/50	3/50		lun:a/a,a/c.
5418 M m b6c eat 24m24 TR179 :					0	89.2mg	178.mg		
TBA MXB		936.mg *	P<.6	- 178.mg n.s.s.	5/18	20/50	22/50		
liv MXB		1.23kg	P<1.	398.mg n.s.s.	5/18	6/50	12/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	466.mg n.s.s.	2/18	7/50	6/50		lun:a/a,a/c.
5419 R f f34 eat 24m24 TR179 :					0	18.6mg	37.1mg		
ubl MXA		106.mg *	P<.003	c 57.2mg 514.mg	0/20	3/49	11/50		ubl:sqc,tcc,tpp.
ubl tcc		182.mg *	P<.02	c 82.6mg n.s.s.	0/20	1/49	7/50		
TBA MXB		no dre	P=1.	39.7mg n.s.s.	14/20	30/49	28/50		
liv MXB		no dre	P=1.	204.mg n.s.s.	0/20	2/49	0/50		liv:hpa,hpc,nnd.
5420 R m f34 eat 24m24 TR179 :					0	14.9mg	29.7mg		
TBA MXB		349.mg *	P<.9	- 31.3mg n.s.s.	11/20	21/50	24/50		
liv MXB		1.13gm *	P<.4	184.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
RAMOSETRON.HCl (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole.HCl 132907-72-3									
5421 M f b6c gav 24m24 2419					0	100.mg			Tabata;arzn,46,560-566;1996
liv hpc	e	1.04gm	P<.2	- 314.mg n.s.s.	6/132	7/66			
liv hpa	e	no dre	P=1.	- 504.mg n.s.s.	18/132	7/66			
lun ade	e	no dre	P=1.	- 1.36gm n.s.s.	4/132	0/66			
lun car	e	no dre	P=1.	- 1.36gm n.s.s.	2/132	0/66			
5422 M m b6c gav 24m24 2419					0	100.mg			
liv hpa	e	no dre	P=1.	- 235.mg n.s.s.	54/132	25/66			
lun ade	e	no dre	P=1.	- 370.mg n.s.s.	24/132	11/66			
liv hpc	e	no dre	P=1.	- 543.mg n.s.s.	16/132	6/66			
lun car	e	no dre	P=1.	- 904.mg n.s.s.	3/132	1/66			
5423 R f f34 gav 24m24 2419					0	100.mg			
liv hpa	e	no dre	P=1.	- 869.mg n.s.s.	4/114	1/60			
5424 R m f34 gav 24m24 2419					0	100.mg			
liv hpa	e	no dre	P=1.	- 863.mg n.s.s.	4/120	1/60			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
C.I. ACID RED 114 6459-94-5									
5425 R f f34 wat 23m24 TR405 :				0	8.42mg	16.8mg	34.3mg		
MXB MXB a	3.11mg Z	P<.0005	2.14mg 4.68mg	12/50	22/35	54/65	39/50	cli:ade,anb,car,cnb; col:adp,muc; duo:adp,muc; jej:adp; liv:hpc,nnd; lun:a/a,a/c; phr:sqc,sqp; rec:adp; ski:bca,bcc; ton:sqc,sqp; zym:ade,car.	C
cli MXA a	4.75mg Z	P<.0005 c	2.95mg 8.36mg	11/50	17/35	28/65	23/50	cli:ade,anb,car,cnb.	
cli MXA a	8.97mg Z	P<.0005	5.19mg 17.0mg	4/50	9/35	19/65	15/50	cli:car,cnb.	S
mul MXA a	9.44mg *	P<.0005 e	5.10mg 24.3mg	12/50	13/35	18/65	5/50	mul:leu,mnl.	
pit pda a	11.1mg *	P<.003	5.14mg 73.3mg	25/50	17/35	17/65	5/50		S
mgl fba a	11.4mg *	P<.008	4.86mg 282.mg	19/50	13/35	12/65	1/50		S
cli MXA a	11.9mg Z	P<.0005	6.08mg 30.5mg	7/50	10/35	10/65	10/50	cli:ade,anb.	S
liv MXA a	14.2mg Z	P<.0005 c	8.08mg 26.0mg	0/50	0/35	19/65	8/50	liv:hpc,nnd.	
zym MXA a	15.6mg Z	P<.0005 c	8.95mg 25.7mg	0/50	3/35	18/65	19/50	zym:ade,car.	
ute MXA a	16.4mg *	P<.0005	7.79mg 63.7mg	5/50	9/35	10/65	2/50	ute:esp,ess.	S
zym car a	18.0mg *	P<.0005	9.72mg 31.6mg	0/50	3/35	17/65	13/50		S
liv nnd a	18.0mg Z	P<.0005	9.57mg 35.4mg	0/50	0/35	15/65	6/50		S
ute esp a	20.1mg *	P<.002	9.03mg 98.6mg	4/50	8/35	8/65	2/50		S
ski MXA a	21.9mg *	P<.0005 c	10.2mg 51.0mg	0/50	4/35	7/65	5/50	ski:bca,bcc.	
lun MXA a	23.6mg *	P<.0005 c	11.2mg 62.9mg	1/50	2/35	9/65	4/50	lun:a/a,a/c.	
lun a/a a	26.3mg *	P<.0005	12.1mg 75.0mg	1/50	2/35	8/65	4/50		S
ski bca a	28.2mg *	P<.0005	11.6mg 82.7mg	0/50	3/35	5/65	3/50		S
thy MXA a	28.8mg *	P<.0005	11.0mg 125.mg	0/50	3/35	3/65	1/50	thy:fca,fcc.	S
MXA MXA a	31.4mg *	P<.0005 c	13.7mg 71.1mg	0/50	3/35	9/65	6/50	phr:sqc,sqp; ton:sqc,sqp.	
amd MXA a	31.6mg *	P<.003 e	12.3mg 220.mg	1/50	3/35	5/65	1/50	amd:phm,pob.	
MXA sqp a	36.5mg *	P<.0005	14.6mg 102.mg	0/50	3/35	6/65	4/50	phr:sqp; ton:sqp.	S
amd pob a	38.3mg *	P<.007	13.4mg 763.mg	1/50	3/35	4/65	1/50		S
mgl adc a	40.6mg *	P<.0005 e	16.7mg 124.mg	0/50	3/35	6/65	3/50		
liv hpc a	42.5mg Z	P<.0005	17.7mg 121.mg	0/50	0/35	6/65	3/50		S
ski MXA a	49.7mg *	P<.002	16.5mg 264.mg	0/50	0/35	4/65	1/50	ski:sqc,sqp.	S
thy fca a	53.5mg *	P<.007	16.2mg 878.mg	0/50	1/35	3/65	0/50		S
ski sqc a	57.3mg *	P<.005	17.2mg 705.mg	0/50	0/35	3/65	0/50		S
zym ade a	65.4mg Z	P<.0005	20.9mg 210.mg	0/50	0/35	2/65	6/50		S
ton MXA a	65.7mg *	P<.002	21.3mg 300.mg	0/50	2/35	4/65	3/50	ton:sqc,sqp.	S
phr sqp a	72.4mg *	P<.004	21.7mg 566.mg	0/50	1/35	4/65	1/50		S
ton sqp a	75.0mg *	P<.003	22.0mg 509.mg	0/50	2/35	2/65	3/50		S
MXA MXA a	136.mg Z	P<.007 c	31.5mg 3.20gm	0/50	1/35	0/65	3/50	col:adp,muc; rec:adp.	
thy cca a	48.7mg Z	P<.05	13.9mg n.s.s.	6/50	2/35	2/65	3/50		S
mgl ade a	67.0mg *	P<.04	19.9mg n.s.s.	1/50	1/35	4/65	0/50		S
thy fcc a	68.9mg *	P<.03	17.6mg n.s.s.	0/50	2/35	0/65	1/50		S
sub MXA a	78.2mg Z	P<.05	20.9mg n.s.s.	3/50	0/35	3/65	2/50	sub:fbs,fib.	S
MXA MXA a	213.mg *	P<.02 c	46.1mg n.s.s.	0/50	0/35	1/65	2/50	duo:adp,muc; jej:adp.	
MXA sqc a	227.mg *	P<.02	81.3mg n.s.s.	0/50	0/35	3/65	2/50	phr:sqc; ton:sqc.	S
TBA MXB a	2.31mg Z	P<.0005	1.58mg 3.59mg	47/50	35/35	61/65	47/50		
liv MXB a	14.2mg Z	P<.0005	8.08mg 26.0mg	0/50	0/35	19/65	8/50	liv:hpa,hpc,nnd.	
5426 R m f34 wat 24m24 TR405 :				0	3.45mg	7.39mg	14.8mg		
MXB MXB	2.80mg Z	P<.0005	1.96mg 4.26mg	6/50	9/35	40/65	40/50	liv:hpc,nnd; ski:bca,bcc,ker,sbr,sea,sqc,sqp; zym:ade,car.	C
ski MXA	3.30mg Z	P<.0005 c	2.29mg 5.00mg	1/50	5/35	28/65	32/50	ski:bca,bcc.	
tes MXA	3.39mg Z	P<.0005	1.97mg 8.88mg	44/50	35/35	59/65	43/50	tes:iab,ica.	S
ski bca	3.58mg Z	P<.0005	2.45mg 5.50mg	1/50	4/35	26/65	30/50		S
amd MXA	5.94mg Z	P<.0005 e	3.39mg 15.5mg	17/50	11/35	27/65	22/50	amd:pbb,phm,pob.	
amd pob	6.69mg Z	P<.0005	3.71mg 19.5mg	16/50	11/35	24/65	20/50		S
liv MXA	7.02mg Z	P<.0005 c	4.34mg 12.7mg	2/50	2/35	15/65	20/50	liv:hpc,nnd.	
liv nnd	10.4mg Z	P<.0005	5.97mg 21.8mg	2/50	1/35	10/65	15/50		S
ski MXA	12.7mg *	P<.0005 c	6.90mg 30.1mg	1/50	2/35	11/65	9/50	ski:sqc,sqp.	
ski sqc	16.2mg *	P<.0005	8.33mg 37.2mg	0/50	2/35	8/65	7/50		S
liv hpc	20.2mg *	P<.0005	9.95mg 48.9mg	0/50	1/35	6/65	7/50		S
ski ker	20.4mg Z	P<.0005 c	9.42mg 73.0mg	1/50	1/35	4/65	7/50		
ski bcc	22.8mg *	P<.0005	10.8mg 61.0mg	0/50	1/35	5/65	6/50		S
ski MXA	23.4mg *	P<.002 c	10.5mg 100.mg	1/50	1/35	5/65	6/50	ski:sbr,sea.	
zym MXA	27.0mg *	P<.0005 c	13.3mg 62.3mg	0/50	0/35	8/65	7/50	zym:ade,car.	
zym car	29.8mg *	P<.0005	14.1mg 76.6mg	0/50	0/35	7/65	6/50		S
lun a/a	39.0mg Z	P<.008	15.1mg 1.09gm	0/50	2/35	1/65	3/50		S
mul mnl	12.3mg *	P<.05	4.95mg n.s.s.	20/50	20/35	37/65	12/50		S
lun MXA	47.2mg Z	P<.1 e	14.5mg n.s.s.	2/50	2/35	2/65	3/50	lun:a/a,a/c.	
MXA sqp	71.0mg Z	P<.02 e	20.0mg n.s.s.	0/50	0/35	1/65	2/50	phr:sqp; ton:sqp.	
TBA MXB	3.23mg Z	P<.0005	1.95mg 7.30mg	43/50	33/35	62/65	48/50		
liv MXB	7.02mg Z	P<.0005	4.34mg 12.7mg	2/50	2/35	15/65	20/50	liv:hpa,hpc,nnd.	
C.I. FOOD RED 3 (carmoisine, C.I. acid red 14, disodium salt) 3567-69-9									
5427 M f b6c eat 24m24 TR220 :				0	386.mg	773.mg			
TBA MXB	no dre	P=1. -	1.45gm n.s.s.	28/50	29/50	23/49			
liv MXB	no dre	P=1.	3.32gm n.s.s.	3/50	5/50	2/49		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	2.93gm n.s.s.	4/50	4/50	4/49		lun:a/a,a/c.	
5428 M m b6c eat 24m24 TR220 :				0	357.mg	713.mg			
TBA MXB	no dre	P=1. -	680.mg n.s.s.	31/50	28/50	31/50			
liv MXB	no dre	P=1.	1.28gm n.s.s.	15/50	9/50	14/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	2.18gm n.s.s.	4/50	4/50	4/50		lun:a/a,a/c.	
5429 M f asp eat 80w80 1325				0	13.0mg	65.0mg	325.mg 1.63gm	Mason;fctx,12,601-607;1974	
lun ppa e	32.9gm *	P<.9 -	1.65gm n.s.s.	4/55	2/23	4/26	4/27 2/19		
liv tum e	no dre	P=1. -	29.9mg n.s.s.	0/55	0/23	0/26	0/27 0/19		
5430 M m asp eat 80w80 1325				0	12.0mg	60.0mg	300.mg 1.50gm		
lun ppa e	12.3gm *	P<.7 -	1.33gm n.s.s.	13/48	5/26	7/26	4/24 8/28		
liv nod e	no dre	P=1. -	3.17gm n.s.s.	6/48	1/26	0/26	0/24 2/28		
liv ade e	no dre	P=1. -	30.4mg n.s.s.	1/48	0/26	0/26	0/24 0/28		
5431 R f f34 eat 24m24 TR220 :				0	613.mg	1.23gm			
ute esp #	3.27gm *	P<.02 -	1.47gm n.s.s.	9/90	11/50	14/50			S
cli sea	16.4gm *	P<.02	4.96gm n.s.s.	0/90	0/50	3/50			S
TBA MXB	7.18gm *	P<.7	1.01gm n.s.s.	68/90	34/50	44/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB	no dre	P=1.		9.34gm n.s.s.	3/90	1/50	1/50		liv:hpa,hpc,nnd.
5432 R m f34 eat 24m24 TR220 :					0	238.mg	495.mg		
TBA MXB	1.86gm *	P<.5	-	407.mg n.s.s.	61/90	22/50	34/50		
liv MXB	9.85gm *	P<.7		1.34gm n.s.s.	5/90	3/50	3/50		liv:hpa,hpc,nnd.
C.I. PIGMENT RED 3 2425-85-6									
5433 M f b6c eat 24m24 TR407 :					0	1.60gm	3.20gm	6.42gm	
lyd MXA #	104.gm *	P<.03	-	31.0gm n.s.s.	0/51	0/50	0/50	3/50	lyd:ahs,dhs,ihs,nhs,rhs,shs. S
TBA MXB	13.8gm *	P<.3		4.15gm n.s.s.	36/51	29/50	23/50	33/50	
liv MXB	204.gm *	P<.9		10.9gm n.s.s.	10/51	14/50	4/50	9/50	liv:hpa,hpc,nnd.
lun MXB	252.gm *	P<.8		24.6gm n.s.s.	4/51	0/50	1/50	3/50	lun:a/a,a/c.
5434 M m b6c eat 24m24 TR407 :					0	1.47gm	2.96gm	5.92gm	
MXB MXB	19.5gm *	P<.0005		9.79gm 49.6gm	0/50	0/50	1/51	10/52	kcx:ade; thy:fca. P
kcx ade	35.5gm *	P<.003	p	14.5gm 176.gm	0/50	0/50	0/51	6/52	
thy fca	38.3gm *	P<.005	p	15.6gm 271.gm	0/50	0/50	1/51	5/52	
--- MXA	22.7gm *	P<.05		9.42gm n.s.s.	2/50	2/50	6/51	7/52	---:mlh,mlm. S
TBA MXB	9.42gm *	P<.2		3.15gm n.s.s.	25/50	27/50	33/51	35/52	
liv MXB	17.9gm *	P<.3		5.12gm n.s.s.	12/50	16/50	16/51	19/52	liv:hpa,hpc,nnd.
lun MXB	36.9gm *	P<.4		9.86gm n.s.s.	2/50	5/50	7/51	5/52	lun:a/a,a/c.
5435 R f f34 eat 24m24 TR407 :					0	295.mg	617.mg	1.23gm	
liv hpa	5.24gm *	P<.0005	p	2.63gm 13.4gm	0/50	0/50	1/50	10/50	
TBA MXB	no dre	P=1.		1.41gm n.s.s.	46/50	35/50	38/50	41/50	
liv MXB	5.24gm *	P<.0005		2.63gm 13.4gm	0/50	0/50	1/50	10/50	liv:hpa,hpc,nnd.
5436 R m f34 eat 24m24 TR407 :					0	236.mg	493.mg	988.mg	
amd MXA	661.mg *	P<.005	p	332.mg 6.55gm	24/50	32/51	37/51	36/51	amd:phm,pob.
amd pob	674.mg *	P<.004		343.mg 5.48gm	22/50	29/51	35/51	34/51	S
ski sqp	2.54gm *	P<.004	e	1.30gm 21.7gm	0/50	4/51	2/51	6/51	
ski MXA	3.66gm *	P<.04		1.49gm n.s.s.	1/50	4/51	2/51	6/51	ski:car,sqp. S
zym car	9.01gm *	P<.02	e	3.34gm n.s.s.	0/50	0/51	2/51	3/51	
TBA MXB	906.mg *	P<.2		332.mg n.s.s.	47/50	47/51	46/51	48/51	
liv MXB	5.17gm *	P<.08		2.08gm n.s.s.	0/50	1/51	4/51	1/51	liv:hpa,hpc,nnd.
C.I. PIGMENT RED 23 6471-49-4									
5437 M f b6c eat 24m24 TR411 :					0	1.29gm	3.23gm	6.46gm	
TBA MXB	29.7gm *	P<.6	-	5.16gm n.s.s.	27/50	31/50	31/50	32/50	
liv MXB	no dre	P=1.		16.2gm n.s.s.	5/50	8/50	10/50	4/50	liv:hpa,hpc,nnd.
lun MXB	45.2gm *	P<.09		15.9gm n.s.s.	1/50	2/50	2/50	5/50	lun:a/a,a/c.
5438 M m b6c eat 24m24 TR411 :					0	1.19gm	2.98gm	5.96gm	
TBA MXB	20.2gm *	P<.6	-	3.71gm n.s.s.	35/52	27/53	33/52	41/51	
liv MXB	15.1gm *	P<.2		5.46gm n.s.s.	13/52	8/53	14/52	21/51	liv:hpa,hpc,nnd.
lun MXB	112.gm *	P<.8		10.0gm n.s.s.	5/52	7/53	8/52	7/51	lun:a/a,a/c.
5439 R f f34 eat 24m24 TR411 :					0	490.mg	1.23gm	2.47gm	
TBA MXB	no dre	P=1.	-	2.99gm n.s.s.	48/50	48/50	44/50	44/50	
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpc,nnd.
5440 R m f34 eat 24m24 TR411 :					0	392.mg	983.mg	1.97gm	
kid MXA	19.8gm *	P<.04	e	6.85gm n.s.s.	0/50	0/50	1/50	3/51	kid:rua,ruc.
TBA MXB	no dre	P=1.		2.64gm n.s.s.	46/50	45/50	40/50	45/51	
liv MXB	no dre	P=1.		9.92gm n.s.s.	3/50	1/50	1/50	3/51	liv:hpa,hpc,nnd.
5441 R m f34 eat 24m24 TR411 with step					0	1.97gm			
kid MXA	16.3gm	P<.09	e	5.28gm n.s.s.	1/50	5/51			kid:rua,ruc.
D & C RED NO. 5 (ponceau MX) 3761-53-3									
5442 M f ddy eat 81w81 244					0	260.mg	1.27gm	6.22gm	Ikeda;fctx,6,591-598;1968
liv hpc erv	784.mg Z	P<.0005	+	365.mg 2.43gm	0/34	4/27	5/11	(5/12)	
liv hpa erv	21.5gm *	P<.2	+	4.19gm n.s.s.	1/34	2/27	0/11	2/12	
5443 M m ddy eat 81w81 244					0	240.mg	1.18gm	5.74gm	
liv hpc erv	659.mg Z	P<.0005	+	218.mg 3.45gm	0/31	0/8	4/6	(6/12)	
liv hpa erv	8.79gm *	P<.06	+	2.47gm n.s.s.	1/31	1/8	1/6	3/12	
5444 R f cfe eat 24m24 242					0	62.5mg	125.mg	250.mg	500.mg Grasso;fctx,7,425-442;1969
liv nod e	704.mg *	P<.0005		414.mg 1.34gm	0/30	1/30	0/29	5/28	14/25
5445 R m cfe eat 24m24 242					0	50.0mg	100.mg	200.mg	400.mg
liv nod e	2.91gm *	P<.02		1.10gm n.s.s.	0/30	0/30	1/29	1/30	3/29
5446 R f wal eat 52w91 1730m					0	714.mg			Grasso;txcy,7,327-347;1977/pers.comm.
liv mix er	233.mg	P<.0005	+	107.mg 641.mg	0/6	12/15			
liv hpc er	2.62gm	P<.3	+	643.mg n.s.s.	0/6	2/15			
5447 R f wal eat 91w91 1730n					0	1.25gm			
liv mix er	noTD50	P<.0005	+	n.s.s. 488.mg	0/6	11/11			
liv hpc er	3.27gm	P<.2	+	800.mg n.s.s.	0/6	2/11			
5448 R m wis eat 65w65 243					0	80.0mg	400.mg	2.00gm	Ikeda;fctx,4,485-492;1966
liv lca es	1.13gm *	P<.06	+	368.mg n.s.s.	0/12	4/15	4/12	6/14	
D & C RED NO. 9 (brilliant red) 5160-02-1									
5449 M f b6c eat 24m24 TR225 :					0	128.mg	255.mg		
TBA MXB	18.2gm *	P<1.	-	319.mg n.s.s.	26/50	25/50	27/50		
liv MXB	9.24gm *	P<.8		803.mg n.s.s.	5/50	3/50	6/50		liv:hpa,hpc,nnd.
lun MXB	9.20gm *	P<.7		1.13gm n.s.s.	2/50	1/50	3/50		lun:a/a,a/c.
5450 M m b6c eat 24m24 TR225 :					0	118.mg	235.mg		
TBA MXB	2.12gm *	P<.8	-	258.mg n.s.s.	23/50	28/50	24/50		
liv MXB	781.mg *	P<.2		293.mg n.s.s.	8/50	13/50	15/50		liv:hpa,hpc,nnd.
lun MXB	5.39gm *	P<.7		703.mg n.s.s.	4/50	4/50	5/50		lun:a/a,a/c.
5451 R f f34 eat 24m24 TR225 :					0	49.5mg	149.mg		
liv nnd	1.14gm *	P<.08	a	386.mg n.s.s.	1/50	1/50	5/50		
TBA MXB	no dre	P=1.		149.mg n.s.s.	44/50	42/50	40/50		
liv MXB	1.14gm *	P<.08		386.mg n.s.s.	1/50	1/50	5/50		liv:hpa,hpc,nnd.
5452 R m f34 eat 24m24 TR225 :					0	39.6mg	119.mg		
MXB MXB	104.mg /	P<.0005		66.0mg 190.mg	1/50	6/50	26/50		liv:hpc,nnd; spl:fbs,lei,ost,srn. C
spl MXA	146.mg /	P<.0005	c	88.7mg 265.mg	0/50	0/50	23/50		spl:fbs,lei,ost,srn.
spl fbs	211.mg /	P<.0005	c	119.mg 425.mg	0/50	0/50	17/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv nnd	265.mg *	P<.004	c	140.mg 1.80gm	0/50	6/50	7/50		
spl ost	728.mg *	P<.005	c	276.mg 5.35gm	0/50	0/50	5/50		
liv MXA	357.mg *	P<.03	c	154.mg n.s.s.	1/50	6/50	7/50		liv:hpc,nnd.
TBA MXB	331.mg /	P<.5		69.0mg n.s.s.	43/50	34/50	44/50		
liv MXB	357.mg *	P<.03		154.mg n.s.s.	1/50	6/50	7/50		liv:hpa,hpc,nnd.
5453 R f osm eat 25m25 262a					0	5.00mg	25.0mg	125.mg	500.mg	Davis;txap,4,200-205;1962
pit ade e	no dre	P=1.	-	998.mg n.s.s.	4/25	1/25	9/25	6/25	4/25	
5454 R m osm eat 25m25 262a					0	4.00mg	20.0mg	100.mg	400.mg	
tes ica e	28.6gm *	P<.8	-	1.65gm n.s.s.	0/25	2/25	0/25	0/25	1/25	
--- fbs e	no dre	P=1.	-	1.68gm n.s.s.	0/25	1/25	1/25	2/25	0/25	
D & C RED NO. 10 1248-18-6										
5455 R f osm eat 24m24 263					0	5.00mg	25.0mg	125.mg	500.mg	Davis;txap,5,728-734;1963
pit ade e	3.56gm *	P<.5	-	666.mg n.s.s.	2/25	5/25	9/25	3/25	7/25	
liv ade e	no dre	P=1.	-	21.0mg n.s.s.	0/25	0/25	0/25	0/25	0/25	
5456 R m osm eat 24m24 263					0	4.00mg	20.0mg	100.mg	400.mg	
liv hpa e	no dre	P=1.	-	2.70gm n.s.s.	1/25	1/25	0/25	0/25	0/25	
FD & C RED NO. 1 (ponceau 3R) 3564-09-8										
5457 R b bbl eat 24m24 246					0	900.mg				Hansen;txap,5,105-118;1963
liv mix	746.mg	P<.0005		460.mg 1.36gm	2/50	29/50				
liv car	2.48gm	P<.0005	+	1.24gm 6.19gm	0/50	11/50				
liv nod	3.04gm	P<.003		1.40gm 17.3gm	1/50	10/50				
liv bht	3.54gm	P<.002	+	1.60gm 12.0gm	0/50	8/50				
5458 R f nss eat 65w65 245					0	150.mg	500.mg	1.50gm		Grice;txap,3,509-520;1961
bil ade r	1.57gm *	P<.002		596.mg 8.32gm	0/45	0/15	2/15	3/15		
liv car r	1.99gm *	P<.003	+	684.mg 13.2gm	0/45	0/15	1/15	3/15		
5459 R m nss eat 65w65 245					0	120.mg	400.mg	1.20gm		
bil ade r	755.mg *	P<.0005		340.mg 2.92gm	0/45	1/15	3/15	4/15		
liv car r	1.24gm *	P<.0005	+	468.mg 5.35gm	0/45	0/15	1/15	4/15		
5460 R b osm eat 24m24 246					0	225.mg	450.mg	900.mg	2.25gm	Hansen;txap,5,105-118;1963
liv nod	639.mg Z	P<.0005		411.mg 1.08gm	0/49	12/50	18/50	(9/50 | 4/49)	
liv bht	909.mg Z	P<.0005	+	616.mg 1.69gm	1/49	12/50	17/50	22/50	(25/49)	
liv car	7.54gm *	P<.0005	+	4.21gm 19.9gm	0/49	1/50	2/50	4/50	9/49	
tba mal	12.9gm *	P<.2		4.09gm n.s.s.	10/49	8/50	7/50	7/50	14/49	
5461 R b wis eat 65w65 247m					0	1.35gm				Mannell;fctx,2,169-174;1964
liv tum ekr	225.mg	P<.0005	+	88.2mg 785.mg	0/6	8/10				
5462 R b wis eat 65w65 247n					0	1.35gm				
liv tum ekr	394.mg	P<.006	+	153.mg 4.09gm	0/6	6/10				
5463 R b wis eat 70w70 247o					0	1.35gm				
liv tum er	314.mg	P<.0005	+	158.mg 711.mg	0/23	14/19				
5464 R b wis eat 70w70 247r					0	1.35gm				
liv tum er	420.mg	P<.0005	+	208.mg 1.00gm	0/24	12/19				
FD & C RED NO. 2 (amaranth) 915-67-3										
5465 R b mgr eat 25m25 1427					0	758.mg				Baigusheva;vpit,27,46-50;1968
liv tum e	no dre	P=1.		3.03gm n.s.s.	0/35	0/18				
tba mix e	632.mg	P<.0005	+	295.mg 1.87gm	2/35	11/18				
5466 R b non eat 33m33 1429					0	771.mg				Andrianova;vpit,29,61-65;1970
liv hpt	49.5gm	P<.3		8.06gm n.s.s.	0/50	1/50				
tba mix	3.32gm	P<.0005	+	1.75gm 7.50gm	0/50	13/50				
5467 R f nss eat 64w64 1358					0	15.0mg	150.mg	750.mg		Mannell;jphp,10,625-634;1958
liv tum e	no dre	P=1.	-	14.4mg n.s.s.	0/10	0/14	0/13	0/9		
tba mix e	1.64gm *	P<.6	-	192.mg n.s.s.	2/10	1/14	4/13	2/9		
5468 R m nss eat 64w64 1358					0	12.0mg	120.mg	600.mg		
liv tum e	no dre	P=1.	-	8.41mg n.s.s.	0/11	0/10	0/11	0/9		
tba mix e	no dre	P=1.	-	8.41mg n.s.s.	1/11	0/10	0/11	0/9		
5469 R f sda eat 52w52 2600					0	1.00gm				Sekigawa;jnma,29,709-721;1978
liv tum e	no dre	P=1.	-	1.03gm n.s.s.	0/20	0/20				
tba tum e	no dre	P=1.	-	1.03gm n.s.s.	1/20	0/20				
5470 R b wis eat 91w91 1136					0	1.80gm				Willheim;gaga,23,1-19;1953
abd mly er	6.13gm	P<.04	+	993.mg n.s.s.	0/50	1/7				
FD & C RED NO. 3 (erythrosine) 16423-68-0										
5471 M f cd1 eat 24m24 1811					0	3.90gm				Borzelleca;fctx,25,735-737;1987
tba mix e	no dre	P=1.	-	11.7gm n.s.s.	67/120	25/60				
tba ben e	no dre	P=1.	-	14.4gm n.s.s.	40/120	13/60	9/60	16/60		
tba mal e	no dre	P=1.	-	16.0gm n.s.s.	35/120	14/60	17/60	12/60		
5472 M m cd1 eat 24m24 1811					0	360.mg	1.20gm	3.60gm		
--- lcl e	3.14gm Z	P<.02	-	1.11gm n.s.s.	1/120	5/60	(2/60 | 2/60)		
tba mix e	17.0gm	P<.3		4.50gm n.s.s.	46/120			28/60		
tba ben e	25.9gm *	P<.3	-	7.34gm n.s.s.	29/120	5/60	12/60	17/60		
tba mal e	87.6gm *	P<.8	-	9.15gm n.s.s.	17/120	18/60	12/60	12/60		
5473 R b osm gav 20m24 130m					0	23.3mg	54.7mg	175.mg	349.mg	Hansen;fctx,11,535-545;1973
--- lys e	122.mg Z	P<.004	-	49.8mg 759.mg	0/49	6/49	(3/47	2/46	1/43)	
liv tum e	no dre	P=1.	-	141.mg n.s.s.	0/49	0/49	0/47	0/46	0/43	
tba mal e	no dre	P=1.	-	1.36gm n.s.s.	5/49	12/49	6/47	9/46	4/43	
5474 R b osm eat 20m24 130n					0	185.mg	371.mg	742.mg	1.48gm	
liv hpt e	84.9gm *	P<.4	-	13.8gm n.s.s.	0/89	0/48	0/41	1/45	0/45	
tba mal e	14.1gm *	P<.5	-	3.08gm n.s.s.	20/89	6/48	8/41	9/45	12/45	
5475 R f osm eat 24m24 1371					0	250.mg	500.mg	1.00gm	2.50gm	Hansen;fctx,11,527-534;1973
liv tum	no dre	P=1.		334.mg n.s.s.	0/12	0/12	0/12	0/12	0/12	
tba mix	no dre	P=1.	-	7.16gm n.s.s.	5/12	4/12	1/12	2/12	0/12	
5476 R m osm eat 24m24 1371					0	200.mg	400.mg	800.mg	2.00gm	
liv tum	no dre	P=1.		267.mg n.s.s.	0/12	0/12	0/12	0/12	0/12	
tba mix	4.81gm *	P<.2	-	1.42gm n.s.s.	2/12	0/12	2/12	5/12	3/12	
5477 R f sda eat 52w52 2600					0	1.00gm				Sekigawa;jnma,29,709-721;1978
liv tum e	no dre	P=1.	-	1.03gm n.s.s.	0/20	0/20				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba tum e		no dre	P=1.	- 1.03gm n.s.s.	1/20	0/20			
5478 R f sls eat 52w52 2601					0	1.00gm			Sekigawa;jnma,30,179-191;1979
liv tum e		no dre	P=1.	- 1.03gm n.s.s.	0/20	0/20			
tba mix e		no dre	P=1.	- 617.mg n.s.s.	1/20	1/20			
5479 R m sls eat 52w52 2601					0	800.mg			
liv tum e		no dre	P=1.	- 824.mg n.s.s.	0/20	0/20			
tba mix e		no dre	P=1.	- 824.mg n.s.s.	1/20	0/20			
FD & C RED NO. 4 (ponceau SX) 4548-53-2									
5480 D f beg eat 85m85 248m					0	250.mg			Davis;txap,8,306-317;1966
adr mda e		316.mg	P<.2	51.0mg n.s.s.	0/9	1/5			
mgl adc e		316.mg	P<.2	- 51.0mg n.s.s.	0/9	1/5			
liv nod e		no dre	P=1.	106.mg n.s.s.	1/9	0/5			
tba mix e		670.mg	P<.9	39.1mg n.s.s.	3/9	2/5			
5481 M b che eat 24m24 248m					0	1.25gm	2.50gm		
liv hpt e		57.1gm	* P<.7	- 7.69gm n.s.s.	12/91	6/47	9/56		
tba mix e		20.3gm	* P<.3	- 5.60gm n.s.s.	13/91	8/47	12/56		
5482 M b chj eat 24m24 248m					0	1.25gm	2.50gm		
liv hpt e		no dre	P=1.	- 6.80gm n.s.s.	0/66	0/50	0/28		
tba mix e		no dre	P=1.	- 6.80gm n.s.s.	5/66	0/50	0/28		
5483 R b non eat 33m33 1429					0	771.mg			Andrianova;vpit,29,61-65;1970
liv hpt		49.5gm	P<.3	8.06gm n.s.s.	0/50	1/50			
tba mix		12.0gm	P<.02	+ 4.14gm n.s.s.	0/50	4/50			
5484 R b osm eat 24m24 248m					0	225.mg	450.mg	900.mg 2.25gm	Davis;txap,8,306-317;1966
liv ade e		59.8gm	* P<.2	- 9.74gm n.s.s.	0/16	0/19	0/23	0/22 1/24	
tba mix e		no dre	P=1.	- 5.14gm n.s.s.	7/16	10/19	8/23	10/22 5/24	
5485 R b osm eat 24m24 248n					0	450.mg	900.mg		
--- fbs e		20.3gm	* P<.006	- 7.00gm 239.gm	0/171	0/89	4/89		
tba mix e		no dre	P=1.	- 3.48gm n.s.s.	67/171	23/89	32/89		
5486 R b sda eat 24m24 248m					0	450.mg	900.mg		
tba mix e		no dre	P=1.	- 4.95gm n.s.s.	38/147	16/83	14/74		
5487 R b wis eat 91w91 1136					0	1.80gm			Willheim;gaga,23,1-19;1953
abd mly er		6.13gm	P<.04	+ 993.mg n.s.s.	0/50	1/7			
FOOD RED NO. 106 (C.I. No. 45100, Red 106) 3520-42-1									
5488 R f f3d eat 25m25 2376					0	1.25gm	2.50gm		Konishi;jtxp,5,157-165;1992/pers.comm.
liv tum e		no dre	P=1.	- 8.13gm n.s.s.	0/47	0/47	0/43		
tba mix e		4.10gm	* P<.2	- 1.51gm n.s.s.	28/47	26/47	33/43		
5489 R m f3d eat 25m25 2376					0	1.00gm	2.00gm		
liv nnd e		no dre	P=1.	- 21.8gm n.s.s.	3/48	0/45	1/48		
tba mix e		2.35gm	* P<.6	- 363.mg n.s.s.	45/48	45/45	46/48		
HC RED NO. 3 2871-01-4									
5490 M f b6c gav 24m24 TR281 :					0	88.4mg	177.mg		
for sqp s#		721.mg	* P<.04	i 208.mg n.s.s.	0/50	0/50	3/50		S
TBA MXB s		292.mg	* P<.5	67.0mg n.s.s.	16/50	15/50	18/50		
liv MXB s		no dre	P=1.	273.mg n.s.s.	4/50	1/50	2/50		liv:hpa,hpc,nnd.
lun MXB s		4.67gm	* P<.9	241.mg n.s.s.	1/50	2/50	1/50		lun:a/a,a/c.
5491 M m b6c gav 24m24 TR281 :					0	88.4mg	177.mg		
liv MXA		427.mg	/ P<.2	e 141.mg n.s.s.	25/50	15/50	35/50		liv:hpa,hpc.
TBA MXB		no dre	P=1.	142.mg n.s.s.	44/50	36/50	42/50		
liv MXB		427.mg	/ P<.2	141.mg n.s.s.	25/50	15/50	35/50		liv:hpa,hpc,nnd.
lun MXB		1.75gm	* P<.7	251.mg n.s.s.	11/50	13/50	13/50		lun:a/a,a/c.
5492 R f f34 gav 24m25 TR281 :					0	177.mg	354.mg		
TBA MXB		4.87gm	* P<.9	- 238.mg n.s.s.	45/50	44/50	41/50		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
5493 R m f34 gav 24m25 TR281 :					0	177.mg	356.mg		
TBA MXB		500.mg	* P<.3	- 154.mg n.s.s.	44/50	38/50	38/50		
liv MXB		1.51kg	P<1.	1.18gm n.s.s.	4/50	1/50	3/50		liv:hpa,hpc,nnd.
RESERPINE 50-55-5									
5494 M f b6c eat 24m24 TR193 :					0	.650mg	1.30mg		
mgl ---		3.58mg	* P<.002	c 1.92mg 12.2mg	0/50	7/50	7/50		
TBA MXB		6.42mg	* P<.5	1.44mg n.s.s.	21/50	19/50	23/50		
liv MXB		no dre	P=1.	10.1mg n.s.s.	2/50	0/50	1/50		liv:hpa,hpc,nnd.
lun MXB		54.5mg	* P<.9	4.03mg n.s.s.	4/50	4/50	4/50		lun:a/a,a/c.
5495 M m b6c eat 24m24 TR193 :					0	.600mg	1.20mg		
sev ulc		8.39mg	* P<.01	c 3.42mg 947.mg	0/50	1/50	5/50		
TBA MXB		no dre	P=1.	1.78mg n.s.s.	30/50	34/50	25/50		
liv MXB		5.46mg	\ P<.6	.868mg n.s.s.	12/50	14/50	(4/50)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.89mg n.s.s.	9/50	9/50	6/50		lun:a/a,a/c.
5496 M f c3h eat 24m24 1187					0	9.60ug			Lacassagne;adsc,810-812;1959
mgl adc Lr		34.2ug	P<.6	5.54ug n.s.s.	12/22	15/24			
5497 R f f34 eat 24m24 TR193 :					0	.250mg	.500mg		
TBA MXB		.727mg	* P<.3	- .216mg n.s.s.	42/50	45/50	45/50		
liv MXB		no dre	P=1.	6.05mg n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
5498 R m f34 eat 24m24 TR193 :					0	.200mg	.400mg		
adr MXA		.306mg	* P<.0005	c .181mg 1.01mg	3/50	18/50	24/50		adr:phe,phm.
TBA MXB		no dre	P=1.	.367mg n.s.s.	43/50	42/50	42/50		
liv MXB		6.77mg	* P<.4	1.64mg n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
5499 R f wis eat 75w75 1008					0	1.50mg	3.00mg		Tatematsu;txlt,1,201-205;1978
pit mix e		no dre	P=1.	- 5.14mg n.s.s.	1/22	1/18	1/24		
mgl fba e		no dre	P=1.	- 7.52mg n.s.s.	1/22	1/18	0/24		
5500 R m wis eat 75w75 1008					0	1.20mg	2.40mg		
pit ade e		38.3mg	* P<.8	- 2.81mg n.s.s.	1/22	1/18	1/15		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
RESORCINOL 108-46-3								
5501 M f b6c gav 24m24 TR403 :				0	79.5mg	160.mg		
TBA MXB	1.88gm	/ P<.9	- 140.mg n.s.s.	35/60	21/60	33/60		
liv MXB	1.56gm	* P<.3	441.mg n.s.s.	2/60	1/60	5/60		liv:hpa,hpc,nnd.
lun MXB	1.35gm	* P<.2	465.mg n.s.s.	0/60	3/60	1/60		lun:a/a,a/c.
5502 M m b6c gav 24m24 TR403 :				0	79.5mg	160.mg		
TBA MXB	no dre	P=1.	- 251.mg n.s.s.	33/60	29/60	22/60		
liv MXB	no dre	P=1.	447.mg n.s.s.	12/60	11/60	7/60		liv:hpa,hpc,nnd.
lun MXB	6.80gm	* P<.9	412.mg n.s.s.	6/60	6/60	6/60		lun:a/a,a/c.
5503 R f f34 gav 24m24 TR403 :				0	35.3mg	70.5mg	106.mg	
TBA MXB s	219.mg	* P<.5	- 49.5mg n.s.s.	49/50	46/50	44/50	42/50	
liv MXB s	no dre	P=1.	1.20gm n.s.s.	1/50	0/50	0/50	0/50	liv:hpa,hpc,nnd.
5504 R m f34 gav 24m24 TR403 :				0	79.1mg	159.mg		
tes ica s#	84.0mg	* P<.05	- 35.2mg n.s.s.	45/50	44/50	31/60		S
TBA MXB s	213.mg	* P<.4	51.0mg n.s.s.	42/50	45/50	20/60		
liv MXB s	no dre	P=1.	951.mg n.s.s.	2/50	0/50	0/60		liv:hpa,hpc,nnd.
RETINOIC ACID (vitamin A acid) 302-79-4								
5505 M f swn gav 52w52 2597				0	9.00mg	18.0mg		Yamamoto;jnma,27,437-451;1976
liv tum e	no dre	P=1.	2.51mg n.s.s.	0/12	0/7	0/12		
lun ade e	no dre	P=1.	2.51mg n.s.s.	1/12	0/7	0/12		
5506 M m swn gav 52w52 2597				0	9.00mg	18.0mg		
liv tum e	no dre	P=1.	3.71mg n.s.s.	0/12	0/12	0/12		
lun ade e	no dre	P=1.	3.71mg n.s.s.	2/12	0/12	0/12		
5507 R f sda ipj 24m24 1134				0	.714mg			Schmahl;zkko,86,77-84;1976
tba mal e	no dre	P=1.	- 2.80mg n.s.s.	3/33	2/35			
5508 R m sda ipj 24m24 1134				0	.714mg			
liv hae e	no dre	P=1.	4.86mg n.s.s.	1/36	0/33			
tba mal e	188.mg	P<1.	- 2.91mg n.s.s.	1/36	1/33			
RETINOL ACETATE (vitamin A, acetate) 127-47-9								
5509 R f f3d wat 24m25 1693m				0	68.8mg	138.mg		Kurokawa;jnci,74,715-723;1985/pers.comm.
amd phe ej	227.mg	* P<.0005 +	135.mg 539.mg	3/50	11/49	20/48		
amd phm ej	7.34gm	* P<.9	1.20gm n.s.s.	0/50	1/49	0/48		
liv nnd ej	7.34gm	* P<.9	1.20gm n.s.s.	0/50	1/49	0/48		
cli ade ej	no dre	P=1.	1.64gm n.s.s.	7/50	1/49	1/48		
mgl mix ej	no dre	P=1.	955.mg n.s.s.	5/50	6/49	1/48		
thy cca ej	no dre	P=1.	251.mg n.s.s.	7/50	6/49	(1/48)		
tba mix ej	no dre	P=1.	115.mg n.s.s.	39/50	40/49	36/48		
5510 R m f3d wat 24m25 1693m				0	60.2mg	120.mg		
amd phe ej	86.4mg	* P<.0005 +	51.8mg 212.mg	18/49	27/50	39/48		
spl mnl ej	548.mg	* P<.04	251.mg n.s.s.	1/49	8/50	6/48		
amd phm ej	552.mg	* P<.02 +	246.mg n.s.s.	3/49	4/50	11/48		
thy cca ej	671.mg	* P<.06	270.mg n.s.s.	3/49	5/50	9/48		
thy mix ej	976.mg	* P<.3	284.mg n.s.s.	6/49	6/50	10/48		
liv nnd ej	2.06gm	* P<.3	533.mg n.s.s.	1/49	2/50	3/48		
liv mix ej	3.67gm	* P<.7	537.mg n.s.s.	2/49	3/50	3/48		
liv cho ej	6.47gm	* P<1.	1.05gm n.s.s.	0/49	1/50	0/48		
liv hpc ej	no dre	P=1.	440.mg n.s.s.	1/49	0/50	0/48		
mgl mix ej	no dre	P=1.	146.mg n.s.s.	12/49	12/50	(3/48)		
tba mix ej	noTD50	P=1.	n.s.s. n.s.s.	49/49	50/50	48/48		
5511 R m f3d wat 52w52 1883				0	125.mg			Hasegawa;gann,79,320-328;1988/pers.comm.
for neo	no dre	P=1.	- 64.4mg n.s.s.	0/10	0/10			
liv tum	no dre	P=1.	64.4mg n.s.s.	0/10	0/10			
5512 R m f3d eat 52w52 2192				0	4.00mg			Shibata;carc,14,1265-1269;1993/pers.comm.
for tum er	no dre	P=1.	2.06mg n.s.s.	0/10	0/10			
RETINOL PALMITATE (vitamin A, palmitate) 79-81-2								
5513 M m icr wat 66w66 2415				0	1.50mg			Yamada;surg,25,729-736;1995
for tum er	no dre	P=1.	- 3.49mg n.s.s.	0/28	0/28			
5514 R m cdr eat 28m28 1833				0	1.60mg			Arnold;fctx,23,779-793;1985
liv tum e	no dre	P=1.	16.8mg n.s.s.	0/38	0/39			
RETRORSINE 480-54-6								
5515 R m wis wat 24m24 1871				0	.643mg			Schoental;bjca,8,458-465;1954
liv hpt r	.862mg	P<.03 +	.292mg n.s.s.	0/7	4/10			
RHODAMINE 6G (C.I. basic red 1.HCl) 989-38-8								
5516 M f b6c eat 24m24 TR364 :				0	63.8mg	128.mg		
TBA MXB	no dre	P=1.	- 144.mg n.s.s.	29/50	33/50	25/50		
liv MXB	no dre	P=1.	481.mg n.s.s.	8/50	4/50	5/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	397.mg n.s.s.	4/50	6/50	3/50		lun:a/a,a/c.
5517 M m b6c eat 24m24 TR364 :				0	118.mg	235.mg		
thy MXA #	1.21gm	* P<.05	- 523.mg n.s.s.	0/50	4/50	3/50		thy:fca,fcc. S
TBA MXB	no dre	P=1.	351.mg n.s.s.	39/50	33/50	29/50		
liv MXB	no dre	P=1.	527.mg n.s.s.	13/50	12/50	11/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	831.mg n.s.s.	9/50	7/50	5/50		lun:a/a,a/c.
5518 R f f34 eat 24m24 TR364 :				0	5.89mg	12.3mg		
amd MXA	47.1mg	* P<.06	e 18.8mg n.s.s.	3/50	3/50	10/50		amd:phm,pob.
TBA MXB	no dre	P=1.	7.23mg n.s.s.	48/50	47/50	49/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
5519 R m f34 eat 24m24 TR364 :				0	4.71mg	9.81mg		
ski ker	34.5mg	* P<.02	e 14.9mg n.s.s.	1/50	2/50	8/50		
TBA MXB	no dre	P=1.	6.86mg n.s.s.	48/50	49/50	46/50		
liv MXB	553.mg	/ P<.9	23.7mg n.s.s.	5/50	0/50	6/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
RIDDELLIINE 23246-96-0										
5520 M f b6c gav 24m24 TR508 :				0	2.14mg					
lun MXA	1.99mg	P<.0005 c	.848mg 6.53mg	2/50	13/50					lun:a/a,a/c.
lun a/a	2.68mg	P<.0005	1.05mg 10.6mg	1/50	9/50					S
--- MXA	10.0mg	P<.02	3.38mg 1.44gm	0/50	4/50					---:hem,hes. S
TBA MXB	.691mg	P<.0005	.355mg 2.06mg	31/50	41/50					
liv MXB	no dre	P=1.	4.70mg n.s.s.	16/50	0/50					liv:hpa,hpb,hpc.
lun MXB	1.99mg	P<.0005	.848mg 6.53mg	2/50	13/50					lun:a/a,a/c.
5521 M m b6c gav 24m24 TR508 :				0	71.4ug	.214mg	.714mg	2.14mg		
--- hes	1.63mg Z	P<.0005	1.06mg 2.76mg	3/50	2/50	4/50	3/50	33/50		S
liv hes	1.96mg Z	P<.0005 c	1.26mg 3.31mg	2/50	1/50	0/50	2/50	31/50		
TBA MXB	1.09mg *	P<.004	.541mg 8.13mg	48/50	48/50	50/50	45/50	50/50		
liv MXB	no dre	P=1.	.246mg n.s.s.	36/50	40/50	33/50	(24/50	3/50)		liv:hpa,hpb,hpc.
lun MXB	5.57mg *	P<.2	1.85mg n.s.s.	18/50	16/50	15/50	9/50	17/50		lun:a/a,a/c.
5522 R f f34 gav 24m24 TR508 :				0	7.14ug	23.6ug	71.4ug	.236mg	.714mg	
MXB MXB a	.143mg Z	P<.0005	98.9ug .218mg	12/50	8/50	13/50	18/50	20/50	46/50	---:mnl; liv:hes,hpa. M
MXB MXB a	.234mg Z	P<.0005	.141mg .468mg	12/50	8/50	13/50	18/50	18/50	20/50	---:mnl; liv:hpa. P
--- mnl a	.293mg Z	P<.0005 p	.162mg .722mg	12/50	8/50	13/50	18/50	18/50	14/50	
--- hes a	.446mg Z	P<.0005	.291mg .687mg	0/50	0/50	0/50	0/50	3/50	39/50	S
liv hes a	.457mg Z	P<.0005 c	.296mg .708mg	0/50	0/50	0/50	0/50	3/50	38/50	
liv MXA a	1.20mg Z	P<.0005	.520mg 3.41mg	1/50	0/50	0/50	0/50	2/50	8/50	liv:hpa,hpc. S
liv hpa a	1.63mg Z	P<.0005 p	.650mg 5.42mg	1/50	0/50	0/50	0/50	1/50	7/50	
thy MXA a	.620mg *	P<.02	.253mg n.s.s.	2/50	4/50	4/50	6/50	11/50	0/50	thy:cca,cdb. S
TBA MXB a	70.6ug Z	P<.0005	47.8ug .116mg	47/50	45/50	49/50	47/50	50/50	50/50	
liv MXB a	1.20mg Z	P<.0005	.520mg 3.41mg	1/50	0/50	0/50	0/50	2/50	8/50	liv:hpa,hpb,hpc.
5523 R m f34 gav 71w71 TR508 :				0	.714mg					
MXB MXB	66.5ug	P<.0005	37.3ug .117mg	2/50	44/50					---:mnl; liv:hes,hpa. M
liv hes	74.4ug	P<.0005 c	42.7ug .118mg	0/50	43/50					
MXB MXB	.179mg	P<.0005	70.9ug .556mg	2/50	12/50					---:mnl; liv:hpa. P
--- mnl	.232mg	P<.0005 p	81.9ug .902mg	2/50	9/50					
lun a/a	.528mg	P<.002	.125mg 4.88mg	0/50	3/50					S
liv hpa	.584mg	P<.002 p	.154mg 3.83mg	0/50	4/50					
TBA MXB	26.7ug	P<.0005	15.3ug 51.4ug	41/50	49/50					
liv MXB	.584mg	P<.002	.154mg 3.83mg	0/50	4/50					liv:hpa,hpb,hpc.
RIFAMPICIN 13292-46-1										
5524 M f bal wat 14m26 400				0	10.7mg	32.1mg	64.3mg			Della Porta;txap,43,293-302;1978
lun tum e	1.01gm *	P<.8 -	115.mg n.s.s.	13/37	10/36	10/37	14/38			
liv hpt e	3.18gm *	P<.6 -	518.mg n.s.s.	0/37	0/36	1/37	0/38			
tba mix e	no dre	P=1. -	84.1mg n.s.s.	26/37	30/36	25/37	25/38			
5525 M m bal wat 14m26 400				0	8.93mg	26.8mg	53.6mg			
lun tum es	320.mg *	P<.3 -	88.4mg n.s.s.	6/42	9/41	14/42	10/43			
liv hpt es	3.00gm *	P<.6 -	489.mg n.s.s.	0/42	0/41	1/42	0/43			
tba mix es	509.mg *	P<.6 -	88.5mg n.s.s.	11/42	13/41	15/42	14/43			
5526 M f c3d wat 14m25 400				0	11.3mg	34.0mg	67.9mg			
liv hpt e	33.6mg *	P<.0005 +	21.6mg 63.7mg	8/40	16/40	27/44	29/36			
lun tum e	no dre	P=1.	244.mg n.s.s.	3/40	6/40	2/44	4/36			
tba mix e	39.3mg *	P<.0005	21.0mg 148.mg	18/40	27/40	30/44	31/36			
5527 M m c3d wat 14m25 400				0	9.43mg	28.3mg	56.6mg			
lun tum e	356.mg *	P<.2 -	114.mg n.s.s.	3/30	5/40	3/40	9/40			
liv hpt e	1.05gm *	P<.9 -	59.8mg n.s.s.	18/30	20/40	21/40	23/40			
tba mix e	474.mg *	P<.9 -	38.5mg n.s.s.	20/30	30/40	29/40	29/40			
5528 R f wis wat 24m32 400				0	12.9mg	25.8mg				
liv hpt e	436.mg *	P<.09 -	107.mg n.s.s.	0/20	0/20	2/19				
tba mix e	no dre	P=1. -	22.0mg n.s.s.	17/20	19/20	14/19				
5529 R m wis wat 24m32 400				0	11.3mg	22.6mg				
liv hpt e	no dre	P=1. -	130.mg n.s.s.	1/19	1/21	1/22				
tba mix e	1.38gm *	P<1. -	26.2mg n.s.s.	12/19	12/21	14/22				
RIPAZEPAM (pyrazapon) 26308-28-1										
5530 M f cd1 eat 78w78 1602				0	15.0mg	150.mg				Fitzgerald;faat,4,178-190;1984
liv hpa e	352.mg *	P<.02 +	142.mg n.s.s.	5/50	2/50	11/50				
lun car e	1.03gm *	P<.2	252.mg n.s.s.	0/50	2/50	3/50				
lun ade e	no dre	P=1.	633.mg n.s.s.	3/50	1/50	1/50				
tba ben e	287.mg *	P<.04	111.mg n.s.s.	10/50	6/50	16/50				
tba mal e	1.19gm *	P<.5	214.mg n.s.s.	2/50	7/50	6/50				
tba mix e	219.gm \	P=1.	17.8mg n.s.s.	13/50	13/50	(2/50)				
5531 M m cd1 eat 78w78 1602				0	15.0mg	150.mg				
liv hpa e	67.8mg *	P<.0005 +	38.9mg 157.mg	10/50	15/50	33/50				
liv hpc e	3.15gm *	P<.2	513.mg n.s.s.	0/50	0/50	1/50				
lun car e	no dre	P=1.	496.mg n.s.s.	3/50	6/50	2/50				
tba mix e	72.2mg *	P<.004	33.7mg 618.mg	24/50	31/50	39/50				
tba ben e	79.4mg *	P<.002	39.2mg 394.mg	21/50	23/50	36/50				
tba mal e	35.0mg \	P<.05	13.5mg n.s.s.	4/50	11/50	(5/50)				
5532 R f cdr eat 24m24 1602				0	15.0mg	150.mg				
liv hpc e	2.77gm *	P<.05 -	683.mg n.s.s.	0/50	0/50	2/50				
liv hpa e	3.67gm *	P<.7 -	429.mg n.s.s.	4/50	6/50	6/50				
tba mal e	1.44gm *	P<.5 -	301.mg n.s.s.	9/50	7/50	11/50				
tba ben e	no dre	P=1. -	74.0mg n.s.s.	45/50	43/50	44/50				
tba mix e	no dre	P=1. -	68.2mg n.s.s.	48/50	47/50	46/50				
5533 R m cdr eat 24m24 1602				0	15.0mg	150.mg				
pit ade e	147.mg *	P<.004 -	69.5mg 1.14gm	20/50	28/50	36/50				
liv hpa e	988.mg *	P<.2 -	304.mg n.s.s.	5/50	4/50	9/50				
tba mix e	89.7mg *	P<.04 -	31.6mg n.s.s.	40/50	43/50	47/50				
tba ben e	106.mg *	P<.03 -	41.3mg n.s.s.	36/50	40/50	45/50				
tba mal e	2.25gm *	P<.7 -	324.mg n.s.s.	7/50	10/50	10/50				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ROSANILINE.HCl (magenta I) 632-99-5									
5534 H f syg gav 68w68 1151					0	114.mg			Green;zkko,95,51-55;1979
liv tum e	no dre	P=1.		403.mg n.s.s.	0/40	0/40			
lun tum e	no dre	P=1.		403.mg n.s.s.	0/40	0/40			
tba mix e	no dre	P=1.	-	248.mg n.s.s.	5/40	2/40			
5535 H m syg gav 84w84 1151					0	114.mg			
lun bcd e	2.02gm	P<.3	-	329.mg n.s.s.	0/40	1/40			
liv tum e	no dre	P=1.		615.mg n.s.s.	0/40	0/40			
tba mix e	no dre	P=1.	-	331.mg n.s.s.	3/40	2/40			
5536 R f sda gav 25m25 1524					0	30.4mg			Ketkar;clet,16,203-206;1982
liv tum ev	no dre	P=1.		266.mg n.s.s.	0/40	0/40			
tba mix ev	no dre	P=1.	-	210.mg n.s.s.	23/40	3/40			
5537 R m sda gav 26m26 1524					0	30.4mg			
liv tum ev	no dre	P=1.		285.mg n.s.s.	0/40	0/40			
tba mix ev	no dre	P=1.	-	244.mg n.s.s.	10/40	1/40			
p-ROSANILINE.HCl (p-magenta, C.I. basic red 9.HCl) 569-61-9									
5538 H f syg gav 84w84 1151					0	85.7mg			Green;zkko,95,51-55;1979
liv tum e	no dre	P=1.		461.mg n.s.s.	0/40	0/40			
lun tum e	no dre	P=1.		461.mg n.s.s.	0/40	0/40			
tba mix e	no dre	P=1.	-	187.mg n.s.s.	5/40	4/40			
5539 H m syg gav 84w84 1151					0	85.7mg			
liv tum e	no dre	P=1.		461.mg n.s.s.	0/40	0/40			
lun tum e	no dre	P=1.		461.mg n.s.s.	0/40	0/40			
tba mix e	no dre	P=1.	-	331.mg n.s.s.	3/40	1/40			
5540 M f b6c eat 24m24 TR285 :					0	63.8mg	128.mg		
liv MXA	20.3mg	* P<.0005		13.5mg 32.3mg	5/50	35/50	41/50		liv:hpa,hpc. S
MXB MXB	28.8mg	* P<.0005		18.9mg 46.5mg	4/50	25/50	37/50		adr:phe,phm; liv:hpc. C
liv hpc	32.3mg	* P<.0005	c	20.9mg 52.5mg	3/50	19/50	37/50		
liv hpa	35.9mg	\ P<.0005		18.6mg 85.9mg	2/50	18/50	(4/50)		S
--- MXA	62.2mg	* P<.0005	e	33.7mg 179.mg	17/50	24/50	25/50		---:mlh,mlm,mlp,mlu,mno.
adr MXA	90.6mg	* P<.0005	c	45.0mg 245.mg	1/50	8/50	8/50		adr:phe,phm.
--- mlp	151.mg	\ P<.002	e	51.6mg 810.mg	0/50	5/50	(1/50)		
lun MXA	302.mg	* P<.002		108.mg 1.35gm	0/50	2/50	5/50		lun:a/a,a/c. S
hag MXA	316.mg	/ P<.002		106.mg 1.58gm	0/50	0/50	5/50		hag:adn,cyn. S
lun a/a	326.mg	* P<.003		111.mg 1.95gm	0/50	2/50	4/50		S
--- mlh	380.mg	* P<.004	e	163.mg 2.64gm	1/50	3/50	8/50		
hag ade	548.mg	* P<.01		147.mg 45.2gm	0/50	0/50	3/50		S
hag MXA	388.mg	/ P<.02		121.mg n.s.s.	1/50	0/50	5/50		hag:adn,can,cyn. S
TBA MXB	23.4mg	* P<.0005		14.7mg 44.0mg	31/50	50/50	49/50		
liv MXB	20.3mg	* P<.0005		13.5mg 32.3mg	5/50	35/50	41/50		liv:hpa,hpc,nnd.
lun MXB	302.mg	* P<.002		108.mg 1.35gm	0/50	2/50	5/50		lun:a/a,a/c.
5541 M m b6c eat 24m24 TR285 :					0	58.9mg	118.mg		
liv hpc	127.mg	* P<.002	c	69.0mg 582.mg	10/50	20/50	27/50		
liv MXA	116.mg	* P<.04		50.1mg n.s.s.	29/50	37/50	41/50		liv:hpa,hpc. S
--- mlm	610.mg	* P<.02		263.mg n.s.s.	0/50	3/50	4/50		S
TBA MXB	222.mg	* P<.4		56.8mg n.s.s.	44/50	43/50	46/50		
liv MXB	116.mg	* P<.04		50.1mg n.s.s.	29/50	37/50	41/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		284.mg n.s.s.	11/50	7/50	8/50		lun:a/a,a/c.
5542 R f f34 eat 24m24 TR285 :					0	24.6mg	49.3mg		
mgl MXA	25.4mg	* P<.0005	e	14.1mg 83.6mg	23/50	32/50	32/50		mgl:acn,adn,fba.
mgl fba	27.9mg	* P<.0005	e	15.0mg 108.mg	22/50	31/50	29/50		
MXB MXB	32.2mg	* P<.0005		21.2mg 51.7mg	0/50	16/50	21/50		sub:fib; thy:fca,fcc; zym:can. C
sub MXA	40.9mg	* P<.0005		25.1mg 82.0mg	1/50	17/50	12/50		sub:fbs,fib,srn. S
sub MXA	42.8mg	* P<.0005		26.5mg 76.6mg	0/50	16/50	10/50		sub:fbs,fib. S
sub fib	44.5mg	* P<.0005	c	27.2mg 80.7mg	0/50	15/50	10/50		
ute ess	133.mg	* P<.006		60.0mg 1.50gm	1/50	5/50	6/50		S
thy MXA	154.mg	* P<.0005	c	68.8mg 534.mg	0/50	2/50	6/50		thy:fca,fcc.
zym can	190.mg	* P<.002	c	86.5mg 651.mg	0/50	2/50	7/50		
thy fca	318.mg	/ P<.007		108.mg 5.07gm	0/50	0/50	4/50		S
mgl MXA	156.mg	* P<.03	e	63.2mg n.s.s.	2/50	4/50	6/50		mgl:acn,adn.
liv MXA	189.mg	* P<.04		73.0mg n.s.s.	1/50	4/50	4/50		liv:hpc,nnd. S
mgl acn	232.mg	* P<.06	e	79.3mg n.s.s.	2/50	2/50	5/50		
TBA MXB	17.8mg	* P<.0005		10.1mg 57.5mg	41/50	50/50	48/50		
liv MXB	189.mg	* P<.04		73.0mg n.s.s.	1/50	4/50	4/50		liv:hpa,hpc,nnd.
5543 R m f34 eat 24m24 TR285 :					0	39.2mg	79.2mg		
tes ict	15.6mg	/ P<.0005		9.57mg 33.0mg	43/50	46/50	37/50		S
MXB MXB	21.2mg	/ P<.0005		14.8mg 32.0mg	3/50	26/50	40/50	liv:hpc; ski:sea,sqc,tri; sub:fib; thy:fca,fcc; zym:can. C	
sub MXA	33.0mg	/ P<.0005		20.6mg 59.7mg	3/50	22/50	16/50		sub:fbs,fib. S
sub MXA	33.4mg	/ P<.0005		20.8mg 62.6mg	6/50	24/50	19/50		sub:fbs,fib,srn. S
sub fib	35.3mg	/ P<.0005	c	22.2mg 62.9mg	2/50	20/50	16/50		
liv MXA	41.5mg	/ P<.0005		24.0mg 89.4mg	5/50	15/50	14/50		liv:hpc,nnd. S
thy MXA	57.0mg	/ P<.0005	c	34.9mg 97.5mg	0/50	5/50	25/50		thy:fca,fcc.
liv nnd	62.2mg	* P<.0005		31.0mg 246.mg	5/50	14/50	6/50		S
thy fcc	73.9mg	/ P<.0005	c	42.1mg 137.mg	0/50	5/50	18/50		
ski MXA	93.8mg	/ P<.0005		47.9mg 235.mg	2/50	2/50	14/50		ski:sqc,sqp. S
zym can	124.mg	/ P<.0005	c	61.6mg 314.mg	1/50	1/50	13/50		
ski sqc	130.mg	/ P<.0005	c	61.7mg 317.mg	0/50	1/50	10/50		
liv hpc	140.mg	/ P<.0005	c	65.7mg 357.mg	0/50	2/50	8/50		
pni MXA	152.mg	* P<.006		62.5mg 2.26gm	2/50	5/50	4/50		pni:isa,isc. S
thy fca	176.mg	/ P<.0005	c	78.3mg 477.mg	0/50	0/50	9/50		
ski tri	221.mg	/ P<.0005	c	90.5mg 711.mg	0/50	0/50	7/50		
lun a/a	281.mg	* P<.006		98.7mg 2.79gm	0/50	3/50	3/50		S
ski sea	424.mg	/ P<.003	c	157.mg 2.29gm	0/50	0/50	5/50		
MXA MXA	184.mg	* P<.02		70.1mg 42.6gm	1/50	5/50	3/50	bod:men; mls:men; mul:men; tnv:men,msm. S	
pni isc	252.mg	* P<.02		85.2mg n.s.s.	0/50	3/50	1/50		S
lun MXA	254.mg	* P<.02		90.9mg n.s.s.	1/50	3/50	4/50		lun:a/a,a/c. S
ski bcc	385.mg	/ P<.03		116.mg n.s.s.	1/50	0/50	4/50		S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv MXA	557.mg /	P<.02		162.mg n.s.s.	0/50	0/50	3/50			liv:bda,bdc. S
TBA MXB	15.7mg /	P<.0005		9.99mg 29.7mg	41/50	47/50	45/50			
liv MXB	41.5mg /	P<.0005		24.0mg 89.4mg	5/50	15/50	14/50			liv:hpa,hpc,nnd.
5544 R f sda gav 30m30 1524					0	48.6mg				Ketkar;clet,16,203-206;1982
liv tum ev	no dre	P=1.		597.mg n.s.s.	0/40	0/40				
tba mix ev	no dre	P=1.	-	244.mg n.s.s.	23/40	11/40				
5545 R m sda gav 29m29 1524					0	48.7mg				
liv tum ev	no dre	P=1.		571.mg n.s.s.	0/40	0/40				
tba mix ev	no dre	P=1.	-	201.mg n.s.s.	10/40	7/40				
ROTENONE (tubatoxin) 83-79-4										
5546 M f b6c eat 24m24 TR320 :					0	77.3mg	155.mg			
TBA MXB	no dre	P=1.	-	345.mg n.s.s.	26/50	16/50	22/50			
liv MXB	no dre	P=1.		658.mg n.s.s.	4/50	3/50	4/50			liv:hpa,hpc,nnd.
lun MXB	15.0gm *	P<1.		607.mg n.s.s.	4/50	2/50	5/50			lun:a/a,a/c.
5547 M f b6c orl 76w76 1253					0	.414mg				Innes;ntis,1968/1969
liv hpt evx	2.65mg	P<.3	-	.431mg n.s.s.	0/16	1/18				
lun car evx	2.65mg	P<.3	-	.431mg n.s.s.	0/16	1/18				
tba mix evx	.831mg	P<.05	-	.251mg n.s.s.	0/16	3/18				
5548 M m b6c eat 24m24 TR320 :					0	71.3mg	143.mg			
TBA MXB	no dre	P=1.	-	88.4mg n.s.s.	25/50	26/50	(18/50)			
liv MXB	no dre	P=1.		139.mg n.s.s.	12/50	12/50	(1/50)			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		346.mg n.s.s.	6/50	12/50	8/50			lun:a/a,a/c.
5549 M m b6c orl 76w76 1253					0	.385mg				Innes;ntis,1968/1969
liv mix evx	.773mg	P<.05	-	.233mg n.s.s.	0/16	3/18				
lun ade evx	2.47mg	P<.3	-	.401mg n.s.s.	0/16	1/18				
tba mix evx	.433mg	P<.009	-	.163mg 9.50mg	0/16	5/18				
5550 M f b6a orl 76w76 1253					0	.414mg				
lun ade evx	2.65mg	P<.6	-	.348mg n.s.s.	1/17	2/18				
liv hpt evx	no dre	P=1.	-	.820mg n.s.s.	0/17	0/18				
tba mix evx	no dre	P=1.	-	.391mg n.s.s.	2/17	2/18				
5551 M m b6a orl 76w76 1253					0	.385mg				
liv hpt evx	no dre	P=1.	-	.455mg n.s.s.	1/18	1/18				
lun ade evx	no dre	P=1.	-	.505mg n.s.s.	2/18	1/18				
tba mix evx	no dre	P=1.	-	.303mg n.s.s.	3/18	3/18				
5552 R f f34 eat 24m24 TR320 :					0	1.88mg	3.71mg			
TBA MXB	no dre	P=1.	-	2.86mg n.s.s.	45/50	43/50	45/50			
liv MXB	no dre	P=1.		36.7mg n.s.s.	1/50	0/50	0/50			liv:hpa,hpc,nnd.
5553 R m f34 eat 24m24 TR320 :					0	1.51mg	2.97mg			
pty adn	35.6mg *	P<.3	e	9.37mg n.s.s.	1/50	0/50	4/50			
TBA MXB	no dre	P=1.		2.98mg n.s.s.	48/50	36/50	47/50			
liv MXB	no dre	P=1.		12.0mg n.s.s.	3/50	1/50	3/50			liv:hpa,hpc,nnd.
RUTIN SULFATE 12768-44-4										
5554 R f sda gav 24m32 1604					0	3.48mg	8.75mg	23.0mg	65.4mg 162.mg	Habs;clet,23,103-108;1984
liv hpc e	44.8gm *	P<1.	-	480.mg n.s.s.	0/12	0/12	0/12	1/12	1/12 0/12	
5555 R m sda gav 24m31 1604					0	3.48mg	9.14mg	24.7mg	65.4mg 167.mg	
liv hpc e	no dre	P=1.	-	8.95mg n.s.s.	1/12	0/12	0/12	0/12	0/12 0/12	
RUTIN TRIHYDRATE 153-18-4										
5556 H f syg eat 24m24 1144					0	10.5gm				Morino;carc,3,93-97;1982
adr coa	132.gm	P<.6	-	18.4gm n.s.s.	1/20	2/20				
ute ley	140.gm	P<.3	-	22.7gm n.s.s.	0/20	1/20				
5557 H m syg eat 24m24 1144					0	9.20gm				
adr coa	no dre	P=1.	-	18.0gm n.s.s.	2/20	2/20				
for pam	no dre	P=1.	-	22.7gm n.s.s.	1/20	1/20				
5558 R f aci eat 77w77 1145m					0	2.50gm				Hirono;clet,13,15-21;1981
pit ade	8.91gm	P<.2	-	1.45gm n.s.s.	0/22	1/10				
ubl pam	8.91gm	P<.2	-	1.45gm n.s.s.	0/22	1/10				
5559 R f aci eat 28m28 1145n					0	5.00gm				
adr phe	90.4gm	P<.2	-	14.7gm n.s.s.	0/33	1/20				
hea sar	90.4gm	P<.2	-	14.7gm n.s.s.	0/33	1/20				
5560 R m aci eat 77w77 1145m					0	2.00gm				
tes ict	3.53gm	P<.2	-	777.mg n.s.s.	3/30	3/11				
adr coa	5.71gm	P<.3	-	990.mg n.s.s.	2/30	2/11				
5561 R m aci eat 28m28 1145n					0	4.00gm				
col ade	72.3gm	P<.2	-	11.8gm n.s.s.	0/33	1/20				
ilm ade	72.3gm	P<.2	-	11.8gm n.s.s.	0/33	1/20				
SACCHARIN 81-07-2										
5562 M f swa eat 76w76 1090					0	6.50gm				Roe;fctx,8,135-145;1970
lun tum e	56.3gm	P<.7	-	7.21gm n.s.s.	7/45	8/42				
liv hpt e	no dre	P=1.	-	21.4gm n.s.s.	3/45	1/42				
5563 M f swi eat 91w91 1349					0	260.mg	650.mg			Kroes;txcy,8,285-300;1977
ubl apc eg	no dre	P=1.	-	1.12gm n.s.s.	1/41	0/37	0/42			
5564 M m swi eat 91w91 1349					0	240.mg	600.mg			
ubl tcc e	no dre	P=1.	-	3.40gm n.s.s.	0/40	1/39	0/48			
5565 R m f34 eat 72w73 2110					0	1.66gm				Cohen;canr,51,1766-1777;1991
for pam e	no dre	P=1.	-	6.75gm n.s.s.	0/40	0/40				
ubl car e	no dre	P=1.	-	6.75gm n.s.s.	2/39	0/40				
SACCHARIN, CALCIUM 6485-34-3										
5566 R m f34 eat 72w73 2110					0	2.05gm				Cohen;canr,51,1766-1777;1991
ubl car e	no dre	P=1.	-	8.12gm n.s.s.	2/39	0/39				
for pam e	no dre	P=1.	-	8.33gm n.s.s.	0/40	0/40				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
SACCHARIN, SODIUM 128-44-9									
5567 M f chi eat 24m24 1450					0	1.30gm	6.50gm		Homburger;ctxf,359-373;1978
liv tum e	no dre	P=1.	-	6.49gm n.s.s.	0/17	0/28	0/36		
lun tum e	no dre	P=1.	-	18.9gm n.s.s.	4/17	6/28	5/36		
tba mix e	26.1gm *	P<.7	-	4.12gm n.s.s.	11/17	16/28	24/36		
5568 M m chi eat 24m24 1450					0	1.20gm	6.00gm		
lun tum e	1.36gm \	P<.002	-	686.mg 4.99gm	1/19	14/29	(9/34)		
liv hpt e	no dre	P=1.	-	19.6gm n.s.s.	1/19	5/29	2/34		
tba mix e	881.mg \	P<.002	-	442.mg 3.79gm	4/19	20/29	(21/34)		
5569 P b cym eat 23y23 2003 :					0	17.9mg			Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.
tba mal w	no dre	P=1.		6.84mg n.s.s.	3/15	0/4			
5570 P b rhe eat 23y23 2003 :					0	17.9mg			
thy lym w	43.3mg	P<.07		7.06mg n.s.s.	0/13	1/3			
tba mal Ww	610.mg	P<1.		11.4mg n.s.s.	6/74	1/7			
5571 R m aaa eat 80w80 2016m					0	2.00gm			Honma;fctx,29,373-376;1991
ubl car er	no dre	P=1.	-	8.54gm n.s.s.	0/12	0/35			
5572 R m aci eat 52w52 1537					0	2.00gm			Fukushima;gann,74,8-20;1983
ubl pam r	1.11gm	P<.0005	+	523.mg 3.41gm	0/30	9/34			
ubl tcc r	3.71gm	P<.05	+	1.12gm n.s.s.	0/30	3/34			
5573 R f cdr eat 26m26 1114					0	90.0mg	270.mg	810.mg 2.43gm	Munro;txap,32,513-526;1975
liv clc e	78.2gm *	P<.03	-	19.2gm n.s.s.	0/56	0/56	0/52	0/56 2/54	
liv nod e	98.4gm *	P<.2	-	20.1gm n.s.s.	1/56	0/56	0/52	0/56 2/54	
5574 R f cdr eat 33m33 1398					0	2.50gm			Arnold;txap,52,113-152;1980
liv blc eg	155.gm	P<.6		20.8gm n.s.s.	1/48	2/49			
liv nnd eg	155.gm	P<.3		25.2gm n.s.s.	0/48	1/49			
5575 R m cdr eat 26m26 1114					0	90.0mg	270.mg	810.mg 2.43gm	Munro;txap,32,513-526;1975
liv hpc e	no dre	P=1.	-	31.5gm n.s.s.	0/57	0/51	1/54	0/52 0/54	
5576 R m cdr eat 33m33 1398					0	2.00gm			Arnold;txap,52,113-152;1980
pty ade e	23.2gm	P<.008		8.81gm 378.gm	0/49	5/48			
ubl tcc e	31.1gm	P<.05	+	9.40gm n.s.s.	0/36	3/38			
liv blc e	60.0gm	P<.1		14.8gm n.s.s.	0/49	2/48			
ubl tpp e	30.8gm	P<.2	+	8.50gm n.s.s.	1/36	4/38			
5577 R m cdr eat 24m24 1450					0	400.mg	2.00gm		Homburger;ctxf,359-373;1978
tba mix e	no dre	P=1.	-	1.96gm n.s.s.	11/16	21/28	15/26		
5578 R m f34 eat 24m24 1479m					0	1.96gm			Cohen;canr,42,65-71;1982
ubl tum r	no dre	P=1.	-	8.49gm n.s.s.	0/37	0/21			
5579 R m f34 eat 24m24 1479n					0	2.00gm			
ubl tum r	no dre	P=1.	-	8.66gm n.s.s.	0/37	0/21			
5580 R m f34 eat 52w52 1537					0	2.00gm			Fukushima;gann,74,8-20;1983
ubl tum r	no dre	P=1.	-	2.58gm n.s.s.	0/25	0/25			
5581 R m f34 eat 24m24 1722					0	2.00gm			Hasegawa;canr,45,1469-1473;1985/pers.comm.
ubl pam	54.1gm	P<.3	+	8.81gm n.s.s.	0/40	1/40			
5582 R m f34 eat 95w95 1783					0	2.00gm			Imaida;canr,46,6160-6164;1986
liv nnd	no dre	P=1.		14.4gm n.s.s.	1/42	0/42			
5583 R m f34 eat 61w68 1786					0	1.79gm			Sakata;canr,46,3903-3906;1986
liv tum e	no dre	P=1.		4.58gm n.s.s.	0/36	0/29			
5584 R m f34 eat 24m24 1986					0	2.00gm			Hasegawa;txcy,62,333-347;1990
ubl tum r	no dre	P=1.	-	16.5gm n.s.s.	0/40	0/40			
5585 R m f34 eat 72w73 2110					0	1.97gm			Cohen;canr,51,1766-1777;1991
ubl car e	no dre	P=1.	-	5.39gm n.s.s.	2/40	1/40			
for pam e	no dre	P=1.	-	8.01gm n.s.s.	0/40	0/40			
5586 R m f34 eat 72w72 2298					0	2.00gm			Ogawa;carc,17,961-965;1996/pers.comm.
ubl tum r	no dre	P=1.	-	5.73gm n.s.s.	0/23	0/29			
5587 R m fis eat 23m24 1430					0	1.92gm			Fukushima;canr,41,3100-3103;1981
ubl mix	no dre	P=1.	-	10.3gm n.s.s.	0/27	0/26			
5588 R m fis eat 24m24 1574					0	2.00gm			Murasaki;carc,4,97-99;1983
liv tum	no dre	P=1.		8.24gm n.s.s.	0/30	0/20			
ubl tum	no dre	P=1.		8.24gm n.s.s.	0/30	0/20			
5589 R m fis eat 77w98 1657					0	1.57gm			Cohen;canr,39,1207-1217;1979
tes ict	613.mg	P<.003		232.mg 4.71gm	22/42	18/20			
liv tum	no dre	P=1.		5.75gm n.s.s.	0/42	0/20			
ubl tum	no dre	P=1.		5.75gm n.s.s.	0/42	0/20			
5590 R b sda eat 30m30 1416					0	90.0mg	225.mg		Schmahl;arzn,23,1466-1470;1973
ubl tum e	no dre	P=1.	-	1.94gm n.s.s.	0/98	0/94	0/93		
tba mal e	4.10gm *	P<.4	-	1.11gm n.s.s.	13/98	11/94	17/93		
5591 R m sda eat 52w52 1537					0	2.00gm			Fukushima;gann,74,8-20;1983
ubl tum r	no dre	P=1.	-	2.58gm n.s.s.	0/25	0/25			
5592 R m sda eat 80w80 2016n					0	2.00gm			Honma;fctx,29,373-376;1991
ubl car er	no dre	P=1.	-	8.78gm n.s.s.	0/14	0/36			
5593 R b wis wat 24m24 1465					0	2.00gm			Hicks;carm,2,475-489;1978
ubl tum er	no dre	P=1.		47.4gm n.s.s.	0/98	0/115			
5594 R b wis eat 24m24 1465m					0	4.00gm			
ubl tum er	125.gm	P<.08		37.8gm n.s.s.	0/98	3/138			
5595 R m wis eat 52w52 1537					0	2.00gm			Fukushima;gann,74,8-20;1983
ubl tum r	no dre	P=1.	-	2.58gm n.s.s.	0/25	0/25			
SAFROLE 94-59-7									
5596 M f b6a orl 81w81 267					0	156.mg			Innes;ntis,1968/1969
liv hpt evx	23.5mg	P<.0005	+	9.22mg 60.3mg	1/15	16/17			
lun ade evx	no dre	P=1.		332.mg n.s.s.	2/15	0/17			
tba mix evx	24.2mg	P<.0005		9.32mg 66.2mg	2/15	16/17			
5597 M m b6a orl 81w81 267					0	146.mg			
liv hpt evx	312.mg	P<.04		94.1mg n.s.s.	0/18	3/17			
lun mix evx	no dre	P=1.		310.mg n.s.s.	3/18	0/17			
tba mix evx	5.12gm	P<1.		120.mg n.s.s.	3/18	3/17			
5598 M f b6c orl 81w81 267					0	156.mg			
liv hpt evx	noTD50	P<.0005	+	n.s.s. 38.8mg	0/17	16/16			

Chemical / Synonym / CAS number	Spe	Strain	Xpo+Xpt	Sex	Route	Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference

Site	Notes	DR	AuOp	UpConf							Brkly Code
	Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
lun	mix evx	no dre	P=1.	313.mg n.s.s.		0/17	0/16				
tba	mix evx	noTD50	P<.0005	n.s.s. 40.5mg		1/17	16/16				
5599	M f b6c gav 90w90 1039					0	34.3mg				Vesselinovitch;canr,39,4378-4380;1979
liv	mix e	27.0mg	P<.0005	+ 16.2mg 49.9mg		0/98	22/46				
liv	hpc e	33.0mg	P<.0005	+ 19.1mg 64.0mg		0/98	19/46				
lun	tum e	no dre	P=1.	243.mg n.s.s.		0/98	0/46				
5600	M m b6c orl 81w81 267					0	146.mg				Innes;ntis,1968/1969
liv	hpt evx	61.7mg	P<.0005	+ 28.6mg 202.mg		1/17	11/17				
lun	ade evx	no dre	P=1.	310.mg n.s.s.		1/17	0/17				
tba	mix evx	119.mg	P<.2	35.3mg n.s.s.		7/17	11/17				
5601	M m b6c gav 90w90 1039					0	34.3mg				Vesselinovitch;canr,39,4378-4380;1979
liv	mix e	178.mg	P<.07	- 50.7mg n.s.s.		3/100	4/33				
liv	hpc e	281.mg	P<.02	- 69.2mg n.s.s.		0/100	2/33				
lun	mix e	no dre	P=1.	185.mg n.s.s.		3/100	0/35				
5602	M m bal eat 52w52 1474m					0	480.mg				Lipsky;jnci,67,365-371;1981
liv	hpa ek	68.3mg	P<.0005	+ 27.1mg 234.mg		0/10	7/10				
liv	hpc ek	368.mg	P<.09	+ 90.1mg n.s.s.		0/10	2/10				
lun	tum ek	no dre	P=1.	247.mg n.s.s.		0/10	0/10				
5603	M m bal eat 52w75 1474n					0	333.mg				
liv	hpa ek	noTD50	P<.009	+ n.s.s. 164.mg		0/5	5/5				
liv	hpc ek	129.mg	P<.02	+ 36.1mg n.s.s.		0/5	3/5				
lun	tum ek	no dre	P=1.	178.mg n.s.s.		0/5	0/5				
5604	M f cd1 eat 51w73 1035a					0	439.mg				Wislocki;canr,37,1883-1891;1977
liv	hpc ev	125.mg	P<.0005	+ 74.9mg 225.mg		0/53	25/36				
lun	tum ev	no dre	P=1.	2.23gm n.s.s.		0/55	0/50				
5605	M f cd1 eat 52w69 1581					0	125.mg	241.mg			Boberg;canr,43,5163-5173;1983
liv	hpt ev	59.7mg	* P<.0005	+ 39.3mg 95.8mg		0/32	13/28	24/34			
lun	tum ev	3.50gm	* P<1.	571.mg n.s.s.		0/32	1/28	0/34			
5606	M f cd1 eat 50w78 1582m					0	176.mg				Miller;canr,43,1124-1134;1983
liv	hpt v	56.4mg	P<.0005	+ 32.3mg 108.mg		0/30	21/30				
lun	ade v	no dre	P=1.	370.mg n.s.s.		1/30	1/30				
5607	M f cd1 eat 51w86 1582n					0	80.7mg	161.mg			
liv	hpt v	41.5mg	* P<.0005	+ 30.2mg 58.5mg		0/50	34/50	39/50			
---	ang v	213.mg	* P<.0005	130.mg 389.mg		0/50	7/50	16/50			
lun	ade v	no dre	P=1.	1.09gm n.s.s.		2/50	2/50	0/50			
5608	M m cd1 eat 51w73 1035a					0	405.mg				Wislocki;canr,37,1883-1891;1977
liv	car ev	249.mg	P<.0005	+ 123.mg 612.mg		0/44	11/26				
lun	tum ev	no dre	P=1.	1.07gm n.s.s.		0/44	0/26				
5609	M m cd1 eat 56w69 1042a					0	390.mg	488.mg			Borchert;canr,33,590-600;1973
liv	hpc	731.mg	* P<.03	335.mg n.s.s.		4/50	11/40	8/40			
lun	ade	no dre	P=1.	786.mg n.s.s.		1/50	0/40	0/40			
5610	M m cd1 eat 56w69 1042b					0	390.mg				
liv	car	3.71gm	P<.7	417.mg n.s.s.		3/35	4/35				
tba	mix	3.71gm	P<.7	417.mg n.s.s.		3/35	4/35				
5611	R m cdr eat 73w95 1035a					0	68.0mg				Wislocki;canr,37,1883-1891;1977
liv	hpc e	no dre	P=1.	- 210.mg n.s.s.		0/18	0/18				
5612	R m cdr eat 95w95 1035b					0	200.mg				
liv	hpc e	627.mg	P<.05	+ 189.mg n.s.s.		0/15	3/18				
5613	R m cdr eat 43w69 1042a					0	125.mg				Borchert;canr,33,590-600;1973
liv	tum	no dre	P=1.	136.mg n.s.s.		0/12	0/12				
tba	tum	no dre	P=1.	136.mg n.s.s.		0/12	0/12				
5614	R m cdr eat 47w69 1042b					0	82.5mg	138.mg			
liv	mix	576.mg	* P<.2	142.mg n.s.s.		0/18	0/18	2/18			
tba	mix	1.32gm	* P<.7	157.mg n.s.s.		1/18	0/18	2/18			
5615	R m cdr eat 36w52 1042c					0	142.mg				
liv	car	425.mg	P<.3	+ 69.1mg n.s.s.		0/18	1/18				
tba	mix	425.mg	P<.3	69.1mg n.s.s.		0/18	1/18				
5616	R b osm eat 24m24 268					0	4.50mg	22.5mg	45.0mg	225.mg	Long;arpa,75,595-604;1963
liv	hpa s	250.mg	Z P<.004	113.mg 1.90gm		1/50	1/50	2/50	8/50	(6/50)	
liv	mix s	340.mg	* P<.0005	+ 199.mg 736.mg		3/50	1/50	3/50	8/50	19/50	
liv	mal s	624.mg	* P<.0005	+ 331.mg 1.53gm		2/50	0/50	2/50	0/50	14/50	
liv	hpc s	921.mg	* P<.0005	433.mg 3.23gm		2/50	0/50	2/50	0/50	10/50	
liv	mhc s	1.96gm	* P<.0005	743.mg 8.16gm		0/50	0/50	0/50	0/50	5/50	
5617	R f osm eat 24m24 268					0	5.00mg	25.0mg	50.0mg	250.mg	
liv	tum s	231.mg	* P<.0005	133.mg 457.mg		0/25	0/25	1/25	6/25	12/25	
5618	R m osm eat 24m24 268					0	4.00mg	20.0mg	40.0mg	200.mg	
liv	tum s	593.mg	* P<.02	221.mg n.s.s.		3/25	1/25	2/25	2/25	7/25	
SALBUTAMOL 18559-94-9											
5619	R f cdr eat 24m24 1734					0	2.00mg	20.0mg			Jack;txcy,27,315-320;1983
meo	ley er	44.6mg	* P<.0005	+ 24.8mg 92.0mg		0/105	0/55	16/55			
5620	R f cdr eat 80w80 1734m					0	20.0mg			Gopinath;enhp,73,107-113;1987/Jack 1983/pers.comm.	
meo	ley ekr	36.3mg	P<.0005	+ 17.7mg 93.4mg		0/105	10/50				
SALICYLAZOSULFAPYRIDINE 599-79-1											
5621	M f b6c gav 24m24 TR457 :					0	477.mg	954.mg	1.91gm		
liv	MXA	1.03gm	Z P<.02	c 490.mg n.s.s.		14/50	32/50	28/50	(29/50)		liv:hpa,hpc.
liv	hpa	2.20gm	* P<.02	999.mg n.s.s.		12/50	28/50	25/50	28/50		S
liv	hpc	5.43gm	* P<.06	2.23gm n.s.s.		2/50	10/50	10/50	9/50		
TBA	MXB	5.98gm	* P<.6	1.16gm n.s.s.		34/50	37/50	42/50	36/50		
liv	MXB	1.03gm	Z P<.02	490.mg n.s.s.		14/50	32/50	28/50	(29/50)		liv:hpa,hpb,hpc.
lun	MXB	41.3gm	* P<.7	5.51gm n.s.s.		3/50	4/50	4/50	4/50		lun:a/a,a/c.
5622	M m b6c gav 24m24 TR457 :					0	476.mg	952.mg	1.90gm		
liv	hpa	1.58gm	Z P<.004	c 807.mg 12.4gm		13/50	32/50	28/50	42/50		
liv	MXA	2.62gm	* P<.2	c 953.mg n.s.s.		24/50	38/50	38/50	44/50		liv:hpa,hpc.
TBA	MXB	no dre	P=1.	1.52gm n.s.s.		40/50	45/50	41/50	45/50		
liv	MXB	2.62gm	* P<.2	953.mg n.s.s.		24/50	38/50	38/50	44/50		liv:hpa,hpb,hpc.
lun	MXB	no dre	P=1.	5.23gm n.s.s.		14/50	18/50	15/50	11/50		lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
5623 R f f34 gav 24m24 TR457 :	0	59.1mg	118.mg	238.mg	
MXB MXB 2.22gm * P<.04 765.mg n.s.s.	0/50	0/50	2/50	2/50	kid:tpp; ubl:tpp. P
kid tpp 4.26gm * P<.06 p 1.05gm n.s.s.	0/50	0/50	0/50	2/50	
ubl tpp h 4.72gm * P<.4 p 1.15gm n.s.s.	0/50	0/50	2/50	0/50	
TBA MXB no dre P=1. 182.mg n.s.s.	44/50	41/50	47/50	31/50	
liv MXB 8.65gm * P<.6 1.41gm n.s.s.	0/50	0/50	1/50	0/50	liv:hpa,hpb,hpc.
5624 R m f34 gav 24m24 TR457 :	0	59.2mg	118.mg	238.mg	
ubl tpp 974.mg * P<.0005 p 439.mg 3.35gm	0/50	0/50	2/50	6/50	
TBA MXB 447.mg * P<.4 111.mg n.s.s.	42/50	43/50	43/50	38/50	
liv MXB no dre P=1. 1.53gm n.s.s.	2/50	1/50	1/50	0/50	liv:hpa,hpb,hpc.
5625 R m f34 gav 6m24 TR457a :	0	60.2mg			
TBA MXB 144.mg P<.5 - 29.3mg n.s.s.	42/50	41/50			
liv MXB no dre P=1. 376.mg n.s.s.	2/50	0/50			liv:hpa,hpb,hpc.
SARCOPHYTOL A 72629-69-7					
5626 M m cen eat 65w65 2021	0	12.0mg			Yamauchi;gann,82,1234-1238;1991
liv hpt er no dre P=1. - 4.15mg n.s.s.	34/40	30/40			
SCOPOLAMINE HYDROBROMIDE TRIHYDRATE 6533-68-2					
5627 M f b6c gav 24m24 TR445 :	0	.714mg	3.57mg	17.9mg	
TBA MXB no dre P=1. - 30.2mg n.s.s.	40/51	36/50	35/50	29/51	
liv MXB no dre P=1. 7.28mg n.s.s.	22/51	21/50	16/50	(9/51)	liv:hpa,hpb,hpc.
lun MXB no dre P=1. 82.9mg n.s.s.	4/51	7/50	2/50	3/51	lun:a/a,a/c.
5628 M m b6c gav 24m24 TR445 :	0	.714mg	3.57mg	17.9mg	
TBA MXB no dre P=1. - 4.81mg n.s.s.	43/50	41/50	31/50	(29/50)	
liv MXB no dre P=1. 55.8mg n.s.s.	30/50	33/50	13/50	15/50	liv:hpa,hpb,hpc.
lun MXB no dre P=1. 55.4mg n.s.s.	15/50	11/50	10/50	8/50	lun:a/a,a/c.
5629 R f f34 gav 24m24 TR445 :	0	.714mg	3.57mg	17.9mg	
TBA MXB 312.mg * P<1. - 9.88mg n.s.s.	48/50	23/60	39/50	31/50	
liv MXB no dre P=1. 103.mg n.s.s.	1/50	0/60	0/50	0/50	liv:hpa,hpb,hpc.
5630 R m f34 gav 24m24 TR445 :	0	.714mg	3.57mg	17.9mg	
TBA MXB no dre P=1. - 2.24mg n.s.s.	47/50	48/50	46/50	(41/50)	
liv MXB no dre P=1. 62.5mg n.s.s.	2/50	3/50	2/50	2/50	liv:hpa,hpb,hpc.
SDZ 200-110 122784-89-8					
5631 R m sda eat 24m24 2272m	0	2.50mg	12.5mg	62.5mg	Roberts;jact,8,487-505;1989
tes ldc er 212.mg * P<.002 + 103.mg 1.03gm	15/150	5/74	11/75	19/75	
5632 R m sda eat 24m24 2272n	0	6.25mg	62.5mg		
tes ldc er 251.mg * P<.002 + 119.mg 1.12gm	1/65	3/65	11/65		
SELENIUM 7782-49-2					
5633 M f c3s eat 81w81 1431	0	.111mg			Schrauzer;carc,1,199-201;1980
mgl adc Lr no dre P=1. .218mg n.s.s.	20/30	7/30			
5634 M f c3s eat 53w81 1431m	0	72.1ug			
mgl adc Lr no dre P=1. 40.4ug n.s.s.	20/30	18/30			
SELENIUM DIETHYLDITHIOCARBAMATE (ethyl selenac) 5456-28-0					
5635 M f b6a orl 81w81 1211	0	3.63mg			Innes;ntis,1968/1969
lun ade evx no dre P=1. 4.59mg n.s.s.	1/17	1/17			
liv hpt evx no dre P=1. 7.70mg n.s.s.	0/17	0/17			
tba mix evx 10.5mg P<.4 2.21mg n.s.s.	2/17	4/17			
5636 M m b6a orl 81w81 1211	0	3.37mg			
liv hpt evx 10.2mg P<.3 2.34mg n.s.s.	1/18	3/17			
lun ade evx 18.4mg P<.6 2.54mg n.s.s.	2/18	3/17			
tba mix evx 8.45mg P<.4 1.80mg n.s.s.	3/18	5/17			
5637 M f b6c orl 81w81 1211	0	3.63mg			
liv hpt evx 7.76mg P<.04 2.34mg n.s.s.	0/16	3/17			
lun mix evx no dre P=1. 7.70mg n.s.s.	0/16	0/17			
tba mix evx 3.46mg P<.003 1.40mg 18.8mg	0/16	6/17			
5638 M m b6c orl 81w81 1211	0	3.37mg			
liv mix evx 1.28mg P<.0005 .627mg 3.07mg	0/16	12/18			
liv hpt evx 1.49mg P<.0005 + .718mg 3.71mg	0/16	11/18			
lun mix evx no dre P=1. 7.59mg n.s.s.	0/16	0/18			
tba mix evx .638mg P<.0005 .296mg 1.45mg	0/16	16/18			
SELENIUM DIMETHYLDITHIOCARBAMATE (methyl selenac) 144-34-3					
5639 M f b6a orl 76w76 1205	0	4.64mg			Innes;ntis,1968/1969
liv hpt evx no dre P=1. - 8.68mg n.s.s.	0/17	0/17			
lun ade evx no dre P=1. - 8.68mg n.s.s.	1/17	0/17			
tba mix evx no dre P=1. - 4.08mg n.s.s.	2/17	2/17			
5640 M m b6a orl 76w76 1205	0	4.31mg			
liv hpt evx no dre P=1. - 8.54mg n.s.s.	1/18	0/18			
lun ade evx no dre P=1. - 8.54mg n.s.s.	2/18	0/18			
tba mix evx no dre P=1. - 6.05mg n.s.s.	3/18	1/18			
5641 M f b6c orl 76w76 1205	0	4.64mg			
liv hpt evx no dre P=1. - 8.68mg n.s.s.	0/16	0/17			
lun mix evx no dre P=1. - 8.68mg n.s.s.	0/16	0/17			
tba tum evx no dre P=1. - 8.68mg n.s.s.	0/16	0/17			
5642 M m b6c orl 76w76 1205	0	4.31mg			
liv hpt evx 26.0mg P<.3 - 4.24mg n.s.s.	0/16	1/17			
lun mix evx no dre P=1. - 8.07mg n.s.s.	0/16	0/17			
tba mix evx 5.88mg P<.02 - 2.02mg n.s.s.	0/16	4/17			
SELENIUM DIOXIDE (selenite) 7446-08-4					
5643 M f c3s wat 24m24 2367	0	.562mg			Schrauzer;bnch,9,245-253;1978
mgl adc Ler no dre P=1. 1.78mg n.s.s.	12/29	5/30			
5644 M f c3s wat 24m25 2369	0	.400mg	1.00mg	3.00mg	Schrauzer;ancl,4,441-447;1974/1976
mgl adc Laer no dre P=1. 3.11mg n.s.s.	22/30	3/30	10/28	(15/46)	

Chemical / Synonym / CAS number	Spe	Strain	Xpo+Xpt	Sex	Route	Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
SELENIUM SULFIDE 7446-34-6											
5645	M	f	b6c	gav	24m24	TR194 :	0	14.1mg	70.7mg		
MXB MXB	46.8mg	*	P<.0005		31.4mg	74.2mg	0/50	5/50	32/50		liv:hpa,hpc; lun:a/a,a/c. C
liv MXA	69.3mg	*	P<.0005	c	43.7mg	119.mg	0/50	2/50	25/50		liv:hpa,hpc.
liv hpc	85.2mg	*	P<.0005	c	51.8mg	154.mg	0/50	1/50	22/50		
lun MXA	137.mg	*	P<.0005	c	74.9mg	338.mg	0/50	3/50	12/50		lun:a/a,a/c.
lun a/c	433.mg	*	P<.02	c	164.mg	n.s.s.	0/50	1/50	4/50		
TBA MXB	69.7mg	*	P<.02		31.5mg	n.s.s.	24/50	31/50	42/50		
liv MXB	69.3mg	*	P<.0005		43.7mg	119.mg	0/50	2/50	25/50		liv:hpa,hpc,nnd.
lun MXB	137.mg	*	P<.0005		74.9mg	338.mg	0/50	3/50	12/50		lun:a/a,a/c.
5646	M	m	b6c	gav	24m24	TR194 :	0	14.1mg	70.7mg		
TBA MXB	735.mg	*	P<.9	-	53.5mg	n.s.s.	29/50	35/50	36/50		
liv MXB	202.mg	*	P<.3		59.9mg	n.s.s.	15/50	14/50	23/50		liv:hpa,hpc,nnd.
lun MXB	183.mg	*	P<.07		68.1mg	n.s.s.	4/50	10/50	14/50		lun:a/a,a/c.
5647	R	f	f34	gav	24m24	TR194 :	0	2.10mg	10.6mg		
liv MXA	6.14mg	/	P<.0005	c	4.08mg	10.1mg	1/50	0/50	37/50		liv:hpc,nnd.
liv hpc	13.2mg	/	P<.0005	c	7.90mg	24.7mg	0/50	0/50	21/50		
TBA MXB	19.3mg	*	P<.3		5.48mg	n.s.s.	38/50	37/50	47/50		
liv MXB	6.14mg	/	P<.0005		4.08mg	10.1mg	1/50	0/50	37/50		liv:hpa,hpc,nnd.
5648	R	m	f34	gav	24m24	TR194 :	0	2.10mg	10.6mg		
liv MXA	11.5mg	/	P<.0005	c	6.96mg	22.1mg	1/50	0/50	24/50		liv:hpc,nnd.
liv hpc	21.0mg	*	P<.0005	c	11.3mg	45.8mg	0/50	0/50	14/50		
TBA MXB	25.0mg	*	P<.4		6.01mg	n.s.s.	33/50	40/50	43/50		
liv MXB	11.5mg	/	P<.0005		6.96mg	22.1mg	1/50	0/50	24/50		liv:hpa,hpc,nnd.
SENKIRKINE (renardine) 2318-18-5											
5649	R	m	aci	ipj	56w92	1396	0	2.03mg			Hirono;jnci,63,469-472;1979
liv lca ev	1.70mg		P<.0005	+	.784mg	4.77mg	0/19	9/19			
SERTRALINE.HCl 79559-97-0											
5650	M	f	cd1	eat	24m24	2589	0	11.2mg	22.4mg	44.8mg	Davies;dact,21,521-537;1998
lun a/a e	247.mg	Z	P<.05	-	95.3mg	n.s.s.	8/100	9/49	1/50	12/50	
5651	M	m	cd1	eat	24m24	2589	0	11.2mg	22.4mg	44.8mg	
liv hpa e	147.mg	*	P<.006		70.3mg	1.74gm	7/100	8/50	8/50	12/50	
liv hpc e	425.mg	*	P<.3		111.mg	n.s.s.	12/100	4/50	10/50	8/50	
5652	R	f	lev	eat	24m24	2589	0	11.2mg	22.4mg	44.8mg	
thy fca e	352.mg	*	P<.03	-	144.mg	n.s.s.	1/49	1/50	2/50	6/50	
SESAMOL (3,4-(methylenedioxy)-phenol) 533-31-3											
5653	M	f	b6c	eat	96w96	2011	0	2.60gm			Tamano;gann,83,1279-1285;1992
for sqc	8.33gm		P<.008	+	3.15gm	124.gm	0/30	5/30			
for sar	44.8gm		P<.3		7.29gm	n.s.s.	0/30	1/30			
liv hnd	44.8gm		P<.3		7.29gm	n.s.s.	0/30	1/30			
liv hpc	no dre		P=1.		13.7gm	n.s.s.	1/30	0/30			
lun adc	no dre		P=1.		8.27gm	n.s.s.	1/30	1/30			
5654	M	m	b6c	eat	96w96	2011	0	2.40gm			
for sqc	3.07gm		P<.0005	+	1.53gm	7.58gm	0/30	11/30			
lun ade	41.3gm		P<.3		6.73gm	n.s.s.	0/30	1/30			
stg sar	41.3gm		P<.3		6.73gm	n.s.s.	0/30	1/30			
liv hnd	no dre		P=1.		4.87gm	n.s.s.	7/30	5/30			
liv hpc	no dre		P=1.		7.75gm	n.s.s.	5/30	2/30			
5655	R	f	f3d	eat	24m24	2011	0	1.00gm			
for pam	1.09gm		P<.0005		579.mg	2.40gm	0/30	14/30			
for sqc	6.50gm		P<.04	+	1.97gm	n.s.s.	0/30	3/30			
liv hnd	no dre		P=1.		6.18gm	n.s.s.	2/30	0/30			
5656	R	m	f3d	eat	24m24	2011	0	800.mg			
for pam	1.35gm		P<.0005		655.mg	3.56gm	0/30	10/30			
for sqc	1.54gm		P<.0005	+	720.mg	4.43gm	0/30	9/30			
stg ade	16.2gm		P<.3		2.63gm	n.s.s.	0/30	1/30			
liv hnd	no dre		P=1.		4.95gm	n.s.s.	2/30	0/30			
liv hpc	no dre		P=1.		4.95gm	n.s.s.	1/30	0/30			
5657	R	m	f3d	eat	60w60	2134	0	800.mg			Ito;anti,183-194;1990/pers.comm.
for mix er	708.mg		P<.01	+	268.mg	40.1gm	0/19	5/22			
for sqp er	909.mg		P<.03	+	313.mg	n.s.s.	0/19	4/22			
for sqc er	3.92gm		P<.3		638.mg	n.s.s.	0/19	1/22			
SIMAZINE (CDT) 122-34-9											
5658	M	f	b6a	orl	76w76	1243	0	83.8mg			Innes;ntis,1968/1969
liv hpt evx	no dre		P=1.	-	166.mg	n.s.s.	0/17	0/18			
lun ade evx	no dre		P=1.	-	166.mg	n.s.s.	1/17	0/18			
tba mix evx	no dre		P=1.	-	166.mg	n.s.s.	2/17	0/18			
5659	M	m	b6a	orl	76w76	1243	0	78.0mg			
lun ade evx	442.mg		P<.7	-	55.5mg	n.s.s.	2/18	3/18			
liv hpt evx	no dre		P=1.	-	154.mg	n.s.s.	1/18	0/18			
tba mix evx	199.mg		P<.5	-	39.7mg	n.s.s.	3/18	5/18			
5660	M	f	b6c	orl	76w76	1243	0	83.8mg			
lun ade evx	536.mg		P<.3	-	87.3mg	n.s.s.	0/16	1/18			
liv hpt evx	no dre		P=1.	-	166.mg	n.s.s.	0/16	0/18			
tba mix evx	260.mg		P<.2	-	63.9mg	n.s.s.	0/16	2/18			
5661	M	m	b6c	orl	76w76	1243	0	78.0mg			
liv hpt evx	106.mg		P<.02	-	36.5mg	n.s.s.	0/16	4/17			
lun mix evx	no dre		P=1.	-	146.mg	n.s.s.	0/16	0/17			
tba mix evx	65.5mg		P<.003	-	26.4mg	355.mg	0/16	6/17			
SODIUM BICARBONATE 144-55-8											
5662	M	m	b6c	wat	52w52	2455	0	1.33gm			Fujii;tmrl,40,298-306;1989/pers.comm.
liv hpa e	1.33gm		P<.04	-	401.mg	n.s.s.	0/20	3/19			

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
5663 R m f3d eat 24m24 1930					0	256.mg			Fukushima;carc,10,1635-1640;1989
ubl car r		5.35gm	P<.3	- 871.mg n.s.s.	0/30	1/31			
SODIUM BITHIONOLATE (vancide BN) 6385-58-6									
5664 M f b6a orl 76w76 1284					0	.959mg			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1.	- 1.79mg n.s.s.	0/17	0/17			
lun ade evx		no dre	P=1.	- 1.79mg n.s.s.	1/17	0/17			
tba mix evx		5.08mg	P<.7	- .641mg n.s.s.	2/17	3/17			
5665 M m b6a orl 76w76 1284					0	.891mg			
lun ade evx		no dre	P=1.	- .833mg n.s.s.	2/18	2/18			
liv hpt evx		no dre	P=1.	- 1.77mg n.s.s.	1/18	0/18			
tba mix evx		no dre	P=1.	- .922mg n.s.s.	3/18	2/18			
5666 M f b6c orl 76w76 1284					0	.959mg			
liv hpt evx		no dre	P=1.	- 1.90mg n.s.s.	0/16	0/18			
lun mix evx		no dre	P=1.	- 1.90mg n.s.s.	0/16	0/18			
tba tum evx		no dre	P=1.	- 1.90mg n.s.s.	0/16	0/18			
5667 M m b6c orl 76w76 1284					0	.891mg			
liv mix evx		2.28mg	P<.09	- .559mg n.s.s.	0/16	2/15			
lun mix evx		no dre	P=1.	- 1.47mg n.s.s.	0/16	0/15			
tba mix evx		.805mg	P<.005	- .302mg 6.34mg	0/16	5/15			
SODIUM CHLORIDE 7647-14-5									
5668 M f b6c wat 24m24 1806					0	880.mg			Van Duuren;enhp,69,109-117;1986
lun ptm e		4.98gm	P<.2	1.50gm n.s.s.	13/96	11/47			
liv hnd e		1.33kg	P<1.	5.27gm n.s.s.	2/96	1/47			
tba mix e		no dre	P=1.	547.mg n.s.s.	84/96	40/47			
5669 M m b6c wat 24m24 1806					0	733.mg			
lun ptm e		3.74gm	P<.3	1.08gm n.s.s.	22/99	16/50			
liv hnd e		5.97gm	P<.4	1.44gm n.s.s.	15/99	11/50			
liv hem e		9.55gm	P<.2	2.34gm n.s.s.	3/99	4/50			
liv hpt e		no dre	P=1.	2.51gm n.s.s.	12/99	6/50			
tba mix e		992.mg	P<.2	297.mg n.s.s.	76/99	43/50			
5670 R m aci eat 52w52 2076					0	4.00gm			Watanabe;gann,83,588-593;1992/pers.comm.
for pam er		2.66gm	P<.007	1.00gm 32.6gm	0/22	5/22			
stg adc er		no dre	P=1.	4.53gm n.s.s.	0/22	0/22			
5671 R m cdr eat 52w52 2074					0	400.mg	4.00gm		Watanabe;gann,83,1267-1272;1992/pers.comm.
stg adc er		no dre	P=1.	352.mg n.s.s.	0/12	0/19	0/17		
5672 R m f34 eat 24m24 1807					0	1.60gm			Imai;jnma,37,115-127;1986
amd phe		2.98gm	P<.02	- 1.36gm n.s.s.	11/50	23/50			
5673 R m f3d eat 51w52 2564					0	1.96gm			Wada;clet,124,127-134;1998
for tum er		no dre	P=1.	- 1.62gm n.s.s.	0/15	0/16			
stg tum er		no dre	P=1.	- 1.62gm n.s.s.	0/15	0/16			
5674 R m wis eat 82w82 2158					0	1.00gm	2.00gm	4.00gm	Takahashi;carc,15,1429-1432;1994
stg tum r		no dre	P=1.	- 732.mg n.s.s.	0/10	0/10	0/10	0/10	
SODIUM CHLORITE 7758-19-2									
5675 M f b6c wat 85w85 1789					0	50.0mg	100.mg		Kurokawa;enhp,69,221-235;1986
liv mix e		3.06gm *	P<.9	225.mg n.s.s.	5/47	5/50	6/50		
liv hnd e		no dre	P=1.	292.mg n.s.s.	5/47	3/50	5/50		
lun mix e		no dre	P=1.	442.mg n.s.s.	3/47	2/50	2/50		
tba mix e		no dre	P=1.	151.mg n.s.s.	14/47	17/50	13/50		
5676 M m b6c wat 85w85 1789					0	41.7mg	83.3mg		
lun mix e		237.mg *	P<.004	115.mg 1.26gm	0/35	3/47	7/43		
liv mix e		110.mg *	P<.07	46.8mg n.s.s.	7/35	22/47	17/43		
liv hnd e		146.mg *	P<.06	65.1mg n.s.s.	3/35	14/47	11/43		
lun ade e		346.mg *	P<.02	149.mg n.s.s.	0/35	2/47	5/43		
tba mix e		169.mg *	P<.4	45.5mg n.s.s.	14/35	27/47	22/43		
5677 R f f34 wat 85w85 1789					0	17.1mg	34.3mg		
tba mix es		no dre	P=1.	- 69.9mg n.s.s.	21/47	14/44	15/50		
5678 R m f34 wat 85w85 1789					0	15.0mg	30.0mg		
tba mix es		no dre	P=1.	- 155.mg n.s.s.	28/34	3/30	6/43		
SODIUM COPPER CHLOROPHYLLIN 28302-36-5									
5679 R m f34 wat 35w52 2263					0	33.7mg			Guo;clet,95,161-165;1995/pers.comm.
liv hpc e		no dre	P=1.	34.7mg n.s.s.	0/20	0/20			
tba mix e		no dre	P=1.	34.7mg n.s.s.	0/20	0/20			
5680 R f f3d eat 54w54 2195					0	500.mg			Hasegawa;carc,16,2243-2246;1995/pers.comm.
col tum er		no dre	P=1.	528.mg n.s.s.	0/20	0/19			
mgl tum er		no dre	P=1.	528.mg n.s.s.	0/20	0/19			
SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE (SDDC) 148-18-5									
5681 M f b6c eat 25m25 TR172 :					0	65.0mg	520.mg		
TBA MXB a		no dre	P=1.	- 774.mg n.s.s.	13/20	20/50	26/50		
liv MXB a		27.0gm *	P<.8	1.98gm n.s.s.	0/20	2/50	2/50		liv:hpa,hpc,nnd.
lun MXB a		4.76gm *	P<.5	941.mg n.s.s.	0/20	7/50	8/50		lun:a/a,a/c.
5682 M f b6c orl 76w76 273					0	94.9mg			Innes;ntis,1968/1969
liv hpt evx		no dre	P=1.	188.mg n.s.s.	0/18	0/18			
lun ade evx		no dre	P=1.	188.mg n.s.s.	1/18	0/18			
tba mix evx		no dre	P=1.	133.mg n.s.s.	3/18	1/18			
5683 M m b6c eat 25m25 TR172 :					0	60.0mg	480.mg		
TBA MXB a		no dre	P=1.	- 530.mg n.s.s.	13/20	37/50	30/50		
liv MXB a		no dre	P=1.	1.01gm n.s.s.	7/20	11/50	11/50		liv:hpa,hpc,nnd.
lun MXB a		10.3gm *	P<.9	742.mg n.s.s.	6/20	14/50	14/50		lun:a/a,a/c.
5684 M m b6c orl 76w76 273					0	88.2mg			Innes;ntis,1968/1969
liv hpt evx		68.7mg	P<.02	27.0mg n.s.s.	1/17	7/17			
lun ade evx		468.mg	P<.7	58.9mg n.s.s.	2/17	3/17			
tba mix evx		71.4mg	P<.2	21.3mg n.s.s.	6/17	10/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
5685 M f b6a orl 76w76 273					0	94.9mg			
lun ade evx	607.mg	P<.3	98.9mg	n.s.s.	0/17	1/18			
liv hpt evx	no dre	P=1.	188.mg	n.s.s.	0/17	0/18			
tba mix evx	no dre	P=1.	89.6mg	n.s.s.	2/17	2/18			
5686 M m b6a orl 76w76 273					0	88.2mg			
lun ade evx	155.mg	P<.3	42.0mg	n.s.s.	2/18	5/18			
liv hpt evx	no dre	P=1.	175.mg	n.s.s.	3/18	0/18			
tba mix evx	403.mg	P<.8	43.4mg	n.s.s.	5/18	6/18			
5687 R f f34 eat 24m24 TR172 :					0	62.5mg	125.mg		
TBA MXB	no dre	P=1.	- 146.mg	n.s.s.	17/20	26/50	34/50		
liv MXB	no dre	P=1.	1.79gm	n.s.s.	1/20	0/50	0/50		liv:hpa,hpc,nnd.
5688 R m f34 eat 24m24 TR172 :					0	50.0mg	100.mg		
TBA MXB	no dre	P=1.	- 88.9mg	n.s.s.	14/16	38/50	34/50		
liv MXB	no dre	P=1.	684.mg	n.s.s.	0/16	1/50	0/50		liv:hpa,hpc,nnd.
SODIUM HYPOCHLORITE (clorox; hypochlorous acid, sodium salt) 7681-52-9									
5689 M f b6c wat 24m25 1789					0	97.2mg	194.mg		Kurokawa;enhp,69,221-235;1986
lun mix e	22.9gm *	P<1.	- 734.mg	n.s.s.	7/72	6/50	5/50		
liv mix e	no dre	P=1.	- 965.mg	n.s.s.	9/72	9/50	3/50		
liv hpc e	no dre	P=1.	- 1.96gm	n.s.s.	4/72	1/50	1/50		
tba mix e	no dre	P=1.	- 285.mg	n.s.s.	42/72	34/50	26/50		
5690 M m b6c wat 24m25 1789					0	81.0mg	162.mg		
liv mix e	876.mg *	P<.5	- 187.mg	n.s.s.	31/73	27/50	24/50		
lun mix e	2.04gm *	P<.5	- 402.mg	n.s.s.	10/73	9/50	9/50		
liv hpc e	no dre	P=1.	- 377.mg	n.s.s.	24/73	17/50	15/50		
tba mix e	350.mg *	P<.4	- 92.1mg	n.s.s.	53/73	39/50	40/50		
5691 R f f3d wat 24m26 1780					0	53.1mg	106.mg		Hasegawa;fctx,24,1295-1302;1986
liv mix e	6.30gm *	P<1.	- 1.03gm	n.s.s.	0/50	1/50	0/50		
5692 R m f3d wat 24m26 1780					0	23.2mg	46.4mg		
liv cho e	no dre	P=1.	- 450.mg	n.s.s.	0/49	1/50	0/50		
liv fih e	no dre	P=1.	- 450.mg	n.s.s.	0/49	1/50	0/50		
liv mix e	no dre	P=1.	- 589.mg	n.s.s.	1/49	1/50	0/50		
SODIUM METAPHOSPHATE 10361-03-2									
5693 R f f3d eat 25m25 2582					0	750.mg	1.50gm		Kitahori;jtxp,11,41-47;1998/pers.comm.
liv tum e	no dre	P=1.	- 4.73gm	n.s.s.	0/47	0/46	0/37		
tba mix e	5.10gm *	P<.5	- 1.11gm	n.s.s.	25/47	33/46	22/37		
5694 R m f3d eat 25m25 2582					0	600.mg	1.20gm		
liv tum e	no dre	P=1.	- 3.43gm	n.s.s.	0/39	0/40	0/36		
tba mix e	no dre	P=1.	- 166.mg	n.s.s.	38/39	40/40	35/36		
SORBIC ACID 110-44-1									
5695 M f asp eat 80w80 409					0	1.30gm	6.50gm	13.0gm	Hendy;fctx,14,181-186;1976
liv hnd e	362.gm *	P<.2	- 58.9gm	n.s.s.	0/48	0/46	0/43	1/43	
lun ade e	no dre	P=1.	- 32.3gm	n.s.s.	14/48	5/46	10/43	5/43	
5696 M m asp eat 80w80 409					0	1.20gm	6.00gm	12.0gm	
liv hnd e	no dre	P=1.	- 5.10gm	n.s.s.	1/44	0/46	0/43	0/43	
lun ade e	no dre	P=1.	- 14.6gm	n.s.s.	19/44	16/46	16/43	15/43	
5697 R f wis eat 24m24 412					0	750.mg	5.00gm		Gaunt;fctx,13,31-45;1975
liv hem e	34.0gm *	P<.2	- 10.9gm	n.s.s.	3/42	2/45	7/46		
tba mal e	no dre	P=1.	- 44.7gm	n.s.s.	3/42	3/45	0/46		
tba mix e	no dre	P=1.	- 1.02gm	n.s.s.	35/42	30/45	(17/46)		
5698 R m wis eat 24m24 412					0	600.mg	4.00gm		
liv hem e	no dre	P=1.	- 25.8gm	n.s.s.	0/43	1/43	0/41		
tba mix e	33.9gm *	P<.7	- 4.11gm	n.s.s.	20/43	21/43	21/41		
tba mal e	51.4gm *	P<.5	- 9.48gm	n.s.s.	5/43	3/43	6/41		
SOTALOL.HCl 959-24-0									
5699 M f cd1 eat 78w92 1635					0	254.mg	509.mg		Weikel;jcph,19,591-604;1979
lun ade e	3.50gm *	P<.2	- 1.16gm	n.s.s.	3/60	6/60	7/60		
lun car e	24.5gm *	P=1.	- 3.99gm	n.s.s.	0/60	1/60	0/60		
liv tum e	no dre	P=1.	- 1.64gm	n.s.s.	0/60	0/60	0/60		
tba ben e	1.74gm *	P<.05	- 752.mg	n.s.s.	4/60	11/60	11/60		
tba mix e	1.91gm *	P<.3	- 589.mg	n.s.s.	16/60	18/60	22/60		
tba mal e	no dre	P=1.	- 1.33gm	n.s.s.	13/60	9/60	12/60		
5700 M m cd1 eat 78w92 1635					0	254.mg	509.mg		
lun ade e	31.4gm *	P<1.	- 1.07gm	n.s.s.	11/57	12/57	12/60		
liv car e	no dre	P=1.	- 4.45gm	n.s.s.	1/57	0/57	1/60		
liv ade e	no dre	P=1.	- 4.33gm	n.s.s.	6/57	1/57	2/60		
lun car e	no dre	P=1.	- 1.59gm	n.s.s.	1/57	0/57	0/60		
tba ben e	no dre	P=1.	- 1.60gm	n.s.s.	19/57	14/57	13/60		
tba mal e	no dre	P=1.	- 1.94gm	n.s.s.	5/57	4/57	5/60		
tba mix e	no dre	P=1.	- 1.47gm	n.s.s.	23/57	17/57	16/60		
5701 R f lev eat 18m24 1635					0	102.mg	206.mg		
liv cho e	12.6gm *	P<.3	- 2.05gm	n.s.s.	0/60	0/60	1/60		
tba mix e	477.mg *	P<.4	- 118.mg	n.s.s.	44/60	47/60	48/60		
tba mal e	1.60gm *	P<.2	- 535.mg	n.s.s.	5/60	6/60	10/60		
tba ben e	no dre	P=1.	- 186.mg	n.s.s.	43/60	43/60	43/60		
5702 R m lev eat 18m24 1635					0	102.mg	206.mg		
liv hpc e	12.4gm *	P<.3	- 2.03gm	n.s.s.	0/60	0/60	1/59		
liv hpa e	309.gm *	P<1.	- 1.53gm	n.s.s.	1/60	2/60	1/59		
tba mix e	796.mg *	P<.6	- 142.mg	n.s.s.	44/60	43/60	46/59		
tba mal e	2.27gm *	P<.5	- 468.mg	n.s.s.	12/60	10/60	15/59		
tba ben e	no dre	P=1.	- 224.mg	n.s.s.	41/60	36/60	40/59		
SOYBEAN LECITHIN (Glycine max) 8002-43-5									
5703 R f wis eat 24m24 1359					0	2.00gm			Brantom;fctx,11,755-769;1973
liv nod e	no dre	P=1.	- 19.4gm	n.s.s.	1/47	0/47			

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf | Brkly Code
Path TD_{50} 2Tailpvl LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

```
5704 R m wis eat 24m24 1359                                    0     1.60gm
 liv cho e       42.2gm    P<.3     -  6.87gm n.s.s.    0/41     1/39

STERIGMATOCYSTIN   10048-13-2
5705 M f bd1 eat 55w68 1492m                                   0     3.15mg                    Enomoto;fctx,20,547-556;1982
 liv hae ek       .574mg    P<.0005     .226mg 1.80mg    0/10     8/10
 liv ang ek      1.33mg     P<.004   +  .490mg 9.33mg    0/10     5/10
 brf ang ek      8.77mg     P<.3     +  1.43mg n.s.s.    0/10     1/10
 liv hpa ek      8.77mg     P<.3        1.43mg n.s.s.    0/10     1/10
 lun ade ek      8.77mg     P<.3        1.43mg n.s.s.    0/10     1/10
5706 M f bd1 eat 55w73 1492n                                   0     2.94mg
 liv ang e        .689mg    P<.0005  +  .420mg 1.20mg    0/35    29/38
 liv hae e       5.77mg     P<.005      2.35mg 41.4mg    0/35     6/38
 brf ang e       7.03mg     P<.01    +  2.67mg 320.mg    0/35     5/38
 lun ade e       8.92mg     P<.03       3.08mg n.s.s.    0/35     4/38
 liv hpc e       37.2mg     P<.3        6.06mg n.s.s.    0/35     1/38
 lun ang e       37.2mg     P<.3        6.06mg n.s.s.    0/35     1/38
5707 P b cym gav 17y17 2004 :                                  0     .117mg    .214mg    Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/
                                                                                                                  Thorgeirsson&Seiber pers.comm.
 MXB MXB jw       .110mg *  P<.0005      46.8ug .310mg    0/47     5/15     5/14
 liv mix jw       .127mg *  P<.0005  +   49.8ug .441mg    0/47     4/15     4/14
 liv hpc jw       .176mg *  P<.002   +   67.6ug .683mg    0/47     3/15     4/14
 liv clc jw       .906mg *  P<.09    +   .219mg n.s.s.    0/35     1/12     1/13
 liv hpa jw       .455mg *  P<.4         74.2ug n.s.s.    0/5      1/6      0/1
 kid rcc jw      1.16mg  *  P<.9         74.9ug n.s.s.    1/22     2/12     0/10
 adr coa jw      1.36mg  *  P<.2         .221mg n.s.s.    0/16     0/10     1/7
 ute ley jw      1.49mg  *  P<.9         80.1ug n.s.s.    1/15     2/10     0/6
 liv chc jw      1.76mg  *  P<.2     +   .287mg n.s.s.    0/22     0/11     1/10
 tba mix Wjw     88.1ug  *  P<.008       35.2ug 2.35mg    3/47     8/15     5/14
 tba mal Wjw      .113mg *  P<.005       44.7ug 1.21mg    2/47     6/15     5/14
 tba ben jw       .459mg *  P<.6         67.4ug n.s.s.    2/20     3/11     1/8
5708 R m ain eat 28m28 1184                                    0     4.00ug    40.0ug    .400mg                    Maekawa;gann,70,777-781;1979
 liv mix aeh     1.67mg  *  P<.003   +   .679mg 10.4mg    0/11     0/27     1/29     5/26
 liv hnd aeh     3.48mg  *  P<.008   +   1.05mg 91.1mg    0/11     0/27     0/29     3/26
 liv hes aeh     2.60mg  *  P<.03    +   .898mg n.s.s.    0/11     0/27     1/29     3/26
 liv hpc aeh     10.8mg  *  P<.2     +   1.76mg n.s.s.    0/11     0/27     0/29     1/26
 tba mix ae      no dre     P=1.         .753mg n.s.s.    7/11    13/27     6/29    10/26
5709 R m don eat 23m23 392                                     0     .200mg    .400mg                    Ohtsubo;fctx,16,143-149;1978
 liv mix ae      82.5ug  *  P<.0005  +   42.6ug .166mg    0/17    11/13    12/13
 liv ade ae       .727mg *  P<.007       .295mg 9.46mg    0/17     2/13     4/13
 liv hes ae      1.57mg  *  P<.07        .474mg n.s.s.    0/17     1/13     2/13
5710 R b wis gav 12m29 275m                                    0     .107mg    .213mg    1.07mg                    Purchase;fctx,8,289-295;1970
 liv hpc          .322mg *  P<.0005  +   .165mg .982mg    0/10     4/10     5/10     9/10
5711 R b wis eat 12m29 275n                                    0     .239mg    .477mg    2.39mg
 liv hpc sv       .124mg Z  P<.0005  +   53.6ug .286mg    0/10     8/10    10/10     (3/10)
5712 R m wis eat 54w69 707                                     0     .313mg                                Terao;fctx,16,591-596;1978
 liv car er       .111mg    P<.0005  +   48.6ug .333mg    0/25     8/14

STEVIOSIDE   57817-89-7
5713 R f f3d eat 24m25 2553                                    0     1.20gm    2.41gm                    Toyoda;fctx,35,597-603;1997
 liv tum e       no dre     P=1.     -   8.26gm n.s.s.    0/49     0/46     0/47
 tba mix e       34.4gm  *  P<.9     -   1.68gm n.s.s.   37/49    37/46    36/47
5714 R m f3d eat 24m25 2553                                    0     963.mg    1.93gm
 liv hpc e       101.gm  *  P<.9     -   16.4gm n.s.s.    0/49     1/48     0/47
 liv hpa e       no dre     P=1.     -   11.6gm n.s.s.    5/49     3/48     3/47
 tba mix e       no dre     P=1.     -   163.mg n.s.s.   49/49    47/48    47/47

STODDARD SOLVENT IIC   64742-88-7
5715 M f b6c inh 24m24 TR519 :                                 0     170.mg    339.mg    679.mg
 liv hpa         1.49gm  *  P<.06    e   602.mg n.s.s.    9/50    12/50    15/50    18/50
 TBA MXB         1.42gm  *  P<.4         343.mg n.s.s.   39/50    41/50    44/50    45/50
 liv MXB         1.72gm  *  P<.2         583.mg n.s.s.   13/50    17/50    18/50    21/50                    liv:hpa,hpb,hpc.
 lun MXB         11.9gm  *  P<.6         2.03gm n.s.s.    2/50     2/50     3/50     3/50                        lun:a/a,a/c.
5716 M m b6c inh 24m24 TR519 :                                 0     170.mg    339.mg    679.mg
 TBA MXB         no dre     P=1.     -   541.mg n.s.s.   50/50    48/50    42/50    43/50
 liv MXB         no dre     P=1.         648.mg n.s.s.   34/50    37/50    30/50    32/50                    liv:hpa,hpb,hpc.
 lun MXB         no dre     P=1.         1.14gm n.s.s.   13/50     4/50     6/50    (6/50)                       lun:a/a,a/c.
5717 R f f34 inh 24m24 TR519 :                                 0     129.mg    257.mg    514.mg
 cli ade #       1.24gm  *  P<.002   -   664.mg 5.27gm    0/50     3/50     5/50     6/50                                                S
 cli MXA         1.24gm  *  P<.01        599.mg 133.gm    1/50     5/50     6/50     7/50                        cli:ade,car.            S
 mgl car         1.56gm  *  P<.03        672.mg n.s.s.    4/50     2/50    10/50     8/50                                                S
 MXA MXA         3.44gm  *  P<.03        1.39gm n.s.s.    0/50     0/50     4/50     2/50                    ski:fba,fbs,sar; sub:fib.   S
 TBA MXB         499.mg  *  P<.2         177.mg n.s.s.   46/50    50/50    50/50    48/50
 liv MXB         no dre     P=1.         n.s.s. n.s.s.    0/50     0/50     0/50     0/50                    liv:hpa,hpb,hpc.
5718 R m f34 inh 24m24 TR519 :                                 0     28.4mg    113.mg    226.mg
 amd MXA         219.mg  *  P<.0005  p   115.mg 838.mg    6/50     9/50    13/50    19/50                        amd:phm,pob.
 amd pob         225.mg  *  P<.002   p   116.mg 952.mg    5/50     9/50    13/50    17/50
 ski bcc         1.03gm  *  P<.03        387.mg n.s.s.    0/50     1/50     1/50     3/50                                                S
 kid rua         12.1gm  *  P<.6         1.97gm n.s.s.    0/50     0/50     1/50     0/50
 TBA MXB         200.mg  *  P<.2         68.1mg n.s.s.   50/50    50/50    50/50    50/50
 liv MXB         7.05gm  *  P<.6         773.mg n.s.s.    0/50     1/50     0/50     1/50                    liv:hpa,hpb,hpc.
5719 R m f34 inh 24m24 TR519 with step                         0     28.4mg    113.mg    226.mg
 kid rua         1.88gm  *  P<.1     e   645.mg n.s.s.    3/50     2/50     3/50     7/50

STREPTOZOTOCIN   18883-66-4
5720 M f swi ipj 26w78 1336m                                   0     .855mg    2.50mg    Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm.
 lun mix e        .193mg \  P<.0005  +   91.5ug .477mg   20/154   16/19    (14/21)
 kid ade e       1.39mg  \  P<.0005  +   .480mg 7.18mg    0/154    4/19     (2/21)
```

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ute sar e		13.9mg *	P<.04	3.19mg n.s.s.	1/154	0/19	2/21		
liv lys e		no dre	P=1.	1.44mg n.s.s.	1/154	0/19	0/21		
tba ben e		.188mg \	P<.0005	90.2ug .443mg	13/154	16/19	(9/21)		
tba mix e		.486mg *	P<.0005	.263mg 1.09mg	42/154	16/19	17/21		
tba mal e		6.32mg /	P<.2	1.66mg n.s.s.	29/154	0/19	8/21		
5721 M m swi ipj 26w72 1336m					0	.930mg	2.08mg		
lun mix e		.462mg \	P<.0005 +	.197mg 1.82mg	9/101	9/17	(5/16)		
kid tla e		2.44mg \	P<.006 +	.599mg 47.1mg	0/101	2/17	(0/16)		
liv mix e		27.3mg *	P<.6	2.74mg n.s.s.	2/101	0/17	1/16		
tba mix e		.217mg \	P<.0005	92.5ug .761mg	28/101	14/17	(6/16)		
tba ben e		.698mg \	P<.003	.264mg 5.53mg	9/101	7/17	(2/16)		
tba mal e		3.53mg *	P<.3	.890mg n.s.s.	19/101	7/17	4/16		
5722 R f cdr ipj 26w78 1336n					0	.859mg	1.82mg		
kid mix e		1.27mg *	P<.0005 +	.693mg 2.70mg	0/182	5/23	10/23		
mgl car e		1.41mg \	P<.009	.487mg 65.7mg	12/182	6/23	(1/23)		
ute sar e		2.46mg \	P<.003	.724mg 30.7mg	1/182	3/23	(0/23)		
liv mix e		4.43mg *	P<.0005	1.68mg 18.4mg	0/182	1/23	4/23		
liv cvh e		5.63mg *	P<.0005	1.94mg 29.0mg	0/182	1/23	3/23		
tba mal e		.363mg \	P<.0005	.169mg 1.22mg	44/182	16/23	(8/23)		
tba mix e		1.14mg *	P<.06	.410mg n.s.s.	103/182	21/23	15/23		
tba ben e		no dre	P=1.	2.05mg n.s.s.	59/182	5/23	7/23		
5723 R m cdr ipj 26w78 1336n					0	.859mg	1.72mg		
kid mix e		.776mg *	P<.0005 +	.446mg 1.51mg	0/177	7/22	12/20		
liv lcc e		20.4mg *	P<.2	3.31mg n.s.s.	0/177	1/22	0/20		
tba mix e		.751mg *	P<.0005	.365mg 2.94mg	59/177	15/22	13/20		
tba mal e		1.03mg *	P<.0005	.504mg 3.83mg	32/177	14/22	8/20		
tba ben e		16.8mg *	P<.7	1.86mg n.s.s.	27/177	1/22	5/20		

STROBANE (dichloricide mothproofer) 8001-50-1

5724 M f b6a orl 79w79 277					0	1.55mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.		3.32mg n.s.s.	0/17	0/18			
lun ade evx	no dre	P=1.		3.32mg n.s.s.	1/17	0/18			
tba mix evx	no dre	P=1.		3.32mg n.s.s.	2/17	0/18			
5725 M m b6a orl 79w79 277					0	1.45mg			
liv hpt evx	.644mg	P<.0005 +		.300mg 2.14mg	1/18	11/18			
lun ade evx	no dre	P=1.		3.10mg n.s.s.	2/18	0/18			
tba mix evx	.750mg	P<.006		.319mg 9.63mg	3/18	11/18			
5726 M f b6c orl 79w79 277					0	1.55mg			
lun ade evx	10.7mg	P<.3		1.75mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.		3.32mg n.s.s.	0/16	0/18			
tba mix evx	3.37mg	P<.05		1.02mg n.s.s.	0/16	3/18			
5727 M m b6c orl 79w79 277					0	1.45mg			
--- rts evx	1.41mg	P<.005	+	.530mg 11.1mg	0/16	5/15			
liv hpt evx	4.00mg	P<.09		.980mg n.s.s.	0/16	2/15			
lun ade evx	8.29mg	P<.3		1.35mg n.s.s.	0/16	1/15			
tba mix evx	.750mg	P<.0005		.330mg 2.28mg	0/16	8/15			

STYRENE 100-42-5

5728 M f b6c gav 78w91 TR185 :					0	92.0mg	184.mg		
liv hpa #	905.mg *	P<.04	-	369.mg n.s.s.	0/20	1/50	5/50		S
TBA MXB	625.mg *	P<.4		188.mg n.s.s.	2/20	11/50	10/50		
liv MXB	905.mg *	P<.04		369.mg n.s.s.	0/20	1/50	5/50		liv:hpa,hpc,nnd.
lun MXB	1.38gm *	P<.2		477.mg n.s.s.	0/20	1/50	3/50		lun:a/a,a/c.
5729 M m b6c gav 78w91 TR185 :					0	92.0mg	184.mg		
lun MXA	360.mg *	P<.007	a	198.mg 4.60gm	0/20	6/49	9/50		lun:a/a,a/c.
TBA MXB	659.mg *	P<.5		154.mg n.s.s.	9/20	14/49	21/50		
liv MXB	895.mg *	P<.5		219.mg n.s.s.	5/20	8/49	13/50		liv:hpa,hpc,nnd.
lun MXB	360.mg *	P<.007		198.mg 4.60gm	0/20	6/49	9/50		lun:a/a,a/c.
5730 M f cd1 inh 52w52 2650m					0	26.8mg	53.6mg	107.mg 214.mg	Cruzan;japt,21,185-198;2001
lun a/a ek	no dre	P=1.		99.9mg n.s.s.	1/10	2/10	0/9	2/10 0/10	
5731 M f cd1 inh 78w78 2650n					0	26.8mg	53.6mg	107.mg 214.mg	
lun a/a ek	no dre	P=1.		96.6mg n.s.s.	1/10	4/10	5/10	1/10 3/10	
5732 M f cd1 inh 98w98 2650o					0	26.8mg	53.6mg	107.mg 214.mg	
lun a/a e	331.mg *	P<.003	+	168.mg 1.94gm	6/50	16/50	16/50	11/50 24/50	
lun a/c e	1.30gm *	P<.0005	+	614.mg 4.59gm	0/50	0/50	2/50	0/50 7/50	
liv mix e	13.6gm *	P<.6		1.66gm n.s.s.	1/50	0/50	0/50	1/50 1/50	
tba mix e	400.mg *	P<.3		123.mg n.s.s.	27/50	34/50	37/50	28/50 37/50	
5733 M m cd1 inh 52w52 2650m					0	22.3mg	44.6mg	89.3mg 179.mg	
lun a/a ek	no dre	P=1.		83.2mg n.s.s.	1/10	2/10	0/9	2/10 0/10	
5734 M m cd1 inh 78w78 2650n					0	22.3mg	44.6mg	89.3mg 179.mg	
lun a/a ek	465.mg *	P<.8		46.5mg n.s.s.	3/10	5/10	5/10	7/10 4/10	
lun a/c ek	no dre	P=1.		256.mg n.s.s.	1/10	0/10	0/10	1/10 0/10	
5735 M m cd1 inh 24m24 2650o					0	22.1mg	44.2mg	88.4mg 177.mg	
lun a/a e	154.mg *	P<.0005	+	83.1mg 606.mg	15/50	21/50	35/50	30/50 33/50	
lun a/c e	1.77gm *	P<.3		487.mg n.s.s.	4/50	5/50	3/50	6/50 7/50	
liv hpc e	2.86gm *	P<.3		729.mg n.s.s.	1/50	1/50	4/50	0/50 4/50	
liv hpa e	no dre	P=1.		868.mg n.s.s.	15/50	10/50	5/50	3/50 10/50	
tba mix e	209.mg *	P<.08		79.4mg n.s.s.	38/50	33/50	39/50	34/50 44/50	
5736 R f f34 gav 90w97 TR185 :					0	354.mg	530.mg	1.06gm	
TBA MXB as	no dre	P=1.	-	1.08gm n.s.s.	23/40	25/50	17/50	3/50	
liv MXB as	25.2gm *	P<.4		4.11gm n.s.s.	0/40	0/50	1/50	0/50	liv:hpa,hpc,nnd.
5737 R m f34 gav 90w97 TR185 :					0	354.mg	530.mg	1.06gm	
TBA MXB as	3.41gm Z	P<.5	-	765.mg n.s.s.	14/40	14/50	15/50	4/50	
liv MXB as	no dre	P=1.		6.85gm n.s.s.	1/40	0/50	0/50	0/50	liv:hpa,hpc,nnd.
5738 R f cdr inh 52w52 2579m					0	15.9mg	63.8mg	159.mg 319.mg	Cruzan;faat,46,266-281;1998
liv tum ek	no dre	P=1.	-	5.80mg n.s.s.	0/9	0/10	0/10	0/9 0/9	
5739 R f cdr inh 24m25 2579n					0	15.6mg	62.6mg	156.mg 313.mg	
liv hpa e	12.2gm *	P<.4	-	2.28gm n.s.s.	0/60	1/60	1/60	0/60 2/60	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site / Path	Notes	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
5740 R m cdr inh 52w52 2579m					0	11.2mg	44.6mg	112.mg	223.mg	
liv tum ek		no dre	P=1.	- 4.11mg n.s.s.	0/10	0/10	0/10	0/10	0/10	
5741 R m cdr inh 24m25 2579n					0	10.9mg	43.8mg	109.mg	219.mg	
liv mix e		9.93gm	* P<.4	- 1.64gm n.s.s.	0/60	1/60	0/60	1/54	1/52	
5742 R f sda inh 12m24 BT101					0	2.66mg	5.31mg	10.6mg	21.2mg	31.9mg	Conti;anya,534,203-234;1988
mam mal		57.1mg	* P<.002	+ 28.9mg 316.mg	6/60	6/30	4/30	9/30	12/30	9/30	
mam mix		23.3mg	* P<.02	+ 10.5mg 8.37gm	34/60	24/30	21/30	23/30	24/30	25/30	
tba mix		48.7mg	* P<.3	13.0mg n.s.s.	43/60	24/30	25/30	26/30	24/30	25/30	
tba mal		205.mg	* P<.5	41.7mg n.s.s.	16/60	9/30	9/30	13/30	10/30	10/30	
5743 R f sda gav 12m24 BT102					0	16.1mg	80.4mg			
tba mix		12.0mg	\ P<.03	4.97mg n.s.s.	25/40	34/40	(19/40)			
tba mal		no dre	P=1.	176.mg n.s.s.	9/40	15/40	9/40			
5744 R m sda inh 12m24 BT101					0	1.86mg	3.72mg	7.44mg	14.9mg	22.3mg	
tba mix		107.mg	* P<.4	27.7mg n.s.s.	17/60	12/30	6/30	11/30	10/30	12/30	
tba mal		no dre	P=1.	75.8mg n.s.s.	10/60	5/30	5/30	8/30	3/30	4/30	
5745 R m sda gav 12m24 BT102					0	16.1mg	80.4mg			
tba mix		1.22gm	* P<.7	143.mg n.s.s.	9/40	8/40	10/40			
tba mal		1.09gm	* P<.5	206.mg n.s.s.	2/40	3/40	4/40			

STYRENE AND beta-NITROSTYRENE MIXTURE (CAS# 100-42-5 and 102-96-5) mixture

5746 M f b6c gav 78w92 TR170 :					0	31.8mg	63.6mg		
TBA MXB		216.mg	* P<.3	- 70.1mg n.s.s.	2/20	10/50	10/50		
liv MXB		no dre	P=1.	467.mg n.s.s.	1/20	1/50	0/50		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	288.mg n.s.s.	0/20	2/50	0/50		lun:a/a,a/c.
5747 M m b6c gav 79w92 TR170 :					0	31.8mg	63.6mg		
lun MXA #		61.5mg	\ P<.007	- 30.8mg 556.mg	0/20	11/50	(2/50)		lun:a/a,a/c. S
TBA MXB		no dre	P=1.	72.9mg n.s.s.	8/20	19/50	12/50		
liv MXB		no dre	P=1.	118.mg n.s.s.	6/20	6/50	8/50		liv:hpa,hpc,nnd.
lun MXB		61.5mg	\ P<.007	30.8mg 556.mg	0/20	11/50	(2/50)		lun:a/a,a/c.
5748 R f f34 gav 18m25 TR170 :					0	23.5mg	47.0mg		
TBA MXB		no dre	P=1.	- 34.7mg n.s.s.	12/20	34/50	30/50		
liv MXB		no dre	P=1.	270.mg n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
5749 R m f34 gav 18m25 TR170 :					0	47.0mg	94.0mg		
TBA MXB		no dre	P=1.	- 198.mg n.s.s.	10/20	18/50	11/50		
liv MXB		1.57gm	* P<.4	387.mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.

STYRENE OXIDE 96-09-3

5750 M f b6c gav 24m25 1791					0	155.mg	311.mg		Lijinsky;jnci,77,471-476;1986
for mix e		172.mg	\ P<.0005	+ 105.mg 309.mg	0/51	24/50	(20/51)		
for sqp e		460.mg	* P<.0005	+ 298.mg 775.mg	0/51	14/50	17/51		
for sqc e		505.mg	\ P<.0005	+ 246.mg 1.35gm	0/51	10/50	(3/51)		
liv mix e		5.96gm	* P<.6	969.mg n.s.s.	7/51	4/50	9/51		
5751 M m b6c gav 24m25 1791					0	155.mg	311.mg		
for mix e		90.0mg	\ P<.0005	+ 57.8mg 150.mg	2/51	37/51	(21/52)		
for sqp e		215.mg	\ P<.0005	+ 124.mg 458.mg	2/51	22/51	(8/52)		
liv mix e		223.mg	\ P<.002	113.mg 1.17gm	12/51	28/52	(15/52)		
for sqc e		475.mg	* P<.0005	+ 308.mg 828.mg	0/51	16/51	15/52		
5752 R f f34 gav 24m25 1791					0	114.mg	228.mg		
for mix e		42.9mg	* P<.0005	+ 29.8mg 61.7mg	0/52	46/52	50/52		
for sqc e		114.mg	* P<.0005	+ 83.0mg 161.mg	0/52	32/52	36/52		
for sqp e		217.mg	* P<.0005	+ 150.mg 328.mg	0/52	21/52	24/52		
liv nnd e		no dre	P=1.	472.mg n.s.s.	8/52	6/52	(0/52)		
5753 R m f34 gav 24m25 1791					0	114.mg	228.mg		
for mix e		30.7mg	* P<.0005	+ 19.4mg 47.0mg	1/52	50/52	50/51		
for sqc e		81.6mg	* P<.0005	+ 59.6mg 114.mg	0/52	35/52	43/51		
for sqp e		146.mg	\ P<.0005	+ 87.2mg 283.mg	1/52	23/52	(18/51)		
liv nnd e		10.3gm	* P<.7	1.33gm n.s.s.	2/52	1/52	3/52		
5754 R f sda gav 12m36 BT105					0	10.7mg	53.6mg		Conti;anya,534,203-234;1988
for mix ej		96.5mg	* P<.0005	+ 60.6mg 167.mg	0/40	7/37	21/38		
for sqc ej		102.mg	* P<.0005	+ 63.7mg 180.mg	0/40	7/37	20/38		
for sqn ej		129.mg	* P<.0005	+ 78.0mg 264.mg	0/40	7/37	16/38		
for sqi ej		301.mg	* P<.0005	+ 151.mg 755.mg	0/40	1/37	10/38		
for ben ej		503.mg	* P<.009	+ 217.mg 19.7gm	0/40	2/37	5/38		
tba mix j		164.mg	* P<.009	74.1mg 7.47gm	10/40	16/40	22/40		
tba mal j		166.mg	* P<.002	83.2mg 771.mg	7/40	9/40	20/40		
5755 R f sda gav 12m36 1702					0	10.7mg	53.6mg		Maltoni;amet,2,97-110;1981
for mix er		96.5mg	* P<.0005	+ 60.6mg 167.mg	0/40	7/37	21/38		
for sqc er		102.mg	* P<.0005	+ 63.7mg 180.mg	0/40	7/37	20/38		
for sqn er		129.mg	* P<.0005	+ 78.0mg 264.mg	0/40	7/37	16/38		
for sqi er		301.mg	* P<.0005	+ 151.mg 755.mg	0/40	1/37	10/38		
for ben er		503.mg	* P<.009	+ 217.mg 19.7gm	0/40	2/37	5/38		
5756 R m sda gav 12m36 BT105					0	10.7mg	53.6mg		Conti;anya,534,203-234;1988
for sqc ej		63.0mg	\ P<.0005	+ 29.6mg 184.mg	0/39	9/39	(16/39)		
for mix ej		99.6mg	* P<.0005	+ 63.2mg 194.mg	0/39	10/39	19/39		
for sqn ej		140.mg	* P<.0005	+ 84.3mg 284.mg	0/39	6/39	16/39		
for sqi ej		267.mg	* P<.004	+ 141.mg 2.30gm	0/39	5/39	8/39		
for ben ej		354.mg	* P<.003	+ 172.mg 2.23gm	0/39	3/39	7/39		
tba mal j		189.mg	* P<.004	89.2mg 1.75gm	6/40	11/40	18/40		
tba mix j		191.mg	* P<.02	84.0mg n.s.s.	9/40	14/40	20/40		
5757 R m sda gav 12m36 1702					0	10.7mg	53.6mg		Maltoni;amet,2,97-110;1981
for sqc er		63.0mg	\ P<.0005	+ 29.6mg 184.mg	0/39	9/39	(16/39)		
for mix er		99.6mg	* P<.0005	+ 63.2mg 194.mg	0/39	10/39	19/39		
for sqn er		140.mg	* P<.0005	+ 84.3mg 284.mg	0/39	6/39	16/39		
for sqi er		267.mg	* P<.004	+ 141.mg 2.30gm	0/39	5/39	8/39		
for ben er		354.mg	* P<.003	+ 172.mg 2.23gm	0/39	3/39	7/39		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
SUCCINIC ANHYDRIDE 108-30-5								
5758 M f b6c gav 24m24 TR373 :				0	52.8mg	106.mg		
TBA MXB	no dre	P=1.	- 309.mg n.s.s.	27/50	14/50	16/50		
liv MXB	no dre	P=1.	759.mg n.s.s.	2/50	1/50	1/50		liv:hpa,hpc,nnd.
lun MXB	4.69gm *	P<.8	424.mg n.s.s.	3/50	1/50	4/50		lun:a/a,a/c.
5759 M m b6c gav 24m24 TR373 :				0	26.9mg	53.1mg		
TBA MXB	no dre	P=1.	- 118.mg n.s.s.	28/50	13/50	24/50		
liv MXB	no dre	P=1.	81.4mg n.s.s.	13/50	6/50	(7/50)		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	144.mg n.s.s.	5/50	4/50	7/50		lun:a/a,a/c.
5760 R f f34 gav 24m24 TR373 :				0	35.0mg	70.1mg		
TBA MXB	no dre	P=1.	- 56.3mg n.s.s.	55/60	47/60	39/60		
liv MXB	1.30gm *	P<.6	198.mg n.s.s.	2/60	1/60	3/60		liv:hpa,hpc,nnd.
5761 R m f34 gav 24m24 TR373 :				0	35.0mg	70.1mg		
TBA MXB	no dre	P=1.	- 63.1mg n.s.s.	54/60	47/60	43/60		
liv MXB	no dre	P=1.	729.mg n.s.s.	1/60	0/60	0/60		liv:hpa,hpc,nnd.
SUCRALOSE (1,6-dichloro-1,6-dideoxy-beta-D-fructofuranosyl-4-chloro-4-deoxy-alpha-D-galactopyranoside) 56038-13-2								
5762 M f cd1 eat 24m24 2637				0	390.mg	1.30gm	3.90gm	Mann;fctx,38,S91-S98;2000
liv hpc e	98.2gm *	P<.04	- 24.2gm n.s.s.	0/71	0/52	0/52	2/52	
liv hpa e	no dre	P=1.	- 41.9gm n.s.s.	8/71	2/52	1/52	1/52	
lun ade e	no dre	P=1.	- 20.4gm n.s.s.	5/71	3/52	3/52	3/52	
lun car e	no dre	P=1.	- 28.7gm n.s.s.	7/71	5/52	7/52	1/52	
tba mix e	no dre	P=1.	- 10.2gm n.s.s.	47/72	29/52	29/52	24/52	
5763 M m cd1 eat 24m24 2637				0	360.mg	1.20gm	3.60gm	
lun ade e	35.1gm *	P<.3	- 8.72gm n.s.s.	7/72	5/52	7/52	8/52	
liv hpc e	no dre	P=1.	- 14.1gm n.s.s.	12/72	7/52	6/52	7/52	
liv hpa e	no dre	P=1.	- 8.51gm n.s.s.	27/72	22/52	23/52	17/52	
lun car e	no dre	P=1.	- 12.4gm n.s.s.	10/72	13/52	12/52	7/52	
tba mix e	no dre	P=1.	- 3.15gm n.s.s.	54/72	38/52	41/52	38/52	
SUCROSE 57-50-1								
5764 M f cd1 eat 80w80 2126				0	13.0gm			Burdock;fctx,37,233-264;1999/pers.comm.
liv hpa e	no dre	P=1.	- 74.5gm n.s.s.	0/49	0/47			
5765 M m cd1 eat 80w80 2126				0	12.0gm			
liv hpa e	68.9gm	P<.4	- 15.8gm n.s.s.	5/49	8/49			
5766 M f scp eat 24m24 1979				0	13.0gm			Smits-van Prooije;fctx,28,243-251;1990
lun act e	135.gm	P<.4	- 31.8gm n.s.s.	3/44	6/47			
liv nnd e	405.gm	P<.3	- 66.0gm n.s.s.	0/44	1/46			
tba tum e	no dre	P=1.	- 14.3gm n.s.s.	28/46	29/49			
5767 M m scp eat 94w94 1979				0	12.0gm			
lun act e	89.9gm	P<.4	- 21.3gm n.s.s.	5/49	8/48			
liv hpc e	150.gm	P<.3	- 33.3gm n.s.s.	1/48	3/47			
liv nnd e	264.gm	P<.8	- 29.5gm n.s.s.	4/48	5/47			
tba tum e	78.9gm	P<.7	- 12.0gm n.s.s.	20/50	22/49			
5768 M f swa eat 76w76 1090				0	13.0gm			Roe;fctx,8,135-145;1970
lun mix e	129.gm	P<.8	- 14.9gm n.s.s.	7/45	8/43			
liv hpt e	no dre	P=1.	- 32.9gm n.s.s.	3/45	2/43			
SUCROSE ACETATE ISOBUTYRATE 126-13-6								
5769 M f b6c eat 24m24 2581n				0	5.00gm			Mackenzie;fctx,36,111-120;1998
tba mix	no dre	P=1.	- 19.6gm n.s.s.	48/100	14/50			
5770 M m b6c eat 24m24 2581n				0	5.00gm			
tba mix	no dre	P=1.	- 7.23gm n.s.s.	51/100	25/50			
5771 R f f34 eat 52w52 2581m				0	2.00gm			
liv hpa	3.25gm	P<.1	- 799.mg n.s.s.	0/20	2/20			
tba mix	3.25gm	P<.1	- 799.mg n.s.s.	0/20	2/20			
5772 R f f34 eat 24m24 2581n				0	2.00gm			
tba mix	no dre	P=1.	- 3.44gm n.s.s.	81/100	33/50			
5773 R m f34 eat 52w52 2581m				0	2.00gm			
liv tum	no dre	P=1.	- 2.06gm n.s.s.	0/20	0/20			
tba mix	no dre	P=1.	- 2.06gm n.s.s.	3/20	0/20			
5774 R m f34 eat 24m24 2581n				0	2.00gm			
tba mix	no dre	P=1.	- 334.mg n.s.s.	99/100	49/50			
SULFALLATE 95-06-7								
5775 M f b6c eat 78w90 TR115 :				0	73.1mg	146.mg		
mgl MXA dv	27.3mg *	P<.0005 c	18.4mg 41.6mg	0/20	33/50	27/50		mgl:acn,asm.
mgl acn dv	39.3mg *	P<.0005 c	24.0mg 72.5mg	0/20	23/50	11/50		
lun MXA dv	87.5mg *	P<.007	42.8mg 1.16gm	1/20	13/50	4/50		lun:a/a,a/c. S
mgl asm dv	98.3mg *	P<.0005 c	57.4mg 190.mg	0/20	10/50	16/50		
liv hpc dv	107.mg *	P<.0005	53.4mg 272.mg	0/20	5/50	8/50		S
TBA MXB dv	21.3mg *	P<.0005	13.7mg 39.2mg	7/20	42/50	37/50		
liv MXB dv	107.mg *	P<.0005	53.4mg 272.mg	0/20	5/50	8/50		liv:hpa,hpc,nnd.
lun MXB dv	87.5mg *	P<.007	42.8mg 1.16gm	1/20	13/50	4/50		lun:a/a,a/c.
5776 M m b6c eat 78w91 TR115 :				0	69.6mg	140.mg		
lun MXA dv	92.5mg *	P<.0005 c	59.6mg 276.mg	0/20	14/50	17/50		lun:a/a,a/c.
lun a/c dv	269.mg *	P<.006	138.mg 2.29gm	0/20	3/50	9/50		S
--- hes dv	539.mg *	P<.03	230.mg n.s.s.	0/20	1/50	6/50		S
TBA MXB dv	65.5mg *	P<.03	31.1mg n.s.s.	8/20	37/50	39/50		
liv MXB dv	188.mg *	P<.3	62.4mg n.s.s.	7/20	22/50	24/50		liv:hpa,hpc,nnd.
lun MXB dv	92.5mg *	P<.0005	59.6mg 276.mg	0/20	14/50	17/50		lun:a/a,a/c.
5777 R f osm eat 18m24 TR115 :				0	6.70mg	10.8mg		
mgl acn dv	17.2mg *	P<.0005 c	9.63mg 34.8mg	0/50	7/50	11/50		
TBA MXB dv	9.06mg *	P<.03	4.01mg n.s.s.	36/50	37/50	30/50		
liv MXB dv	69.1mg *	P<.2	21.4mg n.s.s.	1/50	3/50	2/50		liv:hpa,hpc,nnd.
5778 R m osm eat 18m24 TR115 :				0	5.40mg	8.80mg		
thy MXA dv	24.0mg *	P<.007	9.75mg 321.mg	0/50	4/50	2/50		thy:cca,ccr. S
sto MXA dv	53.9mg /	P<.007 c	18.7mg 703.mg	0/50	0/50	5/50		sto:ppn,sqc,sqp.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
TBA MXB dv		12.6mg *	P<.3	3.94mg n.s.s.	28/50	27/50	19/50				
liv MXB dv		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50				liv:hpa,hpc,nnd.
SULFAMETHAZINE (4-amino-N-(4,6-dimethyl-2-pyrimidinyl)-benzenesulfonamide) 57-68-1											
5779 M f b6c eat 52w52 1924m					0	39.0mg	156.mg	624.mg	Littlefield;fctx,27,455-463;1989/1989a/pers.comm.		
lun a/c e		3.10gm *	P<.2	505.mg n.s.s.	0/24	0/24	0/24	1/22			
liv hpa e		no dre	P=1.	760.mg n.s.s.	0/24	1/24	0/24	0/22			
thy fca e		no dre	P=1.	535.mg n.s.s.	0/24	0/24	1/24	0/22			
5780 M f b6c eat 78w78 1924n					0	39.0mg	156.mg	624.mg			
thy fca e		618.mg *	P<.0005	299.mg 1.76gm	0/24	1/24	0/24	9/23			
liv hpa e		2.82gm *	P<.2	645.mg n.s.s.	0/24	1/24	1/24	2/23			
lun a/c e		no dre	P=1.	1.25gm n.s.s.	0/24	0/24	1/24	0/23			
5781 M f b6c eat 24m24 1924o					0	39.0mg	78.0mg	156.mg	312.mg	624.mg	
thy mix e		2.06gm Z	P<.0005 +	1.33gm 3.54gm	7/184	2/95	1/94	0/96	2/96	34/94	
thy fca e		2.16gm Z	P<.0005 +	1.39gm 3.75gm	7/184	2/95	0/94	0/96	2/96	33/94	
liv mix e		8.74gm *	P<.2	2.69gm n.s.s.	10/184	6/95	12/94	5/96	7/96	11/94	
liv hpa e		12.3gm *	P<.3	3.26gm n.s.s.	8/184	5/95	8/94	4/96	6/96	8/94	
lun a/c e		12.7gm *	P<.2	3.80gm n.s.s.	5/184	4/95	4/94	1/96	5/96	6/94	
liv hpc e		16.5gm *	P<.2	4.64gm n.s.s.	2/184	1/95	4/94	1/96	2/96	4/94	
thy fcc e		54.8gm *	P<.3	9.74gm n.s.s.	0/184	0/95	1/94	0/96	0/96	1/94	
5782 M m b6c eat 52w52 1924m					0	36.0mg	144.mg	576.mg			
lun a/c e		no dre	P=1.	33.9mg n.s.s.	1/24	0/24	0/24	0/24			
liv hpa e		no dre	P=1.	153.mg n.s.s.	3/24	0/24	1/24	(0/24)			
5783 M m b6c eat 78w78 1924n					0	36.0mg	144.mg	576.mg			
thy fca e		3.37gm *	P<.2	720.mg n.s.s.	0/24	1/24	0/24	2/24			
liv hpc e		no dre	P=1.	1.95gm n.s.s.	3/24	2/24	0/24	0/24			
liv mix e		no dre	P=1.	1.04gm n.s.s.	4/24	5/24	2/24	2/24			
lun a/c e		no dre	P=1.	1.58gm n.s.s.	3/24	1/24	2/24	0/24			
liv hpa e		no dre	P=1.	635.mg n.s.s.	1/24	3/24	5/24	2/24			
5784 M m b6c eat 24m24 1924o					0	36.0mg	72.0mg	144.mg	288.mg	576.mg	
thy mix e		1.19gm Z	P<.0005 +	846.mg 1.77gm	3/191	0/96	1/96	5/92	4/96	44/94	
thy fca e		1.22gm Z	P<.0005 +	861.mg 1.81gm	3/191	0/96	1/96	5/92	3/96	44/94	
liv mix e		11.7gm *	P<.7	1.71gm n.s.s.	44/191	20/96	23/96	27/92	28/96	22/94	
liv hpa e		14.9gm *	P<.6	2.37gm n.s.s.	26/191	12/96	12/96	14/92	15/96	14/94	
thy fcc e		72.1gm *	P<.3	11.7gm n.s.s.	0/191	0/96	0/96	0/92	1/96	0/94	
liv hpc e		no dre	P=1.	3.16gm n.s.s.	21/191	9/96	11/96	15/92	13/96	9/94	
lun a/c e		no dre	P=1.	7.05gm n.s.s.	25/191	7/96	9/96	6/92	9/96	5/94	
SULFATE, SODIUM (disodium sulfate) 7757-82-6											
5785 M f swi eat 32w52 1118					0	811.mg					Cohen;canr,38,1398-1405;1978
--- leu v		3.96gm	P<.6	544.mg n.s.s.	1/30	2/30					
liv tum v		no dre	P=1.	1.25gm n.s.s.	0/30	0/30					
lun tum v		no dre	P=1.	1.25gm n.s.s.	0/30	0/30					
SULFISOXAZOLE 127-69-5											
5786 M f b6c eat 24m24 TR138 :					0	490.mg	1.96gm				
liv hpc #		2.65gm \	P<.008 -	1.01gm 11.0gm	0/50	5/50	(2/50)				S
lun MXA		11.9gm *	P<.007	4.84gm 161.gm	0/50	1/50	5/50				lun:a/a,a/c. S
TBA MXB		8.18gm *	P<.5	1.71gm n.s.s.	24/50	29/50	31/50				
liv MXB		2.65gm \	P<.008	1.01gm 11.0gm	0/50	5/50	(2/50)				liv:hpa,hpc,nnd.
lun MXB		11.9gm *	P<.007	4.84gm 161.gm	0/50	1/50	5/50				lun:a/a,a/c.
5787 M m b6c eat 24m24 TR138 :					0	495.mg	1.98gm				
TBA MXB		no dre	P=1.	- 2.17gm n.s.s.	29/50	31/50	28/50				
liv MXB		6.91gm *	P<.3	1.87gm n.s.s.	15/50	13/50	21/50				liv:hpa,hpc,nnd.
lun MXB		49.5gm \	P<1.	1.30gm n.s.s.	4/50	5/50	(0/50)				lun:a/a,a/c.
5788 R f f34 eat 24m25 TR138 :					0	97.2mg	389.mg				
TBA MXB		no dre	P=1.	- 470.mg n.s.s.	38/50	37/50	35/50				
liv MXB		no dre	P=1.	4.33gm n.s.s.	1/50	0/50	0/50				liv:hpa,hpc,nnd.
5789 R m f34 eat 24m24 TR138 :					0	97.2mg	392.mg				
TBA MXB		135.mg \	P<.09 -	50.6mg n.s.s.	28/50	36/50	(31/50)				
liv MXB		26.3gm *	P<.9	1.10gm n.s.s.	1/50	4/50	2/50				liv:hpa,hpc,nnd.
SULFITE, POTASSIUM METABI- 4429-42-9											
5790 M f icr wat 24m24 1391					0	2.00gm	4.00gm				Tanaka;eaes,3,451-453;1979
lun ade		33.6gm \	P<.1 -	8.26gm n.s.s.	0/50	2/50	(0/50)				
lun adc		100.gm *	P<.4 -	22.0gm n.s.s.	1/50	0/50	3/50				
liv hms		204.gm *	P<.3 -	33.3gm n.s.s.	0/50	0/50	1/50				
5791 M m icr wat 24m24 1391					0	1.67gm	3.33gm				
lun adc		84.8gm *	P<.3 -	20.9gm n.s.s.	0/50	1/50	1/50				
lun ade		84.8gm *	P<.3 -	20.9gm n.s.s.	0/50	1/50	1/50				
liv tum		no dre	P=1. -	11.4gm n.s.s.	0/50	0/50	0/50				
3-SULFOLENE 77-79-2											
5792 M f b6c gav 78w90 TR102 :					0	235.mg	470.mg				
TBA MXB sv		no dre	P=1. -	426.mg n.s.s.	4/20	10/50	1/50				
liv MXB sv		no dre	P=1.	n.s.s. n.s.s.	0/20	1/50	0/50				liv:hpa,hpc,nnd.
lun MXB sv		1.94gm *	P<.4	480.mg n.s.s.	1/20	5/50	1/50				lun:a/a,a/c.
5793 M m b6c gav 78w90 TR102 :					0	190.mg	381.mg				
TBA MXB sv		631.mg *	P<.5 -	152.mg n.s.s.	5/20	20/50	8/50				
liv MXB sv		415.mg *	P<.09	179.mg n.s.s.	1/20	11/50	5/50				liv:hpa,hpc,nnd.
lun MXB sv		882.mg *	P<.2	350.mg n.s.s.	0/20	4/50	2/50				lun:a/a,a/c.
5794 R f osm gav 18m26 TR102 :					0	52.5mg	105.mg				
TBA MXB dv		5.37gm *	P<1. -	60.1mg n.s.s.	14/20	39/50	21/50				
liv MXB dv		no dre	P=1.	n.s.s. n.s.s.	0/20	2/50	0/50				liv:hpa,hpc,nnd.
5795 R m osm gav 16m26 TR102 :					0	88.5mg	249.mg				
TBA MXB adsv		30.8mg *	P<.04 -	8.90mg n.s.s.	9/20	13/50	1/50				
liv MXB adsv		no dre	P=1.	n.s.s. n.s.s.	0/20	1/50	0/50				liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

4,4'-SULFONYLBISACETANILIDE 77-46-3

5796 R f buf eat 43w92 144 | 0 | 5.93mg | | | Morris;jnci,24,149-180;1960
mgl adc e | 55.6mg | P<.3 | + | 9.05mg n.s.s. | 0/18 | 1/18

SULINDAC SULFONE (exisulind) 59973-80-7

5797 R m f34 eat 53w53 2625 | 0 | 48.0mg | | | Reddy;canr,59,3387-3391;1999
col tum er | no dre | P=1. | - | 15.4mg n.s.s. | 0/6 | 0/6

SUXIBUZONE 27470-51-5

5798 R f f3d eat 24m24 2439 | 0 | 31.2mg | 62.5mg | 125.mg | 250.mg | Inoue;iyke,18,345-359;1987
liv tum | no dre | P=1. | - | 172.mg n.s.s. | 0/50 | 0/50 | 0/50 | 0/50 | 0/50
5799 R m f3d eat 24m24 2439 | 0 | 25.0mg | 50.0mg | 100.mg | 200.mg
adr phe | 471.mg Z | P<.02 | - | 211.mg n.s.s. | 6/50 | 2/50 | 1/50 | 15/50 | (8/50)
liv hpa | no dre | P=1. | - | 2.96gm n.s.s. | 1/50 | 0/50 | 1/50 | 0/50 | 0/50
liv hpc | no dre | P=1. | - | 2.27gm n.s.s. | 0/50 | 0/50 | 1/50 | 0/50 | 0/50

SYMPHYTINE 22571-95-5

5800 R m aci ipj 56w92 1396 | 0 | 1.20mg | | | Hirono;jnci,63,469-472;1979
liv mix ev | 1.91mg | P<.02 | + | .655mg n.s.s. | 0/13 | 4/14
tba mix ev | 4.50mg | P<.5 | | .895mg n.s.s. | 3/18 | 5/18

T-2 TOXIN (FUSARIOTOXIN T-2) 21259-20-1

5801 M f cd1 eat 71w71 2357 | 0 | .195mg | .390mg | | Schiefer;fctx,25,593-601;1987
lun adc e | 1.53mg \ | P<.1 | | .375mg n.s.s. | 0/50 | 2/50 | (0/50)
lun ade e | 2.63mg * | P<.5 | | .563mg n.s.s. | 3/50 | 5/50 | 5/50
liv hpc e | 9.31mg * | P=1. | | 1.52mg n.s.s. | 0/50 | 1/50 | 0/50
liv hpa e | no dre | P=1. | | 1.05mg n.s.s. | 2/50 | 2/50 | 2/50
5802 M m cd1 eat 71w71 2357 | 0 | .180mg | .360mg
liv hpa e | .883mg * | P<.05 | + | .362mg n.s.s. | 3/46 | 3/50 | 10/48
lun ade e | .771mg * | P<.2 | + | .295mg n.s.s. | 4/40 | 7/47 | 11/48
lun adc e | 10.6mg * | P<.8 | | .975mg n.s.s. | 2/40 | 0/47 | 3/48
liv hpc e | no dre | P=1. | | 1.23mg n.s.s. | 1/46 | 1/50 | 1/48

TACE (chlorotrianisene) 569-57-3

5803 R f cdr eat 24m24 108 | 0 | 50.0ug | .200mg | 2.00mg | Gibson;txap,11,489-510;1967
liv tum e | no dre | P=1. | - | .162mg n.s.s. | 0/20 | 0/20 | 0/20 | 0/20
5804 R m cdr eat 24m24 108 | 0 | 50.0ug | .200mg | 2.00mg
liv tum e | no dre | P=1. | - | .162mg n.s.s. | 0/20 | 0/20 | 0/20 | 0/20

TALTIRELIN TETRAHYDRATE ---

5805 M f cd1 gav 24m24 2519 | 0 | 50.0mg | | | Yamamura;jtxs,22,II,419-430;1997
lun car e | 1.01gm | P<.5 | - | 182.mg n.s.s. | 3/58 | 5/60
liv mix e | 2.08gm | P<.6 | - | 274.mg n.s.s. | 1/58 | 2/60
lun ade e | no dre | P=1. | - | 338.mg n.s.s. | 3/58 | 2/60
5806 M m cd1 gav 24m24 2519 | 0 | 50.0mg
liv hpa e | 796.mg | P<.6 | - | 141.mg n.s.s. | 6/60 | 8/58
liv hpc e | no dre | P=1. | - | 317.mg n.s.s. | 6/60 | 3/58
lun ade e | no dre | P=1. | - | 268.mg n.s.s. | 9/60 | 5/58
lun car e | no dre | P=1. | - | 250.mg n.s.s. | 13/60 | 7/58
5807 R f cdr gav 94w94 2519 | 0 | 20.0mg | 60.0mg | 200.mg
liv hpa e | no dre | P=1. | - | 1.87gm n.s.s. | 0/55 | 1/55 | 0/55 | 0/55
5808 R m cdr gav 90w90 2519 | 0 | 20.0mg | 60.0mg | 200.mg
liv hpa e | 2.61gm * | P<.3 | - | 789.mg n.s.s. | 0/55 | 0/55 | 2/55 | 1/55

TAMOXIFEN CITRATE 54965-24-1

5809 M f aps mix 65w65 2334m | 0 | 5.00mg | 50.0mg | | Tucker;stnd,125-161;1984
ova gca e | 3.00mg \ | P<.0005 | + | 1.40mg 8.79mg | 0/23 | 9/25 | (9/24)
lun ade e | no dre | P=1. | | 78.2mg n.s.s. | 0/23 | 1/25 | 0/24
liv tum e | no dre | P=1. | | 9.11mg n.s.s. | 0/23 | 0/25 | 0/24
5810 M m aps mix 65w65 2334m | 0 | 5.00mg | 50.0mg
tes ica e | 8.18mg * | P<.0005 | + | 4.66mg 15.4mg | 0/25 | 2/24 | 21/25
liv mhp e | no dre | P=1. | | 81.0mg n.s.s. | 0/25 | 1/24 | 0/25
lun ade e | no dre | P=1. | | 60.5mg n.s.s. | 1/25 | 1/24 | 1/25
liv bhp e | no dre | P=1. | | 101.mg n.s.s. | 2/25 | 1/24 | 0/25
5811 M m aps mix 56w56 2334n | 0 | 20.0mg
tes ict rs | 9.80mg | P<.08 | | 2.36mg n.s.s. | 0/6 | 2/6
5812 M m aps mix 56w56 2334o | 0 | 20.0mg
tes ict rs | 9.80mg | P<.08 | | 2.36mg n.s.s. | 0/6 | 2/6
5813 M f b6c eat 24m24 2323m | 0 | 21.0mg | | | Martin;carc,18,2209-2215;1997/pers.comm.
liv hpa Cv | 101.mg | P<.09 | - | 24.7mg n.s.s. | 0/15 | 2/15
lun alc v | no dre | P=1. | - | 64.9mg n.s.s. | 0/15 | 0/15
ute ley v | no dre | P=1. | - | 64.9mg n.s.s. | 0/15 | 0/15
5814 M f cb6 eat 52w52 2323n | 0 | 23.8mg
liv hpc Crv | no dre | P=1. | - | 40.5mg n.s.s. | 0/33 | 0/33
5815 M f dba eat 52w52 2323o | 0 | 23.7mg
liv hpc Crv | no dre | P=1. | - | 40.3mg n.s.s. | 0/33 | 0/33
5816 R f aap gav 20m25 2044 | 0 | 5.00mg | 20.0mg | 35.0mg | Greaves;canr,53,3919-3924;1993
liv hpc e | 17.0mg * | P<.0005 | + | 12.7mg 23.4mg | 0/104 | 6/52 | 37/52 | 37/52
liv hpa e | 135.mg * | P<.0005 | + | 72.9mg 370.mg | 1/104 | 2/52 | 6/52 | 9/52
liv hcc e | 241.mg * | P<.0005 | | 114.mg 681.mg | 0/104 | 0/52 | 4/52 | 5/52
liv blc e | 706.mg * | P<.2 | | 204.mg n.s.s. | 1/104 | 0/52 | 2/52 | 2/52
liv cho e | 2.26gm * | P<.4 | | 367.mg n.s.s. | 0/104 | 0/52 | 1/52 | 0/52
5817 R m aap gav 20m25 2044 | 0 | 5.00mg | 20.0mg | 35.0mg
liv hpc e | 18.7mg * | P<.0005 | + | 13.8mg 26.0mg | 1/102 | 8/51 | 34/51 | 34/51
liv hpa e | 47.9mg Z | P<.0005 | + | 26.4mg 130.mg | 1/102 | 8/51 | 11/51 | (8/51)
liv hcc e | 306.mg * | P<.0005 | | 132.mg 1.04gm | 0/102 | 0/51 | 2/51 | 5/51
liv blc e | 1.10gm * | P<.08 | | 271.mg n.s.s. | 0/102 | 0/51 | 1/51 | 1/51

Chemical / Synonym / CAS number	Spe	Strain	Xpo+Xpt	Sex	Route	Paper Num	0 Dose	1 Dose	2 Dose	3 Dose	Literature Reference
Site / Path	Notes	DR	TD_{50}	AuOp	2Tailpvl	UpConf	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
5818	R	f	cdr	gav	52w52	2049m			0	11.3mg	22.6mg	Hard;canr,53,4534-4541;1993/pers.comm.
liv	mix	ek		1.44mg	*	P<.0005	+	.939mg	2.27mg	0/18	24/36	24/24	
liv	hpa	ek		1.68mg	*	P<.0005		1.10mg	2.65mg	0/18	21/36	24/24	
liv	hpc	ek		2.12mg	*	P<.0005	+	1.39mg	3.40mg	0/18	16/36	24/24	
5819	R	f	cdr	gav	52w65	2049n			0	9.04mg	18.1mg	
liv	mix	e		3.86mg	*	P<.0005	+	2.56mg	6.23mg	0/21	16/30	22/33	
liv	hpa	e		4.35mg	*	P<.0005		2.84mg	7.11mg	0/21	13/30	22/33	
liv	hpc	e		4.62mg	*	P<.0005	+	3.01mg	7.77mg	0/21	14/30	20/33	
5820	R	f	cdr	gav	52w52	2116m			0	2.80mg	11.3mg	45.2mg	Williams;carc,14,315-317;1993/pers.comm.
liv	hpa	ekr		5.80mg	*	P<.002	+	2.43mg	29.2mg	0/10	0/10	5/10	2/4	
liv	hpc	ekr		10.3mg	*	P<.002	+	3.43mg	59.0mg	0/10	0/10	1/10	3/4	
5821	R	f	cdr	gav	51w65	2116n			0	2.24mg	9.04mg	45.2mg	
liv	hpa	aer		7.77mg	Z	P<.002	+	2.93mg	35.9mg	0/12	0/27	5/12	(7/22)	
liv	hpc	aer		7.77mg	Z	P<.002	+	2.93mg	35.9mg	0/12	0/27	5/12	(6/22)	
5822	R	f	f3t	eat	86w86	2250r	:		0	21.0mg		Carthew;carc,16,1299-1304;1995/pers.comm.
liv	hpc	Cr		4.18mg		P<.0005	+	1.96mg	12.8mg	0/10	10/10	
5823	R	f	lew	eat	48w48	2250u	:	()	0	21.0mg		
liv	hpc	Cr		1.38mg		P<.0005	+	.658mg	3.59mg	0/10	10/10	
5824	R	f	sda	gav	39m39	BT5T			0	2.83mg		Maltoni;anya,837,469-512;1997
liv	hpc			164.mg		P<.05		49.7mg	n.s.s.	0/100	3/100	
ute	fib			247.mg		P<.1		60.9mg	n.s.s.	0/100	2/100	
ute	sar			487.mg		P<.7		58.6mg	n.s.s.	2/100	3/100	
liv	hpa			497.mg		P<.3		81.0mg	n.s.s.	0/100	1/100	
vag	sqc			497.mg		P<.3		81.0mg	n.s.s.	0/100	1/100	
ute	sqc			497.mg		P<.3		81.0mg	n.s.s.	0/100	1/100	
ute	esp			no dre		P=1.		150.mg	n.s.s.	13/100	0/100	
ute	car			no dre		P=1.		91.9mg	n.s.s.	1/100	1/100	
ute	agf			no dre		P=1.		91.9mg	n.s.s.	1/100	1/100	
ute	adc			no dre		P=1.		150.mg	n.s.s.	1/100	0/100	
pit	ade			no dre		P=1.		122.mg	n.s.s.	16/100	2/100	
mam	mal			no dre		P=1.		150.mg	n.s.s.	9/100	0/100	
mam	fbs			no dre		P=1.		150.mg	n.s.s.	1/100	0/100	
mam	ben			no dre		P=1.		150.mg	n.s.s.	36/100	0/100	
mam	adc			no dre		P=1.		150.mg	n.s.s.	8/100	0/100	
adr	phe			no dre		P=1.		46.5mg	n.s.s.	17/100	12/100	
tba	mal			88.7mg		P<.6		16.7mg	n.s.s.	27/100	31/100	
tba	ben			no dre		P=1.		59.8mg	n.s.s.	57/100	26/100	
5825	R	f	sda	gav	52w52	2043m			0	11.3mg	45.0mg	Hirsimaki;artx,67,49-54;1993/pers.comm.
liv	hpc	ekr		11.8mg	*	P<.02	+	3.43mg	n.s.s.	0/5	0/5	3/5	
5826	R	f	sda	gav	52w65	2043n			0	9.04mg	36.0mg	
liv	hpc	er		18.9mg	*	P<.002	+	7.04mg	95.0mg	0/10	0/10	5/10	
5827	R	f	sda	gav	52w52	2159m			0	11.3mg	45.0mg	Ahotupa;carc,15,863-868;1994
liv	hpc	er		7.56mg	*	P<.003	+	2.40mg	52.5mg	0/5	0/5	4/5	
5828	R	f	sda	gav	52w65	2159n			0	9.04mg	36.0mg	
liv	hpc	er		6.00mg	*	P<.0005	+	1.88mg	27.3mg	0/5	0/5	5/5	
5829	R	f	sda	gav	52w52	2633m			0	45.0mg		Karki;artx,74,249-256;2000/pers.comm.
liv	mix	Cer		noTD50		P<.009	+	n.s.s.	10.7mg	0/5	5/5	
liv	hpc	Cer		4.79mg		P<.005	+	1.33mg	42.7mg	0/5	4/5	
5830	R	f	sda	gav	52w65	2633n			0	36.0mg		
liv	hpc	Cer		noTD50		P<.009	+	n.s.s.	13.3mg	0/5	5/5	
5831	R	m	sda	gav	39m39	BT5T			0	2.83mg		Maltoni;anya,837,469-512;1997
mam	ben			96.4mg		P<.05		34.8mg	n.s.s.	1/100	6/100	
liv	hpc			247.mg		P<.1		60.9mg	n.s.s.	0/100	2/100	
mam	adc			247.mg		P<.1		60.9mg	n.s.s.	0/100	2/100	
liv	hpa			497.mg		P<.3		81.0mg	n.s.s.	0/100	1/100	
adr	phe			no dre		P=1.		35.4mg	n.s.s.	19/100	16/100	
pan	isa			no dre		P=1.		123.mg	n.s.s.	7/100	1/100	
pit	ade			no dre		P=1.		76.0mg	n.s.s.	11/100	5/100	
tes	ldc			no dre		P=1.		150.mg	n.s.s.	4/100	0/100	
tba	mal			187.mg		P<.8		20.4mg	n.s.s.	24/100	26/100	
tba	ben			no dre		P=1.		25.3mg	n.s.s.	33/100	29/100	
5832	R	f	sls	gav	52w52	2247			0	2.86mg		Machishi;carc,16,2965-2971;1995
liv	hpc	Cr		no dre		P=1.		1.18mg	n.s.s.	0/8	0/8	
5833	R	f	wil	eat	49w49	2250s	:	()	0	21.0mg		Carthew;carc,16,1299-1304;1995/pers.comm.
liv	hpc	Cr		1.36mg		P<.0005	+	.637mg	4.18mg	0/10	10/10	
TANNIC ACIDS, PHARMACEUTICAL GRADE (85.69% TANNIC ACIDS, 8.84% GALLIC ACIDS) 1401-55-4												
5834	R	f	f3d	wat	24m26	2142			0	130.mg	261.mg	Onodera;fctx,32,1101-1106;1994
liv	hpa	e		16.0gm	*	P=1.	-	2.61gm	n.s.s.	0/50	1/50	0/50	
tba	mix	e		620.mg	*	P<.5	-	141.mg	n.s.s.	40/50	41/50	43/50	
5835	R	m	f3d	wat	24m26	2142			0	114.mg	228.mg	
liv	hpa	e		no dre		P=1.	-	2.47gm	n.s.s.	1/45	0/47	1/48	
tba	mix	e		noTD50		P=1.	-	n.s.s.	n.s.s.	45/45	47/47	48/48	
TARA GUM 39300-88-4												
5836	M	f	b6c	eat	24m24	TR224	:		0	3.19gm	6.38gm	
TBA	MXB			no dre		P=1.	-	10.4gm	n.s.s.	34/50	26/50	26/50	
liv	MXB			no dre		P=1.		9.39gm	n.s.s.	10/50	6/50	(3/50)	liv:hpa,hpc,nnd.
lun	MXB			no dre		P=1.		38.2gm	n.s.s.	8/50	2/50	3/50	lun:a/a,a/c.
5837	M	m	b6c	eat	24m24	TR224	:		0	2.94gm	5.89gm	
TBA	MXB			31.0gm	*	P<.7	-	5.09gm	n.s.s.	31/50	28/50	36/50	
liv	MXB			289.gm	*	P<1.		10.5gm	n.s.s.	17/50	12/50	18/50	liv:hpa,hpc,nnd.
lun	MXB			85.6gm	*	P<.8		10.5gm	n.s.s.	10/50	11/50	12/50	lun:a/a,a/c.
5838	R	f	f34	eat	24m25	TR224	:		0	1.21gm	2.43gm	
TBA	MXB			5.03gm	*	P<.5	-	1.19gm	n.s.s.	41/50	48/50	47/50	
liv	MXB			no dre		P=1.		21.2gm	n.s.s.	2/50	0/50	1/50	liv:hpa,hpc,nnd.
5839	R	m	f34	eat	24m24	TR224	:		0	972.mg	1.96gm	
TBA	MXB			93.3gm	*	P<1.	-	1.47gm	n.s.s.	36/50	39/50	38/50	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf						Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB	24.5gm *	P<.4	6.14gm n.s.s.	1/50	2/50	3/50		liv:hpa,hpc,nnd.
TAURINE 107-35-7								
5840 R f wis eat 78w78 2382				0	250.mg	2.50gm		Takahashi;phrm,6,529-534;1972
mgl fba	no dre	P=1.	- 2.03gm n.s.s.	2/9	1/7	0/7		
5841 R m wis eat 78w78 2382				0	200.mg	2.00gm		
mgl fba	no dre	P=1.	- 1.00gm n.s.s.	2/9	1/7	1/7		
TEGAFUR (Ftorafur, N1-2-FURAMIDYL-5-FLUOROURACIL) 37076-68-9								
5842 M f cb7 gav 52w84 2545				0	7.03mg			Griciute;ponr,2,69-70;1996/pers.comm.
liv tum e	no dre	P=1.	- 38.8mg n.s.s.	0/29	0/41			
tba mix e	no dre	P=1.	- 15.9mg n.s.s.	6/29	5/41			
5843 M m cb7 gav 52w86 2545				0	6.86mg			
liv tum e	no dre	P=1.	- 32.9mg n.s.s.	0/32	0/34			
tba mix e	no dre	P=1.	- 32.9mg n.s.s.	3/32	0/34			
5844 R f wis gav 12m27 2545				0	7.62mg			
liv tum e	no dre	P=1.	- 51.7mg n.s.s.	0/25	0/26			
tba mix e	no dre	P=1.	- 37.0mg n.s.s.	3/25	1/26			
5845 R m wis gav 12m29 2545				0	7.09mg			
liv tum e	no dre	P=1.	- 62.2mg n.s.s.	0/28	0/29			
tba mix e	no dre	P=1.	- 22.0mg n.s.s.	8/28	6/29			
TELODRIN (isobenzan) 297-78-9								
5846 M f b6a orl 76w76 1249				0	89.1ug			Innes;ntis,1968/1969
lun ade evx	no dre	P=1.	- .106mg n.s.s.	1/17	1/18			
liv hpt evx	no dre	P=1.	- .177mg n.s.s.	0/17	0/18			
tba mix evx	no dre	P=1.	- 84.1ug n.s.s.	2/17	2/18			
5847 M m b6a orl 76w76 1249				0	82.9ug			
lun ade evx	.146mg	P<.3	- 39.4ug n.s.s.	2/18	5/18			
liv hpt evx	no dre	P=1.	- 98.0ug n.s.s.	1/18	1/18			
tba mix evx	.136mg	P<.3	- 35.4ug n.s.s.	3/18	6/18			
5848 M f b6c orl 76w76 1249				0	89.1ug			
lun ade evx	.571mg	P<.3	- 92.9ug n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.	- .177mg n.s.s.	0/16	0/18			
tba mix evx	.277mg	P<.2	- 68.0ug n.s.s.	0/16	2/18			
5849 M m b6c orl 76w76 1249				0	82.9ug			
liv hpt evx	.500mg	P<.3	- 81.5ug n.s.s.	0/16	1/17			
lun ade evx	.500mg	P<.3	- 81.5ug n.s.s.	0/16	1/17			
tba mix evx	.242mg	P<.1	- 59.5ug n.s.s.	0/16	2/17			
TELONE II, TECHNICAL GRADE (WITH 1% EPICHLOROHYDRIN) (1,3-dichloropropene) 542-75-6								
5850 M f b6c gav 24m25 TR269 :				0	20.8mg	41.7mg		
MXB MXB	36.3mg *	P<.0005	24.5mg 57.1mg	0/50	12/50	26/50		lun:a/a; sto:sqc,sqp; ubl:tcc. C
ubl tcc	49.6mg *	P<.0005 c	31.8mg 83.7mg	0/50	8/50	21/50		
lun a/a	149.mg *	P<.0005 c	74.7mg 446.mg	0/50	3/50	8/50		
liv MXA	89.3mg \	P<.02	37.3mg n.s.s.	1/50	8/50	(3/50)		liv:hpa,hpc. S
lun MXA	182.mg *	P<.03	77.8mg n.s.s.	2/50	4/50	8/50		lun:a/a,a/c. S
liv hpa	215.mg *	P<.03	97.3mg n.s.s.	0/50	5/50	3/50		S
sto MXA	344.mg *	P<.02 c	130.mg n.s.s.	0/50	1/50	4/50		sto:sqc,sqp.
TBA MXB	34.9mg *	P<.002	19.3mg 140.mg	16/50	33/50	34/50		
liv MXB	89.3mg \	P<.02	37.3mg n.s.s.	1/50	8/50	(3/50)		liv:hpa,hpc,nnd.
lun MXB	182.mg *	P<.03	77.8mg n.s.s.	2/50	4/50	8/50		lun:a/a,a/c.
5851 M m b6c gav 24m24 TR269 :				0	21.2mg	42.2mg		
TBA MXB s	309.mg *	P<.9 i	26.7mg n.s.s.	8/50	28/50	30/50		
liv MXB s	1.93gm *	P<1.	63.6mg n.s.s.	5/50	7/50	13/50		liv:hpa,hpc,nnd.
lun MXB s	127.mg *	P<.4	37.2mg n.s.s.	1/50	13/50	12/50		lun:a/a,a/c.
5852 R f f34 gav 24m25 TR269 :				0	10.4mg	21.0mg		
thy MXA	137.mg *	P<.03	55.8mg n.s.s.	0/52	2/52	4/52		thy:fca,fcc. S
sto sqp	176.mg *	P<.05 p	66.3mg n.s.s.	0/52	2/52	3/52		
TBA MXB	no dre	P=1.	17.6mg n.s.s.	45/52	44/52	44/52		
liv MXB	168.mg *	P<.5	39.0mg n.s.s.	6/52	6/52	10/52		liv:hpa,hpc,nnd.
5853 R m f34 gav 24m25 TR269 :				0	10.5mg	21.0mg		
MXB MXB	33.2mg *	P<.0005	19.3mg 85.7mg	2/52	7/52	19/52		for:sqp; liv:nnd; sto:sqc,sqp. C
MXA MXA	64.1mg /	P<.0005 c	32.9mg 217.mg	1/52	1/52	13/52		for:sqp; sto:sqc,sqp.
liv MXA	68.0mg *	P<.01	32.9mg 4.91gm	1/52	6/52	8/52		liv:hpc,nnd. S
MXA sqp	97.0mg *	P<.006 c	43.9mg 1.16gm	1/52	1/52	9/52		for:sqp; sto:sqp.
liv nnd	76.0mg *	P<.02 c	35.1mg n.s.s.	1/52	6/52	7/52		
sto sqc	213.mg *	P<.02 c	73.6mg n.s.s.	0/52	0/52	4/52		
TBA MXB	no dre	P=1.	17.1mg n.s.s.	44/52	39/52	41/52		
liv MXB	68.0mg *	P<.01	32.9mg 4.91gm	1/52	6/52	8/52		liv:hpa,hpc,nnd.
TELONE II, TECHNICAL GRADE (WITHOUT EPICHLOROHYDRIN) (1,3-dichloropropene) 542-75-6								
5854 M f b6c inh 52w52 2458m				0	7.13mg	28.5mg	85.6mg	Lomax;faat,12,418-431;1989/pers.comm.
lun tum k	no dre	P=1.	- 2.76mg n.s.s.	0/10	0/10	0/10	0/10	
5855 M f b6c inh 24m24 2458n				0	7.13mg	28.5mg	85.6mg	
pit ade	19.0mg Z	P<.02	- 8.35mg n.s.s.	6/50	16/50	(11/50	7/50)	
liv mix	1.81gm *	P<.8	- 206.mg n.s.s.	10/50	7/50	9/50	10/50	
lun a/a	no dre	P=1.	- 384.mg n.s.s.	4/50	3/50	5/50	3/50	
mln lys	no dre	P=1.	- 294.mg n.s.s.	3/50	11/50	5/50	6/50	
tba mix	no dre	P=1.	- 96.6mg n.s.s.	39/50	40/50	36/50	36/50	
5856 M f b6c eat 52w52 2628m				0	2.50mg	25.0mg	50.0mg	Stebbins;rtxp,32,1-13;2000
sto tum ek	no dre	P=1.	- 1.12mg n.s.s.	0/10	0/10	0/10	0/10	
5857 M f b6c eat 24m24 2628n				0	2.50mg	25.0mg	50.0mg	
lun a/a e	no dre	P=1.	- 217.mg n.s.s.	3/50	8/50	4/50	5/50	
liv hpc e	no dre	P=1.	- 474.mg n.s.s.	0/50	1/50	1/50	0/50	
liv hpa e	no dre	P=1.	- 566.mg n.s.s.	2/50	5/50	0/50	1/50	
lun a/c e	no dre	P=1.	- 696.mg n.s.s.	0/50	1/50	0/50	0/50	

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
5858 M m b6c inh 52w52 2458m	0	5.95mg	23.8mg	71.3mg	Lomax;faat,12,418-431;1989/pers.comm.
lun tum k no dre P=1. - 2.30mg n.s.s.	0/10	0/10	0/10	0/10	
5859 M m b6c inh 24m24 2458n	0	5.95mg	23.8mg	71.3mg	
lun a/a 118.mg * P<.0005 + 62.9mg 426.mg	9/50	6/50	13/50	22/50	
lcg cye 82.2mg Z P<.02 37.4mg 19.8gm	1/50	6/50	9/50	(4/50)	
liv mix no dre P=1. 281.mg n.s.s.	25/50	22/50	16/50	14/50	
tba mix 229.mg * P<.5 48.3mg n.s.s.	32/50	34/50	35/50	36/50	
5860 M m b6c eat 52w52 2628m	0	2.50mg	25.0mg	50.0mg	Stebbins;rtxp,32,1-13;2000
sto tum ek no dre P=1. - 1.12mg n.s.s.	0/10	0/10	0/10	0/10	
5861 M m b6c eat 24m24 2628n	0	2.50mg	25.0mg	50.0mg	
liv hpa e 78.2mg Z P<.04 - 30.6mg n.s.s.	7/50	10/50	16/50	(6/50)	
lun a/a e 368.mg * P<.3 - 101.mg n.s.s.	5/50	10/50	9/50	11/50	
liv hpc e no dre P=1. - 451.mg n.s.s.	6/50	6/50	2/50	2/50	
lun a/c e no dre P=1. - 643.mg n.s.s.	3/50	4/50	1/50	0/50	
5862 R f f34 inh 52w52 2458m	0	1.70mg	6.79mg	20.4mg	Lomax;faat,12,418-431;1989/pers.comm.
tba tum k no dre P=1. - .656mg n.s.s.	0/10	0/10	0/10	0/10	
5863 R f f34 inh 24m24 2458n	0	1.70mg	6.79mg	20.4mg	
liv hpa 1.59gm * P<.7 - 142.mg n.s.s.	1/50	0/50	1/50	1/50	
tba mix no dre P=1. - 19.6mg n.s.s.	45/50	46/50	43/50	41/50	
5864 R f f34 eat 52w52 2628m	0	2.50mg	12.5mg	25.0mg	Stebbins;rtxp,32,1-13;2000
sto tum ek no dre P=1. - .991mg n.s.s.	0/10	0/10	0/10	0/10	
5865 R f f34 eat 24m24 2628n	0	2.50mg	12.5mg	25.0mg	
liv hpa e 334.mg * P<.007 115.mg 5.12gm	0/50	0/50	0/50	4/50	
ute esp e 61.4mg * P<.02 27.6mg n.s.s.	12/50	13/50	10/50	24/50	
5866 R m f34 inh 52w52 2458m	0	1.19mg	4.76mg	14.3mg	Lomax;faat,12,418-431;1989/pers.comm.
tba tum k no dre P=1. - .459mg n.s.s.	0/10	0/10	0/10	0/10	
5867 R m f34 inh 24m24 2458n	0	1.19mg	4.76mg	14.3mg	
liv hpa no dre P=1. - 138.mg n.s.s.	3/50	3/50	3/50	0/50	
tba mix no dre P=1. - 3.47mg n.s.s.	49/50	48/50	50/50	48/50	
5868 R m f34 eat 52w52 2628m	0	2.50mg	12.5mg	25.0mg	Stebbins;rtxp,32,1-13;2000
sto tum ek no dre P=1. - .991mg n.s.s.	0/10	0/10	0/10	0/10	
5869 R m f34 eat 24m24 2628n	0	2.50mg	12.5mg	25.0mg	
liv hpa e 100.mg * P<.003 + 48.8mg 633.mg	2/50	1/50	6/50	9/50	
liv hpc e 1.36gm * P<.2 222.mg n.s.s.	0/50	0/50	0/50	1/50	
TEMAZEPAM, PHARMACEUTICAL GRADE 846-50-4					
5870 M f cd1 eat 78w78 1994	0	10.0mg	80.0mg	160.mg	Robison;faat,4,394-405;1984
liv hpa e 1.86gm * P<.03 - 658.mg n.s.s.	0/100	1/100	1/100	4/100	
lun bro e 9.61gm * P<.2 - 1.56gm n.s.s.	0/100	0/100	0/100	1/100	
lun alc e no dre P=1. - 670.mg n.s.s.	11/100	12/100	10/100	9/100	
tba tum e no dre P=1. - 546.mg n.s.s.	30/100	31/100	16/100	25/100	
5871 M m cd1 eat 78w78 1994	0	10.0mg	80.0mg	160.mg	
liv hpa e 2.57gm * P<.4 - 561.mg n.s.s.	8/100	4/99	2/100	10/100	
lun alc e no dre P=1. - 1.76gm n.s.s.	24/100	11/99	3/100	5/100	
tba tum e no dre P=1. - 970.mg n.s.s.	39/100	21/99	13/100	17/100	
TERBUTALINE 23031-25-6					
5872 R f cdr eat 24m24 1734	0	8.42mg	84.2mg		Jack;txcy,27,315-320;1983
meo ley erv 410.mg * P<.0005 + 186.mg 1.33gm	0/105	1/55	7/55		
3,3',4,4'-TETRAAMINOBIPHENYL.4HCl (3,3'-diaminobenzidine.4HCl) 7411-49-6					
5873 M f chi eat 77w98 381 :	0	468.mg	851.mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
lun mix 1.03gm * P<.07 - 377.mg n.s.s.	4/17	6/19	4/17		
liv mix 1.69gm * P<.03 - 526.mg n.s.s.	0/17	1/19	3/17		
tba mix 599.mg * P<.05 - 231.mg n.s.s.	11/17	9/19	11/17		
5874 M m chi eat 77w94 381 :	0	432.mg	785.mg		
lun mix 288.mg \ P<.003 + 117.mg 1.52gm	1/19	6/18	(7/22)		
liv mix 4.17gm * P<.7 - 321.mg n.s.s.	1/19	1/18	1/22		
tba mix 224.mg \ P<.003 95.1mg 1.50gm	4/19	9/18	(13/22)		
5875 R m cdr eat 18m25 381 :	0	120.mg	240.mg		
liv mix 259.mg * P<.02 89.7mg n.s.s.	0/16	1/16	3/15		
tba mix 200.mg * P<.2 63.4mg n.s.s.	11/16	8/16	12/15		
5876 R m cdr eat 18m25 381 : pool	0	120.mg	240.mg		
liv hpt 395.mg * P<.02 + 115.mg n.s.s.	2/111	1/16	3/15		
2,3,5,6-TETRACHLORO-4-NITROANISOLE 2438-88-2					
5877 M f b6c eat 24m24 TR114 :	0	7.70mg	15.5mg		
TBA MXB 61.7mg * P<.6 - 11.8mg n.s.s.	34/55	37/55	38/55		
liv MXB no dre P=1. 83.1mg n.s.s.	11/55	3/55	5/55		liv:hpa,hpc,nnd.
lun MXB 1.77gm * P<1. 43.3mg n.s.s.	4/55	8/55	4/55		lun:a/a,a/c.
5878 M m b6c eat 24m24 TR114 :	0	7.20mg	14.3mg		
TBA MXB no dre P=1. - 16.9mg n.s.s.	43/55	38/55	36/55		
liv MXB no dre P=1. 17.9mg n.s.s.	28/55	16/55	(10/55)		liv:hpa,hpc,nnd.
lun MXB 215.mg * P<.8 22.9mg n.s.s.	12/55	17/55	13/55		lun:a/a,a/c.
5879 R f f34 eat 24m24 TR114 :	0	3.00mg	5.90mg		
ute esp # 19.1mg * P<.05 - 8.30mg n.s.s.	2/50	9/50	8/50		S
liv MXA 45.8mg * P<.02 17.4mg n.s.s.	0/50	1/50	4/50		liv:hpc,nnd. S
TBA MXB 106.mg * P<.9 5.10mg n.s.s.	27/50	34/50	28/50		
liv MXB 45.8mg * P<.02 17.4mg n.s.s.	0/50	1/50	4/50		liv:hpa,hpc,nnd.
5880 R m f34 eat 24m24 TR114 :	0	2.40mg	4.70mg	4.60mg	
liv MXA # 20.0mg * P<.03 - 9.41mg n.s.s.	0/50	5/50	1/25	3/24	liv:hpc,nnd. S
TBA MXB no dre P=1. 6.57mg n.s.s.	28/50	27/50	12/25	14/24	
liv MXB 20.0mg * P<.03 9.41mg n.s.s.	0/50	5/50	1/25	3/24	liv:hpa,hpc,nnd.
2,2',5,5'-TETRACHLOROBENZIDINE 15721-02-5					
5881 M f ddx eat 24m24 558	0	130.mg			Yoshimoto;jkmj,25,123-128;1978
--- mly e 109.mg P<.0005 57.0mg 240.mg	0/20	14/25			
tba mal e 87.2mg P<.0005 47.0mg 184.mg	0/20	16/25			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
5882 R f wis eat 24m24 558					0	150.mg					
liv hpt e	735.mg	P<.2		222.mg n.s.s.	0/10	3/23					
ubl tcc e	2.31gm	P<.4		376.mg n.s.s.	0/10	1/23					
5883 R m wis eat 24m24 558					0	120.mg					
ubl tcc e	561.mg	P<.2		169.mg n.s.s.	0/11	3/22					
liv tum e	no dre	P=1.		544.mg n.s.s.	0/11	0/22					
2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN (TCDD, dioxin) 1746-01-6											
5884 M f b6c gav 24m24 TR209 :					0	5.55ng	27.8ng	278.ng			
MXB MXB	526.ng Z	P<.002		236.ng 2.99ug	3/75	9/50	7/50	15/50			liv:hpa,hpc; thy:fca. C
--- lhc	705.ng *	P<.008		294.ng 19.3ug	9/75	4/50	8/50	14/50			S
liv MXA	756.ng *	P<.008	c	303.ng 20.5ug	3/75	6/50	6/50	11/50			liv:hpa,hpc.
--- lym	682.ng *	P<.04		262.ng n.s.s.	18/75	11/50	13/50	20/50			S
--- MXA	709.ng *	P<.05		266.ng n.s.s.	18/75	12/50	13/50	20/50			---:leu,lym. S
liv hpc	1.30ug *	P<.02	c	466.ng n.s.s.	1/75	2/50	2/50	6/50			
thy fca	1.59ug *	P<.03	c	523.ng n.s.s.	0/75	3/50	1/50	5/50			
sub fbs	1.72ug *	P<.02		594.ng n.s.s.	1/75	1/50	1/50	5/50			S
TBA MXB	494.ng *	P<.06		184.ng n.s.s.	36/75	25/50	28/50	34/50			
liv MXB	756.ng *	P<.008		303.ng 20.5ug	3/75	6/50	6/50	11/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		956.ng n.s.s.	2/75	3/50	4/50	2/50			lun:a/a,a/c.
5885 M m b6c gav 24m24 TR209 :					0	1.39ng	6.94ng	69.4ng			
liv MXA	86.8ng *	P<.003	c	40.6ng 613.ng	15/75	12/50	13/50	27/50			liv:hpa,hpc.
liv hpc	147.ng *	P<.02	c	59.8ng n.s.s.	8/75	9/50	8/50	17/50			
lun MXA	198.ng *	P<.02		78.4ng n.s.s.	10/75	2/50	4/50	13/50			lun:a/a,a/c. S
lun a/a	219.ng *	P<.02		84.1ng n.s.s.	7/75	2/50	4/50	11/50			S
liv hpa	271.ng *	P<.07	c	90.3ng n.s.s.	7/75	3/50	5/50	10/50			
TBA MXB	141.ng *	P<.2		43.3ng n.s.s.	40/75	25/50	27/50	37/50			
liv MXB	86.8ng *	P<.003		40.6ng 613.ng	15/75	12/50	13/50	27/50			liv:hpa,hpc,nnd.
lun MXB	198.ng *	P<.02		78.4ng n.s.s.	10/75	2/50	4/50	13/50			lun:a/a,a/c.
5886 M m shr gav 12m24 383a					0	.502ng	50.2ng	502.ng			Toth;natu,278,548-549;1979
lun tum e	no dre	P=1.	-	105.ng n.s.s.	15/38	27/44	18/44	(11/43)			
liv mix e	no dre	P=1.	+	890.ng n.s.s.	7/38	13/44	21/44	13/43			
tba mix e	no dre	P=1.		899.ng n.s.s.	27/38	39/44	36/44	27/43			
5887 R f osm gav 24m24 TR209 :					0	1.39ng	6.94ng	69.4ng			
liv MXA	127.ng *	P<.0005	c	60.1ng 520.ng	5/75	1/50	3/50	14/50			liv:hpc,nnd.
liv nnd	154.ng *	P<.003	c	67.7ng 1.05ug	5/75	1/50	3/50	12/50			
TBA MXB	1.58ug *	P<1.		52.1ng n.s.s.	54/75	40/50	36/50	43/50			
liv MXB	127.ng *	P<.0005		60.1ng 520.ng	5/75	1/50	3/50	14/50			liv:hpa,hpc,nnd.
5888 R m osm gav 24m24 TR209 :					0	1.39ng	6.94ng	69.4ng			
thy MXA	101.ng *	P<.002	c	41.9ng 664.ng	1/75	5/50	6/50	11/50			thy:fca,fcc.
thy fca	113.ng *	P<.003	c	45.9ng 875.ng	1/75	5/50	4/50	10/50			
liv nnd	391.ng *	P<.004		110.ng 3.83ug	0/75	0/50	0/50	3/50			S
liv MXA	391.ng *	P<.004		110.ng 3.83ug	0/75	0/50	0/50	3/50			liv:hpc,nnd. S
adr coa	12.1ng Z	P<.04		4.62ng n.s.s.	6/75	9/50	12/50	(9/50)			S
sub fib	169.ng *	P<.02		60.1ng n.s.s.	3/75	1/50	3/50	7/50			S
TBA MXB	133.ng *	P<.3		33.8ng n.s.s.	40/75	29/50	33/50	32/50			
liv MXB	391.ng *	P<.004		110.ng 3.83ug	0/75	0/50	0/50	3/50			liv:hpa,hpc,nnd.
5889 R m sda eat 78w95 377 :					0	.004ng	.117ng	1.17ng	11.7ng	51.2ng	248.ng Van Miller;cmsp,6,625-632; 1977/pers.comm.
lun sqa	79.6ng *	P<.0005		17.5ng 545.ng	0/9	0/9	0/10	0/9	0/10	0/10	4/10
liv mix	83.1ng *	P<.0005		26.4ng 360.ng	0/9	0/9	0/10	0/9	0/10	1/10	4/10
5890 R f sss eat 24m24 366 :					0	1.00ng	10.0ng	100.ng			Kociba;txap,46,279-303;1978/pers.comm.
liv hph	6.67ng Z	P<.0005	+	3.26ng 22.5ng	8/86	3/50	18/50	(23/50)			
liv mix	14.9ng Z	P<.0005	+	8.86ng 27.8ng	9/86	3/50	18/50	34/50			
liv hpc	65.1ng *	P<.0005	+	28.9ng 173.ng	1/86	0/50	2/50	11/50			
lun sqk	192.ng *	P<.0005	+	66.7ng 559.ng	0/86	0/50	0/50	7/50			
hnt sqs	205.ng *	P<.0005	+	73.9ng 972.ng	0/86	0/50	1/50	4/50			
5891 R m sss eat 24m24 366 :					0	1.00ng	10.0ng	100.ng			
adr coa	217.ng *	P<.002		81.1ng 1.27ug	0/86	0/50	2/50	5/50			
hnt sqs	393.ng *	P<.002	+	126.ng 2.05ug	0/86	0/50	0/50	4/50			
ton sqs	628.ng *	P<.04	+	161.ng n.s.s.	0/86	1/50	1/50	3/50			
2,4,5,4'-TETRACHLORODIPHENYL SULFONE (tetrafidon) 116-29-0											
5892 M f b6a orl 76w76 1282					0	36.4mg					Innes;ntis,1968/1969
liv hpt evx	233.mg	P<.3	-	37.9mg n.s.s.	0/17	1/18					
lun ade evx	no dre	P=1.	-	43.3mg n.s.s.	1/17	1/18					
tba mix evx	233.mg	P<.7	-	26.1mg n.s.s.	2/17	3/18					
5893 M m b6a orl 76w76 1282					0	33.9mg					
lun ade evx	no dre	P=1.	-	31.7mg n.s.s.	2/18	2/18					
liv hpt evx	no dre	P=1.	-	67.2mg n.s.s.	1/18	0/18					
tba mix evx	no dre	P=1.	-	35.1mg n.s.s.	3/18	2/18					
5894 M f b6c orl 76w76 1282					0	36.4mg					
liv hpt evx	no dre	P=1.	-	68.1mg n.s.s.	0/16	0/17					
lun mix evx	no dre	P=1.	-	68.1mg n.s.s.	0/16	0/17					
tba mix evx	220.mg	P<.3	-	35.8mg n.s.s.	0/16	1/17					
5895 M m b6c orl 76w76 1282					0	33.9mg					
liv hpt evx	46.2mg	P<.02	-	15.9mg n.s.s.	0/16	4/17					
lun ade evx	205.mg	P<.3	-	33.3mg n.s.s.	0/16	1/17					
tba mix evx	35.6mg	P<.007	-	13.4mg 481.mg	0/16	5/17					
1,1,1,2-TETRACHLOROETHANE 630-20-6											
5896 M f b6c gav 24m24 TR237 :					0	177.mg	357.mg				
liv MXA as	175.mg /	P<.0005	c	108.mg 316.mg	5/50	13/50	30/50				liv:hpa,hpc.
liv hpa as	254.mg /	P<.0005	c	145.mg 517.mg	4/50	8/50	24/50				
liv hpc as	640.mg *	P<.0005	c	275.mg 2.68gm	1/50	5/50	6/50				
TBA MXB as	110.mg /	P<.0005		66.5mg 225.mg	25/50	31/50	30/50				
liv MXB as	175.mg /	P<.0005		108.mg 316.mg	5/50	13/50	30/50				liv:hpa,hpc,nnd.
lun MXB as	1.82gm *	P<.07		447.mg n.s.s.	0/50	2/50	0/50				lun:a/a,a/c.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
5897 M m b6c gav 24m24 TR237 :				0	177.mg	357.mg			
liv MXA as	124.mg / P<.0005		75.3mg 255.mg	18/50	27/50	27/50		liv:hpa,hpc.	S
liv hpa as	190.mg / P<.0005	c	112.mg 391.mg	6/50	14/50	21/50			
TBA MXB as	97.9mg / P<.0005		58.4mg 215.mg	28/50	36/50	27/50			
liv MXB as	124.mg / P<.0005		75.3mg 255.mg	18/50	27/50	27/50		liv:hpa,hpc,nnd.	
lun MXB as	1.33gm / P<.3		334.mg n.s.s.	6/50	5/50	3/50		lun:a/a,a/c.	
5898 R f f34 gav 24m24 TR237 :				0	88.4mg	177.mg			
mgl fba s#	170.mg \ P<.04	-	68.8mg n.s.s.	6/50	15/50	(7/50)			S
TBA MXB s	no dre P=1.		194.mg n.s.s.	33/50	31/50	21/50			
liv MXB s	3.98gm * P<.5		601.mg n.s.s.	1/50	0/50	2/50		liv:hpa,hpc,nnd.	
5899 R m f34 gav 24m24 TR237 :				0	88.4mg	177.mg			
MXA MXA s#	842.mg * P<.03	-	337.mg n.s.s.	0/50	3/50	3/50		mul:msm; per:men; tnv:men.	S
liv MXA s	1.13gm * P<.04		385.mg n.s.s.	0/50	1/50	3/50		liv:hpa,hpc,nnd.	S
TBA MXB s	464.mg * P<.4		115.mg n.s.s.	25/50	19/50	26/50			
liv MXB s	1.13gm * P<.04		385.mg n.s.s.	0/50	1/50	3/50		liv:hpa,hpc,nnd.	
1,1,2,2-TETRACHLOROETHANE 79-34-5									
5900 M f b6c gav 78w92 TR27 :				0	87.7mg	175.mg			
liv hpc v	35.4mg / P<.0005	c	25.9mg 50.2mg	0/20	30/50	43/50			
TBA MXB v	37.2mg * P<.0005		26.1mg 61.6mg	2/20	33/50	43/50			
liv MXB v	35.4mg / P<.0005		25.9mg 50.2mg	0/20	30/50	43/50		liv:hpa,hpc,nnd.	
lun MXB v	1.91gm * P<.3		449.mg n.s.s.	0/20	1/50	1/50		lun:a/a,a/c.	
5901 M f b6c gav 78w91 TR27 : pool				0	87.7mg	175.mg			
liv hpc v	35.8mg * P<.0005	c	26.2mg 50.3mg	0/40	30/50	43/50			
5902 M m b6c gav 78w92 TR27 :				0	87.7mg	175.mg			
liv hpc av	41.6mg / P<.0005	c	27.4mg 66.8mg	1/20	13/50	44/50			
TBA MXB av	38.7mg / P<.0005		25.2mg 66.6mg	4/20	17/50	45/50			
liv MXB av	41.6mg / P<.0005		27.4mg 66.8mg	1/20	13/50	44/50		liv:hpa,hpc,nnd.	
lun MXB av	895.mg * P<.5		162.mg n.s.s.	1/20	2/50	2/50		lun:a/a,a/c.	
5903 M m b6c gav 78w91 TR27 : pool				0	87.7mg	175.mg			
liv hpc av	45.4mg / P<.0005	c	29.7mg 75.1mg	3/40	13/50	44/50			
5904 R f osm gav 18m26 TR27 :				0	21.9mg	39.0mg			
TBA MXB adv	84.2mg * P<.5	-	20.7mg n.s.s.	12/20	28/50	23/50			
liv MXB adv	no dre P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.	
5905 R m osm gav 18m26 TR27 :				0	31.6mg	55.2mg			
TBA MXB adv	no dre P=1.	-	60.2mg n.s.s.	11/20	17/50	20/50			
liv MXB adv	624.mg * P<.2		185.mg n.s.s.	0/20	0/50	3/50		liv:hpa,hpc,nnd.	
TETRACHLOROETHYLENE (perchloroethylene) 127-18-4									
5906 M f b6c gav 78w90 TR13 :				0	240.mg	478.mg			
liv hpc v	75.6mg * P<.0005	c	47.1mg 130.mg	0/20	19/50	19/50			
TBA MXB v	98.1mg * P<.0005		54.1mg 259.mg	5/20	19/50	19/50			
liv MXB v	75.6mg * P<.0005		47.1mg 130.mg	0/20	19/50	19/50		liv:hpa,hpc,nnd.	
lun MXB v	2.95gm * P<.2		480.mg n.s.s.	0/20	0/50	1/50		lun:a/a,a/c.	
5907 M f b6c inh 24m24 TR311 :				0	211.mg	422.mg			
liv MXA	188.mg / P<.0005		127.mg 314.mg	4/50	17/50	38/50		liv:hpa,hpc.	S
liv hpc	200.mg / P<.0005	c	137.mg 313.mg	1/50	13/50	36/50			
TBA MXB	211.mg * P<.0005		119.mg 712.mg	27/50	35/50	43/50			
liv MXB	188.mg / P<.0005		127.mg 314.mg	4/50	17/50	38/50		liv:hpa,hpc,nnd.	
lun MXB	no dre P=1.		1.20gm n.s.s.	6/50	3/50	3/50		lun:a/a,a/c.	
5908 M m b6c gav 78w90 TR13 :				0	332.mg	663.mg			
liv hpc v	123.mg * P<.0005	c	79.5mg 260.mg	2/20	32/50	27/50			
TBA MXB v	160.mg * P<.002		90.1mg 622.mg	6/20	33/50	27/50			
liv MXB v	123.mg * P<.0005		79.5mg 260.mg	2/20	32/50	27/50		liv:hpa,hpc,nnd.	
lun MXB v	no dre P=1.		n.s.s. n.s.s.	0/20	3/50	0/50		lun:a/a,a/c.	
5909 M m b6c inh 24m24 TR311 :				0	176.mg	352.mg			
liv hpc	162.mg \ P<.0005		90.4mg 407.mg	7/50	25/50	(26/50)			S
liv MXA	190.mg * P<.0005	c	115.mg 459.mg	17/50	31/50	41/50		liv:hpa,hpc.	
liv hpa	668.mg * P<.04		283.mg n.s.s.	12/50	8/50	19/50			S
MXA mno	681.mg \ P<.05		234.mg n.s.s.	3/50	7/50	(3/50)		mln:mno; mul:mno; spl:mno; sub:mno.	S
TBA MXB	225.mg * P<.003		119.mg 1.30gm	29/50	38/50	43/50			
liv MXB	190.mg * P<.0005		115.mg 459.mg	17/50	31/50	41/50		liv:hpa,hpc,nnd.	
lun MXB	6.05gm * P<.8		706.mg n.s.s.	6/50	6/50	5/50		lun:a/a,a/c.	
5910 M f bdj inh 24m24 2378				0	21.2mg	106.mg	531.mg	Nagano;apor,741-746;1998/pers.comm.	
liv mix e	396.mg * P<.0005	+	259.mg 668.mg	3/50	3/50	7/50	33/50		
liv hpa e	560.mg * P<.0005	+	346.mg 1.06gm	3/50	3/50	7/50	26/50		
liv hpc e	1.42gm * P<.0005	+	764.mg 3.10gm	0/50	0/50	0/50	14/50		
5911 M m bdj inh 24m24 2378				0	17.7mg	88.4mg	442.mg		
liv mix e	257.mg * P<.0005	+	152.mg 542.mg	13/50	21/50	19/50	40/50		
liv hpc e	555.mg * P<.0005	+	308.mg 1.46gm	7/50	8/50	12/50	25/50		
liv hpa e	602.mg * P<.0005	+	325.mg 1.73gm	7/50	13/50	8/50	26/50		
hag ade e	2.33gm * P<.02	+	927.mg 1.67kg	2/50	2/50	2/50	8/50		
5912 R f osm gav 18m26 TR13 :				0	240.mg	480.mg			
TBA MXB dsv	1.71gm * P<.7	i	263.mg n.s.s.	7/20	17/50	15/50			
liv MXB dsv	no dre P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.	
5913 R f f34 inh 24m24 TR311 :				0	101.mg	201.mg			
MXA mnl	287.mg * P<.2	p	110.mg n.s.s.	18/50	30/50	29/50		mul:mnl; spl:mnl.	
TBA MXB	869.mg * P<.8		101.mg n.s.s.	42/50	45/50	45/50			
liv MXB	no dre P=1.		706.mg n.s.s.	2/50	0/50	2/50		liv:hpa,hpc,nnd.	
5914 R m osm gav 18m26 TR13 :				0	238.mg	477.mg			
TBA MXB dsv	3.02gm * P<.9	i	239.mg n.s.s.	5/20	5/50	5/50			
liv MXB dsv	no dre P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.	
5915 R m f34 inh 24m24 TR311 :				0	70.4mg	141.mg			
MXB MXB	90.8mg * P<.007		44.4mg 1.34gm	28/50	37/50	39/50		kid:tla,uac; liv:mnl; mul:mnl; spl:mnl.	C
tes ict	68.6mg * P<.02		31.7mg n.s.s.	35/50	39/50	41/50			S
MXA mnl	101.mg * P<.02	c	47.4mg n.s.s.	28/50	37/50	37/50		liv:mnl; mul:mnl; spl:mnl.	
kid MXA	504.mg * P<.07	c	173.mg n.s.s.	1/50	3/50	4/50		kid:tla,uac.	
TBA MXB	77.7mg * P<.04		33.7mg n.s.s.	46/50	48/50	50/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
liv MXB		368.mg *	P<.2	112.mg n.s.s.	4/50	7/50	5/50				liv:hpa,hpc,nnd.
5916 R f f3d inh 24m24 2378					0	25.3mg	101.mg	303.mg			Nagano;apor,741-746;1998/pers.comm.
spl mnl e		1.08gm *	P<.2 +	356.mg n.s.s.	10/50	17/50	16/50	19/50			
liv hpa e		no dre	P=1.	2.42gm n.s.s.	0/50	0/50	1/50	0/50			
5917 R m f3d inh 24m24 2378					0	17.7mg	70.7mg	212.mg			
spl mnl e		257.mg *	P<.0005 +	136.mg 1.01gm	11/50	14/50	22/50	27/50			
liv hpa e		28.3gm *	P<.9	1.50gm n.s.s.	3/50	0/50	0/50	2/50			
TETRACHLORVINPHOS 961-11-5											
5918 M f b6c eat 80w92 TR33 :					0	904.mg	1.81gm				
liv MXA u		905.mg \	P<.02 a	528.mg n.s.s.	0/9	19/50	(11/49)				liv:hpc,nnd.
TBA MXB		7.88gm *	P<.8	1.04gm n.s.s.	1/9	25/50	19/49				
liv MXB		905.mg \	P<.02	528.mg n.s.s.	0/9	19/50	(11/49)				liv:hpa,hpc,nnd.
lun MXB		7.79gm *	P<.5	2.87gm n.s.s.	0/9	5/50	5/49				lun:a/a,a/c.
5919 M f b6c eat 80w90 TR33 : pool					0	904.mg	1.81gm				
liv MXA u		1.07gm \	P<.002 a	558.mg 4.20gm	3/49	19/50	(11/49)				liv:hpc,nnd.
liv nnd u		1.38gm \	P<.0005 a	705.mg 4.79gm	1/49	14/50	(9/49)				
5920 M f b6c eat 24m24 1696m					0	2.08gm					Parker;faat,5,840-854;1985
liv mix er		10.2gm	P<.0005	4.17gm 36.9gm	0/99	6/47					
liv hpc er		12.4gm	P<.002	4.72gm 54.7gm	0/99	5/47					
kid mix er		32.1gm	P<.04	7.91gm n.s.s.	0/99	2/47					
liv hpa er		65.0gm	P<.2	10.6gm n.s.s.	0/99	1/47					
5921 M f b6c eat 24m24 1696n					0	2.28mg	8.32mg	41.6mg	208.mg	1.04gm 2.08gm	
liv mix er		6.33gm *	P<.0005	4.04gm 15.4gm	0/99	1/48	0/49	0/50	4/49	7/49 7/50	
liv hpc er		8.99gm *	P<.0005	4.63gm 25.8gm	0/99	0/48	0/49	0/50	3/49	5/49 4/50	
liv hpa er		21.4gm *	P<.007	12.2gm 428.gm	0/99	1/48	0/49	0/50	1/49	2/49 3/50	
kid tum er		no dre	P=1.	16.5mg n.s.s.	0/99	0/48	0/49	0/50	0/49	0/49 0/50	
5922 M m b6c eat 80w92 TR33 :					0	835.mg	1.67gm				
liv MXA		228.mg \	P<.0005 c	158.mg 432.mg	0/10	47/50	(42/50)				liv:hpc,nnd.
liv hpc		466.mg *	P<.002 c	348.mg 1.93gm	0/10	36/50	40/50				
TBA MXB		295.mg \	P<.007	175.mg 3.98gm	2/10	47/50	(42/50)				
liv MXB		228.mg \	P<.0005	158.mg 432.mg	0/10	47/50	(42/50)				liv:hpa,hpc,nnd.
lun MXB		401.gm *	P<1.	3.40gm n.s.s.	0/10	4/50	2/50				lun:a/a,a/c.
5923 M m b6c eat 80w90 TR33 : pool					0	835.mg	1.67gm				
liv MXA		280.mg \	P<.0005 c	176.mg 541.mg	8/50	47/50	(42/50)				liv:hpc,nnd.
liv hpc		534.mg *	P<.0005 c	371.mg 905.mg	5/50	36/50	40/50				
liv nnd		1.77gm \	P<.02 a	737.mg n.s.s.	3/50	11/50	(2/50)				
5924 M m b6c eat 24m24 1696m					0	1.92gm					Parker;faat,5,840-854;1985
liv mix er		1.15gm	P<.0005	660.mg 2.42gm	26/99	35/46					
liv hpc er		1.53gm	P<.0005	855.mg 3.63gm	24/99	31/46					
kid mix er		4.42gm	P<.0005	2.23gm 11.3gm	1/99	12/46					
kid tuc er		5.26gm	P<.0005	2.56gm 13.5gm	0/99	10/46					
liv hpa er		18.3gm	P<.08	5.26gm n.s.s.	2/99	4/46					
kid tua er		37.6gm	P<.3	7.50gm n.s.s.	1/99	2/46					
5925 R f osm eat 19m26 TR33 :					0	153.mg	306.mg				
pit cra v#		1.58gm *	P<.03 -	743.mg n.s.s.	0/10	1/50	8/50				s
TBA MXB v		no dre	P=1.	454.mg n.s.s.	7/10	23/50	25/50				
liv MXB v		no dre	P=1.	2.01gm n.s.s.	0/10	2/50	0/50				liv:hpa,hpc,nnd.
5926 R f osm eat 19m25 TR33 : pool					0	153.mg	306.mg				
thy cca uv		1.92gm *	P<.05 a	775.mg n.s.s.	1/55	2/50	7/50				
adr coa uv		2.28gm *	P<.4 a	667.mg n.s.s.	2/55	7/50	6/50				
5927 R m osm eat 19m26 TR33 :					0	122.mg	245.mg				
TBA MXB v		no dre	P=1. -	226.mg n.s.s.	6/10	24/50	18/50				
liv MXB v		no dre	P=1.	1.10gm n.s.s.	0/10	2/50	0/50				liv:hpa,hpc,nnd.
TETRACYCLINE.HCl 64-75-5											
5928 M f b6c eat 24m24 TR344 :					0	1.61gm	3.22gm				
TBA MXB		no dre	P=1. -	5.96gm n.s.s.	35/50	19/50	26/50				
liv MXB		no dre	P=1.	36.7gm n.s.s.	10/50	0/50	0/50				liv:hpa,hpc,nnd.
lun MXB		37.2gm *	P<.4	8.64gm n.s.s.	4/50	1/50	7/50				lun:a/a,a/c.
5929 M m b6c eat 24m24 TR344 :					0	1.49gm	2.97gm				
TBA MXB		no dre	P=1. -	3.44gm n.s.s.	31/50	23/50	(21/50)				
liv MXB		no dre	P=1.	8.76gm n.s.s.	12/50	12/50	10/50				liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	12.9gm n.s.s.	6/50	6/50	4/50				lun:a/a,a/c.
5930 R f f34 eat 24m24 TR344 :					0	619.mg	1.24gm				
TBA MXB		no dre	P=1. -	712.mg n.s.s.	46/50	44/50	(41/50)				
liv MXB		no dre	P=1.	15.0gm n.s.s.	1/50	0/50	0/50				liv:hpa,hpc,nnd.
5931 R m f34 eat 24m24 TR344 :					0	495.mg	990.mg				
TBA MXB		no dre	P=1. -	722.mg n.s.s.	46/50	49/50	45/50				
liv MXB		6.09gm *	P<.06	2.28gm n.s.s.	0/50	2/50	3/50				liv:hpa,hpc,nnd.
TETRAETHYLTHIURAM DISULFIDE (ethyl tuads) 97-77-8											
5932 M f b6c eat 25m25 TR166 :					0	13.0mg	65.0mg				
TBA MXB		no dre	P=1. -	99.5mg n.s.s.	8/20	18/50	20/50				
liv MXB		120.mg \	P<.2	36.4mg n.s.s.	0/20	3/50	(0/50)				liv:hpa,hpc,nnd.
lun MXB		323.mg *	P<.2	111.mg n.s.s.	1/20	4/50	9/50				lun:a/a,a/c.
5933 M f b6c orl 76w76 1100					0	44.3mg					Innes;ntis,1968/1969
lun mix evx		138.mg	P<.2	33.8mg n.s.s.	0/16	2/18					
lun ade evx		283.mg	P<.3	46.1mg n.s.s.	0/16	1/18					
lun car evx		283.mg	P<.3	46.1mg n.s.s.	0/16	1/18					
liv hpt evx		283.mg	P<.3	46.1mg n.s.s.	0/16	1/18					
tba mix evx		64.5mg	P<.02	22.2mg n.s.s.	0/16	4/18					
5934 M m b6c eat 25m25 TR166 :					0	60.0mg	240.mg				
TBA MXB		no dre	P=1. -	110.mg n.s.s.	11/20	21/50	(18/50)				
liv MXB		no dre	P=1.	232.mg n.s.s.	5/20	6/50	(4/50)				liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	127.mg n.s.s.	4/20	11/50	(4/50)				lun:a/a,a/c.
5935 M m b6c orl 76w76 1100					0	41.2mg					Innes;ntis,1968/1969
liv hpt evx		23.7mg	P<.0005	10.5mg 75.4mg	0/16	8/17					

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD50 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
lun ade evx 43.2mg P<.007 16.3mg 585.mg	0/16	5/17			
tba mix evx 17.0mg P<.0005 7.99mg 44.6mg	0/16	10/17			
5936 M f b6a orl 76w76 1100	0	44.3mg			
lun ade evx 4.14gm P<1. 46.0mg n.s.s.	1/17	1/16			
liv hpt evx no dre P=1. 77.9mg n.s.s.	0/17	0/16			
tba mix evx 1.94gm P<1. 36.1mg n.s.s.	2/17	2/16			
5937 M m b6a orl 76w76 1100	0	41.2mg			
sub fbs evx 15.4mg P<.0005 7.17mg 40.4mg	0/18	10/16			
liv hpt evx 197.mg P<.5 30.1mg n.s.s.	1/18	2/16			
lun ade evx no dre P=1. 47.2mg n.s.s.	2/18	1/16			
tba mix evx 10.1mg P<.0005 4.45mg 34.4mg	3/18	13/16			
5938 R f f34 eat 25m25 TR166 :	0	15.0mg	30.0mg		
TBA MXB no dre P=1. - 49.6mg n.s.s.	19/20	28/50	33/50		
liv MXB 1.43gm * P<.4 232.mg n.s.s.	0/20	0/50	1/50		liv:hpa,hpc,nnd.
5939 R m f34 eat 25m25 TR166 :	0	12.0mg	24.0mg		
TBA MXB no dre P=1. - 13.2mg n.s.s.	15/20	33/50	(24/50)		
liv MXB no dre P=1. 164.mg n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
5940 R f cdr eat 78w78 1032	0	25.0mg			Wong;txap,63,155-165;1982/Plotnick pers.comm.
mgl mix e 68.9mg P<.04 26.1mg n.s.s.	2/48	8/48			
liv hem e no dre P=1. 139.mg n.s.s.	0/48	0/48			
liv hct e no dre P=1. 139.mg n.s.s.	0/48	0/48			
tba mix e 193.mg P<.6 30.7mg n.s.s.	7/48	9/48			
5941 R f cdr eat 24m24 1962	0	25.0mg			Cheever;faat,14,243-261;1990
liv nnd e 41.1gm P<1. - 153.mg n.s.s.	1/50	1/49			
tba tum e no dre P=1. - 10.0mg n.s.s.	47/50	46/50			
5942 R m cdr eat 78w78 1032	0	20.0mg			Wong;txap,63,155-165;1982/Plotnick pers.comm.
liv hct e 366.mg P<.3 59.6mg n.s.s.	0/48	1/48			
tba mix e no dre P=1. 55.5mg n.s.s.	8/48	4/48			
5943 R m cdr eat 24m24 1962	0	20.0mg			Cheever;faat,14,243-261;1990
liv nnd e 678.mg P<.3 - 110.mg n.s.s.	0/50	1/50			
liv hpc e no dre P=1. - 206.mg n.s.s.	1/50	0/50			
tba tum e no dre P=1. - 34.6mg n.s.s.	42/50	32/50			
TETRAFLUORO-m-PHENYLENEDIAMINE.2HCl 63886-77-1					
5944 M f chi eat 77w94 381 :	0	106.mg	213.mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv mix 6.50gm * P<1. - 221.mg n.s.s.	1/15	2/20	2/15		
lun mix no dre P=1. - 94.8mg n.s.s.	5/15	5/20	(1/15)		
tba mix no dre P=1. 53.6mg n.s.s.	10/15	14/20	(7/15)		
5945 M m chi eat 77w94 381 :	0	103.mg	206.mg		
liv mix 78.3mg * P<.02 42.7mg n.s.s.	1/14	8/18	7/16		
liv hpt 86.3mg * P<.02 + 46.1mg n.s.s.	0/14	7/18	7/16		
lun mix 1.13gm * P<.7 - 160.mg n.s.s.	3/14	2/18	4/16		
tba mix 331.mg * P<.7 51.1mg n.s.s.	7/14	13/18	10/16		
5946 M m chi eat 77w94 381 : pool	0	103.mg	206.mg		
liv hpt 109.mg * P<.0005 + 53.0mg 324.mg	7/99	7/18	7/16		
5947 R m cdr eat 77w98 381 :	0	19.1mg	38.2mg		
liv mix v no dre P=1. - n.s.s. n.s.s.	0/16	0/16	0/15		
tba mix v 14.6mg * P<.003 - 6.81mg 101.mg	10/16	8/16	12/15		
TETRAFLUOROBORATE, SODIUM 13755-29-8					
5948 H f syg gav 70w70 1329	0	3.03mg			Gold;clet,15,289-300;1982
liv cho es no dre P=1. 4.24mg n.s.s.	1/15	0/15			
lun tum es no dre P=1. 4.24mg n.s.s.	0/15	0/15			
5949 H m syg gav 90w90 1329	0	3.03mg			
liv hem es no dre P=1. 7.01mg n.s.s.	1/15	0/15			
lun tum es no dre P=1. 7.01mg n.s.s.	0/15	0/15			
1,1,1,2-TETRAFLUOROETHANE (fluorocarbon 134a, HCFC 134a) 811-97-2					
5950 M f b6c inh 24m24 2417	0	765.mg	4.59gm	23.0gm	Alexander;huet,14,706-714;1995
liv hpa e no dre P=1. - 119.gm n.s.s.	8/120	1/60	6/60	3/60	
lun abt e no dre P=1. - 136.gm n.s.s.	3/120	4/60	4/60	2/60	
liv hpc e no dre P=1. - 188.gm n.s.s.	4/120	0/60	2/60	1/60	
5951 M m b6c inh 24m24 2417	0	638.mg	3.83gm	19.1gm	
liv hpc e 260.gm * P<.5 - 48.9gm n.s.s.	16/120	6/60	12/60	10/60	
liv hpa e 1.50kg P<.9 - 61.3gm n.s.s.	18/120	11/60	9/60	10/60	
lun abt e no dre P=1. - 65.0gm n.s.s.	23/120	11/60	7/60	11/60	
5952 R m aap inh 52w52 2355m	0	549.mg	2.19gm	11.0gm	Collins;faat,25,271-280;1995
tes lya k no dre P=1. 217.mg n.s.s.	0/10	0/10	0/10	0/10	
5953 R m aap inh 24m24 2355n	0	549.mg	2.19gm	11.0gm	
tes lya 29.9gm * P<.0005 + 15.1gm 127.gm	9/75	7/69	12/75	23/75	
5954 R f whb inh 25m25 2417	0	182.mg	729.mg	3.64gm	Alexander;huet,14,706-714;1995
liv hpc e 2.80kg P<1. - 35.6gm n.s.s.	2/120	1/60	0/60	1/60	
5955 R m whb inh 25m25 2417	0	128.mg	510.mg	2.55gm	
liv hpc e 140.gm * P<.1 - 22.9gm n.s.s.	0/120	0/60	0/60	1/60	
liv hpa e 70.1gm * P<.2 - 17.2gm n.s.s.	0/120	0/60	1/60	1/60	
tes ict e no dre P=1. - 37.1gm n.s.s.	1/120	2/60	0/60	0/60	
TETRAFLUOROETHYLENE 116-14-3					
5956 M f b6c inh 95w95 TR450 :	0	400.mg	801.mg	1.60gm	
MXB MXB 54.0mg Z P<.0005 29.2mg 109.mg	18/48	45/48	(45/48	44/48)	---:hcs; liv:hem,hes,hpa,hpc. C
--- MXA 61.3mg Z P<.0005 30.4mg 122.mg	0/48	31/48	(28/48	35/48)	---:hem,hes. S
liv MXA 61.3mg Z P<.0005 c 30.4mg 122.mg	0/48	31/48	(28/48	35/48)	liv:hem,hes.
liv MXA 63.3mg Z P<.0005 c 32.2mg 144.mg	17/48	33/48	(29/48	28/48)	liv:hpa,hpc.
liv hes 66.5mg Z P<.0005 c 31.6mg 141.mg	0/48	27/48	(27/48	34/48)	
--- hes 66.5mg Z P<.0005 31.6mg 141.mg	0/48	27/48	(27/48	34/48)	S
liv hpc 80.8mg Z P<.0005 c 40.6mg 176.mg	4/48	28/48	(22/48	20/48)	
--- hcs 176.mg Z P<.0005 c 85.8mg 376.mg	1/48	21/48	(19/48	18/48)	
liv hpa 217.mg Z P<.0005 111.mg 577.mg	15/48	17/48	20/48	(15/48)	S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hem	530.mg Z	P<.0005 c	164.mg	2.64gm	0/48	5/48	(2/48	1/48)	
--- hem	835.mg Z	P<.0005	347.mg	2.69gm	0/48	5/48	4/48	(1/48)	S
pit pda	1.45gm *	P<.006	547.mg	26.4gm	4/48	5/48	2/48	6/48	S
hag ade	1.47gm *	P<.002	542.mg	10.8gm	2/48	3/48	0/48	6/48	S
lun MXA	1.64gm *	P<.03	554.mg	n.s.s.	6/48	1/48	8/48	4/48	lun:a/a,a/c,car. S
TBA MXB	48.4mg Z	P<.0005	26.3mg	104.mg	34/48	47/48	(45/48	46/48)	
liv MXB	63.3mg Z	P<.0005	32.2mg	144.mg	17/48	33/48	(29/48	28/48)	liv:hpa,hpb,hpc.
lun MXB	1.01gm Z	P<.02	324.mg	n.s.s.	6/48	0/48	8/48	(4/48)	lun:a/a,a/c.
5957 M m b6c inh 95w95 TR450 :					0	334.mg	669.mg	1.34gm	
MXB MXB	71.6mg Z	P<.0005	45.3mg	123.mg	26/48	42/48	48/48	(46/48)	---:hcs; liv:hem,hes,hpa,hpc. C
liv MXA	87.0mg *	P<.0005 c	56.3mg	136.mg	0/48	26/48	30/48	38/48	liv:hem,hes.
--- MXA	88.3mg *	P<.0005	56.7mg	142.mg	2/48	27/48	30/48	38/48	---:hem,hes. S
liv MXA	91.0mg Z	P<.0005 c	54.7mg	171.mg	26/48	34/48	39/48	(35/48)	liv:hpa,hpc.
liv hes	108.mg *	P<.0005 c	69.6mg	170.mg	0/48	21/48	27/48	37/48	
--- hes	109.mg *	P<.0005	69.6mg	176.mg	2/48	21/48	27/48	37/48	S
liv hpc	190.mg Z	P<.0005 c	113.mg	361.mg	11/48	20/48	33/48	(26/48)	
lun MXA	216.mg Z	P<.0005	110.mg	577.mg	12/48	13/48	16/48	(7/48)	lun:a/a,a/c,car. S
liv hpa	222.mg *	P<.0005	118.mg	520.mg	17/48	17/48	12/48	20/48	S
--- hem	297.mg Z	P<.0005	143.mg	669.mg	0/48	11/48	6/48	(3/48)	S
liv hem	308.mg Z	P<.0005 c	146.mg	722.mg	0/48	10/48	5/48	(2/48)	
lun a/a	348.mg Z	P<.0005	159.mg	1.33gm	10/48	8/48	13/48	(5/48)	S
--- hcs	429.mg Z	P<.0005 c	223.mg	868.mg	0/48	12/48	7/48	(7/48)	
lun MXA	830.mg *	P<.005	307.mg	10.7gm	2/48	5/48	3/48	2/48	lun:a/c,car. S
thy MXA	988.mg *	P<.01	325.mg	73.6gm	0/48	4/48	0/48	0/48	thy:fca,fcc. S
hag MXA	1.27gm *	P<.04	380.mg	n.s.s.	6/48	8/48	4/48	5/48	hag:ade,car. S
hag ade	1.39gm *	P<.05	398.mg	n.s.s.	5/48	7/48	4/48	4/48	S
thy fca	1.44gm *	P<.03	406.mg	n.s.s.	0/48	3/48	0/48	0/48	S
TBA MXB	69.9mg Z	P<.0005	44.0mg	124.mg	37/48	44/48	48/48	(46/48)	
liv MXB	91.0mg Z	P<.0005	54.7mg	171.mg	26/48	34/48	39/48	(35/48)	liv:hpa,hpb,hpc.
lun MXB	220.mg Z	P<.0005	111.mg	597.mg	12/48	12/48	16/48	(6/48)	lun:a/a,a/c.
5958 R f f34 inh 24m24 TR450 :					0	93.7mg	188.mg	376.mg	
MXB MXB	56.3mg Z	P<.0005	29.8mg	185.mg	16/50	33/50	(31/50	39/50)	---:mnl; liv:hes,hpa,hpc. C
liv MXA	156.mg Z	P<.0005 c	89.9mg	317.mg	0/50	7/50	12/50	(8/50)	liv:hpa,hpc.
--- mnl	228.mg Z	P<.0005 c	127.mg	803.mg	16/50	31/50	23/50	36/50	
liv hpc	251.mg Z	P<.0005 c	130.mg	630.mg	0/50	4/50	9/50	(2/50)	
liv hpa	528.mg *	P<.002 c	289.mg	2.30gm	0/50	4/50	5/50	6/50	
liv hes	886.mg Z	P<.005 c	326.mg	7.22gm	0/50	0/50	5/50	(1/50)	
--- hes	886.mg Z	P<.005	326.mg	7.22gm	0/50	0/50	5/50	(1/50)	S
kid MXA	958.mg *	P<.008	444.mg	22.2gm	0/50	3/50	1/50	5/50	kid:rua,ruc. S
TBA MXB	287.mg *	P<.2	106.mg	n.s.s.	49/50	50/50	49/50	48/50	
liv MXB	156.mg Z	P<.0005	89.9mg	317.mg	0/50	7/50	12/50	(8/50)	liv:hpa,hpb,hpc.
5959 R f f34 inh 24m24 TR450 with step					0	93.7mg	188.mg	376.mg	
kid MXA	1.31gm *	P<.0005 c	729.mg	3.47gm	0/50	3/50	3/50	10/50	kid:rua,ruc.
kid rua	1.51gm *	P<.002	814.mg	5.72gm	0/50	3/50	3/50	8/50	S
kid ruc	7.38gm *	P<.03	2.23gm	n.s.s.	0/50	0/50	0/50	3/50	S
5960 R m f34 inh 24m24 TR450 :					0	32.9mg	65.8mg	132.mg	
tes MXA	27.5mg Z	P<.0005 e	16.3mg	65.5mg	39/50	40/50	48/50	47/50	tes:iab,ica.
--- mnl	59.7mg *	P<.01 e	27.6mg	3.51gm	34/50	43/50	38/50	31/50	
liv MXA	81.6mg *	P<.002 c	40.9mg	362.mg	4/50	7/50	15/50	8/50	liv:hpa,hpc.
liv hpc	163.mg *	P<.003 c	74.5mg	1.01gm	1/50	1/50	10/50	3/50	
kid MXA	242.mg *	P<.002	103.mg	876.mg	0/50	0/50	6/50	3/50	kid:rab,rua. S
kid MXA	292.mg *	P<.01	114.mg	25.5gm	1/50	0/50	6/50	3/50	kid:rab,rua,ruc. S
liv hpa	136.mg *	P<.02	55.9mg	n.s.s.	3/50	6/50	8/50	5/50	S
TBA MXB	35.4mg Z	P<.0005	18.9mg	141.mg	48/50	49/50	50/50	46/50	
liv MXB	81.6mg *	P<.002	40.9mg	362.mg	4/50	7/50	15/50	8/50	liv:hpa,hpb,hpc.
5961 R m f34 inh 24m24 TR450 with step					0	32.9mg	65.8mg	132.mg	
kid MXA	334.mg *	P<.0005	186.mg	1.22gm	2/50	4/50	9/50	13/50	kid:rab,rua. S
kid MXA	367.mg *	P<.003 c	191.mg	2.40gm	3/50	5/50	9/50	13/50	kid:rab,rua,ruc.
TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE 40548-68-3									
5962 R b sda wat 66w82 1417					0	31.1mg			Wiessler;zkko,79,114-117;1973
lun mix	46.1mg	P<.007	17.4mg	531.mg	0/20	5/20			
tba mix	17.6mg	P<.004	7.81mg	123.mg	3/20	12/20			
tba mal	24.3mg	P<.003 +	10.6mg	142.mg	1/20	9/20			
1-trans-delta9-TETRAHYDROCANNABINOL 1972-08-3									
5963 M f b6c gav 24m24 TR446 :					0	89.1mg	178.mg	356.mg	
thy fca	no dre	P=1. e	587.mg	n.s.s.	4/60	9/60	3/60	(1/60)	
TBA MXB	no dre	P=1.	190.mg	n.s.s.	46/60	31/60	(26/60	16/60)	
liv MXB	no dre	P=1.	285.mg	n.s.s.	22/60	14/60	(11/60	4/60)	liv:hpa,hpb,hpc.
lun MXB	13.4gm *	P<.7	1.69gm	n.s.s.	2/60	1/60	3/60	2/60	lun:a/a,a/c.
5964 M m b6c gav 24m24 TR446 :					0	89.1mg	178.mg	355.mg	
thy fca	950.mg Z	P<.04 e	448.mg	n.s.s.	0/62	6/60	3/61	(1/60)	
TBA MXB	no dre	P=1.	186.mg	n.s.s.	45/62	33/60	(27/61	18/60)	
liv MXB	no dre	P=1.	422.mg	n.s.s.	31/62	13/60	(9/61	3/60)	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	1.05gm	n.s.s.	14/62	14/60	7/61	8/60	lun:a/a,a/c.
5965 R f f34 gav 24m24 TR446 :					0	8.86mg	17.7mg	35.4mg	
TBA MXB	no dre	P=1. -	19.8mg	n.s.s.	44/51	42/51	44/51	(35/50)	
liv MXB	243.mg Z	P<.06	73.0mg	n.s.s.	0/51	0/51	3/51	(0/50)	liv:hpa,hpb,hpc.
5966 R m f34 gav 24m24 TR446 :					0	8.93mg	17.9mg	35.7mg	
TBA MXB	no dre	P=1. -	24.5mg	n.s.s.	42/52	37/51	36/52	(30/52)	
liv MXB	no dre	P=1.	229.mg	n.s.s.	5/52	0/51	1/52	2/52	liv:hpa,hpb,hpc.
TETRAHYDROFURAN 109-99-9									
5967 M f b6c inh 24m24 TR475 :					0	185.mg	555.mg	1.67gm	
liv MXA	1.30gm *	P<.003 c	638.mg	9.47gm	17/50	24/50	26/50	41/50	liv:hpa,hpc.
liv hpa	1.72gm *	P<.005	816.mg	18.7gm	12/50	17/50	18/50	31/50	S
sub sar	14.1gm *	P<.02	4.83gm	n.s.s.	0/50	0/50	1/50	3/50	S

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf / Path TD50 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
TBA MXB 3.60gm * P<.5 824.mg n.s.s.	34/50	38/50	41/50	44/50	
liv MXB 1.30gm * P<.003 638.mg 9.47gm	17/50	24/50	26/50	41/50	liv:hpa,hpb,hpc.
lun MXB 12.5gm * P<.4 2.99gm n.s.s.	2/50	3/50	5/50	5/50	lun:a/a,a/c.
5968 M m b6c inh 24m24 TR475 :	0	154.mg	464.mg	1.39gm	
TBA MXB 2.93gm * P<.6 - 524.mg n.s.s.	47/50	39/50	44/50	21/50	
liv MXB 3.17gm * P<.5 697.mg n.s.s.	35/50	31/50	30/50	18/50	liv:hpa,hpb,hpc.
lun MXB no dre P=1. 1.37gm n.s.s.	21/50	16/50	14/50	7/50	lun:a/a,a/c.
5969 R f f34 inh 24m24 TR475 :	0	44.1mg	132.mg	397.mg	
TBA MXB 3.44gm * P<.9 - 198.mg n.s.s.	46/50	47/50	49/50	48/50	
liv MXB no dre P=1. n.s.s. n.s.s.	0/50	0/50	0/50	0/50	liv:hpa,hpb,hpc.
5970 R m f34 inh 24m24 TR475 :	0	30.9mg	92.7mg	278.mg	
tes MXA 40.1mg Z P<.03 15.6mg n.s.s.	23/50	31/50	31/50	(34/50)	tes:iab,ica. S
kid MXA 407.mg * P<.03 p 143.mg n.s.s.	1/50	1/50	4/50	5/50	kid:rua,ruc.
mgl fba 629.mg * P<.05 202.mg n.s.s.	0/50	2/50	3/50	4/50	S
TBA MXB 369.mg * P<.5 72.1mg n.s.s.	48/50	48/50	48/50	50/50	
liv MXB no dre P=1. 595.mg n.s.s.	1/50	1/50	1/50	0/50	liv:hpa,hpb,hpc.
3,4,5,6-TETRAHYDROURIDINE 18771-50-1					
5971 R m f34 ipj 52w52 1906	0	11.8mg			Carr;bjca,57,395-402;1988
liv tum e no dre P=1. 6.07mg n.s.s.	0/49	0/10			
tba tum e 15.7mg P<.6 2.06mg n.s.s.	10/49	3/10			
TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM CHLORIDE (THPC) 124-64-1					
5972 M f b6c gav 24m24 TR296 :	0	10.5mg	21.2mg		
TBA MXB 908.mg * P<1. - 19.2mg n.s.s.	35/50	32/50	36/50		
liv MXB 200.mg * P<.4 47.9mg n.s.s.	4/50	4/50	7/50		liv:hpa,hpc,nnd.
lun MXB no dre P=1. 101.mg n.s.s.	3/50	3/50	2/50		lun:a/a,a/c.
5973 M m b6c gav 24m24 TR296 :	0	5.31mg	10.6mg		
TBA MXB no dre P=1. - 12.9mg n.s.s.	33/50	31/50	33/50		
liv MXB no dre P=1. 25.8mg n.s.s.	17/50	15/50	13/50		liv:hpa,hpc,nnd.
lun MXB 103.mg * P<.6 19.1mg n.s.s.	4/50	6/50	8/50		lun:a/a,a/c.
5974 R f f34 gav 24m24 TR296 :	0	2.65mg	5.31mg		
TBA MXB 4.78mg * P<.09 - 1.84mg n.s.s.	40/50	45/50	36/50		
liv MXB no dre P=1. n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
5975 R m f34 gav 24m24 TR296 :	0	2.65mg	5.31mg		
sub fib # 24.9mg * P<.03 - 9.06mg n.s.s.	0/50	2/50	3/50		S
TBA MXB 14.7mg * P<.7 2.34mg n.s.s.	42/50	42/50	36/50		
liv MXB 24.5mg * P<.3 6.80mg n.s.s.	1/50	4/50	2/50		liv:hpa,hpc,nnd.
TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE (THPS) 55566-30-8					
5976 M f b6c gav 24m24 TR296 :	0	3.54mg	7.07mg		
mul mlm # 15.7mg * P<.02 - 7.73mg n.s.s.	1/50	8/50	9/50		S
TBA MXB no dre P=1. 5.58mg n.s.s.	32/50	35/50	35/50		
liv MXB no dre P=1. 33.4mg n.s.s.	7/50	3/50	3/50		liv:hpa,hpc,nnd.
lun MXB 234.mg * P<.8 21.4mg n.s.s.	2/50	3/50	3/50		lun:a/a,a/c.
5977 M m b6c gav 24m24 TR296 :	0	3.54mg	7.07mg		
mul MXA # 11.4mg \ P<.04 - 4.59mg n.s.s.	2/50	10/50	(1/50)		mul:mlh,mlm,mlp,mlu,ule. S
TBA MXB 47.3mg * P<.8 4.26mg n.s.s.	33/50	38/50	38/50		
liv MXB no dre P=1. 10.9mg n.s.s.	18/50	12/50	17/50		liv:hpa,hpc,nnd.
lun MXB 78.5mg * P<.8 9.59mg n.s.s.	7/50	10/50	9/50		lun:a/a,a/c.
5978 R f f34 gav 24m25 TR296 :	0	3.50mg	7.01mg		
TBA MXB 23.3mg * P<.7 - 3.69mg n.s.s.	45/50	46/50	41/50		
liv MXB no dre P=1. 30.1mg n.s.s.	3/50	2/50	2/50		liv:hpa,hpc,nnd.
5979 R m f34 gav 24m25 TR296 :	0	3.50mg	7.01mg		
mul mnl # 2.42mg \ P<.02 - 1.03mg n.s.s.	30/50	36/50	(20/50)		S
pta MXA 3.30mg \ P<.02 1.38mg n.s.s.	21/50	27/50	(14/50)		pta:adn,can. S
pta adn 3.56mg \ P<.03 1.44mg n.s.s.	21/50	26/50	(14/50)		S
TBA MXB 1.78mg \ P<.02 .766mg n.s.s.	46/50	49/50	(37/50)		
liv MXB 12.4mg \ P<.2 3.19mg n.s.s.	3/50	5/50	(1/50)		liv:hpa,hpc,nnd.
TETRAMETHYLTHIURAM DISULFIDE (TMTD, thiram) 137-26-8					
5980 M f b6a orl 76w76 1194	0	3.64mg			Innes;ntis,1968/1969
lun ade evx 159.mg P<1. - 3.52mg n.s.s.	1/17	1/15			
liv hpt evx no dre P=1. - 6.01mg n.s.s.	0/17	0/15			
tba mix evx no dre P=1. - 3.90mg n.s.s.	2/17	1/15			
5981 M m b6a orl 76w76 1194	0	3.39mg			
lun ade evx no dre P=1. - 3.17mg n.s.s.	2/18	2/18			
liv hpt evx no dre P=1. - 4.01mg n.s.s.	1/18	1/18			
tba mix evx no dre P=1. - 2.67mg n.s.s.	3/18	3/18			
5982 M f b6c orl 76w76 1194	0	3.64mg			
liv hpt evx no dre P=1. - 7.21mg n.s.s.	0/16	0/18			
lun mix evx no dre P=1. - 7.21mg n.s.s.	0/16	0/18			
tba mix evx no dre P=1. - 7.21mg n.s.s.	0/16	0/18			
5983 M m b6c orl 76w76 1194	0	3.39mg			
liv hpt evx 9.91mg P<.1 - 2.43mg n.s.s.	0/16	2/17			
lun mix evx no dre P=1. - 6.34mg n.s.s.	0/16	0/17			
tba mix evx 6.39mg P<.04 - 1.93mg n.s.s.	0/16	3/17			
5984 R f f34 eat 24m30 1645	0	20.3mg			Lijinsky;jtxe,13,609-614;1984
liv nnd ev 97.3mg P<.2 28.8mg n.s.s.	4/24	8/24			
5985 R m f34 eat 24m30 1645	0	16.2mg			
liv nnd ev 374.mg P<.7 46.3mg n.s.s.	2/24	3/24			
liv mix ev no dre P=1. 51.1mg n.s.s.	3/24	3/24			
liv car ev no dre P=1. 125.mg n.s.s.	1/24	0/24			
5986 R f f3d eat 24m26 2140	0	23.2mg	46.4mg		Hasegawa;txcy,51,155-165;1988/pers.comm.
liv nnd e no dre P=1. - 190.mg n.s.s.	9/49	12/50	6/50		
5987 R m f3d eat 24m26 2140	0	18.6mg	37.1mg		
liv nnd e 427.mg * P<.7 - 55.7mg n.s.s.	22/50	20/49	24/50		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
5988 R f wis eat 52w52 2146m					0	.150mg	1.50mg	15.0mg	Maita;faat,16,667-686;1991/pers.comm.
liv tum ek	no dre	P=1.		55.7ug n.s.s.	0/8	0/8	0/8	0/8	
5989 R f wis eat 24m24 2146n					0	.150mg	1.50mg	15.0mg	
liv hpa e	no dre	P=1.	-	1.14mg n.s.s.	1/40	0/41	0/40	0/40	
5990 R m wis eat 52w52 2146m					0	.120mg	1.20mg	12.0mg	
liv tum ek	no dre	P=1.		44.6ug n.s.s.	0/8	0/8	0/8	0/8	
5991 R m wis eat 24m24 2146n					0	.120mg	1.20mg	12.0mg	
liv hpa e	no dre	P=1.	-	.891mg n.s.s.	0/40	0/40	0/40	0/40	
TETRAMETHYLTHIURAM MONOSULFIDE (unads) 97-74-5									
5992 M f b6a orl 76w76 1199					0	51.0mg			Innes;ntis,1968/1969
liv hpt evx	327.mg	P<.3	-	53.2mg n.s.s.	0/17	1/18			
lun ade evx	no dre	P=1.	-	101.mg n.s.s.	1/17	0/18			
tba mix evx	148.mg	P<.5	-	29.4mg n.s.s.	2/17	4/18			
5993 M m b6a orl 76w76 1199					0	47.4mg			
lun ade evx	no dre	P=1.	-	58.3mg n.s.s.	2/18	1/17			
liv hpt evx	no dre	P=1.	-	88.7mg n.s.s.	1/18	0/17			
tba mix evx	no dre	P=1.	-	62.3mg n.s.s.	3/18	1/17			
5994 M f b6c orl 76w76 1199					0	51.0mg			
liv hpt evx	no dre	P=1.	-	89.8mg n.s.s.	0/16	0/16			
lun mix evx	no dre	P=1.	-	89.8mg n.s.s.	0/16	0/16			
tba tum evx	no dre	P=1.	-	89.8mg n.s.s.	0/16	0/16			
5995 M m b6c orl 76w76 1199					0	47.4mg			
lun ade evx	89.3mg	P<.04	-	26.9mg n.s.s.	0/16	3/17			
liv hpt evx	139.mg	P<.1	-	34.0mg n.s.s.	0/16	2/17			
tba mix evx	49.8mg	P<.007	-	18.8mg 673.mg	0/16	5/17			
TETRANITROMETHANE 509-14-8									
5996 M f b6c inh 24m24 TR386 :					0	1.24mg	4.98mg		
lun MXA	1.33mg *	P<.0005	c	.891mg 2.31mg	4/50	24/50	49/50		lun:a/a,a/c.
lun a/a	1.50mg *	P<.0005		1.04mg 2.49mg	1/50	19/50	41/50		S
lun a/c	1.73mg *	P<.0005		1.16mg 2.88mg	3/50	11/50	45/50		S
TBA MXB	4.90mg *	P<.2		1.68mg n.s.s.	40/50	44/50	49/50		
liv MXB	no dre	P=1.		12.1mg n.s.s.	13/50	3/50	7/50		liv:hpa,hpc,nnd.
lun MXB	1.33mg *	P<.0005		.891mg 2.31mg	4/50	24/50	49/50		lun:a/a,a/c.
5997 M m b6c inh 24m24 TR386 :					0	1.04mg	4.15mg		
lun MXA	1.07mg *	P<.0005	c	.695mg 1.91mg	12/50	27/50	47/50		lun:a/a,a/c.
lun a/c	1.15mg *	P<.0005		.771mg 1.90mg	6/50	16/50	46/50		S
lun a/a	1.56mg *	P<.0005		.975mg 2.95mg	7/50	17/50	34/50		S
TBA MXB	1.58mg *	P<.0005		.852mg 5.23mg	39/50	40/50	48/50		
liv MXB	no dre	P=1.		3.89mg n.s.s.	23/50	24/50	12/50		liv:hpa,hpc,nnd.
lun MXB	1.07mg *	P<.0005		.695mg 1.91mg	12/50	27/50	47/50		lun:a/a,a/c.
5998 R f f34 inh 24m24 TR386 :					0	1.19mg	2.97mg		
lun MXB	.705mg /	P<.0005		.513mg .998mg	0/50	23/50	50/50		lun:a/a,a/c,sqc. C
lun MXA	.710mg /	P<.0005	c	.516mg 1.01mg	0/50	22/50	50/50		lun:a/a,a/c.
lun a/c	.775mg /	P<.0005		.559mg 1.11mg	0/50	19/50	50/50		S
lun sqc	5.66mg /	P<.0005	c	2.91mg 13.0mg	0/50	1/50	12/50		
adr MXA	18.5mg *	P<.01		6.23mg 1.15gm	0/50	0/50	4/50		adr:coa,coc. S
lun a/a	7.13mg *	P<.03		3.29mg n.s.s.	0/50	6/50	3/50		S
adr coa	24.4mg *	P<.03		7.13mg n.s.s.	0/50	0/50	3/50		S
TBA MXB	2.22mg *	P<.1		.839mg n.s.s.	47/50	49/50	50/50		
liv MXB	144.mg *	P<.8		9.27mg n.s.s.	1/50	1/50	1/50		liv:hpa,hpc,nnd.
5999 R m f34 inh 24m24 TR386 :					0	.832mg	2.08mg		
lun MXB	.304mg *	P<.0005		.210mg .453mg	1/50	34/50	50/50		lun:a/a,a/c,sqc. C
lun MXA	.326mg *	P<.0005	c	.224mg .491mg	1/50	33/50	46/50		lun:a/a,a/c.
lun a/c	.370mg *	P<.0005		.252mg .551mg	0/50	26/50	46/50		S
tes MXA	.488mg /	P<.0005		.265mg 1.52mg	33/50	38/50	39/50		tes:iab,ica. S
lun a/a	1.25mg *	P<.0005		.655mg 3.33mg	1/50	13/50	11/50		S
lun sqc	1.80mg /	P<.0005	c	.956mg 3.50mg	0/50	1/50	19/50		
pni isa	3.59mg *	P<.04		1.25mg n.s.s.	3/50	5/50	6/50		S
TBA MXB	.552mg *	P<.0005		.289mg 2.20mg	47/50	49/50	50/50		
liv MXB	no dre	P=1.		4.71mg n.s.s.	1/50	2/50	0/50		liv:hpa,hpc,nnd.
THENYLDIAMINE 91-79-2									
6000 R f f34 wat 19m30 1790					0	25.1mg			Lijinsky;zkko,112,57-60;1986
tyf mix e	10.7gm	P<1.	-	96.3mg n.s.s.	1/21	1/20			
liv mix e	no dre	P=1.	-	53.7mg n.s.s.	6/21	5/20			
6001 R m f34 wat 19m30 1790					0	17.6mg			
liv mix e	96.8mg	P<.4	-	23.0mg n.s.s.	4/19	7/20			
tyf mix e	no dre	P=1.	-	75.6mg n.s.s.	2/19	1/20			
THEOPHYLLINE 58-55-9									
6002 M f b6c gav 24m24 TR473 :					0	5.31mg	17.7mg	53.2mg	
--- hcs #	20.5mg Z	P<.02	-	8.45mg n.s.s.	1/50	8/50	(4/50	2/50)	S
TBA MXB	no dre	P=1.		13.9mg n.s.s.	46/50	39/50	41/50	(28/50)	
liv MXB	no dre	P=1.		35.2mg n.s.s.	29/50	14/50	18/50	(8/50)	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		186.mg n.s.s.	4/50	5/50	4/50	3/50	lun:a/a,a/c.
6003 M m b6c gav 24m24 TR473 :					0	10.7mg	35.5mg	107.mg	
TBA MXB	no dre	P=1.	-	7.34mg n.s.s.	44/50	42/50	(38/50	13/50)	
liv MXB	no dre	P=1.		13.4mg n.s.s.	34/50	27/50	(22/50	4/50)	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		239.mg n.s.s.	13/50	9/50	15/50	5/50	lun:a/a,a/c.
6004 R f f34 gav 24m24 TR473 :					0	5.31mg	17.8mg	53.3mg	
TBA MXB	no dre	P=1.	-	61.0mg n.s.s.	44/50	41/50	40/50	36/50	
liv MXB	no dre	P=1.		284.mg n.s.s.	0/50	0/50	1/50	0/50	liv:hpa,hpb,hpc.
6005 R m f34 gav 24m24 TR473 :					0	5.34mg	17.8mg	53.5mg	
TBA MXB	no dre	P=1.	-	33.8mg n.s.s.	43/50	41/50	39/50	34/50	
liv MXB	no dre	P=1.		267.mg n.s.s.	2/50	2/50	0/50	1/50	liv:hpa,hpb,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
THIABENDAZOLE (2-(4-thiazolyl)-benzimazole) 148-79-8									
6006 M m b6c eat 52w52 2456				0	240.mg			Mikuriya;tmrl,40,289-297;1989/pers.comm.	
liv hpa e	390.mg	P<.1	- 95.9mg n.s.s.	0/20	2/20				
6007 M f cdj eat 78w78 2656				0	40.3mg	162.mg	650.mg	Tada;txcy,169,163-176;2001	
lun a/a e	4.88gm *	P<.4	- 1.02gm n.s.s.	5/50	2/50	5/50	6/50		
ubl mnp e	16.3gm *	P<.2	- 2.66gm n.s.s.	0/50	0/50	0/50	1/50		
liv tum e	no dre	P=1.	- 178.mg n.s.s.	0/50	0/50	0/50	0/50		
lun a/c e	no dre	P=1.	- 3.69gm n.s.s.	1/50	0/50	1/50	0/50		
6008 M m cdj eat 78w78 2656				0	36.0mg	150.mg	600.mg		
ubl tpp e	15.0gm *	P<.2	- 2.45gm n.s.s.	0/50	0/50	0/50	1/50		
liv hpc e	no dre	P=1.	- 3.45gm n.s.s.	3/50	2/50	2/50	0/50		
lun a/a e	no dre	P=1.	- 964.mg n.s.s.	7/50	10/50	11/50	8/50		
lun a/c e	no dre	P=1.	- 2.34gm n.s.s.	1/50	2/50	1/50	1/50		
liv hpa e	no dre	P=1.	- 2.68gm n.s.s.	3/50	6/50	3/50	1/50		
6009 R f f3d eat 65w65 1777				0	100.mg			Fujii;fctx,24,207-211;1986	
ubl mix er	no dre	P=1.	113.mg n.s.s.	0/15	0/14				
6010 R f f3d eat 24m24 2314				0	25.0mg	50.0mg	100.mg 200.mg	Fujii;fctx,29,771-775;1991	
ubl tpp e	7.64gm *	P<.5	- 1.24gm n.s.s.	0/29	0/30	0/29	1/30 0/30		
liv tum e	no dre	P=1.	- 81.7mg n.s.s.	0/29	0/30	0/29	0/30 0/30		
kid tcc e	no dre	P=1.	- 81.7mg n.s.s.	0/29	0/30	0/29	0/30 0/30		
6011 R m f3d eat 65w65 1777				0	80.0mg			Fujii;fctx,24,207-211;1986	
ubl mix er	no dre	P=1.	96.6mg n.s.s.	1/14	0/15				
ubl tcc er	no dre	P=1.	96.6mg n.s.s.	1/14	0/15				
6012 R m f3d eat 24m24 2314				0	20.0mg	40.0mg	80.0mg 160.mg	Fujii;fctx,29,771-775;1991	
pre ade e	571.mg *	P<.0005	278.mg 1.87gm	0/30	1/30	0/30	2/30 7/30		
kid tcc e	3.05gm *	P<.3	- 750.mg n.s.s.	0/29	0/30	1/30	0/30 1/30		
liv tum e	no dre	P=1.	- 65.9mg n.s.s.	0/29	0/30	0/30	0/30 0/30		
ubl tpp e	no dre	P=1.	- 65.9mg n.s.s.	0/29	0/30	0/30	0/30 0/30		
THIAMPHENICOL 15318-45-3									
6013 R f f3d wat 24m25 2521				0	6.88mg	27.5mg		Kitamura;fctx,35,1075-1080;1997	
liv tum e	no dre	P=1.	- 60.2mg n.s.s.	0/50	0/49	0/50			
tba tum e	43.2mg *	P<.4	- 10.1mg n.s.s.	42/50	42/49	45/50			
6014 R m f3d wat 24m25 2521				0	6.02mg	24.1mg			
liv hpa e	683.mg *	P<.5	- 111.mg n.s.s.	2/50	1/49	3/49			
tba tum e	noTD50	P=1.	- n.s.s. n.s.s.	50/50	49/49	49/49			
THIO-TEPA 52-24-4									
6015 M f b6c ipj 47w86 TR58 :				0	.300mg	1.00mg			
--- MXA as	.216mg /	P<.0005 c	.133mg .352mg	0/15	5/35	32/35		---:lle,lym.	
TBA MXB as	85.5ug /	P<.0005	53.3ug .142mg	0/15	17/35	32/35			
liv MXB as	1.12mg *	P<.2	.277mg n.s.s.	0/15	2/35	0/35		liv:hpa,hpc,nnd.	
lun MXB as	.408mg *	P<.02	.155mg n.s.s.	0/15	5/35	0/35		lun:a/a,a/c.	
6016 M f b6c ipj 47w86 TR58 : pool				0	.300mg	1.00mg			
--- MXA as	.210mg /	P<.0005 c	.127mg .357mg	1/30	5/35	32/35		---:lle,lym.	
lun a/a as	.408mg *	P<.003	.155mg 2.35mg	0/30	5/35	0/35			S
6017 M m b6c ipj 52w83 TR58 :				0	.300mg	.900mg			
--- sqc s	.102mg /	P<.0005	55.1ug .281mg	0/15	15/34	1/35			S
--- MXB s	.241mg /	P<.0005	.133mg .461mg	1/15	3/34	26/35		---:leu,lle,lym.	C
--- MXA s	.241mg /	P<.0005 c	.133mg .461mg	1/15	3/34	26/35		---:leu,lym.	
--- MXA s	.265mg /	P<.0005 c	.146mg .506mg	1/15	2/34	26/35		---:lle,lym.	
TBA MXB s	69.0ug /	P<.0005	40.6ug .137mg	4/15	19/34	27/35			
liv MXB s	1.12mg *	P<.6	.187mg n.s.s.	1/15	4/34	0/35		liv:hpa,hpc,nnd.	
lun MXB s	.584mg *	P<.4	.140mg n.s.s.	1/15	5/34	0/35		lun:a/a,a/c.	
6018 M m b6c ipj 52w83 TR58 : pool				0	.300mg	.900mg			
--- sqc s	.102mg /	P<.0005	55.1ug .218mg	0/30	15/34	1/35			S
--- MXA s	.238mg /	P<.0005 c	.134mg .441mg	1/30	3/34	26/35		---:leu,lym.	
--- MXA s	.262mg /	P<.0005 c	.146mg .485mg	1/30	2/34	26/35		---:lle,lym.	
ski sqc s	.280mg *	P<.003 c	.119mg 1.28mg	0/30	7/34	0/35			
pre sqc s	.300mg /	P<.002 c	.126mg 1.25mg	0/30	6/34	1/35			
6019 R f sda ipj 36w81 TR58 :				0	.190mg	.250mg			
MXA sqc aes	.217mg /	P<.0005 c	.101mg .666mg	0/20	2/31	8/35		eac:sqc; ski:sqc.	
ute acn aes	.243mg /	P<.002	.107mg .868mg	0/20	2/31	7/35			S
MXA MXA aesh	.819mg *	P<.07 a	.260mg n.s.s.	0/20	2/31	2/35		bra:oln; nas:can.	
TBA MXB aes	40.4ug /	P<.0005	24.2ug 88.2ug	8/20	26/31	26/35			
liv MXB aes	no dre	P=1.	n.s.s. n.s.s.	0/20	0/31	0/35		liv:hpa,hpc,nnd.	
6020 R f sda ipj 36w79 TR58 : pool				0	.190mg	.250mg			
mgl acn as	.182mg *	P<.0005	89.5ug .491mg	2/60	7/31	8/35			S
MXA sqc as	.214mg /	P<.0005 c	.101mg .537mg	0/60	2/31	8/35		eac:sqc; ski:sqc.	
ute acn as	.236mg /	P<.0005	.105mg .637mg	0/60	2/31	7/35			S
eac sqc as	.327mg /	P<.0005 c	.138mg 1.05mg	0/60	2/31	5/35			
6021 R m sda ipj 32w82 TR58 :				0	.190mg	.270mg			
--- leu aes	.312mg *	P<.002 c	.144mg 1.14mg	0/20	5/39	6/35			
MXA MXA aesh	.285mg *	P<.03 a	68.7ug n.s.s.	0/20	3/39	0/35		bra:neu,oln; nas:can.	
TBA MXB aes	33.2ug /	P<.0005	17.6ug 75.6ug	8/20	27/39	14/35			
liv MXB aes	no dre	P=1.	n.s.s. n.s.s.	0/20	0/39	0/35		liv:hpa,hpc,nnd.	
6022 R m sda ipj 32w79 TR58 : pool				0	.190mg	.270mg			
MXA sqc aes	.122mg *	P<.0005 c	52.4ug .317mg	0/60	7/39	3/35		eac:sqc; ski:sqc.	
ski sqc aes	.155mg *	P<.0005 c	59.5ug .482mg	0/60	5/39	3/35			
sub srn aes	.220mg *	P<.0005	68.9ug 1.07mg	0/60	5/39	0/35			S
--- MXA aes	.224mg *	P<.0005 c	91.5ug .674mg	1/60	6/39	6/35		---:leu,lym.	
--- leu aes	.290mg *	P<.0005 c	.134mg .708mg	0/60	5/39	6/35			
--- lle aes	.374mg *	P<.0005 c	.153mg 1.15mg	0/60	3/39	5/35			
6023 R m b46 ivj 12m24 1017				0	71.4ug			Schmahl;arzn,20,1461-1467;1970	
tba mix	.186mg	P<.002 +	86.1ug 1.02mg	7/89	14/48				
tba mal	.303mg	P<.009	.122mg 13.2mg	4/89	9/48				
tba ben	.646mg	P<.2	.188mg n.s.s.	3/89	5/48				

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes / Path	DR / TD_{50}	AuOp / 2Tailpvl	UpConf / LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code / NCI/NTPPathology
THIOACETAMIDE 62-55-5								
6024 M m icm eat 40w88 1959				0	19.1mg			Akao;chpb,38,2012-2014;1990
liv hnd er	12.0mg	P<.0005	6.19mg 28.4mg	0/15	13/24			
liv hpc er	15.3mg	P<.0005 +	7.55mg 42.3mg	0/15	11/24			
6025 M f swi eat 65w65 282				0	39.0mg			Gothoskar;bjca,24,498-503;1970
liv hpt kr	5.36mg	P<.0005 +	1.69mg 22.6mg	0/6	6/7			
6026 M m swi eat 65w65 282				0	36.0mg			
liv hpt kr	noTD50	P<.005 +	n.s.s. 11.3mg	0/6	6/6			
6027 R m don eat 40w80 1836				0	7.00mg			Kuroda;jnci,79,1047-1051;1987
liv mix er	11.5mg	P<.02 +	5.38mg n.s.s.	0/15	9/41			
liv thc er	21.8mg	P<.08	8.28mg n.s.s.	0/15	5/41			
liv pac er	27.6mg	P<.2	9.55mg n.s.s.	0/15	4/41			
4,4'-THIOBIS(6-tert-BUTYL-m-CRESOL) 96-69-5								
6028 M f b6c eat 24m24 TR435 :				0	32.3mg	64.8mg	130.mg	
TBA MXB	484.mg *	P<.6 -	86.4mg n.s.s.	38/51	37/50	38/50	38/50	
liv MXB	no dre	P=1.	190.mg n.s.s.	20/51	23/50	24/50	14/50	liv:hpa,hpb,hpc.
lun MXB	2.02gm *	P<.5	415.mg n.s.s.	2/51	3/50	1/50	4/50	lun:a/a,a/c.
6029 M m b6c eat 24m24 TR435 :				0	29.9mg	59.8mg	120.mg	
TBA MXB	no dre	P=1. -	64.2mg n.s.s.	38/50	38/50	39/50	(25/50)	
liv MXB	no dre	P=1.	78.1mg n.s.s.	25/50	30/50	27/50	(16/50)	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.	599.mg n.s.s.	8/50	9/50	9/50	3/50	lun:a/a,a/c.
6030 R f f34 eat 24m24 TR435 :				0	24.9mg	49.9mg	125.mg	
ute MXA #	262.mg *	P<.008 -	125.mg 7.44gm	2/50	6/50	9/50	10/50	ute:esp,ess. S
ute esp	286.mg *	P<.02	133.mg n.s.s.	2/50	5/50	9/50	9/50	S
thy MXA	325.mg *	P<.03	141.mg n.s.s.	3/50	4/50	8/50	9/50	thy:cca,ccr,cdb. S
thy MXA	361.mg *	P<.03	155.mg n.s.s.	3/50	2/50	8/50	8/50	thy:cca,cdb. S
TBA MXB	196.mg *	P<.3	54.8mg n.s.s.	47/50	45/50	43/50	47/50	
liv MXB	3.99gm *	P<.2	650.mg n.s.s.	0/50	0/50	0/50	1/50	liv:hpa,hpb,hpc.
6031 R m f34 eat 24m24 TR435 :				0	19.9mg	40.0mg	99.9mg	
TBA MXB	449.mg *	P<.8 -	47.0mg n.s.s.	47/50	47/50	47/50	44/50	
liv MXB	324.mg *	P<.07	119.mg n.s.s.	1/50	3/50	3/50	5/50	liv:hpa,hpb,hpc.
2,2'-THIOBIS(4,6-DICHLOROPHENOL) (TBP, Vancide BL) 97-18-7								
6032 M f b6a orl 76w76 1283				0	15.7mg			Innes;ntis,1968/1969
lun ade evx	100.mg	P<.6	13.2mg n.s.s.	1/17	2/18			
liv hpt evx	no dre	P=1.	31.1mg n.s.s.	0/17	0/18			
tba mix evx	28.7mg	P<.3	7.51mg n.s.s.	2/17	5/18			
6033 M m b6a orl 76w76 1283				0	14.6mg			
liv hpt evx	no dre	P=1.	27.4mg n.s.s.	1/18	0/17			
lun ade evx	no dre	P=1.	27.4mg n.s.s.	2/18	0/17			
tba mix evx	no dre	P=1.	19.2mg n.s.s.	3/18	1/17			
6034 M f b6c orl 76w76 1283				0	15.7mg			
liv hpt evx	no dre	P=1.	27.6mg n.s.s.	0/16	0/16			
lun mix evx	no dre	P=1.	27.6mg n.s.s.	0/16	0/16			
tba mix evx	43.0mg	P<.09	10.6mg n.s.s.	0/16	2/16			
6035 M m b6c orl 76w76 1283				0	14.6mg			
liv agm evx	88.2mg	P<.3	14.4mg n.s.s.	0/16	1/17			
lun ade evx	88.2mg	P<.3	14.4mg n.s.s.	0/16	1/17			
tba mix evx	10.1mg	P<.002	4.29mg 38.7mg	0/16	7/17			
THIOCYANATE, SODIUM 540-72-7								
6036 R f f34 wat 26m30 1898				0	107.mg			Lijinsky;txih,5,25-29;1989
liv tum e	no dre	P=1. -	289.mg n.s.s.	4/24	3/20			
6037 R m f34 wat 26m30 1898				0	74.7mg			
ssu tum e	224.mg	P<.002 -	90.8mg 968.mg	0/24	6/20			
liv tum e	2.76gm	P<.9 -	185.mg n.s.s.	3/24	3/20			
4,4'-THIODIANILINE 139-65-1								
6038 M f b6c eat 78w91 TR47 :				0	232.mg	464.mg		
MXB MXB a	33.2mg *	P<.0005	18.5mg 60.2mg	0/14	33/35	30/35		liv:hpc; thy:fca,fcc. C
liv hpc a	33.3mg *	P<.0005 c	18.5mg 60.5mg	0/14	32/35	30/35		
thy MXA a	88.4mg *	P<.0005 c	45.5mg 178.mg	0/14	11/35	18/35		thy:fca,fcc.
thy fcc a	165.mg /	P<.0005 c	72.9mg 386.mg	0/14	3/35	15/35		
TBA MXB a	33.2mg *	P<.0005	18.5mg 60.2mg	2/14	33/35	30/35		
liv MXB a	33.3mg *	P<.0005	18.5mg 60.5mg	0/14	32/35	30/35		liv:hpa,hpc,nnd.
lun MXB a	no dre	P=1.	n.s.s. n.s.s.	0/14	0/35	0/35		lun:a/a,a/c.
6039 M m b6c eat 78w91 TR47 :				0	214.mg	428.mg		
MXB MXB a	32.7mg *	P<.0005	20.1mg 54.0mg	4/14	34/35	24/35		liv:hpa,hpc; thy:fca,fcc. C
liv MXA a	33.2mg *	P<.0005 c	20.3mg 55.3mg	4/14	33/35	23/35		liv:hpa,hpc.
liv hpc a	33.8mg *	P<.0005 c	20.5mg 56.9mg	1/14	32/35	22/35		
thy MXA a	51.8mg /	P<.0005 c	30.7mg 88.8mg	0/14	22/35	20/35		thy:fca,fcc.
thy fcc a	70.7mg /	P<.0005 c	40.7mg 125.mg	0/14	15/35	20/35		
TBA MXB a	32.7mg *	P<.0005	20.1mg 54.0mg	4/14	34/35	24/35		
liv MXB a	33.2mg *	P<.0005	20.3mg 55.3mg	4/14	33/35	23/35		liv:hpa,hpc,nnd.
lun MXB a	1.07gm *	P<.3	174.mg n.s.s.	0/14	1/35	0/35		lun:a/a,a/c.
6040 R f f34 eat 16m24 TR47 :				0	53.5mg	107.mg		
MXB MXB s	8.53mg *	P<.0005	4.53mg 15.2mg	0/15	32/35	33/35		eac:sqc,sqp; thy:fcc; ute:acn. C
ute acn s	8.79mg *	P<.0005 c	4.61mg 16.0mg	0/15	31/35	23/35		
thy fcc s	11.5mg /	P<.0005 c	6.13mg 20.2mg	0/15	24/35	32/35		
eac MXA sh	121.mg *	P<.006 c	49.8mg 1.34gm	0/15	6/35	3/35		eac:sqc,sqp.
TBA MXB s	8.35mg *	P<.0005	4.44mg 16.1mg	6/15	32/35	33/35		
liv MXB s	42.0mg *	P<.0005	15.9mg 137.mg	0/15	6/35	3/35		liv:hpa,hpc,nnd.
6041 R m f34 eat 16m24 TR47 :				0	42.8mg	85.6mg		
MXB MXB	5.52mg \	P<.0005	2.00mg 11.7mg	0/15	32/35	(33/35)		col:acn; eac:sqc,sqp; liv:hpa,hpc; thy:fca,fcc. C
thy MXA	5.59mg \	P<.0005 c	2.01mg 12.2mg	0/15	30/35	(32/35)		thy:fca,fcc.
thy fcc	6.36mg \	P<.0005 c	2.08mg 15.3mg	0/15	28/35	(32/35)		
liv MXA	7.18mg \	P<.0005 c	2.15mg 18.5mg	0/15	23/35	(12/35)		liv:hpa,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpc		7.31mg	\ P<.0005 c	2.16mg 19.3mg	0/15	21/35	(10/35)		
eac MXA		20.3mg	\ P<.0005 c	6.42mg 57.0mg	0/15	15/35	(8/35)		eac:sqc,sqp.
col acn h		97.4mg	\ P<.02 c	38.5mg n.s.s.	0/15	6/35	(1/35)		
TBA MXB		5.96mg	\ P<.0005	2.28mg 13.6mg	4/15	32/35	(33/35)		
liv MXB		7.18mg	\ P<.0005	2.15mg 18.5mg	0/15	23/35	(12/35)		liv:hpa,hpc,nnd.
6042 R m f3d eat 52w52 2024					0	1.84mg			Hasegawa;carc,12,1515-1518;1991/pers.comm.
lun ade r		1.41mg	P<.02	.486mg n.s.s.	0/20	4/20			
liv hpc r		1.94mg	P<.04 +	.586mg n.s.s.	0/20	3/20			
thy fcc r		2.99mg	P<.1	.735mg n.s.s.	0/20	2/20			
beta-THIOGUANINE DEOXYRIBOSIDE (beta-TGdR) 64039-27-6									
6043 M f b6c ipj 43w77 TR57 :					0	.300mg	.600mg	1.70mg	
TBA MXB as		4.48mg Z	P<1. i	.150mg n.s.s.	21/30	20/35	21/35	(1/35)	
liv MXB as		no dre	P=1.	n.s.s. n.s.s.	0/30	0/35	0/35	0/35	liv:hpa,hpc,nnd.
lun MXB as		6.87mg *	P<.3	1.12mg n.s.s.	0/30	0/35	1/35	0/35	lun:a/a,a/c.
6044 M m b6c ipj 38w77 TR57 :					0	.300mg	.600mg	1.70mg	
TBA MXB as		no dre	P=1. i	.173mg n.s.s.	20/30	19/35	19/35	0/35	
liv MXB as		no dre	P=1.	.421mg n.s.s.	2/30	1/35	1/35	0/35	liv:hpa,hpc,nnd.
lun MXB as		no dre	P=1.	n.s.s. n.s.s.	0/30	0/35	0/35	0/35	lun:a/a,a/c.
6045 R f sda ipj 52w78 TR57 :					0	1.00mg	2.00mg		
eac MXA es		2.10mg /	P<.005 c	.938mg 14.3mg	0/10	2/35	6/35		eac:can,sqc.
eac sqc es		2.31mg /	P<.008	.990mg 44.0mg	0/10	2/35	5/35		S
TBA MXB es		4.11mg /	P<.7	.572mg n.s.s.	9/10	17/35	10/35		
liv MXB es		no dre	P=1.	n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
6046 R f sda ipj 52w78 TR57 : pool					0	1.00mg	2.00mg		
eac MXA es		2.10mg /	P<.0005 c	.938mg 6.68mg	0/30	2/35	6/35		eac:can,sqc.
eac sqc es		2.31mg /	P<.002	.990mg 8.66mg	0/30	2/35	5/35		S
6047 R m sda ipj 52w78 TR57 :					0	1.00mg	2.00mg		
eac MXA es		4.38mg *	P<.08 a	1.32mg n.s.s.	0/10	1/35	2/35		eac:can,sqc.
TBA MXB es		no dre	P=1.	.839mg n.s.s.	7/10	9/35	5/35		
liv MXB es		no dre	P=1.	n.s.s. n.s.s.	0/10	0/35	0/35		liv:hpa,hpc,nnd.
6048 R m sda ipj 52w78 TR57 : pool					0	1.00mg	2.00mg		
eac MXA es		4.38mg *	P<.02 a	1.32mg n.s.s.	0/30	1/35	2/35		eac:can,sqc.
--- lym es		5.75mg *	P<.03	1.73mg n.s.s.	0/30	1/35	2/35		S
THIOSEMICARBAZIDE (thiocarbamylhydrazine) 79-19-6									
6049 M f swa wat 29m29 1675					0	31.2mg	62.4mg		Toth;faat,2,173-176;1982/1980
liv hpt aes		no dre	P=1. -	38.4mg n.s.s.	1/15	0/14	0/3		
lun tum aes		no dre	P=1. -	469.mg n.s.s.	24/98	9/49	4/39		
6050 M m swa wat 27m28 1675					0	26.0mg	52.0mg		
liv hpt aes		no dre	P=1. -	204.mg n.s.s.	0/100	0/49	0/33		
lun tum aes		no dre	P=1. -	207.mg n.s.s.	26/100	5/49	(3/33)		
6051 R f cdr eat 18m24 1112					0	1.41mg	2.81mg		Weisburger;jnci,67,75-88;1981
mgl tum e		3.07mg *	P<.2	1.11mg n.s.s.	3/10	19/26	16/26		
THIOURACIL 141-90-2									
6052 M f c3h eat 73w73 284					0	390.mg			Casas;pseb,113,493-494;1963
liv hpt r		63.3mg	P<.0005 +	28.6mg 152.mg	0/24	14/16			
6053 M m c3h eat 73w73 284					0	360.mg			
liv hpt r		48.6mg	P<.0005 +	17.9mg 139.mg	2/32	12/13			
6054 M f tmm eat 73w73 284					0	390.mg			
liv hpt r		no dre	P=1. -	871.mg n.s.s.	0/20	0/22			
6055 M m tmm eat 73w73 284					0	360.mg			
liv hpt r		no dre	P=1. -	804.mg n.s.s.	0/20	0/22			
6056 R f f34 eat 24m24 1947					0	4.15mg	12.5mg	37.5mg	Fears;txih,5,1-23;1989
thy mal e		22.9mg *	P<.0005 +	13.8mg 42.0mg	5/214	2/23	6/24	18/24	
liv hpc e		no dre	P=1.	14.0mg n.s.s.	0/214	0/24	0/24	0/24	
6057 R m f34 eat 24m24 1947					0	3.32mg	10.0mg	30.0mg	
thy mal es		8.05mg Z	P<.0005 +	4.59mg 16.2mg	5/214	6/24	14/24	(5/24)	
liv hpc es		no dre	P=1.	11.2mg n.s.s.	0/214	0/24	0/24	0/24	
THIOUREA 62-56-6									
6058 M f c3h wat 6m24 1135					0	25.1mg			Vazquez-Lopez;bjca,3,401-414;1949
lun tum e		no dre	P=1.	331.mg n.s.s.	1/94	0/64			
6059 R m hew mix 95w95 288a					0	159.mg			Rosin;canr,17,302-305;1957
aur epc emv		104.mg	P<.0005 +	43.0mg 363.mg	0/12	7/12			
eld epc emv		225.mg	P<.02 +	76.6mg n.s.s.	0/12	4/12			
tba mix emv		50.8mg	P<.0005	21.2mg 141.mg	0/12	10/12			
6060 R m hew wat 26m26 288b					0	100.mg			
aur epc e		93.5mg	P<.0005 +	45.5mg 249.mg	0/12	11/19			
eld epc e		93.5mg	P<.0005 +	45.5mg 249.mg	0/12	11/19			
tba mix e		27.5mg	P<.0005	11.2mg 64.0mg	0/12	18/19			
6061 R f osm eat 26m26 21					0	2.50mg			Deichmann;txap,11,88-103;1967
liv tum		no dre	P=1. -	18.2mg n.s.s.	0/30	0/30			
tba mix		16.2mg	P<.7 -	2.51mg n.s.s.	13/30	15/30			
6062 R f osm eat 24m24 84a					0	4.00mg			Radomski;txap,7,652-656;1965
liv tum		no dre	P=1. -	24.7mg n.s.s.	1/30	0/30			
tba ben		15.0mg	P<.3 -	4.19mg n.s.s.	6/30	10/30			
tba mal		no dre	P=1. -	19.7mg n.s.s.	6/30	1/30			
6063 R m osm eat 26m26 21					0	2.00mg			Deichmann;txap,11,88-103;1967
liv tum		no dre	P=1. -	14.6mg n.s.s.	0/30	0/30			
tba mix		46.1mg	P<.6 -	6.34mg n.s.s.	1/30	2/30			
6064 R m osm eat 24m24 84a					0	3.20mg			Radomski;txap,7,652-656;1965
liv tum		no dre	P=1. -	19.8mg n.s.s.	0/30	0/30			
tba ben		64.7mg	P<.3 -	10.5mg n.s.s.	0/30	1/30			
tba mal		no dre	P=1. -	19.8mg n.s.s.	3/30	0/30			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site | Notes | DR | AuOp | UpConf | Brkly Code
Path | TD_{50} | 2Tailpvl | LoConf | Cntrl | 1 Inc | 2 Inc | 3 Inc | NCI/NTPPathology

TILIDINE FUMARATE (valoron) 55567-81-2
6065 M f cf1 eat 80w80 1794 | 0 | 16.0mg | 40.0mg | 100.mg | McGuire;txcy,39,149-163;1986
lun agc e | 207.mg * | P<.02 | - | 88.4mg n.s.s. | 10/100 | 7/50 | 11/50 | 12/50
liv hpa e | no dre | P=1. | - | 62.5mg n.s.s. | 2/100 | 0/50 | 0/50 | 0/50
tba mix e | 643.mg * | P<.7 | - | 79.7mg n.s.s. | 38/100 | 24/50 | 25/50 | 21/50
tba mal e | 970.mg * | P<.8 | - | 96.3mg n.s.s. | 32/100 | 21/50 | 19/50 | 18/50
tba ben e | 1.48gm * | P<.7 | - | 172.mg n.s.s. | 14/100 | 6/50 | 7/50 | 8/50
6066 M m cf1 eat 80w80 1794 | 0 | 16.0mg | 40.0mg | 100.mg
lun agc e | 936.mg * | P<.6 | - | 148.mg n.s.s. | 15/100 | 7/50 | 9/50 | 9/50
liv hem e | 2.72gm Z | P<.6 | - | 334.mg n.s.s. | 0/100 | 2/50 | 0/50 | 1/50
liv hpa e | no dre | P=1. | - | 401.mg n.s.s. | 9/100 | 3/50 | 4/50 | 2/50
tba mix e | 249.mg * | P<.3 | - | 73.9mg n.s.s. | 25/100 | 17/50 | 22/50 | 17/50
tba mal e | 391.mg * | P<.4 | - | 90.9mg n.s.s. | 21/100 | 16/50 | 18/50 | 14/50
tba ben e | no dre | P=1. | - | 243.mg n.s.s. | 9/100 | 5/50 | 6/50 | 4/50
6067 R f wal eat 24m24 1794 | 0 | 16.0mg | 40.0mg | 100.mg
liv hpa e | 476.mg * | P<.003 | - | 222.mg 2.88gm | 2/100 | 1/50 | 5/50 | 7/50
tba mal e | 525.mg * | P<.2 | - | 169.mg n.s.s. | 17/100 | 8/50 | 12/50 | 13/50
tba ben e | no dre | P=1. | - | 136.mg n.s.s. | 74/100 | 36/50 | 32/50 | 34/50
tba mix e | no dre | P=1. | - | 83.8mg n.s.s. | 81/100 | 39/50 | 36/50 | 40/50
6068 R m wal eat 24m24 1794 | 0 | 16.0mg | 40.0mg | 100.mg
liv hpa e | 11.3gm * | P<1. | - | 413.mg n.s.s. | 4/100 | 6/50 | 3/50 | 3/50
tba mix e | 122.mg * | P<.02 | - | 54.3mg n.s.s. | 55/100 | 29/50 | 29/50 | 38/50
tba ben e | 300.mg * | P<.2 | - | 97.6mg n.s.s. | 45/100 | 22/50 | 20/50 | 29/50
tba mal e | 537.mg * | P<.2 | - | 166.mg n.s.s. | 16/100 | 9/50 | 14/50 | 12/50

TILISOLOL.HCl (N-696) 62774-96-3
6069 M f cd1 gav 80w80 2373 | 0 | 3.00mg | 10.0mg | 30.0mg | James;phrm,36,261-270;1988
lun ade e | 843.mg * | P<.9 | - | 53.2mg n.s.s. | 7/52 | 8/52 | 6/52 | 8/52
lun adc e | no dre | P=1. | - | 109.mg n.s.s. | 2/52 | 2/52 | 4/52 | 1/52
liv tum e | no dre | P=1. | - | 13.6mg n.s.s. | 0/52 | 0/52 | 0/52 | 0/52
tba mix e | no dre | P=1. | - | 29.5mg n.s.s. | 23/52 | 19/52 | 24/52 | 21/52
6070 M m cd1 gav 80w80 2373 | 0 | 3.00mg | 10.0mg | 30.0mg
lun adc e | 99.2mg * | P<.03 | - | 45.7mg n.s.s. | 0/52 | 1/52 | 4/52 | 4/52
liv hpa e | 131.mg * | P<.3 | - | 36.9mg n.s.s. | 4/52 | 5/52 | 9/52 | 8/52
lun ade e | 7.20gm * | P<1. | - | 47.7mg n.s.s. | 6/52 | 13/52 | 9/52 | 9/52
liv hpc e | no dre | P=1. | - | 98.7mg n.s.s. | 4/52 | 3/52 | 2/52 | 3/52
tba mix e | 256.mg * | P<.8 | - | 24.7mg n.s.s. | 20/52 | 24/52 | 22/52 | 23/52
6071 R f cdr gav 24m24 2372 | 0 | 3.00mg | 8.00mg | 20.0mg | James;phrm,35,425-435;1988
liv hpa e | no dre | P=1. | - | 156.mg n.s.s. | 1/55 | 1/55 | 1/55 | 1/55
tba mix e | 40.0mg * | P<.7 | - | 4.62mg n.s.s. | 53/55 | 51/55 | 53/55 | 53/55
6072 R m cdr gav 24m24 2372 | 0 | 3.00mg | 8.00mg | 20.0mg
liv hpa e | 384.mg * | P<.05 | - | 116.mg n.s.s. | 0/55 | 0/55 | 1/55 | 2/55
liv hpc e | no dre | P=1. | - | 159.mg n.s.s. | 2/55 | 0/55 | 2/55 | 1/55
tba mix e | 128.mg * | P<.8 | - | 13.1mg n.s.s. | 47/55 | 36/55 | 45/55 | 44/55

TIN (II) CHLORIDE (stannous chloride) 7772-99-8
6073 M f b6c eat 24m24 TR231 : | 0 | 130.mg | 258.mg
pit ade ae# | 1.39gm * | P<.05 | - | 564.mg n.s.s. | 0/50 | 4/50 | 2/50 | S
liv hpc ae | 1.42gm * | P<.03 | | 574.mg n.s.s. | 0/50 | 3/50 | 3/50 | S
--- lhc ae | 2.55gm * | P<.02 | | 871.mg n.s.s. | 0/50 | 0/50 | 4/50 | S
TBA MXB ae | 386.mg * | P<.09 | | 150.mg n.s.s. | 22/50 | 32/50 | 27/50
liv MXB ae | 1.02gm * | P<.06 | | 396.mg n.s.s. | 3/50 | 4/50 | 8/50 | liv:hpa,hpc,nnd.
lun MXB ae | no dre | P=1. | | 1.06gm n.s.s. | 4/50 | 1/50 | 3/50 | lun:a/a,a/c.
6074 M m b6c eat 24m24 TR231 : | 0 | 120.mg | 240.mg
TBA MXB | no dre | P=1. | - | 373.mg n.s.s. | 33/50 | 29/50 | 33/50
liv MXB | no dre | P=1. | | 655.mg n.s.s. | 16/50 | 10/50 | 15/50 | liv:hpa,hpc,nnd.
lun MXB | no dre | P=1. | | 671.mg n.s.s. | 10/50 | 10/50 | 10/50 | lun:a/a,a/c.
6075 M b cd1 wat 24m24 1512 | 0 | .877mg | Kanisawa;canr,27,1192-1195;1967
lun mix e | no dre | P=1. | - | 5.26mg n.s.s. | 26/170 | 10/86
lun ade e | no dre | P=1. | - | 12.0mg n.s.s. | 7/170 | 1/86
tba mix e | no dre | P=1. | - | 3.83mg n.s.s. | 55/170 | 22/86
tba mal e | no dre | P=1. | - | 6.06mg n.s.s. | 15/170 | 6/86
tba ben e | no dre | P=1. | - | 6.42mg n.s.s. | 29/170 | 9/86
6076 R f f34 eat 24m24 TR231 : | 0 | 50.0mg | 100.mg
TBA MXB | 12.0gm * | P<1. | - | 87.0mg n.s.s. | 40/50 | 38/50 | 37/50
liv MXB | 676.gm * | P<1. | | 891.mg n.s.s. | 1/50 | 0/50 | 1/50 | liv:hpa,hpc,nnd.
6077 R m f34 eat 24m24 TR231 : | 0 | 40.0mg | 80.0mg
thy MXA ae# | 87.4mg \ | P<.004 | - | 41.4mg 628.mg | 2/50 | 13/50 | (8/50) | thy:cca,ccr. S
thy ccr ae | 405.mg * | P<.03 | | 174.mg n.s.s. | 0/50 | 4/50 | 3/50 | S
lun a/a ae | 951.mg * | P<.04 | | 287.mg n.s.s. | 0/50 | 0/50 | 3/50 | S
TBA MXB ae | 180.mg * | P<.4 | | 49.0mg n.s.s. | 36/50 | 37/50 | 38/50
liv MXB ae | no dre | P=1. | | 598.mg n.s.s. | 2/50 | 0/50 | 1/50 | liv:hpa,hpc,nnd.
6078 R b leb wat 36m36 1036 | 0 | .265mg | Kanisawa;canr,29,892-895;1969
liv tum e | no dre | P=1. | - | 11.5mg n.s.s. | 1/82 | 0/94
tba tum e | no dre | P=1. | - | 2.08mg n.s.s. | 31/82 | 29/94
tba mal e | no dre | P=1. | - | 5.54mg n.s.s. | 9/82 | 5/94

TITANIUM DIOXIDE 13463-67-7
6079 M f b6c eat 24m24 TR97 : | 0 | 3.22gm | 6.44gm
TBA MXB | 55.8gm * | P<.8 | - | 6.64gm n.s.s. | 30/50 | 24/50 | 26/50
liv MXB | 55.5gm * | P<.2 | | 17.0gm n.s.s. | 1/50 | 3/50 | 3/50 | liv:hpa,hpc,nnd.
lun MXB | 50.4gm * | P<.1 | | 16.9gm n.s.s. | 1/50 | 2/50 | 4/50 | lun:a/a,a/c.
6080 M m b6c eat 24m24 TR97 : | 0 | 2.97gm | 5.94gm
TBA MXB | no dre | P=1. | - | 9.26gm n.s.s. | 29/50 | 25/50 | 28/50
liv MXB | 38.7gm * | P<.4 | | 9.45gm n.s.s. | 8/50 | 9/50 | 14/50 | liv:hpa,hpc,nnd.
lun MXB | no dre | P=1. | | 24.2gm n.s.s. | 6/50 | 3/50 | 5/50 | lun:a/a,a/c.
6081 R f f34 eat 24m24 TR97 : | 0 | 1.24gm | 2.48gm
thy MXA # | 17.2gm / | P<.04 | - | 6.25gm n.s.s. | 1/50 | 0/50 | 6/50 | thy:cca,ccr. S

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site Path	Notes	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
TBA MXB		5.01gm *	P<.4	1.23gm n.s.s.	41/50	43/50	46/50		
liv MXB		no dre	P=1.	28.2gm n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
6082 R m f34 eat 24m24 TR97 :					0	990.mg	1.98gm		
--- ker #		25.9gm *	P<.05 -	7.81gm n.s.s.	0/50	0/50	3/50		s
TBA MXB		23.0gm *	P<.9	1.54gm n.s.s.	32/50	40/50	36/50		
liv MXB		no dre	P=1.	16.7gm n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
TITANIUM OXALATE, POTASSIUM 14481-26-6									
6083 M f cd1 wat 31m31 56					0	1.00mg			Schroeder;jnut,83,239-250;1964
lun tum e		150.mg	P<1. -	3.59mg n.s.s.	9/60	5/32			
tba tum e		no dre	P=1. -	4.45mg n.s.s.	22/60	7/32			
6084 M f cd1 wat 26m26 1395					0	1.00mg			Schroeder;jnut,105,452-458;1975
tba mix e		3.66mg	P<.2 -	1.24mg n.s.s.	9/45	13/36			
6085 M m cd1 wat 25m25 56					0	.833mg			Schroeder;jnut,83,239-250;1964
lun tum e		no dre	P=1. -	6.12mg n.s.s.	8/44	1/40			
tba tum e		no dre	P=1. -	4.09mg n.s.s.	11/44	4/40			
6086 M m cd1 wat 28m28 1395					0	.833mg			Schroeder;jnut,105,452-458;1975
tba mix e		3.62mg	P<.2 -	1.23mg n.s.s.	10/43	17/45			
TITANOCENE DICHLORIDE 1271-19-8									
6087 R f f34 gav 24m25 TR399 :					0	17.4mg	34.8mg		
for sqp		378.mg *	P<.08 e	114.mg n.s.s.	0/60	1/61	2/60		
TBA MXB		no dre	P=1.	21.7mg n.s.s.	55/60	53/61	46/60		
liv MXB		378.mg *	P<.08	114.mg n.s.s.	0/60	1/61	2/60		liv:hpa,hpc,nnd.
6088 R m f34 gav 24m24 TR399 :					0	17.5mg	35.2mg		
for sqp		88.6mg \	P<.01 e	30.6mg 10.4gm	0/60	4/60	(1/60)		
mul msm		158.mg *	P<.007	67.1mg 1.74gm	0/60	3/60	4/60		s
pan ana		97.6mg \	P<.02	33.4mg n.s.s.	0/60	4/60	(0/60)		s
for MXA		157.mg *	P<.03 e	64.2mg n.s.s.	0/60	4/60	2/60		for:bsb,sqc,sqp.
TBA MXB		40.0mg *	P<.2	13.0mg n.s.s.	52/60	52/60	43/60		
liv MXB		143.mg *	P<.07	52.4mg n.s.s.	4/60	3/60	8/60		liv:hpa,hpc,nnd.
DL-alpha-TOCOPHEROL (vitamin E) 10191-41-0									
6089 R f f3d eat 54w54 2612					0	250.mg			Hagiwara;gann,90,399-405;1999
col tum e		no dre	P=1. -	139.mg n.s.s.	0/10	0/10			
mgl tum e		no dre	P=1. -	139.mg n.s.s.	0/10	0/10			
6090 R m f3d eat 52w52 1900					0	400.mg			Hirose;carc,8,1731-1735;1987/pers.comm.
eso tum er		no dre	P=1. -	206.mg n.s.s.	0/10	0/10			
for tum er		no dre	P=1. -	206.mg n.s.s.	0/10	0/10			
liv tum er		no dre	P=1. -	206.mg n.s.s.	0/10	0/10			
DL-alpha-TOCOPHEROL ACETATE (vitamin E acetate) 7695-91-2									
6091 R f cdr eat 52w52 1558m					0	500.mg	1.00gm	2.00gm	Wheldon;ijvn,53,287-296;1983
liv tum ek		no dre	P=1. -	147.mg n.s.s.	0/10	0/10	0/10	0/10	
6092 R f cdr eat 24m24 1558n					0	500.mg	1.00gm	2.00gm	
liv tum e		no dre	P=1. -	24.4gm n.s.s.	2/50	1/49	1/50	0/50	
tba mix e		no dre	P=1. -	911.mg n.s.s.	46/50			45/50	
tba mal e		no dre	P=1. -	8.01gm n.s.s.	9/50			6/50	
6093 R m cdr eat 52w52 1558m					0	500.mg	1.00gm	2.00gm	
liv tum ek		no dre	P=1. -	147.mg n.s.s.	0/10	0/10	0/10	0/10	
6094 R m cdr eat 24m24 1558n					0	500.mg	1.00gm	2.00gm	
liv tum e		no dre	P=1. -	21.4gm n.s.s.	2/49	1/50	0/50	1/50	
tba mix e		67.8gm	P<1. -	2.12gm n.s.s.	28/49			29/50	
tba mal e		67.8gm	P<.9 -	5.23gm n.s.s.	7/49			8/50	
DL-TOCOPHEROL, MIXTURE OF NATURAL ISOMERS (alpha, beta, gamma and delta) (E-mix 80, natural vitamin E) 1406-66-2									
6095 M m b6c eat 96w96 2398					0	6.00gm			Nitta;jtxp,4,55-61;1991/pers.comm.
liv mix		3.61gm	P<.0005 +	2.07gm 8.62gm	12/46	36/50			
liv hpc		5.22gm	P<.0005 +	2.85gm 15.9gm	10/46	30/50			
lun mix		no dre	P=1.	16.0gm n.s.s.	9/46	8/50			
TOLAZAMIDE 1156-19-0									
6096 M f b6c eat 24m24 TR51 :					0	455.mg	919.mg		
TBA MXB		no dre	P=1. -	867.mg n.s.s.	8/15	6/35	9/34		
liv MXB		no dre	P=1.	1.61gm n.s.s.	1/15	1/35	1/34		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	3.33gm n.s.s.	1/15	0/35	1/34		lun:a/a,a/c.
6097 M m b6c eat 24m24 TR51 :					0	420.mg	848.mg		
TBA MXB		no dre	P=1. -	643.mg n.s.s.	8/15	11/35	(5/35)		
liv MXB		no dre	P=1.	2.87gm n.s.s.	3/15	2/35	3/35		liv:hpa,hpc,nnd.
lun MXB		24.6gm *	P<.9	2.07gm n.s.s.	0/15	2/35	1/35		lun:a/a,a/c.
6098 R f f34 eat 24m24 TR51 :					0	175.mg	354.mg		
TBA MXB		no dre	P=1. -	214.mg n.s.s.	13/15	23/35	20/35		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/15	1/35	0/35		liv:hpa,hpc,nnd.
6099 R m f34 eat 24m24 TR51 :					0	140.mg	283.mg		
TBA MXB		no dre	P=1. -	277.mg n.s.s.	9/15	19/35	20/35		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
TOLBUTAMIDE 64-77-7									
6100 M f b6c eat 18m24 TR31 :					0	1.76gm	3.52gm		
TBA MXB		24.2gm \	P<.9 -	1.63gm n.s.s.	3/15	11/35	(3/35)		
liv MXB		no dre	P=1.	10.6gm n.s.s.	1/15	2/35	1/35		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	10.3gm n.s.s.	0/15	2/35	0/35		lun:a/a,a/c.
6101 M m b6c eat 18m24 TR31 :					0	1.62gm	3.28gm		
TBA MXB		no dre	P=1. -	1.16gm n.s.s.	8/15	13/35	(2/35)		
liv MXB		no dre	P=1.	1.96gm n.s.s.	3/15	4/35	(1/35)		liv:hpa,hpc,nnd.
lun MXB		no dre	P=1.	9.12gm n.s.s.	1/15	2/35	0/35		lun:a/a,a/c.
6102 R f f34 eat 18m25 TR31 :					0	315.mg	631.mg		
TBA MXB		no dre	P=1. -	662.mg n.s.s.	13/15	15/35	16/35		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
6103 R m f34 eat 18m25 TR31 :					0	252.mg	505.mg		
TBA MXB		no dre	P=1.	- 654.mg n.s.s.	8/15	13/35	17/35		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/15	0/35	0/35		liv:hpa,hpc,nnd.
TOLUENE (monomethyl benzene) 108-88-3									
6104 M f b6c inh 24m24 TR371 :					0	151.mg	766.mg	1.51gm	
TBA MXB		3.53gm	* P<.6	- 607.mg n.s.s.	33/50	36/50	42/50	38/50	
liv MXB		5.39gm	* P<.3	1.57gm n.s.s.	7/50	9/50	8/50	13/50	liv:hpa,hpc,nnd.
lun MXB		10.2gm	* P<.4	2.27gm n.s.s.	5/50	3/50	4/50	7/50	lun:a/a,a/c.
6105 M m b6c inh 24m24 TR371 :					0	126.mg	630.mg	1.26gm	
TBA MXB		3.00gm	* P<.6	- 511.mg n.s.s.	29/60	29/60	26/60	33/60	
liv MXB		12.6gm	* P<.9	985.mg n.s.s.	19/60	17/60	18/60	19/60	liv:hpa,hpc,nnd.
lun MXB		9.44gm	Z P<.5	1.87gm n.s.s.	9/60	1/60	2/60	9/60	lun:a/a,a/c.
6106 R f f34 inh 24m24 TR371 :					0	180.mg	360.mg		
TBA MXB		8.89gm	* P<1.	- 176.mg n.s.s.	46/50	43/50	43/50		
liv MXB		no dre	P=1.	1.41gm n.s.s.	2/50	3/50	0/50		liv:hpa,hpc,nnd.
6107 R f f34 inh 25m25 1578					0	84.6mg			Gralla;ctfr;1983/Gibson 1983
liv mix e		1.76gm	P<.2	- 490.mg n.s.s.	1/90	4/90			
6108 R m f34 inh 24m24 TR371 :					0	126.mg	252.mg		
TBA MXB		481.mg	* P<.6	- 94.1mg n.s.s.	43/50	44/50	42/50		
liv MXB		no dre	P=1.	756.mg n.s.s.	4/50	3/50	0/50		liv:hpa,hpc,nnd.
6109 R m f34 inh 25m25 1578					0	59.2mg			Gralla;ctfr;1983/Gibson 1983
liv mix e		1.21gm	P<.4	- 297.mg n.s.s.	3/89	6/90			
6110 R f sda gav 24m29 BT910					0	387.mg			Maltoni;anya,837,15-52;1997
--- lkm		8.52gm	P<.5	1.62gm n.s.s.	3/50	5/50			
orc car		8.89gm	P<.3	1.96gm n.s.s.	1/50	3/50			
tba mal		3.42gm	P<.4	834.mg n.s.s.	11/50	15/50			
tba mix		no dre	P=1.	845.mg n.s.s.	35/50	29/50			
6111 R f sda gav 24m33 BT903m					0	237.mg			Maltoni;ajim,7,415-446;1985/1997a
--- lkm j		1.73gm	P<.009	696.mg 52.1gm	1/50	7/40			
hed car jh		5.82gm	P<.07 +	1.43gm n.s.s.	0/50	2/40			
mam car j		2.18gm	P<.2	644.mg n.s.s.	7/50	10/40			
nas car j		11.8gm	P<.3	1.92gm n.s.s.	0/50	1/40			
orc car j		11.8gm	P<.3	1.92gm n.s.s.	0/50	1/40			
tba mix j		215.mg	P<.002	98.7mg 1.07gm	30/50	36/40			
tba mal ej		578.mg	P<.002	281.mg 3.19gm	10/49	21/40			
6112 R m sda gav 24m29 BT910					0	387.mg			Maltoni;anya,837,15-52;1997
hed car h		2.08gm	P<.005 +	914.mg 20.4gm	1/50	9/50			
orc car		2.46gm	P<.002	1.06gm 10.3gm	0/50	7/50			
--- lkm		5.37gm	P<.4	1.23gm n.s.s.	5/50	8/50			
edu car		18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50			
nas car		18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50			
zym car		no dre	P=1.	5.57gm n.s.s.	1/50	0/50			
tba mal		1.57gm	P<.09	583.mg n.s.s.	12/50	20/50			
tba mix		2.65gm	P<.6	482.mg n.s.s.	27/50	30/50			
6113 R m sda gav 24m33 BT903m					0	237.mg			Maltoni;ajim,7,415-446;1985/1997a
tba mix j		478.mg	P<.05	184.mg n.s.s.	29/50	31/40			
tba mal ej		940.mg	P<.05	371.mg n.s.s.	11/45	18/40			
TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4 (80%)- AND 2,6 (20%)-) 26471-62-5									
6114 M f b6c gav 24m25 TR251 :					0	42.5mg	84.1mg		
MXB MXB		181.mg	/ P<.0005	97.9mg 612.mg	2/50	4/50	16/50		abc:hes; liv:hes,hpa; ova:hes; spl:hem; sub:hem. C
liv MXA		215.mg	/ P<.008	103.mg 5.59gm	4/50	5/50	15/50		liv:hpa,hpc. S
liv hpa		250.mg	/ P<.005 c	121.mg 2.38gm	2/50	3/50	12/50		
MXA MXA		580.mg	* P<.008 c	236.mg 10.7gm	0/50	1/50	5/50		abc:hes; liv:hes; ova:hes; spl:hem; sub:hem.
MXA hes		1.20gm	* P<.04	362.mg n.s.s.	0/50	0/50	3/50		abc:hes; liv:hes; ova:hes. S
TBA MXB		305.mg	* P<.5	66.0mg n.s.s.	26/50	31/50	30/50		
liv MXB		215.mg	/ P<.008	103.mg 5.59gm	4/50	5/50	15/50		liv:hpa,hpc,nnd.
lun MXB		815.mg	* P<.3	282.mg n.s.s.	0/50	3/50	1/50		lun:a/a,a/c.
6115 M m b6c gav 24m25 TR251 :					0	84.9mg	168.mg		
TBA MXB		253.mg	\ P<.3	- 75.0mg n.s.s.	22/50	27/50	(9/50)		
liv MXB		no dre	P=1.	371.mg n.s.s.	11/50	12/50	5/50		liv:hpa,hpc,nnd.
lun MXB		1.92gm	* P<.5	416.mg n.s.s.	2/50	5/50	2/50		lun:a/a,a/c.
6116 M f cd1 inh 24m24 2178					0	.112mg	.336mg		Loeser;txlt,15,71-81;1983
lun ade es		no dre	P=1.	- .422mg n.s.s.	23/90	20/90	(11/89)		
lun car es		no dre	P=1.	- 1.22mg n.s.s.	4/90	2/90	(0/89)		
liv hpc es		no dre	P=1.	- 4.72mg n.s.s.	0/90	1/90	0/89		
liv hpa es		no dre	P=1.	- 6.31mg n.s.s.	5/90	0/90	1/89		
tba mix es		no dre	P=1.	- .233mg n.s.s.	56/90	50/90	(22/89)		
tba mal es		no dre	P=1.	- .344mg n.s.s.	30/90	27/90	(10/89)		
tba ben es		no dre	P=1.	- .389mg n.s.s.	39/90	31/90	(14/89)		
6117 M m cd1 inh 24m24 2178					0	93.3ug	.280mg		
lun ade e		.300mg	\ P<.02	- .136mg n.s.s.	17/90	31/90	(22/90)		
liv hpc e		no dre	P=1.	- .370mg n.s.s.	24/90	20/90	(12/90)		
liv hpa e		no dre	P=1.	- .376mg n.s.s.	21/90	18/90	(9/90)		
lun car e		no dre	P=1.	- 2.45mg n.s.s.	6/90	4/90	4/90		
tba mix e		1.63mg	\ P<.9	- 96.1ug n.s.s.	64/90	65/90	(43/90)		
tba mal e		no dre	P=1.	- .186mg n.s.s.	39/90	39/90	(23/90)		
tba ben e		no dre	P=1.	- 1.08mg n.s.s.	38/90	44/90	29/90		
6118 R f f34 gav 25m25 TR251 :					0	42.1mg	83.3mg		
MXB MXB		25.4mg	* P<.0005	14.7mg 57.3mg	19/50	26/50	24/50		liv:nnd; mgl:fba; pni:isa; sub:fbs,fib. C
mgl fba		33.4mg	* P<.0005 c	18.5mg 87.1mg	15/50	21/50	18/50		
liv nnd		92.2mg	* P<.0005 c	44.4mg 344.mg	3/50	8/50	8/50		
pni MXA		115.mg	* P<.0005	51.9mg 383.mg	0/50	7/50	2/50		pni:isa,isc. S
pni isa		135.mg	* P<.002 c	58.3mg 523.mg	0/50	6/50	2/50		
adr phe		143.mg	* P<.007	58.4mg 2.25gm	2/50	5/50	4/50		S
adr coa		174.mg	* P<.007	67.1mg 3.51gm	2/50	3/50	5/50		S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
sub	fib	256.mg *	P<.004	87.6mg 1.88gm	0/50	1/50	3/50		S
pit	cra	77.3mg *	P<.03	32.1mg n.s.s.	25/50	15/50	16/50		S
pit	MXA	86.9mg *	P<.05	33.7mg n.s.s.	27/50	15/50	16/50		pit:cra,crc. S
sub	MXA	206.mg /	P<.02 c	73.7mg 43.3gm	2/50	1/50	5/50		sub:fbs,fib.
cli	adn	260.mg *	P<.03	87.3mg n.s.s.	0/50	4/50	0/50		S
TBA	MXB	25.1mg *	P<.0005	13.6mg 82.8mg	45/50	36/50	34/50		
liv	MXB	92.2mg *	P<.0005	44.4mg 344.mg	3/50	8/50	8/50		liv:hpa,hpc,nnd.
6119 R m f34 gav 25m25 TR251 :					0	21.0mg	41.7mg		
tes	MXA	13.6mg *	P<.002	6.93mg 71.9mg	48/50	35/50	30/50		tes:ict,itm. S
MXB	MXB	27.3mg *	P<.0005	14.9mg 65.4mg	4/50	8/50	14/50		pan:ana; sub:fbs,fib. C
sub	MXA	34.1mg *	P<.0005 c	18.0mg 88.4mg	3/50	6/50	12/50		sub:fbs,fib.
pan	ana	51.6mg *	P<.0005 c	23.2mg 183.mg	1/50	3/50	7/50		
sub	fib	56.0mg *	P<.0005	25.2mg 239.mg	3/50	3/50	9/50		S
pit	cra	76.4mg *	P<.005	32.2mg 732.mg	3/50	4/50	7/50		S
sub	fbs	92.4mg *	P<.002	36.9mg 421.mg	0/50	3/50	3/50		S
pit	MXA	83.7mg *	P<.02	33.6mg 12.8gm	4/50	4/50	7/50		pit:cra,crc. S
sub	MXA	103.mg *	P<.02	39.2mg n.s.s.	1/50	4/50	3/50		sub:fbs,ost,srn. S
pni	MXA	201.mg *	P<.03	57.7mg n.s.s.	1/50	0/50	4/50		pni:isa,isc. S
TBA	MXB	18.4mg *	P<.002	9.29mg 94.4mg	40/50	24/50	29/50		
liv	MXB	196.mg *	P<.4	42.4mg n.s.s.	7/50	3/50	4/50		liv:hpa,hpc,nnd.
6120 R f cdr inh 25m25 2178					0	26.7ug	80.0ug		Loeser;txlt,15,71-81;1983
liv	hpc e	8.24mg *	P<.3 -	1.34mg n.s.s.	0/104	0/105	1/105		
tba	mal e	1.09mg *	P<.5 -	.247mg n.s.s.	21/104	18/105	25/105		
tba	ben e	no dre	P=1. -	80.1ug n.s.s.	102/104	94/105	96/105		
tba	mix e	no dre	P=1. -	46.5ug n.s.s.	104/104	98/105	101/105		
6121 R m cdr inh 26m26 2178					0	18.7ug	56.0ug		
liv	hpc e	no dre	P=1. -	1.03mg n.s.s.	0/104	1/104	0/104		
tba	mix e	no dre	P=1. -	76.3ug n.s.s.	86/104	67/104	81/104		
tba	ben e	no dre	P=1. -	.103mg n.s.s.	77/104	64/104	71/104		
tba	mal e	6.18mg *	P<1. -	.263mg n.s.s.	17/104	14/104	17/104		
o-TOLUENESULFONAMIDE 88-19-7									
6122 R f cdr eat 33m33 1398					0	2.50mg	25.0mg	250.mg	Arnold;txap,52,113-152;1980
mgl	adc eg	12.2mg Z	P<.02	5.34mg n.s.s.	6/48	16/49	(6/49	5/49)	
liv	kcs eg	8.52gm *	P<.03	2.10gm n.s.s.	0/48	0/49	0/49	2/49	
liv	nnd eg	21.7gm *	P<.6	2.01gm n.s.s.	0/48	0/49	2/49	1/49	
6123 R m cdr eat 33m33 1398					0	2.50mg	25.0mg	250.mg	
liv	ang e	17.2gm *	P<.2	2.81gm n.s.s.	0/49	0/49	0/50	1/49	
liv	nnd e	35.9gm *	P<.7	4.05gm n.s.s.	0/49	1/49	1/50	1/49	
liv	blc e	no dre	P=1.	5.04gm n.s.s.	0/49	1/49	0/50	0/49	
6124 R b sda eat 31m33 1397					0	20.0mg	200.mg		Schmahl;zkko,91,19-22;1978
---	leu a	375.mg \	P<.009	143.mg 8.60gm	0/76	5/76	(3/76)		
ubl	mix a	3.96gm *	P<.06 +	1.26gm n.s.s.	0/76	3/76	5/76		
liv	car a	no dre	P=1.	531.mg n.s.s.	1/76	0/76	0/76		
tba	mal a	13.3gm *	P<.9	1.02gm n.s.s.	13/76	20/76	17/76		
6125 R f wis wat 24m24 1433					0	57.1mg			Hooson;bjca,42,129-147;1980
liv	hpc e	no dre	P=1. -	544.mg n.s.s.	1/50	0/48			
m-TOLUIDINE.HCl 638-03-9									
6126 M f chi eat 77w90 381 :					0	1.14gm			Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv	mix v	9.99gm	P<.6 -	1.29gm n.s.s.	1/22	2/18			
lun	mix v	no dre	P=1. -	1.04gm n.s.s.	5/22	4/18			
tba	mix v	no dre	P=1. -	919.mg n.s.s.	18/22	10/18			
6127 M f chi eat 77w81 381m :					0	2.66gm			
lun	mix v	no dre	P=1. -	2.75gm n.s.s.	8/15	2/19			
liv	mix v	no dre	P=1. -	n.s.s. n.s.s.	0/15	0/19			
tba	mix v	1.95gm	P<.09 -	410.mg n.s.s.	11/15	7/19			
6128 M m chi eat 77w90 381 :					0	754.mg	1.51gm		
liv	mix v	6.77gm *	P<.7	1.06gm n.s.s.	1/18	4/16	2/16		
lun	mix v	no dre	P=1. -	1.45gm n.s.s.	8/18	2/16	5/16		
tba	mix v	no dre	P=1.	751.mg n.s.s.	13/18	10/16	10/16		
6129 M m chi eat 77w90 381 : pool					0	754.mg	1.51gm		
liv	hpt v	1.44gm \	P<.2 +	368.mg n.s.s.	7/99	4/16	(1/16)		
6130 R m cdr eat 77w98 381 :					0	146.mg	292.mg		
liv	mix v	no dre	P=1. -	n.s.s. n.s.s.	0/16	0/20	0/18		
tba	mix v	98.4mg \	P<.2 -	31.7mg n.s.s.	9/16	17/20	(9/18)		
o-TOLUIDINE.HCl 636-21-5									
6131 M f b6c eat 24m24 TR153 :					0	130.mg	390.mg		
liv	MXA	754.mg *	P<.002 c	428.mg 2.86gm	0/20	4/50	13/50		liv:hpa,hpc.
liv	hpc	1.52gm *	P<.02 c	716.mg n.s.s.	0/20	2/50	7/50		
TBA	MXB	1.35gm *	P<.4	344.mg n.s.s.	8/20	19/50	26/50		
liv	MXB	754.mg *	P<.002	428.mg 2.86gm	0/20	4/50	13/50		liv:hpa,hpc,nnd.
lun	MXB	no dre	P=1.	1.66gm n.s.s.	1/20	2/50	2/50		lun:a/a,a/c.
6132 M m b6c eat 24m24 TR153 :					0	120.mg	360.mg		
---	MXA a	926.mg *	P<.005 c	453.mg 8.19gm	1/20	2/50	12/50		---:hem,hes.
---	hes a	1.22gm /	P<.01 c	554.mg 80.1gm	1/20	1/50	10/50		
TBA	MXB a	no dre	P=1.	304.mg n.s.s.	17/20	28/50	30/50		
liv	MXB a	12.7gm *	P<1.	404.mg n.s.s.	5/20	19/50	14/50		liv:hpa,hpc,nnd.
lun	MXB a	no dre	P=1.	473.mg n.s.s.	5/20	5/50	(3/50)		lun:a/a,a/c.
6133 M f chi eat 68w90 381 :					0	1.09gm	2.50gm		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv	mix av	1.65gm *	P<.008 -	544.mg 46.2gm	0/15	3/18	2/21		
lun	mix av	no dre	P=1. -	1.18gm n.s.s.	8/15	3/18	0/21		
tba	mix av	699.mg *	P<.007	283.mg 12.1gm	11/15	12/18	8/21		
6134 M f chi eat 68w90 381 : pool					0	1.09gm	2.50gm		
---	vsc av	1.24gm *	P<.0005 +	513.mg 3.75gm	8/102	4/18	8/21		
6135 M m chi eat 68w90 381 :					0	1.01gm	2.30gm		
---	vsc av	646.mg /	P<.0005 +	300.mg 1.75gm	0/14	4/14	8/11		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv mix av	1.40gm *	P<.005 -	474.mg 12.0gm	1/14	2/14	4/11		
lun mix av	1.16gm *	P<.1 -	353.mg n.s.s.	4/14	5/14	2/11		
tba mix av	325.mg /	P<.0005	154.mg 1.13gm	8/14	10/14	11/11		
6136 M m chi eat 68w90 381 : pool				0	1.01gm	2.30gm		
--- vsc av	660.mg /	P<.0005 +	301.mg 1.84gm	5/99	4/14	8/11		
6137 R f f34 eat 24m24 TR153 :				0	150.mg	300.mg		
MXB MXB s	77.9mg /	P<.0005	51.9mg 141.mg	7/20	32/50	48/50	mgl:adn,fba; mul:ang,fbs,ost,srn; spl:ang,ost,srn; ubl: tcc,tpp.	C
mgl fba s	115.mg /	P<.0005 c	72.0mg 244.mg	6/20	20/50	35/50		
mgl MXA s	119.mg /	P<.0005 c	73.4mg 268.mg	7/20	20/50	35/50	mgl:adn,fba.	
ubl MXA s	175.mg /	P<.0005 c	111.mg 299.mg	0/20	10/50	22/50	ubl:tcc,tpp.	
ubl tcc s	185.mg /	P<.0005 c	116.mg 318.mg	0/20	9/50	22/50		
mul MXA s	332.mg /	P<.0005 c	199.mg 605.mg	0/20	3/50	21/50	mul:ang,fbs,ost,srn.	
spl MXA s	337.mg *	P<.0005 c	193.mg 810.mg	0/20	9/50	12/50	spl:ang,ost,srn.	
mul ost s	423.mg /	P<.0005 c	236.mg 844.mg	0/20	0/50	18/50		
spl ang s	450.mg *	P<.002 c	239.mg 1.53gm	0/20	7/50	9/50		
TBA MXB s	75.8mg *	P<.0005	47.1mg 174.mg	13/20	43/50	48/50		
liv MXB s	no dre	P=1.	n.s.s. n.s.s.	0/20	2/50	0/50	liv:hpa,hpc,nnd.	
6138 R m f34 eat 24m24 TR153 :				0	120.mg	240.mg		
MXB MXB as	23.3mg /	P<.0005	15.5mg 35.3mg	0/20	44/50	48/50	mul:ang,fbs,mso,ost,srn; spl:fib; sub:fib; tnv:mso.	C
sub fib as	33.3mg /	P<.0005 c	20.9mg 54.6mg	0/20	28/50	27/50		
mul MXA as	93.2mg /	P<.0005 c	59.7mg 140.mg	0/20	15/50	37/50	mul:ang,fbs,ost,srn.	
MXA mso as	97.4mg *	P<.0005 c	53.3mg 189.mg	0/20	17/50	9/50	mul:mso; tnv:mso.	
spl fib as	134.mg *	P<.0005 c	64.1mg 355.mg	0/20	10/50	2/50		
mul fbs as	184.mg /	P<.0005 c	99.1mg 336.mg	0/20	8/50	20/50		
mul srn as	394.mg /	P<.0005 c	192.mg 981.mg	0/20	3/50	11/50		
TBA MXB as	24.4mg /	P<.0005	15.8mg 40.6mg	10/20	50/50	48/50		
liv MXB as	645.mg /	P<.06	169.mg n.s.s.	1/20	1/50	3/50	liv:hpa,hpc,nnd.	
6139 R m f34 eat 72w93 1487				0	124.mg		Hecht;clet,16,103-108;1982	
ski fib e	38.7mg	P<.0005 +	21.8mg 74.2mg	1/27	25/30			
mam fba e	149.mg	P<.0005 +	74.0mg 372.mg	0/27	11/30			
spl fib e	167.mg	P<.0005 +	81.0mg 452.mg	0/27	10/30			
pec scs e	190.mg	P<.0005	89.2mg 571.mg	0/27	9/30			
ubl mix e	474.mg	P<.03 +	164.mg n.s.s.	0/27	4/30			
liv mix e	1.00gm	P<.4	212.mg n.s.s.	1/27	3/30			
6140 R m cdr eat 64w68 381 :				0	192.mg	384.mg	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
sub mix v	36.7mg *	P<.0005 +	22.4mg 62.5mg	0/16	18/23	21/24		
liv mix v	2.96gm *	P<.3 -	482.mg n.s.s.	0/16	0/23	1/24		
tba mix v	36.1mg *	P<.0005	20.2mg 82.4mg	9/16	19/23	23/24		
6141 R m cdr eat 64w68 381 : pool				0	192.mg	384.mg		
sub mix v	38.8mg *	P<.0005 +	23.6mg 65.9mg	18/111	18/23	21/24		
ubl mix v	131.mg *	P<.0005 +	48.9mg 535.mg	5/111	3/23	4/24		
p-TOLUIDINE.HCl 540-23-8								
6142 M f chi eat 77w98 381 :				0	74.3mg	142.mg	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
liv mix v	256.mg *	P<.06	93.6mg n.s.s.	0/20	2/21	3/17		
lun mix v	400.mg *	P<.5 -	86.3mg n.s.s.	6/20	3/21	7/17		
tba mix v	no dre	P=1.	97.1mg n.s.s.	17/20	6/21	10/17		
6143 M f chi eat 77w98 381 : pool				0	74.3mg	142.mg		
liv hpt v	278.mg *	P<.01 +	94.7mg 29.2gm	1/102	2/21	3/17		
6144 M m chi eat 77w98 381 :				0	68.6mg	131.mg		
liv hpt v	49.1mg \	P<.02 +	19.3mg n.s.s.	3/18	8/17	(9/18)		
liv mix v	49.1mg \	P<.02 +	19.3mg n.s.s.	3/18	8/17	(9/18)		
lun mix v	78.6mg \	P<.06 -	26.8mg n.s.s.	5/18	6/17	(8/18)		
tba mix v	49.4mg \	P<.06	17.2mg n.s.s.	12/18	12/17	(14/18)		
6145 M m chi eat 77w98 381 : pool				0	68.6mg	131.mg		
liv hpt v	50.1mg \	P<.0005 +	20.2mg 212.mg	7/99	8/17	(9/18)		
6146 R m cdr eat 77w98 381 :				0	31.3mg	62.6mg		
liv mix	no dre	P=1. -	116.mg n.s.s.	1/22	1/22	1/21		
tba mix	no dre	P=1. -	42.9mg n.s.s.	14/22	12/22	12/21		
p-TOLYLUREA 622-51-5								
6147 M f cb6 eat 52w69 1343 pool				0	196.mg		Fleischman;jept,3,149-170;1980	
liv hpc e	no dre	P=1. -	674.mg n.s.s.	1/89	0/38			
lun a/a e	no dre	P=1. -	674.mg n.s.s.	2/89	0/38			
6148 M m cb6 eat 52w69 1343 pool				0	181.mg			
--- mly e	206.mg	P<.0005 +	100.mg 529.mg	0/95	10/43			
--- mlh e	265.mg	P<.0005	120.mg 776.mg	0/95	8/43			
mul mlh e	441.mg	P<.002	167.mg 1.93gm	0/91	5/43			
mln mlh e	626.mg	P<.009	189.mg 17.3gm	0/79	3/36			
liv hpc e	722.mg	P<.08 -	207.mg n.s.s.	2/91	4/43			
lun a/a e	no dre	P=1. -	705.mg n.s.s.	1/87	0/43			
6149 R f f34 eat 52w69 1343				0	75.3mg			
liv tum e	no dre	P=1. -	287.mg n.s.s.	0/49	0/42			
6150 R m f34 eat 52w69 1343				0	60.2mg			
liv hpc e	699.mg	P<.2 -	114.mg n.s.s.	0/50	1/39			
TOREMIFENE CITRATE 89778-27-8								
6151 R f cdr gav 52w52 2049m				0	12.0mg	24.0mg	Hard;canr,53,4534-4541;1993/pers.comm.	
liv hpa ek	no dre	P=1. -	7.95mg n.s.s.	0/18	0/36	0/10		
liv hpc ek	no dre	P=1. -	7.95mg n.s.s.	0/18	0/36	0/10		
6152 R f cdr gav 52w65 2049n				0	9.60mg	19.2mg		
liv hpa e	no dre	P=1. -	17.6mg n.s.s.	0/21	0/30	0/47		
liv hpc e	no dre	P=1. -	17.6mg n.s.s.	0/21	0/30	0/47		
6153 R f sda gav 52w52 2043m				0	12.0mg	48.0mg	Hirsimaki;artx,67,49-54;1993/pers.comm.	
liv tum ekr	no dre	P=1. -	2.47mg n.s.s.	0/5	0/5	0/5		
6154 R f sda gav 52w65 2043n				0	9.60mg	38.4mg		
liv tum er	no dre	P=1. -	6.18mg n.s.s.	0/10	0/10	0/10		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
6155 R f sda gav 52w52 2159m					0	12.0mg	48.0mg		Ahotupa;carc,15,863-868;1994
liv mix er	no dre	P=1.	-	2.47mg n.s.s.	0/5	0/5	0/5		
6156 R f sda gav 52w65 2159n					0	9.60mg	38.4mg		
liv mix er	no dre	P=1.	-	2.58mg n.s.s.	0/5	0/4	0/5		
6157 R f sda eat 24m24 2276					0	.120mg	1.20mg	5.00mg	12.0mg	Karlsson;dact,19,245-266;1996
liv hpa e	344.mg *	P<.5	-	96.5mg n.s.s.	0/50	1/49	2/50	1/50	2/50	
liv hpc e	no dre	P=1.	-	1.07mg n.s.s.	0/50	0/49	0/50	0/50	0/50	
mgl tum e	no dre	P=1.	-	152.mg n.s.s.	30/50	7/49	2/49	1/49	2/50	
pit tum e	no dre	P=1.	-	57.6mg n.s.s.	42/49	26/50	1/49	1/48	(0/50)	
6158 R f sda gav 52w52 2633m					0	48.0mg				Karki;artx,74,249-256;2000/pers.comm.
liv tum Cer	no dre	P=1.	-	12.4mg n.s.s.	0/5	0/5				
6159 R f sda gav 52w65 2633n					0	38.4mg				
liv tum Cer	no dre	P=1.	-	15.5mg n.s.s.	0/5	0/5				
6160 R m sda eat 24m24 2276					0	.120mg	1.20mg	5.00mg	12.0mg	Karlsson;dact,19,245-266;1996
liv hpc e	1.04gm *	P<.7	-	92.4mg n.s.s.	1/50	0/37	0/33	0/27	1/50	
liv hpa e	no dre	P=1.	-	55.2mg n.s.s.	3/50	4/37	1/33	3/27	3/50	
mgl tum e	no dre	P=1.	-	130.mg n.s.s.	0/50	3/24	1/23	0/12	0/50	
pit tum e	no dre	P=1.	-	157.mg n.s.s.	26/48	19/50	2/50	1/50	2/50	
tes tum e	no dre	P=1.	-	185.mg n.s.s.	5/50	6/50	0/50	0/50	0/50	
TOXAPHENE 8001-35-2										
6161 M f b6c eat 80w90 TR37r					0	11.3mg	22.9mg		NTP TR37/Goodman;faat,55,3-16;2000/NTP pers.comm.
liv MXA jv	10.6mg /	P<.0005	c	7.40mg 16.0mg	0/10	11/49	39/47		
liv hpa jv	11.4mg /	P<.0005		7.91mg 17.4mg	0/10	11/49	37/47		
liv hpc jv	273.mg *	P<.2		82.6mg n.s.s.	0/10	0/49	3/47		
lun MXB ejv	no dre	P=1.		50.4mg n.s.s.	1/9	0/47	0/37		
6162 M f b6c eat 80w90 TR37r pool					0	11.3mg	22.9mg		
liv MXA jv	10.8mg /	P<.0005	c	7.49mg 16.5mg	1/50	11/49	39/47		
liv hpa jv	11.6mg /	P<.0005		8.01mg 17.9mg	1/50	11/49	37/47		
liv hpc jv	273.mg *	P<.04		82.6mg n.s.s.	0/50	0/49	3/47		
6163 M f b6c eat 18m24 2448					0	.683mg	1.95mg	4.88mg		Goodman;faat,55,3-16;2000/Litton 1978
liv mix er	37.0mg *	P<.08	+	13.2mg n.s.s.	2/53	2/53	4/52	6/52		
liv hpc er	66.2mg *	P<.3		18.6mg n.s.s.	1/53	1/53	3/52	3/52		
liv hpa er	91.6mg *	P<.3		22.9mg n.s.s.	1/53	1/53	1/52	3/52		
6164 M m b6c eat 80w90 TR37r					0	10.4mg	21.1mg		NTP TR37/Goodman;faat,55,3-16;2000/NTP pers.comm.
liv MXA jv	4.20mg *	P<.0005	c	2.82mg 7.68mg	2/10	37/50	45/47		
liv hpa jv	6.12mg *	P<.0005		4.10mg 12.4mg	2/10	30/50	42/47		
liv hpc jv	248.mg *	P<.8		30.7mg n.s.s.	0/10	8/50	5/47		
lun MXB ejv	no dre	P=1.		72.2mg n.s.s.	1/10	1/45	2/33		
6165 M m b6c eat 80w90 TR37r pool					0	10.4mg	21.1mg		
liv MXA jv	4.08mg *	P<.0005	c	2.81mg 6.19mg	7/48	37/50	45/47		
liv hpa jv	5.76mg *	P<.0005		4.03mg 8.72mg	5/48	30/50	42/47		
liv hpc jv	168.mg *	P<.5		38.9mg n.s.s.	3/48	8/50	5/47		
6166 M m b6c eat 18m24 2448					0	.630mg	1.80mg	4.50mg		Goodman;faat,55,3-16;2000/Litton 1978
liv hpa er	21.2mg Z	P<.002		10.0mg 106.mg	3/53	0/54	2/53	11/51		
liv mix er	13.6mg *	P<.03	+	5.70mg n.s.s.	10/53	10/54	12/53	18/51		
liv hpc er	27.5mg *	P<.3		7.66mg n.s.s.	7/53	11/54	12/53	12/51		
6167 R f osm eat 19m25 TR37 :					0	20.0mg	40.0mg			
TBA MXB v	596.mg *	P<1.	-	22.5mg n.s.s.	6/10	31/50	40/50			
liv MXB v	no dre	P=1.		106.mg n.s.s.	1/10	5/50	4/50			liv:hpa,hpc,nnd.
6168 R f osm eat 19m25 TR37 : pool					0	20.0mg	40.0mg			
thy fca v	209.mg *	P<.03	a	84.2mg n.s.s.	1/55	1/50	7/50			
6169 R m osm eat 19m25 TR37 :					0	16.5mg	33.0mg			
TBA MXB v	1.02gm *	P<1.	-	17.2mg n.s.s.	7/10	33/50	24/50			
liv MXB v	949.mg *	P<1.		46.9mg n.s.s.	1/10	6/50	4/50			liv:hpa,hpc,nnd.
6170 R m osm eat 19m25 TR37 : pool					0	16.5mg	33.0mg			
thy MXA v	58.9mg *	P<.002	a	29.3mg 298.mg	2/55	7/50	9/50			thy:fca,fcc.
liv nnd v	92.1mg *	P<.03		39.4mg n.s.s.	1/55	6/50	4/50			S
TRAGACANTH GUM 9000-65-1										
6171 M f b6c eat 22m25 2086					0	1.47gm	5.89gm			Hagiwara;fctx,30,673-679;1992/pers.comm.
for mix e	111.gm *	P<.2	-	27.4gm n.s.s.	1/50	0/50	3/50			
liv mix e	no dre	P=1.	-	39.5gm n.s.s.	7/50	1/50	3/50			
lun mix e	no dre	P=1.	-	69.0gm n.s.s.	3/50	1/50	0/50			
6172 M m b6c eat 22m25 2086					0	1.36gm	5.43gm			
for sqp e	240.gm *	P<.2	-	39.1gm n.s.s.	0/50	0/50	1/50			
liv mix e	no dre	P=1.	-	17.8gm n.s.s.	24/50	21/50	15/50			
lun mix e	no dre	P=1.	-	18.4gm n.s.s.	10/50	5/50	8/50			
TRENIMON 68-76-8										
6173 R m b46 ivj 12m24 1017					0	2.14ug				Schmahl;arzn,20,1461-1467;1970
liv lcc es	65.3ug	P<.2		10.6ug n.s.s.	0/65	1/45				
tba mix es	5.04ug	P<.005	+	2.29ug 48.2ug	7/65	15/45				
tba mal es	6.77ug	P<.007	+	2.91ug .117mg	4/65	11/45				
tba ben es	32.0ug	P<.4		6.37ug n.s.s.	3/65	4/45				
TRIAMCINOLONE ACETONIDE 76-25-5										
6174 R m cdr wat 24m24 2059					0	6.39ug				Ryrfeldt;txpy,20,115-117;1992
liv mix ersv	53.0ug	P<.03	+	20.6ug n.s.s.	11/200	13/100				
liv hpa ersv	91.7ug	P<.2		28.7ug n.s.s.	7/200	8/100				
liv hpc ersv	.141mg	P<.2		37.3ug n.s.s.	4/200	5/100				
3,4,4'-TRIAMINODIPHENYL ETHER 6264-66-0										
6175 M m icr eat 52w52 2594					0	120.mg				Osanai;jsol,52,179-201;1976
liv hpt e	13.3mg	P<.0005	+	7.08mg 29.3mg	2/21	21/26				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TRIAMTERENE 396-01-0									
6176 M f b6c eat 24m24 TR420 :					0	13.0mg	25.9mg	51.8mg	
liv hpa	46.0mg	* P<.0005	p	25.4mg 181.mg	10/50	22/50	23/50	36/60	
liv MXA	51.3mg	* P<.004	p	26.0mg 444.mg	13/50	26/50	25/50	37/60	liv:hpa,hpc.
TBA MXB	132.mg	* P<.4		32.1mg n.s.s.	34/50	40/50	40/50	46/60	
liv MXB	51.3mg	* P<.004		26.0mg 444.mg	13/50	26/50	25/50	37/60	liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		266.mg n.s.s.	4/50	6/50	2/50	3/60	lun:a/a,a/c.
6177 M f b6c eat 24m24 TR420a :					0	51.9mg			
liv MXA	45.3mg	P<.0005	p	23.7mg 178.mg	10/50	31/51			liv:hpa,hpc.
liv hpa	45.7mg	P<.0005	p	24.7mg 147.mg	7/50	28/51			
TBA MXB	64.4mg	P<.07		25.3mg n.s.s.	29/50	43/51			
liv MXB	45.3mg	P<.0005		23.7mg 178.mg	10/50	31/51			liv:hpa,hpb,hpc.
lun MXB	no dre	P=1.		291.mg n.s.s.	3/50	1/51			lun:a/a,a/c.
6178 M m b6c eat 24m24 TR420 :					0	12.0mg	23.9mg	47.8mg	
liv hpc	227.mg	* P<.07	p	87.7mg n.s.s.	5/50	7/50	3/50	13/60	
liv MXA	162.mg	* P<.3	p	45.8mg n.s.s.	20/50	26/50	19/50	29/60	liv:hpa,hpc.
TBA MXB	205.mg	* P<.6		37.1mg n.s.s.	32/50	38/50	35/50	38/60	
liv MXB	169.mg	* P<.3		46.2mg n.s.s.	20/50	27/50	19/50	29/60	liv:hpa,hpb,hpc.
lun MXB	233.mg	* P<.3		66.4mg n.s.s.	9/50	12/50	16/50	14/60	lun:a/a,a/c.
6179 M m b6c eat 24m24 TR420a :					0	48.0mg			
liv hpa	54.8mg	P<.02	p	24.1mg n.s.s.	21/50	36/50			
liv MXA	61.2mg	P<.05	p	24.9mg n.s.s.	25/50	38/50			liv:hpa,hpc.
hag ade	235.mg	P<.04		85.4mg n.s.s.	1/50	6/50			S
TBA MXB	86.7mg	P<.3		25.8mg n.s.s.	37/50	44/50			
liv MXB	61.2mg	P<.05		24.9mg n.s.s.	25/50	38/50			liv:hpa,hpb,hpc.
lun MXB	265.mg	P<.5		58.0mg n.s.s.	13/50	16/50			lun:a/a,a/c.
6180 R f f34 eat 24m24 TR420 :					0	4.99mg	15.0mg	29.9mg	
TBA MXB	no dre	P=1.	-	21.6mg n.s.s.	46/50	43/50	42/50	41/50	
liv MXB	520.mg	* P<.06		128.mg n.s.s.	0/50	0/50	0/50	2/50	liv:hpa,hpb,hpc.
6181 R m f34 eat 24m24 TR420 :					0	3.99mg	12.0mg	23.9mg	
liv hpa	11.8mg	Z P<.005	e	4.72mg 41.5mg	0/50	6/50	(4/50	3/50)	
TBA MXB	no dre	P=1.		18.1mg n.s.s.	40/50	43/50	40/50	39/50	
liv MXB	11.8mg	Z P<.005		4.72mg 41.5mg	0/50	6/50	(4/50	3/50)	liv:hpa,hpb,hpc.
TRIBROMOMETHANE (bromoform) 75-25-2									
6182 M f b6c gav 24m25 TR350 :					0	69.4mg	140.mg		
MXA hes s#	1.11gm	* P<.04	-	311.mg n.s.s.	0/50	0/50	3/50		liv:hes; spl:hes. S
TBA MXB s	no dre	P=1.		109.mg n.s.s.	24/50	18/50	18/50		
liv MXB s	570.mg	* P<.3		152.mg n.s.s.	4/50	6/50	6/50		liv:hpa,hpc,nnd.
lun MXB s	no dre	P=1.		349.mg n.s.s.	3/50	1/50	2/50		lun:a/a,a/c.
6183 M m b6c gav 24m25 TR350 :					0	34.9mg	69.7mg		
sub MXA #	81.9mg	\ P<.02	-	28.0mg 17.5gm	2/50	8/50	(4/50)		sub:fbs,sar. S
TBA MXB	41.0mg	\ P<.2		13.8mg n.s.s.	34/50	33/50	(27/50)		
liv MXB	53.6mg	\ P<.07		18.1mg n.s.s.	16/50	19/50	(14/50)		liv:hpa,hpc,nnd.
lun MXB	2.45gm	\ P<1.		44.0mg n.s.s.	11/50	7/50	(2/50)		lun:a/a,a/c.
6184 R f f34 gav 24m25 TR350 :					0	69.4mg	139.mg		
lgi MXA h	469.mg	* P<.002	c	219.mg 1.55gm	0/50	1/50	8/50		lgi:adc,pla.
lgi pla	632.mg	* P<.004		270.mg 3.60gm	0/50	1/50	6/50		S
TBA MXB	no dre	P=1.		104.mg n.s.s.	47/50	37/50	38/50		
liv MXB	676.mg	* P<.06		276.mg n.s.s.	0/50	4/50	2/50		liv:hpa,hpc,nnd.
6185 R m f34 gav 24m24 TR350 :					0	69.7mg	140.mg		
tes MXA s	75.0mg	* P<.03		33.3mg n.s.s.	46/50	45/50	37/50		tes:iab,ica. S
thy fcc s	656.mg	* P<.03		237.mg n.s.s.	0/50	3/50	2/50		S
lgi MXA sh	1.05gm	* P<.02	p	298.mg n.s.s.	0/50	0/50	3/50		lgi:adc,pla.
TBA MXB s	513.mg	* P<.7		71.8mg n.s.s.	45/50	37/50	25/50		
liv MXB s	no dre	P=1.		541.mg n.s.s.	5/50	2/50	1/50		liv:hpa,hpc,nnd.
TRIBUTYL PHOSPHATE 126-73-8									
6186 M f cd1 eat 77w77 2572					0	19.5mg	130.mg	455.mg	Auletta;txcy,128,135-141;1998/SOCMA 1994
liv hpa e	3.60gm	* P<.04	-	1.09gm n.s.s.	0/50	0/50	1/50	2/48	
lun a/a e	no dre	P=1.	-	1.35gm n.s.s.	4/50	6/50	3/50	3/48	
lun a/c e	no dre	P=1.	-	2.69gm n.s.s.	2/50	3/50	1/50	0/48	
6187 M m cd1 eat 77w77 2572					0	18.0mg	120.mg	420.mg	
lun a/c e	532.mg	Z P<.07		173.mg n.s.s.	1/50	2/50	5/50	(0/50)	
liv hpa e	1.12gm	* P<.06	+	404.mg n.s.s.	3/50	6/50	7/50	10/50	
liv hpc e	no dre	P=1.		1.20gm n.s.s.	4/50	4/50	3/50	3/50	
lun a/a e	no dre	P=1.		1.12gm n.s.s.	3/50	5/50	4/50	3/50	
6188 R f cdr eat 24m24 2571					0	10.0mg	35.0mg	150.mg	Auletta;txcy,128,125-134;1998/SOCMA 1994
ubl mix e	426.mg	* P<.0005	+	229.mg 928.mg	0/50	0/50	1/49	13/49	
liv hpa e	2.23gm	* P<.05		675.mg n.s.s.	0/50	0/50	1/50	2/50	
ubl tcc e	3.29gm	* P<.04	+	809.mg n.s.s.	0/50	0/50	0/49	2/49	
6189 R m cdr eat 24m24 2571					0	8.00mg	28.0mg	120.mg	
ubl mix e	123.mg	Z P<.0005	+	79.5mg 202.mg	0/50	0/50	2/49	30/49	
ubl mal e	721.mg	* P<.0005	+	311.mg 2.31gm	0/50	0/50	0/49	7/49	
ubl tcc e	848.mg	* P<.0005	+	346.mg 3.06gm	0/50	0/50	0/49	6/49	
liv hpa e	1.37gm	* P<.07		413.mg n.s.s.	0/50	1/50	1/50	3/50	
ubl sqc e	5.30gm	* P<.2		864.mg n.s.s.	0/50	0/50	0/49	1/49	
TRICAPRYLIN 538-23-8									
6190 R m f34 gav 24m24 TR426 :					0	1.68gm	3.37gm	6.76gm	
pan ana	5.49gm	* P<.0005	+	3.40gm 12.5gm	2/50	6/50	13/50	18/53	
for sqp	15.7gm	* P<.0005		8.26gm 36.2gm	0/50	0/50	3/50	10/53	S
liv hpa	37.1gm	* P<.05		13.9gm n.s.s.	1/50	0/50	3/50	4/53	S
TBA MXB	69.9gm	* P<.9		3.40gm n.s.s.	47/50	47/50	46/50	36/53	
liv MXB	37.1gm	* P<.05		13.9gm n.s.s.	1/50	0/50	3/50	4/53	liv:hpa,hpb,hpc.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
1,2,3-TRICHLORO-4,6-DINITROBENZENE (vancide PB) 6379-46-0								
6191 M f b6a orl 76w76 1262				0	16.9mg			Innes;ntis,1968/1969
lun ade evx	108.mg	P<.3	17.6mg n.s.s.	0/18	1/18			
liv hpt evx	no dre	P=1.	33.5mg n.s.s.	0/18	0/18			
tba mix evx	52.6mg	P<.09	12.9mg n.s.s.	0/18	2/18			
6192 M m b6a orl 76w76 1262				0	15.8mg			
lun ade evx	49.0mg	P<.09	12.0mg n.s.s.	0/18	2/18			
liv hpt evx	no dre	P=1.	31.2mg n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	14.7mg n.s.s.	2/18	2/18			
6193 M f b6c orl 76w76 1262				0	16.9mg			
liv hpt evx	no dre	P=1.	33.5mg n.s.s.	0/18	0/18			
lun ade evx	no dre	P=1.	33.5mg n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	22.2mg n.s.s.	2/18	1/18			
6194 M m b6c orl 76w76 1262				0	15.8mg			
liv hpt evx	no dre	P=1.	18.5mg n.s.s.	3/14	1/15			
lun mix evx	no dre	P=1.	26.0mg n.s.s.	0/14	0/15			
tba mix evx	19.8mg	P<.4	4.75mg n.s.s.	4/14	7/15			
1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE (CFC 113, fluorocarbon 113) 76-13-1								
6195 R f cdr inh 24m24 1876				0	1.15gm	5.74gm	11.5gm	Trochimowicz;faat,11,68-75;1988
pni isa e	160.gm *	P<.005 -	60.9gm 1.25kg	0/85	0/36	0/30	5/86	
6196 R m cdr inh 24m24 1876				0	803.mg	4.02gm	8.03gm	
pni isa e	9.14kg	P<1. -	95.1gm n.s.s.	2/88	1/64	0/58	2/87	
TRICHLOROACETIC ACID 76-03-9								
6197 M f b6c wat 51w51 2191m ()				0	65.4mg	218.mg	654.mg	Pereira;faat,31,192-199;1996/pers.comm.
liv hpc Cekr	576.mg *	P<.0005 +	218.mg 2.40gm	0/40	0/40	0/19	5/19	
liv hpa Cekr	891.mg *	P<.3	212.mg n.s.s.	1/40	3/40	3/19	2/19	
6198 M f b6c wat 82w82 2191n				0	65.4mg	218.mg	654.mg	
liv hpa Cer	688.mg *	P<.0005 +	334.mg 2.31gm	2/90	4/53	3/27	7/19	
liv hpc Cer	916.mg *	P<.0005 +	421.mg 3.25gm	2/90	0/53	5/27	5/19	
6199 M m b6c wat 61w61 2071				0	833.mg			Herren-Freund;txap,90,183-189;1987
liv hpc er	513.mg	P<.002 +	220.mg 1.97gm	0/22	7/22			
liv hpa er	551.mg	P<.03	211.mg n.s.s.	2/22	8/22			
6200 R m f34 wat 24m24 2327				0	2.50mg	25.0mg	250.mg	DeAngelo;jtxe,52,425-445;1997
liv hpc C	5.48gm *	P<.2 -	893.mg n.s.s.	0/29	0/32	0/32	1/29	
liv hpa C	6.72gm *	P<.7 -	623.mg n.s.s.	1/29	1/32	3/32	2/29	
liv mix C	6.72gm *	P<.7 -	623.mg n.s.s.	1/29	1/32	3/32	2/29	
2,4,6-TRICHLOROANILINE 634-93-5								
6201 M f chi eat 68w77 381 :				0	780.mg	1.56gm		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv mix a	927.mg *	P<.02 -	369.mg n.s.s.	0/13	5/21	1/14		
lun mix a	1.37gm *	P<.02 -	490.mg n.s.s.	3/13	3/21	2/14		
tba mix a	914.mg *	P<.06 -	333.mg n.s.s.	9/13	7/21	4/14		
6202 M m chi eat 68w77 381 :				0	720.mg	1.44gm		
--- vsc a	273.mg *	P<.0005 +	140.mg 725.mg	2/16	8/18	12/16		
lun mix a	385.mg *	P<.0005 -	166.mg 1.45gm	2/16	6/18	3/16		
liv mix a	452.mg *	P<.004	178.mg 3.14gm	2/16	5/18	1/16		
tba mix a	206.mg *	P<.0005	104.mg 590.mg	9/16	12/18	12/16		
6203 M m chi eat 68w77 381 : pool				0	720.mg	1.44gm		
--- vsc a	259.mg *	P<.0005 +	137.mg 537.mg	5/99	8/18	12/16		
liv hpt a	560.mg *	P<.0005 +	202.mg 2.72gm	7/99	5/18	1/16		
6204 R m cdr eat 18m27 381 :				0	57.5mg	102.mg		
liv mix v	no dre	P=1. -	462.mg n.s.s.	1/17	0/18	0/16		
tba mix v	45.9mg \	P<.01 -	18.7mg 3.80gm	13/17	13/18	(10/16)		
1,1,2-TRICHLOROETHANE 79-00-5								
6205 M f b6c gav 78w90 TR74 :				0	119.mg	239.mg		
liv hpc v	47.6mg *	P<.0005 c	33.3mg 70.8mg	0/20	16/50	40/50		
MXB MXB v	47.6mg *	P<.0005	33.3mg 70.8mg	0/20	16/50	40/50		adr:phe; liv:hpc. C
adr phe v	248.mg /	P<.0005 c	127.mg 611.mg	0/20	0/50	12/50		
TBA MXB v	52.9mg *	P<.0005	33.9mg 106.mg	5/20	20/50	41/50		
liv MXB v	47.6mg *	P<.0005	33.3mg 70.8mg	0/20	16/50	40/50		liv:hpa,hpc,nnd.
lun MXB v	787.mg *	P<.2	287.mg n.s.s.	0/20	3/50	2/50		lun:a/a,a/c.
6206 M m b6c gav 78w90 TR74 :				0	121.mg	239.mg		
liv hpc v	65.0mg /	P<.0005 c	42.2mg 146.mg	2/20	18/50	37/50		
MXB MXB v	65.0mg /	P<.0005	42.2mg 146.mg	2/20	18/50	37/50		adr:phe; liv:hpc. C
adr phe v	588.mg /	P<.007 c	263.mg 6.05gm	0/20	0/50	8/50		
TBA MXB v	79.5mg *	P<.006	42.3mg 872.mg	6/20	28/50	38/50		
liv MXB v	65.0mg /	P<.0005	42.2mg 146.mg	2/20	18/50	37/50		liv:hpa,hpc,nnd.
lun MXB v	1.56gm *	P<.8	338.mg n.s.s.	0/20	3/50	1/50		lun:a/a,a/c.
6207 R f osm gav 18m26 TR74 :				0	23.0mg	45.5mg		
TBA MXB v	no dre	P=1. -	31.0mg n.s.s.	4/20	34/50	22/50		
liv MXB v	771.mg *	P<.7	182.mg n.s.s.	0/20	1/50	1/50		liv:hpa,hpc,nnd.
6208 R m osm gav 18m26 TR74 :				0	23.0mg	45.9mg		
TBA MXB v	no dre	P=1. -	11.8mg n.s.s.	6/20	21/50	(11/50)		
liv MXB v	no dre	P=1.	436.mg n.s.s.	1/20	0/50	0/50		liv:hpa,hpc,nnd.
1,1,1-TRICHLOROETHANE, TECHNICAL GRADE (methyl chloroform) 71-55-6								
6209 M f b6c gav 78w90 TR3 :				0	1.72gm	3.44gm		
TBA MXB sv	no dre	P=1. i	6.79gm n.s.s.	7/20	2/50	3/50		
liv MXB sv	no dre	P=1.	13.6gm n.s.s.	1/20	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB sv	260.gm *	P<.9	7.97gm n.s.s.	1/20	0/50	1/50		lun:a/a,a/c.
6210 M f b6c inh 24m24 1892				0	257.mg	858.mg	2.57gm	Quast;faat,11,611-625;1988
liv mix e	no dre	P=1. -	11.4gm n.s.s.	13/50	10/50	10/50	7/50	
liv hpc e	no dre	P=1. -	13.2gm n.s.s.	4/50	1/50	5/50	2/50	
liv hpa e	no dre	P=1. -	14.2gm n.s.s.	10/50	9/50	5/50	5/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
6211 M m b6c gav 78w90 TR3 :					0	1.74gm	3.48gm		
TBA MXB sv	30.5gm *	P<.8	i	3.09gm n.s.s.	5/20	2/50	6/50		
liv MXB sv	39.7gm /	P<.8		4.18gm n.s.s.	3/20	0/50	4/50		liv:hpa,hpc,nnd.
lun MXB sv	5.08kg	P<1.		5.52gm n.s.s.	1/20	1/50	1/50		lun:a/a,a/c.
6212 M m b6c inh 24m24 1892					0	214.mg	715.mg	2.14gm	Quast;faat,11,611-625;1988
liv hpc e	66.3gm *	P<.9	-	4.67gm n.s.s.	12/50	10/50	12/50	12/50	
liv hpa e	no dre	P=1.	-	5.83gm n.s.s.	26/50	13/50	19/50	16/50	
liv mix e	no dre	P=1.	-	3.43gm n.s.s.	29/50	22/50	28/50	24/50	
6213 R f osm gav 18m26 TR3 :					0	380.mg	760.mg		
TBA MXB s	226.mg *	P<.0005	i	81.4mg 685.mg	10/20	6/50	9/50		
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.
6214 R m osm gav 18m25 TR3 :					0	380.mg	760.mg		
TBA MXB s	950.mg \	P<.009	i	334.mg 22.2gm	7/20	6/50	(4/50)		
liv MXB s	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
6215 R f f34 inh 24m24 1892					0	61.3mg	204.mg	613.mg	Quast;faat,11,611-625;1988
liv hpc e	no dre	P=1.	-	451.mg n.s.s.	1/50	0/50	0/50	0/50	
liv nnd e	no dre	P=1.	-	7.94gm n.s.s.	1/50	1/50	0/50	0/50	
6216 R m f34 inh 24m24 1892					0	42.9mg	143.mg	429.mg	
liv hpc e	2.07gm Z	P<.03	-	627.mg n.s.s.	0/50	0/50	3/50	(0/50)	
liv nnd e	5.12gm *	P<.09	-	1.57gm n.s.s.	1/50	1/50	1/50	4/50	
TRICHLOROETHYLENE (TCE) 79-01-6									
6217 H f syg inh 18m30 1010m					0	46.1mg	230.mg		Henschler;artx,43,237-248;1980/pers.comm.
liv mix ej	no dre	P=1.	-	2.14gm n.s.s.	1/30	1/29	0/30		
tba mal ej	9.22gm *	P<.8	-	821.mg n.s.s.	2/30	3/29	3/30		
tba ben ej	no dre	P=1.	-	2.14gm n.s.s.	1/30	1/29	0/30		
6218 H m syg inh 18m30 1010m					0	40.5mg	203.mg		
liv mix ej	no dre	P=1.	-	326.mg n.s.s.	1/30	0/30	0/30		
tba mal ej	no dre	P=1.	-	863.mg n.s.s.	6/30	2/30	4/30		
tba ben ej	5.64gm *	P<.4	-	999.mg n.s.s.	1/30	0/30	2/30		
6219 M f b6c gav 78w90 TR2 :					0	538.mg	1.08gm		
liv hpc sv	1.93gm *	P<.004	c	1.06gm 9.81gm	0/20	4/50	11/50		
TBA MXB sv	1.85gm *	P<.2		716.mg n.s.s.	4/20	14/50	19/50		
liv MXB sv	1.93gm *	P<.004		1.06gm 9.81gm	0/20	4/50	11/50		liv:hpa,hpc,nnd.
lun MXB sv	4.35gm *	P<.2		1.55gm n.s.s.	1/20	4/50	7/50		lun:a/a,a/c.
6220 M f b6c inh 18m36 BT306m					0	99.8mg	299.mg	599.mg	Maltoni;aric,5,1-393;1986
lun tum e	6.32gm *	P<.002	+	3.33gm 28.9gm	2/90	6/90	7/89	14/87	
liv hpt e	13.6gm *	P<.06	+	5.28gm n.s.s.	3/88	4/89	4/88	9/85	
thy car e	131.gm *	P<.2		21.4gm n.s.s.	0/90	0/90	0/89	1/87	
thy ade e	2.23kg	P<1.		17.3gm n.s.s.	1/90	1/90	1/89	1/87	
tba mix e	1.32gm *	P<.002		700.mg 6.89gm	51/90	58/90	60/89	69/87	
tba mal e	2.08gm *	P<.02		986.mg n.s.s.	42/90	52/90	53/89	58/87	
6221 M m b6c gav 78w90 TR2 :					0	724.mg	1.45gm		
liv hpc sv	421.mg *	P<.0005	c	277.mg 1.13gm	1/20	26/50	30/50		
TBA MXB sv	553.mg *	P<.01		288.mg 28.9gm	5/20	30/50	33/50		
liv MXB sv	421.mg *	P<.0005		277.mg 1.13gm	1/20	26/50	30/50		liv:hpa,hpc,nnd.
lun MXB sv	7.16gm *	P<.7		1.79gm n.s.s.	0/20	5/50	2/50		lun:a/a,a/c.
6222 M m b6c inh 18m36 BT306m					0	83.2mg	250.mg	499.mg	Maltoni;aric,5,1-393;1986
liv hpt es	5.03gm *	P<.006	+	2.22gm 59.8gm	1/59	1/31	3/38	6/37	
lun tum es	no dre	P=1.		12.3gm n.s.s.	1/85	2/86	2/88	1/88	
thy ade es	no dre	P=1.		2.17gm n.s.s.	0/85	0/86	0/88	0/88	
tba mal es	no dre	P=1.		8.59gm n.s.s.	9/85	3/86	3/88	7/88	
tba mix es	no dre	P=1.		7.93gm n.s.s.	11/85	4/86	5/88	8/88	
6223 M m b6c inh 18m31 BT306n					0	94.9mg	285.mg	569.mg	
liv hpt e	4.53gm *	P<.3	+	1.34gm n.s.s.	17/77	19/47	27/67	21/63	
liv ang e	77.0gm *	P<.8		6.47gm n.s.s.	1/77	1/47	3/67	1/63	
lun tum e	no dre	P=1.		7.94gm n.s.s.	12/90	6/89	7/90	7/90	
tba mal e	no dre	P=1.		3.14gm n.s.s.	40/90	27/89	34/90	31/90	
tba mix e	no dre	P=1.		994.mg n.s.s.	51/90	30/89	46/90	(36/90)	
6224 M f hic gav 88w88 1011					0	2.86mg			Van Duuren;jnci,63,1433-1439;1979
for tum r	41.3mg	P<.3	-	6.73mg n.s.s.	0/30	1/30			
6225 M m hic gav 88w88 1011					0	2.38mg			
for tum r	16.9mg	P<.1	-	4.16mg n.s.s.	0/30	2/30			
6226 M f icm inh 24m25 1626					0	95.8mg	287.mg	862.mg	Fukuda;indh,21,243-254;1983
lun mix e	3.37gm *	P<.07		1.26gm n.s.s.	6/49	5/50	13/50	11/46	
lun adc e	3.38gm *	P<.02	+	1.46gm n.s.s.	1/49	3/50	8/50	7/46	
liv ade e	42.3gm *	P<.2		6.90gm n.s.s.	0/49	0/50	0/50	1/46	
tba mix e	1.90gm *	P<.08		704.mg n.s.s.	18/49	18/50	27/50	24/46	
6227 M f nmh inh 18m30 1010m					0	102.mg	509.mg		Henschler;artx,43,237-248;1980/pers.comm.
--- mly ej	846.mg *	P<.03		339.mg n.s.s.	9/29	17/30	18/28		
liv mix ej	no dre	P=1.	-	809.mg n.s.s.	0/29	0/30	0/28		
lun a/a ej	no dre	P=1.	-	3.80gm n.s.s.	3/29	0/30	1/28		
lun a/c ej	no dre	P=1.	-	3.63gm n.s.s.	1/29	3/30	0/28		
tba mal ej	573.mg *	P<.03	-	230.mg n.s.s.	13/29	22/30	22/28		
tba ben ej	no dre	P=1.	-	2.03gm n.s.s.	6/29	1/30	4/28		
6228 M m nmh inh 18m30 1010m					0	84.8mg	424.mg		
liv bhp ej	no dre	P=1.	-	663.mg n.s.s.	1/30	0/29	0/30		
liv hpc ej	no dre	P=1.	-	663.mg n.s.s.	1/30	0/29	0/30		
--- mly ej	no dre	P=1.	-	1.33gm n.s.s.	7/30	7/29	6/30		
lun a/a ej	no dre	P=1.	-	2.25gm n.s.s.	1/30	3/29	1/30		
lun mal ej	no dre	P=1.	-	3.19gm n.s.s.	5/30	3/29	1/30		
liv hpa ej	no dre	P=1.	-	3.49gm n.s.s.	1/30	2/29	0/30		
tba mal ej	no dre	P=1.	-	1.12gm n.s.s.	11/30	10/29	9/30		
tba ben ej	no dre	P=1.	-	2.37gm n.s.s.	8/30	6/29	3/30		
6229 M f swi inh 18m34 BT305					0	106.mg	318.mg	636.mg	Maltoni;aric,5,1-393;1986
lun tum e	35.4gm *	P<.7		4.57gm n.s.s.	15/88	12/89	12/88	16/88	
liv hpt e	121.gm *	P<.2		19.8gm n.s.s.	0/84	0/89	0/86	1/86	
tba mix e	9.19gm *	P<.6		1.70gm n.s.s.	54/90	43/89	46/90	54/89	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mal e		9.84gm *	P<.5	2.32gm n.s.s.	36/90	27/89	30/90	38/89	
6230 M m swi inh 18m34 BT305					0	88.4mg	265.mg	530.mg	
liv hpt e		3.91gm *	P<.003 +	1.98gm 22.7gm	4/66	2/53	8/59	13/61	
lun tum e		10.1gm *	P<.3 +	3.02gm n.s.s.	10/78	5/73	12/78	12/74	
tba mal e		6.32gm *	P<.08	2.45gm n.s.s.	10/88	13/89	15/89	19/90	
tba mix e		8.07gm *	P<.3	2.23gm n.s.s.	23/88	17/89	27/89	26/90	
6231 R f osm gav 18m26 TR2 :					0	242.mg	484.mg		
TBA MXB dsv		5.62gm *	P<.9 -	302.mg n.s.s.	7/20	12/50	12/50		
kid uac dsv		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		
kid tla dsv		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		
liv MXB dsv		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
6232 R m osm gav 18m26 TR2 :					0	242.mg	484.mg		
kid uac dsv		7.22gm *	P<.9	1.18gm n.s.s.	0/20	1/50	0/50		
TBA MXB dsv		16.0gm *	P<1.	305.mg n.s.s.	5/20	7/50	5/50		
liv MXB dsv		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
6233 R f cdr inh 24m25 1626					0	22.8mg	68.4mg	205.mg	Fukuda;indh,21,243-254;1983
mgl fba e		982.mg *	P<.2	320.mg n.s.s.	6/50	12/50	10/47	14/51	
kid uac e		10.7gm *	P<.2	1.74gm n.s.s.	0/50	0/50	0/47	1/51	
liv mix e		12.3gm *	P<.6	1.40gm n.s.s.	0/50	1/50	0/47	1/51	
tba mix e		no dre	P=1.	288.mg n.s.s.	32/50	39/50	31/47	32/51	
6234 R f sda gav 12m33 BT301					0	11.9mg	59.7mg		Maltoni;aric,5,1-393;1986
mgl mix e		no dre	P=1.	98.3mg n.s.s.	16/30	22/30	16/29		
kid mix e		no dre	P=1.	106.mg n.s.s.	0/30	0/29	0/26		
--- leu e		no dre	P=1.	109.mg n.s.s.	1/30	0/30	0/26		
liv mix e		no dre	P=1.	111.mg n.s.s.	0/30	0/30	0/29		
tba mix e		no dre	P=1.	98.1mg n.s.s.	18/30	23/30	17/29		
tba mal e		no dre	P=1.	297.mg n.s.s.	7/30	4/30	4/29		
6235 R f sda inh 24m37 BT304m					0	30.7mg	92.1mg	184.mg	
liv ang e		8.01gm *	P<.3	1.30gm n.s.s.	0/17	0/4	0/26	1/14	
kid mix e		41.3gm *	P<.6	5.46gm n.s.s.	0/101	1/89	0/88	1/88	
kid uac e		43.2gm *	P<.2	7.03gm n.s.s.	0/101	0/89	0/88	1/88	
--- leu e		no dre	P=1.	3.56gm n.s.s.	7/105	6/90	0/90	7/90	
liv hpt e		no dre	P=1.	6.53gm n.s.s.	0/81	1/63	0/63	0/70	
tba mix e		3.89gm *	P<.8	406.mg n.s.s.	84/105	60/90	72/90	69/90	
tba mal e		6.23gm Z	P<.6	1.10gm n.s.s.	38/105	17/90	21/90	32/90	
6236 R f sda inh 24m37 BT304n					0	30.7mg	92.1mg	184.mg	
--- leu e		2.85gm *	P<.09	1.01gm n.s.s.	0/40	3/40	2/40	4/40	
liv nnd e		9.68gm *	P<.07	2.38gm n.s.s.	0/40	0/40	0/40	2/40	
kid tum e		no dre	P=1.	384.mg n.s.s.	0/38	0/39	0/39	0/39	
liv hpt e		no dre	P=1.	269.mg n.s.s.	0/28	0/26	0/31	0/29	
tba mal e		1.62gm *	P<.2	532.mg n.s.s.	9/40	12/40	8/40	16/40	
tba mix e		no dre	P=1.	312.mg n.s.s.	35/40	28/40	26/40	33/40	
6237 R m sda gav 12m33 BT301					0	11.9mg	59.7mg		
--- leu e		428.mg *	P<.08	162.mg n.s.s.	0/25	2/28	3/25		
kid mix e		no dre	P=1.	87.1mg n.s.s.	0/22	0/24	0/21		
liv mix e		no dre	P=1.	108.mg n.s.s.	0/28	0/29	0/30		
mgl mix e		no dre	P=1.	363.mg n.s.s.	1/28	4/29	1/30		
tba mal e		818.mg *	P<.4	177.mg n.s.s.	1/28	4/29	4/30		
tba mix e		no dre	P=1.	191.mg n.s.s.	7/28	8/29	7/30		
6238 R m sda inh 24m37 BT304m					0	21.5mg	64.5mg	129.mg	
tes ldc e		557.mg *	P<.0005 +	336.mg 1.44gm	5/81	11/73	24/71	22/76	
kid uac e		9.49gm *	P<.03	2.87gm n.s.s.	0/87	0/86	0/80	3/85	
--- leu e		5.93gm *	P<.5	1.17gm n.s.s.	6/95	10/90	11/90	9/89	
kid tla e		29.2gm *	P<.6	3.65gm n.s.s.	0/87	1/86	0/80	1/85	
liv nnd e		30.7gm *	P<.2	4.99gm n.s.s.	0/95	0/90	0/90	1/89	
liv ang e		no dre	P=1.	40.5mg n.s.s.	1/22	0/5	0/9	0/9	
liv hpt e		no dre	P=1.	4.36gm n.s.s.	1/71	0/62	1/63	0/62	
tba mix e		1.88gm *	P<.6	329.mg n.s.s.	69/95	54/90	55/90	65/89	
tba mal e		10.8gm *	P<.9	789.mg n.s.s.	31/95	25/90	26/90	29/89	
6239 R m sda inh 24m37 BT304n					0	21.5mg	64.5mg	129.mg	
mgl tum e		120.mg Z	P<.0005	56.2mg 348.mg	0/36	9/36	(7/39	10/39)	
tes ldc e		835.mg *	P<.02 +	375.mg n.s.s.	1/33	5/32	6/36	9/37	
--- leu e		2.81gm *	P<.3	755.mg n.s.s.	3/39	3/40	3/40	6/40	
kid uac e		12.4gm *	P<.2	2.01gm n.s.s.	0/33	0/32	0/36	1/37	
liv hpt e		no dre	P=1.	2.59gm n.s.s.	1/28	1/23	0/27	0/32	
tba mix e		428.mg *	P<.2	154.mg n.s.s.	21/39	26/40	27/40	29/40	
tba mal e		1.94gm *	P<.4	466.mg n.s.s.	8/39	11/40	7/40	13/40	
6240 R f wsh inh 18m36 1010m					0	20.1mg	101.mg		Henschler;artx,43,237-248;1980/pers.comm.
kid tla ej		5.50gm *	P<.2 -	896.mg n.s.s.	0/28	0/30	1/30		
liv hpa ej		no dre	P=1. -	1.06gm n.s.s.	0/28	1/30	0/30		
tba ben ej		2.12gm *	P<.4 -	448.mg n.s.s.	2/28	2/30	4/30		
tba mal ej		no dre	P=1. -	277.mg n.s.s.	16/28	12/30	14/30		
6241 R m wsh inh 18m36 1010m					0	14.1mg	70.4mg		
kid uac ej		3.85gm *	P<.2 -	627.mg n.s.s.	0/29	0/30	1/30		
kid tla ej		10.7gm *	P<.9 -	502.mg n.s.s.	2/29	1/30	2/30		
liv hpa ej		no dre	P=1. -	738.mg n.s.s.	0/29	1/30	0/30		
tba mal ej		351.mg *	P<.03 -	141.mg n.s.s.	4/29	5/30	11/30		
tba ben ej		no dre	P=1. -	385.mg n.s.s.	7/29	2/30	5/30		

TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN) (TCE) 79-01-6

6242 M f b6c gav 24m24 TR243 :					0	704.mg			
liv MXA	411.mg	P<.0005 c	215.mg 1.10gm	6/50	22/50				liv:hpa,hpc.
liv hpa	579.mg	P<.0005 c	283.mg 1.89gm	4/50	16/50				
liv hpc	673.mg	P<.0005 c	314.mg 2.22gm	2/50	13/50				
lun a/a	2.78gm	P<.009	877.mg 81.4gm	0/50	4/50				S
MXA MXA	1.35gm	P<.03	538.mg n.s.s.	7/50	14/50				liv:mlh; mul:mlh,mlm,mlp,mlu,mno,myo; spl:mno. S
MXA MXA	1.47gm	P<.04	558.mg n.s.s.	7/50	13/50				liv:mlh; mul:mlh,mlm,mlp,mlu,mno; spl:mno. S
mul mlp	4.88gm	P<.04	1.48gm n.s.s.	0/50	3/50				S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
TBA MXB		359.mg	P<.0005	187.mg 1.19gm	21/50	38/50			
liv MXB		411.mg	P<.0005	215.mg 1.10gm	6/50	22/50			liv:hpa,hpc,nnd.
lun MXB		3.85gm	P<.1	1.04gm n.s.s.	1/50	4/50			lun:a/a,a/c.
6243 M m b6c gav 24m24 TR243 :					0	701.mg			
liv MXA		239.mg	P<.0005	134.mg 539.mg	14/50	39/50			liv:hpa,hpc. S
liv hpc		294.mg	P<.0005 c	163.mg 672.mg	8/50	31/50			
liv hpa		855.mg	P<.006	365.mg 11.6gm	7/50	14/50			S
hag MXA		3.83gm	P<.02	1.29gm n.s.s.	0/50	4/50			hag:adn,ana,ppa. S
TBA MXB		332.mg	P<.002	165.mg 1.55gm	33/50	45/50			
liv MXB		239.mg	P<.0005	134.mg 539.mg	14/50	39/50			liv:hpa,hpc,nnd.
lun MXB		4.25gm	P<.5	744.mg n.s.s.	7/50	6/50			lun:a/a,a/c.
6244 M m b6c wat 61w61 2071					0	6.67mg			Herren-Freund;txap,90,183-189;1987
liv hpc er		16.0mg	P<.08	4.83mg n.s.s.	0/22	3/32			
liv hpa er		502.mg	P<1.	6.06mg n.s.s.	2/22	3/32			
6245 R f f34 gav 24m24 TR243 :					0	354.mg	714.mg		
TBA MXB		5.71gm *	P<.9 -	486.mg n.s.s.	38/50	31/50	30/50		
kid uac		23.0gm *	P<.3	3.74gm n.s.s.	0/50	0/50	1/50		
kid tla		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		
liv MXB		9.98gm *	P<.2	2.46gm n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
6246 R f aci gav 24m24 TR273 :					0	349.mg	707.mg		
kid MXA s		3.76gm *	P<.07 i	1.29gm n.s.s.	0/50	3/50	1/50		kid:acn,tla,uac.
kid MXA s		7.80gm *	P<.2	1.90gm n.s.s.	0/50	1/50	1/50		kid:acn,uac.
TBA MXB s		61.7gm *	P<1.	461.mg n.s.s.	33/50	21/50	18/50		
liv MXB s		no dre	P=1.	4.26gm n.s.s.	2/50	0/50	0/50		liv:hpa,hpc,nnd.
6247 R f aug gav 24m24 TR273 :					0	354.mg	707.mg		
kid MXA		2.24gm \	P<.2 i	604.mg n.s.s.	1/50	4/50	(0/50)		kid:tla,uac.
kid uac		no dre	P=1.	2.32gm n.s.s.	0/50	2/50	0/50		
TBA MXB		no dre	P=1.	660.mg n.s.s.	43/50	35/50	29/50		
liv MXB		no dre	P=1.	5.95gm n.s.s.	2/50	0/50	0/50		liv:hpa,hpc,nnd.
6248 R f mar gav 24m24 TR273 :					0	354.mg	707.mg		
kid uac s		4.11gm *	P<.08 i	1.01gm n.s.s.	0/50	1/50	1/50		
kid MXA s		4.37gm *	P<.3	934.mg n.s.s.	1/50	2/50	1/50		kid:tla,uac.
TBA MXB s		709.mg *	P<.3	196.mg n.s.s.	47/50	32/50	22/50		
liv MXB s		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
6249 R f osm gav 24m24 TR273 :					0	354.mg	711.mg		
adr coa s#		556.mg *	P<.04 i	217.mg n.s.s.	16/50	13/50	19/50		S
kid tla s		10.7gm *	P<.2	1.74gm n.s.s.	0/50	0/50	1/50		
kid uac s		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		
TBA MXB s		372.mg *	P<.07	143.mg n.s.s.	40/50	36/50	37/50		
liv MXB s		3.50gm *	P<.05	839.mg n.s.s.	0/50	0/50	2/50		liv:hpa,hpc,nnd.
6250 R m f34 gav 24m24 TR243 :					0	357.mg	714.mg		
kid MXA s#		2.78gm *	P<.009 i	1.03gm 116.gm	0/50	2/50	3/50		kid:tla,uac. S
per MXA s		1.49gm \	P<.04	497.mg n.s.s.	1/50	5/50	(1/50)		per:men,msm. S
per msm s		1.49gm \	P<.04	497.mg n.s.s.	1/50	5/50	(0/50)		S
kid uac s		3.92gm *	P<.02	1.19gm n.s.s.	0/50	0/50	3/50		S
TBA MXB s		2.24gm *	P<.6	392.mg n.s.s.	33/50	26/50	18/50		
liv MXB s		12.2gm *	P<.2	1.99gm n.s.s.	0/50	0/50	1/50		liv:hpa,hpc,nnd.
6251 R m aci gav 24m24 TR273 :					0	354.mg	707.mg		
kid uac s		12.0gm *	P<.4 i	1.95gm n.s.s.	0/50	1/50	0/50		
TBA MXB s		820.mg *	P<.4	198.mg n.s.s.	44/50	27/50	17/50		
liv MXB s		9.40gm *	P<.5	1.47gm n.s.s.	1/50	1/50	1/50		liv:hpa,hpc,nnd.
6252 R m aug gav 24m24 TR273 :					0	354.mg	707.mg		
sub MXA #		3.73gm *	P<.03 i	1.24gm n.s.s.	0/50	1/50	3/50		sub:spm,srn. S
kid MXA		3.81gm *	P<.2	1.14gm n.s.s.	0/50	2/50	1/50		kid:tla,uac.
kid uac		10.8gm *	P<.7	1.76gm n.s.s.	0/50	1/50	0/50		
TBA MXB		no dre	P=1.	347.mg n.s.s.	45/50	32/50	27/50		
liv MXB		6.44gm *	P<.2	1.55gm n.s.s.	0/50	1/50	1/50		liv:hpa,hpc,nnd.
6253 R m mar gav 24m24 TR273 :					0	354.mg	707.mg		
tes MXA s#		153.mg *	P<.0005 i	90.6mg 316.mg	17/50	21/50	32/50		tes:ict,itm. S
kid MXA s		5.71gm *	P<.1	1.26gm n.s.s.	0/50	1/50	1/50		kid:tla,uac.
tes itm s		6.54gm *	P<.2	1.07gm n.s.s.	0/50	0/50	1/50		
kid uac s		8.00gm *	P<.2	1.30gm n.s.s.	0/50	0/50	1/50		
TBA MXB s		199.mg *	P<.002	101.mg 906.mg	38/50	23/50	32/50		
liv MXB s		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
6254 R m osm gav 24m24 TR273 :					0	354.mg	707.mg		
kid tla #		628.mg \	P<.003 i	253.mg 3.23gm	0/50	6/50	(1/50)		S
kid MXA		628.mg \	P<.003	253.mg 3.23gm	0/50	6/50	(2/50)		kid:tla,uac. S
TBA MXB		1.49gm *	P<.6	257.mg n.s.s.	37/50	35/50	29/50		
liv MXB		8.95gm *	P<.5	1.46gm n.s.s.	1/50	0/50	2/50		liv:hpa,hpc,nnd.

TRICHLOROFLUOROMETHANE (CFC 11, fluorocarbon 11) 75-69-4

6255 M f b6c gav 78w91 TR106 :					0	1.20gm	2.40gm		
TBA MXB sv		11.5gm *	P<.6 -	2.49gm n.s.s.	3/20	11/50	9/50		
liv MXB sv		no dre	P=1.	5.59gm n.s.s.	1/20	4/50	2/50		liv:hpa,hpc,nnd.
lun MXB sv		111.gm *	P<.8	9.23gm n.s.s.	1/20	0/50	2/50		lun:a/a,a/c.
6256 M m b6c gav 78w91 TR106 :					0	1.20gm	2.40gm		
TBA MXB sv		5.81gm *	P<.6 -	1.14gm n.s.s.	7/20	22/50	16/49		
liv MXB sv		15.0gm *	P<.8	1.54gm n.s.s.	5/20	15/50	10/49		liv:hpa,hpc,nnd.
lun MXB sv		no dre	P=1.	10.3gm n.s.s.	2/20	0/50	1/49		lun:a/a,a/c.
6257 M f swi inh 18m24 BT604m					0	883.mg	4.42gm		Maltoni;anya,534,261-282;1988
mam car		31.6gm *	P<.01 -	12.6gm 4.71kg	1/90	2/60	6/60		
--- leu		23.7gm *	P<.09 -	8.28gm n.s.s.	8/90	10/60	12/60		
lun ade		34.9gm *	P<.06 -	12.1gm n.s.s.	2/90	4/60	6/60		
tba mix		11.1gm *	P<.02 -	4.82gm n.s.s.	15/90	20/60	22/60		
tba mal		14.6gm *	P<.02 -	6.27gm n.s.s.	9/90	12/60	16/60		
6258 M m swi inh 18m24 BT604m					0	736.mg			
lun ade		no dre	P=1. -	9.10gm n.s.s.	3/90	0/60			
tba mal		7.54gm	P<.2 -	2.11gm n.s.s.	5/90	7/60			

Chemical Synonym CAS number
Spe Strain Xpo+Xpt 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf							Brkly Code
Path TD_{50} 2Tailpvl LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
tba mix 13.4gm P<.6 - 2.23gm n.s.s.	9/90	8/60					
6259 M m swi inh 18m24 BT604n	0	3.68gm					
lun ade no dre P=1. - 32.9gm n.s.s.	4/90	1/60					
tba mix no dre P=1. - 30.7gm n.s.s.	9/90	2/60					
tba mal no dre P=1. - 35.1gm n.s.s.	6/90	1/60					
6260 R f osm gav 18m26 TR106 :	0	270.mg	540.mg				
TBA MXB sv 326.mg * P<.09 i 91.0mg n.s.s.	7/20	4/50	7/50				
liv MXB sv no dre P=1. n.s.s. n.s.s.	0/20	0/50	0/50				liv:hpa,hpc,nnd.
6261 R m osm gav 18m26 TR106 :	0	257.mg	490.mg				
TBA MXB sv no dre P=1. i 117.mg n.s.s.	5/20	4/50	1/50				
liv MXB sv no dre P=1. n.s.s. n.s.s.	0/20	0/50	0/50				liv:hpa,hpc,nnd.
6262 R f sda inh 24m24 BT603	0	280.mg	1.40gm				Maltoni;anya,534,261-282;1988
liv ang no dre P=1. - 20.8gm n.s.s.	1/150	2/90	0/90				
tba mix no dre P=1. - 1.77gm n.s.s.	124/150	65/90	70/90				
tba mal no dre P=1. - 9.88gm n.s.s.	43/150	23/90	15/90				
6263 R m sda inh 24m24 BT603	0	196.mg	981.mg				
liv ang no dre P=1. - 3.03gm n.s.s.	1/150	0/90	0/90				
tba mix 631.mg \ P<.06 - 252.mg n.s.s.	51/150	42/90	(25/90)				
tba mal no dre P=1. - 6.05gm n.s.s.	25/150	16/90	11/90				
N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE (folpet) 133-07-3							
6264 M f b6a orl 76w76 1239	0	83.8mg					Innes;ntis,1968/1969
liv hpt evx no dre P=1. - 138.mg n.s.s.	0/17	0/15					
lun ade evx no dre P=1. - 138.mg n.s.s.	1/17	0/15					
tba mix evx no dre P=1. - 89.8mg n.s.s.	2/17	1/15					
6265 M m b6a orl 76w76 1239	0	78.0mg					
liv hpt evx 8.23gm P<1. - 86.4mg n.s.s.	1/18	1/17					
lun ade evx no dre P=1. - 95.9mg n.s.s.	2/18	1/17					
tba mix evx no dre P=1. - 75.1mg n.s.s.	3/18	2/17					
6266 M f b6c orl 76w76 1239	0	83.8mg					
liv hpt evx no dre P=1. - 166.mg n.s.s.	0/16	0/18					
lun mix evx no dre P=1. - 166.mg n.s.s.	0/16	0/18					
tba mix evx 260.mg P<.2 - 63.9mg n.s.s.	0/16	2/18					
6267 M f b6c eat 24m24 2175	0	130.mg	494.mg	989.mg			Nyska;gann,81,545-549;1990/pers.comm.
duo mix ev 1.67gm * P<.0005 + 1.05gm 3.11gm	1/51	2/52	10/52	19/52			
duo adc ev 2.09gm * P<.0005 + 1.28gm 3.73gm	0/51	1/52	5/52	18/52			
--- mly ev 2.20gm * P<.03 950.mg n.s.s.	16/51	16/52	19/52	26/52			
stn sqp ev 5.78gm * P<.02 2.49gm n.s.s.	2/51	1/52	5/52	7/52			
stn mix ev 6.00gm * P<.04 2.45gm n.s.s.	2/51	2/52	5/52	7/52			
liv mix ev 18.9gm * P<.05 5.71gm n.s.s.	0/51	0/52	1/52	2/52			
duo ade ev 29.2gm * P<.7 4.30gm n.s.s.	1/51	1/52	5/52	1/52			
lun mix ev no dre P=1. 9.76gm n.s.s.	3/51	2/52	1/52	1/52			
stn sqc ev no dre P=1. 12.1gm n.s.s.	0/51	1/52	0/52	0/52			
6268 M m b6c orl 76w76 1239	0	78.0mg					Innes;ntis,1968/1969
lun ade evx 156.mg P<.05 - 47.2mg n.s.s.	0/16	3/18					
liv hpt evx 242.mg P<.2 - 59.5mg n.s.s.	0/16	2/18					
tba mix evx 87.7mg P<.009 - 33.1mg 1.92gm	0/16	5/18					
6269 M m b6c eat 24m24 2175	0	120.mg	456.mg	913.mg			Nyska;gann,81,545-549;1990/pers.comm.
duo mix ev 899.mg * P<.0005 + 625.mg 1.36gm	0/52	4/52	17/52	25/52			
duo adc ev 981.mg * P<.0005 + 675.mg 1.50gm	0/52	3/52	17/52	23/52			
stn mix ev 5.46gm * P<.06 2.35gm n.s.s.	0/52	2/52	6/52	3/52			
stn sqc ev 13.1gm * P<.09 4.52gm n.s.s.	0/52	0/52	3/52	1/52			
stn sqp ev 12.9gm * P<.3 3.36gm n.s.s.	0/52	2/52	3/52	2/52			
duo ade ev 23.0gm * P<.3 5.36gm n.s.s.	0/52	1/52	0/52	2/52			
liv mix ev no dre P=1. 1.83gm n.s.s.	20/52	13/52	11/52	(8/52)			
lun mix ev no dre P=1. 2.56gm n.s.s.	11/52	4/52	5/52	(3/52)			
6270 M f cd1 eat 26m26 2133m	0	130.mg	650.mg	1.56gm			Quest;rtxp,17,19-34;1993/pers.comm.
dgt mix er 2.38gm Z P<.0005 + 1.68gm 3.52gm	0/104	1/80	8/80	41/80			
duo adc er 3.31gm * P<.0005 + 2.18gm 5.34gm	0/88	0/63	5/67	29/74			
duo ade er 7.28gm * P<.0005 + 4.13gm 15.3gm	0/88	1/63	3/67	13/74			
stn pam er no dre P=1. 14.0gm n.s.s.	1/102	4/79	5/79	1/80			
6271 M m cd1 eat 26m26 2133m	0	120.mg	600.mg	1.44gm			
dgt mix er 2.19gm Z P<.0005 + 1.54gm 3.28gm	1/104	2/80	8/80	41/80			
duo adc er 2.40gm * P<.0005 + 1.65gm 3.69gm	0/87	1/61	7/67	34/75			
duo ade er 10.3gm * P<.0005 + 5.02gm 38.3gm	1/87	1/61	2/67	10/75			
stn pam er 13.4gm * P<.006 + 6.05gm 178.gm	1/103	1/79	5/80	6/78			
6272 R f cdr eat 24m24 2133m	0	10.0mg	40.0mg	160.mg			
thy cca r no dre P=1. 1.22gm n.s.s.	4/60	4/60	3/60	2/60			
thy ccr r no dre P=1. 1.48gm n.s.s.	1/60	1/60	3/60	0/60			
thy mix r no dre P=1. 1.49gm n.s.s.	3/60	5/60	3/60	1/60			
6273 R m cdr eat 24m24 2133m	0	8.00mg	32.0mg	128.mg			
tes ict r 839.mg * P<.05 303.mg n.s.s.	1/60	5/60	4/60	8/60			
thy mix r 2.94gm Z P<.6 436.mg n.s.s.	1/60	9/60	4/60	6/60			
thy cca r no dre P=1. 893.mg n.s.s.	0/60	8/60	2/60	2/60			
6274 R f f34 eat 24m24 2133n	0	25.0mg	50.0mg	100.mg			
--- mly er 947.mg * P<.07 409.mg n.s.s.	0/55	2/58	2/57	3/56			
6275 R m f34 eat 24m24 2133n	0	20.0mg	40.0mg	80.0mg			
--- mly er 1.07gm * P<.1 407.mg n.s.s.	0/57	1/56	2/57	2/57			
2,4,6-TRICHLOROPHENOL (dowicide-2S) 88-06-2							
6276 M f b6c eat 24m24 TR155 :	0	678.mg	1.36gm				
liv MXA v 1.41gm * P<.0005 c 874.mg 4.56gm	1/20	12/50	24/50				liv:hpa,hpc.
TBA MXB v 1.51gm * P<.05 686.mg n.s.s.	6/20	30/50	33/50				
liv MXB v 1.41gm * P<.0005 874.mg 4.56gm	1/20	12/50	24/50				liv:hpa,hpc,nnd.
lun MXB v 114.gm * P<1. 4.39gm n.s.s.	1/20	4/50	3/50				lun:a/a,a/c.
6277 M f b6c orl 76w76 292	0	36.4mg					Innes;ntis,1968/1969
liv hpt evx 113.mg P<.2 27.8mg n.s.s.	0/16	2/18					
lun ade evx 113.mg P<.2 27.8mg n.s.s.	0/16	2/18					

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix evx	27.0mg	P<.002	11.5mg	110.mg	0/16	7/18			
6278 M m b6c eat 24m24 TR155 :					0	600.mg	1.20gm		
liv MXA	856.mg *	P<.01 c	457.mg	66.3gm	4/20	32/50	39/50		liv:hpa,hpc.
TBA MXB	10.7gm *	P<.9	708.mg	n.s.s.	14/20	42/50	42/50		
liv MXB	856.mg *	P<.01	457.mg	66.3gm	4/20	32/50	39/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	2.89gm	n.s.s.	3/20	13/50	7/50		lun:a/a,a/c.
6279 M m b6c orl 76w76 292					0	33.9mg			Innes;ntis,1968/1969
liv hpt evx	68.0mg	P<.05	20.5mg	n.s.s.	0/16	3/18			
lun ade evx	105.mg	P<.2	25.9mg	n.s.s.	0/16	2/18			
tba mix evx	17.9mg	P<.0005	8.25mg	51.6mg	0/16	9/18			
6280 M f b6a orl 76w76 292					0	36.4mg			
liv hpt evx	220.mg	P<.3	35.8mg	n.s.s.	0/17	1/17			
lun ade evx	no dre	P=1.	68.1mg	n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	32.0mg	n.s.s.	2/17	2/17			
6281 M m b6a orl 76w76 292					0	33.9mg			
lun ade evx	1.68gm	P<1.	29.5mg	n.s.s.	2/18	2/17			
liv hpt evx	3.58gm	P<1.	37.6mg	n.s.s.	1/18	1/17			
tba mix evx	1.05gm	P<1.	24.7mg	n.s.s.	3/18	3/17			
6282 R f f34 eat 25m25 TR155 :					0	250.mg	500.mg		
TBA MXB a	no dre	P=1. -	301.mg	n.s.s.	16/20	32/50	(27/50)		
liv MXB a	no dre	P=1.	n.s.s.	n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
6283 R m f34 eat 25m25 TR155 :					0	200.mg	400.mg		
--- mle	405.mg *	P<.008 c	222.mg	8.89gm	3/20	23/50	28/50		
--- MXA	445.mg *	P<.02 c	227.mg	n.s.s.	4/20	25/50	29/50		---:leu,lym.
--- MXB	445.mg *	P<.02	227.mg	n.s.s.	4/20	25/50	29/50		---:leu,lym,mle. C
TBA MXB	1.43gm *	P<.7	229.mg	n.s.s.	16/20	40/50	41/50		
liv MXB	no dre	P=1.	3.93gm	n.s.s.	1/20	1/50	0/50		liv:hpa,hpc,nnd.
2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID 93-72-1									
6284 M f b6a orl 76w76 1234					0	16.9mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1. -	29.8mg	n.s.s.	0/17	0/16			
lun ade evx	no dre	P=1. -	29.8mg	n.s.s.	1/17	0/16			
tba mix evx	no dre	P=1. -	19.6mg	n.s.s.	2/17	1/16			
6285 M m b6a orl 76w76 1234					0	15.8mg			
lun ade evx	no dre	P=1. -	20.7mg	n.s.s.	2/18	1/18			
liv hpt evx	no dre	P=1. -	31.2mg	n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1. -	22.1mg	n.s.s.	3/18	1/18			
6286 M f b6c orl 76w76 1234					0	16.9mg			
liv hpt evx	no dre	P=1. -	33.5mg	n.s.s.	0/16	0/18			
lun mix evx	no dre	P=1. -	33.5mg	n.s.s.	0/16	0/18			
tba mix evx	52.6mg	P<.2 -	12.9mg	n.s.s.	0/16	2/18			
6287 M m b6c orl 76w76 1234					0	15.8mg			
liv hpt evx	16.6mg	P<.007 -	6.24mg	224.mg	0/16	5/17			
lun ade evx	95.2mg	P<.3 -	15.5mg	n.s.s.	0/16	1/17			
tba mix evx	9.07mg	P<.0005 -	4.03mg	28.9mg	0/16	8/17			
2,4,5-TRICHLOROPHENOXYACETIC ACID (2,4,5-T) 93-76-5									
6288 M f b6a orl 76w76 1233					0	8.34mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1. -	16.5mg	n.s.s.	0/17	0/18			
lun ade evx	no dre	P=1. -	16.5mg	n.s.s.	1/17	0/18			
tba mix evx	no dre	P=1. -	7.87mg	n.s.s.	2/17	2/18			
6289 M m b6a orl 76w76 1233					0	7.76mg			
liv hpt evx	no dre	P=1. -	9.17mg	n.s.s.	1/18	1/18			
lun ade evx	no dre	P=1. -	15.4mg	n.s.s.	2/18	0/18			
tba mix evx	no dre	P=1. -	6.10mg	n.s.s.	3/18	3/18			
6290 M f b6c orl 76w76 1233					0	8.34mg			
lun ade evx	53.4mg	P<.3 -	8.69mg	n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1. -	16.5mg	n.s.s.	0/16	0/18			
tba mix evx	53.4mg	P<.3 -	8.69mg	n.s.s.	0/16	1/18			
6291 M m b6c orl 76w76 1233					0	7.76mg			
liv hpt evx	11.3mg	P<.02 -	3.89mg	n.s.s.	0/16	4/18			
lun ade evx	49.7mg	P<.3 -	8.09mg	n.s.s.	0/16	1/18			
tba mix evx	7.00mg	P<.004 -	2.83mg	42.8mg	0/16	6/18			
6292 R f mrw eat 87w87 2038					0	30.0mg			Mirvish;jtxe,32,59-74;1991/pers.comm.
liv tum	no dre	P=1. -	43.3mg	n.s.s.	0/10	0/10			
tba tum	no dre	P=1. -	43.3mg	n.s.s.	0/10	0/10			
6293 R m mrw eat 87w87 2038					0	24.0mg			
liv tum	no dre	P=1. -	17.3mg	n.s.s.	0/5	0/5			
tba tum	no dre	P=1. -	17.3mg	n.s.s.	0/5	0/5			
6294 R f sda eat 24m24 1353					0	3.00mg	10.0mg	30.0mg	Kociba;fctx,17,205-221;1979
thy cca e	488.mg Z	P<.5 -	87.9mg	n.s.s.	3/86	10/50	2/50	6/50	
liv hnd e	no dre	P=1. -	208.mg	n.s.s.	4/86	2/50	3/50	1/50	
tba mix e	10.6mg *	P<.2 -	2.34mg	n.s.s.	83/86	48/50	48/50	50/50	
6295 R m sda eat 24m24 1353					0	3.00mg	10.0mg	30.0mg	
liv hpc e	no dre	P=1. -	279.mg	n.s.s.	3/86	1/50	0/50	1/50	
tba mix e	no dre	P=1. -	17.5mg	n.s.s.	76/86	44/50	40/50	44/50	
TRICHLOROPHONE 52-68-6									
6296 R b wis gav 24m24 2386					0	4.29mg			Stieglitz;ahae,52,70-76;1974/Gibel 1973/Gibel 1975
liv hpc e	80.7mg	P<.2	13.1mg	n.s.s.	0/36	1/28			
tba ben e	2.80mg	P<.0005	1.51mg	6.37mg	3/36	19/28			
tba mal e	10.2mg	P<.0005	4.39mg	35.0mg	0/36	7/28			
1,2,3-TRICHLOROPROPANE 96-18-4									
6297 M f b6c gav 20m24 TR384 :					0	4.26mg	14.3mg	42.9mg	
MXB MXB a	.826mg Z	P<.0005	.547mg	1.29mg	9/50	48/50	50/51	54/55	for:sqc,sqp; hag:ade,anb; liv:hpa,hpc; pal:sqc; phr:sqc; ute:ead,edc,esp. C
for MXA a	.828mg *	P<.0005 c	.551mg	1.26mg	0/50	48/50	50/51	54/55	for:sqc,sqp.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
for sqc a	.970mg *	P<.0005 c	.649mg	1.46mg	0/50	46/50	49/51	49/55	
for sqp a	1.64mg *	P<.0005 c	.972mg	2.90mg	0/50	23/50	18/51	29/55	
liv MXA a	2.93mg Z	P<.0005 c	1.60mg	5.95mg	7/50	11/50	8/51	31/55	liv:hpa,hpc.
liv hpa a	3.33mg Z	P<.0005 c	1.77mg	6.82mg	6/50	9/50	8/51	31/55	
ute MXA a	6.62mg Z	P<.0005 c	2.81mg	18.0mg	0/50	5/50	3/51	9/55	ute:ead,edc.
hag MXA a	7.05mg Z	P<.0005 c	3.10mg	18.1mg	2/50	6/50	7/51	10/55	hag:ade,anb.
--- MXA a	7.08mg *	P<.002	2.54mg	63.7mg	15/50	6/50	3/51	3/55	---:mlh,mlm,mlp,mlu. S
ute edc a	8.47mg Z	P<.0005 c	3.36mg	25.0mg	0/50	4/50	3/51	6/55	
--- MXA a	8.64mg *	P<.006	2.80mg	193.mg	17/50	7/50	3/51	3/55	---:hcs,mlh,mlm,mlp,mlu. S
lun MXA a	14.3mg Z	P<.0005	4.56mg	68.9mg	7/50	3/50	0/51	10/55	lun:a/a,a/c. S
lun a/a a	14.6mg Z	P<.0005	4.46mg	71.5mg	4/50	3/50	0/51	10/55	S
ute esp a	22.9mg *	P<.0005 c	5.82mg	148.mg	0/50	2/50	1/51	6/55	
liv hpc a	28.7mg *	P<.01	6.25mg	6.07gm	1/50	3/50	0/51	2/55	S
ute ead a	34.9mg *	P<.002 c	6.33mg	522.mg	0/50	1/50	0/51	3/55	
MXA MXA a	47.0mg *	P<.0005	8.63mg	323.mg	1/50	0/50	2/51	5/55	pal:sqc,sqp; phr:sqc; ton:sqp. S
MXA sqc a	154.mg *	P<.0005 c	50.7mg	600.mg	0/50	0/50	1/51	5/55	pal:sqc; phr:sqc.
TBA MXB a	.806mg Z	P<.0005	.537mg	1.27mg	36/50	48/50	50/51	55/55	
liv MXB a	2.93mg Z	P<.0005	1.60mg	5.95mg	7/50	11/50	8/51	31/55	liv:hpa,hpb,hpc.
lun MXB a	14.3mg Z	P<.0005	4.56mg	68.9mg	7/50	3/50	0/51	10/55	lun:a/a,a/c.
6298 M m b6c gav 21m24 TR384 :					0	4.24mg	14.3mg	42.8mg	
for MXA a	.928mg *	P<.0005 c	.626mg	1.39mg	3/52	50/52	53/54	55/56	for:sqc,sqp.
MXB MXB a	.996mg *	P<.0005	.686mg	1.55mg	15/52	50/52	53/54	55/56	for:sqc,sqp; hag:ade; liv:hpa,hpc. C
for sqc a	1.34mg *	P<.0005 c	.910mg	1.98mg	0/52	40/52	50/54	51/56	
for sqp a	1.63mg *	P<.0005 c	1.01mg	2.71mg	3/52	28/52	22/54	33/56	
liv MXA a	2.13mg Z	P<.0005 c	1.31mg	3.64mg	13/52	24/52	24/54	31/56	liv:hpa,hpc.
liv hpa a	2.87mg Z	P<.0005 c	1.67mg	5.26mg	11/52	18/52	21/54	29/56	
liv hpc a	6.28mg *	P<.0005	2.93mg	19.9mg	4/52	11/52	5/54	3/56	S
lun MXA a	9.32mg *	P<.0005	3.57mg	49.7mg	8/52	11/52	5/54	6/56	lun:a/a,a/c. S
lun a/a a	11.2mg *	P<.0005	3.85mg	87.3mg	7/52	11/52	3/54	6/56	S
hag ade a	13.7mg Z	P<.0005 c	6.13mg	30.8mg	1/52	2/52	10/54	11/56	
ton sqp a	454.mg *	P<.02 e	103.mg	n.s.s.	0/52	0/52	0/54	2/56	
TBA MXB a	1.06mg *	P<.0005	.703mg	1.67mg	29/52	50/52	54/54	56/56	
liv MXB a	2.13mg Z	P<.0005	1.31mg	3.64mg	13/52	24/52	24/54	31/56	liv:hpa,hpb,hpc.
lun MXB a	9.32mg *	P<.0005	3.57mg	49.7mg	8/52	11/52	5/54	6/56	lun:a/a,a/c.
6299 R f f34 gav 21m24 TR384 :					0	2.12mg	7.05mg	21.4mg	
MXB MXB a	1.07mg Z	P<.0005	.759mg	1.58mg	23/50	38/49	49/52	47/52	cli:ade,anb,car,cnb; for:sqc,sqp; mgl:adc,ade, fba; pal:sqp; phr:sqc; ton:sqc,sqp; zym:car. C
for MXA a	1.64mg Z	P<.0005 c	1.14mg	2.43mg	0/50	16/49	37/52	19/52	for:sqc,sqp.
for sqp a	1.94mg Z	P<.0005 c	1.31mg	2.97mg	0/50	13/49	32/52	17/52	
mgl MXA a	1.98mg Z	P<.0005 c	1.26mg	3.43mg	17/50	26/49	29/52	22/52	mgl:adc,ade,fba.
MXA MXA a	2.93mg Z	P<.0005 c	1.94mg	4.48mg	1/50	6/49	28/52	32/52	pal:sqp; phr:sqc; ton:sqc,sqp.
mgl MXA a	3.32mg *	P<.0005	1.77mg	10.2mg	16/50	23/49	22/52	1/52	mgl:ade,fba. S
mgl fba a	3.42mg *	P<.0005	1.79mg	11.3mg	15/50	23/49	20/52	1/52	S
cli MXA a	3.58mg Z	P<.0005 c	2.12mg	6.90mg	5/50	10/49	17/52	15/52	cli:ade,anb,car,cnb.
cli MXA a	4.04mg Z	P<.0005 c	2.30mg	8.76mg	5/50	10/49	13/52	10/52	cli:ade,anb.
ton MXA a	4.70mg Z	P<.0005	2.84mg	7.94mg	0/50	3/49	18/52	23/52	ton:sqc,sqp. S
MXA sqc a	5.12mg Z	P<.0005 c	3.17mg	8.36mg	0/50	1/49	21/52	21/52	phr:sqc; ton:sqc.
mgl MXA a	5.50mg Z	P<.0005 c	3.21mg	10.0mg	2/50	6/49	14/52	21/52	mgl:adc,ade.
mgl adc a	5.91mg Z	P<.0005 c	3.38mg	10.9mg	1/50	6/49	12/52	21/52	
MXA sqp a	5.98mg Z	P<.0005 c	3.36mg	11.4mg	1/50	5/49	10/52	18/52	pal:sqp; ton:sqp.
for sqc a	7.77mg *	P<.0005 c	4.00mg	17.1mg	0/50	3/49	9/52	4/52	
MXA sqc a	8.87mg Z	P<.0005	4.89mg	16.3mg	0/50	1/49	10/52	15/52	pal:sqc; phr:sqc. S
ton sqp a	9.61mg Z	P<.0005	4.88mg	19.3mg	0/50	3/49	5/52	16/52	S
ton sqc a	10.1mg Z	P<.0005	5.10mg	20.3mg	0/50	0/49	13/52	7/52	S
pal sqp a	18.5mg *	P<.002	7.05mg	106.mg	1/50	2/49	5/52	2/52	S
thy MXA a	25.2mg *	P<.0005	8.60mg	127.mg	0/50	1/49	3/52	2/52	thy:fca,fcc. S
thy fca a	36.9mg *	P<.0005	11.2mg	196.mg	0/50	0/49	3/52	2/52	S
cli MXA a	49.5mg *	P<.0005 c	22.5mg	131.mg	0/50	0/49	4/52	6/52	cli:car,cnb.
zym car a	59.0mg Z	P<.003 c	15.8mg	579.mg	0/50	1/49	0/52	3/52	
MXA adc a	78.4mg *	P<.004 e	18.6mg	925.mg	0/50	0/49	1/52	2/52	col:adc; jej:adc.
--- mnl a	7.11mg *	P<.02	2.96mg	n.s.s.	13/50	17/49	14/52	0/52	S
TBA MXB a	1.02mg Z	P<.0005	.710mg	1.54mg	48/50	46/49	51/52	48/52	
liv MXB a	81.4mg *	P<.1	13.3mg	n.s.s.	0/50	0/49	1/52	0/52	liv:hpa,hpb,hpc.
6300 R m f34 gav 22m24 TR384 :					0	2.11mg	7.06mg	21.4mg	
MXB MXB a	1.10mg Z	P<.0005	.803mg	1.57mg	8/50	41/50	45/49	51/52	for:sqc,sqp; kid:rua; pal:sqc,sqp; pan:ade,ana, aoc; pre:ade,car; ton:sqc,sqp; zym:car. C
for MXA a	1.15mg Z	P<.0005 c	.860mg	1.58mg	0/50	33/50	42/49	43/52	for:sqc,sqp.
tes MXA a	1.35mg Z	P<.0005	.928mg	2.14mg	47/50	48/50	45/49	44/52	tes:iab,ica. S
for sqp a	1.53mg Z	P<.0005 c	1.12mg	2.13mg	0/50	29/50	33/49	38/52	
pan MXA a	1.65mg Z	P<.0005 c	1.17mg	2.47mg	5/50	21/50	36/49	29/52	pan:ade,ana,aoc.
pan MXA a	1.65mg Z	P<.0005 c	1.17mg	2.47mg	5/50	21/50	36/49	29/52	pan:ade,ana.
for sqc a	3.00mg Z	P<.0005 c	2.00mg	4.70mg	0/50	9/50	27/49	13/52	
kid rua a	4.44mg Z	P<.0005 c	2.83mg	7.28mg	0/50	2/50	20/49	21/52	
MXA MXA a	4.48mg Z	P<.0005 c	2.96mg	6.96mg	1/50	4/50	18/49	40/52	pal:sqc,sqp; ton:sqc,sqp.
ton MXA a	7.86mg Z	P<.0005	4.84mg	12.7mg	0/50	2/50	8/49	37/52	ton:sqc,sqp. S
thy MXA a	8.15mg Z	P<.0005	3.89mg	36.7mg	4/50	16/50	6/49	5/52	thy:cca,ccr. S
MXA sqp a	8.16mg Z	P<.0005 c	4.75mg	14.7mg	0/50	4/50	9/49	19/52	pal:sqp; ton:sqp.
MXA sqc a	8.65mg Z	P<.0005 c	4.98mg	15.7mg	1/50	0/50	11/49	25/52	pal:sqc; ton:sqc.
pre MXA a	9.59mg Z	P<.0005 c	5.16mg	21.5mg	5/50	6/50	8/49	16/52	pre:ade,car.
ton sqp a	10.2mg Z	P<.0005	5.67mg	19.1mg	0/50	2/50	8/49	18/52	S
thy cca a	10.3mg Z	P<.002	4.49mg	66.6mg	4/50	15/50	4/49	5/52	S
pal sqc a	11.7mg Z	P<.0005	5.94mg	27.6mg	1/50	0/50	11/49	7/52	S
--- mnl a	11.9mg Z	P<.005	4.98mg	144.mg	16/50	11/50	9/49	6/52	S
pre ade a	14.0mg Z	P<.0005 c	6.69mg	39.0mg	5/50	3/50	5/49	11/52	
sub MXA a	19.6mg *	P<.008	7.64mg	665.mg	3/50	3/50	7/49	1/52	sub:fib,sar. S
sub fib a	20.2mg *	P<.006	7.87mg	295.mg	2/50	2/50	6/49	1/52	S
ski MXA a	20.8mg Z	P<.0005	8.39mg	99.7mg	3/50	3/50	3/49	6/52	ski:bcc,ker,sqc,sqp,tri. S
liv MXA a	23.0mg *	P<.0005	9.02mg	116.mg	1/50	1/50	4/49	3/52	liv:hpa,hpc. S

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
pre	car a	28.0mg *	P<.0005 c	11.5mg 127.mg	0/50	3/50	3/49	5/52	
ton	sqc a	34.7mg Z	P<.0005	19.6mg 67.0mg	0/50	0/50	0/49	19/52	S
thy	MXA a	35.2mg *	P<.008	11.7mg 1.25gm	1/50	1/50	3/49	2/52	thy:fca,fcc. S
pal	sqp a	36.6mg *	P<.002	12.7mg 309.mg	0/50	2/50	1/49	3/52	S
ski	MXA a	39.6mg *	P<.002	14.2mg 283.mg	0/50	2/50	1/49	3/52	ski:sqc,sqp. S
pan	aoc a	51.5mg *	P<.005	14.2mg 771.mg	0/50	0/50	2/49	1/52	S
MXA	MXA a	73.4mg *	P<.0005 e	25.5mg 357.mg	0/50	0/50	2/49	3/52	col:adc,adp; jej:adc; rec:adp.
amd	MXA a	11.4mg *	P<.03	4.64mg n.s.s.	11/50	8/50	14/49	0/52	amd:pbb,phc,phm,pob. S
amd	MXA a	12.4mg *	P<.03	5.00mg n.s.s.	10/50	7/50	13/49	0/52	amd:pbb,pob. S
liv	hpa a	31.7mg *	P<.02	10.4mg n.s.s.	1/50	1/50	3/49	1/52	S
ski	sqp a	51.0mg Z	P<.02	15.6mg n.s.s.	0/50	2/50	0/49	2/52	S
MXA	adc a	102.mg *	P<.02 e	28.8mg n.s.s.	0/50	0/50	2/49	1/52	col:adc; jej:adc.
MXA	adp a	264.mg *	P<.02 e	60.1mg n.s.s.	0/50	0/50	0/49	2/52	col:adp; rec:adp.
zym	car a	297.mg *	P<.02 c	89.8mg 454.gm	0/50	0/50	0/49	3/52	
TBA	MXB a	1.36mg Z	P<.0005	.943mg 2.10mg	44/50	48/50	45/49	51/52	
liv	MXB a	23.0mg *	P<.0005	9.02mg 116.mg	1/50	1/50	4/49	3/52	liv:hpa,hpb,hpc.
TRICRESYL PHOSPHATE 1330-78-5									
6301	M f b6c eat 24m24 TR433 :				0	7.69mg	16.0mg	32.1mg	
TBA	MXB	no dre	P=1. -	34.6mg n.s.s.	40/50	39/50	32/50	41/51	
liv	MXB	no dre	P=1.	70.9mg n.s.s.	21/50	14/50	14/50	18/51	liv:hpa,hpb,hpc.
lun	MXB	2.31gm *	P<.9	101.mg n.s.s.	5/50	5/50	5/50	6/51	lun:a/a,a/c.
6302	M m b6c eat 24m24 TR433 :				0	7.10mg	14.8mg	29.7mg	
hag	ade #	184.mg *	P<.006 -	83.5mg 2.02gm	0/51	1/50	2/50	5/50	S
TBA	MXB	159.mg *	P<.7	22.6mg n.s.s.	37/51	35/50	39/50	39/50	
liv	MXB	968.mg *	P<1.	35.6mg n.s.s.	28/51	26/50	24/50	28/50	liv:hpa,hpb,hpc.
lun	MXB	187.mg *	P<.4	45.5mg n.s.s.	8/51	11/50	13/50	12/50	lun:a/a,a/c.
6303	R f f34 eat 24m24 TR433 :				0	3.74mg	7.49mg	15.0mg	
---	mnl #	35.0mg *	P<.03 -	15.3mg n.s.s.	8/51	8/53	13/50	15/50	S
TBA	MXB	21.6mg *	P<.3	6.75mg n.s.s.	47/51	39/53	43/50	46/50	
liv	MXB	no dre	P=1.	n.s.s. n.s.s.	0/51	0/53	0/50	0/50	liv:hpa,hpb,hpc.
6304	R m f34 eat 24m24 TR433 :				0	2.99mg	5.99mg	12.0mg	
TBA	MXB	no dre	P=1. -	9.18mg n.s.s.	44/51	39/50	44/50	38/50	
liv	MXB	143.mg *	P<.4	43.4mg n.s.s.	0/51	1/50	1/50	1/50	liv:hpa,hpb,hpc.
TRIETHANOLAMINE 102-71-6									
6305	M f b6c wat 82w82 2054				0	2.00gm	4.00gm		Konishi;faat,18,25-29;1992
liv	hem e	42.0gm *	P<.3 -	12.7gm n.s.s.	0/50	2/50	1/50		
lun	ade e	no dre	P=1. -	23.5gm n.s.s.	1/50	0/50	1/50		
tba	tum e	63.5gm *	P<.9 -	4.86gm n.s.s.	14/50	13/50	15/50		
6306	M m b6c wat 82w82 2054				0	1.67gm	3.33gm		
lun	adc e	no dre	P=1. -	6.64gm n.s.s.	1/43	0/46	0/48		
liv	hpc e	no dre	P=1. -	9.33gm n.s.s.	7/43	5/46	5/48		
lun	ade e	no dre	P=1. -	17.1gm n.s.s.	2/43	1/46	1/48		
tba	tum e	74.7gm *	P<1. -	2.52gm n.s.s.	23/43	21/46	26/48		
6307	M f icr eat 25m25 550				0	39.0mg	390.mg		Hoshino;canr,38,3918-3921;1978
---	mix e	1.29gm *	P<.04	471.mg n.s.s.	1/36	7/37	9/36		
liv	tum e	no dre	P=1.	291.mg n.s.s.	0/36	0/37	0/36		
lun	ade e	no dre	P=1.	2.52gm n.s.s.	0/36	1/37	0/36		
tba	mix e	88.8mg \	P<.002	42.2mg 371.mg	1/36	11/37	(13/36)		
tba	mal e	100.mg \	P<.003 +	46.1mg 559.mg	1/36	10/37	(13/36)		
6308	M m icr eat 26m27 550				0	36.0mg	360.mg		
liv	tum e	no dre	P=1.	277.mg n.s.s.	0/35	0/33	0/28		
lun	mix e	no dre	P=1.	2.38gm n.s.s.	1/35	2/33	0/28		
tba	mal e	no dre	P=1. +	1.53gm n.s.s.	1/35	3/33	1/28		
tba	mix e	no dre	P=1.	1.70gm n.s.s.	2/35	4/33	1/28		
6309	R f f3d wat 24m26 1793				0	412.mg	824.mg		Maekawa;jtxe,19,345-357;1986
liv	nnd ev	47.0gm *	P<.3 -	7.66gm n.s.s.	0/50	0/48	1/47		
tba	mix ev	no dre	P=1. -	1.31gm n.s.s.	44/50	36/48	34/47		
6310	R m f3d wat 24m26 1793				0	460.mg	920.mg		
liv	nnd e	9.59gm *	P<.09 -	3.44gm n.s.s.	1/48	2/49	5/48		
liv	hpc e	53.6gm *	P<.3 -	8.73gm n.s.s.	0/48	0/49	1/48		
tba	mix e	no dre	P=1. -	173.mg n.s.s.	48/48	49/49	47/48		
TRIETHYLENE GLYCOL 112-27-6									
6311	R m osm eat 24m24 105				0	400.mg	800.mg	1.60gm	Fitzhugh;jiht,28,40-43;1946
ubl	tum r	no dre	P=1.	565.mg n.s.s.	0/12	0/12	0/12	0/12	
2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE 42011-48-3									
6312	M f swi eat 46w55 1076				0	132.mg			Cohen;canr,33,1593-1597;1973
for	mix e	9.98mg	P<.0005 +	4.97mg 20.2mg	0/29	23/25			
for	sqc e	38.6mg	P<.0005	19.5mg 91.1mg	0/29	12/25			
for	sqp e	43.5mg	P<.0005	21.5mg 107.mg	0/29	11/25			
liv	tum e	no dre	P=1.	190.mg n.s.s.	0/29	0/25			
lun	tum e	no dre	P=1.	190.mg n.s.s.	0/29	0/25			
tba	mix e	8.01mg	P<.0005	3.39mg 17.7mg	2/29	24/25			
6313	R f sda eat 46w66 1126				0	17.4mg			Cohen;jnci,54,841-850;1975
mgl	mix e	6.79mg	P<.0005 +	3.55mg 20.5mg	2/24	17/31			
mgl	adc e	7.27mg	P<.0005	3.93mg 15.5mg	0/24	15/31			
liv	tum e	no dre	P=1.	44.8mg n.s.s.	0/24	0/31			
tba	mix e	5.58mg	P<.0005	3.01mg 14.2mg	2/24	19/31			
TRIFLURALIN, TECHNICAL GRADE 1582-09-8									
6314	M f b6c eat 78w90 TR34 :				0	309.mg	585.mg		
liv	MXA dv	330.mg *	P<.0005 c	220.mg 577.mg	0/20	15/50	21/50		liv:hpa,hpc.
liv	hpc dv	368.mg *	P<.0005 c	242.mg 648.mg	0/20	12/50	21/50		
TBA	MXB dv	263.mg *	P<.0005	170.mg 639.mg	2/20	24/50	26/50		
liv	MXB dv	330.mg *	P<.0005	220.mg 577.mg	0/20	15/50	21/50		liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun MXB dv	1.36gm * P<.08		664.mg n.s.s.		0/20	7/50	3/50		lun:a/a,a/c.
6315 M f b6c eat 78w90 TR34 : pool					0	309.mg	585.mg		
liv MXA dv	330.mg * P<.0005	c	220.mg	526.mg	0/60	15/50	21/50		liv:hpa,hpc.
liv hpc dv	368.mg * P<.0005	c	242.mg	600.mg	0/60	12/50	21/50		
lun MXA dv	1.36gm * P<.003	c	664.mg	5.71gm	0/60	7/50	3/50		lun:a/a,a/c.
lun a/a dv	1.52gm * P<.003	c	718.mg	7.46gm	0/60	6/50	3/50		
sto sqc dv	3.09gm * P<.05	c	1.17gm n.s.s.		0/60	4/50	1/50		
6316 M f b6c eat 24m24 2123					0	73.2mg	292.mg	585.mg	Francis;fctx,29,549-555;1991
liv hpa e	189.gm * P<1.	-	5.56gm n.s.s.		1/120	2/80	2/80	1/80	
lun ade e	no dre P=1.	-	10.2gm n.s.s.		7/120	4/80	3/80	0/80	
tba ben e	55.5gm Z P<1.	-	912.mg n.s.s.		29/120	16/80	19/80	(4/80)	
tba mal e	no dre P=1.	-	1.65gm n.s.s.		39/120	27/80	16/80	(10/80)	
6317 M m b6c eat 78w90 TR34 :					0	208.mg	389.mg		
TBA MXB dv	1.50gm * P<.8	-	170.mg n.s.s.		9/20	20/50	17/50		
liv MXB dv	1.50gm * P<.8		195.mg n.s.s.		4/20	14/50	9/50		liv:hpa,hpc,nnd.
lun MXB dv	5.44gm * P<.4		886.mg n.s.s.		0/20	0/50	1/50		lun:a/a,a/c.
6318 M m b6c eat 24m24 2123					0	67.6mg	270.mg	540.mg	Francis;fctx,29,549-555;1991
liv hpc e	4.77gm Z P<.4	-	1.06gm n.s.s.		6/120	7/80	7/80	(0/78)	
lun bro e	47.3gm * P<.5	-	7.70gm n.s.s.		0/120	0/80	1/80	0/78	
liv hpa e	no dre P=1.	-	5.90gm n.s.s.		6/120	3/80	5/80	1/78	
lun ade e	no dre P=1.	-	1.63gm n.s.s.		16/120	7/80	8/80	(1/78)	
tba mal e	2.16gm Z P<.3	-	608.mg n.s.s.		24/120	14/80	21/80	(6/78)	
tba ben e	no dre P=1.	-	1.04gm n.s.s.		32/120	15/80	18/80	(4/78)	
6319 M f nmr eat 24m24 2315					0	6.50mg	26.0mg	104.mg	Ebert;fctx,30,1031-1044;1992
liv hpa	2.32gm * P<.2	-	570.mg n.s.s.		0/50	0/50	1/50	1/50	
lun abt	3.49gm * P<.9	-	260.mg n.s.s.		6/50	8/50	10/50	8/50	
tba tum	no dre P=1.	-	151.mg n.s.s.		34/50	37/50	29/50	31/50	
6320 M m nmr eat 24m24 2315					0	6.00mg	24.0mg	96.0mg	
liv hpc	1.36gm * P<.5	-	249.mg n.s.s.		1/50	3/50	7/50	4/50	
lun abt	2.41gm * P<.9	-	146.mg n.s.s.		12/50	19/50	25/50	17/50	
liv hpa	no dre P=1.	-	320.mg n.s.s.		5/50	8/50	7/50	6/50	
tba tum	116.mg * P<.08	-	41.6mg n.s.s.		28/50	36/50	41/50	39/50	
6321 R f osm eat 18m26 TR34 :					0	145.mg	278.mg		
thy MXA dv#	663.mg \ P<.03	-	255.mg n.s.s.		1/50	7/50	(0/50)		thy:fca,fcc. S
TBA MXB dv	2.64gm \ P<1.		118.mg n.s.s.		36/50	39/50	(22/50)		
liv MXB dv	no dre P=1.		3.39gm n.s.s.		1/50	0/50	0/50		liv:hpa,hpc,nnd.
6322 R m osm eat 18m26 TR34 :					0	116.mg	225.mg		
TBA MXB dv	no dre P=1.	-	410.mg n.s.s.		28/50	22/50	22/50		
liv MXB dv	no dre P=1.		n.s.s. n.s.s.		0/50	0/50	0/50		liv:hpa,hpc,nnd.
6323 R f wis eat 28m28 2315					0	10.0mg	40.0mg	160.mg	Ebert;fctx,30,1031-1044;1992
liv hpa	5.89gm * P<.2	-	1.45gm n.s.s.		0/60	0/60	1/60	1/60	
liv hpc	no dre P=1.	-	2.04gm n.s.s.		0/60	0/60	1/60	0/60	
tba tum	no dre P=1.	-	344.mg n.s.s.		43/60	42/60	42/60	38/60	
6324 R m wis eat 28m28 2315					0	8.00mg	32.0mg	128.mg	
bra mnr	1.13gm * P<.0005	-	513.mg	4.77gm	0/60	1/60	0/60	7/60	
liv hpa	3.11gm * P<.01	-	941.mg	341.gm	0/60	0/60	0/60	3/60	
liv hpc	no dre P=1.	-	1.46gm n.s.s.		1/60	2/60	1/60	1/60	
tba tum	no dre P=1.	-	228.mg n.s.s.		37/60	33/60	37/60	35/60	

TRIMETHADIONE (3,5,5-trimethyl-2,4-oxazolidinedione) 127-48-0

6325 R m f34 eat 71w71 2109					0	12.4mg			Diwan;artx,66,413-422;1992
liv hct e	no dre P=1.		17.9mg n.s.s.		0/27	0/15			

(+-)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID (AA-2414) 112665-43-7

6326 R f f3j eat 52w52 2590					0	3.00mg	10.0mg	30.0mg 100.mg	Nonoyama;jjpt,21,S1723-S1738;1993
liv tum e	no dre P=1.	-	1.62mg n.s.s.		0/15	0/15	0/15	0/15 0/15	
6327 R m f3j eat 52w52 2590					0	3.00mg	10.0mg	30.0mg 100.mg	
liv tum e	no dre P=1.	-	1.62mg n.s.s.		0/15	0/15	0/15	0/15 0/15	

2,4,5-TRIMETHYLANILINE 137-17-7

6328 M f b6c eat 23m23 TR160 :					0	6.50mg	13.0mg		
liv hpc	6.13mg * P<.0005	c	4.44mg	9.97mg	0/20	18/50	40/50		
TBA MXB	22.4mg * P<.4		5.84mg n.s.s.		12/20	41/50	45/50		
liv MXB	6.13mg * P<.0005		4.44mg	9.97mg	0/20	18/50	40/50		liv:hpa,hpc,nnd.
lun MXB	47.6mg * P<.09		23.9mg n.s.s.		0/20	5/50	6/50		lun:a/a,a/c.
6329 M m b6c eat 23m23 TR160 :					0	6.00mg	12.0mg		
TBA MXB	52.5mg * P<.7	-	7.35mg n.s.s.		12/20	34/50	32/50		
liv MXB	14.4mg * P<.08		6.14mg n.s.s.		5/20	26/50	27/50		liv:hpa,hpc,nnd.
lun MXB	no dre P=1.		13.1mg n.s.s.		4/20	9/50	(1/50)		lun:a/a,a/c.
6330 R f f34 eat 23m23 TR160 :					0	10.0mg	40.0mg		
MXB MXB	20.4mg * P<.0005		13.8mg	54.5mg	0/20	14/50	33/50		liv:hpc,nnd; lun:a/a,a/c. C
liv MXA	27.2mg * P<.0005	c	17.3mg	88.2mg	0/20	12/50	27/50		liv:hpc,nnd.
lun MXA	88.1mg * P<.003	c	47.4mg	545.mg	0/20	3/50	11/50		lun:a/a,a/c.
liv hpc	142.mg * P<.002	c	67.0mg	388.mg	0/20	0/50	9/50		
TBA MXB	396.mg * P<.9		23.8mg n.s.s.		17/20	39/50	45/50		
liv MXB	27.2mg * P<.0005		17.3mg	88.2mg	0/20	12/50	27/50		liv:hpa,hpc,nnd.
6331 R m f34 eat 23m23 TR160 :					0	8.00mg	32.0mg		
liv MXA	43.8mg * P<.002	c	23.9mg	205.mg	1/20	6/50	20/50		liv:hpc,nnd.
liv hpc	71.8mg * P<.004	c	38.7mg	497.mg	0/20	3/50	11/50		
lun MXA	180.mg * P<.05		68.2mg n.s.s.		1/20	0/50	7/50		lun:a/a,a/c. S
liv bdc	268.mg * P<.03		92.5mg n.s.s.		0/20	0/50	4/50		S
TBA MXB	138.mg * P<.7		19.2mg n.s.s.		17/20	33/50	45/50		
liv MXB	43.8mg * P<.002		23.9mg	205.mg	1/20	6/50	20/50		liv:hpa,hpc,nnd.

2,4,5-TRIMETHYLANILINE.HCl 21436-97-5

6332 M f chi eat 77w98 381 :					0	106.mg	246.mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
lun mix	52.8mg * P<.0005	+	24.8mg	182.mg	6/20	11/15	12/22		
liv mix	60.4mg / P<.0005		31.9mg	123.mg	0/20	6/15	15/22		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpt		62.9mg	/ P<.0005 +	32.6mg 131.mg	0/20	6/15	14/22		
tba mix		47.2mg	/ P<.002	21.2mg 255.mg	17/20	15/15	19/22		
6333 M f chi eat 77w98 381 : pool					0	106.mg	246.mg		
liv hpt		62.3mg	/ P<.0005 +	32.1mg 134.mg	1/102	6/15	14/22		
lun mix		64.7mg	* P<.0005 +	31.3mg 184.mg	31/102	11/15	12/22		
6334 M m chi eat 77w98 381 :					0	98.2mg	227.mg		
liv mix		35.4mg	/ P<.0005	19.1mg 83.5mg	3/18	11/14	19/21		
lun mix		40.0mg	* P<.0005 +	19.4mg 136.mg	5/18	11/14	10/21		
liv hpt		46.2mg	/ P<.0005 +	24.3mg 115.mg	3/18	9/14	18/21		
tba mix		40.3mg	/ P<.0005	19.3mg 140.mg	12/18	13/14	19/21		
6335 M m chi eat 77w98 381 : pool					0	98.2mg	227.mg		
liv hpt		44.2mg	/ P<.0005 +	24.4mg 91.2mg	7/99	9/14	18/21		
lun mix		63.0mg	* P<.0005 +	28.8mg 216.mg	23/99	11/14	10/21		
--- vsc		260.mg	* P<.02 +	78.1mg n.s.s.	5/99	3/14	3/21		
6336 R m cdr eat 77w98 381 :					0	31.3mg	68.6mg		
liv mix		47.9mg	* P<.08	15.0mg n.s.s.	1/22	5/17	2/25		
liv hpt		98.5mg	* P<.2 +	23.5mg n.s.s.	1/22	3/17	2/25		
sub mix		no dre	P=1. +	27.3mg n.s.s.	4/22	7/17	1/25		
tba mix		37.2mg	* P<.3	9.25mg n.s.s.	14/22	15/17	13/25		
2,4,6-TRIMETHYLANILINE.HCl 6334-11-8									
6337 M f chi eat 77w94 381 :					0	37.1mg	78.0mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
liv hpt v		34.6mg	/ P<.0005 +	15.9mg 107.mg	1/15	1/12	12/16		
liv mix v		34.6mg	/ P<.0005 +	15.9mg 107.mg	1/15	1/12	12/16		
lun mix v		23.9mg	* P<.04 -	7.63mg n.s.s.	5/15	7/12	7/16		
tba mix v		20.6mg	* P<.02	7.27mg n.s.s.	10/15	10/12	16/16		
6338 M f chi eat 77w94 381 : pool					0	37.1mg	78.0mg		
liv hpt v		34.6mg	/ P<.0005 +	15.9mg 73.9mg	1/102	1/12	12/16		
6339 M m chi eat 77w94 381 :					0	34.3mg	75.8mg		
liv mix v		18.2mg	/ P<.0005	9.03mg 43.4mg	1/14	5/15	11/13		
liv hpt v		19.3mg	* P<.0005 +	9.31mg 51.4mg	0/14	5/15	9/13		
lun mix v		38.2mg	* P<.05 -	12.9mg n.s.s.	3/14	5/15	5/13		
tba mix v		18.4mg	* P<.009	7.34mg 966.mg	7/14	11/15	12/13		
6340 M m chi eat 77w94 381 : pool					0	34.3mg	75.8mg		
liv hpt v		22.7mg	* P<.0005 +	10.5mg 60.0mg	7/99	5/15	9/13		
--- vsc v		120.mg	* P<.005 +	36.5mg 1.84gm	5/99	1/15	4/13		
6341 R m cdr eat 73w77 381 :					0	5.90mg	11.8mg		
lun mix v		5.17mg	* P<.002 +	2.64mg 17.7mg	0/16	5/20	8/21		
liv mix v		6.15mg	* P<.002 +	3.07mg 21.1mg	0/16	4/20	8/21		
liv hpt v		6.15mg	* P<.002 +	3.07mg 21.1mg	0/16	4/20	8/21		
tba mix v		2.15mg	* P<.0005	1.21mg 6.38mg	10/16	13/20	18/21		
6342 R m cdr eat 73w77 381 : pool					0	5.90mg	11.8mg		
lun mix v		5.27mg	* P<.0005 +	2.65mg 12.9mg	1/111	5/20	8/21		
liv hpt v		6.22mg	* P<.0005 +	3.06mg 15.7mg	2/111	4/20	8/21		
sto mix v		22.0mg	* P<.002 +	6.57mg 159.mg	2/111	0/20	3/21		
TRIMETHYLARSINE OXIDE 4964-14-1									
6343 R m f3d wat 24m24 2630					0	2.50mg	10.0mg		Shen;carc,24,1827-1835;2003
liv hpa Ce		24.1mg	* P<.03 +	10.2mg n.s.s.	6/42	10/42	16/45		
liv hpc Ce		no dre	P=1.	17.5mg n.s.s.	0/42	0/42	0/45		
tba mix e		5.95mg	* P<.6	.662mg n.s.s.	42/42	40/42	45/45		
1,2,4-TRIMETHYLBENZENE 95-63-6									
6344 R f sda gav 24m29 BT913					0	387.mg			Maltoni;anya,837,15-52;1997
tba mix		no dre	P=1.	567.mg n.s.s.	35/50	33/50			
tba mal		14.3gm	P<.9	1.12gm n.s.s.	11/50	12/50			
6345 R m sda gav 24m29 BT913					0	387.mg			
hed car h		4.35gm	P<.08 +	1.42gm n.s.s.	1/50	5/50			
zym car		18.0gm	P<.6	2.46gm n.s.s.	1/50	2/50			
edu car		18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50			
nas ene		18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50			
orc car		18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50			
tba mix		1.94gm	P<.5	441.mg n.s.s.	27/50	31/50			
tba mal		13.9gm	P<.9	1.07gm n.s.s.	12/50	13/50			
TRIMETHYLPHOSPHATE 512-56-1									
6346 M f b6c gav 24m24 TR81 :					0	107.mg	214.mg		
utm acn		335.mg	* P<.002 c	197.mg 995.mg	0/20	7/50	13/49		
TBA MXB		385.mg	* P<.3	125.mg n.s.s.	11/20	29/50	30/49		
liv MXB		6.39gm	\ P<1.	258.mg n.s.s.	2/20	4/50	(0/49)		liv:hpa,hpc,nnd.
lun MXB		3.90gm	/ P<.7	599.mg n.s.s.	3/20	0/50	6/49		lun:a/a,a/c.
6347 M m b6c gav 24m24 TR81 :					0	107.mg	214.mg		
TBA MXB		no dre	P=1. -	227.mg n.s.s.	11/20	26/50	26/49		
liv MXB		no dre	P=1.	471.mg n.s.s.	4/20	10/50	8/49		liv:hpa,hpc,nnd.
lun MXB		61.3gm	* P<1.	381.mg n.s.s.	3/20	11/50	9/49		lun:a/a,a/c.
6348 R f f34 gav 24m24 TR81 :					0	21.2mg	42.5mg		
TBA MXB		73.0mg	* P<.4 -	20.1mg n.s.s.	15/20	40/50	42/49		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/49		liv:hpa,hpc,nnd.
6349 R m f34 gav 24m24 TR81 :					0	21.2mg	42.5mg		
sub fib u		123.mg	* P<.005 a	60.4mg 850.mg	0/20	2/50	9/49		
TBA MXB		54.5mg	* P<.3	16.4mg n.s.s.	12/20	38/50	38/49		
liv MXB		485.mg	* P<.5	119.mg n.s.s.	0/20	1/50	1/49		liv:hpa,hpc,nnd.
6350 R f wsb wat 52w52 2549m					0	1.00mg	10.0mg	100.mg	Bomhard;faat,40,75-89;1997
tba tum ek		no dre	P=1. -	.464mg n.s.s.	0/10	0/10	0/10	0/10	
6351 R f wsb wat 27m30 2549n					0	1.00mg	10.0mg	77.0mg	
liv hpt aes		no dre	P=1. -	883.mg n.s.s.	0/49	0/49	1/50	0/50	
tba mix aes		no dre	P=1. -	430.mg n.s.s.	29/49	29/49	35/50	18/50	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
6352 R m wsb wat 52w52 2549m					0	1.00mg	10.0mg	100.mg	
tba tum ek	no dre	P=1.	-	.464mg n.s.s.	0/10	0/10	0/10	0/10	
6353 R m wsb wat 27m30 2549n					0	1.00mg	10.0mg	77.0mg	
liv hpt aes	no dre	P=1.	-	13.7mg n.s.s.	4/50	0/49	0/48	0/47	
tba mix aes	no dre	P=1.	-	424.mg n.s.s.	24/50	25/49	26/48	14/47	
TRIMETHYLTHIOUREA 2489-77-2									
6354 M f b6c eat 77w91 TR129 :					0	54.6mg	110.mg		
TBA MXB	1.97gm *	P<.8	-	274.mg n.s.s.	1/20	3/50	4/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/20	0/50	0/50		liv:hpa,hpc,nnd.
lun MXB	1.26gm *	P<.3		381.mg n.s.s.	0/20	1/50	2/50		lun:a/a,a/c.
6355 M m b6c eat 77w91 TR129 :					0	50.4mg	102.mg		
TBA MXB	no dre	P=1.	-	174.mg n.s.s.	8/20	11/50	15/50		
liv MXB	no dre	P=1.		244.mg n.s.s.	6/20	2/50	(2/50)		liv:hpa,hpc,nnd.
lun MXB	478.mg *	P<.3		165.mg n.s.s.	1/20	5/50	8/50		lun:a/a,a/c.
6356 R f f34 eat 18m25 TR129 :					0	9.10mg	18.0mg		
thy MXA	25.8mg /	P<.0005 c		15.8mg 47.4mg	0/20	1/50	23/50		thy:fca,fcc.
thy fcc	45.0mg /	P<.0005 c		24.5mg 114.mg	0/20	1/50	14/50		
TBA MXB	17.4mg *	P<.005		9.35mg 169.mg	7/20	20/50	37/50		
liv MXB	no dre	P=1.		143.mg n.s.s.	2/20	2/50	0/50		liv:hpa,hpc,nnd.
6357 R m f34 eat 18m25 TR129 :					0	7.30mg	14.4mg		
TBA MXB	no dre	P=1.	-	33.7mg n.s.s.	9/20	13/50	16/50		
liv MXB	no dre	P=1.		128.mg n.s.s.	1/20	0/50	1/50		liv:hpa,hpc,nnd.
2,4,6-TRINITRO-1,3-DIMETHYL-5-tert-BUTYLBENZENE (musk xylol) 81-15-2									
6358 M f b6c eat 80w90 1989					0	86.7mg	173.mg		Maekawa;fctx,28,581-586;1990/pers.comm.
liv mix	203.mg *	P<.0005	+	125.mg 466.mg	1/50	15/50	15/50		
liv hpa	234.mg *	P<.0005	+	140.mg 641.mg	1/50	14/50	13/50		
ute ess	533.mg \	P<.02		184.mg n.s.s.	0/50	4/50	(0/50)		
lun mix	1.30gm *	P<.1		495.mg n.s.s.	0/50	3/50	2/50		
lun ade	1.63gm *	P<.1		565.mg n.s.s.	0/50	2/50	2/50		
liv hpc	2.19gm *	P<.1		662.mg n.s.s.	0/50	1/50	2/50		
--- lym	1.30gm *	P<.3		361.mg n.s.s.	3/50	5/50	6/50		
hag mix	2.25gm *	P<.5		462.mg n.s.s.	3/50	3/50	5/50		
lun car	6.65gm *	P<1.		1.08gm n.s.s.	0/50	1/50	0/50		
tba mal	418.mg *	P<.06	+	179.mg n.s.s.	5/50	14/50	12/50		
6359 M m b6c eat 80w90 1989					0	80.0mg	160.mg		
liv mix	92.1mg *	P<.0005	+	57.2mg 207.mg	11/50	27/50	33/50		
liv hpc	313.mg *	P<.002	+	168.mg 1.43gm	2/50	8/50	13/50		
liv hpa	232.mg *	P<.02	+	113.mg n.s.s.	9/50	19/50	20/50		
hag ade	383.mg *	P<.02	+	189.mg 136.gm	2/50	9/50	10/50		
hag mix	425.mg *	P<.04	+	192.mg n.s.s.	3/50	10/50	10/50		
lun ade	1.20gm *	P<.3		333.mg n.s.s.	3/50	5/50	6/50		
hag car	no dre	P=1.		1.31gm n.s.s.	1/50	1/50	0/50		
tba mal	334.mg *	P<.07	+	138.mg n.s.s.	9/50	17/50	17/50		
1,3,5-TRINITROBENZENE 99-35-4									
6360 R f f34 eat 52w52 2280m					0	.250mg	3.00mg	15.0mg	Reddy;jtxe,52,447-460;1997/2001
liv tum ek	no dre	P=1.	-	.117mg n.s.s.	0/10	0/10	0/10	0/10	
6361 R f f34 eat 24m24 2280n					0	.250mg	3.00mg	15.0mg	
liv mix e	no dre	P=1.	-	109.mg n.s.s.	1/27	3/43	0/39	1/44	
6362 R m f34 eat 52w52 2280m					0	.200mg	2.40mg	12.0mg	
liv tum ek	no dre	P=1.	-	93.7ug n.s.s.	0/10	0/10	0/10	0/10	
6363 R m f34 eat 24m24 2280n					0	.200mg	2.40mg	12.0mg	
liv mix e	905.mg *	P<.8	-	54.3mg n.s.s.	1/26	0/35	1/36	1/37	
TRINITROGLYCERIN (glyceryl trinitrate, nitroglycerin) 55-63-0									
6364 R f cdr eat 24m24 1995					0	5.00mg	50.0mg	500.mg	Ellis III;faat,4,248-260;1984
liv mix e	329.mg *	P<.0005	+	184.mg 687.mg	0/29	1/32	3/28	16/25	
6365 R m cdr eat 24m24 1995					0	4.00mg	40.0mg	400.mg	
liv mix e	221.mg *	P<.0005	+	121.mg 473.mg	1/24	0/28	4/26	15/21	
tes ict e	405.mg *	P<.0005	+	195.mg 1.24gm	2/24	1/28	3/26	11/21	
6366 R m f34 eat 70w70 2288m					0	400.mg			Tamano;carc,17,2477-2486;1996
liv mix kr	113.mg	P<.01	+	35.4mg 9.38gm	0/5	4/6			
liv hpa kr	179.mg	P<.04		51.7mg n.s.s.	0/5	3/6			
liv clc kr	681.mg	P<.3		110.mg n.s.s.	0/5	1/6			
6367 R m f34 eat 76w76 2288n					0	400.mg			
liv hpa r	106.mg	P<.009		26.3mg 4.74gm	0/5	3/4			
liv cho r	211.mg	P<.05		48.8mg n.s.s.	0/5	2/4			
liv mix r	noTD50	P<.02	+	n.s.s. n.s.s.	0/5	4/4			
liv clc r	509.mg	P<.2		81.4mg n.s.s.	0/5	1/4			
TRIPHENYLTIN ACETATE 900-95-8									
6368 M f b6a orl 76w76 295					0	151.mg			Innes;ntis,1968/1969
lun ade evx	964.mg	P<.6	-	127.mg n.s.s.	1/17	2/18			
liv hpt evx	no dre	P=1.	-	298.mg n.s.s.	0/17	0/18			
tba mix evx	437.mg	P<.5	-	86.9mg n.s.s.	2/17	4/18			
6369 M m b6a orl 76w76 295					0	139.mg			
liv hpt evx	241.mg	P<.2	-	69.2mg n.s.s.	1/18	4/17			
lun ade evx	no dre	P=1.	-	171.mg n.s.s.	2/18	1/17			
tba mix evx	307.mg	P<.4	-	65.4mg n.s.s.	3/18	5/17			
6370 M f b6c orl 76w76 295					0	151.mg			
lun ade evx	440.mg	P<.1	-	108.mg n.s.s.	0/16	2/17			
liv hpt evx	909.mg	P<.3	-	148.mg n.s.s.	0/16	1/17			
tba mix evx	284.mg	P<.04	-	85.6mg n.s.s.	0/16	3/17			
6371 M m b6c orl 76w76 295					0	139.mg			
lun ade evx	262.mg	P<.04	-	79.1mg n.s.s.	0/16	3/17			
liv hpt evx	407.mg	P<.1	-	99.8mg n.s.s.	0/16	2/17			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mix evx	117.mg	P<.003	-	47.2mg 634.mg	0/16	6/17			
TRIPHENYLTIN HYDROXIDE 76-87-9									
6372 M f b6c eat 18m24 TR139 :					0	3.60mg	7.30mg		
TBA MXB	no dre	P=1.	-	12.9mg n.s.s.	10/20	15/50	18/50		
liv MXB	136.mg *	P<.7		22.4mg n.s.s.	1/20	2/50	4/50		liv:hpa,hpc,nnd.
lun MXB	90.9mg *	P<.3		27.5mg n.s.s.	0/20	1/50	2/50		lun:a/a,a/c.
6373 M m b6c eat 18m24 TR139 :					0	3.40mg	6.70mg		
TBA MXB	31.1mg *	P<.6	-	6.34mg n.s.s.	10/20	19/50	22/50		
liv MXB	112.mg *	P<.8		12.9mg n.s.s.	5/20	6/50	10/50		liv:hpa,hpc,nnd.
lun MXB	147.mg *	P<.8		14.3mg n.s.s.	3/20	5/50	6/50		lun:a/a,a/c.
6374 R f f34 eat 18m24 TR139 :					0	1.40mg	2.80mg		
TBA MXB	2.36mg \	P<.3	-	.753mg n.s.s.	12/20	39/50	(31/50)		
liv MXB	no dre	P=1.		21.2mg n.s.s.	0/20	1/50	0/50		liv:hpa,hpc,nnd.
6375 R m f34 eat 18m24 TR139 :					0	1.10mg	2.20mg		
TBA MXB	no dre	P=1.	-	4.24mg n.s.s.	9/20	22/50	16/50		
liv MXB	no dre	P=1.		12.2mg n.s.s.	0/20	2/50	0/50		liv:hpa,hpc,nnd.
TRIPROLIDINE.HCl MONOHYDRATE 6138-79-0									
6376 M f b6c eat 65w65 2254m					0	622.mg			Greenman;faat,25,138-145;1995/NCTR 1991
liv mix ek	no dre	P=1.		601.mg n.s.s.	0/12	0/12			
lun mix ek	no dre	P=1.		601.mg n.s.s.	0/12	0/12			
tba ben ek	no dre	P=1.		601.mg n.s.s.	1/12	0/12			
tba mal ek	no dre	P=1.		601.mg n.s.s.	0/12	0/12			
6377 M f b6c eat 24m24 2254n					0	77.0mg	308.mg	616.mg	
liv hpc e	no dre	P=1.	-	559.mg n.s.s.	2/47	0/48	0/46	0/47	
liv mix e	no dre	P=1.	-	2.73gm n.s.s.	4/47	0/48	1/46	(1/47)	
lun mix e	no dre	P=1.	-	4.31gm n.s.s.	5/47	3/48	3/48	2/48	
liv hpa e	no dre	P=1.	-	5.09gm n.s.s.	2/47	0/48	1/46	1/47	
tba mix e	no dre	P=1.	-	926.mg n.s.s.	25/47	23/48	16/48	(12/48)	
tba mal e	no dre	P=1.	-	1.02gm n.s.s.	17/47	13/48	11/48	(5/48)	
tba ben e	no dre	P=1.	-	2.47gm n.s.s.	9/47	11/48	8/48	7/48	
6378 M m b6c eat 65w65 2254m					0	71.8mg	287.mg	574.mg	
liv hpa ek	no dre	P=1.		50.4mg n.s.s.	2/12	0/12	0/12	0/12	
liv hpc ek	no dre	P=1.		50.4mg n.s.s.	0/12	0/12	0/12	0/12	
lun a/a ek	no dre	P=1.		326.mg n.s.s.	1/12			1/12	
tba ben ek	no dre	P=1.		362.mg n.s.s.	2/12			1/12	
tba mal ek	no dre	P=1.		554.mg n.s.s.	0/12			0/12	
6379 M m b6c eat 24m24 2254n					0	71.1mg	284.mg	568.mg	
liv hpa e	2.33gm *	P<.08	-	882.mg n.s.s.	9/48	6/48	11/48	14/48	
liv mix e	2.75gm *	P<.3	-	816.mg n.s.s.	13/48	10/48	16/48	16/48	
liv hpc e	no dre	P=1.	-	3.42gm n.s.s.	5/48	4/48	5/48	2/48	
lun mix e	no dre	P=1.	-	6.07gm n.s.s.	11/48	12/48	1/48	2/48	
tba ben e	no dre	P=1.	-	1.52gm n.s.s.	20/48	14/48	14/48	15/48	
tba mal e	no dre	P=1.	-	2.64gm n.s.s.	16/48	14/48	12/48	8/48	
tba mix e	no dre	P=1.	-	1.31gm n.s.s.	28/48	25/48	24/48	21/48	
6380 R f f34 eat 65w65 2255m					0	120.mg			Greenman;faat,27,223-231;1995/NCTR 1991
liv mix ek	no dre	P=1.		115.mg n.s.s.	0/12	0/12			
tba mix ek	no dre	P=1.		63.4mg n.s.s.	4/12	2/12			
tba mal ek	no dre	P=1.		67.8mg n.s.s.	1/12	1/12			
tba ben ek	no dre	P=1.		80.7mg n.s.s.	3/12	1/12			
6381 R f f34 eat 24m24 2255n					0	14.8mg	59.2mg	118.mg	
liv hpa e	no dre	P=1.	-	1.33gm n.s.s.	0/48	1/47	0/48	0/47	
liv hpc e	no dre	P=1.	-	1.33gm n.s.s.	0/48	1/47	0/48	0/47	
tba mix e	no dre	P=1.	-	123.mg n.s.s.	42/48	45/47	47/48	36/47	
tba ben e	no dre	P=1.	-	129.mg n.s.s.	39/48	40/47	45/48	33/47	
tba mal e	no dre	P=1.	-	404.mg n.s.s.	16/48	19/47	15/48	11/47	
6382 R m f34 eat 65w65 2255m					0	12.0mg	47.8mg	95.6mg	
liv mix ek	no dre	P=1.		8.40mg n.s.s.	0/12	0/12	0/12	0/12	
tba ben ek	no dre	P=1.		18.7mg n.s.s.	10/12			8/12	
tba mix ek	no dre	P=1.		20.7mg n.s.s.	11/12			8/12	
tba mal ek	no dre	P=1.		92.4mg n.s.s.	2/12			0/12	
6383 R m f34 eat 24m24 2255n					0	11.8mg	47.4mg	94.7mg	
liv hpc e	no dre	P=1.	-	84.7mg n.s.s.	0/47	0/48	0/47	0/47	
liv hpa e	no dre	P=1.	-	764.mg n.s.s.	1/47	1/48	2/47	0/47	
tba ben e	1.17gm *	P<1.	-	18.0mg n.s.s.	45/47	48/48	46/48	47/48	
tba mal e	no dre	P=1.	-	174.mg n.s.s.	25/47	38/48	28/48	25/48	
tba mix e	noTD50	P<.3	-	n.s.s. n.s.s.	46/47	48/48	48/48	48/48	
TRIS(2-CHLOROETHYL)PHOSPHATE 115-96-8									
6384 M f b6c gav 24m24 TR391 :					0	124.mg	249.mg		
ute esp	2.42gm *	P<.05		830.mg n.s.s.	0/51	1/50	3/50		S
mgl adc	3.05gm *	P<.05		923.mg n.s.s.	0/51	0/50	3/50		S
hag MXA	1.39gm *	P<.3	e	403.mg n.s.s.	3/51	8/50	7/50		hag:ade,car.
TBA MXB	610.mg *	P<.3		177.mg n.s.s.	25/51	26/50	37/50		
liv MXB	2.87gm *	P<.6		543.mg n.s.s.	5/51	5/50	8/50		liv:hpa,hpc,nnd.
lun MXB	4.38gm *	P<.6		724.mg n.s.s.	3/51	2/50	5/50		lun:a/a,a/c.
6385 M m b6c gav 24m24 TR391 :					0	125.mg	249.mg		
kid MXA	6.81gm *	P<.6	e	934.mg n.s.s.	1/52	0/50	2/52		kid:rua,ruc.
kid ruc	8.45gm *	P<.3		1.38gm n.s.s.	0/52	0/50	1/52		
kid rua	23.6kg	P=1.		1.18gm n.s.s.	1/52	0/50	1/52		
TBA MXB	807.mg *	P<.7		124.mg n.s.s.	38/52	39/50	42/52		
liv MXB	569.mg *	P<.4		147.mg n.s.s.	26/52	27/50	33/52		liv:hpa,hpc,nnd.
lun MXB	61.7gm *	P<1.		322.mg n.s.s.	10/52	12/50	10/52		lun:a/a,a/c.
6386 M m b6c gav 24m24 TR391 with step					0	51.3mg	98.1mg		
kid MXA	3.51gm *	P<.2	e	1.05gm n.s.s.	1/52	11/50	20/50		kid:rua,ruc.
kid rua	5.09gm *	P<.3		1.22gm n.s.s.	1/52	1/50	3/52		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
6387 M f dds eat 78w78 2374					0	15.6mg	78.0mg	390.mg 1.95gm	Takada;jtxp,2,213-222;1989
for mix e		5.50gm *	P<.0005 +	2.49gm 16.1gm	0/49	0/49	0/50	1/49 7/50	
for sqc e		8.97gm *	P<.0005	3.40gm 37.3gm	0/49	0/49	0/50	0/49 5/50	
--- leu e		4.79gm *	P<.04 +	1.77gm n.s.s.	1/49	3/49	6/50	9/49 9/50	
liv hpa e		23.0gm *	P<.02	5.66gm n.s.s.	0/49	0/49	0/50	0/49 2/50	
tba mix e		880.mg *	P<.006	391.mg 13.3gm	30/49	28/49	33/50	39/49 41/50	
6388 M m dds eat 78w78 2374					0	14.4mg	72.0mg	360.mg 1.80gm	
kid mix e		539.mg Z	P<.0005 +	366.mg 832.mg	2/50	0/49	2/49	5/47 41/50	
kid rcc e		844.mg *	P<.0005	552.mg 1.39gm	2/50	0/49	2/49	3/47 32/50	
liv mix e		1.69gm *	P<.0005 +	883.mg 5.29gm	4/50	5/49	7/49	12/47 19/50	
liv hpc e		28.8gm *	P<.6	3.96gm n.s.s.	1/50	1/49	4/49	2/47 3/50	
tba mix e		185.mg *	P<.0005	79.7mg 565.mg	34/50	38/49	39/49	39/47 50/50	
6389 R f f34 gav 24m24 TR391 :					0	31.3mg	62.6mg		
kid rua		187.mg *	P<.003 c	80.8mg 900.mg	0/50	2/50	5/51		
thy MXA		203.mg *	P<.005 e	87.3mg 1.50gm	0/50	3/50	4/51		thy:fca,fcc.
mul mnl		90.2mg *	P<.03 e	40.3mg n.s.s.	14/50	16/50	20/51		
thy fcc		280.mg *	P<.02	106.mg n.s.s.	0/50	2/50	3/51		S
ute ess		589.mg *	P<.03	174.mg n.s.s.	0/50	0/50	3/51		S
TBA MXB		39.9mg *	P<.04	17.2mg n.s.s.	45/50	46/50	44/51		
liv MXB		no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/51		liv:hpa,hpc,nnd.
6390 R m f34 gav 24m24 TR391 :					0	31.3mg	62.6mg		
kid MXA		56.4mg /	P<.0005 c	34.7mg 111.mg	2/51	5/50	25/50		kid:rua,ruc.
kid rua		56.9mg /	P<.0005 c	35.5mg 106.mg	1/51	5/50	24/50		
amd MXA		49.5mg \	P<.03	20.8mg n.s.s.	10/51	21/50	(13/50)		amd:pbb,pob. S
mul mnl		107.mg *	P<.02 e	50.8mg n.s.s.	5/51	14/50	13/50		
sub fib		246.mg *	P<.03	102.mg n.s.s.	1/51	3/50	6/50		S
thy MXA		338.mg *	P<.06 e	124.mg n.s.s.	1/51	2/50	5/50		thy:fca,fcc.
MXA grb		705.mg *	P<.04	209.mg n.s.s.	0/51	0/50	3/50		bra:grb; clm:grb. S
kid ruc		8.40gm *	P<.9 c	322.mg n.s.s.	1/51	0/50	1/50		
TBA MXB		56.8mg *	P<.08	22.4mg n.s.s.	39/51	44/50	46/50		
liv MXB		633.mg *	P<.08	190.mg n.s.s.	0/51	1/50	2/50		liv:hpa,hpc,nnd.
TRIS-1,2,3-(CHLOROMETHOXY)PROPANE				38571-73-2					
6391 M f hic ipj 76w76 582					0	1.71mg			Van Duuren;canr,35,2553-2557;1975
abd sar		3.44mg	P<.008 +	1.30mg 51.1mg	0/30	5/30			
TRIS(2,3-DIBROMOPROPYL)PHOSPHATE				(TRIS) 126-72-7					
6392 M f b6c eat 24m24 TR76 :					0	64.3mg	129.mg		
MXB MXB		80.1mg *	P<.0005	51.3mg 171.mg	16/55	34/50	40/50		liv:hpa,hpc; lun:a/a,a/c; sto:sqc,sqp. C
liv MXA		95.0mg *	P<.0005 c	62.2mg 188.mg	11/55	23/50	35/50		liv:hpa,hpc.
sto MXA		127.mg *	P<.0005 c	88.1mg 212.mg	2/55	14/50	22/50		sto:sqc,sqp.
liv hpc		221.mg *	P<.005 c	128.mg 692.mg	7/55	12/50	20/50		
lun MXA		225.mg *	P<.002 c	135.mg 576.mg	4/55	9/50	17/50		lun:a/a,a/c.
ute esp		264.mg \	P<.003	130.mg 682.mg	0/55	6/50	(2/50)		S
sto sqc		611.mg *	P<.02 c	328.mg 2.15gm	0/55	4/50	4/50		
TBA MXB		148.mg *	P<.09	67.7mg n.s.s.	34/55	42/50	44/50		
liv MXB		95.0mg *	P<.0005	55.7mg 268.mg	11/55	23/50	35/50		liv:hpa,hpc,nnd.
lun MXB		225.mg *	P<.002	119.mg 1.13gm	4/55	9/50	17/50		lun:a/a,a/c.
6393 M m b6c eat 24m24 TR76 :					0	59.0mg	119.mg		
MXB MXB		103.mg *	P<.0005	58.7mg 336.mg	12/55	23/50	37/50		kid:tla,uac; lun:a/a,a/c; sto:sqc,sqp. C
sto MXA		197.mg *	P<.0005 c	120.mg 406.mg	0/55	10/50	13/50		sto:sqc,sqp.
kid MXA		256.mg *	P<.0005 c	147.mg 531.mg	0/55	4/50	14/50		kid:tla,uac.
kid uac		822.mg *	P<.009 c	335.mg 25.7gm	0/55	1/50	5/50		
lun MXA		211.mg *	P<.03 c	95.1mg n.s.s.	12/55	18/50	25/50		lun:a/a,a/c.
lun a/c		449.mg *	P<.1 c	170.mg n.s.s.	6/55	8/50	13/50		
TBA MXB		2.22gm *	P<1.	86.1mg n.s.s.	43/55	41/50	43/50		
liv MXB		172.mg \	P<.4	43.2mg n.s.s.	28/55	31/50	(23/50)		liv:hpa,hpc,nnd.
lun MXB		211.mg *	P<.03	95.1mg n.s.s.	12/55	18/50	25/50		lun:a/a,a/c.
6394 R f f34 eat 24m24 TR76 :					0	2.50mg	4.95mg		
kid tla		13.8mg *	P<.0005 c	7.41mg 35.7mg	0/55	4/55	10/55		
ova sct		66.4mg *	P<.05	20.1mg n.s.s.	0/55	0/55	3/55		S
TBA MXB		23.0mg *	P<.8	2.88mg n.s.s.	52/55	47/55	54/55		
liv MXB		2.82gm *	P<1.	29.8mg n.s.s.	1/55	1/55	1/55		liv:hpa,hpc,nnd.
6395 R m f34 eat 24m24 TR76 :					0	2.00mg	4.00mg		
kid tla		1.57mg \	P<.0005 c	.975mg 2.75mg	0/55	26/55	(26/55)		
kid MXA		1.57mg \	P<.0005 c	.975mg 2.75mg	0/55	26/55	(29/55)		kid:tla,uac.
pre MXA		20.3mg *	P<.03	8.69mg n.s.s.	1/55	3/55	7/55		pre:acn,adn,can. S
liv MXA		34.3mg *	P<.02	13.0mg n.s.s.	0/55	1/55	4/55		liv:hpc,nnd. S
kid uac		63.3mg *	P<.05 c	18.9mg n.s.s.	0/55	0/55	3/55		
TBA MXB		8.31mg *	P<.4	2.31mg n.s.s.	39/55	44/55	48/55		
liv MXB		34.3mg *	P<.02	13.0mg n.s.s.	0/55	1/55	4/55		liv:hpa,hpc,nnd.
6396 R m f34 gav 52w52 1729					0	71.4mg			Reznik;livt,44,74-83;1981
col pla ekr		13.4mg	P<.006 +	3.72mg 189.mg	0/9	3/5			
kid adc ekr		54.8mg	P<.2 +	8.84mg n.s.s.	0/9	1/5			
liv tum ekr		no dre	P=1.	18.4mg n.s.s.	0/9	0/5			
TRIS-(1,3-DICHLORO-2-PROPYL)PHOSPHATE				(Fyrol FR-2, TDCPP) 13674-87-8					
6397 R f cdr eat 24m24 2662					0	5.00mg	20.0mg	80.0mg	Freudenthal;ijtx,19,119-125;2000/Stauffer 1981/ Henrich 1998/pers.comm.
kid coa e		68.6mg *	P<.0005 +	45.9mg 108.mg	0/49	1/48	8/48	29/50	
adr coa e		192.mg *	P<.004	89.4mg 1.71gm	8/48	5/27	2/33	19/49	
liv mix e		206.mg *	P<.0005	106.mg 692.mg	1/49	2/47	5/47	12/50	
liv hpa e		324.mg *	P<.004 +	147.mg 2.59gm	1/49	1/47	4/47	8/50	
liv hpc e		721.mg *	P<.08	217.mg n.s.s.	0/49	2/47	2/47	4/50	
6398 R m cdr eat 24m24 2662					0	5.00mg	20.0mg	80.0mg	
tes ict e		35.0mg *	P<.0005 +	22.9mg 60.8mg	7/43	8/48	23/47	36/45	
kid coa e		53.1mg *	P<.0005 +	35.7mg 85.2mg	1/45	3/49	9/48	32/46	
liv mix e		144.mg *	P<.0005	74.8mg 462.mg	3/45	9/48	4/48	19/46	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
liv hpa e	252.mg	Z P<.003	+	114.mg 1.76gm	2/45	7/48	1/48	13/46	
liv hpc e	390.mg	* P<.02		157.mg n.s.s.	1/45	2/48	3/48	7/46	
TRIS(2-ETHYLHEXYL)PHOSPHATE 78-42-2									
6399 M f b6c gav 24m24 TR274 :					0	352.mg	704.mg		
liv hpc	2.56gm	* P<.005	p	1.28gm 17.6gm	0/50	4/50	7/50		
liv MXA	2.22gm	* P<.05		995.mg n.s.s.	2/50	8/50	10/50		liv:hpa,hpc. S
TBA MXB	no dre	P=1.		1.01gm n.s.s.	24/50	25/50	25/50		
liv MXB	2.22gm	* P<.05		995.mg n.s.s.	2/50	8/50	10/50		liv:hpa,hpc,nnd.
lun MXB	13.7gm	* P<.6		2.44gm n.s.s.	2/50	2/50	4/50		lun:a/a,a/c.
6400 M m b6c gav 24m24 TR274 :					0	352.mg	704.mg		
TBA MXB	no dre	P=1.	-	1.09gm n.s.s.	33/50	30/50	25/50		
liv MXB	9.00gm	* P<.9		785.mg n.s.s.	15/50	21/50	18/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.		1.99gm n.s.s.	7/50	3/50	7/50		lun:a/a,a/c.
6401 R f f34 gav 24m24 TR274 :					0	704.mg	1.41gm		
TBA MXB	230.gm	* P<1.	-	1.04gm n.s.s.	37/50	38/50	31/50		
liv MXB	no dre	P=1.		13.9gm n.s.s.	1/50	0/50	0/50		liv:hpa,hpc,nnd.
6402 R m f34 gav 24m24 TR274 :					0	1.41gm	2.82gm		
adr phe	5.29gm	* P<.002	e	2.86gm 24.9gm	2/50	9/50	14/50		
adr MXA	5.29gm	* P<.002	e	2.86gm 24.9gm	2/50	9/50	14/50		adr:phe,phm.
MXA MXA	16.7gm	* P<.05		6.54gm n.s.s.	1/50	2/50	6/50		thy:fca,fcc; tyf:cyn. S
MXA MXA	28.0gm	* P<.05		9.66gm n.s.s.	0/50	1/50	3/50		thy:fca; tyf:cyn. S
TBA MXB	14.2gm	* P<.7		2.04gm n.s.s.	32/50	34/50	35/50		
liv MXB	no dre	P=1.		n.s.s. n.s.s.	0/50	1/50	0/50		liv:hpa,hpc,nnd.
TRIS(2-HYDROXYPROPYL)AMINE 122-20-3									
6403 R m wis eat 24m24 1910m					0	800.mg			Yamamoto;clet,45,221-225;1989/1996/pers.comm.
liv tum ej	no dre	P=1.	-	3.01gm n.s.s.	0/17	0/19			
N-TRITRIACONTANE-16-18-DIONE 24514-86-1									
6404 R f f3d eat 54w54 2612					0	50.0mg			Hagiwara;gann,90,399-405;1999
col tum e	no dre	P=1.	-	27.8mg n.s.s.	0/10	0/10			
mgl tum e	no dre	P=1.	-	27.8mg n.s.s.	0/10	0/10			
Trp-P-1 ACETATE (3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole acetate) 75104-43-7									
6405 M f cdf eat 88w88 1224					0	26.0mg			Matsukura;scie,213,346-347;1981
liv mix	25.0mg	P<.0005	+	13.8mg 51.7mg	0/40	16/40			
liv hpc	29.6mg	P<.0005	+	15.8mg 64.8mg	0/40	14/40			
lun adc	no dre	P=1.		110.mg n.s.s.	3/40	1/40			
lun ade	no dre	P=1.		153.mg n.s.s.	1/40	0/40			
6406 M m cdf eat 88w88 1224					0	24.0mg			
liv mix	109.mg	P<.08	+	35.5mg n.s.s.	1/40	5/40			
liv hpc	112.mg	P<.02	+	38.6mg n.s.s.	0/40	4/40			
lun adc	no dre	P=1.		59.4mg n.s.s.	3/40	3/40			
lun ade	no dre	P=1.		142.mg n.s.s.	1/40	0/40			
6407 R f f3d eat 52w52 1683					0	10.0mg			Takayama;gann,76,815-817;1985
liv hpc e	.577mg	P<.0005	+	.310mg 1.04mg	0/50	37/39			
6408 R m f3d eat 52w52 1683					0	6.00mg			
liv hpc e	.574mg	P<.0005	+	.342mg 1.01mg	0/50	30/36			
Trp-P-2 ACETATE (3-amino-1-methyl-5H-pyrido[4,3-b]indole acetate) 72254-58-1									
6409 M f cdf eat 88w88 1224					0	26.0mg			Matsukura;scie,213,346-347;1981
liv hpc e	6.81mg	P<.0005	+	3.70mg 13.3mg	0/24	22/26			
lun adc	no dre	P=1.		64.3mg n.s.s.	3/40	3/40			
lun ade	no dre	P=1.		93.1mg n.s.s.	1/40	1/40			
6410 M m cdf eat 88w88 1224					0	24.0mg			
lun adc	81.1mg	P<.1		27.3mg n.s.s.	3/40	8/40			
liv hpc e	88.2mg	P<.04	+	26.6mg n.s.s.	0/25	3/24			
liv mix e	83.2mg	P<.2	+	23.7mg n.s.s.	1/25	4/24			
lun ade	224.mg	P<.3		49.4mg n.s.s.	1/40	3/40			
6411 R f aci eat 29m29 1225m					0	5.00mg			Hosaka;clet,13,23-28;1981/Ohgaki 1991
liv mix ej	4.43mg	P<.0005	+	1.68mg 16.4mg	0/30	6/9			
liv nnd ej	4.43mg	P<.0005	+	1.68mg 16.4mg	0/30	6/9			
jej adc ej	41.4mg	P<.09	+	6.72mg n.s.s.	0/30	1/9			
liv hms ej	41.4mg	P<.09	+	6.72mg n.s.s.	0/30	1/9			
ilm ade ej	41.4mg	P<.09	+	6.72mg n.s.s.	0/30	1/9			
6412 R m aci eat 29m29 1225m					0	4.00mg			
liv tum ej	no dre	P=1.		11.7mg n.s.s.	0/30	0/10			
6413 R f f3d eat 26m26 2046					0	1.50mg	5.00mg		Takahashi;gann,84,852-858;1993/pers.comm.
cli mix e	9.42mg	* P<.009	+	4.41mg 419.mg	2/28	8/30	11/30		
mgl mix e	9.78mg	* P<.01	+	4.48mg 699.mg	3/28	7/30	12/30		
--- mly e	29.0mg	* P<.005	+	11.0mg 208.mg	0/28	0/30	5/30		
ute esp e	3.60mg	\ P<.02		1.54mg n.s.s.	2/28	10/30	(8/30)		
mgl mix e	11.5mg	* P<.02		5.02mg n.s.s.	3/28	6/30	11/30		
cli ade e	12.8mg	* P<.05		5.18mg n.s.s.	2/28	8/30	9/30		
cli adc e	75.5mg	* P<.07		18.6mg n.s.s.	0/28	0/30	2/30		
liv hpa e	74.3mg	* P<.7		10.5mg n.s.s.	1/28	5/30	3/30		
mgl ade e	76.2mg	* P<.4		18.7mg n.s.s.	0/28	1/30	1/30		
ubl tpp e	no dre	P=1.		23.4mg n.s.s.	1/28	1/30	1/30		
6414 R m f3d eat 26m26 2046					0	1.20mg	4.00mg		
ubl mix e	9.72mg	* P<.0005	+	4.87mg 26.7mg	0/30	2/29	9/30		
ubl tpp e	12.3mg	* P<.002		5.77mg 48.0mg	0/30	2/29	7/30		
mgl mix e	8.43mg	* P<.02	+	3.66mg n.s.s.	6/30	5/29	14/30		
liv hpa e	10.7mg	* P<.03	+	4.47mg n.s.s.	4/30	4/29	11/30		
ubl tcc e	59.9mg	* P<.07		14.7mg n.s.s.	0/30	0/29	2/30		
liv hpc e	no dre	P=1.		6.45mg n.s.s.	1/30	0/29	0/30		

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes DR AuOp UpConf | Brkly Code
Path TD_{50} 2Tailpvl LoConf | Cntrl 1 Inc 2 Inc 3 Inc | NCI/NTPPathology

DL-TRYPTOPHAN 54-12-6
6415 R m fis eat 98w98 1657 | 0 800.mg | Cohen;canr,39,1207-1217;1979
liv tum no dre P=1. - 2.93gm n.s.s. | 0/42 0/20
ubl tum no dre P=1. - 2.93gm n.s.s. | 0/42 0/20

L-TRYPTOPHAN 73-22-3
6416 M f b6c eat 18m24 TR71 : | 0 1.74gm 3.48gm
TBA MXB no dre P=1. - 5.55gm n.s.s. | 3/15 11/35 3/35
liv MXB 30.2gm * P<.6 7.40gm n.s.s. | 0/15 1/35 1/35 | liv:hpa,hpc,nnd.
lun MXB no dre P=1. 11.9gm n.s.s. | 1/15 0/35 1/35 | lun:a/a,a/c.
6417 M m b6c eat 18m24 TR71 : | 0 1.61gm 3.21gm
TBA MXB 1.47gm \ P<.2 - 602.mg n.s.s. | 1/15 15/35 (12/33)
liv MXB no dre P=1. 3.33gm n.s.s. | 1/15 5/35 7/33 | liv:hpa,hpc,nnd.
lun MXB no dre P=1. 4.66gm n.s.s. | 0/15 4/35 2/33 | lun:a/a,a/c.
6418 R f f34 eat 18m24 TR71 : | 0 690.mg 1.33gm
TBA MXB no dre P=1. - 1.53gm n.s.s. | 11/15 24/35 19/35
liv MXB no dre P=1. n.s.s. n.s.s. | 0/15 0/35 0/35 | liv:hpa,hpc,nnd.
6419 R m f34 eat 18m24 TR71 : | 0 552.mg 1.07gm
TBA MXB no dre P=1. - 560.mg n.s.s. | 11/15 21/35 (14/35)
liv MXB no dre P=1. n.s.s. n.s.s. | 0/15 0/35 0/35 | liv:hpa,hpc,nnd.
6420 R m fis eat 23m24 1430 | 0 769.mg | Fukushima;canr,41,3100-3103;1981
ubl mix no dre P=1. - 4.12gm n.s.s. | 0/27 0/26
6421 R m fis eat 24m24 1574 | 0 800.mg | Murasaki;carc,4,97-99;1983
liv tum no dre P=1. 3.30gm n.s.s. | 0/30 0/20
ubl tum no dre P=1. 3.30gm n.s.s. | 0/30 0/20

TUNGSTATE, SODIUM 13472-45-2
6422 R f leb wat 35m35 1456 | 0 .286mg | Schroeder;jnut,105,421-427;1975
tba mix e no dre P=1. - .380mg n.s.s. | 17/24 13/20
tba mal e no dre P=1. - .884mg n.s.s. | 8/24 5/20
6423 R m leb wat 32m32 1456 | 0 .250mg
tba mix es 40.1mg P<1. - .780mg n.s.s. | 4/26 4/25
tba mal es 87.7mg P<1. - 1.05mg n.s.s. | 2/26 2/25

TURMERIC (>98% CURCUMIN) (diferuloylmethane) 458-37-7
6424 R m f34 eat 55w55 2409 | 0 80.0mg | Rao;canr,55,259-266;1995
col tum r no dre P=1. - 55.3mg n.s.s. | 0/12 0/12

TURMERIC OLEORESIN (79%-85% CURCUMIN) 8024-37-1
6425 M f b6c eat 24m24 TR427 : | 0 255.mg 1.28gm 6.41gm
liv MXA 1.84gm Z P<.007 e 850.mg 30.6gm | 13/50 12/50 25/51 (19/50) | liv:hpa,hpc.
liv hpa 2.02gm Z P<.003 e 968.mg 14.4gm | 7/50 8/50 19/51 (14/50)
for MXA 42.8gm * P<.03 16.3gm n.s.s. | 0/50 0/50 2/51 3/50 | for:sqc,sqp. S
for sqp 53.6gm * P<.02 18.5gm n.s.s. | 0/50 0/50 1/51 3/50 | S
TBA MXB no dre P=1. 7.08gm n.s.s. | 30/50 33/50 35/51 33/50
liv MXB 1.84gm Z P<.007 850.mg 30.6gm | 13/50 12/50 25/51 (19/50) | liv:hpa,hpb,hpc.
lun MXB no dre P=1. 42.1gm n.s.s. | 5/50 3/50 3/51 1/50 | lun:a/a,a/c.
6426 M m b6c eat 24m24 TR427 : | 0 235.mg 1.18gm 5.92gm
liv MXA 1.62gm Z P<.1 e 583.mg n.s.s. | 30/50 38/50 41/50 (37/50) | liv:hpa,hpc.
liv hpa 1.65gm Z P<.07 e 624.mg n.s.s. | 25/50 28/50 35/50 (30/50)
MXA adc 7.91gm Z P<.2 e 2.48gm n.s.s. | 0/50 3/50 3/50 (0/50) | duo:adc; ilm:adc; jej:adc.
TBA MXB 90.6gm * P<.9 4.48gm n.s.s. | 38/50 42/50 47/50 42/50
liv MXB 33.3gm * P<.7 4.56gm n.s.s. | 30/50 38/50 41/50 38/50 | liv:hpa,hpb,hpc.
lun MXB no dre P=1. 13.0gm n.s.s. | 14/50 16/50 7/50 13/50 | lun:a/a,a/c.
6427 R f f34 eat 24m24 TR427 : | 0 98.5mg 494.mg 2.48gm
cli MXA 151.mg Z P<.02 e 65.7mg n.s.s. | 6/50 16/50 (15/50 16/51) | cli:adc,ade.
cli ade 842.mg Z P<.03 e 339.mg n.s.s. | 5/50 12/50 15/50 (16/51)
TBA MXB no dre P=1. 2.07gm n.s.s. | 48/50 48/50 47/50 46/51
liv MXB no dre P=1. 21.2gm n.s.s. | 1/50 0/50 0/50 0/51 | liv:hpa,hpb,hpc.
6428 R m f34 eat 24m24 TR427 : | 0 79.7mg 399.mg 2.00gm
TBA MXB no dre P=1. - 1.11gm n.s.s. | 42/50 47/50 48/50 36/51
liv MXB 11.2gm * P<.3 2.51gm n.s.s. | 1/50 1/50 4/50 3/51 | liv:hpa,hpb,hpc.

TYLOSIN LACTATE 11034-63-2
6429 M f cb6 eat 52w52 2595 | 0 130.mg 1.30gm | Tsubura;jnma,30,506-517;1979
liv tum e no dre P=1. - 36.5mg n.s.s. | 0/7 0/6 0/6
lun tum e no dre P=1. - 36.5mg n.s.s. | 0/7 0/6 0/6
6430 M m cb6 eat 52w52 2595 | 0 120.mg 1.20gm
liv tum e no dre P=1. - 34.2mg n.s.s. | 0/8 0/6 0/7
lun tum e no dre P=1. - 34.2mg n.s.s. | 0/8 0/6 0/7

URACIL (2,4-DIOXYPRIMIDINE) 66-22-8
6431 M f b6c eat 96w96 2058 | 0 3.29gm | Fukushima;canr,52,1675-1680;1992/pers.comm.
ubl tcc v 1.45gm P<.0005 + 835.mg 2.75gm | 0/30 22/30
liv hnd v 18.2gm P<.04 5.51gm n.s.s. | 0/30 3/30
ubl cic v 56.7gm P<.3 9.23gm n.s.s. | 0/30 1/30
ubl lei v 56.7gm P<.3 9.23gm n.s.s. | 0/30 1/30
liv hpc v no dre P=1. 10.5gm n.s.s. | 1/30 1/30
lun ade v no dre P=1. 10.5gm n.s.s. | 1/30 1/30
6432 M m b6c eat 96w96 2058 | 0 3.04gm
ubl sqc v 25.7gm P<.1 6.32gm n.s.s. | 0/30 2/30
ubl tcc v 25.7gm P<.1 + 6.32gm n.s.s. | 0/30 2/30
liv hnd v 48.8gm P<.7 6.00gm n.s.s. | 2/30 3/30
lun adc v 52.3gm P<.3 8.52gm n.s.s. | 0/30 1/30
liv hpc v no dre P=1. 11.4gm n.s.s. | 9/30 2/30
lun ade v no dre P=1. 16.0gm n.s.s. | 0/30 0/30
6433 R f f3d eat 24m24 2058 | 0 1.50gm
ubl tcc 5.64gm P<.008 + 2.14gm 83.7gm | 0/30 5/30

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
ubl tpp		4.26gm	P<.04	1.63gm n.s.s.	2/30	8/30			
k/p car		9.76gm	P<.04	2.95gm n.s.s.	0/30	3/30			
ubl sqp		29.3gm	P<.6	4.03gm n.s.s.	1/30	2/30			
6434 R m f3d eat 24m24 2058					0	1.20gm			
ubl tcc		357.mg	P<.0005 +	195.mg 672.mg	0/30	27/30			
ubl tpp		511.mg	P<.0005	293.mg 953.mg	0/30	24/30			
k/p car		3.09gm	P<.002	1.33gm 12.4gm	0/30	7/30			
k/p pam		5.75gm	P<.02	1.98gm n.s.s.	0/30	4/30			
ubl sqc		7.80gm	P<.04	2.36gm n.s.s.	0/30	3/30			
ubl lei		24.3gm	P<.3	3.95gm n.s.s.	0/30	1/30			
ubl sqp		24.3gm	P<.3	3.95gm n.s.s.	0/30	1/30			
URAPIDIL 6-[[3-[4-(o-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil 34661-75-1									
6435 R f sls gav 52w52 2351					0	2.50mg	25.0mg	125.mg	Kudo;phrm,33,473-500;1987/pers.comm.
liv tum	no dre	P=1.	-	2.29mg n.s.s.	0/20	0/20	0/19	0/19	
6436 R m sls gav 52w52 2351					0	2.50mg	25.0mg	125.mg	
liv tum	no dre	P=1.	-	2.20mg n.s.s.	0/20	0/19	0/20	0/20	
UREA 57-13-6									
6437 M f cb6 eat 52w69 1343 pool					0	440.mg	881.mg	4.40gm	Fleischman;jept,3,149-170;1980
liv mlh e		40.4gm *	P<.03	9.95gm n.s.s.	0/89	0/43	0/38	2/50	
--- mly e		19.5gm *	P<.5	3.90gm n.s.s.	10/92	7/43	10/38	9/50	
liv mix e		50.1gm *	P<.2	10.4gm n.s.s.	1/89	0/43	0/38	2/50	
lun a/a e		no dre	P=1.	- 646.mg n.s.s.	2/89	0/28	0/23	0/23	
6438 M m cb6 eat 52w69 1343 pool					0	406.mg	813.mg	4.06gm	
liv fbs e		70.8gm *	P<.2	- 11.5gm n.s.s.	0/91	0/41	0/36	1/47	
liv mix e		275.gm *	P<.9	12.9gm n.s.s.	2/91	0/41	0/36	1/47	
lun a/a e		no dre	P=1.	- 8.00gm n.s.s.	1/87	0/27	1/21	0/24	
6439 R f f34 eat 52w69 1343					0	169.mg	339.mg	1.69gm	
liv tum e		no dre	P=1.	- 473.mg n.s.s.	0/49	0/50	0/48	0/48	
6440 R m f34 eat 52w69 1343					0	135.mg	271.mg	1.35gm	
tes ica e		684.mg *	P<.009	- 305.mg 36.6gm	21/50	27/48	25/47	35/50	
liv tum e		no dre	P=1.	- 369.mg n.s.s.	0/50	0/48	0/48	0/48	
URETHANE (ethyl carbamate) 51-79-6									
6441 H f syg wat 90w90 170					0	136.mg			Toth;ejca,5,165-171;1969
for pam e		44.5mg	P<.0005 +	27.9mg 74.7mg	1/67	35/44			
der mlc e		74.4mg	P<.0005 +	45.2mg 133.mg	0/62	25/41			
cec adp e		294.mg	P<.0005 +	126.mg 949.mg	0/55	7/33			
vag car e		314.mg	P<.002	108.mg 1.77gm	0/49	4/20			
adr mix e		318.mg	P<.003 +	130.mg 2.05gm	1/55	7/33			
adr coc e		349.mg	P<.0005	142.mg 1.31gm	0/55	6/33			
for car e		374.mg	P<.0005 +	161.mg 1.23gm	0/62	7/41			
thy mix e		538.mg	P<.003 +	204.mg 2.94gm	0/62	5/41			
gal pam e		682.mg	P<.007	235.mg 8.99gm	0/62	4/41			
ova car e		682.mg	P<.007	235.mg 8.99gm	0/62	4/41			
lun ade e		1.36gm	P<.2	222.mg n.s.s.	0/49	1/20			
liv tum e		no dre	P=1.	926.mg n.s.s.	0/67	0/44			
6442 H f syg wat 55w55 297a					0	273.mg			Pietra;jnci,25,627-630;1960
for pam e		102.mg	P<.005 +	34.6mg 965.mg	0/14	4/10			
ski mlt e		496.mg	P<.2	80.6mg n.s.s.	0/14	1/10			
6443 H m syg wat 24m24 170					0	120.mg			Toth;ejca,5,165-171;1969
for pam e		64.2mg	P<.0005 +	40.5mg 110.mg	6/88	36/49			
der mlc e		109.mg	P<.0005 +	66.7mg 197.mg	1/62	26/49			
for car e		135.mg	P<.0005 +	76.8mg 267.mg	0/53	18/40			
cec adp e		765.mg	P<.009 +	264.mg 25.2gm	0/53	4/40			
liv mix e		1.28gm	P<.03	386.mg n.s.s.	0/62	3/49			
adr coa e		564.mg	P<.2	114.mg n.s.s.	1/26	2/12			
lun ade e		927.mg	P<.2	151.mg n.s.s.	0/26	1/12			
6444 H m syg wat 76w76 297a					0	240.mg			Pietra;jnci,25,627-630;1960
ski mlt e		74.2mg	P<.0005 +	29.2mg 260.mg	1/49	7/10			
for pam e		95.8mg	P<.0005 +	37.1mg 352.mg	0/49	6/10			
6445 M f b6a orl 73w73 297					0	81.3mg			Innes;ntis,1968/1969
lun mix evx		12.5mg	P<.0005 +	5.80mg 29.5mg	1/17	17/19			
lun ade evx		29.3mg	P<.0005	14.0mg 92.3mg	1/17	12/19			
--- agm evx		31.7mg	P<.0005	15.4mg 79.1mg	0/17	11/19			
hag ade evx		59.7mg	P<.002	25.5mg 245.mg	0/17	7/19			
liv hpt evx		89.9mg	P<.009	33.9mg 2.02gm	0/17	5/19			
lun car evx		89.9mg	P<.009	33.9mg 2.02gm	0/17	5/19			
tba mix evx		9.73mg	P<.0005	3.86mg 24.8mg	2/17	18/19			
6446 M m b6a orl 72w72 297					0	75.6mg			
lun mix evx		24.2mg	P<.0005 +	11.9mg 76.3mg	2/18	15/22			
liv mix evx		26.0mg	P<.0005	13.1mg 72.1mg	1/18	14/22			
lun ade evx		27.8mg	P<.0005	13.4mg 103.mg	2/18	14/22			
hag ade evx		35.8mg	P<.0005	17.6mg 90.2mg	0/18	11/22			
liv hpt evx		39.0mg	P<.002 +	18.2mg 174.mg	1/18	11/22			
--- rts evx		77.9mg	P<.006 +	31.6mg 645.mg	0/18	6/22			
tba mix evx		11.2mg	P<.0005	5.20mg 27.7mg	3/18	20/22			
6447 M f b6c orl 68w68 297					0	81.5mg			
liv mix evx		32.4mg	P<.0005	16.3mg 79.2mg	0/16	12/23			
liv hpt evx		55.9mg	P<.003	25.1mg 238.mg	0/16	8/23			
lun mix evx		79.0mg	P<.009 +	32.1mg 1.76gm	0/16	6/23			
lun ade evx		97.4mg	P<.02	36.9mg n.s.s.	0/16	5/23			
tba mix evx		13.7mg	P<.0005	7.21mg 28.0mg	0/16	19/23			
6448 M m b6c orl 70w70 297					0	75.7mg			
liv mix evx		46.0mg	P<.002	20.6mg 165.mg	0/16	8/20			
lun mix evx		65.9mg	P<.006 +	26.7mg 555.mg	0/16	6/20			
liv hpt evx		81.7mg	P<.02 +	30.8mg n.s.s.	0/16	5/20			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun ade evx	81.7mg	P<.02		30.8mg n.s.s.	0/16	5/20			
tba mix evx	22.4mg	P<.0005		11.3mg 51.7mg	0/16	13/20			
6449 M m b6c wat 65w70 1933					0	.100mg	.500mg	1.00mg	10.0mg 100.mg Inai;gann,82,380-385;1991
lun a/a aes	5.91mg	* P<.0005		3.60mg 10.5mg	9/49	4/49	7/48	8/50	34/50 42/44
lun mix aes	5.91mg	* P<.0005	+	3.60mg 10.5mg	9/49	4/49	7/48	8/50	34/50 42/44
liv hem as	63.3mg	* P<.0005	+	38.0mg 116.mg	0/50	0/50	0/50	0/50	2/50 20/50
liv hes as	122.mg	* P<.0005	+	63.2mg 321.mg	0/50	0/50	0/50	2/50	2/50 11/50
lun a/c aes	242.mg	* P<.0005		98.6mg 865.mg	0/49	0/49	0/48	0/50	0/50 6/44
hea hes as	417.mg	* P<.0005		144.mg 2.14gm	0/50	0/50	0/50	0/50	0/50 4/50
liv hpa as	38.2mg	Z P<.3		9.92mg n.s.s.	8/50	2/50	8/50	4/50	9/50 (0/50)
liv hpc as	no dre	P=1.		418.mg n.s.s.	0/50	2/50	1/50	0/50	2/50 0/50
6450 M f cf1 wat 31m31 90					0	20.0mg			Tomatis;ijcn,10,489-506;1972
lun tum eg	23.8mg	P<.0005	+	13.1mg 59.4mg	13/56	28/40			
liv hpt eg	no dre	P=1.	-	175.mg n.s.s.	2/56	1/40			
tba mix eg	23.3mg	P<.09		7.51mg n.s.s.	45/56	37/40			
6451 M m cf1 wat 29m29 90					0	16.7mg			
lun tum e	13.2mg	P<.0005	+	7.18mg 34.6mg	23/55	40/48			
liv hpt e	no dre	P=1.	-	78.0mg n.s.s.	12/55	8/48			
tba mix e	12.1mg	P<.04		4.11mg n.s.s.	46/55	46/48			
6452 M b nmr wat 23m24 298					0	.100mg	.500mg	2.50mg	12.5mg Schmahl;ijcn,19,77-80;1977
tba ben ae	.434mg	Z P<.004		.198mg 3.14mg	2/74	11/65	(12/69	21/59	30/65)
tba mal ae	14.7mg	* P<.0005	+	8.61mg 32.7mg	6/74	11/65	17/69	21/59	32/65
6453 M b swi eat 27m27 171a					0	125.mg			Van Esch;fctx,10,373-381;1972
lun ade e	36.1mg	P<.0005	+	19.3mg 66.9mg	10/49	46/48			
lun adc e	5.06gm	P<.3		824.mg n.s.s.	0/49	1/48			
liv tum e	no dre	P=1.		1.54gm n.s.s.	0/49	0/48			
6454 P b cym eat 5y23 2004 :					0	22.2mg		Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm.	
MXB MXB jw	16.4mg	P<.004		4.49mg 142.mg	0/34	3/5			
pan adc jw	52.8mg	P<.08	+	8.60mg n.s.s.	0/11	1/3			
liv hes jw	95.0mg	P<.05	+	15.5mg n.s.s.	0/34	1/5			
liv hpa jw	31.7mg	P<.2		5.16mg n.s.s.	0/3	1/2			
lun bro jw	31.7mg	P<.2	+	5.16mg n.s.s.	0/3	1/2			
tba mal jw	21.5mg	P<.2		4.95mg n.s.s.	3/34	3/5			
tba mix jw	25.5mg	P<.3		5.33mg n.s.s.	4/34	3/5			
tba ben jw	128.mg	P<.8		7.96mg n.s.s.	2/20	1/4			
6455 P b rhe eat 5y25 2004 :					0	24.4mg			
MXB MXB jw	44.8mg	P<.004		10.1mg 805.mg	0/42	2/6			
jej adc jw	65.2mg	P<.04	+	10.6mg n.s.s.	0/25	1/3			
adr phe jw	117.mg	P<.04		19.1mg n.s.s.	0/37	1/5			
liv hes jw	143.mg	P<.05	+	23.3mg n.s.s.	0/42	1/6			
liv hpc jw	143.mg	P<.05	+	23.3mg n.s.s.	0/42	1/6			
chp sqp jw	75.5mg	P<.2		10.6mg n.s.s.	1/37	1/4			
tba mix Wjw	26.3mg	P<.2		5.54mg n.s.s.	17/108	4/11			
tba mal Wjw	52.9mg	P<.3		8.50mg n.s.s.	6/74	2/9			
tba ben Wjw	75.9mg	P<.6		7.41mg n.s.s.	12/108	2/11			
6456 R b sda wat 23m24 298					0	.100mg	.500mg	2.50mg	12.5mg Schmahl;ijcn,19,77-80;1977
tba mal ae	41.3mg	* P<.0005	+	21.4mg 129.mg	2/74	2/70	4/65	7/70	15/74
tba ben ae	91.2mg	* P<.02		35.6mg n.s.s.	1/74	3/70	2/65	5/70	8/74
VANADYL SULFATE 27774-13-6									
6457 M b cd1 wat 24m24 1512					0	.877mg			Kanisawa;canr,27,1192-1195;1967
lun mix e	29.2mg	P<.8	-	2.33mg n.s.s.	26/170	8/47			
liv ade e	no dre	P=1.	-	6.00mg n.s.s.	7/170	1/47			
tba mal e	5.00mg	P<.06	-	1.65mg n.s.s.	15/170	9/47			
tba ben e	no dre	P=1.	-	4.10mg n.s.s.	29/170	5/47			
tba mix e	no dre	P=1.	-	1.79mg n.s.s.	55/170	15/47			
6458 M f cd1 wat 33m33 1395					0	1.00mg			Schroeder;jnut,105,452-458;1975
tba mix e	5.11mg	P<.07	-	2.01mg n.s.s.	9/45	19/51			
6459 M m cd1 wat 31m31 1395					0	.833mg			
tba mix e	no dre	P=1.	-	4.93mg n.s.s.	10/43	5/38			
6460 R m wis wat 52w52 2217					0	25.0mg	37.3mg	61.3mg	Dai;phtx,75,265-273;1994
liv tum ev	no dre	P=1.	-	3.10mg n.s.s.	0/5	0/5	0/5	0/5	
VANGUARD GF (ferric nitrosodimethyldithiocarbamate (58.5%) and tetramethylthiuram disulfide (6.5%). 83542-83-0 and 137-26-8) mixture									
6461 M f b6a orl 76w76 1356					0	33.9mg			Innes;ntis,1968/1969
lun ade evx	170.mg	P<.6	-	24.9mg n.s.s.	1/17	2/16			
liv hpt evx	no dre	P=1.	-	59.7mg n.s.s.	0/17	0/16			
tba mix evx	150.mg	P<.6	-	21.0mg n.s.s.	2/17	3/16			
6462 M m b6a orl 76w76 1356					0	31.6mg			
lun mix evx	1.57gm	P<1.	-	27.5mg n.s.s.	2/18	2/17			
liv hpt evx	no dre	P=1.	-	59.1mg n.s.s.	1/18	0/17			
tba mix evx	no dre	P=1.	-	30.4mg n.s.s.	3/18	2/17			
6463 M f b6c orl 76w76 1356					0	33.9mg			
lun ade evx	99.1mg	P<.1	-	24.3mg n.s.s.	0/16	2/17			
liv hpt evx	no dre	P=1.	-	63.4mg n.s.s.	0/16	0/17			
tba mix evx	99.1mg	P<.1	-	24.3mg n.s.s.	0/16	2/17			
6464 M m b6c orl 76w76 1356					0	31.6mg			
lun ade evx	179.mg	P<.3	-	29.2mg n.s.s.	0/16	1/16			
lun car evx	179.mg	P<.3	-	29.2mg n.s.s.	0/16	1/16			
liv hpt evx	no dre	P=1.	-	55.6mg n.s.s.	0/16	0/16			
tba mix evx	40.2mg	P<.02	-	13.8mg n.s.s.	0/16	4/16			
VINBLASTINE 865-21-4									
6465 R m b46 ivj 12m24 1017					0	10.0ug			Schmahl;arzn,20,1461-1467;1970
tba mix es	no dre	P=1.	-	37.8ug n.s.s.	7/65	1/25			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
VINYL ACETATE	108-05-4								
6466 M f cd1 inh 52w52 2167m					0	55.3mg	221.mg	664.mg	Bogdanffy;faat,23,215-229;1994
lun tum kr	no dre	P=1.		21.4mg n.s.s.	0/10	0/10	0/10	0/10	
6467 M f cd1 inh 70w86 2167n					0	45.1mg	180.mg	541.mg	
lun tum kr	no dre	P=1.		47.6mg n.s.s.	0/10	0/10	0/10	0/10	
6468 M f cd1 inh 82w82 2167o					0	55.3mg	221.mg	664.mg	
lun tum kr	no dre	P=1.		53.2mg n.s.s.	0/10	0/10	0/10	0/10	
6469 M f cd1 inh 24m24 2167r					0	55.3mg	221.mg	664.mg	
lun tum r	no dre	P=1.		513.mg n.s.s.	0/60	0/60	0/60	0/60	
6470 M m cd1 inh 52w52 2167m					0	46.1mg	184.mg	554.mg	
lun tum kr	no dre	P=1.		17.8mg n.s.s.	0/10	0/10	0/10	0/10	
6471 M m cd1 inh 70w85 2167n					0	38.0mg	152.mg	456.mg	
lun tum kr	no dre	P=1.		39.2mg n.s.s.	0/10	0/10	0/10	0/10	
6472 M m cd1 inh 82w82 2167o					0	46.1mg	184.mg	554.mg	
lun tum kr	no dre	P=1.		44.3mg n.s.s.	0/10	0/10	0/10	0/10	
6473 M m cd1 inh 24m24 2167r					0	46.1mg	184.mg	554.mg	
lun sqc r	32.0gm *	P<.2		5.22gm n.s.s.	0/60	0/60	0/60	1/60	
lun adc r	no dre	P=1.		428.mg n.s.s.	1/60	0/60	0/60	0/60	
6474 M f swi wat 18m35 BT52					0	103.mg	578.mg		Maltoni;anya,837,209-238;1997
ute mal g	3.92gm *	P<.005	+	1.70gm 39.6gm	1/37	2/37	8/37		
eso sqc g	5.64gm *	P<.002	+	2.30gm 22.1gm	0/37	0/37	6/37		
for ama g	6.85gm *	P<.003	+	2.60gm 36.8gm	0/37	0/37	5/37		
ute adc g	5.57gm *	P<.03		2.09gm n.s.s.	1/37	2/37	6/37		
ton sqc g	8.76gm *	P<.05	+	3.03gm n.s.s.	0/37	1/37	3/37		
for sqc g	11.7gm *	P<.02	+	3.54gm n.s.s.	0/37	0/37	3/37		
lun mix g	7.64gm *	P<.3		1.94gm n.s.s.	3/37	6/37	7/37		
lun ade g	11.7gm *	P<.5		2.22gm n.s.s.	3/37	6/37	6/37		
ute ley g	26.1gm *	P<.4		4.67gm n.s.s.	1/37	0/37	2/37		
ute lei g	26.1gm *	P<.4		4.67gm n.s.s.	1/37	0/37	2/37		
lun adc g	29.9gm *	P<.5		4.50gm n.s.s.	0/37	1/37	1/37		
zym car g	36.0gm *	P<.2		5.86gm n.s.s.	0/37	0/37	1/37		
orc sqc g	36.0gm *	P<.2		5.86gm n.s.s.	0/37	0/37	1/37		
sto adc g	36.0gm *	P<.2		5.86gm n.s.s.	0/37	0/37	1/37		
eso ama g	36.0gm *	P<.2		5.86gm n.s.s.	0/37	0/37	1/37		
liv hpc g	no dre	P=1.		1.41gm n.s.s.	0/37	0/37	0/37		
tba ben g	2.03gm *	P<.03		851.mg n.s.s.	12/37	10/37	20/37		
tba mal g	3.44gm *	P<.5		680.mg n.s.s.	21/37	28/37	26/37		
6475 M m swi wat 18m31 BT52					0	96.3mg	546.mg		
lun ade	5.75gm *	P<.6		852.mg n.s.s.	2/14	2/13	3/13		
for ama	9.33gm *	P<.2		1.52gm n.s.s.	0/14	0/13	1/13		
orc sqc	9.33gm *	P<.2		1.52gm n.s.s.	0/14	0/13	1/13		
sto adc	9.33gm *	P<.2		1.52gm n.s.s.	0/14	0/13	1/13		
ton sqc	9.33gm *	P<.2		1.52gm n.s.s.	0/14	0/13	1/13		
lun mix	28.0gm *	P<1.		778.mg n.s.s.	4/14	4/13	4/13		
lun adc	68.2gm *	P<1.		1.12gm n.s.s.	2/14	2/13	2/13		
liv hpc	no dre	P=1.		1.21gm n.s.s.	3/14	4/13	2/13		
tba mal	552.mg *	P<.04		191.mg n.s.s.	7/14	6/13	11/13		
tba ben	6.04gm *	P<.7		676.mg n.s.s.	5/14	3/13	5/13		
6476 R f cdr inh 52w52 2167m					0	13.2mg	52.7mg	158.mg	Bogdanffy;faat,23,215-229;1994
lun tum kr	no dre	P=1.		5.09mg n.s.s.	0/10	0/10	0/10	0/10	
6477 R f cdr inh 70w86 2167n					0	10.7mg	42.9mg	129.mg	
lun tum kr	no dre	P=1.		11.3mg n.s.s.	0/10	0/10	0/10	0/10	
6478 R f cdr inh 82w82 2167o					0	13.2mg	52.7mg	158.mg	
lun tum kr	no dre	P=1.		12.7mg n.s.s.	0/10	0/10	0/10	0/10	
6479 R f cdr inh 24m24 2167r					0	13.2mg	52.7mg	158.mg	
nse sqc er	2.22gm *	P<.005	+	767.mg 18.2gm	0/60	0/60	0/60	4/59	
lar sqc er	9.05gm *	P<.2		1.47gm n.s.s.	0/60	0/60	0/60	1/59	
lun ade er	no dre	P=1.		122.mg n.s.s.	1/60	0/60	0/60	0/59	
6480 R m cdr inh 52w52 2167m					0	9.23mg	36.9mg	111.mg	
lun tum kr	no dre	P=1.		3.56mg n.s.s.	0/10	0/10	0/10	0/10	
6481 R m cdr inh 70w85 2167n					0	7.60mg	30.4mg	91.2mg	
lun tum kr	no dre	P=1.		7.84mg n.s.s.	0/10	0/10	0/10	0/10	
6482 R m cdr inh 82w82 2167o					0	9.23mg	36.9mg	111.mg	
lun tum kr	no dre	P=1.		8.86mg n.s.s.	0/10	0/10	0/10	0/10	
6483 R m cdr inh 24m24 2167r					0	9.23mg	36.9mg	111.mg	
nse mix er	758.mg *	P<.0005	+	343.mg 2.31gm	0/59	0/60	1/59	7/59	
nse ben er	1.24gm *	P<.005	+	469.mg 10.4gm	0/59	0/60	1/59	4/59	
nse pai er	1.55gm *	P<.005		535.mg 12.9gm	0/59	0/60	0/59	4/59	
nse mal er	2.08gm *	P<.02	+	629.mg n.s.s.	0/59	0/60	0/59	3/59	
nse sqc er	3.14gm *	P<.05		771.mg n.s.s.	0/59	0/60	0/59	2/59	
nse cic er	6.31gm *	P<.2		1.03gm n.s.s.	0/59	0/60	0/59	1/59	
lun tum er	no dre	P=1.		84.5mg n.s.s.	0/58	0/59	0/60	0/60	
nse sqp er	no dre	P=1.		1.04gm n.s.s.	0/59	0/60	1/59	0/59	
6484 R f f34 wat 23m30 1546					0	44.0mg	110.mg		Lijinsky;txap,68,43-53;1983/pers.comm.
thy cca	420.mg *	P<.006	+	181.mg 4.68gm	0/20	2/20	5/20		
liv nnd	488.mg *	P<.003	+	198.mg 2.31gm	0/20	0/20	6/20		
ute adc	494.mg *	P<.006	+	201.mg 4.70gm	0/20	1/20	5/20		
thy ccr	25.5gm *	P<1.	+	590.mg n.s.s.	1/20	0/20	1/20		
tba mix	no dre	P=1.		37.7mg n.s.s.	20/20	18/20	19/20		
6485 R m f34 wat 23m30 1546					0	27.5mg	68.1mg		
liv nnd	132.mg \	P<.02	+	45.4mg n.s.s.	0/20	4/20	(2/20)		
thy ccr	no dre	P=1.	+	254.mg n.s.s.	1/20	2/20	1/20		
tba mix	57.7mg *	P<.3		14.8mg n.s.s.	18/20	16/20	20/20		
VINYL BROMIDE	593-60-2								
6486 R f sda inh 19m24 1466					0	2.95mg	14.4mg	63.5mg 343.mg	Benya;txap,64,367-379;1982
liv nnd aes	18.9mg Z	P<.003		8.74mg 107.mg	3/142	12/101	(9/113	10/118 5/112)	
mix ang aes	19.2mg Z	P<.0005	+	13.9mg 27.9mg	1/144	10/120	50/120	(61/120 41/120)	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
zym sqc aes		2.24gm *	P<.0005 +	1.12gm 6.44gm	0/139	0/99	3/113	2/119	11/114		
liv mix aes		433.mg Z	P<.04 +	175.mg n.s.s.	7/142	18/101	12/113	21/118	(9/112)		
liv hpc aes		749.mg Z	P<.04 +	282.mg n.s.s.	4/142	6/101	3/113	11/118	(4/112)		
6487 R m sda inh 18m24 1466					0	2.11mg	8.88mg	38.9mg	232.mg		
mix ang aes		17.9mg Z	P<.0005 +	12.3mg 27.2mg	0/144	7/120	36/120	(61/120	43/120)		
zym sqc aes		409.mg *	P<.0005 +	281.mg 647.mg	2/142	1/99	1/112	13/114	35/116		
zym pam aes		2.76gm *	P<.004	1.14gm 27.3gm	0/142	0/99	1/112	3/114	5/116		
liv mix aes		303.mg Z	P<.02 +	129.mg n.s.s.	4/143	5/103	10/119	13/120	(5/119)		
liv hpc aes		387.mg Z	P<.02 +	161.mg n.s.s.	3/143	1/103	7/119	9/120	(3/119)		
liv nnd aes		no dre	P=1.	2.91gm n.s.s.	1/143	4/103	3/119	4/120	2/119		
VINYL CARBAMATE (carbamic acid, vinyl ester) 15805-73-9											
6488 M f c5j ipj 35w59 2170					0	.508mg					Wright;txpy,19,258-265;1991/pers.comm.
liv hes er		.138mg	P<.007 +	84.5ug 1.34mg	0/5	25/45					
liv hem er		.147mg	P<.009 +	89.3ug 2.79mg	0/5	24/45					
liv hpc er		.503mg	P<.2 +	.236mg n.s.s.	0/5	9/45					
liv hpa er		4.99mg	P<.7	.813mg n.s.s.	0/5	1/45					
6489 M m c5j ipj 35w59 2170					0	.508mg					
liv hem er		.112mg	P<.003 +	71.2ug .434mg	0/5	31/49					
liv hes er		.118mg	P<.004 +	74.9ug .533mg	0/5	30/49					
liv hpc er		.629mg	P<.2 +	.285mg n.s.s.	0/5	8/49					
liv hpa er		2.69mg	P<.6	.662mg n.s.s.	0/5	2/49					
VINYL CHLORIDE 75-01-4											
6490 H f syg inh 6m24 1536m					0	18.3mg					Drew;txap,68,120-130;1983/Haseman pers.comm.
mgl car es		32.3mg	P<.0005 +	20.5mg 55.1mg	0/143	28/87					
sto ade es		47.2mg	P<.0005 +	27.1mg 105.mg	5/138	23/88					
--- hes es		78.6mg	P<.0005 +	41.4mg 177.mg	0/143	13/88					
6491 H f syg inh 12m24 1536n					0	36.7mg					
mgl car es		27.7mg	P<.0005 +	17.7mg 46.4mg	0/143	31/52					
ski car es		121.mg	P<.0005 +	56.9mg 330.mg	0/133	9/48					
--- hes es		314.mg	P<.002 +	108.mg 1.73gm	0/143	4/52					
sto ade es		1.01gm	P<.5 +	146.mg n.s.s.	5/138	3/50					
6492 H f syg inh 18m24 1536o					0	55.0mg					
mgl car es		61.0mg	P<.0005 +	42.5mg 91.6mg	0/143	47/102					
sto ade es		205.mg	P<.0005 +	110.mg 579.mg	5/138	20/101					
--- hes es		1.92gm	P<.07 +	473.mg n.s.s.	0/143	2/103					
6493 H m syg inh 7m23 1BT8					0	3.18mg	20.9mg	34.6mg	181.mg	454.mg	756.mg Maltoni;aric,2,1-533;1984/1977a/1981
for epo ejz		55.0mg Z	P<.0005 +	31.6mg 110.mg	3/47	3/22	4/18	9/23	17/19	(10/21	10/19)
liv agm ejz		2.38gm *	P<.01 +	821.mg 151.gm	0/38	0/13	0/10	0/15	2/13	1/9	1/11
adu epo ejz		855.mg Z	P<.04 +	268.mg n.s.s.	0/27	0/13	0/9	3/13	1/13	2/8	(1/10)
liv hpt ejz		1.73gm *	P<.07	280.mg n.s.s.	0/15	0/4	0/3	0/5	0/3	1/3	0/1
ski mel ejz		7.63gm *	P<.2	1.90gm n.s.s.	0/52	1/25	1/21	0/26	1/20	2/24	1/23
ski epo ejz		9.35gm Z	P<.6	1.37gm n.s.s.	3/52	9/25	3/21	7/26	3/20	1/24	7/23
ehp agm ejz		9.80gm *	P<.2	2.00gm n.s.s.	0/47	0/22	1/18	1/23	0/19	0/21	2/19
--- leu ejz		25.8gm *	P<.9	1.55gm n.s.s.	8/60	6/30	6/30	5/30	9/30	6/30	5/30
liv ang ejz		91.8gm *	P<1.	2.15gm n.s.s.	0/40	0/19	0/15	2/17	0/15	1/16	0/15
tba mix ejz		no dre	P=1.	992.mg n.s.s.	32/60	18/30	15/30	21/30	22/30	15/30	16/30
6494 M f cd1 inh 26w58 1113m					0	17.9mg	115.mg	459.mg			Hong;jtxe,7,909-924;1981/1980
liv hes ejs		91.9mg *	P<.0005 +	41.6mg 298.mg	1/28	1/8	2/8	8/12			
lun abt ejs		142.mg *	P<.03	50.6mg n.s.s.	7/28	1/8	4/8	7/12			
mgl mal ejs		249.mg *	P<.2	70.4mg n.s.s.	3/28	2/8	5/8	4/12			
6495 M m cd1 inh 26w78 1113m					0	11.2mg	60.9mg	244.mg			
liv hes ejs		32.0mg Z	P<.0005 +	13.4mg 104.mg	0/28	0/8	7/12	(5/12)			
lun abt ejs		88.7mg *	P<.004	37.3mg 927.mg	4/28	2/8	8/12	7/12			
6496 M f swi inh 30w77 1BT4					0	10.4mg	70.5mg	141.mg	758.mg	2.14gm	3.57gm Maltoni;aric,2,1-533;1984/1977a/1981
liv ang ejz		98.8mg Z	P<.0005 +	55.8mg 199.mg	0/62	0/26	9/21	8/26	(10/24	11/21	9/20)
liv agm ejz		196.mg Z	P<.0005 +	95.6mg 687.mg	0/62	1/27	5/21	4/28	(3/26	5/24	5/25)
lun ade ejz		402.mg Z	P<.0005 +	248.mg 709.mg	7/67	3/30	17/29	26/29	22/30	24/29	26/28
ehp ang ejz		736.mg Z	P<.003 +	318.mg 5.59gm	1/59	0/20	1/16	5/24	4/18	(1/14	1/12)
mgl car ejz		3.75gm Z	P<.005 +	1.69gm 41.6gm	1/67	11/30	12/29	7/28	8/30	8/28	13/28
for epo ejz		9.82gm *	P<.02	2.41gm n.s.s.	0/56	0/18	0/13	0/20	1/13	0/9	1/6
liv hpt ejz		12.2gm Z	P<.1	2.59gm n.s.s.	0/62	0/26	2/21	0/26	0/24	2/21	(0/20)
ski epo ejz		25.1gm *	P<.3	5.81gm n.s.s.	1/64	0/27	1/24	0/28	1/28	3/24	0/25
ehp agm ejz		70.9gm *	P<.7	7.02gm n.s.s.	0/65	4/27	1/24	2/28	1/28	1/24	2/27
tba mix ejz		600.mg Z	P<.0005	336.mg 1.34gm	22/70	16/30	22/30	28/30	23/30	25/30	28/30
6497 M f swi inh 6m24 1536m					0	10.1mg					Drew;txap,68,120-130;1983/Haseman pers.comm.
mgl car es		10.6mg	P<.0005 +	6.81mg 18.3mg	2/71	33/67					
--- hes es		12.5mg	P<.0005 +	7.87mg 21.9mg	1/71	29/67					
lun car es		36.6mg	P<.03 +	15.4mg n.s.s.	9/71	18/65					
6498 M f swi inh 12m24 1536n					0	20.2mg					
--- hes es		13.8mg	P<.0005 +	8.64mg 23.7mg	1/71	30/47					
mgl car es		22.9mg	P<.0005 +	13.4mg 45.2mg	2/71	22/47					
lun car es		55.5mg	P<.02 +	23.7mg n.s.s.	9/71	15/47					
6499 M f swi inh 18m24 1536o					0	30.2mg					
mgl car es		32.2mg	P<.0005 +	18.9mg 63.3mg	2/71	22/45					
--- hes es		36.1mg	P<.0005 +	20.9mg 71.4mg	1/71	20/45					
lun car es		143.mg	P<.2 +	47.0mg n.s.s.	9/71	11/45					
6500 M m swi inh 30w77 1BT4					0	11.0mg	43.5mg	149.mg	587.mg	1.96gm	3.62gm Maltoni;aric,2,1-533;1984/1977a/1981
lun ade ejz		14.0mg Z	P<.0005 +	8.17mg 27.3mg	8/75	3/27	24/29	(24/29	18/25	23/27	20/24)
liv ang ejz		70.8mg Z	P<.0005 +	39.2mg 149.mg	0/62	1/18	9/23	6/17	(6/13	2/12	1/9)
ski epo ejz		2.69gm *	P<.0005	1.30gm 8.63gm	1/66	0/20	0/23	2/22	3/15	4/19	4/12
liv agm ejz		1.08gm Z	P<.1 +	257.mg n.s.s.	0/65	0/20	6/23	1/21	2/14	(2/19	1/12)
ehp agm ejz		12.3gm *	P<.09 +	3.30gm n.s.s.	1/67	1/20	2/24	1/24	0/15	2/19	2/15
for epo ejz		5.19gm *	P<.2	863.mg n.s.s.	0/51	1/9	1/19	0/6	0/7	1/3	0/1

Chemical | Synonym | CAS number

Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference

Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
ehp ang ejz	8.03gm Z	P<.7		951.mg n.s.s.	0/56	1/13	2/19	2/8	4/11	0/8	0/2
liv hpt ejz	25.2gm *	P<.5		4.11gm n.s.s.	0/62	0/18	0/23	0/17	1/13	0/12	0/9
tba mix ejz	26.1mg Z	P<.0005		16.2mg 47.9mg	15/80	7/30	25/30	24/30	(18/29	23/30	21/26)
6501 R f cdr inh 26w78 1113m					0	3.19mg	15.9mg	63.8mg			Hong;jtxe,7,909-924;1981/1980
liv hes ejs	115.mg *	P<.03		28.1mg n.s.s.	0/8	0/8	0/8	2/8			
liv nnd ejs	no dre	P=1.		43.4mg n.s.s.	0/8	0/8	1/8	0/8			
6502 R f cdr inh 43w95 1113n					0	4.35mg	21.7mg	87.0mg			
liv hes ejs	69.5mg *	P<.0005	+	34.4mg 195.mg	0/16	0/16	4/12	7/16			
liv hpc ejs	225.mg *	P<.02		77.6mg n.s.s.	0/16	0/16	1/12	3/16			
liv nnd ejs	315.mg *	P<.3		95.4mg n.s.s.	0/16	0/16	2/12	1/16			
6503 R m cdr inh 26w78 1113m					0	2.23mg	11.2mg	44.6mg			
liv nnd ejs	11.5mg Z	P<.02		3.43mg n.s.s.	0/8	0/8	3/8	(1/8)			
liv hpc ejs	52.9mg *	P<.04		15.9mg n.s.s.	0/8	0/8	1/8	2/8			
6504 R m cdr inh 43w95 1113n					0	3.04mg	15.2mg	60.9mg			
liv nnd ejs	34.6mg Z	P<.008		11.9mg 598.mg	0/16	0/10	4/16	(0/16)			
liv hes ejs	103.mg *	P<.002	+	41.7mg 483.mg	0/16	0/10	1/16	5/16			
liv hpc ejs	265.mg *	P<.1		69.5mg n.s.s.	1/16	0/10	0/16	3/16			
6505 R f f34 inh 6m24 1536m					0	4.80mg					Drew;txap,68,120-130;1983/Haseman pers.comm.
liv nnd e	17.6mg	P<.0005		8.77mg 63.2mg	4/112	15/75					
mgl fba e	15.1mg	P<.03	+	6.50mg n.s.s.	24/112	28/76					
--- hes e	91.2mg	P<.2	+	23.2mg n.s.s.	2/112	4/76					
liv hpc e	103.mg	P<.2		25.8mg n.s.s.	1/112	3/75					
6506 R f f34 inh 12m24 1536n					0	9.60mg					
mgl fba e	14.6mg	P<.0005	+	7.52mg 52.0mg	24/112	28/56					
liv nnd e	16.2mg	P<.0005		9.16mg 35.0mg	4/112	20/56					
--- hes e	29.5mg	P<.0005	+	14.5mg 85.5mg	2/112	12/56					
mgl adc e	38.0mg	P<.003	+	16.6mg 272.mg	5/112	11/56					
liv hpc e	101.mg	P<.03	+	31.8mg n.s.s.	1/112	4/56					
6507 R f f34 inh 18m24 1536o					0	14.4mg					
mgl fba e	29.7mg	P<.004	+	13.8mg 269.mg	24/112	24/55					
--- hes e	32.8mg	P<.0005	+	17.4mg 78.1mg	2/112	15/55					
liv hpc e	65.2mg	P<.0005	+	28.5mg 255.mg	1/112	8/54					
mgl adc e	74.2mg	P<.02	+	29.1mg n.s.s.	5/112	9/55					
liv nnd e	96.3mg	P<.03		34.1mg n.s.s.	4/112	7/54					
6508 R f f34 inh 24m24 1536r					0	19.1mg					
--- hes e	23.6mg	P<.0005	+	14.2mg 43.9mg	2/112	24/55					
mgl fba e	32.9mg	P<.002	+	16.3mg 153.mg	24/112	26/55					
liv hpc e	77.2mg	P<.0005	+	35.3mg 260.mg	1/112	9/55					
liv nnd e	166.mg	P<.08		52.2mg n.s.s.	4/112	6/55					
mgl adc e	264.mg	P<.3	+	62.1mg n.s.s.	5/112	5/55					
6509 R f sda inh 71w71 BT4001					0	534.mg					Maltoni;anya,534,145-159;1988/1984
bra neu egjv	184.mg	P<.0005	+	118.mg 306.mg	0/60	32/53					
liv ang egjv	240.mg	P<.0005	+	150.mg 415.mg	0/60	27/53					
zym car egjv	1.19gm	P<.007	+	501.mg 18.9gm	1/60	8/54					
liv hpc egjv	1.72gm	P<.006	+	654.mg 17.3gm	0/60	5/53					
liv agm egjv	9.13gm	P<.3		1.49gm n.s.s.	0/60	1/54					
tba mix egjv	70.5mg	P<.0005		34.1mg 172.mg	35/60	52/54					
6510 R f sda inh 12m30 1BT1					0	2.53mg	16.7mg	29.9mg	149.mg	419.mg	840.mg Maltoni;aric,2,1-533;1984/1977a/1981
liv hpt ejz	244.mg Z	P<.003	+	92.4mg 1.30gm	0/28	0/27	0/21	5/26	(2/23	1/17	0/16)
liv ang ejz	735.mg Z	P<.0005	+	427.mg 2.16gm	0/29	1/29	2/26	6/28	7/24	10/25	(4/25)
zym car ejz	3.64gm *	P<.0005	+	1.87gm 10.5gm	0/29	0/30	0/30	1/30	1/30	4/30	6/30
bra neu ejz	4.85gm *	P<.0005	+	2.19gm 15.9gm	0/29	0/30	0/27	0/27	2/25	1/27	5/26
liv agm ejz	3.14gm *	P<.04	+	789.mg n.s.s.	0/26	0/24	1/15	0/17	0/14	2/7	0/2
ehp ang ejz	21.4gm *	P<.4		4.75gm n.s.s.	0/29	0/30	1/30	1/30	1/30	2/30	1/30
ehp agm ejz	94.9gm *	P<.9		5.40gm n.s.s.	2/29	2/30	0/29	0/30	1/28	2/30	1/29
kid nep ejz	no dre	P=1.		4.75gm n.s.s.	0/29	1/29	4/27	4/28	1/25	1/26	2/25
tba mix ejz	2.77gm *	P<.3		778.mg n.s.s.	19/29	16/30	15/30	20/30	18/30	22/30	20/30
6511 R f sda gav 12m30 1BT11					0	.905mg	4.38mg	13.2mg			
liv ang ejz	38.6mg *	P<.0005	+	21.2mg 84.3mg	0/39	0/37	6/34	9/35			
kid nep ejz	182.mg *	P<.1	+	44.8mg n.s.s.	0/24	0/31	1/23	1/18			
liv agm ejz	207.mg *	P<.03	+	51.0mg n.s.s.	0/27	0/32	0/26	2/21			
ehp agm ejz	408.mg *	P<.5		50.4mg n.s.s.	0/25	1/31	0/25	1/18			
ehp ang ejz	454.mg *	P<.4		73.0mg n.s.s.	0/39	2/38	0/39	2/36			
liv hpt ejz	no dre	P=1.		8.72mg n.s.s.	0/40	0/40	0/40	0/40			
zym car ejz	no dre	P=1.		124.mg n.s.s.	1/36	0/36	1/37	0/29			
tba mix ejz	35.2mg *	P<.07		13.2mg n.s.s.	17/40	19/40	18/40	25/40			
6512 R f sda inh 12m30 1BT15					0	50.6ug	.270mg	.577mg	1.44mg		
mgl adc ejz	1.66mg Z	P<.0005	+	.895mg 6.68mg	6/60	12/60	22/60	21/60	(15/60)		
liv ang ejz	21.0mg *	P<.002	+	7.96mg 106.mg	0/44	0/55	0/47	1/46	4/40		
liv agm ejz	60.1mg *	P<.1		9.78mg n.s.s.	0/34	0/35	0/32	0/29	1/20		
zym car ejz	44.6mg *	P<.2		13.5mg n.s.s.	0/52	0/53	1/57	1/54	1/52		
ehp agm ejz	75.1mg *	P<.5		12.2mg n.s.s.	0/35	0/39	0/34	1/36	0/26		
liv hpt ejz	no dre	P=1.		.758mg n.s.s.	0/60	0/60	0/60	0/60	0/60		
tba mix ejz	1.09mg *	P<.004		.503mg 10.5mg	43/60	46/60	59/60	54/60	55/60		
6513 R f sda inh 12m32 1BT2					0	4.77mg	7.37mg	12.0mg			
liv ang ejz	113.mg *	P<.002	+	56.9mg 369.mg	0/68	1/43	5/46	5/44			
mgl adc ejz	141.mg *	P<.007	+	69.1mg 2.20gm	1/100	3/60	6/60	5/60			
liv hpt ejz	140.mg *	P<.05	+	34.4mg n.s.s.	0/19	0/16	0/11	2/7			
kid nep ejz	230.mg *	P<.03	+	99.3mg n.s.s.	0/86	2/55	3/54	2/57			
liv agm ejz	378.mg *	P<.07	+	92.9mg n.s.s.	0/44	0/27	0/29	2/24			
ehp agm ejz	399.mg *	P<.2		98.1mg n.s.s.	0/51	0/29	1/32	1/24			
zym car ejz	1.07gm *	P<.7		144.mg n.s.s.	2/95	1/59	4/57	1/59			
tba mix ejz	37.4mg *	P<.009		18.6mg 1.25gm	34/100	27/60	33/60	31/60			
6514 R f sda gav 14m30 1BT27					0	8.82ug	97.3ug	.294mg			
liv ang ejz	3.58mg *	P<.07	+	1.08mg n.s.s.	0/23	0/18	1/19	2/29			
zym car ejz	5.05mg *	P<.2		1.30mg n.s.s.	1/28	0/25	0/25	3/32			
ehp ang ejz	10.9mg *	P<.2		1.78mg n.s.s.	0/25	0/18	0/19	1/29			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf							Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc			NCI/NTPPathology
liv agm ejz	no dre	P=1.		.303mg n.s.s.	0/5	0/5	1/3	0/5			
liv hpt ejz	no dre	P=1.		.187mg n.s.s.	0/75	0/75	0/75	0/75			
tba mix ejz	.878mg	* P<.05		.358mg n.s.s.	39/75	46/75	35/73	53/75			
6515 R f sda inh 12m26 1BT9					0	2.99mg					
mgl adc ejz	5.91mg	P<.0005	+	3.83mg 13.7mg	5/50	59/150					
liv ang ejz	20.2mg	P<.007	+	10.4mg 213.mg	0/38	12/110					
liv agm ejz	30.7mg	P<.04	+	12.5mg n.s.s.	0/37	6/82					
ehp ang ejz	52.9mg	P<.08	+	21.6mg n.s.s.	0/41	6/139					
zym car ejz	67.9mg	P<.09	+	25.8mg n.s.s.	0/49	5/148					
kid nep ejz	17.5mg	P<.3		2.83mg n.s.s.	0/8	1/8					
ehp agm ejz	115.mg	P<.2		34.9mg n.s.s.	0/50	3/150					
liv hpt ejz	no dre	P=1.		105.mg n.s.s.	0/50	0/150					
tba mix ejz	2.12mg	P<.0005		1.30mg 5.66mg	29/50	129/150					
6516 R f sda inh 6m30 1BT10m ()					0	31.1mg	50.2mg				
zym car ejyz	1.20gm	* P<.008	+	415.mg 20.2gm	0/119	0/59	4/59				
liv agm ejyz	913.mg	* P<.1		149.mg n.s.s.	0/51	0/15	1/9				
liv ang ejyz	4.46gm	* P<.4		726.mg n.s.s.	0/114	1/52	0/55				
liv hpt ejyz	no dre	P=1.		354.mg n.s.s.	0/120	0/60	0/60				
tba mix ejyz	309.mg	* P<.5		63.2mg n.s.s.	84/120	40/59	46/60				
6517 R f sda inh 6m31 1BT10n ()					0	28.3mg	50.2mg				
mgl adc ejyz	291.mg	* P<.006	+	140.mg 4.08gm	13/120	12/60	16/59				
zym car ejyz	569.mg	* P<.0005	+	268.mg 1.67gm	0/119	3/59	6/59				
liv hpt ejyz	357.mg	* P<.1	+	87.8mg n.s.s.	0/26	2/14	0/5				
liv agm ejyz	507.mg	* P<.02	+	153.mg n.s.s.	0/51	1/24	2/14				
ehp ang ejyz	2.42gm	* P<.4		395.mg n.s.s.	0/62	1/32	0/24				
liv ang ejyz	2.46gm	* P<.2		604.mg n.s.s.	0/114	1/54	1/55				
ehp agm ejyz	2.99gm	* P<.2		486.mg n.s.s.	0/78	0/39	1/30				
kid nep ejyz	3.14gm	* P<.2		511.mg n.s.s.	0/80	0/40	1/32				
bra neu ejyz	3.63gm	* P<.2		592.mg n.s.s.	0/89	0/41	1/40				
tba mix ejyz	51.5mg	* P<.002		26.8mg 224.mg	84/120	51/60	53/59				
6518 R m sda inh 12m30 1BT1					0	1.77mg	10.1mg	19.5mg	113.mg	306.mg	737.mg
liv ang ejz	875.mg	Z P<.0005	+	426.mg 3.28gm	0/22	0/26	1/28	0/22	6/26	3/17	(3/21)
zym car ejz	2.32gm	* P<.0005	+	1.18gm 6.25gm	0/28	0/29	0/29	3/29	1/29	3/29	10/30
bra neu ejz	4.58gm	* P<.006	+	1.87gm 66.3gm	0/22	0/26	0/28	0/22	2/27	2/21	2/22
kid nep ejz	2.96gm	* P<.02	+	1.28gm n.s.s.	0/22	0/26	1/28	2/22	5/26	4/18	3/21
ehp agm ejz	8.18gm	* P<.05	+	2.60gm n.s.s.	0/28	0/29	0/29	1/27	1/27	2/29	2/29
liv hpt ejz	13.4gm	* P<.2		1.95gm n.s.s.	0/19	0/22	1/25	0/20	0/24	0/10	1/8
ehp ang ejz	14.9gm	* P<.3		3.33gm n.s.s.	0/29	1/30	1/29	0/30	2/30	1/29	2/30
tba mix ejz	950.mg	* P<.0005		499.mg 3.06gm	6/29	8/30	11/29	10/30	15/30	13/29	21/30
6519 R m sda gav 12m30 1BT11					0	.968mg	4.38mg	15.1mg			
liv ang ejz	57.4mg	* P<.0005	+	29.5mg 147.mg	0/37	0/34	4/39	8/36			
kid nep ejz	102.mg	* P<.2		30.9mg n.s.s.	0/24	0/17	2/16	1/15			
zym car ejz	315.mg	* P<.2		77.4mg n.s.s.	0/33	0/28	1/30	1/31			
ehp agm ejz	409.mg	* P<.2		66.6mg n.s.s.	0/24	0/18	0/17	1/21			
liv agm ejz	430.mg	* P<.2		70.0mg n.s.s.	0/27	0/19	0/18	1/22			
liv hpt ejz	no dre	P=1.		9.26mg n.s.s.	0/40	0/40	0/40	0/40			
tba mix ejz	37.9mg	* P<.0005		19.2mg 160.mg	7/40	3/40	9/40	17/40			
6520 R m sda inh 12m32 1BT15					0	33.4ug	.167mg	.354mg	.944mg		
ehp ang ejz	11.7mg	* P<.4		2.87mg n.s.s.	0/13	0/11	0/20	2/15	0/11		
ehp agm ejz	18.0mg	* P<.2		5.51mg n.s.s.	1/21	0/31	0/38	2/38	3/38		
kid nep ejz	28.9mg	* P<.2		4.71mg n.s.s.	0/13	0/12	0/21	0/17	1/15		
zym car ejz	50.4mg	* P<.4		9.30mg n.s.s.	2/35	1/51	0/50	1/46	3/54		
liv ang ejz	75.8mg	* P<.2		12.3mg n.s.s.	0/25	0/48	0/43	0/42	1/41		
liv hpt ejz	no dre	P=1.		.555mg n.s.s.	0/60	0/60	0/60	0/60	0/60		
tba mix ejz	8.67mg	* P<.3		2.39mg n.s.s.	17/60	18/60	22/60	21/60	23/60		
6521 R m sda inh 12m29 1BT2					0	3.77mg	5.66mg	7.80mg			
kid nep ejz	37.8mg	* P<.002	+	22.6mg 108.mg	0/69	8/47	8/51	5/54			
liv ang ejz	76.7mg	* P<.002	+	34.8mg 275.mg	0/61	0/37	1/36	7/42			
liv agm ejz	106.mg	* P<.08	+	32.0mg n.s.s.	0/34	1/24	0/18	2/19			
zym car ejz	315.mg	* P<.05	+	95.4mg n.s.s.	0/82	0/57	0/57	3/59			
liv hpt ejz	152.mg	* P<.3		24.8mg n.s.s.	0/16	0/12	0/7	1/10			
ehp ang ejz	no dre	P=1.		201.mg n.s.s.	2/85	0/60	0/59	1/60			
tba mix ejz	66.2mg	* P<.4		18.4mg n.s.s.	26/85	19/60	23/59	22/60			
6522 R m sda gav 14m30 1BT27					0	8.82ug	97.3ug	.313mg			
zym car ejz	4.75mg	* P<.06	+	1.17mg n.s.s.	0/13	0/20	0/20	2/23			
liv hpt ejz	3.36mg	* P<.3		.827mg n.s.s.	0/11	0/13	1/15	1/16			
liv ang ejz	8.45mg	* P<.2		1.38mg n.s.s.	0/11	0/15	0/15	1/21			
tba mix ejz	16.1mg	* P<.8		1.39mg n.s.s.	13/75	15/75	17/75	15/74			
6523 R m sda inh 12m29 1BT9					0	1.89mg					
ehp agm ejz	31.4mg	P<.03	+	14.2mg n.s.s.	0/48	8/143					
liv agm ejz	54.3mg	P<.3		13.3mg n.s.s.	0/23	2/61					
liv ang ejz	62.4mg	P<.3		15.4mg n.s.s.	0/29	2/70					
ehp ang ejz	63.0mg	P<.2		19.1mg n.s.s.	0/34	3/106					
zym car ejz	63.3mg	P<.2		21.9mg n.s.s.	0/49	4/142					
liv hpt ejz	no dre	P=1.		81.6mg n.s.s.	0/50	0/150					
tba mix ejz	8.44mg	P<.05		3.99mg n.s.s.	10/48	52/144					
6524 R m sda inh 6m27 1BT10m ()					0	24.1mg	38.8mg				
zym car ejyz	284.mg	* P<.0005	+	138.mg 832.mg	0/105	5/57	5/56				
ehp ang ejyz	468.mg	* P<.2		115.mg n.s.s.	0/37	2/20	0/17				
liv agm ejyz	580.mg	* P<.2		94.3mg n.s.s.	0/25	0/15	1/9				
liv ang ejyz	871.mg	* P<.2		264.mg n.s.s.	0/61	2/49	1/51				
ehp agm ejyz	5.81gm	* P<.9		225.mg n.s.s.	1/39	0/27	1/22				
liv hpt ejyz	no dre	P=1.		225.mg n.s.s.	0/120	0/60	0/60				
tba mix ejyz	134.mg	* P<.03		59.7mg n.s.s.	25/107	23/59	22/59				
6525 R m sda inh 6m32 1BT10n ()					0	19.8mg	32.1mg				
zym car ejyz	226.mg	\ P<.0005	+	92.4mg 846.mg	0/105	6/59	(2/57)				
liv agm ejyz	1.03gm	* P<.5		168.mg n.s.s.	0/25	1/17	0/16				
kid nep ejyz	1.94gm	* P<.6		317.mg n.s.s.	0/39	1/32	0/30				

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf						Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
liv hpt ejyz	no dre	P=1.		271.mg n.s.s.	0/109	0/60	0/60			
ehp agm ejyz	no dre	P=1.		136.mg n.s.s.	1/39	0/31	0/29			
tba mix ejyz	284.mg	* P<.2		94.1mg n.s.s.	25/107	22/60	18/60			
6526 R m sda inh 12m30 1440					0	21.4mg				Radike;enhp,41,59-62;1981
liv hpc e	40.8mg	P<.0005	+	26.7mg 67.3mg	1/80	35/80				
liv ang e	90.0mg	P<.0005	+	51.7mg 177.mg	0/80	18/80				
adr tum e	251.mg	P<.003		108.mg 1.09gm	0/80	7/80				
liv mix e	294.mg	P<.004	+	120.mg 1.93gm	0/80	6/80				
pit tum e	138.mg	P<.02		61.0mg n.s.s.	8/80	19/80				
tba mix e	17.3mg	P<.0005	+	11.6mg 28.1mg	16/80	63/80				
6527 R f wis inh 52w52 1170					0	1.12gm				Feron;txcy,13,131-141;1979/1979a
liv ang ek	209.mg	P<.002	+	80.8mg 884.mg	0/10	6/10				
nas oec ek	276.mg	P<.004	+	101.mg 1.93gm	0/10	5/10				
zym sqc ek	857.mg	P<.09	+	209.mg n.s.s.	0/10	2/10				
liv hpc ek	1.81gm	P<.3	+	295.mg n.s.s.	0/10	1/10				
liv nnd ek	1.81gm	P<.3	+	295.mg n.s.s.	0/10	1/10				
lun ppa ek	1.81gm	P<.3		295.mg n.s.s.	0/10	1/10				
6528 R m wis inh 12m30 1BT17					0	36.6ug				Maltoni;aric,2,1-533;1984/1977a/1981
ehp agm ejz	.370mg	P<.01	+	.140mg 15.6mg	0/49	5/52				
ehp ang ejz	1.05mg	P<.05	+	.318mg n.s.s.	0/84	3/86				
liv agm ejz	.654mg	P<.3		.106mg n.s.s.	0/13	1/18				
liv hpt ejz	.728mg	P<.3		.119mg n.s.s.	0/16	1/20				
zym car ejz	no dre	P=1.		.596mg n.s.s.	3/90	2/96				
6529 R m wis inh 12m29 1BT7					0	2.05mg	10.6mg	18.6mg	120.mg 276.mg 479.mg	
liv ang ejz	518.mg	* P<.0005	+	271.mg 1.32gm	0/34	0/22	1/17	3/18	3/11 3/14 8/12	
zym car ejz	3.54gm	* P<.002	+	1.22gm 21.2gm	0/36	0/22	0/18	0/19	0/12 2/16 2/18	
bra neu ejz	4.14gm	* P<.002	+	1.57gm 21.8gm	0/38	0/28	0/25	0/26	1/22 1/25 3/24	
liv agm ejz	3.62gm	* P<.1	+	860.mg n.s.s.	0/33	0/22	0/16	1/15	0/9 2/12 0/8	
liv hpt ejz	4.86gm	* P<.05	+	1.47gm n.s.s.	0/36	0/22	0/18	0/19	1/12 2/16 0/18	
kid nep ejz	4.51gm	* P<.2		1.04gm n.s.s.	0/34	1/22	0/17	2/17	0/11 2/14 1/12	
ehp ang ejz	8.49gm	* P<.6		991.mg n.s.s.	1/33	0/21	1/14	0/14	1/8 1/11 0/7	
ehp agm ejz	72.7gm	* P<.9		4.03gm n.s.s.	0/38	0/28	1/27	0/28	0/25 1/26 0/27	
tba mix ejz	1.13gm	* P<.02		485.mg n.s.s.	11/38	7/28	5/27	12/28	11/25 11/26 14/27	
6530 R m wis inh 52w52 1170					0	781.mg				Feron;txcy,13,131-141;1979/1979a
liv ang ek	330.mg	P<.03	+	98.3mg n.s.s.	0/10	3/9				
zym sqc ek	330.mg	P<.03	+	98.3mg n.s.s.	0/10	3/9				
nas oec ek	533.mg	P<.08	+	130.mg n.s.s.	0/10	2/9				
liv hpc ek	1.14gm	P<.3	+	185.mg n.s.s.	0/10	1/9				
lun ppa ek	no dre	P=1.		362.mg n.s.s.	0/10	0/9				
6531 R m wis inh 52w78 1760					0	1.07mg	10.7mg	321.mg		Bi;eaes,10,281-289;1985/pers.comm.
liv ang e	10.2mg	Z P<.0005	+	4.36mg 32.7mg	0/19	0/20	7/19	(17/20)		
lun ang e	193.mg	* P<.0005	+	88.3mg 617.mg	0/19	0/20	2/19	9/20		
lun tum e	867.mg	* P<.2	+	208.mg n.s.s.	1/19	1/20	3/19	4/20		
bra tum e	5.82gm	* P<.8	+	503.mg n.s.s.	0/19	0/20	2/19	1/20		
ski tum e	5.82gm	* P<.8	+	503.mg n.s.s.	0/19	0/20	2/19	1/20		
nse tum e	no dre	P=1.	+	469.mg n.s.s.	1/19	1/20	2/19	1/20		
tes tum e	no dre	P=1.	+	674.mg n.s.s.	0/19	0/20	1/19	0/20		
tba mix e	5.44mg	Z P<.0005	+	2.63mg 15.7mg	1/19	1/20	11/19	(19/20)		
VINYL FLUORIDE 75-02-5										
6532 M f cd1 inh 67w74 2354o					0	14.8mg	148.mg	1.48gm		Bogdanffy;faat,26,223-238;1995/pers.comm.
mgl adc ae	13.6mg	Z P<.0005	+	8.19mg 25.0mg	0/69	22/70	(20/68	19/69)		
mgl mix ae	13.6mg	Z P<.0005	+	8.19mg 25.0mg	0/69	22/70	(20/68	20/69)		
liv hes Cae	25.4mg	Z P<.0005	+	13.4mg 57.5mg	0/71	13/71	(25/70	32/71)		
lun a/a Cae	54.6mg	Z P<.0005	+	34.6mg 101.mg	9/71	23/70	46/70	(50/71)		
lun mix Cae	54.6mg	Z P<.0005	+	34.6mg 101.mg	9/71	23/70	46/70	(50/71)		
hag ade ae	4.01gm	* P<.02	+	1.63gm n.s.s.	1/71	7/71	6/69	12/71		
liv hpa Cae	no dre	P=1.		8.26gm n.s.s.	0/71	0/71	1/70	0/71		
6533 M m cd1 inh 63w78 2354o					0	12.3mg	123.mg	1.23gm		
lun a/a Cae	5.78mg	Z P<.0005	+	3.66mg 10.8mg	11/71	44/70	(48/70	50/71)		
lun mix Cae	5.78mg	Z P<.0005	+	3.66mg 10.8mg	11/71	44/70	(48/70	50/71)		
liv hes Cae	19.4mg	Z P<.0005	+	10.5mg 48.2mg	1/71	16/70	(42/70	42/71)		
hag ade ae	1.00gm	* P<.0005	+	587.mg 2.21gm	3/70	13/69	12/70	31/70		
liv hpa Cae	34.6mg	Z P<.06	+	13.5mg n.s.s.	7/71	15/70	(5/70	3/71)		
lun acb Cae	12.3gm	* P<.3		2.88gm n.s.s.	1/71	1/70	4/70	4/71		
liv hpc Cae	no dre	P=1.		10.4gm n.s.s.	2/71	2/70	1/70	0/71		
6534 R f cdr inh 52w52 2354m					0	3.52mg	35.2mg	352.mg		
zym ssc ek	639.mg	* P<.2		104.mg n.s.s.	0/10	0/10	0/10	1/10		
liv tum Cek	no dre	P=1.		1.64mg n.s.s.	0/10	0/10	0/10	0/10		
6535 R f cdr inh 78w78 2354n					0	3.52mg	35.2mg	352.mg		
zym ssc ek	684.mg	* P<.03		167.mg n.s.s.	0/10	0/10	0/10	2/10		
liv hpc Cek	1.44gm	* P<.2		234.mg n.s.s.	0/10	0/10	0/10	1/10		
liv mix Cek	7.38gm	* P<.9		206.mg n.s.s.	0/10	1/10	2/10	1/10		
liv hpa Cek	no dre	P=1.		347.mg n.s.s.	0/10	1/10	2/10	0/10		
liv hes Cek	no dre	P=1.		307.mg n.s.s.	0/10	0/10	1/10	0/10		
6536 R f cdr inh 22m24 2354o					0	3.52mg	35.2mg	352.mg		
liv hes Cae	16.6mg	Z P<.002	+	7.49mg 56.7mg	0/60	8/60	(18/60	15/60)		
liv hpa Cae	183.mg	Z P<.008		73.8mg 4.10gm	0/60	3/60	7/60	(5/60)		
liv mix Cae	183.mg	Z P<.008	+	73.8mg 4.10gm	0/60	3/60	7/60	(7/60)		
zym ssc ae	1.47gm	* P<.0005	+	715.mg 3.85gm	0/60	0/60	1/60	9/60		
liv hpc Cae	7.77gm	* P<.03		1.91gm n.s.s.	0/60	0/60	0/60	2/60		
6537 R m cdr inh 52w52 2354m					0	2.47mg	24.7mg	247.mg		
zym ssc ek	213.mg	* P<.03		52.1mg n.s.s.	0/10	0/10	0/10	2/10		
liv tum Cek	no dre	P=1.		1.15mg n.s.s.	0/10	0/10	0/10	0/10		
6538 R m cdr inh 78w78 2354n					0	2.47mg	24.7mg	247.mg		
zym tum ek	no dre	P=1.		2.58mg n.s.s.	0/10	0/10	0/10	0/10		
liv hpa Cek	no dre	P=1.		165.mg n.s.s.	1/10	1/10	2/10	1/10		
liv hes Cek	no dre	P=1.		262.mg n.s.s.	0/10	1/10	1/10	0/10		

Chemical | Synonym | CAS number
Spe Strain Xpo+Xpt | 0 Dose 1 Dose 2 Dose 3 Dose | Literature Reference
Sex Route Paper Num

Site Notes Path	DR TD_{50}	AuOp 2Tailpvl	UpConf LoConf	Cntrl	1 Inc	2 Inc	3 Inc	Brkly Code NCI/NTPPathology
liv hpc Cek	no dre	P=1.	269.mg n.s.s.	1/10	0/10	1/10	0/10	
6539 R m cdr inh 22m24 2354o				0	2.47mg	24.7mg	247.mg	
liv hes Cae	25.0mg Z	P<.0005 +	16.3mg 40.9mg	0/60	4/60	29/60	(20/60)	
zym ssc ae	1.09gm *	P<.002 +	686.mg 5.53gm	0/60	2/60	3/60	9/60	
liv hpa Cae	200.mg Z	P<.05	64.0mg n.s.s.	0/60	3/60	5/60	(1/60)	
liv hpc Cae	no dre	P=1.	1.24gm n.s.s.	3/60	6/60	5/60	4/60	
VINYL TOLUENE (65-71% m- and 32-35% p-) 25013-15-4								
6540 M f b6c inh 24m24 TR375 :				0	14.9mg	37.3mg		
TBA MXB	no dre	P=1. -	73.0mg n.s.s.	29/50	27/50	17/50		
liv MXB	no dre	P=1.	52.8mg n.s.s.	9/50	5/50	(2/50)		liv:hpa,hpc,nnd.
lun MXB	750.mg *	P<.6	112.mg n.s.s.	3/50	2/50	4/50		lun:a/a,a/c.
6541 M m b6c inh 24m24 TR375 :				0	12.4mg	31.1mg		
TBA MXB	no dre	P=1. -	17.4mg n.s.s.	33/50	23/50	(20/50)		
liv MXB	no dre	P=1.	73.7mg n.s.s.	17/50	14/50	14/50		liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	38.9mg n.s.s.	12/50	5/50	(2/50)		lun:a/a,a/c.
6542 R f f34 inh 24m24 TR375 :				0	35.8mg	107.mg		
TBA MXB	312.mg *	P<.6 -	52.1mg n.s.s.	48/50	41/50	46/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
6543 R m f34 inh 24m24 TR375 :				0	25.1mg	75.2mg		
TBA MXB	no dre	P=1. -	41.3mg n.s.s.	48/50	48/50	48/50		
liv MXB	no dre	P=1.	213.mg n.s.s.	2/50	2/50	1/50		liv:hpa,hpc,nnd.
4-VINYLCYCLOHEXENE 100-40-3								
6544 M f b6c gav 24m24 TR303 :				0	142.mg	283.mg		
ova MXB	94.4mg *	P<.0005	66.7mg 145.mg	1/50	33/50	24/50		ova:gcc,gct,mtb. C
ova mtb	106.mg \	P<.0005 c	65.9mg 187.mg	0/50	25/50	(11/50)		
ova MXA	309.mg *	P<.0005 c	181.mg 672.mg	1/50	10/50	13/50		ova:gcc,gct.
ova gct	361.mg *	P<.0005 c	204.mg 888.mg	1/50	9/50	11/50		
MXA mlp	839.mg *	P<.01	376.mg 72.6gm	1/50	6/50	5/50		mln:mlp; mul:mlp; smi:mlp. S
arp adn	1.05gm *	P<.004 e	450.mg 6.37gm	0/50	3/50	4/50		
TBA MXB	149.mg *	P<.002	77.9mg 802.mg	28/50	47/50	30/50		
liv MXB	1.48gm *	P<.08	506.mg n.s.s.	1/50	3/50	3/50		liv:hpa,hpc,nnd.
lun MXB	19.0gm /	P<.9	799.mg n.s.s.	6/50	1/50	4/50		lun:a/a,a/c.
6545 M m b6c gav 24m24 TR303 :				0	142.mg	283.mg		
lun MXA #	490.mg *	P<.03 i	206.mg n.s.s.	4/50	11/50	4/50		lun:a/a,a/c. S
MXA MXA	623.mg *	P<.03	245.mg n.s.s.	4/50	7/50	5/50		mln:mlh; mul:mlh,mlm,mlp; spl:mlm. S
lun a/a	926.mg *	P<.03	347.mg n.s.s.	1/50	4/50	3/50		S
TBA MXB	307.mg *	P<.1	112.mg n.s.s.	26/50	33/50	12/50		
liv MXB	1.27gm *	P<.6	216.mg n.s.s.	18/50	20/50	6/50		liv:hpa,hpc,nnd.
lun MXB	490.mg *	P<.03	206.mg n.s.s.	4/50	11/50	4/50		lun:a/a,a/c.
6546 R f f34 gav 24m24 TR303 :				0	141.mg	280.mg		
cli MXA #	580.mg \	P<.04 i	199.mg n.s.s.	1/50	5/50	(0/50)		cli:adn,sqc. S
TBA MXB	305.mg *	P<.2	98.8mg n.s.s.	38/50	37/50	18/50		
liv MXB	3.85kg	P=1.	766.mg n.s.s.	1/50	2/50	0/50		liv:hpa,hpc,nnd.
6547 R m f34 gav 24m24 TR303 :				0	141.mg	280.mg		
tes ict #	62.3mg *	P<.0005 i	34.7mg 166.mg	35/50	30/50	29/50		S
ski MXA	769.mg *	P<.003	265.mg 4.36gm	0/50	1/50	4/50		ski:sqc,sqp. S
ski sqp	935.mg *	P<.006	287.mg 12.5gm	0/50	1/50	3/50		S
adr MXA	159.mg *	P<.02	66.5mg n.s.s.	17/50	16/50	8/50		adr:phe,phm. S
TBA MXB	119.mg *	P<.02	51.9mg n.s.s.	38/50	31/50	19/50		
liv MXB	132.gm *	P<1.	477.mg n.s.s.	1/50	1/50	0/50		liv:hpa,hpc,nnd.
VINYLIDENE CHLORIDE (1,1-dichloroethylene) 75-35-4								
6548 M f b6c gav 24m24 TR228 :				0	1.43mg	7.14mg		
--- MXA #	3.90mg \	P<.05 -	1.54mg n.s.s.	7/50	15/50	(7/50)		---:leu,lym. S
--- lym	4.02mg \	P<.02	1.65mg n.s.s.	2/50	9/50	(6/50)		S
TBA MXB	2.09mg \	P<.06	.838mg n.s.s.	23/50	33/50	(21/50)		
liv MXB	no dre	P=1.	28.7mg n.s.s.	4/50	3/50	3/50		liv:hpa,hpc,nnd.
lun MXB	66.7mg *	P<.2	19.2mg n.s.s.	1/50	1/50	4/50		lun:a/a,a/c.
6549 M m b6c gav 24m24 TR228 :				0	1.43mg	7.14mg		
TBA MXB	34.8mg *	P<.6 -	6.01mg n.s.s.	30/50	22/50	33/50		
liv MXB	133.mg *	P<.8	11.1mg n.s.s.	15/50	9/50	15/50		liv:hpa,hpc,nnd.
lun MXB	60.4mg *	P<.4	12.8mg n.s.s.	5/50	5/50	8/50		lun:a/a,a/c.
6550 M f cd1 inh 52w52 357				0	68.6mg			Lee;jtxe,4,15-30;1978
liv hes e	170.mg	P<.3 +	27.7mg n.s.s.	0/16	1/15			
liv hpt e	170.mg	P<.3	27.7mg n.s.s.	0/16	1/15			
lun tum e	no dre	P=1.	53.0mg n.s.s.	0/16	0/15			
6551 M f cd1 inh 26w78 1113m				0	22.9mg			Hong;jtxe,7,909-924;1981/1980
liv hct e	no dre	P=1. -	31.8mg n.s.s.	1/28	0/12			
liv hes e	no dre	P=1. -	31.8mg n.s.s.	1/28	0/12			
lun abt e	no dre	P=1. -	31.8mg n.s.s.	7/28	0/12			
6552 M m cd1 inh 26w78 1113m				0	19.0mg			
liv hct e	no dre	P=1. -	17.5mg n.s.s.	4/28	1/12			
lun abt e	no dre	P=1. -	17.5mg n.s.s.	4/28	1/12			
6553 M f swi inh 12m29 BT402n				0	7.72mg			Maltoni;aric,3,1-229;1985/1977
mgl mix ej	80.9mg	P<.004 +	38.9mg 578.mg	1/89	12/118			
lun mix ej	124.mg	P<.09 +	46.6mg n.s.s.	3/89	11/119			
liv hpt ej	858.mg	P<.4	140.mg n.s.s.	0/78	1/111			
liv ang ej	no dre	P=1.	178.mg n.s.s.	2/77	1/109			
tba mix ej	30.9mg	P<.003	16.5mg 179.mg	14/89	41/119			
tba mal ej	86.1mg	P<.03	38.1mg n.s.s.	3/90	14/120			
6554 M m swi inh 12m29 BT402n				0	6.43mg			
kid adc ej	22.0mg	P<.0005 +	13.6mg 38.7mg	0/66	25/98			
lun mix ej	59.9mg	P<.02 +	28.3mg n.s.s.	3/87	16/120			
liv ang ej	566.mg	P<.4	92.2mg n.s.s.	0/60	1/88			
liv hpt ej	no dre	P=1.	94.4mg n.s.s.	2/62	2/92			
tba mix ej	17.9mg	P<.0005	11.1mg 39.7mg	9/87	45/120			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf		Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
tba mal ej	50.3mg	P<.004	25.3mg	350.mg	3/90	18/120			
6555 R f f34 gav 24m24 TR228 :					0	.714mg	3.57mg		
TBA MXB	no dre	P=1.	- 3.65mg	n.s.s.	42/50	38/50	36/50		
liv MXB	no dre	P=1.	31.4mg	n.s.s.	4/50	0/50	0/50		liv:hpa,hpc,nnd.
6556 R m f34 gav 24m24 TR228 :					0	.714mg	3.57mg		
TBA MXB	no dre	P=1.	- 2.81mg	n.s.s.	29/50	25/50	43/50		
liv MXB	no dre	P=1.	10.1mg	n.s.s.	1/50	3/50	3/50		liv:hpa,hpc,nnd.
6557 R f cdr inh 52w52 357					0	16.3mg			Lee;jtxe,4,15-30;1978
liv hes e	no dre	P=1.	12.6mg	n.s.s.	0/15	0/15			
6558 R f cdr inh 26w78 1113m					0	5.44mg			Hong;jtxe,7,909-924;1981/1980
liv mix e	no dre	P=1.	- 5.05mg	n.s.s.	0/8	0/8			
6559 R f cdr inh 43w95 1113n					0	7.42mg			
liv mix e	no dre	P=1.	- 20.4mg	n.s.s.	0/16	0/16			
6560 R m cdr inh 26w78 1113m					0	3.81mg			
liv mix e	no dre	P=1.	- 3.53mg	n.s.s.	0/8	0/8			
6561 R m cdr inh 43w95 1113n					0	5.19mg			
liv mix e	no dre	P=1.	- 12.5mg	n.s.s.	1/16	0/14			
6562 R f sda inh 24m35 BT4002					0	23.3mg			Maltoni;aric,3,1-229;1985
liv mix egv	847.mg	P<.3	138.mg	n.s.s.	0/22	1/26			
tba mix egv	119.mg	P<.3	33.9mg	n.s.s.	35/60	37/54			
6563 R f sda gav 12m34 BT403					0	1.14mg	2.27mg	4.55mg	
liv ang e	no dre	P=1.	1.05mg	n.s.s.	1/7	0/4	0/7	0/2	
liv hpt e	no dre	P=1.	6.94mg	n.s.s.	1/7	0/4	1/6	0/2	
tba mix e	no dre	P=1.	19.2mg	n.s.s.	63/99	32/50	28/50	25/48	
6564 R f sda gav 12m32 BT404					0	.123mg			
liv ang e	.501mg	P<.2	80.1ug	n.s.s.	0/10	1/4			
tba mix e	no dre	P=1.	.305mg	n.s.s.	38/74	23/47			
6565 R m sda gav 12m34 BT403					0	1.14mg	2.27mg	4.55mg	
liv ang e	no dre	P=1.	.702mg	n.s.s.	0/17	0/2	0/6	0/3	
liv hpt e	no dre	P=1.	.702mg	n.s.s.	0/17	0/2	0/6	0/3	
tba mix e	no dre	P=1.	42.7mg	n.s.s.	29/100	11/49	9/48	9/49	
6566 R m sda gav 12m32 BT404					0	.123mg			
liv mix e	no dre	P=1.	.303mg	n.s.s.	0/6	0/7			
tba mix e	5.32mg	P<.8	.466mg	n.s.s.	13/68	10/47			
6567 R f sss wat 24m24 1655					0	2.86mg	5.71mg	11.4mg	Quast;faat,3,55-62;1983
liv nnd e	414.mg *	P<.4	- 74.1mg	n.s.s.	1/80	1/48	0/48	2/48	
liv hpc e	654.mg *	P<.2	- 106.mg	n.s.s.	0/80	0/48	0/48	1/48	
mgl fba e	679.mg *	P<1.	- 8.69mg	n.s.s.	53/75	40/47	36/47	35/48	
pit ade e	no dre	P=1.	- 19.3mg	n.s.s.	25/76	22/44	18/46	14/42	
6568 R f sss inh 18m24 1799					0	5.30mg	16.1mg		Quast;faat,6,105-144;1986
mgl fba e	16.0mg *	P<.04	- 6.68mg	n.s.s.	64/84	68/86	74/84		
mgl adc e	49.8mg \	P<.03	- 19.4mg	n.s.s.	1/84	7/86	(4/84)		
liv cho e	no dre	P=1.	- 214.mg	n.s.s.	0/84	1/86	0/84		
6569 R m sss wat 24m24 1655					0	2.50mg	5.00mg	10.0mg	Quast;faat,3,55-62;1983
liv hpc e	22.9gm *	P<1.	- 86.2mg	n.s.s.	2/80	0/48	1/48	1/47	
liv nnd e	no dre	P=1.	- 14.1mg	n.s.s.	1/80	0/48	0/48	0/47	
6570 R m sss inh 18m24 1799					0	3.71mg	11.3mg		Quast;faat,6,105-144;1986
liv sar e	no dre	P=1.	- 49.0mg	n.s.s.	1/86	0/85	0/86		

VINYLIDENE FLUORIDE 75-38-7

6571 R f sda gav 12m33 BT801					0	.977mg	1.96mg		Maltoni;lmdl,5,363-368;1979
fat lip e	60.3mg *	P<.2	14.8mg	n.s.s.	0/30	0/30	2/35		
fat lps e	122.mg *	P<.3	19.9mg	n.s.s.	0/30	0/30	1/35		
liv tum e	no dre	P=1.	7.77mg	n.s.s.	0/30	0/30	0/35		
6572 R m sda gav 12m33 BT801					0	.977mg	1.96mg		
fat lps e	38.8mg *	P<.2	11.7mg	n.s.s.	0/26	1/27	2/35		
fat lip e	no dre	P=1.	22.3mg	n.s.s.	1/26	0/27	1/35		
liv tum e	no dre	P=1.	7.21mg	n.s.s.	0/26	0/27	0/35		

N-VINYLPYRROLIDONE-2 88-12-0

6573 R f cdr inh 52w52 2542m					0	1.70mg	3.40mg	6.80mg	Klimisch;fctx,35,1041-1060;1997/1997a
nre ade e	19.8mg *	P<.2	3.22mg	n.s.s.	0/10	0/10	0/10	1/10	
liv tum e	no dre	P=1.	.501mg	n.s.s.	0/10	0/10	0/10	0/10	
6574 R f cdr inh 24m24 2542n					0	1.70mg	3.40mg	6.80mg	
liv hpc e	12.3mg Z	P<.0005 +	8.05mg	20.8mg	1/70	3/60	6/60	26/60	
nre ade e	20.4mg *	P<.0005 +	12.3mg	39.2mg	0/70	2/60	8/60	12/60	
lar sqc e	120.mg *	P<.009 +	41.5mg	3.56gm	0/70	0/60	0/60	4/60	
nof adc e	120.mg *	P<.009 +	41.5mg	3.56gm	0/70	0/60	0/60	4/60	
tba mal e	6.12mg	P<.0005	3.35mg	18.6mg	25/70			42/60	
tba mix e	no dre	P=1.	8.60mg	n.s.s.	69/70			50/60	
6575 R m cdr inh 52w52 2542m					0	1.19mg	2.38mg	4.76mg	
nre ade e	8.56mg *	P<.5	1.70mg	n.s.s.	0/10	1/10	0/10	1/10	
liv tum e	no dre	P=1.	.351mg	n.s.s.	0/10	0/10	0/10	0/10	
6576 R m cdr inh 24m24 2542n					0	1.19mg	2.38mg	4.76mg	
nre ade e	11.7mg *	P<.0005 +	7.37mg	36.4mg	0/70	8/60	9/60	10/60	
liv hpc e	12.0mg *	P<.0005 +	7.27mg	26.7mg	1/70	6/60	5/60	17/60	
nof adc e	32.9mg *	P<.0005 +	16.1mg	105.mg	0/70	0/60	4/60	6/60	
lar sqc e	84.0mg *	P<.009 +	29.0mg	2.49gm	0/70	0/60	0/60	4/60	
tba mal e	5.00mg	P<.0005	2.88mg	12.1mg	14/70			35/60	
tba mix e	1.99mg	P<.07	.543mg	n.s.s.	64/70			59/60	

FD & C VIOLET NO. 1 (benzyl violet 4B) 1694-09-3

6577 M f asp eat 80w80 1354					0	9.10mg	91.0mg	455.mg	Grasso;fctx,12,21-31;1974
lun ade e	1.91gm *	P<.3	- 480.mg	n.s.s.	8/42	7/43	7/42	12/48	
liv tum e	no dre	P=1.	- 42.6mg	n.s.s.	0/42	0/43	0/42	0/48	
6578 M m asp eat 80w80 1354					0	8.40mg	84.0mg	420.mg	
lun adc e	4.66gm *	P<.3	- 1.15gm	n.s.s.	0/42	0/45	1/42	1/46	
liv tum e	no dre	P=1.	- 40.9mg	n.s.s.	0/42	0/45	0/42	0/46	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path		TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
lun	ade e	no dre	P=1.	- 519.mg	n.s.s.	18/42	13/45	18/42	15/46	
6579	R f asd eat 52w52 1364					0	2.50gm			Uematsu;jnci,51,1337-1338;1973
mgl	car e	1.14gm	P<.02	+ 430.mg	n.s.s.	0/10	5/16			
edu	car e	1.60gm	P<.05	549.mg	n.s.s.	0/10	4/17			
tba	mal e	568.mg	P<.002	261.mg	2.03gm	0/10	9/17			
tba	mix e	660.mg	P<.02	274.mg	n.s.s.	1/10	9/17			
6580	R m asd eat 52w52 1364					0	2.00gm			
tba	tum	no dre	P=1.	2.06gm	n.s.s.	0/10	0/20			
6581	R f sda eat 51w52 1643					0	2.41gm			Ikeda;txcy,2,275-284;1974
mgl	car erv	573.mg	P<.0005	+ 325.mg	1.14gm	0/35	18/35			
ski	sqc erv	1.10gm	P<.0005	+ 547.mg	2.72gm	0/35	11/35			
tba	mix erv	418.mg	P<.0005	+ 246.mg	779.mg	0/35	22/35			
VOGLIBOSE (AO-128) 83480-29-9										
6582	M f cd1 gav 23m23 2446					0	107.mg			Atkinson;jjpt,19,4427-4438;1991/pers.comm.
lun	a/a ae	no dre	P=1.	- 1.00gm	n.s.s.	6/61	1/60			
liv	hpa ae	no dre	P=1.	- 1.25gm	n.s.s.	1/61	0/60			
6583	M m cd1 gav 83w83 2446					0	107.mg			
lun	a/a e	1.37gm	P<.4	- 299.mg	n.s.s.	1/59	3/60			
liv	hpc e	no dre	P=1.	- 417.mg	n.s.s.	2/59	2/60			
liv	hpa e	no dre	P=1.	- 417.mg	n.s.s.	2/59	2/60			
6584	R f f3d gav 24m24 2433					0	2.14mg	7.14mg	21.4mg	Nonoyama;jjpt,19,4415-4425;1991/pers.comm.
mgl	fba e	119.mg	* P<.04	- 46.1mg	n.s.s.	8/120	5/60	8/60	10/60	
liv	tum e	no dre	P=1.	- 265.mg	n.s.s.	0/120			0/60	
6585	R m f3d gav 24m24 2433					0	2.14mg	7.14mg	21.4mg	
tes	ict e	9.27mg	* P<.009	- 3.76mg	448.mg	101/120	55/60	55/60	58/60	
liv	hpa e	575.mg	P<.3	- 112.mg	n.s.s.	1/120			2/60	
liv	hpc e	1.74gm	P<.7	- 153.mg	n.s.s.	1/120			1/60	
WATANIDIPINE.2HCl 133743-71-2										
6586	M f b6c eat 78w78 2576					0	39.0mg			Ishida;jjpt,25,227-246;1997
lun	a/a e	243.mg	P<.04	- 73.5mg	n.s.s.	0/50	3/50			
liv	hpa e	714.mg	P<.7	- 86.7mg	n.s.s.	2/50	3/50			
lun	adc e	no dre	P=1.	- 137.mg	n.s.s.	1/50	1/50			
tba	mix e	293.mg	P<.7	- 43.0mg	n.s.s.	10/50	12/50			
6587	M m b6c eat 78w78 2576					0	10.8mg	36.0mg		
liv	hpc e	898.mg	* P<.8	- 84.6mg	n.s.s.	1/50	3/50	2/50		
liv	hpa e	no dre	P=1.	- n.s.s.	n.s.s.	10/50	10/50	10/50		
lun	a/a e	no dre	P=1.	- 123.mg	n.s.s.	6/50	2/50	3/50		
lun	adc e	no dre	P=1.	- 158.mg	n.s.s.	0/50	1/50	0/50		
tba	mix e	no dre	P=1.	- 47.7mg	n.s.s.	20/50	21/50	16/50		
6588	R f f3d eat 24m24 2575					0	15.0mg			Ishida;jjpt,25,247-270;1997
liv	hpa e	509.mg	P<.3	- 82.9mg	n.s.s.	0/50	1/50			
tba	mix e	46.1mg	P<.7	- 7.26mg	n.s.s.	40/50	42/50			
6589	R m f3d eat 24m24 2575					0	12.0mg			
liv	hpa e	no dre	P=1.	- 52.2mg	n.s.s.	3/50	3/50			
tba	mix e	noTD50	P=1.	- n.s.s.	n.s.s.	50/50	50/50			
WINGSTAY 100 68953-84-4										
6590	R f f34 eat 52w52 2547m					0	2.65mg	15.5mg	95.0mg	Iatropoulos;extp,49,153-165;1997/pers.comm.
liv	tum Cek	no dre	P=1.	- 2.28mg	n.s.s.	0/12	0/20	0/20	0/20	
tba	mix ek	565.mg	* P<.7	- 50.4mg	n.s.s.	1/12	2/20	0/20	2/20	
6591	R f f34 eat 52w64 2547n					0	2.15mg	12.6mg	77.2mg	
liv	tum Ce	no dre	P=1.	- .841mg	n.s.s.	0/5	0/6	0/6	0/6	
ubl	tum Ce	no dre	P=1.	- .841mg	n.s.s.	0/5	0/6	0/6	0/6	
tba	mix e	66.8mg	* P<.3	- 13.4mg	n.s.s.	1/5	0/6	1/6	2/6	
6592	R m f34 eat 52w52 2547m					0	2.12mg	12.4mg	76.0mg	
liv	tum Cek	no dre	P=1.	- 1.82mg	n.s.s.	0/12	0/20	0/20	0/20	
tba	mix ek	195.mg	* P<.3	- 38.4mg	n.s.s.	1/12	0/20	0/20	2/20	
6593	R m f34 eat 52w64 2547n					0	1.72mg	10.1mg	61.8mg	
liv	tum Ce	no dre	P=1.	- .673mg	n.s.s.	0/5	0/6	0/6	0/6	
ubl	tum Ce	no dre	P=1.	- .673mg	n.s.s.	0/5	0/6	0/6	0/6	
tba	mix e	113.mg	* P<.9	- 5.65mg	n.s.s.	5/5	1/6	5/6	4/6	
XIBENOLOL.HCl 15263-30-6										
6594	M f b6c eat 82w92 2380					0	57.6mg	230.mg		Horiuchi;phrm,30,705-721;1985
liv	mix e	no dre	P=1.	- 996.mg	n.s.s.	3/50	3/48	2/50		
lun	mix e	no dre	P=1.	- 1.01gm	n.s.s.	9/50	4/48	4/50		
tba	mix e	no dre	P=1.	- 279.mg	n.s.s.	28/50	26/48	25/50		
6595	M m b6c eat 82w92 2380					0	53.2mg	213.mg		
lun	mix e	1.73gm	* P<.6	- 287.mg	n.s.s.	12/50	12/50	14/49		
liv	mix e	no dre	P=1.	- 431.mg	n.s.s.	19/50	14/50	14/49		
tba	mix e	618.mg	* P<.6	- 115.mg	n.s.s.	33/50	33/50	35/49		
XYLAZINE.HCl (2-(2,6-dimethylpheylamino)-4H-5,6-dihydro-1,3-thiazine.HCl) 23076-35-9										
6596	R m f3d eat 52w53 2655					0	39.2mg			Yasuhara;carc,22,613-618;2001
thy	fca er	66.3mg	P<.3	10.8mg	n.s.s.	0/10	1/10			
XYLENE MIXTURE (50.31% m-XYLENE, 26.9% o-XYLENE, 22.24% p-XYLENE) (CAS# 108-38-3, 95-47-6, and 106-42-3) 1330-20-7										
6597	R f sda gav 24m29 BT911					0	387.mg			Maltoni;anya,837,15-52;1997
---	lkm	4.17gm	P<.2	1.24gm	n.s.s.	3/50	7/50			
hed	car h	5.62gm	P<.3	+ 1.40gm	n.s.s.	3/50	6/50			
orc	car	5.86gm	P<.2	1.64gm	n.s.s.	1/50	4/50			
edu	car	18.0gm	P<.6	2.46gm	n.s.s.	1/50	2/50			
zym	car	no dre	P=1.	5.57gm	n.s.s.	1/50	0/50			
tba	mal	1.87gm	P<.2	652.mg	n.s.s.	11/50	18/50			
tba	mix	no dre	P=1.	697.mg	n.s.s.	35/50	31/50			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology	
6598 R f sda gav 24m33 BT904m				0	237.mg			Maltoni;ajim,7,415-446;1985/1997a	
hed car jh	2.83gm	P<.02	+ 979.mg 420.gm	0/50	4/40				
mam car j	1.75gm	P<.2	581.mg n.s.s.	7/50	11/40				
--- lkm j	5.17gm	P<.3	1.24gm n.s.s.	1/50	3/40				
tba mix j	304.mg	P<.009	132.mg 10.4gm	30/50	34/40				
tba mal ej	524.mg	P<.002	262.mg 2.26gm	10/49	22/40				
6599 R m sda gav 24m29 BT911				0	387.mg			Maltoni;anya,837,15-52;1997	
hed car h	3.44gm	P<.05	+ 1.25gm n.s.s.	1/50	6/50				
orc car	4.44gm	P<.02	1.53gm n.s.s.	0/50	4/50				
--- lkm	8.15gm	P<.6	1.40gm n.s.s.	5/50	7/50				
edu car	18.3gm	P<.3	2.99gm n.s.s.	0/50	1/50				
zym car	no dre	P=1.	3.39gm n.s.s.	1/50	1/50				
tba mal	1.82gm	P<.2	627.mg n.s.s.	12/50	19/50				
tba mix	4.07gm	P<.7	528.mg n.s.s.	27/50	29/50				
6600 R m sda gav 24m33 BT904m				0	237.mg			Maltoni;ajim,7,415-446;1985/1997a	
orc car j	5.82gm	P<.07	1.43gm n.s.s.	0/50	2/40				
--- lkm j	4.17gm	P<.3	991.mg n.s.s.	3/50	5/40				
hed car jh	5.17gm	P<.3	+ 1.24gm n.s.s.	1/50	3/40				
zym car j	58.4gm	P<.9	2.13gm n.s.s.	1/50	1/40				
tba mal ej	1.67gm	P<.3	483.mg n.s.s.	11/45	14/38				
tba mix j	no dre	P=1.	446.mg n.s.s.	29/50	23/40				
XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE, 14% p-XYLENE, 17% ETHYLBENZENE) 1330-20-7									
6601 M f b6c gav 24m24 TR327 :				0	350.mg	707.mg			
thy fca #	4.79gm *	P<.04	- 1.82gm n.s.s.	0/50	2/50	3/50			S
TBA MXB	no dre	P=1.	636.mg n.s.s.	41/50	42/50	32/50			
liv MXB	7.04gm *	P<.4	1.63gm n.s.s.	3/50	3/50	5/50		liv:hpa,hpc,nnd.	
lun MXB	5.13gm *	P<.3	1.40gm n.s.s.	4/50	5/50	7/50		lun:a/a,a/c.	
6602 M m b6c gav 24m24 TR327 :				0	352.mg	707.mg			
TBA MXB	no dre	P=1.	- 847.mg n.s.s.	36/50	37/50	33/50			
liv MXB	no dre	P=1.	1.71gm n.s.s.	18/50	13/50	14/50		liv:hpa,hpc,nnd.	
lun MXB	7.60gm *	P<.6	1.50gm n.s.s.	3/50	5/50	6/50		lun:a/a,a/c.	
6603 R f f34 gav 24m24 TR327 :				0	175.mg	354.mg			
mgl adn #	4.11gm *	P<.04	- 1.24gm n.s.s.	0/50	0/50	3/50			S
TBA MXB	1.93gm *	P<.8	200.mg n.s.s.	46/50	45/50	46/50			
liv MXB	51.3gm *	P<1.	1.40gm n.s.s.	2/50	2/50	2/50		liv:hpa,hpc,nnd.	
6604 R m f34 gav 24m24 TR327 :				0	176.mg	354.mg			
TBA MXB s	700.mg *	P<.5	- 145.mg n.s.s.	45/50	45/50	32/50			
liv MXB s	no dre	P=1.	1.23gm n.s.s.	3/50	2/50	1/50		liv:hpa,hpc,nnd.	
2,4-XYLIDINE.HCl 21436-96-4									
6605 M f chi eat 77w90 381 :				0	13.9mg	29.3mg		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
lun mix	12.4mg /	P<.004	+ 5.45mg 103.mg	5/22	5/18	11/19			
liv mix	no dre	P=1.	- 122.mg n.s.s.	1/22	0/18	0/19			
tba mix	12.2mg /	P<.08	4.28mg n.s.s.	18/22	11/18	16/19			
6606 M f chi eat 77w90 381 : pool				0	13.9mg	29.3mg			
lun mix	13.5mg /	P<.002	+ 5.74mg 89.6mg	31/102	5/18	11/19			
6607 M m chi eat 77w90 381 :				0	12.9mg	27.0mg			
liv mix	65.4mg *	P<.5	- 9.11mg n.s.s.	1/18	2/20	1/19			
lun mix	no dre	P=1.	- 14.5mg n.s.s.	8/18	2/20	3/19			
tba mix	646.mg *	P<1.	- 8.40mg n.s.s.	13/18	8/20	9/19			
6608 R m cdr eat 77w98 381 :				0	23.6mg	47.3mg			
liv mix v	260.mg *	P<.4	- 63.9mg n.s.s.	0/16	1/20	1/24			
tba mix v	16.8mg \	P<.02	- 6.86mg n.s.s.	9/16	14/20	(15/24)			
2,5-XYLIDINE.HCl 51786-53-9									
6609 M f chi eat 68w94 381 :				0	669.mg	1.56gm		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
liv hpt a	552.mg *	P<.003	+ 217.mg 3.20gm	0/13	5/16	2/20			
liv mix a	552.mg *	P<.003	+ 217.mg 3.20gm	0/13	5/16	2/20			
lun mix a	1.29gm *	P<.006	- 403.mg 15.3gm	3/13	2/16	4/20			
tba mix a	475.mg *	P<.003	196.mg 3.12gm	9/13	8/16	7/20			
6610 M f chi eat 68w94 381 : pool				0	669.mg	1.56gm			
liv hpt a	552.mg *	P<.0005 +	217.mg 2.01gm	1/102	5/16	2/20			
6611 M m chi eat 68w94 381 :				0	617.mg	1.44gm			
lun mix a	765.mg *	P<.005	- 294.mg 6.83gm	2/16	4/18	3/19			
liv mix a	805.mg *	P<.01	299.mg 48.4gm	2/16	4/18	2/19			
tba mix a	321.mg /	P<.002	149.mg 1.55gm	9/16	12/18	12/19			
6612 M m chi eat 68w94 381 : pool				0	617.mg	1.44gm			
--- vsc a	723.mg *	P<.0005 +	324.mg 2.11gm	5/99	5/18	7/19			
6613 R m cdr eat 18m24 381 :				0	120.mg	240.mg			
liv mix v	3.26gm *	P<.8	- 272.mg n.s.s.	1/17	1/17	1/17			
tba mix v	67.2mg \	P<.005	19.1mg 747.mg	13/17	12/17	(12/17)			
6614 R m cdr eat 18m24 381 : pool				0	120.mg	240.mg			
sub mix v	152.mg *	P<.0005 +	69.6mg 475.mg	18/111	7/17	9/17			
C.I. DISPERSE YELLOW 3 2832-40-8									
6615 M f b6c eat 24m24 TR222 :				0	319.mg	638.mg			
liv MXA	1.02gm *	P<.0005 c	590.mg 3.05gm	2/50	10/50	17/50		liv:hpa,hpc.	
liv hpa	1.34gm *	P<.0005 c	769.mg 2.96gm	0/50	6/50	12/50			
--- MXA	1.51gm *	P<.05	654.mg n.s.s.	10/50	17/50	20/50		---:leu,lym.	S
--- lym	1.68gm *	P<.07 a	689.mg n.s.s.	10/50	16/50	19/50			
TBA MXB	769.mg *	P<.02	362.mg n.s.s.	20/50	33/50	36/50			
liv MXB	1.02gm *	P<.0005	590.mg 3.05gm	2/50	10/50	17/50		liv:hpa,hpc,nnd.	
lun MXB	no dre	P=1.	3.62gm n.s.s.	6/50	0/50	4/50		lun:a/a,a/c.	
6616 M m b6c eat 24m24 TR222 :				0	294.mg	589.mg			
lun a/a #	2.15gm *	P<.03	- 960.mg n.s.s.	2/50	6/50	9/50			S
TBA MXB	17.2gm *	P<1.	624.mg n.s.s.	33/50	26/50	33/50			
liv MXB	no dre	P=1.	1.31gm n.s.s.	20/50	12/50	16/50		liv:hpa,hpc,nnd.	

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
lun MXB	2.44gm * P<.07		977.mg n.s.s.	3/50	7/50	9/50			lun:a/a,a/c.
6617 R f f34 eat 24m24 TR222 :				0	248.mg	495.mg			
TBA MXB	no dre	P=1.	- 232.mg n.s.s.	38/50	40/50	(25/50)			
liv MXB	46.8gm * P<.9		2.42gm n.s.s.	2/50	1/50	3/50			liv:hpa,hpc,nnd.
6618 R m f34 eat 24m24 TR222 :				0	198.mg	396.mg			
liv nnd	380.mg \ P<.003	c	196.mg 1.80gm	1/50	15/50	(10/50)			
liv MXA	833.mg * P<.04	c	397.mg n.s.s.	2/50	15/50	11/50			liv:hpc,nnd.
sto --- h	4.09gm * P<.4	a	1.41gm n.s.s.	0/50	3/50	1/50			
TBA MXB	no dre	P=1.	569.mg n.s.s.	37/50	37/50	32/50			
liv MXB	833.mg * P<.04		397.mg n.s.s.	2/50	15/50	11/50			liv:hpa,hpc,nnd.
C.I. PIGMENT YELLOW 12 (diarylanilide yellow) 6358-85-6									
6619 M f b6c eat 78w96 TR30 :				0	2.61gm	5.23gm			
TBA MXB	no dre	P=1.	- 10.1gm n.s.s.	12/50	10/50	9/50			
liv MXB	no dre	P=1.	51.7gm n.s.s.	2/50	0/50	0/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	25.5gm n.s.s.	4/50	3/50	1/50			lun:a/a,a/c.
6620 M m b6c eat 78w96 TR30 :				0	2.44gm	4.82gm			
TBA MXB	no dre	P=1.	- 8.17gm n.s.s.	20/50	21/50	13/50			
liv MXB	no dre	P=1.	5.41gm n.s.s.	15/50	11/50	(4/50)			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	16.6gm n.s.s.	7/50	5/50	4/50			lun:a/a,a/c.
6621 M b nmr eat 24m24 1021				0	125.mg	375.mg	1.12gm		Leuschner;txlt,2,253-260;1978
tba tum	9.11gm * P<.3		- 2.46gm n.s.s.	33/100	21/100	26/100	34/100		
6622 R f f34 eat 18m25 TR30 :				0	920.mg	1.84gm			
TBA MXB	4.14gm * P<.4		- 1.13gm n.s.s.	31/50	40/50	34/50			
liv MXB	71.9gm * P<.6		10.4gm n.s.s.	1/50	0/50	2/50			liv:hpa,hpc,nnd.
6623 R m f34 eat 18m25 TR30 :				0	736.mg	1.47gm			
TBA MXB	no dre	P=1.	- 2.64gm n.s.s.	31/50	25/50	23/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	1/50	0/50			liv:hpa,hpc,nnd.
6624 R b sda eat 24m24 1021				0	45.0mg	135.mg	405.mg		Leuschner;txlt,2,253-260;1978
tba tum	5.33gm Z P<.6		- 1.03gm n.s.s.	43/100	20/100	18/100	37/100		
C.I. PIGMENT YELLOW 16 5979-28-2									
6625 M b nmr eat 24m24 1021				0	125.mg	375.mg	1.13gm		Leuschner;txlt,2,253-260;1978
tba tum e	11.7gm * P<.5		- 2.50gm n.s.s.	33/100	22/100	33/100	33/100		
6626 R b sda eat 24m24 1021				0	45.0mg	135.mg	405.mg		
tba tum e	13.7gm Z P<.8		- 1.19gm n.s.s.	43/100	24/100	16/100	36/100		
C.I. PIGMENT YELLOW 83 5567-15-7									
6627 M b nmr eat 24m24 1021				0	125.mg	375.mg	1.13gm		Leuschner;txlt,2,253-260;1978
tba tum e	no dre	P=1.	- 4.66gm n.s.s.	33/100	23/100	19/100	26/100		
6628 R b sda eat 24m24 1021				0	45.0mg	135.mg	405.mg		
tba tum e	3.56gm Z P<.4		- 897.mg n.s.s.	43/100	23/100	20/100	40/100		
C.I. VAT YELLOW 4 128-66-5									
6629 M f b6c eat 25m25 TR134 :				0	1.62gm	3.25gm			
TBA MXB	no dre	P=1.	- 3.77gm n.s.s.	13/20	29/50	29/50			
liv MXB	23.9gm * P<.5		5.84gm n.s.s.	2/20	6/50	9/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	11.6gm n.s.s.	2/20	5/50	3/50			lun:a/a,a/c.
6630 M m b6c eat 25m25 TR134 :				0	3.00gm	6.00gm			
--- lym	10.9gm * P<.009	c	5.66gm 333.gm	3/20	7/50	22/50			
TBA MXB	4.41gm * P<.05		1.94gm n.s.s.	12/20	42/50	48/50			
liv MXB	8.61gm * P<.07		3.87gm n.s.s.	3/20	22/50	21/50			liv:hpa,hpc,nnd.
lun MXB	19.1gm * P<.4		5.69gm n.s.s.	4/20	14/50	15/50			lun:a/a,a/c.
6631 R f f34 eat 24m24 TR134 :				0	175.mg	350.mg			
TBA MXB	no dre	P=1.	- 474.mg n.s.s.	9/20	26/50	23/50			
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/20	0/50	0/50			liv:hpa,hpc,nnd.
6632 R m f34 eat 24m24 TR134 :				0	140.mg	280.mg			
TBA MXB	787.mg * P<.5		- 185.mg n.s.s.	11/20	32/50	31/50			
liv MXB	2.79gm * P<.2		963.mg n.s.s.	0/20	1/50	3/50			liv:hpa,hpc,nnd.
FD & C YELLOW NO. 5 (tartrazine) 1934-21-0									
6633 M f cd1 eat 24m24 1869				0	650.mg	1.95gm	6.50gm		Borzelleca;fctx,26,189-194;1988
--- mlp e	1.43gm Z P<.0005	-	616.mg 5.36gm	3/120	8/28	(4/30)	2/60)		
liv hpa e	200.gm * P<.2	-	40.6gm n.s.s.	1/120	0/28	0/30	2/60		
liv hpd e	no dre	P=1.	- 53.6gm n.s.s.	3/120	0/28	1/30	1/60		
lun a/a e	no dre	P=1.	- 44.4gm n.s.s.	29/120	7/28	7/30	6/60		
lun acb e	no dre	P=1.	- 46.9gm n.s.s.	3/120	1/28	2/30	1/60		
tba mal e	1.56gm Z P<.0005	-	813.mg 4.84gm	34/120	15/28	20/30	(15/60)		
tba ben e	no dre	P=1.	- 32.4gm n.s.s.	52/120	14/28	10/30	15/60		
6634 M m cd1 eat 24m24 1869				0	600.mg	1.80gm	6.00gm		
liv hpa e	2.15gm Z P<.02	-	732.mg n.s.s.	7/120	6/27	(3/33	2/60)		
--- mlp e	11.8gm Z P<.02	-	3.96gm n.s.s.	2/120	1/27	4/33	(3/60)		
lun a/a e	42.5gm * P<.4	-	10.3gm n.s.s.	23/120	11/27	11/33	17/60		
liv hpd e	61.1gm * P<.3	-	14.8gm n.s.s.	9/120	4/27	7/33	8/60		
lun acb e	no dre	P=1.	- 73.5gm n.s.s.	3/120	0/27	1/33	0/60		
tba ben e	388.mg Z P<.0005	-	182.mg 1.36gm	43/120	21/27	(13/33	22/60)		
tba mal e	1.81gm Z P<.0005	-	961.mg 5.11gm	27/120	6/27	22/33	(20/60)		
6635 R f f3d wat 24m26 1857				0	531.mg	1.06gm			Maekawa;fctx,25,891-896;1987
ute esp e	5.78gm * P<.2	-	1.98gm n.s.s.	5/47	13/50	10/49			
liv nnd e	no dre	P=1.	- 9.15gm n.s.s.	1/47	1/50	1/49			
tba tum e	no dre	P=1.	- 2.13gm n.s.s.	39/47	41/50	30/49			
6636 R m f3d wat 24m26 1857				0	464.mg	929.mg			
abc mso e	2.82gm \ P<.004	-	1.15gm 18.3gm	0/48	6/49	(0/49)			
liv hpc e	no dre	P=1.	- 8.82gm n.s.s.	0/48	1/49	0/49			
liv nnd e	no dre	P=1.	- 9.84gm n.s.s.	3/48	3/49	0/49			
tba tum e	noTD50	P<.4	- n.s.s. n.s.s.	47/48	49/49	49/49			
6637 R f nss eat 64w64 1358				0	15.0mg	150.mg	750.mg		Mannell;jphp,10,625-634;1958
liv tum e	no dre	P=1.	- 13.6mg n.s.s.	0/10	0/13	0/14	0/10		

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc		NCI/NTPPathology
tba mix e	no dre	P=1.	- 273.mg n.s.s.	2/10	4/13	5/14	2/10		
6638 R m nss eat 64w64 1358				0	12.0mg	120.mg	600.mg		
liv tum e	no dre	P=1.	- 11.4mg n.s.s.	0/11	0/14	0/12	0/9		
tba mix e	no dre	P=1.	- 439.mg n.s.s.	1/11	2/14	1/12	0/9		
6639 R b osm eat 24m24 305a				0	225.mg	450.mg	900.mg	2.25gm	Davis;txap,6,621-626;1964
liv ade e	231.gm *	P<.9	- 7.86gm n.s.s.	0/18	2/22	0/21	0/24	1/23	
tba mal e	no dre	P=1.	- 4.76gm n.s.s.	6/18	4/22	6/21	6/24	4/23	
tba mix e	no dre	P=1.	- 5.13gm n.s.s.	8/18	9/22	9/21	8/24	5/23	
FD & C YELLOW NO. 6 (sunset yellow FCF) 2783-94-0									
6640 M f b6c eat 24m24 TR208 :				0	1.61gm	3.22gm			
TBA MXB	no dre	P=1.	- 7.16gm n.s.s.	28/50	20/50	21/50			
liv MXB	no dre	P=1.	15.8gm n.s.s.	7/50	3/50	4/50			liv:hpa,hpc,nnd.
lun MXB	66.4gm *	P<.3	16.3gm n.s.s.	0/50	1/50	1/50			lun:a/a,a/c.
6641 M m b6c eat 24m24 TR208 :				0	1.49gm	2.97gm			
ski MXA #	37.5gm *	P<.05	- 11.3gm n.s.s.	0/50	0/49	3/50			ski:fbs,fib. S
TBA MXB	17.8gm *	P<.7	2.42gm n.s.s.	32/50	31/49	34/50			
liv MXB	14.2gm *	P<.5	3.04gm n.s.s.	13/50	23/49	16/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	13.3gm n.s.s.	6/50	4/49	3/50			lun:a/a,a/c.
6642 M f cdr eat 80w80 1355				0	260.mg	520.mg	1.04gm	2.08gm	Gaunt;fctx,12,1-10;1974
liv tum e	no dre	P=1.	- 476.mg n.s.s.	0/47	0/29	0/27	0/27	0/29	
lun ade e	no dre	P=1.	- 6.02gm n.s.s.	12/47	6/29	3/27	2/27	3/29	
6643 M m cdr eat 80w80 1355				0	240.mg	480.mg	960.mg	1.92gm	
liv tum e	no dre	P=1.	- 412.mg n.s.s.	0/50	0/26	0/30	0/27	0/19	
lun ade e	no dre	P=1.	- 2.34gm n.s.s.	7/50	2/26	8/30	2/27	3/19	
6644 R f f34 eat 24m24 TR208 :				0	619.mg	1.24gm			
TBA MXB	9.06gm *	P<.8	- 1.03gm n.s.s.	68/90	37/50	42/50			
liv MXB	no dre	P=1.	8.31gm n.s.s.	3/90	3/50	0/50			liv:hpa,hpc,nnd.
6645 R m f34 eat 24m24 TR208 :				0	495.mg	990.mg			
TBA MXB	11.8gm *	P<.9	- 973.mg n.s.s.	61/90	34/50	35/50			
liv MXB	2.52gm \	P<.08	802.mg n.s.s.	5/90	7/50	(1/50)			liv:hpa,hpc,nnd.
6646 R f nss eat 64w64 1358				0	15.0mg	150.mg	750.mg		Mannell;jphp,10,625-634;1958
liv tum e	no dre	P=1.	- 15.3mg n.s.s.	0/10	0/15	0/13	0/9		
tba mix e	87.4mg Z	P<.02	- 31.1mg n.s.s.	2/10	0/15	6/13	(2/9)		
6647 R m nss eat 64w64 1358				0	12.0mg	120.mg	600.mg		
liv tum e	no dre	P=1.	- 6.91mg n.s.s.	0/11	0/8	0/12	0/9		
tba mix e	14.0gm *	P<1.	- 264.mg n.s.s.	1/11	1/8	1/12	1/9		
GARDENIA YELLOW 94238-00-3									
6648 M f c5n wat 95w95 2397				0	400.mg	1.60gm			Fujimoto;jtxp,7,455-460;1994/pers.comm.
lun tum e	no dre	P=1.	- 9.19gm n.s.s.	0/40	1/45	0/44			
liv hpt e	no dre	P=1.	- 11.9gm n.s.s.	1/40	1/45	0/44			
6649 M m c5n wat 95w95 2397				0	333.mg	1.33gm			
lun tum e	no dre	P=1.	- 2.15gm n.s.s.	2/39	0/47	0/46			
liv hpt e	no dre	P=1.	- 6.68gm n.s.s.	4/39	2/47	2/46			
HC YELLOW 4 59820-43-8									
6650 M f b6c eat 24m24 TR419 :				0	642.mg	1.28gm			
TBA MXB	no dre	P=1.	- 2.85gm n.s.s.	30/50	24/50	21/50			
liv MXB	no dre	P=1.	4.37gm n.s.s.	6/50	8/50	4/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	8.03gm n.s.s.	4/50	2/50	2/50			lun:a/a,a/c.
6651 M m b6c eat 24m24 TR419 :				0	589.mg	1.18gm			
TBA MXB	no dre	P=1.	- 1.95gm n.s.s.	28/50	23/50	23/50			
liv MXB	no dre	P=1.	2.44gm n.s.s.	13/50	10/50	12/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	2.71gm n.s.s.	8/50	9/50	7/50			lun:a/a,a/c.
6652 R f f34 eat 24m24 TR419 :				0	246.mg	495.mg			
TBA MXB	no dre	P=1.	- 389.mg n.s.s.	49/50	49/50	48/50			
liv MXB	no dre	P=1.	3.63gm n.s.s.	1/50	1/50	0/50			liv:hpa,hpc,nnd.
6653 R m f34 eat 24m24 TR419 :				0	98.7mg	198.mg			
pit pda	465.mg *	P<.3	e 142.mg n.s.s.	17/51	20/50	28/50			
TBA MXB	no dre	P=1.	153.mg n.s.s.	47/51	48/50	45/50			
liv MXB	no dre	P=1.	1.81gm n.s.s.	1/51	0/50	0/50			liv:hpa,hpc,nnd.
ZATOSETRON MALEATE (LY277359 maleate) 123482-23-5									
6654 R f f34 gav 52w52 2165				0	13.3mg	40.0mg	140.mg		Bendele;faat,22,494-504;1994
liv tum rv	no dre	P=1.	7.20mg n.s.s.	0/15	0/15	0/15	0/15		
6655 R m f34 gav 52w52 2165				0	13.3mg	40.0mg	120.mg		
liv tum r	no dre	P=1.	7.12mg n.s.s.	0/15	0/15	0/15	0/15		
ZEARALENONE (F-2 TOXIN) 17924-92-4									
6656 M f b6c eat 24m24 TR235 :				0	6.50mg	13.0mg			
MXB MXB	22.0mg *	P<.003	11.4mg 121.mg	6/50	8/50	20/50			liv:hpa,hpc; pit:adn,car. C
pit MXA	32.3mg /	P<.002	c 16.1mg 165.mg	3/50	2/50	15/50			pit:adn,car.
pit adn	37.4mg /	P<.006	c 17.6mg 442.mg	3/50	2/50	13/50			
liv hpa	50.1mg *	P<.002	c 23.5mg 194.mg	0/50	2/50	7/50			
liv MXA	38.8mg *	P<.03	c 17.2mg n.s.s.	3/50	7/50	10/50			liv:hpa,hpc.
TBA MXB	17.9mg *	P<.05	7.55mg n.s.s.	28/50	26/50	40/50			
liv MXB	38.8mg *	P<.03	17.2mg n.s.s.	3/50	7/50	10/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	59.5mg n.s.s.	3/50	4/50	1/50			lun:a/a,a/c.
6657 M m b6c eat 24m24 TR235 :				0	6.00mg	12.0mg			
pit MXA	49.1mg *	P<.005	c 24.6mg 383.mg	0/50	5/50	6/50			pit:ade,car.
pit ade	53.3mg *	P<.005	c 26.0mg 417.mg	0/50	4/50	6/50			
TBA MXB	no dre	P=1.	10.6mg n.s.s.	37/50	41/50	38/50			
liv MXB	no dre	P=1.	25.9mg n.s.s.	19/50	22/50	14/50			liv:hpa,hpc,nnd.
lun MXB	no dre	P=1.	28.9mg n.s.s.	11/50	8/50	11/50			lun:a/a,a/c.
6658 R f f34 eat 24m24 TR235 :				0	1.25mg	2.50mg			
TBA MXB	80.9mg *	P<1.	- 2.26mg n.s.s.	32/50	40/50	33/50			
liv MXB	33.5mg *	P<.1	10.2mg n.s.s.	0/50	1/50	2/50			liv:hpa,hpc,nnd.

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf				Brkly Code
Path	TD_{50}	2Tailpvl	LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
6659 R m f34 eat 24m24 TR235 :				0	1.00mg	2.00mg		
TBA MXB	16.2mg *	P<.8	- 1.71mg n.s.s.	32/50	36/50	33/50		
liv MXB	950.mg *	P<1.	11.9mg n.s.s.	2/50	0/50	2/50		liv:hpa,hpc,nnd.
ZINC (II) ACETATE DIHYDRATE 5970-45-6								
6660 R m crw wat 24m24 2343				0	5.00mg			Waalkes;canr,49,4282-4288;1989/pers.comm.
tes lya e	no dre	P=1.	- 17.3mg n.s.s.	9/83	2/29			
ZINC DIBUTYLDITHIOCARBAMATE (butyl zimate) 136-23-2								
6661 M f b6a orl 76w76 1220				0	364.mg			Innes;ntis,1968/1969
lun ade evx	1.09gm	P<.4	- 239.mg n.s.s.	1/17	3/18			
liv hpt evx	no dre	P=1.	- 721.mg n.s.s.	0/17	0/18			
tba mix evx	2.33gm	P<.7	- 261.mg n.s.s.	2/17	3/18			
6662 M m b6a orl 76w76 1220				0	339.mg			
lun ade evx	no dre	P=1.	- 317.mg n.s.s.	2/18	2/18			
liv hpt evx	no dre	P=1.	- 672.mg n.s.s.	1/18	0/18			
tba mix evx	no dre	P=1.	- 351.mg n.s.s.	3/18	2/18			
6663 M f b6c orl 76w76 1220				0	364.mg			
lun ade evx	2.33gm	P<.3	- 379.mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.	- 721.mg n.s.s.	0/16	0/18			
tba mix evx	731.mg	P<.05	- 220.mg n.s.s.	0/16	3/18			
6664 M m b6c orl 76w76 1220				0	339.mg			
liv hpt evx	680.mg	P<.05	- 205.mg n.s.s.	0/16	3/18			
lun ade evx	1.05gm	P<.2	- 259.mg n.s.s.	0/16	2/18			
tba mix evx	252.mg	P<.002	- 107.mg 1.03gm	0/16	7/18			
ZINC DIETHYLDITHIOCARBAMATE (ethyl zimate) 14324-55-1								
6665 M f b6a orl 76w76 1210				0	36.4mg			Innes;ntis,1968/1969
liv hpt evx	no dre	P=1.	- 68.1mg n.s.s.	0/17	0/17			
lun ade evx	no dre	P=1.	- 68.1mg n.s.s.	1/17	0/17			
tba mix evx	no dre	P=1.	- 32.0mg n.s.s.	2/17	2/17			
6666 M m b6a orl 76w76 1210				0	33.9mg			
liv hpt evx	205.mg	P<.6	- 28.4mg n.s.s.	1/18	2/18			
lun ade evx	no dre	P=1.	- 31.7mg n.s.s.	2/18	2/18			
tba mix evx	86.7mg	P<.5	- 17.3mg n.s.s.	3/18	5/18			
6667 M f b6c orl 76w76 1210				0	36.4mg			
liv hpt evx	no dre	P=1.	- 68.1mg n.s.s.	0/16	0/17			
lun mix evx	no dre	P=1.	- 68.1mg n.s.s.	0/16	0/17			
tba tum evx	no dre	P=1.	- 68.1mg n.s.s.	0/16	0/17			
6668 M m b6c orl 76w76 1210				0	33.9mg			
lun ade evx	46.2mg	P<.02	- 15.9mg n.s.s.	0/16	4/17			
liv hpt evx	no dre	P=1.	- 63.4mg n.s.s.	0/16	0/17			
tba mix evx	28.5mg	P<.003	- 11.5mg 155.mg	0/16	6/17			
ZINC DIMETHYLDITHIOCARBAMATE (methyl zimate, milbam, ziram) 137-30-4								
6669 M f b6c eat 24m24 TR238 :				0	76.5mg	154.mg		
lun a/a	561.mg *	P<.04	e 245.mg n.s.s.	2/50	5/50	10/50		
--- mlp	947.mg *	P<.05	373.mg n.s.s.	1/50	1/50	7/50		s
TBA MXB	no dre	P=1.	338.mg n.s.s.	28/50	19/50	23/50		
liv MXB	no dre	P=1.	341.mg n.s.s.	9/50	4/50	(1/50)		liv:hpa,hpc,nnd.
lun MXB	710.mg *	P<.2	254.mg n.s.s.	4/50	6/50	11/50		lun:a/a,a/c.
6670 M f b6c orl 76w76 1204				0	2.05mg			Innes;ntis,1968/1969
lun ade evx	13.1mg	P<.3	- 2.14mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.	- 4.07mg n.s.s.	0/16	0/18			
tba mix evx	13.1mg	P<.3	- 2.14mg n.s.s.	0/16	1/18			
6671 M m b6c eat 24m24 TR238 :				0	70.6mg	143.mg		
TBA MXB	no dre	P=1.	- 192.mg n.s.s.	31/50	24/50	25/49		
liv MXB	no dre	P=1.	209.mg n.s.s.	19/50	9/50	(9/49)		liv:hpa,hpc,nnd.
lun MXB	765.mg *	P<.3	215.mg n.s.s.	8/50	8/50	12/49		lun:a/a,a/c.
6672 M m b6c orl 76w76 1204				0	1.91mg			Innes;ntis,1968/1969
lun mix evx	5.23mg	P<.09	- 1.28mg n.s.s.	0/16	2/16			
liv hpt evx	10.8mg	P<.3	- 1.76mg n.s.s.	0/16	1/16			
tba mix evx	3.37mg	P<.04	- 1.01mg n.s.s.	0/16	3/16			
6673 M f b6a orl 76w76 1204				0	2.05mg			
liv hpt evx	no dre	P=1.	- 4.07mg n.s.s.	0/17	0/18			
lun ade evx	no dre	P=1.	- 4.07mg n.s.s.	1/17	0/18			
tba mix evx	no dre	P=1.	- 4.07mg n.s.s.	2/17	0/18			
6674 M m b6a orl 76w76 1204				0	1.91mg			
lun ade evx	9.15mg	P<.6	- 1.27mg n.s.s.	2/18	3/17			
liv hpt evx	202.mg	P<1.	- 2.12mg n.s.s.	1/18	1/17			
tba mix evx	4.21mg	P<.4	- .898mg n.s.s.	3/18	5/17			
6675 R f f34 eat 24m24 TR238 :				0	14.6mg	29.6mg		
TBA MXB	no dre	P=1.	- 39.5mg n.s.s.	43/50	42/50	39/50		
liv MXB	no dre	P=1.	n.s.s. n.s.s.	0/50	0/50	0/50		liv:hpa,hpc,nnd.
6676 R m f34 eat 24m24 TR238 :				0	11.8mg	23.8mg		
thy ccr	95.8mg *	P<.004	c 45.1mg 602.mg	0/50	2/50	7/50		
TBA MXB	no dre	P=1.	21.8mg n.s.s.	37/50	42/50	39/50		
liv MXB	no dre	P=1.	140.mg n.s.s.	2/50	2/50	1/50		liv:hpa,hpc,nnd.
6677 R b mgr gav 22m24 1426				0	18.4mg			Andrianova;vpit,29,71-74;1970
liv mhp e	56.5mg	P<.008	13.8mg 1.94gm	0/46	2/10			
tba mix e	25.8mg	P<.002	+ 8.47mg 198.mg	1/46	4/10			
ZINC ETHYLENEBISTHIOCARBAMATE (zineb) 12122-67-7								
6678 M f b6a orl 76w76 1213				0	180.mg			Innes;ntis,1968/1969
lun ade evx	1.15gm	P<.6	- 152.mg n.s.s.	1/17	2/18			
liv hpt evx	no dre	P=1.	- 357.mg n.s.s.	0/17	0/18			
tba mix evx	1.15gm	P<.7	- 130.mg n.s.s.	2/17	3/18			

Chemical | Synonym | CAS number
Spe | Strain | Xpo+Xpt | 0 Dose | 1 Dose | 2 Dose | 3 Dose | Literature Reference
Sex | Route | Paper Num

Site	Notes	DR	AuOp	UpConf					Brkly Code
Path	TD_{50}	2Tailpvl		LoConf	Cntrl	1 Inc	2 Inc	3 Inc	NCI/NTPPathology
6679 M m b6a orl 76w76 1213					0	168.mg			
liv hpt evx	903.mg	P<.6	-	132.mg n.s.s.	1/18	2/17			
lun ade evx	no dre	P=1.	-	206.mg n.s.s.	2/18	1/17			
tba mix evx	715.mg	P<.7	-	96.4mg n.s.s.	3/18	4/17			
6680 M f b6c orl 76w76 1213					0	180.mg			
lun ade evx	1.15gm	P<.3	-	188.mg n.s.s.	0/16	1/18			
liv hpt evx	no dre	P=1.	-	357.mg n.s.s.	0/16	0/18			
tba mix evx	1.15gm	P<.3	-	188.mg n.s.s.	0/16	1/18			
6681 M m b6c orl 76w76 1213					0	168.mg			
liv hpt evx	244.mg	P<.02	-	84.0mg n.s.s.	0/16	4/18			
lun mix evx	no dre	P=1.	-	333.mg n.s.s.	0/16	0/18			
tba mix evx	189.mg	P<.009	-	71.2mg 4.14gm	0/16	5/18			
6682 R b mgr gav 22m24 1426					0	74.9mg			Andrianova;vpit,29,71-74;1970
liv tum e	no dre	P=1.		154.mg n.s.s.	0/46	0/10			
tba mix e	255.mg	P<.06	+	57.5mg n.s.s.	1/46	2/10			
ZIRCONIUM (IV) SULFATE 14644-61-2									
6683 M b cd1 wat 32m32 1036					0	.877mg			Kanisawa;canr,29,892-895;1969
lun tum e	no dre	P=1.	-	8.41mg n.s.s.	15/71	9/72			
liv tum e	no dre	P=1.	-	10.4mg n.s.s.	4/71	3/72			
tba tum e	no dre	P=1.	-	7.10mg n.s.s.	24/71	15/72			
tba mal e	no dre	P=1.	-	9.64mg n.s.s.	8/71	5/72			